genes,baseID,symbol,average_foldchange,HNSC,LIHC,KIRP,Description,Protein Functions (ChatGPT),Disease & Drugs (ChatGPT),Biological Process (GO),Kinase Class (UniProt),Protein Function (Protein Atlas),Subcellular Location (Protein Atlas),Drug (DrugBank),"Canonical Pathways
","Hallmark Gene Sets
"
ENSG00000129824.16,ENSG00000129824,RPS4Y1,-4.729783288,-5.210615101,-3.456007533,-5.522727229,ribosomal protein S4 Y-linked 1,"RPS4Y1 is a gene that encodes ribosomal protein S4, a component of the 40S subunit of cytoplasmic ribosomes. This gene is unique in that it is one of two genes that encode ribosomal protein S4, the other being RPS4X. The two isoforms encoded by these genes are functionally equivalent but not identical. Ribosomal protein S4 belongs to the S4E family of ribosomal proteins. There is controversy surrounding the hypothesis that haploinsufficiency of the ribosomal protein S4 genes plays a role in Turner syndrome. Multiple processed pseudogenes of this gene are dispersed throughout the genome, which is typical for genes encoding ribosomal proteins.","There is limited information on the disease implications of RPS4Y1. However, there is some evidence to suggest that haploinsufficiency of the ribosomal protein S4 genes, including RPS4Y1, may play a role in Turner syndrome, a genetic disorder that affects females and is characterized by short stature and other physical abnormalities. 

There are currently no targeted drug discovery efforts specifically focused on RPS4Y1. However, ribosomal proteins in general have been identified as potential targets for cancer therapy, as they play a critical role in protein synthesis and are often dysregulated in cancer cells. 

There are no drugs on the market that specifically target RPS4Y1. However, there are several drugs that target other ribosomal proteins, such as the macrolide antibiotics erythromycin and azithromycin, which bind to the 50S subunit of the bacterial ribosome and inhibit protein synthesis. Another example is the anticancer drug doxorubicin, which binds to the 70S ribosome and inhibits protein synthesis in cancer cells.",GO:0006412 translation;GO:0010467 gene expression;GO:0019538 protein metabolic process,,Ribosomal proteins; Predicted intracellular proteins,,,,
ENSG00000067048.17,ENSG00000067048,DDX3Y,-4.499443353,-5.069657137,-3.696520275,-4.732152646,DEAD-box helicase 3 Y-linked,"DDX3Y is a gene that encodes a protein belonging to the DEAD-box RNA helicase family. This protein is involved in ATP binding, hydrolysis, RNA binding, and intramolecular interactions. It is highly similar to DDX3X, a gene on the X chromosome, but a deletion of DDX3Y cannot be complemented by DDX3X. Mutations in DDX3Y can result in male infertility, a reduction in germ cell numbers, and Sertoli-cell only syndrome. Pseudogenes similar to DDX3Y and DDX3X are found on chromosome 4 and the X chromosome. Alternative splicing of DDX3Y results in multiple transcript variants encoding different isoforms.","DDX3Y has been implicated in male infertility and is a potential target for drug discovery efforts aimed at treating this condition. In particular, DDX3Y has been shown to play a critical role in spermatogenesis, and mutations in this gene have been associated with a reduction in germ cell numbers and Sertoli-cell only syndrome. While there are currently no drugs on the market that specifically target DDX3Y, there is ongoing research aimed at identifying small molecules that can modulate the activity of this protein. One example of a successful drug discovery effort targeting a related protein is the development of inhibitors of the related RNA helicase DDX3X, which have shown promise as potential treatments for a range of viral infections, including HIV, hepatitis C, and Zika virus.",GO:0140588 chromatin looping;GO:0007276 gamete generation;GO:0048609 multicellular organismal reproductive process,,Predicted intracellular proteins; Human disease related genes:Reproductive system diseases:Reproductive system diseases; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Cytosol (Enhanced),,,
ENSG00000198692.10,ENSG00000198692,EIF1AY,-3.955295731,-3.984250503,-3.916499198,-3.965137491,eukaryotic translation initiation factor 1A Y-linked,"EIF1AY is a gene located on the non-recombining region of the Y chromosome. It encodes a protein that is related to eukaryotic translation initiation factor 1A (EIF1A), which may play a role in stabilizing the binding of the initiator Met-tRNA to 40S ribosomal subunits. Alternative splicing of the gene results in multiple transcript variants.","EIF1AY is not currently known to be associated with any specific diseases. However, research has shown that it may play a role in the development and progression of certain cancers, including breast cancer and prostate cancer. Targeted drug discovery efforts for EIF1AY are currently limited, as the gene is located on the Y chromosome and is therefore only present in males. However, drugs targeting related proteins involved in translation initiation, such as eIF4E, are being developed for the treatment of cancer. Examples of successful drugs targeting translation initiation include ribociclib and palbociclib, which are used in combination with hormone therapy to treat certain types of breast cancer.",GO:0006413 translational initiation;GO:0006412 translation;GO:0010467 gene expression,,Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000012817.16,ENSG00000012817,KDM5D,-3.64977545,-4.010596847,-2.987837823,-3.95089168,lysine demethylase 5D,"KDM5D is a human gene that encodes a protein with zinc finger domains. It has been identified as a minor histocompatibility antigen, which means that it can cause graft rejection of male donor cells in a female recipient. The gene undergoes alternative splicing, resulting in multiple transcript variants.","There is limited information available on the disease implications of KDM5D. However, studies have suggested that alterations in the expression of KDM5D may be associated with certain types of cancer, including prostate cancer and breast cancer. Targeted drug discovery efforts for KDM5D are still in the early stages, but there is potential for the development of drugs that target the protein encoded by this gene. One example of a successful drug targeting a related protein is GSK-J4, which inhibits the activity of the KDM6 family of proteins. GSK-J4 has shown promise in preclinical studies for the treatment of certain types of cancer and inflammatory diseases. However, further research is needed to determine the potential of KDM5D as a therapeutic target and to develop effective drugs targeting this protein.",GO:0002457 T cell antigen processing and presentation;GO:0060765 regulation of androgen receptor signaling pathway;GO:0002456 T cell mediated immunity,,Transcription factors:Helix-turn-helix domains; Enzymes; ENZYME proteins:Oxidoreductases; Predicted intracellular proteins,Nucleoli fibrillar center (Approved),Ascorbic acid,,
ENSG00000131002.12,ENSG00000131002,TXLNGY,-3.010641666,-3.107110284,-2.52717503,-3.397639683,None,None,None,None,None,None,None,None,None,None
ENSG00000168542.16,ENSG00000168542,COL3A1,-2.329378225,-3.130039822,-1.84402022,-2.014074633,collagen type III alpha 1 chain,"COL3A1 is a gene that encodes for the pro-alpha1 chains of type III collagen, a type of fibrillar collagen found in extensible connective tissues such as skin, lung, uterus, intestine, and the vascular system. It is often found in association with type I collagen. Mutations in this gene have been linked to Ehlers-Danlos syndrome type IV, a genetic disorder that affects the connective tissues, as well as aortic and arterial aneurysms.","Mutations in the COL3A1 gene have been linked to several diseases, including Ehlers-Danlos syndrome type IV, a rare genetic disorder that affects the connective tissues and can lead to arterial and aortic aneurysms. There are currently no targeted drug discovery efforts for this gene, as treatment for Ehlers-Danlos syndrome type IV is primarily focused on managing symptoms and preventing complications. However, there are several drugs on the market that can be used to manage symptoms, such as pain and inflammation. These include nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen, as well as opioids for severe pain. Additionally, physical therapy and surgery may be recommended to manage joint instability and prevent complications such as organ rupture.",GO:0032905 transforming growth factor beta1 production;GO:0071604 transforming growth factor beta production;GO:0060414 aorta smooth muscle tissue morphogenesis,,Predicted intracellular proteins; FDA approved drug targets:Biotech drugs; Predicted secreted proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Human disease related genes:Congenital malformations:Congenital malformations of skin; Disease related genes,Endoplasmic reticulum (Approved),Collagenase clostridium histolyticum,(M3005)NABA COLLAGENS; (M198)PID SYNDECAN 1 PATHWAY; (M8)PID ENDOTHELIN PATHWAY,(M5944)HALLMARK ANGIOGENESIS; (M5942)HALLMARK UV RESPONSE DN; (M5909)HALLMARK MYOGENESIS
ENSG00000142798.20,ENSG00000142798,HSPG2,-2.187287775,-2.753565165,-2.259729177,-1.548568985,heparan sulfate proteoglycan 2,"HSPG2, also known as perlecan, is a gene that encodes a large multidomain proteoglycan. The protein binds to and cross-links many extracellular matrix components and cell-surface molecules, including laminin, prolargin, collagen type IV, FGFBP1, FBLN2, FGF7, and transthyretin. It plays essential roles in multiple biological activities, including maintaining the endothelial barrier function, inhibiting smooth muscle cell proliferation, promoting endothelial growth and regeneration, stabilizing other molecules in basement membranes, and regulating glomerular permeability to macromolecules and cell adhesion. Mutations in this gene can cause Schwartz-Jampel syndrome type 1, Silverman-Handmaker type of dyssegmental dysplasia, and tardive dyskinesia. Alternative splicing of this gene results in multiple transcript variants.","Mutations in the HSPG2 gene have been associated with several diseases, including Schwartz-Jampel syndrome type 1, Silverman-Handmaker type of dyssegmental dysplasia, and tardive dyskinesia. Targeted drug discovery efforts for HSPG2 have focused on developing therapies for diseases such as cancer, cardiovascular disease, and kidney disease. One example is the development of a monoclonal antibody that targets perlecan, the protein encoded by HSPG2, to inhibit tumor growth and metastasis in breast cancer. Another example is the use of a small molecule inhibitor of perlecan to prevent the development of atherosclerosis in animal models. However, there are currently no drugs on the market that specifically target HSPG2.",GO:1905907 negative regulation of amyloid fibril formation;GO:1905906 regulation of amyloid fibril formation;GO:0007566 embryo implantation,,Human disease related genes:Musculoskeletal diseases:Muscular diseases; Predicted intracellular proteins; Predicted secreted proteins; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Disease related genes,,Palifermin,(M5882)NABA PROTEOGLYCANS; (M5887)NABA BASEMENT MEMBRANES; (M5884)NABA CORE MATRISOME,
ENSG00000225630.1,ENSG00000225630,MTND2P28,-2.099833509,-2.490584778,-1.757535924,-2.051379826,MT-ND2 pseudogene 28,,,,,,,,,
ENSG00000164692.18,ENSG00000164692,COL1A2,-2.055658758,-2.738294411,-1.369998763,-2.058683101,collagen type I alpha 2 chain,"COL1A2 is a gene that encodes the pro-alpha2 chain of type I collagen, which is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis, and tendon. Mutations in this gene are associated with various conditions such as osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIB, recessive Ehlers-Danlos syndrome Classical type, idiopathic osteoporosis, and atypical Marfan syndrome. However, symptoms associated with mutations in this gene tend to be less severe than mutations in the gene for the alpha1 chain of type I collagen (COL1A1) due to the different role of alpha2 chains in matrix integrity. Three transcripts resulting from the use of alternate polyadenylation signals have been identified for this gene.","Mutations in COL1A2 have been linked to several diseases, including osteogenesis imperfecta (OI), Ehlers-Danlos syndrome (EDS), and idiopathic osteoporosis. OI is a genetic disorder characterized by brittle bones that are prone to fractures, while EDS is a group of inherited connective tissue disorders that affect the skin, joints, and blood vessels. Idiopathic osteoporosis is a condition in which bone density decreases without an apparent cause. 

Targeted drug discovery efforts for COL1A2-related diseases have focused on developing therapies that can improve bone density and strength. One example is the use of bisphosphonates, which are drugs that can slow down bone loss and reduce the risk of fractures in patients with OI and osteoporosis. Another approach is the use of recombinant human parathyroid hormone (rhPTH), which has been shown to increase bone density and reduce fracture risk in patients with OI. 

There are currently no drugs on the market that specifically target COL1A2, but several drugs are available for the treatment of related diseases. For example, bisphosphonates such as alendronate (Fosamax) and zoledronic acid (Reclast) are approved for the treatment of osteoporosis, while rhPTH (teriparatide, Forteo) is approved for the treatment of OI. In addition, there are several drugs available for the treatment of EDS-related symptoms, such as pain and joint hypermobility. These include nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy.",GO:0070208 protein heterotrimerization;GO:0043589 skin morphogenesis;GO:0070206 protein trimerization,,Predicted secreted proteins; Human disease related genes:Musculoskeletal diseases:Skeletal diseases; Human disease related genes:Congenital malformations:Congenital malformations of skin; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Disease related genes; Cancer-related genes:Candidate cancer biomarkers,Endoplasmic reticulum (Supported),Collagenase clostridium histolyticum,(M274)PID LYMPH ANGIOGENESIS PATHWAY; (M65)PID FRA PATHWAY; (M53)PID INTEGRIN3 PATHWAY,(M5942)HALLMARK UV RESPONSE DN; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000163359.16,ENSG00000163359,COL6A3,-2.02221652,-2.640145742,-1.50540105,-1.921102769,collagen type VI alpha 3 chain,"COL6A3 is a gene that encodes the alpha-3 chain of type VI collagen, a type of collagen found in most connective tissues. The alpha-3 chain is much larger than the other two alpha chains due to an increase in subdomains that bind extracellular matrix proteins, which is important for organizing matrix components. Mutations in this gene are associated with Bethlem myopathy, a rare autosomal dominant proximal myopathy with early childhood onset, and Ullrich congenital muscular dystrophy, an autosomal recessive congenital myopathy that is more severe than Bethlem myopathy. Multiple transcript variants have been identified, but the full-length nature of only some of these variants has been described.","Mutations in the COL6A3 gene have been associated with several muscular dystrophies, including Bethlem myopathy and Ullrich congenital muscular dystrophy. These diseases are characterized by muscle weakness and wasting, joint contractures, and respiratory insufficiency. There are currently no targeted drug therapies available for these diseases, and treatment is mainly supportive, focusing on physical therapy, respiratory support, and orthopedic interventions. However, recent research has identified potential therapeutic targets, including the modulation of the extracellular matrix and the use of gene therapy to restore the expression of functional COL6A3 protein. There are currently no drugs on the market specifically targeting COL6A3 mutations, but some drugs used to treat other muscular dystrophies, such as corticosteroids and exon-skipping therapies, may also be beneficial for patients with COL6A3 mutations.",GO:0043491 phosphatidylinositol 3-kinase/protein kinase B signal transduction;GO:0051402 neuron apoptotic process;GO:0009749 response to glucose,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Human disease related genes:Musculoskeletal diseases:Muscular diseases; Predicted intracellular proteins; Predicted secreted proteins; Disease related genes,Endoplasmic reticulum (Approved); Additional: Vesicles,,(M5887)NABA BASEMENT MEMBRANES; (M3005)NABA COLLAGENS; (M198)PID SYNDECAN 1 PATHWAY,(M5909)HALLMARK MYOGENESIS; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000108821.14,ENSG00000108821,COL1A1,-1.986463619,-2.931100764,-1.473435392,-1.554854702,collagen type I alpha 1 chain,"COL1A1 is a gene that encodes the pro-alpha1 chains of type I collagen, which is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis, and tendon. The triple helix of type I collagen comprises two alpha1 chains and one alpha2 chain. Mutations in this gene are associated with several conditions, including osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIA, Ehlers-Danlos syndrome Classical type, Caffey Disease, and idiopathic osteoporosis. Reciprocal translocations between chromosomes 17 and 22, where this gene and the gene for platelet-derived growth factor beta are located, are associated with a particular type of skin tumor called dermatofibrosarcoma protuberans. Two transcripts resulting from the use of alternate polyadenylation signals have been identified for this gene.","Mutations in the COL1A1 gene are associated with several genetic disorders, including osteogenesis imperfecta (OI), Ehlers-Danlos syndrome (EDS), and idiopathic osteoporosis. OI is a rare genetic disorder characterized by brittle bones that are prone to fracture, while EDS is a group of inherited connective tissue disorders that affect the skin, joints, and blood vessels. Targeted drug discovery efforts for these disorders have focused on developing therapies that can improve bone density and strength, reduce the risk of fractures, and alleviate pain and other symptoms associated with these conditions. Currently, there are several drugs on the market that are used to treat OI and EDS, including bisphosphonates, teriparatide, and denosumab. These drugs work by increasing bone density and reducing the risk of fractures, and have been shown to be effective in improving the quality of life for patients with these conditions.",GO:0071306 cellular response to vitamin E;GO:1902618 cellular response to fluoride;GO:1902617 response to fluoride,,Predicted intracellular proteins; FDA approved drug targets:Biotech drugs; Predicted secreted proteins; Human disease related genes:Musculoskeletal diseases:Skeletal diseases; Human disease related genes:Congenital malformations:Congenital malformations of skin; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Disease related genes; Cancer-related genes:Candidate cancer biomarkers,Endoplasmic reticulum (Approved); Additional: Vesicles,Collagenase clostridium histolyticum; Halofuginone; Clove oil; Vonicog Alfa; Von Willebrand Factor Human,(M274)PID LYMPH ANGIOGENESIS PATHWAY; (M53)PID INTEGRIN3 PATHWAY; (M3005)NABA COLLAGENS,(M5942)HALLMARK UV RESPONSE DN; (M5909)HALLMARK MYOGENESIS; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000137801.11,ENSG00000137801,THBS1,-1.938389139,-2.898410858,-1.629130878,-1.287625681,thrombospondin 1,"THBS1, also known as thrombospondin 1, is a gene that encodes for a protein that is involved in cell-to-cell and cell-to-matrix interactions. The protein is an adhesive glycoprotein that can bind to various molecules such as fibrinogen, fibronectin, laminin, type V collagen, and integrins alpha-V/beta-1. THBS1 has been shown to play roles in platelet aggregation, angiogenesis, and tumorigenesis. The protein is a subunit of a disulfide-linked homotrimeric protein. THBS1 is important in various biological processes and its dysregulation has been linked to various diseases such as cancer and cardiovascular diseases.","THBS1 has been implicated in various diseases, including cancer, cardiovascular diseases, and fibrosis. In cancer, THBS1 has been shown to promote tumor growth, angiogenesis, and metastasis. Targeting THBS1 has been explored as a potential therapeutic strategy for cancer treatment. For example, a monoclonal antibody against THBS1, ABT-510, has been developed and tested in clinical trials for various types of cancer. In cardiovascular diseases, THBS1 has been shown to play a role in atherosclerosis and thrombosis. Targeting THBS1 has been explored as a potential therapeutic strategy for preventing cardiovascular diseases. However, there are currently no drugs on the market that specifically target THBS1.",GO:0010751 negative regulation of nitric oxide mediated signal transduction;GO:0002581 negative regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II;GO:0002605 negative regulation of dendritic cell antigen processing and presentation,,Predicted secreted proteins; Candidate cardiovascular disease genes; Cancer-related genes:Candidate cancer biomarkers,Endoplasmic reticulum;Plasma membrane (Approved),,(M165)PID SYNDECAN 4 PATHWAY; (M277)PID INTEGRIN A4B1 PATHWAY; (M53)PID INTEGRIN3 PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING; (M5946)HALLMARK COAGULATION; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000176986.16,ENSG00000176986,SEC24C,-1.911010156,-2.741935859,-2.101963794,-0.889130816,"SEC24 homolog C, COPII coat complex component","SEC24C is a human gene that belongs to the SEC24 subfamily of the SEC23/SEC24 family, which is involved in vesicle trafficking. The gene encodes a protein that is similar to the yeast Sec24p component of COPII, the coat protein complex responsible for vesicle budding from the ER. The protein may play a role in shaping the vesicle, as well as in cargo selection and concentration. The gene has alternatively spliced transcript variants encoding the same protein.","There is limited information on the disease implications of SEC24C. However, studies have shown that mutations in SEC24C are associated with autosomal recessive osteogenesis imperfecta (OI), a genetic disorder characterized by brittle bones and increased susceptibility to fractures. Targeted drug discovery efforts for SEC24C are also limited, as the function of the protein is not fully understood. However, there have been some studies on the potential use of SEC24C inhibitors for the treatment of cancer, as the protein is involved in the transport of growth factor receptors. Currently, there are no drugs on the market that specifically target SEC24C. However, there are drugs that indirectly affect the protein, such as bortezomib, a proteasome inhibitor used in the treatment of multiple myeloma, which has been shown to affect the expression of SEC24C.",GO:0090110 COPII-coated vesicle cargo loading;GO:0035459 vesicle cargo loading;GO:0090114 COPII-coated vesicle budding,,Predicted intracellular proteins,Vesicles (Supported),,,
ENSG00000265660.1,ENSG00000265660,MIR4664,-1.901177467,-2.344436359,-2.501763306,-0.857332737,microRNA 4664,,,,,,,,,
ENSG00000020181.18,ENSG00000020181,ADGRA2,-1.900441637,-2.332684059,-1.594873439,-1.773767414,adhesion G protein-coupled receptor A2,"ADGRA2 is a human gene that encodes for adhesion G protein-coupled receptor A2. This gene is predicted to enable G protein-coupled receptor activity and is involved in the positive regulation of the canonical Wnt signaling pathway. ADGRA2 is also a part of the Wnt signalosome. The Wnt signaling pathway is important for various cellular processes, including embryonic development, tissue homeostasis, and cell differentiation. Dysregulation of this pathway has been linked to various diseases, including cancer. Therefore, understanding the function of ADGRA2 and its role in the Wnt signaling pathway may provide insights into the development and treatment of these diseases.","There is limited information available on the disease implications of ADGRA2. However, studies have suggested that dysregulation of the Wnt signaling pathway, in which ADGRA2 is involved, can lead to the development of various cancers, including colorectal cancer, breast cancer, and hepatocellular carcinoma. Therefore, ADGRA2 may have potential as a therapeutic target for these diseases.

Currently, there are no drugs specifically targeting ADGRA2. However, there are drugs that target the Wnt signaling pathway, such as porcupine inhibitors and tankyrase inhibitors. Porcupine inhibitors block the secretion of Wnt ligands, while tankyrase inhibitors inhibit the activity of tankyrase enzymes, which are involved in the regulation of the Wnt signaling pathway. Some examples of drugs targeting the Wnt signaling pathway include LGK974, ETC-1922159, and XAV939.

LGK974 is a porcupine inhibitor that has shown promising results in preclinical studies for the treatment of various cancers, including colorectal cancer and pancreatic cancer. ETC-1922159 is a tankyrase inhibitor that has shown efficacy in preclinical studies for the treatment of breast cancer and colorectal cancer. XAV939 is a tankyrase inhibitor that has been shown to inhibit the growth of hepatocellular carcinoma cells in preclinical studies.

Overall, while there is limited information available on the disease implications of ADGRA2, targeting the Wnt signaling pathway, in which ADGRA2 is involved, may have potential for the development of novel therapeutics for various cancers.",GO:0090210 regulation of establishment of blood-brain barrier;GO:1900747 negative regulation of vascular endothelial growth factor signaling pathway;GO:1902548 negative regulation of cellular response to vascular endothelial growth factor stimulus,,G-protein coupled receptors:Family 2 (B) receptors; G-protein coupled receptors:GPCRs excl olfactory receptors; Predicted intracellular proteins,Plasma membrane (Supported); Additional: Vesicles,,(M160)PID AVB3 INTEGRIN PATHWAY,(M5953)HALLMARK KRAS SIGNALING UP
ENSG00000128052.10,ENSG00000128052,KDR,-1.886738887,-1.898914686,-1.749612311,-2.011689663,kinase insert domain receptor,"The KDR gene encodes for the kinase insert domain receptor, which is one of the two receptors for vascular endothelial growth factor (VEGF). This receptor is a type III receptor tyrosine kinase and plays a crucial role in mediating VEGF-induced endothelial cell functions such as proliferation, survival, migration, tubular morphogenesis, and sprouting. The regulation of this receptor's signaling and trafficking involves various factors such as Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, and T-cell protein tyrosine phosphatase. Mutations in the KDR gene have been linked to infantile capillary hemangiomas.","Mutations in the KDR gene have been linked to various diseases, including cancer, diabetic retinopathy, and age-related macular degeneration. Targeting the VEGF-KDR signaling pathway has been a promising approach for the treatment of these diseases. Several drugs have been developed to inhibit KDR, including monoclonal antibodies and small molecule inhibitors. Bevacizumab, a monoclonal antibody that targets VEGF, has been approved for the treatment of various cancers, including colorectal, lung, and breast cancer. Aflibercept, another VEGF inhibitor, has been approved for the treatment of wet age-related macular degeneration. Small molecule inhibitors of KDR, such as sorafenib and sunitinib, have also been approved for the treatment of various cancers. These drugs have shown promising results in clinical trials and have improved the survival rates of patients with these diseases.",GO:1904881 cellular response to hydrogen sulfide;GO:0048597 post-embryonic camera-type eye morphogenesis;GO:1904880 response to hydrogen sulfide,yes,Kinases:Tyr protein kinases; RAS pathway related proteins; FDA approved drug targets:Biotech drugs; ENZYME proteins:Transferases; Human disease related genes:Cardiovascular diseases:Vascular diseases; FDA approved drug targets:Small molecule drugs; Disease related genes; CD markers; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Vesicles (Approved); Additional: Connecting piece;Cytosol;Mid piece;Nuclear membrane;Principal piece,"Sorafenib; Sunitinib; 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea; Cediranib; Vatalanib; XL999; TG-100801; XL820; CYC116; Ramucirumab; Pegdinetanib; RAF-265; ABT-869; IMC-1C11; Semaxanib; Pazopanib; Midostaurin; Axitinib; 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide; N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide; N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide; 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide; N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE; N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE; 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one; 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one; N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide; N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine; N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine; Cabozantinib; Regorafenib; Ponatinib; Lenvatinib; Nintedanib; Fostamatinib; Erdafitinib; Foretinib; Ripretinib",(M137)PID VEGF VEGFR PATHWAY; (M103)PID S1P S1P1 PATHWAY; (M44)PID HIF2PATHWAY,
ENSG00000115414.21,ENSG00000115414,FN1,-1.878370272,-3.445601227,-1.034317022,-1.155192568,fibronectin 1,"The FN1 gene encodes for fibronectin, a glycoprotein that exists in a soluble dimeric form in plasma and a dimeric or multimeric form on the cell surface and extracellular matrix. The preproprotein is processed to generate the mature protein, which is involved in various cellular processes such as cell adhesion, migration, wound healing, blood coagulation, host defense, and metastasis. The gene has three regions that undergo alternative splicing, potentially producing 20 different transcript variants, including an isoform that undergoes proteolytic processing. However, the full-length nature of some variants remains unknown.","The FN1 gene has been implicated in various diseases, including cancer, fibrosis, and cardiovascular diseases. In cancer, fibronectin plays a crucial role in tumor growth, invasion, and metastasis by promoting cell adhesion, migration, and angiogenesis. Therefore, targeting fibronectin or its receptors has been explored as a potential therapeutic strategy for cancer. Several drugs targeting fibronectin or its receptors, such as integrins, are currently in clinical trials for various cancers. For example, Cilengitide, a cyclic peptide that targets integrins, is being tested in clinical trials for glioblastoma and other solid tumors. Another drug, Volociximab, a monoclonal antibody that targets ?5?1 integrin, has shown promising results in clinical trials for ovarian cancer and melanoma. In fibrosis and cardiovascular diseases, fibronectin deposition in the extracellular matrix contributes to tissue remodeling and fibrosis. Therefore, targeting fibronectin or its receptors has also been explored as a potential therapeutic strategy for these diseases. However, no drugs targeting fibronectin or its receptors have been approved for clinical use yet.","GO:0150102 negative regulation of monocyte activation;GO:1904235 regulation of substrate-dependent cell migration, cell attachment to substrate;GO:1904237 positive regulation of substrate-dependent cell migration, cell attachment to substrate",,Predicted intracellular proteins; FDA approved drug targets:Biotech drugs; Predicted secreted proteins; Human disease related genes:Urinary system diseases:Kidney diseases; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Candidate cardiovascular disease genes; Disease related genes; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Candidate cancer biomarkers,,"Zinc; Lanoteplase; Ocriplasmin; Zinc acetate; Zinc chloride; Zinc sulfate, unspecified form",(M212)PID INTEGRIN5 PATHWAY; (M118)PID INTEGRIN A9B1 PATHWAY; (M274)PID LYMPH ANGIOGENESIS PATHWAY,(M5946)HALLMARK COAGULATION; (M5921)HALLMARK COMPLEMENT; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000204291.11,ENSG00000204291,COL15A1,-1.865221635,-2.528239326,-1.519958178,-1.5474674,collagen type XV alpha 1 chain,"COL15A1 is a gene that encodes the alpha chain of type XV collagen, which belongs to the FACIT collagen family. This collagen has a broad distribution in tissues, but its strongest expression is found in basement membrane zones, where it may play a role in attaching basement membranes to underlying connective tissue stroma. The C-terminal fragment of type XV collagen is restin, a protein that may have antiangiogenic properties and is closely related to endostatin. Studies in mice have shown that deficiency in collagen XV is associated with deterioration of muscle and microvessels.","There is limited information available on the disease implications of COL15A1 mutations. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast and lung cancer. Targeted drug discovery efforts for COL15A1 are also limited, as the function of this gene is not well understood. However, some studies have suggested that restin, the C-terminal fragment of type XV collagen, may have antiangiogenic properties and could potentially be used as a therapeutic target for cancer treatment. Currently, there are no drugs on the market that specifically target COL15A1 or its products. However, there are several antiangiogenic drugs on the market, such as bevacizumab and sorafenib, that target other proteins involved in angiogenesis and may have similar effects to restin.",GO:0030198 extracellular matrix organization;GO:0043062 extracellular structure organization;GO:0045229 external encapsulating structure organization,,Predicted secreted proteins; Predicted intracellular proteins,Endoplasmic reticulum (Enhanced),,(M5887)NABA BASEMENT MEMBRANES; (M3005)NABA COLLAGENS; (M198)PID SYNDECAN 1 PATHWAY,(M5905)HALLMARK ADIPOGENESIS; (M5909)HALLMARK MYOGENESIS
ENSG00000181104.7,ENSG00000181104,F2R,-1.850087124,-2.043565141,-1.627046855,-1.879649376,coagulation factor II thrombin receptor,"The F2R gene encodes for the coagulation factor II thrombin receptor, which is a 7-transmembrane receptor that plays a role in regulating the body's response to blood clotting. When the receptor is cleaved, it becomes activated and triggers a response. F2R is a member of the G-protein coupled receptor family and can have multiple transcript variants due to alternative splicing.","The F2R gene has been implicated in various diseases, including cardiovascular diseases, cancer, and inflammatory disorders. In cardiovascular diseases, the activation of the thrombin receptor can lead to platelet aggregation and thrombus formation, which can cause heart attacks and strokes. In cancer, the thrombin receptor has been shown to promote tumor growth and metastasis. Inflammatory disorders such as rheumatoid arthritis and inflammatory bowel disease have also been linked to the activation of the thrombin receptor.

Targeted drug discovery efforts have focused on developing drugs that can block the activation of the thrombin receptor. One example is vorapaxar, a selective thrombin receptor antagonist that has been approved for the prevention of cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease. Another example is E5555, a small molecule inhibitor of the thrombin receptor that has shown promise in preclinical studies for the treatment of inflammatory bowel disease.

Overall, the F2R gene and its protein product, the thrombin receptor, have important roles in various diseases and have been targeted for drug discovery efforts. Successful drugs on the market, such as vorapaxar, demonstrate the potential for targeting this gene in the treatment of cardiovascular diseases.",GO:1900134 negative regulation of renin secretion into blood stream;GO:0007529 establishment of synaptic specificity at neuromuscular junction;GO:0036145 dendritic cell homeostasis,,FDA approved drug targets:Small molecule drugs; G-protein coupled receptors:GPCRs excl olfactory receptors; Transporters; Predicted intracellular proteins,,Streptokinase; SR-123781A; Vorapaxar; Thrombin,(M238)PID THROMBIN PAR1 PATHWAY,(M5902)HALLMARK APOPTOSIS; (M5939)HALLMARK P53 PATHWAY; (M5950)HALLMARK ALLOGRAFT REJECTION
ENSG00000116962.15,ENSG00000116962,NID1,-1.849836643,-3.059942762,-0.975718605,-1.513848563,nidogen 1,"NID1, also known as nidogen 1, is a gene that encodes a glycoprotein found in the basement membrane. It belongs to the nidogen family of proteins and interacts with other components of the extracellular matrix. NID1 is involved in cell interactions with the extracellular matrix and may play a role in various biological processes such as cell adhesion, migration, and differentiation. Mutations in this gene have been associated with various diseases, including cancer and muscular dystrophy. Understanding the function of NID1 may provide insights into the development of new therapies for these diseases.","NID1 has been implicated in various diseases, including cancer and muscular dystrophy. In cancer, NID1 has been shown to promote tumor growth and metastasis by enhancing cell adhesion and migration. Targeting NID1 may therefore be a potential strategy for cancer therapy. In muscular dystrophy, mutations in NID1 have been associated with the development of the disease. Targeting NID1 may also be a potential strategy for the treatment of muscular dystrophy. However, there are currently no drugs on the market that specifically target NID1. Drug discovery efforts are ongoing to identify compounds that can modulate the activity of NID1 and potentially be developed into therapies for these diseases.",GO:0032836 glomerular basement membrane development;GO:0110011 regulation of basement membrane organization;GO:2001046 positive regulation of integrin-mediated signaling pathway,,Predicted secreted proteins,Vesicles (Uncertain); Additional: Mitotic spindle,Urokinase,(M5887)NABA BASEMENT MEMBRANES; (M18)PID INTEGRIN1 PATHWAY; (M3008)NABA ECM GLYCOPROTEINS,
ENSG00000133561.15,ENSG00000133561,GIMAP6,-1.816398909,-2.054261717,-1.493543097,-1.901391913,"GTPase, IMAP family member 6",GIMAP6 is a gene that belongs to the GTPases of immunity-associated proteins (GIMAP) family. It contains GTP-binding and coiled-coil motifs and is involved in regulating cell survival. Reduced expression of GIMAP6 may be associated with non-small cell lung cancer. The gene has multiple isoforms due to alternative splicing and is located on the long arm of chromosome 7 along with seven other GIMAP genes.,"There is limited information available on the disease implications of GIMAP6. However, reduced expression of GIMAP6 has been associated with non-small cell lung cancer, suggesting a potential role in cancer development and progression. 

As of now, there are no targeted drug discovery efforts specifically focused on GIMAP6. However, given its potential involvement in cancer, it may be a target for future drug development efforts. 

There are currently no drugs on the market that specifically target GIMAP6. However, there are several drugs that target other members of the GIMAP family, such as GIMAP4 and GIMAP5. For example, the drug lenalidomide has been shown to target GIMAP5 and is used to treat multiple myeloma and myelodysplastic syndromes. Additionally, the drug GSK2831781A targets GIMAP4 and has shown promise in preclinical studies for the treatment of autoimmune diseases.",,,Predicted intracellular proteins,,,,
ENSG00000179144.5,ENSG00000179144,GIMAP7,-1.810703436,-2.122747727,-1.447733946,-1.861628634,"GTPase, IMAP family member 7","GIMAP7 is a human gene that belongs to the GTP-binding superfamily and the immuno-associated nucleotide (IAN) subfamily of nucleotide-binding proteins. It is located in a cluster at 7q36.1 along with other IAN subfamily genes. The function of GIMAP7 is not fully understood, but it is believed to play a role in immune system regulation. Mutations in this gene have been associated with autoimmune diseases such as type 1 diabetes and multiple sclerosis.","Research on GIMAP7 and its association with autoimmune diseases such as type 1 diabetes and multiple sclerosis is ongoing. Studies have shown that GIMAP7 is involved in the regulation of T-cell development and activation, which are key processes in the immune response. Mutations in this gene have been linked to dysregulation of T-cell function, leading to autoimmune disorders.

Targeted drug discovery efforts for GIMAP7 are still in the early stages, but there is potential for the development of drugs that modulate its activity to treat autoimmune diseases. One approach is to target the protein-protein interactions involving GIMAP7, which could lead to the development of small molecule inhibitors or biologics that block its function.

Currently, there are no drugs on the market that specifically target GIMAP7. However, there are several drugs used to treat autoimmune diseases that target T-cell function, which may indirectly affect GIMAP7 activity. For example, drugs such as methotrexate and cyclosporine are commonly used to treat autoimmune diseases by suppressing T-cell activation and proliferation. Additionally, newer biologic drugs such as anti-TNF agents and anti-CD20 antibodies have shown efficacy in treating autoimmune diseases by targeting specific immune cells.",GO:0046039 GTP metabolic process;GO:0009205 purine ribonucleoside triphosphate metabolic process;GO:0009144 purine nucleoside triphosphate metabolic process,,Predicted intracellular proteins,Golgi apparatus;Vesicles (Supported),,,
ENSG00000065534.19,ENSG00000065534,MYLK,-1.810616331,-1.565240658,-1.650838823,-2.215769513,myosin light chain kinase,"The MYLK gene encodes myosin light chain kinase, an enzyme that is dependent on calcium/calmodulin. This enzyme phosphorylates myosin regulatory light chains, which facilitates the interaction between myosin and actin filaments, resulting in contractile activity. The gene produces both smooth muscle and non-muscle isoforms, and also encodes telokin, a small protein that stabilizes unphosphorylated myosin filaments. The gene has four transcript variants that produce four isoforms of the calcium/calmodulin dependent enzyme, as well as two transcripts that produce two isoforms of telokin. A pseudogene is located on the p arm of chromosome 3, and additional variants have been identified but lack full-length transcripts.","The MYLK gene has been implicated in several diseases, including hypertension, asthma, and cancer. In hypertension, MYLK has been shown to play a role in the regulation of vascular smooth muscle contraction, and inhibitors of MYLK have been investigated as potential antihypertensive drugs. In asthma, MYLK has been linked to airway hyperresponsiveness, and inhibitors of MYLK have been explored as potential treatments for asthma. In cancer, MYLK has been found to be overexpressed in several types of tumors, and inhibitors of MYLK have been investigated as potential anticancer agents. One example of a successful drug targeting MYLK is the antihypertensive drug, fasudil, which inhibits MYLK and has been approved for use in Japan and China. Another example is the investigational drug, imatinib, which inhibits MYLK and has shown promise in preclinical studies for the treatment of asthma and cancer.",GO:0060414 aorta smooth muscle tissue morphogenesis;GO:0014820 tonic smooth muscle contraction;GO:0032060 bleb assembly,yes,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the digestive system; ENZYME proteins:Transferases; Human disease related genes:Cardiovascular diseases:Vascular diseases; Potential drug targets; Kinases:CAMK Ser/Thr protein kinases; Disease related genes; Enzymes,Actin filaments (Enhanced); Additional: Plasma membrane,Fostamatinib,(M16801)SIG REGULATION OF THE ACTIN CYTOSKELETON BY RHO GTPASES; (M14)PID AURORA B PATHWAY; (M5193)SIG CHEMOTAXIS,(M5905)HALLMARK ADIPOGENESIS; (M5909)HALLMARK MYOGENESIS; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000113721.14,ENSG00000113721,PDGFRB,-1.748916755,-2.102096239,-1.284774106,-1.859879921,platelet derived growth factor receptor beta,"PDGFRB is a gene that encodes a cell surface tyrosine kinase receptor for platelet-derived growth factors, which are mitogens for mesenchymal cells. The receptor can form homodimers or heterodimers depending on the growth factor bound to it. PDGFRB is important for normal cardiovascular development and actin cytoskeleton rearrangement. It is located on chromosome 5 near the genes for granulocyte-macrophage colony-stimulating factor and macrophage-colony stimulating factor receptor, which may be involved in the 5-q syndrome. A translocation between chromosomes 5 and 12 that fuses PDGFRB with the ETV6 gene can result in chronic myeloproliferative disorder with eosinophilia.","PDGFRB has been implicated in several diseases, including cancer and fibrosis. In cancer, PDGFRB is often overexpressed or mutated, leading to increased cell proliferation, survival, and migration. Targeted drug discovery efforts have focused on developing small molecule inhibitors of PDGFRB, such as imatinib, dasatinib, and nilotinib. These drugs have been successful in treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) that harbor PDGFRB mutations. In addition, several clinical trials are ongoing to evaluate the efficacy of PDGFRB inhibitors in other cancers, such as glioblastoma and ovarian cancer. In fibrosis, PDGFRB is involved in the activation of fibroblasts and the production of extracellular matrix, leading to tissue scarring. Several PDGFRB inhibitors, such as nintedanib and pirfenidone, have been approved for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease (SSc-ILD).",GO:0060981 cell migration involved in coronary angiogenesis;GO:0072262 metanephric glomerular mesangial cell proliferation involved in metanephros development;GO:0071670 smooth muscle cell chemotaxis,yes,"Kinases:Tyr protein kinases; Human disease related genes:Skin diseases:Skin and soft tissue diseases; RAS pathway related proteins; Predicted intracellular proteins; FDA approved drug targets:Biotech drugs; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; ENZYME proteins:Transferases; Human disease related genes:Cancers:Cancers of eye, brain, and central nervous system; Transporters:Accessory Factors Involved in Transport; FDA approved drug targets:Small molecule drugs; Disease related genes; CD markers; Enzymes; Cancer-related genes:Candidate cancer biomarkers",Vesicles (Supported); Additional: Golgi apparatus,Becaplermin; Sorafenib; Imatinib; Dasatinib; Sunitinib; XL999; XL820; Pazopanib; Midostaurin; Regorafenib; Nintedanib; Polaprezinc; Trapidil; Foreskin fibroblast (neonatal); Fostamatinib; Erdafitinib; Pexidartinib; Ripretinib,(M103)PID S1P S1P1 PATHWAY; (M55)PID S1P S1P3 PATHWAY; (M72)PID NECTIN PATHWAY,(M5942)HALLMARK UV RESPONSE DN; (M5902)HALLMARK APOPTOSIS; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000175899.15,ENSG00000175899,A2M,-1.734477236,-1.724053798,-1.780355114,-1.699022796,alpha-2-macroglobulin,"A2M, or alpha-2-macroglobulin, is a gene that encodes a protein that acts as a protease inhibitor and cytokine transporter. It uses a mechanism to inhibit a wide range of proteases and can also inhibit inflammatory cytokines, disrupting inflammatory cascades. Mutations in this gene can cause alpha-2-macroglobulin deficiency. A2M is also implicated in Alzheimer's disease due to its ability to clear and degrade A-beta, a major component of beta-amyloid deposits. A related pseudogene has also been identified.","Alpha-2-macroglobulin (A2M) has been implicated in several diseases, including Alzheimer's disease, osteoarthritis, and cancer. In Alzheimer's disease, A2M has been shown to clear and degrade A-beta, a major component of beta-amyloid deposits, and is being investigated as a potential therapeutic target. In osteoarthritis, A2M has been shown to inhibit cartilage degradation and is being studied as a potential treatment option. In cancer, A2M has been shown to promote tumor growth and metastasis, and efforts are underway to develop drugs that target A2M to inhibit its activity.

Several drugs targeting A2M are currently on the market or in development. One example is Arthrexin, a nonsteroidal anti-inflammatory drug that inhibits A2M and is used to treat osteoarthritis. Another example is the experimental drug A2M-001, which is being developed as a potential treatment for Alzheimer's disease. A2M-001 is a modified form of A2M that has increased activity against A-beta and has shown promising results in preclinical studies. Overall, targeting A2M is a promising avenue for drug discovery and has the potential to lead to new treatments for a range of diseases.","GO:0001868 regulation of complement activation, lectin pathway;GO:0001869 negative regulation of complement activation, lectin pathway;GO:0010037 response to carbon dioxide",,Predicted secreted proteins; Candidate cardiovascular disease genes; Cancer-related genes:Candidate cancer biomarkers,,"Becaplermin; Cisplatin; Bacitracin; Zinc; Ocriplasmin; Silver; Zinc acetate; Zinc chloride; Zinc sulfate, unspecified form",(M183)PID IL6 7 PATHWAY; (M3468)NABA ECM REGULATORS; (M5885)NABA MATRISOME ASSOCIATED,(M5897)HALLMARK IL6 JAK STAT3 SIGNALING; (M5946)HALLMARK COAGULATION
ENSG00000152518.8,ENSG00000152518,ZFP36L2,-1.719055601,-2.236485104,-2.382502662,-0.538179036,ZFP36 ring finger protein like 2,ZFP36L2 is a gene that belongs to the TIS11 family of early response genes. It is induced by various agonists such as TPA and EGF. The gene encodes a protein that contains a putative zinc finger domain with a repeating cys-his motif. This protein is believed to function as a nuclear transcription factor that regulates the response to growth factors.,"ZFP36L2 has been implicated in various diseases, including cancer, inflammation, and neurological disorders. In cancer, ZFP36L2 has been shown to play a role in tumor growth and metastasis by regulating the expression of genes involved in cell proliferation, migration, and invasion. Inflammation is also regulated by ZFP36L2, as it has been shown to control the stability of mRNAs encoding pro-inflammatory cytokines. In neurological disorders, ZFP36L2 has been linked to the regulation of synaptic plasticity and memory formation.

Targeted drug discovery efforts for ZFP36L2 are still in the early stages, but there is potential for the development of drugs that modulate its activity. One approach is to target the zinc finger domain of ZFP36L2, which is essential for its function as a transcription factor. Another approach is to target the upstream signaling pathways that regulate ZFP36L2 expression, such as the MAPK/ERK pathway.

There are currently no drugs on the market that specifically target ZFP36L2, but there are drugs that indirectly affect its activity. For example, nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen have been shown to inhibit ZFP36L2 expression and stabilize mRNAs encoding pro-inflammatory cytokines. Additionally, some cancer drugs such as sorafenib and sunitinib have been shown to downregulate ZFP36L2 expression and inhibit tumor growth.",GO:0048103 somatic stem cell division;GO:0097011 cellular response to granulocyte macrophage colony-stimulating factor stimulus;GO:0097012 response to granulocyte macrophage colony-stimulating factor,,Disease related genes; Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,,,,
ENSG00000132155.13,ENSG00000132155,RAF1,-1.716143906,-2.277056732,-2.026020147,-0.84535484,"Raf-1 proto-oncogene, serine/threonine kinase","The RAF1 gene is a cellular homolog of the viral raf gene and encodes a MAP kinase kinase kinase (MAP3K) that functions downstream of the Ras family of membrane-associated GTPases. The protein binds directly to the Ras family and activates the dual specificity protein kinases MEK1 and MEK2, which in turn activate the serine/threonine specific protein kinases, ERK1 and ERK2. The activated ERKs play a crucial role in controlling gene expression involved in cell physiology, including cell division cycle, apoptosis, cell differentiation, and cell migration. Mutations in the RAF1 gene are associated with Noonan syndrome 5 and LEOPARD syndrome 2.","Mutations in the RAF1 gene have been linked to several genetic disorders, including Noonan syndrome 5 and LEOPARD syndrome 2. Noonan syndrome is a genetic disorder that affects various parts of the body, causing developmental abnormalities and an increased risk of certain cancers. LEOPARD syndrome is a rare genetic disorder that affects multiple systems in the body, including the skin, heart, and eyes. 

Targeted drug discovery efforts have focused on developing inhibitors of the RAF1 protein as a potential treatment for cancer. Several RAF inhibitors have been developed and tested in clinical trials, including sorafenib, vemurafenib, and dabrafenib. These drugs have shown promising results in the treatment of various types of cancer, including melanoma and thyroid cancer. However, the development of resistance to these drugs remains a challenge, and further research is needed to improve their efficacy.

In addition to cancer, RAF inhibitors have also been investigated as a potential treatment for other diseases, including neurofibromatosis type 1 (NF1) and Noonan syndrome. NF1 is a genetic disorder that causes tumors to grow on nerves throughout the body, and RAF inhibitors have shown promise in preclinical studies as a potential treatment for this condition. However, further research is needed to determine their safety and efficacy in humans.

Overall, the RAF1 gene and its protein product have important implications for human health and disease, and ongoing research efforts are focused on developing targeted therapies to treat a range of conditions associated with RAF1 mutations.",GO:0071550 death-inducing signaling complex assembly;GO:0038129 ERBB3 signaling pathway;GO:0038133 ERBB2-ERBB3 signaling pathway,yes,RAS pathway related proteins; Predicted intracellular proteins; Human disease related genes:Cardiovascular diseases:Cardiac diseases; Kinases:TKL Ser/Thr protein kinases; ENZYME proteins:Transferases; FDA approved drug targets:Small molecule drugs; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Cytosol;Plasma membrane (Supported),Sorafenib; LErafAON; XL281; iCo-007; Cholecystokinin; Regorafenib; Dabrafenib; Fostamatinib,(M134)PID TCR RAS PATHWAY; (M199)PID P38 MK2 PATHWAY; (M1718)SIG IL4RECEPTOR IN B LYPHOCYTES,(M5923)HALLMARK PI3K AKT MTOR SIGNALING; (M5921)HALLMARK COMPLEMENT; (M5932)HALLMARK INFLAMMATORY RESPONSE
ENSG00000078596.11,ENSG00000078596,ITM2A,-1.709032768,-2.052271061,-1.322420223,-1.75240702,integral membrane protein 2A,"ITM2A is a gene that encodes a type II membrane protein belonging to the ITM2 family. It is involved in osteo- and chondrogenic differentiation, as suggested by studies in mice. The gene has multiple alternatively spliced transcript variants that encode different isoforms.","There is limited information available on the disease implications of ITM2A. However, some studies have suggested that ITM2A may play a role in Alzheimer's disease (AD) pathogenesis. Specifically, ITM2A has been found to be upregulated in the brains of AD patients, and it may contribute to the formation of amyloid plaques, a hallmark of AD. 

There are currently no targeted drug discovery efforts specifically focused on ITM2A. However, there are several drugs on the market that target amyloid plaques, which may indirectly affect ITM2A. For example, the drug aducanumab was recently approved by the FDA for the treatment of AD. Aducanumab targets amyloid plaques and has been shown to reduce their accumulation in the brain. Other drugs that target amyloid plaques include solanezumab and gantenerumab. 

Overall, while the role of ITM2A in disease is not well understood, there is potential for drugs targeting amyloid plaques to indirectly affect ITM2A and potentially provide therapeutic benefit for diseases such as AD.",GO:0002317 plasma cell differentiation;GO:0042985 negative regulation of amyloid precursor protein biosynthetic process;GO:0010561 negative regulation of glycoprotein biosynthetic process,,Transporters:Transporter channels and pores; Predicted intracellular proteins,Vesicles (Approved); Additional: Golgi apparatus;Plasma membrane,,,
ENSG00000100234.12,ENSG00000100234,TIMP3,-1.70341126,-2.50624535,-1.136120491,-1.46786794,TIMP metallopeptidase inhibitor 3,"TIMP3 is a gene that belongs to the TIMP gene family and encodes for a protein that inhibits the activity of matrix metalloproteinases, which are enzymes involved in breaking down the extracellular matrix. The expression of this gene is stimulated by mitogenic factors and the protein it encodes contains a netrin domain and is localized to the extracellular matrix. Mutations in this gene have been linked to Sorsby's fundus dystrophy, an autosomal dominant disorder that affects the retina and can lead to vision loss.","Sorsby's fundus dystrophy (SFD) is a rare autosomal dominant disorder that affects the retina and can lead to vision loss. Mutations in the TIMP3 gene have been linked to the development of SFD. As a result, there has been significant interest in developing drugs that target TIMP3 to treat this disorder. One approach has been to develop small molecule inhibitors of TIMP3 that can prevent its interaction with matrix metalloproteinases and thereby reduce the breakdown of the extracellular matrix. Several compounds have been identified that show promise in preclinical studies, but none have yet been approved for clinical use. However, there are several drugs on the market that target other members of the TIMP gene family, including marimastat and batimastat, which are used to treat cancer by inhibiting the activity of matrix metalloproteinases.",GO:1904684 negative regulation of metalloendopeptidase activity;GO:0051045 negative regulation of membrane protein ectodomain proteolysis;GO:1905049 negative regulation of metallopeptidase activity,,Disease related genes; Predicted secreted proteins; Human disease related genes:Nervous system diseases:Eye disease; Cancer-related genes:Candidate cancer biomarkers,Vesicles (Approved); Additional: Golgi apparatus,Pimagedine,(M3468)NABA ECM REGULATORS; (M5885)NABA MATRISOME ASSOCIATED; (M5889)NABA MATRISOME,(M5946)HALLMARK COAGULATION; (M5902)HALLMARK APOPTOSIS; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000246575.2,ENSG00000246575,AC093162.1,-1.700438484,-2.358119564,-1.007504739,-1.735691149,None,None,None,None,None,None,None,None,None,None
ENSG00000137033.11,ENSG00000137033,IL33,-1.697679208,-2.31148997,-1.187252945,-1.594294709,interleukin 33,"IL33, also known as interleukin 33, is a cytokine that binds to the IL1RL1/ST2 receptor. It plays a role in the maturation of Th2 cells and the activation of mast cells, basophils, eosinophils, and natural killer cells. The gene has several transcript variants that encode different isoforms.","IL33 has been implicated in various diseases, including asthma, allergic rhinitis, atopic dermatitis, and autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus. In asthma, IL33 is thought to contribute to airway inflammation and hyperresponsiveness. Targeting IL33 has been explored as a potential therapeutic strategy for these diseases. Several drugs targeting IL33 or its receptor, such as monoclonal antibodies and small molecule inhibitors, are currently in development or clinical trials. For example, an anti-IL33 monoclonal antibody called quilizumab has shown promising results in clinical trials for asthma and atopic dermatitis. Another monoclonal antibody, tezepelumab, which targets both IL33 and other cytokines, has been approved for the treatment of severe asthma. These drugs have the potential to provide new treatment options for patients with IL33-related diseases.",GO:0010185 regulation of cellular defense response;GO:0010186 positive regulation of cellular defense response;GO:0120042 negative regulation of macrophage proliferation,,Predicted secreted proteins; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Vesicles,,,(M5953)HALLMARK KRAS SIGNALING UP
ENSG00000107796.13,ENSG00000107796,ACTA2,-1.690536904,-1.652907045,-1.546513424,-1.872190245,"actin alpha 2, smooth muscle","ACTA2 is a gene that encodes for a smooth muscle actin protein involved in cell motility, structure, integrity, and intercellular signaling. It plays a crucial role in vascular contractility and blood pressure regulation. Mutations in this gene have been linked to various vascular diseases, including thoracic aortic disease, coronary artery disease, stroke, and Moyamoya disease, as well as multisystemic smooth muscle dysfunction syndrome.","Mutations in the ACTA2 gene have been associated with various vascular diseases, including thoracic aortic disease, coronary artery disease, stroke, and Moyamoya disease, as well as multisystemic smooth muscle dysfunction syndrome. Targeted drug discovery efforts have focused on developing drugs that can modulate the activity of smooth muscle cells and improve vascular function. One example is losartan, an angiotensin receptor blocker that has been shown to reduce aortic dilation in patients with Marfan syndrome, a genetic disorder that affects connective tissue and can lead to aortic aneurysm. Another example is imatinib, a tyrosine kinase inhibitor that has been used to treat pulmonary arterial hypertension by inhibiting the proliferation of smooth muscle cells in the pulmonary artery. However, more research is needed to fully understand the role of ACTA2 in vascular disease and to develop effective targeted therapies.",GO:0061873 regulation of hepatic stellate cell contraction;GO:0061874 positive regulation of hepatic stellate cell contraction;GO:0061869 regulation of hepatic stellate cell migration,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Cardiovascular diseases:Vascular diseases,Actin filaments (Approved),Phenethyl Isothiocyanate,(M186)PID PDGFRB PATHWAY,(M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000243302.3,ENSG00000243302,AC018638.4,-1.689695672,-2.184282264,-1.644996636,-1.239808115,None,None,None,None,None,None,None,None,None,None
ENSG00000069122.19,ENSG00000069122,ADGRF5,-1.668610593,-1.492317576,-1.399991709,-2.113522494,adhesion G protein-coupled receptor F5,"ADGRF5 is a human gene that encodes for adhesion G protein-coupled receptor F5. This gene is predicted to enable G protein-coupled receptor activity and is involved in G protein-coupled receptor signaling pathway and cell surface receptor signaling pathway. ADGRF5 is also predicted to act upstream of or within several processes, including glomerular filtration, pharyngeal arch artery morphogenesis, and surfactant homeostasis. It is located in both the cell surface and cytoplasmic vesicles.","ADGRF5 has been implicated in several diseases, including nephrotic syndrome, focal segmental glomerulosclerosis, and pulmonary fibrosis. Mutations in this gene have been associated with familial focal segmental glomerulosclerosis, a rare genetic disorder that affects the kidneys and can lead to kidney failure. Targeted drug discovery efforts for ADGRF5 are currently underway, with a focus on developing drugs that can modulate its activity and potentially treat diseases associated with its dysfunction. One example of a successful drug targeting a G protein-coupled receptor is olanzapine, which is used to treat schizophrenia and bipolar disorder by blocking dopamine and serotonin receptors. However, there are currently no drugs on the market that specifically target ADGRF5.",GO:0061626 pharyngeal arch artery morphogenesis;GO:0071073 positive regulation of phospholipid biosynthetic process;GO:1903727 positive regulation of phospholipid metabolic process,,G-protein coupled receptors:Family 2 (B) receptors; G-protein coupled receptors:GPCRs excl olfactory receptors,,,,
ENSG00000152583.12,ENSG00000152583,SPARCL1,-1.655884077,-1.685039669,-1.551054397,-1.731558164,SPARC like 1,"SPARCL1, also known as SPARC-like 1, is a human gene that is predicted to have calcium ion binding activity, collagen binding activity, and extracellular matrix binding activity. It is also predicted to be involved in anatomical structure development and regulation of synapse organization. The gene is located in the extracellular space.","SPARCL1 has been implicated in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, SPARCL1 has been shown to have both tumor-suppressive and tumor-promoting effects, depending on the type of cancer and the stage of the disease. In cardiovascular disease, SPARCL1 has been linked to atherosclerosis and arterial stiffness. In neurological disorders, SPARCL1 has been associated with Alzheimer's disease and schizophrenia.

Targeted drug discovery efforts for SPARCL1 are still in the early stages, but there is potential for the development of drugs that modulate its activity in various diseases. For example, in cancer, drugs that activate SPARCL1 expression or enhance its tumor-suppressive effects could be developed as potential therapies. In cardiovascular disease, drugs that target SPARCL1 could be used to prevent or treat atherosclerosis and arterial stiffness. In neurological disorders, drugs that modulate SPARCL1 expression or activity could be developed to improve cognitive function or treat symptoms of schizophrenia.

There are currently no drugs on the market that specifically target SPARCL1, but there are drugs that indirectly affect its activity. For example, statins, which are commonly used to lower cholesterol levels, have been shown to increase SPARCL1 expression and reduce atherosclerosis. Additionally, some anti-cancer drugs, such as paclitaxel and cisplatin, have been shown to upregulate SPARCL1 expression and enhance its tumor-suppressive effects.",GO:0099560 synaptic membrane adhesion;GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules;GO:0050807 regulation of synapse organization,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins; Predicted secreted proteins; Cancer-related genes:Candidate cancer biomarkers,,,(M3008)NABA ECM GLYCOPROTEINS; (M5884)NABA CORE MATRISOME; (M5889)NABA MATRISOME,(M5905)HALLMARK ADIPOGENESIS; (M5953)HALLMARK KRAS SIGNALING UP
ENSG00000164125.16,ENSG00000164125,GASK1B,-1.652588132,-1.882891111,-1.312187328,-1.762685958,golgi associated kinase 1B,"GASK1B is a human gene that is located in the Golgi apparatus, which is responsible for modifying, sorting, and packaging proteins for transport to their final destinations. The function of GASK1B is not well understood, but it is believed to play a role in regulating protein trafficking and secretion. The gene is expressed in a variety of tissues, including the brain, liver, and pancreas. Mutations in GASK1B have been associated with certain types of cancer, including breast and lung cancer. Further research is needed to fully understand the function of GASK1B and its potential role in disease.","There is limited information available on the disease implications of GASK1B, but mutations in this gene have been associated with certain types of cancer, including breast and lung cancer. Targeted drug discovery efforts for GASK1B are also limited, as the function of the gene is not well understood. However, there are some drugs on the market that target the Golgi apparatus, where GASK1B is located, such as brefeldin A and golgicide A. These drugs are used in research to study the Golgi apparatus and its role in protein trafficking and secretion. Further research is needed to fully understand the function of GASK1B and its potential as a target for drug discovery in cancer and other diseases.",,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol;Golgi apparatus;Nucleoli fibrillar center,,,
ENSG00000186174.12,ENSG00000186174,BCL9L,-1.643251058,-2.473824314,-1.403621507,-1.052307354,BCL9 like,"BCL9L is a human gene that is similar to the BCL9 gene and enables beta-catenin binding activity. It is involved in various processes, including negative regulation of the transforming growth factor beta receptor signaling pathway, positive regulation of epithelial to mesenchymal transition, and positive regulation of transcription by RNA polymerase II. BCL9L is located in the nucleolus and nucleoplasm and is part of the beta-catenin-TCF complex.","Research on BCL9L and its disease implications is still ongoing, but some studies have suggested that it may play a role in the development and progression of certain types of cancer, including colorectal, breast, and liver cancer. Targeted drug discovery efforts are focused on developing drugs that can inhibit the interaction between BCL9L and beta-catenin, which could potentially prevent the activation of oncogenic pathways and inhibit tumor growth.

One example of a successful drug targeting the beta-catenin pathway is the drug napabucasin, which is currently in clinical trials for the treatment of colorectal cancer. Napabucasin works by inhibiting the interaction between beta-catenin and BCL9L, which prevents the activation of oncogenic pathways and inhibits tumor growth. Another example is the drug PRI-724, which is also in clinical trials for the treatment of various types of cancer. PRI-724 works by inhibiting the interaction between beta-catenin and CBP, which prevents the activation of oncogenic pathways and promotes tumor cell death.",GO:0045445 myoblast differentiation;GO:0035019 somatic stem cell population maintenance;GO:0010718 positive regulation of epithelial to mesenchymal transition,,Cancer-related genes; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nucleoli fibrillar center,,,
ENSG00000136205.17,ENSG00000136205,TNS3,-1.634059204,-2.699395444,-1.280246452,-0.922535717,tensin 3,"TNS3, also known as tensin 3, is a human gene that is predicted to have phosphatase activity and be involved in dephosphorylation and intracellular signal transduction. It is also predicted to play a role in cell migration, lung alveolus development, and positive regulation of cell population proliferation. TNS3 is located in the cytosol and focal adhesion.","There is limited information available on the disease implications of TNS3. However, recent studies have suggested that TNS3 may play a role in cancer progression and metastasis. Targeted drug discovery efforts for TNS3 are also limited, but some studies have identified potential small molecule inhibitors of TNS3 that could be developed into drugs for cancer treatment. One example is a compound called NSC87877, which has been shown to inhibit TNS3 activity and reduce cancer cell migration and invasion in vitro. However, there are currently no drugs on the market that specifically target TNS3. Further research is needed to fully understand the role of TNS3 in disease and to develop effective targeted therapies.",GO:0035022 positive regulation of Rac protein signal transduction;GO:0035020 regulation of Rac protein signal transduction;GO:0051057 positive regulation of small GTPase mediated signal transduction,,Predicted intracellular proteins,Focal adhesion sites (Enhanced),,,
ENSG00000163399.16,ENSG00000163399,ATP1A1,-1.632528474,-1.874280682,-2.435890563,-0.587414175,ATPase Na+/K+ transporting subunit alpha 1,"ATP1A1 is a gene that encodes for the alpha 1 subunit of the Na+/K+ -ATPase enzyme, which is responsible for maintaining the electrochemical gradients of sodium and potassium ions across the plasma membrane. This enzyme is essential for osmoregulation, sodium-coupled transport of various molecules, and electrical excitability of nerve and muscle. The Na+/K+ -ATPase enzyme is composed of two subunits, a large catalytic subunit (alpha) and a smaller glycoprotein subunit (beta). Multiple transcript variants encoding different isoforms have been found for this gene.","Mutations in the ATP1A1 gene have been associated with several diseases, including familial hemiplegic migraine type 2 (FHM2), alternating hemiplegia of childhood (AHC), and rapid-onset dystonia-parkinsonism (RDP). FHM2 is a rare form of migraine that is characterized by temporary paralysis on one side of the body, while AHC is a rare neurological disorder that causes recurrent episodes of paralysis, dystonia, and other movement disorders. RDP is a rare movement disorder that is characterized by sudden onset of dystonia and parkinsonism.

Targeted drug discovery efforts for ATP1A1 have focused on developing drugs that modulate the activity of the Na+/K+ -ATPase enzyme. One example is ouabain, a cardiac glycoside that inhibits the Na+/K+ -ATPase enzyme and is used to treat heart failure. Another example is digoxin, a cardiac glycoside that also inhibits the Na+/K+ -ATPase enzyme and is used to treat atrial fibrillation and heart failure. However, these drugs have limited efficacy and can have serious side effects.

More recently, there has been interest in developing drugs that specifically target the ATP1A1 gene and its associated diseases. For example, a small molecule inhibitor of the ATP1A1 gene has been shown to improve motor function in a mouse model of AHC. Additionally, gene therapy approaches have been explored for AHC and RDP, with promising results in preclinical studies.

In summary, ATP1A1 is a gene that encodes for the alpha 1 subunit of the Na+/K+ -ATPase enzyme, and mutations in this gene have been associated with several diseases. Targeted drug discovery efforts have focused on developing drugs that modulate the activity of the Na+/K+ -ATPase enzyme, but more recently, there has been interest in developing drugs that specifically target the ATP1A1 gene and its associated diseases.",GO:0031944 negative regulation of glucocorticoid metabolic process;GO:0031947 negative regulation of glucocorticoid biosynthetic process;GO:0090032 negative regulation of steroid hormone biosynthetic process,,ENZYME proteins; Cancer-related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Transporters:Primary Active Transporters; Human disease related genes:Endocrine and metabolic diseases:Adrenal gland diseases; FDA approved drug targets:Small molecule drugs; Disease related genes; Enzymes; Human disease related genes:Congenital disorders of metabolism:Other congenital disorders of metabolism,Plasma membrane;Vesicles (Approved),Digoxin; Acetyldigitoxin; Hydroflumethiazide; Etacrynic acid; Trichlormethiazide; Deslanoside; Ouabain; Diazoxide; Bretylium; Ciclopirox; Bepridil; Potassium cation; Aluminium; Magnesium cation; Digitoxin; Almitrine; Istaroxime; Magnesium acetate; Potassium acetate; Potassium sulfate; Potassium; Magnesium levulinate; Magnesium lactate; Aluminium phosphate; Aluminum acetate,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000150093.20,ENSG00000150093,ITGB1,-1.622888831,-2.520111496,-1.982061116,-0.366493882,integrin subunit beta 1,"ITGB1 is a gene that encodes for the beta subunit of integrins, which are proteins involved in cell adhesion and recognition. Integrins are made up of alpha and beta subunits, and there are at least 18 alpha and 8 beta subunits in mammals. This gene is involved in various processes including embryogenesis, hemostasis, tissue repair, immune response, and metastatic diffusion of tumor cells. There are multiple alternatively spliced transcript variants of this gene, which encode for different protein isoforms.","ITGB1 has been implicated in various diseases, including cancer, cardiovascular disease, and autoimmune disorders. In cancer, ITGB1 has been shown to play a role in tumor cell invasion and metastasis, making it a potential target for cancer therapy. Several drugs targeting ITGB1 are currently in development, including monoclonal antibodies and small molecule inhibitors. One example is Cilengitide, a small molecule inhibitor of ITGB1 that has shown promise in preclinical studies for the treatment of glioblastoma, a type of brain cancer. However, clinical trials have not yet demonstrated significant efficacy in humans. Another example is Abituzumab, a monoclonal antibody that targets ITGB1 and is being investigated for the treatment of various solid tumors. While there are currently no FDA-approved drugs targeting ITGB1, ongoing research in this area holds promise for the development of novel therapies for cancer and other diseases.",GO:0048626 myoblast fate specification;GO:0051943 positive regulation of amino acid uptake involved in synaptic transmission;GO:0051951 positive regulation of glutamate uptake involved in transmission of nerve impulse,,Predicted intracellular proteins; Transporters; FDA approved drug targets:Biotech drugs; CD markers; Cancer-related genes:Candidate cancer biomarkers,Focal adhesion sites;Plasma membrane (Supported); Additional: Endoplasmic reticulum,Antithymocyte immunoglobulin (rabbit),(M11)PID PRL SIGNALING EVENTS PATHWAY; (M118)PID INTEGRIN A9B1 PATHWAY; (M274)PID LYMPH ANGIOGENESIS PATHWAY,(M5909)HALLMARK MYOGENESIS; (M5915)HALLMARK APICAL JUNCTION; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000228253.1,ENSG00000228253,MT-ATP8,-1.616122117,-2.77499968,-1.467009763,-0.606356908,ATP synthase F0 subunit 8,"ATP8 is a gene that contributes to the activity of proton-transporting ATP synthase, which is involved in mitochondrial ATP synthesis coupled proton transport. It is part of the mitochondrial proton-transporting ATP synthase complex and plays a role in the rotational mechanism. ATP8 has been implicated in multiple sclerosis and urinary bladder cancer.","ATP8 has been implicated in several diseases, including multiple sclerosis and urinary bladder cancer. In multiple sclerosis, ATP8 has been found to be downregulated in the brain tissue of patients, suggesting a potential role in the disease pathogenesis. In urinary bladder cancer, ATP8 has been identified as a potential biomarker for predicting patient prognosis and response to treatment.

Targeted drug discovery efforts for ATP8 are still in the early stages, but there is potential for the development of drugs that target the mitochondrial ATP synthase complex. One example is the drug oligomycin, which inhibits the activity of ATP synthase and is used as an antibiotic and antifungal agent. However, the use of oligomycin as a therapeutic agent for human diseases is limited due to its toxicity.

Another potential drug target is the ATP synthase inhibitor, Bz-423, which has shown promising results in preclinical studies for the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. Bz-423 has been shown to selectively target the mitochondrial ATP synthase complex and inhibit its activity, leading to a reduction in inflammation and tissue damage.

In summary, ATP8 is a gene that plays a crucial role in mitochondrial ATP synthesis and has been implicated in several diseases. While targeted drug discovery efforts are still in the early stages, there is potential for the development of drugs that target the mitochondrial ATP synthase complex, such as Bz-423, for the treatment of autoimmune diseases.",GO:0042776 proton motive force-driven mitochondrial ATP synthesis;GO:0015986 proton motive force-driven ATP synthesis;GO:0006754 ATP biosynthetic process,,Disease related genes; Transporters:Primary Active Transporters; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,,,,
ENSG00000198925.12,ENSG00000198925,ATG9A,-1.602260106,-2.318378236,-1.941552986,-0.546849095,autophagy related 9A,"ATG9A is a human gene that is involved in the process of autophagy, which is the body's way of breaking down and recycling cellular components. The gene is responsible for the assembly of autophagosomes, which are structures that engulf and break down cellular material. ATG9A is located in several areas within the cell, including the endosome, phagophore assembly site, and trans-Golgi network. It acts upstream of or within the autophagosome assembly process. The gene's function is important for maintaining cellular homeostasis and preventing the accumulation of damaged or unnecessary cellular components.","ATG9A has been implicated in several diseases, including cancer, neurodegenerative disorders, and infectious diseases. In cancer, ATG9A has been shown to play a role in tumor growth and survival, making it a potential target for cancer therapy. In neurodegenerative disorders, such as Alzheimer's disease, ATG9A dysfunction has been linked to impaired autophagy and the accumulation of toxic protein aggregates. Targeted drug discovery efforts have focused on identifying small molecules that can modulate ATG9A activity and enhance autophagy. Several compounds have been identified as potential ATG9A modulators, including the natural product spermidine and the synthetic compound SMER28. However, no drugs targeting ATG9A have been approved for clinical use yet.",GO:0034497 protein localization to phagophore assembly site;GO:0034727 piecemeal microautophagy of the nucleus;GO:0061709 reticulophagy,,Transporters,Vesicles (Supported),,,
ENSG00000110344.10,ENSG00000110344,UBE4A,-1.600652049,-2.025754393,-1.530772295,-1.245429458,ubiquitination factor E4A,The UBE4A gene is a member of the U-box ubiquitin ligase family and is involved in multiubiquitin chain assembly. It plays a critical role in chromosome condensation and separation through the polyubiquitination of securin. Autoantibodies against the encoded protein may be markers for scleroderma and Crohn's disease. The gene has a pseudogene located on the long arm of chromosome 3 and alternatively spliced transcript variants encoding multiple isoforms have been observed.,"Research on the UBE4A gene has revealed its potential implications in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In particular, autoantibodies against UBE4A have been identified as potential markers for scleroderma and Crohn's disease. Targeted drug discovery efforts for UBE4A are still in the early stages, but there is growing interest in developing drugs that can modulate the activity of this gene. One example of a successful drug targeting the ubiquitin-proteasome system, of which UBE4A is a part, is bortezomib, which is used to treat multiple myeloma and mantle cell lymphoma. Other drugs targeting the ubiquitin-proteasome system are currently in clinical trials for various types of cancer and neurodegenerative diseases.",GO:0036503 ERAD pathway;GO:0034976 response to endoplasmic reticulum stress;GO:0000209 protein polyubiquitination,,Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Nuclear speckles (Approved),,,
ENSG00000129422.14,ENSG00000129422,MTUS1,-1.579080319,-1.871166125,-1.790712434,-1.075362398,microtubule associated scaffold protein 1,"MTUS1 is a gene that encodes a protein with a C-terminal domain that interacts with the angiotensin II receptor and a coiled-coil region that allows for dimerization. There are multiple transcript variants of this gene, with one variant encoding a mitochondrial protein that acts as a tumor suppressor and participates in AT2 signaling pathways. It is unclear whether other variants encode nuclear or transmembrane proteins that also participate in AT2 signaling pathways.","There is limited information on the disease implications of MTUS1, but some studies suggest that it may play a role in cancer development and progression. Specifically, the mitochondrial variant of MTUS1 has been shown to act as a tumor suppressor and its downregulation has been associated with poor prognosis in various types of cancer. Targeted drug discovery efforts for MTUS1 are also limited, but some studies have explored the potential of using MTUS1 as a therapeutic target for cancer treatment. However, there are currently no drugs on the market that specifically target MTUS1. Nonetheless, some drugs that indirectly affect MTUS1 signaling pathways have been approved for cancer treatment, such as angiotensin II receptor blockers (ARBs) that interact with the C-terminal domain of MTUS1. Additionally, some studies have suggested that MTUS1 may be a potential target for immunotherapy in cancer treatment.",GO:0010758 regulation of macrophage chemotaxis;GO:1905521 regulation of macrophage migration;GO:0002688 regulation of leukocyte chemotaxis,,Disease related genes; Predicted intracellular proteins,Microtubules;Nucleoli (Enhanced),,,
ENSG00000143418.20,ENSG00000143418,CERS2,-1.565463356,-2.126512419,-2.338478102,-0.231399547,ceramide synthase 2,CERS2 is a human gene that encodes a protein with similarities to the yeast longevity assurance gene 1. Studies have shown that mutations or overexpression of the related gene in yeast can alter yeast lifespan. The human protein may play a role in regulating cell growth. There are multiple versions of the gene that encode the same protein due to alternative splicing.,"CERS2 has been implicated in several diseases, including cancer, diabetes, and neurological disorders. In cancer, CERS2 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. In diabetes, CERS2 has been linked to insulin resistance and beta-cell dysfunction, suggesting that targeting CERS2 could improve glucose homeostasis. In neurological disorders, CERS2 has been associated with neuroinflammation and neurodegeneration, indicating that modulating CERS2 activity could have therapeutic benefits.

There have been some efforts to develop drugs targeting CERS2. For example, a small molecule inhibitor of CERS2 was identified in a high-throughput screen and shown to reduce tumor growth in a mouse model of breast cancer. Additionally, a natural compound called resveratrol has been shown to inhibit CERS2 activity and improve insulin sensitivity in diabetic mice.

However, there are currently no drugs on the market that specifically target CERS2. Further research is needed to fully understand the role of CERS2 in disease and to develop effective therapies targeting this protein.",GO:1905045 negative regulation of Schwann cell proliferation involved in axon regeneration;GO:1900148 negative regulation of Schwann cell migration;GO:1905044 regulation of Schwann cell proliferation involved in axon regeneration,,Enzymes; ENZYME proteins:Transferases,Endoplasmic reticulum;Nuclear membrane (Supported),,,
ENSG00000162407.9,ENSG00000162407,PLPP3,-1.563957879,-2.096218428,-1.341098111,-1.254557098,phospholipid phosphatase 3,PLPP3 is a gene that encodes a protein belonging to the phosphatidic acid phosphatase (PAP) family. PAPs are involved in the synthesis of glycerolipids and in receptor-activated signal transduction. The protein encoded by PLPP3 is a membrane glycoprotein found on the cell plasma membrane. It actively hydrolyzes extracellular lysophosphatidic acid and short-chain phosphatidic acid. The expression of PLPP3 is enhanced by epidermal growth factor in Hela cells.,"Research on PLPP3 has revealed its potential involvement in various diseases, including cancer, inflammation, and neurological disorders. Studies have shown that PLPP3 expression is upregulated in several types of cancer, including breast, ovarian, and prostate cancer, and that it plays a role in cancer cell proliferation, migration, and invasion. Therefore, PLPP3 has been proposed as a potential therapeutic target for cancer treatment.

Several drug discovery efforts have been made to target PLPP3, including the development of small molecule inhibitors and monoclonal antibodies. One study identified a small molecule inhibitor of PLPP3 that showed promising anti-cancer activity in vitro and in vivo. Another study demonstrated the efficacy of a monoclonal antibody targeting PLPP3 in reducing tumor growth in a mouse model of breast cancer.

Currently, there are no drugs on the market specifically targeting PLPP3. However, there are several drugs that indirectly affect PLPP3 activity, such as statins, which have been shown to downregulate PLPP3 expression and inhibit cancer cell growth. Additionally, some drugs that target lysophosphatidic acid receptors, such as Edg-2 and Edg-4, may indirectly affect PLPP3 activity by reducing the availability of its substrate.",GO:1902068 regulation of sphingolipid mediated signaling pathway;GO:0033631 cell-cell adhesion mediated by integrin;GO:0060020 Bergmann glial cell differentiation,,ENZYME proteins:Hydrolases; Enzymes,Golgi apparatus (Supported); Additional: Mid piece;Principal piece,,,(M5942)HALLMARK UV RESPONSE DN; (M5890)HALLMARK TNFA SIGNALING VIA NFKB
ENSG00000113810.16,ENSG00000113810,SMC4,-1.542631369,-1.844974646,-1.534016538,-1.248902923,structural maintenance of chromosomes 4,"SMC4 is a gene that belongs to the SMC family, which plays a role in two changes in chromosome structure during mitotic segregation of chromosomes. The protein encoded by this gene is likely a subunit of the 13S condensin complex, which is involved in chromosome condensation. This gene is important for the proper segregation of chromosomes during cell division. A related pseudogene is located on chromosome 2.","There is limited information available on the disease implications of SMC4 mutations. However, studies have shown that alterations in the expression of SMC4 can lead to chromosomal instability and aneuploidy, which are hallmarks of cancer. Therefore, SMC4 may play a role in the development and progression of various types of cancer. 

Targeted drug discovery efforts for SMC4 are currently underway, with the aim of developing drugs that can inhibit the function of the protein. One approach is to target the ATPase activity of SMC4, which is essential for its function in chromosome condensation. Small molecule inhibitors that target the ATPase activity of SMC4 have shown promise in preclinical studies, and are being further developed for potential clinical use.

There are currently no drugs on the market that specifically target SMC4. However, there are several drugs that target other members of the SMC family, such as condensin and cohesin. For example, the drug etoposide targets topoisomerase II, which is a component of the condensin complex, and is used to treat various types of cancer. Another drug, called volasertib, targets the mitotic kinase Aurora A, which is involved in the regulation of cohesin and condensin, and is being developed for the treatment of acute myeloid leukemia.",GO:0010032 meiotic chromosome condensation;GO:1905821 positive regulation of chromosome condensation;GO:0060623 regulation of chromosome condensation,,Predicted intracellular proteins,Cytosol;Nuclear speckles (Supported),,(M14)PID AURORA B PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE; (M5901)HALLMARK G2M CHECKPOINT; (M5925)HALLMARK E2F TARGETS
ENSG00000179776.19,ENSG00000179776,CDH5,-1.542618719,-1.605287433,-1.402718318,-1.619850406,cadherin 5,"CDH5, also known as cadherin 5, is a gene that encodes a protein involved in cell-cell adhesion. The protein is a classical cadherin, meaning it allows cells to adhere to each other in a homophilic manner. CDH5 plays a role in the assembly and maintenance of endothelial adherens junctions. The protein is comprised of five extracellular cadherin repeats, a transmembrane region, and a conserved cytoplasmic tail. CDH5 is located in a gene cluster on chromosome 16 that is associated with loss of heterozygosity events in breast and prostate cancer.","CDH5 has been implicated in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, CDH5 has been shown to play a role in tumor angiogenesis and metastasis. Targeting CDH5 has been explored as a potential therapeutic strategy for cancer treatment. For example, a monoclonal antibody targeting CDH5, called TRC105, has been developed and is currently being evaluated in clinical trials for various types of cancer. In cardiovascular disease, CDH5 has been linked to endothelial dysfunction and atherosclerosis. In neurological disorders, CDH5 has been associated with blood-brain barrier dysfunction and neuroinflammation. However, there are currently no drugs on the market that specifically target CDH5 for the treatment of these diseases.",GO:1902396 protein localization to bicellular tight junction;GO:1901552 positive regulation of endothelial cell development;GO:1903142 positive regulation of establishment of endothelial barrier,,CD markers; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Plasma membrane (Supported); Additional: Nuclear membrane;Nucleoplasm,Lenalidomide; FX06,(M268)PID S1P S1P2 PATHWAY; (M237)PID VEGFR1 2 PATHWAY,
ENSG00000137642.13,ENSG00000137642,SORL1,-1.541764617,-2.350110674,-1.166104167,-1.109079009,sortilin related receptor 1,SORL1 is a gene that encodes a protein belonging to the vacuolar protein sorting 10 (VPS10) domain-containing receptor family and the low density lipoprotein receptor (LDLR) family. The protein also contains fibronectin type III repeats and an epidermal growth factor repeat. The mature receptor likely plays roles in endocytosis and sorting. Mutations in this gene may be associated with Alzheimer's disease.,"Mutations in the SORL1 gene have been associated with an increased risk of developing Alzheimer's disease. SORL1 is involved in the processing and trafficking of amyloid precursor protein (APP), which is a key player in the development of Alzheimer's disease. Studies have shown that decreased expression of SORL1 leads to increased levels of amyloid beta, a protein that forms the plaques found in the brains of Alzheimer's patients. 

Targeted drug discovery efforts for SORL1 are focused on developing drugs that can increase the expression of the protein, thereby reducing the levels of amyloid beta and potentially slowing the progression of Alzheimer's disease. One approach is to use small molecules that can activate the SORL1 promoter, leading to increased expression of the protein. Another approach is to use gene therapy to deliver a functional copy of the SORL1 gene to the brain.

Currently, there are no drugs on the market that specifically target SORL1. However, there are several drugs that target amyloid beta, which is downstream of SORL1 in the Alzheimer's disease pathway. These include monoclonal antibodies such as aducanumab and bapineuzumab, which have shown promise in clinical trials for reducing amyloid beta levels and improving cognitive function in Alzheimer's patients.",GO:1902955 positive regulation of early endosome to recycling endosome transport;GO:1900166 regulation of glial cell-derived neurotrophic factor production;GO:1900168 positive regulation of glial cell-derived neurotrophic factor production,,Disease related genes; Predicted secreted proteins; Potential drug targets; Transporters,,,,
ENSG00000230953.2,ENSG00000230953,AC099677.1,-1.540235977,-1.560218981,-1.931938932,-1.128550018,None,None,None,None,None,None,None,None,None,None
ENSG00000178726.7,ENSG00000178726,THBD,-1.539655006,-2.571699493,-1.127190797,-0.92007473,thrombomodulin,"THBD is a gene that encodes for a protein called thrombomodulin, which is found on the surface of endothelial cells and binds to thrombin. This binding activates protein C, which breaks down clotting factors and reduces the amount of thrombin produced. Mutations in THBD have been linked to thromboembolic disease, a condition characterized by an increased risk of blood clots.","Thrombomodulin (THBD) is a promising target for drug discovery efforts aimed at preventing thromboembolic disease. Several drugs have been developed that target thrombomodulin, including recombinant thrombomodulin (rTM) and anticoagulants such as dabigatran and rivaroxaban. rTM has been approved for use in Japan for the treatment of disseminated intravascular coagulation (DIC), a condition characterized by abnormal clotting and bleeding. Dabigatran and rivaroxaban are direct oral anticoagulants that target thrombin and have been approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Other potential drug targets for thrombomodulin include antibodies that mimic the protein's natural function and small molecules that enhance its activity. Overall, targeting thrombomodulin represents a promising approach for the prevention and treatment of thromboembolic disease.","GO:0072377 blood coagulation, common pathway;GO:0051918 negative regulation of fibrinolysis;GO:0072378 blood coagulation, fibrin clot formation",,Disease related genes; CD markers; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Candidate cardiovascular disease genes,Cytosol;Nucleoplasm (Approved),Drotrecogin alfa; Ibuprofen; Dexibuprofen,(M65)PID FRA PATHWAY,(M5944)HALLMARK ANGIOGENESIS; (M5946)HALLMARK COAGULATION
ENSG00000170989.10,ENSG00000170989,S1PR1,-1.529616712,-1.599812861,-1.346245768,-1.642791506,sphingosine-1-phosphate receptor 1,S1PR1 is a human gene that encodes a protein similar in structure to G protein-coupled receptors. The protein is highly expressed in endothelial cells and binds to the ligand sphingosine-1-phosphate with high affinity and specificity. It is believed to play a role in regulating the differentiation of endothelial cells and induces cell-cell adhesion upon activation. Alternative splicing of the gene results in multiple transcript variants.,"S1PR1 has been implicated in various diseases, including multiple sclerosis, cancer, and cardiovascular diseases. In multiple sclerosis, S1PR1 agonists have been shown to reduce the migration of immune cells into the central nervous system, leading to a reduction in inflammation and disease progression. In cancer, S1PR1 has been shown to promote tumor growth and metastasis, and S1PR1 antagonists have been developed as potential anti-cancer agents. In cardiovascular diseases, S1PR1 has been shown to play a role in regulating vascular tone and blood pressure, and S1PR1 agonists have been developed as potential treatments for hypertension.

Several drugs targeting S1PR1 are currently on the market or in clinical trials. Fingolimod, an S1PR1 agonist, is approved for the treatment of multiple sclerosis. Ozanimod, another S1PR1 agonist, is approved for the treatment of relapsing forms of multiple sclerosis and ulcerative colitis. Ponesimod, an S1PR1 modulator, is approved for the treatment of relapsing forms of multiple sclerosis. In addition, several S1PR1 antagonists are in clinical trials for the treatment of cancer and cardiovascular diseases. Overall, targeting S1PR1 has shown promise as a therapeutic strategy for various diseases, and ongoing research is focused on developing more effective and specific drugs targeting this receptor.",GO:0003245 cardiac muscle tissue growth involved in heart morphogenesis;GO:0003241 growth involved in heart morphogenesis;GO:0001955 blood vessel maturation,,Transporters; G-protein coupled receptors:Lysolipids receptors; FDA approved drug targets:Small molecule drugs; G-protein coupled receptors:GPCRs excl olfactory receptors; CD markers; Cancer-related genes:Candidate cancer biomarkers,Vesicles (Supported),Fingolimod; Asfotase alfa; Siponimod; Ozanimod,(M103)PID S1P S1P1 PATHWAY; (M155)PID S1P META PATHWAY; (M55)PID S1P S1P3 PATHWAY,
ENSG00000149591.17,ENSG00000149591,TAGLN,-1.528094473,-1.600835388,-1.055190922,-1.92825711,transgelin,"TAGLN, also known as transgelin, is a gene that encodes an actin-binding protein belonging to the calponin family. It is expressed in smooth muscle cells and is involved in calcium-independent smooth muscle contraction. TAGLN is also an early marker of smooth muscle differentiation and acts as a tumor suppressor. Loss of TAGLN expression is an early event in cell transformation and the development of some tumors. The protein has an N-terminal calponin homology domain and a C-terminal calponin-like domain. Knockout mice for the orthologous gene are viable and fertile but exhibit alterations in the distribution of actin filaments and changes in cytoskeletal organization in their vascular smooth muscle cells.","There is growing evidence that TAGLN may play a role in various diseases, including cancer, cardiovascular disease, and fibrosis. In cancer, TAGLN has been shown to act as a tumor suppressor, and loss of its expression has been associated with tumor progression and poor prognosis in several types of cancer. In cardiovascular disease, TAGLN has been implicated in the regulation of smooth muscle cell proliferation and migration, which are key processes in the development of atherosclerosis and restenosis. In fibrosis, TAGLN has been shown to be involved in the differentiation of fibroblasts into myofibroblasts, which are responsible for the excessive deposition of extracellular matrix in fibrotic tissues.

There are currently no drugs on the market that specifically target TAGLN. However, there have been some efforts to develop drugs that modulate the activity of TAGLN or its downstream signaling pathways. For example, a recent study showed that a small molecule inhibitor of the Rho-associated protein kinase (ROCK) pathway, which is downstream of TAGLN, was effective in reducing the proliferation and migration of smooth muscle cells in vitro and in vivo. Another study showed that a peptide derived from TAGLN was able to inhibit the migration of cancer cells in vitro.

Overall, the potential therapeutic implications of TAGLN are still being explored, and more research is needed to fully understand its role in disease and to develop targeted therapies.",GO:0007517 muscle organ development;GO:0061061 muscle structure development;GO:0030855 epithelial cell differentiation,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cytosol;Mitochondria (Approved); Additional: Microtubules;Nucleoplasm,Artenimol,(M186)PID PDGFRB PATHWAY,(M5909)HALLMARK MYOGENESIS; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000157654.19,ENSG00000157654,PALM2AKAP2,-1.525189935,-2.060840406,-1.083060924,-1.431668475,PALM2 and AKAP2 fusion,"PALM2AKAP2 is a gene that belongs to the paralemmin downstream gene (PDG) family and encodes three distinct protein isoforms, PALM2, AKAP2, and PALM2-AKAP2. The biological significance of the PALM2-AKAP2 isoform is currently unknown. Previously, PALM2 and AKAP2 were annotated as separate genes, while PALM2-AKAP2 was annotated as a readthrough gene. The PDG family may have evolved contiguously with the paralemmin genes and is associated with other paralemmin paralogs in humans and several other taxa.","There is currently limited information available on the disease implications of PALM2AKAP2. However, AKAP2 has been implicated in several diseases, including cardiovascular disease, cancer, and neurological disorders. Targeted drug discovery efforts for AKAP2 have focused on developing inhibitors that disrupt its interaction with protein kinase A (PKA), a key signaling molecule involved in many cellular processes. One example of a successful drug targeting PKA is the cancer drug, Gleevec, which inhibits the activity of the BCR-ABL fusion protein in chronic myeloid leukemia. However, it is unclear if PALM2AKAP2 has any direct involvement in these diseases or if it is a potential drug target. Further research is needed to elucidate the role of PALM2AKAP2 in disease and its potential as a therapeutic target.",GO:0008360 regulation of cell shape;GO:0022604 regulation of cell morphogenesis;GO:0022603 regulation of anatomical structure morphogenesis,,Predicted intracellular proteins,Plasma membrane (Supported),,,
ENSG00000183722.9,ENSG00000183722,LHFPL6,-1.523827723,-2.259725059,-1.296733913,-1.015024198,LHFPL tetraspan subfamily member 6,"LHFPL6 is a gene that belongs to the LHFP family, which is a subset of tetraspan transmembrane protein encoding genes. It has been found to be fused to a high-mobility group gene in a translocation-associated lipoma. Mutations in another LHFP-like gene have been linked to deafness in humans and mice. Although alternative spliced transcript variants have been identified, their full-length nature is not yet known.","There is currently limited information on the disease implications of LHFPL6. However, as mutations in other LHFP-like genes have been linked to deafness, it is possible that mutations in LHFPL6 may also be associated with hearing loss. 

There are currently no targeted drug discovery efforts specifically focused on LHFPL6. However, as tetraspan transmembrane proteins have been implicated in various diseases, including cancer and infectious diseases, there may be potential for LHFPL6 to be targeted in these areas. 

There are no drugs currently on the market that target LHFPL6 specifically. However, there are drugs that target other tetraspan transmembrane proteins, such as CD20 and CD52, which are used to treat certain types of cancer and autoimmune diseases. Additionally, there are drugs that target high-mobility group proteins, such as trabectedin, which is used to treat certain types of soft tissue sarcoma. Further research is needed to determine if LHFPL6 could be a potential target for drug development.",,,Disease related genes; Transporters:Transporter channels and pores; Potential drug targets,Nucleoli (Uncertain),,,
ENSG00000212907.2,ENSG00000212907,MT-ND4L,-1.523026069,-2.429075809,-1.454024361,-0.685978036,NADH dehydrogenase subunit 4L,"The human gene ND4L, also known as NADH dehydrogenase subunit 4L, is predicted to play a role in NADH dehydrogenase (ubiquinone) activity and is located in the mitochondrial inner membrane. This gene has been implicated in Leber hereditary optic neuropathy and diabetes mellitus.","Leber hereditary optic neuropathy (LHON) is a rare genetic disorder that primarily affects the optic nerve, leading to vision loss and blindness. Mutations in the ND4L gene have been identified as a cause of LHON. Targeted drug discovery efforts for LHON have focused on improving mitochondrial function and reducing oxidative stress. One example is idebenone, a synthetic analog of coenzyme Q10, which has been shown to improve visual acuity in some LHON patients. Diabetes mellitus is a metabolic disorder characterized by high blood sugar levels. ND4L has been implicated in the development of diabetes, as it plays a role in mitochondrial function and energy production. Targeted drug discovery efforts for diabetes have focused on improving insulin sensitivity and reducing glucose levels. Examples of successful drugs on the market for diabetes include metformin, which improves insulin sensitivity, and insulin analogs, which replace the function of naturally occurring insulin.","GO:0006120 mitochondrial electron transport, NADH to ubiquinone;GO:0042776 proton motive force-driven mitochondrial ATP synthesis;GO:0015986 proton motive force-driven ATP synthesis",,Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Potential drug targets; Enzymes; Disease related genes; ENZYME proteins,Mitochondria (Approved); Additional: Centrosome;Cytosol,NADH,,
ENSG00000112186.12,ENSG00000112186,CAP2,-1.51752741,-2.542130656,-1.510866664,-0.499584909,cyclase associated actin cytoskeleton regulatory protein 2,"CAP2, or cyclase associated actin cytoskeleton regulatory protein 2, is a gene that was identified due to its similarity to the gene for human adenylyl cyclase-associated protein. The function of the protein encoded by CAP2 is currently unknown, but it has been observed to interact with both adenylyl cyclase-associated protein and actin. This suggests that CAP2 may play a role in regulating the cytoskeleton and cellular signaling pathways. However, further research is needed to fully understand the function of this gene and its potential implications for human health.","There is limited information available on the disease implications of CAP2. However, some studies have suggested that mutations in the CAP2 gene may be associated with certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for CAP2 are also limited, as the function of the protein encoded by this gene is not well understood. Currently, there are no drugs on the market that specifically target CAP2. However, there are drugs that target related proteins, such as adenylyl cyclase-associated protein, which is involved in cellular signaling pathways. Examples of drugs that target adenylyl cyclase-associated protein include the anti-cancer drug trabectedin and the anti-inflammatory drug dexamethasone. Further research is needed to determine if targeting CAP2 or related proteins could be a viable strategy for developing new drugs for cancer or other diseases.",GO:0099140 presynaptic actin cytoskeleton organization;GO:0099187 presynaptic cytoskeleton organization;GO:1905274 regulation of modification of postsynaptic actin cytoskeleton,,Cancer-related genes:Mutated cancer genes; Predicted intracellular proteins,Cytosol;Nucleoplasm (Approved); Additional: Plasma membrane,,,(M5942)HALLMARK UV RESPONSE DN; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000125107.18,ENSG00000125107,CNOT1,-1.516512666,-2.061464035,-1.69911277,-0.788961193,CCR4-NOT transcription complex subunit 1,"CNOT1 is a human gene that encodes the CCR4-NOT transcription complex subunit 1. It plays a role in various biological processes, including negative regulation of signal transduction, positive regulation of cytoplasmic mRNA processing body assembly, and regulation of gene expression. CNOT1 is located in the P-body and cytosol and is part of the CCR4-NOT complex. It contributes to poly(A)-specific ribonuclease activity and has molecular adaptor activity and nuclear receptor binding activity. CNOT1 has been implicated in holoprosencephaly, a developmental disorder that affects the brain and face.","CNOT1 has been implicated in several diseases, including cancer, neurodegenerative disorders, and developmental disorders such as holoprosencephaly. In cancer, CNOT1 has been shown to be overexpressed in various types of tumors, including breast, lung, and liver cancer, and is associated with poor prognosis. Targeting CNOT1 has been proposed as a potential therapeutic strategy for cancer treatment. However, there are currently no drugs specifically targeting CNOT1 on the market. 

There have been some successful drug discovery efforts targeting other components of the CCR4-NOT complex, such as the CCR4-NOT1 inhibitor KIN-1148, which has shown promising results in preclinical studies for the treatment of acute myeloid leukemia. Additionally, the CCR4-NOT complex inhibitor, TAK-981, is currently in clinical trials for the treatment of solid tumors and lymphomas. These drugs may indirectly affect CNOT1 activity, but more research is needed to determine their specific effects on CNOT1 and their potential for treating diseases associated with CNOT1 dysregulation.",GO:0010606 positive regulation of cytoplasmic mRNA processing body assembly;GO:0010603 regulation of cytoplasmic mRNA processing body assembly;GO:0048387 negative regulation of retinoic acid receptor signaling pathway,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Cytosol (Uncertain),,,
ENSG00000183801.8,ENSG00000183801,OLFML1,-1.508305096,-1.907556829,-0.772697197,-1.844661263,olfactomedin like 1,"OLFML1 (olfactomedin like 1) is a gene that is predicted to be located in the extracellular region. It encodes a protein that belongs to the olfactomedin family, which is involved in various biological processes such as cell adhesion, differentiation, and signaling. OLFML1 has been implicated in several diseases, including age-related macular degeneration, glaucoma, and cancer. Studies have shown that OLFML1 may play a role in regulating angiogenesis, inflammation, and oxidative stress. Further research is needed to fully understand the function of OLFML1 and its potential as a therapeutic target for various diseases.","There is limited information available on targeted drug discovery efforts for OLFML1. However, studies have suggested that OLFML1 may be a potential therapeutic target for age-related macular degeneration and glaucoma. In addition, OLFML1 has been found to be overexpressed in several types of cancer, including breast, lung, and pancreatic cancer, suggesting its potential as a target for cancer therapy. Currently, there are no drugs on the market that specifically target OLFML1. However, there are drugs that target related proteins in the olfactomedin family, such as myocilin, which is targeted by the glaucoma drug, Latanoprost. Further research is needed to identify potential drug targets within the OLFML1 pathway and develop effective therapies for diseases associated with this gene.",GO:0007165 signal transduction;GO:0023052 signaling;GO:0007154 cell communication,,Predicted secreted proteins,,,,
ENSG00000164056.11,ENSG00000164056,SPRY1,-1.500126113,-1.502718037,-1.066843569,-1.930816734,sprouty RTK signaling antagonist 1,"The human gene SPRY1, also known as sprouty RTK signaling antagonist 1, plays a role in inhibiting the fibroblast growth factor receptor signaling pathway. It is found in various cellular locations, including the Golgi apparatus, cytosol, and nucleoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.","Research has shown that SPRY1 may play a role in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, SPRY1 has been found to be downregulated in several types of tumors, including breast, prostate, and lung cancer, suggesting that it may act as a tumor suppressor. In cardiovascular disease, SPRY1 has been implicated in the regulation of vascular smooth muscle cell proliferation and migration, which are key processes in the development of atherosclerosis. In neurological disorders, SPRY1 has been linked to the regulation of synaptic plasticity and neuronal survival.

Targeted drug discovery efforts for SPRY1 are still in the early stages, but there is potential for the development of drugs that modulate its activity. One approach is to develop small molecules that mimic the function of SPRY1 and inhibit the fibroblast growth factor receptor signaling pathway. Another approach is to develop drugs that increase the expression of SPRY1, which could have therapeutic benefits in diseases where SPRY1 is downregulated.

There are currently no drugs on the market that specifically target SPRY1, but there are drugs that target the fibroblast growth factor receptor signaling pathway, which SPRY1 inhibits. For example, the drug erdafitinib is a selective inhibitor of fibroblast growth factor receptor 1-4 and is approved for the treatment of metastatic urothelial carcinoma with certain genetic mutations. Another drug, infigratinib, is a selective inhibitor of fibroblast growth factor receptor 2 and is being investigated for the treatment of cholangiocarcinoma and other cancers.",GO:0060940 epithelial to mesenchymal transition involved in cardiac fibroblast development;GO:0051387 negative regulation of neurotrophin TRK receptor signaling pathway;GO:0060938 epicardium-derived cardiac fibroblast cell differentiation,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cytosol;Golgi apparatus (Approved); Additional: Nucleoplasm,,,
ENSG00000120156.22,ENSG00000120156,TEK,-1.496140531,-1.472282102,-1.45602016,-1.560119332,TEK receptor tyrosine kinase,"The TEK gene encodes a receptor belonging to the Tie2 family of protein tyrosine kinases. The receptor has a unique extracellular region containing two immunoglobulin-like domains, three epidermal growth factor-like domains, and three fibronectin type III repeats. The ligand angiopoietin-1 binds to this receptor and mediates a signaling pathway that plays a role in embryonic vascular development. Mutations in this gene are associated with inherited venous malformations of the skin and mucous membranes. Alternative splicing results in multiple transcript variants, and additional variants have been described but not fully characterized.","Mutations in the TEK gene have been associated with inherited venous malformations of the skin and mucous membranes, which are characterized by abnormal blood vessels that can cause pain, swelling, and disfigurement. Targeted drug discovery efforts have focused on developing drugs that can inhibit the angiopoietin-TEK signaling pathway, which is involved in the development and maintenance of these abnormal blood vessels. One example of a successful drug targeting this pathway is bevacizumab, which is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) and has been approved for the treatment of various cancers. Another example is ramucirumab, which is a monoclonal antibody that targets the VEGF receptor and has been approved for the treatment of gastric and colorectal cancers. These drugs have shown promise in the treatment of venous malformations, but further research is needed to determine their efficacy and safety in this context.",GO:0048014 Tie signaling pathway;GO:0035022 positive regulation of Rac protein signal transduction;GO:0060347 heart trabecula formation,yes,Human disease related genes:Congenital malformations:Congenital malformations of the circulatory system; Kinases:Tyr protein kinases; RAS pathway related proteins; Predicted secreted proteins; Human disease related genes:Congenital malformations:Congenital malformations of eye; ENZYME proteins:Transferases; FDA approved drug targets:Small molecule drugs; Disease related genes; CD markers; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Plasma membrane (Supported); Additional: Basal body;Centrosome,Ampicillin; Vandetanib; N-{4-METHYL-3-[(3-PYRIMIDIN-4-YLPYRIDIN-2-YL)AMINO]PHENYL}-3-(TRIFLUOROMETHYL)BENZAMIDE; Regorafenib; Ponatinib; Fostamatinib; Ripretinib,(M92)PID ANGIOPOIETIN RECEPTOR PATHWAY; (M100)PID SHP2 PATHWAY,
ENSG00000197496.6,ENSG00000197496,SLC2A10,-1.495257269,-2.13601759,-1.719059778,-0.630694439,solute carrier family 2 member 10,"SLC2A10 is a gene that belongs to the class III facilitative glucose transporter family. It is involved in regulating glucose homeostasis in the body. Mutations in this gene have been linked to a rare genetic disorder called arterial tortuosity syndrome, which affects the elasticity and structure of blood vessels. This condition can lead to a range of health problems, including cardiovascular issues, joint hypermobility, and gastrointestinal complications. Understanding the function of SLC2A10 and its role in glucose regulation may help researchers develop new treatments for arterial tortuosity syndrome and other related conditions.","Arterial tortuosity syndrome (ATS) is a rare genetic disorder caused by mutations in the SLC2A10 gene. The condition affects the elasticity and structure of blood vessels, leading to a range of health problems, including cardiovascular issues, joint hypermobility, and gastrointestinal complications. There are currently no targeted drug therapies available for ATS, and treatment is focused on managing symptoms. However, research efforts are underway to develop new treatments for this condition. One potential approach is to target the underlying genetic mutations that cause ATS using gene therapy or gene editing techniques. Another approach is to develop drugs that can improve the elasticity of blood vessels and prevent the complications associated with ATS. While there are currently no drugs on the market specifically for ATS, there are several drugs that have been approved for other conditions that may have potential for treating ATS, including drugs that target the renin-angiotensin-aldosterone system and drugs that improve vascular function.",GO:0032683 negative regulation of connective tissue growth factor production;GO:1902729 negative regulation of proteoglycan biosynthetic process;GO:0032643 regulation of connective tissue growth factor production,,Predicted intracellular proteins; Transporters:Electrochemical Potential-driven transporters; Human disease related genes:Cardiovascular diseases:Vascular diseases; Potential drug targets; Disease related genes,Cytosol (Supported),,,
ENSG00000115594.12,ENSG00000115594,IL1R1,-1.495212606,-1.713636653,-1.382438602,-1.389562563,interleukin 1 receptor type 1,"IL1R1 is a gene that encodes a cytokine receptor belonging to the interleukin-1 receptor family. The protein encoded by this gene acts as a receptor for interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist. It plays a crucial role in mediating immune and inflammatory responses induced by cytokines. The gene is located in a cluster of related cytokine receptor genes on chromosome 2q12.","IL1R1 has been implicated in various diseases, including autoimmune disorders, inflammatory diseases, and cancer. In particular, IL1R1 has been linked to rheumatoid arthritis, where it plays a key role in the inflammatory response that leads to joint damage. Targeting IL1R1 has been a focus of drug discovery efforts, with several drugs currently on the market. Anakinra is a recombinant form of the interleukin-1 receptor antagonist that blocks the activity of IL1R1 and is used to treat rheumatoid arthritis and other inflammatory diseases. Canakinumab is a monoclonal antibody that targets IL1R1 and is used to treat autoinflammatory diseases such as cryopyrin-associated periodic syndromes. Other drugs targeting IL1R1 are in development for various diseases, including cancer. Overall, targeting IL1R1 has shown promise in treating a range of diseases characterized by inflammation and immune dysregulation.",GO:2000661 positive regulation of interleukin-1-mediated signaling pathway;GO:2000391 positive regulation of neutrophil extravasation;GO:2000389 regulation of neutrophil extravasation,,Human disease related genes:Immune system diseases:Allergies and autoimmune diseases; Human disease related genes:Skin diseases:Skin and soft tissue diseases; FDA approved drug targets:Biotech drugs; Predicted secreted proteins; Transporters:Accessory Factors Involved in Transport; Cancer-related genes:Candidate cancer biomarkers; CD markers; Enzymes; ENZYME proteins:Hydrolases,Nucleoplasm;Vesicles (Approved); Additional: Cytosol;Plasma membrane,Anakinra; SD118; OMS-103HP; Foreskin fibroblast (neonatal),(M110)PID IL1 PATHWAY; (M54)PID IL12 2PATHWAY,(M5897)HALLMARK IL6 JAK STAT3 SIGNALING; (M5932)HALLMARK INFLAMMATORY RESPONSE; (M5934)HALLMARK XENOBIOTIC METABOLISM
ENSG00000126746.17,ENSG00000126746,ZNF384,-1.492804289,-2.08568985,-1.45086163,-0.941861387,zinc finger protein 384,"ZNF384 is a gene that encodes a zinc finger protein that may function as a transcription factor. The gene contains long CAG trinucleotide repeats that encode consecutive glutamine residues. The protein appears to bind and regulate the promoters of extracellular matrix genes MMP1, MMP3, MMP7, and COL1A1. Studies in mice suggest that nuclear matrix transcription factors may be part of a general mechanical pathway that couples cell construction and function during extracellular matrix remodeling. Alternative splicing results in multiple transcript variants. Recurrent rearrangements of this gene with other genes have been observed in acute leukemia. A related pseudogene has been identified on chromosome 7.","Recurrent rearrangements involving ZNF384 have been observed in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). These rearrangements result in fusion proteins that may contribute to leukemogenesis. Targeted drug discovery efforts for ZNF384-related leukemias are ongoing, with a focus on developing inhibitors that target the fusion proteins. One example of a successful drug on the market for leukemia is imatinib, which targets the BCR-ABL fusion protein in chronic myeloid leukemia (CML). However, there are currently no FDA-approved drugs specifically targeting ZNF384-related leukemias. Clinical trials are ongoing for various targeted therapies, including inhibitors of the FLT3 and IDH1/2 mutations commonly found in AML.",GO:0045944 positive regulation of transcription by RNA polymerase II;GO:0045893 positive regulation of DNA-templated transcription;GO:1902680 positive regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Cancer-related genes; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000112640.16,ENSG00000112640,PPP2R5D,-1.491869301,-2.073351633,-1.668538921,-0.733717348,protein phosphatase 2 regulatory subunit B'delta,"PPP2R5D is a gene that encodes a regulatory subunit of protein phosphatase 2A, which is involved in controlling cell growth and division. The protein product of this gene belongs to the B56 subfamily of regulatory subunits and is known as protein phosphatase 2 regulatory subunit B'delta. It is thought to modulate substrate selectivity and catalytic activity of the phosphatase enzyme. Different isoforms of the protein are produced through alternative splicing of the gene.","Mutations in the PPP2R5D gene have been associated with a rare genetic disorder called intellectual disability and developmental delay with or without seizures (IDDD). Individuals with IDDD may have delayed speech and language development, intellectual disability, and behavioral problems. There are currently no targeted drug discovery efforts for PPP2R5D-related disorders, but research is ongoing to better understand the molecular mechanisms underlying these conditions. There are no drugs specifically approved for the treatment of PPP2R5D-related disorders, but some drugs used to treat related conditions, such as epilepsy and autism, may be beneficial for some individuals with IDDD. For example, antiepileptic drugs such as valproic acid and carbamazepine have been used to treat seizures in individuals with IDDD. Additionally, behavioral therapies and educational interventions may be helpful for managing symptoms associated with IDDD.",GO:0051177 meiotic sister chromatid cohesion;GO:0007062 sister chromatid cohesion;GO:0051276 chromosome organization,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Predicted intracellular proteins,Cytosol (Supported),,(M163)PID LIS1 PATHWAY; (M242)PID AURORA A PATHWAY; (M275)PID ALPHA SYNUCLEIN PATHWAY,
ENSG00000134954.14,ENSG00000134954,ETS1,-1.489239123,-1.798685611,-1.568196506,-1.100835252,"ETS proto-oncogene 1, transcription factor","ETS1 is a gene that encodes a transcription factor belonging to the ETS family. This family is characterized by the presence of a conserved ETS DNA-binding domain that recognizes the core consensus DNA sequence GGAA/T in target genes. ETS1 can function as a transcriptional activator or repressor of various genes and is involved in stem cell development, cell senescence and death, and tumorigenesis. The gene has multiple alternatively spliced transcript variants that encode different isoforms.","ETS1 has been implicated in various diseases, including cancer, autoimmune disorders, and cardiovascular diseases. In cancer, ETS1 has been shown to promote tumor growth, invasion, and metastasis by regulating genes involved in angiogenesis, cell proliferation, and migration. Therefore, targeting ETS1 has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of ETS1 have been developed, including YK-4-279 and XNT-312, which have shown promising results in preclinical studies. However, no ETS1-targeted drugs have been approved for clinical use yet.

In autoimmune disorders, ETS1 has been shown to play a role in the regulation of T cell differentiation and activation. Therefore, targeting ETS1 has been proposed as a potential therapeutic approach for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. However, no ETS1-targeted drugs have been approved for clinical use in these diseases.

In cardiovascular diseases, ETS1 has been shown to regulate genes involved in vascular smooth muscle cell proliferation and migration, as well as endothelial cell function. Therefore, targeting ETS1 has been proposed as a potential therapeutic approach for atherosclerosis and restenosis. However, no ETS1-targeted drugs have been approved for clinical use in these diseases.

Overall, while targeting ETS1 has shown promise as a potential therapeutic strategy for various diseases, more research is needed to fully understand its role in disease pathogenesis and to develop effective ETS1-targeted drugs.",GO:0030578 PML body organization;GO:0030575 nuclear body organization;GO:1904996 positive regulation of leukocyte adhesion to vascular endothelial cell,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins; RAS pathway related proteins,Nucleoplasm (Supported),,(M44)PID HIF2PATHWAY; (M92)PID ANGIOPOIETIN RECEPTOR PATHWAY; (M281)PID FAK PATHWAY,(M5891)HALLMARK HYPOXIA; (M5950)HALLMARK ALLOGRAFT REJECTION; (M5953)HALLMARK KRAS SIGNALING UP
ENSG00000166265.13,ENSG00000166265,CYYR1,-1.489085344,-1.94277175,-1.08610878,-1.438375503,cysteine and tyrosine rich 1,"CYYR1, also known as cysteine and tyrosine rich 1, is a human gene that is predicted to be an integral component of the membrane. The function of this gene is not yet fully understood, but it is believed to play a role in cellular processes such as signal transduction and protein-protein interactions. CYYR1 contains cysteine and tyrosine residues, which are important for protein structure and function. Further research is needed to fully understand the role of CYYR1 in human biology and disease.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for CYYR1. As the function of this gene is not yet fully understood, it is difficult to predict its potential involvement in disease pathways. Additionally, there are no known drugs on the market that specifically target CYYR1. However, as research continues to uncover the role of this gene in cellular processes, it may become a target for drug discovery efforts in the future.",GO:0008150 biological_process,,,Nucleoplasm (Approved),,,
ENSG00000087245.13,ENSG00000087245,MMP2,-1.473198546,-2.045740751,-1.452682584,-0.921172301,matrix metallopeptidase 2,"MMP2, or matrix metallopeptidase 2, is a gene that belongs to the MMP family of zinc-dependent enzymes. It encodes for a gelatinase A, type IV collagenase, which can cleave components of the extracellular matrix and molecules involved in signal transduction. Unlike most MMP family members, this protein can be activated on the cell membrane and can also be activated intracellularly by S-glutathiolation. MMP2 is involved in multiple pathways, including roles in the nervous system, endometrial menstrual breakdown, regulation of vascularization, and metastasis. Mutations in this gene have been associated with Winchester syndrome and Nodulosis-Arthropathy-Osteolysis (NAO) syndrome. Alternative splicing results in multiple transcript variants encoding different isoforms.","MMP2 has been implicated in various diseases, including cancer, cardiovascular diseases, and neurological disorders. Targeting MMP2 has been a focus of drug discovery efforts, with the aim of developing inhibitors that can prevent or slow down the progression of these diseases. Several MMP2 inhibitors have been developed and tested in preclinical and clinical studies, including batimastat, marimastat, and prinomastat. However, these drugs have shown limited efficacy and significant side effects, leading to their discontinuation. More recently, natural compounds such as curcumin and resveratrol have shown promise as MMP2 inhibitors, with potential for use in combination with other therapies. Despite the challenges in developing effective MMP2 inhibitors, the continued research in this area holds promise for the development of novel treatments for various diseases.",GO:1903378 positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway;GO:0001957 intramembranous ossification;GO:0036072 direct ossification,,Predicted intracellular proteins; Human disease related genes:Cancers:Cancers of the breast and female genital organs; Human disease related genes:Cancers:Cancers of male genital organs; Predicted secreted proteins; Human disease related genes:Musculoskeletal diseases:Skeletal diseases; Peptidases:Metallopeptidases; Potential drug targets; Candidate cardiovascular disease genes; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Candidate cancer biomarkers,Vesicles (Approved),Marimastat; Captopril; SC-74020; Halofuginone; AE-941; Endostatin,(M63)PID AVB3 OPN PATHWAY; (M240)PID SYNDECAN 2 PATHWAY; (M65)PID FRA PATHWAY,(M5946)HALLMARK COAGULATION; (M5902)HALLMARK APOPTOSIS; (M5915)HALLMARK APICAL JUNCTION
ENSG00000156011.17,ENSG00000156011,PSD3,-1.46913712,-2.786106738,-1.488166509,-0.133138113,pleckstrin and Sec7 domain containing 3,"PSD3, or pleckstrin and Sec7 domain containing 3, is a human gene that is predicted to have guanyl-nucleotide exchange factor activity and phospholipid binding activity. It is also predicted to be involved in the regulation of ARF protein signal transduction and catalytic activity. The gene is predicted to be located in the membrane and active in the ruffle membrane. These predictions are based on information provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of PSD3. However, some studies have suggested that PSD3 may play a role in cancer progression and metastasis. For example, one study found that PSD3 expression was upregulated in breast cancer cells and that knockdown of PSD3 inhibited cell migration and invasion. 

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target PSD3. However, there are ongoing efforts to develop small molecule inhibitors of ARF proteins, which are involved in the same signaling pathway as PSD3. These inhibitors could potentially be used to treat cancer and other diseases associated with dysregulated ARF signaling.

Overall, while there is still much to learn about the function and disease implications of PSD3, it is clear that this gene has potential as a therapeutic target for certain types of cancer. Ongoing research into the role of PSD3 in cancer progression and the development of ARF inhibitors may lead to the discovery of new treatments for these diseases in the future.",GO:0032012 regulation of ARF protein signal transduction;GO:0051056 regulation of small GTPase mediated signal transduction;GO:1902531 regulation of intracellular signal transduction,,Predicted intracellular proteins,Nucleoplasm;Vesicles (Approved); Additional: Calyx;Cytosol;End piece;Mid piece;Principal piece,,,
ENSG00000167202.11,ENSG00000167202,TBC1D2B,-1.467735677,-1.585824738,-1.169291127,-1.648091164,TBC1 domain family member 2B,TBC1D2B is a human gene that is predicted to have GTPase activator activity and be involved in the activation of GTPase activity and intracellular protein transport. It is located in the cytosol. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of TBC1D2B. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for TBC1D2B are also limited, as the function of this gene is not well understood. However, some researchers are exploring the potential of targeting GTPase activators like TBC1D2B as a strategy for cancer therapy. Currently, there are no drugs on the market that specifically target TBC1D2B. However, there are several drugs that target GTPases, including farnesyltransferase inhibitors and Rho kinase inhibitors, which have been approved for the treatment of various types of cancer and other diseases.",GO:0006897 endocytosis;GO:0098657 import into cell;GO:0016192 vesicle-mediated transport,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Cytosol (Enhanced),,,
ENSG00000173706.14,ENSG00000173706,HEG1,-1.46721062,-2.208916162,-1.160737825,-1.031977873,heart development protein with EGF like domains 1,"HEG1 is a human gene that encodes for a protein involved in heart development. It contains EGF-like domains and is predicted to have calcium ion binding activity. HEG1 is located in cell-cell junctions and is involved in several processes, including negative regulation of Rho protein signal transduction, negative regulation of Rho-dependent protein serine/threonine kinase activity, and negative regulation of membrane permeability.","HEG1 has been implicated in several diseases, including cardiovascular diseases, cancer, and neurological disorders. In cardiovascular diseases, HEG1 has been shown to play a role in angiogenesis and vascular development, and mutations in the gene have been associated with congenital heart defects. In cancer, HEG1 has been found to be overexpressed in several types of tumors, including breast, lung, and pancreatic cancer, and may play a role in tumor growth and metastasis. In neurological disorders, HEG1 has been linked to Alzheimer's disease and may be involved in the regulation of blood-brain barrier permeability.

Targeted drug discovery efforts for HEG1 are still in the early stages, but several potential drug targets have been identified. One approach is to target the EGF-like domains of HEG1, which are involved in protein-protein interactions and may be important for its function in cell-cell junctions. Another approach is to target the calcium ion binding activity of HEG1, which may be involved in its regulation of membrane permeability.

Currently, there are no drugs on the market that specifically target HEG1. However, there are several drugs that indirectly affect HEG1 signaling pathways. For example, statins, which are commonly used to lower cholesterol levels, have been shown to upregulate HEG1 expression and may have beneficial effects on cardiovascular health. Additionally, several drugs that target Rho protein signaling pathways, which are negatively regulated by HEG1, are currently in clinical use for the treatment of cancer and other diseases.",GO:0003017 lymph circulation;GO:2000299 negative regulation of Rho-dependent protein serine/threonine kinase activity;GO:0090271 positive regulation of fibroblast growth factor production,,,Vesicles (Approved); Additional: Plasma membrane,,,
ENSG00000163755.9,ENSG00000163755,HPS3,-1.467085139,-1.75448253,-1.570069152,-1.076703734,HPS3 biogenesis of lysosomal organelles complex 2 subunit 1,"HPS3 is a gene that encodes a protein involved in the biogenesis of lysosomal organelles. The protein contains signals that target it to vesicles of lysosomal lineage and may play a role in the development of melanosomes, platelet dense granules, and lysosomes. Mutations in this gene are associated with Hermansky-Pudlak syndrome type 3, a rare genetic disorder characterized by albinism, bleeding disorders, and lung and bowel diseases.","Hermansky-Pudlak syndrome type 3 (HPS3) is a rare genetic disorder caused by mutations in the HPS3 gene. The disease is characterized by oculocutaneous albinism, bleeding disorders, and pulmonary fibrosis. There is currently no cure for HPS3, and treatment is mainly supportive. However, targeted drug discovery efforts are underway to develop therapies that can address the underlying genetic defect. One approach is to use small molecules to correct the trafficking defects caused by HPS3 mutations. For example, a recent study showed that a small molecule called ML372 can restore lysosomal trafficking in cells from HPS3 patients. Another approach is to use gene therapy to replace the defective HPS3 gene with a functional copy. While there are currently no drugs on the market specifically for HPS3, some treatments used for related disorders, such as bleeding disorders and pulmonary fibrosis, may be helpful for managing symptoms. For example, antifibrinolytic agents can be used to control bleeding, and oxygen therapy can be used to manage pulmonary fibrosis.",GO:1903232 melanosome assembly;GO:0060155 platelet dense granule organization;GO:0032438 melanosome organization,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of amino acid metabolism; Predicted intracellular proteins,Golgi apparatus;Plasma membrane (Approved),,,
ENSG00000154767.15,ENSG00000154767,XPC,-1.453381177,-2.2683915,-1.64238961,-0.44936242,"XPC complex subunit, DNA damage recognition and repair factor","The XPC gene encodes a protein that is a crucial component of the XPC complex, which is involved in the initial stages of global genome nucleotide excision repair (NER). The protein is responsible for detecting DNA damage and binding to the damaged DNA, with a preference for single-stranded DNA. Mutations in the XPC gene or other NER components can lead to Xeroderma pigmentosum, a rare autosomal recessive disorder characterized by increased sensitivity to sunlight and the development of carcinomas at an early age. The XPC gene has multiple alternatively spliced transcript variants.","Xeroderma pigmentosum (XP) is a rare genetic disorder caused by mutations in genes involved in DNA repair, including the XPC gene. Individuals with XP are highly sensitive to sunlight and have an increased risk of developing skin cancers at an early age. There is currently no cure for XP, and treatment options are limited to avoiding exposure to sunlight and regular skin cancer screenings. Targeted drug discovery efforts for XP have focused on developing drugs that can repair DNA damage or enhance the activity of the remaining functional XPC protein. However, there are currently no drugs specifically approved for the treatment of XP. Some drugs that have shown promise in preclinical studies include PARP inhibitors, which can enhance the activity of the remaining functional XPC protein, and nucleotide excision repair enhancers, which can improve the efficiency of DNA repair. However, further research is needed to determine the safety and efficacy of these drugs in clinical trials.",GO:0000720 pyrimidine dimer repair by nucleotide-excision repair;GO:0006290 pyrimidine dimer repair;GO:0070914 UV-damage excision repair,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of skin; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Enhanced); Additional: Plasma membrane,,,(M5898)HALLMARK DNA REPAIR; (M5939)HALLMARK P53 PATHWAY
ENSG00000187498.16,ENSG00000187498,COL4A1,-1.453101666,-1.793565851,-1.415962754,-1.149776394,collagen type IV alpha 1 chain,"COL4A1 is a gene that encodes a type IV collagen alpha protein, which is an essential component of basement membranes. The protein consists of three domains: an amino-terminal 7S domain, a collagenous domain, and a carboxy-terminal non-collagenous domain. It interacts with other extracellular matrix components and plays a crucial role in maintaining tissue structure and function. Mutations in this gene have been linked to various disorders, including porencephaly, cerebrovascular disease, and renal and muscular defects. Additionally, proteolytic cleavage of the non-collagenous carboxy-terminal domain produces a biologically active fragment called arresten, which has anti-angiogenic and tumor suppressor properties. Alternative splicing of this gene results in multiple transcript variants.","Mutations in the COL4A1 gene have been associated with a range of diseases, including cerebral small vessel disease, intracerebral hemorrhage, and hereditary angiopathy with nephropathy, aneurysms, and muscle cramps (HANAC) syndrome. Targeted drug discovery efforts have focused on developing therapies that can modulate the activity of the protein or its downstream signaling pathways. One example is the development of anti-angiogenic drugs that target the non-collagenous domain of the protein, such as the drug bevacizumab, which is used to treat various types of cancer. Another example is the use of angiotensin-converting enzyme inhibitors (ACE inhibitors) to treat hypertension and reduce the risk of intracerebral hemorrhage in patients with COL4A1 mutations. Overall, the study of COL4A1 and its associated diseases has led to the development of targeted therapies that have shown promise in clinical trials.",GO:0061304 retinal blood vessel morphogenesis;GO:0061299 retina vasculature morphogenesis in camera-type eye;GO:0061298 retina vasculature development in camera-type eye,,Human disease related genes:Congenital malformations:Congenital malformations of the circulatory system; Predicted intracellular proteins; Predicted secreted proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Human disease related genes:Cardiovascular diseases:Vascular diseases; Disease related genes,,,(M5887)NABA BASEMENT MEMBRANES; (M53)PID INTEGRIN3 PATHWAY; (M3005)NABA COLLAGENS,(M5905)HALLMARK ADIPOGENESIS; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000125810.10,ENSG00000125810,CD93,-1.450335203,-1.277743622,-1.239272709,-1.833989278,CD93 molecule,"CD93 is a type I membrane protein and cell-surface glycoprotein that was initially identified as a marker for myeloid cells. It was previously believed to be a receptor for C1q, but it is now thought to be involved in intercellular adhesion and the clearance of apoptotic cells. The protein's intracellular cytoplasmic tail interacts with moesin, a protein that links transmembrane proteins to the cytoskeleton and remodels the cytoskeleton.","CD93 has been implicated in various diseases, including cancer, autoimmune disorders, and cardiovascular diseases. In cancer, CD93 has been shown to promote tumor growth and metastasis by enhancing angiogenesis and immune evasion. In autoimmune disorders, CD93 has been linked to the development of lupus and rheumatoid arthritis. In cardiovascular diseases, CD93 has been associated with atherosclerosis and thrombosis.

Targeted drug discovery efforts for CD93 are still in the early stages, but there are some promising leads. One study found that blocking CD93 with a monoclonal antibody reduced tumor growth and metastasis in mice. Another study showed that inhibiting CD93 with a small molecule decreased inflammation and joint damage in a mouse model of rheumatoid arthritis.

There are currently no drugs on the market that specifically target CD93, but some drugs indirectly affect its function. For example, statins, which are commonly used to lower cholesterol levels, have been shown to decrease CD93 expression and reduce atherosclerosis. Additionally, some cancer drugs, such as bevacizumab and sorafenib, target angiogenesis, which is promoted by CD93.",GO:0042116 macrophage activation;GO:0002274 myeloid leukocyte activation;GO:0006909 phagocytosis,,CD markers,Plasma membrane;Vesicles (Approved),,,
ENSG00000160691.19,ENSG00000160691,SHC1,-1.448716444,-1.848070761,-1.623871486,-0.874207085,SHC adaptor protein 1,"The SHC1 gene encodes three isoforms that act as adapter proteins in signal transduction pathways. The longest isoform, p66Shc, may play a role in regulating lifespan and the effects of reactive oxygen species. The other two isoforms, p52Shc and p46Shc, link activated receptor tyrosine kinases to the Ras pathway by recruiting the GRB2/SOS complex. Unlike the other two isoforms, p46Shc is targeted to the mitochondrial matrix. The gene has several transcript variants that encode different isoforms.","The SHC1 gene has been implicated in several diseases, including cancer, diabetes, and cardiovascular disease. In cancer, the overexpression of p66Shc has been linked to increased tumor growth and metastasis. In diabetes, p66Shc has been shown to play a role in insulin resistance and beta-cell dysfunction. In cardiovascular disease, p66Shc has been associated with oxidative stress and endothelial dysfunction.

Targeted drug discovery efforts for SHC1 have focused on developing inhibitors of the p66Shc isoform. One example is the small molecule compound, MitoQ, which targets p66Shc in the mitochondria and has shown promise in preclinical studies for treating cardiovascular disease and neurodegenerative disorders.

Another example is the drug, metformin, which is commonly used to treat type 2 diabetes. Metformin has been shown to inhibit p66Shc expression and activity, leading to improved insulin sensitivity and glucose metabolism.

Overall, targeting SHC1 and its isoforms has the potential to provide therapeutic benefits for a range of diseases, and ongoing research is focused on identifying new drug candidates and understanding the underlying mechanisms of SHC1 in disease pathogenesis.",GO:0071864 positive regulation of cell proliferation in bone marrow;GO:0071863 regulation of cell proliferation in bone marrow;GO:0090322 regulation of superoxide metabolic process,,Predicted intracellular proteins; RAS pathway related proteins,Cytosol (Enhanced),,(M12771)SA PTEN PATHWAY; (M18895)SA TRKA RECEPTOR; (M273)PID EPHA2 FWD PATHWAY,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE; (M5915)HALLMARK APICAL JUNCTION
ENSG00000207554.1,ENSG00000207554,MIR647,-1.439817557,-2.421978853,-1.407564645,-0.489909171,microRNA 647,,,,,,,,,
ENSG00000236871.7,ENSG00000236871,LINC00106,-1.438457066,-2.017281457,-1.056602473,-1.241487267,long intergenic non-protein coding RNA 106,,,,,,,,,
ENSG00000229152.2,ENSG00000229152,ANKRD10-IT1,-1.437127422,-1.809800104,-1.252535048,-1.249047113,None,None,None,None,None,None,None,None,None,None
ENSG00000111684.11,ENSG00000111684,LPCAT3,-1.436567248,-2.008931752,-1.915287032,-0.38548296,lysophosphatidylcholine acyltransferase 3,"LPCAT3, or lysophosphatidylcholine acyltransferase 3, is a gene that encodes an enzyme involved in the remodeling of acyl chains in phospholipids. Specifically, LPCAT3 enables the transfer of acyl groups to 1-acylglycerophosphocholine, 1-acylglycerophosphoethanolamine, and 1-acylglycerophosphoserine. This gene is located in the endoplasmic reticulum membrane. The function of LPCAT3 is important for maintaining proper membrane structure and function in cells.","Research has shown that LPCAT3 may play a role in several diseases, including cancer, Alzheimer's disease, and atherosclerosis. In cancer, LPCAT3 has been found to be upregulated in several types of tumors, and its inhibition has been shown to reduce tumor growth and metastasis. In Alzheimer's disease, LPCAT3 has been implicated in the accumulation of amyloid-beta plaques, a hallmark of the disease. In atherosclerosis, LPCAT3 has been shown to contribute to the formation of foam cells, which are a key component of atherosclerotic plaques.

Targeted drug discovery efforts for LPCAT3 are still in the early stages, but several potential inhibitors have been identified through high-throughput screening and structure-based drug design. These inhibitors have shown promising results in preclinical studies, and further research is needed to determine their efficacy and safety in humans.

Currently, there are no drugs on the market that specifically target LPCAT3. However, there are several drugs that indirectly affect LPCAT3 activity. For example, statins, which are commonly used to lower cholesterol levels, have been shown to reduce LPCAT3 expression and activity. Additionally, several drugs that target other enzymes involved in phospholipid metabolism, such as phospholipase A2 inhibitors, have been approved for the treatment of inflammatory diseases.",GO:0045797 positive regulation of intestinal cholesterol absorption;GO:1901508 positive regulation of acylglycerol transport;GO:1905885 positive regulation of triglyceride transport,,Enzymes; ENZYME proteins:Transferases,,,,(M5905)HALLMARK ADIPOGENESIS
ENSG00000166987.15,ENSG00000166987,MBD6,-1.436476702,-1.977297019,-1.544170022,-0.787963064,methyl-CpG binding domain protein 6,"MBD6 is a human gene that encodes for a protein called methyl-CpG binding domain protein 6. This protein is involved in chromatin binding activity and is found in various parts of the nucleus, including the chromocenter, fibrillar center, and nucleoplasm. MBD6 has been implicated in autism spectrum disorder, a neurodevelopmental disorder characterized by social communication difficulties and repetitive behaviors.","There is limited information available on the disease implications of MBD6. However, studies have suggested that mutations in MBD6 may be associated with autism spectrum disorder. Targeted drug discovery efforts for MBD6 are also limited, as the function of this protein is not well understood. Currently, there are no drugs on the market that specifically target MBD6. However, there are drugs that target other proteins involved in chromatin binding and gene regulation, such as histone deacetylase inhibitors and DNA methyltransferase inhibitors. These drugs have been used in the treatment of various cancers and other diseases, but their efficacy in treating autism spectrum disorder is not yet known. Further research is needed to better understand the role of MBD6 in disease and to develop targeted therapies for related disorders.",,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000010810.17,ENSG00000010810,FYN,-1.431822995,-2.092511721,-0.879823669,-1.323133595,"FYN proto-oncogene, Src family tyrosine kinase",FYN proto-oncogene is a member of the protein-tyrosine kinase oncogene family that encodes a membrane-associated tyrosine kinase. This gene has been linked to the regulation of cell growth and interacts with the fyn-binding protein. It associates with the p85 subunit of phosphatidylinositol 3-kinase. There are different isoforms of this gene due to alternative splicing of transcript variants.,"The FYN proto-oncogene has been implicated in various diseases, including cancer, Alzheimer's disease, and HIV infection. In cancer, FYN has been shown to play a role in tumor growth, invasion, and metastasis. Targeted drug discovery efforts have focused on developing inhibitors of FYN kinase activity as potential cancer therapeutics. One example is the drug Saracatinib, which has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of solid tumors. In Alzheimer's disease, FYN has been linked to the regulation of synaptic plasticity and memory formation. Targeting FYN activity has been proposed as a potential therapeutic strategy for Alzheimer's disease, although no drugs targeting FYN are currently on the market for this indication. In HIV infection, FYN has been shown to play a role in viral replication and latency. Targeting FYN activity has been proposed as a potential strategy for developing new antiretroviral therapies, although no drugs targeting FYN are currently on the market for this indication.",GO:0000304 response to singlet oxygen;GO:1905430 cellular response to glycine;GO:0010730 negative regulation of hydrogen peroxide biosynthetic process,yes,Kinases:Tyr protein kinases; Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Plasma membrane (Supported); Additional: Cytosol,Dasatinib; Triglyme; Fostamatinib,(M251)PID SYNDECAN 3 PATHWAY; (M184)PID ECADHERIN KERATINOCYTE PATHWAY; (M33)PID GLYPICAN 1PATHWAY,(M5946)HALLMARK COAGULATION; (M5942)HALLMARK UV RESPONSE DN; (M5921)HALLMARK COMPLEMENT
ENSG00000137491.15,ENSG00000137491,SLCO2B1,-1.429358288,-1.559548837,-0.910719587,-1.817806441,solute carrier organic anion transporter family member 2B1,SLCO2B1 is a gene that encodes a membrane protein belonging to the organic anion-transporting polypeptide family. This protein may play a role in regulating the uptake of sulfated steroids in the placenta. Different versions of the gene have been identified due to alternative splicing.,"There is limited information available on the disease implications of SLCO2B1. However, some studies have suggested that variations in this gene may be associated with an increased risk of developing certain types of cancer, such as breast cancer and prostate cancer. Additionally, mutations in SLCO2B1 have been linked to a rare genetic disorder called primary hypertrophic osteoarthropathy, which is characterized by joint pain, swelling, and bone abnormalities.

As for targeted drug discovery efforts, there is ongoing research to develop drugs that can modulate the activity of SLCO2B1. One potential application is in the treatment of cancer, where drugs that inhibit the function of this gene could be used to prevent the uptake of sulfated steroids by cancer cells, thereby reducing their growth and proliferation. Another potential application is in the treatment of inflammatory diseases, where drugs that activate SLCO2B1 could be used to increase the uptake of anti-inflammatory compounds by cells in affected tissues.

Currently, there are no drugs on the market that specifically target SLCO2B1. However, there are several drugs that are known to interact with this gene, including certain antibiotics and cholesterol-lowering drugs. For example, the cholesterol-lowering drug ezetimibe has been shown to inhibit the function of SLCO2B1, which may contribute to its therapeutic effects. Overall, further research is needed to fully understand the role of SLCO2B1 in disease and to develop targeted therapies that can modulate its activity.",GO:0042167 heme catabolic process;GO:0046149 pigment catabolic process;GO:0006787 porphyrin-containing compound catabolic process,,Transporters:Electrochemical Potential-driven transporters; Predicted intracellular proteins,,Gemfibrozil; Telaprevir,,
ENSG00000132274.16,ENSG00000132274,TRIM22,-1.427380296,-2.089196511,-1.044975326,-1.147969053,tripartite motif containing 22,"TRIM22 is a human gene that belongs to the tripartite motif (TRIM) family. It contains three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. The protein encoded by this gene is located in the cytoplasm and is induced by interferon. It plays a role in innate immunity against various DNA and RNA viruses.","TRIM22 has been implicated in various diseases, including viral infections, autoimmune diseases, and cancer. In viral infections, TRIM22 has been shown to inhibit the replication of several viruses, including HIV, hepatitis B virus, and influenza A virus. In autoimmune diseases, TRIM22 has been found to be upregulated in patients with systemic lupus erythematosus and rheumatoid arthritis, suggesting a potential role in the pathogenesis of these diseases. In cancer, TRIM22 has been shown to have both tumor-suppressive and oncogenic properties, depending on the type of cancer.

Targeted drug discovery efforts for TRIM22 are still in the early stages, but several studies have identified potential small molecule inhibitors of TRIM22. For example, a recent study identified a compound that inhibits the E3 ubiquitin ligase activity of TRIM22, which could be a potential therapeutic strategy for diseases where TRIM22 is overactive.

Currently, there are no drugs on the market that specifically target TRIM22. However, there are several drugs that indirectly affect TRIM22 activity. For example, interferon, which induces TRIM22 expression, is used to treat viral infections such as hepatitis C and multiple sclerosis. Additionally, several drugs that target the immune system, such as methotrexate and rituximab, have been used to treat autoimmune diseases where TRIM22 is upregulated.",GO:0002230 positive regulation of defense response to virus by host;GO:0050691 regulation of defense response to virus by host;GO:0070534 protein K63-linked ubiquitination,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nuclear bodies;Nucleoplasm (Supported); Additional: Golgi apparatus,,,
ENSG00000170142.12,ENSG00000170142,UBE2E1,-1.422933119,-1.998978951,-1.643138291,-0.626682116,ubiquitin conjugating enzyme E2 E1,"The UBE2E1 gene encodes a member of the E2 ubiquitin-conjugating enzyme family, which is involved in the modification of proteins with ubiquitin for degradation. This process involves three classes of enzymes: E1s, E2s, and E3s. UBE2E1 has three alternatively spliced transcript variants that encode distinct isoforms.","Research has shown that UBE2E1 may play a role in the development and progression of certain diseases, including cancer and neurodegenerative disorders. In cancer, UBE2E1 has been found to be overexpressed in various types of tumors, including breast, lung, and prostate cancer, and may contribute to tumor growth and metastasis. As a result, UBE2E1 has been identified as a potential therapeutic target for cancer treatment. 

Several drug discovery efforts have focused on targeting UBE2E1, including the development of small molecule inhibitors and RNA interference (RNAi) approaches. One example is the small molecule inhibitor, CC0651, which has been shown to inhibit UBE2E1 activity and reduce tumor growth in preclinical models of breast cancer. 

Another example is the RNAi therapeutic, ALN-VSP02, which targets both UBE2E1 and kinesin spindle protein (KSP) and has shown promising results in preclinical models of liver cancer. 

Currently, there are no drugs on the market that specifically target UBE2E1, but ongoing research suggests that targeting this gene may have therapeutic potential for certain diseases, particularly cancer.",GO:0032020 ISG15-protein conjugation;GO:0006513 protein monoubiquitination;GO:0070936 protein K48-linked ubiquitination,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported),,,(M5926)HALLMARK MYC TARGETS V1
ENSG00000150687.12,ENSG00000150687,PRSS23,-1.422313774,-1.885161627,-1.185247924,-1.196531771,serine protease 23,"PRSS23 is a gene that encodes a serine protease, which is a type of enzyme that breaks down proteins. It belongs to the trypsin family of serine proteases and is conserved across species. Studies in mice have shown that the mRNA levels of this gene decrease after ovulation is induced. The gene undergoes alternative splicing, resulting in multiple transcript variants.","There is limited information available on the disease implications of PRSS23. However, studies have suggested that it may play a role in cancer progression and metastasis. In particular, it has been shown to be upregulated in breast cancer and may contribute to tumor growth and invasion. As such, there is interest in developing drugs that target PRSS23 as a potential therapeutic strategy for cancer treatment. However, there are currently no drugs on the market that specifically target PRSS23. Nonetheless, there are several drugs that target other serine proteases, such as trypsin and thrombin, which are used to treat a variety of conditions including blood clots, stroke, and pancreatitis. Examples of such drugs include heparin, dabigatran, and aprotinin. Further research is needed to determine the potential of targeting PRSS23 for drug discovery efforts.",GO:0006508 proteolysis;GO:0019538 protein metabolic process;GO:0043170 macromolecule metabolic process,,Predicted secreted proteins; Enzymes; Peptidases:Serine-type peptidases; Predicted intracellular proteins,,,,(M5946)HALLMARK COAGULATION; (M5906)HALLMARK ESTROGEN RESPONSE EARLY; (M5907)HALLMARK ESTROGEN RESPONSE LATE
ENSG00000144476.6,ENSG00000144476,ACKR3,-1.422113592,-2.142301987,-0.421291537,-1.702747251,atypical chemokine receptor 3,"ACKR3 is a gene that encodes a G-protein coupled receptor, which was initially believed to be a receptor for vasoactive intestinal peptide (VIP). However, it is now considered an orphan receptor as its endogenous ligand is unknown. The protein is also a coreceptor for human immunodeficiency viruses (HIV). Translocations involving this gene and HMGA2 on chromosome 12 have been observed in lipomas. The function of ACKR3 is not fully understood, but it is believed to play a role in immune response and inflammation.","ACKR3 has been implicated in various diseases, including cancer, HIV infection, and inflammatory disorders. In cancer, ACKR3 has been shown to promote tumor growth and metastasis by regulating angiogenesis and immune cell recruitment. Targeting ACKR3 has been explored as a potential therapeutic strategy for cancer, and several small molecule inhibitors have been developed, including BL-8040 and AZD-5069. BL-8040 is currently in clinical trials for multiple myeloma and acute myeloid leukemia, while AZD-5069 has been tested in clinical trials for chronic obstructive pulmonary disease (COPD). In HIV infection, ACKR3 is a coreceptor for viral entry into host cells, and targeting ACKR3 has been explored as a potential strategy for HIV therapy. However, no drugs targeting ACKR3 for HIV treatment are currently on the market. In inflammatory disorders, ACKR3 has been shown to regulate immune cell recruitment and cytokine production, and targeting ACKR3 has been explored as a potential therapeutic strategy for diseases such as rheumatoid arthritis and asthma. However, no drugs targeting ACKR3 for these indications are currently on the market.",GO:0021557 oculomotor nerve development;GO:1905320 regulation of mesenchymal stem cell migration;GO:1905322 positive regulation of mesenchymal stem cell migration,,G-protein coupled receptors:Chemokines and chemotactic factors receptors; Cancer-related genes; Potential drug targets; G-protein coupled receptors:GPCRs excl olfactory receptors; Disease related genes,Plasma membrane;Vesicles (Supported),,,(M5890)HALLMARK TNFA SIGNALING VIA NFKB; (M5891)HALLMARK HYPOXIA
ENSG00000133574.10,ENSG00000133574,GIMAP4,-1.421278328,-1.567067395,-0.86634885,-1.830418739,"GTPase, IMAP family member 4",GIMAP4 is a gene that encodes a protein belonging to the GTP-binding superfamily and the immuno-associated nucleotide (IAN) subfamily of nucleotide-binding proteins. It is located in a cluster at 7q36.1 in humans. The protein may be negatively regulated by T-cell acute lymphocytic leukemia 1 (TAL1).,"Research on GIMAP4 has suggested its involvement in various diseases, including autoimmune disorders, cancer, and infectious diseases. Studies have shown that GIMAP4 plays a role in regulating T-cell development and function, and its dysregulation has been linked to autoimmune disorders such as type 1 diabetes and multiple sclerosis. Additionally, GIMAP4 has been found to be downregulated in certain types of cancer, including leukemia and breast cancer, suggesting a potential tumor suppressor role.

Targeted drug discovery efforts for GIMAP4 are still in the early stages, but there is potential for the development of drugs that modulate its activity for therapeutic purposes. One study found that a small molecule inhibitor of GIMAP4 could reduce the severity of autoimmune disease in a mouse model, highlighting the potential for targeted therapies.

Currently, there are no drugs on the market that specifically target GIMAP4. However, there are drugs that indirectly affect its activity. For example, immunosuppressive drugs such as cyclosporine and tacrolimus, which are used to treat autoimmune disorders, have been shown to downregulate GIMAP4 expression. Additionally, some cancer treatments, such as chemotherapy and radiation therapy, have been found to upregulate GIMAP4 expression in cancer cells, potentially contributing to their anti-tumor effects.",,,Predicted intracellular proteins,Cytosol;Vesicles (Approved),,,
ENSG00000171115.4,ENSG00000171115,GIMAP8,-1.409915809,-1.538359219,-0.981187138,-1.71020107,"GTPase, IMAP family member 8","GIMAP8 is a human gene that belongs to the GTP-binding superfamily and the immuno-associated nucleotide (IAN) subfamily of nucleotide-binding proteins. It is located in a cluster at 7q36.1 along with other IAN subfamily genes. The function of GIMAP8 is not fully understood, but it is believed to play a role in immune system regulation. Mutations in this gene have been associated with autoimmune diseases such as type 1 diabetes and multiple sclerosis. Further research is needed to fully understand the function and potential therapeutic applications of GIMAP8.","There is limited information available on the disease implications and targeted drug discovery efforts for GIMAP8. However, studies have shown that mutations in this gene are associated with autoimmune diseases such as type 1 diabetes and multiple sclerosis. This suggests that GIMAP8 may be a potential target for drug discovery efforts aimed at treating these diseases. Currently, there are no drugs on the market that specifically target GIMAP8. However, there are several drugs that are used to treat autoimmune diseases, such as insulin for type 1 diabetes and interferon beta-1a for multiple sclerosis. Further research is needed to determine the potential of GIMAP8 as a therapeutic target and to develop drugs that specifically target this gene.",GO:0070232 regulation of T cell apoptotic process;GO:0070228 regulation of lymphocyte apoptotic process;GO:2000106 regulation of leukocyte apoptotic process,,Predicted intracellular proteins,,,,
ENSG00000177311.11,ENSG00000177311,ZBTB38,-1.409024499,-1.575436105,-1.309938578,-1.341698814,zinc finger and BTB domain containing 38,"ZBTB38 is a human gene that encodes a zinc finger transcriptional activator. This protein binds to methylated DNA and can form homodimers or heterodimers through its zinc finger domains. In mice, inhibiting this protein has been linked to apoptosis in certain cell types.","There is limited information available on the disease implications of ZBTB38. However, some studies have suggested that this gene may play a role in cancer development and progression. For example, one study found that ZBTB38 expression was significantly decreased in breast cancer tissues compared to normal breast tissues. Additionally, another study found that ZBTB38 expression was downregulated in hepatocellular carcinoma, a type of liver cancer. 

As of now, there are no targeted drug discovery efforts specifically focused on ZBTB38. However, there are drugs on the market that target other zinc finger transcription factors, which may have similar mechanisms of action to ZBTB38. For example, the drug thalidomide targets the zinc finger transcription factor Ikaros, which is involved in the regulation of immune cell development and function. Thalidomide is used to treat multiple myeloma and leprosy. Another drug, lenalidomide, is a derivative of thalidomide and also targets Ikaros. Lenalidomide is used to treat multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma.",GO:0006275 regulation of DNA replication;GO:0051052 regulation of DNA metabolic process;GO:0006974 DNA damage response,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000074181.9,ENSG00000074181,NOTCH3,-1.40808812,-0.659875899,-1.371018601,-2.19336986,notch receptor 3,"NOTCH3 is a human gene that encodes a type I membrane protein called notch receptor 3. It is the third discovered homologue of the Drosophilia melanogaster notch protein. In Drosophilia, notch interacts with its cell-bound ligands to establish an intercellular signalling pathway that plays a key role in neural development. Homologues of the notch-ligands have also been identified in humans, but their precise interactions with human notch homologues are yet to be determined. Mutations in NOTCH3 have been identified as the underlying cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).","Mutations in NOTCH3 have been linked to cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a rare genetic disorder that affects the small blood vessels in the brain. CADASIL is characterized by recurrent strokes, migraines, cognitive decline, and psychiatric symptoms. There are currently no targeted drug therapies available for CADASIL, and treatment is mainly supportive. However, several drugs have been investigated for their potential to modulate the Notch signaling pathway, including gamma-secretase inhibitors and monoclonal antibodies targeting Notch receptors. One example of a successful drug targeting the Notch pathway is the gamma-secretase inhibitor semagacestat, which was developed for the treatment of Alzheimer's disease but failed in clinical trials due to adverse effects.",GO:0072103 glomerulus vasculature morphogenesis;GO:0072104 glomerular capillary formation;GO:0014016 neuroblast differentiation,,Human disease related genes:Skin diseases:Skin and soft tissue diseases; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm;Plasma membrane (Supported),,(M17)PID NOTCH PATHWAY,(M5903)HALLMARK NOTCH SIGNALING
ENSG00000145703.16,ENSG00000145703,IQGAP2,-1.407315371,-1.582117728,-1.050450949,-1.589377436,IQ motif containing GTPase activating protein 2,"IQGAP2 is a gene that encodes a protein belonging to the IQGAP family. The protein contains several domains that allow it to interact with various cellular components and signaling molecules, regulating cell morphology and motility. It also acts as a tumor suppressor and plays a role in regulating innate antiviral responses. Alternative splicing of the gene results in multiple transcript variants.","Research has shown that IQGAP2 may play a role in several diseases, including cancer, neurological disorders, and viral infections. In cancer, IQGAP2 has been found to be downregulated in several types of tumors, and its loss has been associated with increased tumor growth and metastasis. Targeted drug discovery efforts are ongoing to develop drugs that can restore IQGAP2 expression or function in cancer cells. However, there are currently no drugs on the market that specifically target IQGAP2. In neurological disorders, IQGAP2 has been implicated in the regulation of synaptic plasticity and memory formation, and its dysfunction has been linked to conditions such as schizophrenia and Alzheimer's disease. In viral infections, IQGAP2 has been shown to play a role in the innate immune response to viral pathogens, and drugs that target this pathway may have potential in treating viral infections.",GO:1902407 assembly of actomyosin apparatus involved in mitotic cytokinesis;GO:1903475 mitotic actomyosin contractile ring assembly;GO:1903479 mitotic actomyosin contractile ring assembly actin filament organization,,Predicted intracellular proteins,Plasma membrane;Vesicles (Approved),,,(M5908)HALLMARK ANDROGEN RESPONSE
ENSG00000151208.17,ENSG00000151208,DLG5,-1.405955178,-2.421782152,-1.043045815,-0.753037566,discs large MAGUK scaffold protein 5,"DLG5 is a gene that belongs to the family of discs large homologs, which are a subset of the membrane-associated guanylate kinase superfamily. The protein encoded by this gene is thought to act as a scaffolding molecule at sites of cell-cell contact, and it interacts with components of adherens junctions and the cytoskeleton. DLG5 is proposed to play a role in the transmission of extracellular signals to the cytoskeleton and in the maintenance of epithelial cell structure. It localizes to the plasma membrane and cytoplasm. Alternative splice variants of DLG5 have been described, but their biological function is not yet known.","DLG5 has been implicated in several diseases, including inflammatory bowel disease (IBD) and colorectal cancer. Genome-wide association studies have identified DLG5 as a susceptibility gene for IBD, and mutations in DLG5 have been found in patients with Crohn's disease. DLG5 has also been shown to be overexpressed in colorectal cancer, and its expression levels have been correlated with tumor stage and patient survival.

Targeted drug discovery efforts for DLG5 are still in the early stages, but there is potential for DLG5 inhibitors to be developed as treatments for IBD and colorectal cancer. One study found that a small molecule inhibitor of DLG5 reduced inflammation in a mouse model of colitis, suggesting that targeting DLG5 could be a promising therapeutic strategy for IBD. However, more research is needed to fully understand the role of DLG5 in disease and to develop effective drugs that target this protein.

There are currently no drugs on the market that specifically target DLG5, but there are several drugs used to treat IBD and colorectal cancer that indirectly affect DLG5. For example, anti-inflammatory drugs such as corticosteroids and biologics like infliximab and adalimumab are commonly used to treat IBD, and these drugs may indirectly affect DLG5 expression and function. In colorectal cancer, chemotherapy drugs like 5-fluorouracil and oxaliplatin are used to kill cancer cells, and these drugs may also affect DLG5 expression and function.",GO:0045186 zonula adherens assembly;GO:0071896 protein localization to adherens junction;GO:0072205 metanephric collecting duct development,yes,Predicted intracellular proteins,Cell Junctions (Supported),,,(M5907)HALLMARK ESTROGEN RESPONSE LATE
ENSG00000076706.17,ENSG00000076706,MCAM,-1.40539063,-1.298717546,-1.283993933,-1.633460412,melanoma cell adhesion molecule,"MCAM, also known as melanoma cell adhesion molecule, is a gene that plays a role in glomerular filtration and vascular wound healing. It is involved in angiogenesis and is located on the external side of the plasma membrane. MCAM is a biomarker for chronic obstructive pulmonary disease and uveal melanoma.","MCAM has been implicated in various diseases, including cancer, cardiovascular disease, and chronic obstructive pulmonary disease (COPD). In cancer, MCAM is overexpressed in melanoma and is associated with tumor progression and metastasis. Targeting MCAM with monoclonal antibodies has shown promise in preclinical studies as a potential therapy for melanoma. In cardiovascular disease, MCAM has been shown to play a role in vascular wound healing and angiogenesis, making it a potential target for therapeutic intervention in conditions such as atherosclerosis and restenosis. In COPD, MCAM is a biomarker for disease severity and progression, and targeting MCAM may have potential as a therapeutic strategy. Currently, there are no drugs on the market that specifically target MCAM, but ongoing research efforts are focused on developing targeted therapies for diseases in which MCAM plays a role.",GO:0061042 vascular wound healing;GO:0060055 angiogenesis involved in wound healing;GO:0003094 glomerular filtration,,CD markers,Plasma membrane (Supported),,,
ENSG00000135720.13,ENSG00000135720,DYNC1LI2,-1.398262866,-1.556788197,-1.736740894,-0.901259506,dynein cytoplasmic 1 light intermediate chain 2,"DYNC1LI2 is a gene that encodes for the dynein cytoplasmic 1 light intermediate chain 2 protein. This protein is a component of the cytoplasmic dynein motor complex, which is responsible for transporting various cellular components along microtubules. The cytoplasmic dynein motor complex is involved in a variety of cellular processes, including mitosis, intracellular trafficking, and organelle positioning. Mutations in DYNC1LI2 have been associated with various neurological disorders, including Charcot-Marie-Tooth disease and hereditary spastic paraplegia.","Mutations in DYNC1LI2 have been associated with various neurological disorders, including Charcot-Marie-Tooth disease and hereditary spastic paraplegia. These disorders are characterized by progressive muscle weakness and spasticity, and there are currently no curative treatments available. However, there are ongoing efforts to develop targeted therapies for these disorders, including gene therapy and small molecule drugs that target the dynein motor complex.

One example of a successful drug targeting the dynein motor complex is tetrabenazine, which is used to treat Huntington's disease. Tetrabenazine works by inhibiting the activity of the dynein motor complex, which reduces the release of dopamine in the brain and helps to alleviate the symptoms of Huntington's disease. Another example is the drug ciliobrevin, which targets the dynein motor complex and has shown promise in preclinical studies for the treatment of neurodegenerative diseases.

Overall, while there are currently no approved drugs targeting DYNC1LI2 specifically, ongoing research into the dynein motor complex and its role in neurological disorders holds promise for the development of new treatments for these debilitating conditions.",GO:0051642 centrosome localization;GO:0061842 microtubule organizing center localization;GO:1990090 cellular response to nerve growth factor stimulus,,Predicted intracellular proteins,Centrosome;End piece (Approved); Additional: Cytosol,,,
ENSG00000147526.20,ENSG00000147526,TACC1,-1.390758846,-1.714431082,-1.537495917,-0.920349538,transforming acidic coiled-coil containing protein 1,"TACC1, or transforming acidic coiled-coil containing protein 1, is a gene located near FGFR1 on chromosome 8 that may be a candidate gene for breast cancer. This region of chromosome 8 is often amplified in some breast cancers. The gene has several transcript variants that encode different isoforms.","TACC1 has been implicated in several types of cancer, including breast, lung, and ovarian cancer. In breast cancer, TACC1 overexpression has been associated with poor prognosis and increased metastasis. Targeted drug discovery efforts have focused on developing inhibitors of TACC1 to treat cancer. One example is the small molecule inhibitor, KHS101, which has been shown to inhibit TACC1 and reduce tumor growth in preclinical models of breast cancer. Another example is the antibody-drug conjugate, TAK-164, which targets TACC1-expressing cancer cells and has shown promising results in preclinical studies. However, there are currently no FDA-approved drugs specifically targeting TACC1. Further research is needed to fully understand the role of TACC1 in cancer and to develop effective targeted therapies.",GO:0007097 nuclear migration;GO:0051647 nucleus localization;GO:0007052 mitotic spindle organization,,Predicted intracellular proteins,Cytosol (Approved),,(M242)PID AURORA A PATHWAY; (M14)PID AURORA B PATHWAY,
ENSG00000131788.16,ENSG00000131788,PIAS3,-1.378028724,-2.125846317,-1.204880793,-0.803359062,protein inhibitor of activated STAT 3,"PIAS3 is a gene that encodes a protein inhibitor of activated STAT (signal transducer and activator of transcription) family of transcriptional modulators. The protein acts as a SUMO (small ubiquitin-like modifier)-E3 ligase, which attaches a SUMO protein to specific target substrates. It binds to several transcription factors and either blocks or enhances their activity. The gene has alternatively spliced transcript variants, but the full-length nature of some of these variants is unknown. PIAS3 plays a crucial role in regulating gene expression and is involved in various cellular processes, including cell growth, differentiation, and apoptosis. Dysregulation of PIAS3 has been linked to several diseases, including cancer and autoimmune disorders.","PIAS3 dysregulation has been implicated in various diseases, including cancer and autoimmune disorders. In cancer, PIAS3 has been shown to act as a tumor suppressor by inhibiting the activity of oncogenic transcription factors. Therefore, targeting PIAS3 could be a potential therapeutic strategy for cancer treatment. In autoimmune disorders, PIAS3 has been found to regulate the activity of immune cells, and its dysregulation has been linked to the development of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

There are currently no drugs on the market that specifically target PIAS3. However, there have been efforts to develop drugs that modulate the activity of PIAS3 or its downstream targets. For example, a small molecule inhibitor of STAT3, which is regulated by PIAS3, has been developed and is currently in clinical trials for the treatment of cancer. Additionally, drugs that target other transcription factors regulated by PIAS3, such as NF-?B, are also being developed for the treatment of various diseases.

In summary, PIAS3 plays a crucial role in regulating gene expression and is involved in various cellular processes. Dysregulation of PIAS3 has been linked to several diseases, including cancer and autoimmune disorders. While there are currently no drugs on the market that specifically target PIAS3, there have been efforts to develop drugs that modulate its activity or downstream targets.",GO:0033234 negative regulation of protein sumoylation;GO:0033235 positive regulation of protein sumoylation;GO:0033233 regulation of protein sumoylation,,Predicted intracellular proteins,Nucleoplasm (Supported),,(M183)PID IL6 7 PATHWAY; (M58)PID AR PATHWAY; (M2)PID SMAD2 3NUCLEAR PATHWAY,(M5942)HALLMARK UV RESPONSE DN
ENSG00000149428.19,ENSG00000149428,HYOU1,-1.374082451,-1.788411129,-1.695598755,-0.638237469,hypoxia up-regulated 1,"HYOU1, also known as hypoxia up-regulated 1, belongs to the heat shock protein 70 family and plays an important role in protein folding and secretion in the endoplasmic reticulum (ER) under hypoxic conditions. It is suggested to have an important cytoprotective role in hypoxia-induced cellular perturbation and is up-regulated in tumors, especially in breast tumors, and thus associated with tumor invasiveness. This gene also has an alternative translation initiation site, resulting in a protein that lacks the N-terminal signal peptide and is thought to have a housekeeping function in the cytosol. Alternative splicing results in multiple transcript variants.","There is limited information available on the disease implications of HYOU1. However, studies have shown that HYOU1 is up-regulated in various types of cancer, including breast, lung, and pancreatic cancer, and is associated with tumor invasiveness and poor prognosis. Therefore, HYOU1 has been proposed as a potential therapeutic target for cancer treatment. Several drug discovery efforts have been made to target HYOU1, including the development of small molecule inhibitors and monoclonal antibodies. However, there are currently no drugs on the market that specifically target HYOU1. Nonetheless, some drugs that indirectly affect HYOU1 expression or function have been approved for cancer treatment, such as the proteasome inhibitor bortezomib, which has been shown to down-regulate HYOU1 expression in multiple myeloma cells.",GO:1903382 negative regulation of endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway;GO:1903381 regulation of endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway;GO:1903297 regulation of hypoxia-induced intrinsic apoptotic signaling pathway,,Predicted intracellular proteins; Transporters:Primary Active Transporters; Potential drug targets; Disease related genes; Human disease related genes:Immune system diseases:Primary immunodeficiency,,,,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000100852.13,ENSG00000100852,ARHGAP5,-1.371835581,-1.983060726,-1.373877019,-0.758568996,Rho GTPase activating protein 5,"ARHGAP5 is a human gene that encodes for Rho GTPase activating protein 5, which plays a role in negatively regulating RHO GTPases. These GTPases are involved in mediating changes in the cytoskeleton by stimulating the hydrolysis of bound GTP. The gene has two transcript variants that encode for different isoforms.","Research has shown that ARHGAP5 may play a role in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, ARHGAP5 has been found to be downregulated in certain types of tumors, suggesting a potential tumor suppressor role. In cardiovascular disease, ARHGAP5 has been linked to the regulation of smooth muscle cell migration and proliferation, which are key processes in the development of atherosclerosis. In neurological disorders, ARHGAP5 has been implicated in the regulation of dendritic spine morphology and synaptic plasticity, which are important for learning and memory.

Targeted drug discovery efforts for ARHGAP5 are still in the early stages, but there is potential for the development of drugs that modulate its activity. One approach could be to develop small molecules that mimic the activity of ARHGAP5 and act as Rho GTPase inhibitors. Another approach could be to develop drugs that target the upstream regulators of ARHGAP5, such as microRNAs or transcription factors.

Currently, there are no drugs on the market that specifically target ARHGAP5. However, there are drugs that target Rho GTPases, such as statins, which have been shown to inhibit RhoA activity and reduce atherosclerosis. Additionally, there are drugs that target other Rho GTPase activating proteins, such as p190RhoGAP, which is targeted by the cancer drug fasudil. These drugs could potentially have indirect effects on ARHGAP5 activity.",GO:0002053 positive regulation of mesenchymal cell proliferation;GO:0010631 epithelial cell migration;GO:0010464 regulation of mesenchymal cell proliferation,,Predicted intracellular proteins,Cytosol;Endoplasmic reticulum (Supported),,(M68)PID RHOA REG PATHWAY; (M278)PID RAC1 PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000198642.7,ENSG00000198642,KLHL9,-1.371778832,-2.662201669,-1.12675596,-0.326378866,kelch like family member 9,"KLHL9 is a human gene that encodes a protein belonging to the kelch repeat-containing family. The protein contains an N-terminal BTB/POZ domain, a BACK domain, and six C-terminal kelch repeats. It is a component of a complex with cullin 3-based E3 ligase, which plays a role in mitosis. The protein complex is a cell cycle regulator and is required for the organization and integrity of the spindle midzone in anaphase and the completion of cytokinesis. It is also necessary for the removal of the chromosomal passenger protein aurora B from mitotic chromosomes.","There is limited information available on the disease implications of KLHL9. However, recent studies have suggested that KLHL9 may play a role in the development and progression of certain cancers, including lung cancer and breast cancer. Targeted drug discovery efforts for KLHL9 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and disrupt its function in cancer cells. While there are currently no drugs on the market that specifically target KLHL9, there are several drugs that target other components of the cullin 3-based E3 ligase complex, including thalidomide and lenalidomide, which are used to treat multiple myeloma and other blood cancers. These drugs work by binding to the cereblon protein, which is a component of the E3 ligase complex, and promoting the degradation of certain cancer-causing proteins.",GO:0032465 regulation of cytokinesis;GO:0051302 regulation of cell division;GO:0051301 cell division,,Predicted intracellular proteins,Cytosol (Approved),,(M14)PID AURORA B PATHWAY,
ENSG00000003056.8,ENSG00000003056,M6PR,-1.37126531,-1.748515267,-1.707190533,-0.65809013,"mannose-6-phosphate receptor, cation dependent",The M6PR gene encodes a protein that belongs to the P-type lectin family and plays a crucial role in lysosome function by transporting mannose-6-phosphate-containing acid hydrolases from the Golgi complex to lysosomes. The protein functions as a homodimer and requires divalent cations for ligand binding. Multiple isoforms of the protein have been observed due to alternative splicing of the transcript variants. A pseudogene of this gene is located on the long arm of chromosome X.,"Mutations in the M6PR gene have been associated with several lysosomal storage disorders, including mucolipidosis II and III, which are characterized by the accumulation of undigested material in lysosomes. Targeted drug discovery efforts have focused on developing small molecule inhibitors of M6PR to treat lysosomal storage disorders. One example is the drug miglustat, which inhibits the enzyme glucosylceramide synthase and has been approved for the treatment of Gaucher disease, a lysosomal storage disorder. Another example is the drug eliglustat, which inhibits the enzyme glucosylceramide synthase and has been approved for the treatment of Gaucher disease type 1. These drugs work by reducing the accumulation of glycosphingolipids in lysosomes, which can lead to improved clinical outcomes for patients with lysosomal storage disorders.",GO:0033299 secretion of lysosomal enzymes;GO:0046479 glycosphingolipid catabolic process;GO:0019377 glycolipid catabolic process,,FDA approved drug targets:Biotech drugs; Predicted intracellular proteins; Transporters,,Alglucosidase alfa; 1-3 Sugar Ring of Pentamannosyl 6-Phosphate; alpha-D-mannose 6-phosphate,,(M5910)HALLMARK PROTEIN SECRETION; (M5924)HALLMARK MTORC1 SIGNALING
ENSG00000128567.17,ENSG00000128567,PODXL,-1.369254901,-1.135210321,-1.282619361,-1.689935021,podocalyxin like,"PODXL (podocalyxin-like) is a gene that encodes a protein belonging to the sialomucin protein family. Originally identified as a crucial component of glomerular podocytes, which are specialized cells in the kidney, the protein is also involved in other biological activities such as binding to intracellular cytoskeletal elements, playing a role in hematopoietic cell differentiation, and being expressed in vascular endothelium cells and binding to L-selectin. The protein is known to form a membrane protein complex with Na+/H+ exchanger regulatory factor. The gene is located on chromosome 7 and mutations in this gene have been associated with various diseases including cancer and kidney disease.","Mutations in the PODXL gene have been associated with various diseases, including cancer and kidney disease. In cancer, PODXL has been found to be overexpressed in several types of tumors, including breast, colon, lung, and pancreatic cancer, and is associated with poor prognosis and metastasis. Targeted drug discovery efforts have focused on developing inhibitors of PODXL expression or function, with some promising results in preclinical studies. For example, a monoclonal antibody targeting PODXL has shown efficacy in reducing tumor growth and metastasis in mouse models of breast and pancreatic cancer. However, there are currently no drugs targeting PODXL on the market. Further research is needed to fully understand the role of PODXL in disease and to develop effective therapies targeting this protein.",GO:0032534 regulation of microvillus assembly;GO:0033634 positive regulation of cell-cell adhesion mediated by integrin;GO:0033632 regulation of cell-cell adhesion mediated by integrin,,Transporters:Accessory Factors Involved in Transport,Endoplasmic reticulum;Plasma membrane (Approved); Additional: Centriolar satellite;Nucleoli;Vesicles,,,(M5906)HALLMARK ESTROGEN RESPONSE EARLY
ENSG00000037280.16,ENSG00000037280,FLT4,-1.366227412,-1.708284921,-0.877969172,-1.512428143,fms related receptor tyrosine kinase 4,"The FLT4 gene encodes a receptor tyrosine kinase that binds to vascular endothelial growth factors C and D. It is involved in the growth and maintenance of lymphatic vessels, a process known as lymphangiogenesis. Mutations in this gene have been linked to hereditary lymphedema type IA, a condition characterized by swelling in the limbs due to impaired lymphatic drainage. The FLT4 gene is important for the proper functioning of the lymphatic system and its dysregulation can lead to various diseases.","The FLT4 gene has been implicated in various diseases, including lymphedema, cancer, and inflammatory disorders. Targeted drug discovery efforts have focused on developing inhibitors of the FLT4 receptor tyrosine kinase as potential therapies for these diseases. One example is the drug, nintedanib, which targets multiple receptor tyrosine kinases including FLT4 and has been approved for the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer. Another example is the drug, ramucirumab, which targets vascular endothelial growth factor receptor 2 (VEGFR2) and has been approved for the treatment of gastric and colorectal cancers. While there are currently no drugs specifically targeting FLT4 for the treatment of lymphedema, ongoing research in this area may lead to the development of novel therapies in the future.",GO:0060312 regulation of blood vessel remodeling;GO:0001946 lymphangiogenesis;GO:0036303 lymph vessel morphogenesis,yes,Human disease related genes:Congenital malformations:Congenital malformations of the circulatory system; Kinases:Tyr protein kinases; RAS pathway related proteins; Predicted intracellular proteins; Predicted secreted proteins; ENZYME proteins:Transferases; Human disease related genes:Cardiovascular diseases:Vascular diseases; Transporters:Accessory Factors Involved in Transport; Human disease related genes:Congenital malformations:Congenital malformations of skin; FDA approved drug targets:Small molecule drugs; Disease related genes; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Microtubules;Primary cilium (Approved); Additional: Calyx;Connecting piece;Cytokinetic bridge;Mid piece;Principal piece,Sorafenib; Sunitinib; Vatalanib; TG-100801; Denibulin; ABT-869; IMC-1C11; Pazopanib; Axitinib; Regorafenib; Lenvatinib; Nintedanib; Fostamatinib; Selpercatinib,(M137)PID VEGF VEGFR PATHWAY; (M274)PID LYMPH ANGIOGENESIS PATHWAY,(M5953)HALLMARK KRAS SIGNALING UP
ENSG00000116016.14,ENSG00000116016,EPAS1,-1.364623102,-1.301880123,-1.100294261,-1.691694921,endothelial PAS domain protein 1,"The EPAS1 gene encodes a transcription factor that regulates genes in response to changes in oxygen levels. It contains a domain that responds to oxygen levels and is involved in signal transduction pathways. Mutations in this gene are linked to erythrocytosis familial type 4, a condition characterized by an increase in red blood cells.","EPAS1 gene mutations have been linked to several diseases, including erythrocytosis familial type 4, which is characterized by an increase in red blood cells. This condition can lead to complications such as blood clots, stroke, and heart attack. Targeted drug discovery efforts have focused on developing drugs that can inhibit the activity of EPAS1, which could potentially be used to treat erythrocytosis and other diseases associated with the gene.

One example of a successful drug targeting EPAS1 is Roxadustat, which was approved by the FDA in 2019 for the treatment of anemia in patients with chronic kidney disease. Roxadustat works by activating the hypoxia-inducible factor (HIF) pathway, which is regulated by EPAS1, to increase the production of red blood cells. Another drug in development is FG-4592, which also targets the HIF pathway and is being studied for the treatment of anemia in patients with chronic kidney disease.

Overall, the EPAS1 gene and its associated pathways have significant implications for the treatment of diseases such as erythrocytosis and anemia. Targeted drug discovery efforts have led to the development of successful drugs such as Roxadustat, and ongoing research may lead to the development of additional therapies in the future.",GO:0048625 myoblast fate commitment;GO:0042415 norepinephrine metabolic process;GO:0043129 surfactant homeostasis,,Transcription factors:Basic domains; Human disease related genes:Cancers:Cancers of endocrine organs; Predicted intracellular proteins; FDA approved drug targets:Small molecule drugs; Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported); Additional: Actin filaments;Cytokinetic bridge;Cytosol,PT2977,(M44)PID HIF2PATHWAY,
ENSG00000130723.21,ENSG00000130723,PRRC2B,-1.360312555,-1.80587134,-1.567273242,-0.707793082,None,None,None,None,None,None,None,None,None,None
ENSG00000160294.11,ENSG00000160294,MCM3AP,-1.353585931,-1.686877871,-1.546030387,-0.827849534,minichromosome maintenance complex component 3 associated protein,"MCM3AP is a gene that encodes a protein that binds to the minichromosome maintenance protein 3 (MCM3), which is essential for DNA replication. The protein encoded by MCM3AP has been shown to have phosphorylation-dependent DNA-primase activity and is up-regulated in germinal centers during antigen immunization. It is also an acetyltransferase that acetylates MCM3 and plays a role in DNA replication. MCM3AP may also facilitate MCM3 nuclear localization. The gene is expressed in the brain or in neuronal tissue and an allelic variant has been identified in patients with mild intellectual disability.","There is limited information available on the disease implications of MCM3AP. However, an allelic variant of the gene has been identified in patients with mild intellectual disability. Targeted drug discovery efforts for MCM3AP are also limited, as the function of the protein is not fully understood. However, given its role in DNA replication and potential involvement in neurological disorders, it may be a target for drug development in the future. Currently, there are no drugs on the market that specifically target MCM3AP. However, there are drugs that target other proteins involved in DNA replication, such as gemcitabine and cisplatin, which are used in the treatment of various cancers.",GO:0016446 somatic hypermutation of immunoglobulin genes;GO:0002566 somatic diversification of immune receptors via somatic mutation;GO:0016973 poly(A)+ mRNA export from nucleus,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes; Transporters:Transporter channels and pores,Cytosol;Nuclear membrane (Supported); Additional: Nucleoplasm,,,
ENSG00000111885.7,ENSG00000111885,MAN1A1,-1.352224666,-1.060878072,-1.254448931,-1.741346996,mannosidase alpha class 1A member 1,"The MAN1A1 gene encodes a type II transmembrane protein that belongs to family 47 of glycosyl hydrolases. This protein is a class I mammalian Golgi 1,2-mannosidase that catalyzes the hydrolysis of three terminal mannose residues from peptide-bound Man(9)-GlcNAc(2) oligosaccharides. In simpler terms, this gene provides instructions for making an enzyme that helps break down certain sugar molecules in the body.","Mutations in the MAN1A1 gene have been associated with several diseases, including congenital disorder of glycosylation type IIa (CDG-IIa), which is characterized by developmental delay, intellectual disability, and abnormal glycosylation of proteins. Targeted drug discovery efforts for CDG-IIa have focused on developing small molecule inhibitors of the MAN1A1 enzyme to restore normal glycosylation. One example is the drug Miglustat, which is approved for the treatment of Gaucher disease and has also shown promise in treating CDG-IIa. Another potential drug target is the unfolded protein response (UPR) pathway, which is activated in response to abnormal protein glycosylation and can lead to cell death. Drugs that target the UPR pathway, such as 4-phenylbutyrate, have shown promise in preclinical studies for treating CDG-IIa. Overall, while there are currently no approved drugs specifically targeting MAN1A1, ongoing research efforts hold promise for developing effective treatments for CDG-IIa and other diseases associated with abnormal glycosylation.",GO:0035977 protein deglycosylation involved in glycoprotein catabolic process;GO:1904382 mannose trimming involved in glycoprotein ERAD pathway;GO:1904381 Golgi apparatus mannose trimming,,ENZYME proteins:Hydrolases; Enzymes,Golgi apparatus (Supported),,,(M5934)HALLMARK XENOBIOTIC METABOLISM
ENSG00000137628.17,ENSG00000137628,DDX60,-1.35082817,-1.988296845,-1.592854299,-0.471333368,DExD/H-box helicase 60,"DDX60 is a gene that encodes a DExD/H-box RNA helicase, which is a type of protein that is involved in altering RNA secondary structure and RNA binding. This protein is a part of the DEAD box protein family and is known to function as an antiviral factor. It promotes RIG-I-like receptor-mediated signaling, which is important for the immune response to viral infections. The conserved motif Asp-Glu-Ala-Asp (DEAD) is present in this protein, which is a characteristic feature of DEAD box proteins. Overall, DDX60 plays an important role in the immune response to viral infections by promoting antiviral signaling.","There is limited information available on the disease implications of DDX60. However, recent studies have suggested that DDX60 may play a role in the pathogenesis of certain viral infections, including hepatitis C virus (HCV) and influenza A virus (IAV). Targeted drug discovery efforts for DDX60 are currently underway, with a focus on identifying small molecule inhibitors that can modulate its activity. While there are no drugs currently on the market that specifically target DDX60, there are several antiviral drugs that have been developed to target viral infections that may indirectly affect DDX60 activity. For example, direct-acting antiviral agents (DAAs) such as sofosbuvir and ledipasvir have been developed to treat HCV infections, while neuraminidase inhibitors such as oseltamivir and zanamivir are used to treat IAV infections. These drugs may indirectly affect DDX60 activity by reducing viral replication and promoting antiviral signaling.",GO:1900245 positive regulation of MDA-5 signaling pathway;GO:0039533 regulation of MDA-5 signaling pathway;GO:1900246 positive regulation of RIG-I signaling pathway,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol (Supported); Additional: Intermediate filaments,,,(M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000140688.17,ENSG00000140688,RUSF1,-1.349819266,-1.923081302,-1.865344568,-0.261031928,RUS family member 1,"RUSF1, or RUS family member 1, is a gene that encodes a transmembrane protein with a conserved DUF647 domain. This protein is believed to be involved in protein-protein interaction and is related to a plant protein that plays a role in sensing ultraviolet B light during root development. The exact function of RUSF1 in humans is not yet fully understood, but it is thought to be involved in cellular processes related to growth and development.","There is limited information available on the disease implications of RUSF1. However, recent studies have suggested that mutations in this gene may be associated with developmental disorders such as intellectual disability and autism spectrum disorder. Targeted drug discovery efforts for RUSF1 are currently in the early stages, and there are no drugs on the market that specifically target this gene. However, there are drugs that target related pathways involved in growth and development, such as growth hormone therapy for children with growth hormone deficiency. Additionally, drugs that target protein-protein interactions, which RUSF1 is believed to be involved in, are being developed for various diseases such as cancer and autoimmune disorders. Further research is needed to fully understand the role of RUSF1 in disease and to develop targeted therapies.",,,Predicted intracellular proteins,Golgi apparatus;Nucleoli;Vesicles (Approved); Additional: Cytosol;Nucleoplasm,,,
ENSG00000138172.11,ENSG00000138172,CALHM2,-1.344465854,-1.791417445,-1.003418279,-1.238561839,calcium homeostasis modulator family member 2,CALHM2 is a human gene that is predicted to enable cation channel activity and is involved in the positive regulation of the apoptotic process. It is also predicted to be an integral component of the plasma membrane. The gene is a member of the calcium homeostasis modulator family and its function is related to the regulation of calcium levels in cells. The gene's role in apoptosis suggests that it may play a role in cell death and survival. Further research is needed to fully understand the function of CALHM2 and its potential implications for human health.,"There is limited information available on the disease implications of CALHM2. However, some studies have suggested that mutations in the gene may be associated with an increased risk of Alzheimer's disease. Targeted drug discovery efforts for CALHM2 are also limited, but some studies have suggested that modulating the activity of the gene may have therapeutic potential for Alzheimer's disease. Currently, there are no drugs on the market that specifically target CALHM2. However, there are drugs that target calcium channels, which may indirectly affect the activity of CALHM2. For example, the drug verapamil is a calcium channel blocker that is used to treat hypertension and angina.",GO:1904669 ATP export;GO:1903978 regulation of microglial cell activation;GO:0015867 ATP transport,,Transporters:Transporter channels and pores,Mitochondria;Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000196547.15,ENSG00000196547,MAN2A2,-1.339680442,-1.809114197,-1.602373889,-0.607553239,mannosidase alpha class 2A member 2,The MAN2A2 gene is predicted to encode a protein that has alpha-mannosidase activity and is involved in N-glycan processing and protein deglycosylation. It is also predicted to be an integral component of the membrane and active in the Golgi membrane. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of the MAN2A2 gene. However, mutations in the MAN2A1 gene, which encodes a similar protein, have been associated with lysosomal storage disorders such as alpha-mannosidosis. It is possible that mutations in MAN2A2 could also lead to similar disorders, but further research is needed to confirm this.

As for targeted drug discovery efforts, there are currently no drugs specifically targeting MAN2A2. However, there is ongoing research on developing inhibitors of alpha-mannosidase enzymes for the treatment of lysosomal storage disorders. These inhibitors could potentially be effective for disorders associated with mutations in MAN2A2 as well.

One example of a successful drug targeting alpha-mannosidase is velmanase alfa, which is used to treat alpha-mannosidosis. Velmanase alfa is a recombinant form of human alpha-mannosidase that is administered intravenously. Another example is miglustat, which is used to treat Gaucher disease and Niemann-Pick disease type C. Miglustat is an inhibitor of glucosylceramide synthase, an enzyme involved in glycosphingolipid synthesis, and has been shown to reduce the accumulation of glycosphingolipids in lysosomes.",GO:0006013 mannose metabolic process;GO:0006491 N-glycan processing;GO:0019318 hexose metabolic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytoplasmic bodies (Approved),,,
ENSG00000066056.14,ENSG00000066056,TIE1,-1.3371312,-1.5966964,-0.818678775,-1.596018424,tyrosine kinase with immunoglobulin like and EGF like domains 1,"TIE1 is a gene that encodes a tyrosine protein kinase, which plays a crucial role in angiogenesis and blood vessel stability. It inhibits angiopoietin 1 signaling through the endothelial receptor tyrosine kinase Tie2. The encoded protein is cleaved by multiple factors, including vascular endothelial growth factor, which relieves inhibition of Tie2. The gene has multiple alternatively spliced transcript variants that encode multiple isoforms.","Dysregulation of TIE1 has been implicated in various diseases, including cancer, cardiovascular diseases, and inflammatory disorders. In cancer, TIE1 has been shown to promote tumor angiogenesis and metastasis, making it a potential target for anti-cancer therapies. Several drug discovery efforts have focused on developing small molecule inhibitors of TIE1, with promising preclinical results. One example is the compound TIE-2 inhibitor 1, which has been shown to inhibit tumor growth and angiogenesis in mouse models of breast cancer. Another example is the antibody-drug conjugate, enfortumab vedotin, which targets TIE1-expressing cancer cells and has been approved for the treatment of advanced urothelial cancer. In cardiovascular diseases, TIE1 has been implicated in the regulation of blood vessel stability and permeability, making it a potential target for the treatment of conditions such as atherosclerosis and diabetic retinopathy. Overall, targeting TIE1 holds promise for the development of novel therapies for a range of diseases.",GO:0060854 branching involved in lymph vessel morphogenesis;GO:0060836 lymphatic endothelial cell differentiation;GO:0001946 lymphangiogenesis,yes,Kinases:Tyr protein kinases; Predicted intracellular proteins; ENZYME proteins:Transferases; Human disease related genes:Congenital malformations:Congenital malformations of skin; Potential drug targets; Disease related genes; Enzymes; Cancer-related genes:Candidate cancer biomarkers,,Fostamatinib,,
ENSG00000138449.11,ENSG00000138449,SLC40A1,-1.331950991,-2.12840903,-1.100748257,-0.766695685,solute carrier family 40 member 1,"SLC40A1 is a gene that encodes a protein involved in exporting iron from the cells lining the small intestine. Mutations in this gene can lead to a condition called hemochromatosis type 4, which causes excessive iron accumulation in the body. The protein encoded by SLC40A1 is a cell membrane protein, meaning it is located on the surface of cells and helps regulate the movement of substances in and out of the cell. This gene is important for maintaining proper iron balance in the body, and defects in SLC40A1 can lead to serious health problems.","Hemochromatosis type 4 is a rare genetic disorder caused by mutations in the SLC40A1 gene. This condition leads to excessive iron accumulation in the body, which can cause damage to organs such as the liver, heart, and pancreas. Treatment for hemochromatosis type 4 typically involves regular blood removal (phlebotomy) to reduce iron levels in the body. There are currently no targeted drug therapies available for this condition, but research is ongoing to identify potential drug targets and develop new treatments. One example of a successful drug for treating iron overload disorders is deferasirox, which is used to treat patients with transfusional iron overload. Deferasirox works by binding to excess iron in the body and helping to remove it through urine and feces.",GO:0060345 spleen trabecula formation;GO:1903988 iron ion export across plasma membrane;GO:0034755 iron ion transmembrane transport,,Predicted intracellular proteins; Transporters:Electrochemical Potential-driven transporters; Potential drug targets; Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of ion transport and metabolism,Cytosol;Plasma membrane (Approved); Additional: Nucleoplasm,,,
ENSG00000004700.16,ENSG00000004700,RECQL,-1.330288336,-1.648049809,-1.678949106,-0.663866095,RecQ like helicase,"RECQL is a gene that encodes a protein belonging to the RecQ DNA helicase family. These enzymes are involved in repairing DNA damage, including mismatch repair, nucleotide excision repair, and direct repair. RECQL is specifically involved in processing Holliday junctions, suppressing sister chromatid exchanges, maintaining telomeres, and providing resistance to genotoxic stress. Mutations in this gene have been linked to various types of cancer.","Mutations in the RECQL gene have been associated with several types of cancer, including breast, ovarian, and pancreatic cancer. As a result, there has been interest in developing drugs that target RECQL as a potential cancer therapy. However, there are currently no drugs on the market that specifically target RECQL. 

One approach to targeting RECQL is to develop inhibitors of its helicase activity, which could prevent the protein from carrying out its DNA repair functions. Several compounds have been identified that inhibit RECQL helicase activity in vitro, but their efficacy in vivo remains to be determined. 

Another approach is to target the downstream effects of RECQL mutations, such as defects in DNA repair or telomere maintenance. For example, PARP inhibitors have been approved for the treatment of BRCA-mutated breast and ovarian cancer, which are also associated with RECQL mutations. These drugs exploit defects in DNA repair pathways to selectively kill cancer cells. 

Overall, while there is interest in targeting RECQL for cancer therapy, more research is needed to fully understand its role in cancer and to develop effective drugs that specifically target this protein.",GO:0006268 DNA unwinding involved in DNA replication;GO:0031297 replication fork processing;GO:0045005 DNA-templated DNA replication maintenance of fidelity,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000168906.13,ENSG00000168906,MAT2A,-1.329816689,-1.834812967,-1.308912077,-0.845725024,methionine adenosyltransferase 2A,"MAT2A is a human gene that encodes for the production of S-adenosylmethionine (AdoMet) from methionine and ATP. AdoMet is an important methyl donor in cellular processes. The protein produced by this gene, methionine adenosyltransferase 2A, plays a crucial role in catalyzing the production of AdoMet. This gene is essential for normal cellular function and any mutations or dysregulation of its expression can lead to various diseases and disorders.","Dysregulation of MAT2A expression has been implicated in various diseases, including liver cancer, non-alcoholic fatty liver disease, and depression. In liver cancer, MAT2A expression is often downregulated, leading to a decrease in AdoMet production and subsequent alterations in DNA methylation and gene expression. Targeting MAT2A has been explored as a potential therapeutic strategy for liver cancer and other diseases. Several small molecule inhibitors of MAT2A have been developed and tested in preclinical studies, showing promising results in reducing tumor growth and improving liver function. One example is 3-deazaneplanocin A (DZNep), which has been shown to inhibit MAT2A and induce apoptosis in liver cancer cells. Another example is cycloleucine, which has been shown to inhibit MAT2A and reduce liver fibrosis in animal models. However, further research is needed to fully understand the potential of targeting MAT2A for therapeutic purposes.",GO:0006556 S-adenosylmethionine biosynthetic process;GO:0061431 cellular response to methionine;GO:1904640 response to methionine,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Approved); Additional: Cytosol,Ademetionine,(M195)PID CMYB PATHWAY,
ENSG00000100242.15,ENSG00000100242,SUN2,-1.328530391,-1.806347503,-1.746471472,-0.432772199,Sad1 and UNC84 domain containing 2,"SUN2 is a gene that encodes for a protein found in the inner nuclear membrane (INM) of cells. Along with SUN1, it plays a crucial role in connecting the nucleus to the cytoplasm by forming a bridge called the LINC complex. This complex interacts with nesprins, which are located in the outer nuclear membrane (ONM), via their luminal KASH domain. The LINC complex provides a direct connection between the nuclear lamina and the cytoskeleton, which contributes to nuclear positioning and cellular rigidity. SUN2 is important for maintaining the structural integrity of the nucleus and proper cellular function.","Mutations in the SUN2 gene have been associated with several diseases, including muscular dystrophy, Emery-Dreifuss muscular dystrophy, and cancer. In muscular dystrophy, SUN2 mutations disrupt the LINC complex, leading to abnormal nuclear positioning and muscle weakness. In cancer, SUN2 has been found to play a role in tumor growth and metastasis. Targeted drug discovery efforts for SUN2 are still in the early stages, but there is potential for developing drugs that can modulate the LINC complex and restore proper nuclear positioning in diseased cells. Currently, there are no drugs on the market that specifically target SUN2, but there are drugs that indirectly affect the LINC complex, such as statins, which have been shown to improve muscle function in some muscular dystrophy patients.",GO:0031022 nuclear migration along microfilament;GO:0021817 nucleokinesis involved in cell motility in cerebral cortex radial glia guided migration;GO:0043578 nuclear matrix organization,,Transporters:Transporter channels and pores; Predicted intracellular proteins,Nuclear membrane (Supported),,,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000129675.16,ENSG00000129675,ARHGEF6,-1.328290104,-2.026762672,-1.148422947,-0.809684694,Rac/Cdc42 guanine nucleotide exchange factor 6,"ARHGEF6 is a human gene that encodes a protein called Rac/Cdc42 guanine nucleotide exchange factor 6. This protein is involved in activating Rho GTPases, which play a crucial role in various cellular processes initiated by extracellular stimuli that work through G protein-coupled receptors. ARHGEF6 may form a complex with G proteins and stimulate Rho-dependent signals, and it is activated by PI3-kinase. Mutations in this gene can cause X-chromosomal non-specific cognitive disability.","Mutations in the ARHGEF6 gene have been linked to X-linked non-specific cognitive disability, a condition characterized by intellectual disability, delayed speech and language development, and behavioral problems. There are currently no targeted drug discovery efforts specifically for ARHGEF6, but drugs that target Rho GTPases, such as statins and bisphosphonates, have been investigated for their potential to treat cognitive impairment associated with neurodegenerative diseases. However, these drugs have not been successful in clinical trials for cognitive impairment. There are currently no drugs on the market that specifically target ARHGEF6 or its associated cognitive disability.",GO:0030032 lamellipodium assembly;GO:0097581 lamellipodium organization;GO:0007254 JNK cascade,,Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Cytosol;Plasma membrane (Approved),,(M83)PID CDC42 REG PATHWAY; (M241)PID RAC1 REG PATHWAY; (M71)PID ILK PATHWAY,(M5915)HALLMARK APICAL JUNCTION
ENSG00000111335.13,ENSG00000111335,OAS2,-1.325959021,-1.586423151,-0.434138305,-1.957315607,2'-5'-oligoadenylate synthetase 2,"OAS2 is a gene that belongs to the 2-5A synthetase family and plays a crucial role in the innate immune response to viral infections. This gene is activated by interferons and synthesizes 2',5'-oligoadenylates (2-5As) using adenosine triphosphate in 2'-specific nucleotidyl transfer reactions. These molecules activate latent RNase L, which leads to the degradation of viral RNA and the inhibition of viral replication. OAS2 is one of three known members of this gene family, and all three are located in a cluster on chromosome 12. Different isoforms of OAS2 have been described due to alternative splicing of its transcript variants.","OAS2 has been implicated in various viral infections, including hepatitis C virus (HCV), human immunodeficiency virus (HIV), and influenza A virus. Studies have shown that OAS2 expression is upregulated in response to these infections, and its activation leads to the inhibition of viral replication. Therefore, OAS2 has been considered as a potential therapeutic target for antiviral drug development. Several compounds have been identified that can activate OAS2 and enhance its antiviral activity, including ribavirin, a broad-spectrum antiviral drug used to treat HCV and other viral infections. Additionally, a recent study has shown that a small molecule inhibitor of OAS2 can enhance the replication of oncolytic viruses, which could be used as a novel cancer therapy. However, further research is needed to fully understand the potential of OAS2 as a therapeutic target for viral infections and cancer.",GO:1903487 regulation of lactation;GO:0070106 interleukin-27-mediated signaling pathway;GO:0032728 positive regulation of interferon-beta production,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Centrosome (Approved),,,(M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000054983.17,ENSG00000054983,GALC,-1.325271052,-2.345333888,-0.66070844,-0.969770829,galactosylceramidase,"The GALC gene encodes a lysosomal protein called galactosylceramidase, which breaks down certain types of lipids in the body, including galactosylceramide, galactosylsphingosine, lactosylceramide, and monogalactosyldiglyceride. Mutations in this gene have been linked to Krabbe disease, a rare genetic disorder that affects the nervous system and can lead to developmental delays, muscle weakness, and vision and hearing loss. Different versions of the gene, called alternate transcriptional splice variants, have been identified and characterized.","Krabbe disease is a rare genetic disorder caused by mutations in the GALC gene, which leads to a deficiency in galactosylceramidase activity. This results in the accumulation of toxic lipids in the nervous system, leading to progressive damage to the myelin sheath that surrounds nerve fibers. There is currently no cure for Krabbe disease, and treatment options are limited to supportive care and symptom management. However, there have been efforts to develop targeted therapies for this condition, including enzyme replacement therapy and gene therapy. One example of a successful drug on the market is Zavesca (miglustat), which is approved for the treatment of another lysosomal storage disorder called Gaucher disease. Miglustat has also shown promise in preclinical studies for the treatment of Krabbe disease, and is currently being evaluated in clinical trials. Other potential therapies for Krabbe disease include gene therapy approaches, such as hematopoietic stem cell transplantation and viral vector-mediated gene transfer.",GO:0006683 galactosylceramide catabolic process;GO:0019376 galactolipid catabolic process;GO:0046477 glycosylceramide catabolic process,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Predicted intracellular proteins; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Lysosomal storage diseases; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,,,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000230715.3,ENSG00000230715,AC018638.2,-1.325113735,-2.15861898,-0.982855089,-0.833867136,None,None,None,None,None,None,None,None,None,None
ENSG00000114019.15,ENSG00000114019,AMOTL2,-1.323497058,-1.956191312,-1.30956495,-0.704734911,angiomotin like 2,"AMOTL2 is a human gene that encodes a protein related to angiomotin and belongs to the motin protein family. Angiomotin is a protein that binds angiostatin, which inhibits the formation of new blood vessels. AMOTL2 mediates angiostatin inhibition of endothelial cell migration and tube formation in vitro. Alternative splicing of AMOTL2 results in multiple transcript variants.","There is limited information on the disease implications of AMOTL2. However, recent studies have suggested that AMOTL2 may play a role in cancer progression and metastasis. Specifically, AMOTL2 has been shown to promote the migration and invasion of cancer cells in vitro and in vivo. Targeted drug discovery efforts for AMOTL2 are still in the early stages, but there is potential for the development of drugs that inhibit AMOTL2 activity as a means of preventing cancer metastasis. Currently, there are no drugs on the market that specifically target AMOTL2. However, there are several drugs that target angiogenesis, including bevacizumab and sunitinib, which indirectly affect AMOTL2 activity by inhibiting the formation of new blood vessels.",GO:0003365 establishment of cell polarity involved in ameboidal cell migration;GO:0001886 endothelial cell morphogenesis;GO:0035329 hippo signaling,,Predicted intracellular proteins,Cell Junctions (Approved),,,
ENSG00000173482.17,ENSG00000173482,PTPRM,-1.323037729,-1.98481467,-1.044539826,-0.93975869,protein tyrosine phosphatase receptor type M,"PTPRM is a gene that encodes a protein tyrosine phosphatase (PTP) receptor. PTPs are signaling molecules that regulate various cellular processes, including cell growth, differentiation, and oncogenic transformation. PTPRM has an extracellular region, a single transmembrane region, and two catalytic domains, making it a receptor-type PTP. The extracellular region contains a meprin-A5 antigen-PTP mu (MAM) domain, an Ig-like domain, and four fibronectin type III-like repeats. PTPRM mediates cell-cell aggregation by interacting with another molecule of PTPRM on an adjacent cell. It can also interact with scaffolding protein RACK1/GNB2L1, which is necessary for downstream signaling in response to cell-cell adhesion. Alternative splicing results in multiple transcripts encoding distinct isoforms.","PTPRM has been implicated in various diseases, including cancer, Alzheimer's disease, and schizophrenia. In cancer, PTPRM has been shown to act as a tumor suppressor by inhibiting cell proliferation and promoting cell differentiation. Targeted drug discovery efforts have focused on developing small molecule inhibitors of PTPRM for the treatment of cancer. However, there are currently no drugs targeting PTPRM on the market. In Alzheimer's disease, PTPRM has been shown to regulate the activity of tau protein, which is involved in the formation of neurofibrillary tangles. In schizophrenia, PTPRM has been identified as a potential risk gene, with genetic variations in PTPRM associated with an increased risk of developing the disorder. Further research is needed to fully understand the role of PTPRM in these diseases and to develop targeted therapies.",GO:0031290 retinal ganglion cell axon guidance;GO:0010842 retina layer formation;GO:0060042 retina morphogenesis in camera-type eye,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Plasma membrane (Approved),,(M72)PID NECTIN PATHWAY,(M5942)HALLMARK UV RESPONSE DN
ENSG00000135048.14,ENSG00000135048,CEMIP2,-1.322455505,-2.202452537,-0.942090788,-0.82282319,cell migration inducing hyaluronidase 2,CEMIP2 is a gene that encodes a type II transmembrane protein belonging to the IFITM protein superfamily. It functions as a cell surface hyaluronidase that cleaves high molecular weight hyaluronan into intermediate size fragments before internalization and degradation in the lysosome. It also has an interferon-mediated antiviral function through activation of the JAK STAT signaling pathway. The activation of this gene by transcription factor SOX4 in breast cancer cells has been shown to mediate the pathological effects of SOX4 on cancer progression. Mutations in this gene are associated with autosomal recessive non-syndromic hearing loss.,"There is limited information available on targeted drug discovery efforts for CEMIP2. However, mutations in this gene have been associated with autosomal recessive non-syndromic hearing loss, suggesting potential therapeutic targets for this condition. Currently, there are no drugs specifically targeting CEMIP2 for hearing loss. 

In terms of successful drugs on the market, there are no drugs targeting CEMIP2 directly. However, there are drugs targeting the JAK-STAT signaling pathway, which is activated by CEMIP2 and has been shown to have an interferon-mediated antiviral function. Examples of drugs targeting this pathway include ruxolitinib and tofacitinib, which are used to treat myelofibrosis and rheumatoid arthritis, respectively. These drugs have shown efficacy in clinical trials and are currently on the market.",GO:0030214 hyaluronan catabolic process;GO:0006027 glycosaminoglycan catabolic process;GO:0030212 hyaluronan metabolic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Plasma membrane (Supported); Additional: Cytosol;Vesicles,,,
ENSG00000196730.13,ENSG00000196730,DAPK1,-1.319951627,-2.021332681,-1.305889241,-0.632632958,death associated protein kinase 1,"DAPK1, or death-associated protein kinase 1, is a gene that encodes a unique 160-kD calmodulin dependent serine-threonine kinase. It carries 8 ankyrin repeats and 2 putative P-loop consensus sites and is a positive mediator of gamma-interferon induced programmed cell death. DAPK1 is a candidate tumor suppressor gene and has multiple transcript variants due to alternative splicing.","DAPK1 has been implicated in various diseases, including cancer, Alzheimer's disease, and cardiovascular disease. In cancer, DAPK1 is often downregulated or silenced, leading to increased cell survival and resistance to chemotherapy. Therefore, there have been efforts to develop drugs that can activate DAPK1 and induce cell death in cancer cells. One example is the drug ONC201, which has shown promising results in preclinical studies and is currently in clinical trials for various types of cancer. In Alzheimer's disease, DAPK1 has been shown to play a role in the formation of amyloid plaques and neurofibrillary tangles, making it a potential target for drug development. However, there are currently no drugs targeting DAPK1 specifically for Alzheimer's disease. In cardiovascular disease, DAPK1 has been linked to hypertension and heart failure, and there have been efforts to develop drugs that can inhibit DAPK1 activity to improve cardiovascular outcomes. One example is the drug Fasudil, which is approved in Japan for the treatment of cerebral vasospasm and has been shown to inhibit DAPK1 activity in vitro.",GO:1904094 positive regulation of autophagic cell death;GO:1904092 regulation of autophagic cell death;GO:0071447 cellular response to hydroperoxide,yes,Human disease related genes:Cancers:Cancers of the urinary system; ENZYME proteins:Transferases; Kinases:CAMK Ser/Thr protein kinases; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Centrosome (Approved),"5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine; Phosphoaminophosphonic Acid-Adenylate Ester; 6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE; Fostamatinib",(M108)PID NETRIN PATHWAY; (M161)PID IFNG PATHWAY,
ENSG00000133657.16,ENSG00000133657,ATP13A3,-1.31934467,-1.587125001,-1.396485691,-0.974423317,ATPase 13A3,"ATP13A3 is a gene that belongs to the P-type ATPase family of proteins. These proteins are responsible for transporting various cations across membranes. ATP13A3 is similar to other P-type ATPases such as ATP7B and ATP7A. The function of ATP13A3 is not yet fully understood, but it is believed to play a role in ion transport and homeostasis. Mutations in the ATP13A3 gene have been associated with several diseases, including Parkinson's disease and Kufor-Rakeb syndrome. Further research is needed to fully understand the function and potential therapeutic applications of ATP13A3.","Research on ATP13A3 is still in its early stages, and there are currently no targeted drug discovery efforts or drugs on the market specifically targeting this gene. However, mutations in ATP13A3 have been associated with several diseases, including Parkinson's disease and Kufor-Rakeb syndrome. Parkinson's disease is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the brain, leading to motor symptoms such as tremors and rigidity. Kufor-Rakeb syndrome is a rare autosomal recessive disorder that causes Parkinson's-like symptoms, as well as cognitive impairment and spasticity. Understanding the role of ATP13A3 in these diseases may lead to the development of new therapies in the future.",GO:0015847 putrescine transport;GO:1902047 polyamine transmembrane transport;GO:0015846 polyamine transport,,Human disease related genes:Cardiovascular diseases:Hypertensive diseases; Potential drug targets; Enzymes; Disease related genes; ENZYME proteins,Nucleoli (Approved); Additional: Cytosol;Plasma membrane,,,
ENSG00000139278.10,ENSG00000139278,GLIPR1,-1.319140639,-1.528893116,-1.108747627,-1.319781174,GLI pathogenesis related 1,"GLIPR1 (GLI pathogenesis related 1) is a gene that encodes a protein with similarities to both the pathogenesis-related protein (PR) superfamily and the cysteine-rich secretory protein (CRISP) family. Increased expression of this gene is associated with myelomocytic differentiation in macrophage, while decreased expression through gene methylation is associated with prostate cancer. The protein has proapoptotic activities in prostate and bladder cancer cells. GLIPR1 is a member of a cluster on chromosome 12 containing two other similar genes. There are alternatively spliced variants that encode different protein isoforms, but not all variants have been fully characterized.","GLIPR1 has been implicated in various diseases, including cancer and neurodegenerative disorders. In cancer, GLIPR1 has been shown to have tumor-suppressive effects in prostate, bladder, and breast cancer cells. Targeted drug discovery efforts have focused on developing small molecule inhibitors of GLIPR1 to enhance its proapoptotic activity in cancer cells. However, there are currently no drugs on the market that specifically target GLIPR1. In neurodegenerative disorders, GLIPR1 has been shown to have neuroprotective effects in models of Parkinson's disease and Alzheimer's disease. Further research is needed to fully understand the role of GLIPR1 in these diseases and to develop potential therapeutic strategies.",,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Vesicles (Approved); Additional: Nucleoplasm,SOT-107,,(M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000214717.12,ENSG00000214717,ZBED1,-1.318048382,-2.04295613,-1.114367122,-0.796821895,zinc finger BED-type containing 1,"ZBED1 is a gene located in the pseudoautosomal region 1 of X and Y chromosomes. It was initially thought to have transposase activity but later studies revealed that it functions as a transcription factor. ZBED1 is found in the nucleus and binds to DNA elements in the promoter regions of genes related to cell proliferation, such as histone H1. This suggests that ZBED1 may play a role in regulating genes involved in cell proliferation. Different variants of the gene with varying 5' untranslated regions have been identified.","There is limited information available on the disease implications of ZBED1. However, some studies have suggested that ZBED1 may play a role in cancer development and progression. For example, one study found that ZBED1 expression was significantly higher in breast cancer tissues compared to normal breast tissues. Additionally, ZBED1 has been implicated in the regulation of insulin-like growth factor 2 (IGF2), which is involved in the development of several types of cancer.

There are currently no targeted drug discovery efforts specifically focused on ZBED1. However, drugs that target IGF2, which is regulated by ZBED1, have been developed and are used in the treatment of certain types of cancer. For example, the drug Mecasermin is a recombinant form of human IGF1 that is used to treat growth hormone deficiency and has also been investigated as a potential treatment for cancer.

Overall, more research is needed to fully understand the disease implications and potential therapeutic targets of ZBED1.",GO:1990466 protein autosumoylation;GO:0044828 negative regulation by host of viral genome replication;GO:0044793 negative regulation by host of viral process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Centrosome;Nucleoplasm (Approved); Additional: Nuclear membrane,,,
ENSG00000089177.19,ENSG00000089177,KIF16B,-1.316349159,-1.565549275,-1.197443682,-1.186054521,kinesin family member 16B,"KIF16B is a human gene that encodes a kinesin-like protein that may play a role in intracellular trafficking. The gene has three different transcript variants that produce different isoforms of the protein. The exact function of KIF16B is not fully understood, but it is believed to be involved in the transport of cellular components within cells. The gene was first identified in December 2010 and has since been the subject of ongoing research to better understand its role in human biology.","There is limited information available on the disease implications of KIF16B. However, some studies have suggested that mutations in the gene may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for KIF16B are still in the early stages, but there is potential for the development of drugs that target the protein's role in intracellular trafficking. One example of a successful drug that targets a kinesin protein is Ixabepilone, which is used to treat breast cancer. However, it does not specifically target KIF16B. Further research is needed to fully understand the potential therapeutic applications of targeting KIF16B.",GO:0006895 Golgi to endosome transport;GO:0032801 receptor catabolic process;GO:0001919 regulation of receptor recycling,,Predicted intracellular proteins,Mitochondria (Uncertain),,,
ENSG00000137497.18,ENSG00000137497,NUMA1,-1.310571814,-2.136137744,-1.327570716,-0.468006982,nuclear mitotic apparatus protein 1,NUMA1 is a gene that encodes a large protein that is a structural component of the nuclear matrix. The protein interacts with microtubules and plays a role in the formation and organization of the mitotic spindle during cell division. Chromosomal translocation of this gene with the RARA gene on chromosome 17 has been detected in patients with acute promyelocytic leukemia. Alternative splicing results in multiple transcript variants.,"The chromosomal translocation of NUMA1 with the RARA gene on chromosome 17 has been detected in patients with acute promyelocytic leukemia (APL). This translocation results in the fusion protein PML-RARA, which is a key driver of APL. Targeted drug discovery efforts have focused on developing drugs that can disrupt the interaction between PML-RARA and its binding partners, leading to the degradation of the fusion protein and the induction of apoptosis in APL cells. One successful drug on the market is all-trans retinoic acid (ATRA), which induces differentiation of APL cells and has dramatically improved the prognosis for APL patients. Another successful drug is arsenic trioxide (ATO), which induces apoptosis in APL cells by targeting the PML component of the fusion protein. ATRA and ATO are often used in combination as a first-line treatment for APL, leading to high rates of complete remission and long-term survival.",GO:0055048 anastral spindle assembly;GO:1902363 regulation of protein localization to spindle pole body;GO:1902365 positive regulation of protein localization to spindle pole body,,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,(M220)PID CASPASE PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE; (M5901)HALLMARK G2M CHECKPOINT
ENSG00000133816.17,ENSG00000133816,MICAL2,-1.309636908,-2.257239514,-0.883348678,-0.788322531,"microtubule associated monooxygenase, calponin and LIM domain containing 2",MICAL2 is a human gene that encodes a monooxygenase protein that plays a role in cytoskeletal dynamics by enhancing the depolymerization of F-actin. It also acts as a regulator of the SRF signaling pathway. Increased expression of MICAL2 has been linked to cancer progression and metastasis.,"There is limited information available on targeted drug discovery efforts for MICAL2. However, increased expression of MICAL2 has been linked to cancer progression and metastasis, making it a potential target for cancer therapy. Several studies have shown that inhibition of MICAL2 can reduce cancer cell migration and invasion. However, there are currently no drugs on the market that specifically target MICAL2. 

One example of a drug that indirectly affects MICAL2 is paclitaxel, which is used to treat various types of cancer. Paclitaxel stabilizes microtubules, leading to the depolymerization of F-actin and inhibition of cancer cell migration. Another example is dasatinib, which is used to treat chronic myeloid leukemia. Dasatinib inhibits the activity of Src family kinases, which can activate MICAL2 and promote cancer cell migration. 

Overall, further research is needed to fully understand the role of MICAL2 in cancer progression and to develop targeted therapies for this gene.",GO:0019417 sulfur oxidation;GO:0030042 actin filament depolymerization;GO:0051261 protein depolymerization,,Enzymes; ENZYME proteins:Oxidoreductases; Predicted intracellular proteins,Cytosol (Uncertain); Additional: Nucleoplasm;Plasma membrane,,,
ENSG00000113742.14,ENSG00000113742,CPEB4,-1.309014089,-1.38525217,-1.328188217,-1.213601881,cytoplasmic polyadenylation element binding protein 4,"CPEB4, or cytoplasmic polyadenylation element binding protein 4, is a gene that encodes a protein involved in RNA binding activity. It is predicted to play a role in various cellular processes, including responding to glucose starvation, regulating cytoplasmic translation, and responding to ischemia. CPEB4 is located in both the cytoplasm and nucleus of cells. It has been identified as a biomarker for liver cirrhosis, portal hypertension, and primary biliary cholangitis.","There is limited information available on targeted drug discovery efforts for CPEB4. However, research has identified its potential role in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, CPEB4 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. In neurodegenerative disorders, CPEB4 has been implicated in regulating synaptic plasticity and memory formation, suggesting its potential role in the development of treatments for these diseases. As for successful drugs on the market, there are currently no drugs specifically targeting CPEB4. However, there are drugs that indirectly affect its activity, such as mTOR inhibitors, which have been shown to downregulate CPEB4 expression in cancer cells. Further research is needed to fully understand the potential of CPEB4 as a therapeutic target.",GO:2000766 negative regulation of cytoplasmic translation;GO:0035235 ionotropic glutamate receptor signaling pathway;GO:2000765 regulation of cytoplasmic translation,,Predicted intracellular proteins,Golgi apparatus;Nucleoplasm (Approved); Additional: Vesicles,,,
ENSG00000111331.13,ENSG00000111331,OAS3,-1.308163195,-1.840302397,-1.045299205,-1.038887984,2'-5'-oligoadenylate synthetase 3,"OAS3 is a gene that encodes an enzyme belonging to the 2', 5' oligoadenylate synthase family. This enzyme is activated by interferons and produces 2', 5' oligomers of adenosine, which bind and activate RNase L. The enzyme family is important in inhibiting cellular protein synthesis and providing resistance against viral infections.","OAS3 has been implicated in various diseases, including viral infections such as hepatitis C, West Nile virus, and dengue fever. Studies have shown that OAS3 expression is upregulated in response to these viral infections, indicating its potential as a therapeutic target. Targeted drug discovery efforts have focused on developing small molecule inhibitors of OAS3 to prevent its activation and subsequent inhibition of protein synthesis, thereby limiting viral replication. However, there are currently no drugs on the market that specifically target OAS3. Some drugs that indirectly affect OAS3 activity include interferons, which activate OAS3 expression, and ribavirin, which enhances the antiviral activity of OAS3. Further research is needed to fully understand the role of OAS3 in disease and to develop effective targeted therapies.",GO:0035394 regulation of chemokine (C-X-C motif) ligand 9 production;GO:0035395 negative regulation of chemokine (C-X-C motif) ligand 9 production;GO:0039530 MDA-5 signaling pathway,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Nucleoplasm (Supported); Additional: Plasma membrane,,,(M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000140548.10,ENSG00000140548,ZNF710,-1.304187287,-1.717781041,-1.018156219,-1.176624601,zinc finger protein 710,"ZNF710 is a human gene that encodes for a zinc finger protein 710. This protein is predicted to have the ability to bind to DNA and regulate transcription by RNA polymerase II. It is also predicted to be located in the nucleus. The function of ZNF710 is not yet fully understood, but it is believed to play a role in the regulation of gene expression. Further research is needed to fully understand the role of ZNF710 in human biology and disease.","Unfortunately, there is currently very limited information available on the disease implications and targeted drug discovery efforts for ZNF710. As a relatively newly discovered gene, there have been no drugs developed specifically targeting this gene. However, there is ongoing research into the role of ZNF710 in various diseases, including cancer and neurological disorders. For example, a study published in 2020 found that ZNF710 was significantly downregulated in glioblastoma multiforme, a type of brain cancer, and may play a role in tumor progression. Further research is needed to fully understand the disease implications of ZNF710 and to develop targeted therapies.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Mitochondria (Approved); Additional: Nucleoplasm,,,
ENSG00000163430.12,ENSG00000163430,FSTL1,-1.304077923,-2.186463236,-0.879219755,-0.846550778,follistatin like 1,"The FSTL1 gene encodes a protein that is similar to follistatin, a protein that binds to activin. The protein contains a sequence called FS module, which has 10 conserved cysteine residues. It is believed that this protein is associated with rheumatoid arthritis and may be an autoantigen.","The FSTL1 gene has been implicated in several diseases, including rheumatoid arthritis, cardiovascular disease, and cancer. In rheumatoid arthritis, FSTL1 has been identified as an autoantigen, and its levels are elevated in the synovial fluid of affected joints. In cardiovascular disease, FSTL1 has been shown to play a role in the development of atherosclerosis and cardiac hypertrophy. In cancer, FSTL1 has been found to be overexpressed in several types of tumors, including breast, lung, and pancreatic cancer.

Targeted drug discovery efforts for FSTL1 are still in the early stages, but several potential therapeutic approaches have been proposed. One strategy is to develop small molecule inhibitors that target the interaction between FSTL1 and its binding partners, such as activin. Another approach is to develop antibodies that specifically target FSTL1, which could be used to block its activity in disease states.

Currently, there are no drugs on the market that specifically target FSTL1. However, there are several drugs that indirectly affect FSTL1 levels or activity. For example, statins, which are commonly used to treat high cholesterol, have been shown to reduce FSTL1 expression in vascular smooth muscle cells. Additionally, drugs that target the TGF-? signaling pathway, such as losartan and pirfenidone, have been shown to reduce FSTL1 expression in fibrotic diseases.",GO:0061484 hematopoietic stem cell homeostasis;GO:0043542 endothelial cell migration;GO:0045446 endothelial cell differentiation,,Predicted secreted proteins; Predicted intracellular proteins,Vesicles (Approved); Additional: Cytosol;Golgi apparatus,,(M5883)NABA SECRETED FACTORS; (M5885)NABA MATRISOME ASSOCIATED; (M5889)NABA MATRISOME,(M5944)HALLMARK ANGIOGENESIS; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000038382.20,ENSG00000038382,TRIO,-1.30382763,-1.994910347,-1.013194588,-0.903377956,trio Rho guanine nucleotide exchange factor,"TRIO is a human gene that encodes a protein called trio Rho guanine nucleotide exchange factor. This protein acts as a GDP to GTP exchange factor, which promotes the reorganization of the actin cytoskeleton. This process is important for cell migration and growth. Alternative splicing of the TRIO gene results in multiple transcript variants.","Mutations in the TRIO gene have been associated with several neurological disorders, including autism spectrum disorder, schizophrenia, and intellectual disability. In addition, TRIO has been implicated in cancer progression and metastasis, making it a potential target for cancer therapy. 

Several drug discovery efforts have focused on targeting TRIO, particularly in cancer treatment. One approach is to develop small molecule inhibitors that target the protein's enzymatic activity, which could potentially block cancer cell growth and metastasis. Another approach is to target the protein's interaction with other proteins involved in cancer progression, such as RhoA and Rac1. 

One example of a successful drug targeting TRIO is TAK-659, a small molecule inhibitor developed by Takeda Pharmaceuticals. TAK-659 targets TRIO and other kinases involved in B-cell receptor signaling, and has shown promising results in clinical trials for the treatment of B-cell malignancies. Another example is the drug FAK inhibitor 14, which targets TRIO and other proteins involved in cancer cell migration and invasion. FAK inhibitor 14 has shown efficacy in preclinical studies for the treatment of breast cancer and other solid tumors.",GO:0007185 cell surface receptor protein tyrosine phosphatase signaling pathway;GO:0099170 postsynaptic modulation of chemical synaptic transmission;GO:0045599 negative regulation of fat cell differentiation,yes,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; ENZYME proteins:Transferases; Potential drug targets; Kinases:CAMK Ser/Thr protein kinases; Disease related genes; Enzymes; Cancer-related genes:Mutational cancer driver genes,Cytosol (Approved); Additional: Basal body;Plasma membrane;Primary cilium;Primary cilium tip;Vesicles,,(M108)PID NETRIN PATHWAY; (M241)PID RAC1 REG PATHWAY; (M68)PID RHOA REG PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000184979.10,ENSG00000184979,USP18,-1.303432921,-1.927358018,-1.471545071,-0.511395675,ubiquitin specific peptidase 18,"USP18 is a gene that encodes a protein belonging to the family of ubiquitin-specific proteases (UBP) that cleave ubiquitin from ubiquitinated protein substrates. The protein is highly expressed in the liver and thymus and is localized to the nucleus. It efficiently cleaves only ISG15, a ubiquitin-like protein, and deletion of this gene in mice results in a massive increase of ISG15 conjugates in tissues, indicating that this protein is a major ISG15-specific protease. Mice lacking this gene are also hypersensitive to interferon, suggesting a function of this protein in downregulating interferon responses, independent of its isopeptidase activity towards ISG15.","Research on USP18 has revealed its potential as a therapeutic target for various diseases, including viral infections, autoimmune disorders, and cancer. In viral infections, USP18 has been shown to inhibit the antiviral response of interferons, and targeting USP18 could enhance the immune response against viruses. In autoimmune disorders, USP18 has been implicated in the regulation of immune cell activation and proliferation, and inhibition of USP18 could reduce autoimmune inflammation. In cancer, USP18 has been found to promote tumor growth and metastasis, and targeting USP18 could inhibit tumor progression. However, there are currently no drugs targeting USP18 on the market, and drug discovery efforts are ongoing to develop small molecule inhibitors or antibodies against USP18.",GO:0035634 response to stilbenoid;GO:0060339 negative regulation of type I interferon-mediated signaling pathway;GO:0060338 regulation of type I interferon-mediated signaling pathway,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Predicted intracellular proteins; Peptidases:Cysteine-type peptidases; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Cytosol (Supported); Additional: Vesicles,,,(M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000131378.14,ENSG00000131378,RFTN1,-1.299474222,-1.544296565,-1.418185709,-0.935940392,"raftlin, lipid raft linker 1","RFTN1, also known as raftlin, lipid raft linker 1, is a gene that encodes a protein involved in various cellular processes such as B cell receptor signaling, membrane raft assembly, and growth rate regulation. The protein is capable of binding to double-stranded RNA and is involved in dsRNA transport, response to exogenous dsRNA, and toll-like receptor 3 signaling pathway. RFTN1 is located in the endosome, membrane raft, and plasma membrane and is part of a protein-containing complex.","There is limited information available on the disease implications of RFTN1. However, recent studies have suggested that RFTN1 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for RFTN1 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target RFTN1, there are several drugs that have been approved for the treatment of cancer that may indirectly affect RFTN1 activity, including chemotherapy agents such as doxorubicin and paclitaxel. Additionally, there are several ongoing clinical trials investigating the use of targeted therapies for the treatment of breast cancer and other types of cancer that may involve RFTN1 as a potential therapeutic target.",GO:0033227 dsRNA transport;GO:0040010 positive regulation of growth rate;GO:0002457 T cell antigen processing and presentation,,Predicted intracellular proteins,,,,
ENSG00000164068.16,ENSG00000164068,RNF123,-1.299170217,-2.066345184,-1.557765768,-0.2733997,ring finger protein 123,"RNF123, also known as ring finger protein 123, is a gene that encodes a protein with a RING finger domain at the C-terminus and an SPRY domain at the N-terminus. The RING finger domain is involved in protein-protein and protein-DNA interactions, while the SPRY domain is involved in protein-protein interactions. The protein encoded by RNF123 has E3 ubiquitin ligase activity towards the cyclin-dependent kinase inhibitor 1B, also known as p27 or KIP1. Alternative splicing of RNF123 results in multiple transcript variants.","There is limited information available on the disease implications of RNF123. However, studies have shown that RNF123 may play a role in cancer progression by regulating the degradation of p27, a tumor suppressor protein. Targeted drug discovery efforts for RNF123 are also limited, but there is potential for developing drugs that target the E3 ubiquitin ligase activity of RNF123 towards p27. Currently, there are no drugs on the market that specifically target RNF123. However, there are drugs that target the degradation of p27, such as palbociclib, a CDK4/6 inhibitor used in the treatment of breast cancer. Additionally, there are drugs that target other E3 ubiquitin ligases, such as bortezomib, a proteasome inhibitor used in the treatment of multiple myeloma.",GO:0000209 protein polyubiquitination;GO:0051604 protein maturation;GO:0006511 ubiquitin-dependent protein catabolic process,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Approved),,,(M5945)HALLMARK HEME METABOLISM
ENSG00000120690.16,ENSG00000120690,ELF1,-1.29894282,-1.580999884,-1.630413439,-0.685415136,E74 like ETS transcription factor 1,ELF1 is a gene that encodes for a transcription factor called E74 like ETS transcription factor 1. This protein is mainly found in lymphoid cells and plays a role in regulating the transcription of various genes by acting as both an enhancer and a repressor. Alternative splicing of the gene results in the production of multiple transcript variants.,"Research has shown that ELF1 plays a role in various diseases, including cancer and autoimmune disorders. In cancer, ELF1 has been found to be overexpressed in certain types of leukemia and lymphoma, and its inhibition has been shown to reduce tumor growth in preclinical models. In autoimmune disorders, ELF1 has been implicated in the regulation of immune cell function and the development of autoimmune responses.

Targeted drug discovery efforts for ELF1 are still in the early stages, but there is potential for the development of drugs that target this transcription factor. One approach is to develop small molecule inhibitors that can block the activity of ELF1, which could be useful in treating diseases where ELF1 is overactive. Another approach is to develop drugs that can modulate the expression of ELF1, which could be useful in diseases where ELF1 is underactive.

Currently, there are no drugs on the market that specifically target ELF1. However, there are drugs that indirectly affect ELF1 activity. For example, the immunosuppressive drug cyclosporine A has been shown to inhibit the activity of ELF1 in T cells, which is thought to contribute to its therapeutic effects in autoimmune disorders. Additionally, the chemotherapy drug cytarabine has been shown to reduce the expression of ELF1 in leukemia cells, which may contribute to its anti-tumor effects.",GO:0050860 negative regulation of T cell receptor signaling pathway;GO:0050858 negative regulation of antigen receptor-mediated signaling pathway;GO:0050856 regulation of T cell receptor signaling pathway,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoplasm (Supported),,(M234)PID IL2 STAT5 PATHWAY; (M92)PID ANGIOPOIETIN RECEPTOR PATHWAY; (M279)PID RB 1PATHWAY,(M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5906)HALLMARK ESTROGEN RESPONSE EARLY
ENSG00000102218.6,ENSG00000102218,RP2,-1.297393303,-1.49030251,-1.38607545,-1.015801951,RP2 activator of ARL3 GTPase,"RP2 is a gene that has been linked to X-linked retinitis pigmentosa, a condition that causes progressive vision loss. The gene product is similar to a protein called cofactor C, which is involved in the final step of beta-tubulin folding. It is believed that the accumulation of incorrectly-folded photoreceptor or neuron-specific tubulin isoforms may lead to retinal degeneration and cell death. RP2 is an activator of ARL3 GTPase, which is involved in the transport of proteins within cells. Mutations in RP2 can disrupt this process and lead to the development of retinitis pigmentosa.","There are currently no targeted drug therapies available for X-linked retinitis pigmentosa caused by mutations in the RP2 gene. However, there are ongoing efforts to develop gene therapies that could potentially correct the genetic defect and restore vision. One approach involves using adeno-associated viruses (AAVs) to deliver a functional copy of the RP2 gene to the affected cells in the retina. Clinical trials are currently underway to test the safety and efficacy of this approach.

In addition to gene therapy, there are also efforts to develop drugs that can target the downstream effects of RP2 mutations. For example, researchers are investigating the use of neuroprotective agents that can prevent or slow down the degeneration of retinal cells. Some promising candidates include antioxidants, anti-inflammatory agents, and growth factors.

There are currently no drugs on the market specifically approved for the treatment of X-linked retinitis pigmentosa caused by RP2 mutations. However, there are several drugs that have been approved for other retinal diseases that may have potential for treating this condition. For example, the drug Lucentis (ranibizumab) is approved for the treatment of age-related macular degeneration and diabetic retinopathy, and works by inhibiting the growth of abnormal blood vessels in the retina. This mechanism of action may also be beneficial for treating retinitis pigmentosa, as abnormal blood vessel growth is a common feature of the disease.",GO:0006892 post-Golgi vesicle-mediated transport;GO:0007601 visual perception;GO:0006457 protein folding,,Disease related genes; Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins,End piece;Mid piece;Plasma membrane;Principal piece (Approved); Additional: Acrosome;Cytosol;Nuclear bodies;Nucleoplasm;Vesicles,,,
ENSG00000038358.15,ENSG00000038358,EDC4,-1.28946436,-1.880114965,-1.620253564,-0.368024552,enhancer of mRNA decapping 4,"EDC4 is a human gene that is predicted to play a role in the decapping of nuclear-transcribed mRNA, specifically in a deadenylation-independent manner. It is located in both the P-body and nucleoplasm. The P-body is a cytoplasmic structure involved in mRNA degradation and storage, while the nucleoplasm is the fluid within the nucleus where many cellular processes occur. The function of EDC4 is important for regulating gene expression and maintaining cellular homeostasis.","Mutations in the EDC4 gene have been associated with several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In particular, EDC4 has been found to be overexpressed in certain types of cancer, such as breast and lung cancer, and its inhibition has been shown to reduce tumor growth in preclinical models. As a result, there has been interest in developing drugs that target EDC4 for cancer therapy. However, there are currently no drugs on the market that specifically target EDC4. Nevertheless, there are several ongoing drug discovery efforts aimed at identifying small molecules that can inhibit EDC4 function. One example is the development of small molecule inhibitors of the EDC4-interacting protein DDX6, which has been shown to regulate EDC4 activity. These inhibitors have shown promise in preclinical models of cancer and are currently being evaluated in clinical trials.","GO:0031087 deadenylation-independent decapping of nuclear-transcribed mRNA;GO:0031086 nuclear-transcribed mRNA catabolic process, deadenylation-independent decay;GO:0110156 mRNA methylguanosine-cap decapping",,Predicted intracellular proteins,Cytoplasmic bodies (Enhanced); Additional: Nucleoplasm,,,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000147027.4,ENSG00000147027,TMEM47,-1.288125761,-1.954224032,-1.725556736,-0.184596514,transmembrane protein 47,"TMEM47 is a gene that belongs to the PMP22/EMP/claudin protein family. The protein encoded by this gene is a transmembrane protein that is found in both the endoplasmic reticulum (ER) and the plasma membrane. In dogs, this gene is highly expressed in the brain. The function of TMEM47 is not yet fully understood, but it is believed to play a role in cell signaling and communication. Mutations in this gene have been associated with certain types of cancer, as well as with developmental disorders. Further research is needed to fully understand the function and potential clinical implications of TMEM47.","There is limited information available on the disease implications and targeted drug discovery efforts for TMEM47. However, mutations in this gene have been associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeting TMEM47 may have potential therapeutic implications for these cancers, but further research is needed to fully understand its role in cancer development and progression. Currently, there are no drugs on the market that specifically target TMEM47. However, there are several drugs that target other proteins in the PMP22/EMP/claudin protein family, such as claudin-1 and claudin-18. These drugs are used in the treatment of various cancers, including gastric cancer and pancreatic cancer.",GO:0098609 cell-cell adhesion;GO:0007155 cell adhesion;GO:0009987 cellular process,,Transporters:Accessory Factors Involved in Transport,Nuclear membrane (Approved),,,
ENSG00000118007.13,ENSG00000118007,STAG1,-1.284587592,-1.54130905,-1.438847944,-0.873605781,STAG1 cohesin complex component,"STAG1, also known as stromal antigen 1, is a gene that encodes a component of cohesin, a protein complex that helps to maintain the cohesion between sister chromatids during cell division. This gene is expressed in the nucleus and is involved in the process of DNA replication, prophase, and prometaphase. During anaphase, cohesin is dissociated in preparation for segregation. STAG1 is a member of the SCC3 family and plays an important role in maintaining the integrity of the genome during cell division. Mutations in this gene have been associated with developmental disorders and cancer.","Mutations in the STAG1 gene have been associated with several developmental disorders, including Cornelia de Lange syndrome (CdLS) and intellectual disability. CdLS is a rare genetic disorder characterized by distinctive facial features, growth retardation, and intellectual disability. There are currently no targeted drug discovery efforts for STAG1 mutations specifically, but research is ongoing to develop therapies for CdLS and other developmental disorders associated with cohesin mutations. 

There are currently no drugs on the market that specifically target STAG1 mutations. However, there are drugs that target the cohesin complex, such as the FDA-approved cancer drug, Aclarusdine. Aclarusdine inhibits the activity of the cohesin complex, leading to cell death in cancer cells. Additionally, research is ongoing to develop therapies that target the cohesin complex in developmental disorders associated with cohesin mutations. For example, a recent study showed that a small molecule inhibitor of the cohesin complex improved cognitive function in a mouse model of CdLS. These findings suggest that targeting the cohesin complex may be a promising approach for the treatment of developmental disorders associated with cohesin mutations.",GO:0034087 establishment of mitotic sister chromatid cohesion;GO:0034085 establishment of sister chromatid cohesion;GO:0007064 mitotic sister chromatid cohesion,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nuclear bodies;Primary cilium,,,(M5901)HALLMARK G2M CHECKPOINT; (M5925)HALLMARK E2F TARGETS
ENSG00000254612.2,ENSG00000254612,DNAJB6P1,-1.284505893,-1.936505216,-1.787155333,-0.12985713,DNAJB6 pseudogene 1,,,,,,,,,
ENSG00000079308.19,ENSG00000079308,TNS1,-1.281636128,-1.894970543,-1.151782315,-0.798155525,tensin 1,"TNS1, also known as tensin 1, is a gene that encodes a protein that is involved in the attachment of cells to the extracellular matrix. The protein is found in focal adhesions, which are regions of the plasma membrane where the cell attaches to the extracellular matrix. TNS1 crosslinks actin filaments and contains a Src homology 2 (SH2) domain, which is often found in molecules involved in signal transduction. The protein is a substrate of calpain II. Alternative splicing results in multiple transcript variants encoding different isoforms.","Research has shown that TNS1 may play a role in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, TNS1 has been found to be overexpressed in several types of tumors, including breast, lung, and colon cancer, and may contribute to tumor growth and metastasis. Targeted drug discovery efforts have focused on developing inhibitors of TNS1 to prevent its interaction with other proteins involved in cancer progression. One example of a successful drug targeting TNS1 is the small molecule inhibitor, AZD0530, which has shown promising results in preclinical studies for the treatment of breast cancer. Another example is the drug, dasatinib, which targets multiple tyrosine kinases, including TNS1, and is approved for the treatment of chronic myeloid leukemia and certain types of solid tumors. Overall, targeting TNS1 may hold promise for the development of novel therapies for various diseases.",GO:0010761 fibroblast migration;GO:0007044 cell-substrate junction assembly;GO:0150115 cell-substrate junction organization,,Predicted intracellular proteins,Focal adhesion sites (Enhanced),,(M71)PID ILK PATHWAY,(M5945)HALLMARK HEME METABOLISM
ENSG00000147533.17,ENSG00000147533,GOLGA7,-1.28093915,-1.609898757,-1.590258671,-0.642660021,golgin A7,"GOLGA7, also known as golgin A7, is a human gene that plays a role in transporting proteins from the Golgi to the plasma membrane, as well as in peptidyl-L-cysteine S-palmitoylation and protein stabilization. It is located in the Golgi membrane and Golgi stack and is an intrinsic component of the Golgi membrane. GOLGA7 is part of a palmitoyltransferase complex and acts upstream of or within Golgi to plasma membrane transport. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of GOLGA7. However, recent studies have suggested that GOLGA7 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for GOLGA7 are still in the early stages, but there is potential for the development of novel therapies that target the protein's role in protein transport and stabilization. Currently, there are no drugs on the market that specifically target GOLGA7. However, there are several drugs that target other proteins involved in protein transport and stabilization, such as bortezomib, which is used to treat multiple myeloma, and erlotinib, which is used to treat non-small cell lung cancer. Further research is needed to fully understand the potential therapeutic implications of targeting GOLGA7.",GO:0018230 peptidyl-L-cysteine S-palmitoylation;GO:0018231 peptidyl-S-diacylglycerol-L-cysteine biosynthetic process from peptidyl-cysteine;GO:0018198 peptidyl-cysteine modification,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,,,,
ENSG00000165410.15,ENSG00000165410,CFL2,-1.280194099,-2.428327927,-0.557080452,-0.855173918,cofilin 2,"CFL2, also known as cofilin 2, is a gene that encodes a protein involved in regulating the dynamics of actin filaments within cells. This protein is a major component of actin rods found in the nucleus and cytoplasm of cells. It can bind to both G- and F-actin and controls the polymerization and depolymerization of actin in a pH-dependent manner. Mutations in CFL2 have been linked to nemaline myopathy type 7, a type of congenital myopathy. The gene undergoes alternative splicing, resulting in multiple transcript variants.","Mutations in CFL2 have been linked to nemaline myopathy type 7, a rare genetic disorder characterized by muscle weakness and wasting. There are currently no targeted drug discovery efforts specifically for CFL2, but research is ongoing to develop treatments for nemaline myopathy. One approach being explored is gene therapy, which involves delivering a functional copy of the CFL2 gene to affected cells. Another potential treatment is the use of small molecules that can modulate the activity of the protein. While there are currently no drugs on the market that target CFL2, there are several approved drugs that indirectly affect actin dynamics, such as cytochalasin D and latrunculin A, which are used in research to study actin filaments.",GO:0030043 actin filament fragmentation;GO:0030042 actin filament depolymerization;GO:0030836 positive regulation of actin filament depolymerization,,Disease related genes; Human disease related genes:Musculoskeletal diseases:Muscular diseases; Predicted intracellular proteins,Plasma membrane (Approved); Additional: Cytosol;Nucleoplasm,,(M16801)SIG REGULATION OF THE ACTIN CYTOSKELETON BY RHO GTPASES; (M5193)SIG CHEMOTAXIS; (M220)PID CASPASE PATHWAY,
ENSG00000171940.13,ENSG00000171940,ZNF217,-1.279506938,-1.790279805,-1.373909199,-0.674331809,zinc finger protein 217,ZNF217 is a human gene that encodes for a zinc finger protein 217. This protein is involved in the regulation of gene expression by binding to specific DNA sequences and repressing transcription by RNA polymerase II. ZNF217 is located in both the mitochondrion and nuclear speck and is part of the histone deacetylase complex. Its function is to enable DNA-binding transcription repressor activity and RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. ZNF217 is also involved in negative regulation of transcription by RNA polymerase II.,"ZNF217 has been implicated in several types of cancer, including breast, ovarian, and prostate cancer. Overexpression of ZNF217 has been associated with poor prognosis and resistance to chemotherapy. Therefore, ZNF217 is a potential target for cancer therapy. Several studies have focused on developing drugs that target ZNF217, including small molecule inhibitors and RNA interference-based therapies. However, there are currently no drugs on the market that specifically target ZNF217. Nonetheless, some drugs that indirectly affect ZNF217 expression, such as tamoxifen and trastuzumab, have been successful in treating breast cancer patients. Further research is needed to fully understand the role of ZNF217 in cancer and to develop effective targeted therapies.",GO:0000122 negative regulation of transcription by RNA polymerase II;GO:0045892 negative regulation of DNA-templated transcription;GO:1902679 negative regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nuclear speckles (Enhanced); Additional: Mitochondria,,,
ENSG00000214655.11,ENSG00000214655,ZSWIM8,-1.278567109,-2.146180857,-1.230683128,-0.45883734,zinc finger SWIM-type containing 8,"ZSWIM8 is a human gene that encodes a protein containing zinc finger SWIM-type domains. This protein is involved in several cellular processes, including the regulation of miRNA catabolism, protein ubiquitination, and proteasome-mediated protein degradation. ZSWIM8 functions as an adaptor protein for ubiquitin ligases and is part of the Cul3-RING ubiquitin ligase complex. This gene is important for maintaining proper cellular function and dysregulation of ZSWIM8 has been linked to various diseases, including cancer and neurodegenerative disorders.","There is limited information available on targeted drug discovery efforts for ZSWIM8. However, dysregulation of this gene has been linked to various diseases, including cancer and neurodegenerative disorders. In cancer, ZSWIM8 has been shown to play a role in the regulation of cell proliferation and apoptosis, making it a potential target for cancer therapy. In neurodegenerative disorders, ZSWIM8 has been implicated in the regulation of protein degradation pathways, suggesting that it may play a role in the pathogenesis of these diseases. Currently, there are no drugs on the market that specifically target ZSWIM8. However, there are drugs that target the proteasome-mediated protein degradation pathway, which ZSWIM8 is involved in. Examples of these drugs include bortezomib, carfilzomib, and ixazomib, which are used to treat multiple myeloma.",GO:0140958 target-directed miRNA degradation;GO:2000627 positive regulation of miRNA catabolic process;GO:2000625 regulation of miRNA catabolic process,,Predicted intracellular proteins,Cytosol;Plasma membrane (Approved),,,
ENSG00000213949.10,ENSG00000213949,ITGA1,-1.277399446,-1.476278898,-0.69526717,-1.660652271,integrin subunit alpha 1,"The ITGA1 gene encodes the alpha 1 subunit of integrin receptors, which form a cell-surface receptor for collagen and laminin. This protein heterodimerizes with the beta 1 subunit and is involved in cell-cell adhesion, inflammation, and fibrosis. The alpha 1 subunit contains an inserted von Willebrand factor type I domain that is believed to be involved in collagen binding. The gene's function is essential for the proper functioning of cells and tissues in the body. Mutations in this gene have been associated with various diseases, including cancer, cardiovascular disease, and kidney disease. Understanding the role of ITGA1 in these diseases may lead to the development of new treatments.","Mutations in the ITGA1 gene have been associated with various diseases, including cancer, cardiovascular disease, and kidney disease. In cancer, ITGA1 has been found to promote tumor growth and metastasis, making it a potential target for cancer therapy. Several studies have focused on developing drugs that target ITGA1, including monoclonal antibodies and small molecule inhibitors. However, there are currently no FDA-approved drugs that specifically target ITGA1.

In cardiovascular disease, ITGA1 has been implicated in the development of atherosclerosis and thrombosis. Targeting ITGA1 may therefore be a potential strategy for preventing or treating these conditions. In kidney disease, ITGA1 has been found to play a role in the development of fibrosis, which can lead to kidney failure. Targeting ITGA1 may therefore be a potential strategy for preventing or slowing the progression of kidney disease.

While there are currently no FDA-approved drugs that specifically target ITGA1, there are several drugs on the market that indirectly affect ITGA1 function. For example, aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to inhibit ITGA1-mediated platelet aggregation. Additionally, statins, which are commonly used to lower cholesterol levels, have been found to inhibit ITGA1 expression and activity.",GO:0042059 negative regulation of epidermal growth factor receptor signaling pathway;GO:1901185 negative regulation of ERBB signaling pathway;GO:0033627 cell adhesion mediated by integrin,,CD markers; Transporters:Accessory Factors Involved in Transport; Cancer-related genes:Candidate cancer biomarkers,Endoplasmic reticulum (Approved),,(M11)PID PRL SIGNALING EVENTS PATHWAY; (M274)PID LYMPH ANGIOGENESIS PATHWAY; (M47)PID INTEGRIN CS PATHWAY,
ENSG00000161847.14,ENSG00000161847,RAVER1,-1.276874841,-2.101544357,-1.343575323,-0.385504843,"ribonucleoprotein, PTB binding 1",RAVER1 is a human gene that encodes for a ribonucleoprotein called PTB binding 1. This gene is involved in RNA binding activity and is predicted to play a role in the regulation of alternative mRNA splicing through the spliceosome. RAVER1 is predicted to be located in the cytoplasm and active in the nucleus.,"Research on RAVER1 and its disease implications is still in its early stages, but some studies have suggested that it may play a role in cancer progression and metastasis. For example, one study found that RAVER1 expression was significantly higher in breast cancer tissues compared to normal breast tissues, and that higher levels of RAVER1 were associated with poorer patient outcomes. 

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target RAVER1. However, there are ongoing efforts to develop drugs that target RNA-binding proteins like RAVER1, as they have been implicated in a variety of diseases including cancer, neurodegenerative disorders, and viral infections. 

One example of a successful drug that targets an RNA-binding protein is Spinraza (nusinersen), which was approved by the FDA in 2016 for the treatment of spinal muscular atrophy (SMA). Spinraza works by increasing the production of a specific protein that is deficient in SMA patients, and it does so by targeting an RNA-binding protein called SMN2. While Spinraza does not target RAVER1 specifically, it is an example of the potential for RNA-targeted therapies to treat a variety of diseases.",,,Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000168016.15,ENSG00000168016,TRANK1,-1.276656237,-2.319713234,-0.934584408,-0.575671068,tetratricopeptide repeat and ankyrin repeat containing 1,"TRANK1 is a human gene that encodes a protein containing both tetratricopeptide repeat (TPR) and ankyrin repeat domains. The TPR domain is involved in protein-protein interactions, while the ankyrin repeat domain is involved in protein-DNA interactions. TRANK1 is predicted to have ATP binding activity, which suggests a potential role in energy metabolism. However, the exact function of TRANK1 is not yet fully understood.","There is limited information available on the disease implications of TRANK1. However, recent studies have suggested that TRANK1 may play a role in the development of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TRANK1 are still in the early stages, but there is potential for the development of drugs that target the protein's ATP binding activity. Currently, there are no drugs on the market that specifically target TRANK1. However, there are several drugs that target other proteins involved in energy metabolism, such as metformin, which is used to treat type 2 diabetes, and 2-deoxyglucose, which has shown promise in preclinical studies for the treatment of cancer. Further research is needed to fully understand the potential therapeutic implications of TRANK1.",,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000162654.9,ENSG00000162654,GBP4,-1.276585108,-0.82104771,-0.991742555,-2.016965059,guanylate binding protein 4,"GBP4 is a human gene that is activated by interferon and encodes for a guanylate-binding protein. This protein is responsible for hydrolyzing GTP into both GDP and GMP. The function of GBP4 is not fully understood, but it is believed to play a role in the immune response to viral infections. The gene was first identified in 2005 and is located on chromosome 1.","There is limited information available on the disease implications of GBP4. However, studies have shown that it may play a role in the immune response to viral infections, particularly in the activation of T cells and natural killer cells. As such, it may have implications in the development of antiviral therapies. 

There are currently no targeted drug discovery efforts specifically focused on GBP4. However, there are several drugs on the market that target the immune system and may indirectly affect the function of GBP4. For example, interferon-based therapies, which activate the expression of GBP4, are used to treat viral infections such as hepatitis C and multiple sclerosis. Additionally, drugs that target T cells and natural killer cells, such as checkpoint inhibitors and CAR-T cell therapies, may indirectly affect the function of GBP4. 

In summary, while the function of GBP4 is not fully understood, it may have implications in the immune response to viral infections. There are currently no targeted drug discovery efforts focused on this gene, but several drugs on the market that target the immune system may indirectly affect its function.",GO:0042832 defense response to protozoan;GO:0001562 response to protozoan;GO:0071346 cellular response to type II interferon,,Predicted intracellular proteins,Golgi apparatus (Supported); Additional: Plasma membrane,,,(M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5947)HALLMARK IL2 STAT5 SIGNALING; (M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000256043.4,ENSG00000256043,CTSO,-1.275501525,-2.297897856,-1.17608901,-0.35251771,cathepsin O,"The CTSO gene encodes for a cysteine proteinase called cathepsin O, which is a member of the papain superfamily. This enzyme is involved in breaking down and removing cellular proteins. Studies have shown that the recombinant form of cathepsin O can break down synthetic peptides that are commonly used as substrates for cysteine proteinases. The enzyme's activity can be inhibited by a cyteine proteinase inhibitor.","Research has shown that the CTSO gene may be involved in the development and progression of certain diseases, including cancer and osteoarthritis. In cancer, cathepsin O has been found to be overexpressed in various types of tumors, and its activity has been linked to tumor invasion and metastasis. As a result, there has been interest in developing drugs that target cathepsin O as a potential treatment for cancer. Several small molecule inhibitors of cathepsin O have been developed and tested in preclinical studies, with promising results. However, no cathepsin O inhibitors have yet been approved for clinical use.

In osteoarthritis, cathepsin O has been implicated in the degradation of cartilage, which is a hallmark of the disease. As a result, there has been interest in developing drugs that target cathepsin O as a potential treatment for osteoarthritis. One such drug, called balicatib, was developed by GlaxoSmithKline and tested in clinical trials. However, the drug was ultimately discontinued due to safety concerns.

Overall, while there is interest in targeting cathepsin O for the treatment of various diseases, there are currently no approved drugs that specifically target this enzyme. Further research is needed to better understand the role of cathepsin O in disease and to develop safe and effective drugs that target this enzyme.",GO:0051603 proteolysis involved in protein catabolic process;GO:0030163 protein catabolic process;GO:0009057 macromolecule catabolic process,,Peptidases:Cysteine-type peptidases; ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,,,(M3468)NABA ECM REGULATORS; (M5885)NABA MATRISOME ASSOCIATED; (M5889)NABA MATRISOME,(M5946)HALLMARK COAGULATION; (M5921)HALLMARK COMPLEMENT
ENSG00000198752.11,ENSG00000198752,CDC42BPB,-1.275448359,-1.692831945,-1.905075952,-0.228437179,CDC42 binding protein kinase beta,"CDC42BPB is a gene that encodes a protein kinase, which belongs to the serine/threonine protein kinase family. The protein contains a domain that binds to Cdc42/Rac, similar to that of PAK kinase. The kinase domain of this protein is closely related to that of myotonic dystrophy kinase-related ROK. Research on the similar gene in rats suggests that this kinase may act as a downstream effector of Cdc42 in cytoskeletal reorganization. Overall, CDC42BPB plays a role in regulating cellular processes such as cytoskeletal organization and may be involved in diseases such as myotonic dystrophy.","Mutations in the CDC42BPB gene have been associated with myotonic dystrophy type 2 (DM2), a rare genetic disorder characterized by muscle weakness and wasting, as well as other symptoms such as cataracts, heart conduction defects, and insulin resistance. While there are currently no targeted drug discovery efforts specifically for CDC42BPB, there are several drugs on the market that have been approved for the treatment of myotonic dystrophy, including mexiletine, which is used to treat myotonia (muscle stiffness), and spironolactone, which has been shown to improve cardiac function in patients with DM2. Additionally, there are several drugs in development for the treatment of myotonic dystrophy, including antisense oligonucleotides and small molecule compounds that target the underlying genetic defect.",GO:0031032 actomyosin structure organization;GO:0007163 establishment or maintenance of cell polarity;GO:0006468 protein phosphorylation,yes,Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Kinases:AGC Ser/Thr protein kinases; Enzymes,,,,
ENSG00000138081.21,ENSG00000138081,FBXO11,-1.27475849,-1.569095191,-1.5225208,-0.732659479,F-box protein 11,"FBXO11 is a gene that belongs to the F-box protein family and encodes a protein that functions as an arginine methyltransferase and an adaptor protein. It is involved in phosphorylation-dependent ubiquitination and mediates the neddylation of p53, leading to the suppression of p53 function. FBXO11 is down-regulated in melanocytes from patients with vitiligo, a skin disorder that results in depigmentation. Polymorphisms in this gene are associated with chronic otitis media with effusion and recurrent otitis media, a hearing loss disorder. Knockout of the homologous mouse gene results in the deaf mouse mutant Jeff, a single gene model of otitis media. Different isoforms of FBXO11 have been identified through alternative splicing.","There is limited information available on targeted drug discovery efforts for FBXO11. However, the association of polymorphisms in this gene with chronic otitis media with effusion and recurrent otitis media suggests that it may be a potential therapeutic target for these hearing loss disorders. Currently, there are no drugs on the market that specifically target FBXO11. However, there are drugs that target other members of the F-box protein family, such as thalidomide, which targets cereblon, and lenalidomide, which targets the E3 ubiquitin ligase complex containing CUL4A and DDB1. These drugs have been approved for the treatment of multiple myeloma and myelodysplastic syndromes. Further research is needed to explore the potential of targeting FBXO11 for therapeutic purposes.",GO:0010719 negative regulation of epithelial to mesenchymal transition;GO:0010717 regulation of epithelial to mesenchymal transition;GO:0007605 sensory perception of sound,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Nucleoli;Nucleoplasm (Supported),,(M261)PID P53 REGULATION PATHWAY,
ENSG00000119138.4,ENSG00000119138,KLF9,-1.273164112,-2.221927577,-1.427895152,-0.169669606,KLF transcription factor 9,"KLF9 is a human gene that encodes for a transcription factor. This protein binds to GC box elements in the promoter region of genes. When it binds to a single GC box, it inhibits the expression of mRNA. However, when it binds to multiple GC boxes in tandem, it activates transcription. This gene is important in regulating gene expression and may play a role in various biological processes.","KLF9 has been implicated in various diseases, including cancer, diabetes, and neurological disorders. In cancer, KLF9 has been shown to act as a tumor suppressor by inhibiting cell proliferation and inducing apoptosis. In diabetes, KLF9 has been found to regulate insulin secretion and glucose metabolism. In neurological disorders, KLF9 has been linked to neuroprotection and synaptic plasticity.

Targeted drug discovery efforts for KLF9 have focused on identifying small molecules that can modulate its activity. One study found that a compound called KLF9-activating compound 1 (KAC-1) could activate KLF9 and inhibit the growth of breast cancer cells. Another study identified a compound called KLF9-activating compound 2 (KAC-2) that could activate KLF9 and improve glucose metabolism in diabetic mice.

Currently, there are no drugs on the market that specifically target KLF9. However, there are drugs that indirectly affect KLF9 activity. For example, metformin, a commonly used drug for type 2 diabetes, has been shown to increase KLF9 expression and improve glucose metabolism. Additionally, some chemotherapy drugs, such as cisplatin and doxorubicin, have been found to induce KLF9 expression and promote apoptosis in cancer cells.",GO:0071387 cellular response to cortisol stimulus;GO:0051414 response to cortisol;GO:0010839 negative regulation of keratinocyte proliferation,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol;Plasma membrane,,,(M5890)HALLMARK TNFA SIGNALING VIA NFKB
ENSG00000198771.11,ENSG00000198771,RCSD1,-1.273064889,-1.716974262,-0.944153589,-1.158066816,RCSD domain containing 1,"RCSD1, or RCSD domain containing 1, is a human gene that is involved in the cellular hyperosmotic response. It enables actin filament binding activity and is predicted to be located in the actin filament. The gene's function is not fully understood, but it may play a role in regulating the cytoskeleton and cell shape. Further research is needed to fully understand the role of RCSD1 in human biology.","There is limited information available on the disease implications of RCSD1. However, some studies have suggested that it may be involved in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for RCSD1 are also limited, as its function is not fully understood. Currently, there are no drugs on the market that specifically target RCSD1. However, there are drugs that target the cytoskeleton and actin filaments, which may indirectly affect RCSD1 function. For example, cytochalasin D is a drug that disrupts actin filaments and is used to treat certain types of cancer. Blebbistatin is another drug that inhibits actin-myosin interactions and is being investigated as a potential treatment for heart disease and cancer.",GO:0071474 cellular hyperosmotic response;GO:0036010 protein localization to endosome;GO:0006972 hyperosmotic response,,Predicted intracellular proteins,,,,
ENSG00000135392.18,ENSG00000135392,DNAJC14,-1.272791837,-1.705060013,-1.540248871,-0.573066626,DnaJ heat shock protein family (Hsp40) member C14,DNAJC14 is a member of the DnaJ heat shock protein family (Hsp40) and is predicted to be involved in protein transport. It is located in the membrane. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of DNAJC14. However, mutations in this gene have been associated with autosomal recessive intellectual disability, a condition characterized by significant limitations in intellectual functioning and adaptive behavior. 

As for targeted drug discovery efforts, there is currently no known drug specifically targeting DNAJC14. However, given its predicted involvement in protein transport, it is possible that drugs targeting protein transport pathways may indirectly affect the function of DNAJC14. 

There are currently no successful drugs on the market targeting DNAJC14. However, there are drugs targeting other members of the DnaJ heat shock protein family, such as the Hsp90 inhibitor, ganetespib, which is being investigated for the treatment of various cancers. Additionally, the Hsp70 inhibitor, VER-155008, has shown potential in preclinical studies for the treatment of neurodegenerative diseases.",GO:0015031 protein transport;GO:0045184 establishment of protein localization;GO:0071705 nitrogen compound transport,,,,,,
ENSG00000120279.6,ENSG00000120279,MYCT1,-1.272277622,-1.454955455,-0.872662862,-1.48921455,MYC target 1,"MYCT1, also known as MYC target 1, is a human gene that is predicted to play a role in regulating hematopoietic stem cell homeostasis. It is located in the nucleoplasm, which is the fluid inside the nucleus of a cell. MYCT1 is believed to act upstream of or within the process of maintaining a balance of hematopoietic stem cells in the body. This gene has been identified as a target of the MYC oncogene, which is known to be involved in the development of many types of cancer. Further research is needed to fully understand the function of MYCT1 and its potential role in disease.","There is limited information available on the disease implications of MYCT1, as it is a relatively understudied gene. However, given its association with the MYC oncogene, it is possible that MYCT1 may play a role in the development or progression of certain types of cancer. Targeted drug discovery efforts for MYCT1 are also limited, as there are currently no drugs on the market that specifically target this gene. However, there are several drugs that target the MYC oncogene, such as BET inhibitors and small molecule inhibitors, which may indirectly affect the expression or activity of MYCT1. Examples of successful drugs targeting MYC include venetoclax, which is approved for the treatment of chronic lymphocytic leukemia, and omomyc, which is currently in clinical trials for the treatment of various types of cancer. Further research is needed to determine the potential therapeutic implications of targeting MYCT1 directly.",GO:0061484 hematopoietic stem cell homeostasis;GO:0048872 homeostasis of number of cells;GO:0048871 multicellular organismal-level homeostasis,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nuclear bodies;Vesicles,,(M66)PID MYC ACTIV PATHWAY,
ENSG00000153208.17,ENSG00000153208,MERTK,-1.270716562,-1.387119672,-1.006534877,-1.418495136,"MER proto-oncogene, tyrosine kinase","MERTK is a gene that encodes a transmembrane protein with two fibronectin type-III domains, two Ig-like C2-type domains, and one tyrosine kinase domain. It belongs to the MER/AXL/TYRO3 receptor kinase family. Mutations in this gene have been linked to the onset of autosomal recessive retinitis pigmentosa (RP) due to the disruption of the retinal pigment epithelium (RPE) phagocytosis pathway.","MERTK has been identified as a potential therapeutic target for various diseases, including cancer and autoimmune disorders. In cancer, MERTK is often overexpressed and promotes tumor growth, invasion, and metastasis. Targeting MERTK with small molecule inhibitors or monoclonal antibodies has shown promising results in preclinical studies and clinical trials. For example, the small molecule inhibitor UNC2025 has been shown to inhibit MERTK activity and reduce tumor growth in mouse models of breast cancer and acute myeloid leukemia. In autoimmune disorders, MERTK has been implicated in the regulation of immune cell function and the clearance of apoptotic cells. Targeting MERTK with monoclonal antibodies has shown efficacy in preclinical models of autoimmune diseases such as lupus and rheumatoid arthritis. One example of a successful drug targeting MERTK is the monoclonal antibody efgartigimod, which has been approved for the treatment of myasthenia gravis.",GO:0097350 neutrophil clearance;GO:0060068 vagina development;GO:0001779 natural killer cell differentiation,yes,Kinases:Tyr protein kinases; Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Plasma membrane (Supported); Additional: Acrosome;Cytosol;Mid piece;Midbody;Principal piece,2-({6-[(3-Chlorophenyl)amino]-9-isopropyl-9H-purin-2-yl}amino)ethanol; Fostamatinib,,(M5908)HALLMARK ANDROGEN RESPONSE; (M5937)HALLMARK GLYCOLYSIS
ENSG00000139508.15,ENSG00000139508,SLC46A3,-1.267733893,-1.968592902,-1.276048867,-0.558559912,solute carrier family 46 member 3,"SLC46A3 is a gene that encodes a transmembrane protein responsible for transporting small molecules across membranes. It is primarily found in lysosomal membranes, where it transports catabolites from the lysosomes to the cytoplasm. The protein has been shown to be effective in transporting the cytotoxic drug maytansine, which is used in antibody-based targeting of cancer cells.","There is limited information available on the disease implications of SLC46A3 mutations. However, recent studies have suggested that mutations in this gene may be associated with lysosomal storage disorders, such as Niemann-Pick disease type C. Targeted drug discovery efforts for SLC46A3 have primarily focused on developing drugs that can enhance the transport of cytotoxic drugs, such as maytansine, across lysosomal membranes. One example of a successful drug that targets SLC46A3 is ado-trastuzumab emtansine (Kadcyla), which is used to treat HER2-positive breast cancer. This drug is a conjugate of the antibody trastuzumab and the cytotoxic drug maytansine, and it has been shown to be effective in targeting cancer cells while minimizing damage to healthy cells. Other potential drug candidates targeting SLC46A3 are currently being investigated in preclinical studies.","GO:1904613 cellular response to 2,3,7,8-tetrachlorodibenzodioxine;GO:1904612 response to 2,3,7,8-tetrachlorodibenzodioxine;GO:0035434 copper ion transmembrane transport",,Transporters:Electrochemical Potential-driven transporters,Cytosol;Plasma membrane (Approved); Additional: Actin filaments,,,(M5934)HALLMARK XENOBIOTIC METABOLISM
ENSG00000124126.14,ENSG00000124126,PREX1,-1.266602056,-1.742228296,-0.729763301,-1.327814572,"phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1","PREX1 is a human gene that encodes a protein that acts as a guanine nucleotide exchange factor for the RHO family of small GTP-binding proteins, specifically RAC1. The protein is mainly found in the cytoplasm and is activated by phosphatidylinositol-3,4,5-trisphosphate and the beta-gamma subunits of heterotrimeric G proteins. Its function is to exchange bound GDP for free GTP, which activates RAC1.","PREX1 has been implicated in various types of cancer, including breast, prostate, and colorectal cancer. Overexpression of PREX1 has been shown to promote tumor growth and metastasis by activating RAC1 signaling pathways. Therefore, PREX1 has been identified as a potential therapeutic target for cancer treatment. Several small molecule inhibitors of PREX1 have been developed and tested in preclinical studies, showing promising results in reducing tumor growth and metastasis. However, no PREX1 inhibitors have been approved for clinical use yet. One example of a successful drug targeting RAC1 is the FDA-approved drug, trametinib, which inhibits the downstream effector of RAC1, MEK1/2, and is used to treat melanoma and other cancers.",GO:0042119 neutrophil activation;GO:0030041 actin filament polymerization;GO:0036230 granulocyte activation,,Predicted intracellular proteins,Cytosol;Vesicles (Supported),,(M1315)SIG PIP3 SIGNALING IN B LYMPHOCYTES; (M241)PID RAC1 REG PATHWAY; (M295)SIG PIP3 SIGNALING IN CARDIAC MYOCTES,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000139613.12,ENSG00000139613,SMARCC2,-1.266086896,-1.723902652,-1.394599466,-0.679758569,SWI/SNF related BAF chromatin remodeling complex subunit C2,"SMARCC2 is a gene that belongs to the SWI/SNF family of proteins. These proteins are believed to regulate the transcription of certain genes by modifying the chromatin structure around them. SMARCC2 is part of the SNF/SWI complex, which is an ATP-dependent chromatin remodeling complex. The gene encodes a protein that contains a predicted leucine zipper motif, which is a common feature of many transcription factors. Different isoforms of the protein are produced through alternative splicing of the gene.","Research has shown that SMARCC2 mutations are associated with several types of cancer, including lung, breast, and ovarian cancer. In lung cancer, SMARCC2 mutations have been found to be associated with a poor prognosis. Targeted drug discovery efforts have focused on developing inhibitors of the SWI/SNF complex, including SMARCC2, as a potential treatment for cancer. One example of a successful drug targeting the SWI/SNF complex is EZH2 inhibitors, which have been approved for the treatment of certain types of lymphoma. However, there are currently no drugs specifically targeting SMARCC2. Further research is needed to fully understand the role of SMARCC2 in cancer and to develop targeted therapies for patients with SMARCC2 mutations.",GO:0006337 nucleosome disassembly;GO:0032986 protein-DNA complex disassembly;GO:2000819 regulation of nucleotide-excision repair,,Disease related genes; Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Nucleoplasm (Enhanced),,(M115)PID REG GR PATHWAY,
ENSG00000196535.17,ENSG00000196535,MYO18A,-1.263187964,-1.687661424,-1.558944805,-0.542957662,myosin XVIIIA,"MYO18A is a human gene that encodes for the protein myosin XVIIIA. This protein is involved in linking the Golgi to the cytoskeleton, which affects Golgi membrane trafficking. Additionally, myosin XVIIIA is part of a complex that helps assemble lamellar actomyosin bundles, which are important for cell migration. These functions suggest that MYO18A may play a role in cellular processes such as protein transport and cell movement.","There is limited information available on the disease implications of MYO18A mutations. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast and lung cancer. Targeted drug discovery efforts for MYO18A are also limited, as the function of this protein is not well understood. However, some studies have suggested that targeting myosin proteins, including myosin XVIIIA, may be a potential strategy for cancer therapy. Currently, there are no drugs on the market that specifically target MYO18A. However, there are drugs that target other myosin proteins, such as blebbistatin, which inhibits myosin II and has been used in research to study cell migration and cancer cell invasion. Overall, more research is needed to fully understand the role of MYO18A in disease and to develop targeted therapies for potential clinical applications.",GO:0090164 asymmetric Golgi ribbon formation;GO:1903028 positive regulation of opsonization;GO:0048194 Golgi vesicle budding,,Predicted intracellular proteins,,,,
ENSG00000163297.17,ENSG00000163297,ANTXR2,-1.262544187,-2.276905535,-0.957205151,-0.553521876,ANTXR cell adhesion molecule 2,"ANTXR2 is a gene that encodes a receptor for anthrax toxin. The protein produced by this gene binds to collagen IV and laminin, indicating its potential involvement in extracellular matrix adhesion. Mutations in ANTXR2 have been linked to two rare genetic disorders: juvenile hyaline fibromatosis and infantile systemic hyalinosis. These disorders are characterized by the accumulation of hyaline material in various tissues, leading to a range of symptoms including joint stiffness, skin lesions, and organ dysfunction. Multiple transcript variants of ANTXR2 have been identified, resulting in different isoforms of the protein.","There are currently no targeted drug discovery efforts specifically for ANTXR2, as it is primarily associated with rare genetic disorders. However, there have been some successful drugs developed for the treatment of anthrax, which is caused by the toxin that ANTXR2 binds to. One such drug is Anthrax Immune Globulin (AIG), which is a mixture of antibodies that target the anthrax toxin and neutralize its effects. AIG has been used successfully in the treatment of inhalational anthrax, and is currently approved by the FDA for emergency use. Another drug, raxibacumab, is a monoclonal antibody that specifically targets the protective antigen component of the anthrax toxin. Raxibacumab has also been approved by the FDA for the treatment of inhalational anthrax. While these drugs do not directly target ANTXR2, they are effective in treating the disease caused by the toxin that ANTXR2 binds to.",,,Disease related genes; Human disease related genes:Musculoskeletal diseases:Other musculoskeletal diseases; Predicted intracellular proteins,,MDX-1303,(M267)PID ANTHRAX PATHWAY,(M5892)HALLMARK CHOLESTEROL HOMEOSTASIS
ENSG00000150961.15,ENSG00000150961,SEC24D,-1.260287618,-1.840819703,-1.282691405,-0.657351746,"SEC24 homolog D, COPII coat complex component","SEC24D is a human gene that encodes a protein belonging to the SEC24 subfamily of the SEC23/SEC24 family. This protein is involved in vesicle trafficking and has similarities to the yeast Sec24p component of COPII, which is responsible for vesicle budding from the endoplasmic reticulum (ER). SEC24D is implicated in shaping the vesicle, cargo selection, and concentration. Mutations in this gene have been linked to Cole-Carpenter syndrome, a disorder that affects bone formation and causes craniofacial malformations and fragile bones. Alternative splicing of SEC24D results in multiple transcript variants that encode different isoforms.","Mutations in SEC24D have been linked to Cole-Carpenter syndrome, a rare genetic disorder characterized by craniofacial malformations, multiple fractures, and other skeletal abnormalities. There is currently no cure for Cole-Carpenter syndrome, and treatment is mainly supportive, focusing on managing symptoms and preventing complications. However, understanding the molecular mechanisms underlying the disease may lead to the development of targeted therapies in the future.

There are currently no drugs specifically targeting SEC24D, but efforts are underway to develop drugs that modulate the COPII vesicle trafficking pathway, of which SEC24D is a component. For example, SecinH3 is a small molecule inhibitor of the COPII pathway that has been shown to reduce the secretion of pro-inflammatory cytokines and improve survival in a mouse model of sepsis. Other compounds targeting the COPII pathway are also being investigated for their potential therapeutic applications in various diseases.

In addition, there are drugs on the market that indirectly affect the COPII pathway, such as the anti-cancer drug bortezomib, which inhibits the proteasome and disrupts protein trafficking through the ER-Golgi system. However, the use of these drugs in the context of Cole-Carpenter syndrome or other diseases associated with SEC24D mutations has not been explored.",GO:0090110 COPII-coated vesicle cargo loading;GO:0035459 vesicle cargo loading;GO:0090114 COPII-coated vesicle budding,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Predicted intracellular proteins,Vesicles (Approved),,,(M5910)HALLMARK PROTEIN SECRETION; (M5908)HALLMARK ANDROGEN RESPONSE
ENSG00000095370.20,ENSG00000095370,SH2D3C,-1.260109015,-1.613735752,-0.910664556,-1.255926739,SH2 domain containing 3C,"SH2D3C is a gene that encodes an adaptor protein involved in cell migration. The protein contains a putative Src homology 2 (SH2) domain and guanine nucleotide exchange factor-like domain, allowing it to form a complex with the scaffolding protein Crk-associated substrate. Multiple transcript variants encoding different isoforms have been identified.","There is limited information available on the disease implications of SH2D3C. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for SH2D3C are also limited, as the function of the protein is not well understood. However, some studies have suggested that targeting the SH2 domain of the protein may be a potential therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target SH2D3C. However, there are drugs that target other proteins involved in cell migration and cancer, such as tyrosine kinase inhibitors and monoclonal antibodies targeting growth factor receptors. Examples of such drugs include imatinib, erlotinib, and trastuzumab.",GO:0007254 JNK cascade;GO:0000165 MAPK cascade;GO:0007264 small GTPase-mediated signal transduction,,Predicted intracellular proteins,Cytosol (Supported),,,
ENSG00000178202.13,ENSG00000178202,POGLUT3,-1.257029629,-1.558883294,-1.34472829,-0.867477302,protein O-glucosyltransferase 3,"POGLUT3 is a human gene that encodes for a protein called protein O-glucosyltransferase 3. This protein is involved in the process of protein O-linked glycosylation via serine, which is the addition of sugar molecules to proteins. POGLUT3 enables UDP-glucosyltransferase activity and UDP-xylosyltransferase activity, which are important for the glycosylation process. The gene is predicted to be located in the endoplasmic reticulum lumen and active in the endomembrane system. Overall, POGLUT3 plays a crucial role in the modification of proteins, which is important for their proper function in the body.","Research on POGLUT3 and its disease implications is still in its early stages, but some studies have suggested that mutations in the gene may be associated with certain types of cancer, such as breast cancer and colorectal cancer. Additionally, POGLUT3 has been implicated in the development of Alzheimer's disease, as it is involved in the glycosylation of proteins that are important for neuronal function and survival.

As for targeted drug discovery efforts, there is currently no drug on the market that specifically targets POGLUT3. However, there is ongoing research into the development of drugs that can modulate the glycosylation process, which could potentially have therapeutic benefits for a range of diseases. For example, some drugs that target enzymes involved in glycosylation have shown promise in treating certain types of cancer, such as breast cancer and pancreatic cancer.

Overall, while there is still much to learn about the role of POGLUT3 in disease and the potential for targeted drug discovery, the study of protein glycosylation is an active area of research with promising implications for the development of new therapies.",GO:0018242 protein O-linked glycosylation via serine;GO:0018209 peptidyl-serine modification;GO:0006493 protein O-linked glycosylation,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Vesicles,,,
ENSG00000064313.12,ENSG00000064313,TAF2,-1.251433315,-1.473139269,-1.485211768,-0.795948909,TATA-box binding protein associated factor 2,"TAF2 is a gene that encodes one of the larger subunits of TFIID, a protein complex that coordinates the initiation of transcription by RNA polymerase II. TFIID is composed of the TATA-binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors or TAFs. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. TAF2 contributes to interactions at and downstream of the transcription initiation site, interactions that help determine transcription complex response to activators.","There is limited information available on the disease implications of TAF2 mutations. However, recent studies have suggested that TAF2 may play a role in the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TAF2 are still in the early stages, but there is potential for TAF2 inhibitors to be developed as cancer therapies. Currently, there are no drugs on the market that specifically target TAF2, but there are several drugs that target other components of the transcription machinery, such as RNA polymerase inhibitors and histone deacetylase inhibitors, that have shown promise in clinical trials for cancer treatment.",GO:0042789 mRNA transcription by RNA polymerase II;GO:0000086 G2/M transition of mitotic cell cycle;GO:0009299 mRNA transcription,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Predicted intracellular proteins,,,,
ENSG00000114166.8,ENSG00000114166,KAT2B,-1.250928979,-1.819537811,-1.144087829,-0.789161295,lysine acetyltransferase 2B,"KAT2B, also known as lysine acetyltransferase 2B, is a human gene that encodes a protein that interacts with CBP and p300, two nuclear proteins involved in cell growth and differentiation. KAT2B competes with the adenoviral oncoprotein E1A for binding sites in CBP/p300 and has histone acetyl transferase activity, indicating its role in transcriptional regulation. KAT2B can bind to CBP/p300 in vitro and in vivo and has the ability to acetylate core histones and nucleosome core particles. This suggests that KAT2B plays a direct role in regulating gene expression.","KAT2B has been implicated in several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, KAT2B has been shown to promote tumor growth and metastasis by regulating the expression of genes involved in cell proliferation, angiogenesis, and invasion. Targeting KAT2B with small molecule inhibitors has emerged as a potential therapeutic strategy for cancer treatment. Several KAT2B inhibitors have been developed, including NU9056 and NU9057, which have shown promising results in preclinical studies. However, no KAT2B inhibitors have been approved for clinical use yet. In neurodegenerative disorders, KAT2B has been shown to regulate the expression of genes involved in neuronal survival and synaptic plasticity. In cardiovascular diseases, KAT2B has been implicated in the regulation of vascular smooth muscle cell proliferation and migration. Overall, KAT2B represents a promising target for drug discovery efforts in various diseases.",GO:2000233 negative regulation of rRNA processing;GO:0018076 N-terminal peptidyl-lysine acetylation;GO:0090071 negative regulation of ribosome biogenesis,,Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Enhanced); Additional: Cytosol,Coenzyme A; (3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE; N-(3-AMINOPROPYL)-2-NITROBENZENAMINE,(M32)PID HDAC CLASSIII PATHWAY; (M207)PID RETINOIC ACID PATHWAY; (M136)PID FOXO PATHWAY,(M5945)HALLMARK HEME METABOLISM
ENSG00000137496.18,ENSG00000137496,IL18BP,-1.24651369,-1.771330744,-0.539006681,-1.429203644,interleukin 18 binding protein,"IL18BP is a gene that encodes a protein that acts as an inhibitor of the proinflammatory cytokine, IL18. The protein binds to IL18, preventing it from binding to its receptor and inhibiting the production of IFN-gamma, which results in reduced T-helper type 1 immune responses. The protein is constitutively expressed and secreted in mononuclear cells, and elevated levels of the protein have been detected in the intestinal tissues of patients with Crohn's disease. The gene has alternatively spliced transcript variants that encode different isoforms.","IL18BP has been implicated in various inflammatory diseases, including Crohn's disease, rheumatoid arthritis, and psoriasis. In Crohn's disease, elevated levels of IL18BP have been observed in the intestinal tissues of patients, suggesting a potential role in the pathogenesis of the disease. Targeted drug discovery efforts have focused on developing drugs that can modulate the activity of IL18BP, either by enhancing its inhibitory activity or by reducing its expression. One example of a successful drug targeting IL18BP is ustekinumab, a monoclonal antibody that targets IL12 and IL23, which are cytokines that induce the expression of IL18BP. Ustekinumab has been approved for the treatment of psoriasis and Crohn's disease. Another example is canakinumab, a monoclonal antibody that targets IL1?, which is a cytokine that induces the expression of IL18BP. Canakinumab has been approved for the treatment of various inflammatory diseases, including rheumatoid arthritis and cryopyrin-associated periodic syndromes.",GO:0042088 T-helper 1 type immune response;GO:0070301 cellular response to hydrogen peroxide;GO:0042542 response to hydrogen peroxide,,Disease related genes; Predicted secreted proteins; Predicted intracellular proteins; Human disease related genes:Immune system diseases:Other immune system diseases,Endoplasmic reticulum (Approved),,,(M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000213839.4,ENSG00000213839,TMX2P1,-1.245118168,-2.004635055,-1.361766387,-0.368953061,None,None,None,None,None,None,None,None,None,None
ENSG00000105856.14,ENSG00000105856,HBP1,-1.242827531,-1.693805513,-1.466477736,-0.568199345,HMG-box transcription factor 1,"HBP1 is a human gene that encodes for a transcription factor called HMG-box transcription factor 1. It is predicted to have DNA-binding transcription repressor activity, specifically for RNA polymerase II and cis-regulatory region sequence-specific DNA binding activity. HBP1 is involved in negative regulation of lipid transport, reactive oxygen species biosynthetic process, and transcription by RNA polymerase II. It is located in the nuclear speck and is a biomarker of osteoarthritis.","There is limited information available on the disease implications of HBP1. However, some studies have suggested that HBP1 may play a role in the development and progression of certain cancers, including breast cancer and leukemia. Targeted drug discovery efforts for HBP1 are also limited, but some studies have explored the potential of HBP1 as a therapeutic target for cancer treatment. One study found that inhibiting HBP1 expression in breast cancer cells led to decreased cell proliferation and increased sensitivity to chemotherapy. Currently, there are no drugs on the market that specifically target HBP1, but further research may lead to the development of novel therapies for cancer and other diseases associated with HBP1 dysregulation.",GO:0016055 Wnt signaling pathway;GO:0051726 regulation of cell cycle;GO:0007166 cell surface receptor signaling pathway,,Transcription factors:Other all-alpha-helical DNA-binding domains; Predicted intracellular proteins,Nuclear speckles (Supported),,(M139)PID MYC PATHWAY; (M229)PID P38 ALPHA BETA DOWNSTREAM PATHWAY; (M236)PID DELTA NP63 PATHWAY,
ENSG00000172469.16,ENSG00000172469,MANEA,-1.242335078,-1.332197272,-1.449932431,-0.944875532,mannosidase endo-alpha,"The MANEA gene encodes for an enzyme called mannosidase endo-alpha, which plays a role in the processing of N-glycosylation of proteins. This process begins in the endoplasmic reticulum with the transfer of a preassembled oligosaccharide to the target protein. The core oligosaccharide is then processed by several glycosidases in the ER and by MANEA in the Golgi. MANEA cleaves the alpha-1,2-mannosidic bond that links mono-, di-, and triglucosylmannose oligosaccharides to high-mannose glycans. This process is important for the proper folding and function of glycoproteins. Mutations in the MANEA gene have been associated with developmental delay and intellectual disability.","Mutations in the MANEA gene have been associated with developmental delay and intellectual disability. However, there are currently no targeted drug discovery efforts for this gene. This may be due to the fact that the function of MANEA is not well understood and there are no known diseases directly caused by its dysfunction. Additionally, there are no drugs on the market that specifically target MANEA. However, there are drugs that target the glycosylation pathway, which MANEA is a part of. For example, tunicamycin is an antibiotic that inhibits the first step of N-glycosylation and is used in research to study the effects of glycosylation inhibition. Another example is miglustat, which inhibits the enzyme glucosylceramide synthase and is used to treat Gaucher disease, a lysosomal storage disorder that affects glycosylation.",,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Golgi apparatus (Supported),,,
ENSG00000164684.13,ENSG00000164684,ZNF704,-1.241255546,-1.709764659,-0.751376988,-1.26262499,zinc finger protein 704,ZNF704 is a human gene that encodes for a zinc finger protein 704. This protein is involved in sequence-specific double-stranded DNA binding activity and is predicted to play a role in the regulation of transcription by RNA polymerase II. It is also predicted to be active in the nucleus.,"There is limited information available on the disease implications of ZNF704. However, recent studies have suggested that this gene may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ZNF704 are still in the early stages, but there is potential for this gene to be targeted for cancer therapy. Currently, there are no drugs on the market that specifically target ZNF704. However, there are several drugs that target other zinc finger proteins, such as the anti-cancer drug trabectedin, which targets the zinc finger protein FUS. Further research is needed to fully understand the role of ZNF704 in disease and to develop targeted therapies for its potential implications.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000178878.13,ENSG00000178878,APOLD1,-1.239858993,-1.272616806,-1.022137121,-1.424823053,apolipoprotein L domain containing 1,"APOLD1 is a gene that codes for a protein called apolipoprotein L domain containing 1. This protein is produced by endothelial cells and is involved in regulating endothelial cell signaling and vascular function. It is considered an early response protein, meaning that it is produced quickly in response to certain stimuli. The exact role of APOLD1 in these processes is not fully understood, but it is believed to play a significant role in maintaining proper vascular function.","There is limited information available on the disease implications of APOLD1. However, recent studies have suggested that mutations in this gene may be associated with an increased risk of developing certain types of cancer, including breast and ovarian cancer. Additionally, APOLD1 has been implicated in the development of cardiovascular disease, as it plays a role in regulating endothelial cell function and vascular health.

Despite the limited understanding of APOLD1's disease implications, there have been some targeted drug discovery efforts aimed at developing drugs that target this gene. One such effort involves the development of small molecule inhibitors that can block the activity of APOLD1 and potentially prevent or treat diseases associated with its dysfunction. However, these efforts are still in the early stages of development and it may be some time before any drugs targeting APOLD1 are available on the market.

Currently, there are no drugs on the market that specifically target APOLD1. However, there are several drugs that target other proteins involved in regulating endothelial cell function and vascular health, such as statins and ACE inhibitors, which are commonly used to treat cardiovascular disease. Additionally, there are several drugs that target specific types of cancer, including breast and ovarian cancer, which may be relevant for individuals with mutations in APOLD1 that increase their risk of developing these types of cancer.",GO:0061906 autophagosome localization;GO:0160192 autophagosome-dependent secretion;GO:0045601 regulation of endothelial cell differentiation,,,Nucleoplasm;Plasma membrane (Supported),,,
ENSG00000214357.9,ENSG00000214357,NEURL1B,-1.237003904,-0.661283631,-1.186393508,-1.863334574,neuralized E3 ubiquitin protein ligase 1B,"NEURL1B is a human gene that encodes for a protein called neuralized E3 ubiquitin protein ligase 1B. This protein is predicted to have the ability to act as an enzyme that attaches ubiquitin molecules to other proteins, a process known as ubiquitination. NEURL1B is also predicted to be involved in a specific type of endocytosis that is dependent on ubiquitin. The protein is located in the actin cytoskeleton and cytosol, which are both important components of the cell's structure and function. Overall, NEURL1B plays a role in regulating protein turnover and cellular processes through ubiquitination.","There is limited information available on the disease implications of NEURL1B. However, recent studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for NEURL1B are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein's ubiquitin ligase activity. While there are currently no drugs on the market that specifically target NEURL1B, there are several drugs that target the ubiquitin-proteasome system, which is the cellular pathway that NEURL1B is involved in. Examples of successful drugs in this category include bortezomib, which is used to treat multiple myeloma, and carfilzomib, which is used to treat relapsed or refractory multiple myeloma.",GO:0070086 ubiquitin-dependent endocytosis;GO:0007219 Notch signaling pathway;GO:0072594 establishment of protein localization to organelle,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Supported); Additional: Actin filaments,,,
ENSG00000164741.15,ENSG00000164741,DLC1,-1.235923657,-1.666731284,-0.7726149,-1.268424786,DLC1 Rho GTPase activating protein,"DLC1 is a gene that encodes a protein called Rho GTPase activating protein, which is a member of the rhoGAP family of proteins. These proteins play a role in regulating small GTP-binding proteins and participate in signaling pathways that regulate cell processes involved in cytoskeletal changes. DLC1 functions as a tumor suppressor gene in several common cancers, including prostate, lung, colorectal, and breast cancers. The gene has multiple transcript variants due to alternative promoters and alternative splicing.","DLC1 is a tumor suppressor gene that is frequently inactivated in various types of cancer, including prostate, lung, colorectal, and breast cancers. Loss of DLC1 expression or function has been associated with increased tumor growth, invasion, and metastasis. Therefore, DLC1 has been proposed as a potential therapeutic target for cancer treatment. Several studies have investigated the use of small molecule inhibitors to restore DLC1 function in cancer cells. For example, a study using a high-throughput screening approach identified a compound called CCG-1423 that can activate DLC1 and inhibit cancer cell growth. Another study showed that a combination of a DLC1 activator and a chemotherapy drug can enhance the anti-tumor effect in lung cancer cells. However, there are currently no drugs targeting DLC1 that have been approved for clinical use. Further research is needed to develop effective therapies targeting DLC1 for cancer treatment.",GO:0051895 negative regulation of focal adhesion assembly;GO:0150118 negative regulation of cell-substrate junction organization;GO:1900119 positive regulation of execution phase of apoptosis,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cytosol (Supported); Additional: Endoplasmic reticulum;Vesicles,,(M68)PID RHOA REG PATHWAY,(M5942)HALLMARK UV RESPONSE DN; (M5906)HALLMARK ESTROGEN RESPONSE EARLY
ENSG00000172348.15,ENSG00000172348,RCAN2,-1.234737758,-2.095716661,-1.338505702,-0.269990911,regulator of calcineurin 2,"RCAN2 is a gene that belongs to the regulator of calcineurin (RCAN) protein family. These proteins bind to the catalytic domain of calcineurin A, inhibiting calcineurin-mediated nuclear translocation of the transcription factor NFATC1. RCAN2 is upregulated by thyroid hormone in skin fibroblasts and may play a role in endothelial cell function and angiogenesis. The gene has multiple isoforms due to alternative splicing.","RCAN2 has been implicated in several diseases, including Alzheimer's disease, Down syndrome, and cancer. In Alzheimer's disease, RCAN2 has been shown to be upregulated in the brains of patients, and may play a role in the pathogenesis of the disease. In Down syndrome, RCAN2 is located on chromosome 21, which is triplicated in individuals with the syndrome, leading to overexpression of the gene. This overexpression may contribute to the cognitive deficits seen in Down syndrome. In cancer, RCAN2 has been shown to be downregulated in several types of tumors, and may act as a tumor suppressor.

There are currently no drugs specifically targeting RCAN2, but there have been efforts to develop drugs that target calcineurin, the protein that RCAN2 regulates. Calcineurin inhibitors, such as cyclosporine and tacrolimus, are used clinically as immunosuppressants to prevent organ rejection in transplant patients. These drugs work by inhibiting calcineurin-mediated activation of T cells. However, they have significant side effects, including nephrotoxicity and increased risk of infection.

In recent years, there has been interest in developing more selective calcineurin inhibitors that target specific isoforms of the protein. One such drug, voclosporin, is currently in clinical trials for the treatment of lupus nephritis and dry eye syndrome. Voclosporin has been shown to have a more favorable safety profile than cyclosporine, and may have potential for use in other diseases where calcineurin is implicated, including Alzheimer's disease and cancer.",GO:0019722 calcium-mediated signaling;GO:0141124 intracellular signaling cassette;GO:0035556 intracellular signal transduction,,Predicted intracellular proteins,Mitochondria (Approved); Additional: Microtubules;Nucleoplasm;Primary cilium;Vesicles,,(M235)PID TCR CALCIUM PATHWAY; (M113)PID NFAT 3PATHWAY,
ENSG00000103479.16,ENSG00000103479,RBL2,-1.2343932,-1.17853038,-1.877915449,-0.64673377,RB transcriptional corepressor like 2,"The human gene RBL2, also known as RB transcriptional corepressor like 2, is involved in regulating gene expression by enabling promoter-specific chromatin binding activity. It is also involved in the negative regulation of lipid kinase activity. RBL2 is located in the chromosome, cytosol, and nuclear lumen. Its exact role in gene regulation is still being studied, but it is believed to act upstream of or within the negative regulation of gene expression.","Mutations in the RBL2 gene have been associated with various types of cancer, including breast, lung, and bladder cancer. In breast cancer, RBL2 has been found to be downregulated, leading to increased cell proliferation and tumor growth. Targeted drug discovery efforts have focused on developing drugs that can restore RBL2 function or inhibit its downstream targets. One example is the drug palbociclib, which targets cyclin-dependent kinases (CDKs) that are downstream of RBL2 and are involved in cell cycle progression. Palbociclib has been approved by the FDA for the treatment of advanced breast cancer and has shown promising results in clinical trials for other types of cancer as well. Other drugs targeting CDKs or RBL2-related pathways are also being developed and tested in clinical trials.",GO:0043550 regulation of lipid kinase activity;GO:2000134 negative regulation of G1/S transition of mitotic cell cycle;GO:1902807 negative regulation of cell cycle G1/S phase transition,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Mitotic chromosome;Nucleoli rim;Nucleoplasm (Supported); Additional: Cytosol,,(M12771)SA PTEN PATHWAY; (M136)PID FOXO PATHWAY; (M40)PID E2F PATHWAY,
ENSG00000151414.15,ENSG00000151414,NEK7,-1.231622328,-1.07351443,-1.576803017,-1.044549537,NIMA related kinase 7,"NEK7, also known as NIMA-related kinase 7, is a human gene that encodes a protein belonging to the NIMA-related kinase family. This family of proteins shares a high degree of amino acid sequence identity with the product of the Aspergillus nidulans 'never in mitosis A' gene, which is involved in the initiation of mitosis. NEK7 has been shown to play a role in regulating the cell cycle and cell division, as well as in the development and function of the nervous system. Mutations in NEK7 have been associated with various diseases, including cancer and neurodevelopmental disorders.","NEK7 has been implicated in various diseases, including cancer and neurodevelopmental disorders. In cancer, NEK7 has been shown to be overexpressed in several types of tumors, including breast, lung, and colon cancer, and is associated with poor prognosis. Targeting NEK7 has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of NEK7 have been developed and are currently being evaluated in preclinical studies. In neurodevelopmental disorders, NEK7 mutations have been associated with intellectual disability and developmental delay. However, there are currently no targeted drug discovery efforts for NEK7 in this context. There are no drugs on the market that specifically target NEK7, but several drugs that target other kinases in the same family, such as Nek2 and Nek1, are currently in clinical trials for cancer treatment.",GO:0035865 cellular response to potassium ion;GO:0035864 response to potassium ion;GO:0032212 positive regulation of telomere maintenance via telomerase,yes,Predicted intracellular proteins; Kinases:NEK Ser/Thr protein kinases; ENZYME proteins:Transferases; Enzymes; Transporters:Transporter channels and pores,Nucleoplasm (Supported),,,(M5942)HALLMARK UV RESPONSE DN; (M5945)HALLMARK HEME METABOLISM
ENSG00000147100.11,ENSG00000147100,SLC16A2,-1.231585833,-2.537505635,-1.138503214,-0.018748649,solute carrier family 16 member 2,"SLC16A2 is a gene that encodes a protein responsible for transporting thyroid hormones into cells. The protein facilitates the importation of various thyroid hormones, including T4, T3, rT3, and T2. This gene is expressed in many tissues and plays a crucial role in the development of the central nervous system. Loss of function mutations in SLC16A2 are associated with psychomotor retardation in males, while females exhibit no neurological defects and more moderate thyroid-deficient phenotypes. The gene is subject to X-chromosome inactivation, and mutations in SLC16A2 are the cause of Allan-Herndon-Dudley syndrome.","Allan-Herndon-Dudley syndrome (AHDS) is a rare X-linked disorder caused by mutations in the SLC16A2 gene. The condition is characterized by severe intellectual disability, muscle weakness, and abnormal thyroid hormone levels. There is currently no cure for AHDS, and treatment is mainly supportive, focusing on managing symptoms. However, there have been efforts to develop targeted therapies for the disorder. One approach is to develop drugs that can inhibit the activity of the transporter protein encoded by SLC16A2, which could potentially reduce the uptake of thyroid hormones into cells and alleviate symptoms. One example of a drug that has been developed for this purpose is AZD7325, which has shown promising results in preclinical studies. Another approach is to develop gene therapies that can correct the underlying genetic defect in SLC16A2. While there are currently no gene therapies approved for AHDS, there have been some successful trials in animal models.",GO:0070460 thyroid-stimulating hormone secretion;GO:0070327 thyroid hormone transport;GO:0006590 thyroid hormone generation,,Disease related genes; Human disease related genes:Endocrine and metabolic diseases:Thyroid gland diseases; Transporters:Electrochemical Potential-driven transporters; Potential drug targets,Plasma membrane (Approved),Pyruvic acid,,
ENSG00000112874.10,ENSG00000112874,NUDT12,-1.230572808,-1.349837498,-1.178085123,-1.163795802,nudix hydrolase 12,"NUDT12 is a human gene that encodes for a nudix hydrolase 12 enzyme. This enzyme is responsible for regulating the concentrations of individual nucleotides and nucleotide ratios in response to changing circumstances within the cell. Nucleotides are involved in numerous biochemical reactions and pathways within the cell as substrates, cofactors, and effectors. The function of NUDT12 is important for maintaining proper cellular function and preventing potential damage caused by imbalanced nucleotide concentrations.","There is limited information available on the disease implications of NUDT12 mutations. However, recent studies have suggested that NUDT12 may play a role in cancer development and progression. Specifically, NUDT12 has been found to be overexpressed in several types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts for NUDT12 are still in the early stages, but there is potential for the development of drugs that target NUDT12 to treat cancer. Currently, there are no drugs on the market that specifically target NUDT12. However, there are several drugs that target other nucleotide metabolism enzymes, such as ribonucleotide reductase inhibitors, that have been successful in treating cancer. Further research is needed to fully understand the role of NUDT12 in cancer and to develop targeted therapies.",GO:0006742 NADP catabolic process;GO:0110155 NAD-cap decapping;GO:0034356 NAD biosynthesis via nicotinamide riboside salvage pathway,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,,,,(M5948)HALLMARK BILE ACID METABOLISM
ENSG00000089057.15,ENSG00000089057,SLC23A2,-1.230438946,-1.66167315,-1.02328367,-1.006360018,solute carrier family 23 member 2,"SLC23A2 is a human gene that encodes for a sodium-dependent vitamin C transporter, which is responsible for the tissue-specific uptake of vitamin C. The absorption and distribution of vitamin C in the body require two such transporters, and SLC23A2 is one of them. This gene was previously known as SLC23A1.","Mutations in the SLC23A2 gene have been associated with a variety of diseases, including scurvy, atherosclerosis, and cancer. In scurvy, a lack of vitamin C leads to symptoms such as fatigue, joint pain, and bleeding gums. Atherosclerosis is a condition in which plaque builds up in the arteries, leading to heart disease and stroke. Vitamin C has been shown to have a protective effect against atherosclerosis, and SLC23A2 plays a crucial role in the uptake of vitamin C in the arterial wall. In cancer, SLC23A2 has been found to be downregulated in some types of tumors, suggesting that it may play a role in tumor suppression. 

Targeted drug discovery efforts have focused on developing drugs that can enhance the activity of SLC23A2, thereby increasing the uptake of vitamin C in specific tissues. One such drug is ascorbic acid (vitamin C) itself, which is used to treat scurvy and has been investigated as a potential cancer therapy. Other drugs that have been developed to target SLC23A2 include sodium-dependent vitamin C transport inhibitors and vitamin C analogs. 

One example of a successful drug on the market that targets SLC23A2 is L-ascorbic acid (vitamin C) itself, which is available over-the-counter as a dietary supplement. In addition, high-dose intravenous vitamin C has been used as a complementary therapy in cancer treatment, although its efficacy remains controversial. Other drugs that target SLC23A2, such as sodium-dependent vitamin C transport inhibitors and vitamin C analogs, are still in the early stages of development and have not yet been approved for clinical use.",GO:0015882 L-ascorbic acid transmembrane transport;GO:0019852 L-ascorbic acid metabolic process;GO:1901334 lactone metabolic process,,Transporters:Electrochemical Potential-driven transporters,Vesicles (Uncertain); Additional: Golgi apparatus,,,(M5949)HALLMARK PEROXISOME; (M5948)HALLMARK BILE ACID METABOLISM
ENSG00000109436.8,ENSG00000109436,TBC1D9,-1.228769781,-1.47657353,-1.271516343,-0.938219469,TBC1 domain family member 9,TBC1D9 is a human gene that belongs to the TBC1 domain family member 9. It is predicted to have GTPase activator activity and to be involved in the activation of GTPase activity and intracellular protein transport. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of TBC1D9. However, some studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for TBC1D9 are also limited, as the function of this gene is not well understood. However, some studies have suggested that targeting TBC1D9 may be a potential strategy for the treatment of cancer. Currently, there are no drugs on the market that specifically target TBC1D9. However, there are several drugs that target other members of the TBC1 domain family, including TBC1D1 and TBC1D4, which are involved in insulin signaling and glucose metabolism. Examples of these drugs include insulin sensitizers such as metformin and thiazolidinediones, which are used to treat type 2 diabetes.",,,Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000091039.17,ENSG00000091039,OSBPL8,-1.228657733,-1.532443959,-1.18684524,-0.966683999,oxysterol binding protein like 8,"OSBPL8 is a gene that encodes a protein with a pleckstrin homology domain and an oxysterol-binding protein-like sterol-binding domain. This protein is involved in the exchange of lipid-containing molecules, such as phosphatidylserine, phosphatidylinositol 4-phosphate, and oxysterol, between the endoplasmic reticulum and the plasma membrane. Alternative splicing of the gene results in multiple transcript variants.","There is limited information available on the disease implications of OSBPL8. However, recent studies have suggested that this gene may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for OSBPL8 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target OSBPL8, there are several drugs that target related proteins involved in lipid metabolism and transport, such as statins and ezetimibe, which are used to treat hypercholesterolemia and other lipid disorders. Additionally, recent studies have shown that certain natural compounds, such as resveratrol and curcumin, may also have potential as OSBPL8 inhibitors and could be developed into novel therapeutics in the future.",GO:0090204 protein localization to nuclear pore;GO:0010891 negative regulation of sequestering of triglyceride;GO:0036150 phosphatidylserine acyl-chain remodeling,,Transporters:Electrochemical Potential-driven transporters; Predicted intracellular proteins,Cytosol;Vesicles (Approved),,,
ENSG00000197976.12,ENSG00000197976,AKAP17A,-1.227446113,-1.540088428,-1.241130002,-0.90111991,A-kinase anchoring protein 17A,"AKAP17A is a gene that encodes a protein called A-kinase anchoring protein 17A. This protein is involved in regulating alternate splicing in some mRNA precursors as part of the spliceosome complex. Alternate splicing is a process that allows a single gene to produce multiple protein variants, which can have different functions. Different variants of AKAP17A have been identified due to alternative splicing.","There is limited information available on the disease implications of AKAP17A. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for AKAP17A are still in the early stages, but there is potential for this protein to be targeted in cancer therapy. One example of a successful drug targeting a related protein is the drug Sorafenib, which targets the protein kinase RAF, a member of the same signaling pathway as AKAP17A. Sorafenib is used to treat advanced kidney cancer and liver cancer. However, further research is needed to determine the potential of AKAP17A as a drug target and to develop effective therapies.",GO:0043484 regulation of RNA splicing;GO:0042113 B cell activation;GO:0008380 RNA splicing,,Predicted intracellular proteins,Nuclear speckles (Supported); Additional: Cytosol,,,
ENSG00000196924.19,ENSG00000196924,FLNA,-1.226636998,-1.571038675,-1.373873063,-0.734999257,filamin A,"FLNA, also known as filamin A, is a gene that encodes an actin-binding protein that plays a crucial role in remodeling the cytoskeleton to effect changes in cell shape and migration. The protein crosslinks actin filaments and links them to membrane glycoproteins, and interacts with integrins, transmembrane receptor complexes, and second messengers. Defects in this gene are associated with several syndromes, including periventricular nodular heterotopias, otopalatodigital syndromes, frontometaphyseal dysplasia, Melnick-Needles syndrome, and X-linked congenital idiopathic intestinal pseudoobstruction. Two transcript variants encoding different isoforms have been identified for this gene.","Mutations in the FLNA gene have been associated with a range of disorders, including periventricular nodular heterotopias, which are characterized by the presence of nodules of gray matter in the white matter of the brain, and otopalatodigital syndromes, which affect bone development and can cause hearing loss and cleft palate. Frontometaphyseal dysplasia, Melnick-Needles syndrome, and X-linked congenital idiopathic intestinal pseudoobstruction are also associated with mutations in this gene.

Targeted drug discovery efforts for FLNA-related disorders are still in the early stages, but some promising approaches have been identified. For example, a recent study found that a small molecule inhibitor of the protein kinase CK2 could reduce the severity of periventricular nodular heterotopias in a mouse model of the disorder. Other potential targets for drug development include the RhoA signaling pathway, which is involved in cytoskeletal remodeling, and the PI3K/Akt/mTOR pathway, which regulates cell growth and survival.

There are currently no drugs on the market specifically targeting FLNA-related disorders, but some drugs used to treat related conditions may be effective. For example, antiepileptic drugs such as levetiracetam and topiramate are often used to treat seizures associated with periventricular nodular heterotopias, and bisphosphonates such as pamidronate have been used to treat bone abnormalities in otopalatodigital syndromes. However, more research is needed to identify effective treatments for these rare and complex disorders.",GO:1905000 regulation of membrane repolarization during atrial cardiac muscle cell action potential;GO:0090042 tubulin deacetylation;GO:0021943 formation of radial glial scaffolds,,Human disease related genes:Congenital malformations:Congenital malformations of the circulatory system; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Transporters:Accessory Factors Involved in Transport; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Human disease related genes:Digestive system diseases:Gastrointestinal diseases,Actin filaments;Cytosol;Plasma membrane (Supported),Artenimol,(M23)PID WNT NONCANONICAL PATHWAY; (M16801)SIG REGULATION OF THE ACTIN CYTOSKELETON BY RHO GTPASES; (M34)PID TCR PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION; (M5950)HALLMARK ALLOGRAFT REJECTION
ENSG00000121064.13,ENSG00000121064,SCPEP1,-1.224869881,-1.175061885,-1.146097984,-1.353449775,serine carboxypeptidase 1,"SCPEP1 is a human gene that is predicted to encode a protein with serine-type carboxypeptidase activity. It is also predicted to be involved in negative regulation of blood pressure and retinoic acid metabolic process, and to act upstream of or within blood vessel diameter maintenance. The protein is located in extracellular exosomes, which are small vesicles that are released by cells and play a role in intercellular communication. The function of SCPEP1 in these processes is not yet fully understood, but further research may shed light on its potential therapeutic applications in cardiovascular disease and other conditions.","There is limited information available on the disease implications of SCPEP1, but some studies suggest that it may play a role in cardiovascular disease. Targeted drug discovery efforts for SCPEP1 are also limited, but there is potential for the development of drugs that target its serine-type carboxypeptidase activity and its role in blood pressure regulation. Currently, there are no drugs on the market that specifically target SCPEP1, but there are several drugs that target the renin-angiotensin-aldosterone system, which is involved in blood pressure regulation and may be indirectly affected by SCPEP1. Examples of these drugs include ACE inhibitors and angiotensin receptor blockers. Further research is needed to fully understand the potential therapeutic applications of SCPEP1 and to develop targeted drugs for its regulation.",GO:0042573 retinoic acid metabolic process;GO:0045776 negative regulation of blood pressure;GO:0001523 retinoid metabolic process,,Predicted secreted proteins; Enzymes; Peptidases:Serine-type peptidases; Predicted intracellular proteins,Golgi apparatus (Approved),L-BENZYLSUCCINIC ACID,,
ENSG00000140382.15,ENSG00000140382,HMG20A,-1.224359376,-1.610897519,-1.333641808,-0.728538801,high mobility group 20A,"HMG20A is a human gene that encodes a protein with identical protein binding activity. It is predicted to be involved in the regulation of gene expression and to act upstream or within negative regulation of neuron differentiation, protein sumoylation, and transcription by RNA polymerase II. The protein is predicted to be active in the nucleus.","HMG20A has been implicated in several diseases, including cancer, Alzheimer's disease, and schizophrenia. In cancer, HMG20A has been shown to be overexpressed in several types of tumors, including breast, lung, and ovarian cancer, and may play a role in tumor progression and metastasis. Targeted drug discovery efforts have focused on developing small molecule inhibitors of HMG20A, with the goal of inhibiting its activity and slowing tumor growth. However, there are currently no drugs on the market that specifically target HMG20A. In Alzheimer's disease, HMG20A has been shown to be involved in the regulation of beta-amyloid production, a key pathological feature of the disease. In schizophrenia, HMG20A has been identified as a potential risk gene, although its exact role in the disease is not yet clear. Overall, further research is needed to fully understand the disease implications of HMG20A and to develop targeted therapies for these conditions.",GO:0033234 negative regulation of protein sumoylation;GO:0033233 regulation of protein sumoylation;GO:0045665 negative regulation of neuron differentiation,,Transcription factors:Other all-alpha-helical DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000148516.22,ENSG00000148516,ZEB1,-1.223908871,-2.035927586,-0.971451434,-0.664347594,zinc finger E-box binding homeobox 1,ZEB1 is a gene that encodes a zinc finger transcription factor. This protein is believed to be involved in the repression of interleukin 2 transcription. Mutations in this gene have been linked to two types of corneal dystrophy: posterior polymorphous corneal dystrophy-3 and late-onset Fuchs endothelial corneal dystrophy. The gene has multiple isoforms due to alternative splicing.,"ZEB1 has been implicated in various diseases, including cancer, fibrosis, and corneal dystrophy. In cancer, ZEB1 has been shown to promote epithelial-mesenchymal transition (EMT), a process that allows cancer cells to acquire invasive and metastatic properties. Therefore, ZEB1 has been considered a potential therapeutic target for cancer treatment. Several studies have reported the development of small molecule inhibitors and RNA interference-based approaches to target ZEB1 in cancer cells. However, no ZEB1-targeted drugs have been approved for clinical use yet. In corneal dystrophy, ZEB1 mutations have been linked to the development of posterior polymorphous corneal dystrophy-3 and late-onset Fuchs endothelial corneal dystrophy. Currently, there are no specific drugs available for the treatment of these diseases, and treatment options are limited to corneal transplantation.",GO:0048752 semicircular canal morphogenesis;GO:0060872 semicircular canal development;GO:0045602 negative regulation of endothelial cell differentiation,,Disease related genes; Transcription factors:Helix-turn-helix domains; Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nucleoli,,(M71)PID ILK PATHWAY,(M5921)HALLMARK COMPLEMENT
ENSG00000185305.11,ENSG00000185305,ARL15,-1.223226105,-1.553788817,-0.809645353,-1.306244145,ARF like GTPase 15,"ARL15 is a human gene that is predicted to have GTP binding and GTPase activity. It is located in extracellular exosomes, which are small vesicles that are released by cells and play a role in intercellular communication. The gene is classified as an ADP ribosylation factor like GTPase 15, which suggests that it may be involved in regulating intracellular trafficking and signaling pathways. However, further research is needed to fully understand the function of ARL15 and its potential role in human health and disease.","There is limited information available on the disease implications of ARL15. However, some studies have suggested that it may be involved in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ARL15 are also limited, as its function and role in disease are not yet fully understood. Currently, there are no drugs on the market that specifically target ARL15. However, there are drugs that target other GTPases, such as RAS and RHO, which are involved in similar signaling pathways. Examples of successful drugs targeting these GTPases include KRAS inhibitors for the treatment of lung cancer and RHO kinase inhibitors for the treatment of glaucoma. Further research is needed to determine if ARL15 could be a potential target for drug development in the future.",GO:0008150 biological_process,,Predicted intracellular proteins,Microtubules;Primary cilium (Approved); Additional: Basal body;Cytokinetic bridge;Mitotic spindle,,,
ENSG00000163513.19,ENSG00000163513,TGFBR2,-1.222625622,-1.962037181,-1.204917761,-0.500921922,transforming growth factor beta receptor 2,"The TGFBR2 gene encodes a transmembrane protein that forms a complex with TGF-beta receptor type-1 and binds TGF-beta. This complex phosphorylates proteins that regulate the transcription of genes related to cell proliferation, cell cycle arrest, wound healing, immunosuppression, and tumorigenesis. Mutations in this gene have been linked to Marfan Syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and the development of various types of tumors. The gene has alternatively spliced transcript variants that encode different isoforms.","Mutations in the TGFBR2 gene have been associated with several diseases, including Marfan Syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and various types of cancer. In Marfan Syndrome, mutations in TGFBR2 lead to the weakening of connective tissue, resulting in skeletal abnormalities, cardiovascular defects, and other symptoms. In Loeys-Deitz Aortic Aneurysm Syndrome, mutations in TGFBR2 and other genes in the TGF-beta signaling pathway lead to the development of aortic aneurysms and other vascular abnormalities.

Targeted drug discovery efforts have focused on developing inhibitors of the TGF-beta signaling pathway for the treatment of cancer. Several drugs targeting TGF-beta receptors, including TGFBR2, are currently in clinical trials for various types of cancer. One example is Galunisertib, a small molecule inhibitor of TGF-beta receptor type-1 and type-2, which is being tested in clinical trials for the treatment of pancreatic cancer and other solid tumors.

Another example is Trabedersen, an antisense oligonucleotide that targets TGF-beta2 mRNA and inhibits its expression. Trabedersen has shown promising results in clinical trials for the treatment of malignant glioma, a type of brain cancer.

In summary, mutations in the TGFBR2 gene have been linked to several diseases, including Marfan Syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and cancer. Targeted drug discovery efforts have focused on developing inhibitors of the TGF-beta signaling pathway, with several drugs currently in clinical trials for the treatment of cancer.",GO:0002649 regulation of tolerance induction to self antigen;GO:0002651 positive regulation of tolerance induction to self antigen;GO:1905317 inferior endocardial cushion morphogenesis,yes,Human disease related genes:Congenital malformations:Congenital malformations of the circulatory system; FDA approved drug targets:Biotech drugs; Kinases:TKL Ser/Thr protein kinases; Predicted secreted proteins; Human disease related genes:Cancers:Cancers of the digestive system; ENZYME proteins:Transferases; Human disease related genes:Cardiovascular diseases:Vascular diseases; Disease related genes; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Plasma membrane (Supported),Foreskin fibroblast (neonatal); Foreskin keratinocyte (neonatal); Fostamatinib,(M185)PID ALK1 PATHWAY; (M33)PID GLYPICAN 1PATHWAY; (M53)PID INTEGRIN3 PATHWAY,(M5942)HALLMARK UV RESPONSE DN
ENSG00000173269.14,ENSG00000173269,MMRN2,-1.222502204,-1.379557231,-1.04806406,-1.239885319,multimerin 2,"MMRN2, also known as multimerin 2, is a gene that encodes a protein belonging to the EMILIN protein family. This protein is found in the extracellular matrix and has been shown to inhibit tumor angiogenesis and growth. It acts as an antagonist to transforming growth factor beta and can interfere with the VEGF-A/VEGFR2 pathway. A pseudogene related to MMRN2 has also been identified on chromosome 6.","There is limited information available on the disease implications of MMRN2. However, studies have shown that the protein encoded by this gene may have potential as a therapeutic target for cancer treatment. In particular, MMRN2 has been shown to inhibit tumor angiogenesis and growth, making it a potential target for anti-cancer drugs. Targeted drug discovery efforts for MMRN2 are currently limited, but there is ongoing research to identify compounds that can modulate its activity. Currently, there are no drugs on the market that specifically target MMRN2. However, there are several anti-cancer drugs that target angiogenesis and the VEGF-A/VEGFR2 pathway, which MMRN2 has been shown to interfere with. Examples of such drugs include bevacizumab, ramucirumab, and aflibercept.",GO:1905276 regulation of epithelial tube formation;GO:1905278 positive regulation of epithelial tube formation;GO:0030948 negative regulation of vascular endothelial growth factor receptor signaling pathway,,Predicted secreted proteins; Predicted intracellular proteins,Vesicles (Approved),,(M3008)NABA ECM GLYCOPROTEINS; (M5884)NABA CORE MATRISOME; (M5889)NABA MATRISOME,
ENSG00000104635.15,ENSG00000104635,SLC39A14,-1.221326448,-1.493288739,-1.104416648,-1.066273958,solute carrier family 39 member 14,"SLC39A14 is a gene that belongs to the SLC39A family of divalent metal transporters. It is responsible for the cellular uptake of manganese, zinc, iron, and cadmium. The protein encoded by this gene has eight transmembrane domains, a histidine-rich motif, and a metalloprotease motif. It is expressed on the plasma membrane and the endocytic vesicle membrane. SLC39A14 is an important transporter of nontransferrin-bound iron and a critical regulator of manganese homeostasis. Mutations in this gene are associated with neurodegeneration with brain iron accumulation and early-onset parkinsonism-dystonia with hypermanganesemia.","Mutations in the SLC39A14 gene have been associated with several neurological disorders, including neurodegeneration with brain iron accumulation (NBIA) and early-onset parkinsonism-dystonia with hypermanganesemia. These disorders are characterized by abnormal accumulation of iron and/or manganese in the brain, leading to neurodegeneration and movement disorders. Targeted drug discovery efforts for these disorders have focused on developing drugs that can modulate the activity of SLC39A14 and other metal transporters. One example is the drug deferiprone, which is used to treat iron overload disorders and has been shown to improve symptoms in some patients with NBIA. Another example is the drug edaravone, which has been approved for the treatment of amyotrophic lateral sclerosis (ALS) and has been shown to have neuroprotective effects by reducing oxidative stress and inflammation. While there are currently no drugs specifically targeting SLC39A14, these examples demonstrate the potential for targeting metal transporters in the treatment of neurological disorders.",GO:0055071 manganese ion homeostasis;GO:0015691 cadmium ion transport;GO:0070574 cadmium ion transmembrane transport,,Predicted intracellular proteins; Transporters:Electrochemical Potential-driven transporters; Potential drug targets; Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases,Endoplasmic reticulum;Golgi apparatus;Plasma membrane (Approved),,,
ENSG00000137710.17,ENSG00000137710,RDX,-1.218957456,-1.670463158,-1.185347171,-0.801062039,radixin,"Radixin (RDX) is a cytoskeletal protein that plays a crucial role in linking actin to the plasma membrane. It is highly similar in sequence to ezrin and moesin. The RDX gene has been localized to chromosome 11q23, and a truncated version representing a pseudogene (RDXP2) was assigned to Xp21.3. Another pseudogene lacking introns (RDXP1) was mapped to 11p. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. RDX is important for maintaining the structural integrity of cells and is involved in various cellular processes, including cell adhesion, migration, and signaling. Mutations in the RDX gene have been associated with various diseases, including cancer and hearing loss.","Mutations in the RDX gene have been associated with various diseases, including cancer and hearing loss. In cancer, RDX has been shown to play a role in tumor invasion and metastasis, making it a potential target for cancer therapy. Several studies have investigated the use of RDX inhibitors as a potential treatment for cancer, with promising results in preclinical models. However, no RDX-targeted drugs have been approved for clinical use yet. In hearing loss, mutations in RDX have been linked to a type of non-syndromic deafness. While there are currently no drugs targeting RDX for hearing loss, research in this area is ongoing. Overall, RDX is an important protein with potential implications for disease treatment, but more research is needed to fully understand its role in various diseases and develop effective targeted therapies.",GO:0032487 regulation of Rap protein signal transduction;GO:1903392 negative regulation of adherens junction organization;GO:1903391 regulation of adherens junction organization,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Ear disease,Plasma membrane (Supported); Additional: Nucleoplasm,"1D-myo-inositol 1,4,5-trisphosphate",(M12)PID RHOA PATHWAY,
ENSG00000169744.13,ENSG00000169744,LDB2,-1.21708269,-1.051200293,-0.989761658,-1.610286118,LIM domain binding 2,"LDB2 is a gene that belongs to the LIM-domain binding family. It encodes a protein that acts as an adapter molecule to allow the assembly of transcriptional regulatory complexes. The protein contains a conserved nuclear localization sequence, an amino-terminal homodimerization domain, and a carboxy-terminal LIM interaction domain. Alternative splicing of the gene results in multiple transcript variants. Studies suggest that LDB2 may be involved in rhegmatogenous retinal detachment and coronary artery disease.","There is limited information available on the disease implications of LDB2. However, studies suggest that LDB2 may be involved in rhegmatogenous retinal detachment and coronary artery disease. In rhegmatogenous retinal detachment, LDB2 has been found to be downregulated in the retina, which may contribute to the development of the disease. In coronary artery disease, LDB2 has been identified as a potential biomarker for the disease.

As of now, there are no targeted drug discovery efforts specifically for LDB2. However, there are drugs on the market that target other genes in the LIM-domain binding family, such as LDB1. For example, the drug lenalidomide, which is used to treat multiple myeloma and myelodysplastic syndromes, targets LDB1 by promoting its degradation. Another drug, pomalidomide, also targets LDB1 and is used to treat multiple myeloma.

In conclusion, while there is limited information available on the disease implications of LDB2, studies suggest that it may be involved in rhegmatogenous retinal detachment and coronary artery disease. There are currently no targeted drug discovery efforts for LDB2, but drugs targeting other genes in the LIM-domain binding family, such as LDB1, have been successful in treating certain diseases.",GO:0010669 epithelial structure maintenance;GO:0035019 somatic stem cell population maintenance;GO:0001942 hair follicle development,,Predicted intracellular proteins,Nucleoli;Nucleoplasm (Supported); Additional: Plasma membrane,,,
ENSG00000167615.17,ENSG00000167615,LENG8,-1.216329661,-1.819985915,-0.921442109,-0.907560959,leukocyte receptor cluster member 8,"LENG8, also known as leukocyte receptor cluster member 8, is a gene that is predicted to be active in the nucleus. However, there is currently limited information available about the function of this gene. It is located within a cluster of genes on chromosome 19 that encode leukocyte receptors, which are involved in immune system function. Further research is needed to fully understand the role of LENG8 in human biology and disease.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for LENG8. As a relatively understudied gene, there have been no drugs developed specifically targeting this gene. However, given its location within a cluster of genes involved in immune system function, it is possible that future research may uncover potential disease implications and drug targets related to immune disorders. As of now, there are no known successful drugs on the market targeting LENG8. Further research is needed to fully understand the potential implications of this gene in disease and drug discovery efforts.",,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000154822.18,ENSG00000154822,PLCL2,-1.213104639,-1.440040568,-1.266261875,-0.933011475,phospholipase C like 2,"PLCL2 is a human gene that encodes for a protein called phospholipase C like 2. This protein is predicted to have GABA receptor binding activity and is involved in negative regulation of cold-induced thermogenesis and phosphatidylinositol-mediated signaling. It is also predicted to act upstream of or within several processes, including B cell activation, gamma-aminobutyric acid signaling pathway, and negative regulation of B cell receptor signaling pathway. PLCL2 is predicted to be located in the cytoplasm.","There is limited information available on the disease implications of PLCL2. However, recent studies have suggested that PLCL2 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for PLCL2 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target PLCL2, there are several drugs that have been developed to target related proteins in the phospholipase C family, including U73122 and edelfosine. These drugs have shown promise in preclinical studies and are currently being evaluated in clinical trials for the treatment of various types of cancer.",GO:0002337 B-1a B cell differentiation;GO:0001923 B-1 B cell differentiation;GO:0002322 B cell proliferation involved in immune response,,Predicted intracellular proteins,,,,
ENSG00000166025.18,ENSG00000166025,AMOTL1,-1.213016953,-2.139357062,-1.396519707,-0.10317409,angiomotin like 1,"AMOTL1 is a gene that encodes a protein that is involved in the formation of tight junctions (TJs) in cells. TJs are important for controlling the permeability of cells and maintaining their polarity. The protein is similar to angiomotin, which is involved in regulating the migration of endothelial cells and the formation of capillaries. Two different versions of the protein, or isoforms, have been identified.","AMOTL1 has been implicated in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, AMOTL1 has been shown to play a role in tumor growth, invasion, and metastasis. Targeting AMOTL1 has been proposed as a potential therapeutic strategy for cancer treatment. In cardiovascular disease, AMOTL1 has been linked to the regulation of blood vessel formation and endothelial cell function. In neurological disorders, AMOTL1 has been associated with the development of Alzheimer's disease and Parkinson's disease.

There have been efforts to develop drugs that target AMOTL1. One approach is to inhibit the interaction between AMOTL1 and other proteins involved in disease pathways. For example, a small molecule inhibitor of the interaction between AMOTL1 and YAP, a protein involved in cancer progression, has been developed and shown to inhibit tumor growth in preclinical models. Another approach is to target the expression of AMOTL1 itself. For example, a microRNA that targets AMOTL1 has been shown to inhibit the growth of breast cancer cells.

Currently, there are no drugs on the market that specifically target AMOTL1. However, there are drugs that indirectly affect AMOTL1 signaling pathways. For example, statins, which are commonly used to lower cholesterol levels, have been shown to regulate AMOTL1 expression and inhibit angiogenesis. Additionally, drugs that target other proteins involved in the same pathways as AMOTL1, such as VEGF inhibitors for cancer treatment, indirectly affect AMOTL1 signaling.",GO:0003365 establishment of cell polarity involved in ameboidal cell migration;GO:0035329 hippo signaling;GO:0001667 ameboidal-type cell migration,,Predicted intracellular proteins,Cytosol (Approved); Additional: Cell Junctions,,,
ENSG00000067445.21,ENSG00000067445,TRO,-1.210090875,-1.742254251,-1.129761753,-0.758256621,trophinin,"The TRO gene encodes a membrane protein called trophinin, which plays a crucial role in cell adhesion between trophoblastic cells and the epithelial cells of the endometrium during embryo implantation. Trophinin is also involved in cell signaling during this process and may have a role in cancer formation. The gene is located near other closely related genes on chromosome X and undergoes alternative splicing, resulting in multiple transcript variants.","There is limited information available on the disease implications of the TRO gene. However, studies have suggested that trophinin may be involved in the development and progression of certain types of cancer, including ovarian and endometrial cancer. Targeted drug discovery efforts for TRO have been limited, but some studies have explored the potential of trophinin as a therapeutic target for cancer treatment. One study found that targeting trophinin with a monoclonal antibody inhibited the growth of ovarian cancer cells in vitro and in vivo. However, there are currently no drugs on the market that specifically target the TRO gene or trophinin.",GO:0007566 embryo implantation;GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules;GO:0007565 female pregnancy,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cell Junctions (Approved); Additional: Cytosol,,,(M5915)HALLMARK APICAL JUNCTION
ENSG00000165424.7,ENSG00000165424,ZCCHC24,-1.206444979,-1.964695493,-1.137893282,-0.516746161,zinc finger CCHC-type containing 24,"ZCCHC24 is a human gene that encodes a protein containing a zinc finger CCHC-type domain. This protein is involved in RNA binding activity, which suggests a role in regulating gene expression. The function of ZCCHC24 is not fully understood, but it may play a role in RNA processing or translation. Further research is needed to fully understand the function of this gene and its potential implications for human health.","There is limited information available on the disease implications of ZCCHC24. However, recent studies have suggested that mutations in this gene may be associated with intellectual disability and developmental delay. Targeted drug discovery efforts for ZCCHC24 are currently limited due to the lack of understanding of its function. However, some studies have suggested that ZCCHC24 may be a potential target for cancer therapy due to its involvement in RNA processing. There are currently no drugs on the market that specifically target ZCCHC24. However, there are several drugs that target RNA processing and translation, such as antisense oligonucleotides and ribosome inhibitors, which may indirectly affect ZCCHC24 function. Further research is needed to fully understand the potential disease implications of ZCCHC24 and to develop targeted therapies for related disorders.",,,Predicted intracellular proteins,Mitochondria (Approved); Additional: Nucleoplasm,,,
ENSG00000174233.11,ENSG00000174233,ADCY6,-1.205179428,-1.924969446,-1.117443449,-0.57312539,adenylate cyclase 6,"ADCY6 is a gene that encodes a protein belonging to the adenylyl cyclase family, which is responsible for the synthesis of cyclic AMP. The protein has an intracellular N-terminus, six transmembrane domains, and a C-terminal cytoplasmic domain. Adenylyl cyclases are important effectors of transmembrane signaling pathways and are regulated by G protein coupled receptor signaling. ADCY6 is a member of a small subclass of adenylyl cyclase proteins that are functionally related and are inhibited by protein kinase A, calcium ions, and nitric oxide. A mutation in this gene is associated with arthrogryposis multiplex congenita.","Mutations in the ADCY6 gene have been associated with several diseases, including arthrogryposis multiplex congenita, which is a rare congenital disorder characterized by joint contractures and muscle weakness. Targeted drug discovery efforts for ADCY6 have focused on developing inhibitors that can modulate cyclic AMP signaling pathways. One example of a successful drug targeting ADCY6 is cilostazol, which is used to treat peripheral arterial disease and works by inhibiting phosphodiesterase 3, an enzyme that degrades cyclic AMP. Another example is forskolin, a natural compound that activates adenylyl cyclase and increases cyclic AMP levels. Forskolin has been used in traditional medicine for centuries and is currently being investigated for its potential therapeutic applications in various diseases, including cancer, cardiovascular disease, and neurological disorders.",GO:0007192 adenylate cyclase-activating serotonin receptor signaling pathway;GO:0035811 negative regulation of urine volume;GO:1904116 response to vasopressin,,ENZYME proteins:Lyases; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Disease related genes; Enzymes,Golgi apparatus (Uncertain),,(M56)PID LPA4 PATHWAY; (M8)PID ENDOTHELIN PATHWAY; (M15)PID LYSOPHOSPHOLIPID PATHWAY,(M5898)HALLMARK DNA REPAIR; (M5905)HALLMARK ADIPOGENESIS
ENSG00000069869.16,ENSG00000069869,NEDD4,-1.204635312,-1.462064071,-1.166405119,-0.985436747,NEDD4 E3 ubiquitin protein ligase,"NEDD4 is a human gene that encodes for a protein called NEDD4 E3 ubiquitin protein ligase. This protein is a member of the NEDD4 family of HECT ubiquitin ligases, which are involved in the degradation of proteins in the ubiquitin proteasome system. The NEDD4 protein contains a calcium and phospholipid binding C2 domain, multiple tryptophan-rich WW domains, and a HECT ubiquitin ligase catalytic domain. It plays a critical role in regulating membrane receptors, endocytic machinery components, and the tumor suppressor PTEN. Overall, the NEDD4 gene and its protein product are important for maintaining proper protein degradation and cellular function.","The NEDD4 gene has been implicated in several diseases, including cancer, hypertension, and neurological disorders. In cancer, NEDD4 has been shown to regulate the activity of the tumor suppressor PTEN, and mutations in NEDD4 have been associated with the development of certain types of cancer. In hypertension, NEDD4 has been linked to the regulation of the epithelial sodium channel (ENaC), which plays a role in blood pressure control. In neurological disorders, NEDD4 has been shown to regulate the activity of ion channels and receptors involved in synaptic transmission.

Targeted drug discovery efforts for NEDD4 have focused on developing small molecule inhibitors that can block its activity. One example is the drug compound RA-9, which has been shown to inhibit NEDD4 activity and reduce the growth of cancer cells in vitro and in vivo. Another example is the drug compound amiloride, which is a diuretic that blocks ENaC activity and has been used to treat hypertension.

Overall, the NEDD4 gene and its protein product have important implications for disease development and targeted drug discovery efforts. While there are currently only a few drugs on the market that target NEDD4, ongoing research may lead to the development of new therapies for a range of diseases.",GO:0044111 formation of structure involved in a symbiotic process;GO:0042921 nuclear receptor-mediated glucocorticoid signaling pathway;GO:0031958 nuclear receptor-mediated corticosteroid signaling pathway,,Transporters:Accessory Factors Involved in Transport; Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Nucleoplasm (Supported),,(M13)PID ERBB4 PATHWAY; (M70)PID PS1 PATHWAY; (M237)PID VEGFR1 2 PATHWAY,(M5948)HALLMARK BILE ACID METABOLISM
ENSG00000173905.9,ENSG00000173905,GOLIM4,-1.202670618,-1.217156822,-1.350698723,-1.040156308,golgi integral membrane protein 4,GOLIM4 is a gene that encodes a type II Golgi-resident protein. This protein plays a crucial role in the sorting and modification of proteins that are exported from the endoplasmic reticulum. It is involved in processing proteins synthesized in the rough endoplasmic reticulum and assists in the transport of protein cargo through the Golgi apparatus. The Golgi complex is responsible for modifying and sorting proteins before they are transported to their final destination within the cell or outside of it. GOLIM4 is an important component of this process and is essential for proper protein trafficking within the cell.,"There is limited information available on the disease implications of GOLIM4 mutations. However, recent studies have suggested that GOLIM4 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for GOLIM4 are still in the early stages, but there is potential for the development of drugs that target this protein to treat cancer and other diseases. Currently, there are no drugs on the market that specifically target GOLIM4, but there are several drugs that target other proteins involved in the same cellular pathways as GOLIM4. For example, the drug bortezomib targets the proteasome, which is involved in protein degradation and is also important for protein trafficking through the Golgi apparatus. Bortezomib is used to treat multiple myeloma and mantle cell lymphoma.",,,,Golgi apparatus (Enhanced),,,
ENSG00000179981.11,ENSG00000179981,TSHZ1,-1.200058035,-1.444648927,-1.113734662,-1.041790517,teashirt zinc finger homeobox 1,TSHZ1 is a gene that encodes a protein belonging to the teashirt C2H2-type zinc-finger protein family. It was initially identified as a colon cancer antigen and may be involved in regulating developmental processes through transcriptional regulation. Mutations in this gene have been linked to congenital aural atresia syndrome.,"There is limited information available on targeted drug discovery efforts for TSHZ1, as it is primarily associated with developmental processes and congenital disorders. However, mutations in this gene have been linked to congenital aural atresia syndrome, a rare condition characterized by the absence or underdevelopment of the external ear canal. Currently, there are no targeted drugs available for this condition, and treatment options are limited to surgical interventions such as bone-anchored hearing aids or reconstructive surgery. 

As TSHZ1 is also implicated in colon cancer, there have been some efforts to develop drugs targeting this gene for cancer therapy. However, there are no drugs currently on the market that specifically target TSHZ1. Some successful cancer drugs that target zinc-finger proteins include the proteasome inhibitor bortezomib, which is used to treat multiple myeloma, and the histone deacetylase inhibitor vorinostat, which is used to treat cutaneous T-cell lymphoma. Further research is needed to determine the potential for TSHZ1 as a target for cancer therapy.",GO:0060023 soft palate development;GO:0042474 middle ear morphogenesis;GO:0062009 secondary palate development,,Disease related genes; Transcription factors:Helix-turn-helix domains; Human disease related genes:Congenital malformations:Congenital malformations of ear; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000111348.9,ENSG00000111348,ARHGDIB,-1.197927895,-1.774669395,-0.549648697,-1.269465593,Rho GDP dissociation inhibitor beta,"ARHGDIB is a gene that encodes for Rho GDP dissociation inhibitor beta, a protein that is involved in regulating the cycling between the GTP-bound and GDP-bound states of Ras-like GTPases. These GTPases are important in various cellular events such as cell signaling, proliferation, cytoskeletal organization, and secretion. The GDIs, including ARHGDIB, decrease the rate of GDP dissociation from these GTPases. This gene is important in maintaining the proper balance of GTP-bound and GDP-bound states of these proteins, which is crucial for normal cellular function.","ARHGDIB has been implicated in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, ARHGDIB has been shown to be downregulated in several types of tumors, including breast, lung, and pancreatic cancer. This downregulation is associated with increased tumor growth and metastasis. In cardiovascular disease, ARHGDIB has been linked to the regulation of vascular smooth muscle cell proliferation and migration, which are key processes in the development of atherosclerosis. In neurological disorders, ARHGDIB has been shown to be involved in the regulation of synaptic plasticity and dendritic spine morphology.

Targeted drug discovery efforts for ARHGDIB have focused on developing small molecule inhibitors that can disrupt the interaction between ARHGDIB and its target GTPases. One example is the compound NSC23766, which has been shown to inhibit the activity of the Rho family of GTPases by disrupting their interaction with ARHGDIB. NSC23766 has been used in preclinical studies to inhibit tumor growth and metastasis in various cancer models.

Another example is the drug fasudil, which is a Rho kinase inhibitor that indirectly affects the activity of ARHGDIB. Fasudil has been approved for the treatment of cerebral vasospasm following subarachnoid hemorrhage and is currently being investigated for its potential use in other diseases, including pulmonary hypertension and stroke.

Overall, ARHGDIB is an important gene involved in the regulation of various cellular processes and has potential implications in the development of novel therapeutics for cancer, cardiovascular disease, and neurological disorders.",GO:0071461 cellular response to redox state;GO:1901164 negative regulation of trophoblast cell migration;GO:0051775 response to redox state,,Predicted intracellular proteins,Cytosol (Supported),,(M68)PID RHOA REG PATHWAY; (M220)PID CASPASE PATHWAY,
ENSG00000205730.6,ENSG00000205730,ITPRIPL2,-1.197434953,-1.964278911,-1.152318989,-0.47570696,ITPRIP like 2,"ITPRIPL2 is a human gene that is predicted to be an integral component of the membrane. It is similar to the ITPRIP gene, which is involved in regulating calcium release from intracellular stores. However, the specific function of ITPRIPL2 is not yet fully understood. This gene may play a role in various cellular processes, including signal transduction and membrane trafficking. Further research is needed to determine the exact function of ITPRIPL2 and its potential implications for human health and disease.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for ITPRIPL2. As the specific function of this gene is not yet fully understood, it is difficult to determine its potential role in disease development or progression. Additionally, there are no known drugs on the market that specifically target ITPRIPL2. However, as research continues to uncover more information about the function of this gene, it may become a target for drug discovery efforts in the future.",,,,Centrosome (Approved),,,
ENSG00000110031.13,ENSG00000110031,LPXN,-1.196519491,-2.241746494,-0.773429928,-0.57438205,leupaxin,"LPXN, also known as leupaxin, is a gene that is primarily expressed in hematopoietic cells and belongs to the paxillin protein family. It contains four leucine-rich LD-motifs in the N-terminus and four LIM domains in the C-terminus, similar to other members of the focal-adhesion-associated adaptor-protein family. LPXN may play a role in cell type-specific signaling by interacting with PYK2, a member of the focal adhesion kinase family. It is also a substrate for a tyrosine kinase in lymphoid cells, suggesting that it may be regulated by tyrosine kinase activity. Alternative splicing of LPXN results in multiple transcript variants that encode distinct isoforms.","There is limited information available on the disease implications of LPXN. However, recent studies have suggested that LPXN may play a role in cancer progression and metastasis. In particular, LPXN has been shown to be upregulated in breast cancer and may contribute to tumor cell migration and invasion. Targeted drug discovery efforts for LPXN are currently limited, but there is potential for LPXN to be targeted in cancer therapy. One example of a successful drug targeting a member of the paxillin protein family is dasatinib, which targets the tyrosine kinase activity of BCR-ABL and has been approved for the treatment of chronic myeloid leukemia. However, further research is needed to determine the potential for LPXN as a therapeutic target.",GO:0050859 negative regulation of B cell receptor signaling pathway;GO:0050855 regulation of B cell receptor signaling pathway;GO:0050858 negative regulation of antigen receptor-mediated signaling pathway,,Predicted intracellular proteins,Focal adhesion sites (Supported); Additional: Cytosol;Nuclear speckles,,,
ENSG00000188313.13,ENSG00000188313,PLSCR1,-1.195696052,-1.428605028,-1.316977543,-0.841505586,phospholipid scramblase 1,"PLSCR1 is a gene that encodes a member of the phospholipid scramblase family. The protein produced by this gene is involved in disrupting the asymmetrical distribution of phospholipids in the plasma membrane, leading to the externalization of phosphatidylserine. This process is important in blood coagulation and macrophage clearance of apoptotic cells. Additionally, the protein has been linked to gene regulation and antiviral responses induced by interferon.","There is limited information available on the disease implications of PLSCR1. However, some studies have suggested that the gene may play a role in cancer progression and metastasis. Targeted drug discovery efforts for PLSCR1 are also limited, but some studies have explored the potential of small molecule inhibitors to target the protein and disrupt its function. One example is a study that identified a compound called NSC348884 as a potential inhibitor of PLSCR1, which was found to inhibit cancer cell migration and invasion in vitro. However, there are currently no drugs on the market that specifically target PLSCR1. Overall, more research is needed to fully understand the disease implications of PLSCR1 and to develop targeted therapies for related conditions.",GO:0006659 phosphatidylserine biosynthetic process;GO:2000371 regulation of DNA topoisomerase (ATP-hydrolyzing) activity;GO:2000373 positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity,,Predicted intracellular proteins; Transporters,Golgi apparatus;Nucleoplasm;Plasma membrane (Supported),,,(M5892)HALLMARK CHOLESTEROL HOMEOSTASIS; (M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000134013.16,ENSG00000134013,LOXL2,-1.195585941,-2.291973826,-1.011242792,-0.283541206,lysyl oxidase like 2,"LOXL2 is a gene that belongs to the lysyl oxidase gene family. This gene is responsible for encoding an extracellular copper-dependent amine oxidase that catalyzes the first step in the formation of crosslinks in collagens and elastin, which are essential for the biogenesis of connective tissue. The C-terminus end of LOXL2 contains a highly conserved amino acid sequence that is sufficient for amine oxidase activity, suggesting that each family member may retain this function. The N-terminus, on the other hand, is poorly conserved and may impart additional roles in developmental regulation, senescence, tumor suppression, cell growth control, and chemotaxis to each member of the family.","LOXL2 has been implicated in various diseases, including fibrosis, cancer, and cardiovascular diseases. In fibrosis, LOXL2 promotes the formation of crosslinks in the extracellular matrix, leading to tissue stiffening and impaired organ function. In cancer, LOXL2 promotes tumor growth, invasion, and metastasis by modifying the extracellular matrix and promoting angiogenesis. In cardiovascular diseases, LOXL2 contributes to arterial stiffness and atherosclerosis by promoting collagen crosslinking.

Several drug discovery efforts have targeted LOXL2 for the treatment of fibrosis and cancer. One approach is to inhibit LOXL2 activity using small molecules or antibodies. For example, the small molecule inhibitor PXS-5153A has shown promising results in preclinical models of fibrosis and is currently in clinical trials. Another approach is to target LOXL2 expression using RNA interference or gene editing technologies. However, these approaches are still in the early stages of development.

There are currently no drugs on the market that specifically target LOXL2. However, some drugs that indirectly affect LOXL2 activity have been approved for the treatment of fibrosis and cancer. For example, pirfenidone and nintedanib are approved for the treatment of idiopathic pulmonary fibrosis and have been shown to reduce LOXL2 expression and activity. In cancer, drugs that target the extracellular matrix, such as the integrin inhibitor cilengitide, may indirectly affect LOXL2 activity by disrupting its interactions with other matrix proteins.",GO:0018057 peptidyl-lysine oxidation;GO:0018158 protein oxidation;GO:0070828 heterochromatin organization,,Predicted secreted proteins; Enzymes; ENZYME proteins:Oxidoreductases; Predicted intracellular proteins,Nucleoplasm (Enhanced),,(M3468)NABA ECM REGULATORS; (M5885)NABA MATRISOME ASSOCIATED; (M5889)NABA MATRISOME,(M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000012822.16,ENSG00000012822,CALCOCO1,-1.192932415,-2.109244534,-1.128806099,-0.340746613,calcium binding and coiled-coil domain 1,"CALCOCO1 is a human gene that encodes for a protein with multiple functions, including binding to armadillo repeat domains, beta-catenin, and nuclear receptors. It is involved in the positive regulation of gene expression and transcription, and is located in both the cytosol and nucleus.","CALCOCO1 has been implicated in several diseases, including cancer, Alzheimer's disease, and autoimmune disorders. In cancer, CALCOCO1 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. Targeted drug discovery efforts have focused on identifying small molecules that can inhibit CALCOCO1 function, with the goal of developing new cancer treatments. One example of a successful drug targeting CALCOCO1 is bortezomib, which is used to treat multiple myeloma and mantle cell lymphoma. Bortezomib works by inhibiting the proteasome, which leads to the accumulation of CALCOCO1 and other proteins, ultimately leading to cancer cell death. Other potential drugs targeting CALCOCO1 are currently in development and undergoing clinical trials.",GO:0030518 nuclear receptor-mediated steroid hormone signaling pathway;GO:0043401 steroid hormone receptor signaling pathway;GO:0141193 nuclear receptor-mediated signaling pathway,,Predicted intracellular proteins,Cytosol (Supported),,(M200)PID ERA GENOMIC PATHWAY,
ENSG00000174004.6,ENSG00000174004,NRROS,-1.190679953,-1.459224315,-0.820060455,-1.292755089,negative regulator of reactive oxygen species,"NRROS is a human gene that acts as a negative regulator of reactive oxygen species. It has been predicted to be involved in various processes, including microglia development, sequestering of TGFbeta in extracellular matrix, and transforming growth factor beta1 activation. NRROS enables transforming growth factor beta binding activity and is located in the cell surface.","There is limited information available on the disease implications of NRROS. However, some studies have suggested that NRROS may play a role in neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Targeted drug discovery efforts for NRROS are also limited, as the gene's function and mechanisms are not yet fully understood. Currently, there are no drugs on the market that specifically target NRROS. However, there are drugs that indirectly affect reactive oxygen species and transforming growth factor beta, which are processes that NRROS is involved in. For example, antioxidants such as vitamin E and N-acetylcysteine have been used to reduce oxidative stress and reactive oxygen species levels in various diseases. Additionally, drugs that target transforming growth factor beta, such as TGF-beta inhibitors, have been developed for the treatment of cancer and fibrosis.",GO:0014005 microglia development;GO:0035583 sequestering of TGFbeta in extracellular matrix;GO:0071694 maintenance of protein location in extracellular region,,Disease related genes,,,,
ENSG00000137145.20,ENSG00000137145,DENND4C,-1.189342138,-1.569293735,-1.430726928,-0.568005752,DENN domain containing 4C,"DENND4C is a human gene that encodes a protein containing a DENN domain, which enables guanyl-nucleotide exchange factor activity. This gene is predicted to be involved in various cellular processes, including response to insulin stimulus, protein localization to the plasma membrane, and regulation of Rab protein signal transduction. DENND4C is located in both the Golgi apparatus and cytosol.","There is limited information available on the disease implications of DENND4C. However, recent studies have suggested that DENND4C may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for DENND4C are still in the early stages, but there is potential for the development of drugs that target the protein's guanyl-nucleotide exchange factor activity. Currently, there are no drugs on the market that specifically target DENND4C. However, there are drugs that target other proteins involved in similar cellular processes, such as Rab proteins, which may indirectly affect DENND4C activity. Examples of such drugs include bafilomycin A1, which inhibits the activity of the Rab7 protein, and chloroquine, which inhibits the activity of the Rab5 protein.",GO:0032483 regulation of Rab protein signal transduction;GO:0032869 cellular response to insulin stimulus;GO:0072659 protein localization to plasma membrane,,Predicted intracellular proteins,Cytosol;Golgi apparatus;Vesicles (Supported),,,
ENSG00000137693.14,ENSG00000137693,YAP1,-1.188854057,-1.715793754,-1.326396283,-0.524372133,Yes1 associated transcriptional regulator,"YAP1 is a gene that plays a crucial role in the Hippo signaling pathway, which is involved in various biological processes such as development, growth, repair, and homeostasis. It acts as a transcriptional regulator of this pathway and is known to be associated with the development and progression of multiple cancers. YAP1 has multiple transcript variants due to alternative splicing, resulting in different isoforms. It is considered a potential target for cancer treatment due to its involvement in cancer progression.","YAP1 has been implicated in various types of cancer, including liver, lung, breast, ovarian, and pancreatic cancer. It is often overexpressed in cancer cells, leading to increased cell proliferation, invasion, and metastasis. Targeting YAP1 has emerged as a promising strategy for cancer treatment, and several drugs are currently being developed to inhibit its activity.

One example of a drug targeting YAP1 is verteporfin, which was originally used to treat macular degeneration but has shown promising results in preclinical studies for cancer treatment. Another drug, CA3, has been shown to inhibit YAP1 activity and reduce tumor growth in mouse models of liver cancer. Additionally, several small molecule inhibitors of YAP1 are currently in development, including BI-853520 and GSK-1070916.

Overall, targeting YAP1 is a promising approach for cancer treatment, and ongoing research efforts are focused on developing effective drugs that can inhibit its activity and improve patient outcomes.",GO:1903703 enterocyte differentiation;GO:0061026 cardiac muscle tissue regeneration;GO:0072307 regulation of metanephric nephron tubule epithelial cell differentiation,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of eye; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol;Nucleoli,,(M13)PID ERBB4 PATHWAY; (M236)PID DELTA NP63 PATHWAY; (M286)PID TGFBR PATHWAY,
ENSG00000119285.11,ENSG00000119285,HEATR1,-1.188589195,-1.332203556,-1.387316147,-0.846247883,HEAT repeat containing 1,"HEATR1, or HEAT repeat containing 1, is a human gene that plays a role in RNA binding activity and is involved in positive regulation of rRNA processing and transcription by RNA polymerase I. It is located in the fibrillar center and mitochondrion and has been implicated in pancreatic ductal carcinoma. HEATR1 is also a biomarker of glioblastoma, a type of brain cancer.","HEATR1 has been implicated in several diseases, including pancreatic ductal carcinoma and glioblastoma. In pancreatic ductal carcinoma, HEATR1 has been shown to be overexpressed and may play a role in tumor growth and progression. In glioblastoma, HEATR1 has been identified as a potential biomarker and therapeutic target. Targeted drug discovery efforts for HEATR1 are ongoing, with several small molecule inhibitors being developed to target its RNA binding activity. However, there are currently no drugs on the market that specifically target HEATR1. Successful drugs for pancreatic ductal carcinoma and glioblastoma include gemcitabine, nab-paclitaxel, and temozolomide, which target different aspects of tumor growth and progression.",GO:2000234 positive regulation of rRNA processing;GO:1902570 protein localization to nucleolus;GO:2000232 regulation of rRNA processing,,Predicted intracellular proteins,Nucleoli fibrillar center (Enhanced); Additional: Mitochondria,,,
ENSG00000144959.11,ENSG00000144959,NCEH1,-1.184647015,-2.340150433,-1.095252612,-0.118538,neutral cholesterol ester hydrolase 1,"NCEH1 is a human gene that is predicted to have hydrolase activity and be involved in ether lipid metabolic processes. It is also predicted to act upstream of or within SMAD protein signal transduction, protein dephosphorylation, and xenobiotic metabolic processes. NCEH1 is located in the membrane.","NCEH1 has been implicated in several diseases, including atherosclerosis, Alzheimer's disease, and cancer. In atherosclerosis, NCEH1 plays a role in the metabolism of oxidized phospholipids, which are known to contribute to the development of the disease. In Alzheimer's disease, NCEH1 has been shown to be involved in the metabolism of amyloid-beta, a protein that accumulates in the brains of Alzheimer's patients. In cancer, NCEH1 has been found to be overexpressed in several types of tumors, including breast, lung, and ovarian cancer.

Targeted drug discovery efforts for NCEH1 have focused on developing inhibitors of its hydrolase activity. One such inhibitor, THL, has been shown to reduce atherosclerotic lesion formation in mice. Another inhibitor, WWL70, has been shown to reduce amyloid-beta levels in the brains of mice with Alzheimer's disease.

There are currently no drugs on the market that specifically target NCEH1. However, several drugs that target related enzymes are available. For example, statins, which are commonly used to treat high cholesterol, inhibit HMG-CoA reductase, an enzyme involved in cholesterol synthesis. Another example is aspirin, which inhibits cyclooxygenase, an enzyme involved in the production of prostaglandins.",GO:0034383 low-density lipoprotein particle clearance;GO:0006662 glycerol ether metabolic process;GO:0046485 ether lipid metabolic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Endoplasmic reticulum (Approved),,,
ENSG00000152818.18,ENSG00000152818,UTRN,-1.1845579,-1.929899246,-0.973321643,-0.650452812,utrophin,"UTRN is a human gene that shares structural and functional similarities with the dystrophin gene. It contains an actin-binding N-terminus, a triple coiled-coil repeat central region, and a C-terminus that interacts with dystroglycan protein components. UTRN is located at the neuromuscular synapse and myotendinous junctions, where it participates in post-synaptic membrane maintenance and acetylcholine receptor clustering. Studies in mice suggest that UTRN may serve as a functional substitute for the dystrophin gene and could potentially be used as a therapeutic alternative for muscular dystrophy caused by mutations in the dystrophin gene. Alternative splicing of UTRN has been described, but the full-length nature of these variants is not yet known.","Mutations in the UTRN gene have been associated with congenital myopathy, a rare genetic disorder characterized by muscle weakness and wasting. However, there are currently no targeted drug discovery efforts or approved drugs specifically for UTRN-related myopathy. 

In terms of drug discovery efforts for muscular dystrophy, there has been significant progress in developing therapies that target the dystrophin gene, which shares structural and functional similarities with UTRN. For example, the drug eteplirsen was approved by the FDA in 2016 for the treatment of Duchenne muscular dystrophy, a disease caused by mutations in the dystrophin gene. Eteplirsen is an antisense oligonucleotide that promotes exon skipping, allowing for the production of a partially functional dystrophin protein. Other drugs in development for muscular dystrophy include gene therapies, exon-skipping drugs, and drugs that target downstream pathways involved in muscle degeneration and regeneration.",GO:2000649 regulation of sodium ion transmembrane transporter activity;GO:1902305 regulation of sodium ion transmembrane transport;GO:0001954 positive regulation of cell-matrix adhesion,,Predicted intracellular proteins,Plasma membrane (Supported); Additional: Basal body;Nucleoplasm;Primary cilium,"Zinc; Zinc acetate; Zinc chloride; Zinc sulfate, unspecified form",,
ENSG00000175274.19,ENSG00000175274,TP53I11,-1.183915531,-2.297429523,-0.760786518,-0.493530551,tumor protein p53 inducible protein 11,"The human gene TP53I11, also known as tumor protein p53 inducible protein 11, is predicted to play a role in the negative regulation of cell population proliferation. It is also predicted to be an integral component of the membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of TP53I11. However, some studies have suggested that mutations in TP53I11 may be associated with certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for TP53I11 are also limited, as the function of this gene is not well understood. However, some studies have suggested that TP53I11 may be a potential target for cancer therapy. Currently, there are no drugs on the market that specifically target TP53I11. However, there are several drugs that target the p53 pathway, which is closely related to TP53I11. For example, Nutlin-3 is a small molecule inhibitor that disrupts the interaction between p53 and its negative regulator MDM2, leading to p53 activation and cell cycle arrest. Another example is PRIMA-1, which restores the function of mutant p53 and induces apoptosis in cancer cells.",GO:0008285 negative regulation of cell population proliferation;GO:0042127 regulation of cell population proliferation;GO:0048523 negative regulation of cellular process,,Predicted intracellular proteins,Endoplasmic reticulum;Golgi apparatus (Approved); Additional: Acrosome;Principal piece,,,
ENSG00000187678.10,ENSG00000187678,SPRY4,-1.183380705,-1.360246606,-0.846445875,-1.343449632,sprouty RTK signaling antagonist 4,"The SPRY4 gene encodes a protein that belongs to a family of proteins rich in cysteine and proline. This protein acts as an inhibitor of the MAPK signaling pathway, which is involved in cell growth and differentiation. The activity of SPRY4 impairs the formation of active GTP-RAS, which is a protein that regulates cell proliferation and differentiation. Variations in the nucleotide sequence of this gene have been associated with a condition called hypogonadotropic hypogonadism 17, which is characterized by low levels of sex hormones and a reduced sense of smell. Alternative splicing of the gene results in the production of multiple transcript variants.","Hypogonadotropic hypogonadism 17 is a rare genetic disorder caused by mutations in the SPRY4 gene. This condition is characterized by delayed or absent puberty, low levels of sex hormones, and infertility. There is currently no cure for this disorder, and treatment is focused on hormone replacement therapy to alleviate symptoms. However, targeted drug discovery efforts are underway to develop new therapies that can modulate the activity of SPRY4 and restore normal hormone levels. One example of a successful drug on the market is leuprolide, which is a synthetic hormone that mimics the action of gonadotropin-releasing hormone (GnRH) and is used to treat hypogonadism and other hormone-related disorders. Another example is clomiphene, which is a selective estrogen receptor modulator (SERM) that is used to stimulate ovulation in women with infertility.",GO:1900025 negative regulation of substrate adhesion-dependent cell spreading;GO:0046580 negative regulation of Ras protein signal transduction;GO:0040037 negative regulation of fibroblast growth factor receptor signaling pathway,,Disease related genes; Human disease related genes:Endocrine and metabolic diseases:Hypothalamus and pituitary gland diseases; Predicted intracellular proteins,Golgi apparatus (Approved); Additional: Cytosol,,,(M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000104774.13,ENSG00000104774,MAN2B1,-1.182594916,-1.453212536,-1.202329415,-0.892242796,mannosidase alpha class 2B member 1,"The MAN2B1 gene encodes an enzyme that breaks down alpha-D-mannose residues in alpha-D-mannosides, which is necessary for the breakdown of N-linked carbohydrates during glycoprotein turnover. It belongs to family 38 of glycosyl hydrolases and is processed into several peptides. Defects in this gene have been linked to lysosomal alpha-mannosidosis. Different isoforms of the gene have been identified through alternative splicing.","Lysosomal alpha-mannosidosis is a rare inherited disorder caused by mutations in the MAN2B1 gene, resulting in a deficiency of alpha-mannosidase activity. This leads to the accumulation of mannose-rich oligosaccharides in lysosomes, causing progressive neurological deterioration, skeletal abnormalities, and immune system dysfunction. There is currently no cure for lysosomal alpha-mannosidosis, and treatment is mainly supportive. However, targeted drug discovery efforts are ongoing, with a focus on enzyme replacement therapy and small molecule chaperones to enhance enzyme activity. One example of a successful drug on the market is velmanase alfa, a recombinant human alpha-mannosidase enzyme replacement therapy approved for the treatment of lysosomal alpha-mannosidosis in Europe. Another example is miglustat, a small molecule chaperone that has been shown to improve neurological symptoms in some patients with lysosomal storage disorders, including lysosomal alpha-mannosidosis.",GO:0006013 mannose metabolic process;GO:0009313 oligosaccharide catabolic process;GO:0006517 protein deglycosylation,,Predicted intracellular proteins; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Lysosomal storage diseases; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism,Nucleoplasm;Vesicles (Approved),,,
ENSG00000150938.10,ENSG00000150938,CRIM1,-1.178783655,-1.476792459,-1.439604093,-0.619954414,cysteine rich transmembrane BMP regulator 1,"CRIM1 is a human gene that encodes a transmembrane protein with six cysteine-rich repeat domains and an insulin-like growth factor-binding domain. This protein may be involved in tissue development by interacting with members of the transforming growth factor beta family, such as bone morphogenetic proteins. The exact function of CRIM1 is not fully understood, but it is believed to play a role in regulating the activity of these growth factors. Mutations in this gene have been associated with various developmental disorders, including eye and kidney abnormalities.","Mutations in the CRIM1 gene have been associated with several developmental disorders, including Fraser syndrome, which is characterized by eye, ear, and kidney abnormalities. Additionally, mutations in CRIM1 have been linked to congenital anomalies of the kidney and urinary tract (CAKUT), a group of disorders that affect the development of the kidneys and urinary tract. 

There are currently no drugs specifically targeting CRIM1, but research is ongoing to better understand its role in disease and identify potential therapeutic targets. One study found that CRIM1 expression was increased in breast cancer cells and that targeting CRIM1 with a small molecule inhibitor reduced tumor growth in mice. 

There are currently no drugs on the market targeting CRIM1, but there are several drugs that target members of the transforming growth factor beta family, which CRIM1 interacts with. For example, the drug TGF-beta receptor inhibitors, such as galunisertib, have been approved for the treatment of advanced liver cancer. Additionally, the drug nintedanib, which targets multiple receptors including those in the TGF-beta family, has been approved for the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer.",GO:0045668 negative regulation of osteoblast differentiation;GO:0030514 negative regulation of BMP signaling pathway;GO:0048009 insulin-like growth factor receptor signaling pathway,,Predicted intracellular proteins; Transporters,,,(M3008)NABA ECM GLYCOPROTEINS; (M5884)NABA CORE MATRISOME; (M5889)NABA MATRISOME,
ENSG00000197329.12,ENSG00000197329,PELI1,-1.177536933,-0.967387139,-0.925285853,-1.639937806,pellino E3 ubiquitin protein ligase 1,"PELI1 is a human gene that encodes for the pellino E3 ubiquitin protein ligase 1. This gene is involved in several biological processes, including negative regulation of necroptotic process, protein polyubiquitination, and response to lipopolysaccharide. PELI1 enables ubiquitin protein ligase activity and is predicted to be located in the cytosol.","Research on PELI1 has suggested its potential involvement in various diseases, including cancer, autoimmune disorders, and infectious diseases. For instance, PELI1 has been found to be overexpressed in several types of cancer, including breast, lung, and colon cancer, and its inhibition has been shown to suppress tumor growth. Additionally, PELI1 has been implicated in the pathogenesis of autoimmune disorders such as rheumatoid arthritis and lupus, as well as in the immune response to viral and bacterial infections. 

Targeted drug discovery efforts for PELI1 are still in the early stages, but several small molecule inhibitors have been identified that can block its activity. For example, a recent study identified a compound called PELI1-IN-1 that can inhibit PELI1-mediated ubiquitination and promote the degradation of PELI1 substrates. 

Currently, there are no drugs on the market that specifically target PELI1. However, there are several drugs that indirectly affect PELI1 activity. For example, the anti-inflammatory drug sulfasalazine has been shown to inhibit PELI1 expression and activity in rheumatoid arthritis patients. Additionally, the cancer drug bortezomib has been shown to induce PELI1 degradation in multiple myeloma cells, leading to cell death.",GO:0008592 regulation of Toll signaling pathway;GO:0034141 positive regulation of toll-like receptor 3 signaling pathway;GO:0034139 regulation of toll-like receptor 3 signaling pathway,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Basal body;Nucleoli;Nucleoplasm (Supported); Additional: Centriolar satellite;Centrosome;Cytosol;Intermediate filaments,,,(M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000159023.22,ENSG00000159023,EPB41,-1.175082604,-1.247641679,-1.537963147,-0.739642986,erythrocyte membrane protein band 4.1,"EPB41 is a human gene that encodes for erythrocyte membrane protein band 4.1, which is a component of the red cell membrane cytoskeletal network. This network is crucial for maintaining the shape and deformability of red blood cells. Mutations in this gene have been linked to type 1 elliptocytosis, a condition characterized by abnormally shaped red blood cells. Different isoforms of the EPB41 gene have been identified through alternative splicing.","Mutations in the EPB41 gene have been linked to several diseases, including hereditary elliptocytosis, hereditary spherocytosis, and hereditary pyropoikilocytosis. These conditions are characterized by abnormal red blood cell morphology, leading to anemia, jaundice, and other complications. Targeted drug discovery efforts for these diseases have focused on developing therapies that can improve red blood cell shape and function. One example is the use of erythropoietin-stimulating agents to increase red blood cell production in patients with anemia. Another approach is the use of small molecules that can modulate the cytoskeletal network and improve red blood cell deformability. One successful drug on the market for hereditary spherocytosis is eculizumab, a monoclonal antibody that targets complement protein C5 and reduces hemolysis.",GO:1904778 positive regulation of protein localization to cell cortex;GO:1904776 regulation of protein localization to cell cortex;GO:1904478 regulation of intestinal absorption,,Predicted intracellular proteins; Transporters:Accessory Factors Involved in Transport; Potential drug targets; Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases,Cell Junctions;Plasma membrane (Supported); Additional: Cytokinetic bridge;Cytosol;Mitotic spindle;Nuclear bodies,,(M240)PID SYNDECAN 2 PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE; (M5945)HALLMARK HEME METABOLISM
ENSG00000133121.21,ENSG00000133121,STARD13,-1.174470442,-2.134524515,-0.904542544,-0.484344265,StAR related lipid transfer domain containing 13,"STARD13 is a human gene that encodes a protein with multiple domains, including a sterile alpha motif (SAM), an ATP/GTP-binding motif, a GTPase-activating protein (GAP) domain, and a STAR-related lipid transfer (START) domain. This protein is involved in regulating cytoskeletal reorganization, cell proliferation, and cell motility, and has been identified as a tumor suppressor in hepatoma cells. The gene is located on chromosome 13 and is associated with loss of heterozygosity in hepatocellular carcinomas. Different isoforms of the protein are produced through alternative splicing of the gene.","STARD13 has been implicated in various diseases, including cancer, cardiovascular disease, and neurological disorders. In hepatocellular carcinoma, STARD13 is frequently downregulated, and its loss is associated with poor prognosis. In cardiovascular disease, STARD13 has been shown to regulate vascular smooth muscle cell proliferation and migration, suggesting a potential role in atherosclerosis. In neurological disorders, STARD13 has been linked to autism spectrum disorder and schizophrenia.

There are currently no drugs specifically targeting STARD13, but efforts are underway to develop small molecule inhibitors of the protein. One study identified a compound that selectively inhibits the GAP domain of STARD13, leading to decreased cell migration and invasion in vitro. Another study found that a peptide derived from the SAM domain of STARD13 can inhibit the interaction between STARD13 and its binding partner, RhoA, leading to decreased cell proliferation and migration.

There are currently no drugs on the market targeting STARD13, but the identification of small molecule inhibitors and peptides suggests that targeting this protein may be a viable therapeutic strategy in the future.",GO:0097498 endothelial tube lumen extension;GO:0003159 morphogenesis of an endothelium;GO:0061154 endothelial tube morphogenesis,,Predicted intracellular proteins,Golgi apparatus;Vesicles (Approved); Additional: Nucleoplasm,,,
ENSG00000196313.11,ENSG00000196313,POM121,-1.171994938,-1.745769701,-1.325843715,-0.444371399,POM121 transmembrane nucleoporin,POM121 is a gene that encodes a transmembrane protein that is located in the inner nuclear membrane and is a crucial component of the nuclear pore complex. This complex is responsible for regulating the transport of molecules to and from the nucleus. POM121 may also play a role in anchoring the complex to the nuclear envelope. There are several related genes and pseudogenes for POM121 on different chromosomes. Different isoforms of the protein are produced through alternative splicing of the transcript variants.,"Mutations in the POM121 gene have been associated with several diseases, including autosomal recessive congenital ichthyosis, a rare genetic disorder characterized by dry, scaly skin. Additionally, POM121 has been implicated in the development and progression of certain cancers, such as breast cancer and lung cancer. Targeted drug discovery efforts for POM121 are still in the early stages, but there is potential for the development of drugs that could modulate the function of the nuclear pore complex and potentially treat diseases associated with POM121 dysfunction. Currently, there are no drugs on the market that specifically target POM121, but there are drugs that indirectly affect the nuclear pore complex, such as the cancer drug doxorubicin, which has been shown to disrupt the function of the complex.",GO:0006405 RNA export from nucleus;GO:0006606 protein import into nucleus;GO:0051170 import into nucleus,,Transporters:Transporter channels and pores; Predicted intracellular proteins,Nuclear membrane;Nucleoplasm (Enhanced),,,(M5898)HALLMARK DNA REPAIR; (M5939)HALLMARK P53 PATHWAY
ENSG00000068305.17,ENSG00000068305,MEF2A,-1.171944546,-1.419590174,-1.470171875,-0.626071589,myocyte enhancer factor 2A,"MEF2A is a gene that encodes a transcription factor involved in various cellular processes, including muscle development, neuronal differentiation, cell growth control, and apoptosis. It activates many muscle-specific, growth factor-induced, and stress-induced genes and can act as a homodimer or heterodimer. Defects in this gene can cause autosomal dominant coronary artery disease 1 with myocardial infarction (ADCAD1). Multiple transcript variants encoding different isoforms have been identified.","Mutations in the MEF2A gene have been linked to autosomal dominant coronary artery disease 1 with myocardial infarction (ADCAD1), a condition characterized by early onset of coronary artery disease and an increased risk of heart attack. Targeted drug discovery efforts have focused on identifying compounds that can modulate the activity of MEF2A and potentially prevent or treat ADCAD1. One example is the small molecule inhibitor, BIX-01294, which has been shown to inhibit MEF2A activity and reduce the expression of genes involved in cardiac hypertrophy. Another example is the natural compound, resveratrol, which has been shown to activate MEF2A and improve cardiac function in animal models of heart disease. However, there are currently no drugs on the market specifically targeting MEF2A for the treatment of ADCAD1.",GO:0070375 ERK5 cascade;GO:0055005 ventricular cardiac myofibril assembly;GO:0055015 ventricular cardiac muscle cell development,,Predicted intracellular proteins; Transcription factors:alpha-Helices exposed by beta-structures; Human disease related genes:Cardiovascular diseases:Vascular diseases; Disease related genes; Cancer-related genes:Mutational cancer driver genes,Nucleoplasm (Supported); Additional: Cytosol,,(M229)PID P38 ALPHA BETA DOWNSTREAM PATHWAY,(M5909)HALLMARK MYOGENESIS
ENSG00000184634.16,ENSG00000184634,MED12,-1.170072143,-2.064998361,-0.972263607,-0.47295446,mediator complex subunit 12,"MED12 is a gene that encodes for a protein component of the preinitiation complex, which controls the initiation of transcription. MED12 binds with a CDK8 subcomplex, along with MED13, CDK8 kinase, and cyclin C, to regulate transcription initiation and reinitiation rates. MED12 is essential for activating CDK8 kinase. Defects in this gene cause X-linked Opitz-Kaveggia syndrome, also known as FG syndrome, and Lujan-Fryns syndrome.","Mutations in the MED12 gene have been linked to several genetic disorders, including X-linked Opitz-Kaveggia syndrome (also known as FG syndrome) and Lujan-Fryns syndrome. These syndromes are characterized by intellectual disability, developmental delays, and physical abnormalities. There are currently no targeted drug discovery efforts specifically for MED12 mutations, as the underlying mechanisms of these disorders are not yet fully understood. However, there are several drugs on the market that are used to treat symptoms associated with these disorders, such as antipsychotics and antidepressants. For example, risperidone and aripiprazole are commonly used to treat behavioral problems in individuals with FG syndrome, while selective serotonin reuptake inhibitors (SSRIs) are often prescribed to treat anxiety and depression in individuals with Lujan-Fryns syndrome.",GO:0090245 axis elongation involved in somitogenesis;GO:0048702 embryonic neurocranium morphogenesis;GO:1990403 embryonic brain development,,Predicted intracellular proteins; Human disease related genes:Reproductive system diseases:Reproductive system diseases; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Nucleoplasm (Approved),,(M223)PID BETA CATENIN NUC PATHWAY,
ENSG00000073849.16,ENSG00000073849,ST6GAL1,-1.170061684,-2.171559074,-0.96253853,-0.376087447,"ST6 beta-galactoside alpha-2,6-sialyltransferase 1","ST6GAL1 is a gene that encodes a type II membrane protein belonging to the glycosyltransferase family 29. The protein catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates. It is involved in the generation of cell-surface carbohydrate determinants and differentiation antigens HB-6, CD75, and CD76. The protein is normally found in the Golgi but can be proteolytically processed to a soluble form. Alternative splicing results in multiple transcript variants. This gene has been incorrectly referred to as CD75.","ST6GAL1 has been implicated in various diseases, including cancer, inflammation, and autoimmune disorders. In cancer, ST6GAL1 is upregulated and promotes tumor growth, invasion, and metastasis by modifying cell surface glycan structures. Targeting ST6GAL1 has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors and monoclonal antibodies targeting ST6GAL1 are currently under development for cancer therapy. One example is the monoclonal antibody BCD-100, which has shown promising results in preclinical studies for the treatment of breast cancer. Another example is the small molecule inhibitor Sialyl-Thomsen-nouveau antigen (STn), which has shown efficacy in preclinical models of pancreatic cancer. However, no ST6GAL1-targeted drugs have been approved for clinical use yet.",GO:2000110 negative regulation of macrophage apoptotic process;GO:0097503 sialylation;GO:2000109 regulation of macrophage apoptotic process,,Predicted secreted proteins; Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,,,,(M5953)HALLMARK KRAS SIGNALING UP
ENSG00000261371.6,ENSG00000261371,PECAM1,-1.16985886,-1.180975278,-0.743038128,-1.585563173,platelet and endothelial cell adhesion molecule 1,"PECAM1 is a human gene that encodes a protein found on the surface of platelets, monocytes, neutrophils, and some types of T-cells. It is also a major component of endothelial cell intercellular junctions. The protein is a member of the immunoglobulin superfamily and is believed to play a role in leukocyte migration, angiogenesis, and integrin activation.","PECAM1 has been implicated in various diseases, including atherosclerosis, thrombosis, and cancer. In atherosclerosis, PECAM1 has been shown to play a role in leukocyte recruitment and adhesion to the endothelium, contributing to the formation of plaques. In thrombosis, PECAM1 has been found to regulate platelet activation and aggregation, making it a potential target for anti-thrombotic therapies. In cancer, PECAM1 has been shown to promote tumor angiogenesis and metastasis, making it a potential target for anti-cancer therapies.

Several drug discovery efforts have targeted PECAM1, with a focus on developing anti-thrombotic and anti-cancer agents. One example is the development of monoclonal antibodies that target PECAM1 and inhibit platelet aggregation. Another example is the use of small molecule inhibitors that target PECAM1-mediated signaling pathways involved in angiogenesis and metastasis.

One successful drug on the market that targets PECAM1 is Abciximab, a monoclonal antibody used as an anti-thrombotic agent in patients undergoing percutaneous coronary intervention. Abciximab binds to PECAM1 on platelets, preventing their activation and aggregation. Another drug, Cilengitide, is a small molecule inhibitor that targets PECAM1-mediated signaling pathways involved in angiogenesis and is being investigated as a potential anti-cancer therapy.",GO:0150107 positive regulation of protein localization to cell-cell junction;GO:0035696 monocyte extravasation;GO:0072011 glomerular endothelium development,,CD markers; Candidate cardiovascular disease genes; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Nucleoli;Plasma membrane (Approved),,(M53)PID INTEGRIN3 PATHWAY,(M5946)HALLMARK COAGULATION; (M5915)HALLMARK APICAL JUNCTION; (M5953)HALLMARK KRAS SIGNALING UP
ENSG00000153317.15,ENSG00000153317,ASAP1,-1.169575473,-1.400677627,-1.080921928,-1.027126864,"ArfGAP with SH3 domain, ankyrin repeat and PH domain 1","ASAP1 is a gene that encodes an ADP-ribosylation factor (ARF) GTPase-activating protein. The protein encoded by this gene is stimulated by phosphatidylinositol 4,5-biphosphate (PIP2) and is involved in the regulation of membrane trafficking and cytoskeleton remodeling. The GTPase-activating activity is greater towards ARF1 and ARF5, and lesser for ARF6. There are different isoforms of this gene that have been found due to alternative splicing of transcript variants.","Research has shown that ASAP1 may play a role in cancer progression and metastasis. Specifically, overexpression of ASAP1 has been observed in various types of cancer, including breast, lung, and pancreatic cancer. Targeting ASAP1 has been proposed as a potential therapeutic strategy for cancer treatment. However, there are currently no drugs on the market that specifically target ASAP1.

Efforts to develop drugs targeting ASAP1 are still in the early stages. One study identified a small molecule inhibitor of ASAP1 that was able to reduce cancer cell migration and invasion in vitro. Another study found that a peptide derived from the C-terminus of ASAP1 was able to inhibit cancer cell migration and invasion in vitro and in vivo. These findings suggest that targeting ASAP1 may be a promising approach for cancer therapy.

Overall, while there is still much to learn about the role of ASAP1 in disease, the potential implications for cancer treatment make it an interesting target for drug discovery efforts.",GO:1903527 positive regulation of membrane tubulation;GO:1903525 regulation of membrane tubulation;GO:0061000 negative regulation of dendritic spine development,,Predicted intracellular proteins,Golgi apparatus;Plasma membrane (Approved); Additional: Centriolar satellite,,(M243)PID ARF 3PATHWAY; (M281)PID FAK PATHWAY,
ENSG00000100129.18,ENSG00000100129,EIF3L,-1.165965539,-1.359738441,-1.882385238,-0.255772939,eukaryotic translation initiation factor 3 subunit L,"EIF3L is a gene that encodes for the eukaryotic translation initiation factor 3 subunit L. This protein is involved in translation initiation factor activity and contributes to the initiation of protein synthesis. It also plays a role in viral translational termination-reinitiation. EIF3L is located in the membrane and is part of the eukaryotic translation initiation factor 3 complex. It enables RNA binding activity and is essential for the initiation of protein synthesis. Overall, EIF3L is an important gene involved in the regulation of protein synthesis and is essential for proper cellular function.","There is limited information available on the disease implications of EIF3L. However, some studies have suggested that it may play a role in the development and progression of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for EIF3L are also limited, but some studies have explored the potential of targeting the eukaryotic translation initiation factor 3 complex as a whole for cancer therapy. One example of a successful drug targeting protein synthesis is the mTOR inhibitor, everolimus, which is used to treat certain types of cancer. However, there are currently no drugs specifically targeting EIF3L on the market. Further research is needed to fully understand the potential disease implications of EIF3L and to develop targeted therapies for diseases associated with its dysregulation.",GO:0075525 viral translational termination-reinitiation;GO:0001732 formation of cytoplasmic translation initiation complex;GO:0019081 viral translation,,Predicted intracellular proteins,Nucleoli (Approved); Additional: Nucleoplasm,,,
ENSG00000198786.2,ENSG00000198786,MT-ND5,-1.165654846,-2.166870983,-0.903552377,-0.426541177,NADH dehydrogenase subunit 5,"The human gene ND5, also known as NADH dehydrogenase subunit 5, plays a crucial role in mitochondrial electron transport and is involved in NADH to ubiquinone conversion. It is a part of the mitochondrial respiratory chain complex I and is responsible for the assembly of this complex. Mutations in this gene have been linked to several mitochondrial disorders, including Leber hereditary optic neuropathy, Leigh disease, and MELAS syndrome. ND5 enables NADH dehydrogenase (ubiquinone) activity, which is essential for the proper functioning of the mitochondrial respiratory chain and energy production in the cell.","Mutations in the ND5 gene have been linked to several mitochondrial disorders, including Leber hereditary optic neuropathy, Leigh disease, and MELAS syndrome. These disorders are characterized by a wide range of symptoms, including muscle weakness, vision loss, seizures, and developmental delays. Targeted drug discovery efforts for these disorders have focused on developing drugs that can improve mitochondrial function and reduce oxidative stress. One example of a successful drug on the market is idebenone, which has been approved for the treatment of Leber hereditary optic neuropathy. Idebenone is a synthetic analog of coenzyme Q10, which is involved in the electron transport chain and can improve mitochondrial function. Other drugs that have shown promise in preclinical studies include elamipretide, which targets mitochondrial membrane potential, and KH176, which targets mitochondrial complex I. However, more research is needed to determine the safety and efficacy of these drugs in clinical trials.","GO:0015988 energy coupled proton transmembrane transport, against electrochemical gradient;GO:0015990 electron transport coupled proton transport;GO:0006120 mitochondrial electron transport, NADH to ubiquinone",,Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Potential drug targets; Enzymes; Disease related genes; ENZYME proteins,,NADH,,
ENSG00000197892.13,ENSG00000197892,KIF13B,-1.164940156,-1.912369722,-1.119633684,-0.462817061,kinesin family member 13B,"KIF13B is a human gene that belongs to the kinesin family member 13B. It plays a role in regulating axonogenesis, which is the process of forming the axon of a neuron. KIF13B is located in the axon and cytoplasm and has the ability to bind to 14-3-3 proteins and protein kinases. This gene is important for the proper development and function of the nervous system.","There is limited information available on the disease implications of KIF13B. However, recent studies have suggested that mutations in this gene may be associated with neurodevelopmental disorders such as autism spectrum disorder (ASD) and intellectual disability. Targeted drug discovery efforts for KIF13B are currently underway, with a focus on identifying small molecule inhibitors that can modulate its activity. While there are no drugs currently on the market that specifically target KIF13B, there are several drugs that target other kinesin family members, such as the cancer drug paclitaxel, which targets KIF2A. Additionally, there are ongoing clinical trials for drugs that target kinesin family members, such as KIF11, which is being targeted for the treatment of cancer.",GO:0050770 regulation of axonogenesis;GO:0006605 protein targeting;GO:0042110 T cell activation,,Predicted intracellular proteins,,,(M86)PID ARF6 PATHWAY,(M5939)HALLMARK P53 PATHWAY
ENSG00000076321.11,ENSG00000076321,KLHL20,-1.16453693,-1.493881035,-1.403574284,-0.596155472,kelch like family member 20,"KLHL20 is a human gene that encodes a protein belonging to the kelch family. This family is characterized by a repeat motif of 44-56 amino acids, which can be found in various polypeptide contexts and contains multiple potential protein-protein contact sites. Kelch family members have diverse activities and can be found both inside and outside of cells. The function of KLHL20 is not well understood, but it is thought to play a role in protein-protein interactions.","There is limited information available on the disease implications of KLHL20. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, such as lung cancer and breast cancer. Targeted drug discovery efforts for KLHL20 are also limited, as its function is not well understood. However, some researchers are exploring the potential of targeting kelch family proteins, including KLHL20, as a strategy for cancer therapy. Currently, there are no drugs on the market that specifically target KLHL20. However, there are drugs that target other kelch family proteins, such as Keap1, which is targeted by the cancer drug sulforaphane.",GO:1990390 protein K33-linked ubiquitination;GO:0006895 Golgi to endosome transport;GO:0035455 response to interferon-alpha,,Predicted intracellular proteins,Cytosol;Golgi apparatus (Supported),,(M156)PID ECADHERIN NASCENT AJ PATHWAY,
ENSG00000111252.11,ENSG00000111252,SH2B3,-1.164127483,-1.620182632,-1.062395467,-0.809804349,SH2B adaptor protein 3,"SH2B adaptor protein 3 (SH2B3) is a gene that encodes a protein involved in various signaling activities by growth factor and cytokine receptors. The protein plays a crucial role in hematopoiesis and is a key negative regulator of cytokine signaling. Mutations in the SH2B3 gene have been linked to susceptibility to celiac disease type 13 and insulin-dependent diabetes mellitus. The gene has multiple alternatively spliced transcript variants that encode different isoforms. Overall, SH2B3 is an important gene involved in regulating cytokine signaling and has implications in various diseases.","SH2B3 has been implicated in various diseases, including autoimmune disorders, cardiovascular diseases, and cancer. In particular, mutations in the SH2B3 gene have been linked to an increased risk of developing celiac disease type 13 and insulin-dependent diabetes mellitus. Additionally, SH2B3 has been shown to play a role in the development of atherosclerosis and hypertension, making it a potential target for cardiovascular disease treatment.

Targeted drug discovery efforts for SH2B3 have focused on developing small molecule inhibitors that can block its activity and enhance cytokine signaling. One example is the drug Ruxolitinib, which is a JAK inhibitor that has been approved for the treatment of myelofibrosis and polycythemia vera. Ruxolitinib has been shown to inhibit SH2B3 and enhance cytokine signaling, leading to improved outcomes in patients with these diseases.

Another example is the drug Tofacitinib, which is also a JAK inhibitor that has been approved for the treatment of rheumatoid arthritis. Tofacitinib has been shown to inhibit SH2B3 and enhance cytokine signaling, leading to improved outcomes in patients with rheumatoid arthritis.

Overall, SH2B3 is an important gene with implications in various diseases, and targeted drug discovery efforts have led to the development of successful drugs on the market that target its activity.",GO:1900234 regulation of Kit signaling pathway;GO:1900235 negative regulation of Kit signaling pathway;GO:0035702 monocyte homeostasis,,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Predicted intracellular proteins; Cancer-related genes; Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Human disease related genes:Endocrine and metabolic diseases:Diabetes,Nucleoplasm (Approved),Pazopanib,(M233)PID EPO PATHWAY; (M231)PID KIT PATHWAY,(M5921)HALLMARK COMPLEMENT
ENSG00000129116.19,ENSG00000129116,PALLD,-1.162547542,-1.614018331,-1.401236928,-0.472387367,"palladin, cytoskeletal associated protein","PALLD is a gene that encodes a cytoskeletal protein called palladin. Palladin is essential for organizing the actin cytoskeleton, which controls cell shape, adhesion, and contraction. Polymorphisms in this gene have been linked to an increased risk of pancreatic cancer type 1 and myocardial infarction. Alternative splicing of the gene results in multiple transcript variants.","PALLD has been implicated in several diseases, including cancer and cardiovascular disease. In pancreatic cancer type 1, a missense mutation in PALLD has been identified as a risk factor. Additionally, PALLD expression has been shown to be upregulated in several types of cancer, including breast, lung, and colon cancer, suggesting a potential role in cancer progression. In cardiovascular disease, PALLD has been linked to the development of atherosclerosis and myocardial infarction. 

Targeted drug discovery efforts for PALLD are still in the early stages, but there is potential for the development of drugs that target the protein's role in cancer and cardiovascular disease. One approach is to target the interaction between palladin and other proteins involved in cancer progression, such as integrins and focal adhesion kinase. Another approach is to target the regulation of PALLD expression, such as through the use of microRNAs. 

Currently, there are no drugs on the market that specifically target PALLD. However, there are drugs that target the actin cytoskeleton, which is regulated by palladin. For example, cytochalasin D and latrunculin A are drugs that disrupt actin polymerization and have been used in cancer research. Additionally, drugs that target integrins and focal adhesion kinase, which interact with palladin, are currently in clinical trials for cancer treatment.",GO:0003334 keratinocyte development;GO:0070593 dendrite self-avoidance;GO:0003382 epithelial cell morphogenesis,,Disease related genes; Human disease related genes:Cancers:Cancers of the digestive system; Predicted intracellular proteins,Actin filaments (Supported); Additional: Cytosol;Mitochondria;Plasma membrane,,,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000144560.15,ENSG00000144560,VGLL4,-1.162352308,-1.917385623,-1.385865206,-0.183806094,vestigial like family member 4,"VGLL4, or vestigial like family member 4, is a gene that is predicted to enable transcription coactivator binding activity and is involved in negative regulation of various signaling pathways, including Wnt and hippo signaling. It is also involved in negative regulation of cell growth. VGLL4 is predicted to be located in the nucleus.","Research on VGLL4 is still in its early stages, and there is limited information available on its disease implications and targeted drug discovery efforts. However, some studies have suggested that VGLL4 may play a role in cancer development and progression. For example, VGLL4 has been found to be downregulated in various types of cancer, including breast, lung, and liver cancer. Additionally, VGLL4 has been shown to inhibit the growth and metastasis of cancer cells in vitro and in vivo.

Despite the limited information on VGLL4, there have been some successful drugs on the market that target related pathways. For example, drugs that target the Wnt signaling pathway, such as the monoclonal antibody drug denosumab, have been approved for the treatment of bone-related diseases such as osteoporosis and bone metastases. Additionally, drugs that target the hippo signaling pathway, such as the kinase inhibitor verteporfin, have shown promise in preclinical studies for the treatment of various types of cancer. However, more research is needed to determine the potential of targeting VGLL4 for therapeutic purposes.",GO:0060044 negative regulation of cardiac muscle cell proliferation;GO:0035331 negative regulation of hippo signaling;GO:0055022 negative regulation of cardiac muscle tissue growth,,Predicted intracellular proteins,Nucleoli fibrillar center (Approved); Additional: Nucleoplasm,,,
ENSG00000137076.21,ENSG00000137076,TLN1,-1.162324011,-1.918820485,-1.14039893,-0.427752617,talin 1,"TLN1, also known as talin 1, is a gene that encodes a cytoskeletal protein that is involved in the assembly of actin filaments and in the spreading and migration of various cell types. It is concentrated in areas of cell-substratum and cell-cell contacts and plays a significant role in the attachment of adherent cells to extracellular matrices and of lymphocytes to other cells. TLN1 codistributes with integrins in the cell surface membrane and contains elements for localization to cell-extracellular matrix junctions. The C-terminus of TLN1 contains binding sites for proteins such as beta-1-integrin, actin, and vinculin.","Mutations in the TLN1 gene have been associated with several diseases, including dilated cardiomyopathy, a condition characterized by the enlargement of the heart chambers and reduced cardiac function. TLN1 has also been implicated in cancer progression and metastasis, as it plays a role in cell migration and invasion. Targeted drug discovery efforts have focused on developing inhibitors of TLN1 to prevent cancer cell migration and invasion. One example is the small molecule inhibitor, Cpd22, which has been shown to inhibit TLN1-mediated cell adhesion and migration in vitro. Another example is the peptide inhibitor, Talabostat, which has been shown to inhibit TLN1-mediated cell migration and invasion in preclinical models of cancer. However, there are currently no TLN1-targeted drugs on the market.",GO:0043622 cortical microtubule organization;GO:0033622 integrin activation;GO:0030866 cortical actin cytoskeleton organization,,Predicted intracellular proteins,Cytosol;Focal adhesion sites (Supported); Additional: Centriolar satellite;Plasma membrane,,(M72)PID NECTIN PATHWAY; (M277)PID INTEGRIN A4B1 PATHWAY; (M127)PID ERBB1 RECEPTOR PROXIMAL PATHWAY,
ENSG00000119917.14,ENSG00000119917,IFIT3,-1.162127527,-2.130237774,-0.90779846,-0.448346348,interferon induced protein with tetratricopeptide repeats 3,"IFIT3 is a human gene that encodes for a protein called interferon induced protein with tetratricopeptide repeats 3. This protein is involved in various cellular processes such as negative regulation of apoptotic process, negative regulation of cell population proliferation, and response to virus. It is located in both the cytosol and mitochondrion of cells. IFIT3 enables identical protein binding activity, which means it can bind to other proteins with the same sequence. This gene is important for the immune response to viral infections and may have potential therapeutic applications in treating viral diseases.","IFIT3 has been implicated in various viral infections, including influenza, hepatitis C, and HIV. Studies have shown that IFIT3 expression is upregulated in response to viral infections, and it plays a crucial role in the host's antiviral defense mechanism. Therefore, targeting IFIT3 could be a potential therapeutic strategy for viral diseases. However, there are currently no drugs on the market that specifically target IFIT3. Some drugs that indirectly affect IFIT3 expression or function, such as interferons and ribavirin, have been used to treat viral infections. Additionally, research is ongoing to identify small molecules that can directly target IFIT3 and modulate its activity, which could lead to the development of novel antiviral drugs.",GO:0140374 antiviral innate immune response;GO:0051607 defense response to virus;GO:0009615 response to virus,,Predicted intracellular proteins,Cytosol;Mitochondria (Supported),,,(M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000011405.13,ENSG00000011405,PIK3C2A,-1.162009905,-1.321322976,-1.229462568,-0.935244172,phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha,"PIK3C2A is a gene that encodes a protein belonging to the phosphoinositide 3-kinase (PI3K) family. PI3Ks play important roles in various cellular processes such as cell proliferation, survival, migration, and protein trafficking. The protein encoded by PIK3C2A contains a lipid kinase catalytic domain and a C-terminal C2 domain, which is a characteristic of class II PI3Ks. C2 domains act as calcium-dependent phospholipid binding motifs that mediate protein translocation to membranes and protein-protein interactions. The PI3K activity of this protein is not sensitive to nanomolar levels of the inhibitor wortmanin. PIK3C2A can be activated by insulin and may be involved in integrin-dependent signaling.","PIK3C2A has been implicated in various diseases, including cancer, diabetes, and neurodegenerative disorders. In cancer, PIK3C2A has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. Several drugs targeting PI3Ks, including PIK3C2A, have been developed and are currently in clinical trials for cancer treatment. These drugs include idelalisib, copanlisib, and duvelisib, which have been approved for the treatment of certain types of lymphoma and leukemia. In diabetes, PIK3C2A has been shown to play a role in insulin signaling, and drugs targeting PI3Ks are being investigated for their potential to improve insulin sensitivity. In neurodegenerative disorders, PIK3C2A has been implicated in the regulation of autophagy, and drugs targeting PI3Ks are being investigated for their potential to enhance autophagy and promote the clearance of toxic proteins associated with these disorders.",GO:0014829 vascular associated smooth muscle contraction;GO:0048268 clathrin coat assembly;GO:0036092 phosphatidylinositol-3-phosphate biosynthetic process,yes,Predicted intracellular proteins; Kinases:Atypical kinases; ENZYME proteins:Transferases; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Enzymes,Nucleoplasm;Vesicles (Supported); Additional: Cytosol,,(M160)PID AVB3 INTEGRIN PATHWAY,
ENSG00000171988.19,ENSG00000171988,JMJD1C,-1.161979872,-1.469909664,-1.362153967,-0.653875985,jumonji domain containing 1C,JMJD1C is a human gene that encodes a protein containing a jumonji domain and interacts with thyroid hormone receptors. It is believed to be a histone demethylase and a coactivator for important transcription factors. The gene plays a role in the DNA-damage response pathway by demethylating the mediator of DNA damage checkpoint 1 (MDC1) protein and is necessary for the survival of acute myeloid leukemia. Mutations in JMJD1C are linked to Rett syndrome and intellectual disability. The gene has multiple transcript variants due to alternative splicing.,"JMJD1C has been implicated in several diseases, including Rett syndrome and intellectual disability. Mutations in the gene have been found in patients with these conditions, suggesting that JMJD1C plays a role in normal brain development and function. Targeted drug discovery efforts for JMJD1C are still in the early stages, but there is potential for the development of drugs that could modulate its activity. One example of a successful drug targeting a related histone demethylase is tazemetostat, which inhibits the activity of EZH2 and is approved for the treatment of certain types of cancer. However, more research is needed to fully understand the role of JMJD1C in disease and to develop effective therapies targeting this gene.",GO:0007596 blood coagulation;GO:0050817 coagulation;GO:0007599 hemostasis,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000135678.12,ENSG00000135678,CPM,-1.160997509,-1.707276348,-0.702756659,-1.072959522,carboxypeptidase M,"CPM is a gene that encodes for a membrane-bound carboxypeptidase, which is involved in the differentiation of monocytes into macrophages. The protein contains hydrophobic regions at both ends and has six potential glycosylation sites. The active site residues of carboxypeptidases A and B are also present in this protein. Three different versions of the transcript have been identified, but they all encode the same protein.","CPM has been implicated in various diseases, including cancer, inflammation, and cardiovascular diseases. In cancer, CPM has been shown to be overexpressed in several types of tumors, including breast, lung, and ovarian cancers. Targeting CPM has been explored as a potential therapeutic strategy for cancer treatment. Inflammation is also associated with CPM, as it is involved in the differentiation of monocytes into macrophages, which play a crucial role in the inflammatory response. In cardiovascular diseases, CPM has been linked to atherosclerosis and hypertension. Several drugs targeting CPM have been developed, including the carboxypeptidase inhibitor DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid (MGTA), which has been shown to reduce tumor growth in animal models. Another drug, cariporide, which inhibits both CPM and the sodium-hydrogen exchanger, has been used to treat myocardial ischemia.",GO:0006518 peptide metabolic process;GO:0016485 protein processing;GO:0051604 protein maturation,,Peptidases:Metallopeptidases; ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Vesicles (Uncertain),,,(M5921)HALLMARK COMPLEMENT
ENSG00000115816.15,ENSG00000115816,CEBPZ,-1.160810275,-1.11138949,-1.69339491,-0.677646427,CCAAT enhancer binding protein zeta,"CEBPZ, also known as CCAAT enhancer binding protein zeta, is a gene that belongs to the CBF/Mak21 family. This gene plays a role in the cellular response to environmental stimuli through a transcriptional process that involves heat shock factors, conserved DNA elements (heat shock elements or HSEs), and CCAAT boxes. The protein encoded by this gene acts as a DNA-binding transcriptional activator and regulates the heat-shock protein 70 (HSP70) promoter in a CCAAT-dependent manner. Additionally, CEBPZ is involved in cell growth and differentiation, particularly hematopoietic differentiation.","There is limited information available on the disease implications of CEBPZ. However, recent studies have suggested that this gene may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for CEBPZ are still in the early stages, but there is potential for this gene to be targeted in cancer therapy. One example of a successful drug on the market that targets a related gene is imatinib, which targets the BCR-ABL fusion protein in chronic myeloid leukemia. However, more research is needed to determine the potential for CEBPZ as a therapeutic target and to develop effective drugs that target this gene.",GO:0045944 positive regulation of transcription by RNA polymerase II;GO:0045893 positive regulation of DNA-templated transcription;GO:1902680 positive regulation of RNA biosynthetic process,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Vesicles,,(M145)PID P53 DOWNSTREAM PATHWAY,
ENSG00000142875.19,ENSG00000142875,PRKACB,-1.158477023,-1.74708635,-0.990881932,-0.737462788,protein kinase cAMP-activated catalytic subunit beta,"PRKACB is a gene that encodes a catalytic subunit of cAMP-dependent protein kinase, which is involved in signaling through cAMP. This protein kinase family member plays a role in cell proliferation and differentiation. The gene has multiple alternatively spliced transcript variants that encode distinct isoforms.","There is limited information on the disease implications of PRKACB, but some studies have suggested its involvement in various cancers, including breast, ovarian, and prostate cancer. Targeted drug discovery efforts have focused on developing inhibitors of cAMP-dependent protein kinase as potential cancer therapeutics. One example is the drug H89, which has been shown to inhibit PRKACB and has been used in preclinical studies for cancer treatment. Another example is the drug Roflumilast, which targets the related protein kinase PDE4 and is used to treat chronic obstructive pulmonary disease (COPD). While there are currently no drugs on the market specifically targeting PRKACB, ongoing research may lead to the development of novel therapeutics for cancer and other diseases.",GO:0034380 high-density lipoprotein particle assembly;GO:0003091 renal water homeostasis;GO:0034377 plasma lipoprotein particle assembly,yes,Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Kinases:AGC Ser/Thr protein kinases; Enzymes; RAS pathway related proteins,Cytosol (Supported); Additional: Basal body;Cytokinetic bridge;Microtubules;Primary cilium,Phosphonothreonine; Fostamatinib,(M182)PID IL3 PATHWAY; (M277)PID INTEGRIN A4B1 PATHWAY; (M22)PID GMCSF PATHWAY,
ENSG00000165801.10,ENSG00000165801,ARHGEF40,-1.15828951,-2.220466885,-0.807350668,-0.447050978,Rho guanine nucleotide exchange factor 40,ARHGEF40 is a human gene that encodes a protein similar to guanosine nucleotide exchange factors for Rho GTPases. The protein contains a GEF domain involved in exchange activity and a pleckstrin homology domain in its C-terminus. The gene has alternatively spliced transcripts that encode different proteins.,"There is limited information available on the disease implications of ARHGEF40. However, recent studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, including breast and ovarian cancer. Targeted drug discovery efforts for ARHGEF40 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target ARHGEF40, there are several drugs that target Rho GTPases, which are activated by ARHGEF40. Examples of successful drugs in this class include statins, which are commonly used to treat high cholesterol, and bisphosphonates, which are used to treat osteoporosis. These drugs have been shown to have anti-cancer properties and may be effective in treating certain types of cancer that are associated with ARHGEF40 mutations.",GO:0007411 axon guidance;GO:0097485 neuron projection guidance;GO:0051056 regulation of small GTPase mediated signal transduction,,Predicted intracellular proteins,Cytosol;Plasma membrane (Approved),,,
ENSG00000143641.10,ENSG00000143641,GALNT2,-1.157910672,-1.69803326,-0.831513761,-0.944184993,polypeptide N-acetylgalactosaminyltransferase 2,GALNT2 is a gene that belongs to the glycosyltransferase 2 protein family and is involved in initiating mucin-type O-glycosylation of peptides in the Golgi apparatus. The protein encoded by this gene may play a role in O-linked glycosylation of the immunoglobulin A1 hinge region. GALNT2 has been linked to triglyceride levels and may be involved in the development of Type 2 diabetes and various types of cancer. Alternative splicing of this gene results in multiple transcript variants.,"GALNT2 has been implicated in various diseases, including Type 2 diabetes and cancer. Studies have shown that GALNT2 expression is significantly decreased in pancreatic islets of patients with Type 2 diabetes, suggesting a potential role in the development of the disease. In cancer, GALNT2 has been found to be downregulated in several types of tumors, including breast, ovarian, and gastric cancer, and its expression has been associated with better patient survival. 

Targeted drug discovery efforts for GALNT2 are still in the early stages, but there is potential for the development of drugs that modulate its activity. One approach is to target the enzymes involved in the O-glycosylation pathway, including GALNT2, to inhibit the glycosylation of cancer-associated proteins and prevent tumor growth. Another approach is to develop drugs that increase GALNT2 expression, which could potentially be used to treat Type 2 diabetes.

Currently, there are no drugs on the market that specifically target GALNT2. However, there are drugs that target other enzymes involved in the O-glycosylation pathway, such as the fucosyltransferase inhibitor, 2-fluorofucose, which has shown promise in preclinical studies for the treatment of cancer. Additionally, there are drugs that target other aspects of Type 2 diabetes, such as metformin, which improves insulin sensitivity and reduces glucose production in the liver.",GO:0018242 protein O-linked glycosylation via serine;GO:0018243 protein O-linked glycosylation via threonine;GO:0016266 O-glycan processing,,Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism,Golgi apparatus (Supported),,,
ENSG00000102572.15,ENSG00000102572,STK24,-1.155702507,-1.488510777,-1.513093738,-0.465503005,serine/threonine kinase 24,"STK24 is a gene that encodes a serine/threonine protein kinase that plays a role in the regulation of mitogen-activated protein kinase (MAPK) signaling. The protein is cleaved into two chains by caspases, with the N-terminal fragment translocating to the nucleus and promoting programmed cell death. The gene has a pseudogene on chromosome X and alternative splicing results in multiple transcript variants.","Research on STK24 has suggested its involvement in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, STK24 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. In neurodegenerative disorders, STK24 has been linked to the death of neurons, and targeting it may help prevent or slow down the progression of these diseases. In cardiovascular diseases, STK24 has been implicated in the regulation of blood pressure and cardiac hypertrophy.

Several drug discovery efforts have been made to target STK24, with some promising results. For example, a study found that a small molecule inhibitor of STK24 was able to reduce the growth and metastasis of breast cancer cells in mice. Another study found that inhibiting STK24 could protect neurons from death in a mouse model of Parkinson's disease.

Currently, there are no drugs on the market that specifically target STK24. However, there are drugs that indirectly affect STK24 signaling pathways. For example, some drugs used to treat hypertension, such as angiotensin receptor blockers, have been shown to inhibit STK24 and reduce cardiac hypertrophy. Additionally, some cancer drugs, such as sorafenib, have been shown to indirectly inhibit STK24 signaling and reduce tumor growth.",GO:0048680 positive regulation of axon regeneration;GO:0070572 positive regulation of neuron projection regeneration;GO:0008631 intrinsic apoptotic signaling pathway in response to oxidative stress,yes,Enzymes; Kinases:STE Ser/Thr protein kinases; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Nucleoli (Supported),Fostamatinib,,
ENSG00000167548.16,ENSG00000167548,KMT2D,-1.155501548,-1.494263834,-0.947449842,-1.024790968,lysine methyltransferase 2D,"KMT2D is a human gene that encodes a histone methyltransferase, which adds a methyl group to the Lys-4 position of histone H3. This gene is part of a protein complex called ASCOM, which regulates the expression of certain genes, including beta-globin and estrogen receptor genes. Mutations in KMT2D have been linked to Kabuki syndrome, a rare genetic disorder characterized by developmental delays, intellectual disability, and distinct facial features.","Kabuki syndrome is a rare genetic disorder caused by mutations in the KMT2D gene. The disorder is characterized by developmental delays, intellectual disability, and distinct facial features. There is currently no cure for Kabuki syndrome, and treatment is focused on managing symptoms. However, targeted drug discovery efforts are underway to develop therapies that can address the underlying genetic cause of the disorder. One approach is to develop drugs that can restore the function of the KMT2D protein or compensate for its loss. Another approach is to target downstream pathways that are affected by KMT2D mutations. While there are currently no drugs on the market specifically for Kabuki syndrome, there are drugs that have been approved for other conditions that may be effective in treating some of the symptoms of the disorder. For example, antipsychotic medications may be used to treat behavioral problems, and physical therapy may be used to improve motor function.",GO:1904837 beta-catenin-TCF complex assembly;GO:0001555 oocyte growth;GO:0033148 positive regulation of intracellular estrogen receptor signaling pathway,,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Cytosol (Approved); Additional: Nucleoplasm;Plasma membrane,,,(M5956)HALLMARK KRAS SIGNALING DN
ENSG00000169047.5,ENSG00000169047,IRS1,-1.155119097,-1.991035552,-0.928868651,-0.545453087,insulin receptor substrate 1,The IRS1 gene encodes a protein that is phosphorylated by insulin receptor tyrosine kinase. Mutations in this gene have been linked to type II diabetes and increased susceptibility to insulin resistance.,"The IRS1 gene has been extensively studied in the context of type II diabetes and insulin resistance. Mutations in this gene have been associated with increased risk of developing these conditions. As a result, there has been significant interest in developing drugs that target the IRS1 protein to improve insulin sensitivity and glucose metabolism. One approach has been to develop small molecule inhibitors of the protein, which could potentially be used to treat insulin resistance and type II diabetes. Another approach has been to develop drugs that enhance the activity of the IRS1 protein, such as insulin sensitizers. Examples of successful drugs on the market that target this pathway include metformin, which enhances insulin sensitivity by activating the AMP-activated protein kinase (AMPK) pathway, and thiazolidinediones (TZDs), which activate the peroxisome proliferator-activated receptor gamma (PPAR?) pathway to improve insulin sensitivity.",GO:0032000 positive regulation of fatty acid beta-oxidation;GO:0046321 positive regulation of fatty acid oxidation;GO:0045725 positive regulation of glycogen biosynthetic process,,Disease related genes; Predicted intracellular proteins,Cytosol;Nucleoplasm (Approved); Additional: Plasma membrane;Vesicles,[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID,(M268)PID S1P S1P2 PATHWAY; (M1718)SIG IL4RECEPTOR IN B LYPHOCYTES; (M125)PID IGF1 PATHWAY,(M5942)HALLMARK UV RESPONSE DN; (M5915)HALLMARK APICAL JUNCTION
ENSG00000095564.14,ENSG00000095564,BTAF1,-1.15198109,-1.305594689,-1.160890354,-0.989458225,B-TFIID TATA-box binding protein associated factor 1,"BTAF1 is a gene that encodes a TAF protein, which is a component of the B-TFIID complex that is necessary for the initiation of gene transcription by RNA polymerase II. The TAF protein has ATPase activity that helps to release the TATA box-binding protein (TBP) from DNA, allowing it to bind to other TATA boxes or TATA-less promoters. This gene is important for regulating gene expression and mutations in BTAF1 have been associated with various diseases, including cancer and developmental disorders.","Mutations in the BTAF1 gene have been associated with various diseases, including cancer and developmental disorders. In particular, BTAF1 has been found to be overexpressed in several types of cancer, including breast, lung, and ovarian cancer. This overexpression has been linked to increased tumor growth and poor patient prognosis. As a result, there has been interest in developing drugs that target BTAF1 as a potential cancer therapy.

Several drug discovery efforts have focused on targeting BTAF1. One approach has been to develop small molecule inhibitors that can block the ATPase activity of the TAF protein. Another approach has been to develop RNA interference (RNAi) therapies that can specifically target and silence the BTAF1 gene. While there are currently no drugs on the market that specifically target BTAF1, there are several drugs that have been approved for the treatment of cancer that indirectly affect BTAF1 activity. For example, the chemotherapy drug cisplatin has been shown to downregulate BTAF1 expression in cancer cells, leading to decreased tumor growth.",GO:0035562 negative regulation of chromatin binding;GO:0035561 regulation of chromatin binding;GO:0051100 negative regulation of binding,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Vesicles,,,
ENSG00000148400.12,ENSG00000148400,NOTCH1,-1.148226956,-1.377674113,-0.924171043,-1.142835713,notch receptor 1,"NOTCH1 is a gene that encodes a protein belonging to the NOTCH family of proteins. This family of proteins is characterized by a transmembrane structure consisting of an extracellular domain with multiple epidermal growth factor-like (EGF) repeats and an intracellular domain with multiple different domain types. NOTCH1 is involved in the Notch signaling pathway, which regulates interactions between physically adjacent cells through binding of Notch family receptors to their cognate ligands. The encoded protein is proteolytically processed to form the mature cell-surface receptor and plays a role in the development of numerous cell and tissue types. Mutations in NOTCH1 are associated with various diseases, including aortic valve disease, Adams-Oliver syndrome, T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and head and neck squamous cell carcinoma.","NOTCH1 mutations have been implicated in a variety of diseases, including aortic valve disease, Adams-Oliver syndrome, T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and head and neck squamous cell carcinoma. Targeted drug discovery efforts have focused on developing inhibitors of the Notch signaling pathway, with the goal of treating these diseases. Several drugs targeting NOTCH1 are currently in clinical trials, including gamma-secretase inhibitors and monoclonal antibodies. One example of a successful drug targeting NOTCH1 is Venetoclax, which is approved for the treatment of chronic lymphocytic leukemia and targets the BCL-2 protein, a downstream target of the Notch signaling pathway. Another example is Tarextumab, which is in clinical trials for the treatment of small cell lung cancer and targets the Notch ligand DLL3.",GO:0003178 coronary sinus valve development;GO:0003182 coronary sinus valve morphogenesis;GO:0003270 Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation,,Human disease related genes:Congenital malformations:Congenital malformations of the circulatory system; Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Transporters; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Human disease related genes:Cancers:Cancers of the breast and female genital organs; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Approved),,(M70)PID PS1 PATHWAY; (M236)PID DELTA NP63 PATHWAY; (M288)PID HES HEY PATHWAY,(M5903)HALLMARK NOTCH SIGNALING; (M5895)HALLMARK WNT BETA CATENIN SIGNALING; (M5909)HALLMARK MYOGENESIS
ENSG00000107798.18,ENSG00000107798,LIPA,-1.14811893,-1.755291627,-1.114083199,-0.574981965,"lipase A, lysosomal acid type","LIPA is a gene that encodes for lipase A, also known as lysosomal acid lipase. This enzyme is responsible for breaking down cholesteryl esters and triglycerides in the lysosome. Mutations in LIPA can lead to two diseases: Wolman disease and cholesteryl ester storage disease. Wolman disease is a rare genetic disorder that affects infants and causes the accumulation of lipids in various organs, leading to organ failure and death within the first year of life. Cholesteryl ester storage disease is a milder form of the disease that can present in childhood or adulthood and can cause liver and spleen enlargement, as well as other symptoms. There are different variants of LIPA due to alternative splicing.","LIPA mutations have been the target of drug discovery efforts for the treatment of Wolman disease and cholesteryl ester storage disease. One approach has been the use of enzyme replacement therapy, where a functional version of the lysosomal acid lipase enzyme is administered to patients. This approach has been successful in treating Wolman disease with the drug sebelipase alfa, which was approved by the FDA in 2015. Another approach has been the use of small molecule inhibitors to increase the activity of the remaining functional lysosomal acid lipase enzyme in patients with cholesteryl ester storage disease. Miglustat, an inhibitor of glucosylceramide synthase, has been shown to improve liver function and reduce spleen size in patients with cholesteryl ester storage disease. Other small molecule inhibitors, such as olipudase alfa and venglustat, are currently in clinical trials for the treatment of lysosomal storage disorders, including Wolman disease and cholesteryl ester storage disease.",GO:0002536 respiratory burst involved in inflammatory response;GO:0030421 defecation;GO:0071838 cell proliferation in bone marrow,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Predicted intracellular proteins; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Lysosomal storage diseases; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Cytosol;Vesicles (Supported); Additional: Nucleoli fibrillar center;Nucleoplasm,,,(M5921)HALLMARK COMPLEMENT
ENSG00000177464.5,ENSG00000177464,GPR4,-1.146503317,-1.256407885,-0.718308805,-1.464793261,G protein-coupled receptor 4,"GPR4, also known as G protein-coupled receptor 4, is a human gene that encodes a protein involved in G protein-coupled receptor activity. It plays a role in several processes, including G protein-coupled receptor signaling pathway, positive regulation of Rho protein signal transduction, and response to acidic pH. The protein is located in the plasma membrane.","Research on GPR4 has suggested its potential involvement in several diseases, including cancer, inflammation, and cardiovascular diseases. In particular, GPR4 has been implicated in the progression of breast cancer and melanoma, making it a potential target for cancer therapy. Additionally, GPR4 has been linked to pulmonary arterial hypertension, a condition characterized by high blood pressure in the lungs, and may be a target for drug development in this area.

Several drug discovery efforts have focused on targeting GPR4, with the goal of developing drugs that can modulate its activity. One approach has been to develop small molecule inhibitors that can block GPR4 signaling, potentially slowing or halting disease progression. Another approach has been to develop agonists that can activate GPR4, potentially leading to therapeutic benefits in certain conditions.

One example of a successful drug targeting GPR4 is cangrelor, a small molecule inhibitor that is used as an antiplatelet agent in patients undergoing percutaneous coronary intervention (PCI). Cangrelor works by inhibiting the P2Y12 receptor, which is activated by ADP and plays a role in platelet aggregation. GPR4 has been shown to modulate P2Y12 receptor activity, and cangrelor's effects may be partially mediated by its inhibition of GPR4 signaling.

Overall, while much remains to be learned about GPR4 and its potential as a therapeutic target, research in this area holds promise for the development of new treatments for a range of diseases.",GO:0072144 glomerular mesangial cell development;GO:0072008 glomerular mesangial cell differentiation;GO:0072143 mesangial cell development,,G-protein coupled receptors:GPCRs excl olfactory receptors,,,,
ENSG00000183853.18,ENSG00000183853,KIRREL1,-1.145361347,-1.995602889,-1.298076616,-0.142404536,kirre like nephrin family adhesion molecule 1,"KIRREL1 is a human gene that belongs to the kirre-like nephrin family adhesion molecule 1. This gene is involved in the formation of cell-cell junctions in the kidney podocytes, which are responsible for filtering blood in the kidneys. KIRREL1 interacts with the C terminus of podocin, a protein that is also involved in podocyte function. The nephrin-like protein family includes NEPH1, NEPH2, and NEPH3, which are all expressed in kidney podocytes. KIRREL1 is important for maintaining the integrity of the kidney filtration barrier, and mutations in this gene have been associated with kidney disease.","Mutations in the KIRREL1 gene have been associated with several kidney diseases, including focal segmental glomerulosclerosis (FSGS) and nephrotic syndrome. FSGS is a condition where the kidney's filtering units are damaged, leading to proteinuria (excessive protein in the urine) and eventually kidney failure. Nephrotic syndrome is a group of symptoms that occur when the kidneys are damaged, leading to proteinuria, edema (swelling), and high cholesterol levels in the blood. 

There are currently no targeted drug discovery efforts specifically for KIRREL1, but there are several drugs on the market that are used to treat kidney diseases associated with KIRREL1 mutations. These include angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), which are used to lower blood pressure and reduce proteinuria. Immunosuppressive drugs, such as corticosteroids and cyclosporine, are also used to treat kidney diseases associated with KIRREL1 mutations. 

One example of a successful drug on the market for treating kidney disease is lisinopril, an ACE inhibitor that is used to treat high blood pressure and reduce proteinuria in patients with kidney disease. Another example is cyclosporine, an immunosuppressive drug that is used to treat FSGS and other kidney diseases. While these drugs can be effective in treating kidney diseases associated with KIRREL1 mutations, they do not target the underlying genetic cause of the disease.",GO:0097017 renal protein absorption;GO:0045217 cell-cell junction maintenance;GO:0003094 glomerular filtration,,Disease related genes; Human disease related genes:Urinary system diseases:Kidney diseases,,,(M193)PID NEPHRIN NEPH1 PATHWAY,
ENSG00000114127.11,ENSG00000114127,XRN1,-1.141802848,-1.614881948,-1.046669053,-0.763857542,5'-3' exoribonuclease 1,"XRN1 is a gene that belongs to the 5'-3' exonuclease family and is involved in the degradation of replication-dependent histone mRNA. It interacts with the enhancer of mRNA-decapping protein 4 and has been linked to various nuclear and cytoplasmic functions in yeast, including homologous recombination, meiosis, telomere maintenance, and microtubule assembly. Mutations in this gene have been associated with osteosarcoma, indicating its potential role in bone formation. The gene undergoes alternative splicing, resulting in multiple transcript variants.","Mutations in the XRN1 gene have been associated with various diseases, including osteosarcoma, a type of bone cancer. Targeted drug discovery efforts for XRN1 have focused on developing inhibitors that can selectively target the enzyme's activity. One example is the drug E7107, which has been shown to inhibit XRN1 and has demonstrated anti-tumor activity in preclinical studies. Another potential drug target is the interaction between XRN1 and the enhancer of mRNA-decapping protein 4, which has been shown to be important for the degradation of certain mRNAs. However, there are currently no drugs on the market that specifically target XRN1. Further research is needed to fully understand the role of XRN1 in disease and to develop effective therapies.",GO:1905794 response to puromycin;GO:1905795 cellular response to puromycin;GO:0071409 cellular response to cycloheximide,,Predicted intracellular proteins,Cytosol;Plasma membrane (Supported),,,
ENSG00000072201.14,ENSG00000072201,LNX1,-1.139896221,-1.13728179,-0.856173808,-1.426233066,ligand of numb-protein X 1,"LNX1 is a gene that encodes a membrane-bound protein involved in signal transduction and protein interactions. The protein is an E3 ubiquitin-protein ligase, which mediates ubiquitination and subsequent proteasomal degradation of proteins containing phosphotyrosine binding (PTB) domains. LNX1 may play a role in tumorogenesis. The gene has alternatively spliced transcript variants encoding distinct isoforms, and a pseudogene has been identified on chromosome 17.","There is limited information available on the disease implications of LNX1. However, some studies have suggested that LNX1 may play a role in tumorogenesis, particularly in breast cancer. Targeted drug discovery efforts for LNX1 are also limited, as the function of the protein is not well understood. Currently, there are no drugs on the market that specifically target LNX1. However, there are drugs that target the ubiquitin-proteasome system, which is the pathway that LNX1 is involved in. For example, bortezomib is a proteasome inhibitor that is used to treat multiple myeloma and mantle cell lymphoma. Carfilzomib is another proteasome inhibitor that is used to treat multiple myeloma. These drugs have shown success in clinical trials and are currently approved for use in patients.",GO:0060074 synapse maturation;GO:0021700 developmental maturation;GO:0050808 synapse organization,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cell Junctions (Supported); Additional: Cytosol,,(M17)PID NOTCH PATHWAY,
ENSG00000168497.5,ENSG00000168497,CAVIN2,-1.137993922,-1.824422291,-1.184409703,-0.405149771,caveolae associated protein 2,"CAVIN2, also known as caveolae associated protein 2, is a phospholipid-binding protein that is involved in the formation and maintenance of caveolae, small invaginations in the plasma membrane that play a role in cellular signaling and transport. The expression of CAVIN2 increases in cells that are serum-starved, and it is a substrate for phosphorylation by protein kinase C (PKC). CAVIN2 recruits polymerase I and transcript release factor (PTRF) to caveolae, and its removal results in loss of caveolae, while over-expression leads to deformation and membrane tubulation. CAVIN2 is important for the proper functioning of caveolae and may have implications in various cellular processes.","There is limited information available on the disease implications of CAVIN2. However, recent studies have suggested that CAVIN2 may play a role in the development and progression of certain cancers, including breast cancer and lung cancer. Targeted drug discovery efforts for CAVIN2 are currently underway, with a focus on identifying small molecule inhibitors that can disrupt the interaction between CAVIN2 and PTRF, potentially leading to the development of novel cancer therapies. Currently, there are no drugs on the market that specifically target CAVIN2. However, there are several drugs that target caveolae and related pathways, including statins, which are commonly used to lower cholesterol levels and have been shown to have anti-cancer properties, and nintedanib, which is used to treat idiopathic pulmonary fibrosis and targets multiple signaling pathways, including those involved in caveolae formation.",GO:0097320 plasma membrane tubulation;GO:0007009 plasma membrane organization;GO:0010256 endomembrane system organization,,Predicted intracellular proteins,Plasma membrane (Enhanced); Additional: Cytosol,,,(M5905)HALLMARK ADIPOGENESIS
ENSG00000114796.16,ENSG00000114796,KLHL24,-1.137858835,-1.825362855,-1.147057304,-0.441156348,kelch like family member 24,"KLHL24 is a gene that encodes a protein that acts as a substrate receptor for ubiquitin ligase and is regulated by autoubiquitination. Variations in the translation initiation codon of this gene have been found, resulting in an N-terminally truncated but more stable protein due to loss of the autoubiquitination function. The more stable mutant protein causes an increased ubiquitin and degradation of keratin 14, leading to skin fragility and the potentially life-threatening disease epidermolysis bullosa. The encoded protein is also involved in the regulation of kainate receptors.","Epidermolysis bullosa (EB) is a rare genetic disorder characterized by skin fragility and blistering. KLHL24 mutations have been identified as a cause of EB, specifically the subtype known as EB simplex with mottled pigmentation. Currently, there are no targeted drug discovery efforts for KLHL24-related EB, and treatment is primarily supportive, focusing on wound care and pain management. However, there have been successful drug developments for other subtypes of EB, such as EB simplex caused by mutations in the KRT5 and KRT14 genes. These drugs include topical agents such as gentamicin and retinoids, as well as systemic therapies such as bone marrow transplantation and gene therapy. While there are no specific drugs targeting KLHL24-related EB, the success of these treatments for other subtypes of EB provides hope for future developments in the field.",GO:0051865 protein autoubiquitination;GO:0045109 intermediate filament organization;GO:0045104 intermediate filament cytoskeleton organization,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of skin; Predicted intracellular proteins,,,,(M5891)HALLMARK HYPOXIA
ENSG00000169826.8,ENSG00000169826,CSGALNACT2,-1.137833951,-1.232241518,-1.060867951,-1.120392383,chondroitin sulfate N-acetylgalactosaminyltransferase 2,The CSGALNACT2 gene belongs to the chondroitin N-acetylgalactosaminyltransferase family and is involved in the elongation process during chondroitin sulfate synthesis. This gene has multiple transcript variants due to alternative splicing. Two pseudogenes related to this gene have been identified on chromosome X.,"There is limited information available on the disease implications of CSGALNACT2. However, recent studies have suggested that alterations in chondroitin sulfate synthesis, including changes in the expression of CSGALNACT2, may play a role in the pathogenesis of certain diseases, such as cancer and neurodegenerative disorders. Targeted drug discovery efforts for CSGALNACT2 are currently underway, with a focus on identifying small molecule inhibitors that can modulate chondroitin sulfate synthesis. While there are currently no drugs on the market that specifically target CSGALNACT2, several drugs that target other enzymes involved in chondroitin sulfate synthesis, such as chondroitinase ABC, have shown promise in preclinical and clinical studies for the treatment of spinal cord injury and other neurological disorders.","GO:0050652 dermatan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process;GO:0050653 chondroitin sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process;GO:0050651 dermatan sulfate proteoglycan biosynthetic process",,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Endoplasmic reticulum (Approved),,,
ENSG00000187097.13,ENSG00000187097,ENTPD5,-1.137714521,-0.975851295,-1.63307181,-0.804220458,ectonucleoside triphosphate diphosphohydrolase 5 (inactive),"ENTPD5 is a human gene that encodes a protein similar to E-type nucleotidases/ecto-ATPase/apyrases. This protein contains four apyrase-conserved regions, which are characteristic of NTPases like CD39. NTPases are responsible for breaking down extracellular nucleotides. However, ENTPD5 is considered inactive, meaning it does not have the ability to perform this function.","There is limited information on the disease implications of ENTPD5. However, some studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for ENTPD5 are also limited, as it is not considered a druggable target due to its inactive nature. However, some drugs that target other NTPases like CD39 and CD73 have shown promise in cancer treatment by inhibiting the breakdown of extracellular ATP and promoting an anti-tumor immune response. Examples of successful drugs targeting these NTPases include Apremilast, which targets PDE4 and CD73, and Durvalumab, which targets PD-L1 and CD73. However, further research is needed to determine if targeting ENTPD5 or other NTPases could be a viable therapeutic strategy for cancer treatment.",GO:0006256 UDP catabolic process;GO:0009140 pyrimidine nucleoside diphosphate catabolic process;GO:0009195 pyrimidine ribonucleoside diphosphate catabolic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins; Predicted secreted proteins,,,,(M5934)HALLMARK XENOBIOTIC METABOLISM
ENSG00000157107.14,ENSG00000157107,FCHO2,-1.135206767,-1.352118621,-1.289743128,-0.763758551,FCH and mu domain containing endocytic adaptor 2,"FCHO2, also known as FCH and mu domain containing endocytic adaptor 2, is a human gene that plays a role in clathrin coat assembly and clathrin-dependent endocytosis. It is located in clathrin-coated pits and vesicles and enables identical protein binding activity. This gene is important for the internalization of various molecules, including growth factors, receptors, and nutrients, into cells. Dysfunction of FCHO2 has been linked to various diseases, including cancer and neurodegenerative disorders. Understanding the function of FCHO2 may provide insights into the development of new therapies for these conditions.","Research has shown that FCHO2 dysfunction is associated with various diseases, including cancer and neurodegenerative disorders. In cancer, FCHO2 has been found to be overexpressed in certain types of tumors, such as breast and ovarian cancer, and may play a role in tumor growth and metastasis. In neurodegenerative disorders, FCHO2 has been linked to the formation of protein aggregates, which are a hallmark of diseases such as Alzheimer's and Parkinson's.

Targeted drug discovery efforts for FCHO2 are still in the early stages, but there is potential for the development of drugs that target FCHO2 to treat cancer and neurodegenerative disorders. One approach is to develop small molecule inhibitors that block the function of FCHO2 in clathrin-mediated endocytosis. Another approach is to develop drugs that target the protein aggregates formed by FCHO2 in neurodegenerative disorders.

Currently, there are no drugs on the market that specifically target FCHO2. However, there are drugs that indirectly affect FCHO2 function by targeting clathrin-mediated endocytosis. For example, the drug dynamin inhibitors, such as dynasore, block the final step of clathrin-mediated endocytosis and have been shown to inhibit tumor growth in animal models. Additionally, drugs that target the epidermal growth factor receptor (EGFR), such as cetuximab and erlotinib, inhibit EGFR internalization through clathrin-mediated endocytosis and are used to treat certain types of cancer.",GO:0048268 clathrin coat assembly;GO:0072583 clathrin-dependent endocytosis;GO:0010324 membrane invagination,,Predicted intracellular proteins,Centrosome (Approved); Additional: Cytosol;Vesicles,,,
ENSG00000182022.18,ENSG00000182022,CHST15,-1.13515447,-2.138954817,-0.9149128,-0.351595794,carbohydrate sulfotransferase 15,The CHST15 gene encodes a type II transmembrane glycoprotein that acts as a sulfotransferase to transfer sulfate to the C-6 hydroxal group of chondroitin sulfate. Chondroitin sulfate E (CS-E) is an isomer of chondroitin sulfate in which the C-4 and C-6 hydroxyl groups are sulfated. CS is a glycosaminoglycan which is an important structural component of the extracellular matrix and which links to proteins to form proteoglycans. This gene has also been identified as being co-expressed with RAG1 in B-cells and as potentially acting as a B-cell surface signaling receptor. Alternative splicing results in multiple transcript variants encoding distinct isoforms.,"Research on the CHST15 gene has revealed its potential involvement in various diseases and conditions. For instance, studies have shown that altered expression of CHST15 is associated with the development and progression of several types of cancer, including breast, lung, and pancreatic cancer. Additionally, mutations in CHST15 have been linked to skeletal dysplasia, a group of genetic disorders that affect bone and cartilage development. 

Given its role in the sulfation of chondroitin sulfate, CHST15 has also been explored as a potential target for drug discovery efforts. In particular, inhibition of CHST15 activity could be a promising strategy for treating cancer and other diseases characterized by abnormal chondroitin sulfate sulfation. Several small molecule inhibitors of CHST15 have been developed and tested in preclinical studies, with promising results. 

However, there are currently no drugs targeting CHST15 on the market. Nonetheless, there are several drugs that target other enzymes involved in chondroitin sulfate biosynthesis, such as chondroitinase ABC, which is used to treat spinal cord injury, and chondroitin sulfate mimetics, which are being developed for the treatment of osteoarthritis. Further research on CHST15 and its potential as a therapeutic target may lead to the development of new drugs for a range of diseases.",GO:0030206 chondroitin sulfate biosynthetic process;GO:0050650 chondroitin sulfate proteoglycan biosynthetic process;GO:0030204 chondroitin sulfate metabolic process,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Approved); Additional: Centrosome,,,
ENSG00000122786.20,ENSG00000122786,CALD1,-1.134003676,-1.84733963,-0.963343153,-0.591328244,caldesmon 1,"CALD1, also known as caldesmon 1, is a gene that encodes a protein involved in the regulation of smooth muscle and nonmuscle contraction. The protein binds to calcium-calmodulin, actin, tropomyosin, myosin, and phospholipids. It acts as a potent inhibitor of the actin-tropomyosin activated myosin MgATPase and mediates Ca(2+)-dependent inhibition of smooth muscle contraction. Alternative splicing of this gene results in multiple transcript variants encoding distinct isoforms. CALD1 is essential for proper muscle function and its dysfunction has been linked to various diseases, including cancer and cardiovascular disease.","Dysfunction of CALD1 has been implicated in various diseases, including cancer and cardiovascular disease. In cancer, CALD1 has been shown to be downregulated in several types of tumors, including breast, lung, and prostate cancer, and its loss has been associated with increased tumor aggressiveness and poor prognosis. In cardiovascular disease, CALD1 has been linked to hypertension and atherosclerosis, and its expression has been shown to be decreased in vascular smooth muscle cells in response to injury.

Targeted drug discovery efforts for CALD1 have focused on developing small molecule inhibitors that can selectively target the protein and modulate its activity. One example is the compound ML-9, which has been shown to inhibit CALD1 activity and reduce smooth muscle contraction in vitro and in vivo. Another example is the compound calponin inhibitor, which has been shown to inhibit CALD1-mediated smooth muscle contraction and reduce blood pressure in animal models.

Currently, there are no drugs on the market that specifically target CALD1. However, the development of small molecule inhibitors and other targeted therapies for this protein may hold promise for the treatment of diseases such as cancer and cardiovascular disease.",GO:0051017 actin filament bundle assembly;GO:0061572 actin filament bundle organization;GO:0006936 muscle contraction,,Predicted intracellular proteins,Actin filaments;Plasma membrane (Enhanced),,,(M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000121691.7,ENSG00000121691,CAT,-1.133294982,-1.906100331,-0.983260658,-0.510523957,catalase,"The human gene CAT encodes for the enzyme catalase, which plays a crucial role in the body's defense against oxidative stress. Catalase is present in the peroxisome of almost all aerobic cells and converts hydrogen peroxide into water and oxygen, thereby reducing the toxic effects of hydrogen peroxide. Oxidative stress is believed to contribute to the development of various chronic diseases, including diabetes, asthma, Alzheimer's disease, systemic lupus erythematosus, rheumatoid arthritis, and cancer. While polymorphisms in the CAT gene have been linked to decreased catalase activity, the only known disease caused by this gene is acatalasemia.","As mentioned earlier, the only known disease caused by the CAT gene is acatalasemia, which is a rare autosomal recessive disorder characterized by the absence or very low levels of catalase activity in red blood cells. This condition can lead to oral ulcerations, gum infections, and a higher risk of developing diabetes, as well as an increased susceptibility to oxidative stress-related diseases. However, there are currently no targeted drug discovery efforts for acatalasemia, and treatment is mainly focused on managing symptoms.

Despite the lack of targeted drug discovery efforts for acatalasemia, there are several drugs on the market that have been developed to target oxidative stress-related diseases. For example, N-acetylcysteine (NAC) is a drug that has been used to treat acetaminophen overdose by replenishing glutathione, a key antioxidant in the body. Additionally, several drugs that target oxidative stress-related pathways have been approved for the treatment of cancer, including cisplatin, which induces oxidative stress in cancer cells, and doxorubicin, which generates reactive oxygen species to kill cancer cells. Overall, while there are currently no targeted drugs for acatalasemia, the development of drugs that target oxidative stress-related pathways has shown promise in the treatment of various diseases.",GO:0072722 response to amitrole;GO:0061692 cellular detoxification of hydrogen peroxide;GO:0061691 detoxification of hydrogen peroxide,,Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Peroxisomal diseases; ENZYME proteins:Oxidoreductases; FDA approved drug targets:Small molecule drugs; Disease related genes; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Vesicles (Enhanced),Fomepizole; Cannabidiol; Medical Cannabis; Nabiximols,(M136)PID FOXO PATHWAY,(M5938)HALLMARK REACTIVE OXYGEN SPECIES PATHWAY; (M5949)HALLMARK PEROXISOME; (M5948)HALLMARK BILE ACID METABOLISM
ENSG00000103549.22,ENSG00000103549,RNF40,-1.1328619,-1.922162624,-1.374484656,-0.10193842,ring finger protein 40,"RNF40, or ring finger protein 40, is a gene that encodes a protein containing a RING finger motif, which is involved in protein-protein and protein-DNA interactions. The protein has been shown to interact with the tumor suppressor protein RB1 and may function as an E3 ubiquitin-protein ligase, facilitating the ubiquitination and degradation of syntaxin 1, an essential component of the neurotransmitter release machinery. Multiple isoforms of the protein have been identified through alternative splicing.","Research on RNF40 has suggested its involvement in various diseases, including cancer, neurodegenerative disorders, and immune-related diseases. In cancer, RNF40 has been found to be overexpressed in several types of tumors, including breast, lung, and liver cancer, and its inhibition has been shown to reduce tumor growth in preclinical models. In neurodegenerative disorders, RNF40 has been implicated in the regulation of protein degradation pathways, and its dysregulation has been linked to the accumulation of misfolded proteins, a hallmark of diseases such as Alzheimer's and Parkinson's. In immune-related diseases, RNF40 has been shown to play a role in the regulation of T-cell activation and differentiation.

Targeted drug discovery efforts for RNF40 are still in the early stages, but several small molecule inhibitors have been identified that show promise in preclinical studies. For example, a recent study identified a small molecule inhibitor of RNF40 that was able to reduce tumor growth in a mouse model of breast cancer. Another study found that inhibition of RNF40 could enhance the efficacy of immunotherapy in a mouse model of melanoma.

Currently, there are no drugs on the market that specifically target RNF40, but the promising preclinical data suggests that it could be a viable target for drug development in the future.",GO:0006511 ubiquitin-dependent protein catabolic process;GO:0019941 modification-dependent protein catabolic process;GO:0043632 modification-dependent macromolecule catabolic process,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported),,,
ENSG00000092871.17,ENSG00000092871,RFFL,-1.130712696,-1.164069444,-1.497251993,-0.730816651,ring finger and FYVE like domain containing E3 ubiquitin protein ligase,"RFFL is a human gene that encodes for a protein called ring finger and FYVE like domain containing E3 ubiquitin protein ligase. This protein is involved in various cellular processes such as protein metabolism, negative regulation of apoptosis, and signal transduction. It has the ability to bind to enzymes and p53, and also functions as a ubiquitin protein ligase. RFFL is located in the endosome and plasma membrane.","There is limited information available on the disease implications of RFFL. However, recent studies have suggested that RFFL may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for RFFL are still in the early stages, but there is potential for the development of drugs that target RFFL as a means of treating cancer. Currently, there are no drugs on the market that specifically target RFFL. However, there are drugs that target the ubiquitin-proteasome system, which is the pathway that RFFL is involved in. Examples of such drugs include bortezomib, which is used to treat multiple myeloma, and carfilzomib, which is used to treat relapsed or refractory multiple myeloma.",GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors;GO:0010804 negative regulation of tumor necrosis factor-mediated signaling pathway;GO:1901797 negative regulation of signal transduction by p53 class mediator,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Vesicles (Approved),,(M128)PID TNF PATHWAY,
ENSG00000179941.9,ENSG00000179941,BBS10,-1.130125607,-1.707666388,-1.136126555,-0.546583879,Bardet-Biedl syndrome 10,"BBS10 is a gene that is part of the Bardet-Biedl syndrome (BBS) gene family. BBS is an autosomal recessive disorder that causes progressive retinal degeneration, obesity, polydactyly, renal malformation, and cognitive disability. BBS proteins are structurally diverse, but mutations in BBS gene family members lead to similar phenotypes due to their shared roles in cilia formation and function. BBS proteins are involved in intracellular trafficking and may localize to the basal bodies, ciliary axonemes, and pericentriolar regions of cells. BBS10 is not a ciliary protein but has distant sequence homology to type II chaperonins. As a molecular chaperone, BBS10 may affect the folding or stability of other ciliary or basal body proteins. Mutations in BBS10 cause Bardet-Biedl syndrome type 10.","There are currently no targeted drug discovery efforts for BBS10 or Bardet-Biedl syndrome (BBS) as a whole. Treatment for BBS is primarily supportive and focuses on managing the symptoms of the disease. For example, patients with obesity may be advised to follow a healthy diet and exercise regimen, while those with retinal degeneration may require regular eye exams and vision aids. There are no drugs specifically approved for the treatment of BBS, but some medications may be used to manage specific symptoms. For example, medications used to treat diabetes may be prescribed for patients with insulin resistance, while antihypertensive drugs may be used to manage high blood pressure. Overall, the management of BBS is multidisciplinary and requires a team of healthcare professionals to address the various symptoms and complications associated with the disease.",GO:1904390 cone retinal bipolar cell differentiation;GO:0060040 retinal bipolar neuron differentiation;GO:0042670 retinal cone cell differentiation,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Other congenital disorders of metabolism; Predicted intracellular proteins,,,,
ENSG00000168310.11,ENSG00000168310,IRF2,-1.128289633,-1.671886191,-1.113354144,-0.599628563,interferon regulatory factor 2,"IRF2 is a gene that encodes for interferon regulatory factor 2, a protein that belongs to the IRF family of transcription factors. IRF2 is known to inhibit the transcriptional activation of interferons alpha and beta, as well as other genes that use IRF1 for transcription activation. However, IRF2 also has the ability to activate the transcription of histone H4.","IRF2 has been implicated in various diseases, including cancer, autoimmune disorders, and viral infections. In cancer, IRF2 has been shown to act as a tumor suppressor by inhibiting cell proliferation and inducing apoptosis. However, in some types of cancer, such as breast cancer, IRF2 expression is downregulated, leading to tumor growth and progression. In autoimmune disorders, IRF2 has been found to play a role in regulating the immune response, and its dysregulation has been linked to the development of autoimmune diseases such as lupus and rheumatoid arthritis. In viral infections, IRF2 has been shown to play a role in the host immune response to viral infections, and its dysregulation can lead to increased susceptibility to viral infections.

Targeted drug discovery efforts for IRF2 have focused on developing drugs that can modulate its activity, either by activating or inhibiting its function. Some examples of successful drugs on the market that target IRF2 include interferon alpha and beta, which activate IRF2 and induce an antiviral response, and imiquimod, which activates IRF2 and induces an immune response against viral infections and skin cancer. Other potential drug targets for IRF2 include small molecules that can inhibit its activity, which could be useful in treating autoimmune disorders and some types of cancer.",GO:0051607 defense response to virus;GO:0009615 response to virus;GO:0008283 cell population proliferation,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Cell Junctions;Cytosol,,,(M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5913)HALLMARK INTERFERON GAMMA RESPONSE; (M5921)HALLMARK COMPLEMENT
ENSG00000138448.12,ENSG00000138448,ITGAV,-1.127817053,-1.823567717,-1.255410807,-0.304472636,integrin subunit alpha V,"ITGAV is a gene that encodes for the alpha V subunit of integrin, a protein that plays a role in cell adhesion and signaling. The preproprotein encoded by this gene is processed to generate light and heavy chains that make up the alpha V subunit. This subunit can associate with several beta subunits, including beta 1, beta 3, beta 5, beta 6, and beta 8. The alpha V and beta 3 subunits together form the vitronectin receptor. This integrin may be involved in regulating angiogenesis and cancer progression. Alternative splicing of this gene results in multiple transcript variants. It is important to note that the alpha 5 and alpha V subunits of integrin are encoded by separate genes.","ITGAV has been implicated in various diseases, including cancer, osteoporosis, and fibrosis. In cancer, ITGAV has been shown to play a role in tumor growth, invasion, and metastasis. Targeting ITGAV has been explored as a potential therapeutic strategy for cancer treatment. Several drugs targeting ITGAV are currently in clinical trials, including monoclonal antibodies and small molecule inhibitors. One example is the monoclonal antibody Abituzumab, which targets both ITGAV and ITGB6 and is being tested in clinical trials for the treatment of solid tumors. Another example is the small molecule inhibitor Cilengitide, which targets ITGAV and ITGB3 and has shown promising results in preclinical studies for the treatment of glioblastoma. However, despite these efforts, no ITGAV-targeted drugs have been approved for clinical use yet.",GO:0085017 entry into host cell by a symbiont-containing vacuole;GO:2000536 negative regulation of entry of bacterium into host cell;GO:0050748 negative regulation of lipoprotein metabolic process,,Predicted intracellular proteins; FDA approved drug targets:Biotech drugs; Transporters:Accessory Factors Involved in Transport; FDA approved drug targets:Small molecule drugs; CD markers; Cancer-related genes:Candidate cancer biomarkers,Cytosol;Focal adhesion sites (Approved),Antithymocyte immunoglobulin (rabbit); Levothyroxine,(M212)PID INTEGRIN5 PATHWAY; (M103)PID S1P S1P1 PATHWAY; (M206)PID PDGFRA PATHWAY,(M5944)HALLMARK ANGIOGENESIS; (M5908)HALLMARK ANDROGEN RESPONSE; (M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000114439.19,ENSG00000114439,BBX,-1.127658358,-1.689097363,-1.057291769,-0.636585942,BBX high mobility group box domain containing,BBX (high mobility group box domain containing) is a human gene that encodes a protein with sequence-specific double-stranded DNA binding activity. It is predicted to be involved in the regulation of transcription by RNA polymerase II and to play a role in bone development. The protein is located in both the cytosol and nucleoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of BBX. However, some studies have suggested that it may be involved in the development of certain cancers, such as breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for BBX are also limited, but some studies have identified potential small molecule inhibitors that could be used to target the protein. One example is a compound called NSC-87877, which has been shown to inhibit the DNA binding activity of BBX in vitro. However, there are currently no drugs on the market that specifically target BBX. Overall, more research is needed to fully understand the role of BBX in disease and to develop targeted therapies for related conditions.",GO:0060348 bone development;GO:0001501 skeletal system development;GO:0006357 regulation of transcription by RNA polymerase II,,Transcription factors:Other all-alpha-helical DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000163104.18,ENSG00000163104,SMARCAD1,-1.127600136,-1.578209115,-1.104952771,-0.699638522,SNF2 related chromatin remodeling ATPase with DExD box 1,"SMARCAD1 is a gene that belongs to the SNF subfamily of helicase proteins. It is involved in the restoration of heterochromatin organization and the propagation of epigenetic patterns after DNA replication by mediating histone H3/H4 deacetylation. Mutations in this gene have been linked to adermatoglyphia, a rare genetic disorder characterized by the absence of fingerprints. Multiple isoforms of SMARCAD1 have been observed due to alternative splicing.","Adermatoglyphia, also known as the ""immigration delay disease,"" is a rare genetic disorder caused by mutations in the SMARCAD1 gene. This disorder is characterized by the absence of fingerprints, which can cause significant delays in immigration processes and identification. There are currently no targeted drug discovery efforts for adermatoglyphia, as the disorder is considered benign and does not require treatment. However, research on SMARCAD1 has shown potential for drug development in other areas, such as cancer treatment. SMARCAD1 has been found to play a role in the regulation of DNA damage response and repair, making it a potential target for cancer therapies. Currently, there are no drugs on the market that specifically target SMARCAD1, but there are several drugs that target other proteins in the same pathway, such as PARP inhibitors. These drugs have shown promise in the treatment of certain types of cancer, particularly those with defects in DNA repair mechanisms.",GO:0051304 chromosome separation;GO:0000729 DNA double-strand break processing;GO:0032508 DNA duplex unwinding,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of skin; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Nucleoplasm (Enhanced),,,
ENSG00000116128.11,ENSG00000116128,BCL9,-1.122595837,-1.659302314,-1.097571789,-0.610913409,BCL9 transcription coactivator,"BCL9 is a gene that is associated with B-cell acute lymphoblastic leukemia, a type of blood cancer. It may be involved in translocation in B-cell malignancies with abnormalities of 1q21. The function of BCL9 is not yet fully understood, but its overexpression may play a role in the development of B-cell malignancies.","BCL9 is a promising target for drug discovery efforts in B-cell acute lymphoblastic leukemia (B-ALL). Several studies have shown that targeting BCL9 can inhibit the growth and survival of B-ALL cells. One approach is to develop small molecule inhibitors that disrupt the interaction between BCL9 and its binding partner, ?-catenin, which is involved in the Wnt signaling pathway. Another approach is to target the BCL9 gene itself using RNA interference or CRISPR/Cas9 gene editing. However, there are currently no drugs targeting BCL9 that have been approved for clinical use. Some drugs that have shown promise in preclinical studies include PRI-724, a small molecule inhibitor of the ?-catenin/BCL9 interaction, and siRNA targeting BCL9. Further research is needed to develop effective BCL9-targeted therapies for B-ALL.",GO:0014908 myotube differentiation involved in skeletal muscle regeneration;GO:0043403 skeletal muscle tissue regeneration;GO:0045445 myoblast differentiation,,Disease related genes; Cancer-related genes; Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Approved),,(M223)PID BETA CATENIN NUC PATHWAY; (M5493)WNT SIGNALING,
ENSG00000067113.17,ENSG00000067113,PLPP1,-1.121262551,-1.20242749,-1.096367454,-1.06499271,phospholipid phosphatase 1,"PLPP1 is a gene that encodes a protein belonging to the phosphatidic acid phosphatase (PAP) family. PAPs are involved in the synthesis of glycerolipids and in phospholipase D-mediated signal transduction by converting phosphatidic acid to diacylglycerol. The protein encoded by PLPP1 is an integral membrane glycoprotein that plays a role in the hydrolysis and uptake of lipids from extracellular space. The gene undergoes alternate splicing, resulting in multiple transcript variants.","Research on PLPP1 has revealed its potential involvement in various diseases, including cancer, atherosclerosis, and Alzheimer's disease. In cancer, PLPP1 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. In atherosclerosis, PLPP1 has been implicated in the regulation of lipid metabolism and inflammation, suggesting that it may be a therapeutic target for the prevention and treatment of cardiovascular disease. In Alzheimer's disease, PLPP1 has been found to be upregulated in the brains of patients, and may play a role in the accumulation of beta-amyloid plaques.

Targeted drug discovery efforts for PLPP1 are still in the early stages, but several potential inhibitors have been identified through high-throughput screening and structure-based design. These inhibitors have shown promising results in preclinical studies, and may eventually lead to the development of new drugs for the treatment of cancer, atherosclerosis, and other diseases.

One example of a successful drug targeting a related enzyme is Orlistat, which inhibits pancreatic lipase and is used for the treatment of obesity. Another example is the drug Ezetimibe, which inhibits the Niemann-Pick C1-like 1 (NPC1L1) protein and is used to lower cholesterol levels in patients with hypercholesterolemia. While there are currently no drugs on the market targeting PLPP1 specifically, ongoing research may lead to the development of new therapies in the future.",GO:0006670 sphingosine metabolic process;GO:0046519 sphingoid metabolic process;GO:0030521 androgen receptor signaling pathway,,ENZYME proteins:Hydrolases; Enzymes,Plasma membrane (Supported),,(M7)PID FCER1 PATHWAY; (M19)PID P73PATHWAY,(M5908)HALLMARK ANDROGEN RESPONSE; (M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000152291.14,ENSG00000152291,TGOLN2,-1.119431885,-1.449830433,-1.17263202,-0.735833203,trans-golgi network protein 2,"TGOLN2 is a gene that encodes a type I integral membrane protein that is found in the trans-Golgi network, which is a crucial sorting station for secretory and membrane proteins. The protein encoded by this gene moves between early endosomes and the trans-Golgi network and may be involved in the formation of exocytic vesicles. Multiple isoforms of the protein have been observed due to alternative splicing of the transcript variants.","There is limited information available on the disease implications of TGOLN2. However, recent studies have suggested that the protein may play a role in the progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TGOLN2 are still in the early stages, but there is potential for the protein to be targeted in cancer therapy. One example of a successful drug targeting a similar protein is Herceptin, which targets the HER2 protein in breast cancer. However, more research is needed to fully understand the role of TGOLN2 in cancer and to develop effective targeted therapies.",,,,Golgi apparatus (Supported); Additional: Nucleoplasm,,,
ENSG00000225507.1,ENSG00000225507,AC069282.1,-1.118495275,-1.410992147,-1.51122084,-0.433272839,None,None,None,None,None,None,None,None,None,None
ENSG00000168488.18,ENSG00000168488,ATXN2L,-1.11732147,-1.958634748,-0.971722337,-0.421607326,ataxin 2 like,"ATXN2L is a gene that encodes a protein similar to ataxin 2, but its function is currently unknown. It belongs to the spinocerebellar ataxia (SCAs) family, which is associated with a group of neurodegenerative disorders. Different isoforms of the protein have been identified due to alternative splicing of the gene. However, further research is needed to understand the role of ATXN2L in the development of SCAs and other related disorders.","Currently, there is limited information on the disease implications of ATXN2L. However, as it belongs to the spinocerebellar ataxia (SCAs) family, it is possible that mutations in this gene could contribute to the development of SCAs and other related neurodegenerative disorders. Targeted drug discovery efforts for SCAs have focused on identifying compounds that can modulate the expression or activity of disease-causing proteins, such as ataxin 2. While there are currently no drugs on the market specifically targeting ATXN2L, there are several drugs approved for the treatment of SCAs, including riluzole and valproic acid. These drugs have been shown to improve symptoms and slow disease progression in some patients, but there is still a need for more effective treatments for these devastating disorders.",GO:0034063 stress granule assembly;GO:0140694 membraneless organelle assembly;GO:0016071 mRNA metabolic process,,Predicted intracellular proteins,Cytosol (Enhanced),,,
ENSG00000167447.12,ENSG00000167447,SMG8,-1.116728138,-1.410843367,-1.417931849,-0.521409199,SMG8 nonsense mediated mRNA decay factor,"SMG8 is a human gene that plays a role in the degradation of mRNA through a process called nonsense-mediated decay. It is also involved in regulating protein kinase activity. SMG8 is predicted to be located in the cytosol, which is the fluid inside cells where many cellular processes occur. Overall, SMG8 is important for maintaining proper gene expression and protein regulation in human cells.","There is limited information available on the disease implications of SMG8. However, recent studies have suggested that mutations in SMG8 may be associated with neurodevelopmental disorders such as autism spectrum disorder and intellectual disability. Targeted drug discovery efforts for SMG8 are also limited, as the gene is not currently considered a therapeutic target. However, research on SMG8 and its role in mRNA degradation may have implications for the development of therapies for diseases caused by abnormal mRNA processing, such as cystic fibrosis and beta-thalassemia. Currently, there are no drugs on the market that specifically target SMG8. However, there are drugs that target other components of the nonsense-mediated decay pathway, such as Ataluren, which is approved for the treatment of Duchenne muscular dystrophy caused by nonsense mutations.","GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay;GO:0000956 nuclear-transcribed mRNA catabolic process;GO:0006402 mRNA catabolic process",,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000177189.14,ENSG00000177189,RPS6KA3,-1.114310579,-1.376351903,-1.019704259,-0.946875576,ribosomal protein S6 kinase A3,"RPS6KA3 is a gene that encodes a protein belonging to the RSK family of serine/threonine kinases. This protein contains two kinase catalytic domains and is responsible for phosphorylating various substrates, including those involved in the MAPK signaling pathway. The activity of RPS6KA3 is important in regulating cell growth and differentiation. Mutations in this gene have been linked to Coffin-Lowry syndrome (CLS), a rare genetic disorder characterized by intellectual disability, facial abnormalities, and skeletal abnormalities.","Coffin-Lowry syndrome (CLS) is a rare genetic disorder caused by mutations in the RPS6KA3 gene. The symptoms of CLS include intellectual disability, delayed speech and language development, facial abnormalities, and skeletal abnormalities. There is currently no cure for CLS, and treatment is focused on managing the symptoms of the disease. However, targeted drug discovery efforts are underway to develop therapies that can address the underlying genetic cause of the disease. One approach is to develop drugs that can restore the activity of the RPS6KA3 protein. Several drugs have been developed that target the MAPK signaling pathway, which is regulated by RPS6KA3. Examples include trametinib, dabrafenib, and vemurafenib, which are used to treat various types of cancer. These drugs have shown promise in preclinical studies for the treatment of CLS, but further research is needed to determine their safety and efficacy in humans.",GO:0038202 TORC1 signaling;GO:0043555 regulation of translation in response to stress;GO:0031929 TOR signaling,yes,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; ENZYME proteins:Transferases; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Kinases:AGC Ser/Thr protein kinases; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Cytosol;Nucleoli;Nucleoplasm (Supported),Acetylsalicylic acid; Fostamatinib,(M17200)SA B CELL RECEPTOR COMPLEXES; (M1315)SIG PIP3 SIGNALING IN B LYMPHOCYTES; (M7955)SIG INSULIN RECEPTOR PATHWAY IN CARDIAC MYOCYTES,(M5910)HALLMARK PROTEIN SECRETION; (M5908)HALLMARK ANDROGEN RESPONSE; (M5923)HALLMARK PI3K AKT MTOR SIGNALING
ENSG00000065308.5,ENSG00000065308,TRAM2,-1.113607027,-1.458268432,-0.992102824,-0.890449825,translocation associated membrane protein 2,"TRAM2 is a gene that encodes for a protein called translocation associated membrane protein 2. This protein is a part of the translocon, which is a channel that controls the processing of newly synthesized secretory and membrane proteins at the endoplasmic reticulum (ER) membrane. TRAM2 plays a crucial role in the proper folding and transport of these proteins, ensuring their correct localization and function within the cell. Mutations in TRAM2 have been associated with various diseases, including cancer and neurological disorders. Overall, TRAM2 is an important gene involved in the regulation of protein processing and function within the cell.","There is limited information available on the disease implications of TRAM2 mutations. However, studies have suggested that TRAM2 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Additionally, mutations in TRAM2 have been linked to neurological disorders such as hereditary spastic paraplegia.

As of now, there are no targeted drug discovery efforts specifically focused on TRAM2. However, given its potential role in cancer and neurological disorders, it may be a target for future drug development efforts.

There are currently no drugs on the market that specifically target TRAM2. However, there are drugs that target the translocon, of which TRAM2 is a part. For example, the drug Sec61 inhibitor, which targets the Sec61 translocon, has shown promise in preclinical studies for the treatment of certain types of cancer. Additionally, the drug Lumacaftor, which targets the cystic fibrosis transmembrane conductance regulator (CFTR) protein, has been shown to interact with the translocon and improve the folding and trafficking of CFTR.","GO:0006616 SRP-dependent cotranslational protein targeting to membrane, translocation;GO:0032964 collagen biosynthetic process;GO:0006614 SRP-dependent cotranslational protein targeting to membrane",,Transporters,Cytosol (Approved),,,
ENSG00000135473.15,ENSG00000135473,PAN2,-1.11295142,-1.347764688,-1.487404743,-0.503684828,poly(A) specific ribonuclease subunit PAN2,"The PAN2 gene encodes a protein that is part of a complex involved in degrading messenger RNA (mRNA) in the cytoplasm. Specifically, the protein is a deadenylase, which means it removes the poly(A) tail from the end of mRNA molecules. This deadenylation process is important for regulating gene expression and controlling the stability of mRNA. The PAN2 protein is the catalytic subunit of the polyadenylate binding protein dependent poly(A) nuclease complex, which requires magnesium to function. There are multiple transcript variants of the PAN2 gene due to alternative splicing.","Mutations in the PAN2 gene have been associated with a variety of diseases, including cancer, neurodegenerative disorders, and developmental disorders. For example, a study found that mutations in PAN2 were associated with an increased risk of developing breast cancer. Additionally, mutations in PAN2 have been linked to intellectual disability and autism spectrum disorders.

Targeted drug discovery efforts for PAN2 have focused on developing inhibitors of the deadenylase activity of the protein. One study identified a small molecule inhibitor of PAN2 that was able to reduce the growth of cancer cells in vitro. Another study found that inhibiting PAN2 could enhance the efficacy of chemotherapy drugs in treating cancer.

There are currently no drugs on the market that specifically target PAN2, but there are drugs that indirectly affect its function. For example, the chemotherapy drug 5-fluorouracil has been shown to inhibit deadenylation by the PAN2 complex. Additionally, the drug rapamycin has been shown to indirectly affect the activity of the PAN2 complex by regulating the expression of its binding partner, the polyadenylate binding protein.",GO:0010606 positive regulation of cytoplasmic mRNA processing body assembly;GO:0010603 regulation of cytoplasmic mRNA processing body assembly;GO:0000289 nuclear-transcribed mRNA poly(A) tail shortening,,Peptidases:Cysteine-type peptidases; ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,,,,(M5925)HALLMARK E2F TARGETS
ENSG00000150540.14,ENSG00000150540,HNMT,-1.112291079,-1.164273102,-0.740434475,-1.432165659,histamine N-methyltransferase,"The HNMT gene encodes the enzyme histamine N-methyltransferase, which is responsible for metabolizing histamine in mammals through N(tau)-methylation. This enzyme is found in the cytosol and uses S-adenosyl-L-methionine as the methyl donor. In the mammalian brain, the activity of histamine as a neurotransmitter is controlled by N(tau)-methylation, as diamine oxidase is not present in the central nervous system. A common genetic polymorphism affects the activity levels of this gene product in red blood cells. Multiple alternatively spliced transcript variants that encode different proteins have been found for this gene.","The HNMT gene has been implicated in various diseases, including allergic disorders, schizophrenia, and Parkinson's disease. In allergic disorders, decreased activity of HNMT has been associated with increased histamine levels and symptoms such as itching, hives, and asthma. In schizophrenia, decreased HNMT activity has been linked to increased histamine levels in the brain, which may contribute to the development of psychotic symptoms. In Parkinson's disease, decreased HNMT activity has been associated with increased levels of toxic metabolites that may contribute to the degeneration of dopaminergic neurons.

Targeted drug discovery efforts have focused on developing drugs that modulate HNMT activity for the treatment of these diseases. One example is the development of HNMT inhibitors for the treatment of allergic disorders. These inhibitors have been shown to reduce histamine levels and alleviate symptoms in animal models of allergic asthma and rhinitis. Another example is the development of HNMT activators for the treatment of Parkinson's disease. These activators have been shown to increase HNMT activity and reduce the levels of toxic metabolites in animal models of the disease.

One successful drug on the market that targets HNMT is metoprine, which is used for the treatment of allergic disorders. Metoprine is a non-specific inhibitor of HNMT that has been shown to reduce histamine levels and alleviate symptoms in patients with allergic rhinitis and asthma. However, due to its non-specific nature, metoprine may also inhibit other methyltransferases and have off-target effects. Therefore, more specific HNMT inhibitors and activators are currently being developed for the treatment of various diseases.",GO:0001695 histamine catabolic process;GO:0001692 histamine metabolic process;GO:0052805 imidazole-containing compound catabolic process,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Cytosol;Nucleoplasm (Approved); Additional: Centrosome,Amodiaquine; S-adenosyl-L-homocysteine; Metoprine; SKF-91488; Harmaline,,
ENSG00000120709.11,ENSG00000120709,FAM53C,-1.111597856,-1.188495525,-0.985846294,-1.160451747,family with sequence similarity 53 member C,"FAM53C is a human gene that belongs to the FAM53 protein family. This family of proteins binds to a transcriptional regulator that controls cell proliferation. The FAM53C gene undergoes alternative splicing, resulting in multiple transcript variants.","There is limited information available on the disease implications of FAM53C. However, recent studies have suggested that this gene may play a role in the development and progression of certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for FAM53C are still in the early stages, but there is potential for this gene to be targeted in cancer therapy. Currently, there are no drugs on the market that specifically target FAM53C. However, there are several drugs that target other proteins in the same pathway as FAM53C, such as PI3K inhibitors and mTOR inhibitors, which have shown promise in the treatment of various types of cancer. Further research is needed to fully understand the role of FAM53C in cancer and to develop targeted therapies for this gene.",GO:0006606 protein import into nucleus;GO:0051170 import into nucleus;GO:0034504 protein localization to nucleus,,Predicted intracellular proteins,,,,
ENSG00000100393.14,ENSG00000100393,EP300,-1.11106913,-1.565059377,-1.13431058,-0.633837434,E1A binding protein p300,"EP300 is a gene that encodes a protein called E1A binding protein p300, which functions as a histone acetyltransferase that regulates transcription via chromatin remodeling. It plays an important role in cell proliferation and differentiation and mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. EP300 has also been identified as a co-activator of HIF1A, which stimulates hypoxia-induced genes such as VEGF. Defects in this gene are associated with Rubinstein-Taybi syndrome and may also play a role in epithelial cancer.","EP300 mutations have been linked to Rubinstein-Taybi syndrome (RTS), a rare genetic disorder characterized by intellectual disability, distinctive facial features, and broad thumbs and toes. RTS is caused by mutations in either EP300 or CREBBP, another gene that encodes a protein similar to p300. Targeted drug discovery efforts for EP300 have focused on developing small molecule inhibitors that can block its histone acetyltransferase activity and potentially treat cancer. One example is C646, a selective inhibitor of p300/CBP that has shown promising results in preclinical studies for the treatment of various cancers, including breast, prostate, and lung cancer. Another example is A-485, a potent and selective inhibitor of p300/CBP that is currently in clinical trials for the treatment of solid tumors.",GO:0036268 swimming;GO:0061921 peptidyl-lysine propionylation;GO:0140066 peptidyl-lysine crotonylation,,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Nucleoplasm (Enhanced),,(M32)PID HDAC CLASSIII PATHWAY; (M207)PID RETINOIC ACID PATHWAY; (M44)PID HIF2PATHWAY,
ENSG00000143153.13,ENSG00000143153,ATP1B1,-1.110872112,-1.857794038,-1.474533016,-0.000289283,ATPase Na+/K+ transporting subunit beta 1,"ATP1B1 is a gene that encodes for the beta 1 subunit of the Na+/K+ ATPase enzyme. This enzyme is responsible for maintaining the electrochemical gradients of sodium and potassium ions across the plasma membrane, which is essential for osmoregulation, sodium-coupled transport of molecules, and electrical excitability of nerve and muscle. The beta subunit of the enzyme regulates the number of sodium pumps transported to the plasma membrane through assembly of alpha/beta heterodimers. Multiple genes encode for the glycoprotein subunit of Na+/K+ ATPase, but ATP1B1 specifically encodes for the beta 1 subunit. Different isoforms of the gene have been described, but their biological significance is unknown.","Mutations in ATP1B1 have been associated with several diseases, including hypertension, renal tubular acidosis, and neurological disorders such as migraine and epilepsy. In hypertension, genetic variations in ATP1B1 have been linked to altered sodium transport and increased blood pressure. In renal tubular acidosis, mutations in ATP1B1 have been shown to impair the function of the Na+/K+ ATPase enzyme, leading to acidosis and electrolyte imbalances. 

Targeted drug discovery efforts have focused on developing drugs that modulate the activity of the Na+/K+ ATPase enzyme, particularly in the treatment of hypertension and heart failure. One example is the drug ouabain, which binds to the Na+/K+ ATPase enzyme and inhibits its activity, leading to increased intracellular calcium levels and improved cardiac contractility. Another example is digoxin, which has a similar mechanism of action and is used to treat heart failure and atrial fibrillation.

In conclusion, ATP1B1 is a gene that encodes for the beta 1 subunit of the Na+/K+ ATPase enzyme, which is essential for maintaining the electrochemical gradients of sodium and potassium ions across the plasma membrane. Mutations in ATP1B1 have been associated with several diseases, including hypertension and renal tubular acidosis. Targeted drug discovery efforts have focused on developing drugs that modulate the activity of the Na+/K+ ATPase enzyme, with successful examples including ouabain and digoxin.",GO:0044861 protein transport into plasma membrane raft;GO:1903406 regulation of P-type sodium:potassium-exchanging transporter activity;GO:1903408 positive regulation of P-type sodium:potassium-exchanging transporter activity,,Transporters:Primary Active Transporters; Predicted intracellular proteins,,,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000140526.18,ENSG00000140526,ABHD2,-1.110694291,-1.730794262,-0.935425414,-0.665863198,"abhydrolase domain containing 2, acylglycerol lipase","ABHD2 is a gene that encodes a protein with an alpha/beta hydrolase fold, which is a catalytic domain found in many enzymes. The protein is an acylglycerol lipase that breaks down endocannabinoid arachidonoylglycerol from the cell membrane. This leads to the activation of the sperm calcium channel CatSper, which results in sperm activation. The gene has two transcript variants that encode the same protein.","Research on ABHD2 has shown its potential implications in various diseases, including cancer, obesity, and neurological disorders. In cancer, ABHD2 has been found to be overexpressed in certain types of tumors, and its inhibition has been shown to reduce tumor growth and metastasis. In obesity, ABHD2 has been linked to the regulation of lipid metabolism, and its inhibition has been shown to reduce body weight gain in animal models. In neurological disorders, ABHD2 has been implicated in the regulation of endocannabinoid signaling, which is involved in pain, anxiety, and depression.

Targeted drug discovery efforts for ABHD2 have focused on developing inhibitors that can selectively block its activity. Several small molecule inhibitors have been identified, including WWL70 and WWL123, which have been shown to reduce tumor growth and improve metabolic parameters in animal models. Additionally, a recent study identified a natural compound, 6-OAU, that can selectively inhibit ABHD2 and reduce pain in animal models.

Currently, there are no drugs on the market that specifically target ABHD2. However, the identification of small molecule inhibitors and natural compounds that can selectively inhibit its activity provides promising avenues for drug development in the future.",GO:0051793 medium-chain fatty acid catabolic process;GO:0051792 medium-chain fatty acid biosynthetic process;GO:0014909 smooth muscle cell migration,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol;Flagellar centriole (Approved); Additional: Connecting piece;Nucleoplasm,,,(M5908)HALLMARK ANDROGEN RESPONSE; (M5906)HALLMARK ESTROGEN RESPONSE EARLY; (M5907)HALLMARK ESTROGEN RESPONSE LATE
ENSG00000081320.11,ENSG00000081320,STK17B,-1.109816956,-1.264543978,-1.030098162,-1.034808729,serine/threonine kinase 17b,"STK17B is a human gene that encodes for a protein called serine/threonine kinase 17b. This protein has the ability to bind to ATP and perform protein serine/threonine kinase activity. It is involved in intracellular signal transduction, positive regulation of fibroblast apoptotic process, and protein phosphorylation. STK17B is located in the nucleus of cells.","There is limited information available on the disease implications of STK17B. However, some studies have suggested that alterations in the expression of this gene may be associated with certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for STK17B are also limited, but some studies have identified potential small molecule inhibitors of the protein kinase activity of STK17B. One example is a compound called 4-phenylpyridine-2-one, which has been shown to inhibit the activity of STK17B in vitro. However, there are currently no drugs on the market that specifically target STK17B. Further research is needed to fully understand the role of this gene in disease and to develop targeted therapies for related conditions.",GO:2000271 positive regulation of fibroblast apoptotic process;GO:2000269 regulation of fibroblast apoptotic process;GO:0046777 protein autophosphorylation,yes,Enzymes; Predicted intracellular proteins; Kinases:CAMK Ser/Thr protein kinases; ENZYME proteins:Transferases,Nucleoplasm (Supported),Quercetin; Fostamatinib,,
ENSG00000089050.16,ENSG00000089050,RBBP9,-1.108943193,-1.589082846,-0.876503051,-0.861243682,"RB binding protein 9, serine hydrolase","RBBP9 is a gene that encodes for a protein called RB binding protein 9, which is involved in regulating cell proliferation and differentiation. There are two versions of the gene that have been identified, but they both produce the same protein. One of the versions is a candidate for nonsense-mediated decay, which is a process that eliminates faulty mRNA molecules that could produce non-functional proteins. Overall, RBBP9 is an important gene that plays a role in controlling cell growth and development.","RBBP9 has been implicated in several diseases, including cancer, Alzheimer's disease, and cardiovascular disease. In cancer, RBBP9 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. Several drug discovery efforts have focused on targeting RBBP9, including the development of small molecule inhibitors and monoclonal antibodies. However, there are currently no drugs on the market that specifically target RBBP9. 

One example of a successful drug that indirectly affects RBBP9 is the cancer drug tamoxifen, which is used to treat breast cancer. Tamoxifen works by blocking the activity of estrogen receptors, which can lead to the downregulation of RBBP9 expression. Another example is the Alzheimer's drug memantine, which has been shown to increase RBBP9 expression and improve cognitive function in animal models. 

Overall, RBBP9 is an important gene with potential implications for several diseases, and further research is needed to fully understand its role in disease pathogenesis and to develop targeted therapies.",GO:0060510 type II pneumocyte differentiation;GO:0009624 response to nematode;GO:0061140 lung secretory cell differentiation,,Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000164168.8,ENSG00000164168,TMEM184C,-1.108932334,-1.787371204,-1.114495425,-0.424930373,transmembrane protein 184C,"TMEM184C is a human gene that is predicted to be an integral component of the membrane. It encodes for a transmembrane protein, which means that it spans the membrane of a cell and is involved in various cellular processes. However, the exact function of TMEM184C is not yet fully understood. The gene is located on chromosome 16 and mutations in TMEM184C have been associated with developmental disorders such as intellectual disability and autism spectrum disorder. Further research is needed to fully elucidate the role of TMEM184C in human biology and disease.","There is currently limited information available on the disease implications of TMEM184C mutations. However, studies have suggested that mutations in this gene may be associated with developmental disorders such as intellectual disability and autism spectrum disorder. As of now, there are no targeted drug discovery efforts for TMEM184C, and no drugs have been developed specifically to target this gene. However, there are drugs on the market that are used to treat the symptoms of intellectual disability and autism spectrum disorder, such as antipsychotics and antidepressants. These drugs work by targeting neurotransmitters in the brain and can help to alleviate symptoms such as anxiety, aggression, and mood disturbances. Further research is needed to fully understand the role of TMEM184C in disease and to develop targeted therapies for individuals with mutations in this gene.",GO:0055085 transmembrane transport;GO:0006810 transport;GO:0051234 establishment of localization,,,Vesicles (Approved); Additional: Nucleoplasm,,,
ENSG00000144674.16,ENSG00000144674,GOLGA4,-1.108904692,-1.623188756,-1.209280173,-0.494245146,golgin A4,"GOLGA4, also known as golgin A4, is a gene that encodes for a protein belonging to the golgin family of proteins localized to the Golgi apparatus. The Golgi apparatus is responsible for glycosylation and transport of proteins and lipids in the secretory pathway. GOLGA4 has been postulated to play a role in Rab6-regulated membrane-tethering events in the Golgi apparatus, which are important for the reorganization of the Golgi after it fragments during mitosis. Different isoforms of GOLGA4 have been identified through alternative splicing of its transcript variants.","There is limited information available on the disease implications of GOLGA4. However, recent studies have suggested that mutations in GOLGA4 may be associated with neurodevelopmental disorders such as autism spectrum disorder (ASD) and intellectual disability (ID). Targeted drug discovery efforts for GOLGA4 are currently limited due to the lack of understanding of its exact function and role in disease. However, some studies have suggested that targeting the Golgi apparatus and its associated proteins may have therapeutic potential for certain diseases, including cancer. There are currently no drugs on the market that specifically target GOLGA4, but there are drugs that target the Golgi apparatus and its associated proteins, such as brefeldin A, which is used to treat certain types of cancer. Further research is needed to fully understand the role of GOLGA4 in disease and to develop targeted therapies.",GO:0043001 Golgi to plasma membrane protein transport;GO:0045773 positive regulation of axon extension;GO:0061951 establishment of protein localization to plasma membrane,,Predicted intracellular proteins,Golgi apparatus (Supported); Additional: Nucleoplasm,,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000196428.12,ENSG00000196428,TSC22D2,-1.107847025,-1.678792826,-0.827331832,-0.817416417,TSC22 domain family member 2,"TSC22D2 is a human gene that belongs to the TSC22 domain family. It is predicted to play a role in regulating transcription by RNA polymerase II and to be involved in the response to osmotic stress. The gene's function is not fully understood, but it is believed to act upstream of or within the response to osmotic stress. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of TSC22D2. However, some studies have suggested that it may be involved in the development and progression of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TSC22D2 are also limited, as its function is not fully understood. However, some studies have suggested that it may be a potential therapeutic target for cancer treatment. Currently, there are no drugs on the market that specifically target TSC22D2. However, there are several drugs that have been approved for the treatment of breast cancer and hepatocellular carcinoma, which may indirectly affect the expression or activity of TSC22D2. Examples of these drugs include tamoxifen, trastuzumab, and sorafenib. Further research is needed to fully understand the role of TSC22D2 in disease and to develop targeted therapies for its potential implications.",GO:0006970 response to osmotic stress;GO:0045786 negative regulation of cell cycle;GO:0051726 regulation of cell cycle,,Transcription factors:Basic domains; Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000197724.11,ENSG00000197724,PHF2,-1.107750061,-1.301628882,-1.402489169,-0.619132131,PHD finger protein 2,"PHF2 is a human gene that encodes a protein containing a unique zinc finger-like PHD finger and a highly conserved domain. The PHD finger has a typical Cys4-His-Cys3 arrangement and is thought to belong to a diverse group of transcriptional regulators that may affect gene expression by influencing chromatin structure. The function of PHF2 is not fully understood, but it has been implicated in various cellular processes, including cell differentiation, DNA damage response, and tumorigenesis. Mutations in PHF2 have been associated with developmental disorders and cancer.","There is limited information available on targeted drug discovery efforts for PHF2. However, mutations in PHF2 have been associated with developmental disorders and cancer, suggesting that targeting this gene may have therapeutic potential. For example, PHF2 has been shown to play a role in the development of acute myeloid leukemia (AML), and inhibition of PHF2 has been proposed as a potential therapeutic strategy for this disease. Additionally, PHF2 has been implicated in the regulation of adipogenesis, and targeting PHF2 may have potential for the treatment of obesity and related metabolic disorders. Currently, there are no drugs on the market that specifically target PHF2. However, there are several drugs that target chromatin-modifying enzymes, which may indirectly affect PHF2 function. Examples of such drugs include histone deacetylase inhibitors and DNA methyltransferase inhibitors, which are used in the treatment of various cancers.",GO:0061187 regulation of rDNA heterochromatin formation;GO:0061188 negative regulation of rDNA heterochromatin formation;GO:0006482 protein demethylation,,Predicted intracellular proteins,Nucleoli rim;Nucleoplasm (Supported),,,
ENSG00000172943.20,ENSG00000172943,PHF8,-1.107232032,-1.447056478,-1.013646534,-0.860993083,PHD finger protein 8,"PHF8, or PHD finger protein 8, is a gene that encodes a histone lysine demethylase that primarily targets histones in the monomethyl or dimethyl states. The protein requires Fe(2+) ion, 2-oxoglutarate, and oxygen for its catalytic activity and has an N-terminal PHD finger and a central Jumonji C domain. PHF8 is believed to function as a transcription activator and defects in this gene are associated with syndromic X-linked Siderius type intellectual disability (MRXSSD). Over-expression of PHF8 is also linked to several forms of cancer. Multiple transcript variants encoding different isoforms have been identified for this gene.","Mutations in the PHF8 gene have been linked to syndromic X-linked Siderius type intellectual disability (MRXSSD), which is characterized by intellectual disability, facial dysmorphism, and skeletal abnormalities. Targeted drug discovery efforts for PHF8 have focused on developing small molecule inhibitors that can selectively inhibit its demethylase activity. Several compounds have been identified as potential PHF8 inhibitors, including IOX1, which has been shown to inhibit PHF8 activity in vitro and in vivo. However, no PHF8-specific drugs have been approved for clinical use yet. In terms of cancer, over-expression of PHF8 has been linked to several forms of cancer, including breast, prostate, and lung cancer. Successful drugs targeting PHF8 in cancer have not yet been developed, but research in this area is ongoing.",GO:0061187 regulation of rDNA heterochromatin formation;GO:0061188 negative regulation of rDNA heterochromatin formation;GO:0031452 negative regulation of heterochromatin formation,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; ENZYME proteins:Oxidoreductases; Potential drug targets; Disease related genes; Enzymes,Nucleoplasm (Supported),,,
ENSG00000170802.16,ENSG00000170802,FOXN2,-1.106511278,-1.164747806,-1.248549944,-0.906236084,forkhead box N2,"FOXN2 is a gene that encodes a protein with a forkhead domain binding. It is believed to play a role in the transcriptional regulation of the long terminal repeat of the human T-cell leukemia virus. The function of this gene is not fully understood, but it is thought to be involved in the regulation of gene expression. The protein encoded by FOXN2 may be a potential target for therapeutic interventions in diseases such as leukemia. Further research is needed to fully understand the role of FOXN2 in human biology and disease.","There is limited information available on the disease implications and targeted drug discovery efforts for FOXN2. However, some studies have suggested that FOXN2 may play a role in the development and progression of certain types of leukemia. Targeting FOXN2 may therefore be a potential therapeutic strategy for these diseases. Currently, there are no drugs on the market that specifically target FOXN2. However, there are several drugs that have been approved for the treatment of leukemia, such as imatinib, dasatinib, and nilotinib, which target specific molecular pathways involved in the development and progression of the disease. Further research is needed to determine whether targeting FOXN2 may be a viable therapeutic approach for leukemia and other diseases.",GO:0035914 skeletal muscle cell differentiation;GO:0007519 skeletal muscle tissue development;GO:0060538 skeletal muscle organ development,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Vesicles,,,
ENSG00000182158.15,ENSG00000182158,CREB3L2,-1.104249801,-1.958865086,-0.88703079,-0.466853527,cAMP responsive element binding protein 3 like 2,CREB3L2 is a gene that encodes a transcriptional activator belonging to the oasis bZIP transcription factor family. This gene can form homodimers and has multiple transcript variants that encode different isoforms. Translocations between CREB3L2 and the gene fused in sarcoma on chromosome 16 have been found in some tumors.,"CREB3L2 has been implicated in several diseases, including cancer, neurodegenerative disorders, and metabolic disorders. In cancer, translocations involving CREB3L2 have been found in some cases of Ewing sarcoma and myxoid liposarcoma. In neurodegenerative disorders, CREB3L2 has been linked to Alzheimer's disease and Huntington's disease, where it plays a role in regulating the processing of amyloid precursor protein and huntingtin protein, respectively. In metabolic disorders, CREB3L2 has been shown to regulate glucose and lipid metabolism, and mutations in this gene have been associated with type 2 diabetes.

Targeted drug discovery efforts for CREB3L2 are still in the early stages, but there is potential for this gene to be a therapeutic target in cancer and metabolic disorders. One study found that inhibiting CREB3L2 expression in cancer cells reduced their proliferation and induced apoptosis, suggesting that targeting this gene could be a promising strategy for cancer therapy. In metabolic disorders, targeting CREB3L2 could potentially improve glucose and lipid metabolism and reduce the risk of type 2 diabetes.

There are currently no drugs on the market that specifically target CREB3L2, but there are drugs that indirectly affect this gene. For example, metformin, a commonly used drug for type 2 diabetes, has been shown to activate CREB3L2 and improve glucose metabolism. Additionally, some cancer drugs, such as trabectedin and eribulin, have been shown to induce the expression of CREB3L2 and inhibit the growth of cancer cells. Further research is needed to fully understand the potential of targeting CREB3L2 for therapeutic purposes.",GO:0002062 chondrocyte differentiation;GO:0006888 endoplasmic reticulum to Golgi vesicle-mediated transport;GO:0006986 response to unfolded protein,,Disease related genes; Cancer-related genes; Transcription factors:Basic domains; Predicted intracellular proteins,Endoplasmic reticulum;Nucleoplasm (Supported),,,
ENSG00000104324.16,ENSG00000104324,CPQ,-1.104121432,-1.732654958,-0.681928289,-0.89778105,carboxypeptidase Q,"CPQ is a gene that encodes a metallopeptidase belonging to the peptidase M28 family. The protein produced by this gene may catalyze the cleavage of dipeptides with unsubstituted terminals into amino acids. This information is provided by RefSeq, a database of curated genomic information.","There is limited information available on the disease implications of CPQ. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, such as colorectal cancer. Targeted drug discovery efforts for CPQ are also limited, as the function of this gene is not well understood. However, some studies have suggested that inhibitors of metallopeptidases, such as CPQ, may have potential therapeutic applications in cancer treatment. Currently, there are no drugs on the market that specifically target CPQ. However, there are several drugs on the market that target other metallopeptidases, such as angiotensin-converting enzyme (ACE) inhibitors, which are used to treat hypertension and heart failure.",GO:0006590 thyroid hormone generation;GO:0043171 peptide catabolic process;GO:0042403 thyroid hormone metabolic process,,Peptidases:Metallopeptidases; Predicted secreted proteins; Enzymes; Predicted intracellular proteins,Golgi apparatus;Vesicles (Supported),Glutamic acid,,(M5946)HALLMARK COAGULATION; (M5921)HALLMARK COMPLEMENT
ENSG00000114857.18,ENSG00000114857,NKTR,-1.103318613,-1.523658636,-0.923470519,-0.862826685,natural killer cell triggering receptor,The NKTR gene encodes a protein that is anchored to the membrane and has a hydrophobic amino terminal domain and a cyclophilin-like PPIase domain. This protein is found on the surface of natural killer cells and helps them bind to their targets. The expression of this gene is regulated by the activation of the cells through the cytokine IL2.,"The NKTR gene has been implicated in various diseases, including cancer and autoimmune disorders. In cancer, the expression of NKTR has been found to be downregulated, leading to a decrease in natural killer cell activity and an increase in tumor growth. As a result, there have been efforts to develop drugs that target NKTR to enhance natural killer cell activity and improve cancer treatment outcomes. One such drug is NKTR-214, a PEGylated form of IL2 that selectively activates natural killer cells and CD8+ T cells. NKTR-214 has shown promising results in clinical trials for various types of cancer, including melanoma and renal cell carcinoma. Another drug, lirilumab, is a monoclonal antibody that targets the NKTR protein and enhances natural killer cell activity. Lirilumab has been approved for the treatment of acute myeloid leukemia and is being investigated for other types of cancer. Overall, targeting the NKTR gene and protein has shown potential for improving cancer treatment outcomes and may have implications for other diseases as well.",GO:0006457 protein folding;GO:0051604 protein maturation;GO:0006357 regulation of transcription by RNA polymerase II,,Enzymes; ENZYME proteins:Isomerase; Predicted intracellular proteins,Cytosol;Nucleoplasm;Plasma membrane (Supported),,,
ENSG00000164187.7,ENSG00000164187,LMBRD2,-1.102607583,-1.487133501,-1.165837911,-0.654851337,LMBR1 domain containing 2,"LMBRD2, also known as LMBR1 domain containing 2, is a human gene that plays a role in the adrenergic receptor signaling pathway. It is located in the membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of LMBRD2. However, mutations in this gene have been associated with methylmalonic aciduria and homocystinuria, cblF type, which is a rare genetic disorder characterized by the inability to process certain amino acids and fatty acids. There are currently no targeted drug discovery efforts for LMBRD2, as its function in the adrenergic receptor signaling pathway is not well understood. There are also no drugs on the market that specifically target LMBRD2. However, there are treatments available for methylmalonic aciduria and homocystinuria, cblF type, such as vitamin B12 supplementation and dietary modifications.",GO:0071875 adrenergic receptor signaling pathway;GO:0007186 G protein-coupled receptor signaling pathway;GO:0007165 signal transduction,,Disease related genes; Potential drug targets; Transporters,Cytosol;Nucleoplasm (Approved),,,
ENSG00000166128.13,ENSG00000166128,RAB8B,-1.101273396,-1.391814201,-0.99018689,-0.921819098,"RAB8B, member RAS oncogene family","RAB8B is a human gene that belongs to the RAB family of low molecular mass monomeric GTPases. These proteins are found on the cytoplasmic surfaces of various membrane-bound organelles and play a crucial role in intracellular vesicle transport. RAB8B helps in the docking and/or fusion of vesicles with their target membranes. Dysfunction of RAB8B has been associated with various diseases, including cancer and neurological disorders. Understanding the function of RAB8B and other RAB proteins can provide insights into the mechanisms of intracellular transport and the development of new therapies for related diseases.","There is limited information available on the disease implications of RAB8B. However, studies have suggested that RAB8B may play a role in cancer progression and metastasis. In particular, RAB8B has been found to be overexpressed in several types of cancer, including breast, lung, and pancreatic cancer. Targeted drug discovery efforts for RAB8B are currently limited, but there is potential for the development of drugs that target RAB proteins involved in intracellular transport. One example of a successful drug targeting intracellular transport is bortezomib, which targets the proteasome and is used to treat multiple myeloma. Another example is imatinib, which targets the BCR-ABL fusion protein and is used to treat chronic myeloid leukemia. However, further research is needed to identify specific RAB proteins that could be targeted for drug development.",GO:0051461 positive regulation of corticotropin secretion;GO:0045046 protein import into peroxisome membrane;GO:0051459 regulation of corticotropin secretion,,Predicted intracellular proteins,,Phosphoaminophosphonic acid guanylate ester; Guanosine-5'-Diphosphate,,
ENSG00000103249.18,ENSG00000103249,CLCN7,-1.099397436,-1.823358386,-1.373013993,-0.101819928,chloride voltage-gated channel 7,"CLCN7 is a gene that encodes for chloride channel 7, which belongs to the CLC chloride channel family of proteins. Chloride channels are important for various cellular functions. Mutations in this gene can cause osteopetrosis, a rare genetic disease characterized by abnormally dense bone due to defective resorption of immature bone. CLCN7 mutations are responsible for both autosomal recessive type 4 (OPTB4) and autosomal dominant type 2 (OPTA2) osteopetrosis. OPTA2 is the most common form of osteopetrosis, occurring in adolescence or adulthood.","There are currently no targeted drug therapies available for osteopetrosis caused by CLCN7 mutations. Treatment options for osteopetrosis are limited to supportive care, such as pain management and physical therapy. However, there have been some promising preclinical studies exploring potential drug targets for osteopetrosis, including inhibitors of the RANKL signaling pathway and cathepsin K inhibitors. Additionally, bisphosphonates, which are commonly used to treat osteoporosis, have been shown to improve bone density in some patients with osteopetrosis. While there are no drugs specifically approved for osteopetrosis caused by CLCN7 mutations, there are several drugs on the market for other forms of osteopetrosis, such as carbonic anhydrase II inhibitors for autosomal recessive osteopetrosis type 3 and interferon gamma-1b for malignant infantile osteopetrosis.",GO:0030321 transepithelial chloride transport;GO:0070633 transepithelial transport;GO:1902476 chloride transmembrane transport,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Transporters:Electrochemical Potential-driven transporters; Potential drug targets,,,,
ENSG00000164164.17,ENSG00000164164,OTUD4,-1.098851609,-1.225608433,-1.303100382,-0.767846011,OTU deubiquitinase 4,"OTUD4 is a gene that encodes for a protein called OTU deubiquitinase 4. This gene has multiple transcript variants, meaning that it can produce different versions of the protein. One of these variants produces a smaller isoform of the protein that is only found in cells infected with HIV-1. The function of OTUD4 is to remove ubiquitin molecules from other proteins, which can affect their stability and activity. The exact role of OTUD4 in HIV-1 infection is not yet fully understood, but it may play a role in regulating the immune response to the virus.","There is limited information available on the disease implications of OTUD4. However, some studies have suggested that it may play a role in cancer development and progression. For example, one study found that OTUD4 expression was significantly higher in breast cancer tissues compared to normal tissues, and that higher OTUD4 expression was associated with poorer patient outcomes. 

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target OTUD4. However, there is ongoing research into developing drugs that can modulate the activity of deubiquitinases like OTUD4, as they have been implicated in a variety of diseases including cancer, neurodegenerative disorders, and viral infections. 

One example of a successful drug that targets a deubiquitinase is bortezomib, which is used to treat multiple myeloma. Bortezomib inhibits the activity of the deubiquitinase proteasome, leading to the accumulation of ubiquitinated proteins and ultimately inducing cancer cell death. While there are currently no drugs that target OTUD4 specifically, the development of drugs that modulate the activity of deubiquitinases like OTUD4 may hold promise for the treatment of various diseases.",GO:1903093 regulation of protein K48-linked deubiquitination;GO:2000660 negative regulation of interleukin-1-mediated signaling pathway;GO:0006307 DNA alkylation repair,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol (Supported),,,
ENSG00000110756.18,ENSG00000110756,HPS5,-1.09825035,-1.696672328,-0.837253139,-0.760825585,HPS5 biogenesis of lysosomal organelles complex 2 subunit 2,"HPS5 is a gene that encodes a protein involved in the biogenesis of organelles such as melanosomes, platelet dense granules, and lysosomes. The protein interacts with Hermansky-Pudlak syndrome 6 protein and the cytoplasmic domain of integrin, alpha-3. Mutations in this gene are associated with Hermansky-Pudlak syndrome type 5. There are multiple transcript variants of the gene that encode two distinct isoforms.","Hermansky-Pudlak syndrome (HPS) is a rare genetic disorder characterized by oculocutaneous albinism, bleeding diathesis, and lysosomal storage defects. HPS5 mutations are associated with HPS type 5, which is characterized by severe bleeding, pulmonary fibrosis, and granulomatous colitis. There is currently no cure for HPS, and treatment is mainly supportive. However, targeted drug discovery efforts are underway to develop therapies that can alleviate the symptoms of the disease. One such approach is the use of small molecule chaperones that can stabilize the HPS5 protein and improve its function. Several drugs targeting HPS5 are currently in preclinical development, including HPS5 stabilizers and modulators of the HPS5-HPS6 protein complex. While there are no drugs currently on the market specifically for HPS5-related disorders, some drugs used to treat related conditions, such as bleeding disorders and lysosomal storage diseases, may be beneficial for HPS5 patients. For example, desmopressin, a synthetic analogue of vasopressin, can be used to treat bleeding in HPS patients, while enzyme replacement therapy with recombinant enzymes can improve lysosomal storage defects.",GO:1903232 melanosome assembly;GO:0060155 platelet dense granule organization;GO:0032438 melanosome organization,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of amino acid metabolism; Predicted intracellular proteins,Cytosol (Supported),,,
ENSG00000138496.16,ENSG00000138496,PARP9,-1.096246734,-1.461018657,-1.25372661,-0.573994936,poly(ADP-ribose) polymerase family member 9,"PARP9 is a member of the poly(ADP-ribose) polymerase family and is involved in various cellular processes such as regulation of gene expression, defense response, and nitrogen compound metabolic process. It possesses ADP-D-ribose binding activity, NAD+ ADP-ribosyltransferase activity, and STAT family protein binding activity. PARP9 is located in different cellular components, including mitochondrion, nucleoplasm, and site of DNA damage. It is part of a protein-containing complex and colocalizes with the nucleus.","PARP9 has been implicated in various diseases, including cancer, autoimmune disorders, and viral infections. In cancer, PARP9 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. Several drug discovery efforts have focused on developing PARP9 inhibitors as cancer therapeutics. One example is the PARP inhibitor olaparib, which has been approved for the treatment of ovarian and breast cancer. Olaparib has been shown to inhibit PARP9 activity, leading to DNA damage and cell death in cancer cells. Another example is the PARP inhibitor talazoparib, which has been approved for the treatment of breast cancer. Talazoparib has also been shown to inhibit PARP9 activity and induce DNA damage in cancer cells. Overall, PARP9 is an important target for drug discovery efforts in cancer therapy.",GO:0060332 positive regulation of response to type II interferon;GO:0060335 positive regulation of type II interferon-mediated signaling pathway;GO:0035563 positive regulation of chromatin binding,,Disease related genes; Predicted intracellular proteins,Cytosol;Nucleoplasm (Supported); Additional: Mitochondria,,,(M5911)HALLMARK INTERFERON ALPHA RESPONSE
ENSG00000109756.9,ENSG00000109756,RAPGEF2,-1.095136054,-1.53040412,-1.265189245,-0.489814797,Rap guanine nucleotide exchange factor 2,"RAPGEF2 is a gene that encodes for a protein called Rap guanine nucleotide exchange factor 2. This protein is a guanine nucleotide exchange factor (GEF) that activates members of the RAS subfamily of GTPases, which are important in signal transduction. RAPGEF2 promotes the acquisition of GTP to maintain the active GTP-bound state of RAS, which is necessary for proper cell signaling. It serves as a key link between cell surface receptors and RAS activation. Mutations in RAPGEF2 have been associated with various diseases, including intellectual disability and epilepsy.","Mutations in RAPGEF2 have been associated with various diseases, including intellectual disability and epilepsy. In particular, a deletion in the RAPGEF2 gene has been linked to intellectual disability and developmental delay. Additionally, mutations in RAPGEF2 have been found in patients with epilepsy, suggesting a potential role in the regulation of neuronal excitability.

There are currently no targeted drug discovery efforts specifically focused on RAPGEF2. However, drugs that target the RAS pathway, which is activated by RAPGEF2, have been developed for the treatment of cancer. These drugs include MEK inhibitors, which block the downstream signaling of RAS, and farnesyltransferase inhibitors, which prevent the activation of RAS by inhibiting its post-translational modification.

Examples of successful drugs on the market that target the RAS pathway include trametinib and cobimetinib, which are MEK inhibitors approved for the treatment of melanoma, and tipifarnib, a farnesyltransferase inhibitor approved for the treatment of acute myeloid leukemia. While these drugs do not directly target RAPGEF2, they demonstrate the potential for targeting the RAS pathway in disease treatment.",GO:2000481 positive regulation of cAMP-dependent protein kinase activity;GO:2000670 positive regulation of dendritic cell apoptotic process;GO:0048022 negative regulation of melanin biosynthetic process,,Disease related genes; Human disease related genes:Nervous system diseases:Epilepsy; Predicted intracellular proteins,Cytosol;Plasma membrane (Supported),,,
ENSG00000198961.10,ENSG00000198961,PJA2,-1.094681696,-1.322671654,-1.004668375,-0.956705059,praja ring finger ubiquitin ligase 2,"PJA2 is a human gene that encodes for a protein called praja ring finger ubiquitin ligase 2. This protein is involved in several processes, including protein ubiquitination, regulation of macrophage activation, and regulation of signal transduction. PJA2 enables protein kinase A catalytic subunit binding activity, protein kinase A regulatory subunit binding activity, and ubiquitin-protein transferase activity. The protein is located in the cytoplasm, intermediate filament cytoskeleton, and plasma membrane.","There is limited information available on the disease implications of PJA2. However, recent studies have suggested that PJA2 may play a role in the development and progression of certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for PJA2 are still in the early stages, but there is potential for the development of drugs that target the protein's ubiquitin-protein transferase activity. Currently, there are no drugs on the market that specifically target PJA2. However, there are several drugs that target the ubiquitin-proteasome system, which is involved in protein ubiquitination and degradation, and may indirectly affect PJA2 activity. Examples of such drugs include bortezomib, carfilzomib, and ixazomib, which are used to treat multiple myeloma and mantle cell lymphoma.",GO:0034137 positive regulation of toll-like receptor 2 signaling pathway;GO:0010738 regulation of protein kinase A signaling;GO:0034135 regulation of toll-like receptor 2 signaling pathway,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Basal body;Cytosol;Microtubules (Supported); Additional: Primary cilium;Primary cilium transition zone,,,
ENSG00000018408.15,ENSG00000018408,WWTR1,-1.094459029,-1.245285918,-1.387826413,-0.650264756,WW domain containing transcription regulator 1,"WWTR1, also known as WW domain containing transcription regulator 1, is a gene that plays a role in various cellular processes, including hippo signaling, cell differentiation, and signal transduction. It enables transcription coactivator activity and is located in both the cytosol and nuclear body. The gene is involved in the regulation of gene expression and is essential for normal cellular function. Mutations in WWTR1 have been associated with various diseases, including cancer and cardiovascular disorders. Understanding the function of WWTR1 may provide insights into the development of new therapies for these conditions.","WWTR1 has been implicated in various diseases, including cancer and cardiovascular disorders. In cancer, WWTR1 has been found to be overexpressed in several types of tumors, including breast, lung, and liver cancer. WWTR1 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. Several drugs targeting WWTR1 are currently in development, including inhibitors of the Hippo signaling pathway, which regulates WWTR1 activity. One example of a successful drug targeting WWTR1 is verteporfin, which is used to treat macular degeneration. Verteporfin inhibits WWTR1 activity and has been shown to have anti-tumor effects in preclinical studies. Other potential drugs targeting WWTR1 are currently being investigated in clinical trials for various types of cancer.",GO:0072307 regulation of metanephric nephron tubule epithelial cell differentiation;GO:0072182 regulation of nephron tubule epithelial cell differentiation;GO:2000696 regulation of epithelial cell differentiation involved in kidney development,,Cancer-related genes; Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Supported); Additional: Cytosol,,,(M5896)HALLMARK TGF BETA SIGNALING; (M5909)HALLMARK MYOGENESIS
ENSG00000104763.20,ENSG00000104763,ASAH1,-1.09062174,-1.197483372,-1.222314102,-0.852067746,N-acylsphingosine amidohydrolase 1,"ASAH1 is a gene that encodes a protein belonging to the acid ceramidase family. The gene undergoes alternative splicing, resulting in multiple transcript variants, one of which encodes a preproprotein that is proteolytically processed. The processed protein generates alpha and beta subunits that heterodimerize to form the mature lysosomal enzyme. This enzyme is responsible for breaking down ceramide into sphingosine and free fatty acid. ASAH1 is overexpressed in multiple human cancers and may play a role in cancer progression. Mutations in this gene are associated with Farber lipogranulomatosis, a lysosomal storage disorder, and spinal muscular atrophy with progressive myoclonic epilepsy, a neuromuscular disorder.","ASAH1 has been implicated in several diseases, including Farber lipogranulomatosis and spinal muscular atrophy with progressive myoclonic epilepsy. Farber lipogranulomatosis is a rare lysosomal storage disorder characterized by the accumulation of ceramide in various tissues, leading to inflammation and tissue damage. Mutations in ASAH1 result in reduced acid ceramidase activity, leading to the accumulation of ceramide and the development of Farber lipogranulomatosis. Spinal muscular atrophy with progressive myoclonic epilepsy is a neuromuscular disorder characterized by muscle weakness, seizures, and progressive myoclonus. Mutations in ASAH1 have been identified in patients with this disorder, although the exact mechanism by which these mutations lead to disease is not yet fully understood.

Targeted drug discovery efforts for ASAH1 have focused on developing small molecule inhibitors of acid ceramidase as potential therapies for cancer and other diseases. Several inhibitors of acid ceramidase have been developed and are currently in preclinical or clinical development for the treatment of cancer. One example is the drug LCL161, which is a small molecule inhibitor of acid ceramidase that has shown promising results in preclinical studies for the treatment of multiple myeloma and other cancers.

In addition to cancer, ASAH1 has also been implicated in other diseases, including neurodegenerative disorders and cardiovascular disease. Targeting ASAH1 and acid ceramidase may therefore have broad therapeutic potential for a range of diseases.",GO:0046512 sphingosine biosynthetic process;GO:0046520 sphingoid biosynthetic process;GO:0006670 sphingosine metabolic process,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Predicted intracellular proteins; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Lysosomal storage diseases; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,,,(M144)PID CERAMIDE PATHWAY,
ENSG00000107186.17,ENSG00000107186,MPDZ,-1.090271995,-1.404647021,-1.374875213,-0.491293752,multiple PDZ domain crumbs cell polarity complex component,"The human gene MPDZ encodes a protein with multiple PDZ domains, which are important for protein-protein interactions. This protein has been shown to interact with the HTR2C receptor and may cause it to clump at the cell surface. There are multiple transcript variants of this gene that encode different isoforms.","Research on the MPDZ gene has revealed its potential implications in various diseases. For instance, studies have shown that mutations in this gene may be associated with intellectual disability, schizophrenia, and autism spectrum disorders. Additionally, MPDZ has been identified as a potential therapeutic target for cancer treatment, as it plays a role in regulating cell proliferation and migration.

Efforts to discover drugs targeting MPDZ are still in the early stages, but some promising leads have been identified. One study found that a small molecule inhibitor of MPDZ was able to reduce the growth of cancer cells in vitro and in vivo. Another study identified a peptide that disrupts the interaction between MPDZ and the HTR2C receptor, which could potentially be developed into a therapeutic agent for psychiatric disorders.

Currently, there are no drugs on the market that specifically target MPDZ. However, there are drugs that indirectly affect the protein's function. For example, antipsychotic drugs such as clozapine and risperidone have been shown to interact with the HTR2C receptor, which is regulated by MPDZ. Additionally, some cancer drugs such as dasatinib and imatinib have been found to inhibit the activity of proteins that interact with MPDZ.",GO:0120192 tight junction assembly;GO:0120193 tight junction organization;GO:0007043 cell-cell junction assembly,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Centriolar satellite (Approved); Additional: Basal body,,,
ENSG00000143379.12,ENSG00000143379,SETDB1,-1.089862879,-1.593227926,-1.055490453,-0.620870258,SET domain bifurcated histone lysine methyltransferase 1,"SETDB1 is a gene that encodes a histone methyltransferase, which is responsible for regulating histone methylation, gene silencing, and transcriptional repression. This gene has been identified as a potential target for treatment in Huntington Disease, as gene silencing and transcription dysfunction are believed to contribute to the development of the disease. The gene has multiple alternatively spliced transcript variants.","SETDB1 has been implicated in several diseases, including cancer, neurodegenerative disorders, and viral infections. In Huntington Disease, SETDB1 has been identified as a potential therapeutic target due to its role in gene silencing and transcriptional repression. Several drug discovery efforts have focused on developing small molecule inhibitors of SETDB1, which could potentially restore normal gene expression and alleviate symptoms of the disease. However, no SETDB1 inhibitors have yet been approved for clinical use. In cancer, SETDB1 inhibitors have shown promise in preclinical studies, and several are currently in clinical trials. One example is GSK-923295, a SETDB1 inhibitor that is being evaluated in phase I clinical trials for the treatment of solid tumors. Another example is AZD5153, a SETDB1 inhibitor that is being evaluated in phase II clinical trials for the treatment of acute myeloid leukemia.",GO:0070828 heterochromatin organization;GO:0141005 transposable element silencing by heterochromatin formation;GO:0010526 transposable element silencing,,Enzymes; Cancer-related genes:Mutated cancer genes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported); Additional: Vesicles,,(M23)PID WNT NONCANONICAL PATHWAY,
ENSG00000166444.19,ENSG00000166444,DENND2B,-1.087732712,-1.868844242,-1.360234128,-0.034119766,DENN domain containing 2B,"DENND2B is a human gene that has been found to suppress the tumorigenicity of Hela cells in nude mice. The protein encoded by this gene contains a C-terminal region that is similar to the Rab 3 family of small GTP binding proteins. It binds to the SH3 domain of c-Abl kinase and acts as a regulator of MAPK1/ERK2 kinase, which may contribute to its ability to reduce the tumorigenic phenotype in cells. There are three alternatively spliced transcript variants of this gene that encode distinct isoforms. This gene was first identified based on its ability to suppress tumor growth, and its function as a regulator of MAPK1/ERK2 kinase suggests that it may have potential as a therapeutic target for cancer treatment.","There is limited information available on the disease implications of DENND2B. However, its role in suppressing tumorigenicity suggests that it may have potential as a therapeutic target for cancer treatment. Targeted drug discovery efforts for DENND2B are currently underway, with researchers exploring small molecule inhibitors and other compounds that can modulate its activity. As of now, there are no drugs on the market that specifically target DENND2B. However, there are several drugs that target the MAPK/ERK pathway, which is regulated by DENND2B. Examples include vemurafenib and dabrafenib, which are used to treat melanoma, and trametinib, which is used to treat several types of cancer. These drugs have shown promising results in clinical trials and have been approved by the FDA for use in cancer patients.",GO:0070374 positive regulation of ERK1 and ERK2 cascade;GO:0070372 regulation of ERK1 and ERK2 cascade;GO:0043410 positive regulation of MAPK cascade,,Predicted intracellular proteins,Nucleoplasm (Approved),,,(M5909)HALLMARK MYOGENESIS
ENSG00000185722.18,ENSG00000185722,ANKFY1,-1.087582965,-1.880541145,-1.194268403,-0.187939347,ankyrin repeat and FYVE domain containing 1,"ANKFY1 is a gene that encodes a cytoplasmic protein with a coiled-coil structure, a BTB/POZ domain at its N-terminus, ankyrin repeats in the middle portion, and a FYVE-finger motif at its C-terminus. This protein is part of a group of double zinc finger proteins that may be involved in vesicle or protein transport. The gene has multiple transcript variants due to alternate splicing.","There is limited information available on the disease implications of ANKFY1. However, recent studies have suggested that ANKFY1 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ANKFY1 are still in the early stages, but there is potential for the development of drugs that target ANKFY1 to treat cancer and other diseases. Currently, there are no drugs on the market that specifically target ANKFY1. However, there are drugs that target other proteins involved in vesicle or protein transport, such as bortezomib, which is used to treat multiple myeloma, and erlotinib, which is used to treat non-small cell lung cancer. Further research is needed to fully understand the role of ANKFY1 in disease and to develop targeted therapies.",GO:0048549 positive regulation of pinocytosis;GO:0090160 Golgi to lysosome transport;GO:0048548 regulation of pinocytosis,,Predicted intracellular proteins,Endosomes (Enhanced),,,
ENSG00000198909.8,ENSG00000198909,MAP3K3,-1.087183361,-1.86956244,-1.032429047,-0.359558595,mitogen-activated protein kinase kinase kinase 3,"MAP3K3 is a human gene that encodes a protein called mitogen-activated protein kinase kinase kinase 3. This protein is highly similar to the mouse Mekk3 and is involved in regulating the stress-activated protein kinase (SAPK) and extracellular signal-regulated protein kinase (ERK) pathways by activating SEK and MEK1/2, respectively. It does not regulate the p38 pathway. The gene is expressed ubiquitously and has been observed to have alternatively spliced transcript variants encoding distinct isoforms. In cotransfection assays, it has been shown to enhance transcription from a nuclear factor kappa-B (NFKB)-dependent reporter gene, indicating a role in the SAPK pathway.","MAP3K3 has been implicated in various diseases, including cancer, inflammation, and neurodegenerative disorders. In cancer, MAP3K3 has been shown to promote tumor growth and metastasis by activating the ERK and SAPK pathways. Targeted drug discovery efforts have focused on developing inhibitors of MAP3K3 as potential cancer therapeutics. One example is the small molecule inhibitor URMC-099, which has been shown to inhibit MAP3K3 and improve cognitive function in animal models of Alzheimer's disease. Another example is the compound BIX02189, which inhibits MAP3K3 and has been shown to reduce tumor growth in preclinical models of breast cancer. However, there are currently no MAP3K3 inhibitors approved for clinical use.",GO:1900745 positive regulation of p38MAPK cascade;GO:1900744 regulation of p38MAPK cascade;GO:0046777 protein autophosphorylation,yes,Predicted intracellular proteins; ENZYME proteins:Transferases; Enzymes; Kinases:STE Ser/Thr protein kinases; Cancer-related genes:Mutational cancer driver genes,Nucleoplasm (Approved),Fostamatinib,(M20)PID P38 MKK3 6PATHWAY; (M76)PID P38 ALPHA BETA PATHWAY; (M110)PID IL1 PATHWAY,
ENSG00000101974.14,ENSG00000101974,ATP11C,-1.087162869,-1.29689143,-1.129947176,-0.834650002,ATPase phospholipid transporting 11C,"ATP11C is a human gene that encodes a protein called ATPase phospholipid transporting 11C. This protein is involved in the transport of phospholipids, specifically phosphatidylethanolamine and phosphatidylserine, across cell membranes. It is predicted to play a role in phospholipid translocation, as well as in the regulation of B cell differentiation and pre-B cell differentiation. ATP11C is located in both the endoplasmic reticulum and plasma membrane, where it serves as an integral component. Mutations in ATP11C have been implicated in X-linked congenital hemolytic anemia, a condition characterized by the destruction of red blood cells.","Mutations in ATP11C have been linked to X-linked congenital hemolytic anemia, a rare genetic disorder characterized by the destruction of red blood cells. While there are currently no targeted drug discovery efforts specifically for ATP11C, there are several drugs on the market that are used to treat hemolytic anemia, including corticosteroids, immunosuppressive agents, and blood transfusions. In severe cases, bone marrow transplantation may be necessary. One successful drug used to treat hemolytic anemia is eculizumab, a monoclonal antibody that targets complement protein C5 and prevents the destruction of red blood cells. Another drug, hydroxyurea, is used to increase the production of fetal hemoglobin, which can help reduce the severity of symptoms in some patients. However, more research is needed to fully understand the role of ATP11C in hemolytic anemia and to develop targeted therapies for this condition.",GO:0140331 aminophospholipid translocation;GO:0015917 aminophospholipid transport;GO:0045332 phospholipid translocation,,Transporters:Primary Active Transporters; Potential drug targets; Enzymes; Disease related genes; ENZYME proteins,,,,
ENSG00000107263.18,ENSG00000107263,RAPGEF1,-1.086117123,-1.459592729,-1.110881563,-0.687877077,Rap guanine nucleotide exchange factor 1,"RAPGEF1 is a human gene that encodes a guanine nucleotide exchange factor. It plays a role in transducing signals from CRK by binding to its SH3 domain and activating several members of the Ras family of GTPases. This signaling cascade is believed to be involved in various cellular processes such as apoptosis, integrin-mediated signal transduction, and cell transformation. The gene has several alternatively spliced transcript variants, but the full-length nature of some of these variants is still unknown.","There is limited information available on the disease implications of RAPGEF1. However, some studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for RAPGEF1 are also limited, but some studies have identified potential small molecule inhibitors that could target its activity. One example is a study that identified a compound called NSC23766, which was found to inhibit RAPGEF1-mediated activation of the Ras family of GTPases. However, this compound has not yet been developed into a drug for clinical use. Currently, there are no drugs on the market that specifically target RAPGEF1.",GO:0032486 Rap protein signal transduction;GO:0038180 nerve growth factor signaling pathway;GO:0038179 neurotrophin signaling pathway,,Predicted intracellular proteins,Vesicles (Supported),,(M206)PID PDGFRA PATHWAY; (M69)PID REELIN PATHWAY; (M72)PID NECTIN PATHWAY,
ENSG00000124198.9,ENSG00000124198,ARFGEF2,-1.085051093,-1.150991579,-1.25783752,-0.846324179,ARF guanine nucleotide exchange factor 2,"ARFGEF2 is a human gene that encodes a protein involved in intracellular vesicular trafficking. The protein activates ADP-ribosylation factors (ARFs) by replacing bound GDP with GTP and is involved in Golgi transport. It contains a Sec7 domain, which is responsible for its guanine-nucleotide exchange activity and brefeldin A inhibition. ARFs play a crucial role in the regulation of vesicular trafficking, and mutations in ARFGEF2 have been associated with developmental disorders and intellectual disabilities.","Mutations in ARFGEF2 have been associated with developmental disorders and intellectual disabilities, including autosomal recessive periventricular heterotopia (ARPH) and intellectual disability with seizures. ARPH is a disorder characterized by abnormal migration of neurons during brain development, leading to the formation of nodules of gray matter in the white matter surrounding the ventricles. There are currently no targeted drug discovery efforts specifically for ARFGEF2, but drugs targeting the broader pathway of intracellular vesicular trafficking, such as brefeldin A and golgicide A, have been developed. These drugs inhibit the activity of ARFGEF2 and other proteins involved in vesicular trafficking, leading to disruption of cellular processes and potential therapeutic effects. However, these drugs have not been approved for clinical use due to their non-specific effects and potential toxicity.",GO:0032012 regulation of ARF protein signal transduction;GO:0001881 receptor recycling;GO:0043112 receptor metabolic process,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Golgi apparatus (Supported),,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000197081.16,ENSG00000197081,IGF2R,-1.084199147,-1.796052289,-0.97041626,-0.486128892,insulin like growth factor 2 receptor,"The IGF2R gene encodes a receptor that binds to both insulin-like growth factor 2 and mannose 6-phosphate. The receptor has various functions, including intracellular trafficking of lysosomal enzymes, activation of transforming growth factor beta, and degradation of insulin-like growth factor 2. Loss or mutation of this gene has been associated with an increased risk of hepatocellular carcinoma. In mice, the gene is imprinted and only expressed from the maternal allele, but in humans, imprinting may be polymorphic, with only a minority of individuals showing biased expression from the maternal allele.","The IGF2R gene has been implicated in several diseases, including cancer, diabetes, and lysosomal storage disorders. In hepatocellular carcinoma, loss or mutation of the gene has been associated with an increased risk of developing the disease. Targeted drug discovery efforts have focused on developing drugs that can modulate the activity of the IGF2R receptor, either by enhancing its function or inhibiting its activity. One example of a successful drug targeting the IGF2R receptor is laronidase, which is used to treat mucopolysaccharidosis type I, a lysosomal storage disorder caused by a deficiency in the enzyme alpha-L-iduronidase. Laronidase is a recombinant form of the enzyme that is targeted to the lysosome via the IGF2R receptor. Other potential drug targets include the mannose 6-phosphate binding site on the receptor, which could be targeted to enhance lysosomal enzyme delivery in lysosomal storage disorders.",GO:1904772 response to tetrachloromethane;GO:0044794 positive regulation by host of viral process;GO:0044788 modulation by host of viral process,,Predicted intracellular proteins; Transporters; Human disease related genes:Cancers:Cancers of the digestive system; CD markers; Cancer-related genes:Candidate cancer biomarkers,Golgi apparatus (Supported); Additional: Vesicles,Mecasermin; alpha-D-mannose 6-phosphate; Cerliponase alfa; Mecasermin rinfabate,,(M5910)HALLMARK PROTEIN SECRETION; (M5902)HALLMARK APOPTOSIS; (M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000100441.10,ENSG00000100441,KHNYN,-1.083826687,-1.299666993,-1.195386377,-0.756426691,KH and NYN domain containing,"KHNYN is a human gene that encodes a protein containing a ribonuclease NYN domain and belongs to the N4BP1 family. This protein acts as a cofactor for the zinc finger antiviral protein (ZAP protein), which targets viral RNA for degradation and restricts SARS-CoV-2 infection. The protein's function is to enhance the antiviral activity of ZAP protein, which is crucial in the body's defense against viral infections. This gene's discovery may lead to the development of new therapies for viral infections, including COVID-19.","There is limited information available on the disease implications of KHNYN gene mutations. However, the discovery of its role as a cofactor for ZAP protein in restricting SARS-CoV-2 infection suggests that it may have implications in COVID-19. Targeted drug discovery efforts for KHNYN are currently underway, with researchers exploring the potential of developing drugs that enhance the antiviral activity of ZAP protein by targeting KHNYN. While there are no drugs currently on the market that target KHNYN specifically, there are several antiviral drugs that target viral RNA degradation pathways, including ribavirin, sofosbuvir, and remdesivir. These drugs have shown efficacy in treating viral infections such as hepatitis C and Ebola virus disease.",GO:0008150 biological_process,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,(M5945)HALLMARK HEME METABOLISM
ENSG00000038219.13,ENSG00000038219,BOD1L1,-1.08377082,-1.33418839,-1.209973416,-0.707150653,biorientation of chromosomes in cell division 1 like 1,BOD1L1 is a human gene that is involved in the biorientation of chromosomes during cell division. It is predicted to have protein phosphatase 2A binding activity and protein phosphatase inhibitor activity. The gene is also involved in the cellular response to DNA damage stimulus and replication fork processing. BOD1L1 is located in the nucleoplasm.,"There is limited information available on the disease implications of BOD1L1. However, recent studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, including breast cancer and ovarian cancer. Targeted drug discovery efforts for BOD1L1 are still in the early stages, but there is potential for the development of drugs that target the protein phosphatase activity of this gene. Currently, there are no drugs on the market that specifically target BOD1L1. However, there are several drugs that target other proteins involved in the biorientation of chromosomes during cell division, such as paclitaxel and vinblastine, which are used in the treatment of various types of cancer. Further research is needed to fully understand the potential therapeutic implications of BOD1L1 and to develop targeted drugs for its treatment.",GO:0031297 replication fork processing;GO:0045005 DNA-templated DNA replication maintenance of fidelity;GO:0006261 DNA-templated DNA replication,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000102024.18,ENSG00000102024,PLS3,-1.083299577,-0.515539044,-1.332751668,-1.40160802,plastin 3,"PLS3, also known as plastin 3, is a gene that encodes for an actin-binding protein called plastin. Plastins are found in most tissues of higher eukaryotes and are involved in various cellular processes such as cell migration and adhesion. In humans, there are two ubiquitous isoforms of plastin (L and T) and a third isoform (plastin 1 or Fimbrin) that is specifically expressed in the small intestine. The L isoform is only expressed in hemopoietic cell lineages, while the T isoform is found in all other normal cells of solid tissues that have replicative potential. The C-terminal region of the T and L isoforms are highly similar and contain a potential calcium-binding site near the N terminus. The gene undergoes alternate splicing, resulting in multiple transcript variants.","Research has shown that mutations in the PLS3 gene are associated with X-linked osteoporosis, a rare genetic disorder characterized by low bone density and an increased risk of fractures. In addition, PLS3 has been implicated in the progression of various types of cancer, including breast, prostate, and colorectal cancer. As a result, there has been interest in developing drugs that target PLS3 as a potential therapeutic strategy for these diseases. However, there are currently no FDA-approved drugs that specifically target PLS3. Nonetheless, there are several drugs on the market that indirectly affect PLS3 expression or function, such as bisphosphonates for osteoporosis and various chemotherapeutic agents for cancer. Further research is needed to fully understand the role of PLS3 in disease and to develop targeted therapies.",GO:0051639 actin filament network formation;GO:0051017 actin filament bundle assembly;GO:0061572 actin filament bundle organization,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Musculoskeletal diseases:Skeletal diseases,Cytosol;Plasma membrane (Approved),,,
ENSG00000106723.17,ENSG00000106723,SPIN1,-1.082723175,-1.607111864,-1.404323934,-0.236733728,spindlin 1,"SPIN1, also known as spindlin 1, is a human gene that encodes a protein involved in various cellular processes. The protein has the ability to bind to methylated histones and is involved in the positive regulation of the Wnt signaling pathway, transcription of DNA, and transcription of ribosomal RNA. SPIN1 is located in both the cytosol and nucleus of cells.","There is limited information available on the disease implications of SPIN1. However, recent studies have suggested that SPIN1 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for SPIN1 are still in the early stages, but there is potential for the development of drugs that target the protein's ability to bind to methylated histones and regulate the Wnt signaling pathway. Currently, there are no drugs on the market that specifically target SPIN1, but there are drugs that target the Wnt signaling pathway, such as Vantictumab and OMP-54F28, which are being investigated for the treatment of various types of cancer. Further research is needed to fully understand the potential therapeutic implications of targeting SPIN1.",GO:0141176 gene silencing by piRNA-directed DNA methylation;GO:0141196 transposable element silencing by piRNA-mediated DNA methylation;GO:0140966 piRNA-mediated heterochromatin formation,,Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000122042.10,ENSG00000122042,UBL3,-1.081977014,-1.623521342,-1.007900364,-0.614509335,ubiquitin like 3,"The human gene UBL3, also known as ubiquitin like 3, is located in the extracellular exosome. This gene is involved in the process of ubiquitination, which is the attachment of ubiquitin molecules to proteins to regulate their function and degradation. The exact function of UBL3 is not yet fully understood, but it is believed to play a role in protein modification and cellular signaling pathways. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of UBL3. However, research has suggested that dysregulation of the ubiquitination process, in which UBL3 is involved, can lead to the development of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Therefore, UBL3 may have potential as a therapeutic target for these diseases.

Currently, there are no targeted drug discovery efforts specifically focused on UBL3. However, there are drugs on the market that target the ubiquitination process, such as proteasome inhibitors, which are used to treat multiple myeloma and mantle cell lymphoma. Additionally, there are ongoing efforts to develop drugs that target specific components of the ubiquitination pathway, which may have potential for treating a wider range of diseases.

In conclusion, while the exact role of UBL3 in disease is not yet fully understood, its involvement in the ubiquitination process suggests that it may have potential as a therapeutic target for various diseases. Further research is needed to fully elucidate the function of UBL3 and its potential as a drug target.",,,Predicted intracellular proteins,Centrosome (Approved),,,
ENSG00000111145.8,ENSG00000111145,ELK3,-1.081621053,-1.466896215,-1.180248156,-0.597718786,ETS transcription factor ELK3,"ELK3 is a gene that belongs to the ETS-domain transcription factor family and the ternary complex factor subfamily. It regulates transcription by binding to serum response elements when recruited by serum response factor. The protein is activated by signal-induced phosphorylation and acts as a transcriptional inhibitor in the absence of Ras, but activates transcription when Ras is present. The gene undergoes alternate splicing, resulting in multiple transcript variants. Studies in rodents suggest that ELK3 plays a role in the regulation of gene expression and may be involved in various cellular processes.","There is limited information available on the disease implications of ELK3. However, some studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for ELK3 are also limited, but some studies have identified potential small molecule inhibitors that could target the protein. One example is a compound called CCG-1423, which has been shown to inhibit ELK3 activity and reduce cancer cell migration and invasion in vitro. However, there are currently no drugs on the market that specifically target ELK3. Further research is needed to fully understand the potential therapeutic implications of targeting this gene.",GO:0042060 wound healing;GO:0001525 angiogenesis;GO:0048514 blood vessel morphogenesis,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported); Additional: Mitochondria,,,
ENSG00000137507.11,ENSG00000137507,LRRC32,-1.08106573,-1.711807201,-0.829901145,-0.701488843,leucine rich repeat containing 32,"LRRC32 is a gene that encodes a type I membrane protein with 20 leucine-rich repeats. This gene is located in the chromosomal region 11q13-11q14, which is associated with various pathologies. The function of LRRC32 is not fully understood, but it is believed to play a role in immune regulation and inflammation. Alterations in this gene have been linked to autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. Further research is needed to fully understand the role of LRRC32 in human health and disease.","LRRC32 has been implicated in various autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus. Studies have shown that LRRC32 is involved in the regulation of T cell activation and differentiation, and its dysregulation can lead to the development of autoimmune disorders. Targeted drug discovery efforts have focused on developing drugs that can modulate the activity of LRRC32 and its downstream signaling pathways. One example is the drug abatacept, which is a fusion protein that binds to LRRC32 and inhibits T cell activation. Abatacept has been approved by the FDA for the treatment of rheumatoid arthritis and is currently being investigated for its potential use in other autoimmune diseases. Another drug, tocilizumab, targets the interleukin-6 receptor, which is downstream of LRRC32 signaling, and has been approved for the treatment of rheumatoid arthritis and other autoimmune diseases.",GO:0046007 negative regulation of activated T cell proliferation;GO:0062009 secondary palate development;GO:0046006 regulation of activated T cell proliferation,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000197256.11,ENSG00000197256,KANK2,-1.080728146,-1.79961347,-1.119308445,-0.323262522,KN motif and ankyrin repeat domains 2,"KANK2 is a gene that belongs to the KN motif and ankyrin repeat domains (KANK) family of proteins. These proteins are involved in regulating actin polymerization, which is important for cytoskeletal formation. KANK2 plays a role in sequestering steroid receptor coactivators and other proteins. Mutations in this gene have been linked to impaired kidney podocyte function and nephrotic syndrome, as well as keratoderma and woolly hair.","Mutations in the KANK2 gene have been linked to several diseases, including nephrotic syndrome and keratoderma with woolly hair. Nephrotic syndrome is a kidney disorder characterized by excessive protein loss in the urine, leading to edema and other complications. KANK2 mutations have been found to impair podocyte function, which are specialized cells in the kidney responsible for filtering blood. Targeted drug discovery efforts for nephrotic syndrome have focused on developing drugs that can improve podocyte function and reduce proteinuria. One example is the use of angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs), which have been shown to reduce proteinuria and slow the progression of kidney disease. Another example is the use of glucocorticoids, which can reduce inflammation and improve podocyte function. However, these drugs can have side effects and are not effective for all patients. Therefore, there is a need for further research and drug development to improve treatment options for patients with nephrotic syndrome and other KANK2-related diseases.",GO:0070563 negative regulation of vitamin D receptor signaling pathway;GO:0090521 podocyte cell migration;GO:0070562 regulation of vitamin D receptor signaling pathway,,Disease related genes; Human disease related genes:Urinary system diseases:Kidney diseases; Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000116984.14,ENSG00000116984,MTR,-1.080041998,-1.621923626,-1.031663397,-0.58653897,5-methyltetrahydrofolate-homocysteine methyltransferase,"The MTR gene encodes the 5-methyltetrahydrofolate-homocysteine methyltransferase enzyme, which is also known as cobalamin-dependent methionine synthase. This enzyme is responsible for the final step in methionine biosynthesis. Mutations in the MTR gene have been identified as the cause of methylcobalamin deficiency complementation group G. This gene has multiple alternatively spliced transcript variants that encode distinct isoforms.","Mutations in the MTR gene have been associated with a range of diseases, including homocystinuria, megaloblastic anemia, and neural tube defects. Methylcobalamin deficiency complementation group G is a rare autosomal recessive disorder caused by mutations in the MTR gene. This disorder is characterized by developmental delay, neurological symptoms, and megaloblastic anemia. 

Targeted drug discovery efforts for MTR-related disorders have focused on developing therapies that can restore the function of the MTR enzyme. One approach has been to use small molecules that can act as cofactors for the enzyme, such as adenosylcobalamin and methylcobalamin. Another approach has been to develop gene therapies that can introduce functional copies of the MTR gene into affected cells.

There are currently no drugs on the market that specifically target the MTR gene. However, there are several drugs that are used to treat the symptoms of MTR-related disorders. For example, patients with megaloblastic anemia may be treated with folic acid supplements, while those with homocystinuria may be treated with a low-methionine diet and vitamin B6 supplements. In addition, patients with severe MTR-related disorders may require regular injections of hydroxocobalamin, a form of vitamin B12 that can bypass the MTR enzyme and be converted into methylcobalamin by other enzymes in the body.",GO:0009235 cobalamin metabolic process;GO:0009086 methionine biosynthetic process;GO:0050667 homocysteine metabolic process,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of amino acid metabolism; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; ENZYME proteins:Transferases; FDA approved drug targets:Small molecule drugs; Disease related genes; Enzymes,Microtubules;Primary cilium (Approved); Additional: Basal body;Cytokinetic bridge;Cytosol,Cyanocobalamin; Tetrahydrofolic acid; Methionine; Hydroxocobalamin; Mecobalamin; Thimerosal,,
ENSG00000151304.6,ENSG00000151304,SRFBP1,-1.079531149,-1.152764634,-1.031364181,-1.054464633,serum response factor binding protein 1,"SRFBP1, also known as serum response factor binding protein 1, is a gene that encodes a protein with RNA binding activity. It is predicted to be involved in the maturation of SSU-rRNA and located in the perinuclear region of the cytoplasm. It is also predicted to be part of the 90S preribosome and active in the nucleus. This information was provided by the Alliance of Genome Resources in April 2022.","There is limited information available on the disease implications of SRFBP1. However, some studies have suggested that it may play a role in cancer progression and metastasis. For example, one study found that SRFBP1 expression was significantly higher in breast cancer tissues compared to normal tissues, and that its overexpression was associated with poor prognosis. 

As for targeted drug discovery efforts, there are currently no drugs specifically targeting SRFBP1. However, there are ongoing efforts to develop drugs that target RNA-binding proteins in general, which could potentially include SRFBP1. 

There are currently no drugs on the market that target SRFBP1. However, there are drugs that target other RNA-binding proteins, such as the splicing factor SF3B1, which is mutated in certain types of cancer. One example is the drug H3B-8800, which is currently in clinical trials for the treatment of myelodysplastic syndromes and other hematologic malignancies.",GO:0030490 maturation of SSU-rRNA;GO:0042274 ribosomal small subunit biogenesis;GO:0006364 rRNA processing,,Predicted intracellular proteins,Nucleoli rim (Approved),,,
ENSG00000108175.17,ENSG00000108175,ZMIZ1,-1.079381794,-1.847440301,-1.219698685,-0.171006396,zinc finger MIZ-type containing 1,"ZMIZ1 is a gene that belongs to the PIAS family of proteins and is involved in regulating the activity of various transcription factors, including androgen receptor, Smad3/4, and p53. It may also play a role in sumoylation. A translocation between this gene on chromosome 10 and the ABL1 gene on chromosome 9 has been linked to acute lymphoblastic leukemia.","Research on ZMIZ1 has revealed its involvement in various diseases, including cancer. The translocation between ZMIZ1 and ABL1 has been linked to acute lymphoblastic leukemia, a type of blood cancer that affects white blood cells. Additionally, ZMIZ1 has been found to be overexpressed in breast cancer, and its inhibition has been shown to reduce tumor growth in preclinical models.

Targeted drug discovery efforts for ZMIZ1 are still in the early stages, but there is potential for the development of drugs that target its activity in cancer cells. One approach is to develop small molecule inhibitors that block the interaction between ZMIZ1 and its target transcription factors, such as androgen receptor or p53. Another approach is to target the sumoylation pathway, which is regulated by ZMIZ1 and has been implicated in cancer.

Currently, there are no drugs on the market that specifically target ZMIZ1. However, there are drugs that indirectly affect its activity. For example, enzalutamide is a drug used to treat prostate cancer that targets the androgen receptor, which is regulated by ZMIZ1. Additionally, the chemotherapy drug doxorubicin has been shown to reduce ZMIZ1 expression in breast cancer cells. Further research is needed to fully understand the role of ZMIZ1 in disease and to develop targeted therapies.",GO:0021852 pyramidal neuron migration to cerebral cortex;GO:0007296 vitellogenesis;GO:0140650 radial glia-guided pyramidal neuron migration,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,(M58)PID AR PATHWAY,(M5908)HALLMARK ANDROGEN RESPONSE; (M5942)HALLMARK UV RESPONSE DN
ENSG00000132694.19,ENSG00000132694,ARHGEF11,-1.079249552,-1.594260143,-1.064288635,-0.579199878,Rho guanine nucleotide exchange factor 11,"ARHGEF11 is a human gene that encodes for Rho guanine nucleotide exchange factor 11, which plays a crucial role in various cellular processes initiated by extracellular stimuli that work through G protein coupled receptors. The protein may form a complex with G proteins and stimulate Rho-dependent signals. In rats, a similar protein interacts with glutamate transporter EAAT4 and modulates its glutamate transport activity. The expression of the rat protein induces the reorganization of the actin cytoskeleton and its overexpression induces the formation of membrane ruffling and filopodia. Two alternative transcripts encoding different isoforms have been described.","There is limited information available on the disease implications of ARHGEF11. However, some studies have suggested that mutations in this gene may be associated with the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ARHGEF11 are also limited, but some studies have explored the potential of targeting Rho GTPases, which are activated by ARHGEF11, as a therapeutic strategy for cancer. One example of a successful drug targeting Rho GTPases is the FDA-approved drug, Fasudil, which is used to treat cerebral vasospasm following subarachnoid hemorrhage. Fasudil inhibits Rho kinase, which is downstream of Rho GTPases, and has been shown to have anti-tumor effects in preclinical studies. However, further research is needed to determine the potential of targeting ARHGEF11 and its downstream signaling pathways for therapeutic purposes.",GO:0007266 Rho protein signal transduction;GO:0006941 striated muscle contraction;GO:0030010 establishment of cell polarity,,Predicted intracellular proteins,Plasma membrane (Supported); Additional: Nucleoplasm,,(M5193)SIG CHEMOTAXIS; (M68)PID RHOA REG PATHWAY; (M281)PID FAK PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000125249.7,ENSG00000125249,RAP2A,-1.079159383,-1.23387907,-0.981626883,-1.021972197,"RAP2A, member of RAS oncogene family","RAP2A is a human gene that belongs to the RAS oncogene family. It encodes a protein that has GTPase activity, guanyl ribonucleotide binding activity, and magnesium ion binding activity. The protein is involved in various processes, including actin cytoskeleton reorganization, microvillus assembly, and positive regulation of protein autophosphorylation. It acts upstream of or within the establishment of protein localization and is located in the plasma membrane and recycling endosome membrane.","There is limited information available on the disease implications of RAP2A. However, studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for RAP2A are also limited, but some studies have explored the potential of inhibiting RAP2A as a therapeutic strategy for cancer treatment. One study found that inhibiting RAP2A expression in breast cancer cells reduced their ability to migrate and invade. Another study found that inhibiting RAP2A expression in pancreatic cancer cells reduced their ability to form tumors in mice. Currently, there are no drugs on the market that specifically target RAP2A. However, there are drugs that target other members of the RAS oncogene family, such as KRAS and NRAS, which are frequently mutated in cancer. Examples of successful drugs targeting these genes include cetuximab, panitumumab, and trametinib.",GO:0030033 microvillus assembly;GO:0032486 Rap protein signal transduction;GO:0032528 microvillus organization,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,,Guanosine-5'-Triphosphate; Guanosine-5'-Diphosphate,,
ENSG00000198369.10,ENSG00000198369,SPRED2,-1.078265832,-1.542119827,-0.993202649,-0.69947502,sprouty related EVH1 domain containing 2,"SPRED2 is a human gene that belongs to the Sprouty/SPRED family of proteins. These proteins are involved in regulating the activation of the MAP kinase cascade, which is important for cell growth and differentiation. SPRED2 is thought to play a role in the development of the nervous system and has been linked to conditions such as autism and intellectual disability. Mutations in the SPRED2 gene have also been associated with a rare genetic disorder called Legius syndrome, which is characterized by caf-au-lait spots and other symptoms similar to neurofibromatosis type 1.","Research on SPRED2 has primarily focused on its role in the development of the nervous system and its association with neurodevelopmental disorders such as autism and intellectual disability. However, mutations in the SPRED2 gene have also been linked to Legius syndrome, a rare genetic disorder characterized by caf-au-lait spots and other symptoms similar to neurofibromatosis type 1. 

Currently, there are no targeted drug discovery efforts specifically for SPRED2. However, there are drugs on the market that target the MAP kinase cascade, which SPRED2 is involved in regulating. For example, BRAF inhibitors such as vemurafenib and dabrafenib are used to treat melanoma patients with BRAF mutations, which activate the MAP kinase pathway. Additionally, MEK inhibitors such as trametinib and cobimetinib are used in combination with BRAF inhibitors to treat melanoma patients with BRAF mutations. These drugs have shown promising results in clinical trials and have been approved by the FDA for use in certain patient populations. However, their efficacy in treating neurodevelopmental disorders associated with SPRED2 mutations remains to be seen.",GO:1902747 negative regulation of lens fiber cell differentiation;GO:1902746 regulation of lens fiber cell differentiation;GO:0010801 negative regulation of peptidyl-threonine phosphorylation,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Nucleoplasm (Uncertain); Additional: Cytosol,,(M231)PID KIT PATHWAY,(M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000166889.14,ENSG00000166889,PATL1,-1.076361556,-1.508799519,-1.102144363,-0.618140784,"PAT1 homolog 1, processing body mRNA decay factor","PATL1, also known as PAT1 homolog 1, is a gene that encodes a protein involved in the decay of messenger RNA (mRNA) in cells. The protein has the ability to bind to poly(G) and poly(U) RNA, and is involved in the assembly of P-bodies, which are cytoplasmic structures involved in mRNA degradation. PATL1 is also involved in the process of deadenylation-dependent decapping of nuclear-transcribed mRNA. The protein is located in both the cytosol and P-bodies, and colocalizes with the CCR4-NOT complex, which is involved in mRNA degradation. Overall, PATL1 plays an important role in regulating gene expression by controlling the degradation of mRNA.","There is limited information available on the disease implications of PATL1. However, recent studies have suggested that PATL1 may play a role in the development of certain cancers, including breast cancer and ovarian cancer. Targeted drug discovery efforts for PATL1 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and inhibit its function. While there are currently no drugs on the market that specifically target PATL1, there are several drugs that target related proteins involved in mRNA degradation, such as the CCR4-NOT complex. Examples of such drugs include PTC299, which targets the CCR4-NOT complex and is currently in clinical trials for the treatment of solid tumors, and KPT-9274, which targets the CCR4-NOT complex and is in preclinical development for the treatment of various cancers.",GO:0000290 deadenylation-dependent decapping of nuclear-transcribed mRNA;GO:0110156 mRNA methylguanosine-cap decapping;GO:0033962 P-body assembly,,Predicted intracellular proteins,Cytoplasmic bodies (Supported),,,
ENSG00000014123.10,ENSG00000014123,UFL1,-1.073371514,-1.431893203,-1.134883926,-0.653337413,UFM1 specific ligase 1,"UFL1 is a human gene that encodes for UFM1 specific ligase 1, which is involved in various cellular processes such as protein modification, signal transduction regulation, and reticulophagy. It enables UFM1 ligase activity and protein kinase binding activity and acts upstream or within processes such as positive regulation of cell population proliferation, regulation of proteasomal ubiquitin-dependent protein catabolic process, and response to endoplasmic reticulum stress. UFL1 is located in the endoplasmic reticulum membrane, nucleus, and site of double-strand break and is part of a protein-containing complex.","There is limited information available on the disease implications of UFL1. However, recent studies have suggested that mutations in UFL1 may be associated with a rare genetic disorder called CCFDN (Cerebellar Ataxia, Hypogonadism, and Choroidal Dystrophy). This disorder is characterized by progressive cerebellar ataxia, hypogonadism, and retinal degeneration. 

Currently, there are no targeted drug discovery efforts for UFL1. However, there are several drugs on the market that target related pathways. For example, bortezomib is a proteasome inhibitor that is used to treat multiple myeloma and mantle cell lymphoma. It works by inhibiting the proteasomal ubiquitin-dependent protein catabolic process, which is regulated by UFL1. Additionally, drugs that target the endoplasmic reticulum stress response, such as tunicamycin and thapsigargin, have been investigated for their potential therapeutic effects in various diseases, including cancer and neurodegenerative disorders. 

In conclusion, while there is limited information available on the disease implications of UFL1, drugs that target related pathways have shown promise in treating various diseases. Further research is needed to fully understand the role of UFL1 in disease and to develop targeted therapies.",GO:0140500 regulation of reticulophagy;GO:0140501 positive regulation of reticulophagy;GO:0002841 negative regulation of T cell mediated immune response to tumor cell,,Predicted intracellular proteins,Endoplasmic reticulum (Supported),,,
ENSG00000114904.13,ENSG00000114904,NEK4,-1.073285885,-1.037257629,-1.600119285,-0.58248074,NIMA related kinase 4,"NEK4, also known as NIMA-related kinase 4, is a protein kinase that is essential for normal entry into replicative senescence. It is also involved in cell cycle arrest in response to double-stranded DNA damage and plays a role in maintaining cilium integrity. Defects in the NEK4 gene have been associated with ciliopathies, which are a group of disorders caused by abnormalities in the structure or function of cilia. Cilia are hair-like structures that protrude from the surface of cells and play important roles in cell signaling, movement, and sensory perception.","There is currently limited information available on targeted drug discovery efforts for NEK4. However, defects in the NEK4 gene have been associated with ciliopathies, which are a group of disorders caused by abnormalities in the structure or function of cilia. Some examples of ciliopathies include Bardet-Biedl syndrome, Joubert syndrome, and polycystic kidney disease. While there are currently no drugs specifically targeting NEK4, there are some drugs on the market that have been approved for the treatment of ciliopathies. For example, the drug tolvaptan has been approved for the treatment of autosomal dominant polycystic kidney disease, which is a ciliopathy characterized by the formation of fluid-filled cysts in the kidneys. Tolvaptan works by inhibiting the activity of a protein called vasopressin, which is involved in the formation of cysts.",GO:2000772 regulation of cellular senescence;GO:0006468 protein phosphorylation;GO:0016310 phosphorylation,yes,Enzymes; Predicted intracellular proteins; Kinases:NEK Ser/Thr protein kinases; ENZYME proteins:Transferases,Cytosol (Supported),Fostamatinib,,
ENSG00000140396.13,ENSG00000140396,NCOA2,-1.072065452,-1.131003189,-1.33310803,-0.752085137,nuclear receptor coactivator 2,"NCOA2, or nuclear receptor coactivator 2, is a gene that encodes a protein that acts as a transcriptional coactivator for nuclear hormone receptors, including those for steroids, thyroid hormones, retinoids, and vitamin D. This protein helps regulate the activity of these receptors, which in turn regulate the expression of target genes. NCOA2 has been found to be involved in translocations that result in fusions with other genes in various cancers, including acute myeloid leukemia, acute lymphoblastic leukemia, and mesenchymal chondrosarcoma. Alternative splicing of the NCOA2 gene results in multiple transcript variants.","NCOA2 has been implicated in various cancers due to its involvement in translocations that result in fusions with other genes. In acute myeloid leukemia, for example, the NCOA2 gene has been found to fuse with the genes for various transcription factors, resulting in the formation of chimeric proteins that drive leukemogenesis. Targeting NCOA2 and its associated pathways may therefore be a promising approach for developing new cancer therapies. However, there are currently no drugs on the market that specifically target NCOA2. Some drugs that indirectly affect NCOA2 activity, such as tamoxifen and raloxifene, are used in the treatment and prevention of breast cancer. Further research is needed to fully understand the role of NCOA2 in cancer and to develop targeted therapies.",GO:1904017 cellular response to Thyroglobulin triiodothyronine;GO:1904016 response to Thyroglobulin triiodothyronine;GO:0035357 peroxisome proliferator activated receptor signaling pathway,,Disease related genes; Cancer-related genes; Transcription factors:Basic domains; Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Supported),"Diethylstilbestrol; Genistein; Metribolone; 17-METHYL-17-ALPHA-DIHYDROEQUILENIN; 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol; TO-901317; 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL; 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL; 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL; (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL; (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL; 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL; 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL; 2-chloro-5-nitro-N-phenylbenzamide; dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate; 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol; 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL; (2E,4E)-11-METHOXY-3,7,11-TRIMETHYLDODECA-2,4-DIENOIC ACID; DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE; 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID; 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL; Tributyltin; 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol; Estradiol acetate; Estradiol benzoate; Estradiol cypionate; Estradiol dienanthate; Estradiol valerate",(M119)PID ERB GENOMIC PATHWAY; (M207)PID RETINOIC ACID PATHWAY; (M151)PID AR TF PATHWAY,
ENSG00000225733.6,ENSG00000225733,FGD5-AS1,-1.071375772,-1.505064578,-1.175683078,-0.533379659,FGD5 antisense RNA 1,,,,,,,,,
ENSG00000116539.14,ENSG00000116539,ASH1L,-1.070888928,-1.326039231,-1.307731256,-0.578896297,ASH1 like histone lysine methyltransferase,"ASH1L is a gene that belongs to the trithorax group of transcriptional activators. It encodes a protein that contains four AT hooks, a SET domain, a PHD-finger motif, and a bromodomain. The protein is found in many small speckles in the nucleus and also in cell-cell tight junctions. ASH1L is an ASH1-like histone lysine methyltransferase, which means it adds a methyl group to lysine residues on histone proteins, leading to changes in gene expression. The exact function of ASH1L is not fully understood, but it is thought to play a role in regulating gene expression during development and differentiation.","ASH1L has been implicated in several diseases, including cancer, developmental disorders, and neurological disorders. In cancer, ASH1L has been shown to be overexpressed in various types of tumors, including breast, lung, and liver cancer. This overexpression is associated with poor prognosis and increased tumor growth and metastasis. Therefore, ASH1L is being investigated as a potential therapeutic target for cancer treatment.

Several drug discovery efforts have been made to target ASH1L. One approach is to develop small molecule inhibitors that can block the activity of ASH1L. Another approach is to develop drugs that can target the protein-protein interactions involving ASH1L. These efforts have led to the identification of several potential drug candidates, some of which are currently in preclinical development.

One example of a successful drug targeting a histone methyltransferase is tazemetostat, which targets the EZH2 enzyme. EZH2 is overexpressed in several types of cancer, and tazemetostat has been approved by the FDA for the treatment of certain types of lymphoma and solid tumors. This success has encouraged further research into targeting other histone methyltransferases, including ASH1L, for the treatment of cancer and other diseases.",GO:1903699 tarsal gland development;GO:1903709 uterine gland development;GO:0061038 uterus morphogenesis,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Golgi apparatus;Nucleoplasm (Supported),,,
ENSG00000174718.12,ENSG00000174718,RESF1,-1.067571856,-0.997018176,-0.947652529,-1.258044862,retroelement silencing factor 1,"RESF1, or retroelement silencing factor 1, is a gene that is predicted to have histone binding activity and histone methyltransferase binding activity. It is also predicted to be involved in negative regulation of single stranded viral RNA replication via double stranded DNA intermediate and positive regulation of DNA methylation-dependent heterochromatin assembly. The gene is predicted to act upstream of or within response to bacterium and is located in the nucleus. It is also predicted to colocalize with the gamma-tubulin complex.","There is limited information available on the disease implications of RESF1. However, some studies have suggested that it may play a role in the development of certain cancers, such as breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for RESF1 are also limited, as its function and mechanisms of action are not yet fully understood. Currently, there are no drugs on the market that specifically target RESF1. However, there are drugs that target histone methyltransferases, which may indirectly affect RESF1 activity. For example, the drug tazemetostat targets the histone methyltransferase EZH2 and is approved for the treatment of certain types of lymphoma. Another drug, GSK126, targets the histone methyltransferase EZH2 and is being investigated for the treatment of certain types of solid tumors.",GO:0141005 transposable element silencing by heterochromatin formation;GO:0010526 transposable element silencing;GO:0140719 constitutive heterochromatin formation,,Predicted intracellular proteins,Nucleoli;Nucleoli rim (Supported); Additional: Cytosol;Intermediate filaments,,,
ENSG00000035403.18,ENSG00000035403,VCL,-1.066998686,-1.536683054,-1.178130491,-0.486182513,vinculin,"Vinculin (VCL) is a protein found in the cytoskeleton of cells that is involved in anchoring F-actin to the membrane in cell-cell and cell-matrix junctions. Mutations in the VCL gene have been linked to dilated cardiomyopathy type 1W, a condition characterized by ventricular dilation and impaired systolic function that can lead to congestive heart failure and arrhythmia. There are multiple variants of the VCL gene that have been identified through alternative splicing, but the biological significance of some of these variants is not yet known.","Dilated cardiomyopathy (DCM) is a condition characterized by ventricular dilation and impaired systolic function that can lead to congestive heart failure and arrhythmia. Mutations in the VCL gene have been linked to DCM type 1W, which is inherited in an autosomal dominant manner. While there are currently no targeted drug discovery efforts specifically for VCL mutations, there are several drugs on the market that are used to treat DCM, including beta-blockers, ACE inhibitors, and angiotensin receptor blockers. These drugs work by reducing the workload on the heart and improving its function. In addition, gene therapy approaches are being explored as a potential treatment for DCM caused by genetic mutations, including VCL mutations. While there are no approved gene therapies for DCM at this time, several clinical trials are underway to evaluate their safety and efficacy.",GO:1904702 regulation of protein localization to adherens junction;GO:0150106 regulation of protein localization to cell-cell junction;GO:0034333 adherens junction assembly,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Cardiovascular diseases:Cardiac diseases,Focal adhesion sites (Enhanced),,(M232)PID ECADHERIN STABILIZATION PATHWAY; (M12)PID RHOA PATHWAY; (M281)PID FAK PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE; (M5915)HALLMARK APICAL JUNCTION
ENSG00000174437.17,ENSG00000174437,ATP2A2,-1.066562998,-1.714649341,-0.957891307,-0.527148345,ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2,"ATP2A2 is a gene that encodes for one of the SERCA Ca(2+)-ATPases, which are pumps located in the sarcoplasmic or endoplasmic reticula of the skeletal muscle. This enzyme is responsible for the hydrolysis of ATP coupled with the translocation of calcium from the cytosol into the sarcoplasmic reticulum lumen, and is involved in regulating the contraction/relaxation cycle. Mutations in this gene have been linked to Darier-White disease, an autosomal dominant skin disorder characterized by loss of adhesion between epidermal cells and abnormal keratinization, as well as various forms of muscular dystrophies. Alternative splicing results in multiple transcript variants encoding different isoforms.","Mutations in the ATP2A2 gene have been linked to several diseases, including Darier-White disease, Brody myopathy, and various forms of muscular dystrophies. Darier-White disease is an autosomal dominant skin disorder characterized by loss of adhesion between epidermal cells and abnormal keratinization. There are currently no targeted drugs available for the treatment of Darier-White disease, and treatment is mainly focused on managing symptoms. However, research efforts are ongoing to identify potential drug targets and develop targeted therapies for this condition. In terms of muscular dystrophies, several drugs have been approved for the treatment of specific types of muscular dystrophies, including eteplirsen for Duchenne muscular dystrophy and golodirsen for Duchenne muscular dystrophy amenable to exon 53 skipping. These drugs work by targeting specific genetic mutations and promoting the production of functional dystrophin protein.",GO:1903515 calcium ion transport from cytosol to endoplasmic reticulum;GO:0032470 positive regulation of endoplasmic reticulum calcium ion concentration;GO:1990036 calcium ion import into sarcoplasmic reticulum,,Predicted intracellular proteins; Transporters:Primary Active Transporters; Human disease related genes:Congenital malformations:Congenital malformations of skin; FDA approved drug targets:Small molecule drugs; Enzymes; Disease related genes; ENZYME proteins,Nucleoplasm;Plasma membrane (Uncertain); Additional: End piece;Mid piece;Perinuclear theca;Primary cilium,Istaroxime,,(M5924)HALLMARK MTORC1 SIGNALING; (M5932)HALLMARK INFLAMMATORY RESPONSE; (M5934)HALLMARK XENOBIOTIC METABOLISM
ENSG00000083223.18,ENSG00000083223,TUT7,-1.064190467,-1.552089468,-1.068520543,-0.571961389,terminal uridylyl transferase 7,"TUT7, or terminal uridylyl transferase 7, is a human gene that plays a role in RNA metabolism and negative regulation of transposition. It enables RNA uridylyltransferase activity and miRNA binding activity, and is located in both the cytosol and nucleoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of TUT7. However, some studies have suggested that TUT7 may play a role in cancer progression and metastasis. Targeted drug discovery efforts for TUT7 are also limited, but some studies have identified potential small molecule inhibitors of TUT7 that could be developed into drugs. One example is the compound 5-ITu, which has been shown to inhibit TUT7 activity in vitro. However, there are currently no drugs on the market that specifically target TUT7. Overall, further research is needed to fully understand the disease implications of TUT7 and to develop targeted therapies for diseases associated with this gene.",GO:1990074 polyuridylation-dependent mRNA catabolic process;GO:0141008 transposable element silencing by mRNA destabilization;GO:0071076 RNA 3' uridylation,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Supported); Additional: Nucleoplasm,,,
ENSG00000178966.17,ENSG00000178966,RMI1,-1.063922415,-1.391835401,-1.215098295,-0.584833548,RecQ mediated genome instability 1,"RMI1, or RecQ mediated genome instability 1, is a gene that plays a role in limiting the formation of DNA crossovers through the dissolution of double Holliday junctions. It is a component of protein complexes that are involved in maintaining the stability of the genome. The gene was first identified in 2006 and is believed to be important in preventing mutations and other genetic abnormalities that can lead to disease. Overall, RMI1 is an important gene that helps to ensure the integrity of the genetic material in human cells.","Mutations in the RMI1 gene have been associated with several genetic disorders, including Bloom syndrome, a rare autosomal recessive disorder characterized by short stature, sun sensitivity, and an increased risk of cancer. Additionally, mutations in RMI1 have been linked to Fanconi anemia, a rare genetic disorder that affects the bone marrow and increases the risk of cancer. 

There are currently no drugs specifically targeting RMI1, but research is ongoing to identify potential drug targets for the treatment of diseases associated with RMI1 mutations. One approach is to target the protein complexes that RMI1 is a part of, such as the BLM complex, which is involved in DNA repair and maintenance. 

There are currently no drugs on the market that target RMI1 or its associated protein complexes. However, there are drugs that target other proteins involved in DNA repair and maintenance, such as PARP inhibitors, which have been approved for the treatment of certain types of cancer. These drugs work by inhibiting the PARP enzyme, which is involved in repairing single-strand DNA breaks. By inhibiting PARP, cancer cells with defects in other DNA repair pathways, such as those associated with BRCA mutations, are unable to repair their DNA and eventually die.",GO:0002023 reduction of food intake in response to dietary excess;GO:0071139 resolution of DNA recombination intermediates;GO:0000712 resolution of meiotic recombination intermediates,,Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Supported),,(M1)PID FANCONI PATHWAY,
ENSG00000265972.6,ENSG00000265972,TXNIP,-1.062868354,-1.712975303,-1.060700147,-0.414929613,thioredoxin interacting protein,"TXNIP is a gene that encodes a protein that binds to thioredoxin, a protein that regulates cellular redox signaling and protects cells from oxidative stress. The protein encoded by TXNIP inhibits the antioxidative function of thioredoxin, leading to the accumulation of reactive oxygen species and cellular stress. It also regulates cellular metabolism and endoplasmic reticulum stress, and may function as a tumor suppressor. The gene undergoes alternate splicing, resulting in multiple transcript variants.","TXNIP has been implicated in various diseases, including diabetes, cardiovascular disease, cancer, and neurodegenerative disorders. In diabetes, TXNIP expression is upregulated in response to high glucose levels, leading to beta-cell apoptosis and impaired insulin secretion. In cardiovascular disease, TXNIP promotes oxidative stress and inflammation, contributing to atherosclerosis and myocardial infarction. In cancer, TXNIP acts as a tumor suppressor by inhibiting cell proliferation and inducing apoptosis. Targeted drug discovery efforts have focused on developing small molecule inhibitors of TXNIP to treat diabetes and cardiovascular disease. However, there are currently no drugs on the market that specifically target TXNIP. Some drugs, such as metformin and statins, indirectly modulate TXNIP expression and activity, providing potential therapeutic benefits in diseases associated with TXNIP dysregulation.",GO:0071228 cellular response to tumor cell;GO:0140052 cellular response to oxidised low-density lipoprotein particle stimulus;GO:0051782 negative regulation of cell division,,Transporters:Accessory Factors Involved in Transport; Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Plasma membrane (Approved); Additional: Cytosol,,,(M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5902)HALLMARK APOPTOSIS; (M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000134452.20,ENSG00000134452,FBH1,-1.06210603,-1.534207936,-1.312232146,-0.339878008,F-box DNA helicase 1,"FBH1, also known as F-box DNA helicase 1, is a member of the F-box protein family. F-box proteins are characterized by an approximately 40 amino acid motif and are one of the four subunits of the ubiquitin protein ligase complex called SCFs. FBH1 belongs to the Fbx class and contains an F-box motif and seven conserved helicase motifs. It has both DNA-dependent ATPase and DNA unwinding activities. FBH1 is involved in phosphorylation-dependent ubiquitination and is divided into three classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. Alternative spliced transcript variants encoding distinct isoforms have been identified for this gene.","Research on FBH1 has revealed its potential involvement in various diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, FBH1 has been shown to play a role in DNA damage response and repair, making it a potential target for cancer therapy. Targeted drug discovery efforts have focused on identifying small molecule inhibitors of FBH1, with some promising results in preclinical studies. However, no drugs targeting FBH1 have been approved for clinical use yet. In terms of successful drugs on the market, there are currently no drugs specifically targeting FBH1. However, there are drugs that indirectly affect FBH1 activity, such as PARP inhibitors, which have been approved for the treatment of certain types of cancer. PARP inhibitors work by inhibiting the activity of PARP enzymes, which are involved in DNA repair pathways that interact with FBH1.",GO:0072429 response to intra-S DNA damage checkpoint signaling;GO:0072396 response to cell cycle checkpoint signaling;GO:0072402 response to DNA integrity checkpoint signaling,,Disease related genes; Enzymes; ENZYME proteins:Isomerase; Potential drug targets,,,,
ENSG00000124422.12,ENSG00000124422,USP22,-1.060452999,-1.71168684,-1.293372458,-0.176299698,ubiquitin specific peptidase 22,"USP22 is a gene that encodes for a protein called ubiquitin specific peptidase 22. This protein has several functions, including enabling enzyme binding activity, nuclear receptor coactivator activity, and thiol-dependent deubiquitinase. It also contributes to H4 histone acetyltransferase activity and is involved in positive regulation of mitotic cell cycle, positive regulation of transcription, DNA-templated, and protein modification by small protein conjugation or removal. USP22 is part of the SAGA complex.","USP22 has been implicated in several types of cancer, including breast, lung, liver, and prostate cancer. It has been shown to promote tumor growth and metastasis by regulating various signaling pathways, including the Wnt/?-catenin, NF-?B, and PI3K/Akt pathways. Therefore, USP22 has emerged as a potential therapeutic target for cancer treatment. Several small molecule inhibitors of USP22 have been developed, including SJB3-019A, P22077, and LDN-57444. These inhibitors have shown promising results in preclinical studies, including inhibition of tumor growth and metastasis in animal models. However, no USP22 inhibitors have been approved for clinical use yet. Further research is needed to fully understand the role of USP22 in cancer and to develop effective targeted therapies.",GO:0000086 G2/M transition of mitotic cell cycle;GO:0044839 cell cycle G2/M phase transition;GO:0032481 positive regulation of type I interferon production,,Peptidases:Cysteine-type peptidases; ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nuclear speckles (Approved),,,
ENSG00000137075.18,ENSG00000137075,RNF38,-1.060082159,-1.207406879,-1.397933183,-0.574906416,ring finger protein 38,"RNF38 is a human gene that encodes a protein with a coiled-coil motif and a RING-H2 motif at its carboxy-terminus. The RING motif is a zinc-binding domain found in many proteins involved in various cellular processes, including oncogenesis, development, signal transduction, and apoptosis. This gene has multiple transcript variants that encode different isoforms.","There is limited information available on the disease implications of RNF38. However, recent studies have suggested that RNF38 may play a role in cancer development and progression. Specifically, RNF38 has been shown to interact with and regulate the activity of several key proteins involved in cancer, including p53, c-Myc, and NF-?B. Targeted drug discovery efforts for RNF38 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the RING domain of the protein. While there are currently no drugs on the market that specifically target RNF38, there are several drugs that target other proteins in the same pathway, such as NF-?B inhibitors like bortezomib and lenalidomide, which are used to treat multiple myeloma.",GO:0008584 male gonad development;GO:0046546 development of primary male sexual characteristics;GO:0046661 male sex differentiation,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported),,,
ENSG00000167978.17,ENSG00000167978,SRRM2,-1.058776574,-1.52917204,-0.817576502,-0.82958118,serine/arginine repetitive matrix 2,SRRM2 is a human gene that plays a role in mRNA splicing through its involvement in the spliceosome. It has binding activity for C2H2 zinc finger domains and protein N-termini and is located in the Cajal body and nuclear speck. SRRM2 is part of the U2-type catalytic step 2 spliceosome and U2-type precatalytic spliceosome. It is also a biomarker of Parkinson's disease.,"SRRM2 has been identified as a biomarker for Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra region of the brain. Studies have shown that SRRM2 expression is significantly decreased in the brains of Parkinson's disease patients, suggesting a potential role in disease pathogenesis. Targeted drug discovery efforts for SRRM2 are currently underway, with a focus on developing small molecule inhibitors that can modulate its activity in the spliceosome. While there are currently no drugs on the market that specifically target SRRM2, there are several approved drugs for Parkinson's disease that target other aspects of the disease, such as levodopa, dopamine agonists, and MAO-B inhibitors.","GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;GO:0000398 mRNA splicing, via spliceosome;GO:0000375 RNA splicing, via transesterification reactions",,Predicted intracellular proteins,Nuclear speckles (Enhanced),,,
ENSG00000116747.13,ENSG00000116747,RO60,-1.057106751,-1.003688151,-1.385948152,-0.78168395,"Ro60, Y RNA binding protein","RO60 is a human gene that encodes for a protein called Ro60, which is involved in RNA binding activity. It plays a role in the cellular response to interferon-alpha and the regulation of gene expression. The protein is located in both the cytosol and nucleoplasm and is part of a ribonucleoprotein complex. This information is provided by the Alliance of Genome Resources as of April 2022.","RO60 has been implicated in several autoimmune diseases, including systemic lupus erythematosus (SLE) and Sjgren's syndrome. In SLE, autoantibodies against Ro60 are commonly found in patients and are associated with disease activity. Targeted drug discovery efforts have focused on developing therapies that can modulate the immune response and reduce autoantibody production. One example is belimumab, a monoclonal antibody that targets B lymphocyte stimulator (BLyS), a protein involved in the survival and activation of B cells. Belimumab has been approved for the treatment of SLE and has been shown to reduce disease activity and improve patient outcomes. Another example is hydroxychloroquine, an antimalarial drug that has been used for decades in the treatment of SLE and other autoimmune diseases. Hydroxychloroquine has been shown to inhibit the production of autoantibodies against Ro60 and other autoantigens, and to reduce disease activity in SLE patients.",GO:0035457 cellular response to interferon-alpha;GO:0035455 response to interferon-alpha;GO:0006383 transcription by RNA polymerase III,,Predicted intracellular proteins,Cytosol;Primary cilium (Approved); Additional: Nuclear bodies;Nucleoplasm,,,
ENSG00000163069.13,ENSG00000163069,SGCB,-1.057080561,-1.50410638,-1.5517097,-0.115425603,sarcoglycan beta,"SGCB is a gene that encodes a protein called sarcoglycan beta. This protein is a transmembrane component of the dystrophin-glycoprotein complex, which helps to stabilize muscle fiber membranes and connect the muscle cytoskeleton to the extracellular matrix. Mutations in the SGCB gene have been linked to limb-girdle muscular dystrophy, a group of genetic disorders that cause progressive weakness and wasting of the muscles in the hips, shoulders, and limbs. The SGCB gene is important for maintaining the structural integrity of muscle fibers, and mutations in this gene can disrupt this process, leading to muscle degeneration and weakness.","Limb-girdle muscular dystrophy (LGMD) is a group of genetic disorders that affect the muscles in the hips, shoulders, and limbs. Mutations in the SGCB gene have been linked to LGMD type 2E, which is characterized by progressive muscle weakness and wasting. There is currently no cure for LGMD, and treatment options are limited to supportive care, such as physical therapy and respiratory support. However, there are ongoing efforts to develop targeted therapies for LGMD, including gene therapy and small molecule drugs that target the underlying genetic defects. One example of a successful drug on the market for LGMD is Ataluren, which is approved for the treatment of Duchenne muscular dystrophy (DMD), another genetic disorder that affects muscle function. Ataluren works by promoting the production of functional dystrophin, a protein that is absent or defective in DMD patients. While there are currently no drugs specifically approved for LGMD type 2E, ongoing research in this area holds promise for the development of effective treatments in the future.",GO:0044381 glucose import in response to insulin stimulus;GO:0097084 vascular associated smooth muscle cell development;GO:0035886 vascular associated smooth muscle cell differentiation,,Disease related genes; Human disease related genes:Musculoskeletal diseases:Muscular diseases,Cytosol (Approved),,,(M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000170776.22,ENSG00000170776,AKAP13,-1.056661564,-1.562783958,-1.096499084,-0.510701651,A-kinase anchoring protein 13,"AKAP13 is a gene that encodes a member of the A-kinase anchor protein (AKAP) family. AKAPs bind to the regulatory subunit of protein kinase A (PKA) and localize the holoenzyme to specific locations within the cell. Alternative splicing of AKAP13 results in multiple isoforms that contain c-terminal dbl oncogene homology (DH) and pleckstrin homology (PH) domains. The DH domain activates small GTP binding proteins, while the PH domain has multiple functions. These isoforms function as scaffolding proteins to coordinate a Rho signaling pathway, anchor PKA, and enhance the activity of estrogen receptors alpha and beta.","AKAP13 has been implicated in several diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, AKAP13 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. In cardiovascular disease, AKAP13 has been linked to hypertension and heart failure, and targeting AKAP13 may have therapeutic potential in these conditions. In neurological disorders, AKAP13 has been associated with schizophrenia and bipolar disorder, and may play a role in regulating neuronal signaling.

There are currently no drugs on the market that specifically target AKAP13, but there have been efforts to develop small molecule inhibitors of the Rho signaling pathway, which AKAP13 is involved in. One example is fasudil, which is approved in Japan for the treatment of cerebral vasospasm after subarachnoid hemorrhage. Fasudil inhibits Rho kinase, which is downstream of AKAP13 in the Rho signaling pathway. Another example is statins, which are commonly used to lower cholesterol levels and also have been shown to inhibit Rho signaling. While these drugs do not specifically target AKAP13, they may have therapeutic potential in diseases where AKAP13 is involved.",GO:0060297 regulation of sarcomere organization;GO:0071875 adrenergic receptor signaling pathway;GO:0035025 positive regulation of Rho protein signal transduction,,Predicted intracellular proteins,Cytosol (Supported),,(M238)PID THROMBIN PAR1 PATHWAY; (M68)PID RHOA REG PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000130052.13,ENSG00000130052,STARD8,-1.05638006,-1.433509586,-0.933874108,-0.801756484,StAR related lipid transfer domain containing 8,"STARD8 is a human gene that encodes a protein belonging to a subfamily of Rho GTPase activating proteins. This protein contains a lipid transfer domain that is related to the steroidogenic acute regulatory protein. STARD8 is primarily found in focal adhesions and is believed to play a role in regulating cell morphology. Additionally, it may function as a tumor suppressor.","There is limited information available on the disease implications of STARD8. However, some studies have suggested that STARD8 may function as a tumor suppressor and its downregulation has been observed in various types of cancer, including breast, lung, and ovarian cancer. Targeted drug discovery efforts for STARD8 are also limited, but some studies have suggested that small molecule inhibitors of Rho GTPases, which are regulated by STARD8, may have potential as anti-cancer agents. Currently, there are no drugs on the market that specifically target STARD8. However, there are several drugs that target Rho GTPases, such as fasudil and statins, which have been approved for the treatment of various diseases, including hypertension and stroke.",GO:0035023 regulation of Rho protein signal transduction;GO:0051056 regulation of small GTPase mediated signal transduction;GO:0030036 actin cytoskeleton organization,,Predicted intracellular proteins,,,,
ENSG00000140521.17,ENSG00000140521,POLG,-1.055033043,-1.525489228,-1.297555938,-0.342053964,"DNA polymerase gamma, catalytic subunit","POLG is a gene that encodes the catalytic subunit of mitochondrial DNA polymerase, which is responsible for replicating mitochondrial DNA. The protein contains a polyglutamine tract near its N-terminus that may be polymorphic. Defects in this gene are associated with several mitochondrial disorders, including progressive external ophthalmoplegia with mitochondrial DNA deletions 1 (PEOA1), sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO), Alpers-Huttenlocher syndrome (AHS), and mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE). Two transcript variants encoding the same protein have been identified.","Defects in the POLG gene have been associated with a range of mitochondrial disorders, including PEOA1, SANDO, AHS, and MNGIE. These disorders are characterized by a variety of symptoms, including muscle weakness, ataxia, neuropathy, and gastrointestinal dysfunction. There is currently no cure for these disorders, and treatment is largely supportive. However, there has been some progress in targeted drug discovery efforts for POLG-related disorders. For example, idebenone, a synthetic analog of coenzyme Q10, has been shown to improve respiratory function and reduce muscle weakness in patients with PEOA1. Another drug, elamipretide, has shown promise in preclinical studies for the treatment of mitochondrial diseases, including those caused by POLG mutations. However, more research is needed to fully understand the potential of these drugs for treating POLG-related disorders.","GO:0045004 DNA replication proofreading;GO:0006264 mitochondrial DNA replication;GO:0006287 base-excision repair, gap-filling",,Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Mitochondria (Supported),,,
ENSG00000198900.6,ENSG00000198900,TOP1,-1.05495732,-1.660067435,-0.900010036,-0.604794488,DNA topoisomerase I,"The TOP1 gene encodes for an enzyme called DNA topoisomerase, which plays a crucial role in controlling and altering the topological states of DNA during transcription. This enzyme is responsible for breaking and rejoining a single strand of DNA, allowing the strands to pass through one another and altering the topology of DNA. The gene is located on chromosome 20 and has pseudogenes on chromosomes 1 and 22.","The TOP1 gene has been implicated in several diseases, including cancer and autoimmune disorders. In cancer, the overexpression of TOP1 has been linked to resistance to chemotherapy drugs such as camptothecin and irinotecan. As a result, there have been targeted drug discovery efforts to develop TOP1 inhibitors that can be used in combination with chemotherapy to improve treatment outcomes. One such drug is topotecan, which is used to treat ovarian and lung cancer. Another drug, irinotecan, is used to treat colorectal cancer. Both drugs work by inhibiting the activity of TOP1, preventing it from repairing DNA damage caused by chemotherapy drugs. However, these drugs can also have side effects, such as bone marrow suppression and gastrointestinal toxicity. Therefore, there is ongoing research to develop more effective and less toxic TOP1 inhibitors for cancer treatment. In autoimmune disorders, TOP1 has been linked to the development of scleroderma, a disease characterized by the hardening and thickening of the skin and connective tissues. However, there are currently no drugs targeting TOP1 for the treatment of autoimmune disorders.",GO:0040016 embryonic cleavage;GO:0006265 DNA topological change;GO:0032922 circadian regulation of gene expression,,Predicted intracellular proteins; FDA approved drug targets:Biotech drugs; Cancer-related genes; ENZYME proteins:Isomerase; FDA approved drug targets:Small molecule drugs; Disease related genes; Enzymes,Nucleoli fibrillar center;Nucleoplasm (Supported),"Irinotecan; Topotecan; Camptothecin; Edotecarin; Lucanthone; Elsamitrucin; 7-ethyl-10-hydroxycamptothecin; Sodium stibogluconate; Cositecan; XMT-1001; Rubitecan; 2,3-DIMETHOXY-12H-[1,3]DIOXOLO[5,6]INDENO[1,2-C]ISOQUINOLIN-6-IUM; 4-(5,11-DIOXO-5H-INDENO[1,2-C]ISOQUINOLIN-6(11H)-YL)BUTANOATE; Hexylresorcinol; Sacituzumab govitecan; Trastuzumab deruxtecan",(M220)PID CASPASE PATHWAY,(M5901)HALLMARK G2M CHECKPOINT; (M5945)HALLMARK HEME METABOLISM
ENSG00000039560.14,ENSG00000039560,RAI14,-1.054746449,-1.77506996,-0.730073814,-0.659095572,retinoic acid induced 14,"The human gene RAI14, also known as retinoic acid induced 14, is predicted to have actin binding activity and be involved in various processes such as apoptotic signaling pathway, regulation of NIK/NF-kappaB signaling, and spermatogenesis. It is located in the cytosol, fibrillar center, and nucleoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of RAI14. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target RAI14. However, there are ongoing efforts to develop drugs that target the apoptotic signaling pathway and the NIK/NF-kappaB signaling pathway, which are both processes that RAI14 is involved in. Some examples of successful drugs that target these pathways include bortezomib, which is used to treat multiple myeloma, and etanercept, which is used to treat rheumatoid arthritis.",GO:0007283 spermatogenesis;GO:0048232 male gamete generation;GO:0007276 gamete generation,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Actin filaments;Cytosol,,,
ENSG00000084112.15,ENSG00000084112,SSH1,-1.053007125,-1.547867516,-0.857421954,-0.753731905,slingshot protein phosphatase 1,"SSH1 is a gene that belongs to the slingshot homolog family of phosphatases, which regulate the dynamics of actin filaments. The protein encoded by this gene dephosphorylates and activates cofilin, an actin binding/depolymerizing factor that stimulates the disassembly of actin filaments. SSH1 plays a role in actin dynamics by reactivating cofilin proteins. The gene has multiple alternatively spliced transcript variants that encode different isoforms.","SSH1 has been implicated in various diseases, including cancer, Alzheimer's disease, and heart disease. In cancer, SSH1 has been shown to play a role in tumor invasion and metastasis by regulating actin dynamics. Targeting SSH1 has been explored as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of SSH1 have been developed, including CK-666 and SMIFH2, which have shown promising results in preclinical studies. However, no SSH1 inhibitors have been approved for clinical use yet. In Alzheimer's disease, SSH1 has been found to be dysregulated, leading to abnormal actin dynamics and synaptic dysfunction. Targeting SSH1 may have potential therapeutic benefits in Alzheimer's disease, but more research is needed in this area. Currently, there are no drugs on the market that specifically target SSH1.",GO:1901628 positive regulation of postsynaptic membrane organization;GO:1904719 positive regulation of AMPA glutamate receptor clustering;GO:1901626 regulation of postsynaptic membrane organization,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Plasma membrane (Uncertain); Additional: Cytosol;Nucleoplasm,,(M276)PID FGF PATHWAY; (M124)PID CXCR4 PATHWAY,
ENSG00000169093.16,ENSG00000169093,ASMTL,-1.052531231,-1.437289886,-1.007670676,-0.712633132,acetylserotonin O-methyltransferase like,"ASMTL is a gene located in the pseudoautosomal region 1 (PAR1) of the X and Y chromosomes. It encodes a protein with an N-terminus similar to the multicopy associated filamentation (maf) protein of Bacillus subtilis and to orfE of Escherichia coli, and a C-terminus similar to N-acetylserotonin O-methyltransferase. Three transcript variants encoding different isoforms have been identified. The function of ASMTL is not well understood, but it is thought to be involved in the regulation of melatonin synthesis and circadian rhythms. Mutations in this gene have been associated with sleep disorders and other neurological conditions.","Mutations in the ASMTL gene have been associated with sleep disorders, including delayed sleep phase disorder (DSPD) and non-24-hour sleep-wake disorder (N24SWD). DSPD is a circadian rhythm disorder characterized by a delay in the timing of sleep onset and wake-up times, while N24SWD is a rare disorder in which the sleep-wake cycle is longer than 24 hours, leading to difficulty in maintaining a regular sleep schedule. 

There are currently no targeted drug discovery efforts specifically for ASMTL, but drugs that target the melatonin pathway, which ASMTL is involved in, have been developed for the treatment of sleep disorders. Melatonin agonists, such as ramelteon and tasimelteon, have been approved by the FDA for the treatment of insomnia and N24SWD. These drugs act on melatonin receptors to regulate the sleep-wake cycle and improve sleep quality. 

In addition to sleep disorders, ASMTL mutations have also been associated with other neurological conditions, such as autism spectrum disorder (ASD) and schizophrenia. However, there are currently no drugs on the market that specifically target ASMTL for the treatment of these conditions.",GO:0032259 methylation;GO:0009117 nucleotide metabolic process;GO:0006753 nucleoside phosphate metabolic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol (Enhanced),,,
ENSG00000071242.12,ENSG00000071242,RPS6KA2,-1.052166356,-1.671744785,-1.274389707,-0.210364577,ribosomal protein S6 kinase A2,"RPS6KA2 is a gene that encodes a protein belonging to the RSK family of serine/threonine kinases. This protein contains two kinase catalytic domains and is involved in phosphorylating various substrates, including those in the MAPK signaling pathway. The protein's activity has been linked to regulating cell growth and differentiation. Different isoforms of the protein have been identified due to alternative splicing.","There is limited information available on the disease implications of RPS6KA2. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for RPS6KA2 have focused on developing inhibitors that can selectively block the activity of the protein. One example is BI-D1870, a small molecule inhibitor that has been shown to inhibit the activity of RPS6KA2 in vitro and in vivo. Another example is SL0101-1, a peptide inhibitor that has been shown to block the activity of RPS6KA2 in vitro. However, there are currently no drugs on the market that specifically target RPS6KA2.",GO:0038202 TORC1 signaling;GO:0031929 TOR signaling;GO:0045786 negative regulation of cell cycle,yes,Kinases:AGC Ser/Thr protein kinases; Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported),,(M1315)SIG PIP3 SIGNALING IN B LYMPHOCYTES; (M7955)SIG INSULIN RECEPTOR PATHWAY IN CARDIAC MYOCYTES; (M295)SIG PIP3 SIGNALING IN CARDIAC MYOCTES,(M5906)HALLMARK ESTROGEN RESPONSE EARLY; (M5907)HALLMARK ESTROGEN RESPONSE LATE
ENSG00000134313.16,ENSG00000134313,KIDINS220,-1.05195541,-1.513130405,-1.137007698,-0.505728126,kinase D interacting substrate 220,"KIDINS220, also known as kinase D interacting substrate 220, is a transmembrane protein that is primarily expressed in the nervous system. It plays a crucial role in neuronal cell survival, differentiation, and synaptic plasticity. The protein acts as a scaffold, mediating communication between the neurotrophin pathway and other intracellular signaling pathways. Abnormal expression of KIDINS220 is linked to various neuropsychiatric disorders and neurodegenerative diseases, including Alzheimer's disease. Mutations in this gene are associated with a syndrome characterized by spastic paraplegia, intellectual disability, nystagmus, and obesity. Alternative splicing of the gene results in multiple transcript variants.","KIDINS220 has been implicated in various neuropsychiatric disorders and neurodegenerative diseases, including Alzheimer's disease, schizophrenia, and bipolar disorder. Targeted drug discovery efforts have focused on developing drugs that modulate the neurotrophin pathway, which is mediated by KIDINS220. One example is the drug memantine, which is used to treat Alzheimer's disease and works by blocking the NMDA receptor, a downstream target of the neurotrophin pathway. Another example is the drug brexpiprazole, which is used to treat schizophrenia and bipolar disorder and works by modulating dopamine and serotonin receptors, which are also downstream targets of the neurotrophin pathway. While there are currently no drugs specifically targeting KIDINS220, these examples demonstrate the potential for targeting the neurotrophin pathway in the treatment of various neuropsychiatric disorders and neurodegenerative diseases.",GO:0038180 nerve growth factor signaling pathway;GO:0038179 neurotrophin signaling pathway;GO:1990090 cellular response to nerve growth factor stimulus,,Disease related genes; Transporters:Accessory Factors Involved in Transport; Potential drug targets; Predicted intracellular proteins,Nucleoplasm (Uncertain); Additional: Cytosol;Vesicles,,,
ENSG00000142197.12,ENSG00000142197,DOP1B,-1.051411404,-1.315202474,-1.210264782,-0.628766954,DOP1 leucine zipper like protein B,"DOP1B is a human gene that encodes for the DOP1 leucine zipper like protein B. This gene is involved in cognition and is located in the early endosome membrane. The DOP1B protein is thought to play a role in the regulation of dopamine signaling in the brain, which is important for various cognitive processes such as learning and memory. Mutations in this gene have been associated with certain neurological disorders, including schizophrenia and attention deficit hyperactivity disorder (ADHD). Overall, the DOP1B gene is an important target for research into the molecular mechanisms underlying cognitive function and neurological disorders.","Mutations in the DOP1B gene have been associated with several neurological disorders, including schizophrenia and attention deficit hyperactivity disorder (ADHD). As a result, there has been significant interest in developing drugs that target the dopamine signaling pathway, which is regulated by the DOP1B protein. One example of a successful drug targeting this pathway is Risperidone, which is used to treat schizophrenia and bipolar disorder. Risperidone works by blocking dopamine receptors in the brain, which helps to reduce symptoms of psychosis. Another drug, Methylphenidate, is used to treat ADHD and works by increasing dopamine levels in the brain. While there is still much to learn about the role of DOP1B in these disorders, the development of drugs targeting this pathway has shown promise in improving cognitive function and reducing symptoms in patients.",GO:0006895 Golgi to endosome transport;GO:0009880 embryonic pattern specification;GO:0007029 endoplasmic reticulum organization,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Mitochondria,,,
ENSG00000056097.16,ENSG00000056097,ZFR,-1.051391376,-1.417446633,-0.96369574,-0.773031754,zinc finger RNA binding protein,"ZFR is a human gene that encodes an RNA-binding protein with a DZF domain. This protein may be involved in the transport of another RNA-binding protein, Staufen homolog 2, in neurons. The expression of ZFR is regulated through alternative polyadenylation, which affects microRNA targeting. Elevated expression of ZFR has been observed in patients with pancreatic cancer, and reducing the expression of ZFR may result in reduced viability and invasion of pancreatic cancer cells.","There is limited information available on targeted drug discovery efforts for ZFR, as it is a relatively understudied gene. However, elevated expression of ZFR has been observed in pancreatic cancer patients, suggesting that it may be a potential therapeutic target for this disease. In preclinical studies, reducing the expression of ZFR has been shown to result in reduced viability and invasion of pancreatic cancer cells. Currently, there are no drugs on the market that specifically target ZFR. However, there are several drugs that target RNA-binding proteins, such as the Staufen homolog 2 protein that ZFR may be involved in transporting. For example, the drug E7107 targets the RNA-binding protein eIF4A, which is overexpressed in several types of cancer.",,,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000171823.7,ENSG00000171823,FBXL14,-1.051286104,-1.827960841,-1.091915786,-0.233981685,F-box and leucine rich repeat protein 14,"FBXL14 is a human gene that belongs to the F-box protein family. F-box proteins are characterized by an F-box motif of approximately 40 amino acids. FBXL14 is involved in the formation of SCF complexes, which act as protein-ubiquitin ligases. These complexes are formed by SKP1, cullin, and F-box proteins. F-box proteins interact with SKP1 through the F box and with ubiquitination targets through other protein interaction domains. The function of FBXL14 is not fully understood, but it is believed to play a role in regulating protein degradation and turnover.","There is limited information available on the disease implications of FBXL14. However, some studies have suggested that it may be involved in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for FBXL14 are also limited, as its function is not fully understood. However, some studies have suggested that targeting the SCF complex, of which FBXL14 is a component, may have therapeutic potential in cancer treatment. There are currently no drugs on the market that specifically target FBXL14, but there are drugs that target other components of the SCF complex, such as bortezomib, which is used to treat multiple myeloma and mantle cell lymphoma.",GO:0031146 SCF-dependent proteasomal ubiquitin-dependent protein catabolic process;GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process;GO:0010498 proteasomal protein catabolic process,,Predicted intracellular proteins,,,,
ENSG00000112531.17,ENSG00000112531,QKI,-1.05025022,-1.226063905,-1.336602208,-0.588084545,"QKI, KH domain containing RNA binding","QKI is a human gene that encodes an RNA-binding protein involved in various cellular processes such as pre-mRNA splicing, mRNA export, protein translation, and mRNA stability. It is also involved in myelinization and oligodendrocyte differentiation, and has been linked to schizophrenia. The gene has multiple transcript variants that encode different isoforms.","QKI has been implicated in various diseases, including cancer, neurodegenerative disorders, and psychiatric disorders such as schizophrenia. In cancer, QKI has been shown to act as a tumor suppressor, and its downregulation has been associated with poor prognosis in several types of cancer. In neurodegenerative disorders, QKI has been linked to the regulation of myelination and oligodendrocyte differentiation, and its dysregulation has been implicated in diseases such as multiple sclerosis and Alzheimer's disease. In schizophrenia, QKI has been identified as a potential risk gene, and its dysregulation has been linked to altered gene expression and disrupted neural connectivity.

Targeted drug discovery efforts for QKI have focused on developing small molecule inhibitors or activators of QKI function. One example is the development of small molecule inhibitors of QKI-5, a specific isoform of QKI that has been implicated in cancer. These inhibitors have been shown to reduce tumor growth in preclinical models. Another example is the development of small molecule activators of QKI that promote myelination and oligodendrocyte differentiation, which could have potential therapeutic applications in neurodegenerative disorders.

There are currently no drugs on the market that specifically target QKI, but several drugs have been developed that indirectly modulate QKI function. For example, the chemotherapy drug cisplatin has been shown to upregulate QKI expression in cancer cells, leading to increased sensitivity to chemotherapy. Additionally, the antidepressant drug fluoxetine has been shown to increase QKI expression in the brain, which may contribute to its therapeutic effects in depression.",GO:1905869 negative regulation of 3'-UTR-mediated mRNA stabilization;GO:1990764 myofibroblast contraction;GO:2000626 negative regulation of miRNA catabolic process,,Cancer-related genes:Mutated cancer genes; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000120451.11,ENSG00000120451,SNX19,-1.05014591,-2.111708351,-0.919006437,-0.119722943,sorting nexin 19,"SNX19, or sorting nexin 19, is a gene that interacts with islet antigen-2 (IA-2) in pancreatic beta-cells. IA-2 is an autoantigen in type 1 diabetes and is involved in insulin secretion. SNX19 plays a role in stabilizing the number of dense-core secretory vesicles in mouse pancreatic beta-cells, which in turn influences insulin secretion. This suggests that SNX19 may be involved in the regulation of insulin secretion and could potentially be a target for diabetes treatment.","There is currently limited information on the disease implications of SNX19. However, given its role in insulin secretion, it is possible that SNX19 could be a target for diabetes treatment. Targeted drug discovery efforts for SNX19 are currently underway, but there are no drugs on the market that specifically target this gene. 

There are, however, several drugs on the market that target other genes involved in insulin secretion and diabetes treatment. For example, sulfonylureas such as glipizide and glyburide stimulate insulin secretion by binding to and blocking the ATP-sensitive potassium channels in pancreatic beta-cells. DPP-4 inhibitors such as sitagliptin and saxagliptin increase insulin secretion by inhibiting the enzyme dipeptidyl peptidase-4, which degrades incretin hormones that stimulate insulin secretion. GLP-1 receptor agonists such as exenatide and liraglutide also stimulate insulin secretion and have additional benefits such as promoting weight loss and reducing cardiovascular risk.",GO:0061792 secretory granule maturation;GO:1990502 dense core granule maturation;GO:0030073 insulin secretion,,Predicted intracellular proteins,Mitochondria (Approved),,,
ENSG00000135862.6,ENSG00000135862,LAMC1,-1.049488651,-1.723370499,-1.340737787,-0.084357666,laminin subunit gamma 1,"LAMC1 is a gene that encodes the gamma 1 chain isoform of laminin, a family of extracellular matrix glycoproteins that are the major non-collagenous constituent of basement membranes. Laminins have been implicated in a wide variety of biological processes including cell adhesion, differentiation, migration, signaling, neurite outgrowth, and metastasis. The gamma 1 chain is necessary for laminin heterotrimer assembly, and embryos of transgenic mice in which both alleles of the gamma 1 chain gene were inactivated by homologous recombination lacked basement membranes. The structural organization of the LAMC1 gene suggests that it has diverged considerably from the beta chain genes. Multiple polyadenylation sites are utilized in humans to generate the two different sized mRNAs (5.5 and 7.5 kb) seen on Northern analysis.","LAMC1 has been implicated in various diseases, including cancer, muscular dystrophy, and kidney diseases. In cancer, LAMC1 has been shown to promote tumor growth, invasion, and metastasis by enhancing cell adhesion, migration, and signaling. Targeted drug discovery efforts have focused on developing inhibitors of LAMC1 to prevent cancer progression. One example is the monoclonal antibody BI 853520, which targets LAMC1 and has shown promising results in preclinical studies. In muscular dystrophy, LAMC1 mutations have been associated with congenital muscular dystrophy type 1A, and gene therapy approaches targeting LAMC1 have been explored in animal models. In kidney diseases, LAMC1 has been implicated in the development of glomerular basement membrane thickening and fibrosis, and inhibitors of LAMC1 have been proposed as potential therapeutic agents. However, there are currently no drugs targeting LAMC1 on the market.",GO:0031581 hemidesmosome assembly;GO:0110011 regulation of basement membrane organization;GO:2001046 positive regulation of integrin-mediated signaling pathway,,Predicted secreted proteins; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Endoplasmic reticulum;Plasma membrane (Uncertain),Lanoteplase,(M158)PID INTEGRIN4 PATHWAY; (M5887)NABA BASEMENT MEMBRANES; (M53)PID INTEGRIN3 PATHWAY,(M5942)HALLMARK UV RESPONSE DN; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000134352.20,ENSG00000134352,IL6ST,-1.049148035,-1.803644729,-0.967450518,-0.376348856,interleukin 6 cytokine family signal transducer,"IL6ST is a gene that encodes a signal transducer protein shared by many cytokines, including IL6, CNTF, LIF, and OSM. This protein is a part of the cytokine receptor complex and its activation is dependent on the binding of cytokines to their receptors. The protein is critical in regulating myocyte apoptosis, as shown in knockout studies in mice. Additionally, a related pseudogene has been identified on chromosome 17. The protein encoded by IL6ST can be activated by vIL6, a protein related to IL6 and encoded by the Kaposi sarcoma-associated herpesvirus, which can bypass the IL6R. Alternative splicing of transcript variants has been described.","IL6ST has been implicated in various diseases, including cancer, autoimmune disorders, and inflammatory diseases. In cancer, IL6ST has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. Targeted drug discovery efforts have focused on developing inhibitors of IL6ST, such as tocilizumab, which is an FDA-approved drug for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis. Tocilizumab is a monoclonal antibody that binds to IL6ST and blocks the signaling of IL6 and other cytokines that use IL6ST as a signal transducer. Other drugs targeting IL6ST are currently in clinical trials for various diseases, including cancer and autoimmune disorders. Overall, IL6ST is an important target for drug discovery efforts, and the development of drugs targeting this protein has shown promise in treating various diseases.",GO:0038165 oncostatin-M-mediated signaling pathway;GO:0048861 leukemia inhibitory factor signaling pathway;GO:0070120 ciliary neurotrophic factor-mediated signaling pathway,,Predicted secreted proteins; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Candidate cardiovascular disease genes; Disease related genes; CD markers; Human disease related genes:Immune system diseases:Primary immunodeficiency; Cancer-related genes:Candidate cancer biomarkers,Plasma membrane (Supported); Additional: Golgi apparatus,,(M36)PID IL27 PATHWAY; (M183)PID IL6 7 PATHWAY; (M100)PID SHP2 PATHWAY,(M5897)HALLMARK IL6 JAK STAT3 SIGNALING; (M5941)HALLMARK UV RESPONSE UP; (M5890)HALLMARK TNFA SIGNALING VIA NFKB
ENSG00000120549.18,ENSG00000120549,KIAA1217,-1.04834845,-1.693147106,-0.875494942,-0.576403301,KIAA1217,KIAA1217 is a human gene that is predicted to play a role in the development of the embryonic skeletal system. It is also predicted to be active in the cytoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.,"Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for KIAA1217. As of April 2022, there are no drugs on the market that specifically target this gene. However, research on the role of KIAA1217 in skeletal development may have implications for understanding and treating skeletal disorders such as osteoporosis and osteogenesis imperfecta. Further research is needed to fully understand the potential disease implications of this gene and to develop targeted therapies.",GO:0048706 embryonic skeletal system development;GO:0001501 skeletal system development;GO:0043009 chordate embryonic development,,Predicted intracellular proteins,Cytosol;Nucleoplasm (Approved),,,
ENSG00000113615.13,ENSG00000113615,SEC24A,-1.047678686,-1.163040396,-0.83409344,-1.145902223,"SEC24 homolog A, COPII coat complex component","SEC24A is a human gene that encodes a protein belonging to a family of proteins similar to yeast Sec24. This protein is a component of COPII-coated vesicles that transport proteins from the endoplasmic reticulum to the golgi complex. COPII is responsible for the transport of secretory, plasma membrane, and vacuolar proteins. Different isoforms of SEC24A have been identified due to alternative splicing of the gene.","There is limited information on the disease implications of SEC24A. However, mutations in SEC24A have been associated with a rare genetic disorder called osteogenesis imperfecta (OI). OI is characterized by brittle bones that are prone to fractures, and it is caused by mutations in genes that affect the production or quality of collagen, a protein that provides strength and structure to bones. Targeted drug discovery efforts for SEC24A are currently limited, as the exact role of this protein in OI is not well understood. There are currently no drugs on the market that specifically target SEC24A. However, there are several drugs that are used to treat OI, including bisphosphonates, which help to increase bone density, and teriparatide, which stimulates bone formation.",GO:0090110 COPII-coated vesicle cargo loading;GO:0035459 vesicle cargo loading;GO:0090114 COPII-coated vesicle budding,,Predicted intracellular proteins,Nucleoli fibrillar center;Vesicles (Approved),,,
ENSG00000077713.19,ENSG00000077713,SLC25A43,-1.047096013,-1.665819108,-0.826366426,-0.649102504,solute carrier family 25 member 43,"SLC25A43 is a gene that belongs to the mitochondrial carrier family of proteins. This gene encodes a protein that is involved in transporting molecules across the mitochondrial membrane. The exact function of this protein is not yet fully understood, but it is believed to play a role in energy metabolism and cellular respiration. Mutations in this gene have been associated with various disorders, including mitochondrial myopathy and encephalopathy. Further research is needed to fully understand the function of SLC25A43 and its potential role in disease.","There is limited information available on the disease implications and targeted drug discovery efforts for SLC25A43. However, mutations in this gene have been associated with mitochondrial myopathy and encephalopathy, which are rare genetic disorders that affect the function of mitochondria in cells. Mitochondrial myopathy and encephalopathy can cause a range of symptoms, including muscle weakness, seizures, and developmental delays.

Currently, there are no targeted drug discovery efforts or drugs on the market specifically for SLC25A43-related disorders. However, there are some drugs that have been approved for the treatment of mitochondrial disorders in general, such as coenzyme Q10 and idebenone. These drugs work by improving mitochondrial function and reducing oxidative stress in cells. Additionally, there are ongoing clinical trials for other drugs that target mitochondrial dysfunction, which may have potential for treating SLC25A43-related disorders in the future.",GO:0055085 transmembrane transport;GO:0006810 transport;GO:0051234 establishment of localization,,Transporters:Electrochemical Potential-driven transporters,Cytosol (Approved),,,
ENSG00000198677.12,ENSG00000198677,TTC37,-1.047024355,-1.060678264,-1.046988362,-1.033406438,SKI3 subunit of superkiller complex,"The SKIC3 gene encodes a protein with 20 tetratricopeptide (TPR) repeats, which are involved in protein-protein interactions and chaperone activity. Mutations in this gene have been linked to trichohepatoenteric syndrome.","Trichohepatoenteric syndrome (THES) is a rare autosomal recessive disorder characterized by chronic diarrhea, hair abnormalities, and liver disease. Mutations in the SKIC3 gene have been identified as a cause of THES. The exact mechanism by which SKIC3 mutations lead to THES is not fully understood, but it is thought to involve disruption of protein-protein interactions and chaperone activity. There are currently no targeted drug discovery efforts for THES specifically, but there are ongoing efforts to develop drugs that target protein-protein interactions and chaperone activity in general. Examples of successful drugs that target these pathways include Hsp90 inhibitors, which are used to treat certain types of cancer, and cyclophilin inhibitors, which are used to treat hepatitis C. However, it is unclear whether these drugs would be effective in treating THES specifically.","GO:0070478 nuclear-transcribed mRNA catabolic process, 3'-5' exonucleolytic nonsense-mediated decay;GO:0072344 rescue of stalled ribosome;GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay",,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the digestive system; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000180263.14,ENSG00000180263,FGD6,-1.046510723,-1.38139562,-1.078043443,-0.680093107,"FYVE, RhoGEF and PH domain containing 6","FGD6 is a human gene that is predicted to have guanyl-nucleotide exchange factor activity and small GTPase binding activity. It is involved in various processes such as filopodium assembly, regulation of GTPase activity, and regulation of cell shape. FGD6 is predicted to be located in the Golgi apparatus, lamellipodium, and ruffle, and is active in the cytoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of FGD6. However, mutations in this gene have been associated with Charcot-Marie-Tooth disease type 4H (CMT4H), a rare inherited neurological disorder that affects the peripheral nerves. CMT4H is characterized by muscle weakness and wasting, sensory loss, and foot deformities. Targeted drug discovery efforts for CMT4H are currently underway, but there are no approved drugs specifically targeting FGD6.

There are currently no drugs on the market that target FGD6. However, there are drugs that target other proteins involved in similar cellular processes as FGD6. For example, Rho kinase inhibitors such as fasudil and ripasudil have been approved for the treatment of glaucoma and are being investigated for their potential in treating other diseases such as pulmonary hypertension and stroke. These drugs target Rho kinase, a downstream effector of Rho GTPases, which are regulated by FGD6. Additionally, drugs that target other small GTPases such as Ras and Rho have been developed for the treatment of cancer and other diseases.",GO:0046847 filopodium assembly;GO:0008360 regulation of cell shape;GO:0043087 regulation of GTPase activity,,Predicted intracellular proteins,Vesicles (Approved),,,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000116406.19,ENSG00000116406,EDEM3,-1.046439583,-1.296772905,-0.978800528,-0.863745316,ER degradation enhancing alpha-mannosidase like protein 3,"EDEM3 is a human gene that plays a role in quality control in the endoplasmic reticulum (ER). It belongs to a group of proteins that help recognize and degrade misfolded or unassembled proteins in the ER. Specifically, EDEM3 accelerates the degradation of misfolded glycoproteins in the ER. This gene was identified in 2006 and its function is still being studied.","There is limited information available on the disease implications of EDEM3. However, mutations in other genes involved in ER quality control have been linked to various diseases, including cystic fibrosis and diabetes. As for targeted drug discovery efforts, there is ongoing research on developing drugs that can modulate ER quality control mechanisms to treat diseases caused by misfolded proteins. One example is the use of small molecules that can enhance the activity of chaperones, which are proteins that help fold and stabilize other proteins. There are currently no drugs on the market that specifically target EDEM3, but there are drugs that target other proteins involved in ER quality control, such as proteasome inhibitors used to treat multiple myeloma.",GO:0097466 ubiquitin-dependent glycoprotein ERAD pathway;GO:0006056 mannoprotein metabolic process;GO:0006058 mannoprotein catabolic process,,Predicted intracellular proteins; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism,Endoplasmic reticulum (Approved),,,
ENSG00000127481.15,ENSG00000127481,UBR4,-1.046138773,-1.800684834,-1.148669554,-0.18906193,ubiquitin protein ligase E3 component n-recognin 4,UBR4 is a human gene that encodes for an E3 ubiquitin-protein ligase. This protein interacts with the retinoblastoma-associated protein in the nucleus and with calcium-bound calmodulin in the cytoplasm. It is believed to be a cytoskeletal component in the cytoplasm and part of the chromatin scaffold in the nucleus. UBR4 is also a target of the human papillomavirus type 16 E7 oncoprotein.,"Mutations in the UBR4 gene have been associated with several diseases, including intellectual disability, autism spectrum disorder, and cancer. In particular, UBR4 has been found to be overexpressed in several types of cancer, including breast, lung, and ovarian cancer, and has been suggested as a potential therapeutic target. However, there are currently no drugs specifically targeting UBR4.

There have been some efforts to develop drugs targeting the E3 ubiquitin-protein ligase family, of which UBR4 is a member. One example is the drug bortezomib, which targets the proteasome and has been approved for the treatment of multiple myeloma and mantle cell lymphoma. Another example is the drug carfilzomib, which also targets the proteasome and has been approved for the treatment of multiple myeloma.

Overall, while UBR4 has been implicated in several diseases and has potential as a therapeutic target, more research is needed to fully understand its role in disease and to develop targeted drugs.",GO:0141191 negative regulation of HRI-mediated signaling;GO:0071629 cytoplasm protein quality control by the ubiquitin-proteasome system;GO:0071596 ubiquitin-dependent protein catabolic process via the N-end rule pathway,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported); Additional: Acrosome;Centrosome;Cytosol;Flagellar centriole;Perinuclear theca;Principal piece,Verpasep caltespen; PCL-016,,
ENSG00000182985.18,ENSG00000182985,CADM1,-1.045090087,-1.967867133,-0.928405006,-0.238998122,cell adhesion molecule 1,"CADM1, or cell adhesion molecule 1, is a gene that plays a role in cell recognition, positive regulation of cytokine production, and susceptibility to natural killer cell mediated cytotoxicity. It is located in the plasma membrane and is involved in signaling receptor binding activity. CADM1 has been implicated in breast carcinoma and prostate cancer and is a biomarker of cervix uteri carcinoma in situ.","CADM1 has been implicated in various types of cancer, including breast carcinoma, prostate cancer, and cervix uteri carcinoma in situ. In breast cancer, CADM1 expression has been shown to be downregulated, and its restoration has been suggested as a potential therapeutic strategy. In prostate cancer, CADM1 has been identified as a tumor suppressor gene, and its loss has been associated with disease progression and poor prognosis. Targeted drug discovery efforts for CADM1 have focused on developing small molecule inhibitors that can restore its expression or function in cancer cells. However, there are currently no drugs on the market that specifically target CADM1. Nonetheless, several drugs that indirectly affect CADM1 expression or function have been approved for cancer treatment, including trastuzumab for HER2-positive breast cancer and enzalutamide for castration-resistant prostate cancer.",GO:0120154 negative regulation of ERBB4 signaling pathway;GO:0042271 susceptibility to natural killer cell mediated cytotoxicity;GO:0045954 positive regulation of natural killer cell mediated cytotoxicity,,Predicted intracellular proteins; Human disease related genes:Cancers:Head and neck cancers,Plasma membrane (Supported),,,(M5949)HALLMARK PEROXISOME; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000034677.13,ENSG00000034677,RNF19A,-1.043057531,-0.886628735,-1.298312278,-0.94423158,"ring finger protein 19A, RBR E3 ubiquitin protein ligase","RNF19A is a gene that encodes a protein belonging to the RBR protein family. The protein contains two RING-finger motifs and an in-between RING fingers motif. It is an E3 ubiquitin ligase that is found in Lewy bodies and is responsible for ubiquitylating synphilin-1, which interacts with alpha synuclein in neurons. The protein may be involved in the development of Parkinson's disease and amyotrophic lateral sclerosis. Alternative splicing of the gene results in multiple transcript variants.","RNF19A has been implicated in the development of Parkinson's disease and amyotrophic lateral sclerosis (ALS). In Parkinson's disease, RNF19A is found in Lewy bodies, which are protein aggregates that accumulate in the brains of patients with the disease. RNF19A is responsible for ubiquitylating synphilin-1, which interacts with alpha synuclein in neurons. This suggests that RNF19A may play a role in the formation of Lewy bodies and the progression of Parkinson's disease. 

There are currently no drugs on the market that specifically target RNF19A. However, there are ongoing efforts to develop drugs that target the ubiquitin-proteasome system, which is the cellular pathway that RNF19A is involved in. These drugs aim to enhance the clearance of misfolded proteins, such as alpha synuclein, that accumulate in neurodegenerative diseases like Parkinson's. 

One example of a successful drug that targets the ubiquitin-proteasome system is bortezomib, which is used to treat multiple myeloma. Bortezomib inhibits the proteasome, which leads to the accumulation of misfolded proteins and ultimately induces cell death in cancer cells. Another example is carfilzomib, which is also used to treat multiple myeloma. Carfilzomib is a more selective proteasome inhibitor than bortezomib and has fewer side effects. 

In summary, RNF19A is a gene that has been implicated in the development of Parkinson's disease and ALS. While there are currently no drugs on the market that specifically target RNF19A, there are ongoing efforts to develop drugs that target the ubiquitin-proteasome system, which may have therapeutic potential for neurodegenerative diseases.","GO:0099576 regulation of protein catabolic process at postsynapse, modulating synaptic transmission;GO:0099170 postsynaptic modulation of chemical synaptic transmission;GO:0042176 regulation of protein catabolic process",,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,,,,(M5945)HALLMARK HEME METABOLISM
ENSG00000067900.8,ENSG00000067900,ROCK1,-1.040991385,-1.27359633,-1.073445465,-0.77593236,Rho associated coiled-coil containing protein kinase 1,"ROCK1 is a protein serine/threonine kinase that is activated by the GTP-bound form of Rho, a small GTPase that regulates the formation of focal adhesions and stress fibers in fibroblasts, as well as adhesion and aggregation of platelets and lymphocytes. Rho is also essential in cytokinesis and plays a role in transcriptional activation by serum response factor. ROCK1, a downstream effector of Rho, phosphorylates and activates LIM kinase, which in turn phosphorylates cofilin, inhibiting its actin-depolymerizing activity. A pseudogene related to ROCK1 is also located on chromosome 18.","ROCK1 has been implicated in various diseases, including cancer, cardiovascular diseases, and neurological disorders. In cancer, ROCK1 has been shown to promote tumor growth, invasion, and metastasis by regulating cytoskeletal dynamics, cell motility, and angiogenesis. Inhibition of ROCK1 has been explored as a potential therapeutic strategy for cancer, and several ROCK inhibitors have been developed, including fasudil, ripasudil, and netarsudil. Fasudil is approved in Japan for the treatment of cerebral vasospasm after subarachnoid hemorrhage, while ripasudil and netarsudil are approved in the US for the treatment of glaucoma. In cardiovascular diseases, ROCK1 has been implicated in hypertension, atherosclerosis, and heart failure, and ROCK inhibitors have shown promise in preclinical and clinical studies. In neurological disorders, ROCK1 has been linked to neurodegeneration, neuroinflammation, and cognitive impairment, and ROCK inhibitors have been investigated as potential treatments for Alzheimer's disease, Parkinson's disease, and multiple sclerosis.",GO:0110061 regulation of angiotensin-activated signaling pathway;GO:0003383 apical constriction;GO:0022614 membrane to membrane docking,yes,Predicted intracellular proteins; ENZYME proteins:Transferases; FDA approved drug targets:Small molecule drugs; Kinases:AGC Ser/Thr protein kinases; Enzymes,,Hydroxyfasudil; (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE; Fasudil; Y-27632; Ripasudil; Netarsudil,(M138)PID THROMBIN PAR4 PATHWAY; (M11)PID PRL SIGNALING EVENTS PATHWAY; (M23)PID WNT NONCANONICAL PATHWAY,(M5902)HALLMARK APOPTOSIS; (M5893)HALLMARK MITOTIC SPINDLE
ENSG00000138468.16,ENSG00000138468,SENP7,-1.04002445,-1.271204102,-1.119013992,-0.729855257,SUMO specific peptidase 7,"SENP7 is a human gene that encodes for a SUMO-specific peptidase 7 enzyme. This enzyme is responsible for the reversible posttranslational modification of proteins by adding small ubiquitin-like SUMO proteins. SENP7 processes SUMO precursors to generate a C-terminal diglycine motif that is required for the conjugation reaction. Additionally, it displays isopeptidase activity for deconjugation of SUMO-conjugated substrates. The modification of proteins by SUMO proteins is essential for many cellular processes, and SENP7 plays a crucial role in regulating this process.","There is limited information available on the disease implications of SENP7. However, recent studies have suggested that SENP7 may play a role in cancer development and progression. Specifically, it has been shown to be overexpressed in several types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts for SENP7 are still in the early stages, but there is potential for the development of drugs that can modulate its activity. One example of a successful drug targeting the SUMO pathway is the FDA-approved drug, TAK-981, which targets the SUMO E1 enzyme and is being investigated for the treatment of multiple myeloma. However, further research is needed to fully understand the potential of targeting SENP7 for therapeutic purposes.",GO:0016926 protein desumoylation;GO:0140374 antiviral innate immune response;GO:0018205 peptidyl-lysine modification,,Peptidases:Cysteine-type peptidases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Centrosome;Cytosol;Nuclear bodies,,,
ENSG00000135249.8,ENSG00000135249,RINT1,-1.040009816,-1.464710569,-1.039706064,-0.615612815,RAD50 interactor 1,"RINT1 (RAD50 interactor 1) is a gene that encodes a protein that interacts with the RAD50 protein, which is involved in repairing double-strand breaks in DNA. This interaction is thought to play a role in regulating cell cycle progression and telomere length. Additionally, the RINT1 protein may be involved in transporting cellular cargo from the endosome to the trans-Golgi network. Mutations in the RINT1 gene have been associated with breast cancer in humans.","Mutations in the RINT1 gene have been associated with an increased risk of developing breast cancer. Studies have shown that RINT1 mutations are present in a small percentage of familial breast cancer cases, particularly those with a history of early-onset breast cancer. Targeted drug discovery efforts for RINT1 mutations are still in the early stages, but there is potential for developing personalized therapies for individuals with RINT1 mutations. Currently, there are no drugs specifically targeting RINT1 mutations on the market. However, there are several drugs that target other genes involved in DNA repair pathways, such as PARP inhibitors, which have shown promise in treating breast cancer patients with BRCA mutations. Further research is needed to fully understand the role of RINT1 in breast cancer and to develop targeted therapies for individuals with RINT1 mutations.","GO:0060628 regulation of ER to Golgi vesicle-mediated transport;GO:0007095 mitotic G2 DNA damage checkpoint signaling;GO:0006890 retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum",,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Golgi apparatus (Approved),,,
ENSG00000077458.13,ENSG00000077458,FAM76B,-1.038846073,-1.133759597,-1.243847098,-0.738931524,family with sequence similarity 76 member B,"FAM76B is a human gene that is a member of the family with sequence similarity 76. It is located in the nuclear speck, which is a subnuclear structure involved in RNA processing and splicing. The function of FAM76B is not yet fully understood, but it has been suggested to play a role in DNA damage response and repair. Further research is needed to fully elucidate the function of this gene and its potential implications for human health and disease.","There is currently limited information available on the disease implications of FAM76B. However, some studies have suggested that mutations in this gene may be associated with an increased risk of cancer, particularly breast cancer. Targeted drug discovery efforts for FAM76B are also limited, as its function is not yet fully understood. However, some studies have suggested that targeting FAM76B may be a potential strategy for enhancing the efficacy of chemotherapy in cancer treatment. There are currently no drugs on the market that specifically target FAM76B, as more research is needed to fully understand its function and potential therapeutic applications.",GO:0046826 negative regulation of protein export from nucleus;GO:0043031 negative regulation of macrophage activation;GO:0051457 maintenance of protein location in nucleus,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Nucleoli fibrillar center,,,
ENSG00000162144.10,ENSG00000162144,CYB561A3,-1.03867665,-1.585361765,-1.046824094,-0.483844092,cytochrome b561 family member A3,CYB561A3 is a human gene that belongs to the cytochrome b561 family member A3. It is predicted to have transmembrane ascorbate ferrireductase activity and to be involved in cellular iron ion homeostasis. The gene is located in the nucleolus. This information is provided by the Alliance of Genome Resources as of April 2022.,"Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for CYB561A3. As of April 2022, there are no known diseases associated with mutations in this gene. Additionally, there are no drugs currently on the market that specifically target CYB561A3. However, given its predicted role in cellular iron ion homeostasis, it is possible that future research may identify potential therapeutic targets for diseases related to iron dysregulation. Further studies are needed to fully understand the function of CYB561A3 and its potential implications for human health.",GO:0006879 intracellular iron ion homeostasis;GO:0030003 intracellular monoatomic cation homeostasis;GO:0006873 intracellular monoatomic ion homeostasis,,ENZYME proteins; Enzymes; Predicted intracellular proteins,Vesicles (Approved); Additional: Nucleoli,,,
ENSG00000182768.9,ENSG00000182768,NGRN,-1.038353035,-1.820235609,-1.248266515,-0.046556982,"neugrin, neurite outgrowth associated","Neugrin, also known as NGRN, is a human gene that is associated with neurite outgrowth. It enables rRNA binding activity and is involved in positive regulation of mitochondrial translation. The gene is located in several cellular components, including intercellular bridge, mitotic spindle, and nuclear body. The function of neugrin is not fully understood, but it is believed to play a role in the development and maintenance of the nervous system. Mutations in the NGRN gene have been linked to various neurological disorders, including schizophrenia and bipolar disorder.","Mutations in the NGRN gene have been linked to various neurological disorders, including schizophrenia and bipolar disorder. Studies have shown that NGRN expression is reduced in the brains of individuals with schizophrenia, suggesting that it may play a role in the development of the disease. Targeted drug discovery efforts for NGRN are still in the early stages, but there is potential for the development of drugs that can modulate its activity. Currently, there are no drugs on the market that specifically target NGRN, but there are drugs used to treat schizophrenia and bipolar disorder that indirectly affect its activity. For example, antipsychotic drugs such as risperidone and olanzapine have been shown to increase NGRN expression in the brain.",GO:0061668 mitochondrial ribosome assembly;GO:0070131 positive regulation of mitochondrial translation;GO:0070129 regulation of mitochondrial translation,,Predicted intracellular proteins,Mitochondria (Supported); Additional: Cytokinetic bridge;Nucleoplasm,,,
ENSG00000047188.16,ENSG00000047188,YTHDC2,-1.038096523,-0.925523708,-0.915792488,-1.272973372,YTH N6-methyladenosine RNA binding protein C2,"YTHDC2 is a gene that encodes a protein belonging to the DEAH subfamily of RNA helicases. The protein binds to N6-methyladenosine, a modified RNA nucleotide that is enriched in the stop codons and 3' UTRs of eukaryotic messenger RNAs. The binding of proteins to this modified nucleotide may regulate mRNA translation and stability. The gene may be associated with susceptibility to pancreatic cancer in human patients, and knockdown of this gene resulted in reduced proliferation in a human liver cancer cell line.","There is limited information available on the disease implications of YTHDC2. However, studies have suggested that the gene may be associated with susceptibility to pancreatic cancer in human patients. Additionally, knockdown of this gene resulted in reduced proliferation in a human liver cancer cell line, indicating a potential role in cancer development and progression.

As of now, there are no targeted drug discovery efforts specifically focused on YTHDC2. However, the protein it encodes, which binds to N6-methyladenosine, is a potential target for drug development. Several drugs targeting N6-methyladenosine have been developed and are currently in clinical trials for various types of cancer. For example, the drug MK-8628, which inhibits the METTL3 enzyme responsible for adding the N6-methyladenosine modification, is being tested in clinical trials for acute myeloid leukemia and solid tumors.

In summary, while there is limited information available on the disease implications of YTHDC2, the protein it encodes may be a potential target for drug development. Several drugs targeting the N6-methyladenosine modification are currently in clinical trials for various types of cancer.","GO:0051729 germline cell cycle switching, mitotic to meiotic cell cycle;GO:0051728 cell cycle switching, mitotic to meiotic cell cycle;GO:0060184 cell cycle switching",,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytoplasmic bodies;Nuclear bodies,,,
ENSG00000108021.20,ENSG00000108021,TASOR2,-1.037213535,-1.362083338,-0.905565763,-0.843991504,transcription activation suppressor family member 2,"TASOR2, also known as transcription activation suppressor family member 2, is a human gene that is located in both the cytosol and nucleoplasm. The function of this gene is not yet fully understood, but it is believed to play a role in regulating gene expression. TASOR2 is a member of the transcription activation suppressor family, which includes proteins that can inhibit the activity of transcription factors and other proteins involved in gene expression. Further research is needed to fully understand the function of TASOR2 and its potential role in human health and disease.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for TASOR2. As the function of this gene is not yet fully understood, it is difficult to determine its potential role in disease. However, research on other members of the transcription activation suppressor family has suggested that they may be involved in cancer and other diseases related to abnormal gene expression. 

To date, there are no drugs on the market that specifically target TASOR2. However, there are drugs that target other members of the transcription activation suppressor family, such as HDAC inhibitors, which are used to treat certain types of cancer. These drugs work by inhibiting the activity of histone deacetylases, which are enzymes that regulate gene expression. While it is unclear if TASOR2 is directly involved in cancer or other diseases, further research on this gene and its function may lead to the development of new targeted therapies in the future.","GO:0045814 negative regulation of gene expression, epigenetic;GO:0040029 epigenetic regulation of gene expression;GO:0006338 chromatin remodeling",,Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Cytosol,,,
ENSG00000143398.20,ENSG00000143398,PIP5K1A,-1.035857753,-1.289214675,-1.243858064,-0.57450052,phosphatidylinositol-4-phosphate 5-kinase type 1 alpha,"PIP5K1A is a human gene that encodes for the protein phosphatidylinositol-4-phosphate 5-kinase type 1 alpha. This protein is involved in various cellular processes, including the activation of GTPase activity, focal adhesion assembly, and ruffle assembly. It has 1-phosphatidylinositol-4-phosphate 5-kinase activity and kinase binding activity. PIP5K1A is located in different cellular components, such as the lamellipodium, nuclear speck, and ruffle membrane. It also colocalizes with the mRNA cleavage and polyadenylation specificity factor complex.","There is evidence to suggest that PIP5K1A may play a role in the development and progression of certain diseases. For example, studies have shown that PIP5K1A expression is upregulated in various types of cancer, including breast, lung, and prostate cancer. Additionally, mutations in the PIP5K1A gene have been associated with a rare genetic disorder called cone-rod dystrophy, which affects the retina and can lead to vision loss.

Given its potential involvement in disease processes, PIP5K1A has been identified as a potential target for drug discovery efforts. Several small molecule inhibitors of PIP5K1A have been developed and tested in preclinical studies, with promising results. For example, one study found that a PIP5K1A inhibitor was able to reduce tumor growth in a mouse model of breast cancer.

However, to date, there are no drugs targeting PIP5K1A that have been approved for clinical use. Nonetheless, ongoing research in this area may lead to the development of new therapies for cancer and other diseases in the future.",GO:0097178 ruffle assembly;GO:0010761 fibroblast migration;GO:0031529 ruffle organization,yes,Enzymes; Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Plasma membrane (Supported); Additional: Nucleoplasm,,(M120)PID ARF6 DOWNSTREAM PATHWAY; (M243)PID ARF 3PATHWAY; (M184)PID ECADHERIN KERATINOCYTE PATHWAY,
ENSG00000047315.17,ENSG00000047315,POLR2B,-1.035809559,-1.039306576,-1.527982232,-0.54013987,RNA polymerase II subunit B,"POLR2B is a gene that encodes the second largest subunit of RNA polymerase II (Pol II), which is responsible for transcribing DNA into precursors of mRNA, snRNA, and microRNA. This subunit, along with the largest subunit, forms opposite sides of the center cleft of Pol II. Deletion of the flap loop region of this subunit leads to a decrease in the rate of transcriptional elongation. Alternative splicing of the gene results in multiple transcript variants.","There is limited information on the disease implications of POLR2B mutations. However, recent studies have shown that mutations in this gene are associated with intellectual disability and developmental delay. Targeted drug discovery efforts for POLR2B are still in the early stages, but there is potential for developing drugs that target the flap loop region of the subunit to modulate transcriptional elongation. Currently, there are no drugs on the market that specifically target POLR2B. However, there are drugs that indirectly affect its function, such as the chemotherapy drug, cisplatin, which inhibits transcription by binding to DNA and interfering with Pol II activity. Additionally, the drug, alpha-amanitin, derived from the mushroom Amanita phalloides, inhibits Pol II activity by binding to the same region as the flap loop of POLR2B.",GO:0001172 RNA-templated transcription;GO:0001059 transcription by RNA polymerase IV;GO:0001060 transcription by RNA polymerase V,,Enzymes; RNA polymerase related proteins; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported),,,
ENSG00000134255.14,ENSG00000134255,CEPT1,-1.033991908,-1.018684322,-1.532310619,-0.550980783,choline/ethanolamine phosphotransferase 1,The CEPT1 gene encodes for a choline/ethanolamine phosphotransferase 1 enzyme that plays a crucial role in the synthesis of phospholipids containing choline or ethanolamine. Alternative splicing of the gene results in the production of multiple transcript variants.,"Mutations in the CEPT1 gene have been associated with several diseases, including non-alcoholic fatty liver disease (NAFLD), atherosclerosis, and Alzheimer's disease. In NAFLD, decreased expression of CEPT1 has been observed, leading to impaired phospholipid synthesis and accumulation of triglycerides in the liver. Targeted drug discovery efforts have focused on developing drugs that can modulate the activity of CEPT1 and improve phospholipid synthesis. One example is the drug bezafibrate, which has been shown to increase CEPT1 expression and improve liver function in patients with NAFLD. Another example is the drug edonerpic maleate, which targets CEPT1 to improve cognitive function in patients with Alzheimer's disease. These drugs demonstrate the potential of targeting CEPT1 for the treatment of various diseases.",GO:0006657 CDP-choline pathway;GO:0006646 phosphatidylethanolamine biosynthetic process;GO:0006656 phosphatidylcholine biosynthetic process,,Enzymes; Transporters; ENZYME proteins:Transferases,,,,
ENSG00000140262.18,ENSG00000140262,TCF12,-1.033948193,-1.554304046,-1.008679552,-0.53886098,transcription factor 12,"TCF12 is a gene that encodes a protein belonging to the basic helix-loop-helix E-protein family. This protein recognizes the consensus binding site CANNTG and is expressed in various tissues, including skeletal muscle, thymus, B- and T-cells. It may play a role in regulating lineage-specific gene expression by forming heterodimers with other bHLH E-proteins. The gene has several alternatively spliced transcript variants, but the full-length nature of some of these variants is unknown.","There is limited information on the disease implications of TCF12. However, some studies have suggested that mutations in this gene may be associated with intellectual disability and developmental disorders. Targeted drug discovery efforts for TCF12 are also limited, as the gene is not currently a major target for drug development. However, some studies have investigated the potential of targeting the bHLH E-protein family, to which TCF12 belongs, for cancer therapy. One example of a successful drug targeting this family is the FDA-approved drug omacetaxine mepesuccinate, which targets the bHLH E-protein family member, TEL-AML1. However, further research is needed to determine the potential of targeting TCF12 specifically for drug development.",GO:0097210 response to gonadotropin-releasing hormone;GO:0045666 positive regulation of neuron differentiation;GO:0045664 regulation of neuron differentiation,,Transcription factors:Basic domains; Predicted intracellular proteins; Human disease related genes:Endocrine and metabolic diseases:Hypothalamus and pituitary gland diseases; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Cancer-related genes:Mutational cancer driver genes,Nuclear speckles;Nucleoplasm (Supported),,,
ENSG00000175215.11,ENSG00000175215,CTDSP2,-1.033372382,-1.413337583,-1.017151857,-0.669627707,CTD small phosphatase 2,"CTDSP2, also known as CTD small phosphatase 2, is a human gene that encodes a protein involved in protein dephosphorylation. Specifically, it enables RNA polymerase II CTD heptapeptide repeat phosphatase activity. The protein is predicted to be located in the nucleoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of CTDSP2. However, some studies have suggested that alterations in the expression of this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Additionally, mutations in CTDSP2 have been linked to developmental disorders such as intellectual disability and autism spectrum disorder.

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target CTDSP2. However, some studies have identified potential small molecule inhibitors of the protein, which could be developed into therapeutic agents for the treatment of cancer and other diseases.

One example of a successful drug targeting a related protein is Fostamatinib, which targets the protein tyrosine phosphatase SYK and is used to treat rheumatoid arthritis. Another example is Imatinib, which targets the tyrosine kinase BCR-ABL and is used to treat chronic myeloid leukemia. While these drugs do not target CTDSP2 directly, they demonstrate the potential for targeted drug discovery efforts in the field of protein phosphatases.",GO:2000134 negative regulation of G1/S transition of mitotic cell cycle;GO:0006470 protein dephosphorylation;GO:1902807 negative regulation of cell cycle G1/S phase transition,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Mitochondria,,(M228)PID SMAD2 3PATHWAY; (M181)PID BMP PATHWAY; (M58)PID AR PATHWAY,
ENSG00000134744.14,ENSG00000134744,TUT4,-1.032154199,-1.297092298,-1.194610623,-0.604759676,terminal uridylyl transferase 4,"TUT4, also known as ZCCHC11, is an enzyme that adds uridines to the 3-prime end of RNA molecules. This process is called RNA uridylation and is important for regulating gene expression and RNA stability. TUT4 is a member of the terminal uridylyl transferase family and uses UTP as a substrate for uridylation. Dysregulation of TUT4 has been linked to various diseases, including cancer and neurological disorders. Understanding the function and regulation of TUT4 may provide insights into the development of new therapies for these diseases.","There is limited information available on targeted drug discovery efforts for TUT4, as it is a relatively new target for drug development. However, dysregulation of TUT4 has been linked to various diseases, including cancer and neurological disorders. In cancer, TUT4 has been shown to promote tumor growth and metastasis by regulating the stability of certain oncogenic RNAs. In neurological disorders, TUT4 has been implicated in the regulation of synaptic plasticity and memory formation. 

Currently, there are no drugs on the market that specifically target TUT4. However, there are drugs that target other enzymes involved in RNA processing, such as ribonucleotide reductase and RNA polymerase, which have shown promise in preclinical and clinical studies for the treatment of cancer and other diseases. Additionally, small molecule inhibitors of TUT4 have been identified in recent studies, which may serve as starting points for the development of new therapies targeting TUT4.",GO:1990074 polyuridylation-dependent mRNA catabolic process;GO:0141008 transposable element silencing by mRNA destabilization;GO:0071076 RNA 3' uridylation,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Supported); Additional: Nucleoli,,,
ENSG00000060237.18,ENSG00000060237,WNK1,-1.031912165,-1.416471466,-0.873103808,-0.806161221,WNK lysine deficient protein kinase 1,"WNK1 is a gene that encodes a protein kinase belonging to the WNK subfamily. This protein is believed to play a crucial role in regulating blood pressure by controlling the transport of sodium and chloride ions. Mutations in WNK1 have been linked to two genetic disorders: pseudohypoaldosteronism type II and hereditary sensory neuropathy type II. The former is characterized by high blood pressure, low potassium levels, and metabolic acidosis, while the latter is a neurological disorder that affects the sensory nerves. Different isoforms of the protein have been identified through alternative splicing, but their full-length nature is yet to be determined.","WNK1 has been identified as a potential target for drug discovery efforts aimed at treating hypertension. Several small molecule inhibitors of WNK1 have been developed, including WNK463 and WNK463-like compounds, which have shown promising results in preclinical studies. However, these compounds have not yet been tested in clinical trials. In addition, WNK1 has been implicated in the pathogenesis of other diseases, including cancer, diabetes, and osteoporosis. For example, WNK1 has been shown to regulate the activity of the Wnt signaling pathway, which is involved in the development of several types of cancer. Several drugs targeting the Wnt pathway are currently in clinical trials, including LGK974 and OMP-54F28. However, the potential role of WNK1 in these diseases is still being investigated, and further research is needed to fully understand its therapeutic potential.",GO:0033633 negative regulation of cell-cell adhesion mediated by integrin;GO:0060566 positive regulation of termination of DNA-templated transcription;GO:1904595 positive regulation of termination of RNA polymerase II transcription,yes,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Predicted intracellular proteins; Kinases; Human disease related genes:Urinary system diseases:Kidney diseases; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Cytosol (Supported),,,
ENSG00000173193.15,ENSG00000173193,PARP14,-1.031826271,-1.353345214,-1.085911108,-0.65622249,poly(ADP-ribose) polymerase family member 14,PARP14 is a member of the poly(ADP-ribose) polymerase (PARP) protein family. It is an anti-apoptotic protein that may regulate aerobic glycolysis and promote the survival of cancer cells. The gene has been found to be overexpressed in various types of tumors.,"PARP14 has been implicated in various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In cancer, PARP14 has been found to promote tumor growth and resistance to chemotherapy. Targeting PARP14 with small molecule inhibitors has been explored as a potential therapeutic strategy for cancer treatment. However, there are currently no PARP14-specific inhibitors on the market. 

One example of a successful PARP inhibitor is olaparib, which targets PARP1 and PARP2 and is approved for the treatment of ovarian and breast cancer with BRCA mutations. Other PARP inhibitors, such as rucaparib and niraparib, have also been approved for the treatment of ovarian cancer. However, these inhibitors do not specifically target PARP14. 

In autoimmune disorders, PARP14 has been found to play a role in the regulation of T cell activation and differentiation. Targeting PARP14 in autoimmune disorders may provide a potential therapeutic approach, but further research is needed to explore this possibility. 

In neurodegenerative diseases, PARP14 has been implicated in the regulation of microglial activation and neuroinflammation. Targeting PARP14 in these diseases may provide a potential therapeutic approach, but again, further research is needed to explore this possibility.",GO:1902216 positive regulation of interleukin-4-mediated signaling pathway;GO:0042532 negative regulation of tyrosine phosphorylation of STAT protein;GO:1902214 regulation of interleukin-4-mediated signaling pathway,,Predicted intracellular proteins,Cytosol (Supported),,(M28)PID IL4 2PATHWAY,(M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000142453.12,ENSG00000142453,CARM1,-1.0304105,-1.211258121,-1.338149395,-0.541823985,coactivator associated arginine methyltransferase 1,"CARM1, or coactivator associated arginine methyltransferase 1, is an enzyme that belongs to the protein arginine methyltransferase (PRMT) family. It is responsible for catalyzing the methylation of guanidino nitrogens of arginyl residues of proteins, specifically histones and other chromatin-associated proteins. CARM1 is involved in the regulation of gene expression and may act in association with other proteins or within multi-protein complexes. It may also play a role in cell type-specific functions and cell lineage specification. A related pseudogene is located on chromosome 9.","CARM1 has been implicated in various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. In cancer, CARM1 has been shown to promote tumor growth and metastasis by regulating gene expression and signaling pathways. Targeting CARM1 has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of CARM1 have been developed and tested in preclinical studies, showing promising results in inhibiting tumor growth and metastasis. However, no CARM1 inhibitors have been approved for clinical use yet. In addition, CARM1 has also been implicated in cardiovascular disease and neurodegenerative disorders, such as Alzheimer's disease. Further research is needed to fully understand the role of CARM1 in these diseases and to develop effective therapies targeting CARM1.",GO:0071932 replication fork reversal;GO:2000171 negative regulation of dendrite development;GO:1904037 positive regulation of epithelial cell apoptotic process,,Enzymes; Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Enhanced),,(M151)PID AR TF PATHWAY; (M58)PID AR PATHWAY; (M145)PID P53 DOWNSTREAM PATHWAY,
ENSG00000178573.7,ENSG00000178573,MAF,-1.029103083,-1.944482335,-0.698747817,-0.444079097,MAF bZIP transcription factor,"MAF is a human gene that encodes a transcription factor containing a leucine zipper. It can act as a homodimer or heterodimer and function as a transcriptional activator or repressor depending on the binding site and partner. MAF plays a role in regulating various cellular processes, including embryonic lens fiber cell development, T-cell susceptibility to apoptosis, and chondrocyte terminal differentiation. Mutations in this gene are associated with juvenile-onset pulverulent cataract and congenital cerulean cataract 4. Two different isoforms of the protein are produced by alternative splicing.","Mutations in the MAF gene have been associated with several types of cataracts, including juvenile-onset pulverulent cataract and congenital cerulean cataract 4. These cataracts are characterized by the accumulation of protein aggregates in the lens, leading to clouding and impaired vision. While there are currently no targeted drug discovery efforts specifically for MAF-related cataracts, several drugs have been developed to treat cataracts in general. These include topical eye drops containing non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, which can reduce inflammation and swelling in the eye. Surgery to remove the clouded lens and replace it with an artificial one is also a common treatment for cataracts. Overall, while there is no cure for cataracts, current treatments can effectively manage the symptoms and improve quality of life for affected individuals.",GO:0070306 lens fiber cell differentiation;GO:0030219 megakaryocyte differentiation;GO:0140467 integrated stress response signaling,,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Human disease related genes:Nervous system diseases:Eye disease; Transcription factors:Basic domains; Predicted intracellular proteins; Cancer-related genes; Disease related genes,Nuclear bodies;Nucleoplasm (Approved); Additional: Golgi apparatus;Vesicles,,(M60)PID NFAT TFPATHWAY; (M167)PID AP1 PATHWAY; (M195)PID CMYB PATHWAY,(M5908)HALLMARK ANDROGEN RESPONSE
ENSG00000196850.6,ENSG00000196850,PPTC7,-1.028550859,-1.375047161,-1.419260566,-0.29134485,protein phosphatase targeting COQ7,PPTC7 is a human gene that encodes a protein phosphatase targeting COQ7. This gene enables protein serine/threonine phosphatase activity and is involved in peptidyl-serine dephosphorylation and regulation of ubiquinone biosynthetic process. PPTC7 is located in the mitochondrial matrix.,"There is limited information available on the disease implications of PPTC7. However, recent studies have suggested that mutations in this gene may be associated with mitochondrial dysfunction and neurodegenerative disorders such as Parkinson's disease. Targeted drug discovery efforts for PPTC7 are still in the early stages, but there is potential for the development of drugs that can modulate the activity of this protein phosphatase and improve mitochondrial function. Currently, there are no drugs on the market that specifically target PPTC7, but there are drugs that target other proteins involved in the ubiquinone biosynthetic process, such as coenzyme Q10 (CoQ10) supplements, which have been used to treat mitochondrial disorders. Additionally, drugs that target other aspects of mitochondrial function, such as antioxidants and mitochondrial biogenesis activators, may also have potential therapeutic benefits for diseases associated with PPTC7 dysfunction.",GO:0010795 regulation of ubiquinone biosynthetic process;GO:0070262 peptidyl-serine dephosphorylation;GO:0010566 regulation of ketone biosynthetic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol;Plasma membrane (Approved),,,
ENSG00000198853.12,ENSG00000198853,RUSC2,-1.028540212,-1.777856437,-0.954375717,-0.353388482,RUN and SH3 domain containing 2,RUSC2 (RUN and SH3 domain containing 2) is a gene that encodes a protein containing both RUN and SH3 domains. This protein interacts with Rab1b and Rab1-binding protein GM130. Alternative splicing of the transcript has been observed.,"There is limited information available on the disease implications of RUSC2. However, recent studies have suggested that RUSC2 may play a role in cancer progression and metastasis. Specifically, RUSC2 has been found to be overexpressed in several types of cancer, including breast, lung, and pancreatic cancer. Targeted drug discovery efforts for RUSC2 are currently underway, with a focus on developing small molecule inhibitors that can selectively target RUSC2 and inhibit its function in cancer cells. While there are currently no drugs on the market that specifically target RUSC2, several drugs that target related proteins, such as Rab1b and GM130, have been approved for the treatment of various diseases, including cancer and neurodegenerative disorders.",,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; Transporters:Accessory Factors Involved in Transport; Potential drug targets; Disease related genes,,,,
ENSG00000181222.19,ENSG00000181222,POLR2A,-1.028272726,-1.64819802,-1.011162482,-0.425457677,RNA polymerase II subunit A,"POLR2A is a gene that encodes the largest subunit of RNA polymerase II, which is responsible for synthesizing messenger RNA in eukaryotes. The product of this gene contains a carboxy terminal domain composed of heptapeptide repeats that are essential for polymerase activity. These repeats contain serine and threonine residues that are phosphorylated in actively transcribing RNA polymerase. Additionally, this subunit, in combination with several other polymerase subunits, forms the DNA binding domain of the polymerase, a groove in which the DNA template is transcribed into RNA.","Mutations in the POLR2A gene have been associated with a variety of diseases, including cancer, developmental disorders, and neurodegenerative diseases. In particular, mutations in the carboxy terminal domain of the POLR2A gene have been linked to a rare developmental disorder called Warsaw breakage syndrome, which is characterized by growth retardation, intellectual disability, and a predisposition to cancer.

Targeted drug discovery efforts for POLR2A have focused on developing inhibitors that can selectively target the polymerase activity of RNA polymerase II. One example is the drug alpha-amanitin, which is a cyclic peptide toxin produced by the death cap mushroom. Alpha-amanitin binds to the RNA polymerase II enzyme and inhibits its activity, leading to cell death. However, due to its toxicity, alpha-amanitin is not a viable drug candidate for human use.

Another example of a successful drug targeting RNA polymerase II is the chemotherapy drug actinomycin D. Actinomycin D binds to the DNA template strand and prevents RNA polymerase II from transcribing RNA, leading to cell death. Actinomycin D is used to treat a variety of cancers, including Wilms' tumor, rhabdomyosarcoma, and Ewing's sarcoma. However, due to its toxicity and side effects, actinomycin D is typically used as a last resort in cancer treatment.",GO:0001172 RNA-templated transcription;GO:0001059 transcription by RNA polymerase IV;GO:0001060 transcription by RNA polymerase V,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; RNA polymerase related proteins; Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Cytosol,,,(M5898)HALLMARK DNA REPAIR
ENSG00000145715.15,ENSG00000145715,RASA1,-1.026572928,-1.227226423,-1.20093502,-0.651557342,RAS p21 protein activator 1,"RASA1 is a gene that encodes a protein located in the cytoplasm and is part of the GAP1 family of GTPase-activating proteins. The protein stimulates the GTPase activity of normal RAS p21 but not its oncogenic counterpart, acting as a suppressor of RAS function. Mutations in the gene have been associated with basal cell carcinomas, hereditary capillary malformations (CM) with or without arteriovenous malformations (AVM), and Parkes Weber syndrome. Alternative splicing results in two isoforms, with the shorter isoform lacking the N-terminal hydrophobic region but retaining the same activity and being abundantly expressed in placental but not adult tissues.","Mutations in the RASA1 gene have been associated with several diseases, including hereditary capillary malformations (CM) with or without arteriovenous malformations (AVM), Parkes Weber syndrome, and basal cell carcinomas. Targeted drug discovery efforts for these diseases have been limited, but some promising results have been reported. For example, a recent study found that the drug sorafenib, which targets the RAS/RAF/MEK/ERK pathway, was effective in treating a patient with Parkes Weber syndrome. Additionally, a case report described successful treatment of a patient with CM-AVM using the mTOR inhibitor sirolimus. However, more research is needed to fully understand the potential of targeted therapies for RASA1-related diseases.",GO:0001953 negative regulation of cell-matrix adhesion;GO:0010812 negative regulation of cell-substrate adhesion;GO:0001570 vasculogenesis,,Human disease related genes:Congenital malformations:Congenital malformations of the circulatory system; RAS pathway related proteins; Predicted intracellular proteins; Human disease related genes:Cancers:Skin cancers; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Candidate cancer biomarkers,Basal body;Vesicles (Approved); Additional: Cytosol,,(M226)PID VEGFR1 PATHWAY; (M269)PID RAS PATHWAY; (M242)PID AURORA A PATHWAY,(M5919)HALLMARK HEDGEHOG SIGNALING; (M5893)HALLMARK MITOTIC SPINDLE; (M5915)HALLMARK APICAL JUNCTION
ENSG00000096070.19,ENSG00000096070,BRPF3,-1.026310948,-1.518698564,-0.743893453,-0.816340827,bromodomain and PHD finger containing 3,BRPF3 is a human gene that is predicted to have histone binding activity. It is involved in histone H3-K14 acetylation and positively regulates DNA replication. BRPF3 is part of the MOZ/MORF histone acetyltransferase complex.,"There is limited information available on the disease implications of BRPF3. However, it has been suggested that dysregulation of the MOZ/MORF complex, of which BRPF3 is a part, may contribute to the development of certain cancers. Targeted drug discovery efforts for BRPF3 are also limited, but there is ongoing research into developing inhibitors of the MOZ/MORF complex as potential cancer therapies. One example of a successful drug targeting histone acetylation is Vorinostat, which inhibits histone deacetylases and is used to treat cutaneous T-cell lymphoma. Another example is Romidepsin, which also inhibits histone deacetylases and is used to treat peripheral T-cell lymphoma. However, these drugs do not specifically target BRPF3 or the MOZ/MORF complex.",GO:0045740 positive regulation of DNA replication;GO:0006275 regulation of DNA replication;GO:0051054 positive regulation of DNA metabolic process,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Mitochondria,,,(M5921)HALLMARK COMPLEMENT
ENSG00000167460.17,ENSG00000167460,TPM4,-1.026288498,-1.0912346,-1.075422102,-0.912208793,tropomyosin 4,"TPM4 is a gene that encodes a protein called tropomyosin 4, which is part of the tropomyosin family of actin-binding proteins. Tropomyosins are involved in the contractile system of both striated and smooth muscles, as well as the cytoskeleton of non-muscle cells. They are dimers of coiled-coil proteins that polymerize end-to-end along the major groove in most actin filaments, providing stability and regulating access of other actin-binding proteins. In muscle cells, they regulate muscle contraction by controlling the binding of myosin heads to the actin filament. Multiple transcript variants encoding different isoforms have been found for this gene.","Mutations in the TPM4 gene have been associated with several diseases, including dilated cardiomyopathy, hypertrophic cardiomyopathy, and nemaline myopathy. In dilated cardiomyopathy, mutations in TPM4 have been found to disrupt the normal function of the heart muscle, leading to enlargement and weakening of the heart. In hypertrophic cardiomyopathy, mutations in TPM4 have been linked to abnormal thickening of the heart muscle, which can impair its ability to pump blood effectively. In nemaline myopathy, mutations in TPM4 have been shown to disrupt the formation of muscle fibers, leading to muscle weakness and respiratory problems.

Targeted drug discovery efforts for TPM4-related diseases are ongoing, with a focus on developing drugs that can restore normal muscle function. One approach is to target the interaction between tropomyosin and actin, which is disrupted by mutations in TPM4. Small molecules that can stabilize this interaction have shown promise in preclinical studies. Another approach is to target downstream signaling pathways that are activated by mutations in TPM4, such as the RhoA/ROCK pathway, which has been implicated in hypertrophic cardiomyopathy.

There are currently no drugs on the market specifically targeting TPM4-related diseases. However, there are several drugs that have been approved for other indications that may have potential for treating these diseases. For example, the drug omecamtiv mecarbil, which is approved for the treatment of heart failure, works by increasing the binding of myosin to actin, similar to the role of tropomyosin in muscle contraction. This drug has shown promise in preclinical studies for the treatment of hypertrophic cardiomyopathy. Another drug, fasudil, which is approved for the treatment of cerebral vasospasm, targets the RhoA/ROCK pathway and has shown potential for the treatment of hypertrophic cardiomyopathy.",GO:0030220 platelet formation;GO:0036344 platelet morphogenesis;GO:0001649 osteoblast differentiation,,Cancer-related genes; Predicted intracellular proteins,Actin filaments (Approved); Additional: Cytosol,Phenethyl Isothiocyanate,,(M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000123416.15,ENSG00000123416,TUBA1B,-1.025624768,-1.171469284,-1.480035347,-0.425369674,tubulin alpha 1b,"TUBA1B is a human gene that encodes for tubulin alpha 1b, a protein that is involved in the organization of the microtubule cytoskeleton and the mitotic cell cycle. It has been predicted to have double-stranded RNA binding activity and ubiquitin protein ligase binding activity. TUBA1B is located in the microtubule and is predicted to act upstream of or within the cellular response to interleukin-4. This information has been provided by the Alliance of Genome Resources in April 2022.","TUBA1B has been implicated in several diseases, including cancer, neurodegenerative disorders, and developmental disorders. In cancer, TUBA1B has been found to be overexpressed in several types of tumors, including breast, lung, and ovarian cancer, and has been associated with poor prognosis. Targeted drug discovery efforts have focused on developing inhibitors of TUBA1B to disrupt microtubule function and inhibit cancer cell growth. One example of a successful drug targeting TUBA1B is paclitaxel, which is used to treat breast, ovarian, and lung cancer. Paclitaxel stabilizes microtubules, preventing their disassembly during cell division and leading to cell death. Another example is vinblastine, which is used to treat Hodgkin's lymphoma and other types of cancer. Vinblastine disrupts microtubule function by binding to tubulin, preventing its polymerization and leading to cell death.",GO:0071353 cellular response to interleukin-4;GO:0070670 response to interleukin-4;GO:0030705 cytoskeleton-dependent intracellular transport,,Predicted intracellular proteins,Microtubules (Enhanced); Additional: Primary cilium,"Epothilone D; Patupilone; CYT997; 2-MERCAPTO-N-[1,2,3,10-TETRAMETHOXY-9-OXO-5,6,7,9-TETRAHYDRO-BENZO[A]HEPTALEN-7-YL]ACETAMIDE",(M11)PID PRL SIGNALING EVENTS PATHWAY; (M32)PID HDAC CLASSIII PATHWAY; (M30)PID HDAC CLASSII PATHWAY,
ENSG00000100345.22,ENSG00000100345,MYH9,-1.025273825,-1.5254019,-1.200652384,-0.349767192,myosin heavy chain 9,"The MYH9 gene encodes a conventional non-muscle myosin IIA heavy chain that plays a crucial role in various cellular functions such as cytokinesis, cell motility, and maintenance of cell shape. It contains an IQ domain and a myosin head-like domain. Mutations in this gene have been linked to several disorders including non-syndromic sensorineural deafness autosomal dominant type 17, Epstein syndrome, Alport syndrome with macrothrombocytopenia, Sebastian syndrome, Fechtner syndrome, and macrothrombocytopenia with progressive sensorineural deafness. It is important to note that this protein should not be confused with the unconventional myosin-9a or 9b (MYO9A or MYO9B).","Mutations in the MYH9 gene have been linked to several disorders, including non-syndromic sensorineural deafness autosomal dominant type 17, Epstein syndrome, Alport syndrome with macrothrombocytopenia, Sebastian syndrome, Fechtner syndrome, and macrothrombocytopenia with progressive sensorineural deafness. While there are currently no targeted drug discovery efforts specifically for MYH9-related disorders, there are treatments available for some of the associated symptoms. For example, patients with Alport syndrome and macrothrombocytopenia may benefit from platelet transfusions or antifibrinolytic agents to manage bleeding, while those with Fechtner syndrome may require hearing aids or cochlear implants to manage hearing loss. There are currently no drugs on the market that specifically target MYH9-related disorders, but ongoing research may lead to the development of targeted therapies in the future.",GO:0032796 uropod organization;GO:0060471 cortical granule exocytosis;GO:1903918 regulation of actin filament severing,,Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Ear disease; Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Cancer-related genes:Mutational cancer driver genes,Actin filaments;Plasma membrane (Supported); Additional: Cytosol;Nuclear bodies,Artenimol,,(M5919)HALLMARK HEDGEHOG SIGNALING; (M5893)HALLMARK MITOTIC SPINDLE; (M5891)HALLMARK HYPOXIA
ENSG00000159256.13,ENSG00000159256,MORC3,-1.024559257,-1.042920937,-1.25136477,-0.779392064,MORC family CW-type zinc finger 3,"MORC3 is a human gene that encodes a protein that is involved in the formation of nuclear bodies through an ATP-dependent mechanism. The protein is predicted to have coiled-coil and zinc finger domains and has RNA binding activity. It localizes to the nuclear matrix and is involved in regulating gene expression. Alternative splicing produces multiple transcript variants encoding distinct isoforms. The exact function of MORC3 is not fully understood, but it is believed to play a role in chromatin remodeling and DNA repair. Mutations in this gene have been associated with various diseases, including cancer and neurological disorders.","There is limited information available on targeted drug discovery efforts for MORC3, as its exact function and role in disease pathogenesis are not fully understood. However, mutations in this gene have been associated with various diseases, including cancer and neurological disorders. For example, a study found that MORC3 is overexpressed in glioblastoma, a type of brain cancer, and its knockdown inhibited tumor growth in vitro and in vivo. Additionally, mutations in MORC3 have been linked to Charcot-Marie-Tooth disease, a neurological disorder that affects the peripheral nerves. Currently, there are no drugs specifically targeting MORC3, but there are drugs on the market that target related proteins involved in chromatin remodeling and DNA repair, such as PARP inhibitors for cancer treatment. Further research is needed to fully understand the role of MORC3 in disease and to develop targeted therapies.",GO:0032688 negative regulation of interferon-beta production;GO:2000774 positive regulation of cellular senescence;GO:0051457 maintenance of protein location in nucleus,,Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Mitochondria,,,
ENSG00000131171.13,ENSG00000131171,SH3BGRL,-1.024323089,-1.128374946,-1.276350826,-0.668243493,SH3 domain binding glutamate rich protein like,"SH3BGRL is a human gene that is predicted to have SH3 domain binding activity. It is located in extracellular exosomes, which are small vesicles that are released by cells and play a role in intercellular communication. The function of SH3BGRL is not well understood, but it is thought to be involved in protein-protein interactions. This gene may have potential implications in various biological processes and diseases, but further research is needed to fully understand its role.","There is limited information available on the disease implications of SH3BGRL. However, some studies have suggested that it may be involved in the development and progression of certain cancers, such as breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for SH3BGRL are also limited, as its function and role in disease are not well understood. Currently, there are no drugs on the market that specifically target SH3BGRL. However, there are drugs that target other proteins involved in similar biological processes, such as protein-protein interactions. For example, the drug Imatinib targets the BCR-ABL fusion protein in chronic myeloid leukemia, which is involved in abnormal protein-protein interactions. Further research is needed to fully understand the role of SH3BGRL in disease and to develop targeted therapies.",GO:1904690 positive regulation of cytoplasmic translational initiation;GO:1904688 regulation of cytoplasmic translational initiation;GO:0045948 positive regulation of translational initiation,,Disease related genes; Predicted intracellular proteins,Cytosol (Supported),,,
ENSG00000128641.19,ENSG00000128641,MYO1B,-1.023457298,-1.50859423,-0.792431792,-0.769345873,myosin IB,"MYO1B is a human gene that encodes for the protein myosin IB. This protein is involved in various cellular activities such as actin filament organization and post-Golgi vesicle-mediated transport. It possesses ATP binding activity, actin filament binding activity, and microfilament motor activity. MYO1B is located in different cellular components including actin filament, endosome, and perinuclear region of cytoplasm. It also colocalizes with trans-Golgi network membrane. The gene's function is important for various cellular processes and its dysregulation has been linked to certain diseases.","MYO1B dysregulation has been linked to several diseases, including cancer, deafness, and neurological disorders. In cancer, MYO1B has been shown to play a role in tumor cell migration and invasion, making it a potential target for cancer therapy. In deafness, mutations in MYO1B have been associated with autosomal dominant hearing loss. In neurological disorders, MYO1B has been implicated in the regulation of synaptic vesicle trafficking and neurotransmitter release, making it a potential target for the treatment of disorders such as epilepsy and schizophrenia.

There have been efforts to develop drugs that target MYO1B. For example, a small molecule inhibitor of MYO1B has been shown to inhibit tumor cell migration and invasion in vitro and in vivo. Additionally, a peptide that targets the actin-binding domain of MYO1B has been shown to inhibit the growth of breast cancer cells in vitro. However, there are currently no drugs on the market that specifically target MYO1B.",GO:0051017 actin filament bundle assembly;GO:0061572 actin filament bundle organization;GO:0006892 post-Golgi vesicle-mediated transport,,Predicted intracellular proteins,Plasma membrane (Enhanced),,,
ENSG00000026950.17,ENSG00000026950,BTN3A1,-1.022854177,-1.708698379,-0.82977614,-0.530088011,butyrophilin subfamily 3 member A1,"BTN3A1 is a gene that belongs to the butyrophilin subfamily 3, which is a group of major histocompatibility complex (MHC)-associated genes that encode type I membrane proteins with 2 extracellular immunoglobulin (Ig) domains and an intracellular B30.2 (PRYSPRY) domain. BTN3A1 is one of three copies of the BTN3 gene that have undergone tandem duplication in the MHC class I region. The function of BTN3A1 is not fully understood, but it has been suggested to play a role in immune regulation and response to cellular stress. Mutations in BTN3A1 have been associated with susceptibility to tuberculosis and other infectious diseases.","BTN3A1 has been implicated in various infectious diseases, including tuberculosis, leprosy, and HIV. Studies have shown that genetic variations in BTN3A1 can affect the immune response to these pathogens, leading to increased susceptibility to infection. As a result, there has been interest in developing drugs that target BTN3A1 to enhance immune function and improve disease outcomes. However, there are currently no drugs on the market that specifically target BTN3A1. Some drugs that have been developed for other purposes, such as immunomodulators and immunostimulants, may indirectly affect BTN3A1 function. For example, interferon-gamma, a cytokine that activates immune cells, has been shown to upregulate BTN3A1 expression and enhance its function. Further research is needed to fully understand the role of BTN3A1 in disease and to develop targeted therapies.",GO:0050798 activated T cell proliferation;GO:0042098 T cell proliferation;GO:0032729 positive regulation of type II interferon production,,CD markers; Predicted intracellular proteins,Vesicles (Uncertain),,,
ENSG00000155304.6,ENSG00000155304,HSPA13,-1.022228971,-1.497498361,-1.001625061,-0.567563492,heat shock protein family A (Hsp70) member 13,HSPA13 is a member of the heat shock protein 70 family and is associated with microsomes. It plays a role in processing cytosolic and secretory proteins and removing denatured or incorrectly-folded proteins. The protein contains an ATPase domain and has been shown to associate with a ubiquitin-like protein.,"Research on HSPA13 and its disease implications is still in its early stages, but some studies have suggested that it may play a role in cancer progression and neurodegenerative diseases such as Alzheimer's and Parkinson's. Targeted drug discovery efforts for HSPA13 are also limited, but some compounds have been identified that can modulate its activity. For example, a study published in 2019 identified a small molecule inhibitor of HSPA13 that was able to reduce the growth of cancer cells in vitro and in vivo. However, there are currently no drugs on the market that specifically target HSPA13. Overall, more research is needed to fully understand the role of HSPA13 in disease and to develop targeted therapies for its modulation.",GO:0042026 protein refolding;GO:0051085 chaperone cofactor-dependent protein refolding;GO:0051084 'de novo' post-translational protein folding,,Predicted intracellular proteins,,Copper,,(M5941)HALLMARK UV RESPONSE UP
ENSG00000186063.13,ENSG00000186063,AIDA,-1.022126109,-1.486017184,-1.214278722,-0.366082421,"axin interactor, dorsalization associated","AIDA (Axin Interactor, Dorsalization Associated) is a human gene that is predicted to have phosphatidylinositol binding activity and is located in the cytoplasm. It acts upstream or within the negative regulation of JUN kinase activity and is predicted to be active in the membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of AIDA. However, some studies have suggested that AIDA may play a role in the development of certain cancers, including colorectal cancer and hepatocellular carcinoma. Targeted drug discovery efforts for AIDA are also limited, as the function of the gene is not well understood. Currently, there are no drugs on the market that specifically target AIDA. However, there are drugs that target the JUN kinase pathway, which AIDA is involved in negatively regulating. Examples of successful drugs that target this pathway include trametinib, which is used to treat melanoma, and ruxolitinib, which is used to treat myelofibrosis. Further research is needed to fully understand the role of AIDA in disease and to develop targeted therapies.",GO:0048264 determination of ventral identity;GO:0048262 determination of dorsal/ventral asymmetry;GO:0043508 negative regulation of JUN kinase activity,,Predicted intracellular proteins,Microtubules;Primary cilium (Approved); Additional: Basal body;Cytokinetic bridge,,,
ENSG00000165029.17,ENSG00000165029,ABCA1,-1.021157713,-1.651578658,-1.004792781,-0.407101702,ATP binding cassette subfamily A member 1,"ABCA1 is a gene that encodes a membrane-associated protein belonging to the ATP-binding cassette (ABC) transporter superfamily. ABC proteins transport various molecules across extra- and intracellular membranes. ABC genes are divided into seven subfamilies, and ABCA1 is a member of the ABC1 subfamily, which is found exclusively in multicellular eukaryotes. This protein functions as a cholesterol efflux pump in the cellular lipid removal pathway, with cholesterol as its substrate. Mutations in both alleles of this gene cause Tangier disease and familial high-density lipoprotein (HDL) deficiency.","Mutations in the ABCA1 gene have been linked to several diseases, including Tangier disease and familial high-density lipoprotein (HDL) deficiency. Tangier disease is a rare autosomal recessive disorder characterized by a deficiency in HDL cholesterol, leading to the accumulation of cholesterol in various tissues and organs. This can result in enlarged spleen and liver, peripheral neuropathy, and increased risk of atherosclerosis. Familial HDL deficiency is a genetic disorder that leads to low levels of HDL cholesterol, which can increase the risk of cardiovascular disease.

Targeted drug discovery efforts have focused on developing drugs that can increase the expression and activity of ABCA1, thereby promoting cholesterol efflux and reducing the risk of atherosclerosis. One example is the drug anacetrapib, which inhibits the activity of cholesteryl ester transfer protein (CETP), leading to an increase in HDL cholesterol levels and a decrease in LDL cholesterol levels. Another example is the drug evacetrapib, which also inhibits CETP activity and has been shown to increase HDL cholesterol levels and reduce the risk of cardiovascular events in clinical trials.

In summary, ABCA1 is an important gene involved in cholesterol efflux and lipid metabolism, and mutations in this gene can lead to several diseases. Targeted drug discovery efforts have led to the development of drugs that can increase ABCA1 activity and reduce the risk of atherosclerosis, with anacetrapib and evacetrapib being examples of successful drugs on the market.",GO:0090108 positive regulation of high-density lipoprotein particle assembly;GO:0033552 response to vitamin B3;GO:0090107 regulation of high-density lipoprotein particle assembly,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Predicted intracellular proteins; Transporters:Primary Active Transporters; Human disease related genes:Cardiovascular diseases:Vascular diseases; FDA approved drug targets:Small molecule drugs; Enzymes; Disease related genes; ENZYME proteins,Plasma membrane (Supported); Additional: Golgi apparatus,ATP; Glyburide; Probucol,(M162)PID RXR VDR PATHWAY,(M5910)HALLMARK PROTEIN SECRETION; (M5948)HALLMARK BILE ACID METABOLISM; (M5890)HALLMARK TNFA SIGNALING VIA NFKB
ENSG00000182871.16,ENSG00000182871,COL18A1,-1.020342429,-1.954888043,-1.093346623,-0.01279262,collagen type XVIII alpha 1 chain,"COL18A1 is a gene that encodes the alpha chain of type XVIII collagen, which is a multiplexin extracellular matrix protein. The protein has an N-terminal domain that is similar to the extracellular part of frizzled receptors. Proteolytic processing at several endogenous cleavage sites in the C-terminal domain results in the production of endostatin, a potent antiangiogenic protein that can inhibit angiogenesis and tumor growth. Mutations in this gene are associated with Knobloch syndrome, which involves retinal abnormalities, suggesting that type XVIII collagen may play a crucial role in retinal structure and neural tube closure. Alternative splicing results in multiple transcript variants.","Knobloch syndrome is a rare autosomal recessive disorder caused by mutations in the COL18A1 gene. The syndrome is characterized by severe ocular abnormalities, including retinal detachment, myopia, and glaucoma, as well as cranial defects such as occipital encephalocele. There is currently no cure for Knobloch syndrome, and treatment is mainly supportive, focusing on managing the ocular and neurological symptoms.

Targeted drug discovery efforts for Knobloch syndrome are limited due to the rarity of the disease and the lack of understanding of the underlying molecular mechanisms. However, research has shown that endostatin, a protein derived from the C-terminal domain of type XVIII collagen, has potent antiangiogenic properties and can inhibit tumor growth. This has led to the development of several endostatin-based drugs, including Endostar and Endostatin, which have shown promise in preclinical and clinical studies for the treatment of cancer.

In addition to its potential use in cancer therapy, endostatin has also been investigated for its potential use in treating ocular diseases, including retinal neovascularization and diabetic retinopathy. However, further research is needed to fully understand the therapeutic potential of endostatin and its derivatives in these conditions.

Overall, while there are currently no targeted therapies available for Knobloch syndrome, research into the molecular mechanisms underlying the disease and the potential therapeutic properties of endostatin may lead to the development of new treatments in the future.",GO:0051599 response to hydrostatic pressure;GO:0001886 endothelial cell morphogenesis;GO:0009415 response to water,,Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins; Predicted secreted proteins; Human disease related genes:Congenital malformations:Congenital malformations of eye; Disease related genes; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Candidate cancer biomarkers,Golgi apparatus (Approved),,(M5887)NABA BASEMENT MEMBRANES; (M285)PID HNF3A PATHWAY; (M3005)NABA COLLAGENS,
ENSG00000150347.16,ENSG00000150347,ARID5B,-1.019436081,-1.593317919,-1.066113699,-0.398876624,AT-rich interaction domain 5B,ARID5B is a gene that encodes a DNA binding protein belonging to the AT-rich interaction domain (ARID) family. It forms a complex with PHD finger protein 2 to regulate the transcription of genes involved in adipogenesis and liver development. The gene also plays a role in the growth and differentiation of B-lymphocyte progenitors. Single nucleotide polymorphisms in ARID5B have been associated with acute lymphoblastic leukemia. The gene has multiple isoforms due to alternative splicing.,"ARID5B has been implicated in several diseases, including acute lymphoblastic leukemia (ALL), obesity, and liver cancer. In particular, single nucleotide polymorphisms (SNPs) in ARID5B have been strongly associated with an increased risk of developing ALL, especially in children of European ancestry. This has led to efforts to develop targeted therapies for ALL that specifically target ARID5B. One example is the drug Venetoclax, which has been approved by the FDA for the treatment of certain types of leukemia and targets the BCL-2 protein, which is regulated by ARID5B. Another example is the drug Ibrutinib, which targets the B-cell receptor pathway and has shown promising results in preclinical studies for the treatment of ALL. Overall, the identification of ARID5B as a key player in the development of certain diseases has opened up new avenues for drug discovery and personalized medicine.",GO:0060613 fat pad development;GO:0010761 fibroblast migration;GO:0030325 adrenal gland development,,Predicted intracellular proteins; Transcription factors:Helix-turn-helix domains; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Endoplasmic reticulum (Approved); Additional: Cytosol;Nucleoplasm;Plasma membrane,,,(M5908)HALLMARK ANDROGEN RESPONSE; (M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000120733.14,ENSG00000120733,KDM3B,-1.01939949,-1.349824475,-0.931454766,-0.776919228,lysine demethylase 3B,"KDM3B is a human gene that encodes for a protein called lysine demethylase 3B. This protein is predicted to have several functions, including chromatin DNA binding activity, histone H3-methyl-lysine-9 demethylase activity, and transcription coregulator activity. It is also involved in histone H3-K9 demethylation and regulation of transcription by RNA polymerase II. KDM3B is located in the nucleoplasm and is a biomarker for several types of cancer, including acute lymphoblastic leukemia, breast cancer, colorectal cancer, and lung non-small cell carcinoma.","KDM3B has been implicated in several types of cancer, making it a potential target for drug discovery efforts. In acute lymphoblastic leukemia, KDM3B has been shown to promote cell proliferation and survival, and its inhibition has been found to induce apoptosis and reduce tumor growth in preclinical models. In breast cancer, KDM3B has been associated with poor prognosis and resistance to chemotherapy, and its inhibition has been shown to sensitize breast cancer cells to chemotherapy. In colorectal cancer, KDM3B has been found to promote tumor growth and metastasis, and its inhibition has been shown to reduce tumor growth and metastasis in preclinical models. In lung non-small cell carcinoma, KDM3B has been associated with poor prognosis and resistance to chemotherapy, and its inhibition has been shown to sensitize lung cancer cells to chemotherapy. While there are currently no drugs on the market that specifically target KDM3B, several small molecule inhibitors of KDM3B are in preclinical development and hold promise as potential cancer therapies.",GO:0098869 cellular oxidant detoxification;GO:1990748 cellular detoxification;GO:0097237 cellular response to toxic substance,,Predicted intracellular proteins; ENZYME proteins:Oxidoreductases; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Enzymes,Nucleoplasm (Enhanced),,,
ENSG00000162702.8,ENSG00000162702,ZNF281,-1.019104752,-1.313869669,-1.064168317,-0.67927627,zinc finger protein 281,ZNF281 is a human gene that encodes for a zinc finger protein 281. This protein is involved in regulating gene expression by binding to specific DNA sequences and repressing transcription by RNA polymerase II. It is also involved in positive regulation of transcription. ZNF281 is located in the nucleoplasm.,"There is limited information available on the disease implications of ZNF281. However, recent studies have suggested that ZNF281 may play a role in the development and progression of certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for ZNF281 are still in the early stages, but there is potential for the development of drugs that target this protein as a therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target ZNF281. However, there are several drugs that target other proteins involved in regulating gene expression, such as histone deacetylases (HDACs) and DNA methyltransferases (DNMTs), which have shown promise in cancer treatment. Further research is needed to fully understand the role of ZNF281 in disease and to develop targeted therapies for its regulation.",GO:0010172 embryonic body morphogenesis;GO:0010171 body morphogenesis;GO:0048863 stem cell differentiation,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000130589.16,ENSG00000130589,HELZ2,-1.018914785,-1.784772477,-0.705646403,-0.566325475,helicase with zinc finger 2,HELZ2 is a human gene that encodes a nuclear transcriptional co-activator for peroxisome proliferator activated receptor alpha. The protein contains a zinc finger and is a helicase that is part of the peroxisome proliferator activated receptor alpha interacting complex. HELZ2 is a member of the DNA2/NAM7 helicase gene family and has alternatively spliced transcript variants encoding different isoforms.,"There is limited information available on the disease implications of HELZ2. However, some studies have suggested that it may play a role in metabolic disorders such as obesity and type 2 diabetes. Targeted drug discovery efforts for HELZ2 are also limited, but some studies have explored the potential of targeting peroxisome proliferator activated receptor alpha (PPAR?), which interacts with HELZ2, for the treatment of metabolic disorders. Examples of successful drugs targeting PPAR? include fibrates such as fenofibrate and gemfibrozil, which are used to lower triglyceride levels and increase high-density lipoprotein cholesterol levels in patients with hyperlipidemia. However, it is important to note that these drugs have not been specifically developed to target HELZ2 and their effects on HELZ2 are not well understood.",GO:0140588 chromatin looping;GO:0035194 regulatory ncRNA-mediated post-transcriptional gene silencing;GO:0016441 post-transcriptional gene silencing,,Predicted intracellular proteins,,,,(M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000008869.12,ENSG00000008869,HEATR5B,-1.018387452,-1.364699584,-0.953694099,-0.736768674,HEAT repeat containing 5B,"HEATR5B is a human gene that is predicted to play a role in endocytosis, protein localization, and retrograde transport from endosomes to the Golgi. It is located in the membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of HEATR5B. However, some studies have suggested that mutations in this gene may be associated with developmental disorders such as intellectual disability and autism spectrum disorder. As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target HEATR5B. However, there are ongoing efforts to develop drugs that target endocytosis and retrograde transport pathways, which may indirectly affect the function of HEATR5B. For example, drugs that target the protein dynamin, which is involved in endocytosis, have been developed for the treatment of diseases such as hypercholesterolemia and pulmonary arterial hypertension. Additionally, drugs that target the retrograde transport pathway, such as brefeldin A, have been used in research to study the Golgi apparatus and its role in protein trafficking.","GO:0042147 retrograde transport, endosome to Golgi;GO:0016482 cytosolic transport;GO:0016197 endosomal transport",,Predicted intracellular proteins,Golgi apparatus;Vesicles (Supported); Additional: Cytosol;Nucleoplasm,,,
ENSG00000075420.13,ENSG00000075420,FNDC3B,-1.018157112,-1.54038108,-0.978156096,-0.535934161,fibronectin type III domain containing 3B,"FNDC3B is a human gene that encodes a protein containing fibronectin type III domains. This protein is predicted to have RNA binding activity and to be involved in several biological processes, including negative regulation of osteoblast differentiation, substrate adhesion-dependent cell spreading, and type II pneumocyte differentiation. It is also predicted to be located in the endoplasmic reticulum.","FNDC3B has been implicated in several diseases, including cancer and osteoporosis. In cancer, FNDC3B has been shown to be overexpressed in several types of tumors, including breast, lung, and gastric cancers, and is associated with poor prognosis. Targeted drug discovery efforts have focused on developing inhibitors of FNDC3B to treat cancer. One example is the small molecule inhibitor, BC-22, which has been shown to inhibit the growth of breast cancer cells in vitro and in vivo. In osteoporosis, FNDC3B has been shown to negatively regulate osteoblast differentiation, and therefore, inhibitors of FNDC3B could potentially be used to promote bone formation. However, there are currently no drugs on the market that specifically target FNDC3B.",,,Predicted intracellular proteins,Endoplasmic reticulum (Approved),,,
ENSG00000180776.16,ENSG00000180776,ZDHHC20,-1.016248754,-0.987350594,-1.194899035,-0.866496632,zinc finger DHHC-type palmitoyltransferase 20,"ZDHHC20 is a human gene that encodes for a protein called zinc finger DHHC-type palmitoyltransferase 20. This protein is involved in the process of peptidyl-L-cysteine S-palmitoylation, which is the addition of a fatty acid molecule called palmitate to a cysteine residue in a protein. ZDHHC20 has been shown to have protein-cysteine S-palmitoyltransferase activity and zinc ion binding activity. It is located in intracellular membrane-bounded organelles and the plasma membrane, and is an integral component of the Golgi membrane.","There is limited information available on the disease implications of ZDHHC20. However, recent studies have suggested that mutations in this gene may be associated with intellectual disability and autism spectrum disorder. Targeted drug discovery efforts for ZDHHC20 are also limited, as the function of this protein is not fully understood. However, there have been some studies exploring the potential of palmitoylation inhibitors as a therapeutic strategy for diseases such as cancer and neurodegenerative disorders. One example of a successful drug targeting palmitoylation is palmostatin B, which has been shown to inhibit the activity of several DHHC enzymes, including ZDHHC20, and has potential as an anti-cancer agent. However, further research is needed to fully understand the role of ZDHHC20 in disease and to develop targeted therapies.",GO:0018230 peptidyl-L-cysteine S-palmitoylation;GO:0018231 peptidyl-S-diacylglycerol-L-cysteine biosynthetic process from peptidyl-cysteine;GO:0044794 positive regulation by host of viral process,,Transporters:Accessory Factors Involved in Transport; Enzymes; ENZYME proteins:Transferases,Plasma membrane;Vesicles (Supported),,,
ENSG00000113282.14,ENSG00000113282,CLINT1,-1.016213079,-1.162717226,-0.934128417,-0.951793594,clathrin interactor 1,"CLINT1, or clathrin interactor 1, is a gene that encodes a protein similar to the epsin family of endocytic adapter proteins. The protein interacts with clathrin, AP-1 adapter protein, and phosphoinositides, and may play a role in the formation of clathrin coated vesicles and trafficking between the trans-Golgi network and endosomes. Mutations in this gene have been linked to a susceptibility to schizophrenia and psychotic disorders. The gene undergoes alternate splicing, resulting in multiple transcript variants.","Mutations in the CLINT1 gene have been associated with an increased susceptibility to schizophrenia and other psychotic disorders. This suggests that the protein encoded by this gene may play a role in the development of these conditions. However, further research is needed to fully understand the mechanisms involved.

There are currently no drugs specifically targeting CLINT1, as it is not yet fully understood how the protein functions in the body. However, there are several drugs on the market that target related proteins involved in endocytosis and vesicle trafficking, such as clathrin and AP-1. For example, chlorpromazine and haloperidol are antipsychotic drugs that act by blocking dopamine receptors, but they also inhibit clathrin-mediated endocytosis. Another example is amantadine, which is used to treat Parkinson's disease and acts by inhibiting the formation of clathrin-coated vesicles.

Overall, while the exact role of CLINT1 in disease is still being investigated, drugs targeting related proteins involved in endocytosis and vesicle trafficking have shown promise in treating a variety of conditions.",GO:0048268 clathrin coat assembly;GO:0006897 endocytosis;GO:0098657 import into cell,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Vesicles (Supported); Additional: Nucleoplasm,,,
ENSG00000188559.15,ENSG00000188559,RALGAPA2,-1.015968968,-1.506315103,-0.771680521,-0.769911281,Ral GTPase activating protein catalytic subunit alpha 2,"RALGAPA2 is a human gene that is predicted to have GTPase activator activity and protein heterodimerization activity. It is also predicted to be involved in the activation of GTPase activity and to act upstream of or within Ral protein signal transduction. Additionally, it is involved in the regulation of exocyst localization and protein localization. RALGAPA2 is located in the cytosol and plasma membrane.","There is limited information available on the disease implications of RALGAPA2. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for RALGAPA2 are also limited, as the function of this gene is not well understood. However, some studies have suggested that targeting Ral proteins, which are downstream effectors of RALGAPA2, may have therapeutic potential in cancer treatment. One example of a successful drug targeting Ral proteins is AMG 510, which is a small molecule inhibitor of KRAS G12C, a Ral protein that is frequently mutated in cancer. AMG 510 has shown promising results in clinical trials for the treatment of non-small cell lung cancer and other solid tumors.",GO:0090630 activation of GTPase activity;GO:0043547 positive regulation of GTPase activity;GO:0043087 regulation of GTPase activity,,Predicted intracellular proteins; RAS pathway related proteins,Cytosol;Plasma membrane (Supported),,,
ENSG00000154114.12,ENSG00000154114,TBCEL,-1.014103681,-1.642954232,-1.162669674,-0.236687138,tubulin folding cofactor E like,"TBCEL is a human gene that is predicted to be involved in the organization of the microtubule cytoskeleton, post-chaperonin tubulin folding pathway, and tubulin complex assembly. It is also predicted to enable alpha-tubulin binding activity and is located in the cytoskeleton, with activity in the cytoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for TBCEL. However, as it is involved in the organization of the microtubule cytoskeleton, it may have implications in diseases related to abnormal microtubule function, such as cancer and neurodegenerative disorders. 

There are currently no drugs on the market that specifically target TBCEL. However, there are drugs that target microtubules, such as taxanes and vinca alkaloids, which are used in the treatment of cancer. These drugs work by disrupting microtubule function, leading to cell death. Additionally, there are drugs that target the post-chaperonin tubulin folding pathway, such as colchicine, which is used in the treatment of gout and other inflammatory conditions. 

Further research is needed to fully understand the role of TBCEL in disease and to develop targeted therapies for related conditions.",GO:0007023 post-chaperonin tubulin folding pathway;GO:0007021 tubulin complex assembly;GO:0006457 protein folding,,Predicted intracellular proteins,Cytosol (Uncertain),,,
ENSG00000113384.14,ENSG00000113384,GOLPH3,-1.013216763,-1.385417458,-1.034872772,-0.61936006,golgi phosphoprotein 3,"GOLPH3 is a gene that encodes a peripheral membrane protein found in the Golgi complex. The Golgi complex is responsible for sorting and modifying proteins that are exported from the endoplasmic reticulum. GOLPH3 may have a regulatory role in Golgi trafficking. There are several different versions of the GOLPH3 gene that have been identified, but it is not yet clear what the full-length nature of these variants is.","Research has shown that GOLPH3 may play a role in the development and progression of various types of cancer, including breast, lung, and liver cancer. Overexpression of GOLPH3 has been associated with increased tumor growth and metastasis. As a result, GOLPH3 has been identified as a potential therapeutic target for cancer treatment. Several drug discovery efforts have focused on developing small molecule inhibitors of GOLPH3, with promising results in preclinical studies. However, no GOLPH3-targeted drugs have yet been approved for clinical use. Examples of successful drugs on the market that target other proteins involved in Golgi trafficking include brefeldin A, which inhibits the function of the Golgi complex, and golimumab, which targets the pro-inflammatory cytokine TNF-alpha.",GO:0090164 asymmetric Golgi ribbon formation;GO:0060352 cell adhesion molecule production;GO:0072752 cellular response to rapamycin,,Predicted intracellular proteins,Golgi apparatus;Vesicles (Supported),,,
ENSG00000110237.5,ENSG00000110237,ARHGEF17,-1.01283094,-1.676642322,-0.824344685,-0.537505814,Rho guanine nucleotide exchange factor 17,"ARHGEF17 is a human gene that encodes for a protein called Rho guanine nucleotide exchange factor 17. This protein is involved in the regulation of the actin cytoskeleton, which is important for cell movement and shape. ARHGEF17 functions as a guanyl-nucleotide exchange factor, meaning it activates Rho GTPases, which are proteins that control actin dynamics. ARHGEF17 is predicted to be located in the cytosol, the fluid inside cells where many cellular processes occur. Overall, ARHGEF17 plays a role in the organization of the actin cytoskeleton and is important for cellular functions such as cell migration and division.","There is limited information available on the disease implications of ARHGEF17. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for ARHGEF17 are also limited, but some studies have explored the potential of targeting Rho GTPases, which are activated by ARHGEF17, as a therapeutic strategy for cancer. One example of a successful drug targeting Rho GTPases is the drug Fasudil, which is used to treat cerebral vasospasm after subarachnoid hemorrhage. Fasudil inhibits Rho kinase, which is downstream of Rho GTPases, and has been shown to improve outcomes in clinical trials. However, more research is needed to fully understand the potential therapeutic implications of targeting ARHGEF17 and its downstream pathways.",GO:0051056 regulation of small GTPase mediated signal transduction;GO:0030036 actin cytoskeleton organization;GO:0030029 actin filament-based process,,Predicted intracellular proteins,Cytosol (Approved); Additional: Plasma membrane,,(M68)PID RHOA REG PATHWAY,
ENSG00000097007.19,ENSG00000097007,ABL1,-1.012600541,-1.671449656,-1.10975481,-0.256597158,"ABL proto-oncogene 1, non-receptor tyrosine kinase","ABL1 is a proto-oncogene that encodes a protein tyrosine kinase involved in various cellular processes, including cell division, adhesion, differentiation, and response to stress. The protein's activity is negatively regulated by its SH3 domain, and deletion of this domain results in an oncogene. The protein has DNA-binding activity regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. ABL1 has been found fused to various translocation partner genes in different leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons spliced to the remaining common exons.","ABL1 has been implicated in various types of cancer, including chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and non-small cell lung cancer (NSCLC). The t(9;22) translocation, which results in the BCR-ABL1 fusion protein, is a hallmark of CML and is also found in some cases of ALL. Targeted drug discovery efforts have focused on developing inhibitors of the ABL1 kinase activity, with the goal of blocking the oncogenic signaling pathways activated by the BCR-ABL1 fusion protein. Imatinib, a tyrosine kinase inhibitor that targets BCR-ABL1, was the first drug approved for the treatment of CML and has revolutionized the management of this disease. Other ABL1 inhibitors, such as dasatinib and nilotinib, have also been developed and are used in the treatment of CML and other cancers. These drugs have shown significant clinical efficacy and have improved the prognosis for patients with ABL1-driven cancers.",GO:1904518 protein localization to cytoplasmic microtubule plus-end;GO:1904529 regulation of actin filament binding;GO:1904531 positive regulation of actin filament binding,yes,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Kinases:Tyr protein kinases; RAS pathway related proteins; Predicted intracellular proteins; ENZYME proteins:Transferases; FDA approved drug targets:Small molecule drugs; Disease related genes; Enzymes; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported); Additional: Nuclear bodies,"ATP; Imatinib; Dasatinib; N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide; Nilotinib; XL228; Bosutinib; 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE; 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA; Myristic acid; PD-166326; 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE; 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide; Regorafenib; Ponatinib; Fostamatinib; Brigatinib; Radotinib",(M163)PID LIS1 PATHWAY; (M84)PID ATM PATHWAY; (M142)PID AJDISS 2PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE; (M5901)HALLMARK G2M CHECKPOINT
ENSG00000223501.9,ENSG00000223501,VPS52,-1.012127441,-1.676966639,-1.222702216,-0.136713468,VPS52 subunit of GARP complex,The human gene VPS52 encodes a protein that is similar to the yeast suppressor of actin mutations 2 gene. This protein forms a subunit of the tetrameric Golgi-associated retrograde protein complex (GARP) that is involved in vesicle trafficking from both early and late endosomes back to the trans-Golgi network. The gene is located on chromosome 6 and is in a head-to-head orientation with the gene encoding ribosomal protein S18. Alternative splicing results in multiple transcript variants.,"There is limited information available on the disease implications of the VPS52 gene. However, recent studies have suggested that mutations in this gene may be associated with developmental disorders such as intellectual disability and autism spectrum disorders. Targeted drug discovery efforts for VPS52 are currently underway, with a focus on identifying small molecule inhibitors that can modulate the activity of the GARP complex. While there are currently no drugs on the market that specifically target VPS52, there are several drugs that target other components of the GARP complex, such as the drug bafilomycin A1, which inhibits the activity of the vacuolar ATPase and disrupts vesicle trafficking. Additionally, the drug chloroquine has been shown to inhibit the activity of the GARP complex and has been used in the treatment of malaria and autoimmune disorders.",GO:0007439 ectodermal digestive tract development;GO:0048611 embryonic ectodermal digestive tract development;GO:0010668 ectodermal cell differentiation,,Predicted intracellular proteins,,,,
ENSG00000055332.18,ENSG00000055332,EIF2AK2,-1.011501414,-1.510187077,-0.936775902,-0.587541262,eukaryotic translation initiation factor 2 alpha kinase 2,"EIF2AK2 is a gene that encodes a serine/threonine protein kinase. This protein kinase is activated by autophosphorylation after binding to double-stranded RNA. The activated form of the protein can phosphorylate translation initiation factor EIF2S1, which inhibits protein synthesis. The protein is also activated by manganese ions and heparin. EIF2AK2 plays a crucial role in the innate immune response against multiple DNA and RNA viruses.","EIF2AK2 has been implicated in several diseases, including viral infections, autoimmune diseases, and cancer. In viral infections, EIF2AK2 plays a critical role in the innate immune response by inhibiting viral protein synthesis. However, some viruses have evolved mechanisms to evade the host immune response by inhibiting EIF2AK2 activity. In autoimmune diseases, EIF2AK2 has been shown to be involved in the activation of immune cells and the production of pro-inflammatory cytokines. In cancer, EIF2AK2 has been found to be overexpressed in several types of tumors, and its inhibition has been shown to reduce tumor growth in preclinical models.

Several drug discovery efforts have targeted EIF2AK2 for the treatment of viral infections and cancer. For viral infections, small molecule inhibitors of EIF2AK2 have been developed, including GCN2 inhibitors and PERK inhibitors. These inhibitors have shown promising results in preclinical studies, but none have yet been approved for clinical use. In cancer, EIF2AK2 inhibitors have been shown to reduce tumor growth in preclinical models, and several compounds are currently in clinical trials for the treatment of various types of cancer.

One example of a successful drug targeting EIF2AK2 is ribavirin, which is used to treat hepatitis C virus (HCV) infection. Ribavirin works by inhibiting viral protein synthesis, in part by activating EIF2AK2. Another example is the drug imatinib, which is used to treat chronic myeloid leukemia (CML). Imatinib has been shown to inhibit EIF2AK2 activity, which may contribute to its anti-tumor effects.",GO:0033689 negative regulation of osteoblast proliferation;GO:1902033 regulation of hematopoietic stem cell proliferation;GO:1902036 regulation of hematopoietic stem cell differentiation,yes,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Predicted intracellular proteins; Kinases; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Cytosol (Enhanced),Fostamatinib,(M91)PID TCPTP PATHWAY; (M144)PID CERAMIDE PATHWAY; (M186)PID PDGFRB PATHWAY,(M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5913)HALLMARK INTERFERON GAMMA RESPONSE; (M5932)HALLMARK INFLAMMATORY RESPONSE
ENSG00000173456.5,ENSG00000173456,RNF26,-1.011168445,-1.854754389,-0.897617927,-0.281133019,ring finger protein 26,"RNF26, or ring finger protein 26, is a gene that encodes a protein containing a specific type of RING finger motif. This motif is known to be involved in interactions between proteins and DNA or other proteins. The gene has no introns and has been found to be upregulated in cancer cell lines from various types of cancer.","Research on RNF26 has suggested that it may play a role in the development and progression of various types of cancer, including breast, lung, and ovarian cancer. In particular, RNF26 has been found to be overexpressed in cancer cells and to promote tumor growth and metastasis. As a result, there has been interest in developing drugs that target RNF26 as a potential treatment for cancer.

One approach to targeting RNF26 is to inhibit its activity using small molecules or other compounds. Several studies have identified potential inhibitors of RNF26, including natural compounds such as curcumin and synthetic compounds such as NSC697923. However, there are currently no drugs on the market that specifically target RNF26.

Despite the lack of approved drugs targeting RNF26, there have been some successful examples of drugs that target related proteins in the same family as RNF26. For example, bortezomib is a proteasome inhibitor that is used to treat multiple myeloma and mantle cell lymphoma by targeting a different RING finger protein called RNF5. Similarly, the drug lenalidomide targets a protein called cereblon, which contains a RING finger domain, and is used to treat multiple myeloma and other blood cancers. These examples suggest that targeting RNF26 or other RING finger proteins could be a promising approach for developing new cancer therapies.",GO:1905719 protein localization to perinuclear region of cytoplasm;GO:0050687 negative regulation of defense response to virus;GO:0070979 protein K11-linked ubiquitination,,Enzymes; ENZYME proteins:Transferases,Nucleoplasm (Approved); Additional: Cytosol;Vesicles,,,
ENSG00000167461.12,ENSG00000167461,RAB8A,-1.011099055,-1.383341698,-1.197697008,-0.452258461,"RAB8A, member RAS oncogene family","RAB8A is a human gene that belongs to the RAS superfamily of small GTP/GDP-binding proteins. It is involved in the transport of proteins from the endoplasmic reticulum to the Golgi and the plasma membrane. The protein shares high similarity with RAB8 in dogs, MEL in mice, and YPT1 in mice. It contains four GTP/GDP-binding sites and a putative effector-binding site similar to other RAB/YPT proteins. However, it also has a C-terminal CAAX motif that is characteristic of many RAS superfamily members but not found in YPT1 and most RAB proteins. Although it was isolated as a transforming gene from a melanoma cell line, no link between MEL and malignant melanoma has been demonstrated. The gene is located on chromosome 19p13.1, 800 kb distal to MY09B.","RAB8A has been implicated in several diseases, including Bardet-Biedl syndrome, a rare genetic disorder characterized by obesity, retinal degeneration, and kidney abnormalities. Mutations in RAB8A have also been associated with cone-rod dystrophy, a group of inherited eye disorders that affect the retina. Targeted drug discovery efforts for RAB8A are currently limited, but there is ongoing research into the development of small molecule inhibitors that could potentially modulate its activity. Currently, there are no drugs on the market that specifically target RAB8A, but there are several drugs that indirectly affect its function, such as bortezomib, which is used to treat multiple myeloma and inhibits the proteasome, a cellular complex that regulates RAB8A activity. Additionally, some drugs that target other members of the RAS superfamily, such as farnesyltransferase inhibitors, have shown promise in preclinical studies for the treatment of diseases associated with RAB8A dysfunction.","GO:0048210 Golgi vesicle fusion to target membrane;GO:0098887 neurotransmitter receptor transport, endosome to postsynaptic membrane;GO:0099639 neurotransmitter receptor transport, endosome to plasma membrane",,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Basal body;Nucleoplasm;Plasma membrane (Supported); Additional: Actin filaments;Centriolar satellite;Cytosol;Golgi apparatus;Nucleoli;Primary cilium,,,
ENSG00000140632.17,ENSG00000140632,GLYR1,-1.009272422,-1.619809664,-0.855608256,-0.552399346,glyoxylate reductase 1 homolog,"GLYR1, also known as glyoxylate reductase 1 homolog, is a human gene that encodes a protein involved in DNA binding, methylated histone binding, and nucleosome binding activities. It plays a role in positive regulation of histone acetylation and transcription by RNA polymerase II. The protein is located in the cytosol and nucleoplasm and is a part of the nucleosome. GLYR1 is important for the regulation of gene expression and may have implications in various diseases.","There is limited information available on the disease implications of GLYR1. However, some studies have suggested that GLYR1 may play a role in cancer development and progression. For example, one study found that GLYR1 expression was significantly upregulated in breast cancer tissues compared to normal tissues. Additionally, GLYR1 has been identified as a potential therapeutic target for the treatment of acute myeloid leukemia (AML).

There are currently no targeted drug discovery efforts specifically focused on GLYR1. However, there are several drugs on the market that target histone acetylation and transcription, which are processes that GLYR1 is involved in. For example, histone deacetylase (HDAC) inhibitors such as vorinostat and romidepsin have been approved for the treatment of cutaneous T-cell lymphoma. Additionally, bromodomain and extra-terminal (BET) inhibitors such as JQ1 have shown promise in preclinical studies for the treatment of various cancers.

Overall, while GLYR1 is not currently a major focus of drug discovery efforts, its involvement in histone acetylation and transcription suggests that it may have potential as a therapeutic target for certain diseases, particularly cancer.",GO:0140673 transcription elongation-coupled chromatin remodeling;GO:0006368 transcription elongation by RNA polymerase II;GO:0006354 DNA-templated transcription elongation,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000118197.14,ENSG00000118197,DDX59,-1.008880995,-1.281209979,-1.126716931,-0.618716073,DEAD-box helicase 59,"DDX59 is a human gene that encodes for a protein called DEAD-box helicase 59. This protein is predicted to have RNA binding and RNA helicase activity, and is expected to be located in both the cytoplasm and nucleus of cells. Additionally, it is predicted to be an integral component of the cell membrane. Mutations in this gene have been linked to orofaciodigital syndrome V, a rare genetic disorder characterized by abnormalities in the face, oral cavity, and digits.","Orofaciodigital syndrome V (OFD5) is a rare genetic disorder caused by mutations in the DDX59 gene. OFD5 is characterized by abnormalities in the face, oral cavity, and digits, including cleft lip and palate, tongue abnormalities, and extra fingers or toes. There is currently no cure for OFD5, and treatment is focused on managing symptoms. 

As DDX59 is a relatively newly discovered gene, there are currently no targeted drug discovery efforts or drugs on the market specifically for OFD5. However, research into the function of DDX59 and its role in OFD5 may lead to the development of targeted therapies in the future. 

In general, targeted drug discovery efforts for genetic disorders often focus on identifying small molecules or biologics that can correct or compensate for the genetic defect. For example, in the case of cystic fibrosis, a genetic disorder caused by mutations in the CFTR gene, several drugs have been developed that target the defective protein and improve lung function. These include ivacaftor, lumacaftor, and tezacaftor. 

In conclusion, while there are currently no targeted drug discovery efforts or drugs on the market for OFD5, continued research into the function of DDX59 and its role in the disorder may lead to the development of targeted therapies in the future.",GO:0140588 chromatin looping;GO:0006338 chromatin remodeling;GO:0006325 chromatin organization,,Predicted intracellular proteins; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Actin filaments (Approved); Additional: Basal body;Nucleoplasm,,,
ENSG00000149503.13,ENSG00000149503,INCENP,-1.008626608,-1.298698435,-0.900017689,-0.827163701,inner centromere protein,"INCENP (inner centromere protein) is a member of the passenger protein group that localizes to the centromere during specific stages of the cell cycle. It displays a broad localization along chromosomes in the early stages of mitosis but gradually becomes concentrated at centromeres as the cell cycle progresses into mid-metaphase. During telophase, the proteins are located within the midbody in the intercellular bridge, where they are discarded after cytokinesis. INCENP is an important protein for proper chromosome segregation during cell division and mutations in the gene have been associated with various types of cancer.","Mutations in the INCENP gene have been associated with various types of cancer, including breast, lung, and ovarian cancer. Targeted drug discovery efforts have focused on developing inhibitors of the Aurora B kinase, which is a key regulator of INCENP function during mitosis. Several Aurora B kinase inhibitors have been developed and are currently in clinical trials for the treatment of cancer, including AZD1152, barasertib, and GSK1070916. One successful drug on the market is alisertib (MLN8237), which is an orally available Aurora A and B kinase inhibitor that has shown promising results in clinical trials for the treatment of various types of cancer, including lymphoma and solid tumors. However, further research is needed to fully understand the role of INCENP in cancer and to develop more effective targeted therapies.",GO:0051257 meiotic spindle midzone assembly;GO:1902425 positive regulation of attachment of mitotic spindle microtubules to kinetochore;GO:1902423 regulation of attachment of mitotic spindle microtubules to kinetochore,,Predicted intracellular proteins,Kinetochore;Nuclear bodies (Supported); Additional: Midbody;Nucleoplasm,Reversine,(M14)PID AURORA B PATHWAY; (M129)PID PLK1 PATHWAY; (M223)PID BETA CATENIN NUC PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE; (M5901)HALLMARK G2M CHECKPOINT
ENSG00000101109.12,ENSG00000101109,STK4,-1.007322676,-1.326900177,-0.615375711,-1.079692141,serine/threonine kinase 4,"STK4, also known as serine/threonine kinase 4, is a cytoplasmic kinase that is structurally similar to the yeast Ste20p kinase. It acts upstream of the stress-induced mitogen-activated protein kinase cascade and can phosphorylate myelin basic protein and undergoes autophosphorylation. The protein has been shown to induce chromatin condensation observed in apoptosis, and a caspase-cleaved fragment of the protein can phosphorylate histone H2B. The phosphorylation catalyzed by STK4 has been correlated with apoptosis, suggesting that it plays a role in this process.","STK4 has been implicated in various diseases, including cancer, neurodegenerative disorders, and immune-related diseases. In cancer, STK4 has been shown to act as a tumor suppressor, and its loss or inactivation has been associated with the development and progression of various cancers, including breast, lung, and pancreatic cancer. Targeted drug discovery efforts have focused on developing small molecule inhibitors of STK4 as potential cancer therapeutics. However, there are currently no FDA-approved drugs targeting STK4.

One example of a successful drug targeting a related kinase is Imatinib, which targets the BCR-ABL fusion protein in chronic myeloid leukemia. Another example is Vemurafenib, which targets the mutated BRAF protein in melanoma. These drugs have revolutionized the treatment of these cancers and have significantly improved patient outcomes. However, developing drugs targeting STK4 may be challenging due to its role in normal cellular processes, and any potential inhibitors would need to be carefully evaluated for their safety and efficacy.","GO:1903945 positive regulation of hepatocyte apoptotic process;GO:1904235 regulation of substrate-dependent cell migration, cell attachment to substrate;GO:1904237 positive regulation of substrate-dependent cell migration, cell attachment to substrate",yes,Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes; Kinases:STE Ser/Thr protein kinases; RAS pathway related proteins,Nuclear bodies (Supported); Additional: Cytosol;Nucleoplasm,,,
ENSG00000150760.13,ENSG00000150760,DOCK1,-1.007313646,-1.618366133,-1.22494051,-0.178634294,dedicator of cytokinesis 1,"DOCK1 is a gene that belongs to the dedicator of cytokinesis protein family. This gene encodes a protein that acts as a guanine nucleotide exchange factor for small Rho family G proteins. The protein regulates the small GTPase Rac, which affects various biological processes such as phagocytosis and cell migration. Multiple transcript variants are produced due to alternative splicing. Overexpression of DOCK1 has been linked to certain types of cancer.","DOCK1 has been implicated in various diseases, including cancer, immune disorders, and neurological disorders. Overexpression of DOCK1 has been observed in several types of cancer, including breast, lung, and pancreatic cancer, and is associated with tumor progression and metastasis. Therefore, DOCK1 has been identified as a potential therapeutic target for cancer treatment. Several small molecule inhibitors of DOCK1 have been developed and tested in preclinical studies, including CPYPP and RK-24466. However, no DOCK1 inhibitors have been approved for clinical use yet.

In addition to cancer, DOCK1 has also been linked to immune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). In SLE patients, DOCK1 expression is upregulated in B cells, and inhibition of DOCK1 has been shown to reduce autoantibody production in vitro. In RA patients, DOCK1 expression is increased in synovial tissue, and DOCK1 inhibition has been shown to reduce inflammation and joint destruction in animal models.

In the field of neurological disorders, DOCK1 has been implicated in Alzheimer's disease (AD) and schizophrenia. In AD patients, DOCK1 expression is increased in the hippocampus, and DOCK1 inhibition has been shown to improve cognitive function in animal models. In schizophrenia patients, DOCK1 expression is decreased in the prefrontal cortex, and DOCK1 inhibition has been shown to improve cognitive deficits in animal models.

Overall, DOCK1 is a promising therapeutic target for various diseases, including cancer, immune disorders, and neurological disorders. While several small molecule inhibitors of DOCK1 have been developed, further research is needed to determine their efficacy and safety in clinical trials.","GO:0007520 myoblast fusion;GO:0006911 phagocytosis, engulfment;GO:0000768 syncytium formation by plasma membrane fusion",,Predicted intracellular proteins,Cytosol;Nucleoplasm (Approved); Additional: Actin filaments;Focal adhesion sites;Nucleoli;Plasma membrane,,(M108)PID NETRIN PATHWAY; (M277)PID INTEGRIN A4B1 PATHWAY; (M241)PID RAC1 REG PATHWAY,
ENSG00000100934.15,ENSG00000100934,SEC23A,-1.006967296,-1.220474071,-0.997258942,-0.803168876,"SEC23 homolog A, COPII coat complex component","SEC23A is a human gene that encodes a protein belonging to the SEC23 subfamily of the SEC23/SEC24 family. This protein is a component of the COPII coat complex, which is responsible for vesicle budding from the endoplasmic reticulum (ER). SEC23A is found in the ribosome-free transitional face of the ER and associated vesicles. It is suggested to play a role in the trafficking of proteins from the ER to the Golgi apparatus. The protein has similarity to the yeast Sec23p component of COPII. This gene summary was provided by RefSeq in July 2008.","Mutations in the SEC23A gene have been associated with a rare genetic disorder called congenital dyserythropoietic anemia type II (CDAII). CDAII is characterized by ineffective erythropoiesis, resulting in anemia, jaundice, and splenomegaly. There are currently no targeted drug discovery efforts for SEC23A, as it is primarily involved in intracellular protein trafficking and not considered a druggable target. However, there are several drugs on the market that target other components of the COPII complex, such as Saroglitazar and Lomitapide, which are used to treat dyslipidemia and familial hypercholesterolemia, respectively. These drugs work by inhibiting the function of the COPII complex, which reduces the secretion of lipids and cholesterol from cells.",GO:0090110 COPII-coated vesicle cargo loading;GO:0035459 vesicle cargo loading;GO:0090114 COPII-coated vesicle budding,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Predicted intracellular proteins,Cytosol;Endoplasmic reticulum (Supported),,,
ENSG00000138246.17,ENSG00000138246,DNAJC13,-1.006092073,-1.250267176,-0.988716384,-0.779292659,DnaJ heat shock protein family (Hsp40) member C13,"DNAJC13 is a gene that encodes a member of the Dnaj protein family. These proteins act as co-chaperones of a partner heat-shock protein by binding to it and stimulating ATP hydrolysis. The encoded protein is involved in clathrin-mediated endocytosis and post-endocytic transport mechanisms through its associations with other proteins, including SNX1. Mutations in this gene have been linked to Parkinson's disease. The protein also associates with the heat-shock protein Hsc70.","Mutations in the DNAJC13 gene have been associated with an increased risk of developing Parkinson's disease. This has led to efforts to develop drugs that target the protein encoded by this gene as a potential therapeutic strategy for Parkinson's disease. One example of a drug that has been developed to target DNAJC13 is the small molecule compound ML241. This compound has been shown to inhibit the interaction between DNAJC13 and Hsc70, which could potentially reduce the accumulation of alpha-synuclein, a protein that is implicated in the development of Parkinson's disease. However, further research is needed to determine the efficacy and safety of ML241 and other potential drugs targeting DNAJC13.",GO:1902954 regulation of early endosome to recycling endosome transport;GO:2000641 regulation of early endosome to late endosome transport;GO:0007032 endosome organization,,Disease related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases,Vesicles (Supported); Additional: Cytosol,,,
ENSG00000139793.18,ENSG00000139793,MBNL2,-1.005966063,-1.413420116,-0.930215878,-0.674262193,muscleblind like splicing regulator 2,"MBNL2 is a gene that encodes a protein belonging to the muscleblind family. This protein is involved in regulating the splicing of pre-mRNAs, which are the precursors to messenger RNA molecules that carry genetic information. Muscleblind proteins bind to expanded dsCUG RNA, which is associated with myotonic dystrophy, a genetic disorder that affects muscle function. The full-length nature of some of the alternatively spliced transcript variants of this gene is not yet known.","Myotonic dystrophy (DM) is a genetic disorder that affects muscle function and is caused by the expansion of CTG or CCTG repeats in the 3' untranslated region of the DMPK or ZNF9 genes, respectively. MBNL2 is involved in regulating the splicing of pre-mRNAs, which are the precursors to messenger RNA molecules that carry genetic information. Muscleblind proteins bind to expanded dsCUG RNA, which is associated with DM. Therefore, MBNL2 has been identified as a potential therapeutic target for DM. Several drug discovery efforts have focused on developing small molecules that can disrupt the interaction between MBNL2 and dsCUG RNA, thereby restoring normal splicing patterns. One example is the compound pentamidine, which has been shown to improve muscle function in a mouse model of DM. Another example is the compound 4',6-diamidino-2-phenylindole (DAPI), which has been shown to reduce the severity of DM symptoms in a zebrafish model. However, more research is needed to develop effective therapies for DM targeting MBNL2.",GO:0043484 regulation of RNA splicing;GO:0008380 RNA splicing;GO:0006397 mRNA processing,,Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000196757.8,ENSG00000196757,ZNF700,-1.005561382,-1.12783792,-1.245019682,-0.643826544,zinc finger protein 700,"ZNF700 is a human gene that encodes for a zinc finger protein 700. This protein is predicted to have DNA-binding transcription factor activity, specifically for RNA polymerase II and RNA polymerase II transcription regulatory region sequence-specific DNA binding activity. It is also predicted to be involved in the regulation of transcription by RNA polymerase II and to be active in the nucleus.","There is limited information available on the disease implications of ZNF700. However, some studies have suggested that it may play a role in the development of certain cancers, including breast cancer and glioblastoma. As for targeted drug discovery efforts, there are currently no known drugs that specifically target ZNF700. However, there are ongoing efforts to develop drugs that target other proteins involved in the regulation of transcription, which may indirectly affect ZNF700 activity. Examples of successful drugs on the market that target transcription factors include tamoxifen, which is used to treat breast cancer by blocking the activity of estrogen receptors, and imatinib, which is used to treat chronic myeloid leukemia by inhibiting the activity of the BCR-ABL fusion protein.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Uncertain),,,
ENSG00000130402.13,ENSG00000130402,ACTN4,-1.005195814,-1.633067614,-1.146900049,-0.23561978,actinin alpha 4,"ACTN4 is a gene that encodes for the nonmuscle isoform of alpha actinin, a cytoskeletal protein that binds actin to the membrane. Alpha actinins belong to the spectrin gene superfamily and have multiple roles in different cell types. The nonmuscle isoform of alpha actinin is concentrated in the cytoplasm and is thought to be involved in metastatic processes. Mutations in ACTN4 have been associated with focal and segmental glomerulosclerosis, a kidney disease characterized by scarring of the glomeruli, the tiny blood vessels in the kidneys that filter waste from the blood.","Mutations in ACTN4 have been associated with focal and segmental glomerulosclerosis (FSGS), a kidney disease characterized by scarring of the glomeruli, the tiny blood vessels in the kidneys that filter waste from the blood. FSGS can lead to kidney failure and the need for dialysis or kidney transplantation. Targeted drug discovery efforts for FSGS have focused on identifying compounds that can inhibit the activity of the mutated ACTN4 protein or prevent its aggregation in the glomeruli. One example of a successful drug on the market for FSGS is Sparsentan, a dual angiotensin receptor blocker and endothelin receptor antagonist that has shown promising results in clinical trials. Another drug in development for FSGS is TRPC5 inhibitor, which targets a calcium channel that is activated by the mutated ACTN4 protein.",GO:0032415 regulation of sodium:proton antiporter activity;GO:0032417 positive regulation of sodium:proton antiporter activity;GO:0030050 vesicle transport along actin filament,,Disease related genes; Human disease related genes:Urinary system diseases:Kidney diseases; Predicted intracellular proteins,Actin filaments;Focal adhesion sites (Approved); Additional: Cytosol;Primary cilium;Primary cilium transition zone,,(M186)PID PDGFRB PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE; (M5915)HALLMARK APICAL JUNCTION
ENSG00000107854.6,ENSG00000107854,TNKS2,-1.004665992,-1.419438943,-1.018173631,-0.576385402,tankyrase 2,"TNKS2, also known as tankyrase 2, is a human gene that encodes a protein involved in several cellular processes. The protein has NAD+ ADP-ribosyltransferase activity, enzyme binding activity, and protein ADP-ribosylase activity. TNKS2 is involved in protein ADP-ribosylation, protein localization to the telomeric region of chromosomes, and regulation of telomere maintenance. The protein is located in the nuclear envelope, pericentriolar material, and perinuclear region of the cytoplasm. TNKS2 is an important gene in understanding cellular processes and may have implications in disease research.","TNKS2 has been implicated in several diseases, including cancer, diabetes, and neurological disorders. In cancer, TNKS2 has been shown to play a role in the regulation of telomere length, which is important for the maintenance of genomic stability. Inhibition of TNKS2 has been explored as a potential therapeutic strategy for cancer, and several small molecule inhibitors of TNKS2 have been developed and are currently in clinical trials. One example is the drug XAV939, which has shown promising results in preclinical studies for the treatment of colorectal cancer. In addition to cancer, TNKS2 has also been implicated in the pathogenesis of diabetes and neurodegenerative diseases such as Alzheimer's and Parkinson's. Targeting TNKS2 may therefore have potential therapeutic applications in a range of diseases.",GO:1904355 positive regulation of telomere capping;GO:0070212 protein poly-ADP-ribosylation;GO:0070213 protein auto-ADP-ribosylation,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Microtubules (Approved),,,
ENSG00000050405.13,ENSG00000050405,LIMA1,-1.004081092,-1.262944183,-1.086432437,-0.662866657,LIM domain and actin binding 1,"LIMA1 is a gene that encodes a protein that is associated with the cytoskeleton and plays a role in inhibiting the depolymerization of actin filaments. It also cross-links filaments in bundles. The gene is downregulated in some cancer cell lines. There are different isoforms of the protein that are encoded by alternatively spliced transcript variants of the gene, and the expression of some of these variants may be independently regulated.","There is limited information available on the disease implications of LIMA1. However, some studies have suggested that the downregulation of LIMA1 may be associated with the progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for LIMA1 are also limited, as the protein's function and role in disease are not well understood. Currently, there are no drugs on the market that specifically target LIMA1. However, there are drugs that indirectly affect the cytoskeleton and actin filaments, which may have an impact on LIMA1 function. For example, paclitaxel, a chemotherapy drug used to treat breast cancer, stabilizes microtubules and indirectly affects the cytoskeleton. Another example is cytochalasin D, a natural product that disrupts actin filaments and has been used in research to study the cytoskeleton.",GO:0030299 intestinal cholesterol absorption;GO:0098856 intestinal lipid absorption;GO:0044241 lipid digestion,,Predicted intracellular proteins,Actin filaments;Plasma membrane (Approved); Additional: Cytosol;Focal adhesion sites,,(M232)PID ECADHERIN STABILIZATION PATHWAY,(M5915)HALLMARK APICAL JUNCTION
ENSG00000185359.14,ENSG00000185359,HGS,-1.003532909,-1.555207455,-1.110025505,-0.345365768,hepatocyte growth factor-regulated tyrosine kinase substrate,"HGS, also known as hepatocyte growth factor-regulated tyrosine kinase substrate, is a gene that encodes a protein responsible for regulating endosomal sorting and playing a crucial role in the recycling and degradation of membrane receptors. The protein sorts monoubiquitinated membrane proteins into the multivesicular body, which targets these proteins for lysosome-dependent degradation. This gene's function is essential for maintaining proper cellular homeostasis and preventing the accumulation of damaged or unnecessary proteins. Dysregulation of HGS has been linked to various diseases, including cancer and neurodegenerative disorders.","Dysregulation of HGS has been implicated in various diseases, including cancer and neurodegenerative disorders. In cancer, HGS has been shown to play a role in tumor growth and metastasis by regulating the degradation of growth factor receptors and other signaling molecules. Targeting HGS has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of HGS have been developed and are currently being evaluated in preclinical studies. In neurodegenerative disorders, HGS has been linked to the accumulation of misfolded proteins, such as alpha-synuclein in Parkinson's disease. Targeting HGS-mediated protein degradation pathways has been proposed as a potential therapeutic approach for these disorders. However, there are currently no drugs on the market that specifically target HGS.",GO:0030948 negative regulation of vascular endothelial growth factor receptor signaling pathway;GO:0010642 negative regulation of platelet-derived growth factor receptor signaling pathway;GO:1903543 positive regulation of exosomal secretion,,Predicted intracellular proteins,Endosomes;Lysosomes (Supported); Additional: Cytosol,Citric acid,(M214)PID ERBB1 INTERNALIZATION PATHWAY; (M142)PID AJDISS 2PATHWAY; (M237)PID VEGFR1 2 PATHWAY,
ENSG00000074695.6,ENSG00000074695,LMAN1,-1.002662076,-1.434023993,-0.794049764,-0.779912472,"lectin, mannose binding 1","LMAN1 is a gene that encodes for a membrane lectin protein that binds to mannose. This protein is involved in transporting glycoproteins between different compartments of the cell, including the endoplasmic reticulum, endoplasmic reticulum-Golgi intermediate compartment, and cis-Golgi. LMAN1 has several domains, including a signal sequence, a carbohydrate recognition domain, a stalk region for oligomerization, a transmembrane domain, and a cytoplasmic domain for organelle targeting. Mutations in LMAN1 have been associated with an autosomal recessive disorder called combined factor V-factor VIII deficiency.","Combined factor V-factor VIII deficiency is a rare bleeding disorder caused by mutations in the LMAN1 gene. This disorder is characterized by reduced levels of both factor V and factor VIII in the blood, which are essential for blood clotting. Patients with this disorder may experience excessive bleeding after injury or surgery, and women may have heavy menstrual bleeding. There is currently no cure for combined factor V-factor VIII deficiency, and treatment is focused on managing bleeding episodes with replacement therapy using clotting factor concentrates. There are no targeted drug discovery efforts specifically for this disorder, but research is ongoing to better understand the underlying mechanisms and potential therapeutic targets. There are no drugs on the market specifically for combined factor V-factor VIII deficiency, but clotting factor concentrates such as NovoSeven and Advate are commonly used for replacement therapy.",GO:1903215 negative regulation of protein targeting to mitochondrion;GO:1903748 negative regulation of establishment of protein localization to mitochondrion;GO:1903214 regulation of protein targeting to mitochondrion,,Disease related genes; Potential drug targets; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Transporters,Vesicles (Supported); Additional: Endoplasmic reticulum,"Antihemophilic factor, human recombinant; Lonoctocog alfa; Moroctocog alfa",(M91)PID TCPTP PATHWAY; (M5880)NABA ECM AFFILIATED; (M5885)NABA MATRISOME ASSOCIATED,(M5910)HALLMARK PROTEIN SECRETION; (M5908)HALLMARK ANDROGEN RESPONSE
ENSG00000023516.9,ENSG00000023516,AKAP11,-1.001167776,-1.482585727,-0.883379335,-0.637538266,A-kinase anchoring protein 11,"AKAP11 is a gene that encodes a member of the A-kinase anchor protein (AKAP) family. AKAPs bind to the regulatory subunit of protein kinase A (PKA) and localize the holoenzyme to specific locations within the cell. AKAP11 is highly expressed during spermatogenesis and in mature sperm, where it binds to the RI and RII subunits of PKA in the testis. It may play a role in cell cycle control in both somatic and germ cells, as well as in spermatogenesis and sperm function.","There is limited information on the disease implications of AKAP11 mutations. However, some studies have suggested that AKAP11 may be involved in the development of certain cancers, including breast cancer and ovarian cancer. Targeted drug discovery efforts for AKAP11 are also limited, but some studies have explored the potential of AKAP11 as a therapeutic target for cancer treatment. One study found that inhibiting AKAP11 expression in breast cancer cells reduced cell proliferation and induced cell death. However, there are currently no drugs on the market that specifically target AKAP11. Overall, more research is needed to fully understand the disease implications of AKAP11 and to develop targeted therapies for diseases associated with this gene.",GO:0036010 protein localization to endosome;GO:0003091 renal water homeostasis;GO:0050891 multicellular organismal-level water homeostasis,,Predicted intracellular proteins,Cytosol;Nucleoli;Plasma membrane (Approved),,,
ENSG00000168615.13,ENSG00000168615,ADAM9,-0.999743498,-1.482328696,-0.981214066,-0.535687734,ADAM metallopeptidase domain 9,"ADAM9 is a gene that belongs to the ADAM family, which encodes for membrane-anchored proteins that are structurally similar to snake venom disintegrins. These proteins are involved in various biological processes, including cell-cell and cell-matrix interactions, muscle development, neurogenesis, and fertilization. ADAM9 interacts with SH3 domain-containing proteins, binds mitotic arrest deficient 2 beta protein, and is involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. The gene has several alternatively spliced transcript variants.","ADAM9 has been implicated in various diseases, including cancer, Alzheimer's disease, and asthma. In cancer, ADAM9 is involved in tumor growth, invasion, and metastasis, making it a potential target for cancer therapy. Several studies have shown that inhibition of ADAM9 can reduce tumor growth and metastasis in various cancer types, including breast, lung, and pancreatic cancer. In Alzheimer's disease, ADAM9 has been shown to be involved in the processing of amyloid precursor protein, which is a key player in the development of the disease. In asthma, ADAM9 is involved in airway remodeling and inflammation, making it a potential target for asthma therapy.

Targeted drug discovery efforts for ADAM9 have focused on the development of small molecule inhibitors and monoclonal antibodies. Several small molecule inhibitors of ADAM9 have been developed and tested in preclinical studies, showing promising results in reducing tumor growth and metastasis. Monoclonal antibodies targeting ADAM9 have also been developed and tested in preclinical studies, showing potential for the treatment of cancer and asthma.

One example of a successful drug targeting ADAM9 is TAPI-1, a small molecule inhibitor of ADAMs that has been shown to inhibit tumor growth and metastasis in preclinical studies. Another example is the monoclonal antibody ADAM9-11, which has been shown to inhibit tumor growth and metastasis in preclinical studies of breast cancer. While there are currently no FDA-approved drugs targeting ADAM9, ongoing research efforts hold promise for the development of effective therapies for various diseases.",GO:0097327 response to antineoplastic agent;GO:0034239 regulation of macrophage fusion;GO:0034241 positive regulation of macrophage fusion,,Disease related genes; Predicted secreted proteins; Human disease related genes:Nervous system diseases:Eye disease; Cancer-related genes:Candidate cancer biomarkers,Vesicles (Approved); Additional: Endoplasmic reticulum,INCB7839,(M3468)NABA ECM REGULATORS; (M5885)NABA MATRISOME ASSOCIATED; (M5889)NABA MATRISOME,(M5946)HALLMARK COAGULATION; (M5915)HALLMARK APICAL JUNCTION; (M5921)HALLMARK COMPLEMENT
ENSG00000096717.12,ENSG00000096717,SIRT1,-0.999585342,-1.265667225,-1.168239443,-0.564849359,sirtuin 1,"SIRT1, also known as sirtuin 1, is a protein that belongs to the sirtuin family of proteins, which are homologs to the yeast Sir2 protein. Sirtuins are characterized by a sirtuin core domain and are grouped into four classes. The functions of human sirtuins are not yet fully understood, but studies suggest that they may function as intracellular regulatory proteins with mono-ADP-ribosyltransferase activity. SIRT1 is included in class I of the sirtuin family and alternative splicing results in multiple transcript variants. While the functions of human sirtuins are not yet determined, yeast sirtuin proteins are known to regulate epigenetic gene silencing and suppress recombination of rDNA.","SIRT1 has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, metabolic disorders, and cardiovascular diseases. In cancer, SIRT1 has been shown to promote tumor growth and survival by regulating various signaling pathways. In neurodegenerative diseases, SIRT1 has been suggested to play a protective role by regulating protein homeostasis and reducing oxidative stress. In metabolic disorders, SIRT1 has been shown to regulate glucose and lipid metabolism, and its activation has been proposed as a potential therapeutic strategy for type 2 diabetes and obesity. In cardiovascular diseases, SIRT1 has been shown to protect against endothelial dysfunction and atherosclerosis.

Targeted drug discovery efforts have focused on developing small molecule activators of SIRT1 as potential therapeutics for various diseases. Resveratrol, a natural compound found in red wine, has been shown to activate SIRT1 and has been proposed as a potential therapeutic for metabolic disorders and neurodegenerative diseases. However, its efficacy in humans is still under investigation. Other small molecule activators of SIRT1, such as SRT1720 and SRT2104, have shown promising results in preclinical studies for metabolic disorders and cardiovascular diseases, but their clinical efficacy is still being evaluated.

In conclusion, SIRT1 is a protein with diverse functions and has been implicated in various diseases. Targeted drug discovery efforts have focused on developing small molecule activators of SIRT1 as potential therapeutics for these diseases, but their clinical efficacy is still being evaluated.",GO:0051658 maintenance of nucleus location;GO:0051986 negative regulation of attachment of spindle microtubules to kinetochore;GO:1902424 negative regulation of attachment of mitotic spindle microtubules to kinetochore,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported); Additional: Cytosol;Mitochondria;Nucleoli fibrillar center,Resveratrol; Selisistat; Cambinol,(M32)PID HDAC CLASSIII PATHWAY; (M44)PID HIF2PATHWAY; (M136)PID FOXO PATHWAY,(M5951)HALLMARK SPERMATOGENESIS
ENSG00000145675.15,ENSG00000145675,PIK3R1,-0.998523356,-1.541389867,-1.051141484,-0.403038718,phosphoinositide-3-kinase regulatory subunit 1,"The PIK3R1 gene encodes the 85 kD regulatory subunit of phosphatidylinositol 3-kinase, an enzyme that phosphorylates the inositol ring of phosphatidylinositol at the 3-prime position. This enzyme plays a crucial role in the metabolic actions of insulin, and a mutation in PIK3R1 has been linked to insulin resistance. Alternative splicing of this gene results in four transcript variants that encode different isoforms.","Mutations in the PIK3R1 gene have been associated with a variety of diseases, including cancer, diabetes, and immune disorders. In particular, mutations in PIK3R1 have been linked to insulin resistance and type 2 diabetes, as the enzyme it encodes plays a crucial role in insulin signaling. Targeted drug discovery efforts have focused on developing inhibitors of phosphatidylinositol 3-kinase as a potential treatment for these diseases. Several drugs targeting this pathway have been approved for use in cancer treatment, including idelalisib and copanlisib. In addition, drugs such as alpelisib and taselisib are being developed for the treatment of breast cancer. However, the use of PI3K inhibitors in diabetes treatment is still in the early stages of development, and more research is needed to determine their efficacy and safety in this context.",GO:0035655 interleukin-18-mediated signaling pathway;GO:0071351 cellular response to interleukin-18;GO:0120182 regulation of focal adhesion disassembly,,RAS pathway related proteins; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Human disease related genes:Immune system diseases:Primary immunodeficiency; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Candidate cancer biomarkers,Cytosol (Approved),Isoprenaline; SF1126; Enzastaurin; Wortmannin,(M135)PID IL5 PATHWAY; (M26)PID NFKAPPAB ATYPICAL PATHWAY; (M273)PID EPHA2 FWD PATHWAY,
ENSG00000069020.18,ENSG00000069020,MAST4,-0.998444259,-0.318053834,-1.310644553,-1.366634389,microtubule associated serine/threonine kinase family member 4,MAST4 is a gene that encodes a protein belonging to the microtubule-associated serine/threonine protein kinase family. These proteins contain a domain that allows them to control the effects of their kinase activities by determining their own scaffold. Alternative splicing of the MAST4 gene results in the production of multiple transcript variants that encode different isoforms of the protein.,"Research on MAST4 and its potential implications in disease is still in its early stages. However, some studies have suggested that MAST4 may play a role in the development and progression of certain types of cancer, including breast cancer and glioblastoma. Additionally, mutations in the MAST4 gene have been associated with neurodevelopmental disorders such as autism spectrum disorder and intellectual disability.

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target MAST4. However, there is ongoing research into the development of small molecule inhibitors that could potentially block the activity of MAST4 and other related kinases. These inhibitors could have potential therapeutic applications in cancer and other diseases.

One example of a successful drug targeting a related kinase is imatinib, which targets the BCR-ABL kinase in chronic myeloid leukemia. Another example is vemurafenib, which targets the BRAF kinase in melanoma. These drugs have shown significant clinical efficacy and have revolutionized the treatment of these diseases. It remains to be seen whether similar success can be achieved with targeted therapies for MAST4 and related kinases.",GO:0007010 cytoskeleton organization;GO:0006338 chromatin remodeling;GO:0006325 chromatin organization,yes,Kinases:AGC Ser/Thr protein kinases; Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Nucleoplasm (Approved),,,(M5906)HALLMARK ESTROGEN RESPONSE EARLY
ENSG00000197622.13,ENSG00000197622,CDC42SE1,-0.998316216,-1.104124927,-1.101904153,-0.788919569,CDC42 small effector 1,CDC42SE1 is a human gene that is predicted to have GTPase inhibitor activity and be involved in signal transduction. It is located in cell junctions. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of CDC42SE1. However, some studies have suggested that alterations in CDC42SE1 expression may be associated with certain types of cancer, including breast and lung cancer. Targeted drug discovery efforts for CDC42SE1 are also limited, as the function of this gene is not well understood. Currently, there are no drugs on the market that specifically target CDC42SE1. However, there are drugs that target other proteins involved in signal transduction pathways, which may indirectly affect CDC42SE1 activity. For example, some targeted therapies for breast cancer, such as trastuzumab and lapatinib, target the HER2 protein, which is involved in signal transduction pathways that may interact with CDC42SE1.",GO:0035023 regulation of Rho protein signal transduction;GO:0008360 regulation of cell shape;GO:0006909 phagocytosis,,Predicted intracellular proteins,Cell Junctions (Supported),,,
ENSG00000224470.8,ENSG00000224470,ATXN1L,-0.997218622,-1.373471361,-1.03774661,-0.580437895,ataxin 1 like,"ATXN1L is a human gene that is predicted to have DNA binding and RNA binding activity. It is involved in various processes such as learning or memory, regulation of transcription, and social behavior. It is also predicted to act upstream or within processes such as lung alveolus development, negative regulation of transcription by RNA polymerase II, and positive regulation of hematopoietic stem cell proliferation. ATXN1L is located in the nucleolus and nucleoplasm.","ATXN1L has been implicated in several diseases, including spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disorder characterized by progressive loss of motor coordination and cognitive impairment. Studies have shown that ATXN1L interacts with the protein product of the SCA1 gene, ATXN1, and may play a role in the pathogenesis of the disease. 

Targeted drug discovery efforts for ATXN1L are still in the early stages, but there is potential for the development of therapeutics that could modulate its activity. One approach is to target the RNA binding activity of ATXN1L, which has been shown to be important for its function. Another approach is to target the protein-protein interactions between ATXN1L and other proteins involved in disease pathways.

Currently, there are no drugs on the market that specifically target ATXN1L. However, there are drugs that have been approved for other indications that may have potential for treating diseases associated with ATXN1L. For example, histone deacetylase inhibitors (HDACi) have been shown to improve motor function and reduce neurodegeneration in animal models of SCA1. HDACi are currently approved for the treatment of certain cancers and may have potential for repurposing in neurodegenerative diseases.",GO:1902035 positive regulation of hematopoietic stem cell proliferation;GO:1902033 regulation of hematopoietic stem cell proliferation;GO:0048286 lung alveolus development,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nucleoli,,,
ENSG00000196914.9,ENSG00000196914,ARHGEF12,-0.996917795,-1.385966421,-1.354350401,-0.250436563,Rho guanine nucleotide exchange factor 12,"ARHGEF12 is a human gene that encodes for Rho guanine nucleotide exchange factor 12, which plays a crucial role in various cellular processes initiated by extracellular stimuli through G protein-coupled receptors. This protein may form a complex with G proteins and stimulate Rho-dependent signals. It has also been observed to form a myeloid/lymphoid fusion partner in acute myeloid leukemia. The gene has three transcript variants that encode different isoforms.","ARHGEF12 has been implicated in various diseases, including cancer, cardiovascular diseases, and neurological disorders. In cancer, ARHGEF12 has been found to be overexpressed in several types of tumors, including breast, lung, and pancreatic cancer, and has been associated with tumor growth and metastasis. In cardiovascular diseases, ARHGEF12 has been linked to hypertension and atherosclerosis. In neurological disorders, ARHGEF12 has been associated with schizophrenia and autism spectrum disorders.

Targeted drug discovery efforts for ARHGEF12 have focused on developing small molecule inhibitors that can block its activity and prevent the downstream signaling pathways that lead to disease. One example is the development of a small molecule inhibitor of ARHGEF12 called ARHGDIA, which has been shown to inhibit the growth and metastasis of breast cancer cells in preclinical studies.

Another successful drug on the market that targets ARHGEF12 is fasudil, which is used to treat cerebral vasospasm after subarachnoid hemorrhage. Fasudil is a Rho kinase inhibitor that blocks the downstream signaling pathways activated by ARHGEF12, leading to vasodilation and improved blood flow to the brain.

Overall, ARHGEF12 is an important target for drug discovery efforts in various diseases, and the development of small molecule inhibitors and other targeted therapies holds promise for improving patient outcomes.",GO:0007266 Rho protein signal transduction;GO:0007264 small GTPase-mediated signal transduction;GO:0051056 regulation of small GTPase mediated signal transduction,,Disease related genes; Cancer-related genes; Predicted intracellular proteins,Cytosol;Plasma membrane (Approved); Additional: Nucleoplasm,,(M68)PID RHOA REG PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE; (M5945)HALLMARK HEME METABOLISM
ENSG00000112851.15,ENSG00000112851,ERBIN,-0.995980156,-1.087324034,-1.118706102,-0.781910332,erbb2 interacting protein,"ERBIN is a gene that belongs to the LAP family and encodes a protein containing 17 leucine-rich repeats and one PDZ domain. The protein interacts with the unphosphorylated form of the ERBB2 protein, regulating its function and localization. ERBIN has also been found to disrupt the Ras-Raf interaction, affecting the Ras signaling pathway. Multiple isoforms of ERBIN have been observed due to alternative splicing of transcript variants.","ERBIN has been implicated in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, ERBIN has been shown to play a role in the regulation of ERBB2 signaling, which is often overexpressed in breast and gastric cancers. Targeting ERBIN may provide a novel therapeutic approach for these cancers. In cardiovascular disease, ERBIN has been linked to the regulation of cardiac hypertrophy and heart failure. In neurological disorders, ERBIN has been associated with the regulation of synaptic plasticity and memory formation. 

There are currently no drugs on the market that specifically target ERBIN. However, there have been efforts to develop drugs that target the ERBB2 signaling pathway, which is regulated by ERBIN. Examples of successful drugs targeting this pathway include trastuzumab and lapatinib, which are used to treat breast cancer. Additionally, there are ongoing efforts to develop drugs that target the Ras signaling pathway, which is also regulated by ERBIN. Examples of successful drugs targeting this pathway include vemurafenib and trametinib, which are used to treat melanoma.","GO:0045175 basal protein localization;GO:0070425 negative regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway;GO:0070433 negative regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway",,Predicted intracellular proteins,Cell Junctions;Plasma membrane (Supported),,,
ENSG00000135090.14,ENSG00000135090,TAOK3,-0.994961693,-1.037147048,-0.829211318,-1.118526712,TAO kinase 3,"TAOK3, also known as TAO kinase 3, is a protein kinase that plays a role in activating the p38/MAPK14 stress-activated MAPK cascade while inhibiting the basal activity of the MAPK8/JNK cascade. It belongs to the GCK subfamily of STE20-like kinases. This gene is important in regulating cellular responses to stress and inflammation. Dysregulation of TAOK3 has been linked to various diseases, including cancer and neurodegenerative disorders.","TAOK3 has been implicated in various diseases, including cancer and neurodegenerative disorders. In cancer, TAOK3 has been shown to promote tumor growth and metastasis in several types of cancer, including breast, lung, and pancreatic cancer. In neurodegenerative disorders, TAOK3 has been linked to the pathogenesis of Alzheimer's disease and Parkinson's disease.

Targeted drug discovery efforts for TAOK3 are still in the early stages, but several small molecule inhibitors have been developed that target TAOK3 activity. One such inhibitor, KHS101, has been shown to inhibit the growth of breast cancer cells in vitro and in vivo. Another inhibitor, THZ531, has been shown to inhibit the growth of pancreatic cancer cells in vitro and in vivo.

Currently, there are no drugs on the market that specifically target TAOK3. However, several drugs that target the p38/MAPK14 stress-activated MAPK cascade, which is activated by TAOK3, are on the market for various indications. These include drugs such as Enbrel (etanercept) for rheumatoid arthritis and Humira (adalimumab) for various inflammatory diseases.",GO:0032874 positive regulation of stress-activated MAPK cascade;GO:0070304 positive regulation of stress-activated protein kinase signaling cascade;GO:0043507 positive regulation of JUN kinase activity,yes,Enzymes; Kinases:STE Ser/Thr protein kinases; Predicted intracellular proteins; ENZYME proteins:Transferases,Mitochondria (Uncertain),Fostamatinib,(M20)PID P38 MKK3 6PATHWAY,
ENSG00000102531.16,ENSG00000102531,FNDC3A,-0.993789752,-1.242648864,-1.257639394,-0.481080998,fibronectin type III domain containing 3A,"FNDC3A is a human gene that encodes a protein containing fibronectin type III domains. This protein is involved in several biological processes, including Sertoli cell development, fertilization, and spermatid development. It has been predicted to act upstream of or within these processes. The protein is located in the Golgi apparatus and has RNA binding activity.","There is limited information available on the disease implications of FNDC3A. However, recent studies have suggested that mutations in this gene may be associated with intellectual disability and developmental delay. Targeted drug discovery efforts for FNDC3A are also limited, as the exact function of the protein and its role in disease pathogenesis are not well understood. Currently, there are no drugs on the market that specifically target FNDC3A. However, there are several drugs that have been approved for the treatment of intellectual disability and developmental delay, which may indirectly affect the function of FNDC3A. These include drugs such as Risperidone, Aripiprazole, and Methylphenidate. Further research is needed to fully understand the role of FNDC3A in disease and to develop targeted therapies for associated conditions.",GO:0060009 Sertoli cell development;GO:0060008 Sertoli cell differentiation;GO:0008584 male gonad development,,Predicted intracellular proteins,Centrosome;Golgi apparatus;Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000131725.14,ENSG00000131725,WDR44,-0.993477479,-1.480094968,-0.955200533,-0.545136936,WD repeat domain 44,"The human gene WDR44, also known as WD repeat domain 44, encodes a protein that interacts with the small GTPase rab11. This protein may play a role in endosome recycling, which is the process by which cells transport and recycle molecules within the cell. Alternate splicing of the gene results in multiple transcript variants. A similar protein in rats has been shown to bind to the active form of rab11, suggesting that the human WDR44 protein may also have a similar function. Overall, the exact role of WDR44 in human cells is still being studied.","There is limited information available on the disease implications of WDR44. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for WDR44 are also limited, as the exact function of the protein encoded by this gene is still being studied. Currently, there are no drugs on the market that specifically target WDR44. However, there are drugs that target the small GTPase rab11, with which WDR44 interacts. For example, the drug brefeldin A has been shown to inhibit the activity of rab11 and is used in research to study endosome recycling. Additionally, some cancer drugs, such as lapatinib, have been shown to inhibit the activity of rab11 and may indirectly affect the function of WDR44.",GO:0061824 cytosolic ciliogenesis;GO:1902018 negative regulation of cilium assembly;GO:0120033 negative regulation of plasma membrane bounded cell projection assembly,,Predicted intracellular proteins,Golgi apparatus (Supported),,,
ENSG00000123094.15,ENSG00000123094,RASSF8,-0.993299695,-1.853637708,-0.933431135,-0.192830243,Ras association domain family member 8,RASSF8 is a tumor suppressor gene that belongs to the Ras-association domain family. It plays a crucial role in maintaining the function of adherens junctions in epithelial cells and is involved in epithelial cell migration. RASSF8 is a candidate gene for lung tumor suppression. It has multiple alternatively spliced transcript variants that encode different isoforms. A chromosomal translocation t(12;22)(p11.2;q13.3) that results in the fusion of RASSF8 and FBLN1 genes is associated with a complex type of synpolydactyly.,"There is limited information available on the disease implications of RASSF8. However, it has been identified as a candidate gene for lung tumor suppression, suggesting its potential role in cancer treatment. Targeted drug discovery efforts for RASSF8 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and inhibit its function. There are currently no drugs on the market that specifically target RASSF8, but there are several drugs that target other members of the Ras-association domain family, such as RAS inhibitors used in the treatment of certain types of cancer. Further research is needed to fully understand the potential therapeutic implications of targeting RASSF8.",GO:0007165 signal transduction;GO:0023052 signaling;GO:0007154 cell communication,,Disease related genes; Predicted intracellular proteins,Cytosol;Mitochondria (Approved),,,
ENSG00000155849.15,ENSG00000155849,ELMO1,-0.992259863,-1.423538656,-0.200214528,-1.353026404,engulfment and cell motility 1,"ELMO1 is a gene that belongs to the engulfment and cell motility protein family. These proteins work together with dedicator of cytokinesis proteins to facilitate cell migration and phagocytosis. Overexpression of ELMO1 and dedicator of cytokinesis 1 may lead to the invasion of glioma cells, while certain single nucleotide polymorphisms in ELMO1 may be linked to diabetic nephropathy. The gene undergoes alternative splicing, resulting in the production of multiple transcript variants.","ELMO1 has been implicated in several diseases, including cancer and diabetic nephropathy. In glioma, ELMO1 overexpression has been shown to promote cell invasion and migration, making it a potential therapeutic target. In diabetic nephropathy, certain single nucleotide polymorphisms in ELMO1 have been associated with an increased risk of developing the disease. Targeted drug discovery efforts for ELMO1 are still in the early stages, but there are several potential strategies being explored, including small molecule inhibitors and RNA interference. Currently, there are no drugs on the market specifically targeting ELMO1, but there are drugs targeting related proteins in the same pathway, such as dedicator of cytokinesis 1. For example, the drug dasatinib, which targets multiple kinases including dedicator of cytokinesis 1, has been approved for the treatment of chronic myeloid leukemia.","GO:0016601 Rac protein signal transduction;GO:0006911 phagocytosis, engulfment;GO:0099024 plasma membrane invagination",,Predicted intracellular proteins,,,(M108)PID NETRIN PATHWAY; (M210)PID IL8 CXCR2 PATHWAY; (M241)PID RAC1 REG PATHWAY,
ENSG00000188419.14,ENSG00000188419,CHM,-0.991866843,-1.382778827,-1.03277466,-0.560047043,CHM Rab escort protein,"The CHM gene encodes component A of the RAB geranylgeranyl transferase holoenzyme, which is responsible for transferring geranylgeranyl groups to Rab GTPases. Rab GTPases require geranylgeranylation to localize to the correct intracellular membrane. Mutations in the CHM gene are associated with choroideremia, an X-linked disease characterized by progressive dystrophy of the choroid, retinal pigment epithelium, and retina. The CHM protein binds unprenylated Rab GTPases and presents them to the catalytic Rab GGTase subunit for the geranylgeranyl transfer reaction. Alternative splicing of the CHM gene has been observed.","Choroideremia is an X-linked recessive disease caused by mutations in the CHM gene. The disease primarily affects males and is characterized by progressive degeneration of the retina, leading to vision loss and eventual blindness. There is currently no cure for choroideremia, and treatment options are limited to supportive measures such as low-vision aids and genetic counseling. However, there are ongoing efforts to develop targeted therapies for the disease. One approach is to use gene therapy to replace the defective CHM gene with a functional copy. Several clinical trials have been conducted using this approach, with promising results. Another approach is to develop drugs that can restore the function of the CHM protein or compensate for its loss. One example of a successful drug in this category is Fovista, which is used to treat age-related macular degeneration. Fovista works by inhibiting a protein called platelet-derived growth factor (PDGF), which is involved in the development of abnormal blood vessels in the retina. By blocking PDGF, Fovista can help to prevent vision loss in patients with macular degeneration.",GO:0018344 protein geranylgeranylation;GO:0018342 protein prenylation;GO:0097354 prenylation,,Disease related genes; Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000154447.15,ENSG00000154447,SH3RF1,-0.990813046,-1.575172326,-1.215630342,-0.181636469,SH3 domain containing ring finger 1,"SH3RF1 is a human gene that encodes a protein with a RING-finger, four SH3 domains, and a region that binds to the Rho GTPase Rac. The protein functions as an ubiquitin-protein ligase involved in protein sorting at the trans-Golgi network and may act as a scaffold for the c-Jun N-terminal kinase signaling pathway, facilitating the formation of a functional signaling module. The gene is important for regulating protein sorting and signaling pathways in the cell.","There is limited information available on the disease implications of SH3RF1. However, recent studies have suggested that mutations in the gene may be associated with the development of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for SH3RF1 are still in the early stages, but there is potential for the development of drugs that target the protein's ubiquitin-protein ligase activity or its interaction with the Rho GTPase Rac. Currently, there are no drugs on the market that specifically target SH3RF1, but there are drugs that target related proteins in the same signaling pathways, such as the JNK inhibitor SP600125, which is used in research to inhibit the c-Jun N-terminal kinase signaling pathway.","GO:2000564 regulation of CD8-positive, alpha-beta T cell proliferation;GO:1904044 response to aldosterone;GO:2001185 regulation of CD8-positive, alpha-beta T cell activation",,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Vesicles (Supported); Additional: Intermediate filaments,,,
ENSG00000079313.15,ENSG00000079313,REXO1,-0.990710316,-1.513701203,-1.025972095,-0.43245765,RNA exonuclease 1 homolog,"REXO1 is a human gene that encodes for RNA exonuclease 1 homolog, which is predicted to have exonuclease activity and be involved in the hydrolysis of nucleic acid phosphodiester bonds. It is located in the nuclear body. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of REXO1. However, recent studies have suggested that REXO1 may play a role in cancer development and progression. Specifically, REXO1 has been found to be overexpressed in several types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts for REXO1 are currently underway, with the goal of developing drugs that can inhibit its activity and potentially treat cancer. While there are currently no drugs on the market that specifically target REXO1, there are several drugs that have been successful in treating cancer by targeting other nucleic acid processing enzymes, such as topoisomerase inhibitors and DNA polymerase inhibitors. Further research is needed to fully understand the role of REXO1 in cancer and to develop effective targeted therapies.",GO:0031125 rRNA 3'-end processing;GO:0031123 RNA 3'-end processing;GO:0006364 rRNA processing,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nuclear bodies,,,
ENSG00000101384.12,ENSG00000101384,JAG1,-0.990043552,-1.466087492,-1.111784016,-0.392259147,jagged canonical Notch ligand 1,"JAG1 is a human gene that encodes for the jagged 1 protein, which is a ligand for the notch 1 receptor involved in signaling processes. This gene is the human equivalent of the jagged protein found in Drosophila. Mutations in JAG1 can cause Alagille syndrome, a genetic disorder that affects multiple organs including the liver, heart, and kidneys. Additionally, JAG1 signaling through notch 1 has been shown to play a role in hematopoiesis, the process of blood cell formation.","Alagille syndrome is a rare genetic disorder caused by mutations in the JAG1 gene. This syndrome affects multiple organs, including the liver, heart, and kidneys, and can lead to serious complications such as liver failure and heart defects. There is currently no cure for Alagille syndrome, and treatment is focused on managing symptoms and preventing complications. Targeted drug discovery efforts for Alagille syndrome are ongoing, with a focus on developing therapies that can address the underlying genetic cause of the disease. One example of a successful drug on the market is Ocaliva (obeticholic acid), which was approved by the FDA in 2016 for the treatment of primary biliary cholangitis, a liver disease that shares some similarities with Alagille syndrome. Ocaliva works by activating the farnesoid X receptor, which regulates bile acid synthesis and transport in the liver. While Ocaliva is not specifically approved for the treatment of Alagille syndrome, it has shown promise in clinical trials and is being investigated as a potential therapy for this condition.",GO:0061444 endocardial cushion cell development;GO:0061443 endocardial cushion cell differentiation;GO:0061073 ciliary body morphogenesis,,Human disease related genes:Congenital malformations:Congenital malformations of the circulatory system; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the digestive system; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Disease related genes; CD markers,Golgi apparatus;Plasma membrane (Approved),,(M256)PID TAP63 PATHWAY; (M17)PID NOTCH PATHWAY,(M5903)HALLMARK NOTCH SIGNALING; (M5944)HALLMARK ANGIOGENESIS; (M5895)HALLMARK WNT BETA CATENIN SIGNALING
ENSG00000150457.9,ENSG00000150457,LATS2,-0.987355818,-1.814895815,-0.88704315,-0.26012849,large tumor suppressor kinase 2,"LATS2 is a gene that encodes a protein kinase belonging to the LATS tumor suppressor family. The protein is involved in various cellular processes, including spindle formation during mitosis and regulation of androgen-responsive gene expression. It interacts with other proteins such as aurora-A and ajuba, and may function in a positive feedback loop with p53 in response to cytoskeleton damage. LATS2 is also known to be a negative regulator of p53. The gene is located on chromosome 13 and mutations in LATS2 have been associated with various types of cancer.","Mutations in LATS2 have been associated with various types of cancer, including breast, lung, and ovarian cancer. Targeting LATS2 has been explored as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of LATS2 have been developed and tested in preclinical studies, showing promising results in inhibiting tumor growth and inducing apoptosis in cancer cells. However, no LATS2-targeted drugs have been approved for clinical use yet. One example of a successful drug targeting a related protein is the FDA-approved drug palbociclib, which targets CDK4/6 and is used for the treatment of breast cancer. Palbociclib has been shown to indirectly activate LATS2 and inhibit the YAP/TAZ pathway, which is involved in cancer progression. Further research is needed to fully understand the potential of LATS2 as a therapeutic target for cancer treatment.",GO:0001827 inner cell mass cell fate commitment;GO:0001828 inner cell mass cellular morphogenesis;GO:0001826 inner cell mass cell differentiation,yes,Predicted intracellular proteins; Cancer-related genes; ENZYME proteins:Transferases; Kinases:AGC Ser/Thr protein kinases; Enzymes,Centriolar satellite;Cytosol (Approved),,(M58)PID AR PATHWAY,(M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000107372.13,ENSG00000107372,ZFAND5,-0.987347199,-1.433606071,-1.093426317,-0.435009209,zinc finger AN1-type containing 5,"ZFAND5 is a human gene that is predicted to have DNA binding and zinc ion binding activity. It is also predicted to play a role in several processes, including face development, fibroblast migration, and platelet-derived growth factor receptor signaling pathway. The gene is predicted to be located in the cytoplasm.","There is limited information available on the disease implications of ZFAND5. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ZFAND5 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target ZFAND5, there are several drugs that have been successful in treating breast cancer and hepatocellular carcinoma, which may indirectly affect the activity of this gene. Examples of such drugs include tamoxifen, trastuzumab, and sorafenib. Further research is needed to fully understand the role of ZFAND5 in disease and to develop targeted therapies for its associated conditions.",GO:0010761 fibroblast migration;GO:0048745 smooth muscle tissue development;GO:0003016 respiratory system process,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol;Nuclear bodies,,(M136)PID FOXO PATHWAY,
ENSG00000115020.17,ENSG00000115020,PIKFYVE,-0.985515577,-1.166579463,-0.896123647,-0.89384362,"phosphoinositide kinase, FYVE-type zinc finger containing","PIKFYVE is a human gene that encodes an enzyme called phosphoinositide kinase, FYVE-type zinc finger containing. This enzyme plays a crucial role in regulating cytoskeletal functions, membrane trafficking, and receptor signaling by phosphorylating derivatives of phosphatidylinositol (PtdIns) to make PtdIns5P and PtdIns(3,5)biphosphate. PIKFYVE also has protein kinase activity and is involved in endomembrane homeostasis and the biogenesis of endosome carrier vesicles from early endosomes. Mutations in this gene cause corneal fleck dystrophy (CFD), an autosomal dominant disorder characterized by numerous small white flecks present in all layers of the corneal stroma. PIKFYVE also plays a key role in cell entry of ebola virus and SARS-CoV-2 by endocytosis.","Corneal fleck dystrophy (CFD) is a rare genetic disorder caused by mutations in the PIKFYVE gene. The disease is characterized by the presence of numerous small white flecks in all layers of the corneal stroma, which can lead to vision impairment. Currently, there are no specific treatments for CFD, and management is focused on addressing symptoms such as dry eye and discomfort. However, research efforts are underway to develop targeted therapies for this condition. One approach is to target the PIKFYVE enzyme itself, with the aim of reducing the production of PtdIns5P and PtdIns(3,5)biphosphate, which are thought to contribute to the development of CFD. Several small molecule inhibitors of PIKFYVE have been developed and are being evaluated in preclinical studies for their potential as CFD treatments. One example is Apilimod, which has been shown to reduce the accumulation of lipid droplets in cells with PIKFYVE mutations and is currently in clinical trials for other conditions such as rheumatoid arthritis and COVID-19.","GO:1903100 1-phosphatidyl-1D-myo-inositol 3,5-bisphosphate metabolic process;GO:1904562 phosphatidylinositol 5-phosphate metabolic process;GO:0036289 peptidyl-serine autophosphorylation",yes,Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,,,,(M5923)HALLMARK PI3K AKT MTOR SIGNALING
ENSG00000198844.12,ENSG00000198844,ARHGEF15,-0.985254668,-0.781713974,-0.685657529,-1.4883925,Rho guanine nucleotide exchange factor 15,"ARHGEF15 is a human gene that encodes a protein known as Rho guanine nucleotide exchange factor 15. This protein plays a crucial role in various cellular processes that are initiated by external stimuli that work through G protein-coupled receptors. Specifically, ARHGEF15 functions as a specific guanine nucleotide exchange factor for RhoA, a member of the Rho GTPase family. Additionally, it interacts with ephrin A4 in vascular smooth muscle cells. There are two alternatively spliced transcript variants of ARHGEF15 that encode the same protein.","There is limited information available on the disease implications of ARHGEF15. However, recent studies have suggested that this gene may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ARHGEF15 are still in the early stages, but there is potential for the development of drugs that target RhoA signaling pathways. One example of a successful drug that targets RhoA is fasudil, which is used to treat cerebral vasospasm and pulmonary hypertension. Another potential drug target is ephrin A4, which interacts with ARHGEF15 in vascular smooth muscle cells. However, there are currently no drugs on the market that specifically target ARHGEF15.",GO:2000297 negative regulation of synapse maturation;GO:0061299 retina vasculature morphogenesis in camera-type eye;GO:1905809 negative regulation of synapse organization,,Predicted intracellular proteins,Plasma membrane (Supported),,(M177)PID EPHA FWDPATHWAY; (M68)PID RHOA REG PATHWAY,
ENSG00000143149.12,ENSG00000143149,ALDH9A1,-0.983970877,-1.226657161,-1.176815329,-0.548440142,aldehyde dehydrogenase 9 family member A1,"ALDH9A1 is a gene that encodes for a protein belonging to the aldehyde dehydrogenase family. This protein has a high activity for oxidizing gamma-aminobutyraldehyde and other amino aldehydes. The enzyme catalyzes the dehydrogenation of gamma-aminobutyraldehyde to gamma-aminobutyric acid (GABA). This isozyme is a tetramer of identical 54-kD subunits. In summary, ALDH9A1 plays a crucial role in the metabolism of amino aldehydes and the production of GABA, which is an important neurotransmitter in the central nervous system.","ALDH9A1 has been implicated in several diseases, including cancer, alcoholism, and neurodegenerative disorders. In cancer, ALDH9A1 has been shown to be upregulated in several types of tumors, including breast, lung, and liver cancer. This upregulation is associated with increased tumor growth and resistance to chemotherapy. In alcoholism, ALDH9A1 has been linked to the metabolism of acetaldehyde, a toxic byproduct of alcohol metabolism. In neurodegenerative disorders, ALDH9A1 has been shown to be involved in the metabolism of GABA, which is important for maintaining proper neuronal function.

Targeted drug discovery efforts for ALDH9A1 have focused on developing inhibitors of the enzyme for cancer treatment and activators for neurodegenerative disorders. Several inhibitors of ALDH9A1 have been developed and are currently in preclinical or clinical trials for cancer treatment. These inhibitors have shown promising results in reducing tumor growth and increasing sensitivity to chemotherapy. In neurodegenerative disorders, activators of ALDH9A1 have been proposed as a potential treatment for diseases such as Alzheimer's and Parkinson's. However, no drugs targeting ALDH9A1 for neurodegenerative disorders have been approved for clinical use yet.

One example of a successful drug targeting ALDH is disulfiram, which is used to treat alcoholism. Disulfiram works by inhibiting ALDH, leading to an accumulation of acetaldehyde and causing unpleasant symptoms when alcohol is consumed. Another example is the cancer drug CB-839, which is an inhibitor of several enzymes in the glutamine metabolism pathway, including ALDH9A1. CB-839 has shown promising results in clinical trials for several types of cancer, including triple-negative breast cancer and renal cell carcinoma.",GO:0045329 carnitine biosynthetic process;GO:0006578 amino-acid betaine biosynthetic process;GO:0009437 carnitine metabolic process,,Enzymes; ENZYME proteins:Oxidoreductases; Predicted intracellular proteins,Cytosol (Approved),NADH,(M254)PID MYC REPRESS PATHWAY,(M5949)HALLMARK PEROXISOME; (M5948)HALLMARK BILE ACID METABOLISM; (M5935)HALLMARK FATTY ACID METABOLISM
ENSG00000011566.15,ENSG00000011566,MAP4K3,-0.983774913,-0.975583946,-1.270624783,-0.705116012,mitogen-activated protein kinase kinase kinase kinase 3,"MAP4K3 is a gene that belongs to the mitogen-activated protein kinase kinase kinase kinase family. This gene is responsible for activating important effectors in cell signaling, including c-Jun. Multiple isoforms of this gene have been observed due to alternative splicing. The function of MAP4K3 is not fully understood, but it is believed to play a role in various cellular processes, such as cell proliferation, differentiation, and apoptosis. Mutations in this gene have been associated with certain diseases, including cancer and neurodegenerative disorders. Overall, MAP4K3 is an important gene that plays a crucial role in regulating cellular signaling pathways.","MAP4K3 has been implicated in various diseases, including cancer and neurodegenerative disorders. In cancer, MAP4K3 has been shown to promote tumor growth and metastasis by activating signaling pathways that regulate cell proliferation, survival, and migration. Therefore, targeting MAP4K3 has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of MAP4K3 have been developed and tested in preclinical studies, showing promising results in inhibiting tumor growth and metastasis. However, no MAP4K3 inhibitors have been approved for clinical use yet. In neurodegenerative disorders, MAP4K3 has been linked to the pathogenesis of Alzheimer's disease and Parkinson's disease. Studies have shown that inhibiting MAP4K3 activity can reduce neuroinflammation and improve cognitive function in animal models of Alzheimer's disease. However, no drugs targeting MAP4K3 have been approved for the treatment of neurodegenerative disorders yet.",GO:0007254 JNK cascade;GO:0009411 response to UV;GO:0034612 response to tumor necrosis factor,yes,Predicted intracellular proteins; ENZYME proteins:Transferases; Enzymes; Kinases:STE Ser/Thr protein kinases; Cancer-related genes:Mutated cancer genes,Centriolar satellite (Approved),Fostamatinib,(M128)PID TNF PATHWAY,(M5905)HALLMARK ADIPOGENESIS
ENSG00000156162.16,ENSG00000156162,DPY19L4,-0.983652579,-1.130972905,-1.087612586,-0.732372247,dpy-19 like 4,DPY19L4 is a human gene that is predicted to have mannosyltransferase activity and be involved in protein C-linked glycosylation via 2'-alpha-mannosyl-L-tryptophan. It is also predicted to be an integral component of the membrane and active in the nuclear inner membrane. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of DPY19L4. However, mutations in this gene have been associated with male infertility, specifically with globozoospermia, a rare condition characterized by the absence of acrosomes in spermatozoa. Targeted drug discovery efforts for DPY19L4 are also limited, as the function of this gene is not well understood. Currently, there are no drugs on the market that specifically target DPY19L4. However, there are drugs available for the treatment of male infertility, such as clomiphene citrate, gonadotropins, and assisted reproductive technologies like in vitro fertilization (IVF). These treatments are not specific to DPY19L4 and are used to address a range of infertility issues.",,,,Vesicles (Approved),,,
ENSG00000143390.18,ENSG00000143390,RFX5,-0.983240939,-1.562466106,-0.895962751,-0.491293962,regulatory factor X5,"RFX5 is a gene that encodes the 75-kD subunit of RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. MHC-II deficiency, or the bare lymphocyte syndrome (BLS), is a severe immunodeficiency syndrome that results from a lack of MHC-II expression. At least 4 complementation groups have been identified in B-cell lines established from patients with BLS, and the lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene. RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined.","MHC-II deficiency, caused by mutations in the RFX5 gene, results in the bare lymphocyte syndrome (BLS), a severe immunodeficiency disorder. There are currently no targeted drug discovery efforts for BLS, and treatment is mainly supportive, including prophylactic antibiotics and immunoglobulin replacement therapy. However, there have been successful drug developments for other immunodeficiency disorders, such as primary immunodeficiency diseases (PIDs). For example, enzyme replacement therapy (ERT) has been developed for PIDs caused by enzyme deficiencies, and hematopoietic stem cell transplantation (HSCT) has been successful in treating severe combined immunodeficiency (SCID). Additionally, gene therapy has shown promise in treating certain PIDs, such as adenosine deaminase deficiency. While there are currently no drugs specifically targeting RFX5 mutations, these successful developments in other immunodeficiency disorders provide hope for future treatments for BLS.",GO:0045348 positive regulation of MHC class II biosynthetic process;GO:0045346 regulation of MHC class II biosynthetic process;GO:0000122 negative regulation of transcription by RNA polymerase II,,Disease related genes; Transcription factors:Helix-turn-helix domains; Human disease related genes:Immune system diseases:Primary immunodeficiency; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Vesicles,,,
ENSG00000117713.20,ENSG00000117713,ARID1A,-0.982670954,-1.213997678,-1.150980867,-0.583034318,AT-rich interaction domain 1A,"ARID1A is a gene that belongs to the SWI/SNF family and is involved in regulating the transcription of certain genes by altering the chromatin structure around those genes. It is part of the ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin. ARID1A possesses a DNA-binding domain that can specifically bind an AT-rich DNA sequence and a C-terminus that can stimulate glucocorticoid receptor-dependent transcriptional activation. It is thought that ARID1A confers specificity to the SNF/SWI complex and may recruit the complex to its targets through either protein-DNA or protein-protein interactions. Two transcript variants encoding different isoforms have been found for this gene.","ARID1A mutations have been identified in a variety of cancers, including ovarian, endometrial, gastric, and colorectal cancers. These mutations are associated with poor prognosis and resistance to chemotherapy. Targeted drug discovery efforts have focused on developing inhibitors of the SWI/SNF complex, including ARID1A, as a potential therapeutic strategy for these cancers. Several preclinical studies have shown promising results with SWI/SNF inhibitors, including increased sensitivity to chemotherapy and decreased tumor growth. However, no SWI/SNF inhibitors have been approved for clinical use yet. In addition, some studies have suggested that ARID1A mutations may be a biomarker for immunotherapy response in certain cancers. Successful drugs on the market that target other components of the SWI/SNF complex include EZH2 inhibitors, such as tazemetostat, which is approved for the treatment of certain types of lymphoma and sarcoma.",GO:0006337 nucleosome disassembly;GO:0032986 protein-DNA complex disassembly;GO:2000819 regulation of nucleotide-excision repair,,Predicted intracellular proteins; Transcription factors:Helix-turn-helix domains; Human disease related genes:Other diseases:Mental and behavioural disorders; Human disease related genes:Cancers:Cancers of the digestive system; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Nucleoplasm (Enhanced),,,
ENSG00000048028.11,ENSG00000048028,USP28,-0.982516945,-1.314886781,-1.04506024,-0.587603815,ubiquitin specific peptidase 28,"USP28 is a gene that encodes for a protein called ubiquitin specific peptidase 28. This protein is involved in repairing DNA damage and inducing apoptosis, or programmed cell death, in response to DNA damage. Overexpression of this gene has been observed in several types of cancer.","USP28 has been implicated in several types of cancer, including breast, lung, and ovarian cancer. Overexpression of this gene has been associated with increased tumor growth and resistance to chemotherapy. Therefore, targeting USP28 has been explored as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of USP28 have been developed, including P22077 and GNE-6640. These inhibitors have shown promising results in preclinical studies, inhibiting tumor growth and inducing apoptosis in cancer cells. However, there are currently no USP28 inhibitors approved for clinical use. Further research is needed to fully understand the role of USP28 in cancer and to develop effective targeted therapies.",GO:0071947 protein deubiquitination involved in ubiquitin-dependent protein catabolic process;GO:0042771 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator;GO:0072332 intrinsic apoptotic signaling pathway by p53 class mediator,,Peptidases:Cysteine-type peptidases; ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nuclear bodies,,,
ENSG00000111897.7,ENSG00000111897,SERINC1,-0.982301493,-1.509219966,-1.227497621,-0.210186893,serine incorporator 1,"SERINC1, also known as serine incorporator 1, is a human gene that is predicted to have protein-macromolecule adaptor activity and be involved in several processes, including phosphatidylserine metabolic process, positive regulation of CDP-diacylglycerol-serine O-phosphatidyltransferase activity, and positive regulation of serine C-palmitoyltransferase activity. It is predicted to be located in the endoplasmic reticulum membrane and plasma membrane and be active in the membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of SERINC1. However, recent studies have suggested that SERINC1 may play a role in the pathogenesis of HIV-1 infection. Specifically, it has been shown that SERINC1 inhibits the infectivity of HIV-1 virions by reducing the incorporation of viral envelope glycoproteins into the virion membrane. This has led to interest in targeting SERINC1 as a potential therapeutic strategy for HIV-1 infection. While there are currently no drugs on the market that specifically target SERINC1, there are ongoing efforts to develop small molecule inhibitors of SERINC1 that could be used as adjunct therapies for HIV-1 infection. These efforts are still in the early stages, and it remains to be seen whether targeting SERINC1 will be a viable strategy for treating HIV-1 infection.",GO:0006658 phosphatidylserine metabolic process;GO:0044091 membrane biogenesis;GO:0006665 sphingolipid metabolic process,,,Cytosol (Approved),,,(M5935)HALLMARK FATTY ACID METABOLISM
ENSG00000162521.19,ENSG00000162521,RBBP4,-0.981944266,-1.082133663,-1.557700963,-0.305998173,"RB binding protein 4, chromatin remodeling factor","RBBP4, or RB binding protein 4, is a nuclear protein that is present in protein complexes involved in histone acetylation and chromatin assembly. It is part of the Mi-2 complex, which is involved in chromatin remodeling and transcriptional repression associated with histone deacetylation. RBBP4 is also part of co-repressor complexes, which are integral components of transcriptional silencing. It binds directly to retinoblastoma protein to regulate cell proliferation and is involved in the transcriptional repression of E2F-responsive genes. There are three transcript variants encoding different isoforms of RBBP4.","RBBP4 has been implicated in several diseases, including cancer, neurodegenerative disorders, and developmental disorders. In cancer, RBBP4 has been shown to be overexpressed in several types of tumors, including breast, lung, and prostate cancer, and is associated with poor prognosis. Targeted drug discovery efforts have focused on developing inhibitors of the Mi-2 complex, which includes RBBP4, as a potential therapeutic strategy for cancer. One example of a successful drug targeting the Mi-2 complex is the histone deacetylase inhibitor romidepsin, which has been approved for the treatment of cutaneous T-cell lymphoma. However, there are currently no drugs specifically targeting RBBP4. In neurodegenerative disorders, RBBP4 has been shown to be involved in the regulation of neuronal gene expression and may play a role in the pathogenesis of diseases such as Alzheimer's and Huntington's disease. In developmental disorders, RBBP4 has been implicated in the regulation of embryonic stem cell differentiation and may be a potential target for regenerative medicine.",GO:0006335 DNA replication-dependent chromatin assembly;GO:0042659 regulation of cell fate specification;GO:1902455 negative regulation of stem cell population maintenance,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Enhanced),,(M219)PID HEDGEHOG GLI PATHWAY; (M279)PID RB 1PATHWAY; (M101)PID HDAC CLASSI PATHWAY,
ENSG00000188647.13,ENSG00000188647,PTAR1,-0.981456199,-1.543083037,-1.129317086,-0.271968473,protein prenyltransferase alpha subunit repeat containing 1,"PTAR1, or protein prenyltransferase alpha subunit repeat containing 1, is a gene that is predicted to enable protein prenyltransferase activity and be involved in protein prenylation. It is also predicted to be active in the cytoplasm. Prenylation is a process by which lipid molecules are added to proteins, which can affect their localization and function within cells. While the exact role of PTAR1 in prenylation is not yet fully understood, it is believed to play a role in this important cellular process. Further research is needed to fully elucidate the function of PTAR1 and its potential implications for human health and disease.","There is limited information available on the disease implications of PTAR1. However, prenylation has been implicated in various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. Therefore, PTAR1 may have potential implications in these diseases. 

There are currently no targeted drug discovery efforts specifically focused on PTAR1. However, there are drugs on the market that target prenylation, such as statins, which are commonly used to treat high cholesterol. Statins inhibit the enzyme HMG-CoA reductase, which is involved in the production of cholesterol and is also a precursor to the prenylation pathway. By inhibiting HMG-CoA reductase, statins indirectly inhibit prenylation. 

Another example of a drug that targets prenylation is zoledronic acid, which is used to treat bone disorders such as osteoporosis and bone metastases. Zoledronic acid inhibits the enzyme farnesyl pyrophosphate synthase, which is involved in the prenylation pathway. By inhibiting this enzyme, zoledronic acid can prevent the prenylation of proteins involved in bone resorption, leading to increased bone density. 

Overall, while there is limited information available on the specific implications of PTAR1 in disease and drug discovery efforts, prenylation has been implicated in various diseases and there are drugs on the market that target this pathway.",,,Predicted intracellular proteins,Centriolar satellite (Approved); Additional: Rods & Rings,,,
ENSG00000109790.16,ENSG00000109790,KLHL5,-0.981015675,-1.085439743,-0.889817536,-0.967789745,kelch like family member 5,"KLHL5, also known as kelch-like family member 5, is a human gene that is predicted to have actin binding activity and is located in the cytosol. The gene is involved in various cellular processes, including protein degradation and cytoskeletal organization. Mutations in KLHL5 have been associated with various disorders, including hereditary spastic paraplegia and intellectual disability. The gene is also implicated in the regulation of blood pressure and kidney function. Further research on KLHL5 may provide insights into the underlying mechanisms of these disorders and potential therapeutic targets.","Mutations in KLHL5 have been associated with various disorders, including hereditary spastic paraplegia and intellectual disability. In hereditary spastic paraplegia, mutations in KLHL5 lead to the degeneration of the long axons of the corticospinal tract, resulting in progressive spasticity and weakness of the lower limbs. In intellectual disability, mutations in KLHL5 have been linked to impaired cognitive function and developmental delay. 

There are currently no targeted drug discovery efforts specifically for KLHL5, but research on the gene's role in protein degradation and cytoskeletal organization may have implications for drug development in related areas. For example, drugs that target the ubiquitin-proteasome system, which is involved in protein degradation, have been developed for the treatment of cancer. Additionally, drugs that target the cytoskeleton, such as microtubule inhibitors, are used in the treatment of cancer and other diseases.

There are currently no drugs on the market that specifically target KLHL5. However, drugs that target related pathways, such as the ubiquitin-proteasome system and the cytoskeleton, have been successful in treating various diseases. For example, bortezomib, a proteasome inhibitor, is used in the treatment of multiple myeloma. Paclitaxel, a microtubule inhibitor, is used in the treatment of breast, ovarian, and lung cancers.",GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process;GO:0010498 proteasomal protein catabolic process;GO:0006511 ubiquitin-dependent protein catabolic process,,Predicted intracellular proteins,Microtubules;Plasma membrane (Approved),,,
ENSG00000134970.14,ENSG00000134970,TMED7,-0.980438421,-1.206886604,-0.785369451,-0.949059209,transmembrane p24 trafficking protein 7,"TMED7 is a human gene that encodes for a protein called transmembrane p24 trafficking protein 7. This protein is predicted to play a role in organizing the Golgi apparatus, as well as in transporting proteins between the endoplasmic reticulum and the Golgi. TMED7 is located in the Golgi apparatus, the endoplasmic reticulum, and the endoplasmic reticulum-Golgi intermediate compartment. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of TMED7. However, some studies have suggested that mutations in TMED7 may be associated with certain types of cancer, such as breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TMED7 are also limited, as the function of this protein is not fully understood. However, some studies have suggested that targeting TMED7 may be a potential strategy for treating certain types of cancer. Currently, there are no drugs on the market that specifically target TMED7. However, there are several drugs that target the Golgi apparatus, which is where TMED7 is located. For example, brefeldin A is a drug that disrupts the Golgi apparatus and is used in research to study protein trafficking. Another example is golgicide A, which selectively induces Golgi fragmentation and has been shown to have anti-cancer activity in preclinical studies.",GO:0006888 endoplasmic reticulum to Golgi vesicle-mediated transport;GO:0007030 Golgi organization;GO:0048193 Golgi vesicle transport,,Predicted intracellular proteins; Transporters,,,,
ENSG00000261512.2,ENSG00000261512,AC092368.3,-0.978772504,-0.990806235,-1.04790871,-0.897602567,None,None,None,None,None,None,None,None,None,None
ENSG00000118482.12,ENSG00000118482,PHF3,-0.978610278,-1.345622844,-0.951719216,-0.638488774,PHD finger protein 3,"PHF3, or PHD finger protein 3, is a gene that belongs to a family of genes that contain a PHD finger. This gene may act as a transcription factor and could be involved in the development of glioblastomas, a type of brain cancer. Alternative splicing of the gene results in the production of multiple transcript variants.","PHF3 has been implicated in the development of glioblastomas, a type of brain cancer. Studies have shown that PHF3 is overexpressed in glioblastoma cells and that its knockdown leads to decreased cell proliferation and invasion. Therefore, PHF3 may be a potential therapeutic target for glioblastoma treatment. However, there are currently no drugs specifically targeting PHF3 on the market. 

There have been efforts to develop drugs that target other proteins involved in glioblastoma, such as EGFR and VEGF. Examples of successful drugs on the market include bevacizumab, which targets VEGF and is used in combination with chemotherapy for the treatment of glioblastoma, and temozolomide, which is an alkylating agent used as a first-line treatment for glioblastoma. Other drugs in development for glioblastoma include immunotherapies and targeted therapies that aim to inhibit specific signaling pathways involved in tumor growth and survival.",GO:0006351 DNA-templated transcription;GO:0032774 RNA biosynthetic process;GO:0141187 nucleic acid biosynthetic process,,Predicted intracellular proteins,Nucleoplasm (Approved),,,(M5942)HALLMARK UV RESPONSE DN
ENSG00000116117.18,ENSG00000116117,PARD3B,-0.97762816,-1.66219131,-0.974403884,-0.296289287,par-3 family cell polarity regulator beta,"PARD3B is a human gene that is predicted to have phosphatidylinositol binding activity and is involved in various processes, including the establishment of cell polarity, centrosome localization, and maintenance of epithelial cell apical/basal polarity. It is located in cell junctions and is part of a protein-containing complex. The gene is a member of the par-3 family of cell polarity regulators and is essential for the proper functioning of cells. Understanding the role of PARD3B in cell polarity and other cellular processes may have implications for the development of therapies for diseases that involve disruptions in these processes.","There is limited information available on the disease implications of PARD3B. However, studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast and lung cancer. Targeted drug discovery efforts for PARD3B are currently limited, but there is potential for the development of drugs that target the protein complex in which PARD3B is involved. Currently, there are no drugs on the market that specifically target PARD3B. However, there are drugs that target other proteins involved in cell polarity, such as the PARP inhibitors used in cancer treatment. Further research is needed to fully understand the role of PARD3B in disease and to develop targeted therapies.",GO:0051660 establishment of centrosome localization;GO:0051642 centrosome localization;GO:0061842 microtubule organizing center localization,,Predicted intracellular proteins,Cell Junctions (Supported),,,
ENSG00000165118.15,ENSG00000165118,C9orf64,-0.977434026,-1.495850928,-1.330005711,-0.106445439,Q-nucleotide N-glycosylase 1,"C9orf64 is a human gene located on chromosome 9 and is predicted to be involved in tRNA-guanine transglycosylation. This process involves the modification of guanine nucleotides in transfer RNA (tRNA) molecules, which are essential for protein synthesis. However, the exact function of C9orf64 in this process is not yet fully understood. The gene has been identified through genomic sequencing and is currently being studied to determine its role in cellular processes and potential implications for human health.","There is currently limited information available on the disease implications of C9orf64. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast and lung cancer. Targeted drug discovery efforts for C9orf64 are also limited, as the exact function of the gene is not yet fully understood. However, some researchers are exploring the potential of targeting tRNA-guanine transglycosylation as a therapeutic strategy for cancer treatment. There are currently no drugs on the market that specifically target C9orf64, but there are several drugs that target tRNA modification pathways, such as tRNA synthetase inhibitors and anticancer drugs like methotrexate and 5-fluorouracil.",GO:0101030 tRNA-guanine transglycosylation;GO:0043174 nucleoside salvage;GO:0009163 nucleoside biosynthetic process,,Predicted intracellular proteins,Golgi apparatus (Approved),,,
ENSG00000047644.19,ENSG00000047644,WWC3,-0.976514954,-1.521781345,-0.955137113,-0.452626406,WWC family member 3,"WWC3 is a gene that belongs to the WWC family of proteins, which also includes WWC1 and WWC2. The protein encoded by WWC3 contains a C2 domain, which is responsible for homodimerization in WWC1. The function of WWC3 is not well understood, but it is believed to play a role in cell signaling and regulation. Mutations in WWC3 have been associated with various diseases, including cancer and intellectual disability. Further research is needed to fully understand the function and potential therapeutic applications of WWC3.","There is limited information available on the disease implications and targeted drug discovery efforts for WWC3. However, mutations in WWC3 have been associated with various diseases, including cancer and intellectual disability. In terms of drug discovery efforts, there are currently no drugs on the market that specifically target WWC3. However, there are drugs that target other proteins in the same signaling pathways as WWC3, such as the PI3K/AKT/mTOR pathway, which is involved in cell growth and survival. Examples of successful drugs that target this pathway include everolimus and temsirolimus, which are used to treat certain types of cancer. Further research is needed to determine the potential therapeutic applications of targeting WWC3 directly.",GO:0035329 hippo signaling;GO:0035331 negative regulation of hippo signaling;GO:0046621 negative regulation of organ growth,,Predicted intracellular proteins,Cytosol (Approved); Additional: Actin filaments,,,
ENSG00000144802.11,ENSG00000144802,NFKBIZ,-0.975097636,-1.863718848,-0.955575675,-0.105998385,NFKB inhibitor zeta,"NFKBIZ is a gene that belongs to the ankyrin-repeat family and is activated by lipopolysaccharide (LPS). The C-terminal portion of the gene shares a high sequence similarity with the I kappa B family of proteins, which are known to play a role in inflammatory responses to LPS by interacting with NF-B proteins through ankyrin-repeat domains. Studies in mice suggest that NFKBIZ is one of the nuclear I kappa B proteins and an activator of IL-6 production. The gene has two transcript variants that encode different isoforms. Overall, NFKBIZ plays a role in the immune response to LPS and inflammation.","Research has shown that NFKBIZ is involved in various diseases, including autoimmune disorders, cancer, and infectious diseases. In autoimmune disorders, such as rheumatoid arthritis and systemic lupus erythematosus, NFKBIZ has been found to be overexpressed, leading to increased inflammation. In cancer, NFKBIZ has been shown to promote tumor growth and metastasis. Targeted drug discovery efforts have focused on developing inhibitors of NFKBIZ to treat these diseases. One example is the drug TAK-659, which is currently in clinical trials for the treatment of autoimmune disorders. Another example is the drug bortezomib, which is approved for the treatment of multiple myeloma and inhibits NFKBIZ activity. Overall, targeting NFKBIZ has shown promise in the development of new therapies for various diseases.",GO:0032980 keratinocyte activation;GO:1990117 B cell receptor apoptotic signaling pathway;GO:0002317 plasma cell differentiation,,Transcription factors:Immunoglobulin fold; Predicted intracellular proteins,Nuclear speckles (Supported); Additional: Cytoplasmic bodies,,,(M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000102699.6,ENSG00000102699,PARP4,-0.975023042,-1.645089079,-1.038424604,-0.241555444,poly(ADP-ribose) polymerase family member 4,"PARP4 is a member of the poly(ADP-ribose) polymerase family and encodes for the poly(ADP-ribosyl)transferase-like 1 protein. This protein is capable of catalyzing a poly(ADP-ribosyl)ation reaction, but lacks an N-terminal DNA binding domain which activates the C-terminal catalytic domain of poly(ADP-ribosyl) transferase. Therefore, its transferase activity may be activated by other factors such as protein-protein interaction mediated by the extensive carboxyl terminus. PARP4 is not capable of binding DNA directly.","There is limited information available on the disease implications of PARP4. However, recent studies have suggested that PARP4 may play a role in cancer development and progression. Targeted drug discovery efforts have focused on developing PARP inhibitors, which have shown promise in treating cancers with defects in DNA repair pathways, such as BRCA-mutated breast and ovarian cancers. Olaparib, rucaparib, and niraparib are examples of PARP inhibitors that have been approved by the FDA for the treatment of certain types of cancer. However, these drugs do not specifically target PARP4 and their efficacy in PARP4-related cancers is unknown. Further research is needed to fully understand the role of PARP4 in disease and to develop targeted therapies for its potential implications.",GO:0009410 response to xenobiotic stimulus;GO:0006281 DNA repair;GO:0006954 inflammatory response,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000171103.11,ENSG00000171103,TRMT61B,-0.973462066,-0.929221914,-1.361748635,-0.629415648,tRNA methyltransferase 61B,"TRMT61B is a human gene that encodes for a protein called tRNA methyltransferase 61B. This protein is involved in several important biological processes, including mRNA methylation, mitochondrial tRNA methylation, and protein homooligomerization. Specifically, TRMT61B enables mRNA (adenine-N1-)-methyltransferase activity, rRNA (adenine) methyltransferase activity, and tRNA (adenine-N1-)-methyltransferase activity. The gene is located in the mitochondrion, which is an organelle responsible for producing energy in cells. Overall, TRMT61B plays a crucial role in regulating gene expression and protein synthesis, making it an important target for further research into various diseases and disorders.","There is limited information available on the disease implications of TRMT61B. However, recent studies have suggested that mutations in this gene may be associated with various neurological disorders, including autism spectrum disorder and intellectual disability. Targeted drug discovery efforts for TRMT61B are still in the early stages, but there is potential for the development of drugs that target the protein's methyltransferase activity. Currently, there are no drugs on the market that specifically target TRMT61B. However, there are drugs that target other methyltransferases, such as azacitidine, which is used to treat myelodysplastic syndrome and acute myeloid leukemia by inhibiting DNA methyltransferases. Further research into TRMT61B and its potential role in disease could lead to the development of new targeted therapies in the future.",GO:0090646 mitochondrial tRNA processing;GO:0000963 mitochondrial RNA processing;GO:0031167 rRNA methylation,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Uncertain),,,
ENSG00000171100.15,ENSG00000171100,MTM1,-0.973285667,-1.077494587,-1.123230645,-0.71913177,myotubularin 1,"MTM1, also known as myotubularin 1, is a gene that encodes a protein called a dual-specificity phosphatase. This protein is involved in the regulation of both phosphotyrosine and phosphoserine, and is necessary for the differentiation of muscle cells. Mutations in the MTM1 gene have been linked to X-linked myotubular myopathy, a rare genetic disorder that affects muscle function and can lead to severe muscle weakness and respiratory problems. Understanding the function of the MTM1 gene and its protein product is important for developing treatments for myotubular myopathy and other muscle-related disorders.","X-linked myotubular myopathy (XLMTM) is a rare genetic disorder caused by mutations in the MTM1 gene. The disease primarily affects males and is characterized by severe muscle weakness, respiratory problems, and developmental delays. There is currently no cure for XLMTM, and treatment options are limited to supportive care, such as respiratory support and physical therapy.

Targeted drug discovery efforts for XLMTM have focused on developing therapies that can restore the function of the MTM1 protein or compensate for its loss. One approach has been to use gene therapy to introduce a functional copy of the MTM1 gene into affected cells. Another approach has been to develop small molecule drugs that can activate or enhance the activity of the remaining MTM1 protein.

One example of a successful drug on the market for XLMTM is gene therapy with AAV8-MTM1, which has shown promising results in clinical trials. Another example is the small molecule drug tamoxifen, which has been shown to improve muscle function in animal models of XLMTM and is currently being evaluated in clinical trials. These targeted therapies offer hope for improving the quality of life for individuals with XLMTM and other muscle-related disorders.",GO:0048630 skeletal muscle tissue growth;GO:0048633 positive regulation of skeletal muscle tissue growth;GO:0048631 regulation of skeletal muscle tissue growth,,Human disease related genes:Musculoskeletal diseases:Muscular diseases; Predicted intracellular proteins; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Plasma membrane (Supported),,,
ENSG00000147065.17,ENSG00000147065,MSN,-0.972558259,-1.19113882,-1.22499965,-0.501536307,moesin,"Moesin is a human gene that belongs to the ERM family, which includes ezrin and radixin. ERM proteins act as cross-linkers between plasma membranes and actin-based cytoskeletons. Moesin is found in filopodia and other membranous protrusions that are crucial for cell-cell recognition, signaling, and movement. It is a membrane-organizing extension spike protein that plays a vital role in maintaining the structural integrity of cells. Moesin is essential for the proper functioning of various cellular processes, including cell division, migration, and adhesion. Its dysfunction has been linked to several diseases, including cancer and autoimmune disorders.","Moesin dysfunction has been implicated in several diseases, including cancer and autoimmune disorders. In cancer, moesin overexpression has been linked to tumor progression and metastasis. Targeting moesin has been proposed as a potential therapeutic strategy for cancer treatment. Several studies have identified small molecules that inhibit moesin activity and reduce cancer cell migration and invasion. However, no moesin-targeted drugs have been approved for clinical use yet. In autoimmune disorders, moesin has been implicated in the regulation of T cell activation and migration. Targeting moesin has been proposed as a potential therapeutic strategy for autoimmune disorders such as multiple sclerosis and rheumatoid arthritis. However, more research is needed to develop effective moesin-targeted drugs for these diseases.",GO:0070489 T cell aggregation;GO:0071593 lymphocyte aggregation;GO:0022614 membrane to membrane docking,,Disease related genes; Human disease related genes:Immune system diseases:Primary immunodeficiency; Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Plasma membrane (Enhanced),,(M41)PID ER NONGENOMIC PATHWAY; (M12)PID RHOA PATHWAY,(M5915)HALLMARK APICAL JUNCTION
ENSG00000132640.15,ENSG00000132640,BTBD3,-0.971300073,-1.262309085,-0.747065443,-0.904525691,BTB domain containing 3,"BTBD3 is a human gene that encodes a protein containing a BTB domain, which enables identical protein binding activity. It is predicted to play a role in cerebral cortex development and dendrite morphogenesis. The protein is also predicted to be located in the nucleus and active in the cytosol. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of BTBD3. However, recent studies have suggested that mutations in this gene may be associated with neurodevelopmental disorders such as autism spectrum disorder (ASD) and intellectual disability (ID). Targeted drug discovery efforts for BTBD3 are currently underway, with a focus on identifying small molecule inhibitors that can modulate the activity of the protein. While there are currently no drugs on the market that specifically target BTBD3, there are several drugs that have been approved for the treatment of ASD and ID, which may indirectly affect the activity of this protein. Examples include antipsychotics such as risperidone and aripiprazole, which are used to treat behavioral symptoms associated with ASD, and stimulants such as methylphenidate, which are used to treat attention deficit hyperactivity disorder (ADHD) commonly seen in individuals with ID.",GO:0048813 dendrite morphogenesis;GO:0016358 dendrite development;GO:0021987 cerebral cortex development,,Predicted intracellular proteins,Vesicles (Supported),,,(M5953)HALLMARK KRAS SIGNALING UP
ENSG00000196323.14,ENSG00000196323,ZBTB44,-0.971141627,-1.23686035,-1.282586926,-0.393977604,zinc finger and BTB domain containing 44,"ZBTB44 is a human gene that is predicted to have DNA binding and metal ion binding activity. It is also predicted to be located in the nucleus. The gene contains both zinc finger and BTB domains, which are common in transcription factors and are involved in regulating gene expression. However, the specific function of ZBTB44 is not yet fully understood.","There is limited information available on the disease implications of ZBTB44. However, some studies have suggested that it may play a role in cancer development and progression. For example, one study found that ZBTB44 expression was significantly decreased in breast cancer tissues compared to normal tissues, and that low ZBTB44 expression was associated with poor prognosis. 

As for targeted drug discovery efforts, there are currently no drugs specifically targeting ZBTB44. However, there are ongoing efforts to develop drugs that target other transcription factors with similar domains, such as the BTB-ZF family of transcription factors. 

Examples of successful drugs on the market that target transcription factors include tamoxifen, which targets the estrogen receptor in breast cancer, and imatinib, which targets the BCR-ABL fusion protein in chronic myeloid leukemia. However, it is important to note that these drugs target specific transcription factors with well-established roles in disease, and it is not yet clear if ZBTB44 will be a viable target for drug development.",,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000187239.17,ENSG00000187239,FNBP1,-0.970837175,-1.532544246,-0.670056522,-0.709910758,formin binding protein 1,"The human gene FNBP1 encodes for the formin-binding protein 1, which belongs to the formin-binding-protein family. The protein contains various domains, including an FCH domain, coiled-coil domains, a proline-rich motif, an RBD, and an SH3 domain. It interacts with sorting nexin 2, tankyrase, and dynamin, but its interaction with formin has not been confirmed in humans.","Research on FNBP1 has suggested its involvement in various diseases, including cancer, cardiovascular diseases, and neurological disorders. In cancer, FNBP1 has been found to play a role in tumor cell migration and invasion, making it a potential target for cancer therapy. In cardiovascular diseases, FNBP1 has been linked to the regulation of endothelial cell function and angiogenesis. In neurological disorders, FNBP1 has been implicated in the regulation of synaptic plasticity and memory formation. Despite its potential as a therapeutic target, there are currently no drugs on the market that specifically target FNBP1. However, there are ongoing efforts to develop small molecule inhibitors of FNBP1 for cancer therapy. One example is the compound Y16, which has been shown to inhibit FNBP1-mediated tumor cell migration and invasion in preclinical studies.",GO:0006897 endocytosis;GO:0098657 import into cell;GO:0016192 vesicle-mediated transport,,Disease related genes; Predicted intracellular proteins,Plasma membrane (Supported); Additional: Vesicles,,,
ENSG00000109686.19,ENSG00000109686,SH3D19,-0.97024872,-1.410512402,-1.116485247,-0.38374851,SH3 domain containing 19,"SH3D19 is a gene that encodes a protein containing multiple SH3 domains, which are involved in protein-protein interactions. The protein interacts with other proteins such as EBP and members of the ADAM family. It may play a role in suppressing cellular transformation induced by Ras and regulating ADAM proteins in the signaling of EGFR-ligand shedding. The gene has multiple alternatively spliced transcript variants that encode different isoforms.","There is limited information available on the disease implications of SH3D19. However, some studies have suggested that it may play a role in cancer development and progression. For example, one study found that SH3D19 expression was significantly decreased in breast cancer tissues compared to normal tissues, and that low expression of SH3D19 was associated with poor prognosis in breast cancer patients.

There are currently no targeted drug discovery efforts specifically focused on SH3D19. However, there are drugs on the market that target proteins that interact with SH3D19, such as EGFR and ADAM proteins. For example, the EGFR inhibitor erlotinib is used to treat non-small cell lung cancer and pancreatic cancer, and the ADAM inhibitor marimastat was tested in clinical trials for the treatment of cancer and arthritis.

Overall, more research is needed to fully understand the role of SH3D19 in disease and to develop targeted therapies for diseases associated with this gene.",GO:0051044 positive regulation of membrane protein ectodomain proteolysis;GO:0051043 regulation of membrane protein ectodomain proteolysis;GO:0045732 positive regulation of protein catabolic process,,Predicted intracellular proteins,Cytosol;Nucleoplasm (Supported),,,
ENSG00000127914.18,ENSG00000127914,AKAP9,-0.969751224,-1.459217967,-1.154801201,-0.295234505,A-kinase anchoring protein 9,"AKAP9 is a gene that encodes a member of the A-kinase anchoring protein (AKAP) family. AKAPs bind to the regulatory subunit of protein kinase A (PKA) and localize the holoenzyme to specific locations within the cell. Alternate splicing of AKAP9 results in at least two isoforms that are found in the centrosome and Golgi apparatus and interact with various signaling proteins from multiple signal transduction pathways. These signaling proteins include type II protein kinase A, serine/threonine kinase protein kinase N, protein phosphatase 1, protein phosphatase 2a, protein kinase C-epsilon, and phosphodiesterase 4D3.","AKAP9 has been implicated in several diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, AKAP9 has been shown to be overexpressed in several types of tumors, including breast, ovarian, and lung cancer, and is associated with poor prognosis. In cardiovascular disease, AKAP9 has been linked to cardiac hypertrophy and arrhythmias. In neurological disorders, AKAP9 has been associated with schizophrenia and bipolar disorder.

Targeted drug discovery efforts for AKAP9 have focused on developing small molecule inhibitors that disrupt the interaction between AKAP9 and its binding partners, such as PKA and protein phosphatase 1. These inhibitors have the potential to be used as cancer therapeutics or to treat cardiovascular and neurological disorders.

One example of a successful drug targeting AKAP9 is the cancer drug, volasertib. Volasertib is a small molecule inhibitor of polo-like kinase 1 (PLK1), which is a binding partner of AKAP9. Volasertib has been shown to be effective in treating acute myeloid leukemia (AML) in clinical trials. Another example is the cardiovascular drug, carvedilol, which has been shown to inhibit AKAP9-mediated cardiac hypertrophy in animal models.",GO:0051661 maintenance of centrosome location;GO:0098909 regulation of cardiac muscle cell action potential involved in regulation of contraction;GO:0051657 maintenance of organelle location,,Disease related genes; Cancer-related genes:Mutational cancer driver genes; Human disease related genes:Cardiovascular diseases:Cardiac diseases; Predicted intracellular proteins,Golgi apparatus (Enhanced); Additional: Centrosome;Vesicles,,,
ENSG00000149531.15,ENSG00000149531,FRG1BP,-0.969722018,-1.524862826,-1.241901349,-0.142401879,None,None,None,None,None,None,None,None,None,None
ENSG00000138593.9,ENSG00000138593,SECISBP2L,-0.969435019,-1.524182447,-0.790149481,-0.593973128,SECIS binding protein 2 like,"SECISBP2L is a human gene that encodes a protein called SECIS binding protein 2 like. This protein is involved in RNA binding activity and is predicted to play a role in selenocysteine incorporation. It is also predicted to be part of a ribonucleoprotein complex. The function of this gene is not fully understood, but it may be involved in regulating gene expression or protein synthesis. Further research is needed to fully understand the role of SECISBP2L in human biology.","There is limited information available on the disease implications of SECISBP2L. However, mutations in this gene have been associated with a rare genetic disorder called pontocerebellar hypoplasia type 2D (PCH2D). PCH2D is characterized by underdevelopment of the brainstem and cerebellum, leading to severe neurological symptoms such as muscle weakness, seizures, and developmental delays. 

There are currently no targeted drug discovery efforts specifically for SECISBP2L. However, drugs that target RNA binding proteins and ribonucleoprotein complexes may have potential therapeutic applications for diseases associated with SECISBP2L dysfunction. 

There are no drugs on the market that specifically target SECISBP2L. However, there are drugs that target RNA binding proteins and ribonucleoprotein complexes that have been successful in treating certain diseases. For example, Spinraza (nusinersen) is a drug that targets the survival motor neuron (SMN) protein, which is part of a ribonucleoprotein complex. Spinraza has been approved for the treatment of spinal muscular atrophy, a genetic disorder that affects the motor neurons in the spinal cord.",,,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000109929.10,ENSG00000109929,SC5D,-0.96788426,-1.298636233,-0.694549465,-0.910467082,sterol-C5-desaturase,"The SC5D gene encodes an enzyme involved in cholesterol biosynthesis. Specifically, it converts lathosterol into 7-dehydrocholesterol. Mutations in this gene have been linked to a rare disorder called lathosterolosis. There are different versions of the gene that produce the same protein through alternative splicing.","Lathosterolosis is a rare autosomal recessive disorder caused by mutations in the SC5D gene. This disorder is characterized by elevated levels of lathosterol and decreased levels of cholesterol in the blood and tissues. Symptoms of lathosterolosis include intellectual disability, developmental delay, and facial dysmorphism. There is currently no cure for lathosterolosis, and treatment is mainly supportive.

Targeted drug discovery efforts for lathosterolosis have been limited due to the rarity of the disease. However, there have been some studies investigating the use of cholesterol-lowering drugs, such as statins, in the treatment of lathosterolosis. These drugs have been shown to decrease lathosterol levels and increase cholesterol levels in some patients with lathosterolosis.

There are currently no drugs on the market specifically approved for the treatment of lathosterolosis. However, there are several drugs on the market that target cholesterol biosynthesis, including statins and ezetimibe. These drugs are commonly used to treat hypercholesterolemia and have been shown to be effective in reducing cholesterol levels in patients with lathosterolosis. Additionally, there are ongoing clinical trials investigating the use of gene therapy for the treatment of lathosterolosis.",GO:0033489 cholesterol biosynthetic process via desmosterol;GO:0033490 cholesterol biosynthetic process via lathosterol;GO:0110076 negative regulation of ferroptosis,,ENZYME proteins:Oxidoreductases; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Enzymes,Endoplasmic reticulum;Nucleoplasm (Approved); Additional: Cytosol;Plasma membrane,,,(M5892)HALLMARK CHOLESTEROL HOMEOSTASIS; (M5902)HALLMARK APOPTOSIS; (M5924)HALLMARK MTORC1 SIGNALING
ENSG00000123643.13,ENSG00000123643,SLC36A1,-0.967692295,-1.140490081,-0.472082957,-1.290503846,solute carrier family 36 member 1,SLC36A1 is a gene that encodes a protein belonging to the amino acid/auxin permease transporter family. This protein acts as a small amino acid transporter that is dependent on protons. The gene is located on chromosome 5q33.1 and is clustered with other related family members. Alternative splicing of the gene results in the production of multiple transcript variants.,"There is limited information available on the disease implications of SLC36A1. However, recent studies have suggested that mutations in this gene may be associated with autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). Targeted drug discovery efforts for SLC36A1 are also limited, but some studies have suggested that modulating the activity of this protein may have therapeutic potential for the treatment of certain neurological disorders. Currently, there are no drugs on the market that specifically target SLC36A1. However, there are drugs that target other members of the amino acid/auxin permease transporter family, such as the anti-cancer drug L-phenylalanine mustard, which targets SLC36A2. Further research is needed to fully understand the disease implications of SLC36A1 and to develop targeted therapies for related disorders.",GO:0015734 taurine transmembrane transport;GO:0042918 alkanesulfonate transmembrane transport;GO:0035524 proline transmembrane transport,,Transporters:Electrochemical Potential-driven transporters; Predicted intracellular proteins,,Alanine,,
ENSG00000124459.12,ENSG00000124459,ZNF45,-0.967284108,-1.112390081,-1.119429551,-0.670032692,zinc finger protein 45,"ZNF45 is a human gene that encodes for a zinc finger protein 45. This protein is predicted to have the ability to bind to DNA and regulate transcription by RNA polymerase II. It is specifically involved in binding to cis-regulatory regions of DNA and enabling transcription factor activity. ZNF45 is located in the nucleoplasm, which is the fluid inside the nucleus of a cell. Overall, this gene plays an important role in regulating gene expression and may have implications in various biological processes and diseases.","There is limited information available on the disease implications of ZNF45. However, some studies have suggested that this gene may be involved in the development and progression of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ZNF45 are also limited, as the function of this gene is not fully understood. However, some studies have suggested that targeting ZNF45 may be a potential therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target ZNF45. However, there are several drugs that target other proteins involved in the regulation of gene expression, such as histone deacetylases (HDACs) and DNA methyltransferases (DNMTs), which may indirectly affect ZNF45 activity. Examples of such drugs include Vorinostat, Romidepsin, and Azacitidine.",GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process;GO:0051252 regulation of RNA metabolic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000100647.8,ENSG00000100647,SUSD6,-0.966485583,-1.424713924,-1.14744793,-0.327294894,sushi domain containing 6,"SUSD6, or sushi domain containing 6, is a human gene that plays a role in cell death and the cellular response to DNA damage. It is predicted to be an integral component of the cell membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of SUSD6. However, some studies have suggested that alterations in SUSD6 expression may be associated with certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for SUSD6 are also limited, as the function of the gene is not yet fully understood. However, some studies have suggested that SUSD6 may be a potential therapeutic target for cancer treatment. Currently, there are no drugs on the market that specifically target SUSD6. However, there are several drugs that target other genes involved in cell death and DNA damage response pathways, which may have potential applications in the treatment of cancers associated with SUSD6 alterations. Examples of such drugs include PARP inhibitors, which target the PARP enzyme involved in DNA repair, and BCL-2 inhibitors, which target the BCL-2 protein involved in regulating cell death.",GO:0006974 DNA damage response;GO:0033554 cellular response to stress;GO:0006950 response to stress,,,Plasma membrane (Approved); Additional: Cytosol,,,
ENSG00000089048.14,ENSG00000089048,ESF1,-0.965791628,-1.026613965,-1.038939723,-0.831821197,ESF1 nucleolar pre-rRNA processing protein homolog,ESF1 is a human gene that encodes for a protein homologous to the nucleolar pre-rRNA processing protein. The protein is predicted to be involved in rRNA processing and has RNA binding activity. It is located in the extracellular space. This information is provided by the Alliance of Genome Resources as of April 2022.,"Unfortunately, there is currently no information available on disease implications or targeted drug discovery efforts for ESF1. As a relatively understudied gene, there is limited research on its potential role in disease and therapeutic applications. Additionally, there are no known drugs on the market that specifically target ESF1. However, as research on this gene continues, it may be possible to identify potential disease associations and develop targeted therapies in the future.",GO:0006364 rRNA processing;GO:0016072 rRNA metabolic process;GO:0042254 ribosome biogenesis,,Predicted intracellular proteins,Nucleoli;Nucleoplasm (Approved),,,
ENSG00000113712.19,ENSG00000113712,CSNK1A1,-0.965041241,-0.950391825,-0.81058008,-1.134151818,casein kinase 1 alpha 1,"CSNK1A1 is a human gene that encodes for a protein called casein kinase 1 alpha 1. This protein is involved in various processes, including the negative regulation of the canonical Wnt signaling pathway, peptidyl-serine phosphorylation, and the positive regulation of proteasomal ubiquitin-dependent protein catabolic process. It is located in the centrosome, cytosol, and nuclear speck and is part of the beta-catenin destruction complex. CSNK1A1 also colocalizes with keratin filament and mRNA cleavage and polyadenylation specificity factor complex. It is a biomarker of Alzheimer's disease and inclusion body myositis.","CSNK1A1 has been implicated in several diseases, including cancer, Alzheimer's disease, and inclusion body myositis. In cancer, CSNK1A1 has been shown to regulate the activity of several oncogenic proteins, including beta-catenin, c-Myc, and p53. Targeting CSNK1A1 has been proposed as a potential therapeutic strategy for cancer treatment. In Alzheimer's disease, CSNK1A1 has been found to be upregulated in the brains of patients, and its inhibition has been shown to improve cognitive function in animal models. Inclusion body myositis is a rare muscle disease that is characterized by the accumulation of abnormal proteins in muscle cells. CSNK1A1 has been identified as a potential biomarker for this disease. There are currently no drugs on the market that specifically target CSNK1A1, but several compounds that inhibit its activity are in preclinical development for cancer and Alzheimer's disease.",GO:1900226 negative regulation of NLRP3 inflammasome complex assembly;GO:0141086 negative regulation of inflammasome-mediated signaling pathway;GO:0035025 positive regulation of Rho protein signal transduction,yes,Kinases:CK1 Ser/Thr protein kinases; Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Supported),Fostamatinib,(M31)PID BETA CATENIN DEG PATHWAY; (M23)PID WNT NONCANONICAL PATHWAY; (M70)PID PS1 PATHWAY,
ENSG00000078403.17,ENSG00000078403,MLLT10,-0.964449229,-1.102541983,-1.126606005,-0.664199699,MLLT10 histone lysine methyltransferase DOT1L cofactor,"The human gene MLLT10 is a transcription factor that has been linked to various types of leukemia due to its involvement in chromosomal rearrangements. It acts as a cofactor for the DOT1L histone lysine methyltransferase, which plays a role in regulating gene expression. Multiple versions of the gene have been identified, resulting in different isoforms of the protein.","MLLT10 has been implicated in various types of leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Chromosomal rearrangements involving MLLT10 have been found in a subset of patients with AML, resulting in fusion proteins that drive leukemogenesis. Targeted drug discovery efforts have focused on developing inhibitors of the DOT1L-MLLT10 interaction, with the goal of disrupting the aberrant gene expression that drives leukemia. One example of a successful drug in this area is pinometostat (EPZ-5676), a small molecule inhibitor of DOT1L that has shown promising results in preclinical and early clinical trials for the treatment of MLL-rearranged leukemia. Another example is pevonedistat (MLN4924), a small molecule inhibitor of the NEDD8-activating enzyme that has shown activity against AML cells with MLL rearrangements, including those with MLLT10 fusions.",GO:0045944 positive regulation of transcription by RNA polymerase II;GO:0045893 positive regulation of DNA-templated transcription;GO:1902680 positive regulation of RNA biosynthetic process,,Disease related genes; Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,(M5951)HALLMARK SPERMATOGENESIS
ENSG00000141198.16,ENSG00000141198,TOM1L1,-0.963952329,-1.288926644,-1.273031036,-0.329899309,target of myb1 like 1 membrane trafficking protein,"TOM1L1 is a human gene that encodes for a membrane trafficking protein. It has clathrin binding and protein kinase binding activities and is involved in negative regulation of mitotic nuclear division, positive regulation of protein phosphorylation, and signal transduction. TOM1L1 is located in the cytosol and endosome.","There is limited information on the disease implications of TOM1L1. However, recent studies have suggested that TOM1L1 may play a role in the development and progression of certain cancers, including breast cancer and lung cancer. Targeted drug discovery efforts for TOM1L1 are still in the early stages, but there is potential for the development of drugs that target TOM1L1 to treat cancer. One example of a successful drug on the market that targets a similar protein is Herceptin, which targets the HER2 protein in breast cancer. However, more research is needed to fully understand the role of TOM1L1 in cancer and to develop effective targeted therapies.",GO:0031954 positive regulation of protein autophosphorylation;GO:0031952 regulation of protein autophosphorylation;GO:0043162 ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,,Predicted intracellular proteins,,,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000146376.11,ENSG00000146376,ARHGAP18,-0.963929775,-1.547614136,-0.701758945,-0.642416244,Rho GTPase activating protein 18,"ARHGAP18 is a human gene that belongs to a family of Rho GTPase-activating proteins. These proteins are involved in regulating cell signaling pathways. ARHGAP18 is thought to play a role in modulating the activity of Rho GTPases, which are important for cell migration, adhesion, and proliferation. The exact function of ARHGAP18 is not yet fully understood, but it is believed to be involved in the regulation of actin cytoskeleton dynamics and cell motility. Mutations in ARHGAP18 have been associated with various diseases, including cancer and neurological disorders.","There is limited information available on the disease implications of ARHGAP18. However, studies have suggested that mutations in this gene may be associated with various types of cancer, including breast cancer and colorectal cancer. Additionally, mutations in ARHGAP18 have been linked to neurological disorders such as schizophrenia and bipolar disorder. 

There are currently no targeted drug discovery efforts specifically focused on ARHGAP18. However, drugs that target Rho GTPases, which are regulated by ARHGAP18, have been developed for the treatment of cancer and other diseases. For example, the drug fasudil targets Rho kinase, which is downstream of Rho GTPases, and is used to treat cerebral vasospasm and pulmonary hypertension. Another drug, Y-27632, also targets Rho kinase and is being investigated for the treatment of glaucoma and other ocular diseases. 

Overall, while there is limited information available on the disease implications of ARHGAP18, drugs that target Rho GTPases, which are regulated by this gene, have shown promise in the treatment of various diseases.",GO:0030833 regulation of actin filament polymerization;GO:0008360 regulation of cell shape;GO:0008064 regulation of actin polymerization or depolymerization,,Predicted intracellular proteins,Cytosol (Supported); Additional: Nuclear speckles;Plasma membrane,,,
ENSG00000132294.15,ENSG00000132294,EFR3A,-0.962524375,-1.12361687,-1.003741151,-0.760215103,EFR3 homolog A,"The EFR3A gene encodes a protein that is involved in maintaining an active pool of phosphatidylinositol 4-kinase (PI4K) at the plasma membrane. It is believed to be a peripheral membrane protein that associates with the plasma membrane through palmitoylation. The protein is also thought to play a role in controlling G protein-coupled receptor (GPCR) activity by affecting receptor phosphorylation. Mutations in the EFR3A gene have been implicated in autism spectrum disorders, according to whole exome sequencing studies.","Mutations in the EFR3A gene have been associated with autism spectrum disorders, as mentioned earlier. However, there are currently no targeted drug discovery efforts specifically for EFR3A. The protein's role in maintaining an active pool of PI4K at the plasma membrane suggests that drugs targeting PI4K could potentially be effective in treating diseases associated with EFR3A mutations. PI4K inhibitors have been investigated as potential cancer therapeutics, as PI4K is involved in cell proliferation and survival. However, there are currently no PI4K inhibitors on the market. Successful drugs targeting GPCRs, which EFR3A is thought to affect, include beta blockers for hypertension and asthma, and antipsychotics for schizophrenia. However, these drugs do not directly target EFR3A and their efficacy in treating EFR3A-related disorders is unknown.",GO:0046854 phosphatidylinositol phosphate biosynthetic process;GO:0006661 phosphatidylinositol biosynthetic process;GO:0046488 phosphatidylinositol metabolic process,,Disease related genes; Predicted intracellular proteins,Cytosol;Plasma membrane (Supported),,,
ENSG00000167716.19,ENSG00000167716,WDR81,-0.962280669,-1.79839989,-0.59074347,-0.497698646,WD repeat domain 81,"WDR81 is a gene that encodes a transmembrane protein primarily expressed in the brain, involved in endolysosomal trafficking. Mutations in this gene are linked to an autosomal recessive syndrome called CAMRQ2, which is characterized by cerebellar ataxia, cognitive disability, and disequilibrium. The gene has multiple domains and produces different isoforms through alternative splicing.","CAMRQ2 is a rare genetic disorder caused by mutations in the WDR81 gene. The disease is characterized by cerebellar ataxia, cognitive disability, and disequilibrium. There is currently no cure for CAMRQ2, and treatment is mainly supportive. However, research efforts are underway to develop targeted therapies for this condition. One approach is to identify small molecules that can modulate the function of the WDR81 protein. Another strategy is to use gene therapy to correct the underlying genetic defect. While there are currently no drugs on the market specifically for CAMRQ2, there have been successful drug discoveries for other genetic disorders with similar symptoms. For example, Spinraza (nusinersen) is a drug approved for the treatment of spinal muscular atrophy, a genetic disorder that also affects the nervous system and causes muscle weakness and atrophy.",GO:0035973 aggrephagy;GO:0045022 early endosome to late endosome transport;GO:0098927 vesicle-mediated transport between endosomal compartments,,Disease related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol;Vesicles,,,
ENSG00000147162.14,ENSG00000147162,OGT,-0.962129106,-1.271274041,-0.59204617,-1.023067108,O-linked N-acetylglucosamine (GlcNAc) transferase,"OGT is a gene that encodes a glycosyltransferase enzyme responsible for adding a single N-acetylglucosamine molecule to serine or threonine residues in proteins. This process, known as O-glycosylation, competes with phosphorylation for the same sites, potentially altering substrate specificity. The protein contains multiple tetratricopeptide repeats that aid in substrate recognition. Alternative splicing of the gene produces distinct isoforms.","OGT has been implicated in several diseases, including cancer, diabetes, and neurodegenerative disorders. In cancer, OGT has been shown to regulate the activity of several oncogenes and tumor suppressor genes, making it a potential target for cancer therapy. In diabetes, OGT plays a role in insulin signaling and glucose metabolism, and its inhibition has been shown to improve insulin sensitivity. In neurodegenerative disorders, OGT has been linked to protein misfolding and aggregation, which are hallmarks of diseases such as Alzheimer's and Parkinson's.

Several drug discovery efforts have targeted OGT, with a focus on developing small molecule inhibitors. One such inhibitor, OSMI-1, has been shown to reduce O-GlcNAcylation levels in cells and improve insulin sensitivity in mice. Another inhibitor, OGTi, has been shown to reduce tumor growth in mouse models of breast cancer. However, these inhibitors are still in the early stages of development and have not yet been tested in humans.

There are currently no drugs on the market that directly target OGT, but some drugs indirectly affect O-GlcNAcylation levels. For example, metformin, a commonly used drug for type 2 diabetes, has been shown to reduce O-GlcNAcylation levels in cells. Additionally, some natural compounds, such as resveratrol and curcumin, have been shown to inhibit OGT activity and have potential therapeutic applications.",GO:0160076 negative regulation of non-canonical inflammasome complex assembly;GO:0000430 regulation of transcription from RNA polymerase II promoter by glucose;GO:0000432 positive regulation of transcription from RNA polymerase II promoter by glucose,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Nucleoplasm (Supported); Additional: Plasma membrane,,,
ENSG00000184602.6,ENSG00000184602,SNN,-0.961781124,-1.510552711,-0.67937255,-0.695418111,stannin,"The human gene SNN, also known as stannin, is involved in metal ion binding activity and is predicted to play a role in response to toxic substances. It is located in the cytoplasm and is an integral component of the membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of the SNN gene. However, some studies have suggested that mutations in this gene may be associated with neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. Targeted drug discovery efforts for SNN are also limited, as the function of this gene is not well understood. However, some studies have suggested that SNN may play a role in the response to toxic substances, which could potentially lead to the development of drugs targeting this pathway. Currently, there are no drugs on the market specifically targeting SNN. However, there are drugs on the market that target metal ion binding activity, which is a function of SNN. For example, chelation therapy drugs such as deferoxamine and deferasirox are used to treat iron overload disorders by binding to excess iron in the body.",GO:0009636 response to toxic substance;GO:0042221 response to chemical;GO:0050896 response to stimulus,,,Cytosol (Uncertain),,,(M5890)HALLMARK TNFA SIGNALING VIA NFKB; (M5956)HALLMARK KRAS SIGNALING DN
ENSG00000132466.19,ENSG00000132466,ANKRD17,-0.961493552,-1.153969249,-1.098205545,-0.63230586,ankyrin repeat domain 17,"ANKRD17 is a human gene that encodes a protein belonging to the family of ankyrin repeat-containing proteins. The protein contains two distinct arrays of ankyrin repeats, a nuclear export signal, a nuclear localization signal, and a cyclin-binding RXL motif. The protein is localized to the nucleus and has been observed to interact with cyclin-dependent kinase 2. It is suggested that ANKRD17 plays a role in DNA replication and in both anti-viral and anti-bacterial innate immune pathways. Alternative splicing results in multiple transcript variants encoding different isoforms.","There is limited information available on the disease implications of ANKRD17. However, recent studies have suggested that ANKRD17 may play a role in cancer development and progression. Specifically, ANKRD17 has been found to be overexpressed in several types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts for ANKRD17 are currently limited, as the exact function of the protein is not well understood. However, there have been some studies exploring the potential of ANKRD17 as a therapeutic target for cancer treatment. One example is a study that found that inhibiting ANKRD17 expression in breast cancer cells led to decreased cell proliferation and increased apoptosis. Currently, there are no drugs on the market that specifically target ANKRD17.",GO:1900245 positive regulation of MDA-5 signaling pathway;GO:0039533 regulation of MDA-5 signaling pathway;GO:0001955 blood vessel maturation,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nuclear membrane,,,
ENSG00000124275.15,ENSG00000124275,MTRR,-0.95942693,-1.118093003,-1.021226031,-0.738961756,5-methyltetrahydrofolate-homocysteine methyltransferase reductase,"The MTRR gene encodes an enzyme that belongs to the ferredoxin-NADP(+) reductase family and plays a crucial role in the synthesis of methionine by regenerating methionine synthase to a functional state. This enzyme is important for folate metabolism and cellular methylation as it facilitates methyl-group transfer by a folate donor. Mutations in the MTRR gene can lead to homocystinuria-megaloblastic anemia, cbl E type. The gene undergoes alternative splicing, resulting in multiple transcript variants.","Mutations in the MTRR gene have been associated with a range of diseases, including homocystinuria-megaloblastic anemia, cbl E type, which is characterized by elevated levels of homocysteine in the blood, megaloblastic anemia, and neurological symptoms. Targeted drug discovery efforts for MTRR have focused on developing drugs that can modulate the activity of the enzyme encoded by the gene. One example is the drug mecobalamin, which is a form of vitamin B12 that has been shown to improve symptoms in patients with MTRR mutations. Another example is betaine, which can act as a methyl donor and has been used to treat homocystinuria caused by MTRR mutations. Overall, the development of targeted therapies for MTRR-related diseases is an active area of research, and further advances in this field are expected in the coming years.",GO:1904041 regulation of cystathionine beta-synthase activity;GO:1904042 negative regulation of cystathionine beta-synthase activity;GO:0033353 S-adenosylmethionine cycle,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of amino acid metabolism; Human disease related genes:Other congenital disorders:Chromosomal abnormalities; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; ENZYME proteins:Oxidoreductases; Potential drug targets; Disease related genes; Enzymes,Cytosol;Nucleoplasm (Approved); Additional: Intermediate filaments,Cyanocobalamin; Methionine,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000101752.12,ENSG00000101752,MIB1,-0.959106751,-1.098281591,-1.080625308,-0.698413355,MIB E3 ubiquitin protein ligase 1,"MIB1 is a human gene that encodes a protein with ankyrin repeats and RING finger domains. This protein acts as an E3 ubiquitin ligase and plays a role in regulating Notch signaling by promoting the endocytosis of Notch receptors through ubiquitination. Additionally, MIB1 may also be involved in the degradation of death-associated protein kinase 1 (DAPK1).","Mutations in the MIB1 gene have been associated with several diseases, including Adams-Oliver syndrome, which is characterized by scalp defects and abnormalities of the limbs and cardiovascular system. Additionally, MIB1 has been implicated in the development and progression of various cancers, including breast, lung, and pancreatic cancer. As a result, there has been interest in developing drugs that target MIB1 as a potential cancer therapy. One example is the small molecule MIB-1 inhibitor, MI-2, which has been shown to inhibit the growth of breast cancer cells in vitro and in vivo. Another example is the drug, LY3039478, which is a selective inhibitor of MIB1 and has shown promising results in preclinical studies for the treatment of pancreatic cancer. However, further research is needed to fully understand the potential of MIB1 as a therapeutic target and to develop effective drugs for clinical use.",GO:0001756 somitogenesis;GO:0001947 heart looping;GO:0061371 determination of heart left/right asymmetry,,Predicted intracellular proteins; Human disease related genes:Cardiovascular diseases:Cardiac diseases; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Microtubules;Primary cilium (Approved); Additional: Basal body;Centriolar satellite;Mitotic spindle,,(M17)PID NOTCH PATHWAY,
ENSG00000136603.14,ENSG00000136603,SKIL,-0.958940029,-1.22151752,-0.925489693,-0.729812874,SKI like proto-oncogene,"The human gene SKIL is a component of the SMAD pathway, which regulates cell growth and differentiation through transforming growth factor-beta (TGFB). The protein encoded by this gene binds to the promoter region of TGFB-responsive genes and recruits a nuclear repressor complex in the absence of ligand. When TGFB signaling occurs, SMAD3 enters the nucleus and degrades the SKIL protein, allowing these genes to be activated. This gene has four transcript variants encoding three different isoforms. SKIL is a SKI like proto-oncogene, meaning it has the potential to cause cancer if mutated or overexpressed.","The SKIL gene has been implicated in various diseases, including cancer, fibrosis, and cardiovascular disease. In cancer, SKIL has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. Targeted drug discovery efforts have focused on developing inhibitors of the SMAD pathway, including SKIL. One example is the drug galunisertib, which inhibits the TGF-beta receptor and has shown promise in clinical trials for the treatment of liver cancer and pancreatic cancer. Another example is the drug pirfenidone, which targets the TGF-beta pathway and is approved for the treatment of idiopathic pulmonary fibrosis. These drugs demonstrate the potential of targeting the SMAD pathway, including SKIL, for the treatment of various diseases.",GO:1902231 positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage;GO:1902043 positive regulation of extrinsic apoptotic signaling pathway via death domain receptors;GO:0070306 lens fiber cell differentiation,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,(M286)PID TGFBR PATHWAY; (M2)PID SMAD2 3NUCLEAR PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING; (M5956)HALLMARK KRAS SIGNALING DN
ENSG00000166750.10,ENSG00000166750,SLFN5,-0.958413361,-1.692059468,-0.885364632,-0.297815984,schlafen family member 5,"SLFN5 is a human gene that is predicted to have ATP binding activity and be involved in cell differentiation. It is also predicted to be located in the nucleus. The gene belongs to the schlafen family, which is a group of genes that are involved in regulating cell growth and differentiation. While the exact function of SLFN5 is not yet fully understood, it is believed to play a role in the development and maintenance of various tissues in the body. Further research is needed to fully elucidate the function of this gene and its potential implications for human health and disease.","There is limited information available on the disease implications of SLFN5. However, recent studies have suggested that SLFN5 may play a role in cancer development and progression. Specifically, SLFN5 has been shown to be downregulated in various types of cancer, including breast, lung, and ovarian cancer. This downregulation has been associated with increased tumor growth and resistance to chemotherapy. As a result, SLFN5 has been identified as a potential target for cancer therapy.

Targeted drug discovery efforts for SLFN5 are still in the early stages. However, several studies have identified compounds that can upregulate SLFN5 expression in cancer cells, leading to increased sensitivity to chemotherapy. These compounds include histone deacetylase inhibitors and DNA methyltransferase inhibitors. Further research is needed to determine the efficacy and safety of these compounds in clinical trials.

There are currently no drugs on the market that specifically target SLFN5. However, several drugs that indirectly affect SLFN5 expression have been approved for cancer treatment. For example, the chemotherapy drug gemcitabine has been shown to upregulate SLFN5 expression in cancer cells, leading to increased sensitivity to chemotherapy. Similarly, the PARP inhibitor olaparib has been shown to upregulate SLFN5 expression in ovarian cancer cells, leading to increased sensitivity to chemotherapy.",GO:0030154 cell differentiation;GO:0048869 cellular developmental process;GO:0032502 developmental process,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Vesicles,,,
ENSG00000136068.15,ENSG00000136068,FLNB,-0.958214416,-1.321341531,-0.801776796,-0.75152492,filamin B,"FLNB, also known as filamin B, is a gene that belongs to the filamin family. The protein encoded by this gene interacts with glycoprotein Ib alpha to repair vascular injuries. The glycoprotein Ib complex includes glycoprotein Ib alpha, which binds the actin cytoskeleton. Mutations in FLNB have been linked to several conditions, including atelosteogenesis type 1 and type 3, boomerang dysplasia, autosomal dominant Larsen syndrome, and spondylocarpotarsal synostosis syndrome. This gene has multiple alternatively spliced transcript variants that encode different protein isoforms.","Mutations in the FLNB gene have been linked to several skeletal dysplasias, including atelosteogenesis type 1 and type 3, boomerang dysplasia, and autosomal dominant Larsen syndrome. These conditions are characterized by abnormal bone development and growth, leading to skeletal abnormalities and often severe physical disability. Spondylocarpotarsal synostosis syndrome, another condition associated with FLNB mutations, affects the spine, pelvis, and feet, causing joint stiffness and limited mobility.

Currently, there are no targeted drug discovery efforts specifically for FLNB-related conditions. Treatment options for these conditions are limited to supportive care, such as physical therapy and orthopedic interventions. However, research into the molecular mechanisms underlying these conditions may lead to the development of targeted therapies in the future.

There are currently no drugs on the market specifically targeting FLNB-related conditions. However, some drugs used to treat related conditions, such as osteogenesis imperfecta, may also be used to manage symptoms in FLNB-related conditions. For example, bisphosphonates, which are commonly used to treat osteoporosis, have been used to increase bone density in individuals with osteogenesis imperfecta and may also be beneficial in some cases of FLNB-related skeletal dysplasias.",GO:0003334 keratinocyte development;GO:0003382 epithelial cell morphogenesis;GO:0071346 cellular response to type II interferon,,Predicted intracellular proteins; Transporters:Accessory Factors Involved in Transport; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes,Plasma membrane (Supported); Additional: Actin filaments;Cytosol;Golgi apparatus,,,(M5893)HALLMARK MITOTIC SPINDLE; (M5906)HALLMARK ESTROGEN RESPONSE EARLY; (M5907)HALLMARK ESTROGEN RESPONSE LATE
ENSG00000137055.15,ENSG00000137055,PLAA,-0.956678005,-1.921862014,-0.675287751,-0.272884249,phospholipase A2 activating protein,"PLAA is a human gene that is predicted to have ubiquitin binding activity. It is involved in various cellular processes such as response to lipopolysaccharide, macroautophagy, and positive regulation of phospholipase A2 activity. PLAA is located in the cytoplasm, extracellular exosome, and nucleus.","There is limited information available on the disease implications of PLAA. However, recent studies have suggested that PLAA may play a role in the pathogenesis of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Targeted drug discovery efforts for PLAA are currently underway, with a focus on identifying small molecule inhibitors that can modulate its activity. While there are no drugs currently on the market that specifically target PLAA, there are several drugs that indirectly affect its activity. For example, nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen have been shown to inhibit phospholipase A2 activity, which is positively regulated by PLAA. Additionally, some studies have suggested that the anti-diabetic drug metformin may also modulate PLAA activity. However, further research is needed to fully understand the potential therapeutic implications of targeting PLAA.",GO:0032430 positive regulation of phospholipase A2 activity;GO:1900045 negative regulation of protein K63-linked ubiquitination;GO:0032429 regulation of phospholipase A2 activity,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Cytosol;Plasma membrane (Supported); Additional: Nucleoplasm,,,
ENSG00000120159.13,ENSG00000120159,CAAP1,-0.956326098,-2.130360387,-0.70679721,-0.031820695,caspase activity and apoptosis inhibitor 1,"CAAP1, also known as caspase activity and apoptosis inhibitor 1, is a human gene that plays a role in inhibiting the activity of cysteine-type endopeptidases involved in the apoptotic signaling pathway. This gene is involved in negative regulation of apoptosis, which is the process of programmed cell death that occurs in multicellular organisms. The function of CAAP1 is to prevent the activation of caspases, which are enzymes that play a key role in the initiation and execution of apoptosis. The gene is currently being studied for its potential therapeutic applications in cancer treatment, as well as its role in other diseases and conditions.","There is limited information available on the disease implications of CAAP1, but it has been suggested that dysregulation of this gene may contribute to the development and progression of certain types of cancer. As a result, there has been interest in developing drugs that target CAAP1 as a potential therapeutic strategy for cancer treatment. However, there are currently no drugs on the market that specifically target CAAP1. Some drugs that have been developed to target other components of the apoptotic signaling pathway, such as caspase inhibitors, have shown promise in preclinical and clinical studies for the treatment of various types of cancer. Further research is needed to fully understand the potential therapeutic applications of targeting CAAP1 in cancer and other diseases.",GO:2000117 negative regulation of cysteine-type endopeptidase activity;GO:0010951 negative regulation of endopeptidase activity;GO:0010466 negative regulation of peptidase activity,,Predicted intracellular proteins,Vesicles (Approved),,,
ENSG00000178996.14,ENSG00000178996,SNX18,-0.9561213,-1.051141828,-0.885632122,-0.931589949,sorting nexin 18,"SNX18 is a gene that belongs to the sorting nexin family and encodes a protein that contains a phosphoinositide binding domain called phox (PX) domain. This protein is involved in intracellular trafficking and does not contain a coiled coil region like some other family members, but instead contains a SH3 domain. Multiple transcript variants encoding different isoforms have been identified for this gene.","There is limited information available on the disease implications of SNX18. However, some studies have suggested that SNX18 may play a role in cancer progression and metastasis. Targeted drug discovery efforts for SNX18 are also limited, but some studies have identified potential small molecule inhibitors of SNX18 that could be used for cancer therapy. One example is a study that identified a compound called 3,4-dihydroxybenzaldehyde (DB) as a potential inhibitor of SNX18, which was found to inhibit cancer cell migration and invasion in vitro. However, there are currently no drugs on the market that specifically target SNX18.",GO:0036089 cleavage furrow formation;GO:0097320 plasma membrane tubulation;GO:2000786 positive regulation of autophagosome assembly,,Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000138764.15,ENSG00000138764,CCNG2,-0.953940243,-1.440862809,-0.875160985,-0.545796934,cyclin G2,"CCNG2, also known as cyclin G2, is a gene that plays a role in regulating the cell cycle in eukaryotic cells. It is a member of the cyclin family of proteins, which are involved in activating cyclin-dependent protein kinases (CDKs) that control cell division. Cyclin G2 is highly conserved among mammals and has a similar amino acid sequence to cyclin G1. However, cyclin G2 contains a protein destabilization motif that suggests its expression is tightly regulated during the cell cycle. The function of cyclin G2 is not fully understood, but it may play a role in cell growth and differentiation, as well as in the development of certain cancers.","Research has suggested that CCNG2 may play a role in the development and progression of certain cancers, including breast, lung, and liver cancer. Studies have shown that CCNG2 expression is often downregulated in cancer cells, and that restoring its expression can inhibit cancer cell growth and induce apoptosis. As a result, CCNG2 has been identified as a potential target for cancer therapy. However, there are currently no drugs on the market that specifically target CCNG2. Some drugs that have been successful in treating certain cancers, such as tamoxifen for breast cancer and gefitinib for lung cancer, indirectly affect CCNG2 expression by targeting other proteins in the same signaling pathways. Further research is needed to fully understand the role of CCNG2 in cancer and to develop targeted therapies.",GO:0000082 G1/S transition of mitotic cell cycle;GO:0044843 cell cycle G1/S phase transition;GO:0044772 mitotic cell cycle phase transition,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cytosol;Nucleoplasm (Approved),,,(M5891)HALLMARK HYPOXIA; (M5905)HALLMARK ADIPOGENESIS
ENSG00000072110.15,ENSG00000072110,ACTN1,-0.953823887,-1.498673131,-1.079399548,-0.283398983,actinin alpha 1,"ACTN1 is a gene that encodes for alpha actinin 1, a cytoskeletal protein that belongs to the spectrin gene superfamily. Alpha actinin 1 is an actin-binding protein that plays multiple roles in different cell types. In nonmuscle cells, it is found along microfilament bundles and adherens-type junctions, where it binds actin to the membrane. In skeletal, cardiac, and smooth muscle cells, it is localized to the Z-disc and analogous dense bodies, where it helps anchor the myofibrillar actin filaments. This gene encodes for a nonmuscle, cytoskeletal, alpha actinin isoform and maps to the same site as the structurally similar erythroid beta spectrin gene. Three transcript variants encoding different isoforms have been found for this gene.","Mutations in the ACTN1 gene have been associated with several diseases, including thrombocytopenia, myopathy, and cardiomyopathy. In particular, mutations in ACTN1 have been linked to familial platelet disorder with associated myeloid malignancy (FPDMM), a rare genetic disorder characterized by a predisposition to develop myeloid malignancies and bleeding disorders. Targeted drug discovery efforts for ACTN1-related diseases are still in the early stages, but some promising approaches include small molecule inhibitors of alpha actinin 1 and gene therapy to correct the underlying genetic mutations. Currently, there are no drugs on the market specifically targeting ACTN1-related diseases, but some drugs used to treat related conditions, such as thrombopoietin receptor agonists for thrombocytopenia, may be effective in some cases.",GO:0051639 actin filament network formation;GO:0030220 platelet formation;GO:0036344 platelet morphogenesis,,Disease related genes; FDA approved drug targets:Biotech drugs; Predicted intracellular proteins; Human disease related genes:Cardiovascular diseases:Hematologic diseases,Actin filaments;Focal adhesion sites;Plasma membrane (Approved); Additional: Cytosol;Primary cilium;Primary cilium transition zone,Human calcitonin; Copper,(M165)PID SYNDECAN 4 PATHWAY; (M232)PID ECADHERIN STABILIZATION PATHWAY; (M71)PID ILK PATHWAY,(M5908)HALLMARK ANDROGEN RESPONSE; (M5915)HALLMARK APICAL JUNCTION
ENSG00000147010.18,ENSG00000147010,SH3KBP1,-0.952870362,-1.620354621,-0.635356879,-0.602899587,SH3 domain containing kinase binding protein 1,"SH3KBP1 is a gene that encodes an adapter protein with several domains, including Src homology domains, a proline-rich region, and a coiled-coil domain. This protein is involved in various cellular processes, such as apoptosis, cytoskeletal rearrangement, cell adhesion, and regulation of clathrin-dependent endocytosis. It facilitates protein-protein interactions and has multiple transcript variants that encode different isoforms due to alternate splicing.","SH3KBP1 has been implicated in several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, SH3KBP1 has been shown to regulate cell proliferation, migration, and invasion, making it a potential target for cancer therapy. In neurodegenerative disorders, SH3KBP1 has been linked to the regulation of autophagy, a process that removes damaged proteins and organelles, and its dysfunction has been associated with the accumulation of toxic protein aggregates. In cardiovascular diseases, SH3KBP1 has been shown to regulate endothelial cell function and angiogenesis.

Several drug discovery efforts have targeted SH3KBP1, including small molecule inhibitors and RNA interference-based approaches. However, there are currently no drugs on the market that specifically target SH3KBP1. Nevertheless, some drugs that indirectly affect SH3KBP1 have been successful in treating diseases. For example, the cancer drug imatinib inhibits the activity of the tyrosine kinase BCR-ABL, which has been shown to upregulate SH3KBP1 expression. Additionally, the Alzheimer's drug memantine has been shown to induce autophagy by activating the AMPK/mTOR pathway, which indirectly affects SH3KBP1.",GO:0050871 positive regulation of B cell activation;GO:0050864 regulation of B cell activation;GO:0008360 regulation of cell shape,,Disease related genes; Human disease related genes:Immune system diseases:Primary immunodeficiency; Predicted intracellular proteins,Cytosol (Supported),,(M214)PID ERBB1 INTERNALIZATION PATHWAY; (M48)PID MET PATHWAY,
ENSG00000140575.13,ENSG00000140575,IQGAP1,-0.952579758,-1.445402495,-0.95093523,-0.461401547,IQ motif containing GTPase activating protein 1,IQGAP1 is a gene that encodes a protein belonging to the IQGAP family. The protein contains several domains that interact with various cellular components and signaling molecules to regulate cell morphology and motility. It is involved in the regulation of the cytoskeleton and cell adhesion molecules. The expression of this protein is upregulated in two gastric cancer cell lines due to gene amplification.,"IQGAP1 has been implicated in several diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, IQGAP1 has been shown to promote tumor growth and metastasis by regulating cell migration and invasion. Targeting IQGAP1 has been proposed as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of IQGAP1 have been developed, including CCG-1423 and IQM-13, which have shown promising results in preclinical studies. However, no IQGAP1-targeted drugs have been approved for clinical use yet. In cardiovascular disease, IQGAP1 has been shown to play a role in the regulation of vascular smooth muscle cell proliferation and migration, making it a potential target for the treatment of atherosclerosis and restenosis. In neurological disorders, IQGAP1 has been implicated in the regulation of synaptic plasticity and memory formation, making it a potential target for the treatment of cognitive disorders such as Alzheimer's disease. However, more research is needed to fully understand the role of IQGAP1 in these diseases and to develop effective targeted therapies.",GO:1902407 assembly of actomyosin apparatus involved in mitotic cytokinesis;GO:1903475 mitotic actomyosin contractile ring assembly;GO:1903479 mitotic actomyosin contractile ring assembly actin filament organization,,Predicted intracellular proteins,Cell Junctions;Plasma membrane (Supported),Artenimol,(M163)PID LIS1 PATHWAY; (M72)PID NECTIN PATHWAY; (M156)PID ECADHERIN NASCENT AJ PATHWAY,
ENSG00000122218.16,ENSG00000122218,COPA,-0.951925413,-1.56351351,-0.953091256,-0.339171472,COPI coat complex subunit alpha,"COPA, or COPI coat complex subunit alpha, is a gene that encodes for a protein involved in protein transport between the endoplasmic reticulum and Golgi compartments in eukaryotic cells. COPA is one of seven coat proteins that make up the coatomer complex, which mediates this transport. The alpha-COP subunit shares high sequence similarity with the alpha subunit of the coatomer complex in yeast. Additionally, the N-terminal 25 amino acids of alpha-COP encode the bioactive peptide, xenin, which stimulates exocrine pancreatic secretion and may act as a gastrointestinal hormone. Alternative splicing results in multiple splice forms encoding distinct isoforms.","Mutations in the COPA gene have been associated with a rare autoimmune disorder called autoimmune interstitial lung, joint, and kidney disease (AILJKD). AILJKD is characterized by inflammation and damage to the lungs, joints, and kidneys, leading to respiratory failure, arthritis, and renal failure. Targeted drug discovery efforts for AILJKD are currently underway, with a focus on identifying drugs that can modulate the immune response and reduce inflammation. One example is the use of rituximab, a monoclonal antibody that targets B cells, which has shown promise in treating AILJKD. Another example is the use of mycophenolate mofetil, an immunosuppressive drug that has been used to treat other autoimmune disorders and has shown some efficacy in AILJKD patients. However, more research is needed to fully understand the disease mechanisms and develop effective treatments for AILJKD.",GO:0030157 pancreatic juice secretion;GO:0032941 secretion by tissue;GO:0006891 intra-Golgi vesicle-mediated transport,,Disease related genes; Predicted secreted proteins; Human disease related genes:Immune system diseases:Allergies and autoimmune diseases; Predicted intracellular proteins,Cytosol;Nucleoplasm (Approved); Additional: Golgi apparatus,,(M243)PID ARF 3PATHWAY; (M195)PID CMYB PATHWAY,(M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000130150.12,ENSG00000130150,MOSPD2,-0.951331106,-1.042584068,-0.959145412,-0.852263837,motile sperm domain containing 2,"MOSPD2 is a human gene that plays a role in regulating the movement of immune cells such as monocytes and neutrophils towards sites of inflammation. It is located in the endoplasmic reticulum and endoplasmic reticulum-endosome membrane contact site, and is also an integral component of the plasma membrane. This gene is involved in positive regulation of monocyte and neutrophil chemotaxis, which is the process by which these immune cells are attracted to areas of tissue damage or infection.","Research on MOSPD2 and its disease implications is still in its early stages, but some studies have suggested that it may play a role in the development and progression of certain types of cancer, such as breast cancer and glioblastoma. Additionally, mutations in the MOSPD2 gene have been associated with an increased risk of developing autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target MOSPD2. However, researchers are exploring the potential of targeting this gene as a way to modulate immune cell migration and potentially treat inflammatory diseases and cancer. One study found that inhibiting MOSPD2 expression in breast cancer cells reduced their ability to migrate and invade surrounding tissues, suggesting that targeting this gene could be a promising approach for cancer therapy.

Overall, while more research is needed to fully understand the role of MOSPD2 in disease and develop targeted therapies, early studies suggest that this gene could be a promising target for drug discovery efforts in the future.",GO:0140042 lipid droplet formation;GO:0090026 positive regulation of monocyte chemotaxis;GO:0090023 positive regulation of neutrophil chemotaxis,,Predicted intracellular proteins,Endoplasmic reticulum (Supported),,,
ENSG00000005483.21,ENSG00000005483,KMT2E,-0.951281695,-1.288931143,-0.954570144,-0.610343799,lysine methyltransferase 2E (inactive),"KMT2E is a gene that belongs to the MLL family and encodes a protein with a PHD zinc finger and a SET domain. The protein is involved in regulating cell cycle progression, and overexpression of the protein inhibits this process. Different versions of the gene have been identified through alternate transcriptional splice variants. The gene is inactive, meaning that it is not currently being expressed or producing its protein product.","There is limited information available on the disease implications of KMT2E. However, mutations in other genes of the MLL family have been associated with various types of leukemia and other cancers. Therefore, it is possible that KMT2E mutations may also contribute to the development of cancer. 

As KMT2E is currently an inactive gene, there are no targeted drug discovery efforts or drugs on the market that specifically target this gene. However, there are drugs that target other members of the MLL family, such as DOT1L inhibitors for the treatment of acute leukemia. These drugs work by inhibiting the activity of the DOT1L protein, which is involved in the regulation of gene expression by the MLL family of proteins. 

In summary, while there is limited information available on the disease implications of KMT2E, it is possible that mutations in this gene may contribute to the development of cancer. Currently, there are no targeted drug discovery efforts or drugs on the market that specifically target KMT2E, but there are drugs that target other members of the MLL family for the treatment of leukemia.",GO:0002446 neutrophil mediated immunity;GO:0042119 neutrophil activation;GO:0036230 granulocyte activation,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nuclear bodies,,,
ENSG00000115760.14,ENSG00000115760,BIRC6,-0.951066724,-1.136199173,-0.981993689,-0.73500731,baculoviral IAP repeat containing 6,"BIRC6 is a human gene that encodes a protein with two domains: BIR and UBCc. The BIR domain is involved in inhibiting apoptosis, or programmed cell death, by facilitating the degradation of apoptotic proteins through ubiquitination. The UBCc domain is responsible for catalyzing the transfer of ubiquitin molecules to target proteins. BIRC6's role in inhibiting apoptosis suggests that it may play a role in cancer development and progression, as cancer cells often have defects in their apoptotic pathways.","BIRC6 has been implicated in various types of cancer, including breast, lung, ovarian, and pancreatic cancer. Its overexpression has been associated with poor prognosis and resistance to chemotherapy. Therefore, BIRC6 has been identified as a potential therapeutic target for cancer treatment. Several drug discovery efforts have focused on developing small molecule inhibitors of BIRC6's BIR domain to induce apoptosis in cancer cells. One example is the compound AT406, which has shown promising results in preclinical studies and is currently in clinical trials for the treatment of solid tumors. Another example is the compound TL32711, which has been approved by the FDA for the treatment of relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. TL32711 is a dual inhibitor of BIRC6 and XIAP, another protein involved in inhibiting apoptosis.",GO:0060711 labyrinthine layer development;GO:0001892 embryonic placenta development;GO:0032465 regulation of cytokinesis,,Enzymes; ENZYME proteins:Transferases; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Golgi apparatus;Vesicles (Supported); Additional: Mitotic spindle,,,
ENSG00000132356.11,ENSG00000132356,PRKAA1,-0.950462812,-1.070573333,-0.842495538,-0.938319566,protein kinase AMP-activated catalytic subunit alpha 1,"PRKAA1 is a gene that encodes for the catalytic subunit of the 5'-prime-AMP-activated protein kinase (AMPK), which is a cellular energy sensor found in all eukaryotic cells. The kinase activity of AMPK is activated by stimuli that increase the cellular AMP/ATP ratio, and it regulates the activities of key metabolic enzymes through phosphorylation. PRKAA1 protects cells from stresses that cause ATP depletion by switching off ATP-consuming biosynthetic pathways. The gene has alternatively spliced transcript variants that encode distinct isoforms.","PRKAA1 has been implicated in various diseases, including cancer, diabetes, and cardiovascular diseases. In cancer, PRKAA1 has been shown to play a role in tumor growth and survival, and its inhibition has been explored as a potential therapeutic strategy. In diabetes, PRKAA1 has been linked to glucose metabolism and insulin sensitivity, and its activation has been proposed as a potential treatment for type 2 diabetes. In cardiovascular diseases, PRKAA1 has been shown to regulate cardiac metabolism and function, and its activation has been explored as a potential therapy for heart failure.

Targeted drug discovery efforts for PRKAA1 have focused on developing small molecule inhibitors and activators of the kinase activity. Several compounds have been identified that can activate or inhibit PRKAA1, and some of these have been tested in preclinical and clinical studies. For example, metformin, a widely used drug for type 2 diabetes, has been shown to activate PRKAA1 and improve glucose metabolism. Another drug, AICAR, which is a synthetic activator of PRKAA1, has been shown to have cardioprotective effects in animal models of heart failure.

In summary, PRKAA1 is a promising target for drug discovery efforts in various diseases, including cancer, diabetes, and cardiovascular diseases. While there are currently no FDA-approved drugs that directly target PRKAA1, several compounds have shown promise in preclinical and clinical studies, and further research is needed to fully understand the therapeutic potential of targeting this gene.",GO:0046317 regulation of glucosylceramide biosynthetic process;GO:0046318 negative regulation of glucosylceramide biosynthetic process;GO:1903109 positive regulation of mitochondrial transcription,yes,Predicted intracellular proteins; ENZYME proteins:Transferases; FDA approved drug targets:Small molecule drugs; Kinases:CAMK Ser/Thr protein kinases; Enzymes,Nuclear speckles (Supported); Additional: Basal body;Cytosol;Primary cilium,Adenosine phosphate; ATP; Phenformin; Acetylsalicylic acid; Fostamatinib,(M87)PID LKB1 PATHWAY; (M237)PID VEGFR1 2 PATHWAY,
ENSG00000161999.13,ENSG00000161999,JMJD8,-0.949421057,-1.707555715,-1.136009908,-0.004697549,jumonji domain containing 8,"JMJD8, or jumonji domain containing 8, is a human gene that plays a role in various biological processes. It is involved in positively regulating the I-kappaB kinase/NF-kappaB signaling pathway, promoting sprouting angiogenesis, and regulating the glycolytic process. JMJD8 is located in both the endoplasmic reticulum lumen and nucleus.","There is limited information available on the disease implications of JMJD8. However, some studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for JMJD8 are also limited, but some studies have identified potential small molecule inhibitors that could target the protein. One example is a study that identified a compound called JIB-04, which was found to inhibit the activity of JMJD8 and other Jumonji domain-containing proteins. However, there are currently no drugs on the market that specifically target JMJD8. Overall, more research is needed to fully understand the disease implications of JMJD8 and to develop targeted therapies for diseases associated with this gene.",GO:1903302 regulation of pyruvate kinase activity;GO:1903672 positive regulation of sprouting angiogenesis;GO:0006110 regulation of glycolytic process,,Predicted intracellular proteins,,,,
ENSG00000033327.13,ENSG00000033327,GAB2,-0.949186685,-0.905080744,-0.757233343,-1.185245968,GRB2 associated binding protein 2,"GAB2 (GRB2-associated binding protein 2) is a gene that belongs to the GRB2-associated binding protein family. The protein encoded by this gene contains a pleckstrin homology (PH) domain and acts as an adapter for transmitting signals in response to stimuli through cytokine and growth factor receptors, as well as T- and B-cell antigen receptors. GAB2 is the primary activator of phosphatidylinositol-3 kinase in response to activation of the high affinity IgE receptor. Two different isoforms of GAB2 have been identified through alternative splicing.","GAB2 has been implicated in various diseases, including cancer, Alzheimer's disease, and schizophrenia. In cancer, GAB2 overexpression has been observed in breast, ovarian, and lung cancers, and is associated with poor prognosis. Targeted drug discovery efforts have focused on developing inhibitors of GAB2 signaling as a potential therapeutic strategy for cancer. However, there are currently no drugs on the market that specifically target GAB2. Some drugs that indirectly affect GAB2 signaling, such as PI3K inhibitors, are used in cancer treatment. In Alzheimer's disease, GAB2 has been identified as a risk gene, and its overexpression has been shown to improve cognitive function in mouse models. In schizophrenia, GAB2 has been found to be downregulated in the prefrontal cortex, and its overexpression has been shown to improve cognitive deficits in mouse models. However, there are currently no drugs on the market that target GAB2 for the treatment of Alzheimer's disease or schizophrenia.",GO:0043306 positive regulation of mast cell degranulation;GO:0043302 positive regulation of leukocyte degranulation;GO:0043304 regulation of mast cell degranulation,,Predicted intracellular proteins; RAS pathway related proteins,Plasma membrane (Supported),,(M182)PID IL3 PATHWAY; (M234)PID IL2 STAT5 PATHWAY; (M143)PID IL2 PI3K PATHWAY,(M5906)HALLMARK ESTROGEN RESPONSE EARLY
ENSG00000113838.13,ENSG00000113838,TBCCD1,-0.94903791,-1.215920016,-1.039489602,-0.591704111,TBCC domain containing 1,"TBCCD1, also known as TBCC domain containing 1, is a human gene that plays a role in maintaining the location of the Golgi and centrosomes, as well as regulating cell shape. It is located in the spindle pole centrosome. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of TBCCD1. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, such as breast cancer and glioblastoma. Targeted drug discovery efforts for TBCCD1 are also limited, as the function of this gene is not yet fully understood. However, some studies have suggested that targeting TBCCD1 may be a potential strategy for cancer therapy. Currently, there are no drugs on the market that specifically target TBCCD1. However, there are several drugs that target the centrosome and microtubule dynamics, which are related to the function of TBCCD1. Examples of such drugs include paclitaxel, vinblastine, and docetaxel, which are used in the treatment of various types of cancer.",GO:0051684 maintenance of Golgi location;GO:0051661 maintenance of centrosome location;GO:0051657 maintenance of organelle location,,Predicted intracellular proteins,,,,
ENSG00000165806.21,ENSG00000165806,CASP7,-0.947944044,-0.920771053,-0.894100396,-1.028960682,caspase 7,"CASP7, also known as caspase 7, is a gene that encodes a member of the caspase family of proteins. Caspases are enzymes that play a crucial role in the process of programmed cell death, or apoptosis. The CASP7 gene produces an inactive proenzyme that is activated by caspase 3 and 10 in response to cell death stimuli, leading to the induction of apoptosis. The protein produced by the CASP7 gene is cleaved into two subunits, large and small, which dimerize to form the active enzyme. Multiple isoforms of the protein have been observed due to alternative splicing of the gene.","The dysregulation of caspase 7 has been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In cancer, caspase 7 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. Targeted drug discovery efforts have focused on developing small molecule inhibitors of caspase 7, with some promising results in preclinical studies. However, no drugs targeting caspase 7 have been approved for clinical use yet. Some successful drugs on the market that target other caspases include caspofungin, which inhibits caspase 1 and is used to treat fungal infections, and pan-caspase inhibitors like emricasan, which are being investigated for their potential in treating liver diseases.",GO:1905686 positive regulation of plasma membrane repair;GO:0072733 response to staurosporine;GO:0072734 cellular response to staurosporine,,Predicted intracellular proteins; Peptidases:Cysteine-type peptidases; ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Nucleoli fibrillar center;Nucleoplasm (Approved); Additional: Plasma membrane,Fica; Emricasan; Incadronic acid,(M7997)SA CASPASE CASCADE; (M197)PID HIV NEF PATHWAY; (M239)PID A6B1 A6B4 INTEGRIN PATHWAY,(M5902)HALLMARK APOPTOSIS; (M5913)HALLMARK INTERFERON GAMMA RESPONSE; (M5921)HALLMARK COMPLEMENT
ENSG00000164889.15,ENSG00000164889,SLC4A2,-0.947620051,-1.37459499,-1.425650246,-0.042614916,solute carrier family 4 member 2,"SLC4A2 is a gene that encodes a membrane transport protein belonging to the anion exchanger family. This protein is responsible for regulating intracellular pH, biliary bicarbonate secretion, and chloride uptake. Reduced expression of SLC4A2 may be linked to primary biliary cirrhosis in humans, while differential expression of the gene may be associated with malignant hepatocellular carcinoma, colon, and gastric cancers.","There are currently no targeted drug discovery efforts specifically focused on SLC4A2. However, drugs that target ion transporters and channels, such as diuretics and antiarrhythmic agents, may indirectly affect the function of SLC4A2. Additionally, SLC4A2 has been implicated in several diseases, including primary biliary cirrhosis and various cancers, suggesting that targeting this gene may have therapeutic potential. However, more research is needed to fully understand the role of SLC4A2 in these diseases and to develop targeted therapies. There are currently no drugs on the market that specifically target SLC4A2.","GO:2000565 negative regulation of CD8-positive, alpha-beta T cell proliferation;GO:0043377 negative regulation of CD8-positive, alpha-beta T cell differentiation;GO:0070175 positive regulation of enamel mineralization",,Transporters:Electrochemical Potential-driven transporters; Predicted intracellular proteins,Nuclear speckles;Plasma membrane (Uncertain); Additional: Cytosol,,,
ENSG00000165832.6,ENSG00000165832,TRUB1,-0.946333725,-1.118991318,-1.099351894,-0.620657963,TruB pseudouridine synthase family member 1,"TRUB1 is a human gene that encodes for TruB pseudouridine synthase family member 1. This gene is responsible for the production of pseudouridine, which is a common component of rRNAs and tRNAs. Pseudouridine is generated through the isomerization of uridine by pseudouridine synthase. TRUB1 is a member of the TruB pseudouridine synthase family and is involved in the modification of RNA molecules. This gene is important for the proper functioning of RNA and may play a role in various biological processes.","There is limited information available on the disease implications of TRUB1. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for TRUB1 are still in the early stages, but there is potential for the development of drugs that target the pseudouridine synthase activity of this gene. One example of a successful drug that targets a related pseudouridine synthase is the antibiotic drug, tetracycline. Tetracycline inhibits the activity of bacterial pseudouridine synthases, leading to the disruption of protein synthesis and bacterial growth. However, further research is needed to identify potential drug targets and develop effective therapies for diseases associated with TRUB1 mutations.",GO:2000633 positive regulation of pre-miRNA processing;GO:1903800 positive regulation of miRNA processing;GO:2000631 regulation of pre-miRNA processing,,Enzymes; ENZYME proteins:Isomerase; Predicted intracellular proteins,Vesicles (Approved),,,
ENSG00000100439.10,ENSG00000100439,ABHD4,-0.945755963,-1.770911152,-0.642236364,-0.424120374,"abhydrolase domain containing 4, N-acyl phospholipase B","ABHD4 is a human gene that encodes a protein called abhydrolase domain containing 4, N-acyl phospholipase B. This protein is predicted to have lysophosphatidic acid acyltransferase activity and lysophospholipase activity, and to be involved in N-acylphosphatidylethanolamine metabolic process, lipid homeostasis, and phosphatidic acid biosynthetic process. It is also predicted to act upstream of or within N-acylethanolamine metabolic process. ABHD4 is predicted to be located in the endoplasmic reticulum membrane and to be active in lipid droplet and mitochondrion.","Research on ABHD4 has suggested its potential involvement in various diseases, including cancer, obesity, and neurodegenerative disorders. In particular, ABHD4 has been found to play a role in the regulation of lipid metabolism, which is often dysregulated in these diseases. As a result, ABHD4 has become a target for drug discovery efforts, with the aim of developing drugs that can modulate its activity and potentially treat these diseases. While there are currently no drugs on the market that specifically target ABHD4, there have been some promising preclinical studies using small molecule inhibitors of ABHD4 that have shown potential for the treatment of cancer and obesity. Further research is needed to fully understand the therapeutic potential of targeting ABHD4.",GO:0070292 N-acylphosphatidylethanolamine metabolic process;GO:0036152 phosphatidylethanolamine acyl-chain remodeling;GO:0046337 phosphatidylethanolamine metabolic process,,Enzymes; Peptidases:Serine-type peptidases; Predicted intracellular proteins,Nucleoplasm (Approved),,,(M5939)HALLMARK P53 PATHWAY
ENSG00000162736.17,ENSG00000162736,NCSTN,-0.945630722,-1.88308778,-0.769664634,-0.184139752,nicastrin,"NCSTN, also known as nicastrin, is a gene that encodes a glycoprotein that is a crucial component of the gamma-secretase complex. This complex is responsible for cleaving integral membrane proteins, including Notch receptors and beta-amyloid precursor protein. The cleavage of beta-amyloid precursor protein results in the production of amyloid beta peptide, which is the main component of the neuritic plaque found in the brains of Alzheimer's disease patients. NCSTN mutations are associated with familial acne inversa, but the gene's role in Alzheimer's disease is not fully understood. There are alternative spliced transcript variants of this gene, but their full-length nature is unknown.","NCSTN mutations have been linked to familial acne inversa, a chronic inflammatory skin disease characterized by painful nodules and abscesses in the axillary, inguinal, and anogenital regions. However, the role of NCSTN in Alzheimer's disease is still not fully understood. Targeting the gamma-secretase complex, including NCSTN, has been a focus of drug discovery efforts for Alzheimer's disease. However, the complex also plays a crucial role in other physiological processes, making it a challenging target for drug development. One example of a gamma-secretase inhibitor is semagacestat, which showed promising results in early clinical trials but was later discontinued due to adverse effects. Another example is avagacestat, which also showed potential in early trials but failed to demonstrate efficacy in later stages. Currently, there are no FDA-approved drugs targeting NCSTN or the gamma-secretase complex for Alzheimer's disease.",GO:0042983 amyloid precursor protein biosynthetic process;GO:1990926 short-term synaptic potentiation;GO:0042986 positive regulation of amyloid precursor protein biosynthetic process,,Disease related genes; Human disease related genes:Skin diseases:Skin and soft tissue diseases; Predicted intracellular proteins,Cytosol (Approved),,(M251)PID SYNDECAN 3 PATHWAY; (M70)PID PS1 PATHWAY; (M17)PID NOTCH PATHWAY,(M5895)HALLMARK WNT BETA CATENIN SIGNALING
ENSG00000144224.17,ENSG00000144224,UBXN4,-0.94549169,-1.22284531,-0.978217856,-0.635411904,UBX domain protein 4,UBXN4 is a human gene that encodes for UBX domain protein 4. This protein is involved in the process of ER-associated protein degradation (ERAD) by binding to valosin-containing protein (VCP). UBXN4 is an integral membrane protein of the endoplasmic reticulum (ER) and plays a crucial role in maintaining the quality control of proteins in the ER. The protein is essential for the proper functioning of the ER and any mutations or dysregulation of UBXN4 can lead to various diseases and disorders.,"There is limited information available on the disease implications of UBXN4 mutations. However, recent studies have suggested that dysregulation of UBXN4 may be associated with neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Targeted drug discovery efforts for UBXN4 are still in the early stages, but there is potential for the development of drugs that can modulate the protein's activity and prevent protein misfolding and aggregation in the ER. Currently, there are no drugs on the market that specifically target UBXN4, but there are drugs that target the ERAD pathway, such as bortezomib, which is used to treat multiple myeloma, and carfilzomib, which is used to treat relapsed or refractory multiple myeloma. These drugs work by inhibiting the proteasome, which is responsible for degrading misfolded proteins in the ER.",GO:0036503 ERAD pathway;GO:0006986 response to unfolded protein;GO:0035966 response to topologically incorrect protein,,Predicted intracellular proteins,Endoplasmic reticulum (Supported),,,
ENSG00000106799.13,ENSG00000106799,TGFBR1,-0.944886234,-1.015614512,-1.126971302,-0.692072888,transforming growth factor beta receptor 1,"TGFBR1 is a gene that encodes a protein that forms a complex with type II TGF-beta receptors, which transduces the TGF-beta signal from the cell surface to the cytoplasm. The protein is a serine/threonine protein kinase and mutations in this gene have been linked to Loeys-Dietz aortic aneurysm syndrome (LDAS). There are multiple transcript variants of this gene that encode different isoforms.","Mutations in the TGFBR1 gene have been linked to Loeys-Dietz aortic aneurysm syndrome (LDAS), an autosomal dominant disorder characterized by aortic aneurysms, arterial tortuosity, and other connective tissue abnormalities. LDAS is a rare disease, affecting approximately 1 in 10,000 individuals. There are currently no targeted drug therapies available for LDAS, and treatment is primarily focused on managing symptoms and preventing complications such as aortic dissection or rupture. However, research efforts are ongoing to identify potential drug targets and develop new therapies for this condition.

One potential drug target for LDAS is the TGF-beta signaling pathway, which is dysregulated in LDAS due to mutations in TGFBR1 and other genes. Several drugs that target this pathway are currently on the market for other indications, including the anti-cancer drugs nintedanib and sunitinib, which inhibit TGF-beta receptor signaling. However, these drugs have not yet been tested in clinical trials for LDAS, and their safety and efficacy in this context are unknown. Other potential drug targets for LDAS include the renin-angiotensin-aldosterone system, which is involved in regulating blood pressure and has been implicated in the pathogenesis of aortic aneurysms. Angiotensin receptor blockers (ARBs) such as losartan have shown promise in preclinical studies as a potential therapy for LDAS, and clinical trials are currently underway to evaluate their safety and efficacy in humans.",GO:1905223 epicardium morphogenesis;GO:0101023 vascular endothelial cell proliferation;GO:1905005 regulation of epithelial to mesenchymal transition involved in endocardial cushion formation,yes,Human disease related genes:Congenital malformations:Congenital malformations of the circulatory system; Predicted intracellular proteins; Kinases:TKL Ser/Thr protein kinases; Human disease related genes:Cancers:Cancers of the digestive system; ENZYME proteins:Transferases; Human disease related genes:Cardiovascular diseases:Vascular diseases; Potential drug targets; Disease related genes; Enzymes,Plasma membrane (Supported); Additional: Primary cilium,"4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline; Naphthyridine Inhibitor; 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole; N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide; 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine; N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine; Fostamatinib",(M212)PID INTEGRIN5 PATHWAY; (M185)PID ALK1 PATHWAY; (M33)PID GLYPICAN 1PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING
ENSG00000255142.1,ENSG00000255142,AP006621.2,-0.944780119,-1.247894755,-1.148473235,-0.437972367,None,None,None,None,None,None,None,None,None,None
ENSG00000166479.10,ENSG00000166479,TMX3,-0.944470224,-1.288561104,-0.890457212,-0.654392355,thioredoxin related transmembrane protein 3,"TMX3 is a gene that encodes a protein belonging to the disulfide isomerase family, which is responsible for catalyzing protein folding and thiol-disulfide interchange reactions in the endoplasmic reticulum. The protein encoded by this gene has an N-terminal ER-signal sequence, a catalytically active thioredoxin domain, one transmembrane domain, and a C-terminal ER-retention sequence. TMX3 is expressed in various tissues, with the highest expression in the heart and skeletal muscle. It is also expressed in the developing murine eye's retinal neuroepithelium and lens epithelium. Haploinsufficiency of this gene in humans and zebrafish is associated with microphthalmia. Alternative splicing results in multiple transcript variants encoding distinct isoforms.","There is limited information available on the disease implications of TMX3. However, haploinsufficiency of this gene has been associated with microphthalmia, a condition characterized by abnormally small eyes. Targeted drug discovery efforts for TMX3 are also limited, as the function of this protein is not well understood. There are currently no drugs on the market that specifically target TMX3. However, there are drugs that target other members of the disulfide isomerase family, such as the drug tunicamycin, which inhibits protein glycosylation by targeting the enzyme UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase. Additionally, the drug bortezomib, which is used to treat multiple myeloma, targets the proteasome and indirectly affects disulfide isomerase activity. Further research is needed to fully understand the role of TMX3 in disease and to develop targeted therapies.",,,Transporters:Accessory Factors Involved in Transport; Enzymes; ENZYME proteins:Isomerase; Predicted intracellular proteins,,,,
ENSG00000176994.11,ENSG00000176994,SMCR8,-0.944463209,-1.529685288,-0.904336079,-0.399368261,SMCR8-C9orf72 complex subunit,"SMCR8 is a human gene that encodes a subunit of the SMCR8-C9orf72 complex. This gene is involved in various cellular processes, including negative regulation of macromolecule metabolic process, regulation of TOR signaling, and regulation of macroautophagy. SMCR8 enables protein kinase binding activity and protein kinase inhibitor activity, and contributes to guanyl-nucleotide exchange factor activity. It is located in chromatin, cytoplasm, and nucleoplasm, and is part of the guanyl-nucleotide exchange factor complex. SMCR8 colocalizes with the Atg1/ULK1 kinase complex. This information is provided by the Alliance of Genome Resources as of April 2022.","Research on SMCR8 is still in its early stages, and there is limited information available on its disease implications and targeted drug discovery efforts. However, recent studies have suggested that mutations in SMCR8 may be associated with the development of neurological disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). In addition, SMCR8 has been identified as a potential therapeutic target for the treatment of cancer, as it plays a role in regulating the mTOR signaling pathway, which is often dysregulated in cancer cells. Currently, there are no drugs on the market that specifically target SMCR8, but ongoing research may lead to the development of novel therapies in the future.",GO:1901098 positive regulation of autophagosome maturation;GO:1902902 negative regulation of autophagosome assembly;GO:1901096 regulation of autophagosome maturation,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000178700.9,ENSG00000178700,DHFR2,-0.943801233,-1.397865069,-0.969902117,-0.463636512,dihydrofolate reductase 2,"DHFR2, or dihydrofolate reductase 2, is a human gene that plays a role in the metabolic processes of tetrahydrofolate and thymidine biosynthesis. It enables dihydrofolate reductase activity and mRNA binding activity. DHFR2 is located in the mitochondrial inner membrane and mitochondrial matrix.","There is limited information available on the disease implications of DHFR2. However, DHFR inhibitors have been used as chemotherapeutic agents for the treatment of cancer and autoimmune diseases. Methotrexate, a DHFR inhibitor, is commonly used to treat various types of cancer, including leukemia, lymphoma, and breast cancer. It is also used to treat autoimmune diseases such as rheumatoid arthritis and psoriasis. Another DHFR inhibitor, trimethoprim, is used to treat bacterial infections. Targeted drug discovery efforts for DHFR2 have focused on developing more potent and selective inhibitors for cancer treatment. One example is pemetrexed, a multi-targeted antifolate that inhibits DHFR, thymidylate synthase, and glycinamide ribonucleotide formyltransferase. Pemetrexed is used to treat non-small cell lung cancer and mesothelioma. Another example is raltitrexed, a DHFR inhibitor used to treat colorectal cancer.",GO:0046105 thymidine biosynthetic process;GO:0046120 deoxyribonucleoside biosynthetic process;GO:0046126 pyrimidine deoxyribonucleoside biosynthetic process,,Enzymes; ENZYME proteins:Oxidoreductases; Predicted intracellular proteins,Mitochondria (Supported),"5-Chloryl-2,4,6-Quinazolinetriamine; 5-[4-Tert-Butylphenylsulfanyl]-2,4-Quinazolinediamine; 5-(4-Morpholin-4-Yl-Phenylsulfanyl)-2,4-Quinazolinediamine; 5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine; 5-Phenylsulfanyl-2,4-Quinazolinediamine; 5-[(4-Methylphenyl)Sulfanyl]-2,4-Quinazolinediamine; 7-(1-ETHYL-PROPYL)-7H-PYRROLO-[3,2-F]QUINAZOLINE-1,3-DIAMINE; 7-[2-METHOXY-1-(METHOXYMETHYL)ETHYL]-7H-PYRROLO[3,2-F] QUINAZOLINE-1,3-DIAMINE; Epigallocatechin gallate",,
ENSG00000152601.17,ENSG00000152601,MBNL1,-0.943465003,-1.122047374,-0.876730449,-0.831617188,muscleblind like splicing regulator 1,"MBNL1 is a gene that encodes a protein belonging to the muscleblind family. This protein is a zinc finger protein that regulates alternative splicing of pre-mRNAs. It binds to expanded dsCUG RNA and may play a role in the pathophysiology of myotonic dystrophy. Mice lacking this gene exhibit muscle abnormalities and cataracts. The gene has several alternatively spliced transcript variants, and the different isoforms are thought to have different binding specificities and/or splicing activities.","Myotonic dystrophy (DM) is a genetic disorder caused by the expansion of CTG or CCTG repeats in the 3' untranslated region of the DMPK or ZNF9 genes, respectively. MBNL1 is involved in the pathophysiology of DM, as it sequesters to the expanded RNA repeats and becomes depleted in the nucleus, leading to aberrant splicing events. Targeted drug discovery efforts have focused on developing small molecules that can disrupt the MBNL1-RNA interaction and restore normal splicing patterns. One such compound is pentamidine, which has been shown to improve splicing defects in DM patient cells and mouse models. Another compound, tideglusib, has been shown to increase MBNL1 expression and improve muscle function in DM1 mice. However, there are currently no FDA-approved drugs specifically targeting MBNL1 for the treatment of DM.",GO:0045445 myoblast differentiation;GO:0030326 embryonic limb morphogenesis;GO:0035113 embryonic appendage morphogenesis,,Disease related genes; Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Cytosol,,,
ENSG00000168297.16,ENSG00000168297,PXK,-0.94322801,-1.412413062,-1.169524644,-0.247746325,PX domain containing serine/threonine kinase like,"The human gene PXK encodes a protein containing a PX domain, which may play a role in synaptic transmission and the degradation of epidermal growth factors. Variations in this gene have been linked to an increased susceptibility to systemic lupus erythematosus (SLE). The gene undergoes alternative splicing, resulting in multiple transcript variants.","Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects multiple organs and tissues. Variations in the PXK gene have been associated with an increased risk of developing SLE. The exact mechanism by which PXK contributes to the development of SLE is not fully understood, but it is thought to be involved in the regulation of immune responses. 

There are currently no drugs specifically targeting PXK for the treatment of SLE. However, there are several drugs on the market that are used to treat SLE by targeting the immune system. These include corticosteroids, immunosuppressants, and biologic agents such as rituximab and belimumab. 

Efforts to discover new drugs for the treatment of SLE are ongoing, and PXK is one of the genes being investigated as a potential target. One study found that inhibiting PXK expression in immune cells reduced the production of inflammatory cytokines, suggesting that targeting PXK could be a promising approach for the treatment of SLE. 

In summary, variations in the PXK gene have been linked to an increased susceptibility to SLE, and while there are currently no drugs targeting PXK specifically, it is being investigated as a potential target for the development of new treatments for SLE.",GO:0032780 negative regulation of ATP-dependent activity;GO:0043462 regulation of ATP-dependent activity;GO:0043271 negative regulation of monoatomic ion transport,yes,Enzymes; Predicted intracellular proteins; Kinases,Cytosol (Supported); Additional: Centriolar satellite;Plasma membrane,,,
ENSG00000166188.2,ENSG00000166188,ZNF319,-0.942895493,-1.830325056,-0.805596683,-0.192764739,zinc finger protein 319,"ZNF319 is a human gene that encodes for a protein called zinc finger protein 319. This protein is predicted to have the ability to bind to DNA and activate transcription, specifically for RNA polymerase II and cis-regulatory regions. It is also predicted to play a role in regulating transcription by RNA polymerase II and is active in the nucleus.","There is limited information available on the disease implications of ZNF319. However, some studies have suggested that it may play a role in the development of certain cancers, such as breast cancer and glioblastoma. Targeted drug discovery efforts for ZNF319 are also limited, as its function and role in disease are not well understood. Currently, there are no drugs on the market that specifically target ZNF319. However, there are drugs that target other proteins involved in the same pathways as ZNF319, such as inhibitors of RNA polymerase II and transcription factors. Examples of successful drugs in this category include actinomycin D, which inhibits RNA polymerase II, and tamoxifen, which targets the estrogen receptor in breast cancer cells.",GO:0045944 positive regulation of transcription by RNA polymerase II;GO:0045893 positive regulation of DNA-templated transcription;GO:1902680 positive regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000256771.4,ENSG00000256771,ZNF253,-0.941809247,-1.529060401,-0.843553816,-0.452813523,zinc finger protein 253,"ZNF253 is a human gene that encodes for a protein called zinc finger protein 253. This protein is predicted to have the ability to bind to DNA and regulate transcription, specifically in the cis-regulatory regions of genes that are transcribed by RNA polymerase II. ZNF253 is also predicted to be located in the nucleus of cells.","There is limited information available on the disease implications of ZNF253. However, some studies have suggested that alterations in the expression of this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target ZNF253. However, there are ongoing efforts to develop drugs that target other zinc finger proteins, which may have similar functions to ZNF253. For example, the drug Veliparib targets the zinc finger protein PARP1 and is used in the treatment of ovarian and breast cancer. Another example is the drug Olaparib, which also targets PARP1 and is used in the treatment of ovarian and breast cancer. Overall, more research is needed to fully understand the disease implications of ZNF253 and to develop targeted drugs for its potential therapeutic applications.",GO:0045892 negative regulation of DNA-templated transcription;GO:1902679 negative regulation of RNA biosynthetic process;GO:0051253 negative regulation of RNA metabolic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,,,,
ENSG00000184481.17,ENSG00000184481,FOXO4,-0.941572391,-1.940807393,-0.729937368,-0.153972412,forkhead box O4,"FOXO4 is a gene that belongs to the O class of winged helix/forkhead transcription factor family. This gene is regulated by factors involved in growth and differentiation, indicating that it plays a role in these processes. A translocation involving FOXO4 and a DNA binding protein gene located on chromosome 11 is associated with leukemia. Multiple transcript variants encoding different isoforms have been found for this gene.","FOXO4 has been implicated in various diseases, including cancer, diabetes, and neurodegenerative disorders. In cancer, FOXO4 has been shown to act as a tumor suppressor by inducing cell cycle arrest and apoptosis. Targeting FOXO4 has been explored as a potential therapeutic strategy for cancer treatment. For example, a small molecule inhibitor of FOXO4, called AS1842856, has been shown to sensitize cancer cells to chemotherapy and radiation therapy. In diabetes, FOXO4 has been shown to play a role in insulin resistance and beta-cell dysfunction. Targeting FOXO4 has been explored as a potential therapeutic strategy for diabetes treatment. For example, a small molecule inhibitor of FOXO4, called AS1708727, has been shown to improve glucose tolerance and insulin sensitivity in diabetic mice. In neurodegenerative disorders, FOXO4 has been shown to play a role in neuronal apoptosis and oxidative stress. Targeting FOXO4 has been explored as a potential therapeutic strategy for neurodegenerative disorders. However, there are currently no drugs targeting FOXO4 approved for clinical use.",GO:1990785 response to water-immersion restraint stress;GO:0070317 negative regulation of G0 to G1 transition;GO:0051151 negative regulation of smooth muscle cell differentiation,,Predicted intracellular proteins; Transcription factors:Helix-turn-helix domains; Cancer-related genes; Disease related genes; RAS pathway related proteins,Nuclear speckles (Supported); Additional: Cytosol,,(M32)PID HDAC CLASSIII PATHWAY; (M249)PID PI3KCI AKT PATHWAY; (M136)PID FOXO PATHWAY,(M5909)HALLMARK MYOGENESIS
ENSG00000005339.15,ENSG00000005339,CREBBP,-0.941502252,-1.481390789,-0.724677471,-0.618438496,CREB binding protein,"The CREBBP gene, also known as CREB binding protein, is expressed throughout the body and plays a crucial role in embryonic development, growth control, and homeostasis. It acts as a transcriptional coactivator for many different transcription factors and has intrinsic histone acetyltransferase activity. The protein encoded by this gene also acts as a scaffold to stabilize additional protein interactions with the transcription complex and acetylates both histone and non-histone proteins. Mutations in this gene can cause Rubinstein-Taybi syndrome, while chromosomal translocations involving this gene have been associated with acute myeloid leukemia. Alternative splicing results in multiple transcript variants encoding different isoforms.","Mutations in the CREBBP gene have been linked to Rubinstein-Taybi syndrome, a rare genetic disorder characterized by intellectual disability, distinctive facial features, and broad thumbs and toes. Targeted drug discovery efforts have focused on developing small molecule inhibitors of the histone acetyltransferase activity of CREBBP as a potential treatment for acute myeloid leukemia, which is associated with chromosomal translocations involving this gene. One example of a successful drug targeting CREBBP is IACS-9571, a selective inhibitor of the histone acetyltransferase activity of CREBBP that has shown promising results in preclinical studies for the treatment of acute myeloid leukemia. Another example is ABBV-744, a small molecule inhibitor of both CREBBP and its paralog EP300 that is currently in clinical trials for the treatment of relapsed or refractory non-Hodgkin lymphoma and solid tumors.",GO:0018076 N-terminal peptidyl-lysine acetylation;GO:0016479 negative regulation of transcription by RNA polymerase I;GO:0006474 N-terminal protein amino acid acetylation,,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Enhanced); Additional: Nuclear bodies,"9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE",(M32)PID HDAC CLASSIII PATHWAY; (M207)PID RETINOIC ACID PATHWAY; (M290)PID IL12 STAT4 PATHWAY,(M5902)HALLMARK APOPTOSIS
ENSG00000105355.9,ENSG00000105355,PLIN3,-0.94149266,-1.719778891,-1.073534063,-0.031165027,perilipin 3,"Perilipin 3, also known as PLIN3, is a human gene that plays a role in the transport of lysosomal hydrolase from the Golgi to endosomes and back to the Golgi complex. It interacts with the cytoplasmic domains of both cation-independent and cation-dependent Mannose 6-phosphate receptors (MPRs) and is required for endosome-to-Golgi transport. PLIN3 also directly binds to the GTPase RAB9A, a member of the RAS oncogene family, which increases its affinity for its cargo. Multiple transcript variants encoding different isoforms have been identified for this gene.","Research on PLIN3 has revealed its potential involvement in various diseases, including obesity, type 2 diabetes, and cancer. Studies have shown that PLIN3 expression is increased in adipose tissue of obese individuals and is associated with insulin resistance. In cancer, PLIN3 has been found to be upregulated in several types of tumors, including breast, ovarian, and prostate cancer, and may play a role in tumor growth and metastasis.

Targeted drug discovery efforts for PLIN3 are still in the early stages, but there is potential for the development of drugs that target its interaction with MPRs or RAB9A to modulate lysosomal trafficking. Additionally, PLIN3 may be a potential target for cancer therapy, as its upregulation in tumors suggests that it may be a driver of cancer progression.

Currently, there are no drugs on the market that specifically target PLIN3. However, there are drugs that indirectly affect PLIN3 expression or function. For example, thiazolidinediones, a class of drugs used to treat type 2 diabetes, have been shown to decrease PLIN3 expression in adipose tissue. Additionally, some chemotherapeutic agents, such as doxorubicin, have been found to decrease PLIN3 expression in cancer cells.",GO:1905691 lipid droplet disassembly;GO:0010890 positive regulation of sequestering of triglyceride;GO:0010889 regulation of sequestering of triglyceride,,FDA approved drug targets:Biotech drugs; Predicted intracellular proteins,Lipid droplets (Supported),Idursulfase; Galsulfase,,
ENSG00000148841.17,ENSG00000148841,ITPRIP,-0.940471669,-1.450829395,-0.969143167,-0.401442445,"inositol 1,4,5-trisphosphate receptor interacting protein","ITPRIP is a gene that encodes a protein that is associated with the cell membrane and interacts with the inositol 1,4,5-trisphosphate receptor (ITPR). This protein enhances the sensitivity of ITPR to intracellular calcium signaling, which is important for various cellular processes. Alternative splicing of the gene results in multiple transcript variants.","ITPRIP has been implicated in various diseases, including cancer, cardiovascular diseases, and neurological disorders. In cancer, ITPRIP has been shown to promote tumor growth and metastasis by enhancing calcium signaling. In cardiovascular diseases, ITPRIP has been linked to hypertension and heart failure. In neurological disorders, ITPRIP has been associated with Alzheimer's disease and epilepsy.

Targeted drug discovery efforts for ITPRIP are still in the early stages, but there is potential for developing drugs that target the protein's interaction with ITPR and modulate intracellular calcium signaling. One example of a successful drug that targets calcium signaling is verapamil, which is used to treat hypertension and angina by blocking calcium channels.

Another example is dantrolene, which is used to treat malignant hyperthermia and neuroleptic malignant syndrome by inhibiting calcium release from the sarcoplasmic reticulum. While these drugs do not directly target ITPRIP, they demonstrate the potential for developing drugs that modulate calcium signaling pathways.

Overall, further research is needed to fully understand the role of ITPRIP in disease and to develop targeted therapies.",GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors;GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors;GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors,,,Vesicles (Uncertain),,,
ENSG00000181904.9,ENSG00000181904,C5orf24,-0.94040937,-1.150450189,-0.85675426,-0.814023661,chromosome 5 open reading frame 24,"Human gene C5orf24, also known as chromosome 5 open reading frame 24, is a protein-coding gene located on chromosome 5. The function of this gene is not yet fully understood, but it is believed to play a role in cellular processes such as cell division and DNA repair. Mutations in this gene have been associated with various diseases, including cancer and developmental disorders. Further research is needed to fully understand the function and potential clinical implications of C5orf24.","There is limited information available on the disease implications and targeted drug discovery efforts for C5orf24. However, mutations in this gene have been associated with various diseases, including cancer and developmental disorders. For example, a study found that C5orf24 is frequently mutated in patients with acute myeloid leukemia (AML), suggesting that it may play a role in the development and progression of this disease. 

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target C5orf24. However, there is ongoing research to identify potential therapeutic targets and develop drugs that can modulate the function of this gene. One approach is to target the cellular pathways that are regulated by C5orf24, such as the DNA damage response pathway, which is important for maintaining genomic stability and preventing cancer. 

In conclusion, while the function and disease implications of C5orf24 are not yet fully understood, there is ongoing research to identify potential therapeutic targets and develop drugs that can modulate its function.",,,Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000036257.13,ENSG00000036257,CUL3,-0.93988491,-1.185684827,-1.2168567,-0.417113203,cullin 3,"CUL3, also known as cullin 3, is a gene that encodes a protein belonging to the cullin family. This protein is a crucial component of an E3 ubiquitin ligase complex, which is responsible for the polyubiquitination and subsequent degradation of specific protein substrates. CUL3 may also play a role in the maturation of late endosomes. Mutations in this gene have been linked to type 2E pseudohypoaldosteronism. Multiple isoforms of the protein are produced due to alternative splicing of the transcript variants.","Mutations in the CUL3 gene have been linked to type 2E pseudohypoaldosteronism (PHA2E), a rare genetic disorder characterized by salt wasting and high blood potassium levels. This condition is caused by impaired renal tubular reabsorption of sodium, leading to excessive salt excretion in the urine. There are currently no targeted drug discovery efforts specifically for CUL3 mutations in PHA2E, and treatment is mainly supportive with salt and mineralocorticoid replacement therapy.

However, CUL3 has been identified as a potential therapeutic target in cancer due to its role in regulating the stability of various oncogenic proteins. Several small molecule inhibitors targeting CUL3 have been developed and are currently being evaluated in preclinical studies for their anti-cancer activity. One example is MLN4924, a small molecule inhibitor of the NEDD8-activating enzyme that prevents the activation of cullin-RING E3 ubiquitin ligases, including CUL3. MLN4924 has shown promising results in preclinical studies and is currently in clinical trials for the treatment of various types of cancer.

Another example of a successful drug targeting the ubiquitin-proteasome system is bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib inhibits the degradation of ubiquitinated proteins, leading to the accumulation of misfolded and damaged proteins and ultimately inducing apoptosis in cancer cells. While bortezomib does not directly target CUL3, it highlights the potential of targeting the ubiquitin-proteasome system for the treatment of cancer and other diseases.",GO:0001831 trophectodermal cellular morphogenesis;GO:0071630 nuclear protein quality control by the ubiquitin-proteasome system;GO:0140252 regulation protein catabolic process at postsynapse,,Disease related genes; Human disease related genes:Urinary system diseases:Kidney diseases; Predicted intracellular proteins,,,(M90)PID WNT CANONICAL PATHWAY; (M14)PID AURORA B PATHWAY; (M166)PID ATF2 PATHWAY,(M5901)HALLMARK G2M CHECKPOINT
ENSG00000115904.14,ENSG00000115904,SOS1,-0.93982265,-1.274836948,-0.909170382,-0.63546062,SOS Ras/Rac guanine nucleotide exchange factor 1,"SOS1 is a gene that encodes a protein that acts as a guanine nucleotide exchange factor for RAS proteins. RAS proteins are membrane proteins that bind guanine nucleotides and play a role in signal transduction pathways. The activation and inactivation of RAS proteins is regulated by GTP binding and hydrolysis. The product of the SOS1 gene facilitates the exchange of GTP for GDP, which may regulate RAS proteins. Mutations in the SOS1 gene are associated with gingival fibromatosis 1 and Noonan syndrome type 4.","Mutations in the SOS1 gene have been linked to several genetic disorders, including Noonan syndrome type 4 and gingival fibromatosis 1. Noonan syndrome is a genetic disorder that affects various parts of the body, causing developmental abnormalities and an increased risk of certain cancers. Gingival fibromatosis 1 is a rare condition characterized by overgrowth of the gums. 

Targeted drug discovery efforts for SOS1 have focused on developing small molecule inhibitors that can block the activity of the SOS1 protein. One such inhibitor, BI-3406, has shown promising results in preclinical studies for the treatment of RAS-driven cancers. BI-3406 works by binding to the SOS1 protein and preventing it from activating RAS proteins, which can slow or stop the growth of cancer cells. 

Other drugs that target RAS proteins, such as MEK inhibitors and RAF inhibitors, have been approved for the treatment of certain types of cancer. However, these drugs have limited efficacy and can cause significant side effects. Therefore, there is a need for more effective and targeted therapies for RAS-driven cancers, which may include targeting the SOS1 protein.",GO:1904693 midbrain morphogenesis;GO:0007296 vitellogenesis;GO:0003344 pericardium morphogenesis,,Predicted intracellular proteins; Human disease related genes:Digestive system diseases:Mouth and dental diseases; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes; RAS pathway related proteins,Cytosol (Approved),,(M12771)SA PTEN PATHWAY; (M18895)SA TRKA RECEPTOR; (M206)PID PDGFRA PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000117335.20,ENSG00000117335,CD46,-0.93962284,-1.154202876,-1.3178119,-0.346853743,CD46 molecule,"CD46 is a type I membrane protein that regulates the complement system by inactivating complement components C3b and C4b through cofactor activity with serum factor I. This protects host cells from damage by complement. CD46 also acts as a receptor for the Edmonston strain of measles virus, human herpesvirus-6, and type IV pili of pathogenic Neisseria. It may also be involved in the fusion of spermatozoa with the oocyte during fertilization. Mutations in CD46 have been linked to susceptibility to hemolytic uremic syndrome. Different isoforms of CD46 have been identified through alternative splicing.","Mutations in CD46 have been linked to susceptibility to hemolytic uremic syndrome (HUS), a rare but serious condition characterized by the breakdown of red blood cells and the formation of blood clots in small blood vessels throughout the body. There are currently no targeted drugs available for CD46-related HUS, and treatment typically involves supportive care such as blood transfusions and dialysis. However, research is ongoing to develop targeted therapies for HUS and other complement-mediated diseases. One example is the drug eculizumab, which targets complement component C5 and is approved for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Another example is the drug ravulizumab, a longer-acting version of eculizumab that was recently approved for the treatment of paroxysmal nocturnal hemoglobinuria.","GO:0045959 negative regulation of complement activation, classical pathway;GO:0030450 regulation of complement activation, classical pathway;GO:0043382 positive regulation of memory T cell differentiation",,Predicted intracellular proteins; Disease related genes; CD markers; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Cancer-related genes:Candidate cancer biomarkers,Plasma membrane (Approved),,,(M5921)HALLMARK COMPLEMENT
ENSG00000138660.12,ENSG00000138660,AP1AR,-0.939561246,-1.018596666,-1.088450426,-0.711636648,adaptor related protein complex 1 associated regulatory protein,"AP1AR is a human gene that encodes for a protein called adaptor related protein complex 1 associated regulatory protein. This protein is involved in enabling the binding activity of the AP-1 adaptor complex and kinesin, which are important for intracellular transport. AP1AR is also involved in negative regulation of receptor recycling and vesicle targeting, specifically from the trans-Golgi to endosome. It plays a role in negative regulation of substrate adhesion-dependent cell spreading, which is important for cell migration. AP1AR is located in the Golgi apparatus and transport vesicles.","There is limited information available on the disease implications of AP1AR. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for AP1AR are also limited, as the function of this protein is not well understood. However, some studies have suggested that targeting AP1AR may be a potential strategy for inhibiting cancer cell growth and metastasis. Currently, there are no drugs on the market that specifically target AP1AR. However, there are drugs that target the AP-1 adaptor complex, such as brefeldin A, which is used to treat certain types of cancer and autoimmune diseases. Additionally, there are drugs that target kinesin, such as the anti-cancer drug ixabepilone. Further research is needed to fully understand the potential therapeutic implications of targeting AP1AR.","GO:0048203 vesicle targeting, trans-Golgi to endosome;GO:0001920 negative regulation of receptor recycling;GO:1900025 negative regulation of substrate adhesion-dependent cell spreading",,Predicted intracellular proteins,Golgi apparatus (Supported),,,
ENSG00000107789.16,ENSG00000107789,MINPP1,-0.938755868,-1.250646095,-0.737268508,-0.828353001,multiple inositol-polyphosphate phosphatase 1,"The MINPP1 gene encodes an enzyme called multiple inositol polyphosphate phosphatase, which is responsible for removing 3-phosphate from inositol phosphate substrates. This enzyme is unique in its ability to hydrolyze inositol pentakisphosphate and inositol hexakisphosphate. Additionally, it has been found to convert 2,3 bisphosphoglycerate (2,3-BPG) to 2-phosphoglycerate, a function that was previously thought to be exclusive to 2,3-BPG synthase/2-phosphatase (BPGM) in the Rapoport-Luebering shunt of the glycolytic pathway. Overall, the MINPP1 gene plays an important role in regulating inositol phosphate signaling and metabolism.","Research has shown that mutations in the MINPP1 gene can lead to a rare genetic disorder called oculocerebrorenal syndrome of Lowe (OCRL), which is characterized by congenital cataracts, intellectual disability, and kidney dysfunction. As a result, there has been interest in developing drugs that can target the enzyme encoded by the MINPP1 gene as a potential treatment for OCRL. One such drug is vildagliptin, which was originally developed as a treatment for type 2 diabetes but has also been shown to inhibit MINPP1 activity. Another drug, called SAR245409, has been developed specifically to target MINPP1 and is currently in preclinical development for the treatment of OCRL. While there are currently no drugs on the market that directly target MINPP1, these efforts suggest that there is potential for the development of targeted therapies for OCRL and other diseases associated with MINPP1 dysfunction.",GO:0043647 inositol phosphate metabolic process;GO:0030282 bone mineralization;GO:0019751 polyol metabolic process,,Predicted intracellular proteins; Human disease related genes:Cancers:Cancers of endocrine organs; Predicted secreted proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,,,,(M5945)HALLMARK HEME METABOLISM
ENSG00000169925.17,ENSG00000169925,BRD3,-0.937263637,-1.244505773,-1.171102417,-0.396182721,bromodomain containing 3,"BRD3 is a human gene located on chromosome 9q34, which is homologous to the gene encoding the RING3 protein, a serine/threonine kinase. The function of the encoded protein is not yet known. The gene is located in a region that contains several major histocompatibility complex (MHC) genes.","Research on BRD3 has suggested its involvement in various diseases, including cancer, neurological disorders, and viral infections. In cancer, BRD3 has been found to play a role in the regulation of cell proliferation and differentiation, making it a potential target for cancer therapy. Several small molecule inhibitors targeting BRD3 have been developed and are currently being evaluated in preclinical studies. In neurological disorders, BRD3 has been implicated in the regulation of synaptic plasticity and memory formation, making it a potential target for the treatment of cognitive impairments. In viral infections, BRD3 has been shown to interact with viral proteins and play a role in viral replication, making it a potential target for antiviral therapy. However, there are currently no drugs targeting BRD3 on the market.",GO:0035987 endodermal cell differentiation;GO:0071168 protein localization to chromatin;GO:0001706 endoderm formation,,Disease related genes; Cancer-related genes; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000136518.17,ENSG00000136518,ACTL6A,-0.937215667,-1.168542462,-1.223010589,-0.42009395,actin like 6A,"ACTL6A is a gene that encodes a protein belonging to the actin-related protein (ARP) family, which shares a significant amino acid sequence similarity with conventional actins. ARPs and actins have an ATP-binding cleft as a common feature and are involved in various cellular processes, including vesicular transport, spindle orientation, nuclear migration, and chromatin remodeling. In mammals, ACTL6A encodes a 53 kDa subunit protein of the BAF complex, which is functionally related to the SWI/SNF complex in yeast and Drosophila. The BAF complex is thought to facilitate transcriptional activation of specific genes by antagonizing chromatin-mediated transcriptional repression. ACTL6A, along with beta-actin, is required for maximal ATPase activity of BRG1 and for the association of the BAF complex with chromatin/matrix. Three transcript variants that encode two different protein isoforms have been described.","Research has shown that mutations in the ACTL6A gene are associated with a range of diseases, including intellectual disability, autism spectrum disorder, and cancer. In particular, alterations in the BAF complex, which includes ACTL6A, have been linked to various types of cancer, including ovarian, lung, and pancreatic cancer. As a result, there has been significant interest in developing drugs that target the BAF complex and its associated proteins, including ACTL6A. Several compounds have been identified that show promise in inhibiting the BAF complex, including PFI-3 and BI-2536. Additionally, some drugs that target other components of the BAF complex, such as EZH2 inhibitors, have been approved for use in cancer treatment. However, further research is needed to fully understand the role of ACTL6A and the BAF complex in disease and to develop effective targeted therapies.",GO:1904507 positive regulation of telomere maintenance in response to DNA damage;GO:0060382 regulation of DNA strand elongation;GO:1904505 regulation of telomere maintenance in response to DNA damage,,Disease related genes; Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Cytosol,,(M139)PID MYC PATHWAY; (M66)PID MYC ACTIV PATHWAY,
ENSG00000059758.8,ENSG00000059758,CDK17,-0.93650678,-1.144289488,-0.926474633,-0.738756218,cyclin dependent kinase 17,"CDK17, also known as cyclin dependent kinase 17, is a protein kinase that belongs to the cdc2/cdkx subfamily of the ser/thr family of protein kinases. It shares similarity with a rat protein that is believed to be involved in terminally differentiated neurons. The CDK17 gene can produce different isoforms due to alternative splicing of its transcript variants. The exact function of CDK17 is not yet fully understood, but it is thought to play a role in cell cycle regulation and neuronal differentiation. Mutations in the CDK17 gene have been associated with various diseases, including cancer and neurodevelopmental disorders.","CDK17 has been implicated in various diseases, including cancer and neurodevelopmental disorders. In cancer, CDK17 has been shown to be overexpressed in several types of tumors, including breast, lung, and ovarian cancers. Targeting CDK17 has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of CDK17 have been developed and are currently being evaluated in preclinical studies. In neurodevelopmental disorders, mutations in the CDK17 gene have been associated with intellectual disability and autism spectrum disorder. However, there are currently no targeted drug discovery efforts for CDK17 in these disorders. There are no drugs on the market that specifically target CDK17, but several CDK inhibitors, such as palbociclib and ribociclib, have been approved for the treatment of breast cancer and are being evaluated in clinical trials for other types of cancer.",GO:0006468 protein phosphorylation;GO:0016310 phosphorylation;GO:1901987 regulation of cell cycle phase transition,yes,Enzymes; Kinases:CMGC Ser/Thr protein kinases; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Nucleoplasm (Approved),Fostamatinib,,
ENSG00000181894.15,ENSG00000181894,ZNF329,-0.936138611,-1.809220188,-0.794041481,-0.205154164,zinc finger protein 329,"ZNF329 is a human gene that encodes for a zinc finger protein. It is predicted to have DNA-binding transcription factor activity, specifically for RNA polymerase II and RNA polymerase II transcription regulatory region sequence-specific DNA binding activity. The gene is also predicted to be involved in the regulation of transcription by RNA polymerase II and is located in the nucleus.","There is limited information available on the disease implications of ZNF329. However, some studies have suggested that it may play a role in the development of certain cancers, including breast cancer and hepatocellular carcinoma. As for targeted drug discovery efforts, there are currently no known drugs that specifically target ZNF329. However, there are ongoing efforts to develop drugs that target other zinc finger proteins, which may have implications for ZNF329 as well. Examples of successful drugs that target zinc finger proteins include thalidomide, which is used to treat multiple myeloma and leprosy, and lenalidomide, which is used to treat multiple myeloma and myelodysplastic syndromes.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000165819.12,ENSG00000165819,METTL3,-0.935529365,-1.315504251,-1.021092184,-0.46999166,"methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit","METTL3 is a gene that encodes the 70 kDa subunit of MT-A, which is a part of the N6-adenosine-methyltransferase complex. This enzyme is responsible for the posttranscriptional methylation of internal adenosine residues in eukaryotic mRNAs, forming N6-methyladenosine. This process is important for regulating gene expression and has been linked to various biological processes, including stem cell differentiation, RNA splicing, and cancer development. Mutations in METTL3 have been associated with various diseases, including acute myeloid leukemia and intellectual disability.","METTL3 has been implicated in various diseases, including acute myeloid leukemia (AML) and intellectual disability. In AML, METTL3 mutations have been found to be associated with poor prognosis and increased relapse rates. Targeting METTL3 has emerged as a potential therapeutic strategy for AML, and several small molecule inhibitors of METTL3 have been developed and are currently being evaluated in preclinical studies. In addition, METTL3 has also been linked to other cancers, including lung cancer and hepatocellular carcinoma, and targeting METTL3 may have therapeutic potential in these diseases as well. However, there are currently no FDA-approved drugs targeting METTL3.",GO:0098508 endothelial to hematopoietic transition;GO:1903677 regulation of cap-independent translational initiation;GO:1903679 positive regulation of cap-independent translational initiation,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Nucleoplasm (Supported); Additional: Golgi apparatus;Nuclear bodies,,,(M5907)HALLMARK ESTROGEN RESPONSE LATE
ENSG00000143337.19,ENSG00000143337,TOR1AIP1,-0.935337522,-1.283910632,-1.176195329,-0.345906605,torsin 1A interacting protein 1,"TOR1AIP1 is a gene that encodes a type 2 integral membrane protein that binds to A- and B-type lamins. The protein is located in the inner nuclear membrane and may play a role in maintaining the attachment of the nuclear membrane to the nuclear lamina during cell division. The gene undergoes alternate splicing, resulting in multiple transcript variants.","Mutations in the TOR1AIP1 gene have been associated with several diseases, including muscular dystrophy, dilated cardiomyopathy, and Emery-Dreifuss muscular dystrophy. However, the exact mechanisms by which these mutations lead to disease are not fully understood. 

There are currently no drugs specifically targeting TOR1AIP1, but there have been efforts to develop drugs that target the nuclear lamina, which TOR1AIP1 interacts with. One example is the drug A-type lamin inhibitor, which has been shown to improve muscle function in a mouse model of muscular dystrophy. 

Another example is the drug edasalonexent, which is currently in clinical trials for the treatment of Duchenne muscular dystrophy. Edasalonexent works by inhibiting the NF-kB pathway, which is involved in inflammation and muscle damage. It has been shown to improve muscle function and reduce muscle damage in preclinical studies. 

Overall, while there are currently no drugs targeting TOR1AIP1 specifically, there is ongoing research into drugs that target the nuclear lamina and related pathways, which may have potential therapeutic benefits for diseases associated with TOR1AIP1 mutations.",GO:0090435 protein localization to nuclear envelope;GO:0032781 positive regulation of ATP-dependent activity;GO:0071763 nuclear membrane organization,,Disease related genes; Human disease related genes:Musculoskeletal diseases:Muscular diseases; Predicted intracellular proteins,Nuclear membrane (Supported),,,
ENSG00000183340.7,ENSG00000183340,JRKL,-0.934986061,-1.362325953,-0.987431047,-0.455201182,JRK like,"The function of the human gene JRKL is currently unknown. However, the protein it encodes shares similarities with the jerky gene products found in humans and mice. It is believed that this protein may act as a nuclear regulatory protein, but further research is needed to confirm this. Different versions of the gene have been identified through alternative splicing.","Unfortunately, there is currently no information available on disease implications or targeted drug discovery efforts for the JRKL gene. As the function of the gene is still unknown, it is difficult to determine any potential disease associations or drug targets. Additionally, there are no known drugs on the market that target this gene or its protein product. However, as research continues to uncover more information about the function of JRKL, it may become a target for drug discovery efforts in the future.",GO:0007417 central nervous system development;GO:0007399 nervous system development;GO:0048731 system development,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytokinetic bridge,,,
ENSG00000198265.12,ENSG00000198265,HELZ,-0.933961667,-1.348976332,-0.866647878,-0.586260792,helicase with zinc finger,"HELZ is a gene that belongs to the RNA helicase superfamily I class. RNA helicases are enzymes that change the shape of RNA by unwinding double-stranded regions, which affects the RNA's biological activity and regulates access to other proteins. HELZ contains a zinc finger domain, which is a protein motif that binds to DNA and RNA. The function of HELZ is not fully understood, but it is thought to play a role in regulating gene expression and cell differentiation. Mutations in the HELZ gene have been associated with developmental disorders and cancer.","There is limited information available on the disease implications of HELZ mutations. However, studies have suggested that mutations in the HELZ gene may be associated with developmental disorders such as intellectual disability and autism spectrum disorder. Additionally, HELZ has been found to be overexpressed in certain types of cancer, including breast cancer and hepatocellular carcinoma, suggesting a potential role in cancer development and progression.

There are currently no targeted drug discovery efforts specifically focused on HELZ. However, RNA helicases in general have been identified as potential therapeutic targets for a variety of diseases, including viral infections and cancer. Several small molecule inhibitors of RNA helicases are currently in preclinical development.

There are no drugs currently on the market that specifically target HELZ. However, there are several drugs that target RNA helicases in general, including the hepatitis C virus (HCV) NS3/4A protease inhibitors telaprevir and boceprevir, which have been approved for the treatment of HCV infection. Additionally, the RNA helicase DDX3X has been identified as a potential target for the treatment of HIV, and several small molecule inhibitors of DDX3X are currently in preclinical development.",GO:0035194 regulatory ncRNA-mediated post-transcriptional gene silencing;GO:0016441 post-transcriptional gene silencing;GO:0031047 regulatory ncRNA-mediated gene silencing,,Predicted intracellular proteins,Nucleoli;Nucleoli rim (Approved); Additional: Actin filaments;Plasma membrane,,,
ENSG00000153339.15,ENSG00000153339,TRAPPC8,-0.933130109,-1.055704854,-1.239240374,-0.504445098,trafficking protein particle complex subunit 8,"TRAPPC8 is a human gene that encodes for the trafficking protein particle complex subunit 8. This gene is involved in the organization of the Golgi apparatus, which is responsible for processing and sorting proteins and lipids in the cell. TRAPPC8 is part of the TRAPP complex, which is a multi-subunit protein complex that regulates vesicle trafficking between the endoplasmic reticulum and the Golgi. Mutations in TRAPPC8 have been associated with a rare genetic disorder called SEDT, which is characterized by skeletal abnormalities and developmental delays. Overall, TRAPPC8 plays an important role in intracellular transport and cellular homeostasis.","Mutations in the TRAPPC8 gene have been linked to a rare genetic disorder called SEDT (Spondyloepiphyseal dysplasia tarda), which is characterized by skeletal abnormalities and delayed development. There is currently no cure for SEDT, and treatment is mainly supportive, focusing on managing symptoms such as joint pain and stiffness. 

As TRAPPC8 is involved in intracellular transport, it has been suggested as a potential target for drug discovery efforts aimed at treating diseases related to trafficking defects. However, there are currently no drugs on the market that specifically target TRAPPC8. 

There are, however, drugs that target other components of the TRAPP complex, such as the small molecule inhibitor golgicide A, which disrupts the function of the TRAPP complex and inhibits vesicle trafficking. Golgicide A has been shown to have anti-tumor activity in preclinical studies and is currently being investigated as a potential cancer therapy. 

Overall, while TRAPPC8 has been implicated in disease and is a potential target for drug discovery efforts, there are currently no drugs on the market that specifically target this gene.","GO:0032964 collagen biosynthetic process;GO:0048207 vesicle targeting, rough ER to cis-Golgi;GO:0048208 COPII vesicle coating",,Predicted intracellular proteins,Cytosol (Approved); Additional: Microtubules,,,
ENSG00000145391.13,ENSG00000145391,SETD7,-0.933007239,-1.344168831,-1.182638961,-0.272213925,"SET domain containing 7, histone lysine methyltransferase","SETD7 is a human gene that encodes for a protein called SET domain containing 7, histone lysine methyltransferase. This protein is involved in modifying histones, which are proteins that help package DNA in the nucleus of cells. Specifically, SETD7 enables histone-lysine N-methyltransferase activity and peptidyl-lysine dimethylation and monomethylation. It also has p53 binding activity and is involved in cellular response to DNA damage stimulus and heterochromatin organization. SETD7 is located in the chromosome and nucleolus.","Research has shown that SETD7 plays a role in various diseases, including cancer, diabetes, and cardiovascular disease. In cancer, SETD7 has been found to be overexpressed in several types of tumors, including breast, prostate, and lung cancer. Inhibition of SETD7 has been shown to reduce tumor growth and metastasis in preclinical models, making it a potential target for cancer therapy. In diabetes, SETD7 has been linked to insulin resistance and glucose metabolism, and inhibition of SETD7 has been shown to improve insulin sensitivity in animal models. In cardiovascular disease, SETD7 has been implicated in the development of atherosclerosis and hypertension.

There have been efforts to develop drugs that target SETD7, particularly for cancer therapy. One example is a small molecule inhibitor called PFI-2, which has been shown to inhibit SETD7 activity and reduce tumor growth in preclinical models of breast cancer. Another example is a peptide inhibitor called SETD7i, which has been shown to inhibit SETD7 activity and reduce tumor growth in preclinical models of prostate cancer.

Currently, there are no drugs targeting SETD7 on the market. However, the promising preclinical results suggest that targeting SETD7 could be a viable strategy for the development of new cancer therapies. Further research is needed to fully understand the role of SETD7 in disease and to develop effective drugs that target this protein.",GO:0018027 peptidyl-lysine dimethylation;GO:0018026 peptidyl-lysine monomethylation;GO:0070828 heterochromatin organization,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoli;Nucleoli rim (Enhanced); Additional: Mitotic chromosome,S-adenosyl-L-homocysteine,(M261)PID P53 REGULATION PATHWAY,
ENSG00000163960.12,ENSG00000163960,UBXN7,-0.93203572,-1.222851804,-1.04150898,-0.531746375,UBX domain protein 7,UBXN7 is a human gene that encodes for a protein called UBX domain protein 7. This protein is involved in enabling ubiquitin binding activity and ubiquitin protein ligase binding activity. It is located in the nuclear body and is part of the VCP-NPL4-UFD1 AAA ATPase complex. The function of this complex is to regulate protein degradation and quality control in the cell. The UBXN7 protein plays a crucial role in this process by binding to ubiquitin and facilitating its degradation. This gene is important for maintaining cellular homeostasis and preventing the accumulation of damaged or misfolded proteins.,"There is limited information available on the disease implications of UBXN7. However, recent studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for UBXN7 are still in the early stages, but there is potential for the development of drugs that target the protein's role in protein degradation and quality control. Currently, there are no drugs on the market that specifically target UBXN7. However, there are drugs that target the VCP-NPL4-UFD1 AAA ATPase complex, of which UBXN7 is a part. For example, the drug bortezomib is a proteasome inhibitor that is used to treat multiple myeloma and mantle cell lymphoma by inhibiting the degradation of proteins.",GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process;GO:0010498 proteasomal protein catabolic process;GO:0006511 ubiquitin-dependent protein catabolic process,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000107863.18,ENSG00000107863,ARHGAP21,-0.931135368,-1.247264575,-1.153885903,-0.392255627,Rho GTPase activating protein 21,"ARHGAP21 is a human gene that encodes for a protein called Rho GTPase activating protein 21. This protein functions as a GTPase-activating protein (GAP) for CDC42, a protein involved in cell signaling and cytoskeletal organization. ARHGAP21 regulates the ARP2/3 complex and F-actin dynamics at the Golgi by controlling the activity of CDC42. This gene is important for the proper functioning of cells and mutations in ARHGAP21 have been associated with various diseases, including cancer and developmental disorders.","Mutations in ARHGAP21 have been associated with various diseases, including cancer and developmental disorders. In particular, ARHGAP21 has been found to be downregulated in several types of cancer, including breast, lung, and ovarian cancer. This suggests that ARHGAP21 may function as a tumor suppressor gene. Targeted drug discovery efforts for ARHGAP21 are currently underway, with a focus on developing small molecule inhibitors that can activate the protein's GAP activity and restore its tumor suppressor function. While there are currently no drugs on the market that specifically target ARHGAP21, several drugs that target CDC42, the protein regulated by ARHGAP21, are in clinical trials for cancer treatment. These include the CDC42 inhibitor ML141 and the CDC42/MRCK inhibitor CASIN.",GO:0051684 maintenance of Golgi location;GO:0051683 establishment of Golgi localization;GO:0051657 maintenance of organelle location,,Predicted intracellular proteins,Cell Junctions;Plasma membrane (Approved); Additional: Actin filaments,,,
ENSG00000158467.16,ENSG00000158467,AHCYL2,-0.929807425,-1.303965649,-0.857649693,-0.627806933,adenosylhomocysteinase like 2,AHCYL2 is a gene that encodes a protein that acts as a homotetramer and may be involved in the conversion of S-adenosyl-L-homocysteine to L-homocysteine and adenosine. The gene has several transcript variants that encode different isoforms.,"Research on AHCYL2 has suggested its potential involvement in various diseases, including cancer, cardiovascular disease, and neurological disorders. In particular, studies have shown that AHCYL2 expression is upregulated in certain types of cancer, such as breast and lung cancer, and may play a role in tumor progression and metastasis. Additionally, AHCYL2 has been linked to cardiovascular disease through its involvement in homocysteine metabolism, which is a risk factor for atherosclerosis and other cardiovascular conditions.

Targeted drug discovery efforts for AHCYL2 have focused on developing inhibitors that can block its activity and potentially treat diseases associated with its dysregulation. One example is the development of small molecule inhibitors that target the active site of AHCYL2 and have shown promising results in preclinical studies for cancer treatment.

Currently, there are no drugs on the market that specifically target AHCYL2. However, there are drugs that indirectly affect its activity, such as methotrexate, which is used to treat cancer and autoimmune diseases by inhibiting enzymes involved in folate metabolism, including AHCYL2. Additionally, drugs that target homocysteine metabolism, such as folic acid and vitamin B12 supplements, are commonly used to treat cardiovascular disease and other conditions associated with elevated homocysteine levels.",GO:0033353 S-adenosylmethionine cycle;GO:0046500 S-adenosylmethionine metabolic process;GO:0006730 one-carbon metabolic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol (Approved); Additional: Nucleoplasm,,,
ENSG00000110172.12,ENSG00000110172,CHORDC1,-0.929708644,-1.090913599,-0.701897516,-0.996314819,cysteine and histidine rich domain containing 1,"The human gene CHORDC1, also known as cysteine and histidine rich domain containing 1, is involved in various cellular processes such as centrosome duplication, chaperone-mediated protein folding, and regulation of cellular response to heat. It enables Hsp90 protein binding activity, which is important for protein folding and stability. The gene is predicted to have a role in maintaining cellular homeostasis and responding to stress.","There is limited information available on the disease implications of CHORDC1. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast and ovarian cancer. Targeted drug discovery efforts for CHORDC1 are also limited, as the exact role of this gene in disease pathogenesis is not well understood. However, some studies have suggested that targeting Hsp90, which is enabled by CHORDC1, may be a potential therapeutic strategy for cancer treatment. Several Hsp90 inhibitors, such as geldanamycin and 17-AAG, have been developed and are currently being evaluated in clinical trials for various types of cancer. However, these drugs have shown limited success and significant side effects, highlighting the need for further research in this area.",GO:1900034 regulation of cellular response to heat;GO:0051298 centrosome duplication;GO:0010824 regulation of centrosome duplication,,Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000049239.13,ENSG00000049239,H6PD,-0.92935629,-1.494196193,-0.994903662,-0.298969016,hexose-6-phosphate dehydrogenase/glucose 1-dehydrogenase,"The human gene H6PD encodes for the H form of glucose-6-phosphate dehydrogenase, which is autosomally linked and shows activity with other hexose-6-phosphates, particularly galactose-6-phosphate. There are two forms of glucose-6-phosphate dehydrogenase, with the G form being X-linked and specific for glucose-6-phosphate. Both forms are present in most tissues, except for the H form which is not found in red cells.","Mutations in the H6PD gene have been associated with a variety of diseases, including diabetes, obesity, and metabolic syndrome. Targeted drug discovery efforts have focused on developing inhibitors of glucose-6-phosphate dehydrogenase as potential treatments for these conditions. One example of a successful drug on the market is 6-aminonicotinamide, which is a competitive inhibitor of glucose-6-phosphate dehydrogenase and has been used in cancer treatment. Another example is the drug dapagliflozin, which inhibits glucose reabsorption in the kidneys and has been approved for the treatment of type 2 diabetes. Overall, the H6PD gene and its associated enzyme have important implications for metabolic health and have been the target of drug discovery efforts for a variety of diseases.","GO:0009051 pentose-phosphate shunt, oxidative branch;GO:2000064 regulation of cortisol biosynthetic process;GO:0031946 regulation of glucocorticoid biosynthetic process",,Predicted intracellular proteins; ENZYME proteins:Oxidoreductases; Human disease related genes:Endocrine and metabolic diseases:Adrenal gland diseases; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Cytosol (Uncertain),NADH,,
ENSG00000103657.14,ENSG00000103657,HERC1,-0.929306623,-1.306909643,-0.915972627,-0.565037599,HECT and RLD domain containing E3 ubiquitin protein ligase family member 1,"HERC1 is a gene that belongs to the HECT and RLD domain containing E3 ubiquitin protein ligase family. This gene is responsible for encoding a protein that is a member of the HERC protein family. The protein encoded by HERC1 stimulates guanine nucleotide exchange on ARF1 and Rab proteins, which may be involved in membrane transport processes. This gene is important for the proper functioning of the body and any mutations or abnormalities in HERC1 can lead to various diseases and disorders.","Mutations in the HERC1 gene have been associated with several neurological disorders, including intellectual disability, autism spectrum disorder, and schizophrenia. In addition, HERC1 has been implicated in the development of certain cancers, such as breast cancer and glioblastoma. 

There are currently no drugs specifically targeting HERC1, but research is ongoing to identify potential therapeutic targets. One approach is to target the downstream pathways affected by HERC1, such as the ARF1 and Rab proteins. 

One example of a successful drug targeting a related protein is bortezomib, which targets the proteasome and is used to treat multiple myeloma. Another example is imatinib, which targets the BCR-ABL fusion protein and is used to treat chronic myeloid leukemia. These drugs demonstrate the potential for targeted therapies in treating diseases associated with abnormal protein function.",GO:0021702 cerebellar Purkinje cell differentiation;GO:0021694 cerebellar Purkinje cell layer formation;GO:0021692 cerebellar Purkinje cell layer morphogenesis,,Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Enzymes,,,,
ENSG00000153207.16,ENSG00000153207,AHCTF1,-0.928375876,-1.127365326,-0.9215872,-0.736175101,AT-hook containing transcription factor 1,"AHCTF1, also known as AT-hook containing transcription factor 1, is a gene that is predicted to enable DNA binding activity. It is involved in nuclear pore complex assembly and regulation of cytokinesis. AHCTF1 is located in the nuclear membrane and colocalizes with chromatin, kinetochore, and nuclear pore outer ring. This gene plays an important role in the regulation of gene expression and cell division. Mutations in AHCTF1 have been associated with various diseases, including cancer and developmental disorders. Further research on AHCTF1 may provide insights into the mechanisms underlying these diseases and potential therapeutic targets.","There is limited information available on targeted drug discovery efforts for AHCTF1. However, mutations in this gene have been associated with various diseases, including cancer and developmental disorders. In particular, AHCTF1 has been implicated in the development and progression of breast cancer, where it is overexpressed in tumor tissues. Targeting AHCTF1 may therefore be a potential therapeutic strategy for breast cancer treatment. Currently, there are no drugs specifically targeting AHCTF1 on the market. However, there are several drugs that target other proteins involved in the regulation of gene expression and cell division, which may indirectly affect AHCTF1 activity. Examples include tamoxifen, which targets estrogen receptors in breast cancer, and paclitaxel, which targets microtubules and is used in the treatment of various cancers.",GO:0051292 nuclear pore complex assembly;GO:0006999 nuclear pore organization;GO:0046931 pore complex assembly,,Transporters:Transporter channels and pores; Predicted intracellular proteins,Nuclear bodies;Nuclear membrane;Nucleoplasm (Supported),,,
ENSG00000144306.15,ENSG00000144306,SCRN3,-0.927497864,-1.213546735,-0.858348742,-0.710598115,secernin 3,"SCRN3, also known as secernin 3, is a human gene that is predicted to have cysteine-type exopeptidase activity and dipeptidase activity. It is also predicted to be involved in proteolysis, which is the breakdown of proteins into smaller peptides or amino acids. The exact function of SCRN3 is not yet fully understood, but it may play a role in regulating protein turnover and degradation. Further research is needed to fully elucidate the function of SCRN3 and its potential implications for human health and disease.","There is currently limited information available on the disease implications of SCRN3. However, some studies have suggested that it may be involved in the development and progression of certain types of cancer, such as breast cancer and glioblastoma. Targeted drug discovery efforts for SCRN3 are also limited, as its exact function and role in disease are not yet fully understood. There are currently no drugs on the market that specifically target SCRN3. However, there are drugs that target other proteins involved in proteolysis, such as proteasome inhibitors used in the treatment of multiple myeloma and mantle cell lymphoma. Further research is needed to fully elucidate the role of SCRN3 in disease and to develop targeted therapies for its potential implications in cancer and other diseases.",GO:0006508 proteolysis;GO:0019538 protein metabolic process;GO:0043170 macromolecule metabolic process,,Peptidases:Cysteine-type peptidases; Enzymes; Predicted intracellular proteins,Cytosol;Vesicles (Approved),,,
ENSG00000107897.20,ENSG00000107897,ACBD5,-0.926770413,-1.191579227,-1.280807108,-0.307924905,acyl-CoA binding domain containing 5,"ACBD5 is a gene that belongs to the acyl-Coenzyme A binding protein family and is involved in the transport and distribution of long chain acyl-Coenzyme A in cells. It may also play a role in the differentiation of megakaryocytes and the formation of platelets. In yeast, a related protein is involved in autophagy of peroxisomes. A mutation in this gene has been linked to autosomal dominant thrombocytopenia, a condition characterized by a low platelet count. The gene undergoes alternative splicing, resulting in multiple transcript variants.","A mutation in the ACBD5 gene has been linked to autosomal dominant thrombocytopenia, a condition characterized by a low platelet count. This condition can lead to excessive bleeding and bruising, and in severe cases, can be life-threatening. Targeted drug discovery efforts for this condition are ongoing, with a focus on developing drugs that can increase platelet production or prevent platelet destruction. One example of a successful drug on the market for thrombocytopenia is eltrombopag, which works by stimulating the production of platelets in the bone marrow. Another drug, romiplostim, works by mimicking the action of a protein that stimulates platelet production. Both of these drugs have been shown to be effective in increasing platelet counts in patients with thrombocytopenia.",GO:0000425 pexophagy;GO:0030242 autophagy of peroxisome;GO:0016236 macroautophagy,,Disease related genes; Transporters:Transporter channels and pores; Potential drug targets; Predicted intracellular proteins,Peroxisomes (Enhanced),,,
ENSG00000135164.19,ENSG00000135164,DMTF1,-0.926622561,-1.408238184,-1.028099652,-0.343529848,cyclin D binding myb like transcription factor 1,"DMTF1, also known as cyclin D binding myb like transcription factor 1, is a transcription factor that plays a role in tumor suppression and hematopoietic cell differentiation. It contains a cyclin D-binding domain, three central Myb-like repeats, and two flanking acidic transactivation domains. The protein is induced by the oncogenic Ras signaling pathway and activates the transcription of ARF, which activates the ARF-p53 pathway to arrest cell growth or induce apoptosis. DMTF1 also activates the transcription of aminopeptidase N. Its transcriptional activity is regulated by binding of D-cyclins. The gene is hemizygously deleted in approximately 40% of human non-small-cell lung cancer and is a potential prognostic and gene-therapy target for non-small-cell lung cancer.","DMTF1 has been implicated in various types of cancer, including non-small-cell lung cancer, breast cancer, and colorectal cancer. In non-small-cell lung cancer, DMTF1 is frequently hemizygously deleted, and its loss is associated with poor prognosis. Therefore, DMTF1 is a potential therapeutic target for non-small-cell lung cancer. However, there are currently no drugs specifically targeting DMTF1. Instead, efforts have focused on targeting downstream effectors of DMTF1, such as the ARF-p53 pathway. For example, Nutlin-3a is a small molecule that inhibits the interaction between MDM2 and p53, leading to p53 stabilization and activation of the ARF-p53 pathway. Nutlin-3a has shown promising results in preclinical studies and is currently in clinical trials for various types of cancer. Other drugs targeting the ARF-p53 pathway, such as PRIMA-1 and APR-246, are also in clinical trials for cancer treatment.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoplasm (Supported),,(M65)PID FRA PATHWAY; (M167)PID AP1 PATHWAY,
ENSG00000164402.14,ENSG00000164402,SEPTIN8,-0.925966267,-1.140512062,-0.749881216,-0.887505522,septin 8,"SEPTIN8, also known as septin 8, is a gene that belongs to the septin family of nucleotide binding proteins. Septins were first identified in yeast as proteins that regulate cell division cycle. They are highly conserved in yeast, Drosophila, and mouse, and are involved in regulating cytoskeletal organization. Disruption of septin function can lead to abnormal cytokinesis and the formation of large multinucleate or polyploid cells. The SEPTIN8 gene has multiple alternatively spliced transcript variants that encode different isoforms. The exact function of SEPTIN8 is not fully understood, but it is believed to play a role in cell division and cytoskeletal organization.","SEPTIN8 has been implicated in several diseases, including cancer, neurodegenerative disorders, and infectious diseases. In cancer, SEPTIN8 has been shown to be overexpressed in several types of tumors, including breast, lung, and colon cancer. Targeting SEPTIN8 has been proposed as a potential therapeutic strategy for cancer treatment. In neurodegenerative disorders, SEPTIN8 has been linked to the formation of abnormal protein aggregates, such as those found in Alzheimer's and Parkinson's disease. In infectious diseases, SEPTIN8 has been shown to play a role in the replication of viruses, such as hepatitis C virus and human immunodeficiency virus (HIV).

There have been efforts to develop drugs that target SEPTIN8 for the treatment of cancer and infectious diseases. For example, a study showed that a small molecule inhibitor of SEPTIN8, called forchlorfenuron, was able to inhibit the growth of breast cancer cells in vitro and in vivo. Another study showed that a peptide derived from SEPTIN8 was able to inhibit the replication of hepatitis C virus in vitro. However, there are currently no drugs on the market that specifically target SEPTIN8.",GO:0035542 regulation of SNARE complex assembly;GO:0061640 cytoskeleton-dependent cytokinesis;GO:0000910 cytokinesis,,Predicted intracellular proteins,Cytosol (Approved); Additional: Actin filaments;Annulus;Mid piece;Primary cilium;Principal piece,,,
ENSG00000065243.20,ENSG00000065243,PKN2,-0.924909714,-0.955154754,-1.224195374,-0.595379015,protein kinase N2,"PKN2, also known as protein kinase N2, is a human gene that encodes a protein with multiple functions. It enables RNA polymerase binding activity, histone deacetylase binding activity, and protein serine/threonine kinase activity. PKN2 is involved in several processes, including apical junction assembly, positive regulation of cell cycle, and positive regulation of viral genome replication. It is located in several cellular components, including cleavage furrow, cytoskeleton, and midbody. Overall, PKN2 plays an important role in various cellular processes and may have implications in disease development and treatment.","There is limited information available on the disease implications of PKN2. However, some studies have suggested that PKN2 may be involved in the development and progression of certain cancers, including breast cancer and prostate cancer. Targeted drug discovery efforts for PKN2 are still in the early stages, but some preclinical studies have shown promising results with small molecule inhibitors of PKN2. One example is the compound BI 882370, which has been shown to inhibit PKN2 activity and reduce tumor growth in preclinical models of breast cancer. Currently, there are no drugs on the market that specifically target PKN2, but ongoing research may lead to the development of novel therapies for cancer and other diseases.",GO:0045070 positive regulation of viral genome replication;GO:0010631 epithelial cell migration;GO:0090132 epithelium migration,yes,Kinases:AGC Ser/Thr protein kinases; Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Intermediate filaments;Nucleoplasm (Supported); Additional: Centrosome;Cytosol;Nuclear bodies;Plasma membrane,Fostamatinib,(M12)PID RHOA PATHWAY,
ENSG00000124201.15,ENSG00000124201,ZNFX1,-0.924601364,-1.489532672,-0.565049617,-0.719221802,zinc finger NFX1-type containing 1,"The human gene ZNFX1, also known as zinc finger NFX1-type containing 1, is involved in RNA binding activity and is predicted to play a role in heterochromatin assembly by small RNA. It is also predicted to be part of the nuclear RNA-directed RNA polymerase complex. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of ZNFX1. However, some studies have suggested that it may be involved in the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ZNFX1 are also limited, as its exact role in disease pathogenesis is not well understood. Currently, there are no drugs on the market that specifically target ZNFX1. However, there are several drugs that target RNA binding proteins, which may indirectly affect ZNFX1 activity. For example, the drug Rigosertib targets the RNA binding protein eIF4E, which has been shown to play a role in breast cancer development. Another drug, Quarfloxin, targets the RNA binding protein nucleolin and has shown promise in preclinical studies for the treatment of various cancers.",GO:0031048 regulatory ncRNA-mediated heterochromatin formation;GO:0045071 negative regulation of viral genome replication;GO:0045069 regulation of viral genome replication,,Disease related genes; Transcription factors:Yet undefined DNA-binding domains; Predicted intracellular proteins,Mitochondria (Approved),,(M105)PID TELOMERASE PATHWAY,(M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000172936.16,ENSG00000172936,MYD88,-0.923986832,-1.572136868,-0.575246941,-0.624576687,MYD88 innate immune signal transduction adaptor,"The MYD88 gene is responsible for encoding a cytosolic adapter protein that plays a crucial role in the innate and adaptive immune response. This protein acts as a signal transducer in the interleukin-1 and Toll-like receptor signaling pathways, which regulate the activation of various proinflammatory genes. The MYD88 gene consists of an N-terminal death domain and a C-terminal Toll-interleukin1 receptor domain. Patients with defects in this gene are more susceptible to pyogenic bacterial infections. Multiple transcript variants are produced through alternate splicing. Overall, the MYD88 gene is an essential component of the immune system and plays a critical role in the body's response to infections.","Mutations in the MYD88 gene have been associated with various diseases, including lymphoma, chronic lymphocytic leukemia, and Waldenstrom macroglobulinemia. In particular, the MYD88 L265P mutation has been identified in a significant proportion of patients with these diseases, suggesting that it may be a potential therapeutic target. Several drugs targeting MYD88 signaling pathways are currently in development, including inhibitors of Bruton's tyrosine kinase (BTK) and interleukin-1 receptor-associated kinase 4 (IRAK4). One example of a successful drug targeting MYD88 is ibrutinib, a BTK inhibitor approved for the treatment of Waldenstrom macroglobulinemia. Another example is tirabrutinib, a highly selective BTK inhibitor currently in clinical trials for the treatment of lymphoma and other B-cell malignancies. These drugs have shown promising results in clinical trials and represent a potential new avenue for the treatment of MYD88-associated diseases.",GO:0009682 induced systemic resistance;GO:0034146 toll-like receptor 5 signaling pathway;GO:0034158 toll-like receptor 8 signaling pathway,,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Predicted intracellular proteins; Disease related genes; Human disease related genes:Immune system diseases:Primary immunodeficiency; Cancer-related genes:Mutated cancer genes,Cytosol (Supported); Additional: Mitochondria;Vesicles,,(M264)PID TOLL ENDOGENOUS PATHWAY; (M110)PID IL1 PATHWAY; (M153)PID P75 NTR PATHWAY,(M5897)HALLMARK IL6 JAK STAT3 SIGNALING; (M5923)HALLMARK PI3K AKT MTOR SIGNALING; (M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000168137.18,ENSG00000168137,SETD5,-0.923744178,-1.37626723,-0.778379595,-0.616585708,SET domain containing 5,"SETD5 is a gene that encodes a protein with a SET domain, which suggests that it may function as a histone methyltransferase. However, the exact function of this gene is still unknown. Mutations in SETD5 have been linked to an autosomal dominant form of intellectual disability. The gene undergoes alternative splicing, resulting in the production of multiple transcript variants that encode different isoforms.","Mutations in SETD5 have been linked to an autosomal dominant form of intellectual disability. This suggests that SETD5 plays a critical role in brain development and function. However, there are currently no targeted drug discovery efforts for SETD5-related intellectual disability. This is likely due to the lack of understanding of the exact function of SETD5 and the complexity of the brain. 

There are currently no drugs on the market that specifically target SETD5. However, there are drugs that have been approved for the treatment of intellectual disability that may indirectly affect SETD5. For example, drugs that enhance cognitive function, such as donepezil and memantine, have been approved for the treatment of Alzheimer's disease and may also be used to treat intellectual disability. Additionally, drugs that target specific neurotransmitter systems, such as dopamine and serotonin, may also be used to treat intellectual disability. However, these drugs are not specific to SETD5 and may have side effects.",GO:0016480 negative regulation of transcription by RNA polymerase III;GO:1902275 regulation of chromatin organization;GO:0006359 regulation of transcription by RNA polymerase III,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Nucleoplasm (Enhanced),,,
ENSG00000107581.13,ENSG00000107581,EIF3A,-0.923737759,-1.063967091,-1.272727333,-0.434518851,eukaryotic translation initiation factor 3 subunit A,"EIF3A is a gene that encodes for a protein called eukaryotic translation initiation factor 3 subunit A. This protein is involved in various processes related to translation initiation, including RNA binding activity and formation of cytoplasmic translation initiation complex. It also contributes to translation initiation factor activity and is involved in IRES-dependent viral translational initiation and viral translational termination-reinitiation. The protein is located in the cytosol, nucleolus, and nucleoplasm and is part of the eukaryotic translation initiation factor 3 complex.","EIF3A has been implicated in various diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, EIF3A has been shown to be overexpressed in several types of tumors, including breast, lung, and prostate cancer, and is associated with poor prognosis. Targeting EIF3A has been proposed as a potential therapeutic strategy for cancer treatment. In neurodegenerative disorders, EIF3A has been found to be involved in the regulation of protein synthesis, which is disrupted in these diseases. In viral infections, EIF3A plays a role in the translation of viral proteins, making it a potential target for antiviral drug development.

Several drugs targeting EIF3A are currently in development, including small molecule inhibitors and RNA interference-based therapies. One example is the small molecule inhibitor, rocaglamide, which has been shown to inhibit EIF3A and has demonstrated antitumor activity in preclinical studies. Another example is the RNA interference-based therapy, siRNA-EIF3A, which has been shown to inhibit the growth of breast cancer cells in vitro.

In conclusion, EIF3A is a promising target for drug discovery efforts in various diseases, including cancer, neurodegenerative disorders, and viral infections. Several drugs targeting EIF3A are currently in development, and some have shown promising results in preclinical studies.",GO:0002188 translation reinitiation;GO:0075525 viral translational termination-reinitiation;GO:0075522 IRES-dependent viral translational initiation,,Predicted intracellular proteins,Cytosol;Nucleoplasm (Approved),,(M143)PID IL2 PI3K PATHWAY,(M5950)HALLMARK ALLOGRAFT REJECTION
ENSG00000182796.14,ENSG00000182796,TMEM198B,-0.922971205,-1.407581445,-0.907995939,-0.453336231,None,None,None,None,None,None,None,None,None,None
ENSG00000032219.19,ENSG00000032219,ARID4A,-0.921941633,-1.153748316,-0.802890396,-0.809186187,AT-rich interaction domain 4A,"ARID4A is a nuclear protein that is expressed in all tissues of the body. It binds to the retinoblastoma protein (pRB), which is involved in regulating cell proliferation. ARID4A acts as a bridging molecule to recruit HDACs, which are enzymes that modify chromatin structure and regulate gene expression. It also has its own transcriptional repression activity, which helps to regulate gene expression. There are multiple variants of the ARID4A gene, but not all of them have been fully characterized.","There is limited information on the disease implications of ARID4A, but some studies suggest that it may play a role in cancer development and progression. For example, ARID4A has been found to be overexpressed in breast cancer and may contribute to tumor growth and metastasis. Targeted drug discovery efforts for ARID4A are still in the early stages, but some compounds have been identified that can inhibit its activity. One example is a small molecule inhibitor called SAH-B, which has been shown to block ARID4A-mediated gene repression and inhibit breast cancer cell growth in vitro. However, there are currently no drugs on the market that specifically target ARID4A. Further research is needed to fully understand the role of ARID4A in disease and to develop effective therapies targeting this protein.",GO:0097368 establishment of Sertoli cell barrier;GO:0060009 Sertoli cell development;GO:0071514 genomic imprinting,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Plasma membrane,,,(M5901)HALLMARK G2M CHECKPOINT
ENSG00000114541.15,ENSG00000114541,FRMD4B,-0.921697445,-1.300139907,-1.31638814,-0.148564289,FERM domain containing 4B,"FRMD4B is a human gene that encodes a protein that interacts with GRP1 and contains a FERM protein interaction domain and two coiled coil domains. This protein may act as a scaffolding protein, which means it could play a role in organizing and stabilizing other proteins within cells.","There is limited information available on the disease implications of FRMD4B. However, some studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for FRMD4B are also limited, as there are currently no drugs on the market that specifically target this gene. However, there are drugs that target other proteins involved in cancer progression and metastasis, which may indirectly affect FRMD4B. For example, drugs that target the epidermal growth factor receptor (EGFR), such as cetuximab and erlotinib, have been successful in treating certain types of cancer. Additionally, drugs that target the vascular endothelial growth factor (VEGF) pathway, such as bevacizumab and aflibercept, have also been successful in treating cancer. Further research is needed to fully understand the role of FRMD4B in disease and to develop targeted therapies.",GO:0090162 establishment of epithelial cell polarity;GO:0030010 establishment of cell polarity;GO:0007163 establishment or maintenance of cell polarity,,Predicted intracellular proteins,Centriolar satellite (Approved); Additional: Golgi apparatus;Nucleoplasm,,,
ENSG00000172888.12,ENSG00000172888,ZNF621,-0.921664957,-1.430709308,-0.781426388,-0.552859174,zinc finger protein 621,"ZNF621 is a human gene that encodes for a zinc finger protein 621. This protein is predicted to have the ability to bind to DNA and regulate transcription by RNA polymerase II. It is also predicted to be located in the nucleus. The function of ZNF621 is not yet fully understood, but it is believed to play a role in the regulation of gene expression. Further research is needed to fully understand the role of ZNF621 in human biology and disease.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for ZNF621. As the function of this gene is not yet fully understood, it is difficult to determine its potential role in disease development or progression. Additionally, there are no known drugs on the market that specifically target ZNF621. However, further research on the function of this gene may lead to the identification of potential therapeutic targets for certain diseases.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nuclear speckles (Enhanced),,,
ENSG00000196455.8,ENSG00000196455,PIK3R4,-0.920100533,-1.076964677,-1.103681173,-0.579655749,phosphoinositide-3-kinase regulatory subunit 4,"PIK3R4 is a human gene that encodes a protein called phosphoinositide-3-kinase regulatory subunit 4. This protein is predicted to have protein serine/threonine kinase activity and is involved in several cellular processes, including positive regulation of phosphatidylinositol 3-kinase activity, receptor catabolic process, and regulation of cytokinesis. PIK3R4 is located in the late endosome and microtubule cytoskeleton.","PIK3R4 has been implicated in several diseases, including cancer, inflammation, and immune disorders. In cancer, PIK3R4 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. Inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease have also been linked to PIK3R4 dysregulation. Targeted drug discovery efforts have focused on developing inhibitors of PIK3R4 to treat these diseases. One example is the drug idelalisib, which targets PIK3R4 and is approved for the treatment of chronic lymphocytic leukemia and follicular lymphoma. Another example is the drug duvelisib, which also targets PIK3R4 and is approved for the treatment of relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. These drugs have shown promising results in clinical trials and provide hope for patients with these diseases.",GO:0000425 pexophagy;GO:0030242 autophagy of peroxisome;GO:0032801 receptor catabolic process,yes,Enzymes; Predicted intracellular proteins; Kinases; ENZYME proteins:Transferases,Microtubules;Primary cilium;Vesicles (Approved); Additional: Basal body;Cytokinetic bridge,,,
ENSG00000118855.21,ENSG00000118855,MFSD1,-0.919047409,-1.328786574,-1.067145938,-0.361209714,major facilitator superfamily domain containing 1,"MFSD1 (major facilitator superfamily domain containing 1) is a human gene that is predicted to play a role in protein homodimerization, protein localization to lysosomes, and protein stabilization. It is also predicted to be located in lysosomes. The function of MFSD1 is not yet fully understood, but it may be involved in the transport of lipids or other molecules across cell membranes. Further research is needed to fully elucidate the role of MFSD1 in human biology and disease.","There is limited information available on the disease implications of MFSD1. However, recent studies have suggested that mutations in MFSD1 may be associated with neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. Targeted drug discovery efforts for MFSD1 are currently underway, with a focus on identifying small molecule inhibitors that can modulate its activity. To date, there are no drugs on the market that specifically target MFSD1. However, there are several drugs that have been approved for the treatment of neurodegenerative disorders, such as acetylcholinesterase inhibitors for Alzheimer's disease and dopamine agonists for Parkinson's disease. Further research is needed to determine the potential therapeutic value of targeting MFSD1 for the treatment of these disorders.",GO:0141204 dipeptide transmembrane transport from lysosomal lumen to cytosol;GO:0035442 dipeptide transmembrane transport;GO:0042938 dipeptide transport,,Predicted intracellular proteins,Plasma membrane (Approved); Additional: Cytosol,,,
ENSG00000077585.14,ENSG00000077585,GPR137B,-0.918669824,-1.164884305,-1.081924453,-0.509200714,G protein-coupled receptor 137B,"GPR137B is a human gene that encodes for a protein called G protein-coupled receptor 137B. This protein is involved in various biological processes, including the positive regulation of TORC1 signaling, the positive regulation of protein localization to lysosome, and the regulation of GTPase activity. It is primarily located in the lysosomal membrane. The gene's function and location suggest that it may play a role in lysosomal function and cellular metabolism.","There is limited information available on the disease implications of GPR137B. However, recent studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for GPR137B are still in the early stages, and there are currently no drugs on the market that specifically target this gene. However, there are several drugs that target lysosomal function, which may indirectly affect GPR137B activity. For example, chloroquine and hydroxychloroquine are lysosomotropic drugs that have been used to treat malaria and autoimmune diseases, and are currently being investigated as potential treatments for cancer. Additionally, the drug rapamycin, which targets the TORC1 signaling pathway, has been approved for the treatment of certain types of cancer and is being investigated for use in other diseases.",GO:0150032 positive regulation of protein localization to lysosome;GO:0150031 regulation of protein localization to lysosome;GO:0045779 negative regulation of bone resorption,,Transporters,,,,
ENSG00000143751.10,ENSG00000143751,SDE2,-0.918386784,-0.709060268,-1.088941098,-0.957158985,SDE2 telomere maintenance homolog,"SDE2 is a human gene that plays a role in DNA damage response and telomere maintenance. It has the ability to bind to damaged DNA and is involved in processes such as cellular response to UV radiation, mitotic G1 DNA damage checkpoint signaling, and protein ubiquitination. SDE2 is found in various cellular components, including the Golgi apparatus, cytosol, and nuclear speck. This information is provided by the Alliance of Genome Resources as of April 2022.","Unfortunately, there is currently limited information available on the disease implications of SDE2 and targeted drug discovery efforts. As of April 2022, there are no known drugs on the market that specifically target SDE2. However, research on the role of SDE2 in DNA damage response and telomere maintenance may have implications for cancer treatment, as these processes are often dysregulated in cancer cells. Further research may lead to the development of targeted therapies that could potentially improve cancer treatment outcomes.","GO:0000479 endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);GO:0031571 mitotic G1 DNA damage checkpoint signaling;GO:0044819 mitotic G1/S transition checkpoint signaling",,Predicted intracellular proteins,Nuclear speckles (Supported); Additional: Cytosol;Golgi apparatus;Plasma membrane,,,
ENSG00000124151.19,ENSG00000124151,NCOA3,-0.91807144,-1.422049486,-0.408285081,-0.923879753,nuclear receptor coactivator 3,"NCOA3, also known as nuclear receptor coactivator 3, is a gene that encodes a protein involved in enhancing the transcriptional activator functions of nuclear hormone receptors. The protein has histone acetyltransferase activity and recruits other proteins as part of a coactivation complex. It is initially found in the cytoplasm but is translocated into the nucleus upon phosphorylation. There are several transcript variants of the gene that encode different isoforms, and a polymorphic repeat region is found in the C-terminus of the encoded protein.","NCOA3 has been implicated in several diseases, including breast cancer, prostate cancer, and endometrial cancer. In breast cancer, NCOA3 is often overexpressed and is associated with poor prognosis. Targeting NCOA3 has been explored as a potential therapeutic strategy for breast cancer, and several small molecule inhibitors have been developed. One example is GSK2110183, which has shown promising results in preclinical studies and is currently in clinical trials for breast cancer. In prostate cancer, NCOA3 has been shown to play a role in the development of castration-resistant disease, and targeting NCOA3 has been explored as a potential therapeutic strategy. In endometrial cancer, NCOA3 has been shown to be a potential therapeutic target for hormone receptor-positive disease. Overall, targeting NCOA3 has shown promise as a therapeutic strategy in several types of cancer, and further research is needed to fully understand its potential as a drug target.",GO:0035624 receptor transactivation;GO:0070561 vitamin D receptor signaling pathway;GO:0043696 dedifferentiation,,Transcription factors:Basic domains; Predicted intracellular proteins; ENZYME proteins:Transferases; Enzymes; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported); Additional: Cytosol,,(M119)PID ERB GENOMIC PATHWAY; (M207)PID RETINOIC ACID PATHWAY; (M285)PID HNF3A PATHWAY,(M5947)HALLMARK IL2 STAT5 SIGNALING; (M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000054267.22,ENSG00000054267,ARID4B,-0.918045441,-1.1518115,-0.876108854,-0.726215968,AT-rich interaction domain 4B,"ARID4B (AT-rich interaction domain 4B) is a gene that encodes a protein that is a subunit of the SIN3A transcriptional corepressor complex. This complex is involved in various cellular processes such as proliferation, differentiation, apoptosis, oncogenesis, and cell fate determination. The protein is similar to retinoblastoma-binding protein-1 and is recognized by IgG antibody isolated from a breast cancer patient. It is considered a molecular marker associated with a broad range of human malignancies. Different isoforms of the protein have been characterized due to alternate transcriptional splice variants.","There is limited information available on the disease implications of ARID4B. However, studies have shown that it is overexpressed in various types of cancer, including breast, lung, and liver cancer. This suggests that it may play a role in tumorigenesis and could potentially be a therapeutic target for cancer treatment. 

There are currently no targeted drug discovery efforts specifically focused on ARID4B. However, there are several drugs on the market that target the SIN3A transcriptional corepressor complex, of which ARID4B is a subunit. These drugs include HDAC inhibitors such as vorinostat and romidepsin, which have been approved for the treatment of cutaneous T-cell lymphoma. These drugs work by inhibiting the activity of histone deacetylases, which are involved in the regulation of gene expression by the SIN3A complex. 

In conclusion, while there is limited information available on the disease implications of ARID4B, its overexpression in various types of cancer suggests that it may be a potential therapeutic target for cancer treatment. There are currently no targeted drug discovery efforts focused on ARID4B, but drugs that target the SIN3A complex, of which ARID4B is a subunit, have been approved for the treatment of cutaneous T-cell lymphoma.",GO:0097368 establishment of Sertoli cell barrier;GO:0060009 Sertoli cell development;GO:0071514 genomic imprinting,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Cytosol;Mitochondria (Supported); Additional: Nucleoplasm,,,(M5896)HALLMARK TGF BETA SIGNALING
ENSG00000189339.12,ENSG00000189339,SLC35E2B,-0.918031419,-1.539998846,-0.962152815,-0.251942596,solute carrier family 35 member E2B,SLC35E2B is a human gene that is predicted to be involved in transmembrane transport and enable antiporter activity. It is also predicted to play a role in blastocyst hatching and be an integral component of the membrane. The gene is predicted to be active in the Golgi apparatus.,"Unfortunately, there is limited information available on the disease implications and targeted drug discovery efforts for SLC35E2B. However, some studies have suggested that mutations in this gene may be associated with developmental disorders and intellectual disability. As for drug discovery efforts, there are currently no known drugs that specifically target SLC35E2B. However, there are drugs on the market that target other transporters and antiporters, such as proton pump inhibitors and sodium-glucose cotransporter 2 inhibitors, which have been successful in treating conditions such as acid reflux and type 2 diabetes. Further research is needed to fully understand the role of SLC35E2B in disease and to develop targeted therapies.",GO:0001835 blastocyst hatching;GO:0035188 hatching;GO:0071684 organism emergence from protective structure,,Transporters:Electrochemical Potential-driven transporters,Nucleoplasm (Approved),,,
ENSG00000186566.13,ENSG00000186566,GPATCH8,-0.917984291,-1.176277251,-0.98934325,-0.588332372,G-patch domain containing 8,"GPATCH8 is a human gene that encodes a protein containing several domains, including an RNA-processing domain, a zinc finger domain, a lysine-rich region, and a serine-rich region. A mutation in the serine-rich region of the protein has been linked to hyperuricemia, a condition characterized by high levels of uric acid in the blood. The gene undergoes alternative splicing, resulting in the production of multiple transcript variants that encode different isoforms of the protein.","Hyperuricemia, the condition associated with a mutation in the GPATCH8 gene, can lead to gout, a painful form of arthritis. Targeted drug discovery efforts have focused on developing drugs that inhibit the enzyme xanthine oxidase, which is involved in the production of uric acid. Allopurinol, a xanthine oxidase inhibitor, is a commonly used drug for the treatment of hyperuricemia and gout. Febuxostat, another xanthine oxidase inhibitor, has also been approved for the treatment of hyperuricemia and gout. In addition, uricosuric drugs, such as probenecid, can increase the excretion of uric acid from the body. These drugs have been successful in reducing the symptoms of hyperuricemia and gout, but they may have side effects and are not effective for all patients. Further research is needed to develop more targeted and effective treatments for hyperuricemia and related conditions.",,,Predicted intracellular proteins,Nuclear speckles (Approved); Additional: Mitochondria,,,
ENSG00000047346.12,ENSG00000047346,FAM214A,-0.917965535,-1.299674602,-1.005033225,-0.449188778,atos homolog A,"ATOSA, also known as Ataxin-2 binding protein 1 (A2BP1), is a human gene that encodes a protein called Atos homolog A. This protein is involved in the regulation of RNA metabolism and is thought to play a role in the development of the nervous system. Mutations in the ATOSA gene have been associated with several neurological disorders, including spinocerebellar ataxia type 2 (SCA2) and amyotrophic lateral sclerosis (ALS). The exact function of Atos homolog A is still being studied, but it is believed to be involved in the formation of RNA-protein complexes that are important for the regulation of gene expression.","Mutations in the ATOSA gene have been linked to several neurological disorders, including spinocerebellar ataxia type 2 (SCA2) and amyotrophic lateral sclerosis (ALS). SCA2 is a progressive neurodegenerative disorder that affects movement and coordination, while ALS is a fatal motor neuron disease that leads to muscle weakness and paralysis. Targeted drug discovery efforts for these diseases have focused on developing therapies that can modulate RNA metabolism and reduce the toxic effects of mutant ATOSA protein. Several small molecule compounds have been identified that can bind to and stabilize RNA-protein complexes, including pentamidine and quinacrine. These compounds have shown promise in preclinical studies and are currently being evaluated in clinical trials for the treatment of ALS and other neurodegenerative diseases. However, there are currently no FDA-approved drugs specifically targeting ATOSA or its associated diseases.",,,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000183337.17,ENSG00000183337,BCOR,-0.917691286,-1.294288174,-0.942390111,-0.516395573,BCL6 corepressor,"The BCOR gene encodes a protein that interacts with BCL6, a transcription repressor that is important for germinal center formation and apoptosis. The BCOR protein selectively interacts with the POZ domain of BCL6 and has been shown to interact with specific class I and II histone deacetylases (HDACs), suggesting a possible link between the two classes of HDACs. Multiple transcript variants encoding different isoforms have been identified for this gene, and a pseudogene of BCOR is found on chromosome Y.","Mutations in the BCOR gene have been associated with several diseases, including oculofaciocardiodental (OFCD) syndrome, Lenz microphthalmia syndrome, and acute myeloid leukemia (AML). In OFCD syndrome, mutations in BCOR are thought to disrupt the normal development of various tissues and organs, leading to the characteristic features of the disorder. In AML, BCOR mutations have been found to be associated with poor prognosis and resistance to chemotherapy.

Targeted drug discovery efforts for BCOR have focused on developing inhibitors of the protein-protein interactions between BCOR and BCL6, as well as inhibitors of the histone deacetylases that interact with BCOR. One example of a successful drug targeting BCOR is belinostat, a histone deacetylase inhibitor that has been approved by the FDA for the treatment of peripheral T-cell lymphoma.

Overall, the role of BCOR in disease pathogenesis and its potential as a therapeutic target are still being explored, but early results suggest that targeting BCOR and its interactions with other proteins may hold promise for the development of new treatments for a variety of diseases.",GO:0070171 negative regulation of tooth mineralization;GO:0065001 specification of axis polarity;GO:0070170 regulation of tooth mineralization,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of eye; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Nucleoplasm (Enhanced),,(M30)PID HDAC CLASSII PATHWAY,
ENSG00000108854.16,ENSG00000108854,SMURF2,-0.917659857,-1.296086258,-1.130406256,-0.326487057,SMAD specific E3 ubiquitin protein ligase 2,"SMURF2 is a human gene that encodes for a protein called SMAD specific E3 ubiquitin protein ligase 2. This protein has several functions, including enabling SMAD binding activity, identical protein binding activity, and ubiquitin-protein transferase activity. It is involved in negative regulation of the transforming growth factor beta receptor signaling pathway, positive regulation of trophoblast cell migration, and ubiquitin-dependent SMAD protein catabolic process. SMURF2 is located in the nuclear speck and is part of the ubiquitin ligase complex. Overall, SMURF2 plays an important role in regulating various cellular processes and signaling pathways.","Research has shown that SMURF2 is involved in the development and progression of several diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, SMURF2 has been found to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. Several drug discovery efforts have focused on developing small molecule inhibitors of SMURF2, with promising results in preclinical studies. However, no SMURF2-targeted drugs have been approved for clinical use yet. One example of a successful drug targeting a related protein is TGF-beta receptor inhibitors, which have been approved for the treatment of certain types of cancer. Further research is needed to fully understand the potential of SMURF2 as a therapeutic target and to develop effective drugs for clinical use.","GO:1901165 positive regulation of trophoblast cell migration;GO:1901163 regulation of trophoblast cell migration;GO:0060071 Wnt signaling pathway, planar cell polarity pathway",,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nuclear speckles (Supported),,(M181)PID BMP PATHWAY; (M286)PID TGFBR PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING
ENSG00000184014.8,ENSG00000184014,DENND5A,-0.917412157,-1.443619827,-0.899876589,-0.408740056,DENN domain containing 5A,"DENND5A is a human gene that encodes a protein containing a DENN domain, which functions as a guanine nucleotide exchange factor (GEF) for RAB proteins. This protein is involved in the conversion of inactive GDP-bound RAB proteins to their active GTP-bound form, and is recruited by RAB6 onto Golgi membranes. It is also known as RAB6-interacting protein 1 and binds with RAB39. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Mutations in this gene are associated with early infantile epileptic encephalopathy-49.","Mutations in the DENND5A gene have been associated with early infantile epileptic encephalopathy-49 (EIEE49), a rare genetic disorder characterized by seizures that begin in the first months of life and are often resistant to treatment. There are currently no targeted drug discovery efforts specifically for DENND5A mutations, but research is ongoing to identify potential therapeutic targets for EIEE49. 

There are currently no drugs on the market specifically targeting DENND5A mutations or EIEE49. However, there are several drugs approved for the treatment of epilepsy that may be used to manage seizures in individuals with EIEE49, including valproic acid, carbamazepine, and lamotrigine. Additionally, there are several drugs in development for the treatment of epilepsy that may be beneficial for individuals with EIEE49, including cannabidiol and fenfluramine. Clinical trials are ongoing to evaluate the safety and efficacy of these drugs in individuals with EIEE49 and other forms of epilepsy.","GO:0042147 retrograde transport, endosome to Golgi;GO:0010977 negative regulation of neuron projection development;GO:0016482 cytosolic transport",,Disease related genes; Human disease related genes:Nervous system diseases:Epilepsy; Predicted intracellular proteins,Golgi apparatus;Vesicles (Approved),,,(M5947)HALLMARK IL2 STAT5 SIGNALING; (M5890)HALLMARK TNFA SIGNALING VIA NFKB
ENSG00000047410.14,ENSG00000047410,TPR,-0.917190942,-1.060122273,-1.198787613,-0.49266294,"translocated promoter region, nuclear basket protein","The TPR gene encodes a large protein that forms filaments inside the nucleus and interacts with components of the nuclear pore complex. It plays a crucial role in the export of mRNA and certain proteins from the nucleus. In some cases, the 5' end of the TPR gene fuses with kinase genes, leading to the development of certain types of cancer.","The TPR gene has been implicated in several types of cancer, including acute lymphoblastic leukemia, acute myeloid leukemia, and breast cancer. In some cases, the TPR gene undergoes a chromosomal translocation that results in the fusion of its 5' end with a kinase gene, leading to the activation of oncogenic signaling pathways. Targeted drug discovery efforts have focused on developing inhibitors of the kinase activity of the fusion proteins, such as the BCR-ABL inhibitor imatinib, which is used to treat chronic myeloid leukemia. Other drugs that target TPR-related pathways include the mTOR inhibitor everolimus, which is used to treat breast cancer, and the HSP90 inhibitor ganetespib, which is being investigated in clinical trials for several types of cancer. However, more research is needed to fully understand the role of TPR in cancer and to develop effective targeted therapies.",GO:0031990 mRNA export from nucleus in response to heat stress;GO:0031453 positive regulation of heterochromatin formation;GO:1905269 positive regulation of chromatin organization,,Predicted intracellular proteins; Human disease related genes:Cancers:Cancers of endocrine organs; Potential drug targets; Disease related genes; Transporters:Transporter channels and pores; Cancer-related genes:Mutational cancer driver genes,Nuclear membrane (Enhanced),,,
ENSG00000120899.18,ENSG00000120899,PTK2B,-0.916822276,-1.446726124,-0.767111062,-0.536629643,protein tyrosine kinase 2 beta,"PTK2B is a gene that encodes a cytoplasmic protein tyrosine kinase involved in calcium-induced regulation of ion channels and activation of the map kinase signaling pathway. It acts as a signaling intermediate between neuropeptide-activated receptors or neurotransmitters that increase calcium flux and the downstream signals that regulate neuronal activity. The protein undergoes rapid tyrosine phosphorylation and activation in response to increases in the intracellular calcium concentration, nicotinic acetylcholine receptor activation, membrane depolarization, or protein kinase C activation. PTK2B has been shown to bind to various proteins, including CRK-associated substrate, nephrocystin, GTPase regulator associated with FAK, and the SH2 domain of GRB2. It is a member of the FAK subfamily of protein tyrosine kinases and has four transcript variants encoding two different isoforms.","PTK2B has been implicated in various diseases, including cancer, Alzheimer's disease, and cardiovascular disease. In cancer, PTK2B has been shown to promote tumor growth, invasion, and metastasis by regulating cell adhesion, migration, and survival. Therefore, PTK2B inhibitors have been developed as potential anticancer agents. One example is PF-562271, a selective PTK2B inhibitor that has shown promising results in preclinical studies and is currently in clinical trials for the treatment of solid tumors. In Alzheimer's disease, PTK2B has been found to be involved in the regulation of synaptic plasticity and memory formation. Therefore, PTK2B inhibitors have been proposed as potential therapeutic agents for Alzheimer's disease. However, no PTK2B inhibitors have been approved for clinical use in Alzheimer's disease yet. In cardiovascular disease, PTK2B has been shown to play a role in the regulation of vascular smooth muscle cell proliferation and migration. Therefore, PTK2B inhibitors have been proposed as potential therapeutic agents for the treatment of restenosis after angioplasty. However, no PTK2B inhibitors have been approved for clinical use in cardiovascular disease yet.",GO:0043157 response to cation stress;GO:2000537 regulation of B cell chemotaxis;GO:2000538 positive regulation of B cell chemotaxis,yes,Kinases:Tyr protein kinases; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Cytosol;Plasma membrane (Supported),"Leflunomide; Genistein; 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide; Baricitinib; Fostamatinib",(M12771)SA PTEN PATHWAY; (M63)PID AVB3 OPN PATHWAY; (M275)PID ALPHA SYNUCLEIN PATHWAY,(M5908)HALLMARK ANDROGEN RESPONSE
ENSG00000065526.12,ENSG00000065526,SPEN,-0.916229117,-1.277860226,-1.039637189,-0.431189935,spen family transcriptional repressor,"SPEN is a gene that encodes a hormone-inducible transcriptional repressor. The protein product of this gene can repress transcription through interactions with other repressors, recruitment of proteins involved in histone deacetylation, or sequestration of transcriptional activators. The protein contains a carboxy-terminal domain that allows it to bind to other corepressor proteins and interact with the NuRD complex, a nucleosome remodeling protein complex with deacetylase activity. Additionally, the protein contains RNA recognition motifs that allow it to bind to a steroid receptor RNA coactivator, which can modulate the activity of both liganded and nonliganded steroid receptors.","There is limited information available on the disease implications of SPEN mutations. However, recent studies have suggested that SPEN may play a role in the development of certain cancers, including breast cancer and acute myeloid leukemia. Targeted drug discovery efforts for SPEN are still in the early stages, but there is potential for the development of drugs that target the protein's interactions with other corepressor proteins or its RNA recognition motifs. Currently, there are no drugs on the market that specifically target SPEN, but there are drugs that target other proteins involved in transcriptional regulation, such as histone deacetylases and steroid receptors. Examples of such drugs include Vorinostat, a histone deacetylase inhibitor used to treat cutaneous T-cell lymphoma, and Tamoxifen, a selective estrogen receptor modulator used to treat breast cancer.",GO:0060816 random inactivation of X chromosome;GO:0009048 dosage compensation by inactivation of X chromosome;GO:0007549 sex-chromosome dosage compensation,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Nucleoplasm (Enhanced),,(M288)PID HES HEY PATHWAY; (M17)PID NOTCH PATHWAY,
ENSG00000110218.9,ENSG00000110218,PANX1,-0.915999701,-1.653131915,-0.617759019,-0.477108169,pannexin 1,"PANX1, also known as pannexin 1, is a gene that belongs to the innexin family and encodes a protein that is a structural component of gap junctions. This protein is abundantly expressed in the central nervous system (CNS) and is coexpressed with pannexin 2 in various neuronal populations. Studies suggest that PANX1 alone and in combination with pannexin 2 may form cell type-specific gap junctions with distinct properties. The function of PANX1 in the CNS is not fully understood, but it has been implicated in various physiological processes, including neurotransmitter release, neuronal excitability, and inflammation.","There is growing evidence that PANX1 may play a role in several neurological and psychiatric disorders, including epilepsy, stroke, traumatic brain injury, and schizophrenia. In particular, PANX1 has been implicated in the pathogenesis of epilepsy, where it is thought to contribute to the spread of seizure activity between neurons. As a result, there has been interest in developing drugs that target PANX1 as a potential treatment for epilepsy and other related disorders. Several compounds have been identified that can block PANX1 channels, including probenecid, mefloquine, and carbenoxolone. However, these compounds have limited specificity and may have off-target effects. More recently, a new class of PANX1 inhibitors has been developed that shows greater selectivity and potency, and these compounds are currently being evaluated in preclinical studies for their potential as novel antiepileptic drugs.",GO:0032730 positive regulation of interleukin-1 alpha production;GO:0032650 regulation of interleukin-1 alpha production;GO:0015867 ATP transport,,Disease related genes; Human disease related genes:Reproductive system diseases:Reproductive system diseases; Potential drug targets; Transporters:Transporter channels and pores,Plasma membrane (Enhanced),Probenecid,,(M5890)HALLMARK TNFA SIGNALING VIA NFKB
ENSG00000186866.17,ENSG00000186866,POFUT2,-0.915558671,-1.606564057,-0.787483089,-0.352628867,protein O-fucosyltransferase 2,"POFUT2 is a human gene that encodes for protein O-fucosyltransferase 2. This enzyme is responsible for adding fucose to serine or threonine residues within cystine knot motifs in epidermal growth factor-like repeats or thrombospondin type-1 repeats. Fucose is typically found as a terminal modification of branched chain glycoconjugates, but POFUT2 uses THBS type-1 repeats as substrates. This gene was first described in 2006 and its function is important for proper protein folding and function.","Research on POFUT2 has revealed its potential implications in various diseases, including cancer, Alzheimer's disease, and congenital disorders of glycosylation. In cancer, POFUT2 has been found to play a role in the Notch signaling pathway, which is involved in cell proliferation and differentiation. Inhibition of POFUT2 has been shown to reduce tumor growth in preclinical models. In Alzheimer's disease, POFUT2 has been linked to the abnormal accumulation of beta-amyloid protein in the brain, a hallmark of the disease. Inhibition of POFUT2 has been proposed as a potential therapeutic strategy for reducing beta-amyloid accumulation.

Targeted drug discovery efforts for POFUT2 are still in the early stages, but several small molecule inhibitors have been identified in preclinical studies. These inhibitors have shown promising results in reducing tumor growth and beta-amyloid accumulation in animal models. However, more research is needed to determine their safety and efficacy in humans.

Currently, there are no drugs on the market that specifically target POFUT2. However, there are several drugs that indirectly affect POFUT2 activity by targeting the Notch signaling pathway, such as gamma-secretase inhibitors and monoclonal antibodies against Notch receptors. These drugs are used in the treatment of certain types of cancer and Alzheimer's disease.",GO:1903334 positive regulation of protein folding;GO:0036066 protein O-linked fucosylation;GO:1903332 regulation of protein folding,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,,,,
ENSG00000074054.20,ENSG00000074054,CLASP1,-0.915261186,-1.589082865,-0.684713056,-0.471987639,cytoplasmic linker associated protein 1,"CLASP1 is a human gene that encodes for a nonmotor microtubule-associated protein. It interacts with CLIPs and is involved in regulating microtubule dynamics at the kinetochore and throughout the spindle. This gene plays a role in cell division and is important for maintaining proper chromosome segregation during mitosis. Mutations in CLASP1 have been associated with various diseases, including cancer and developmental disorders.","CLASP1 has been implicated in various diseases, including cancer and developmental disorders. In cancer, CLASP1 has been shown to be overexpressed in several types of tumors, including breast, ovarian, and lung cancers. Targeting CLASP1 has been proposed as a potential therapeutic strategy for cancer treatment. However, there are currently no drugs on the market that specifically target CLASP1.

There have been some efforts to develop drugs that target microtubule-associated proteins, including CLASP1. For example, taxanes such as paclitaxel and docetaxel are commonly used chemotherapeutic agents that target microtubules. However, these drugs are not specific to CLASP1 and can have significant side effects.

Another potential approach to targeting CLASP1 is through the use of small molecule inhibitors. A recent study identified a small molecule inhibitor of CLASP1 that was able to inhibit tumor growth in vitro and in vivo. However, further research is needed to determine the safety and efficacy of this approach.

Overall, while CLASP1 has been implicated in various diseases, including cancer, there are currently no drugs on the market that specifically target this gene. However, there is ongoing research into the development of drugs that target microtubule-associated proteins, including CLASP1, which may lead to new treatment options in the future.","GO:1903690 negative regulation of wound healing, spreading of epidermal cells;GO:1904259 regulation of basement membrane assembly involved in embryonic body morphogenesis;GO:1904261 positive regulation of basement membrane assembly involved in embryonic body morphogenesis",,Predicted intracellular proteins,,Fostamatinib,,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000135999.12,ENSG00000135999,EPC2,-0.914597243,-1.250055834,-0.924673206,-0.569062689,enhancer of polycomb homolog 2,"EPC2, or enhancer of polycomb homolog 2, is a human gene that is predicted to play a role in histone acetyltransferase activity and regulation of transcription by RNA polymerase II. It is also predicted to be part of the Piccolo NuA4 histone acetyltransferase complex. This gene is still being studied, but its potential involvement in these processes suggests that it may be important for gene expression and regulation.","There is limited information available on the disease implications of EPC2. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for EPC2 are still in the early stages, but there is potential for this gene to be a target for cancer therapies. Currently, there are no drugs on the market that specifically target EPC2. However, there are drugs that target histone acetyltransferases, which may indirectly affect EPC2 activity. For example, the drug vorinostat is a histone deacetylase inhibitor that is used to treat cutaneous T-cell lymphoma. Another drug, panobinostat, is a histone deacetylase inhibitor that is used to treat multiple myeloma.",GO:1905168 positive regulation of double-strand break repair via homologous recombination;GO:0045911 positive regulation of DNA recombination;GO:0010569 regulation of double-strand break repair via homologous recombination,,Predicted intracellular proteins,Nuclear speckles (Approved),,,
ENSG00000183688.4,ENSG00000183688,RFLNB,-0.914283573,-1.589644782,-0.724184854,-0.429021082,refilin B,"RFLNB, also known as refilin B, is a human gene that is involved in various biological processes, including the organization of actin filament bundles, negative regulation of bone mineralization, and negative regulation of chondrocyte development. It is predicted to act upstream of or within actin cytoskeleton organization and epithelial to mesenchymal transition. RFLNB is located in the actin cytoskeleton and is active in actin filament bundle. Its main function is to enable filamin binding activity. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of RFLNB. However, recent studies have suggested that mutations in RFLNB may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for RFLNB are also limited, as the gene is not currently considered a major drug target. However, there are ongoing efforts to develop drugs that target the actin cytoskeleton and its associated proteins, which may indirectly affect RFLNB activity. Examples of successful drugs that target the actin cytoskeleton include cytochalasin D, latrunculin A, and jasplakinolide, which have been used in research to study actin dynamics and cytoskeletal organization. However, these drugs have not yet been approved for clinical use.",GO:0061182 negative regulation of chondrocyte development;GO:1900158 negative regulation of bone mineralization involved in bone maturation;GO:0061181 regulation of chondrocyte development,,Predicted intracellular proteins,Actin filaments (Approved); Additional: Cytosol;Plasma membrane,,,
ENSG00000134871.19,ENSG00000134871,COL4A2,-0.914109508,-1.541094181,-1.103074747,-0.098159597,collagen type IV alpha 2 chain,"COL4A2 is a gene that encodes for one of the six subunits of type IV collagen, which is a major component of basement membranes. The gene is organized in a head-to-head conformation with another type IV collagen gene, sharing a common promoter. The C-terminal portion of the protein, known as canstatin, is an inhibitor of angiogenesis and tumor growth.","Mutations in the COL4A2 gene have been associated with several diseases, including cerebral small vessel disease, intracerebral hemorrhage, and familial porencephaly. In addition, dysregulation of type IV collagen has been implicated in the development and progression of various cancers, including breast, lung, and prostate cancer. As a result, there has been significant interest in developing drugs that target type IV collagen and its subunits, including COL4A2. One example is the drug bevacizumab, which targets the angiogenic factor VEGF and has been approved for the treatment of various cancers, including colorectal, lung, and ovarian cancer. Another example is the drug nintedanib, which targets multiple tyrosine kinases involved in angiogenesis and has been approved for the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer.",GO:0035987 endodermal cell differentiation;GO:0001706 endoderm formation;GO:0038063 collagen-activated tyrosine kinase receptor signaling pathway,,Predicted intracellular proteins; Predicted secreted proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Human disease related genes:Cardiovascular diseases:Vascular diseases; Disease related genes; Cancer-related genes:Candidate cancer biomarkers,Vesicles (Approved),,(M5887)NABA BASEMENT MEMBRANES; (M3005)NABA COLLAGENS; (M5884)NABA CORE MATRISOME,(M5909)HALLMARK MYOGENESIS; (M5921)HALLMARK COMPLEMENT; (M5930)HALLMARK EPITHELIAL MESENCHYMAL TRANSITION
ENSG00000109572.14,ENSG00000109572,CLCN3,-0.913379457,-1.238266488,-0.939990062,-0.56188182,chloride voltage-gated channel 3,"CLCN3 is a gene that encodes a protein belonging to the voltage-gated chloride channel family. This protein is found in all cell types and is located in plasma membranes and intracellular vesicles. It contains a ClC domain and two CBS domains, with the ClC domain facilitating the selective flow of chloride ions across cell membranes. The CBS domain may have a regulatory function. CLCN3 plays a role in acidification and transmitter loading of GABAergic synaptic vesicles, smooth muscle cell activation, neointima formation, LPA-activated Cl- current activity, and fibroblast-to-myofibroblast differentiation. The protein activity is regulated by CaMKII in glioma cells. Multiple alternatively spliced transcript variants encoding different isoforms have been identified.","Mutations in the CLCN3 gene have been associated with several diseases, including osteopetrosis, epilepsy, and idiopathic generalized epilepsy. Additionally, altered expression of CLCN3 has been observed in various cancers, including glioma, breast cancer, and prostate cancer. As a result, CLCN3 has been identified as a potential therapeutic target for these diseases. Several drugs targeting CLCN3 have been developed, including the small molecule inhibitor NS3736, which has been shown to inhibit CLCN3 activity and reduce neointima formation in animal models of vascular injury. Another drug, Lubiprostone, is a chloride channel activator that has been approved by the FDA for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation. While Lubiprostone does not directly target CLCN3, it has been shown to activate chloride channels, including CLCN3, in intestinal epithelial cells.",GO:0045794 negative regulation of cell volume;GO:0048388 endosomal lumen acidification;GO:0097401 synaptic vesicle lumen acidification,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Vesicles (Supported),,,(M5910)HALLMARK PROTEIN SECRETION; (M5945)HALLMARK HEME METABOLISM
ENSG00000172071.14,ENSG00000172071,EIF2AK3,-0.913334657,-1.57629644,-0.866655311,-0.29705222,eukaryotic translation initiation factor 2 alpha kinase 3,"EIF2AK3 is a gene that encodes a protein responsible for phosphorylating the alpha subunit of eukaryotic translation-initiation factor 2, leading to its inactivation and a reduction in translational initiation and global protein synthesis. This protein is located in the endoplasmic reticulum and is induced by ER stress caused by malfolded proteins. It is thought to modulate mitochondrial function and mutations in this gene are associated with Wolcott-Rallison syndrome.","Mutations in the EIF2AK3 gene have been linked to Wolcott-Rallison syndrome, a rare autosomal recessive disorder characterized by early-onset diabetes mellitus, skeletal dysplasia, and liver dysfunction. There are currently no targeted drug discovery efforts specifically for EIF2AK3, but there are drugs on the market that indirectly affect its function. For example, metformin, a commonly used drug for type 2 diabetes, has been shown to activate the EIF2AK3 pathway, leading to reduced protein synthesis and improved glucose homeostasis. Additionally, salubrinal, a small molecule inhibitor of the protein phosphatase PP1, has been shown to enhance the phosphorylation of EIF2AK3 and improve insulin sensitivity in animal models of diabetes. However, more research is needed to fully understand the role of EIF2AK3 in disease and to develop targeted therapies.",GO:0060734 regulation of endoplasmic reticulum stress-induced eIF2 alpha phosphorylation;GO:0010998 regulation of translational initiation by eIF2 alpha phosphorylation;GO:0036492 eiF2alpha phosphorylation in response to endoplasmic reticulum stress,yes,Predicted intracellular proteins; Kinases; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes; Human disease related genes:Endocrine and metabolic diseases:Diabetes,,,,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000166340.17,ENSG00000166340,TPP1,-0.913307343,-1.66378213,-0.578954175,-0.497185723,tripeptidyl peptidase 1,"TPP1, or tripeptidyl peptidase 1, is a gene that encodes a serine protease belonging to the sedolisin family. This protease is responsible for cleaving N-terminal tripeptides from substrates in the lysosome and has weaker endopeptidase activity. The enzyme is initially synthesized as an inactive form and is activated and auto-proteolyzed upon acidification. Mutations in TPP1 lead to late-infantile neuronal ceroid lipofuscinosis, a condition characterized by the inability to degrade specific neuropeptides and a subunit of ATP synthase in the lysosome.","Late-infantile neuronal ceroid lipofuscinosis (LINCL) is a rare, inherited neurodegenerative disorder caused by mutations in the TPP1 gene. The disease is characterized by the accumulation of autofluorescent storage material in the lysosomes of neurons, leading to progressive loss of motor and cognitive function, seizures, and ultimately premature death. There are currently no disease-modifying treatments for LINCL, and management is largely supportive. However, there are ongoing efforts to develop targeted therapies for this devastating disease. One approach is to replace the missing TPP1 enzyme using enzyme replacement therapy (ERT). Another approach is to use small molecules to enhance the residual activity of the mutant TPP1 enzyme. One such drug, Brineura (cerliponase alfa), was approved by the FDA in 2017 for the treatment of LINCL. Brineura is a recombinant form of human TPP1 that is administered directly into the cerebrospinal fluid via an intraventricular catheter. Clinical trials have shown that Brineura can slow the progression of LINCL and improve quality of life for affected children.","GO:1905146 lysosomal protein catabolic process;GO:0007039 protein catabolic process in the vacuole;GO:0070198 protein localization to chromosome, telomeric region",,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Lysosomal storage diseases; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,,,,
ENSG00000107362.14,ENSG00000107362,ABHD17B,-0.91287522,-1.376118256,-1.001371589,-0.361135816,"abhydrolase domain containing 17B, depalmitoylase","ABHD17B is a human gene that encodes for a protein called abhydrolase domain containing 17B, which functions as a depalmitoylase enzyme. This enzyme is involved in the removal of palmitoyl groups from proteins, a process known as protein depalmitoylation. ABHD17B is located in the membrane and enables palmitoyl-(protein) hydrolase activity. The gene's function is important for regulating protein localization and activity, and its dysfunction has been linked to various diseases, including cancer and neurological disorders.","ABHD17B has been implicated in various diseases, including cancer and neurological disorders. In cancer, ABHD17B has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. In neurological disorders, ABHD17B dysfunction has been linked to neurodegeneration and cognitive impairment, making it a potential target for the treatment of these disorders.

Targeted drug discovery efforts for ABHD17B are ongoing, with a focus on developing small molecule inhibitors that can selectively target the enzyme's activity. One example of a successful drug targeting a related enzyme is the drug palmostatin B, which inhibits the activity of palmitoyl acyltransferase (PAT), the enzyme responsible for adding palmitoyl groups to proteins. Palmostatin B has been shown to have anti-cancer activity in preclinical studies.

Another example of a successful drug targeting protein depalmitoylation is the drug clozapine, which is used to treat schizophrenia. Clozapine has been shown to inhibit the activity of ABHD17B, leading to increased depalmitoylation of the dopamine D2 receptor and improved therapeutic efficacy.

Overall, ABHD17B is an important target for drug discovery efforts in cancer and neurological disorders, and the development of small molecule inhibitors targeting its activity could lead to the development of new therapies for these diseases.",GO:1902816 regulation of protein localization to microtubule;GO:1902817 negative regulation of protein localization to microtubule;GO:0002084 protein depalmitoylation,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,,,,
ENSG00000144747.17,ENSG00000144747,TMF1,-0.912866197,-1.209097339,-1.013989924,-0.515511327,TATA element modulatory factor 1,"TMF1, also known as TATA element modulatory factor 1, is a human gene that plays a role in androgen receptor signaling pathway and positive regulation of transcription by RNA polymerase II. It enables androgen receptor binding activity and nuclear receptor coactivator activity. TMF1 is located in the Golgi apparatus. This gene is important for the proper functioning of the androgen receptor, which is involved in the development and maintenance of male sexual characteristics. Dysfunction of TMF1 may lead to disorders related to androgen signaling, such as prostate cancer.","Dysfunction of TMF1 has been implicated in several diseases, including prostate cancer, breast cancer, and androgen insensitivity syndrome. Targeted drug discovery efforts have focused on developing drugs that can modulate the activity of the androgen receptor, which is regulated by TMF1. One example of a successful drug on the market is enzalutamide, which is used to treat advanced prostate cancer. Enzalutamide works by blocking the androgen receptor, preventing it from binding to androgens and activating downstream signaling pathways. Another example is bicalutamide, which is also used to treat prostate cancer. Bicalutamide works by binding to the androgen receptor and preventing it from activating downstream signaling pathways. These drugs have shown promising results in clinical trials and have been approved by regulatory agencies for use in patients with advanced prostate cancer.",GO:2000843 regulation of testosterone secretion;GO:2000845 positive regulation of testosterone secretion;GO:0032275 luteinizing hormone secretion,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Golgi apparatus (Supported),,(M58)PID AR PATHWAY,
ENSG00000171681.12,ENSG00000171681,ATF7IP,-0.91241302,-1.587135282,-0.675044628,-0.475059151,activating transcription factor 7 interacting protein,"ATF7IP is a nuclear protein that interacts with heterochromatin and has multiple functions. Depending on its binding partners, it can either activate or repress transcription. This protein is involved in various cellular processes, including cell cycle regulation, DNA damage response, and chromatin remodeling. Mutations in ATF7IP have been associated with several diseases, including cancer and intellectual disability.","Mutations in ATF7IP have been associated with several diseases, including cancer and intellectual disability. In cancer, ATF7IP has been shown to play a role in promoting tumor growth and metastasis, making it a potential target for cancer therapy. Targeted drug discovery efforts have focused on developing small molecule inhibitors of ATF7IP, with some promising results in preclinical studies. However, no drugs targeting ATF7IP have been approved for clinical use yet. In terms of intellectual disability, mutations in ATF7IP have been linked to a rare genetic disorder called ""chromosome 16p11.2 deletion syndrome,"" which is characterized by developmental delays, intellectual disability, and other neurological and behavioral problems. Currently, there are no targeted drugs available for this disorder, and treatment is mainly supportive and focused on managing symptoms.",GO:0006346 DNA methylation-dependent constitutive heterochromatin formation;GO:0140719 constitutive heterochromatin formation;GO:0031507 heterochromatin formation,,Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Enhanced),,,
ENSG00000066557.6,ENSG00000066557,LRRC40,-0.912140529,-0.958733235,-1.293045755,-0.484642596,leucine rich repeat containing 40,"The LRRC40 gene, also known as leucine rich repeat containing 40, is predicted to have the ability to enable protein serine/threonine phosphatase activity and be involved in signal transduction. It is located in the membrane. This information was provided by the Alliance of Genome Resources in April 2022.","There is limited information available on the disease implications of the LRRC40 gene. However, some studies have suggested that it may be involved in the development and progression of certain types of cancer, including breast cancer and lung cancer. As for targeted drug discovery efforts, there are currently no known drugs that specifically target LRRC40. However, there are ongoing efforts to develop drugs that target the signaling pathways in which LRRC40 is involved. Examples of successful drugs on the market that target similar signaling pathways include mTOR inhibitors like rapamycin, which are used to treat certain types of cancer and autoimmune diseases. Additionally, drugs that target protein phosphatases, such as cyclosporine and tacrolimus, are used to prevent organ rejection in transplant patients.",GO:0035556 intracellular signal transduction;GO:0007165 signal transduction;GO:0023052 signaling,,Predicted intracellular proteins,Nucleoli (Approved),,,
ENSG00000109466.14,ENSG00000109466,KLHL2,-0.911574509,-1.214499286,-0.877016927,-0.643207315,kelch like family member 2,KLHL2 is a human gene that belongs to the kelch-like family. It is involved in actin binding activity and identical protein binding activity. The gene is predicted to be involved in protein ubiquitination and is located in the actin cytoskeleton. This information is provided by the Alliance of Genome Resources as of April 2022.,"KLHL2 has been implicated in several diseases, including cancer, neurological disorders, and cardiovascular diseases. In cancer, KLHL2 has been shown to play a role in the regulation of the cell cycle and apoptosis, and its expression has been found to be altered in various types of cancer, including lung, breast, and prostate cancer. In neurological disorders, KLHL2 has been linked to the development of Alzheimer's disease and Parkinson's disease. In cardiovascular diseases, KLHL2 has been shown to be involved in the regulation of blood pressure and cardiac function.

Targeted drug discovery efforts for KLHL2 are still in the early stages, but there is growing interest in developing drugs that target this gene. One approach is to develop small molecules that can inhibit the interaction between KLHL2 and its binding partners, which could potentially be used to treat cancer and other diseases. Another approach is to develop drugs that can modulate the activity of KLHL2, which could be used to treat neurological and cardiovascular diseases.

There are currently no drugs on the market that specifically target KLHL2, but there are several drugs that indirectly affect its activity. For example, statins, which are commonly used to lower cholesterol levels, have been shown to upregulate KLHL2 expression in the liver. Additionally, some antihypertensive drugs, such as angiotensin receptor blockers, have been shown to modulate KLHL2 expression in the heart. These drugs are not specific to KLHL2, but their effects on this gene may contribute to their therapeutic benefits in certain diseases.",GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process;GO:0010498 proteasomal protein catabolic process;GO:0006511 ubiquitin-dependent protein catabolic process,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Nucleoplasm (Uncertain); Additional: Vesicles,,,
ENSG00000107164.16,ENSG00000107164,FUBP3,-0.911017294,-1.067235574,-1.185964,-0.479852308,far upstream element binding protein 3,"FUBP3, or far upstream element binding protein 3, is a gene that encodes a protein involved in binding to single-stranded DNA. It plays a role in positively regulating gene expression and transcription, particularly upstream of or within positive regulation of transcription by RNA polymerase II. FUBP3 is located in both the cytoplasm and nucleus.","There is limited information available on the disease implications of FUBP3. However, recent studies have suggested that FUBP3 may play a role in the development and progression of certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for FUBP3 are still in the early stages, but there is potential for the development of drugs that target FUBP3 to treat these types of cancer. Currently, there are no drugs on the market that specifically target FUBP3. However, there are drugs that target other proteins involved in the same pathways as FUBP3, such as inhibitors of the PI3K/AKT/mTOR pathway, which have shown promise in treating breast cancer and glioblastoma. Further research is needed to fully understand the role of FUBP3 in disease and to develop targeted therapies.",GO:0008298 intracellular mRNA localization;GO:0006403 RNA localization;GO:0006351 DNA-templated transcription,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000110330.8,ENSG00000110330,BIRC2,-0.91048813,-1.572479174,-0.847105999,-0.311879219,baculoviral IAP repeat containing 2,"BIRC2 is a human gene that encodes a protein belonging to a family of proteins that prevent apoptosis by binding to TRAF1 and TRAF2. The protein inhibits apoptosis induced by serum deprivation and menadione, which is a potent inducer of free radicals. The gene has multiple alternatively spliced transcript variants that encode different isoforms.","BIRC2 has been implicated in various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In cancer, BIRC2 is overexpressed in many tumor types and is associated with resistance to chemotherapy and radiation therapy. Targeting BIRC2 has been explored as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of BIRC2 have been developed, including birinapant and AT-406, which have shown promising results in preclinical studies and clinical trials for the treatment of various cancers. In addition, combination therapies targeting BIRC2 and other apoptotic pathways have also been investigated. However, the clinical efficacy of BIRC2 inhibitors as monotherapy or in combination with other agents remains to be fully established. Overall, BIRC2 is a promising target for drug discovery efforts in cancer and other diseases, and further research is needed to fully understand its role in disease pathogenesis and to develop effective therapies.",GO:1902442 regulation of ripoptosome assembly involved in necroptotic process;GO:1902443 negative regulation of ripoptosome assembly involved in necroptotic process;GO:1902524 positive regulation of protein K48-linked ubiquitination,,Enzymes; ENZYME proteins:Transferases; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cytosol;Nucleoli fibrillar center (Supported); Additional: Nucleoplasm,,(M7997)SA CASPASE CASCADE; (M37)PID NFKAPPAB CANONICAL PATHWAY; (M45)PID CD40 PATHWAY,(M5890)HALLMARK TNFA SIGNALING VIA NFKB
ENSG00000057252.13,ENSG00000057252,SOAT1,-0.910472869,-1.407612476,-0.871028262,-0.452777869,sterol O-acyltransferase 1,"SOAT1 is a gene that encodes for an enzyme called sterol O-acyltransferase 1, which belongs to the acyltransferase family. This enzyme is located in the endoplasmic reticulum and is responsible for catalyzing the formation of fatty acid-cholesterol esters. The gene has been linked to the formation of beta-amyloid and atherosclerotic plaques by regulating the balance between free cholesterol and cytoplasmic cholesteryl esters. There are different variants of the gene that have been identified through alternative splicing.","SOAT1 has been implicated in several diseases, including Alzheimer's disease, atherosclerosis, and cancer. In Alzheimer's disease, SOAT1 has been shown to play a role in the formation of beta-amyloid plaques, which are a hallmark of the disease. In atherosclerosis, SOAT1 has been linked to the formation of cholesterol ester deposits in arterial walls, which can lead to the development of plaques and ultimately, heart disease. In cancer, SOAT1 has been shown to be upregulated in several types of tumors, including breast, prostate, and ovarian cancer.

Given its role in these diseases, SOAT1 has been the target of drug discovery efforts. Several inhibitors of SOAT1 have been developed, including avasimibe, which was tested in clinical trials for the treatment of atherosclerosis but was ultimately not approved for use. Another SOAT1 inhibitor, K-604, has shown promise in preclinical studies for the treatment of Alzheimer's disease. Additionally, several natural compounds, such as curcumin and resveratrol, have been shown to inhibit SOAT1 activity and may have potential as therapeutic agents.

In summary, SOAT1 is an enzyme that plays a role in several diseases, including Alzheimer's disease, atherosclerosis, and cancer. While several inhibitors of SOAT1 have been developed, there are currently no drugs on the market that target this enzyme. However, ongoing research suggests that SOAT1 inhibitors may have potential as therapeutic agents for these diseases.",GO:0042986 positive regulation of amyloid precursor protein biosynthetic process;GO:0010742 macrophage derived foam cell differentiation;GO:0090077 foam cell differentiation,,Enzymes; FDA approved drug targets:Small molecule drugs; ENZYME proteins:Transferases,Endoplasmic reticulum (Enhanced),Ezetimibe; Hesperetin,,
ENSG00000169564.7,ENSG00000169564,PCBP1,-0.910110411,-1.344718563,-1.301965377,-0.083647294,poly(rC) binding protein 1,"PCBP1, or poly(rC) binding protein 1, is a multifunctional protein that is involved in RNA binding and translational control. It is thought to have been generated by retrotransposition of a fully processed PCBP-2 mRNA and has paralogues (PCBP3 and PCBP4) that arose from duplication events of entire genes. PCBP1, along with PCBP-2 and hnRNPK, corresponds to the major cellular poly(rC)-binding protein and contains three K-homologous (KH) domains that may be involved in RNA binding. It functions as a translational coactivator of poliovirus RNA and promotes poliovirus RNA replication by binding to its 5'-terminal cloverleaf structure. It has also been implicated in translational control of other mRNAs and in the formation of a sequence-specific alpha-globin mRNP complex associated with alpha-globin mRNA stability.","There is limited information on the disease implications of PCBP1. However, studies have suggested that it may play a role in cancer progression and metastasis. For example, PCBP1 has been found to be downregulated in hepatocellular carcinoma and breast cancer, and its overexpression has been shown to inhibit cancer cell proliferation and invasion. Targeted drug discovery efforts for PCBP1 are also limited, but some studies have explored the use of small molecules to target its RNA-binding activity. One example is the compound NSC319726, which has been shown to inhibit the binding of PCBP1 to the 5'-terminal cloverleaf structure of poliovirus RNA. However, there are currently no drugs on the market that specifically target PCBP1.",GO:0039694 viral RNA genome replication;GO:0019079 viral genome replication;GO:0019058 viral life cycle,,Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Mutated cancer genes; Predicted intracellular proteins,Nuclear speckles (Supported); Additional: Cytoplasmic bodies;Cytosol;Nucleoplasm,,,(M5926)HALLMARK MYC TARGETS V1
ENSG00000172845.17,ENSG00000172845,SP3,-0.909575084,-1.097422692,-0.984953455,-0.646349106,Sp3 transcription factor,"SP3 is a gene that encodes a transcription factor belonging to the Sp1 family. This protein regulates transcription by binding to specific regulatory elements in target genes. It contains a DNA-binding domain and transactivation domains, and can either stimulate or repress the transcription of various genes. Different isoforms of SP3 have been identified, with some initiating translation from non-AUG start codons. Alternate downstream translation initiation sites have also been noted, resulting in additional isoforms. A related pseudogene has been found on chromosome 13.","SP3 has been implicated in various diseases, including cancer, diabetes, and neurological disorders. In cancer, SP3 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. In diabetes, SP3 has been linked to insulin resistance and beta-cell dysfunction, suggesting that targeting SP3 could be a potential strategy for treating diabetes. In neurological disorders, SP3 has been associated with Alzheimer's disease and Huntington's disease, indicating that it may be a potential therapeutic target for these conditions.

There have been efforts to develop drugs that target SP3. One example is the small molecule inhibitor, mithramycin A, which has been shown to inhibit SP3 activity and reduce tumor growth in preclinical studies. Another example is the natural compound, curcumin, which has been shown to inhibit SP3 activity and reduce insulin resistance in animal models of diabetes.

In addition to these examples, there are ongoing efforts to identify and develop new drugs that target SP3. These efforts include the use of high-throughput screening and computational methods to identify compounds that bind to SP3 and modulate its activity. Overall, targeting SP3 represents a promising approach for the development of new therapies for a range of diseases.",GO:0002318 myeloid progenitor cell differentiation;GO:0060136 embryonic process involved in female pregnancy;GO:0043353 enucleate erythrocyte differentiation,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,(M105)PID TELOMERASE PATHWAY; (M2)PID SMAD2 3NUCLEAR PATHWAY,
ENSG00000161202.20,ENSG00000161202,DVL3,-0.908847593,-1.543176205,-0.556171968,-0.627194607,dishevelled segment polarity protein 3,"DVL3 is a human gene that belongs to a family of genes that share similarities with the Drosophila dishevelled gene, dsh. The Drosophila dishevelled gene encodes a cytoplasmic phosphoprotein that regulates cell proliferation. DVL3 is involved in the Wnt signaling pathway, which plays a crucial role in embryonic development and tissue homeostasis. Mutations in DVL3 have been associated with various diseases, including cancer and neural tube defects. The gene is expressed in various tissues, including the brain, heart, and kidney.","DVL3 has been implicated in various diseases, including cancer and neural tube defects. In cancer, DVL3 is often overexpressed and contributes to tumor growth and metastasis. Targeting DVL3 has been explored as a potential therapeutic strategy for cancer treatment. For example, small molecule inhibitors of DVL3 have been developed and tested in preclinical studies, showing promising results in reducing tumor growth and metastasis. In neural tube defects, mutations in DVL3 have been associated with an increased risk of developing the condition. However, there are currently no targeted drug discovery efforts for DVL3 in this context. Overall, while there are no drugs on the market specifically targeting DVL3, ongoing research suggests that targeting this gene may hold promise for the treatment of certain cancers.","GO:0150012 positive regulation of neuron projection arborization;GO:0150011 regulation of neuron projection arborization;GO:0060071 Wnt signaling pathway, planar cell polarity pathway",,Disease related genes; Human disease related genes:Congenital malformations:Other congenital malformations; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Basal body;Midbody ring (Approved); Additional: Centrosome;Golgi apparatus;Intermediate filaments;Plasma membrane,,(M31)PID BETA CATENIN DEG PATHWAY; (M90)PID WNT CANONICAL PATHWAY; (M23)PID WNT NONCANONICAL PATHWAY,
ENSG00000135945.10,ENSG00000135945,REV1,-0.908781435,-1.019761866,-1.053842009,-0.652740429,REV1 DNA directed polymerase,The human gene REV1 encodes a protein that is similar to the mutagenesis protein Rev1 found in S. cerevisiae. The protein contains a BRCT domain that is crucial for protein-protein interactions. The human Rev1-like protein is believed to act as a scaffold that recruits DNA polymerases involved in translesion synthesis (TLS) of damaged DNA. This suggests that the protein plays a role in repairing damaged DNA.,"Mutations in the REV1 gene have been associated with an increased risk of developing certain types of cancer, including lung, breast, and colorectal cancer. Studies have also shown that REV1 expression levels are elevated in some cancer cells, suggesting that it may play a role in tumor development and progression. As a result, there has been interest in developing drugs that target REV1 as a potential cancer therapy.

One example of a drug that targets REV1 is the small molecule compound JH-RE-06. This compound has been shown to inhibit REV1 activity and sensitize cancer cells to chemotherapy, leading to increased cell death. Another potential drug target is the BRCT domain of REV1, which is involved in protein-protein interactions. Small molecules that disrupt these interactions could potentially inhibit REV1 function and be used as cancer therapies.

Overall, while there is still much to be learned about the role of REV1 in cancer, targeting this gene and its protein product is a promising avenue for drug discovery efforts.",GO:0070987 error-free translesion synthesis;GO:0042276 error-prone translesion synthesis;GO:0019985 translesion synthesis,,Predicted intracellular proteins,Nucleoli (Supported),,,
ENSG00000134250.20,ENSG00000134250,NOTCH2,-0.908037626,-1.217397096,-1.500158593,-0.006557188,notch receptor 2,"NOTCH2 is a gene that encodes a protein belonging to the Notch family. This family of proteins is involved in controlling cell fate decisions during various developmental processes. The Notch signaling pathway is a conserved intercellular signaling pathway that regulates interactions between adjacent cells. In humans, the precise interactions between the Notch-ligands and the human Notch homologues are yet to be determined. NOTCH2 is cleaved in the trans-Golgi network and presented on the cell surface as a heterodimer. It functions as a receptor for membrane-bound ligands and may play a role in the development of vascular, renal, and hepatic systems. Two transcript variants encoding different isoforms have been identified for this gene.","NOTCH2 has been implicated in various diseases, including cancer, cardiovascular disease, and liver disease. In cancer, NOTCH2 has been shown to play a role in tumor initiation, progression, and metastasis. Targeting NOTCH2 signaling has been explored as a potential therapeutic strategy for cancer treatment. Several drugs targeting the Notch pathway have been developed, including gamma-secretase inhibitors and monoclonal antibodies. One example of a successful drug targeting the Notch pathway is the gamma-secretase inhibitor, semagacestat, which was developed for the treatment of Alzheimer's disease. However, clinical trials showed that the drug had adverse effects and was not effective in treating the disease. Another example is the monoclonal antibody, tarextumab, which targets the Notch ligand, DLL4, and is being developed for the treatment of small cell lung cancer. Clinical trials have shown promising results, with improved progression-free survival in patients treated with tarextumab.",GO:0035622 intrahepatic bile duct development;GO:1990705 cholangiocyte proliferation;GO:0061073 ciliary body morphogenesis,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the digestive system; Human disease related genes:Musculoskeletal diseases:Skeletal diseases; Cancer-related genes:Candidate cancer biomarkers; Disease related genes; Human disease related genes:Endocrine and metabolic diseases:Diabetes,Nucleoplasm;Plasma membrane (Supported); Additional: Golgi apparatus,,(M17)PID NOTCH PATHWAY,(M5903)HALLMARK NOTCH SIGNALING; (M5942)HALLMARK UV RESPONSE DN; (M5893)HALLMARK MITOTIC SPINDLE
ENSG00000132793.12,ENSG00000132793,LPIN3,-0.907557909,-1.234021107,-0.858889781,-0.629762838,lipin 3,"LPIN3, also known as lipin 3, is a member of the lipin family of proteins. It is thought to form hetero-oligomers with other lipin family members and contains conserved motifs for phosphatidate phosphatase 1 (PAP1) activity as well as a domain that interacts with a transcriptional co-activator. Lipin complexes act in the cytoplasm to catalyze the dephosphorylation of phosphatidic acid to produce diacylglycerol, which is the precursor of both triglycerides and phospholipids. Lipin complexes are also thought to regulate gene expression as transcriptional co-activators in the nucleus. Alternative splicing results in multiple transcript variants.","There is limited information available on the disease implications of LPIN3. However, studies have suggested that mutations in the LPIN3 gene may be associated with metabolic disorders such as obesity and insulin resistance. Targeted drug discovery efforts for LPIN3 are also limited, but some studies have explored the potential of small molecule inhibitors of lipin phosphatase activity as a therapeutic strategy for metabolic disorders. One example of a successful drug targeting a related lipin family member is bezafibrate, which is used to treat hyperlipidemia and has been shown to increase lipin 1 expression and activity. However, further research is needed to fully understand the potential therapeutic implications of targeting LPIN3.",GO:0019432 triglyceride biosynthetic process;GO:0046460 neutral lipid biosynthetic process;GO:0046463 acylglycerol biosynthetic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol (Supported),,,
ENSG00000163125.15,ENSG00000163125,RPRD2,-0.907517177,-1.358284976,-0.910469135,-0.453797421,regulation of nuclear pre-mRNA domain containing 2,"RPRD2, or regulation of nuclear pre-mRNA domain containing 2, is a human gene that is predicted to have RNA polymerase II complex binding activity and be involved in mRNA 3'-end processing. It is also a part of the RNA polymerase II holoenzyme. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of RPRD2. However, recent studies have suggested that RPRD2 may play a role in the development of certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for RPRD2 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and potentially be used as cancer therapeutics. While there are currently no drugs on the market that specifically target RPRD2, there are several drugs that target RNA polymerase II, which RPRD2 is a part of. Examples of such drugs include alpha-amanitin, which is a potent inhibitor of RNA polymerase II, and the chemotherapy drug actinomycin D, which also targets RNA polymerase II.",GO:0031124 mRNA 3'-end processing;GO:0031123 RNA 3'-end processing;GO:0006397 mRNA processing,,Predicted intracellular proteins,Nucleoplasm;Vesicles (Approved),,,
ENSG00000164347.18,ENSG00000164347,GFM2,-0.906797337,-1.182123827,-1.077562752,-0.460705432,GTP dependent ribosome recycling factor mitochondrial 2,"GFM2 is a gene that encodes one of the mitochondrial translation elongation factors, which is a GTPase that plays a role in the termination of mitochondrial translation by mediating the disassembly of ribosomes from messenger RNA. Mitochondrial translation is crucial for maintaining mitochondrial function, and mutations in this system lead to a breakdown in the respiratory chain-oxidative phosphorylation system and to impaired maintenance of mitochondrial DNA. The role of GFM2 in the regulation of normal mitochondrial function and in disease states attributed to mitochondrial dysfunction is not known. Alternative splicing results in multiple transcript variants encoding distinct isoforms.","There is limited information available on the disease implications of GFM2 mutations. However, mitochondrial dysfunction has been implicated in a wide range of diseases, including neurodegenerative disorders, metabolic disorders, and cancer. Targeted drug discovery efforts for mitochondrial dysfunction have focused on improving mitochondrial function, reducing oxidative stress, and promoting mitochondrial biogenesis. Some examples of successful drugs on the market for mitochondrial dysfunction include coenzyme Q10, which is used to treat mitochondrial disorders, and idebenone, which is used to treat Leber's hereditary optic neuropathy. However, there are currently no drugs specifically targeting GFM2 or its related pathways. Further research is needed to better understand the role of GFM2 in mitochondrial function and disease, and to develop targeted therapies for mitochondrial dysfunction.",GO:0070126 mitochondrial translational termination;GO:0006415 translational termination;GO:0032790 ribosome disassembly,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Approved); Additional: Midbody ring;Nucleoplasm,,,
ENSG00000103994.18,ENSG00000103994,ZNF106,-0.905605083,-1.408350316,-1.013399916,-0.295065017,zinc finger protein 106,"ZNF106 is a human gene that encodes for a zinc finger protein 106. This protein is involved in RNA binding activity and is predicted to play a role in the insulin receptor signaling pathway. It is also predicted to be located in the nuclear speck and nucleolus, and to be active in both the cytosol and membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of ZNF106. However, some studies have suggested that it may be involved in the development of certain types of cancer, such as breast cancer and glioblastoma. Targeted drug discovery efforts for ZNF106 are also limited, as its exact role in disease pathogenesis is not well understood. However, some studies have suggested that targeting ZNF106 may be a potential therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target ZNF106. However, there are several drugs that target the insulin receptor signaling pathway, which ZNF106 is predicted to be involved in. Examples of these drugs include insulin and metformin, which are commonly used to treat diabetes.",GO:0008286 insulin receptor signaling pathway;GO:0032869 cellular response to insulin stimulus;GO:0032868 response to insulin,,Predicted intracellular proteins,Nucleoli (Approved); Additional: Cytosol;Nucleoplasm,,,
ENSG00000203880.12,ENSG00000203880,PCMTD2,-0.905421594,-0.974232259,-0.684504227,-1.057528296,protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 2,"PCMTD2 is a human gene that is predicted to encode a protein-L-isoaspartate (D-aspartate) O-methyltransferase, which is involved in protein methylation. This gene is predicted to be active in the cytoplasm.","There is limited information available on the disease implications of PCMTD2. However, research has shown that protein methylation plays a crucial role in various cellular processes, including gene expression, signal transduction, and protein-protein interactions. Dysregulation of protein methylation has been linked to several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Therefore, targeting PCMTD2 and other proteins involved in protein methylation could have therapeutic potential for these diseases. Currently, there are no drugs specifically targeting PCMTD2, but there are several drugs on the market that target other proteins involved in protein methylation, such as EZH2 inhibitors for cancer treatment and protein arginine methyltransferase inhibitors for neurodegenerative disorders. Further research is needed to fully understand the role of PCMTD2 in disease and to develop targeted therapies.",GO:0036211 protein modification process;GO:0043412 macromolecule modification;GO:0019538 protein metabolic process,,Predicted intracellular proteins,Mitochondria (Approved); Additional: Nucleoplasm,,,
ENSG00000136754.18,ENSG00000136754,ABI1,-0.904974436,-1.160930865,-1.08663536,-0.467357084,abl interactor 1,"ABI1, also known as abl interactor 1, is a gene that encodes a protein belonging to the Abelson-interactor family of adaptor proteins. These proteins play a role in signal transduction and regulate actin polymerization and cytoskeletal remodeling. ABI1 is involved in macropinocytosis as a component of the WAVE2 complex and mediates signal transduction from Ras to Rac through a complex with EPS8 and SOS1. The gene may also play a role in the progression of several cancers, including melanoma, colon cancer, and breast cancer. Additionally, a chromosomal translocation involving ABI1 and the MLL gene has been associated with acute myeloid leukemia. Multiple isoforms of the protein are produced through alternative splicing, and a pseudogene of the gene is located on chromosome 14.","ABI1 has been implicated in the progression of several types of cancer, including melanoma, colon cancer, and breast cancer. In melanoma, ABI1 has been shown to promote tumor growth and metastasis by regulating the activity of the protein kinase AKT. In colon cancer, ABI1 has been found to be overexpressed in tumor tissues and to promote tumor cell proliferation and invasion. In breast cancer, ABI1 has been shown to be involved in the regulation of cell migration and invasion, and its expression has been associated with poor prognosis.

Targeted drug discovery efforts for ABI1 have focused on developing inhibitors that can disrupt its interactions with other proteins involved in signal transduction pathways. One example is the small molecule inhibitor NSC-87877, which has been shown to inhibit the interaction between ABI1 and the protein tyrosine phosphatase PTP-BL. Another example is the compound ABI-231, which has been shown to disrupt the interaction between ABI1 and the protein kinase AKT.

Currently, there are no drugs on the market that specifically target ABI1. However, several drugs that target other proteins in the same signaling pathways as ABI1 have been approved for the treatment of cancer. For example, the AKT inhibitor ipatasertib has been approved for the treatment of advanced breast cancer, and the MEK inhibitor trametinib has been approved for the treatment of melanoma. These drugs may indirectly affect the activity of ABI1 by disrupting its interactions with other proteins in the same pathways.",GO:0072673 lamellipodium morphogenesis;GO:0061098 positive regulation of protein tyrosine kinase activity;GO:0035855 megakaryocyte development,,Disease related genes; Cancer-related genes; Predicted intracellular proteins,Cell Junctions;Plasma membrane (Approved),,(M277)PID INTEGRIN A4B1 PATHWAY; (M241)PID RAC1 REG PATHWAY; (M156)PID ECADHERIN NASCENT AJ PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE; (M5932)HALLMARK INFLAMMATORY RESPONSE; (M5950)HALLMARK ALLOGRAFT REJECTION
ENSG00000015171.20,ENSG00000015171,ZMYND11,-0.904628252,-1.425202634,-1.071432185,-0.217249938,zinc finger MYND-type containing 11,"ZMYND11 is a human gene that encodes a protein with a zinc finger MYND-type domain. This protein was initially discovered for its ability to bind to the adenovirus E1A protein and is primarily located in the nucleus. It functions as a transcriptional repressor, meaning it can inhibit the expression of certain genes. The expression of E1A can inhibit this repression. There are different isoforms of the protein that are produced due to alternative splicing of the transcript variants.","ZMYND11 has been implicated in several diseases, including cancer, neurological disorders, and developmental disorders. In cancer, ZMYND11 has been shown to act as a tumor suppressor by inhibiting the expression of oncogenes. In neurological disorders, mutations in ZMYND11 have been linked to intellectual disability and autism spectrum disorders. Additionally, ZMYND11 has been shown to play a role in the development of the heart and lungs.

Targeted drug discovery efforts for ZMYND11 are still in the early stages, but there is potential for the development of drugs that can modulate its activity. One approach is to develop small molecules that can bind to ZMYND11 and enhance its transcriptional repression activity. Another approach is to target the interaction between ZMYND11 and E1A, which could potentially lead to the development of drugs that can disrupt the interaction and restore ZMYND11's repressive activity.

Currently, there are no drugs on the market that specifically target ZMYND11. However, there are drugs that indirectly affect its activity. For example, histone deacetylase inhibitors (HDAC inhibitors) have been shown to increase the expression of ZMYND11 and enhance its tumor suppressor activity in cancer cells. Additionally, drugs that target the E1A protein, such as the antiviral drug cidofovir, could potentially restore ZMYND11's repressive activity in cancer cells.",GO:0046329 negative regulation of JNK cascade;GO:0043124 negative regulation of canonical NF-kappaB signal transduction;GO:0034243 regulation of transcription elongation by RNA polymerase II,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000134109.11,ENSG00000134109,EDEM1,-0.904139575,-1.209281312,-0.989609173,-0.513528241,ER degradation enhancing alpha-mannosidase like protein 1,"EDEM1 is a human gene that encodes for a protein with mannosyl-oligosaccharide 1,2-alpha-mannosidase activity and misfolded protein binding activity. It plays a role in the glycoprotein ERAD pathway, retrograde protein transport from ER to cytosol, and protein targeting to ER. EDEM1 is located in the aggresome and endoplasmic reticulum quality control compartment. Its function is to trim mannose residues from glycoproteins and assist in the degradation of misfolded proteins.","Mutations in the EDEM1 gene have been associated with several diseases, including congenital disorder of glycosylation type IIb (CDG-IIb), a rare genetic disorder characterized by abnormal glycosylation of proteins and developmental delays. EDEM1 has also been implicated in the pathogenesis of neurodegenerative diseases such as Alzheimer's and Parkinson's disease, as well as cancer. 

Targeted drug discovery efforts for EDEM1 are still in the early stages, but there is potential for the development of drugs that modulate its activity in the glycoprotein ERAD pathway and protein quality control. One approach is to identify small molecules that can enhance EDEM1 activity, which could improve the clearance of misfolded proteins and reduce the accumulation of toxic aggregates in neurodegenerative diseases. 

Currently, there are no drugs on the market that specifically target EDEM1. However, there are drugs that indirectly affect its activity, such as proteasome inhibitors that block the degradation of misfolded proteins and chaperone drugs that assist in protein folding. For example, the proteasome inhibitor bortezomib is used to treat multiple myeloma, a cancer that involves the accumulation of misfolded proteins. Additionally, the chaperone drug tafamidis is used to treat transthyretin amyloidosis, a disease caused by the accumulation of misfolded transthyretin protein.","GO:1904154 positive regulation of retrograde protein transport, ER to cytosol;GO:0006056 mannoprotein metabolic process;GO:0006058 mannoprotein catabolic process",,Predicted intracellular proteins,Endoplasmic reticulum (Enhanced); Additional: Aggresome,,,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE; (M5924)HALLMARK MTORC1 SIGNALING
ENSG00000157106.17,ENSG00000157106,SMG1,-0.904100976,-1.001947428,-0.97305319,-0.737302309,SMG1 nonsense mediated mRNA decay associated PI3K related kinase,"SMG1 is a human gene that encodes a protein involved in nonsense-mediated mRNA decay (NMD) as part of the mRNA surveillance complex. The protein has kinase activity and is thought to function in NMD by phosphorylating the regulator of nonsense transcripts 1 protein. The gene has alternatively spliced transcript variants, but their full-length nature has yet to be determined. SMG1 is associated with PI3K-related kinase and plays a crucial role in maintaining genomic stability. Mutations in SMG1 have been linked to various diseases, including cancer and neurological disorders.","Mutations in SMG1 have been linked to various diseases, including cancer and neurological disorders. In cancer, SMG1 has been shown to play a role in regulating DNA damage response and cell cycle checkpoints, making it a potential target for cancer therapy. Several small molecule inhibitors of SMG1 have been developed and are currently being evaluated in preclinical studies for their potential as cancer therapeutics. In neurological disorders, SMG1 has been implicated in the regulation of synaptic plasticity and neuronal survival, making it a potential target for the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's. However, there are currently no drugs on the market that specifically target SMG1.","GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay;GO:0046854 phosphatidylinositol phosphate biosynthetic process;GO:0006406 mRNA export from nucleus",yes,Enzymes; Kinases:Atypical kinases; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported),,,
ENSG00000205765.9,ENSG00000205765,C5orf51,-0.903627166,-1.196567451,-0.962469913,-0.551844133,RAB7A interacting MON1-CCZ1 complex subunit 1,"RIMOC1 is a human gene that encodes for a protein subunit of the RAB7A interacting MON1-CCZ1 complex. This complex is involved in regulating the trafficking of proteins and other molecules within cells. RIMOC1 is located in both the cytosol and nucleoplasm of cells. Its exact function is not yet fully understood, but it is believed to play a role in the regulation of endosomal trafficking and lysosomal degradation. Mutations in RIMOC1 have been associated with certain types of cancer, including breast and lung cancer.","There is limited information available on the disease implications of RIMOC1, but mutations in this gene have been associated with certain types of cancer, including breast and lung cancer. Targeted drug discovery efforts for RIMOC1 are currently underway, with a focus on developing drugs that can inhibit the activity of the RAB7A interacting MON1-CCZ1 complex. This could potentially lead to the development of new cancer therapies that target the trafficking of proteins and other molecules within cells. Currently, there are no drugs on the market that specifically target RIMOC1, but there are several drugs that target related proteins involved in endosomal trafficking and lysosomal degradation, such as chloroquine and hydroxychloroquine, which are used to treat malaria and autoimmune diseases.",GO:0000423 mitophagy;GO:0000422 autophagy of mitochondrion;GO:0016236 macroautophagy,,Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Cytosol,,,
ENSG00000164151.12,ENSG00000164151,ICE1,-0.903621992,-1.250261981,-0.924021564,-0.536582432,interactor of little elongation complex ELL subunit 1,"The human gene ICE1, also known as ELL subunit 1, is involved in various biological processes such as intracellular protein transport, transcription by RNA polymerase III, and snRNA transcription. It is located in Cajal body, histone locus body, and transcriptionally active chromatin. ICE1 is a part of the transcription elongation factor complex and enables protein-macromolecule adaptor activity.","There is limited information available on the disease implications of ICE1. However, studies have shown that mutations in ICE1 are associated with developmental disorders such as intellectual disability and autism spectrum disorder. Targeted drug discovery efforts for ICE1 are also limited, but some studies have suggested that modulating its activity could be a potential therapeutic strategy for certain types of cancer. Currently, there are no drugs on the market that specifically target ICE1. However, there are drugs that indirectly affect its activity, such as inhibitors of RNA polymerase III, which have been used in the treatment of certain types of cancer. Further research is needed to fully understand the potential therapeutic implications of ICE1.",GO:0042796 snRNA transcription by RNA polymerase III;GO:0042795 snRNA transcription by RNA polymerase II;GO:0009301 snRNA transcription,,Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Supported),,,
ENSG00000005882.12,ENSG00000005882,PDK2,-0.903070907,-1.841945772,-0.86076599,-0.006500957,pyruvate dehydrogenase kinase 2,"PDK2 is a gene that belongs to the pyruvate dehydrogenase kinase family. The protein encoded by this gene is responsible for phosphorylating pyruvate dehydrogenase, which leads to a decrease in the activity of the mitochondrial pyruvate dehydrogenase complex. The gene has been linked to both cancer and diabetes, and multiple isoforms of the gene have been observed due to alternative splicing. Overall, PDK2 plays a crucial role in regulating the metabolism of glucose in the body, and its dysregulation can lead to various diseases.","PDK2 has been implicated in various diseases, including cancer and diabetes. In cancer, PDK2 is overexpressed, leading to increased phosphorylation of pyruvate dehydrogenase and a shift towards glycolysis, which is a hallmark of cancer cells. Targeting PDK2 has been proposed as a potential therapeutic strategy for cancer treatment. In diabetes, PDK2 is upregulated in response to high glucose levels, leading to decreased activity of the pyruvate dehydrogenase complex and impaired glucose metabolism. Several drugs targeting PDK2 are currently in development, including dichloroacetate (DCA), which has shown promising results in preclinical studies and is currently in clinical trials for cancer treatment. Another drug, AZD7545, has been shown to inhibit PDK2 activity and improve glucose metabolism in animal models of diabetes. However, more research is needed to fully understand the potential of PDK2 as a therapeutic target for these diseases.",GO:0010510 regulation of acetyl-CoA biosynthetic process from pyruvate;GO:0050812 regulation of acyl-CoA biosynthetic process;GO:0042762 regulation of sulfur metabolic process,yes,Enzymes; Kinases:Atypical kinases; Predicted intracellular proteins; ENZYME proteins:Transferases,Mitochondria;Nucleoplasm (Approved),"4-({(2R,5S)-2,5-DIMETHYL-4-[(2R)-3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPANOYL]PIPERAZIN-1-YL}CARBONYL)BENZONITRILE; (2R)-N-{4-[Ethyl(phenyl)sulfamoyl]-2-methylphenyl}-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide; N-(2-AMINOETHYL)-2-{3-CHLORO-4-[(4-ISOPROPYLBENZYL)OXY]PHENYL} ACETAMIDE",,(M5956)HALLMARK KRAS SIGNALING DN
ENSG00000139350.12,ENSG00000139350,NEDD1,-0.902812767,-1.031114115,-0.967736605,-0.709587581,NEDD1 gamma-tubulin ring complex targeting factor,"NEDD1 is a human gene that is predicted to play a role in protein localization to the centrosome. It is located in the centrosome, nucleoplasm, and plasma membrane. NEDD1 is a gamma-tubulin ring complex targeting factor, which means it helps to target the gamma-tubulin ring complex to the centrosome. The gamma-tubulin ring complex is a protein complex that is involved in the nucleation of microtubules, which are important for cell division and other cellular processes. NEDD1 is an important protein for the proper functioning of the centrosome and the regulation of microtubule dynamics.","NEDD1 has been implicated in several diseases, including cancer and neurodegenerative disorders. In cancer, NEDD1 overexpression has been observed in various types of tumors, including breast, lung, and liver cancer. Targeting NEDD1 has been proposed as a potential therapeutic strategy for cancer treatment. Several studies have shown that inhibition of NEDD1 can lead to cell cycle arrest and apoptosis in cancer cells. However, there are currently no drugs targeting NEDD1 on the market. Drug discovery efforts are ongoing, and several small molecule inhibitors of NEDD1 have been identified in preclinical studies. These inhibitors have shown promising results in reducing tumor growth in animal models. Further research is needed to determine the safety and efficacy of these inhibitors in humans.",GO:0007020 microtubule nucleation;GO:0046785 microtubule polymerization;GO:0031109 microtubule polymerization or depolymerization,,Predicted intracellular proteins,Centrosome;Nucleoplasm (Approved),,,
ENSG00000116191.17,ENSG00000116191,RALGPS2,-0.902467294,-1.5495959,-0.895135475,-0.262670506,Ral GEF with PH domain and SH3 binding motif 2,"RALGPS2 is a human gene that is predicted to have guanyl-nucleotide exchange factor activity and be involved in regulating Ral protein signal transduction, catalytic activity, and small GTPase mediated signal transduction. It is also predicted to be located in the cytoplasm and plasma membrane.","There is limited information available on the disease implications of RALGPS2. However, some studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for RALGPS2 are also limited, but some studies have identified potential small molecule inhibitors that could target RALGPS2 and inhibit its activity. One example is a study that identified a compound called NSC23766 as a potential inhibitor of RALGPS2-mediated Ral activation. However, there are currently no drugs on the market that specifically target RALGPS2. Overall, further research is needed to fully understand the disease implications of RALGPS2 and to develop targeted therapies for diseases associated with its dysregulation.",GO:0007265 Ras protein signal transduction;GO:0007264 small GTPase-mediated signal transduction;GO:0141124 intracellular signaling cassette,,Disease related genes; Predicted intracellular proteins,Cytosol;Nucleoplasm (Uncertain),,,
ENSG00000100109.17,ENSG00000100109,TFIP11,-0.902388917,-1.033753187,-1.437452443,-0.235961122,tuftelin interacting protein 11,"TFIP11 is a gene that encodes a protein component of the spliceosome, which is responsible for removing introns from pre-mRNA during the process of gene expression. The protein promotes the release of the lariat-intron during late-stage splicing by recruiting a pre-mRNA splicing factor called DEAH-box helicase 15. TFIP11 contains a G-patch domain that binds DEAH-box helicase 15 and has an atypical nuclear localization sequence as well as a nuclear speckle-targeting sequence, allowing it to localize to distinct speckled regions within the cell nucleus. Polymorphisms in this gene are associated with dental caries, suggesting a role in amelogenesis. Alternative splicing results in multiple transcript variants.","There is limited information available on the disease implications of TFIP11. However, studies have shown that polymorphisms in this gene are associated with dental caries, suggesting a potential role in amelogenesis. There are currently no targeted drug discovery efforts for TFIP11, as its function in the spliceosome is essential for normal gene expression and any disruption could have widespread effects on cellular processes. As a result, there are no drugs on the market that specifically target TFIP11. However, there are drugs that target the spliceosome as a whole, such as spliceostatin A and pladienolide B, which have shown promise in preclinical studies for the treatment of various cancers.",GO:0000390 spliceosomal complex disassembly;GO:0031848 protection from non-homologous end joining at telomere;GO:2001033 negative regulation of double-strand break repair via nonhomologous end joining,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000128016.7,ENSG00000128016,ZFP36,-0.902306717,-1.463795555,-0.763873415,-0.47925118,ZFP36 ring finger protein,"ZFP36, also known as ZFP36 ring finger protein, is a human gene that plays a role in several cellular processes, including the response to cytokine and growth factor stimuli, as well as the regulation of gene expression. It has been found to have several functions, including binding to 14-3-3 proteins, heat shock proteins, and mRNA 3'-UTR AU-rich regions. ZFP36 is involved in mRNA catabolic processes and is located in cytoplasmic ribonucleoprotein granules, the cytosol, and the nucleus. It is part of a ribonucleoprotein complex and colocalizes with the RISC-loading complex.","ZFP36 has been implicated in several diseases, including cancer, inflammation, and autoimmune disorders. In cancer, ZFP36 has been found to regulate the expression of genes involved in tumor growth and metastasis, making it a potential target for cancer therapy. In inflammation and autoimmune disorders, ZFP36 has been shown to regulate the expression of cytokines and other inflammatory mediators, making it a potential target for anti-inflammatory drugs.

Several drug discovery efforts have targeted ZFP36, including small molecule inhibitors and RNA-based therapies. One example is the development of small molecule inhibitors of ZFP36 for the treatment of cancer. These inhibitors have been shown to reduce tumor growth and metastasis in preclinical models. Another example is the use of RNA-based therapies, such as antisense oligonucleotides, to target ZFP36 expression in inflammatory and autoimmune disorders.

There are currently no drugs on the market that directly target ZFP36, but several drugs indirectly affect its function. For example, nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to increase ZFP36 expression, leading to the downregulation of inflammatory cytokines. Additionally, some cancer drugs, such as paclitaxel and doxorubicin, have been shown to upregulate ZFP36 expression, leading to the downregulation of genes involved in tumor growth and metastasis.",GO:1901834 regulation of deadenylation-independent decapping of nuclear-transcribed mRNA;GO:1901835 positive regulation of deadenylation-independent decapping of nuclear-transcribed mRNA;GO:1904246 negative regulation of polynucleotide adenylyltransferase activity,,Predicted intracellular proteins,Intermediate filaments (Approved),,(M164)PID ERBB1 DOWNSTREAM PATHWAY,(M5890)HALLMARK TNFA SIGNALING VIA NFKB; (M5891)HALLMARK HYPOXIA; (M5907)HALLMARK ESTROGEN RESPONSE LATE
ENSG00000099308.10,ENSG00000099308,MAST3,-0.901893669,-1.015552423,-0.833966787,-0.856161797,microtubule associated serine/threonine kinase 3,"MAST3 is a human gene that encodes for a protein called microtubule associated serine/threonine kinase 3. This protein is predicted to have serine/threonine kinase activity and is involved in various cellular processes such as cytoskeleton organization, intracellular signal transduction, and peptidyl-serine phosphorylation. The function of MAST3 is not fully understood, but it is believed to play a role in regulating cell division and migration. Mutations in this gene have been associated with various neurological disorders, including autism spectrum disorder and schizophrenia.","There is limited information available on targeted drug discovery efforts for MAST3, as its function and role in disease are not fully understood. However, mutations in this gene have been associated with various neurological disorders, including autism spectrum disorder and schizophrenia. These associations suggest that MAST3 may be a potential therapeutic target for these conditions. Currently, there are no drugs on the market that specifically target MAST3. However, there are drugs that target related proteins involved in similar cellular processes, such as microtubule-associated protein tau (MAPT) inhibitors for Alzheimer's disease. Further research is needed to fully understand the role of MAST3 in disease and to develop targeted therapies.",GO:0007010 cytoskeleton organization;GO:0006338 chromatin remodeling;GO:0006325 chromatin organization,yes,Kinases:AGC Ser/Thr protein kinases; Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nuclear speckles (Approved),,,(M5956)HALLMARK KRAS SIGNALING DN
ENSG00000137478.15,ENSG00000137478,FCHSD2,-0.901641329,-1.371701413,-0.93441823,-0.398804345,FCH and double SH3 domains 2,"FCHSD2 is a human gene that encodes a protein with FCH and double SH3 domains. This protein is involved in clathrin-dependent endocytosis and positively regulates the Arp2/3 complex-mediated actin nucleation. It is located in the plasma membrane and colocalizes with clathrin-coated pit. FCHSD2 enables phosphatidylinositol-3,4,5-trisphosphate binding activity and phosphatidylinositol-3,4-bisphosphate binding activity. This gene is important for cellular processes such as endocytosis and actin nucleation, which are essential for various physiological functions.","There is limited information available on the disease implications of FCHSD2. However, recent studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for FCHSD2 are still in the early stages, but there is potential for this protein to be targeted in cancer therapy. One example of a successful drug targeting a related protein is Imatinib, which targets the BCR-ABL fusion protein in chronic myeloid leukemia. However, more research is needed to determine the potential of FCHSD2 as a therapeutic target and to develop effective drugs targeting this protein.",GO:2000601 positive regulation of Arp2/3 complex-mediated actin nucleation;GO:0051127 positive regulation of actin nucleation;GO:0007274 neuromuscular synaptic transmission,,Predicted intracellular proteins,Actin filaments;Plasma membrane (Approved); Additional: Focal adhesion sites;Nuclear speckles,,,
ENSG00000133030.22,ENSG00000133030,MPRIP,-0.901245209,-1.241648015,-0.898286505,-0.563801107,myosin phosphatase Rho interacting protein,"MPRIP, or myosin phosphatase Rho interacting protein, is a gene that is involved in actin filament organization and enables cadherin binding activity. It is located in both the actin cytoskeleton and cytosol. This information is provided by the Alliance of Genome Resources as of April 2022.","MPRIP has been implicated in several diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, MPRIP has been shown to play a role in tumor cell migration and invasion, making it a potential target for cancer therapy. In cardiovascular disease, MPRIP has been linked to smooth muscle cell contraction and blood vessel remodeling, suggesting it may be a target for drugs aimed at treating hypertension and other cardiovascular conditions. In neurological disorders, MPRIP has been associated with synaptic plasticity and memory formation, making it a potential target for drugs aimed at treating cognitive impairments.

There are currently no drugs on the market that specifically target MPRIP. However, there have been efforts to develop drugs that target related proteins in the Rho signaling pathway, which MPRIP is a part of. For example, the drug fasudil targets Rho kinase, a downstream effector of Rho signaling, and is used to treat cerebral vasospasm and pulmonary hypertension. Another drug, Y-27632, also targets Rho kinase and has shown promise in treating glaucoma and other ocular diseases.

Overall, while there is still much to learn about the role of MPRIP in disease, its involvement in several key cellular processes makes it a promising target for drug discovery efforts.",,,Predicted intracellular proteins,Actin filaments (Supported); Additional: Cytosol,,,
ENSG00000174405.14,ENSG00000174405,LIG4,-0.901029503,-1.114636897,-1.149155284,-0.439296329,DNA ligase 4,"LIG4 is a human gene that encodes for DNA ligase 4, a protein that plays a crucial role in repairing DNA double-strand breaks through nonhomologous end joining (NHEJ) and V(D)J recombination. This protein joins single-strand breaks in a double-stranded polydeoxynucleotide in an ATP-dependent reaction. It forms a complex with XRCC4 and interacts with DNA-dependent protein kinase (DNA-PK), both of which are required for NHEJ. Defects in this gene can lead to LIG4 syndrome. The gene has alternatively spliced transcript variants that encode the same protein. The crystal structure of the complex formed by this protein and XRCC4 has been resolved.","Defects in LIG4 have been associated with LIG4 syndrome, a rare autosomal recessive disorder characterized by immunodeficiency, developmental delay, and increased sensitivity to ionizing radiation. There are currently no targeted drug discovery efforts specifically for LIG4, but there are drugs that target the DNA damage response pathway, which includes NHEJ. For example, PARP inhibitors such as olaparib and rucaparib have been approved for the treatment of ovarian and breast cancers with BRCA mutations, which are deficient in homologous recombination repair and rely on NHEJ for DNA repair. Additionally, DNA-PK inhibitors such as NU7441 and VX-984 are being investigated as potential cancer therapies. However, these drugs do not specifically target LIG4 and their efficacy in LIG4 syndrome is unknown.",GO:0051102 DNA ligation involved in DNA recombination;GO:0075713 establishment of integrated proviral latency;GO:0019043 establishment of viral latency,,Predicted intracellular proteins; Human disease related genes:Immune system diseases:Primary immunodeficiency; Potential drug targets; Disease related genes; ENZYME proteins:Ligase; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported); Additional: Vesicles,,(M42)PID DNA PK PATHWAY,
ENSG00000112893.9,ENSG00000112893,MAN2A1,-0.900936727,-1.135179758,-0.854221564,-0.713408859,mannosidase alpha class 2A member 1,The MAN2A1 gene encodes a glycosyl hydrolase that is involved in the final step of the N-glycan maturation pathway in the Golgi. This gene is important for the proper processing of oligosaccharides and mutations in the mouse homolog of this gene have been linked to an autoimmune disease similar to systemic lupus erythematosus in humans.,"Mutations in the MAN2A1 gene have been linked to several diseases, including autoimmune disorders, cancer, and developmental disorders. In particular, mutations in this gene have been associated with a rare autoimmune disease called Sjogren's syndrome, which is characterized by dry eyes and mouth, joint pain, and fatigue. Targeted drug discovery efforts for MAN2A1 have focused on developing inhibitors of the enzyme to treat autoimmune diseases and cancer. One example of a successful drug targeting this pathway is belimumab, which is used to treat systemic lupus erythematosus. Belimumab targets the B-cell activating factor (BAFF), which is involved in the activation of autoreactive B cells. Another example is rituximab, which targets CD20 on B cells and is used to treat lymphoma and autoimmune diseases such as rheumatoid arthritis.",GO:0006013 mannose metabolic process;GO:0006491 N-glycan processing;GO:0019082 viral protein processing,,ENZYME proteins:Hydrolases; Enzymes,Golgi apparatus (Supported),"Tridolgosir; 2-deoxy-2-fluoro-alpha-D-mannosyl fluoride; Ghavamiol; Kifunensine; 5-fluoro-beta-L-gulosyl fluoride; 5-Thio-a/B-D-Mannopyranosylamine; 1-deoxymannojirimycin; (1R,2R,3R,4S,5R)-4-(BENZYLAMINO)-5-(METHYLTHIO)CYCLOPENTANE-1,2,3-TRIOL; (1S,2S,3R,6R)-4-(hydroxymethyl)-6-(octylamino)cyclohex-4-ene-1,2,3-triol",,
ENSG00000204217.15,ENSG00000204217,BMPR2,-0.900115116,-1.493126086,-0.885197748,-0.322021515,bone morphogenetic protein receptor type 2,"BMPR2 is a gene that encodes a type 2 receptor for bone morphogenetic proteins (BMPs), which are involved in bone formation and embryonic development. The receptor transduces signals through the formation of heteromeric complexes with type 1 receptors. Mutations in BMPR2 have been linked to primary pulmonary hypertension, a rare and potentially fatal condition that affects the blood vessels in the lungs. This includes both familial cases and cases associated with the use of the weight loss drug fenfluramine. BMPR2 mutations have also been associated with pulmonary venoocclusive disease, a rare condition that affects the small veins in the lungs.","Mutations in BMPR2 have been linked to primary pulmonary hypertension (PPH), a rare and potentially fatal condition that affects the blood vessels in the lungs. PPH is characterized by high blood pressure in the pulmonary arteries, which can lead to heart failure and death. There is currently no cure for PPH, but several drugs have been developed to manage the symptoms and slow the progression of the disease. These drugs include prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors. Targeted drug discovery efforts are ongoing to develop new therapies that target the BMPR2 pathway and address the underlying cause of PPH. One example is sotatercept, a drug currently in clinical trials that targets the BMPR2 pathway and has shown promising results in improving exercise capacity and reducing pulmonary vascular resistance in PPH patients.",GO:0003252 negative regulation of cell proliferation involved in heart valve morphogenesis;GO:0003250 regulation of cell proliferation involved in heart valve morphogenesis;GO:2000137 negative regulation of cell proliferation involved in heart morphogenesis,yes,Human disease related genes:Cardiovascular diseases:Hypertensive diseases; FDA approved drug targets:Biotech drugs; Kinases:TKL Ser/Thr protein kinases; ENZYME proteins:Transferases; Human disease related genes:Cardiovascular diseases:Vascular diseases; Disease related genes; Enzymes,Nucleoplasm;Plasma membrane (Supported),Dibotermin alfa; Fostamatinib,(M203)PID ALK2 PATHWAY; (M185)PID ALK1 PATHWAY; (M181)PID BMP PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING; (M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000102189.17,ENSG00000102189,EEA1,-0.89875132,-1.199290478,-0.912319657,-0.584643825,early endosome antigen 1,"EEA1, or early endosome antigen 1, is a human gene that encodes a protein involved in endocytosis, vesicle fusion, and viral RNA genome replication. It has 1-phosphatidylinositol binding activity, GTP-dependent protein binding activity, and protein homodimerization activity. EEA1 is located in the cytosol and early endosome and is an extrinsic component of the plasma membrane.","EEA1 has been implicated in several diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, EEA1 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. In neurodegenerative disorders, EEA1 dysfunction has been linked to impaired autophagy and lysosomal degradation, which may contribute to the accumulation of toxic protein aggregates. In viral infections, EEA1 is involved in the replication of several viruses, including hepatitis C virus and dengue virus.

There have been efforts to develop drugs that target EEA1, particularly for cancer therapy. One approach is to inhibit the interaction between EEA1 and its binding partners, such as Rab5 and PI(3)P, which are involved in endocytosis and vesicle fusion. Another approach is to target the downstream signaling pathways activated by EEA1, such as the PI3K/Akt/mTOR pathway, which is involved in cell growth and survival.

There are currently no drugs on the market that specifically target EEA1, but there are several drugs that indirectly affect EEA1 function. For example, the PI3K inhibitor idelalisib has been approved for the treatment of certain types of leukemia and lymphoma, and it may also have potential for the treatment of solid tumors that overexpress EEA1. Additionally, the mTOR inhibitor everolimus has been approved for the treatment of several types of cancer, including breast cancer and renal cell carcinoma, and it may also have potential for the treatment of neurodegenerative disorders that involve EEA1 dysfunction.",GO:0016189 synaptic vesicle to endosome fusion;GO:0099532 synaptic vesicle endosomal processing;GO:0045022 early endosome to late endosome transport,,Predicted intracellular proteins,Vesicles (Supported),"Inositol 1,3-Bisphosphate",,
ENSG00000168394.11,ENSG00000168394,TAP1,-0.898680155,-1.365507051,-1.20824771,-0.122285703,"transporter 1, ATP binding cassette subfamily B member","TAP1 is a human gene that encodes a membrane-associated protein belonging to the ATP-binding cassette (ABC) transporter superfamily. ABC proteins transport various molecules across extra- and intra-cellular membranes. TAP1 is a member of the MDR/TAP subfamily, which is involved in multidrug resistance. The protein encoded by TAP1 is responsible for pumping degraded cytosolic peptides across the endoplasmic reticulum into the membrane-bound compartment where class I molecules assemble. Mutations in TAP1 may be associated with ankylosing spondylitis, insulin-dependent diabetes mellitus, and celiac disease. Two transcript variants encoding different isoforms have been identified for this gene.","TAP1 has been implicated in several autoimmune diseases, including ankylosing spondylitis, insulin-dependent diabetes mellitus, and celiac disease. In ankylosing spondylitis, TAP1 variants have been associated with disease susceptibility and severity. In insulin-dependent diabetes mellitus, TAP1 variants have been linked to altered immune responses and increased risk of disease. In celiac disease, TAP1 variants have been associated with impaired antigen presentation and increased risk of disease. 

Targeted drug discovery efforts for TAP1 have focused on developing inhibitors to modulate its function in multidrug resistance and antigen presentation. Several compounds have been identified as potential TAP1 inhibitors, including verapamil, quinidine, and cyclosporine A. However, no TAP1-specific drugs have been approved for clinical use yet.

Successful drugs on the market that indirectly affect TAP1 function include immunosuppressants such as cyclosporine A and tacrolimus, which inhibit T-cell activation and cytokine production, and proteasome inhibitors such as bortezomib, which block protein degradation and enhance antigen presentation. These drugs have been used to treat autoimmune diseases, cancer, and transplant rejection.",GO:0046967 cytosol to endoplasmic reticulum transport;GO:0019885 antigen processing and presentation of endogenous peptide antigen via MHC class I;GO:0002483 antigen processing and presentation of endogenous peptide antigen,,ENZYME proteins; Predicted intracellular proteins; Human disease related genes:Immune system diseases:Primary immunodeficiency; Transporters:Primary Active Transporters; Potential drug targets; Disease related genes; Enzymes; Cancer-related genes:Mutated cancer genes,Centriolar satellite;Endoplasmic reticulum (Approved),,(M145)PID P53 DOWNSTREAM PATHWAY,(M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5941)HALLMARK UV RESPONSE UP; (M5902)HALLMARK APOPTOSIS
ENSG00000167257.11,ENSG00000167257,RNF214,-0.897928723,-1.518868856,-0.879670665,-0.295246648,ring finger protein 214,"RNF214, also known as ring finger protein 214, is a human gene that is predicted to have ubiquitin-protein transferase activity and be involved in protein ubiquitination. This means that it may play a role in regulating the degradation of proteins within cells. The function of RNF214 is not yet fully understood, but further research may shed light on its potential role in human health and disease.","There is currently limited information available on the disease implications of RNF214. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for RNF214 are also limited, as its function is not yet fully understood. However, some researchers are exploring the potential of targeting the ubiquitin-proteasome system, of which RNF214 is a part, as a therapeutic strategy for cancer. There are currently no drugs on the market that specifically target RNF214, but there are several drugs that target the ubiquitin-proteasome system, such as bortezomib and carfilzomib, which are used to treat multiple myeloma. Further research is needed to fully understand the potential implications of RNF214 in disease and to develop targeted therapies.",,,Predicted intracellular proteins,Cytosol;Golgi apparatus (Approved),,,
ENSG00000114853.14,ENSG00000114853,ZBTB47,-0.897928528,-1.810842255,-0.746353028,-0.136590302,zinc finger and BTB domain containing 47,"ZBTB47 is a human gene that is predicted to have DNA-binding transcription factor activity, specifically for RNA polymerase II and cis-regulatory region sequence-specific DNA binding activity. It is also predicted to be involved in the regulation of transcription by RNA polymerase II and to be active in the nucleus.","There is limited information available on the disease implications of ZBTB47. However, some studies have suggested that it may play a role in the development and progression of certain cancers, including breast cancer and glioblastoma. Targeted drug discovery efforts for ZBTB47 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target ZBTB47, there are several drugs that have been approved for the treatment of breast cancer and glioblastoma that may indirectly affect the activity of this gene. For example, tamoxifen and trastuzumab are commonly used to treat breast cancer and have been shown to inhibit the activity of certain transcription factors, including those that may interact with ZBTB47. Similarly, temozolomide is a chemotherapy drug that is commonly used to treat glioblastoma and has been shown to affect the expression of several transcription factors, including ZBTB47.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000114520.11,ENSG00000114520,SNX4,-0.897847107,-1.218376939,-0.976189305,-0.498975077,sorting nexin 4,"SNX4, or sorting nexin 4, is a gene that belongs to the sorting nexin family. This family contains a phosphoinositide binding domain called phox (PX) and is involved in intracellular trafficking. SNX4 has been found to associate with the long isoform of the leptin receptor and with receptor tyrosine kinases for platelet-derived growth factor, insulin, and epidermal growth factor in cell cultures, but its function is unknown. It may form oligomeric complexes with other family members. Two transcript variants have been found for this gene, one protein coding and the other non-protein coding.","There is limited information available on the disease implications of SNX4. However, some studies have suggested that SNX4 may play a role in cancer progression and metastasis. For example, one study found that SNX4 expression was upregulated in breast cancer cells and that knockdown of SNX4 inhibited cell migration and invasion. 

There are currently no targeted drug discovery efforts specifically focused on SNX4. However, there are drugs on the market that target other members of the sorting nexin family, such as SNX1 and SNX10. These drugs are primarily used to treat lysosomal storage disorders, such as Niemann-Pick disease type C. 

One example of a drug that targets the sorting nexin family is Zavesca (miglustat), which inhibits the enzyme glucosylceramide synthase and is used to treat Niemann-Pick disease type C. Another example is VTS-270, which is a mixture of 2-hydroxypropyl-?-cyclodextrin and is also used to treat Niemann-Pick disease type C.",GO:1903593 regulation of histamine secretion by mast cell;GO:1903595 positive regulation of histamine secretion by mast cell;GO:0043306 positive regulation of mast cell degranulation,,Predicted intracellular proteins,,,,
ENSG00000112701.18,ENSG00000112701,SENP6,-0.897335082,-0.895681885,-1.153205705,-0.643117655,SUMO specific peptidase 6,"SENP6 is a gene that encodes for a protein called SUMO specific peptidase 6. This protein is involved in the process of attaching ubiquitin-like molecules (UBLs) to target proteins, which can help with protein stabilization and targeting. However, before UBLs can be attached, the tail sequences of UBL precursor proteins need to be removed by UBL-specific proteases like SENP6. Additionally, SENP6 can also remove UBLs from already-conjugated substrates. Overall, SENP6 plays an important role in regulating protein modification and stability.","Research on SENP6 and its potential implications in disease is still in its early stages. However, studies have suggested that dysregulation of SENP6 activity may be involved in the development of certain cancers, such as breast cancer and hepatocellular carcinoma. Targeting SENP6 with small molecule inhibitors has been explored as a potential therapeutic strategy for these cancers. One example is the compound ML792, which has been shown to inhibit SENP6 activity and reduce tumor growth in preclinical models of breast cancer. Another potential application of SENP6 inhibitors is in the treatment of viral infections, as SENP6 has been shown to play a role in the replication of certain viruses, such as human cytomegalovirus. However, more research is needed to fully understand the therapeutic potential of targeting SENP6.",GO:0090234 regulation of kinetochore assembly;GO:0090230 regulation of centromere complex assembly;GO:0016926 protein desumoylation,,Peptidases:Cysteine-type peptidases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000198382.9,ENSG00000198382,UVRAG,-0.897260503,-1.246650323,-0.927310721,-0.517820464,UV radiation resistance associated,"UVRAG is a human gene that is associated with resistance to UV radiation. It encodes a protein with a C2 domain that activates the Beclin1-PI(3)KC3 complex, which promotes autophagy and suppresses the proliferation and tumorigenicity of human colon cancer cells. Mutations in this gene have been linked to colon cancer, and chromosomal aberrations involving this gene are associated with left-right axis malformation. UVRAG complements the ultraviolet sensitivity of xeroderma pigmentosum group C cells, indicating its role in repairing DNA damage caused by UV radiation. Overall, UVRAG plays a crucial role in maintaining genomic stability and preventing the development of cancer.","Mutations in the UVRAG gene have been associated with the development of colon cancer, and research efforts have focused on targeting this gene for therapeutic purposes. One approach has been to develop small molecule inhibitors of the Beclin1-PI(3)KC3 complex, which is activated by UVRAG and plays a role in autophagy and tumor suppression. Several compounds have been identified that inhibit this complex and show promise as potential cancer therapeutics. For example, the compound SAR405 has been shown to induce autophagy and inhibit the growth of various cancer cell lines, including colon cancer cells with UVRAG mutations. Another compound, PIK-III, has been shown to inhibit the PI(3)KC3 complex and induce autophagy in cancer cells, leading to cell death. These compounds represent promising avenues for targeted drug discovery efforts aimed at treating colon cancer and other UVRAG-associated diseases.",GO:0051684 maintenance of Golgi location;GO:1901098 positive regulation of autophagosome maturation;GO:0097680 double-strand break repair via classical nonhomologous end joining,,Disease related genes; Predicted intracellular proteins,,,,
ENSG00000182287.15,ENSG00000182287,AP1S2,-0.896616143,-1.004182543,-0.712425551,-0.973240334,adaptor related protein complex 1 subunit sigma 2,"AP1S2 is a gene that encodes for the small subunit of the adaptor protein complex 1 (AP-1), which is responsible for recruiting clathrin to the membrane and recognizing sorting signals in transmembrane receptors at the Golgi complex. AP-1 is a heterotetramer composed of two large, one medium, and one small adaptin subunit. The protein encoded by AP1S2 is a member of the adaptin protein family and has different isoforms. Mutations in this gene have been associated with X-linked mental retardation and hypogenesis of the corpus callosum, a condition characterized by a smaller than normal corpus callosum, which is the main connection between the two hemispheres of the brain.","Mutations in the AP1S2 gene have been associated with X-linked mental retardation and hypogenesis of the corpus callosum. This condition is characterized by intellectual disability, delayed speech and language development, and behavioral problems. There is currently no cure for this condition, and treatment is mainly supportive and focused on managing symptoms.

There are currently no targeted drug discovery efforts specifically for AP1S2 mutations. However, there are ongoing efforts to develop drugs that target the AP-1 complex, which could potentially benefit individuals with AP1S2 mutations. For example, a study published in 2019 identified a small molecule inhibitor of the AP-1 complex that was able to reduce the growth of cancer cells in vitro and in vivo.

There are currently no drugs on the market specifically for AP1S2 mutations. However, there are drugs that target the AP-1 complex, such as brefeldin A, which is used in research to disrupt the function of the Golgi complex and inhibit protein trafficking. Additionally, some drugs that target clathrin-mediated endocytosis, such as dynasore and pitstop 2, could potentially benefit individuals with AP1S2 mutations, as AP-1 is involved in this process. However, these drugs are still in the early stages of development and have not yet been approved for clinical use.",GO:1903232 melanosome assembly;GO:0060155 platelet dense granule organization;GO:0032438 melanosome organization,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Predicted intracellular proteins,Golgi apparatus;Vesicles (Supported),,,
ENSG00000168036.18,ENSG00000168036,CTNNB1,-0.89650457,-1.211441535,-0.995311416,-0.482760759,catenin beta 1,"CTNNB1, also known as catenin beta 1, is a gene that encodes a protein that is part of a complex of proteins that make up adherens junctions (AJs). AJs are essential for creating and maintaining epithelial cell layers by regulating cell growth and adhesion between cells. The protein also anchors the actin cytoskeleton and may be responsible for transmitting the contact inhibition signal that causes cells to stop dividing once the epithelial sheet is complete. Mutations in CTNNB1 have been linked to several types of cancer, including colorectal cancer, pilomatrixoma, medulloblastoma, and ovarian cancer. Alternative splicing of the gene results in multiple transcript variants.","Mutations in CTNNB1 have been linked to several types of cancer, including colorectal cancer, pilomatrixoma, medulloblastoma, and ovarian cancer. Targeted drug discovery efforts have focused on developing inhibitors of the Wnt/?-catenin signaling pathway, which is activated by mutations in CTNNB1 and is involved in the development and progression of many cancers. One example of a successful drug targeting this pathway is the monoclonal antibody drug cetuximab, which is used to treat colorectal cancer and head and neck cancer. Another example is the small molecule drug PRI-724, which inhibits the interaction between ?-catenin and its co-activator CBP, and has shown promise in preclinical studies for the treatment of several types of cancer.",GO:0007403 glial cell fate determination;GO:0044338 canonical Wnt signaling pathway involved in mesenchymal stem cell differentiation;GO:0003340 negative regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis,,"Human disease related genes:Skin diseases:Skin and soft tissue diseases; Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins; Human disease related genes:Cancers:Cancers of endocrine organs; Human disease related genes:Other diseases:Mental and behavioural disorders; Human disease related genes:Cancers:Cancers of the digestive system; Human disease related genes:Cancers:Cancers of the urinary system; Human disease related genes:Cancers:Cancers of eye, brain, and central nervous system; Disease related genes; Human disease related genes:Cancers:Cancers of the breast and female genital organs; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Candidate cancer biomarkers",Plasma membrane (Enhanced); Additional: Basal body;Cell Junctions;Primary cilium,Urea,(M31)PID BETA CATENIN DEG PATHWAY; (M90)PID WNT CANONICAL PATHWAY; (M184)PID ECADHERIN KERATINOCYTE PATHWAY,(M5895)HALLMARK WNT BETA CATENIN SIGNALING; (M5896)HALLMARK TGF BETA SIGNALING; (M5892)HALLMARK CHOLESTEROL HOMEOSTASIS
ENSG00000149577.16,ENSG00000149577,SIDT2,-0.895845087,-1.595594354,-0.467688976,-0.62425193,SID1 transmembrane family member 2,"SIDT2, or SID1 transmembrane family member 2, is a human gene that is predicted to have several functions, including binding to the AP-1 and AP-2 adaptor complexes and transporting RNA across membranes. It is involved in RNA transport and is located in both the lysosomal and plasma membranes. This information is provided by the Alliance of Genome Resources as of April 2022.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for SIDT2. However, some studies have suggested that SIDT2 may play a role in the development and progression of certain cancers, such as breast cancer and hepatocellular carcinoma. Additionally, there is some evidence to suggest that SIDT2 may be involved in the pathogenesis of lysosomal storage disorders, such as Niemann-Pick disease.

As of April 2022, there are no drugs on the market that specifically target SIDT2. However, there are several drugs that target lysosomal storage disorders, such as enzyme replacement therapies and substrate reduction therapies. For example, the drug miglustat is used to treat Niemann-Pick disease type C, which is caused by a defect in lysosomal cholesterol transport. Miglustat works by inhibiting the synthesis of glycosphingolipids, which accumulate in the lysosomes of affected individuals. While these drugs do not directly target SIDT2, they may indirectly affect its function by modulating lysosomal activity.",GO:0003323 type B pancreatic cell development;GO:0044342 type B pancreatic cell proliferation;GO:0003309 type B pancreatic cell differentiation,,Transporters:Transporter channels and pores; Predicted intracellular proteins,,,,(M5945)HALLMARK HEME METABOLISM
ENSG00000058272.19,ENSG00000058272,PPP1R12A,-0.895626252,-1.192479597,-0.846803603,-0.647595557,protein phosphatase 1 regulatory subunit 12A,"PPP1R12A is a gene that encodes for the myosin-binding subunit (MBS) of myosin phosphatase, which is responsible for regulating the interaction between actin and myosin downstream of the guanosine triphosphatase Rho. Rho is involved in myosin light chain (MLC) phosphorylation, which leads to the contraction of smooth muscle and the interaction of actin and myosin in nonmuscle cells. The active form of RhoA (GTP.RhoA) interacts with MBS, which regulates the extent of MLC phosphorylation. Rho-kinase, which is activated by GTP.RhoA, phosphorylates MBS and inactivates myosin phosphatase, leading to increased MLC phosphorylation. Different isoforms of PPP1R12A have been identified.","PPP1R12A has been implicated in various diseases, including hypertension, asthma, and cancer. In hypertension, increased RhoA activity and MLC phosphorylation lead to increased vascular smooth muscle contraction and vasoconstriction, contributing to elevated blood pressure. In asthma, RhoA activation and MLC phosphorylation lead to airway smooth muscle contraction and bronchoconstriction. In cancer, RhoA activation and MLC phosphorylation contribute to tumor cell migration and invasion.

Targeted drug discovery efforts have focused on developing inhibitors of Rho-kinase and myosin phosphatase to reduce MLC phosphorylation and smooth muscle contraction. Fasudil, a Rho-kinase inhibitor, has been approved in Japan for the treatment of cerebral vasospasm after subarachnoid hemorrhage. Another Rho-kinase inhibitor, ripasudil, has been approved in Japan for the treatment of glaucoma and ocular hypertension. Mycophenolic acid, an immunosuppressive drug, has been shown to inhibit myosin phosphatase and reduce MLC phosphorylation, and is used in the treatment of autoimmune diseases and organ transplantation.

In conclusion, PPP1R12A plays a crucial role in regulating smooth muscle contraction and cell migration, and its dysregulation has been implicated in various diseases. Targeted drug discovery efforts have led to the development of inhibitors of Rho-kinase and myosin phosphatase, with some drugs already on the market for the treatment of cerebral vasospasm, glaucoma, and autoimmune diseases.",GO:0006470 protein dephosphorylation;GO:0007098 centrosome cycle;GO:0031023 microtubule organizing center organization,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Actin filaments;Cytosol (Supported); Additional: Nucleoli;Plasma membrane,,(M71)PID ILK PATHWAY; (M12)PID RHOA PATHWAY; (M129)PID PLK1 PATHWAY,
ENSG00000197579.8,ENSG00000197579,TOPORS,-0.895347137,-1.010959444,-1.334081511,-0.341000458,"TOP1 binding arginine/serine rich protein, E3 ubiquitin ligase","TOPORS is a gene that encodes a nuclear protein that is rich in serine and arginine and contains a RING-type zinc finger domain. It is highly expressed in the testis and functions as an E3 ubiquitin ligase. This means that it plays a role in attaching ubiquitin molecules to proteins, which can lead to their degradation or modification. Mutations in TOPORS have been linked to retinitis pigmentosa type 31, a genetic disorder that affects the retina and can lead to vision loss. There are different isoforms of the protein that can be produced due to alternative splicing of the gene.","TOPORS mutations have been linked to retinitis pigmentosa type 31, a genetic disorder that affects the retina and can lead to vision loss. However, there are currently no targeted drug discovery efforts specifically for TOPORS. 

There are also no drugs on the market that target TOPORS directly. However, there are drugs that target the ubiquitin-proteasome system, which is the pathway that TOPORS is involved in. These drugs, such as bortezomib and carfilzomib, are used to treat multiple myeloma and mantle cell lymphoma. They work by inhibiting the proteasome, which leads to the accumulation of proteins that are marked for degradation by ubiquitin. 

In addition, there are drugs that target other E3 ubiquitin ligases, such as thalidomide and lenalidomide, which are used to treat multiple myeloma and other blood cancers. These drugs work by modulating the activity of E3 ubiquitin ligases, leading to the degradation of specific proteins that are involved in cancer cell growth and survival. 

Overall, while there are no targeted drug discovery efforts for TOPORS specifically, drugs that target the ubiquitin-proteasome system and other E3 ubiquitin ligases have shown promise in treating certain types of cancer.",GO:0051457 maintenance of protein location in nucleus;GO:0042771 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator;GO:0072595 maintenance of protein localization in organelle,,Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Nucleoplasm (Supported),,,
ENSG00000130340.16,ENSG00000130340,SNX9,-0.895089408,-1.340760671,-1.100835614,-0.243671938,sorting nexin 9,"SNX9 is a gene that belongs to the sorting nexin family and is involved in intracellular trafficking. Unlike some family members, it does not contain a coiled coil region but has a SRC homology domain near its N-terminus. The protein encoded by this gene interacts with several proteins, including adaptor protein 2, dynamin, tyrosine kinase non-receptor 2, Wiskott-Aldrich syndrome-like, and ARP3 actin-related protein 3. It plays a role in various stages of intracellular trafficking, such as endocytosis, macropinocytosis, and F-actin nucleation.","Research on SNX9 has revealed its potential involvement in various diseases, including cancer, neurodegenerative disorders, and infectious diseases. For example, SNX9 has been shown to play a role in the progression of breast cancer by promoting the invasiveness of cancer cells. In neurodegenerative disorders such as Alzheimer's disease, SNX9 has been implicated in the regulation of amyloid precursor protein (APP) trafficking and processing. Additionally, SNX9 has been found to be involved in the entry of viruses such as HIV and Ebola into host cells.

Targeted drug discovery efforts for SNX9 are still in the early stages, but there is potential for the development of drugs that target its interactions with other proteins involved in intracellular trafficking. For example, inhibitors of the interaction between SNX9 and dynamin could potentially be used to block endocytosis and macropinocytosis, which are important processes for the uptake of nutrients and pathogens by cells.

Currently, there are no drugs on the market that specifically target SNX9. However, there are drugs that indirectly affect its function, such as dynamin inhibitors like dynasore and pitstop 2, which have been shown to inhibit endocytosis and macropinocytosis. Additionally, drugs that target F-actin nucleation, such as cytochalasin D and latrunculin A, could indirectly affect SNX9 function as it is involved in this process.",GO:0060988 lipid tube assembly;GO:0036089 cleavage furrow formation;GO:0097320 plasma membrane tubulation,,Predicted intracellular proteins,Plasma membrane (Supported); Additional: Cytosol,,,(M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000091317.8,ENSG00000091317,CMTM6,-0.895063339,-1.193549217,-1.033734248,-0.457906553,CKLF like MARVEL transmembrane domain containing 6,"CMTM6 is a gene that belongs to the chemokine-like factor gene superfamily and is located on chromosome 3. It is widely expressed in many tissues, but its exact function is unknown. The gene is similar to the chemokine and transmembrane 4 superfamilies.","There is limited information available on the disease implications of CMTM6. However, recent studies have suggested that CMTM6 may play a role in the immune response and cancer progression. Specifically, CMTM6 has been shown to regulate the expression of PD-L1, a protein that is often overexpressed in cancer cells and helps them evade the immune system. Targeted drug discovery efforts are currently underway to develop drugs that can modulate the activity of CMTM6 and PD-L1, with the goal of improving the efficacy of cancer immunotherapy. One example of a successful drug that targets PD-L1 is pembrolizumab, which has been approved for the treatment of several types of cancer, including melanoma and non-small cell lung cancer. However, more research is needed to fully understand the role of CMTM6 in disease and to develop effective therapies targeting this gene.",GO:0032456 endocytic recycling;GO:0098876 vesicle-mediated transport to the plasma membrane;GO:0016197 endosomal transport,,,Vesicles (Approved),,,
ENSG00000143442.22,ENSG00000143442,POGZ,-0.895011988,-1.253795433,-0.761516326,-0.669724206,pogo transposable element derived with ZNF domain,"POGZ is a human gene that encodes a protein containing a transposase domain and a zinc finger domain. The protein interacts with the transcription factor SP1 and has multiple isoforms due to alternative splicing. The transposase domain suggests that POGZ may have a role in the movement of genetic elements within the genome. The function of POGZ is not fully understood, but mutations in this gene have been associated with intellectual disability and developmental delay.","Mutations in the POGZ gene have been associated with intellectual disability and developmental delay. Studies have shown that POGZ plays a critical role in the development and function of the nervous system. Targeted drug discovery efforts for POGZ are still in the early stages, but there is potential for developing drugs that can modulate the activity of POGZ and improve cognitive function in individuals with POGZ mutations. Currently, there are no drugs on the market that specifically target POGZ, but there are drugs that have been approved for the treatment of intellectual disability and developmental delay, such as Risperidone and Aripiprazole. These drugs work by targeting neurotransmitter systems in the brain and can improve symptoms associated with these conditions.",GO:0051382 kinetochore assembly;GO:0051383 kinetochore organization;GO:0007064 mitotic sister chromatid cohesion,,Disease related genes; Predicted intracellular proteins; Transcription factors:Zinc-coordinating DNA-binding domains,Nucleoplasm (Supported); Additional: Basal body;Cytosol,,,
ENSG00000126464.14,ENSG00000126464,PRR12,-0.89491309,-1.252958408,-0.895517569,-0.536263293,proline rich 12,"PRR12 is a gene that encodes a proline-rich protein with two A-T hook DNA binding domains. It is expressed in embryonic mouse brain, indicating a potential role in nervous system development. A chromosomal translocation and gene fusion between PRR12 and zinc finger, MIZ-type containing 1 have been linked to intellectual disability and neuropsychiatric problems in a human patient.","There is limited information available on the disease implications of PRR12. However, the chromosomal translocation and gene fusion between PRR12 and zinc finger, MIZ-type containing 1 have been linked to intellectual disability and neuropsychiatric problems in a human patient. As for targeted drug discovery efforts, there is currently no known drug targeting PRR12. This is likely due to the limited understanding of the gene's function and disease implications. Therefore, there are no successful drugs on the market targeting PRR12. However, further research on the gene's role in nervous system development and its potential involvement in intellectual disability and neuropsychiatric disorders may lead to the development of targeted therapies in the future.",,,Disease related genes; Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000177606.8,ENSG00000177606,JUN,-0.892653499,-1.327021843,-0.89303917,-0.457899485,"Jun proto-oncogene, AP-1 transcription factor subunit",The JUN gene is a proto-oncogene that encodes a protein that interacts with specific target DNA sequences to regulate gene expression. It is highly similar to the viral protein of avian sarcoma virus 17 and is involved in both translocations and deletions in human malignancies. The gene is located on chromosome 1p32-p31 and is intronless. Its putative transforming ability suggests that it may play a role in the development of cancer.,"The JUN gene has been implicated in various types of cancer, including breast, lung, and pancreatic cancer. Targeted drug discovery efforts have focused on developing inhibitors of the JUN protein to prevent its interaction with target DNA sequences and thereby reduce the expression of genes involved in cancer progression. One example of a successful drug targeting JUN is TAK-659, a selective inhibitor of JUN N-terminal kinase (JNK) that has shown promising results in preclinical studies for the treatment of B-cell malignancies. Another example is SP600125, a JNK inhibitor that has been shown to inhibit the growth of pancreatic cancer cells in vitro and in vivo. However, further research is needed to fully understand the role of JUN in cancer and to develop effective targeted therapies.",GO:0019045 latent virus replication;GO:0019046 release from viral latency;GO:0019042 viral latency,,FDA approved drug targets:Small molecule drugs; Transcription factors:Basic domains; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Enhanced),Adapalene; Vinblastine; Irbesartan; Arsenic trioxide; LGD-1550,(M190)PID TCR JNK PATHWAY; (M206)PID PDGFRA PATHWAY; (M268)PID S1P S1P2 PATHWAY,(M5897)HALLMARK IL6 JAK STAT3 SIGNALING; (M5902)HALLMARK APOPTOSIS; (M5890)HALLMARK TNFA SIGNALING VIA NFKB
ENSG00000133789.15,ENSG00000133789,SWAP70,-0.89257382,-1.134545228,-1.026064841,-0.517111391,switching B cell complex subunit SWAP70,"SWAP70 is a human gene that is involved in the regulation of actin polymerization or depolymerization and is predicted to act upstream of or within isotype switching. It enables cadherin binding activity and is located in the actin cytoskeleton, cytoplasm, and plasma membrane. The gene is responsible for switching the B cell complex subunit SWAP70, which plays a crucial role in the immune system by regulating the production of antibodies. The information provided by the Alliance of Genome Resources in April 2022 suggests that SWAP70 may be a potential target for therapies aimed at treating immune-related disorders.","There is limited information available on the disease implications of SWAP70. However, studies have suggested that mutations in the gene may be associated with autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Targeted drug discovery efforts for SWAP70 are still in the early stages, but there is potential for the development of drugs that modulate its activity to treat immune-related disorders. Currently, there are no drugs on the market that specifically target SWAP70. However, there are drugs that target other proteins involved in the regulation of actin polymerization, such as cytochalasin D and latrunculin A, which have been used in research to study the role of SWAP70 in B cell activation and antibody production. Further research is needed to fully understand the potential therapeutic implications of targeting SWAP70.",GO:0033633 negative regulation of cell-cell adhesion mediated by integrin;GO:0060754 positive regulation of mast cell chemotaxis;GO:0060753 regulation of mast cell chemotaxis,,Predicted intracellular proteins,Plasma membrane (Supported); Additional: Actin filaments,,,(M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000124942.14,ENSG00000124942,AHNAK,-0.892493422,-1.223325039,-1.097530014,-0.356625212,AHNAK nucleoprotein,"AHNAK nucleoprotein is a large structural scaffold protein that plays a role in various biological processes such as blood-brain barrier formation, cell structure and migration, cardiac calcium channel regulation, and tumor metastasis. It consists of a central domain with 128 amino acid repeats. A shorter variant of the gene encoding a 17 kDa isoform exists, which initiates a feedback loop that regulates alternative splicing of the gene. AHNAK nucleoprotein is believed to be involved in the regulation of gene expression and may have potential as a therapeutic target for cancer and other diseases.","AHNAK nucleoprotein has been implicated in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, AHNAK has been shown to promote tumor metastasis and invasion, making it a potential therapeutic target. Targeted drug discovery efforts have focused on developing small molecule inhibitors of AHNAK, with some promising results in preclinical studies. However, no AHNAK-targeted drugs have been approved for clinical use yet. In cardiovascular disease, AHNAK has been linked to cardiac calcium channel regulation and arrhythmias, and may be a potential target for developing new treatments. In neurological disorders, AHNAK has been implicated in blood-brain barrier formation and may play a role in diseases such as multiple sclerosis. Currently, there are no drugs on the market that specifically target AHNAK nucleoprotein.",GO:1905686 positive regulation of plasma membrane repair;GO:1905684 regulation of plasma membrane repair;GO:1903729 regulation of plasma membrane organization,,Predicted intracellular proteins,Cytosol;Plasma membrane (Enhanced),,,(M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000143870.13,ENSG00000143870,PDIA6,-0.892294276,-0.941464674,-1.534567095,-0.20085106,protein disulfide isomerase family A member 6,"PDIA6 is a gene that encodes a protein belonging to the disulfide isomerase family, which is responsible for catalyzing protein folding and thiol-disulfide interchange reactions in the endoplasmic reticulum. The protein has an N-terminal ER-signal sequence, two catalytically active thioredoxin domains, a TRX-like domain, and a C-terminal ER-retention sequence. It has both isomerase and chaperone activity and can inhibit the aggregation of misfolded proteins. Alternative splicing results in multiple transcript variants encoding different isoforms.","Research has shown that PDIA6 is involved in various diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, PDIA6 has been found to promote tumor growth and metastasis by regulating the activity of several signaling pathways. Targeting PDIA6 has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of PDIA6 have been developed and are currently being evaluated in preclinical studies. In neurodegenerative disorders, PDIA6 has been implicated in the misfolding and aggregation of disease-associated proteins, such as alpha-synuclein in Parkinson's disease and tau in Alzheimer's disease. Targeting PDIA6 may help prevent protein aggregation and neurodegeneration. However, there are currently no drugs targeting PDIA6 approved for clinical use.",GO:0006457 protein folding;GO:0034976 response to endoplasmic reticulum stress;GO:0051604 protein maturation,,Enzymes; ENZYME proteins:Isomerase; Predicted intracellular proteins,Endoplasmic reticulum (Supported); Additional: Basal body;Centriolar satellite;Primary cilium,,,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000179295.18,ENSG00000179295,PTPN11,-0.890868093,-1.129227969,-0.981086312,-0.562289998,protein tyrosine phosphatase non-receptor type 11,"PTPN11 is a gene that encodes a protein tyrosine phosphatase (PTP) known to regulate various cellular processes such as cell growth, differentiation, and oncogenic transformation. The PTP contains two Src homology-2 domains that interact with its substrates. It is widely expressed in most tissues and plays a regulatory role in cell signaling events important for cell functions such as mitogenic activation, metabolic control, transcription regulation, and cell migration. Mutations in this gene are associated with Noonan syndrome and acute myeloid leukemia.","PTPN11 mutations have been linked to Noonan syndrome, a genetic disorder characterized by facial abnormalities, short stature, heart defects, and developmental delays. The mutations in PTPN11 result in the overactivation of the RAS-MAPK signaling pathway, which is involved in cell growth and differentiation. This overactivation leads to abnormal cell proliferation and differentiation, contributing to the development of Noonan syndrome.

In addition, PTPN11 mutations have also been implicated in the development of acute myeloid leukemia (AML). The mutations result in the activation of the FLT3 receptor tyrosine kinase, which promotes the growth and survival of leukemia cells. Targeted therapies that inhibit FLT3 have been developed for the treatment of AML, including midostaurin and gilteritinib.

Efforts to develop targeted therapies for PTPN11-related disorders are ongoing. One approach is to develop small molecule inhibitors that target the PTPN11 protein directly. Another approach is to target downstream effectors of the RAS-MAPK pathway, such as MEK and ERK. Several MEK inhibitors, such as trametinib and cobimetinib, have been approved for the treatment of melanoma and other cancers with RAS mutations.

In conclusion, PTPN11 is an important gene involved in regulating cell signaling events, and mutations in this gene have been linked to Noonan syndrome and AML. Targeted therapies that inhibit the overactivation of the RAS-MAPK pathway are being developed for the treatment of these disorders, with some drugs already on the market.",GO:0051463 negative regulation of cortisol secretion;GO:0060125 negative regulation of growth hormone secretion;GO:0061582 intestinal epithelial cell migration,,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes; RAS pathway related proteins,Nucleoli rim (Supported); Additional: Actin filaments;Cytosol;Nucleoplasm,Dodecyltrimethylammonium,(M135)PID IL5 PATHWAY; (M182)PID IL3 PATHWAY; (M226)PID VEGFR1 PATHWAY,(M5897)HALLMARK IL6 JAK STAT3 SIGNALING; (M5923)HALLMARK PI3K AKT MTOR SIGNALING
ENSG00000142208.17,ENSG00000142208,AKT1,-0.890003993,-1.37769749,-1.015041243,-0.277273247,AKT serine/threonine kinase 1,"AKT1 is a gene that encodes a protein kinase, which is a member of the AKT serine-threonine protein kinase family. This family includes three highly similar proteins, AKT alpha, beta, and gamma, that regulate a wide variety of cellular functions, including cell proliferation, survival, metabolism, and angiogenesis. AKT proteins are phosphorylated by phosphoinositide 3-kinase (PI3K) and are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3). The PI3K/AKT signaling pathway is crucial for tumor cell survival, and mutations in the AKT1 gene are associated with multiple types of cancer and excessive tissue growth. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signaling pathway, which is disregulated in many cancers.","Mutations in the AKT1 gene have been associated with various types of cancer, including breast, ovarian, colorectal, and lung cancer. In particular, the E17K mutation in AKT1 has been found in up to 8% of breast cancer cases and is associated with increased AKT activity and tumor growth. Targeted drug discovery efforts have focused on developing inhibitors of the PI3K/AKT/mTOR pathway, with several drugs currently in clinical trials. One example is ipatasertib, a selective AKT inhibitor that has shown promising results in phase II clinical trials for advanced breast cancer. Another example is capivasertib, a pan-AKT inhibitor that is being tested in combination with other drugs for various types of cancer. Additionally, some drugs that indirectly target AKT, such as the mTOR inhibitor everolimus, have been approved for the treatment of certain cancers.",GO:0019049 virus-mediated perturbation of host defense response;GO:0052031 symbiont-mediated perturbation of host defense response;GO:0110002 regulation of tRNA methylation,yes,"RAS pathway related proteins; Predicted intracellular proteins; Human disease related genes:Cancers:Cancers of the breast and female genital organs; Human disease related genes:Other diseases:Mental and behavioural disorders; ENZYME proteins:Transferases; Human disease related genes:Cancers:Cancers of eye, brain, and central nervous system; Transporters:Accessory Factors Involved in Transport; Human disease related genes:Congenital malformations:Congenital malformations of skin; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Kinases:AGC Ser/Thr protein kinases; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Candidate cancer biomarkers",Microtubules;Nucleoplasm (Approved); Additional: Basal body;Calyx;End piece;Perinuclear theca;Primary cilium;Principal piece,"ATP; Arsenic trioxide; Genistein; Inositol 1,3,4,5-Tetrakisphosphate; Resveratrol; Archexin; Enzastaurin; Perifosine; N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine; 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine",(M12771)SA PTEN PATHWAY; (M18895)SA TRKA RECEPTOR; (M184)PID ECADHERIN KERATINOCYTE PATHWAY,(M5908)HALLMARK ANDROGEN RESPONSE; (M5923)HALLMARK PI3K AKT MTOR SIGNALING; (M5950)HALLMARK ALLOGRAFT REJECTION
ENSG00000162923.17,ENSG00000162923,WDR26,-0.889798146,-1.180033257,-0.826386809,-0.662974373,WD repeat domain 26,"WDR26 is a gene that encodes a member of the WD repeat protein family. This family is involved in various cellular processes, including cell cycle progression, signal transduction, apoptosis, and gene regulation. WD repeats are regions of approximately 40 amino acids that are minimally conserved and are typically bracketed by gly-his and trp-asp (GH-WD). These regions may facilitate the formation of heterotrimeric or multiprotein complexes. Two transcript variants encoding two different isoforms have been identified for this gene.","There is limited information available on the disease implications of WDR26. However, recent studies have suggested that mutations in this gene may be associated with various types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for WDR26 are still in the early stages, but there is potential for this gene to be a target for cancer therapies. One example of a successful drug targeting a WD repeat protein is bortezomib, which targets the proteasome and is used to treat multiple myeloma. Another example is the drug rapamycin, which targets the mTOR pathway and is used to treat various types of cancer. Further research is needed to fully understand the role of WDR26 in disease and to develop targeted therapies.",GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process;GO:0010498 proteasomal protein catabolic process;GO:0006511 ubiquitin-dependent protein catabolic process,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Cytosol;Nucleoplasm (Enhanced); Additional: Mitochondria,,,
ENSG00000125149.12,ENSG00000125149,C16orf70,-0.889715485,-0.965206613,-1.194225161,-0.50971468,phagophore assembly factor 1,"PHAF1, also known as phagosome assembly factor 1, is a human gene that is predicted to be involved in the transport of proteins from the Golgi to the plasma membrane. It is located in the phagophore assembly site, which is a cellular structure involved in the formation of autophagosomes. Autophagosomes are membrane-bound structures that are responsible for the degradation of cellular components, including damaged organelles and proteins. PHAF1 may play a role in the assembly of these structures, although its exact function is not yet fully understood. This gene is currently being studied by researchers to better understand its role in cellular processes.","There is limited information available on the disease implications of PHAF1. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for PHAF1 are also limited, as its exact function in cellular processes is not yet fully understood. Currently, there are no drugs on the market that specifically target PHAF1. However, there are drugs that target autophagy, the cellular process in which PHAF1 is involved. For example, chloroquine and hydroxychloroquine are drugs that have been used to treat malaria and autoimmune diseases, but they have also been shown to inhibit autophagy and are being studied as potential cancer treatments. Additionally, rapamycin and its analogs, which target the mTOR pathway involved in autophagy, have been approved for the treatment of certain types of cancer.",GO:0043001 Golgi to plasma membrane protein transport;GO:0061951 establishment of protein localization to plasma membrane;GO:0006893 Golgi to plasma membrane transport,,Predicted intracellular proteins,Nuclear speckles (Approved); Additional: Cytosol;Nucleoli fibrillar center,,,
ENSG00000198315.11,ENSG00000198315,ZKSCAN8,-0.88962787,-1.171427179,-0.857494044,-0.639962387,zinc finger with KRAB and SCAN domains 8,"ZKSCAN8 is a human gene that is predicted to have DNA-binding transcription factor activity, specifically for RNA polymerase II and cis-regulatory region sequence-specific DNA binding activity. It is also predicted to be involved in the regulation of transcription by RNA polymerase II and located in the nucleus.","There is limited information available on the disease implications of ZKSCAN8. However, some studies have suggested that it may play a role in the development and progression of certain cancers, including breast cancer and hepatocellular carcinoma. As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target ZKSCAN8. However, there are ongoing efforts to develop drugs that target other transcription factors involved in cancer development and progression, which may indirectly affect ZKSCAN8 activity. For example, drugs that target the estrogen receptor, such as tamoxifen, are commonly used to treat breast cancer and may indirectly affect ZKSCAN8 activity. Additionally, drugs that target other transcription factors, such as MYC and p53, are currently being developed and may have implications for ZKSCAN8 activity.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000185009.13,ENSG00000185009,AP3M1,-0.889488181,-1.375410514,-0.778509834,-0.514544196,adaptor related protein complex 3 subunit mu 1,"AP3M1 is a human gene that encodes the medium subunit of AP-3, an adaptor-related protein complex that is associated with the Golgi region and other intracellular structures. AP-3 helps in the budding of vesicles from the Golgi membrane and plays a role in protein sorting to the endosomal/lysosomal system. The AP-3 complex is composed of two large subunits (delta and beta3), a medium subunit (mu3), and a small subunit (sigma 3). Mutations in one of the large subunits of AP-3 have been linked to Hermansky-Pudlak syndrome, a genetic disorder characterized by defective lysosome-related organelles. Alternative splicing of AP3M1 results in multiple transcript variants.","Mutations in the AP3M1 gene have been associated with Hermansky-Pudlak syndrome (HPS), a rare genetic disorder characterized by oculocutaneous albinism, bleeding diathesis, and pulmonary fibrosis. HPS is caused by defects in the biogenesis of lysosome-related organelles, leading to abnormal platelet dense granules, melanosomes, and lysosomes. There are currently no targeted drugs available for HPS, and treatment is mainly supportive, focusing on managing symptoms such as bleeding and pulmonary fibrosis. However, recent studies have identified potential therapeutic targets for HPS, including the use of small molecules to enhance lysosomal biogenesis and function. Examples of successful drugs targeting lysosomal storage disorders include enzyme replacement therapies such as imiglucerase for Gaucher disease and agalsidase alfa and beta for Fabry disease.","GO:0035652 clathrin-coated vesicle cargo loading;GO:0035654 clathrin-coated vesicle cargo loading, AP-3-mediated;GO:0098884 postsynaptic neurotransmitter receptor internalization",,Predicted intracellular proteins,,,,
ENSG00000063587.15,ENSG00000063587,ZNF275,-0.888819359,-1.436796614,-0.671801158,-0.557860304,zinc finger protein 275,"ZNF275 is a gene that encodes for a zinc finger protein. This protein is found in eutheria, a group of mammals that includes humans. The function of this protein is not yet known.","There is currently limited information on the disease implications of ZNF275. However, some studies have suggested that alterations in the expression of this gene may be associated with certain types of cancer, such as breast cancer and hepatocellular carcinoma. As for targeted drug discovery efforts, there are currently no known drugs that specifically target ZNF275. However, there are ongoing efforts to develop drugs that target other zinc finger proteins, which may have implications for ZNF275 as well. One example of a successful drug that targets a zinc finger protein is thalidomide, which is used to treat multiple myeloma and leprosy. Thalidomide works by binding to a zinc finger protein called cereblon, which leads to the degradation of certain proteins involved in cancer cell growth.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoli (Approved),,,
ENSG00000138071.14,ENSG00000138071,ACTR2,-0.888581459,-1.144208886,-1.057288005,-0.464247487,actin related protein 2,"ACTR2 is a human gene that encodes a protein that is a major component of the ARP2/3 complex. The specific function of this gene is not yet known, but the ARP2/3 complex is essential for cell shape and motility through the assembly and protrusion of lamellipodial actin. Two different isoforms of the protein have been identified through transcript variants.","Mutations in the ACTR2 gene have been associated with several diseases, including Baraitser-Winter syndrome, a rare genetic disorder characterized by intellectual disability, epilepsy, and distinctive facial features. Additionally, ACTR2 mutations have been linked to a form of hereditary spastic paraplegia, a group of neurological disorders that affect the ability to walk. 

Targeted drug discovery efforts for ACTR2 are still in the early stages, but there is potential for drugs that modulate the activity of the ARP2/3 complex to be developed for the treatment of diseases associated with ACTR2 mutations. One example of a successful drug that targets the ARP2/3 complex is cytochalasin D, which is used as an anti-cancer agent due to its ability to disrupt actin dynamics and inhibit cell migration. Another example is CK-666, a small molecule inhibitor of the ARP2/3 complex that has shown promise in preclinical studies for the treatment of metastatic cancer. However, more research is needed to fully understand the potential of targeting ACTR2 and the ARP2/3 complex for therapeutic purposes.",GO:0016344 meiotic chromosome movement towards spindle pole;GO:0051305 chromosome movement towards spindle pole;GO:0033206 meiotic cytokinesis,,Predicted intracellular proteins,Cytosol (Uncertain); Additional: Nucleoli,"N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide; (2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one",(M16801)SIG REGULATION OF THE ACTIN CYTOSKELETON BY RHO GTPASES; (M5193)SIG CHEMOTAXIS; (M278)PID RAC1 PATHWAY,(M5923)HALLMARK PI3K AKT MTOR SIGNALING; (M5924)HALLMARK MTORC1 SIGNALING
ENSG00000141503.17,ENSG00000141503,MINK1,-0.887870721,-1.365936977,-1.128846395,-0.168828791,misshapen like kinase 1,MINK1 is a gene that encodes a serine/threonine kinase belonging to the germinal center kinase family. It is structurally similar to kinases related to NIK and may belong to a distinct subfamily of NIK-related kinases within the GCK family. Studies of the mouse homolog suggest that MINK1 is up-regulated during postnatal cerebral development and activates the cJun N-terminal kinase and p38 pathways.,"There is limited information available on the disease implications of MINK1. However, recent studies have suggested that MINK1 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for MINK1 are still in the early stages, but there is potential for the development of small molecule inhibitors that could be used to treat cancer. Currently, there are no drugs on the market that specifically target MINK1, but there are several drugs that target related kinases in the GCK family, including imatinib and dasatinib, which are used to treat certain types of leukemia. Further research is needed to fully understand the potential therapeutic applications of targeting MINK1.",GO:2000311 regulation of AMPA receptor activity;GO:1900745 positive regulation of p38MAPK cascade;GO:0099601 regulation of neurotransmitter receptor activity,yes,Enzymes; Kinases:STE Ser/Thr protein kinases; Predicted intracellular proteins; ENZYME proteins:Transferases,,Fostamatinib,,
ENSG00000061987.16,ENSG00000061987,MON2,-0.887659451,-1.170282917,-0.760382681,-0.732312755,"MON2 homolog, regulator of endosome-to-Golgi trafficking","MON2 is a human gene that is predicted to play a role in the transport of molecules from the Golgi apparatus to the endosome. It is located in the membrane of early endosomes. The gene is a homolog of MON2, a regulator of endosome-to-Golgi trafficking in yeast. While the exact function of MON2 in humans is not yet fully understood, it is believed to be involved in the regulation of intracellular transport pathways. This gene may have implications for understanding diseases related to defects in intracellular trafficking, such as lysosomal storage disorders.","There is limited information available on the disease implications of MON2. However, defects in intracellular trafficking have been linked to lysosomal storage disorders, such as Niemann-Pick disease and Gaucher disease. Therefore, it is possible that mutations in MON2 could contribute to the development of these diseases. 

As of now, there are no targeted drug discovery efforts specifically focused on MON2. However, there are drugs on the market that target intracellular trafficking pathways, such as lysosomal storage disorders. For example, enzyme replacement therapy (ERT) is a treatment for Gaucher disease that involves the administration of a recombinant enzyme to replace the deficient enzyme in patients. Another example is miglustat, a drug used to treat Niemann-Pick disease type C, which inhibits the synthesis of glycosphingolipids, a type of lipid that accumulates in the lysosomes of affected individuals. 

Overall, while the exact role of MON2 in human disease is not yet fully understood, it is possible that it could have implications for lysosomal storage disorders and other diseases related to defects in intracellular trafficking.",GO:0006895 Golgi to endosome transport;GO:0006892 post-Golgi vesicle-mediated transport;GO:0016482 cytosolic transport,,Predicted intracellular proteins,Nucleoli fibrillar center;Nucleoplasm (Approved),,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000146535.14,ENSG00000146535,GNA12,-0.886974795,-1.294294683,-0.881283106,-0.485346596,G protein subunit alpha 12,"GNA12 is a human gene that encodes for a protein called G protein subunit alpha 12. This protein is predicted to have several functions, including the ability to bind to the D5 dopamine receptor, the G-protein beta/gamma-subunit complex, and to have GTPase activity. GNA12 is involved in the regulation of TOR signaling and the proteasomal ubiquitin-dependent protein catabolic process. It is located in focal adhesion, which is a specialized structure that allows cells to attach to their surroundings. Overall, GNA12 plays an important role in various cellular processes and may have implications in disease development and treatment.","There is evidence to suggest that GNA12 may play a role in the development and progression of certain diseases, including cancer and cardiovascular disease. In cancer, GNA12 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. In cardiovascular disease, GNA12 has been implicated in the regulation of blood pressure and vascular smooth muscle cell proliferation, suggesting that it may be a target for the treatment of hypertension and atherosclerosis.

There have been efforts to develop drugs that target GNA12, although none have yet been approved for clinical use. One approach has been to develop small molecule inhibitors that block the interaction between GNA12 and its binding partners, such as the D5 dopamine receptor. Another approach has been to target downstream signaling pathways that are activated by GNA12, such as the RhoA/ROCK pathway.

Examples of successful drugs on the market that target related G proteins include olanzapine, which targets the D2 dopamine receptor and is used to treat schizophrenia and bipolar disorder, and simvastatin, which targets the HMG-CoA reductase enzyme and is used to lower cholesterol levels in patients with hypercholesterolemia.",GO:1904753 negative regulation of vascular associated smooth muscle cell migration;GO:0010762 regulation of fibroblast migration;GO:0014912 negative regulation of smooth muscle cell migration,,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Predicted intracellular proteins,Cytosol (Supported),,(M64)PID S1P S1P4 PATHWAY; (M155)PID S1P META PATHWAY; (M268)PID S1P S1P2 PATHWAY,
ENSG00000073417.15,ENSG00000073417,PDE8A,-0.886694336,-1.073340584,-0.76855306,-0.818189364,phosphodiesterase 8A,"PDE8A is a gene that encodes for a protein belonging to the cyclic nucleotide phosphodiesterase family, specifically the PDE8 subfamily. This protein is responsible for breaking down the second messenger molecule cAMP, which plays a crucial role in regulating cellular responses to external signals. By controlling the concentration of cAMP within cells, PDE8A is involved in many important physiological processes. Different isoforms of the protein are produced through alternative splicing of the gene.","Research on PDE8A has suggested its potential involvement in various diseases, including autoimmune disorders, cancer, and neurological disorders. For example, studies have shown that PDE8A is upregulated in multiple sclerosis patients, and its inhibition may have therapeutic potential in treating the disease. Additionally, PDE8A has been implicated in the development of certain types of cancer, such as melanoma and prostate cancer, and its inhibition may have anti-tumor effects. 

Targeted drug discovery efforts have focused on developing PDE8A inhibitors as potential therapeutics for these diseases. Several compounds have been identified as PDE8A inhibitors, including PF-4957325 and PF-04957325, which have shown promising results in preclinical studies. However, no PDE8A inhibitors have been approved for clinical use yet.

One example of a successful drug targeting the cyclic nucleotide phosphodiesterase family is sildenafil (Viagra), which targets PDE5 and is used to treat erectile dysfunction. Another example is tadalafil (Cialis), which also targets PDE5 and is used to treat both erectile dysfunction and pulmonary arterial hypertension. These drugs have demonstrated the potential of targeting cyclic nucleotide phosphodiesterases for therapeutic purposes, and further research on PDE8A inhibitors may lead to the development of new treatments for various diseases.",GO:0006198 cAMP catabolic process;GO:0009214 cyclic nucleotide catabolic process;GO:0046058 cAMP metabolic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Golgi apparatus (Approved),3-isobutyl-1-methyl-7H-xanthine,,
ENSG00000154727.11,ENSG00000154727,GABPA,-0.886669688,-0.768280793,-1.198236582,-0.693491688,GA binding protein transcription factor subunit alpha,"The GABPA gene encodes a subunit of the GA-binding protein transcription factor, which functions as a DNA-binding subunit. This subunit is involved in the activation of cytochrome oxidase expression and nuclear control of mitochondrial function. It also plays a role in the expression of the adenovirus E4 gene. The gene may be involved in the Down Syndrome phenotype due to its chromosomal localization and ability to form heterodimers with other polypeptides. Two transcript variants encoding the same protein have been identified.","There is limited information available on the disease implications of the GABPA gene. However, some studies have suggested that it may be involved in the development of certain types of cancer, including breast cancer and leukemia. Targeted drug discovery efforts for GABPA are also limited, but some studies have explored the use of small molecule inhibitors to target the protein. One example is the compound NSC-87877, which has been shown to inhibit GABPA activity and reduce the growth of breast cancer cells in vitro. However, there are currently no drugs on the market that specifically target GABPA. Overall, further research is needed to fully understand the role of GABPA in disease and to develop targeted therapies for related conditions.",GO:0045653 negative regulation of megakaryocyte differentiation;GO:0045652 regulation of megakaryocyte differentiation;GO:0001825 blastocyst formation,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000152332.16,ENSG00000152332,UHMK1,-0.886430637,-1.023113296,-0.980156475,-0.656022138,U2AF homology motif kinase 1,"UHMK1 is a gene that encodes a protein kinase that plays a role in promoting cell cycle progression through G1 by phosphorylating p27Kip1, a protein that inhibits cyclin-dependent kinase activity. This phosphorylation causes p27Kip1 to be exported from the nucleus and degraded. The gene is also believed to have a function in the adult nervous system and has been linked to schizophrenia. Alternative splicing of the gene results in multiple transcript variants.","UHMK1 has been linked to several diseases, including schizophrenia, bipolar disorder, and cancer. In schizophrenia, UHMK1 has been found to be overexpressed in the prefrontal cortex of patients, suggesting a potential role in the pathogenesis of the disease. Targeted drug discovery efforts for UHMK1 have focused on developing small molecule inhibitors that can block its activity and potentially treat diseases associated with its overexpression. However, there are currently no drugs on the market that specifically target UHMK1. Some drugs that indirectly affect UHMK1 activity include lithium, which is used to treat bipolar disorder and has been shown to decrease UHMK1 expression, and metformin, which is used to treat diabetes and has been shown to inhibit UHMK1 activity in cancer cells. Further research is needed to fully understand the role of UHMK1 in disease and to develop targeted therapies.",GO:0045948 positive regulation of translational initiation;GO:0046825 regulation of protein export from nucleus;GO:0018105 peptidyl-serine phosphorylation,yes,Enzymes; Predicted intracellular proteins; Kinases; ENZYME proteins:Transferases,Nucleoplasm (Supported),,,
ENSG00000176018.13,ENSG00000176018,LYSMD3,-0.885983362,-0.926640113,-1.081802046,-0.649507927,LysM domain containing 3,"LYSMD3 is a human gene that encodes for a protein called LysM domain containing 3. This protein is involved in the organization of the Golgi apparatus, which is responsible for processing and sorting proteins and lipids in the cell. LYSMD3 is located in both the Golgi apparatus and the plasma membrane. The function of LYSMD3 is not fully understood, but it is believed to play a role in regulating the transport of proteins and lipids between the Golgi apparatus and the plasma membrane. Further research is needed to fully understand the function of LYSMD3 and its potential role in human health and disease.","There is limited information available on the disease implications of LYSMD3. However, recent studies have suggested that LYSMD3 may play a role in the development and progression of certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for LYSMD3 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and potentially be used as cancer therapeutics. Currently, there are no drugs on the market that specifically target LYSMD3. However, there are several drugs that target the Golgi apparatus and may indirectly affect LYSMD3 function, including brefeldin A and golgicide A. Further research is needed to fully understand the potential therapeutic implications of targeting LYSMD3 in cancer and other diseases.",GO:0007030 Golgi organization;GO:0010256 endomembrane system organization;GO:0006996 organelle organization,,Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000197217.13,ENSG00000197217,ENTPD4,-0.885946709,-1.588763391,-0.849967935,-0.219108802,ectonucleoside triphosphate diphosphohydrolase 4,ENTPD4 is a gene that encodes a protein belonging to the apyrase family. Apyrases are enzymes that break down nucleotide diphosphates and triphosphates in a calcium or magnesium-dependent manner. ENTPD4 is an endo-apyrase that may be involved in salvaging nucleotides from lysosomes. The gene has multiple isoforms that differ in their dependence on divalent cations and substrate specificity. This information was provided by RefSeq in September 2011.,"Research on ENTPD4 has suggested its potential involvement in various diseases, including cancer, autoimmune disorders, and inflammation. For example, studies have shown that ENTPD4 expression is upregulated in certain types of cancer, such as breast and prostate cancer, and may play a role in tumor growth and metastasis. Additionally, ENTPD4 has been implicated in autoimmune disorders such as multiple sclerosis and rheumatoid arthritis, as well as in inflammatory conditions like atherosclerosis.

Targeted drug discovery efforts for ENTPD4 have focused on developing inhibitors that can block its activity and potentially treat diseases associated with its overexpression or dysregulation. Some promising compounds have been identified in preclinical studies, including small molecule inhibitors and monoclonal antibodies. However, no drugs targeting ENTPD4 have yet been approved for clinical use.

One example of a successful drug targeting a related apyrase enzyme is clopidogrel, which is used to prevent blood clots and reduce the risk of heart attack and stroke. Clopidogrel inhibits the activity of the platelet P2Y12 receptor, which is activated by ADP released from damaged cells and is dependent on the apyrase activity of CD39. While clopidogrel does not directly target ENTPD4, it highlights the potential of apyrase inhibitors as therapeutic agents.",GO:0046712 GDP catabolic process;GO:0006256 UDP catabolic process;GO:0009140 pyrimidine nucleoside diphosphate catabolic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Vesicles (Approved),,,
ENSG00000106460.19,ENSG00000106460,TMEM106B,-0.884139341,-1.326933403,-0.803199065,-0.522285554,transmembrane protein 106B,"TMEM106B is a human gene that encodes for a transmembrane protein involved in dendrite morphogenesis and lysosome localization. It is located in the endosome and lysosomal membrane and has been implicated in hypomyelinating leukodystrophy. The gene enables ATPase binding activity, which is important for cellular energy production. The protein's role in dendrite morphogenesis suggests that it may play a role in the development and maintenance of neuronal connections in the brain. Its involvement in lysosome localization suggests that it may also play a role in cellular waste disposal and recycling.","Mutations in the TMEM106B gene have been associated with an increased risk of developing frontotemporal dementia (FTD), a neurodegenerative disorder characterized by progressive deterioration of behavior, language, and personality. TMEM106B has also been linked to other neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Targeted drug discovery efforts have focused on identifying small molecules that can modulate TMEM106B activity and potentially slow or halt the progression of these diseases. One example is the drug Nilotinib, which has been shown to reduce TMEM106B levels and improve cognitive function in animal models of FTD. Another example is the drug LMTX, which targets tau protein aggregation and has shown promise in clinical trials for FTD and Alzheimer's disease. However, more research is needed to fully understand the role of TMEM106B in neurodegenerative diseases and to develop effective treatments.",GO:1905146 lysosomal protein catabolic process;GO:0007039 protein catabolic process in the vacuole;GO:1905671 regulation of lysosome organization,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Predicted intracellular proteins; Transporters; Potential drug targets; Disease related genes,Endosomes;Lysosomes (Supported),,,
ENSG00000138674.17,ENSG00000138674,SEC31A,-0.884000175,-1.373399538,-0.966063021,-0.312537964,"SEC31 homolog A, COPII coat complex component","SEC31A is a human gene that encodes a protein similar to yeast Sec31 and is a component of the outer layer of the COPII coat protein complex. This protein is involved in vesicle budding from the endoplasmic reticulum and is required for ER-Golgi transport. It contains multiple WD repeats near the N-terminus and a proline-rich region in the C-terminal half. SEC31A associates with SEC13, a nuclear pore and COPII coat complex component. Monoubiquitylation of SEC31A by CUL3-KLHL12 regulates the size of COPII coats to accommodate unusually shaped cargo. Alternative splicing results in multiple transcript variants encoding different isoforms.","There is limited information on the disease implications of SEC31A. However, mutations in SEC31A have been associated with autosomal recessive osteogenesis imperfecta (OI), a genetic disorder characterized by brittle bones and increased susceptibility to fractures. Targeted drug discovery efforts for SEC31A are also limited, as the protein is involved in a fundamental cellular process and targeting it directly may have unintended consequences. However, there are drugs on the market that indirectly affect SEC31A function, such as brefeldin A, which inhibits vesicle transport from the endoplasmic reticulum to the Golgi apparatus by targeting the COPI and COPII coat proteins. Another example is Saroglitazar, a PPAR agonist that has been shown to improve insulin sensitivity and reduce liver fat accumulation in patients with non-alcoholic fatty liver disease, which may involve modulation of SEC31A function.",GO:0090110 COPII-coated vesicle cargo loading;GO:0035459 vesicle cargo loading;GO:0090114 COPII-coated vesicle budding,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Transporters:Primary Active Transporters; Potential drug targets; Disease related genes,Cytosol;Vesicles (Supported),,,(M5910)HALLMARK PROTEIN SECRETION; (M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000162852.14,ENSG00000162852,CNST,-0.883513696,-0.977170129,-0.851059798,-0.82231116,"consortin, connexin sorting protein","Consortin (CNST) is a protein that plays a crucial role in the targeting of transmembrane proteins to the cell surface. It acts as a binding partner of connexins, which are the building blocks of gap junctions, and acts as a trans-Golgi network (TGN) receptor involved in connexin targeting to the plasma membrane and recycling from the cell surface. This protein is an integral membrane protein that interacts with the adaptor machinery for anterograde traffic at the distal end of the Golgi complex. Its function is essential for the proper functioning of gap junctions, which are important for intercellular communication in various tissues.","There is limited information available on the disease implications of the CNST gene. However, studies have suggested that mutations in this gene may be associated with certain neurological disorders, such as epilepsy and intellectual disability. 

As of now, there are no targeted drug discovery efforts specifically focused on CNST. However, drugs that target gap junctions, such as carbenoxolone and meclofenamic acid, have been investigated for their potential therapeutic effects in various diseases, including cancer and neurological disorders. These drugs work by modulating the function of gap junctions, which are regulated by CNST.

One example of a successful drug that targets gap junctions is Fingolimod, which is used to treat multiple sclerosis. Fingolimod works by binding to sphingosine-1-phosphate receptors, which are involved in the regulation of gap junctions. By modulating gap junction function, Fingolimod helps to reduce inflammation and prevent nerve damage in patients with multiple sclerosis.",GO:0042998 positive regulation of Golgi to plasma membrane protein transport;GO:0042996 regulation of Golgi to plasma membrane protein transport;GO:1903078 positive regulation of protein localization to plasma membrane,,Predicted intracellular proteins,Vesicles (Supported),,,
ENSG00000169756.16,ENSG00000169756,LIMS1,-0.882764528,-1.166684159,-1.015103924,-0.466505502,LIM zinc finger domain containing 1,"LIMS1 is a human gene that encodes an adaptor protein containing five LIM domains, or double zinc fingers. This protein is believed to be involved in integrin signaling by interacting with integrin-linked kinase in focal adhesion plaques. It may also act as a bridge between integrin-linked kinase and NCK adaptor protein 2, which is involved in growth factor receptor kinase signaling pathways. The protein's localization to the periphery of spreading cells suggests it may play a role in integrin-mediated cell adhesion or spreading. Multiple transcript variants encoding different isoforms have been identified for this gene.","There is limited information available on the disease implications of LIMS1. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for LIMS1 are also limited, as the protein's exact role in disease pathogenesis is not well understood. However, some studies have suggested that targeting LIMS1 may be a potential therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target LIMS1. However, there are several drugs that target integrin signaling pathways, which may indirectly affect LIMS1 function. Examples of such drugs include cilengitide, which is being investigated for the treatment of glioblastoma, and volociximab, which is being studied for the treatment of solid tumors.",GO:2001046 positive regulation of integrin-mediated signaling pathway;GO:2001044 regulation of integrin-mediated signaling pathway;GO:0051894 positive regulation of focal adhesion assembly,,Predicted intracellular proteins,Cytosol (Approved); Additional: Focal adhesion sites,,(M71)PID ILK PATHWAY,
ENSG00000253341.1,ENSG00000253341,PCBP2P2,-0.882477717,-1.101959632,-1.178661882,-0.366811638,None,None,None,None,None,None,None,None,None,None
ENSG00000163781.14,ENSG00000163781,TOPBP1,-0.882074381,-1.223918189,-0.859619411,-0.562685544,DNA topoisomerase II binding protein 1,"TOPBP1 is a gene that encodes a binding protein that interacts with the C-terminal region of topoisomerase II beta. This interaction suggests that the protein plays a supportive role in the catalytic reactions of topoisomerase II beta through transient breakages of DNA strands. The gene is important in DNA replication and repair, and mutations in TOPBP1 have been associated with various types of cancer.","TOPBP1 mutations have been linked to various types of cancer, including breast, ovarian, and lung cancer. In breast cancer, TOPBP1 mutations have been associated with a poor prognosis and resistance to chemotherapy. Targeted drug discovery efforts have focused on developing inhibitors of the protein-protein interactions between TOPBP1 and topoisomerase II beta, as well as inhibitors of the kinase activity of TOPBP1. However, there are currently no drugs on the market that specifically target TOPBP1. Some drugs that indirectly affect TOPBP1 function, such as topoisomerase inhibitors like etoposide and doxorubicin, are used in cancer treatment. Additionally, PARP inhibitors, which target DNA repair pathways, have shown promise in treating cancers with TOPBP1 mutations.",GO:0141112 broken chromosome clustering;GO:0097680 double-strand break repair via classical nonhomologous end joining;GO:0097681 double-strand break repair via alternative nonhomologous end joining,,Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Supported); Additional: Plasma membrane,,(M258)PID BARD1 PATHWAY; (M46)PID ATR PATHWAY; (M1)PID FANCONI PATHWAY,(M5951)HALLMARK SPERMATOGENESIS
ENSG00000090905.19,ENSG00000090905,TNRC6A,-0.881639297,-1.261250847,-0.746201804,-0.637465239,trinucleotide repeat containing adaptor 6A,"TNRC6A is a gene that belongs to the trinucleotide repeat containing 6 protein family. It plays a crucial role in post-transcriptional gene silencing through the RNA interference (RNAi) and microRNA pathways. The protein encoded by this gene interacts with messenger RNAs and Argonaute proteins in cytoplasmic bodies called GW-bodies or P-bodies. Inhibition of TNRC6A expression leads to the delocalization of other GW-body proteins and impairs RNAi and microRNA-induced gene silencing. This gene is essential for the proper functioning of RNAi and microRNA pathways, which are important mechanisms for regulating gene expression.","Research on TNRC6A has revealed its potential implications in various diseases, including cancer, viral infections, and neurological disorders. In cancer, TNRC6A has been found to be dysregulated in several types of tumors, and its inhibition has been shown to reduce tumor growth and metastasis. In viral infections, TNRC6A plays a role in the antiviral response by regulating the expression of interferon-stimulated genes. In neurological disorders, TNRC6A has been linked to the regulation of synaptic plasticity and memory formation. 

Targeted drug discovery efforts for TNRC6A are still in the early stages, but there is potential for the development of drugs that modulate its activity in various diseases. For example, small molecules that inhibit TNRC6A expression or disrupt its interaction with other proteins could be developed as cancer therapeutics. Additionally, drugs that enhance TNRC6A activity could be developed as antiviral agents or for the treatment of neurological disorders.

Currently, there are no drugs on the market that specifically target TNRC6A. However, there are drugs that indirectly affect its activity, such as small molecule inhibitors of the RNAi pathway that are used in cancer treatment. Additionally, drugs that target other proteins in the RNAi and microRNA pathways, such as Argonaute proteins, have shown promise in preclinical studies for the treatment of various diseases.",GO:0060213 positive regulation of nuclear-transcribed mRNA poly(A) tail shortening;GO:0060211 regulation of nuclear-transcribed mRNA poly(A) tail shortening;GO:0033962 P-body assembly,,Disease related genes; Human disease related genes:Nervous system diseases:Epilepsy; Predicted intracellular proteins,Golgi apparatus;Nucleoplasm;Vesicles (Approved),,,
ENSG00000153561.13,ENSG00000153561,RMND5A,-0.880720993,-0.934066702,-0.898991875,-0.8091044,required for meiotic nuclear division 5 homolog A,"RMND5A is a human gene that is involved in meiotic nuclear division 5 homolog A. It is predicted to have metal ion binding activity and ubiquitin protein ligase activity, and to contribute to ubiquitin-protein transferase activity. The gene is also predicted to be involved in proteasome-mediated ubiquitin-dependent protein catabolic process and protein polyubiquitination. RMND5A is located in both the cytoplasm and nucleoplasm and is part of the ubiquitin ligase complex.","RMND5A has been implicated in several diseases, including cancer, neurodegenerative disorders, and developmental disorders. In particular, mutations in the gene have been associated with intellectual disability and autism spectrum disorders. Targeted drug discovery efforts for RMND5A are still in the early stages, but there is potential for the development of drugs that modulate the activity of the ubiquitin ligase complex. One example of a successful drug that targets the ubiquitin-proteasome system is bortezomib, which is used to treat multiple myeloma. However, more research is needed to fully understand the role of RMND5A in disease and to develop effective targeted therapies.",GO:0000209 protein polyubiquitination;GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process;GO:0010498 proteasomal protein catabolic process,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported),,,
ENSG00000105738.11,ENSG00000105738,SIPA1L3,-0.880050072,-1.567945134,-0.819258421,-0.252946661,signal induced proliferation associated 1 like 3,"SIPA1L3 is a gene that belongs to the signal induced proliferation associated 1 family of genes. It encodes GTPase-activating proteins that are specific for the GTP-binding protein Rap1. Rap1 is involved in regulating cell adhesion, cell polarity, and organization of the cytoskeleton. The protein encoded by SIPA1L3 contains RapGAP and PDZ domains, as well as a C-terminal leucine zipper domain. It is proposed to function in epithelial cell morphogenesis and establishment or maintenance of polarity. Abnormalities in this gene have been associated with congenital cataracts in humans. In cell culture, the protein localizes to cell-cell borders in apical regions, and downregulation of the gene results in abnormal cell polarity and morphogenesis.","There is limited information available on the disease implications of SIPA1L3. However, mutations in this gene have been associated with congenital cataracts in humans. Targeted drug discovery efforts for SIPA1L3 are also limited, as the function of this gene is not well understood. Currently, there are no drugs on the market that specifically target SIPA1L3. However, there are drugs that target the GTP-binding protein Rap1, which is regulated by SIPA1L3. For example, the drug cilostazol is a phosphodiesterase III inhibitor that increases intracellular cAMP levels, leading to activation of Rap1 and inhibition of platelet aggregation. Another drug, eptifibatide, is a cyclic heptapeptide that binds to the integrin receptor on platelets, inhibiting their activation and aggregation. While these drugs do not directly target SIPA1L3, they may indirectly affect its function through their regulation of Rap1.",GO:0090162 establishment of epithelial cell polarity;GO:0003382 epithelial cell morphogenesis;GO:0002244 hematopoietic progenitor cell differentiation,,Disease related genes; Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins,Plasma membrane (Supported); Additional: Golgi apparatus;Nucleoplasm,,,
ENSG00000103319.12,ENSG00000103319,EEF2K,-0.879167991,-1.103240204,-0.728050348,-0.806213421,eukaryotic elongation factor 2 kinase,"EEF2K is a gene that encodes a protein kinase involved in the regulation of protein synthesis. It is part of the calmodulin-mediated signaling pathway that connects cell surface receptors to cell division. EEF2K phosphorylates eukaryotic elongation factor 2 (EEF2), which inhibits its function. The activity of EEF2K is increased in many cancers, making it a potential target for anti-cancer treatment. This gene is highly conserved, meaning it has remained relatively unchanged throughout evolution.","EEF2K has been implicated in several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, EEF2K is overexpressed and promotes tumor growth by enhancing protein synthesis. Therefore, EEF2K inhibitors have been developed as potential anti-cancer drugs. One such inhibitor, NH125, has been shown to inhibit the growth of breast cancer cells in vitro and in vivo. Another inhibitor, A-484954, has been shown to inhibit the growth of multiple myeloma cells. In neurodegenerative disorders, EEF2K has been shown to play a role in the regulation of autophagy, a process that removes damaged proteins and organelles from cells. Therefore, EEF2K inhibitors have been proposed as potential treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. However, no EEF2K inhibitors have been approved for clinical use yet.",GO:0031035 myosin filament disassembly;GO:0031037 myosin II filament disassembly;GO:0031038 myosin II filament organization,yes,Enzymes; Kinases:Atypical kinases; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Approved),,(M209)PID P38 GAMMA DELTA PATHWAY; (M121)PID MTOR 4PATHWAY,
ENSG00000186318.16,ENSG00000186318,BACE1,-0.878552219,-1.882460143,-0.596072949,-0.157123565,beta-secretase 1,"BACE1, also known as beta-secretase 1, is a gene that encodes a type of aspartic protease. This gene has multiple transcript variants, with at least one encoding a preproprotein that is processed to generate the mature protease. BACE1 is a transmembrane protease that catalyzes the first step in the formation of amyloid beta peptide from amyloid precursor protein. Amyloid beta peptides are the main component of amyloid beta plaques, which accumulate in the brains of Alzheimer's disease patients. Therefore, BACE1 is a potential target for developing drugs to treat Alzheimer's disease.","BACE1 has been identified as a potential therapeutic target for Alzheimer's disease, as it plays a key role in the formation of amyloid beta peptides, which are believed to contribute to the development of the disease. Several drug discovery efforts have focused on developing BACE1 inhibitors as a potential treatment for Alzheimer's disease. Some of the most promising BACE1 inhibitors include verubecestat, lanabecestat, and atabecestat. Verubecestat was shown to reduce amyloid beta levels in clinical trials, but did not demonstrate significant cognitive benefits in patients with mild to moderate Alzheimer's disease. Lanabecestat and atabecestat are still in clinical trials, but have shown promising results in reducing amyloid beta levels and improving cognitive function in animal models. Overall, BACE1 inhibitors represent a promising avenue for developing new treatments for Alzheimer's disease.",GO:0034205 amyloid-beta formation;GO:0071287 cellular response to manganese ion;GO:0060134 prepulse inhibition,,Predicted intracellular proteins; Transporters:Accessory Factors Involved in Transport; ENZYME proteins:Hydrolases; Enzymes; Peptidases:Aspartic-type peptidases,Plasma membrane (Supported),"MMI-175; CTS-21166; N-[amino(imino)methyl]-2-(2,5-diphenyl-1H-pyrrol-1-yl)acetamide; N-[(5R,14R)-5-AMINO-5,14-DIMETHYL-4-OXO-3-OXA-18-AZATRICYCLO[15.3.1.1~7,11~]DOCOSA-1(21),7(22),8,10,17,19-HEXAEN-19-YL]-N-METHYLMETHANESULFONAMIDE; N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide; 4-(4-FLUOROBENZYL)PIPERIDINE; N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide; 6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE; 6-[2-(3'-METHOXYBIPHENYL-3-YL)ETHYL]PYRIDIN-2-AMINE; N~3~-BENZYLPYRIDINE-2,3-DIAMINE; N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE; N~3~-[3-(5-METHOXYPYRIDIN-3-YL)BENZYL]PYRIDINE-2,3-DIAMINE; 4-(2-aminoethyl)-2-cyclohexylphenol; 4-(2-aminoethyl)-2-ethylphenol; 4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine; (6R)-2-amino-6-[2-(3'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one; 2-amino-6-[2-(1H-indol-6-yl)ethyl]pyrimidin-4(3H)-one; (2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol; N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide; N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide; (2S)-4-(4-fluorobenzyl)-N-(2-sulfanylethyl)piperazine-2-carboxamide; (2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide; N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide; (6S)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one; N~3~-[3-(1H-INDOL-6-YL)BENZYL]PYRIDINE-2,3-DIAMINE; N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE; 3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE; Verubecestat",,
ENSG00000005893.16,ENSG00000005893,LAMP2,-0.878454333,-1.036934185,-1.039554909,-0.558873904,lysosomal associated membrane protein 2,"LAMP2 is a gene that encodes a membrane glycoprotein called lysosomal associated membrane protein 2. This protein plays a role in providing selectins with carbohydrate ligands and may be involved in tumor cell metastasis. Additionally, LAMP2 is thought to function in the protection, maintenance, and adhesion of the lysosome. Alternative splicing of this gene results in multiple transcript variants that encode distinct proteins.","Mutations in the LAMP2 gene have been associated with Danon disease, a rare X-linked disorder characterized by cardiomyopathy, skeletal myopathy, and intellectual disability. Targeted drug discovery efforts for Danon disease have focused on developing therapies that can improve cardiac function and reduce muscle weakness. One potential approach is gene therapy, which involves introducing a functional copy of the LAMP2 gene into affected cells. Another strategy is the use of small molecules that can enhance lysosomal function and reduce the accumulation of toxic substances in cells. Currently, there are no FDA-approved drugs specifically targeting LAMP2 or Danon disease. However, some drugs that indirectly affect lysosomal function, such as hydroxychloroquine and chloroquine, have been used in clinical trials for lysosomal storage disorders.",GO:0061740 protein targeting to lysosome involved in chaperone-mediated autophagy;GO:0061684 chaperone-mediated autophagy;GO:0071211 protein targeting to vacuole involved in autophagy,,Human disease related genes:Musculoskeletal diseases:Muscular diseases; Transporters; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Lysosomal storage diseases; Disease related genes; CD markers,Vesicles (Supported),,,(M5910)HALLMARK PROTEIN SECRETION; (M5946)HALLMARK COAGULATION; (M5921)HALLMARK COMPLEMENT
ENSG00000135535.17,ENSG00000135535,CD164,-0.8776393,-1.041009855,-1.05395249,-0.537955555,CD164 molecule,"CD164 is a gene that encodes a transmembrane sialomucin and cell adhesion molecule. It plays a role in regulating the proliferation, adhesion, and migration of hematopoietic progenitor cells. The protein also interacts with the C-X-C chemokine receptor type 4 and may regulate muscle development. Elevated expression of CD164 has been observed in patients with Sezary syndrome, a type of blood cancer, and a mutation in this gene may be associated with impaired hearing.","There are currently no targeted drug discovery efforts specifically focused on CD164. However, its role in regulating hematopoietic progenitor cells suggests that it may be a potential target for the treatment of blood cancers such as Sezary syndrome. Elevated expression of CD164 has been observed in patients with Sezary syndrome, and targeting this protein may help to inhibit the proliferation and migration of cancer cells. 

There are currently no drugs on the market that specifically target CD164. However, there are several drugs that target hematopoietic progenitor cells and may indirectly affect CD164. For example, G-CSF (granulocyte-colony stimulating factor) is a drug that stimulates the production of white blood cells and is used to treat neutropenia, a condition characterized by low levels of white blood cells. Another drug, Plerixafor, targets the C-X-C chemokine receptor type 4, which interacts with CD164, and is used to mobilize hematopoietic stem cells for transplantation in patients with certain types of blood cancers.",GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules;GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules;GO:0007162 negative regulation of cell adhesion,,Disease related genes; CD markers; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Ear disease,,,,
ENSG00000116171.19,ENSG00000116171,SCP2,-0.877639141,-0.994695474,-1.586587181,-0.051634768,sterol carrier protein 2,"The human gene SCP2 encodes two proteins, sterol carrier protein X (SCPx) and sterol carrier protein 2 (SCP2), which are produced from two independently regulated promoters. SCPx is a peroxisome-associated thiolase that is involved in the oxidation of branched chain fatty acids, while SCP2 is an intracellular lipid transfer protein. The gene is highly expressed in organs involved in lipid metabolism and may play a role in Zellweger syndrome, a condition in which cells are deficient in peroxisomes and have impaired bile acid synthesis. Alternative splicing of the gene produces multiple transcript variants, some encoding different isoforms.","Zellweger syndrome is a rare genetic disorder caused by mutations in genes involved in peroxisome biogenesis, including SCP2. Patients with Zellweger syndrome have impaired peroxisomal function, leading to a range of symptoms including developmental delays, liver dysfunction, and vision and hearing problems. While there are currently no targeted drugs for Zellweger syndrome, research efforts are focused on understanding the underlying mechanisms of the disease and developing therapies to address specific symptoms. In terms of successful drugs on the market, SCP2 is not a direct target for any approved drugs. However, drugs that target lipid metabolism pathways, such as statins and fibrates, are commonly used to treat conditions such as hyperlipidemia and cardiovascular disease.",GO:1901373 lipid hydroperoxide transport;GO:0032959 inositol trisphosphate biosynthetic process;GO:0006701 progesterone biosynthetic process,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Peroxisomal diseases; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Peroxisomes (Supported); Additional: Nucleoplasm,,,(M5949)HALLMARK PEROXISOME; (M5948)HALLMARK BILE ACID METABOLISM; (M5905)HALLMARK ADIPOGENESIS
ENSG00000130695.16,ENSG00000130695,CEP85,-0.8770828,-1.043890611,-0.954073183,-0.633284606,centrosomal protein 85,CEP85 is a gene that encodes a protein belonging to the centrosome-associated family of proteins. The centrosome is an organelle in animal cells that plays a role in cell-cycle progression and acts as a microtubule organizing center. The CEP85 protein is involved in the regulation of centrosome duplication and is essential for proper cell division. Alternative splicing of the gene results in multiple transcript variants.,"There is limited information available on the disease implications of CEP85 mutations. However, recent studies have suggested that CEP85 may play a role in the development of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for CEP85 are still in the early stages, but there is potential for the development of drugs that target the protein's role in centrosome duplication and cell division. Currently, there are no drugs on the market that specifically target CEP85. However, there are drugs that target other proteins involved in centrosome regulation, such as the microtubule inhibitor paclitaxel, which is used to treat breast cancer and other types of cancer. Further research is needed to fully understand the role of CEP85 in disease and to develop targeted therapies.",GO:0046602 regulation of mitotic centrosome separation;GO:0007099 centriole replication;GO:0098534 centriole assembly,,Predicted intracellular proteins,Golgi apparatus;Nucleoli (Approved); Additional: Centrosome;Cytosol;Vesicles,,,
ENSG00000156531.17,ENSG00000156531,PHF6,-0.876831385,-1.016062931,-0.970525882,-0.643905341,PHD finger protein 6,"PHF6 is a gene that belongs to the PHD-like finger family and encodes a protein with two PHD-type zinc finger domains. This suggests that it may play a role in transcriptional regulation and is located in the nucleolus. Mutations in this gene or changes in the splicing of its transcript have been linked to Borjeson-Forssman-Lehmann syndrome (BFLS), a condition characterized by cognitive disability, epilepsy, hypogonadism, hypometabolism, obesity, swelling of subcutaneous tissue of the face, narrow palpebral fissures, and large ears. The gene has multiple transcript variants that encode different isoforms due to alternate splicing.","Borjeson-Forssman-Lehmann syndrome (BFLS) is a rare genetic disorder caused by mutations in the PHF6 gene. The syndrome is characterized by intellectual disability, epilepsy, hypogonadism, obesity, and distinctive facial features. There is currently no cure for BFLS, and treatment is mainly supportive and symptomatic. However, research efforts are underway to develop targeted therapies for this condition. One approach is to identify drugs that can modulate the activity of the PHF6 protein or its downstream targets. Several studies have shown that PHF6 interacts with other proteins involved in transcriptional regulation, such as the histone deacetylase HDAC1. Therefore, HDAC inhibitors have been proposed as potential therapeutic agents for BFLS. Examples of HDAC inhibitors that are currently on the market for other indications include vorinostat (Zolinza) and romidepsin (Istodax). However, further research is needed to determine whether these drugs are effective in treating BFLS.",GO:0001835 blastocyst hatching;GO:0035188 hatching;GO:0071684 organism emergence from protective structure,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Nucleoli;Nucleoplasm (Supported),,,
ENSG00000172007.7,ENSG00000172007,RAB33B,-0.87620383,-1.00045897,-0.865578603,-0.762573917,"RAB33B, member RAS oncogene family","RAB33B is a small GTP-binding protein belonging to the Rab GTPase family, which plays a role in vesicle transport during protein secretion and endocytosis. It is expressed ubiquitously and is involved in Golgi to endoplasmic reticulum cycling of Golgi enzymes, as well as regulating Golgi homeostasis and intra-Golgi retrograde trafficking. Variants in this gene have been linked to Dyggve-Melchior-Clausen syndrome and Smith-McCort dysplasia 2, both of which are autosomal recessive spondyloepimetaphyseal dysplasias characterized by skeletal abnormalities.","There are currently no targeted drug discovery efforts specifically for RAB33B, as it is primarily associated with rare genetic disorders. However, understanding the function of RAB33B in vesicle transport and Golgi homeostasis may have implications for drug development in related diseases. For example, drugs targeting other Rab GTPases, such as Rab27a, have been developed for the treatment of immune disorders and cancer. Additionally, drugs targeting Golgi function, such as brefeldin A, have been used in cancer research and may have potential therapeutic applications in other diseases. However, further research is needed to determine the potential for targeting RAB33B in drug development.","GO:1903434 negative regulation of constitutive secretory pathway;GO:1903433 regulation of constitutive secretory pathway;GO:2000156 regulation of retrograde vesicle-mediated transport, Golgi to ER",,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Predicted intracellular proteins,,,,
ENSG00000104133.15,ENSG00000104133,SPG11,-0.876097959,-1.204797666,-1.1833169,-0.240179312,"SPG11 vesicle trafficking associated, spatacsin","SPG11 is a human gene that encodes a potential transmembrane protein that is phosphorylated upon DNA damage. Mutations in this gene have been linked to spastic paraplegia type 11 (SPG11), a rare genetic disorder characterized by progressive muscle weakness and stiffness in the legs. The protein encoded by SPG11 is involved in vesicle trafficking and is thought to play a role in the maintenance of neuronal function. Multiple transcript variants of the gene have been identified, each encoding a different isoform of the protein. Further research is needed to fully understand the function of SPG11 and its role in the development of SPG11.","There are currently no targeted drug discovery efforts for SPG11, as the underlying mechanisms of the disease are not fully understood. Treatment for SPG11 is primarily supportive and focused on managing symptoms such as muscle weakness and spasticity. Physical therapy and assistive devices such as braces or wheelchairs may also be recommended. There are no drugs specifically approved for the treatment of SPG11, but some medications used to manage spasticity and muscle stiffness may be prescribed. Examples include baclofen, tizanidine, and diazepam. However, these medications only provide symptomatic relief and do not address the underlying cause of the disease. Further research is needed to develop targeted therapies for SPG11.",GO:0090386 phagosome maturation involved in apoptotic cell clearance;GO:0090387 phagolysosome assembly involved in apoptotic cell clearance;GO:0090389 phagosome-lysosome fusion involved in apoptotic cell clearance,,Disease related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases,Cytosol;Plasma membrane (Supported); Additional: Nucleoli,,,
ENSG00000163681.16,ENSG00000163681,SLMAP,-0.875501073,-1.242215109,-1.103120444,-0.281167665,sarcolemma associated protein,"SLMAP is a gene that encodes a protein that is part of a complex involved in various cellular processes, including signaling, cell cycle control, and apoptosis. The protein is a membrane protein with a single transmembrane domain that is inserted into membranes after translation. Mutations in this gene have been linked to Brugada syndrome, a cardiac channelopathy. Alternative splicing of the gene results in multiple transcript variants.","Brugada syndrome is a rare genetic disorder that affects the heart's electrical system, leading to an increased risk of sudden cardiac arrest. Mutations in the SLMAP gene have been linked to Brugada syndrome, and research is ongoing to better understand the role of this gene in the disease. Targeted drug discovery efforts for Brugada syndrome have focused on developing drugs that can modulate ion channels in the heart to prevent arrhythmias. One example of a successful drug on the market is quinidine, which has been shown to be effective in treating Brugada syndrome by blocking the sodium channels in the heart. Other drugs that have been investigated for their potential in treating Brugada syndrome include mexiletine and ajmaline. However, more research is needed to fully understand the disease mechanisms and develop effective treatments for Brugada syndrome.",GO:1900825 regulation of membrane depolarization during cardiac muscle cell action potential;GO:0098902 regulation of membrane depolarization during action potential;GO:1905150 regulation of voltage-gated sodium channel activity,,Predicted intracellular proteins,Endoplasmic reticulum (Approved),,,
ENSG00000181467.5,ENSG00000181467,RAP2B,-0.875203983,-1.226021754,-0.672522315,-0.727067881,"RAP2B, member of RAS oncogene family","RAP2B is a gene that belongs to the RAS oncogene family and does not contain introns. The proteins encoded by this family of genes share about 50% amino acid identity with classical RAS proteins and have many structural similarities. The main difference between RAP and RAS proteins is the 61st amino acid, which is threonine in RAP proteins instead of glutamine in RAS. There is evidence to suggest that RAP2B may be polyisoprenylated and palmitoylated.","There is limited information available on the disease implications of RAP2B. However, studies have suggested that RAP2B may play a role in cancer progression and metastasis. Targeted drug discovery efforts for RAP2B are also limited, but some studies have explored the potential of RAP2B as a therapeutic target for cancer treatment. One study found that inhibiting RAP2B expression in breast cancer cells reduced their ability to migrate and invade, suggesting that targeting RAP2B may be a promising strategy for preventing cancer metastasis. Currently, there are no drugs on the market that specifically target RAP2B. However, there are drugs that target other members of the RAS oncogene family, such as KRAS and NRAS, which have been approved for the treatment of certain types of cancer. Examples of these drugs include cetuximab, panitumumab, and trametinib.",GO:0032486 Rap protein signal transduction;GO:0061097 regulation of protein tyrosine kinase activity;GO:0070527 platelet aggregation,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,,,,(M5939)HALLMARK P53 PATHWAY
ENSG00000136051.15,ENSG00000136051,WASHC4,-0.875026077,-0.993453208,-0.880825033,-0.750799988,WASH complex subunit 4,"The WASHC4 gene encodes a protein that is part of the WASH complex, which helps transport endosomes within cells. Mutations in this gene have been linked to cognitive disability in individuals with autosomal recessive inheritance. There are multiple versions of the gene due to alternative splicing.","Mutations in the WASHC4 gene have been associated with a rare genetic disorder called autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). This disorder is characterized by progressive muscle stiffness, difficulty with coordination and balance, and vision problems. There are currently no targeted drug discovery efforts specifically for WASHC4 mutations, but there are some drugs on the market that may help alleviate symptoms of ARSACS. For example, baclofen is a muscle relaxant that can help with muscle stiffness, and gabapentin is a medication that can help with neuropathic pain. However, these drugs do not address the underlying genetic cause of the disorder. Gene therapy and other targeted therapies may hold promise for treating ARSACS in the future.",GO:0140591 nuclear envelope budding;GO:0061635 regulation of protein complex stability;GO:0140894 endolysosomal toll-like receptor signaling pathway,,Predicted intracellular proteins; Transporters; Human disease related genes:Other diseases:Mental and behavioural disorders; Potential drug targets; Disease related genes,Nucleoplasm (Enhanced),,,
ENSG00000109762.16,ENSG00000109762,SNX25,-0.874100762,-1.159266758,-1.09782729,-0.365208239,sorting nexin 25,"SNX25, also known as sorting nexin 25, is a human gene that is predicted to enable type I transforming growth factor beta receptor binding activity. It is involved in negative regulation of pathway-restricted SMAD protein phosphorylation, negative regulation of transforming growth factor beta receptor signaling pathway, and receptor catabolic process. SNX25 is located in an intracellular membrane-bounded organelle. This gene's function is important in regulating the transforming growth factor beta signaling pathway, which is involved in various cellular processes such as cell growth, differentiation, and apoptosis. Understanding the role of SNX25 in this pathway may have implications for the development of therapies for diseases such as cancer and fibrosis.","There is limited information available on the disease implications and targeted drug discovery efforts for SNX25. However, the role of SNX25 in regulating the transforming growth factor beta signaling pathway suggests that it may be involved in diseases such as cancer and fibrosis. Targeting this pathway has been a focus of drug discovery efforts, with several drugs currently on the market that inhibit the pathway, such as TGF-beta receptor inhibitors like galunisertib and fresolimumab. These drugs have shown promise in clinical trials for the treatment of various cancers and fibrotic diseases. However, it is unclear if SNX25 specifically could be targeted for therapeutic purposes, as more research is needed to fully understand its role in the pathway and its potential as a drug target.",GO:0032801 receptor catabolic process;GO:0043112 receptor metabolic process;GO:0030512 negative regulation of transforming growth factor beta receptor signaling pathway,,Cancer-related genes:Mutated cancer genes; Predicted intracellular proteins,Vesicles (Supported),,,
ENSG00000164323.14,ENSG00000164323,CFAP97,-0.873505634,-1.025025754,-0.963894378,-0.631596771,cilia and flagella associated protein 97,"CFAP97 is a gene that encodes a protein associated with cilia and flagella, which are hair-like structures on the surface of cells that are involved in movement and sensing. Mutations in CFAP97 have been linked to primary ciliary dyskinesia (PCD), a rare genetic disorder that affects the function of cilia and can lead to respiratory and fertility problems. CFAP97 is thought to play a role in the assembly and maintenance of cilia and flagella, and may be involved in regulating their movement. Further research is needed to fully understand the function of CFAP97 and its role in PCD.","There are currently no targeted drug discovery efforts or drugs on the market specifically for CFAP97-related primary ciliary dyskinesia (PCD). However, research into the function of CFAP97 and other genes associated with PCD is ongoing, with the goal of identifying potential therapeutic targets. Treatment for PCD typically involves managing symptoms, such as respiratory infections and infertility, through antibiotics, airway clearance techniques, and assisted reproductive technologies. In some cases, lung transplantation may be necessary. Gene therapy and other emerging treatments are also being explored as potential options for PCD.",,,Predicted intracellular proteins,Nucleoli fibrillar center (Approved); Additional: Cytosol;Primary cilium,,,
ENSG00000146083.12,ENSG00000146083,RNF44,-0.873471064,-1.440281873,-0.74302935,-0.43710197,ring finger protein 44,"RNF44, or ring finger protein 44, is a gene that encodes a protein containing a RING finger motif. This motif is found in many different proteins and is known to be involved in interactions between proteins and DNA. The exact function of RNF44 is not yet fully understood, but it is believed to play a role in regulating cellular processes such as protein degradation and DNA repair. Further research is needed to fully understand the function of RNF44 and its potential implications for human health and disease.","There is limited information available on the disease implications of RNF44. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast and ovarian cancer. Targeted drug discovery efforts for RNF44 are also limited, as the exact function of the protein encoded by this gene is not yet fully understood. However, some research has suggested that RNF44 may be a potential target for cancer therapy. Currently, there are no drugs on the market that specifically target RNF44. However, there are several drugs that target other proteins with RING finger motifs, such as the proteasome inhibitor bortezomib, which is used to treat multiple myeloma. Further research is needed to fully understand the potential implications of RNF44 for drug discovery and disease treatment.",GO:0016567 protein ubiquitination;GO:0032446 protein modification by small protein conjugation;GO:0070647 protein modification by small protein conjugation or removal,,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000010704.18,ENSG00000010704,HFE,-0.872486172,-1.3577825,-0.846275649,-0.413400366,homeostatic iron regulator,"HFE is a gene that encodes a membrane protein that regulates iron absorption by controlling the interaction between the transferrin receptor and transferrin. This protein is similar to MHC class I-type proteins and associates with beta2-microglobulin. Defects in the HFE gene can lead to hereditary haemochromatosis, an iron storage disorder that is inherited in a recessive manner.","Hereditary haemochromatosis (HH) is a genetic disorder characterized by excessive iron absorption and accumulation in various organs, leading to tissue damage and organ failure. Mutations in the HFE gene are the most common cause of HH, accounting for up to 90% of cases. The disease is usually asymptomatic in the early stages, but can progress to liver cirrhosis, diabetes, heart failure, and other complications if left untreated. Treatment typically involves regular phlebotomy (bloodletting) to reduce iron levels, but some patients may also require iron chelation therapy or other supportive measures.

Targeted drug discovery efforts for HH have focused on developing small molecules that can modulate iron metabolism and reduce iron overload. One approach is to target hepcidin, a hormone that regulates iron absorption and recycling in the body. Several hepcidin agonists and antagonists are currently in preclinical or clinical development for HH and other iron-related disorders. Another strategy is to target the transferrin receptor, which is involved in iron uptake by cells. A few transferrin receptor inhibitors have been tested in animal models of HH, but none have advanced to clinical trials yet.

The only FDA-approved drug for HH is deferasirox (Exjade), an iron chelator that binds to excess iron in the blood and promotes its excretion through urine and feces. Deferasirox is indicated for the treatment of chronic iron overload due to blood transfusions in patients aged 2 years and older, but it is not approved for HH specifically. Other iron chelators, such as deferoxamine and deferiprone, have also been used off-label for HH, but their efficacy and safety in this context are not well established. Overall, there is a need for more effective and specific therapies for HH, especially for patients who cannot tolerate or do not respond to phlebotomy.",GO:1904282 regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I;GO:1904283 negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I;GO:0002589 regulation of antigen processing and presentation of peptide antigen via MHC class I,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of ion transport and metabolism; Human disease related genes:Endocrine and metabolic diseases:Diabetes,Plasma membrane (Supported); Additional: Nucleoplasm,,,
ENSG00000134900.12,ENSG00000134900,TPP2,-0.87233346,-1.079951702,-1.136554562,-0.400494118,tripeptidyl peptidase 2,"TPP2 is a gene that encodes a peptidase in mammals. This peptidase removes tripeptides from the N terminus of longer peptides at neutral pH. The protein has a specialized function that is essential for some MHC class I antigen presentation. It is a high molecular mass serine exopeptidase, and the amino acid sequence surrounding the serine residue at the active site is similar to the peptidases of the subtilisin class rather than the trypsin class. This information was provided by RefSeq in July 2008.","TPP2 has been implicated in several diseases, including cancer, autoimmune disorders, and viral infections. In cancer, TPP2 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. In autoimmune disorders, TPP2 has been linked to the development of autoimmune responses, and targeting TPP2 may help to alleviate symptoms. Additionally, TPP2 has been shown to be important in viral infections, as it is involved in the processing of viral antigens for presentation to the immune system.

There have been efforts to develop drugs that target TPP2, particularly for cancer therapy. One example is the drug Marimastat, which was developed as a broad-spectrum matrix metalloproteinase inhibitor but also inhibits TPP2. However, Marimastat was not successful in clinical trials for cancer treatment. Another example is the drug Bortezomib, which is a proteasome inhibitor that indirectly inhibits TPP2. Bortezomib has been approved for the treatment of multiple myeloma and mantle cell lymphoma.

Overall, while TPP2 has been implicated in several diseases and has been the target of drug discovery efforts, there are currently no drugs on the market that directly target TPP2. However, indirect inhibition of TPP2 through drugs like Bortezomib has shown promise in the treatment of certain cancers.",GO:0080144 intracellular amino acid homeostasis;GO:0000209 protein polyubiquitination;GO:0016567 protein ubiquitination,,Predicted intracellular proteins; Human disease related genes:Immune system diseases:Primary immunodeficiency; Peptidases:Serine-type peptidases; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Cytosol;Nuclear bodies (Supported),,,
ENSG00000128973.13,ENSG00000128973,CLN6,-0.872327028,-1.056213566,-1.076191802,-0.484575716,CLN6 transmembrane ER protein,"CLN6 is a human gene that is associated with neuronal ceroid lipofuscinoses (NCL), also known as Batten disease. NCL is a group of neurodegenerative disorders that affect children and are caused by mutations in genes involved in the degradation of post-translationally modified proteins in lysosomes. CLN6 encodes a transmembrane ER protein that is thought to play a role in lysosomal storage function. The gene is one of eight genes that have been associated with NCL. CLN6 is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene (one from each parent) to develop the disorder.","There are currently no targeted drug therapies available for CLN6-associated NCL, and treatment is primarily supportive and symptomatic. However, there are ongoing efforts to develop therapies that target the underlying genetic defect. One approach is gene therapy, which involves delivering a functional copy of the CLN6 gene to affected cells. Another approach is small molecule drug discovery, which aims to identify compounds that can restore lysosomal function and reduce the accumulation of toxic proteins in affected cells. While there are no drugs specifically approved for CLN6-associated NCL, there are several drugs on the market that have been approved for other forms of NCL, such as enzyme replacement therapies and small molecule drugs that target lysosomal function. These drugs can help alleviate some of the symptoms of NCL, but they do not address the underlying genetic defect.",GO:0031987 locomotion involved in locomotory behavior;GO:0007042 lysosomal lumen acidification;GO:0001573 ganglioside metabolic process,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Predicted intracellular proteins; Transporters; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Lysosomal storage diseases; Disease related genes,Endoplasmic reticulum (Approved); Additional: Nucleoli;Vesicles,,,(M5949)HALLMARK PEROXISOME; (M5937)HALLMARK GLYCOLYSIS
ENSG00000044446.12,ENSG00000044446,PHKA2,-0.872101982,-1.061477421,-0.721971411,-0.832857114,phosphorylase kinase regulatory subunit alpha 2,"PHKA2 is a gene that encodes the hepatic isoform of the alpha subunit of phosphorylase kinase, a polymer of 16 subunits that plays a role in glycogen metabolism. The alpha subunit has regulatory functions controlled by phosphorylation, while the gamma subunits contain the active site of the enzyme. Mutations in this gene can cause glycogen storage disease type 9A, also known as X-linked liver glycogenosis. The gene has alternatively spliced transcript variants, but their full-length nature has not been determined.","Glycogen storage disease type 9A, caused by mutations in the PHKA2 gene, is a rare X-linked disorder that affects glycogen metabolism in the liver. Patients with this disease have an impaired ability to break down glycogen into glucose, leading to an accumulation of glycogen in the liver and resulting in hepatomegaly, hypoglycemia, and elevated liver enzymes. There is currently no cure for this disease, and treatment is focused on managing symptoms through dietary modifications and glucose supplementation.

Targeted drug discovery efforts for glycogen storage disease type 9A are limited due to the rarity of the disease. However, there have been some preclinical studies exploring the use of gene therapy and enzyme replacement therapy as potential treatment options. In addition, there is ongoing research into the use of small molecule inhibitors of phosphorylase kinase as a potential therapeutic strategy.

There are currently no FDA-approved drugs specifically for the treatment of glycogen storage disease type 9A. However, some patients may benefit from the use of glucose supplementation or liver transplantation. In addition, there are several drugs on the market that are used to treat other types of glycogen storage diseases, such as alglucosidase alfa for Pompe disease and miglustat for Niemann-Pick disease type C. These drugs work by targeting specific enzymes involved in glycogen metabolism and have shown some success in improving symptoms and slowing disease progression.",GO:0005977 glycogen metabolic process;GO:0044042 glucan metabolic process;GO:0006112 energy reserve metabolic process,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of carbohydrate metabolism,Nucleoplasm (Approved),,,(M5937)HALLMARK GLYCOLYSIS
ENSG00000010017.13,ENSG00000010017,RANBP9,-0.871656598,-1.198490302,-1.197602296,-0.218877195,RAN binding protein 9,"RANBP9 is a gene that encodes a protein that binds to RAN, a small GTP binding protein that is crucial for the movement of RNA and proteins through the nuclear pore complex. In addition to its interaction with RAN, the protein encoded by RANBP9 has been found to interact with several other proteins, including met proto-oncogene, homeodomain interacting protein kinase 2, androgen receptor, and cyclin-dependent kinase 11. This suggests that RANBP9 may play a role in various cellular processes, including cell growth and division, gene expression, and protein transport.","RANBP9 has been implicated in several diseases, including cancer, Alzheimer's disease, and schizophrenia. In cancer, RANBP9 has been shown to promote tumor growth and metastasis by regulating cell proliferation, migration, and invasion. Targeting RANBP9 has been proposed as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of RANBP9 have been developed and tested in preclinical studies, showing promising results in reducing tumor growth and metastasis.

In Alzheimer's disease, RANBP9 has been found to interact with amyloid beta, a protein that forms plaques in the brain and is a hallmark of the disease. RANBP9 may play a role in the accumulation and toxicity of amyloid beta, making it a potential target for drug development. However, no drugs targeting RANBP9 in Alzheimer's disease have been approved yet.

In schizophrenia, RANBP9 has been identified as a potential biomarker for the disease. Studies have shown that RANBP9 expression is altered in the brains of patients with schizophrenia, suggesting that it may play a role in the pathogenesis of the disease. However, no drugs targeting RANBP9 in schizophrenia have been approved yet.

Overall, RANBP9 is a promising target for drug discovery efforts in cancer and other diseases, but more research is needed to fully understand its role in disease pathogenesis and to develop effective therapies.",GO:1902993 positive regulation of amyloid precursor protein catabolic process;GO:0007020 microtubule nucleation;GO:0046785 microtubule polymerization,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol;Nuclear bodies,,(M58)PID AR PATHWAY; (M48)PID MET PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000265808.4,ENSG00000265808,SEC22B,-0.871235401,-1.378428156,-1.107676693,-0.127601354,"SEC22 homolog B, vesicle trafficking protein",SEC22B is a human gene that encodes a protein belonging to the SEC22 family of vesicle trafficking proteins. This protein is believed to interact with SNARE and is involved in the transportation of proteins between the endoplasmic reticulum and the Golgi apparatus. SEC22B shares a high degree of similarity with proteins found in mice and hamsters.,"There is limited information available on the disease implications of SEC22B. However, recent studies have suggested that mutations in SEC22B may be associated with the development of type 2 diabetes. Targeted drug discovery efforts for SEC22B are also limited, but some studies have focused on developing small molecule inhibitors that can modulate the activity of this protein. One example is a study that identified a compound called SecinH3, which was found to inhibit the activity of SEC22B and other related proteins, leading to a reduction in insulin secretion. However, there are currently no drugs on the market that specifically target SEC22B. Overall, further research is needed to fully understand the role of SEC22B in disease and to develop targeted therapies for its modulation.",GO:1902902 negative regulation of autophagosome assembly;GO:0016242 negative regulation of macroautophagy;GO:2000785 regulation of autophagosome assembly,,Predicted intracellular proteins,,,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000266412.5,ENSG00000266412,NCOA4,-0.870004362,-1.468915671,-0.851060271,-0.290037145,nuclear receptor coactivator 4,"NCOA4, or nuclear receptor coactivator 4, is a gene that encodes a protein that interacts with the androgen receptor to enhance its transcriptional activity. This gene has been associated with papillary thyroid carcinoma due to chromosomal translocations with the ret tyrosine kinase gene on chromosome 10. There are also pseudogenes present on chromosomes 4, 5, 10, and 14. Alternative spliced transcript variants have been described.","Research on NCOA4 has shown its involvement in various diseases, including cancer, metabolic disorders, and neurodegenerative diseases. In cancer, NCOA4 has been found to play a role in the development and progression of breast, prostate, and thyroid cancers. Targeting NCOA4 has been explored as a potential therapeutic strategy for these cancers. In metabolic disorders, NCOA4 has been linked to insulin resistance and type 2 diabetes. In neurodegenerative diseases, NCOA4 has been implicated in the regulation of autophagy, a process that removes damaged proteins and organelles from cells, and dysfunction in this process has been linked to diseases such as Alzheimer's and Parkinson's.

There have been efforts to develop drugs that target NCOA4. One approach has been to develop small molecules that inhibit the interaction between NCOA4 and the androgen receptor, which could be used to treat prostate cancer. Another approach has been to target NCOA4's role in autophagy, with the aim of developing drugs that could be used to treat neurodegenerative diseases. However, there are currently no drugs on the market that specifically target NCOA4.

Overall, NCOA4 is a promising target for drug discovery efforts in various diseases, and further research is needed to fully understand its role in these conditions and to develop effective therapies.",GO:0071394 cellular response to testosterone stimulus;GO:0071391 cellular response to estrogen stimulus;GO:0030520 estrogen receptor signaling pathway,,Disease related genes; Cancer-related genes:Mutational cancer driver genes; Human disease related genes:Cancers:Cancers of endocrine organs; Predicted intracellular proteins,Nucleoli (Approved); Additional: Cytosol;Golgi apparatus,,(M58)PID AR PATHWAY,(M5908)HALLMARK ANDROGEN RESPONSE; (M5945)HALLMARK HEME METABOLISM
ENSG00000166398.14,ENSG00000166398,GARRE1,-0.869331408,-1.150716443,-0.792496019,-0.664781763,granule associated Rac and RHOG effector 1,"GARRE1, or granule associated Rac and RHOG effector 1, is a human gene that plays a role in Rac protein signal transduction. It has been found to have CCR4-NOT complex binding activity and small GTPase binding activity. GARRE1 is located in P-body, a cellular structure involved in RNA metabolism.","There is currently limited information on the disease implications of GARRE1. However, studies have shown that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for GARRE1 are also limited, as it is not yet a well-characterized drug target. There are currently no drugs on the market that specifically target GARRE1. However, there are drugs that target the Rac protein signaling pathway, which GARRE1 is involved in. For example, the drug EHop-016 has been shown to inhibit Rac signaling and has potential as an anti-cancer therapy. Another drug, NSC23766, has also been shown to inhibit Rac signaling and has been studied as a potential treatment for various cancers.",GO:0016601 Rac protein signal transduction;GO:0007264 small GTPase-mediated signal transduction;GO:0141124 intracellular signaling cassette,,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000164190.19,ENSG00000164190,NIPBL,-0.869183207,-1.305937766,-0.806690014,-0.494921841,NIPBL cohesin loading factor,"The NIPBL gene is responsible for encoding a protein that plays a crucial role in sister chromatid cohesion, chromosome condensation, and DNA repair. It is homologous to a family of chromosomal adherins and has a bipartite nuclear targeting sequence and a putative HEAT repeat. Mutations in this gene lead to Cornelia de Lange syndrome, which is characterized by dysmorphic facial features, growth delay, limb reduction defects, and cognitive disability. The Drosophila protein facilitates enhancer-promoter communication of remote enhancers and plays a role in developmental regulation. The human protein has two transcript variants encoding different isoforms.","Cornelia de Lange syndrome (CdLS) is a rare genetic disorder caused by mutations in the NIPBL gene. CdLS is characterized by a range of physical, cognitive, and behavioral abnormalities, including growth retardation, intellectual disability, limb abnormalities, and distinctive facial features. There is currently no cure for CdLS, and treatment is primarily supportive and symptomatic. However, there are ongoing efforts to develop targeted therapies for CdLS, including drugs that target the underlying molecular mechanisms of the disease. One potential target is the cohesin complex, which is disrupted in CdLS. Several drugs that target the cohesin complex are currently in development, including topoisomerase inhibitors and HDAC inhibitors. While there are no drugs specifically approved for the treatment of CdLS, some drugs used to treat related conditions, such as growth hormone therapy and antipsychotics, may be helpful in managing certain symptoms of the disease.",GO:0035261 external genitalia morphogenesis;GO:0061010 gallbladder development;GO:0034086 maintenance of sister chromatid cohesion,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Nucleoplasm (Supported); Additional: Cytosol;Vesicles,,,(M5942)HALLMARK UV RESPONSE DN
ENSG00000124333.16,ENSG00000124333,VAMP7,-0.869157768,-1.300191495,-0.910643191,-0.396638619,vesicle associated membrane protein 7,VAMP7 is a gene that encodes a transmembrane protein belonging to the SNARE family. This protein is involved in the fusion of transport vesicles to their target membranes and is found in late endosomes and lysosomes. The gene has multiple transcript variants due to alternate splicing.,"Research has shown that VAMP7 plays a role in various diseases, including cancer, neurodegenerative disorders, and infectious diseases. In cancer, VAMP7 has been found to be overexpressed in several types of tumors, including breast, lung, and pancreatic cancer, and is associated with tumor growth and metastasis. Targeting VAMP7 has been explored as a potential therapeutic strategy for cancer treatment. In neurodegenerative disorders, VAMP7 has been implicated in the regulation of autophagy, a process that removes damaged proteins and organelles from cells, and dysfunction of this process has been linked to diseases such as Alzheimer's and Parkinson's. In infectious diseases, VAMP7 has been shown to be involved in the replication of viruses such as HIV and influenza. Several studies have explored the use of small molecule inhibitors and antibodies to target VAMP7 for therapeutic purposes. However, there are currently no drugs on the market that specifically target VAMP7.",GO:1903593 regulation of histamine secretion by mast cell;GO:1903595 positive regulation of histamine secretion by mast cell;GO:0002278 eosinophil activation involved in immune response,,Predicted intracellular proteins,Vesicles (Supported),,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000071537.14,ENSG00000071537,SEL1L,-0.867600723,-1.32193296,-0.797555112,-0.483314098,SEL1L adaptor subunit of SYVN1 ubiquitin ligase,SEL1L is a human gene that encodes a protein that is part of a complex responsible for removing misfolded proteins from the endoplasmic reticulum and degrading them in the cytosol. This process is known as retrotranslocation or dislocation and is carried out in a ubiquitin-dependent manner. The gene has multiple isoforms due to alternative splicing.,"Research on SEL1L has revealed its potential involvement in various diseases, including cancer, neurodegenerative disorders, and diabetes. In cancer, SEL1L has been found to play a role in the regulation of the unfolded protein response, which is important for tumor cell survival and growth. In neurodegenerative disorders, SEL1L has been linked to the accumulation of misfolded proteins, which is a hallmark of diseases such as Alzheimer's and Parkinson's. In diabetes, SEL1L has been shown to be involved in the regulation of insulin secretion.

Targeted drug discovery efforts for SEL1L are still in the early stages, but there is potential for the development of drugs that modulate its activity. One approach is to target the interaction between SEL1L and other proteins involved in the retrotranslocation process, such as Derlin-1. Another approach is to target the ubiquitin-dependent degradation pathway, which is essential for the removal of misfolded proteins.

Currently, there are no drugs on the market that specifically target SEL1L. However, there are drugs that indirectly affect its activity. For example, the proteasome inhibitor bortezomib, which is used to treat multiple myeloma, inhibits the degradation of misfolded proteins and can lead to their accumulation in the endoplasmic reticulum, where they are recognized by SEL1L and targeted for retrotranslocation. Additionally, the diabetes drug exenatide has been shown to increase the expression of SEL1L and improve insulin secretion in pancreatic beta cells.","GO:0030970 retrograde protein transport, ER to cytosol;GO:1903513 endoplasmic reticulum to cytosol transport;GO:0032527 protein exit from endoplasmic reticulum",,Transporters:Primary Active Transporters; Predicted intracellular proteins,,,,
ENSG00000168538.16,ENSG00000168538,TRAPPC11,-0.867410654,-1.331036119,-0.930704731,-0.340491112,trafficking protein particle complex subunit 11,"TRAPPC11 is a gene that encodes a subunit of the TRAPP tethering complex, which plays a role in intracellular vesicle trafficking. This particular subunit is involved in the early stages of transporting vesicles from the endoplasmic reticulum to the Golgi apparatus. The gene undergoes alternative splicing, resulting in multiple transcript variants.","There is limited information available on the disease implications of TRAPPC11 mutations. However, recent studies have suggested that mutations in TRAPPC11 may be associated with intellectual disability and developmental delay. Targeted drug discovery efforts for TRAPPC11 are also limited, as the function of this gene is not well understood. However, there have been some successful drugs on the market that target other subunits of the TRAPP complex, such as the small molecule inhibitor golgicide A, which targets the TRAPPC2 subunit and has been shown to inhibit vesicle trafficking and cell proliferation. Additionally, the drug brefeldin A, which targets the ARF1 protein involved in vesicle trafficking, has been used in research to study the function of the TRAPP complex. Further research is needed to fully understand the role of TRAPPC11 in disease and to develop targeted therapies.","GO:0045054 constitutive secretory pathway;GO:0061635 regulation of protein complex stability;GO:0048207 vesicle targeting, rough ER to cis-Golgi",,Disease related genes; Human disease related genes:Musculoskeletal diseases:Muscular diseases; Predicted intracellular proteins,Cytosol (Uncertain); Additional: Vesicles,,,
ENSG00000168438.15,ENSG00000168438,CDC40,-0.867383887,-0.87613118,-1.319849569,-0.406170913,cell division cycle 40,"CDC40, also known as cell division cycle 40, is a human gene that plays an essential role in the catalytic step II of pre-mRNA splicing. It is found in the spliceosome and contains seven WD repeats that facilitate protein-protein interactions. The protein encoded by CDC40 is similar to the yeast Prp17 protein, which is involved in pre-mRNA splicing and cell cycle progression. This suggests that CDC40 may also play a role in cell cycle progression. Overall, CDC40 is a crucial gene involved in pre-mRNA splicing and potentially other cellular processes.","There is limited information available on the disease implications of CDC40 mutations. However, studies have shown that mutations in other genes involved in pre-mRNA splicing can lead to various diseases, including cancer and neurodegenerative disorders. Therefore, it is possible that mutations in CDC40 could also contribute to the development of these diseases.

As for targeted drug discovery efforts, there are currently no drugs specifically targeting CDC40. However, there are drugs that target other components of the spliceosome, such as spliceosome inhibitors used in cancer treatment. These drugs work by disrupting the splicing process, leading to cell death in cancer cells. Additionally, there are ongoing efforts to develop small molecule inhibitors of specific spliceosome components, which could potentially be used to treat diseases caused by splicing defects.

One example of a successful drug targeting the spliceosome is Spliceostatin A, which was discovered in a marine sponge and inhibits the splicing of specific genes. It has shown promising results in preclinical studies for the treatment of various cancers, including leukemia and breast cancer. Another example is H3B-8800, a small molecule inhibitor of the spliceosome component SF3B1, which is currently in clinical trials for the treatment of myelodysplastic syndromes and other hematological malignancies.","GO:1990403 embryonic brain development;GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;GO:0000398 mRNA splicing, via spliceosome",,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000113580.15,ENSG00000113580,NR3C1,-0.866850861,-0.69602937,-0.743643336,-1.160879877,nuclear receptor subfamily 3 group C member 1,"NR3C1 is a gene that encodes the glucocorticoid receptor, which acts as a transcription factor by binding to glucocorticoid response elements in the promoters of glucocorticoid responsive genes to activate their transcription. It is also involved in regulating other transcription factors. The receptor is typically found in the cytoplasm but is transported into the nucleus upon ligand binding. NR3C1 is involved in inflammatory responses, cellular proliferation, and differentiation in target tissues. Mutations in this gene are associated with generalized glucocorticoid resistance. Alternative splicing of this gene results in transcript variants encoding either the same or different isoforms, which display diverse cytoplasm-to-nucleus trafficking patterns and distinct transcriptional activities.","Mutations in NR3C1 have been associated with a rare genetic disorder called generalized glucocorticoid resistance, which is characterized by a reduced sensitivity to glucocorticoid hormones. This condition can lead to a variety of symptoms, including growth retardation, delayed puberty, and immune dysfunction. Targeted drug discovery efforts have focused on developing compounds that can modulate the activity of the glucocorticoid receptor, either by enhancing or inhibiting its function. Several drugs that target NR3C1 are currently on the market, including glucocorticoids such as prednisone and dexamethasone, which are used to treat a variety of inflammatory and autoimmune disorders. Other drugs, such as mifepristone, have been developed to block the activity of the glucocorticoid receptor and are being investigated for their potential use in treating conditions such as Cushing's syndrome and certain types of cancer.",GO:0043402 glucocorticoid mediated signaling pathway;GO:0042921 nuclear receptor-mediated glucocorticoid signaling pathway;GO:0031958 nuclear receptor-mediated corticosteroid signaling pathway,,Predicted intracellular proteins; Nuclear receptors; Human disease related genes:Musculoskeletal diseases:Skeletal diseases; Human disease related genes:Endocrine and metabolic diseases:Adrenal gland diseases; FDA approved drug targets:Small molecule drugs; Disease related genes; Transcription factors:Zinc-coordinating DNA-binding domains,Cytosol;Nucleoplasm (Supported); Additional: Mitochondria,"Flunisolide; Diflorasone; Alclometasone; Medrysone; Amcinonide; Fluorometholone; Megestrol acetate; Levonorgestrel; Beclomethasone dipropionate; Progesterone; Spironolactone; Betamethasone; Desoximetasone; Fluticasone propionate; Fluocinolone acetonide; Ulobetasol; Triamcinolone; Prednisone; Flumethasone; Fludrocortisone; Norethisterone; Hydrocortisone; Mometasone; Hydrocortamate; Mifepristone; Clocortolone; Flurandrenolide; Prednisolone; Loteprednol etabonate; Rimexolone; Methylprednisolone; Clobetasol propionate; Fluocinonide; Prednicarbate; Fluoxymesterone; Budesonide; Dexamethasone; Desonide; Cortisone acetate; Paramethasone; Drospirenone; Ciclesonide; Hexane-1,6-Diol; Aldosterone; ORG-34517; Difluprednate; Ulipristal; Fluticasone furoate; Tixocortol; Difluocortolone; Gestrinone; Deflazacort; Onapristone; Cortivazol; Clobetasone; Fluticasone; Mometasone furoate; Hydrocortisone aceponate; Hydrocortisone acetate; Hydrocortisone butyrate; Hydrocortisone cypionate; Hydrocortisone phosphate; Hydrocortisone probutate; Hydrocortisone valerate; Segesterone acetate; Prednisolone phosphate; Dexamethasone acetate; Betamethasone phosphate; Prednisolone acetate",(M30)PID HDAC CLASSII PATHWAY; (M106)PID HNF3B PATHWAY; (M151)PID AR TF PATHWAY,(M5942)HALLMARK UV RESPONSE DN; (M5891)HALLMARK HYPOXIA; (M5945)HALLMARK HEME METABOLISM
ENSG00000061676.15,ENSG00000061676,NCKAP1,-0.866186518,-1.004292385,-0.992926925,-0.601340245,NCK associated protein 1,"NCKAP1, also known as NCK associated protein 1, is a gene that contributes to small GTPase binding activity and is involved in Rac protein signal transduction. It positively regulates Arp2/3 complex-mediated actin nucleation and lamellipodium assembly. NCKAP1 is located in extracellular exosome and focal adhesion and is part of the SCAR complex.","There is limited information available on the disease implications of NCKAP1. However, studies have shown that dysregulation of Rac protein signal transduction and actin nucleation can contribute to cancer metastasis and invasion. Therefore, NCKAP1 may play a role in cancer progression and could be a potential target for cancer therapy. 

There are currently no targeted drug discovery efforts specifically focused on NCKAP1. However, drugs that target the Rac signaling pathway and actin nucleation have been developed and are used in cancer treatment. For example, the drug paclitaxel stabilizes microtubules and disrupts the balance between microtubules and actin filaments, leading to cell death. Another drug, Y-27632, inhibits the Rho-associated protein kinase (ROCK) pathway, which is involved in actin cytoskeleton organization and cell migration. 

In summary, while there is limited information on the disease implications of NCKAP1, its involvement in Rac signaling and actin nucleation suggests it may play a role in cancer progression. While there are no targeted drug discovery efforts focused on NCKAP1, drugs that target the Rac signaling pathway and actin nucleation have been developed and are used in cancer treatment.",GO:2000601 positive regulation of Arp2/3 complex-mediated actin nucleation;GO:0051127 positive regulation of actin nucleation;GO:0016601 Rac protein signal transduction,,,Cytosol (Approved),,(M156)PID ECADHERIN NASCENT AJ PATHWAY; (M232)PID ECADHERIN STABILIZATION PATHWAY; (M278)PID RAC1 PATHWAY,
ENSG00000117475.14,ENSG00000117475,BLZF1,-0.864572403,-1.208381124,-0.978254545,-0.407081541,basic leucine zipper nuclear factor 1,"BLZF1, also known as basic leucine zipper nuclear factor 1, is a human gene that encodes a protein with ubiquitin protein ligase binding activity. It plays a role in Golgi organization and Golgi to plasma membrane protein transport, and is located in the Golgi apparatus and nucleoplasm. BLZF1 is also a biomarker of hepatocellular carcinoma, a type of liver cancer. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of BLZF1. However, studies have shown that BLZF1 is overexpressed in hepatocellular carcinoma (HCC), a type of liver cancer, and may serve as a biomarker for HCC diagnosis and prognosis. Targeted drug discovery efforts for BLZF1 are also limited, as the function of the protein is not well understood. However, some studies have suggested that BLZF1 may play a role in cancer progression and metastasis, making it a potential target for cancer therapy. Currently, there are no drugs on the market that specifically target BLZF1. However, there are several drugs that have been approved for the treatment of HCC, including sorafenib, lenvatinib, and regorafenib, which target various signaling pathways involved in cancer growth and progression.",GO:0043001 Golgi to plasma membrane protein transport;GO:0061951 establishment of protein localization to plasma membrane;GO:0006893 Golgi to plasma membrane transport,,Predicted intracellular proteins,Golgi apparatus (Supported); Additional: Nucleoplasm,,,
ENSG00000095139.14,ENSG00000095139,ARCN1,-0.864533534,-1.44605239,-0.793057244,-0.354490967,archain 1,"ARCN1, also known as archain 1, is a gene that is located in a region where multiple disease-associated chromosome translocations occur. It is an intracellular protein that is well conserved among eukaryotes and may play a fundamental role in eukaryotic cell biology. ARCN1 has similarities to heat shock proteins and clathrin-associated proteins, and may be involved in vesicle structure or trafficking. The function of ARCN1 is not fully understood, but it is believed to be involved in the regulation of protein transport within cells. Mutations in this gene have been associated with various diseases, including cancer and developmental disorders.","Mutations in the ARCN1 gene have been associated with various diseases, including cancer and developmental disorders. In particular, ARCN1 has been found to be overexpressed in several types of cancer, including breast, lung, and ovarian cancer. Targeting ARCN1 has been proposed as a potential therapeutic strategy for these cancers. However, there are currently no drugs on the market that specifically target ARCN1. 

There have been some efforts to develop drugs that target related proteins, such as clathrin, which is involved in vesicle trafficking and shares some similarities with ARCN1. For example, pitstop compounds have been developed that inhibit clathrin-mediated endocytosis and have shown promise in preclinical studies for the treatment of cancer and other diseases. However, these compounds are not specific to ARCN1 and may have off-target effects.

Overall, while ARCN1 has been implicated in several diseases, including cancer, there is currently no targeted drug discovery effort focused specifically on this gene. Further research is needed to fully understand the role of ARCN1 in disease and to develop targeted therapies.",GO:0021691 cerebellar Purkinje cell layer maturation;GO:0021590 cerebellum maturation;GO:0021699 cerebellar cortex maturation,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Vesicles (Approved); Additional: Cytosol;Golgi apparatus,,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000177426.22,ENSG00000177426,TGIF1,-0.864402526,-1.400051984,-0.817236964,-0.37591863,TGFB induced factor homeobox 1,"TGIF1 is a gene that encodes a transcription regulator protein belonging to the TALE superclass of atypical homeodomains. This protein binds to a retinoid X receptor responsive element and acts as a transcriptional co-repressor of SMAD2. It is involved in the transmission of nuclear signals during development and in the adult. Mutations in this gene are associated with holoprosencephaly type 4, a structural anomaly of the brain. Alternative splicing has been observed, resulting in multiple splice variants encoding distinct isoforms.","Mutations in the TGIF1 gene have been associated with holoprosencephaly type 4, a rare genetic disorder characterized by incomplete separation of the embryonic forebrain into two hemispheres. This can result in a range of neurological and developmental abnormalities, including intellectual disability, facial deformities, and seizures. There are currently no targeted drug discovery efforts specifically focused on TGIF1, but research into the underlying mechanisms of holoprosencephaly may lead to new therapeutic approaches.

There are currently no drugs on the market that specifically target TGIF1, but there are several drugs that have been approved for the treatment of holoprosencephaly-related symptoms. For example, anticonvulsant medications such as valproic acid and carbamazepine can be used to manage seizures, while growth hormone therapy may be used to address growth and developmental delays. Additionally, surgical interventions may be necessary to correct facial deformities or other structural abnormalities.",GO:0009410 response to xenobiotic stimulus;GO:0071363 cellular response to growth factor stimulus;GO:0070848 response to growth factor,,Predicted intracellular proteins; Transcription factors:Helix-turn-helix domains; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Disease related genes; Cancer-related genes:Mutational cancer driver genes,Nucleoplasm (Supported),,(M58)PID AR PATHWAY; (M2)PID SMAD2 3NUCLEAR PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING; (M5890)HALLMARK TNFA SIGNALING VIA NFKB
ENSG00000205060.11,ENSG00000205060,SLC35B4,-0.863984288,-1.15855724,-0.81953255,-0.613863073,solute carrier family 35 member B4,"SLC35B4 is a gene that encodes for a glycosyltransferase, which is a protein that transports nucleotide sugars from the cytoplasm to the Golgi apparatus. These nucleotide sugars are used in the synthesis of glycoproteins, glycolipids, and proteoglycans. The function of SLC35B4 is important in the process of glycosylation, which is the addition of sugar molecules to proteins and lipids. Mutations in SLC35B4 have been associated with developmental disorders, such as intellectual disability and epilepsy.","There is limited information available on targeted drug discovery efforts for SLC35B4, as it is a relatively newly discovered gene. However, mutations in SLC35B4 have been associated with developmental disorders, such as intellectual disability and epilepsy. Therefore, there is potential for drug discovery efforts to target these conditions by modulating the function of SLC35B4. Currently, there are no drugs on the market that specifically target SLC35B4. However, there are drugs that target glycosylation pathways, which may indirectly affect the function of SLC35B4. For example, tunicamycin is a drug that inhibits the first step of N-linked glycosylation and is used in research to study the effects of glycosylation inhibition. Additionally, some cancer drugs, such as imatinib and erlotinib, target specific glycoproteins that are overexpressed in cancer cells.",GO:0015790 UDP-xylose transmembrane transport;GO:1990569 UDP-N-acetylglucosamine transmembrane transport;GO:0090481 pyrimidine nucleotide-sugar transmembrane transport,,Transporters:Electrochemical Potential-driven transporters,,,,
ENSG00000151239.14,ENSG00000151239,TWF1,-0.863843329,-1.244314535,-0.864436352,-0.482779099,twinfilin actin binding protein 1,"TWF1 is a gene that encodes for twinfilin, a protein that binds to actin monomers. This protein is found in organisms ranging from yeast to mammals. Research on the mouse version of this protein suggests that it may be involved in binding to actin monomers and its location in cortical G-actin-rich structures may be regulated by the small GTPase RAC1.","Research on TWF1 and its protein product twinfilin has suggested potential implications in various diseases, including cancer, Alzheimer's disease, and heart disease. In cancer, twinfilin has been shown to play a role in tumor cell migration and invasion, making it a potential target for cancer therapy. In Alzheimer's disease, twinfilin has been found to be involved in the formation of amyloid-beta plaques, which are a hallmark of the disease. In heart disease, twinfilin has been implicated in the regulation of cardiac contractility.

Targeted drug discovery efforts for TWF1 have focused on identifying small molecules that can inhibit the interaction between twinfilin and actin monomers. One example is the compound SMIFH2, which has been shown to disrupt the binding of twinfilin to actin and inhibit cell migration in vitro. Other potential drug targets include the small GTPase RAC1, which regulates the localization of twinfilin in cells.

Currently, there are no drugs on the market that specifically target TWF1 or twinfilin. However, there are drugs that indirectly affect the function of these proteins. For example, the cancer drug paclitaxel stabilizes microtubules, which indirectly affects the function of actin and may impact the interaction between twinfilin and actin. Additionally, the Alzheimer's drug memantine has been shown to reduce the formation of amyloid-beta plaques, which may indirectly affect the function of twinfilin.",GO:0042989 sequestering of actin monomers;GO:0030042 actin filament depolymerization;GO:0051016 barbed-end actin filament capping,,Disease related genes; Predicted intracellular proteins,Cytosol (Supported),,,
ENSG00000075711.21,ENSG00000075711,DLG1,-0.863811531,-1.242496682,-0.9321777,-0.41676021,discs large MAGUK scaffold protein 1,"DLG1 is a gene that encodes a scaffolding protein that plays a crucial role in normal development. The protein is involved in various cellular processes such as septate junction formation, signal transduction, cell proliferation, synaptogenesis, and lymphocyte activation. The gene produces multiple transcript variants due to alternative splicing and the use of multiple alternate promoters. Some of these splice variants may be specific to certain tissues, including the brain. An upstream uORF may regulate translation at some splice variants of this gene. Overall, DLG1 is an important gene that is involved in various cellular processes and is required for normal development.","DLG1 has been implicated in several diseases, including cancer, neurological disorders, and immune system disorders. In cancer, DLG1 has been shown to be involved in tumor growth and metastasis, making it a potential target for cancer therapy. In neurological disorders, mutations in DLG1 have been linked to schizophrenia, autism, and intellectual disability. DLG1 has also been implicated in immune system disorders such as rheumatoid arthritis and lupus.

Targeted drug discovery efforts for DLG1 have focused on developing small molecule inhibitors that can disrupt the protein-protein interactions involving DLG1. These inhibitors could potentially be used to treat cancer and neurological disorders. However, there are currently no drugs on the market that specifically target DLG1.

One example of a successful drug that indirectly affects DLG1 is lithium, which is used to treat bipolar disorder. Lithium has been shown to increase the expression of DLG1 in the brain, which may contribute to its therapeutic effects. Another example is the cancer drug sorafenib, which has been shown to inhibit the growth of tumors by targeting the protein-protein interactions involving DLG1.

Overall, DLG1 is an important gene with implications in several diseases, and targeted drug discovery efforts are ongoing to develop drugs that can modulate its function.",GO:1903286 regulation of potassium ion import;GO:0099562 maintenance of postsynaptic density structure;GO:0060022 hard palate development,yes,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Vesicles (Approved); Additional: Basal body;Plasma membrane,,(M156)PID ECADHERIN NASCENT AJ PATHWAY; (M81)PID CDC42 PATHWAY,(M5942)HALLMARK UV RESPONSE DN; (M5893)HALLMARK MITOTIC SPINDLE; (M5915)HALLMARK APICAL JUNCTION
ENSG00000101665.9,ENSG00000101665,SMAD7,-0.863285302,-1.260415893,-0.993703365,-0.335736648,SMAD family member 7,"SMAD7 is a human gene that encodes a nuclear protein that binds to the E3 ubiquitin ligase SMURF2. This complex then moves to the cytoplasm where it interacts with TGF-beta receptor type-1 (TGFBR1), leading to the degradation of both SMAD7 and TGFBR1. The expression of SMAD7 is induced by TGFBR1. Variations in this gene are linked to susceptibility to colorectal cancer type 3 (CRCS3). There are several transcript variants of SMAD7 that encode different isoforms.","SMAD7 has been implicated in various diseases, including cancer, fibrosis, and inflammatory disorders. In particular, SMAD7 has been shown to play a role in the development and progression of colorectal cancer. Studies have found that SMAD7 expression is upregulated in colorectal cancer cells, and that targeting SMAD7 can inhibit tumor growth and metastasis. As a result, there has been interest in developing drugs that target SMAD7 for the treatment of colorectal cancer and other diseases.

One example of a drug that targets SMAD7 is a small molecule inhibitor called SIS3. SIS3 has been shown to inhibit SMAD7 expression and activity, leading to reduced tumor growth in preclinical models of colorectal cancer. Another example is a monoclonal antibody called LY315920NA, which targets SMAD7 and has shown promise in preclinical models of fibrosis.

Overall, targeting SMAD7 is a promising approach for the treatment of various diseases, and there is ongoing research to develop new drugs that target this protein.",GO:1903041 regulation of chondrocyte hypertrophy;GO:1903043 positive regulation of chondrocyte hypertrophy;GO:1902761 positive regulation of chondrocyte development,,Disease related genes; Human disease related genes:Cancers:Cancers of the digestive system; Predicted intracellular proteins; Transcription factors:beta-Hairpin exposed by an alpha/beta-scaffold,Basal body;Centrosome;Nucleoplasm (Supported); Additional: Cytosol;Nucleoli fibrillar center,,(M185)PID ALK1 PATHWAY; (M161)PID IFNG PATHWAY; (M181)PID BMP PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING; (M5942)HALLMARK UV RESPONSE DN; (M5902)HALLMARK APOPTOSIS
ENSG00000137845.15,ENSG00000137845,ADAM10,-0.862740308,-1.285087341,-0.919712505,-0.383421079,ADAM metallopeptidase domain 10,"ADAM10 is a gene that belongs to the ADAM family of cell surface proteins. It encodes a protein that has both adhesion and protease domains and is involved in cleaving various proteins, including TNF-alpha and E-cadherin. The gene undergoes alternate splicing, resulting in multiple transcript variants that encode different proteins with similar processing. ADAM10 is important in various biological processes, including cell adhesion, migration, and signaling. Dysregulation of ADAM10 has been linked to various diseases, including cancer, Alzheimer's disease, and asthma.","ADAM10 has been implicated in various diseases, including cancer, Alzheimer's disease, and asthma. In cancer, ADAM10 is involved in tumor growth, invasion, and metastasis. Targeting ADAM10 has been explored as a potential therapeutic strategy for cancer treatment. In Alzheimer's disease, ADAM10 is involved in the processing of amyloid precursor protein (APP) and the production of amyloid beta (A?) peptides, which are implicated in the pathogenesis of the disease. Targeting ADAM10 has been explored as a potential therapeutic strategy for Alzheimer's disease. In asthma, ADAM10 is involved in the shedding of the epithelial cell adhesion molecule (EpCAM), which is implicated in airway inflammation. Targeting ADAM10 has been explored as a potential therapeutic strategy for asthma. Several drugs targeting ADAM10 are currently in development, including small molecule inhibitors and monoclonal antibodies. One example of a successful drug targeting ADAM10 is TAPI-1, a small molecule inhibitor that has been shown to inhibit ADAM10 activity and reduce tumor growth in preclinical studies.",GO:0051089 constitutive protein ectodomain proteolysis;GO:0038004 epidermal growth factor receptor ligand maturation;GO:0140246 protein catabolic process at synapse,,Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Transporters:Accessory Factors Involved in Transport; Potential drug targets; Disease related genes; CD markers; Enzymes; Cancer-related genes:Mutational cancer driver genes; ENZYME proteins:Hydrolases,Plasma membrane;Vesicles (Supported),XL784,(M70)PID PS1 PATHWAY; (M142)PID AJDISS 2PATHWAY; (M17)PID NOTCH PATHWAY,(M5916)HALLMARK APICAL SURFACE; (M5910)HALLMARK PROTEIN SECRETION
ENSG00000198964.14,ENSG00000198964,SGMS1,-0.862739351,-1.039862989,-0.897295705,-0.651059359,sphingomyelin synthase 1,"SGMS1 is a gene that encodes for a protein called sphingomyelin synthase 1. This protein is predicted to have five transmembrane segments and is primarily expressed in the brain. Sphingomyelin synthase 1 is involved in the synthesis of sphingomyelin, a type of lipid that is important for the structure and function of cell membranes. Mutations in SGMS1 have been associated with a rare genetic disorder called Niemann-Pick disease type C, which is characterized by the accumulation of lipids in various organs of the body.","Niemann-Pick disease type C (NPC) is a rare genetic disorder caused by mutations in the SGMS1 gene, which encodes for sphingomyelin synthase 1. NPC is characterized by the accumulation of lipids, including sphingomyelin, in various organs of the body, leading to progressive neurological and visceral symptoms. There is currently no cure for NPC, and treatment options are limited to symptomatic management. However, there are ongoing efforts to develop targeted therapies for NPC, including small molecule drugs that can reduce lipid accumulation and improve neurological function. One example is cyclodextrin, which has been shown to reduce lipid accumulation and improve survival in NPC animal models. Another example is miglustat, which inhibits the synthesis of glycosphingolipids and has been approved for the treatment of NPC in Europe. Despite these advances, there is still a need for more effective and targeted therapies for NPC.",GO:0006686 sphingomyelin biosynthetic process;GO:0006684 sphingomyelin metabolic process;GO:0046513 ceramide biosynthetic process,yes,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Approved); Additional: Cytosol;Golgi apparatus;Nucleoli fibrillar center,,(M143)PID IL2 PI3K PATHWAY,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000130816.17,ENSG00000130816,DNMT1,-0.86241175,-1.150388255,-1.016259079,-0.420587915,DNA methyltransferase 1,"DNMT1 is a gene that encodes an enzyme responsible for transferring methyl groups to cytosine nucleotides of genomic DNA. This enzyme plays a crucial role in maintaining methylation patterns following DNA replication and has a preference for hemi-methylated DNA. Methylation of DNA is an important component of mammalian epigenetic gene regulation, and aberrant methylation patterns are associated with developmental abnormalities and human tumors. Variations in the DNMT1 gene have been linked to cerebellar ataxia, deafness, narcolepsy, and neuropathy, hereditary sensory, type IE. The gene undergoes alternative splicing, resulting in multiple transcript variants.","Aberrant methylation patterns resulting from DNMT1 dysfunction have been implicated in various diseases, including cancer, neurological disorders, and autoimmune diseases. Targeted drug discovery efforts have focused on developing inhibitors of DNMT1 to restore normal methylation patterns and potentially treat these diseases. One example of a successful drug on the market is azacitidine, which is used to treat myelodysplastic syndrome and acute myeloid leukemia by inhibiting DNMT1 and promoting DNA demethylation. Another example is decitabine, which is also used to treat myelodysplastic syndrome and acute myeloid leukemia by inhibiting DNMT1 and promoting DNA demethylation. These drugs have shown promising results in clinical trials and have been approved by the FDA for use in certain patient populations. However, further research is needed to fully understand the potential of DNMT1 inhibitors in treating other diseases associated with aberrant methylation patterns.",GO:0141119 chromosomal DNA methylation maintenance following DNA replication;GO:1900240 negative regulation of phenotypic switching;GO:1905916 negative regulation of cell differentiation involved in phenotypic switching,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Predicted intracellular proteins; ENZYME proteins:Transferases; FDA approved drug targets:Small molecule drugs; Disease related genes; Enzymes; Transcription factors:Zinc-coordinating DNA-binding domains,Nucleoplasm (Supported),Procaine; Azacitidine; Procainamide; Flucytosine; Decitabine; Palifosfamide; Epigallocatechin gallate,(M279)PID RB 1PATHWAY,(M5925)HALLMARK E2F TARGETS
ENSG00000132680.11,ENSG00000132680,KHDC4,-0.862327314,-1.092481657,-0.665467312,-0.829032972,"KH domain containing 4, pre-mRNA splicing factor","KHDC4 is a human gene that encodes for a pre-mRNA splicing factor containing a KH domain, which enables RNA binding activity. This gene is involved in mRNA splice site selection and is located in both the cytoplasm and nucleoplasm. KHDC4 colocalizes with the spliceosomal complex, which is responsible for the removal of introns from pre-mRNA molecules. The function of KHDC4 in pre-mRNA splicing suggests that it plays an important role in regulating gene expression and protein production in human cells.","There is limited information available on the disease implications of KHDC4. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for KHDC4 are also limited, as the exact role of this gene in cancer development and progression is not yet fully understood. Currently, there are no drugs on the market that specifically target KHDC4. However, there are several drugs that target other pre-mRNA splicing factors, such as spliceosome inhibitors, which have shown promise in the treatment of certain types of cancer. Further research is needed to fully understand the potential therapeutic implications of targeting KHDC4 in cancer treatment.",GO:0006376 mRNA splice site recognition;GO:0000245 spliceosomal complex assembly;GO:0022618 protein-RNA complex assembly,,Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000168758.11,ENSG00000168758,SEMA4C,-0.862164401,-1.272176694,-0.719462653,-0.594853855,semaphorin 4C,SEMA4C is a human gene that is predicted to have chemorepellent activity and semaphorin receptor binding activity. It is involved in muscle cell differentiation and positive regulation of stress-activated MAPK cascade. The gene is located in the extracellular space.,"SEMA4C has been implicated in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, SEMA4C has been shown to promote tumor growth and metastasis by enhancing angiogenesis and invasion. In cardiovascular disease, SEMA4C has been linked to atherosclerosis and vascular remodeling. In neurological disorders, SEMA4C has been associated with axonal guidance and synaptic plasticity.

Targeted drug discovery efforts for SEMA4C are still in the early stages, but there is potential for the development of drugs that target its chemorepellent and semaphorin receptor binding activities. One approach is to develop small molecule inhibitors that block the interaction between SEMA4C and its receptors, which could potentially inhibit tumor growth and metastasis. Another approach is to develop antibodies that target SEMA4C, which could be used to treat various diseases.

There are currently no drugs on the market that specifically target SEMA4C, but there are drugs that indirectly affect its activity. For example, statins, which are commonly used to treat high cholesterol, have been shown to downregulate SEMA4C expression and inhibit its pro-angiogenic effects. Additionally, some cancer drugs, such as sorafenib and sunitinib, have been shown to inhibit SEMA4C expression and reduce tumor growth and metastasis.",GO:0021535 cell migration in hindbrain;GO:0032874 positive regulation of stress-activated MAPK cascade;GO:0070304 positive regulation of stress-activated protein kinase signaling cascade,,Predicted intracellular proteins,,,(M5880)NABA ECM AFFILIATED; (M5885)NABA MATRISOME ASSOCIATED; (M5889)NABA MATRISOME,
ENSG00000111727.12,ENSG00000111727,HCFC2,-0.861621486,-1.231678476,-0.772198857,-0.580987125,host cell factor C2,"HCFC2 is a human gene that encodes a protein that interacts with VP16, a protein from the herpes simplex virus that initiates virus infection. The encoded protein and the original Herpes host cell factor both interact with VP16 through a beta-propeller domain, but the original Herpes host cell factor is effective at initiating viral infection while the encoded protein is not. The gene produces transcripts of varying length due to alternative polyadenylation signals.","Research on HCFC2 has primarily focused on its role in viral infection, particularly with the herpes simplex virus. However, there is limited evidence suggesting that mutations in HCFC2 may be associated with certain diseases. For example, a study found that a rare variant in HCFC2 was associated with an increased risk of developing Alzheimer's disease. Further research is needed to fully understand the implications of HCFC2 mutations on disease development.

As for targeted drug discovery efforts, there is currently no known drug that specifically targets HCFC2. However, given its role in viral infection, there has been research on developing drugs that target the interaction between HCFC2 and VP16 to prevent viral infection. One study found that a small molecule inhibitor of the HCFC2-VP16 interaction was effective at reducing herpes simplex virus infection in vitro.

There are currently no drugs on the market that specifically target HCFC2. However, there are antiviral drugs available that target the herpes simplex virus, such as acyclovir and valacyclovir. These drugs work by inhibiting viral DNA synthesis and are effective at reducing the severity and frequency of herpes outbreaks. While they do not directly target HCFC2, they indirectly affect its interaction with VP16 by preventing viral replication.",GO:1902615 immune response involved in response to exogenous dsRNA;GO:0034139 regulation of toll-like receptor 3 signaling pathway;GO:0043330 response to exogenous dsRNA,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol;Plasma membrane,,(M5883)NABA SECRETED FACTORS; (M5885)NABA MATRISOME ASSOCIATED; (M5889)NABA MATRISOME,
ENSG00000165102.15,ENSG00000165102,HGSNAT,-0.861082539,-1.652126932,-0.802981061,-0.128139624,heparan-alpha-glucosaminide N-acetyltransferase,"HGSNAT is a gene that encodes a lysosomal acetyltransferase, which is responsible for the degradation of heparin sulfate in the lysosome. Mutations in this gene are linked to Sanfilippo syndrome C, a type of mucopolysaccharidosis III, which is a lysosomal storage disease caused by the inability to break down heparan sulfate. This condition leads to the accumulation of heparan sulfate in the lysosome, causing damage to various organs and tissues.","Sanfilippo syndrome C, also known as mucopolysaccharidosis III type C, is a rare genetic disorder caused by mutations in the HGSNAT gene. This condition leads to the accumulation of heparan sulfate in the lysosome, causing damage to various organs and tissues. Symptoms of Sanfilippo syndrome C include developmental delay, behavioral problems, seizures, and progressive intellectual disability. Currently, there is no cure for Sanfilippo syndrome C, and treatment is mainly supportive. However, there are ongoing efforts to develop targeted therapies for this condition. One approach is to use enzyme replacement therapy, which involves replacing the missing or defective enzyme with a functional one. Another approach is to use gene therapy to replace the defective gene with a functional one. There are currently no drugs on the market specifically approved for Sanfilippo syndrome C, but there are several drugs approved for other types of mucopolysaccharidosis that may be used off-label to treat this condition. These include enzyme replacement therapies such as Aldurazyme and Vimizim, which are approved for mucopolysaccharidosis I and IV, respectively.",GO:0030200 heparan sulfate proteoglycan catabolic process;GO:0030167 proteoglycan catabolic process;GO:0006516 glycoprotein catabolic process,,Human disease related genes:Nervous system diseases:Eye disease; Transporters; ENZYME proteins:Transferases; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Lysosomal storage diseases; Disease related genes; Enzymes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism,,,,
ENSG00000162298.19,ENSG00000162298,SYVN1,-0.860781757,-1.480777612,-0.627537165,-0.474030493,synoviolin 1,"SYVN1, also known as synoviolin 1, is a gene that encodes a protein involved in the degradation of unfolded proteins that accumulate during endoplasmic reticulum (ER) stress. The protein removes these unfolded proteins by transporting them retrograde to the cytosol from the ER and also uses the ubiquitin-proteasome system for additional degradation. There are two transcript variants of the gene that encode different isoforms. SYVN1 is important for maintaining protein homeostasis and preventing the accumulation of misfolded proteins, which can lead to various diseases such as neurodegenerative disorders and cancer.","SYVN1 has been implicated in various diseases, including neurodegenerative disorders and cancer. In neurodegenerative disorders such as Alzheimer's and Parkinson's disease, the accumulation of misfolded proteins is a hallmark feature. SYVN1 plays a crucial role in preventing the accumulation of these misfolded proteins, and its dysfunction has been linked to the pathogenesis of these diseases. In cancer, SYVN1 has been shown to be overexpressed in various types of tumors, and its inhibition has been proposed as a potential therapeutic strategy.

There have been efforts to develop drugs that target SYVN1 for the treatment of these diseases. One approach is to develop small molecule inhibitors that can block the activity of SYVN1. Another approach is to develop drugs that can enhance the activity of SYVN1, thereby promoting the degradation of misfolded proteins. However, there are currently no drugs on the market that specifically target SYVN1.

One example of a successful drug that indirectly targets SYVN1 is bortezomib, which is used to treat multiple myeloma. Bortezomib inhibits the proteasome, which is the cellular machinery responsible for degrading misfolded proteins. This leads to the accumulation of misfolded proteins, which are then transported to the cytosol by SYVN1 for further degradation. Another example is tafamidis, which is used to treat transthyretin amyloidosis. Tafamidis stabilizes the transthyretin protein, preventing its misfolding and subsequent accumulation. This reduces the workload on SYVN1 and other cellular machinery involved in protein degradation.",GO:0002327 immature B cell differentiation;GO:1904380 endoplasmic reticulum mannose trimming;GO:0036507 protein demannosylation,,Transporters:Primary Active Transporters; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Nucleoplasm (Supported); Additional: Endoplasmic reticulum;Plasma membrane,,,
ENSG00000115306.16,ENSG00000115306,SPTBN1,-0.860021669,-1.634456269,-0.823927499,-0.121681238,"spectrin beta, non-erythrocytic 1","SPTBN1 is a gene that encodes for the spectrin beta protein, which is involved in linking the plasma membrane to the actin cytoskeleton. This protein plays a crucial role in determining cell shape, organizing organelles, and arranging transmembrane proteins. The spectrin beta protein is composed of two antiparallel dimers of alpha- and beta- subunits, and SPTBN1 is one member of a family of beta-spectrin genes. The protein contains an N-terminal actin-binding domain and 17 spectrin repeats that are involved in dimer formation. Multiple transcript variants encoding different isoforms have been identified for this gene.","Mutations in the SPTBN1 gene have been associated with a variety of diseases, including spinocerebellar ataxia type 5 (SCA5), a neurodegenerative disorder characterized by progressive ataxia, dysarthria, and nystagmus. Additionally, mutations in SPTBN1 have been linked to hereditary spherocytosis, a condition in which red blood cells are abnormally shaped and prone to premature destruction. 

There are currently no drugs specifically targeting SPTBN1, but research efforts are underway to identify potential therapeutic targets for diseases associated with this gene. One approach is to target downstream pathways affected by SPTBN1 mutations, such as the RhoA signaling pathway, which has been implicated in SCA5. Another approach is to develop gene therapies to correct the underlying genetic mutations.

There are currently no drugs on the market targeting SPTBN1, but there are drugs available for the treatment of diseases associated with this gene. For example, folic acid supplementation can help alleviate symptoms of hereditary spherocytosis by promoting red blood cell production. Additionally, there are drugs available to treat the symptoms of spinocerebellar ataxia, such as gabapentin and baclofen, which can help alleviate muscle spasms and other neurological symptoms.",GO:0021556 central nervous system formation;GO:0021551 central nervous system morphogenesis;GO:0043001 Golgi to plasma membrane protein transport,,Disease related genes; Transporters:Accessory Factors Involved in Transport; Potential drug targets; Predicted intracellular proteins,Cytosol (Uncertain),"Calcium; 1D-myo-inositol 1,4,5-trisphosphate",(M286)PID TGFBR PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING; (M5893)HALLMARK MITOTIC SPINDLE
ENSG00000070614.15,ENSG00000070614,NDST1,-0.859779228,-1.174865032,-0.5302529,-0.874219752,N-deacetylase and N-sulfotransferase 1,NDST1 is a gene that encodes an enzyme belonging to the heparan sulfate/heparin GlcNAc N-deacetylase/N-sulfotransferase family. This enzyme is a type II transmembrane protein that is located in the Golgi apparatus. Its main function is to transfer sulfate from 3'-phosphoadenosine 5'-phosphosulfate to nitrogen of glucosamine in heparan sulfate. Alternative splicing of this gene results in multiple transcript variants.,"NDST1 has been implicated in various diseases, including cancer, Alzheimer's disease, and developmental disorders. In cancer, NDST1 has been shown to play a role in tumor growth and metastasis by regulating the activity of growth factors and cytokines. Targeting NDST1 has been explored as a potential therapeutic strategy for cancer treatment. In Alzheimer's disease, NDST1 has been found to be dysregulated, leading to abnormal accumulation of amyloid beta peptides. Targeting NDST1 may therefore have potential in the treatment of Alzheimer's disease. There are currently no drugs on the market that specifically target NDST1, but there are ongoing efforts to develop small molecule inhibitors of NDST1 for therapeutic use. One example is the compound ND-336, which has been shown to inhibit NDST1 activity and reduce tumor growth in preclinical models of cancer.","GO:0015014 heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process;GO:0048702 embryonic neurocranium morphogenesis;GO:0048703 embryonic viscerocranium morphogenesis",,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,,"Adenosine 3',5'-diphosphate",,(M5891)HALLMARK HYPOXIA
ENSG00000052126.14,ENSG00000052126,PLEKHA5,-0.859138006,-1.23645127,-0.932621919,-0.40834083,pleckstrin homology domain containing A5,PLEKHA5 is a human gene that encodes a protein containing a pleckstrin homology domain. This protein is predicted to have the ability to bind to phosphatidylinositol phosphate and is involved in reproductive system development. PLEKHA5 is located in both the cytosol and nucleoplasm of cells. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of PLEKHA5. However, recent studies have suggested that PLEKHA5 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for PLEKHA5 are still in the early stages, but there is potential for the development of drugs that target the protein's interaction with phosphatidylinositol phosphate. Currently, there are no drugs on the market that specifically target PLEKHA5. However, there are drugs that target phosphatidylinositol phosphate, such as idelalisib, which is used to treat certain types of leukemia and lymphoma. Further research is needed to fully understand the role of PLEKHA5 in disease and to develop targeted therapies.",GO:0061458 reproductive system development;GO:0048731 system development;GO:0007275 multicellular organism development,,Predicted intracellular proteins,Cytosol;Nucleoplasm (Approved),,,
ENSG00000076108.12,ENSG00000076108,BAZ2A,-0.858687763,-1.023849912,-0.909630227,-0.642583151,bromodomain adjacent to zinc finger domain 2A,"BAZ2A is a human gene that encodes a protein called bromodomain adjacent to zinc finger domain 2A. This protein is involved in binding to histones and DNA, and is predicted to play a role in DNA methylation, histone deacetylation, and negative regulation of macromolecule metabolic processes. BAZ2A is also predicted to act upstream of or within chromatin organization and histone modification. The protein is located in both the cytosol and nuclear speck.","There is limited information available on the disease implications of BAZ2A. However, recent studies have suggested that BAZ2A may play a role in cancer development and progression. Specifically, BAZ2A has been found to be overexpressed in several types of cancer, including breast, lung, and ovarian cancer. Targeted drug discovery efforts for BAZ2A are still in the early stages, but there is potential for the development of drugs that target BAZ2A to treat cancer. Currently, there are no drugs on the market that specifically target BAZ2A. However, there are several drugs that target other proteins involved in chromatin organization and histone modification, which may indirectly affect BAZ2A function. Examples of such drugs include histone deacetylase inhibitors (e.g. vorinostat and romidepsin) and bromodomain inhibitors (e.g. JQ1 and OTX015), which have shown promise in preclinical and clinical studies for the treatment of various types of cancer.",GO:0000183 rDNA heterochromatin formation;GO:1990700 nucleolar chromatin organization;GO:0001188 RNA polymerase I preinitiation complex assembly,,Predicted intracellular proteins,Nuclear speckles (Enhanced),,,(M5905)HALLMARK ADIPOGENESIS
ENSG00000112282.18,ENSG00000112282,MED23,-0.858163362,-1.039967263,-0.986718727,-0.547804096,mediator complex subunit 23,"MED23 is a human gene that encodes a subunit of the CRSP complex, which is required for efficient activation by SP1. It is also a component of other multisubunit complexes, such as thyroid hormone receptor-associated proteins, which facilitate TR function on DNA templates. MED23 acts as a metastasis suppressor and has several alternatively spliced transcript variants encoding different isoforms. The activation of gene transcription is a multistep process that is triggered by factors that recognize transcriptional enhancer sites in DNA. These factors work with co-activators to direct transcriptional initiation by the RNA polymerase II apparatus.","There is limited information available on the disease implications of MED23. However, recent studies have suggested that MED23 may play a role in cancer progression and metastasis. In particular, MED23 has been shown to act as a metastasis suppressor in breast cancer and its downregulation has been associated with poor prognosis in several other cancer types. Targeted drug discovery efforts for MED23 are currently limited, but there is potential for the development of drugs that target the CRSP complex or other complexes that MED23 is a part of. Currently, there are no drugs on the market that specifically target MED23, but there are several drugs that target other components of the transcriptional machinery, such as RNA polymerase II inhibitors and histone deacetylase inhibitors, that may indirectly affect MED23 function.",GO:2000409 positive regulation of T cell extravasation;GO:2000407 regulation of T cell extravasation;GO:0002693 positive regulation of cellular extravasation,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Cancer-related genes:Mutated cancer genes; Predicted intracellular proteins,Nucleoplasm;Vesicles (Approved),,,
ENSG00000144357.18,ENSG00000144357,UBR3,-0.856984651,-1.062346118,-0.666363691,-0.842244143,ubiquitin protein ligase E3 component n-recognin 3,"UBR3 is a human gene that encodes for a protein called ubiquitin protein ligase E3 component n-recognin 3. This protein is predicted to have ubiquitin protein ligase activity and is involved in various processes such as cellular protein metabolic process, sensory perception of smell, and suckling behavior. It is also predicted to play a role in in utero embryonic development and olfactory behavior. UBR3 is predicted to be an integral component of the membrane and part of the ubiquitin ligase complex. It is active in the cytoplasm. These predictions are based on information provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of UBR3. However, recent studies have suggested that mutations in UBR3 may be associated with neurodevelopmental disorders such as autism spectrum disorder and intellectual disability. Targeted drug discovery efforts for UBR3 are currently limited, as the function of the protein is not fully understood. However, given its predicted role in cellular protein metabolism, it is possible that drugs targeting UBR3 could have implications for the treatment of diseases related to protein misfolding and aggregation, such as Alzheimer's disease and Parkinson's disease. Currently, there are no drugs on the market that specifically target UBR3. However, there are drugs that target the ubiquitin-proteasome system, which is involved in protein degradation and is regulated by UBR3. Examples of such drugs include bortezomib, which is used to treat multiple myeloma, and carfilzomib, which is used to treat relapsed or refractory multiple myeloma.",GO:0071596 ubiquitin-dependent protein catabolic process via the N-end rule pathway;GO:1904878 negative regulation of calcium ion transmembrane transport via high voltage-gated calcium channel;GO:0042048 olfactory behavior,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoli;Nucleoplasm (Approved),,,
ENSG00000109920.13,ENSG00000109920,FNBP4,-0.856914488,-1.22306984,-0.621566033,-0.726107591,formin binding protein 4,"FNBP4 is a gene that encodes a protein with two WW domains that bind to the proline-rich formin homology 1 domains of formin family proteins. This suggests that the protein plays a role in regulating cytoskeletal dynamics during cell division and migration. The protein also binds to intersectin family proteins, indicating a role in maintaining membrane curvature at sites of nascent vesicle formation. Mutations in this gene have been associated with Waardenburg anophthalmia syndrome.","Mutations in the FNBP4 gene have been associated with Waardenburg anophthalmia syndrome, a rare genetic disorder characterized by eye abnormalities and hearing loss. However, there are currently no targeted drug discovery efforts specifically for FNBP4-related disorders. 

There are also no drugs on the market that specifically target FNBP4. However, there are drugs that target related proteins involved in cytoskeletal dynamics and membrane curvature, such as actin and dynamin. For example, latrunculin A is a drug that disrupts actin polymerization and has been used to study the role of actin in cell migration and division. Dynasore is a drug that inhibits dynamin, a protein involved in vesicle formation, and has been used to study the role of dynamin in endocytosis and membrane trafficking. 

Overall, while there is currently no targeted drug discovery effort for FNBP4-related disorders, drugs targeting related proteins may provide insights into potential therapeutic strategies.",,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000170365.10,ENSG00000170365,SMAD1,-0.856524406,-1.162883196,-0.999940314,-0.406749708,SMAD family member 1,"SMAD1 is a member of the SMAD family of proteins that act as signal transducers and transcriptional modulators. It mediates the signals of bone morphogenetic proteins (BMPs), which are involved in various biological activities such as cell growth, apoptosis, and immune responses. When activated by BMP ligands, SMAD1 forms a complex with SMAD4, which is crucial for its function in transcription regulation. SMAD1 is also a target for SMAD-specific E3 ubiquitin ligases, which lead to its degradation. Different variants of SMAD1 have been observed, but they all encode the same protein.","Mutations in the SMAD1 gene have been associated with various diseases, including osteoporosis, craniosynostosis, and pulmonary arterial hypertension. In osteoporosis, SMAD1 plays a role in regulating bone formation and remodeling, and mutations in the gene can lead to decreased bone density and increased risk of fractures. In craniosynostosis, mutations in SMAD1 have been found in patients with abnormal skull development. In pulmonary arterial hypertension, SMAD1 is involved in the regulation of vascular smooth muscle cell proliferation, and mutations in the gene can lead to abnormal blood vessel growth and increased pulmonary artery pressure.

Targeted drug discovery efforts for SMAD1-related diseases are ongoing, with a focus on developing drugs that can modulate the BMP signaling pathway. One example is the drug bosentan, which is used to treat pulmonary arterial hypertension by blocking the activity of endothelin receptors and indirectly inhibiting BMP signaling. Another example is romosozumab, a monoclonal antibody that targets sclerostin, a protein that inhibits BMP signaling and bone formation. Romosozumab has been approved for the treatment of osteoporosis in postmenopausal women at high risk of fracture.

Overall, targeting the BMP signaling pathway and SMAD1 specifically holds promise for the development of new therapies for a range of diseases, including osteoporosis, craniosynostosis, and pulmonary arterial hypertension.",GO:0002051 osteoblast fate commitment;GO:0031053 primary miRNA processing;GO:0001710 mesodermal cell fate commitment,,Disease related genes; Transcription factors:beta-Hairpin exposed by an alpha/beta-scaffold; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cytosol;Nucleoplasm (Supported),,(M203)PID ALK2 PATHWAY; (M185)PID ALK1 PATHWAY; (M181)PID BMP PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING
ENSG00000197586.13,ENSG00000197586,ENTPD6,-0.856412397,-0.83941805,-0.718617193,-1.011201948,ectonucleoside triphosphate diphosphohydrolase 6,"ENTPD6 is a human gene that encodes for ectonucleoside triphosphate diphosphohydrolase 6, which is similar to E-type nucleotidases. NTPases, such as CD39, are responsible for breaking down extracellular nucleotides. ENTPD6 contains four apyrase-conserved regions that are typical of NTPases. The gene undergoes alternative splicing, resulting in multiple transcript variants that encode different isoforms. This information was provided by RefSeq in December 2015.","There is limited information available on the disease implications of ENTPD6. However, some studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for ENTPD6 are also limited, but some studies have explored the potential of small molecule inhibitors of NTPases, such as CD39, for cancer therapy. One example of a successful drug targeting NTPases is ARL67156, which is a non-specific inhibitor of NTPases and has been shown to inhibit tumor growth in animal models. Another example is POM-1, which is a specific inhibitor of CD39 and has shown promising results in preclinical studies for cancer therapy. However, further research is needed to determine the potential of targeting ENTPD6 for therapeutic purposes.",GO:0032026 response to magnesium ion;GO:0051592 response to calcium ion;GO:0010038 response to metal ion,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins; Predicted secreted proteins,Golgi apparatus (Supported),,,
ENSG00000165156.15,ENSG00000165156,ZHX1,-0.856356226,-1.08328807,-0.713045626,-0.772734983,zinc fingers and homeoboxes 1,"ZHX1 is a gene that belongs to the zinc fingers and homeoboxes family, which are nuclear transcriptional repressors that interact with the A subunit of nuclear factor-Y. This gene encodes member 1 of this family and contains two C2H2-type zinc fingers and five homeobox DNA-binding domains. The protein encoded by this gene can form homodimers and heterodimerize with members 2 and 3 of the zinc fingers and homeoboxes family. Alternative splicing results in multiple transcript variants, and read-through transcription also exists between this gene and the downstream chromosome 8 open reading frame 76 (C8orf76) gene.","There is limited information available on the disease implications of ZHX1. However, recent studies have suggested that ZHX1 may play a role in the development and progression of certain cancers, including hepatocellular carcinoma and breast cancer. Targeted drug discovery efforts for ZHX1 are still in the early stages, but there is potential for the development of drugs that target the protein's interaction with nuclear factor-Y and its role in cancer development. Currently, there are no drugs on the market that specifically target ZHX1, but there are drugs that target other members of the zinc fingers and homeoboxes family, such as the leukemia drug, arsenic trioxide, which targets the promyelocytic leukemia zinc finger protein. Further research is needed to fully understand the disease implications of ZHX1 and to develop targeted therapies for diseases associated with this gene.",GO:0000122 negative regulation of transcription by RNA polymerase II;GO:0045892 negative regulation of DNA-templated transcription;GO:1902679 negative regulation of RNA biosynthetic process,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000074855.11,ENSG00000074855,ANO8,-0.855942369,-1.420960694,-0.939586286,-0.207280127,anoctamin 8,"The human gene ANO8, also known as anoctamin 8, enables intracellular calcium activated chloride channel activity and is involved in chloride transport. It is located in the plasma membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","Research on ANO8 has linked it to several diseases, including muscular dystrophy, cancer, and neurodegenerative disorders. Mutations in ANO8 have been associated with limb-girdle muscular dystrophy type 2L, a rare genetic disorder that affects the muscles in the hips and shoulders. Additionally, ANO8 has been found to be overexpressed in several types of cancer, including breast, lung, and prostate cancer, and may play a role in tumor growth and metastasis.

Targeted drug discovery efforts for ANO8 are still in the early stages, but there is potential for the development of drugs that modulate its activity. One study found that blocking ANO8 activity in cancer cells reduced their ability to migrate and invade surrounding tissues, suggesting that ANO8 inhibitors could be a promising therapeutic strategy for cancer treatment.

Currently, there are no drugs on the market that specifically target ANO8. However, there are several drugs that target chloride channels more broadly, including the diuretic drug furosemide and the anti-epileptic drug gabapentin. These drugs have been successful in treating a range of conditions, including hypertension, edema, and epilepsy, and may have potential for use in ANO8-related diseases in the future.",GO:1902476 chloride transmembrane transport;GO:0006821 chloride transport;GO:0098661 inorganic anion transmembrane transport,,,,,,
ENSG00000170836.12,ENSG00000170836,PPM1D,-0.854518059,-1.160947815,-0.756719595,-0.645886765,"protein phosphatase, Mg2+/Mn2+ dependent 1D","PPM1D is a gene that encodes a protein phosphatase belonging to the PP2C family. This phosphatase is induced in response to environmental stresses in a p53-dependent manner and negatively regulates the activity of p38 MAP kinase, which reduces the phosphorylation of p53. As a result, it suppresses p53-mediated transcription and apoptosis, contributing to growth inhibition and the suppression of stress-induced apoptosis. PPM1D is located in a chromosomal region that is amplified in breast cancer, and its amplification has been detected in both breast cancer cell lines and primary breast tumors, suggesting a role in cancer development.","PPM1D has been implicated in various types of cancer, including breast, ovarian, lung, and colorectal cancer. Its overexpression has been associated with poor prognosis and resistance to chemotherapy. Therefore, PPM1D has been proposed as a potential therapeutic target for cancer treatment. Several small molecule inhibitors of PPM1D have been developed, including RITA, COTI-2, and GSK2830371. These inhibitors have shown promising results in preclinical studies, including induction of apoptosis and sensitization to chemotherapy. However, no PPM1D inhibitors have been approved for clinical use yet. Further research is needed to evaluate the safety and efficacy of PPM1D inhibitors in clinical trials and to identify biomarkers that can predict patient response to these drugs.","GO:0035970 peptidyl-threonine dephosphorylation;GO:0006346 DNA methylation-dependent constitutive heterochromatin formation;GO:0030330 DNA damage response, signal transduction by p53 class mediator",,Predicted intracellular proteins; Human disease related genes:Cancers:Cancers of the breast and female genital organs; Human disease related genes:Other diseases:Mental and behavioural disorders; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported); Additional: Nucleoli,,(M261)PID P53 REGULATION PATHWAY,(M5925)HALLMARK E2F TARGETS; (M5939)HALLMARK P53 PATHWAY
ENSG00000142207.7,ENSG00000142207,URB1,-0.853531751,-1.11209446,-0.81699559,-0.631505204,URB1 ribosome biogenesis homolog,URB1 is a human gene that is involved in ribosome biogenesis. It is predicted to play a role in the maturation of 5.8S rRNA from a tricistronic rRNA transcript and the maturation of LSU-rRNA from the same transcript. URB1 is located in the fibrillar center and enables RNA binding activity.,"There is limited information available on the disease implications of URB1. However, mutations in URB1 have been associated with Diamond-Blackfan anemia (DBA), a rare genetic disorder characterized by a failure of the bone marrow to produce red blood cells. Targeted drug discovery efforts for DBA have focused on identifying compounds that can stimulate erythropoiesis, the process of red blood cell production. One successful drug on the market for DBA is lenalidomide, which has been shown to increase red blood cell production in patients with DBA. However, it is unclear if lenalidomide directly targets URB1 or if its effects are mediated through other pathways. Further research is needed to fully understand the role of URB1 in DBA and to identify potential drug targets for this disorder.","GO:0000463 maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);GO:0000466 maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);GO:0000470 maturation of LSU-rRNA",,Predicted intracellular proteins,Nucleoli fibrillar center (Supported),,,
ENSG00000167996.16,ENSG00000167996,FTH1,-0.853001409,-1.525428375,-0.890955162,-0.14262069,ferritin heavy chain 1,"FTH1 is a gene that encodes the heavy subunit of ferritin, a protein that stores iron in a soluble and non-toxic state in both prokaryotes and eukaryotes. Ferritin is composed of 24 subunits of heavy and light ferritin chains, and variations in the subunit composition can affect the rates of iron uptake and release in different tissues. Defects in ferritin proteins have been linked to several neurodegenerative diseases. FTH1 has multiple pseudogenes, and while several alternatively spliced transcript variants have been observed, their biological significance is not yet known.","Defects in FTH1 have been linked to several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Targeting FTH1 and ferritin proteins has been explored as a potential therapeutic strategy for these diseases. One approach is to develop small molecules that can modulate ferritin expression or function, such as iron chelators or compounds that can induce ferritin degradation. Another approach is to use gene therapy to deliver functional FTH1 or ferritin genes to affected tissues. While there are currently no drugs on the market that specifically target FTH1, several iron chelators, such as deferiprone and deferasirox, have been approved for the treatment of iron overload disorders and may have potential for neurodegenerative diseases. Additionally, a phase II clinical trial is currently underway to evaluate the safety and efficacy of a gene therapy approach for Huntington's disease that involves delivering a functional FTH1 gene to the brain.",GO:0110076 negative regulation of ferroptosis;GO:0110075 regulation of ferroptosis;GO:0048147 negative regulation of fibroblast proliferation,,Predicted intracellular proteins; ENZYME proteins:Oxidoreductases; FDA approved drug targets:Small molecule drugs; Candidate cardiovascular disease genes; Disease related genes; Enzymes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of ion transport and metabolism; Cancer-related genes:Candidate cancer biomarkers,,Iron Dextran; Iron; Ferric pyrophosphate citrate; Ferrous gluconate; Ferrous succinate; Ferrous ascorbate; Ferrous fumarate; Ferrous glycine sulfate,(M254)PID MYC REPRESS PATHWAY,
ENSG00000170581.14,ENSG00000170581,STAT2,-0.851452685,-1.452007028,-0.453430528,-0.6489205,signal transducer and activator of transcription 2,"The human gene STAT2 encodes a protein that belongs to the STAT protein family. When cytokines and growth factors bind to their receptors, STAT family members are phosphorylated and form homo- or heterodimers that enter the nucleus and activate transcription. In response to interferon, STAT2 forms a complex with STAT1 and ISGF3G, acting as a transactivator to mediate innate antiviral activity. However, it lacks the ability to bind DNA directly. Mutations in this gene lead to Immunodeficiency 44.","Mutations in the STAT2 gene have been linked to Immunodeficiency 44, a rare autosomal recessive disorder characterized by increased susceptibility to viral infections. There are currently no targeted drug discovery efforts specifically for STAT2 mutations, but there are several drugs on the market that target the interferon pathway, which STAT2 is a part of. For example, interferon alpha is used to treat chronic hepatitis B and C, while interferon beta is used to treat multiple sclerosis. Additionally, there are several drugs that target the JAK-STAT pathway, which includes STAT2, such as ruxolitinib and tofacitinib, which are used to treat certain types of cancer and autoimmune diseases. However, these drugs do not specifically target STAT2 mutations and may have off-target effects.",GO:0060339 negative regulation of type I interferon-mediated signaling pathway;GO:0090140 regulation of mitochondrial fission;GO:0060338 regulation of type I interferon-mediated signaling pathway,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Predicted intracellular proteins; Transcription factors:Immunoglobulin fold; Disease related genes; Human disease related genes:Immune system diseases:Primary immunodeficiency,Cytosol;Mid piece (Supported); Additional: Plasma membrane;Principal piece,,(M36)PID IL27 PATHWAY; (M124)PID CXCR4 PATHWAY,(M5897)HALLMARK IL6 JAK STAT3 SIGNALING; (M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5923)HALLMARK PI3K AKT MTOR SIGNALING
ENSG00000082996.20,ENSG00000082996,RNF13,-0.851215375,-0.984582405,-0.959314403,-0.609749317,ring finger protein 13,"RNF13, or ring finger protein 13, is a gene that encodes a protein containing a RING zinc finger motif, which is involved in protein-protein interactions. The function of this gene is not yet fully understood, but it has been found to have multiple alternatively spliced transcript variants that encode the same protein. Additionally, a pseudogene has been identified on chromosome 3 for this gene.","There is limited information available on the disease implications of RNF13. However, recent studies have suggested that RNF13 may play a role in cancer progression and metastasis. Specifically, RNF13 has been found to be overexpressed in several types of cancer, including breast, lung, and pancreatic cancer. Targeted drug discovery efforts for RNF13 are currently underway, with a focus on developing small molecule inhibitors that can selectively target RNF13 and inhibit its activity. While there are currently no drugs on the market that specifically target RNF13, several drugs that target related proteins in the RING finger family have been successful in treating cancer. For example, bortezomib, a proteasome inhibitor that targets the RING finger protein RNF5, is used to treat multiple myeloma and mantle cell lymphoma.",GO:0051865 protein autoubiquitination;GO:0046330 positive regulation of JNK cascade;GO:0046328 regulation of JNK cascade,,Human disease related genes:Nervous system diseases:Epilepsy; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Nucleoplasm;Vesicles (Supported); Additional: Cytosol,,,
ENSG00000139163.16,ENSG00000139163,ETNK1,-0.850714965,-0.97082371,-1.030762822,-0.550558364,ethanolamine kinase 1,"ETNK1 is a gene that encodes for an enzyme called ethanolamine kinase 1. This enzyme plays a crucial role in the first step of the phosphatidylethanolamine synthesis pathway. ETNK1 is specific for ethanolamine and does not exhibit significant kinase activity on choline. The gene undergoes alternative splicing, resulting in multiple transcript variants that encode for different isoforms of the enzyme. ETNK1 is located in the cytosol of cells and is essential for the production of phosphatidylethanolamine, a key component of cell membranes.","There is limited information available on the disease implications of ETNK1. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for ETNK1 are still in the early stages, but there is potential for the development of drugs that target this enzyme for the treatment of cancer. One example of a successful drug that targets a related enzyme in the phosphatidylethanolamine synthesis pathway is erlotinib, which is used to treat non-small cell lung cancer. Erlotinib inhibits the activity of the enzyme EGFR, which is involved in the synthesis of phosphatidylethanolamine. Other potential drug targets in this pathway include choline kinase and phosphoethanolamine cytidylyltransferase.",GO:0006646 phosphatidylethanolamine biosynthetic process;GO:0046337 phosphatidylethanolamine metabolic process;GO:0046474 glycerophospholipid biosynthetic process,yes,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Predicted intracellular proteins; Cancer-related genes; ENZYME proteins:Transferases; Enzymes,Cytosol;Nucleoplasm;Plasma membrane (Approved),,,
ENSG00000154305.18,ENSG00000154305,MIA3,-0.849774698,-1.359051904,-0.732191212,-0.458080979,MIA SH3 domain ER export factor 3,"MIA3, also known as MIA SH3 domain ER export factor 3, is a human gene that plays a role in various cellular processes, including the loading of cargo onto COPII-coated vesicles, cell migration involved in sprouting angiogenesis, and regulation of leukocyte migration. It is located in the endoplasmic reticulum exit site and endoplasmic reticulum membrane and is an integral component of the membrane. MIA3 enables cargo receptor activity, which is essential for the proper transport of proteins and other molecules within cells. Overall, MIA3 is an important gene involved in multiple cellular functions and processes.","There is limited information available on the disease implications of MIA3. However, recent studies have suggested that MIA3 may play a role in cancer progression and metastasis. Specifically, MIA3 has been found to be overexpressed in various types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts for MIA3 are still in the early stages, but there is potential for the development of drugs that target MIA3 to inhibit cancer cell growth and metastasis. Currently, there are no drugs on the market that specifically target MIA3. However, there are drugs that target related pathways, such as the COPII pathway, which is involved in the transport of cargo from the endoplasmic reticulum. Examples of drugs that target the COPII pathway include SecinH3 and Sar1 inhibitors, which have shown promise in preclinical studies for the treatment of cancer and other diseases.",GO:0070973 protein localization to endoplasmic reticulum exit site;GO:0140052 cellular response to oxidised low-density lipoprotein particle stimulus;GO:2000402 negative regulation of lymphocyte migration,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Transporters,Vesicles (Enhanced),,,
ENSG00000107862.6,ENSG00000107862,GBF1,-0.849663183,-1.444378672,-0.624238769,-0.480372108,golgi brefeldin A resistant guanine nucleotide exchange factor 1,"GBF1 is a gene that encodes a guanine nucleotide exchange factor, which is responsible for regulating the recruitment of proteins to membranes by mediating GDP to GTP exchange. This protein is localized to the Golgi apparatus and plays a crucial role in vesicular trafficking by activating ADP ribosylation factor 1. Additionally, GBF1 has been identified as an important host factor for viral replication. Multiple transcript variants have been observed for this gene.","GBF1 has been implicated in several diseases, including cancer, Alzheimer's disease, and viral infections. In cancer, GBF1 has been shown to be overexpressed in several types of tumors, including breast, lung, and prostate cancer, and is associated with tumor growth and metastasis. In Alzheimer's disease, GBF1 has been found to be involved in the processing and trafficking of amyloid precursor protein, which is a key component of the disease pathology. In viral infections, GBF1 has been identified as a host factor for several viruses, including hepatitis C virus and enterovirus 71.

Targeted drug discovery efforts for GBF1 have focused on developing small molecule inhibitors that can block its activity. One such inhibitor, Golgicide A, has been shown to inhibit GBF1-mediated vesicular trafficking and has potential as an anti-cancer and anti-viral agent. Another inhibitor, BD750, has been shown to block GBF1 activity and reduce viral replication in cells infected with enterovirus 71.

In summary, GBF1 is a promising target for drug discovery efforts in cancer and viral infections. While there are currently no drugs on the market that directly target GBF1, Golgicide A and BD750 are examples of promising compounds that could lead to the development of new therapies.",GO:1903420 protein localization to endoplasmic reticulum tubular network;GO:0097111 endoplasmic reticulum-Golgi intermediate compartment organization;GO:0035964 COPI-coated vesicle budding,,Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Predicted intracellular proteins,Golgi apparatus (Supported),,(M243)PID ARF 3PATHWAY,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000198887.9,ENSG00000198887,SMC5,-0.849287939,-1.159867246,-1.183085217,-0.204911353,structural maintenance of chromosomes 5,"SMC5 is a human gene that is involved in various biological processes such as DNA recombination, cellular senescence, and regulation of mitotic sister chromatid cohesion. It is predicted to have ATP binding activity and is located in cell junctions, chromosomes, and nuclear bodies. SMC5 is part of the Smc5-Smc6 complex, which is involved in DNA repair and maintenance of genome stability. Dysfunction of SMC5 has been associated with various diseases, including cancer and developmental disorders.","Dysfunction of SMC5 has been associated with various diseases, including cancer and developmental disorders. Targeted drug discovery efforts for SMC5 are still in the early stages, but there is potential for the development of drugs that target the Smc5-Smc6 complex for cancer therapy. One example of a successful drug that targets DNA repair pathways is PARP inhibitors, which have been approved for the treatment of certain types of breast and ovarian cancers. However, there are currently no drugs specifically targeting SMC5 on the market. Further research is needed to fully understand the role of SMC5 in disease and to develop targeted therapies.",GO:0034093 positive regulation of maintenance of sister chromatid cohesion;GO:0034184 positive regulation of maintenance of mitotic sister chromatid cohesion;GO:0034091 regulation of maintenance of sister chromatid cohesion,,Predicted intracellular proteins,Nuclear speckles (Supported),,,
ENSG00000140992.19,ENSG00000140992,PDPK1,-0.849130087,-1.228523647,-0.956928889,-0.361937725,3-phosphoinositide dependent protein kinase 1,"PDPK1 is a human gene that encodes for 3-phosphoinositide dependent protein kinase 1. This gene is involved in various processes such as cell surface receptor signaling pathway, regulation of protein kinase activity, and regulation of signal transduction. PDPK1 enables 3-phosphoinositide-dependent protein kinase activity, phospholipase activator activity, and phospholipase binding activity. It acts upstream of or within intracellular signal transduction and is located in cell projection, cytosol, and plasma membrane. PDPK1 has been implicated in prostate cancer and is a biomarker of lung non-small cell carcinoma.","PDPK1 has been implicated in various diseases, including cancer, diabetes, and cardiovascular diseases. In prostate cancer, PDPK1 is overexpressed and promotes tumor growth and survival. Therefore, PDPK1 inhibitors have been developed as potential therapeutic agents for prostate cancer. One example is GSK2334470, a PDPK1 inhibitor that has shown promising results in preclinical studies. In diabetes, PDPK1 plays a crucial role in insulin signaling, and its activation has been shown to improve glucose homeostasis in animal models. However, no PDPK1-targeted drugs have been approved for diabetes treatment yet. In cardiovascular diseases, PDPK1 has been shown to regulate vascular smooth muscle cell proliferation and migration, making it a potential target for the treatment of atherosclerosis and restenosis. However, no PDPK1-targeted drugs have been approved for cardiovascular diseases either. Overall, PDPK1 is an attractive target for drug discovery efforts, and several inhibitors are currently in preclinical and clinical development for various diseases.",GO:0010518 positive regulation of phospholipase activity;GO:0003323 type B pancreatic cell development;GO:0010517 regulation of phospholipase activity,yes,Kinases:AGC Ser/Thr protein kinases; Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Enhanced); Additional: Primary cilium tip,"Celecoxib; Inositol 1,3,4,5-Tetrakisphosphate; 7-Hydroxystaurosporine; Bisindolylmaleimide VIII; Staurosporine; Bisindolylmaleimide I; Dexfosfoserine; 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine; 5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE; 1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA; 2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine; 3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; Fostamatinib",(M12771)SA PTEN PATHWAY; (M226)PID VEGFR1 PATHWAY; (M1718)SIG IL4RECEPTOR IN B LYPHOCYTES,
ENSG00000088930.8,ENSG00000088930,XRN2,-0.848930928,-1.141692955,-0.950138902,-0.454960926,5'-3' exoribonuclease 2,The XRN2 gene encodes a 5'-3' exonuclease that plays a role in promoting transcription termination at cleavage sites during gene expression. The gene has multiple transcript variants that result in different isoforms.,"Research on the XRN2 gene has revealed its potential involvement in various diseases. For instance, studies have shown that mutations in the XRN2 gene may contribute to the development of cancer, including breast, lung, and ovarian cancers. Additionally, XRN2 has been implicated in neurological disorders such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). As a result, there is growing interest in developing drugs that target XRN2 to treat these diseases.

Several drug discovery efforts have been made to target XRN2. One approach involves the use of small molecule inhibitors that can block the activity of XRN2. Another approach is to develop RNA-based therapies that can target XRN2 mRNA and reduce its expression. While these efforts are still in the early stages, there have been some promising results in preclinical studies.

One example of a successful drug that targets a related gene is Olaparib, which is used to treat ovarian and breast cancers with BRCA1 or BRCA2 mutations. Olaparib targets the PARP enzyme, which is involved in DNA repair and interacts with XRN2. Another example is Rucaparib, which is also used to treat ovarian and breast cancers with BRCA mutations. Rucaparib inhibits the activity of the enzyme poly(ADP-ribose) polymerase (PARP), which interacts with XRN2 and plays a role in DNA repair. These drugs demonstrate the potential for targeting XRN2 in the treatment of cancer.",GO:0006369 termination of RNA polymerase II transcription;GO:0006353 DNA-templated transcription termination;GO:0021766 hippocampus development,,Predicted intracellular proteins,Nucleoli (Enhanced); Additional: Nucleoplasm,,,
ENSG00000122299.12,ENSG00000122299,ZC3H7A,-0.847297253,-0.973530033,-0.94638006,-0.621981667,zinc finger CCCH-type containing 7A,"ZC3H7A is a human gene that encodes a protein called zinc finger CCCH-type containing 7A. This protein is involved in the production of microRNAs (miRNAs) that are responsible for gene silencing. It has been shown to have miRNA binding activity and is predicted to be located in the nucleus. The exact function of ZC3H7A is not fully understood, but it is believed to play a role in regulating gene expression through miRNA-mediated pathways. Further research is needed to fully understand the function of this gene and its potential implications for human health and disease.","There is limited information available on the disease implications of ZC3H7A. However, recent studies have suggested that mutations in this gene may be associated with intellectual disability and developmental delay. Targeted drug discovery efforts for ZC3H7A are currently limited due to the lack of understanding of its exact function and role in disease. There are currently no drugs on the market that specifically target ZC3H7A. However, there are drugs that target miRNA-mediated pathways, which may indirectly affect the function of ZC3H7A. For example, Miravirsen is a drug that targets miR-122, a liver-specific miRNA, and has been approved for the treatment of hepatitis C virus infection. Further research is needed to fully understand the potential implications of ZC3H7A for drug discovery and development.",GO:0035196 miRNA processing;GO:0070918 regulatory ncRNA processing;GO:0031047 regulatory ncRNA-mediated gene silencing,,Predicted intracellular proteins,Cytosol (Supported),,,
ENSG00000166734.20,ENSG00000166734,GOLM2,-0.847071055,-1.436175862,-1.023405812,-0.081631491,golgi membrane protein 2,"GOLM2 is a gene that encodes for a protein found in the Golgi apparatus, a cellular organelle involved in protein processing and sorting. Overexpression of GOLM2 has been linked to the overexpression of the HER-2/neu proto-oncogene, which is found in a significant percentage of breast and ovarian cancers. Different isoforms of the GOLM2 protein have been identified due to alternative splicing of the gene.","Research has shown that GOLM2 overexpression is associated with poor prognosis in various types of cancer, including breast, ovarian, lung, and liver cancer. Therefore, GOLM2 has been proposed as a potential therapeutic target for cancer treatment. Several studies have investigated the use of GOLM2-targeted therapies, including monoclonal antibodies and small molecule inhibitors, to inhibit cancer cell growth and induce cell death. However, there are currently no drugs targeting GOLM2 on the market. Nonetheless, some drugs targeting other proteins involved in the same signaling pathways as GOLM2 have shown promising results in clinical trials. For example, trastuzumab and lapatinib are FDA-approved drugs that target HER-2/neu, which is overexpressed in some breast and ovarian cancers due to GOLM2 overexpression.",,,Predicted intracellular proteins,Golgi apparatus (Enhanced),,,
ENSG00000126581.13,ENSG00000126581,BECN1,-0.846921272,-0.958622056,-1.508746128,-0.073395631,beclin 1,"BECN1, also known as beclin 1, is a human gene that encodes a protein involved in regulating autophagy, a process of cellular degradation induced by starvation. The protein is a component of the phosphatidylinositol-3-kinase (PI3K) complex, which mediates vesicle-trafficking processes. BECN1 is believed to play a role in various cellular processes, including tumorigenesis, neurodegeneration, and apoptosis. Alternative splicing of the gene results in multiple transcript variants.","BECN1 has been implicated in various diseases, including cancer, neurodegeneration, and infectious diseases. In cancer, BECN1 is often downregulated, leading to impaired autophagy and increased tumor growth. Therefore, targeting BECN1 and autophagy has been explored as a potential therapeutic strategy for cancer. Several drugs targeting autophagy are currently in clinical trials, including chloroquine and hydroxychloroquine, which inhibit autophagy by blocking lysosomal acidification. In neurodegenerative diseases, BECN1 has been shown to play a role in the clearance of misfolded proteins, and enhancing autophagy has been proposed as a potential therapeutic strategy. However, there are currently no drugs targeting BECN1 specifically for neurodegenerative diseases. In infectious diseases, BECN1 has been shown to play a role in the clearance of intracellular pathogens, and targeting autophagy has been explored as a potential therapeutic strategy. However, there are currently no drugs targeting BECN1 specifically for infectious diseases.",GO:0039519 modulation by virus of host autophagy;GO:0039521 suppression by virus of host autophagy;GO:0071275 cellular response to aluminum ion,,Predicted intracellular proteins; Transporters,Cytosol (Supported); Additional: Nuclear bodies,Estradiol; Estradiol acetate; Estradiol benzoate; Estradiol cypionate; Estradiol dienanthate; Estradiol valerate,,
ENSG00000115145.10,ENSG00000115145,STAM2,-0.846567964,-1.217277303,-0.726075354,-0.596351236,signal transducing adaptor molecule 2,"STAM2, or signal transducing adaptor molecule 2, is a protein that is closely related to STAM, another adaptor protein involved in downstream signaling of cytokine receptors. Both STAM and STAM2 contain a SH3 domain and the immunoreceptor tyrosine-based activation motif (ITAM). STAM2 acts downstream of JAK kinases and is phosphorylated in response to cytokine stimulation. It is believed that STAM2 and STAM have compensatory effects on the signaling pathway downstream of JAK kinases upon cytokine stimulation.","There is limited information available on the disease implications of STAM2. However, some studies have suggested that STAM2 may play a role in the development of certain types of cancer, including breast cancer and leukemia. Targeted drug discovery efforts for STAM2 are also limited, as the protein is not currently considered a major drug target. However, some research has focused on developing inhibitors of JAK kinases, which are upstream regulators of STAM2 signaling. Several JAK inhibitors have been approved for the treatment of various autoimmune diseases, including rheumatoid arthritis and psoriasis. Examples of JAK inhibitors on the market include tofacitinib (Xeljanz) and baricitinib (Olumiant).",GO:0043328 protein transport to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway;GO:0032511 late endosome to vacuole transport via multivesicular body sorting pathway;GO:0036258 multivesicular body assembly,,Predicted intracellular proteins,Vesicles (Supported); Additional: Cytosol;Nucleoplasm,,(M122)PID IL2 1PATHWAY,(M5897)HALLMARK IL6 JAK STAT3 SIGNALING; (M5951)HALLMARK SPERMATOGENESIS
ENSG00000131013.4,ENSG00000131013,PPIL4,-0.846170388,-0.831942531,-1.260252876,-0.446315756,peptidylprolyl isomerase like 4,"PPIL4 is a gene that belongs to the cyclophilin family of peptidylprolyl isomerases. This family is highly conserved and plays a crucial role in protein folding, immunosuppression by cyclosporin A, and HIV-1 virion infection. PPIL4 is a peptidylprolyl isomerase-like protein that is expressed in various tissues, including the brain, heart, and liver. Its exact function is not yet fully understood, but it is believed to be involved in protein folding and regulation of the immune system. Mutations in this gene have been associated with various diseases, including cancer and autoimmune disorders.","There is limited information available on the disease implications of PPIL4. However, studies have shown that mutations in this gene are associated with various diseases, including cancer and autoimmune disorders. For example, a study found that PPIL4 is overexpressed in breast cancer and may play a role in tumor progression. Additionally, another study found that PPIL4 is involved in the regulation of T-cell activation and may contribute to the development of autoimmune disorders.

There are currently no targeted drug discovery efforts specifically for PPIL4. However, as a member of the cyclophilin family, PPIL4 may be a potential target for drugs that modulate protein folding and immune system regulation. Cyclosporin A, a drug that targets cyclophilins, is currently used as an immunosuppressant in organ transplantation and has also shown promise in the treatment of autoimmune disorders.

Overall, more research is needed to fully understand the role of PPIL4 in disease and to identify potential drug targets.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Enzymes; ENZYME proteins:Isomerase; Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Cytosol,,,
ENSG00000072364.13,ENSG00000072364,AFF4,-0.845851289,-1.304902515,-0.263263078,-0.969388272,ALF transcription elongation factor 4,AFF4 is a human gene that belongs to the AF4 family of transcription factors involved in leukemia. It is a component of the positive transcription elongation factor b (P-TEFb) complex. A chromosomal translocation involving this gene and MLL gene on chromosome 11 is found in infant acute lymphoblastic leukemia with ins(5;11)(q31;q31q23). This gene is responsible for encoding the ALF transcription elongation factor 4.,"The AFF4 gene has been implicated in various types of leukemia, including infant acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The chromosomal translocation involving AFF4 and MLL gene is a common genetic abnormality found in infant ALL. Targeted drug discovery efforts have focused on developing inhibitors of the P-TEFb complex, which includes AFF4, as a potential treatment for leukemia. One example of a successful drug targeting this pathway is the CDK9 inhibitor, dinaciclib, which has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of AML and other types of cancer. Another potential drug target is the AF4 domain of AFF4, which has been shown to be essential for the interaction with P-TEFb and transcriptional elongation. Small molecule inhibitors targeting this domain are currently being developed as potential therapeutics for leukemia and other diseases.",GO:0007286 spermatid development;GO:0048515 spermatid differentiation;GO:0034976 response to endoplasmic reticulum stress,,Disease related genes; Cancer-related genes; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Nucleoplasm (Supported); Additional: Nuclear bodies;Nucleoli fibrillar center,,,
ENSG00000167962.14,ENSG00000167962,ZNF598,-0.845506985,-1.157437924,-0.907961555,-0.471121475,"zinc finger protein 598, E3 ubiquitin ligase","ZNF598 is a human gene that encodes for a zinc finger protein, which binds to nucleic acids and plays a crucial role in various cellular functions such as cell proliferation, differentiation, and apoptosis. It has been identified as a component of the mammalian 4EHP complex, along with Grb10-interacting GYF protein 2. The complex is believed to function as a translation repressor during embryonic development. ZNF598 is also an E3 ubiquitin ligase, which means it plays a role in the degradation of proteins by attaching ubiquitin molecules to them. This gene is important for understanding the regulation of protein synthesis and degradation in cells.","There is limited information available on the disease implications of ZNF598. However, recent studies have suggested that dysregulation of ZNF598 expression may be associated with various types of cancer, including breast cancer, lung cancer, and hepatocellular carcinoma. Targeted drug discovery efforts for ZNF598 are still in the early stages, but there is potential for the development of drugs that target the E3 ubiquitin ligase activity of ZNF598. Currently, there are no drugs on the market that specifically target ZNF598. However, there are drugs that target the ubiquitin-proteasome system, which is the pathway through which ZNF598 mediates protein degradation. Examples of such drugs include bortezomib, carfilzomib, and ixazomib, which are used to treat multiple myeloma and mantle cell lymphoma.",GO:1990116 ribosome-associated ubiquitin-dependent protein catabolic process;GO:0045947 negative regulation of translational initiation;GO:0072344 rescue of stalled ribosome,,Predicted intracellular proteins,Cytosol;Plasma membrane (Approved),,,
ENSG00000137831.15,ENSG00000137831,UACA,-0.845359541,-1.027337318,-0.769141889,-0.739599415,uveal autoantigen with coiled-coil domains and ankyrin repeats,"The UACA gene encodes a protein that contains ankyrin repeats and coiled coil domains and is involved in apoptosis. Studies in rodents suggest that the protein stimulates apoptosis and regulates mammary gland involution. However, experiments in human cell lines indicate that the protein may negatively regulate apoptosis by interacting with the PRKC apoptosis WT1 regulator protein and inhibiting translocation of the PAR-4 receptor. Autoantibodies to this protein have been found in patients with panuveitis and Graves' disease. The gene is differentially expressed in various human cancers.","There is limited information available on targeted drug discovery efforts for the UACA gene. However, the differential expression of the gene in various human cancers suggests that it may have potential as a therapeutic target. Additionally, the presence of autoantibodies to the UACA protein in patients with panuveitis and Graves' disease suggests that it may play a role in autoimmune disorders.

Currently, there are no drugs on the market that specifically target the UACA gene or protein. However, there are several drugs that target apoptosis, which is a process that the UACA protein is involved in regulating. For example, the chemotherapy drug paclitaxel induces apoptosis in cancer cells by stabilizing microtubules and preventing cell division. Another example is the BCL-2 inhibitor venetoclax, which is used to treat chronic lymphocytic leukemia by promoting apoptosis in cancer cells.

In conclusion, while there is limited information available on targeted drug discovery efforts for the UACA gene, its involvement in apoptosis and differential expression in various human cancers suggest that it may have potential as a therapeutic target. Currently, there are no drugs on the market that specifically target UACA, but there are several drugs that target apoptosis and may be effective in treating diseases where UACA plays a role.",GO:0008631 intrinsic apoptotic signaling pathway in response to oxidative stress;GO:1901223 negative regulation of non-canonical NF-kappaB signal transduction;GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000088812.18,ENSG00000088812,ATRN,-0.845017096,-1.213450343,-0.977767005,-0.343833941,attractin,"The ATRN gene encodes for both membrane-bound and secreted protein isoforms. The membrane-bound isoform is similar to the mouse mahogany protein, which is involved in controlling obesity. The secreted isoform plays a role in the initial clustering of immune cells during inflammatory responses and may regulate the activity of chemokines.","The ATRN gene has been implicated in several diseases, including obesity, type 2 diabetes, and cancer. Targeted drug discovery efforts have focused on developing drugs that can modulate the activity of the ATRN protein isoforms. One example is the development of small molecule inhibitors that can block the activity of the secreted isoform, which may have potential therapeutic applications in inflammatory diseases. Another example is the use of monoclonal antibodies that can target the membrane-bound isoform, which may have potential applications in the treatment of obesity and related metabolic disorders. Currently, there are no drugs on the market that specifically target the ATRN gene, but ongoing research in this area may lead to the development of novel therapeutics in the future.",GO:0040014 regulation of multicellular organism growth;GO:0043473 pigmentation;GO:0021549 cerebellum development,,Predicted secreted proteins,Cytosol (Approved),,,(M5942)HALLMARK UV RESPONSE DN
ENSG00000113658.18,ENSG00000113658,SMAD5,-0.844767646,-0.662597749,-0.918561871,-0.953143318,SMAD family member 5,"SMAD5 is a gene that plays a role in the transforming growth factor beta signaling pathway, which inhibits the proliferation of hematopoietic progenitor cells. It is activated by bone morphogenetic proteins type 1 receptor kinase and may be involved in cancer. Alternative splicing of the gene results in multiple transcript variants.","SMAD5 has been implicated in various diseases, including cancer, cardiovascular disease, and bone disorders. In cancer, SMAD5 has been shown to promote tumor growth and metastasis in several types of cancer, including breast, lung, and pancreatic cancer. Targeted drug discovery efforts have focused on developing inhibitors of the TGF-beta signaling pathway, which includes SMAD5. Several drugs targeting this pathway have been approved for the treatment of cancer, including the monoclonal antibody, Trastuzumab, which targets the HER2 receptor in breast cancer, and the small molecule inhibitor, Vismodegib, which targets the Hedgehog signaling pathway in basal cell carcinoma. Other drugs targeting the TGF-beta pathway are currently in clinical trials for various types of cancer.",GO:1902045 negative regulation of Fas signaling pathway;GO:0002051 osteoblast fate commitment;GO:0001880 Mullerian duct regression,,Predicted intracellular proteins; Transcription factors:beta-Hairpin exposed by an alpha/beta-scaffold,Nucleoplasm (Supported); Additional: Cytosol,,(M203)PID ALK2 PATHWAY; (M185)PID ALK1 PATHWAY; (M181)PID BMP PATHWAY,(M5898)HALLMARK DNA REPAIR
ENSG00000170185.10,ENSG00000170185,USP38,-0.844664596,-1.311359395,-0.832486968,-0.390147426,ubiquitin specific peptidase 38,"USP38 is a human gene that encodes for a protein called ubiquitin specific peptidase 38. This protein is involved in the process of deubiquitination, which is the removal of ubiquitin molecules from proteins. USP38 is predicted to be active in both the cytosol and nucleus of cells. It functions as a thiol-dependent deubiquitinase, meaning that it requires a specific type of amino acid called a thiol to carry out its enzymatic activity. Overall, USP38 plays an important role in regulating protein function and turnover within cells.","There is limited information available on the disease implications of USP38. However, recent studies have suggested that USP38 may play a role in the development and progression of certain types of cancer, including breast cancer and lung cancer. As a result, there has been some interest in developing drugs that target USP38 as a potential therapeutic strategy for these types of cancer. 

Currently, there are no drugs on the market that specifically target USP38. However, there are several drugs that target other proteins involved in the ubiquitin-proteasome system, which is the cellular pathway that regulates protein turnover and degradation. For example, bortezomib is a drug that targets the proteasome and is used to treat multiple myeloma. Carfilzomib is another proteasome inhibitor that is used to treat relapsed or refractory multiple myeloma. These drugs have shown promising results in clinical trials and have been approved by the FDA for use in certain cancer patients.",GO:1990168 protein K33-linked deubiquitination;GO:0032435 negative regulation of proteasomal ubiquitin-dependent protein catabolic process;GO:2000059 negative regulation of ubiquitin-dependent protein catabolic process,,Peptidases:Cysteine-type peptidases; ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Centrosome;Cytosol,,,
ENSG00000145495.16,ENSG00000145495,MARCHF6,-0.844600295,-1.286895833,-0.612053375,-0.634851677,membrane associated ring-CH-type finger 6,"MARCHF6 is a gene that encodes a type of E3 ubiquitin ligase, which contains RING-CH-type zinc finger motifs and is associated with the membrane. The protein encoded by this gene plays a crucial role in regulating thyroid hormone signaling by ubiquitinating type II deiodinase. Multiple isoforms of this gene have been observed due to alternative splicing of its transcript variants.","Research on MARCHF6 has primarily focused on its role in regulating thyroid hormone signaling, and its potential implications in thyroid-related diseases such as hypothyroidism and hyperthyroidism. However, there is limited information available on the direct involvement of MARCHF6 in disease pathogenesis. 

As of now, there are no targeted drug discovery efforts specifically aimed at MARCHF6. However, given its role in thyroid hormone signaling, drugs targeting this pathway may indirectly affect MARCHF6 activity. For example, levothyroxine, a synthetic form of thyroid hormone, is commonly used to treat hypothyroidism. Additionally, drugs that inhibit the activity of type II deiodinase, which is ubiquitinated by MARCHF6, may also indirectly affect MARCHF6 activity. 

One example of a drug that inhibits type II deiodinase is propylthiouracil, which is used to treat hyperthyroidism. Another example is iopanoic acid, which is used to treat hyperthyroidism by inhibiting the conversion of T4 to T3 by type II deiodinase. However, it is important to note that these drugs have multiple targets and may have additional effects beyond their inhibition of type II deiodinase.","GO:1904380 endoplasmic reticulum mannose trimming;GO:0036507 protein demannosylation;GO:0036508 protein alpha-1,2-demannosylation",,Human disease related genes:Nervous system diseases:Epilepsy; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Endoplasmic reticulum (Supported),,,(M5934)HALLMARK XENOBIOTIC METABOLISM
ENSG00000002834.18,ENSG00000002834,LASP1,-0.844522916,-1.599472766,-0.76575415,-0.168341832,LIM and SH3 protein 1,"LASP1 is a gene that encodes a protein belonging to the LIM protein subfamily and the nebulin family of actin-binding proteins. The protein is involved in cAMP and cGMP dependent signaling and binds to the actin cytoskeleton at extensions of the cell membrane. LASP1 has been linked to various types of cancer, including metastatic breast cancer, hematopoietic tumors such as B-cell lymphomas, and colorectal cancer.","LASP1 has been identified as a potential therapeutic target for cancer treatment due to its involvement in cancer progression and metastasis. Several studies have shown that targeting LASP1 can inhibit cancer cell migration and invasion, making it an attractive target for drug discovery efforts. One example of a drug targeting LASP1 is the small molecule inhibitor, LLL12, which has been shown to inhibit LASP1 expression and reduce cancer cell migration and invasion in preclinical studies. Another potential drug target is the LASP1-binding protein, zyxin, which has been shown to play a role in cancer cell migration and invasion. However, there are currently no FDA-approved drugs targeting LASP1 for cancer treatment. Further research is needed to fully understand the role of LASP1 in cancer and to develop effective therapies targeting this protein.",GO:0034220 monoatomic ion transmembrane transport;GO:0006811 monoatomic ion transport;GO:0055085 transmembrane transport,,Cancer-related genes; Predicted intracellular proteins,Cytosol;Plasma membrane (Supported); Additional: Focal adhesion sites,,,
ENSG00000002586.20,ENSG00000002586,CD99,-0.844369999,-1.220824705,-0.693489856,-0.618795435,CD99 molecule (Xg blood group),"CD99 is a gene that encodes a cell surface glycoprotein involved in various cellular processes such as leukocyte migration, T-cell adhesion, and transmembrane protein transport. It is also involved in T-cell death through a caspase-independent pathway and may act as an oncosuppressor in osteosarcoma. CD99 is located in the pseudoautosomal region of chromosomes X and Y and escapes X-chromosome inactivation. A related pseudogene is located adjacent to this gene.","CD99 has been implicated in various diseases, including osteosarcoma, Ewing's sarcoma, and leukemia. In osteosarcoma, CD99 has been shown to act as an oncosuppressor, and its downregulation is associated with poor prognosis. Targeted drug discovery efforts have focused on developing CD99-targeting therapies for these cancers. One example is the monoclonal antibody, huN12-9.3, which targets CD99 and has shown promising results in preclinical studies for Ewing's sarcoma. Another example is the small molecule inhibitor, Ewing sarcoma inhibitor 1 (ESI-1), which targets the interaction between CD99 and its binding partner, EWS-FLI1, and has shown efficacy in preclinical studies for Ewing's sarcoma. However, there are currently no CD99-targeting drugs on the market.",GO:2000391 positive regulation of neutrophil extravasation;GO:0072683 T cell extravasation;GO:2000389 regulation of neutrophil extravasation,,CD markers; Predicted intracellular proteins,Golgi apparatus (Approved),,,(M5915)HALLMARK APICAL JUNCTION
ENSG00000180182.11,ENSG00000180182,MED14,-0.844362386,-1.166877911,-0.779934967,-0.586274279,mediator complex subunit 14,"MED14 is a human gene that encodes a subunit of the CRSP complex, which is required for efficient activation of transcription by SP1. It is also a component of other multisubunit complexes, such as thyroid hormone receptor-associated proteins, which facilitate the function of thyroid hormone receptors on DNA templates. MED14 contains a bipartite nuclear localization signal and is known to escape chromosome X-inactivation. The activation of gene transcription is a multistep process that involves factors recognizing transcriptional enhancer sites in DNA and working with co-activators to direct transcriptional initiation by the RNA polymerase II apparatus.","There is limited information available on the disease implications of MED14 mutations. However, recent studies have suggested that MED14 may play a role in the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for MED14 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and disrupt its function in cancer cells. While there are currently no drugs on the market that specifically target MED14, several drugs that target other components of the transcriptional machinery, such as RNA polymerase II inhibitors and histone deacetylase inhibitors, have shown promise in preclinical studies and clinical trials for the treatment of various types of cancer.","GO:0032968 positive regulation of transcription elongation by RNA polymerase II;GO:0035019 somatic stem cell population maintenance;GO:0032786 positive regulation of DNA-templated transcription, elongation",,Predicted intracellular proteins,Nuclear bodies (Supported); Additional: Nucleoplasm;Vesicles,,,
ENSG00000118873.16,ENSG00000118873,RAB3GAP2,-0.844356516,-1.103409167,-0.823331626,-0.606328756,RAB3 GTPase activating non-catalytic protein subunit 2,"RAB3GAP2 is a gene that belongs to the RAB3 protein family and is primarily expressed in the brain. It forms the Rab3 GTPase-activating complex with RAB3GAP1, where it acts as the regulatory subunit, while RAB3GAP1 functions as the catalytic subunit. This gene plays a crucial role in neurodevelopment, and mutations in it are associated with Martsolf syndrome. The RAB3 protein family is involved in the regulated exocytosis of neurotransmitters and hormones.","Mutations in the RAB3GAP2 gene have been linked to Martsolf syndrome, a rare genetic disorder characterized by developmental delay, intellectual disability, and various physical abnormalities. There are currently no targeted drug discovery efforts specifically for RAB3GAP2, but research is ongoing to better understand the role of this gene in neurodevelopment and to identify potential therapeutic targets. Some drugs that target the RAB3 protein family, such as botulinum toxin, have been successful in treating conditions such as muscle spasms and dystonia. However, these drugs do not specifically target RAB3GAP2 and are not used to treat Martsolf syndrome. Overall, more research is needed to develop targeted therapies for RAB3GAP2-related disorders.",GO:0097051 establishment of protein localization to endoplasmic reticulum membrane;GO:1903373 positive regulation of endoplasmic reticulum tubular network organization;GO:0050747 positive regulation of lipoprotein metabolic process,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Cytosol (Supported); Additional: Plasma membrane,,,
ENSG00000008256.16,ENSG00000008256,CYTH3,-0.842575798,-1.344751348,-1.098583489,-0.084392557,cytohesin 3,"CYTH3, also known as cytohesin 3, is a gene that belongs to the PSCD family. This family consists of proteins that have a coiled-coil motif, a Sec7 domain, and a pleckstrin homology (PH) domain. The coiled-coil motif is involved in homodimerization, the Sec7 domain contains guanine-nucleotide exchange protein (GEP) activity, and the PH domain interacts with phospholipids and is responsible for association of PSCDs with membranes. CYTH3 is involved in regulating Golgi structure and function, and it may also have a role in regulating ADP-ribosylation factor protein 6 (ARF) functions, in addition to acting on ARF1. Overall, members of the PSCD family appear to mediate the regulation of protein sorting and membrane trafficking.","There is limited information available on the disease implications of CYTH3. However, studies have suggested that CYTH3 may play a role in cancer progression and metastasis. For example, one study found that CYTH3 expression was upregulated in breast cancer cells and that knockdown of CYTH3 inhibited cell migration and invasion. 

There are currently no targeted drug discovery efforts specifically focused on CYTH3. However, there are drugs on the market that target other members of the PSCD family, such as cytohesin 2. One example is SecinH3, a small molecule inhibitor of cytohesin 2 that has been shown to inhibit cancer cell migration and invasion in vitro and in vivo. 

Overall, more research is needed to fully understand the disease implications of CYTH3 and to develop targeted therapies for diseases associated with dysregulation of this gene.",GO:0032012 regulation of ARF protein signal transduction;GO:0090162 establishment of epithelial cell polarity;GO:0030010 establishment of cell polarity,,Predicted intracellular proteins,Cytosol (Supported); Additional: Nucleoplasm,"Inositol 1,3,4,5-Tetrakisphosphate; Inositol-(1,3,4,5,6)-Pentakisphosphate",(M86)PID ARF6 PATHWAY; (M1315)SIG PIP3 SIGNALING IN B LYMPHOCYTES; (M141)PID PI3KCI PATHWAY,
ENSG00000102221.14,ENSG00000102221,JADE3,-0.841868987,-1.187925832,-0.638825169,-0.698855959,jade family PHD finger 3,JADE3 is a human gene that encodes a large protein containing PHD-type zinc fingers. This protein may be involved in a nuclear complex that plays a role in histone H4 acetylation. Alternative splicing of the gene results in multiple transcript variants that encode the same protein.,"There is limited information available on the disease implications of JADE3. However, research has suggested that the protein encoded by this gene may play a role in cancer development and progression. Specifically, JADE3 has been found to be overexpressed in several types of cancer, including breast, lung, and liver cancer. This overexpression has been associated with increased tumor growth and metastasis.

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target JADE3. However, there is ongoing research into the development of drugs that target the histone acetylation pathway, which JADE3 is believed to be involved in. These drugs could potentially be used to treat cancer and other diseases.

One example of a successful drug that targets the histone acetylation pathway is Vorinostat, which is used to treat cutaneous T-cell lymphoma. Vorinostat inhibits the activity of histone deacetylases, leading to increased histone acetylation and changes in gene expression. Another example is Romidepsin, which is also used to treat cutaneous T-cell lymphoma. Romidepsin works by inhibiting histone deacetylases and promoting apoptosis in cancer cells.

Overall, while there is still much to learn about the role of JADE3 in disease, research into the histone acetylation pathway and related drugs could hold promise for the development of new treatments for cancer and other diseases.",GO:2000278 regulation of DNA biosynthetic process;GO:0006275 regulation of DNA replication;GO:0001558 regulation of cell growth,,Predicted intracellular proteins,Nucleoli;Nucleoplasm (Approved),,,
ENSG00000177119.16,ENSG00000177119,ANO6,-0.841634758,-1.235217966,-1.01548625,-0.274200059,anoctamin 6,"The ANO6 gene encodes a transmembrane protein that is part of the anoctamin family. This protein is crucial for the exposure of phosphatidylserine on the cell surface in a calcium-dependent manner. Phospholipid scrambling occurs in various biological systems, such as when blood platelets are activated, and they expose phosphatidylserine to trigger the clotting system. Mutations in this gene are linked to Scott syndrome. Different isoforms of the protein are produced due to alternative splicing of the transcript variants.","Mutations in the ANO6 gene have been linked to Scott syndrome, a rare bleeding disorder characterized by impaired blood clotting. Individuals with Scott syndrome have a defect in the ability of their blood platelets to expose phosphatidylserine on their surface, which is necessary for the activation of the clotting system. There are currently no targeted drug discovery efforts specifically for ANO6, but there are drugs on the market that target the clotting system, such as anticoagulants and antiplatelet agents. Examples of successful drugs on the market include warfarin, heparin, and aspirin. These drugs are used to prevent and treat blood clots in various conditions, such as deep vein thrombosis, pulmonary embolism, and stroke. However, these drugs can also increase the risk of bleeding, which can be a concern for individuals with bleeding disorders like Scott syndrome.",GO:0097045 phosphatidylserine exposure on blood platelet;GO:0002543 activation of blood coagulation via clotting cascade;GO:0061589 calcium activated phosphatidylserine scrambling,,Disease related genes; Transporters:Transporter channels and pores; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Potential drug targets,Cytosol;Plasma membrane (Approved),,,
ENSG00000213551.7,ENSG00000213551,DNAJC9,-0.841224884,-1.321530571,-0.848859012,-0.353285068,DnaJ heat shock protein family (Hsp40) member C9,"DNAJC9 is a member of the DnaJ heat shock protein family (Hsp40) that plays a role in chaperone binding, heat shock protein binding, and histone binding activities. It is involved in nucleosome assembly and positive regulation of ATPase activity. DNAJC9 is located in various cellular components, including cytosol, extracellular space, and nucleoplasm. It is also part of a chaperone complex.","There is limited information available on the disease implications of DNAJC9. However, recent studies have suggested that mutations in this gene may be associated with neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease. Targeted drug discovery efforts for DNAJC9 are currently underway, with a focus on identifying small molecule inhibitors that can modulate its activity and potentially treat these diseases. While there are currently no drugs on the market that specifically target DNAJC9, there are several drugs that target other members of the DnaJ heat shock protein family, such as the Hsp90 inhibitor, ganetespib, which is used in clinical trials for various types of cancer. Additionally, the Hsp70 inhibitor, VER-155008, has shown promise in preclinical studies for the treatment of neurodegenerative diseases.",GO:0032781 positive regulation of ATP-dependent activity;GO:0043462 regulation of ATP-dependent activity;GO:0006334 nucleosome assembly,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol;Plasma membrane,,,
ENSG00000145817.17,ENSG00000145817,YIPF5,-0.840868108,-1.098276761,-0.803274746,-0.621052818,Yip1 domain family member 5,"YIPF5, also known as Yip1 domain family member 5, is a gene that is predicted to play a role in the transport of vesicles from the endoplasmic reticulum to the Golgi apparatus. It is also involved in regulating this transport process and in the fusion of vesicles with the Golgi apparatus. YIPF5 is located in the Golgi apparatus, endoplasmic reticulum, and nucleoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of YIPF5. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for YIPF5 are also limited, as the exact role of this gene in disease pathogenesis is not well understood. However, some studies have suggested that targeting YIPF5 may be a potential strategy for inhibiting cancer cell growth and proliferation. Currently, there are no drugs on the market that specifically target YIPF5. However, there are several drugs that target the transport of vesicles from the endoplasmic reticulum to the Golgi apparatus, which is a process that YIPF5 is predicted to be involved in. Examples of such drugs include brefeldin A and golgicide A.",GO:0030070 insulin processing;GO:0048280 vesicle fusion with Golgi apparatus;GO:0060628 regulation of ER to Golgi vesicle-mediated transport,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system,Endoplasmic reticulum;Golgi apparatus;Vesicles (Supported); Additional: Nucleoplasm,,,
ENSG00000126804.13,ENSG00000126804,ZBTB1,-0.840631745,-0.986597461,-1.11191683,-0.423380944,zinc finger and BTB domain containing 1,"ZBTB1 is a human gene that encodes a protein containing both zinc finger and BTB domains. This protein is involved in various cellular processes, including the response to UV radiation and the biosynthesis of nucleobase-containing compounds. ZBTB1 is also capable of binding to proteins through K63-linked polyubiquitin modification, as well as through homodimerization and heterodimerization. The protein is located in the centrosome, nuclear body, and nuclear membrane.","There is limited information available on the disease implications of ZBTB1. However, recent studies have suggested that ZBTB1 may play a role in the development and progression of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ZBTB1 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target ZBTB1, there are several drugs that have been approved for the treatment of breast cancer and hepatocellular carcinoma that may indirectly affect ZBTB1 activity. For example, tamoxifen, a selective estrogen receptor modulator, is commonly used to treat breast cancer and has been shown to downregulate ZBTB1 expression in breast cancer cells. Sorafenib, a multi-kinase inhibitor, is approved for the treatment of hepatocellular carcinoma and has been shown to inhibit ZBTB1 expression in liver cancer cells.",GO:2000174 regulation of pro-T cell differentiation;GO:2000176 positive regulation of pro-T cell differentiation;GO:1905458 positive regulation of lymphoid progenitor cell differentiation,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nuclear membrane,,,
ENSG00000173273.16,ENSG00000173273,TNKS,-0.840627142,-1.222037692,-0.973310617,-0.326533117,tankyrase,"TNKS, also known as tankyrase, is a human gene that encodes a protein with histone binding, pentosyltransferase, and zinc ion binding activities. It is involved in various biological processes, including negative regulation of mitotic sister chromatid cohesion maintenance, telomeric regulation, and nucleobase-containing compound metabolic processes. TNKS acts upstream or within peptidyl-serine phosphorylation, peptidyl-threonine phosphorylation, and protein ADP-ribosylation. It is located in different cellular components, including the telomeric region of chromosomes, mitotic spindle poles, and the nucleus. These findings suggest that TNKS plays a crucial role in regulating various cellular processes and may have implications in disease development and treatment.","TNKS has been implicated in various diseases, including cancer, diabetes, and neurological disorders. In cancer, TNKS is involved in the regulation of telomere length and Wnt signaling, making it a potential target for cancer therapy. Several small molecule inhibitors of TNKS have been developed and are currently being evaluated in clinical trials for the treatment of various cancers, including breast, ovarian, and colorectal cancer. One such drug, called PARP inhibitor, has been approved for the treatment of ovarian and breast cancer. In addition, TNKS inhibitors have also shown promise in the treatment of neurological disorders, such as Alzheimer's disease and Parkinson's disease. However, further research is needed to fully understand the role of TNKS in these diseases and to develop effective therapies.","GO:1904743 negative regulation of telomeric DNA binding;GO:1904742 regulation of telomeric DNA binding;GO:1904907 regulation of maintenance of mitotic sister chromatid cohesion, telomeric",,Enzymes; Transporters:Transporter channels and pores; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Approved); Additional: Nuclear bodies;Nuclear membrane,,(M105)PID TELOMERASE PATHWAY,
ENSG00000102595.20,ENSG00000102595,UGGT2,-0.840511876,-1.393080989,-0.669455684,-0.458998954,UDP-glucose glycoprotein glucosyltransferase 2,"UGGT2 is a human gene that encodes for UDP-glucose glycoprotein glucosyltransferase 2, a protein that plays a crucial role in quality control for protein transport out of the endoplasmic reticulum (ER). UGGT2 selectively reglucosylates unfolded glycoproteins, ensuring that only properly folded proteins are transported out of the ER. This process helps to prevent the accumulation of misfolded proteins, which can lead to cellular dysfunction and disease. UGGT2 is a soluble protein that is located in the ER and is essential for maintaining proper protein folding and quality control in the cell.","There is limited information on the disease implications of UGGT2 mutations. However, studies have shown that UGGT2 plays a role in the development of cancer, as it is involved in the quality control of glycoproteins that are important for cell signaling and growth. Targeted drug discovery efforts for UGGT2 have focused on developing inhibitors that can selectively block its activity, with the goal of disrupting the quality control process and inducing cell death in cancer cells. One example of a successful drug targeting UGGT2 is Tunicamycin, which is a natural product that inhibits the enzyme's activity by binding to its active site. Tunicamycin has been used in research to study the role of UGGT2 in protein quality control and has potential as a therapeutic agent for cancer treatment. However, further research is needed to fully understand the implications of UGGT2 mutations and to develop effective targeted therapies.",GO:0097359 UDP-glucosylation;GO:0006011 UDP-alpha-D-glucose metabolic process;GO:1904380 endoplasmic reticulum mannose trimming,,Predicted intracellular proteins,,,,
ENSG00000163428.4,ENSG00000163428,LRRC58,-0.840445839,-0.688472048,-0.83784885,-0.995016618,leucine rich repeat containing 58,"LRRC58 is a human gene that encodes a protein containing leucine-rich repeats, which are involved in protein-protein interactions. The function of this gene is not well understood, but it has been suggested to play a role in the regulation of cell growth and differentiation. Mutations in this gene have been associated with various diseases, including cancer and developmental disorders. Further research is needed to fully understand the function of LRRC58 and its potential implications for human health.","Unfortunately, there is limited information available on the disease implications and targeted drug discovery efforts for LRRC58. As mentioned earlier, mutations in this gene have been associated with various diseases, including cancer and developmental disorders. However, there are no known drugs that specifically target LRRC58. 

In general, drug discovery efforts for cancer and developmental disorders often focus on targeting specific pathways or proteins that are known to be involved in the disease. For example, drugs that target the epidermal growth factor receptor (EGFR) pathway have been successful in treating certain types of cancer, such as non-small cell lung cancer. However, it is unclear if LRRC58 plays a significant enough role in these diseases to be a viable drug target.

Overall, more research is needed to fully understand the function of LRRC58 and its potential implications for human health, as well as to identify potential drug targets and develop effective treatments.",GO:0035556 intracellular signal transduction;GO:0007165 signal transduction;GO:0023052 signaling,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000104221.13,ENSG00000104221,BRF2,-0.840203011,-1.0564563,-0.954481345,-0.509671386,BRF2 general transcription factor IIIB subunit,BRF2 is a gene that encodes a subunit of the RNA polymerase III transcription factor complex. This complex is necessary for the transcription of genes that have promoter elements upstream of the initiation site. The product of this gene is a TFIIB-like factor that is recruited to the TATA-box of polymerase III small nuclear RNA gene promoters through its interaction with the TATA-binding protein. This gene is important for the proper functioning of RNA polymerase III and the transcription of specific genes.,"There is limited information available on the disease implications of BRF2 mutations. However, recent studies have suggested that BRF2 may play a role in cancer development and progression. Specifically, BRF2 has been found to be overexpressed in several types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts for BRF2 are still in the early stages, but there is potential for the development of drugs that target BRF2 expression or activity as a cancer therapy. Currently, there are no drugs on the market that specifically target BRF2, but there are several drugs that target RNA polymerase III, such as Mycophenolic acid and Azathioprine, which are used as immunosuppressants in transplant patients. These drugs inhibit the activity of RNA polymerase III, which indirectly affects BRF2 function.",GO:0006359 regulation of transcription by RNA polymerase III;GO:0070897 transcription preinitiation complex assembly;GO:0006352 DNA-templated transcription initiation,,Predicted intracellular proteins,Nucleoli (Supported),,,(M5898)HALLMARK DNA REPAIR
ENSG00000101972.19,ENSG00000101972,STAG2,-0.840088379,-1.211467678,-0.84860328,-0.46019418,STAG2 cohesin complex component,"STAG2 is a gene that encodes a subunit of the cohesin complex, which is responsible for regulating the separation of sister chromatids during cell division. When this gene is inactivated, it can lead to defects in chromatid cohesion and aneuploidy, which is an abnormal number of chromosomes in a cell. This suggests that disruptions in the cohesin complex can be a cause of aneuploidy in human cancer. Different isoforms of the gene have been identified through alternative splicing.","Mutations in the STAG2 gene have been implicated in several types of cancer, including bladder cancer, glioblastoma, and Ewing sarcoma. In bladder cancer, STAG2 mutations have been associated with higher tumor grade and stage, as well as worse patient outcomes. Targeted drug discovery efforts have focused on developing inhibitors of the cohesin complex, which could potentially be used to treat cancers with STAG2 mutations. One example is the drug ATR-101, which targets the cohesin complex and has shown promising results in preclinical studies for the treatment of Ewing sarcoma. Another example is the drug volasertib, which targets the kinase activity of the cohesin regulator PLK1 and has been approved for the treatment of acute myeloid leukemia. However, more research is needed to fully understand the role of STAG2 in cancer and to develop effective targeted therapies.",GO:0034087 establishment of mitotic sister chromatid cohesion;GO:0034085 establishment of sister chromatid cohesion;GO:0007064 mitotic sister chromatid cohesion,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Nucleoli;Nucleoli fibrillar center;Nucleoplasm (Supported),,(M129)PID PLK1 PATHWAY,
ENSG00000136870.10,ENSG00000136870,ZNF189,-0.839026512,-1.109510781,-1.029339698,-0.378229058,zinc finger protein 189,"ZNF189 is a human gene that encodes for a zinc finger protein. This protein belongs to the Kruppel-like zinc finger family, which contains a conserved stretch of 7 amino acids that connects a variable number of DNA-binding zinc finger repeats of the cys(2)his(2) (C2H2) type. About 30% of Kruppel-like zinc finger proteins in humans contain an N-terminal Kruppel-associated box (KRAB) domain, which consists of approximately 75 amino acids that may be subdivided into an A box and a B box. The A box is present in every KRAB domain and is essential for transcriptional repression, while the B box is not always present.","There is limited information available on the disease implications of ZNF189. However, some studies have suggested that it may play a role in cancer development and progression. For example, one study found that ZNF189 expression was significantly upregulated in breast cancer tissues compared to normal tissues. Additionally, ZNF189 has been identified as a potential therapeutic target for acute myeloid leukemia (AML) due to its involvement in the regulation of hematopoietic stem cell differentiation.

There are currently no targeted drug discovery efforts specifically focused on ZNF189. However, there are several drugs on the market that target other members of the Kruppel-like zinc finger family, such as the thalidomide analogs lenalidomide and pomalidomide, which are used to treat multiple myeloma and myelodysplastic syndromes. These drugs work by binding to the C2H2 zinc finger domains of Kruppel-like zinc finger proteins and inducing their degradation, leading to anti-tumor effects. It is possible that similar drugs could be developed to target ZNF189 or other Kruppel-like zinc finger proteins involved in cancer development and progression.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Intermediate filaments (Approved),,,
ENSG00000111647.13,ENSG00000111647,UHRF1BP1L,-0.838906381,-1.095927312,-0.826032716,-0.594759116,bridge-like lipid transfer protein family member 3B,BLTP3B is a human gene that belongs to the bridge-like lipid transfer protein family member 3B. It plays a crucial role in enabling GARP complex binding activity and protein homodimerization activity. The gene is located in the cytosol and early endosome. This information has been provided by the Alliance of Genome Resources in April 2022.,"There is limited information available on the disease implications and targeted drug discovery efforts for BLTP3B. However, some studies have suggested that the gene may be involved in the development and progression of certain cancers, including breast cancer and lung cancer. Targeted drug discovery efforts for BLTP3B are currently underway, with researchers exploring potential small molecule inhibitors that could selectively target the protein and inhibit its activity. As of now, there are no drugs on the market that specifically target BLTP3B. However, there are several drugs that have been approved for the treatment of breast and lung cancer, including chemotherapy agents, targeted therapies, and immunotherapies. These drugs target various molecular pathways involved in cancer development and progression, and may indirectly impact BLTP3B activity.","GO:0034498 early endosome to Golgi transport;GO:0120009 intermembrane lipid transfer;GO:0042147 retrograde transport, endosome to Golgi",,Predicted intracellular proteins,Nucleoplasm (Uncertain); Additional: Cytosol;Vesicles,,,
ENSG00000165322.18,ENSG00000165322,ARHGAP12,-0.838527151,-1.207817554,-0.93382557,-0.373938328,Rho GTPase activating protein 12,ARHGAP12 is a gene that encodes a protein that activates enzymes involved in the metabolism of Rho-type guanosine triphosphate (GTP). This protein may play a role in suppressing tumor formation by regulating cell invasion and adhesion. The gene has multiple isoforms due to alternative splicing of its transcript variants.,"There is limited information available on the disease implications of ARHGAP12. However, some studies have suggested that alterations in the expression of this gene may be associated with the development and progression of certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for ARHGAP12 are also limited, but some studies have identified potential small molecule inhibitors that could target the protein encoded by this gene. One example is a compound called NSC23766, which has been shown to inhibit the activity of the protein and reduce cell migration and invasion in cancer cells. However, there are currently no drugs on the market that specifically target ARHGAP12.","GO:0006911 phagocytosis, engulfment;GO:0099024 plasma membrane invagination;GO:0150052 regulation of postsynapse assembly",,Predicted intracellular proteins,,,,
ENSG00000187325.5,ENSG00000187325,TAF9B,-0.837747532,-1.362366993,-0.727115331,-0.423760273,TATA-box binding protein associated factor 9b,"TAF9B is a gene that encodes a protein that is a subunit of TFIID, a complex of proteins that coordinates the initiation of transcription by RNA polymerase II. TFIID binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TAF9B is similar to TBP-associated factor 9, a small subunit of TFIID, and shares some functions but also has distinct roles in the transcriptional regulatory process. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation.","There is limited information available on the disease implications of TAF9B. However, some studies have suggested that TAF9B may play a role in the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TAF9B are also limited, as the function of this gene is not yet fully understood. However, some researchers are exploring the potential of TAF9B as a therapeutic target for cancer treatment. Currently, there are no drugs on the market that specifically target TAF9B. However, there are several drugs that target other components of the transcriptional machinery, such as RNA polymerase inhibitors and histone deacetylase inhibitors, which have been successful in treating certain types of cancer.",GO:1902166 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator;GO:1902165 regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator;GO:1902254 negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator,,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000115170.15,ENSG00000115170,ACVR1,-0.837708731,-1.276151214,-1.036453963,-0.200521017,activin A receptor type 1,"ACVR1 is a human gene that encodes the activin A type I receptor, which is involved in signaling a specific transcriptional response in conjunction with activin type II receptors. Activins are growth and differentiation factors that belong to the TGF-beta superfamily of signaling proteins. The activin A receptor type 1 is a transmembrane protein that consists of a ligand-binding extracellular domain, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling, while type II receptors are required for ligand binding and expression of type I receptors. Mutations in ACVR1 are associated with fibrodysplasia ossificans progressive.","Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder caused by mutations in the ACVR1 gene. FOP is characterized by the formation of heterotopic bone in muscles, tendons, and ligaments, leading to progressive loss of mobility and eventually death. There is currently no cure for FOP, and treatment options are limited to managing symptoms. Targeted drug discovery efforts have focused on inhibiting the ACVR1 receptor to prevent the formation of heterotopic bone. One promising drug candidate is the monoclonal antibody, REGN2477, which has shown efficacy in preclinical studies. Other potential drug targets include BMP signaling pathways and inflammatory cytokines. Currently, there are no drugs approved specifically for the treatment of FOP, but some drugs used to manage symptoms include corticosteroids, bisphosphonates, and nonsteroidal anti-inflammatory drugs.",GO:0060957 endocardial cell fate commitment;GO:0061445 endocardial cushion cell fate commitment;GO:0061443 endocardial cushion cell differentiation,yes,Predicted intracellular proteins; Kinases:TKL Ser/Thr protein kinases; Cancer-related genes; Human disease related genes:Musculoskeletal diseases:Skeletal diseases; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,,ATP; Dorsomorphin; Fostamatinib,(M203)PID ALK2 PATHWAY; (M185)PID ALK1 PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING
ENSG00000163374.19,ENSG00000163374,YY1AP1,-0.836431068,-1.046371661,-0.897025939,-0.565895605,YY1 associated protein 1,"YY1AP1 is a human gene that encodes a protein that is believed to interact with YY1 protein, although its precise function is not yet understood. The gene undergoes alternative splicing, resulting in the production of multiple transcript variants that encode different isoforms of the protein. The gene's function and potential role in human health and disease are still being studied.","There is limited information available on the disease implications of YY1AP1. However, some studies have suggested that it may play a role in cancer development and progression. For example, one study found that YY1AP1 expression was upregulated in breast cancer tissues and was associated with poor prognosis. Additionally, another study found that YY1AP1 was overexpressed in hepatocellular carcinoma and may promote tumor growth and metastasis.

As for targeted drug discovery efforts, there is currently no known drug that specifically targets YY1AP1. However, some drugs that target YY1, the protein that YY1AP1 is believed to interact with, have been developed. For example, the drug JQ1 is a small molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, including YY1. JQ1 has shown promise in preclinical studies for the treatment of various cancers, including breast cancer and hepatocellular carcinoma.

In conclusion, while the precise function and disease implications of YY1AP1 are still being studied, there is some evidence to suggest that it may play a role in cancer development and progression. While there are currently no drugs that specifically target YY1AP1, drugs that target YY1, such as JQ1, have shown promise in preclinical studies for the treatment of various cancers.",GO:0008283 cell population proliferation;GO:0051726 regulation of cell cycle;GO:0030154 cell differentiation,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Nucleoli fibrillar center (Approved),,,
ENSG00000110367.13,ENSG00000110367,DDX6,-0.83625896,-1.47548546,-0.717372372,-0.315919049,DEAD-box helicase 6,"DDX6, also known as DEAD-box helicase 6, is a gene that encodes a protein belonging to the DEAD box protein family. This protein is an RNA helicase that is found in P-bodies and stress granules, and it plays a role in suppressing translation and degrading mRNA. It is also necessary for microRNA-induced gene silencing. There are multiple variants of the gene that have been identified, but they all encode the same protein.","DDX6 has been implicated in several diseases, including cancer, viral infections, and neurodegenerative disorders. In cancer, DDX6 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. In viral infections, DDX6 plays a role in the replication of certain viruses, such as hepatitis C virus, making it a potential target for antiviral drugs. In neurodegenerative disorders, DDX6 has been linked to the formation of protein aggregates, such as those seen in Alzheimer's disease, suggesting a potential role in disease pathogenesis.

There have been efforts to develop drugs that target DDX6, particularly in the context of cancer therapy. One approach has been to develop small molecule inhibitors that block the ATPase activity of DDX6, which is necessary for its function as an RNA helicase. Another approach has been to target the interaction between DDX6 and specific RNA molecules, such as microRNAs, which are involved in gene regulation.

Currently, there are no drugs on the market that specifically target DDX6. However, there are several drugs that indirectly affect DDX6 function, such as ribavirin, which is used to treat hepatitis C virus infection and has been shown to inhibit DDX6 activity. Additionally, several drugs that target other members of the DEAD box protein family, such as pateamine A and hippuristanol, have shown promise in preclinical studies as potential cancer therapeutics.",GO:0019072 viral genome packaging;GO:0019074 viral RNA genome packaging;GO:0033962 P-body assembly,,Predicted intracellular proteins; Cancer-related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Cytoplasmic bodies (Supported); Additional: Cytosol;Plasma membrane,D-tartaric acid,,
ENSG00000095383.20,ENSG00000095383,TBC1D2,-0.835764372,-1.183457177,-0.878899322,-0.444936618,TBC1 domain family member 2,"TBC1D2 is a human gene that belongs to the TBC1 domain family member 2. It plays a role in enabling GTPase activator activity and cadherin binding activity, and is involved in positive regulation of GTPase activity. TBC1D2 is located in various cellular components, including cytoplasmic vesicle, cytosol, and nucleoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of TBC1D2. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. 

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target TBC1D2. However, there is ongoing research into the development of small molecule inhibitors that could potentially target the protein encoded by this gene. 

One example of a successful targeted therapy for cancer is trastuzumab, which targets the HER2 protein and is used to treat HER2-positive breast cancer. Another example is imatinib, which targets the BCR-ABL protein and is used to treat chronic myeloid leukemia. While these drugs do not target TBC1D2 specifically, they demonstrate the potential for targeted therapies to be effective in treating certain types of cancer.",GO:0043547 positive regulation of GTPase activity;GO:0043087 regulation of GTPase activity;GO:0051345 positive regulation of hydrolase activity,,Predicted intracellular proteins,Cytosol;Nucleoplasm;Plasma membrane (Approved),,,
ENSG00000163935.14,ENSG00000163935,SFMBT1,-0.835103278,-0.785167763,-0.580409975,-1.139732095,Scm like with four mbt domains 1,The SFMBT1 gene is similar to the Drosophila Scm gene and encodes a protein with four mbt domains. It is believed to be involved in antigen recognition.,"There is limited information available on the disease implications of SFMBT1 gene mutations. However, some studies have suggested that alterations in SFMBT1 expression may be associated with certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for SFMBT1 are also limited, as the function of the protein encoded by this gene is not well understood. However, some studies have suggested that SFMBT1 may play a role in epigenetic regulation, which could make it a potential target for epigenetic therapies. Currently, there are no drugs on the market that specifically target SFMBT1. However, there are several epigenetic drugs that have been approved for the treatment of cancer, including histone deacetylase inhibitors and DNA methyltransferase inhibitors, which may indirectly affect SFMBT1 function. Further research is needed to fully understand the role of SFMBT1 in disease and to develop targeted therapies for SFMBT1-related conditions.",GO:0048635 negative regulation of muscle organ development;GO:0048634 regulation of muscle organ development;GO:0007283 spermatogenesis,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,(M5942)HALLMARK UV RESPONSE DN
ENSG00000149313.11,ENSG00000149313,AASDHPPT,-0.834411302,-1.214163914,-1.065504767,-0.223565224,aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase,"The AASDHPPT gene encodes a protein that is similar to LYS5 in yeast, which is necessary for the activation of alpha-aminoadipate dehydrogenase in the lysine biosynthetic pathway. The human gene is thought to be involved in pipecolic acidemia, a condition caused by defects in the breakdown of pipecolic acid. The protein produced by AASDHPPT is an aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase, which plays a role in the conversion of alpha-biosynthetic-aminoadipate semialdehyde to alpha-aminoadipate.","Pipecolic acidemia is a rare autosomal recessive disorder caused by mutations in the AASDHPPT gene. This condition is characterized by an accumulation of pipecolic acid in the blood and tissues, leading to neurological symptoms such as seizures, developmental delay, and intellectual disability. There is currently no cure for pipecolic acidemia, and treatment is mainly supportive, focusing on managing symptoms and preventing complications.

Targeted drug discovery efforts for pipecolic acidemia are ongoing, with a focus on developing therapies that can reduce the accumulation of pipecolic acid in the body. One approach is to target the AASDHPPT enzyme itself, either by inhibiting its activity or by increasing its expression. Another approach is to target downstream enzymes in the lysine biosynthetic pathway, which may help to reduce the accumulation of pipecolic acid.

There are currently no drugs on the market specifically approved for the treatment of pipecolic acidemia. However, there are several drugs that have been used off-label to manage symptoms associated with the condition. For example, antiepileptic drugs such as valproic acid and levetiracetam may be used to control seizures, while physical therapy and occupational therapy may be used to manage developmental delays and motor impairments.",GO:0009085 lysine biosynthetic process;GO:0019878 lysine biosynthetic process via aminoadipic acid;GO:0009258 10-formyltetrahydrofolate catabolic process,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,,,,
ENSG00000181555.21,ENSG00000181555,SETD2,-0.834213116,-1.250213355,-0.88759206,-0.364833934,"SET domain containing 2, histone lysine methyltransferase","SETD2 is a human gene that encodes a histone lysine methyltransferase, which is specific for lysine-36 of histone H3. Methylation of this residue is associated with active chromatin. The protein also contains a novel transcriptional activation domain and has been found associated with hyperphosphorylated RNA polymerase II. This gene is a member of a class of huntingtin interacting proteins characterized by WW motifs. Mutations in SETD2 have been associated with several types of cancer, including clear cell renal cell carcinoma, leukemia, and breast cancer. The gene has also been implicated in the development of Huntington's disease, a neurodegenerative disorder characterized by loss of striatal neurons.","SETD2 mutations have been identified in several types of cancer, including clear cell renal cell carcinoma, leukemia, and breast cancer. These mutations are associated with poor prognosis and resistance to chemotherapy. Therefore, targeting SETD2 has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of SETD2 have been developed and tested in preclinical studies, including UNC0379 and UNC0638. These inhibitors have shown promising results in reducing tumor growth and increasing sensitivity to chemotherapy in preclinical models. However, no SETD2 inhibitors have been approved for clinical use yet. In addition to cancer, SETD2 has also been implicated in the development of Huntington's disease, a neurodegenerative disorder. However, there are currently no targeted drug discovery efforts for SETD2 in the context of Huntington's disease.",GO:0035441 cell migration involved in vasculogenesis;GO:0018023 peptidyl-lysine trimethylation;GO:0010793 regulation of mRNA export from nucleus,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Nuclear speckles (Approved); Additional: Cytosol,,,
ENSG00000166326.7,ENSG00000166326,TRIM44,-0.833854628,-1.512994023,-0.478502774,-0.510067087,tripartite motif containing 44,"TRIM44 is a gene that belongs to the tripartite motif (TRIM) family. The TRIM motif consists of three zinc-binding domains, including a RING, a B-box type 1, a B-box type 2, and a coiled-coil region. The function of TRIM44 is not yet fully understood, but it has been suggested to play a role in the regulation of cell growth and differentiation. Studies have also shown that TRIM44 may be involved in the development of certain types of cancer, such as breast cancer and lung cancer. Further research is needed to fully understand the role of TRIM44 in human biology and disease.","There is limited information available on the disease implications of TRIM44, but studies have suggested that it may play a role in the development and progression of certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for TRIM44 are still in the early stages, and there are currently no drugs on the market that specifically target this gene. However, there are several drugs that have been approved for the treatment of breast cancer and lung cancer that may indirectly affect TRIM44, such as tamoxifen and trastuzumab for breast cancer, and gefitinib and erlotinib for lung cancer. Further research is needed to fully understand the potential therapeutic implications of targeting TRIM44 in cancer treatment.",GO:0061944 negative regulation of protein K48-linked ubiquitination;GO:0061945 regulation of protein K48-linked ubiquitination;GO:1902915 negative regulation of protein polyubiquitination,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of eye; Predicted intracellular proteins,Vesicles (Approved); Additional: Plasma membrane,,,
ENSG00000163946.13,ENSG00000163946,TASOR,-0.833761661,-1.44542258,-0.795758673,-0.260103732,transcription activation suppressor,TASOR is a human gene that plays a role in regulating gene expression and inhibiting the replication of single-stranded viral RNA through double-stranded DNA intermediates. It is involved in protein localization to heterochromatin and has chromatin binding activity. TASOR is located in both the nucleoplasm and heterochromatin.,"There is limited information available on the disease implications of TASOR. However, recent studies have suggested that mutations in TASOR may be associated with the development of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TASOR are still in the early stages, but there is potential for the development of drugs that target the gene's role in regulating gene expression and inhibiting viral replication. Currently, there are no drugs on the market that specifically target TASOR. However, there are drugs that target related pathways, such as histone deacetylase inhibitors, which have been approved for the treatment of certain types of cancer. Further research is needed to fully understand the potential therapeutic implications of targeting TASOR.",GO:0060809 mesodermal to mesenchymal transition involved in gastrulation;GO:0097355 protein localization to heterochromatin;GO:0007351 tripartite regional subdivision,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000213866.3,ENSG00000213866,YBX1P10,-0.833119944,-1.04513625,-1.186392515,-0.267831066,None,None,None,None,None,None,None,None,None,None
ENSG00000187189.11,ENSG00000187189,TSPYL4,-0.833109465,-1.364329644,-0.762771284,-0.372227467,TSPY like 4,"TSPYL4 is a human gene that is predicted to have chromatin binding and histone binding activity. It is also predicted to be involved in nucleosome assembly and active in chromatin and nucleus. The gene is similar to TSPY, which is located on the Y chromosome and is involved in spermatogenesis. However, TSPYL4 is located on chromosome 6 and its function is not yet fully understood. Further research is needed to determine the exact role of TSPYL4 in chromatin organization and gene regulation.","There is limited information available on the disease implications of TSPYL4. However, some studies have suggested that it may be involved in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TSPYL4 are currently limited, as its exact role in disease pathogenesis is not yet fully understood. There are currently no drugs on the market that specifically target TSPYL4. However, there are several drugs that target chromatin organization and gene regulation, which may indirectly affect TSPYL4 function. Examples of such drugs include histone deacetylase inhibitors and DNA methyltransferase inhibitors, which are used in the treatment of various types of cancer. Further research is needed to determine the potential therapeutic implications of targeting TSPYL4 in disease treatment.",GO:0006334 nucleosome assembly;GO:0034728 nucleosome organization;GO:0065004 protein-DNA complex assembly,,Predicted intracellular proteins,,,,
ENSG00000182934.12,ENSG00000182934,SRPRA,-0.832185758,-1.550615741,-0.766805589,-0.179135943,SRP receptor subunit alpha,"The SRPRA gene encodes a subunit of the endoplasmic reticulum signal recognition particle receptor. This receptor, along with the signal recognition particle, is responsible for targeting and translocating secretory and membrane proteins across the endoplasmic reticulum. Alternative splicing of the gene results in multiple transcript variants.","There is limited information available on the disease implications of the SRPRA gene. However, mutations in other genes involved in the endoplasmic reticulum signal recognition pathway have been associated with various diseases, including diabetes, cancer, and neurodegenerative disorders. Therefore, it is possible that mutations in SRPRA could also contribute to the development of these diseases.

As for targeted drug discovery efforts, there is currently no known drug specifically targeting the SRPRA gene. However, drugs targeting other components of the endoplasmic reticulum signal recognition pathway, such as the signal recognition particle and its receptor, are being developed for various diseases. For example, the drug Teprotumumab targets the insulin-like growth factor 1 receptor, which is involved in the signal recognition pathway, and is used to treat thyroid eye disease. Another drug, Lumateperone, targets the signal recognition particle receptor and is used to treat schizophrenia.

In conclusion, while there is limited information available on the disease implications of the SRPRA gene, drugs targeting other components of the endoplasmic reticulum signal recognition pathway have shown success in treating various diseases. Further research on the role of SRPRA in disease development may lead to the development of new targeted therapies.","GO:0006617 SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition;GO:0006614 SRP-dependent cotranslational protein targeting to membrane;GO:0006613 cotranslational protein targeting to membrane",,Predicted intracellular proteins,,,,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000165417.12,ENSG00000165417,GTF2A1,-0.831516859,-1.189484252,-0.988904184,-0.316162142,general transcription factor IIA subunit 1,"GTF2A1 is a gene that encodes for a subunit of the general transcription factor IIA, which is involved in the accurate initiation of transcription on TATA-containing class II genes. This process requires the ordered assembly of RNA polymerase II and several general initiation factors, including TFIIA. TFIIA is composed of three subunits, including the 35-, 19-, and 12-kD subunits, which have been purified from HeLa extracts. GTF2A1 is responsible for encoding the 35-kD subunit of TFIIA.","Mutations in the GTF2A1 gene have been associated with various diseases, including breast cancer, ovarian cancer, and leukemia. In breast cancer, GTF2A1 has been found to be overexpressed, leading to increased cell proliferation and tumor growth. Targeted drug discovery efforts have focused on developing inhibitors of TFIIA to disrupt its function in cancer cells. One example is the small molecule inhibitor, triptolide, which has been shown to inhibit TFIIA and induce apoptosis in cancer cells. Another example is the drug, flavopiridol, which targets multiple transcription factors, including TFIIA, and has shown promising results in clinical trials for leukemia and other cancers. Overall, targeting TFIIA and GTF2A1 may provide a novel approach for cancer therapy.",GO:0051123 RNA polymerase II preinitiation complex assembly;GO:0060261 positive regulation of transcription initiation by RNA polymerase II;GO:2000144 positive regulation of DNA-templated transcription initiation,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000135363.12,ENSG00000135363,LMO2,-0.831449219,-1.338989683,-0.627099247,-0.528258728,LIM domain only 2,"LMO2 is a gene that encodes a protein with two LIM domains and is essential for the development of red blood cells in the yolk sac. The protein plays a crucial role in hematopoietic development and is highly conserved. The gene is located downstream from the 11p13 T-cell translocation cluster, where specific translocations occur in T-cell acute lymphoblastic leukemia. Alternative splicing of the gene results in multiple transcript variants that encode different isoforms of the protein.","LMO2 has been implicated in various types of cancer, including T-cell acute lymphoblastic leukemia (T-ALL), B-cell non-Hodgkin lymphoma, and acute myeloid leukemia (AML). In T-ALL, LMO2 is often involved in chromosomal translocations that result in its overexpression, leading to the development of leukemia. Targeted drug discovery efforts have focused on inhibiting LMO2 expression or activity as a potential treatment for these cancers. One approach has been to develop small molecule inhibitors that disrupt the interaction between LMO2 and its binding partners, such as LDB1. Another strategy has been to use RNA interference or gene editing techniques to specifically target LMO2 expression in cancer cells. While there are currently no drugs on the market that directly target LMO2, several drugs have been approved for the treatment of T-ALL and other cancers that may indirectly affect LMO2 activity, such as chemotherapy agents and targeted therapies that inhibit signaling pathways involved in cancer cell growth and survival.",GO:0045944 positive regulation of transcription by RNA polymerase II;GO:0045893 positive regulation of DNA-templated transcription;GO:1902680 positive regulation of RNA biosynthetic process,,Disease related genes; Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Cancer-related genes; Predicted intracellular proteins,Nucleoplasm (Approved),,,(M5957)HALLMARK PANCREAS BETA CELLS; (M5945)HALLMARK HEME METABOLISM
ENSG00000165406.16,ENSG00000165406,MARCHF8,-0.831235003,-1.211795333,-0.767595274,-0.514314402,membrane associated ring-CH-type finger 8,"MARCHF8 is a gene that belongs to the MARCH family of membrane-bound E3 ubiquitin ligases. These enzymes add ubiquitin to target lysines in substrate proteins, signaling their vesicular transport between membrane compartments. MARCHF8 induces the internalization of several membrane glycoproteins.","MARCHF8 has been implicated in several diseases, including cancer, viral infections, and autoimmune disorders. In cancer, MARCHF8 has been shown to regulate the expression of several oncogenic proteins, including EGFR and PD-L1, making it a potential target for cancer therapy. In viral infections, MARCHF8 has been shown to play a role in the immune response to viral infections, making it a potential target for antiviral drugs. In autoimmune disorders, MARCHF8 has been shown to regulate the expression of several immune-related proteins, making it a potential target for immunomodulatory drugs.

Several drug discovery efforts have been focused on targeting MARCHF8. One approach is to develop small molecule inhibitors that can block the activity of MARCHF8. Another approach is to develop monoclonal antibodies that can bind to and neutralize MARCHF8. Some successful drugs on the market that target MARCHF8 include cetuximab, which is used to treat certain types of cancer, and nivolumab, which is used to treat melanoma and other types of cancer. These drugs work by blocking the activity of MARCHF8 and other proteins that regulate the immune response.",GO:0002495 antigen processing and presentation of peptide antigen via MHC class II;GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II;GO:0048002 antigen processing and presentation of peptide antigen,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,,,,(M5945)HALLMARK HEME METABOLISM
ENSG00000060339.14,ENSG00000060339,CCAR1,-0.830546099,-0.930536838,-0.852248259,-0.708853198,cell division cycle and apoptosis regulator 1,"CCAR1, also known as cell division cycle and apoptosis regulator 1, is a gene that plays a role in regulating various cellular processes. It enables specific DNA binding activity and acts as a coactivator or corepressor of transcription. CCAR1 is involved in promoting cell migration and proliferation, and is also involved in the regulation of apoptosis. It is located in the nuclear envelope lumen.","CCAR1 has been implicated in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, CCAR1 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. Targeted drug discovery efforts have focused on developing small molecule inhibitors of CCAR1, with promising results in preclinical studies. One example is the compound CCAR1i, which has been shown to inhibit the growth of breast cancer cells in vitro and in vivo. Another example is the compound GSK2830371, which has been shown to inhibit the growth of lung cancer cells in vitro and in vivo. However, there are currently no drugs targeting CCAR1 on the market. Further research is needed to fully understand the role of CCAR1 in disease and to develop effective therapies targeting this gene.",GO:0006511 ubiquitin-dependent protein catabolic process;GO:0019941 modification-dependent protein catabolic process;GO:0043632 modification-dependent macromolecule catabolic process,,Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Golgi apparatus,,,
ENSG00000155729.13,ENSG00000155729,KCTD18,-0.830425365,-0.898767307,-1.030837005,-0.561671783,potassium channel tetramerization domain containing 18,"KCTD18 is a human gene that is predicted to be involved in protein homooligomerization. The gene encodes a protein that contains a potassium channel tetramerization domain. The function of this protein is not yet fully understood, but it is thought to play a role in the formation of protein complexes. The gene is located on chromosome 19 and has been associated with several diseases, including cancer and neurological disorders. Further research is needed to fully understand the function of KCTD18 and its potential role in disease.","There is limited information available on the disease implications of KCTD18. However, some studies have suggested that the gene may be involved in the development of certain types of cancer, including breast cancer and glioblastoma. Additionally, mutations in KCTD18 have been associated with neurological disorders such as epilepsy and intellectual disability.

As of now, there are no targeted drug discovery efforts specifically focused on KCTD18. However, given its potential role in disease, it is possible that future research may identify KCTD18 as a target for drug development.

There are currently no drugs on the market that target KCTD18. However, there are several drugs that target potassium channels, which are related to the function of KCTD18. For example, potassium channel blockers such as amiodarone and dofetilide are used to treat cardiac arrhythmias. Additionally, potassium channel openers such as minoxidil are used to treat hypertension.",GO:0051260 protein homooligomerization;GO:0051259 protein complex oligomerization;GO:0065003 protein-containing complex assembly,,Predicted intracellular proteins,Mitochondria (Approved),,,
ENSG00000112624.12,ENSG00000112624,BICRAL,-0.829282815,-1.098280517,-0.861681389,-0.527886539,BICRA like chromatin remodeling complex associated protein,"BICRAL is a human gene that is predicted to play a role in the positive regulation of transcription, DNA-templated. It is also a part of the SWI/SNF complex, which is involved in chromatin remodeling. BICRAL is a chromatin remodeling complex associated protein, similar to BICRA.","There is limited information available on the disease implications of BICRAL. However, mutations in the SWI/SNF complex, which BICRAL is a part of, have been associated with various cancers, including ovarian, lung, and breast cancer. Targeted drug discovery efforts for BICRAL are also limited, as it is a relatively new gene with little known about its specific functions and interactions. Currently, there are no drugs on the market that specifically target BICRAL. However, there are drugs that target other components of the SWI/SNF complex, such as EZH2 inhibitors, which have shown promise in treating certain types of cancer. Further research is needed to fully understand the role of BICRAL in disease and to develop targeted therapies.",GO:1902459 positive regulation of stem cell population maintenance;GO:2000036 regulation of stem cell population maintenance;GO:0045596 negative regulation of cell differentiation,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000105323.17,ENSG00000105323,HNRNPUL1,-0.82891589,-1.426563166,-0.688029016,-0.372155486,heterogeneous nuclear ribonucleoprotein U like 1,HNRNPUL1 is a gene that encodes a nuclear RNA-binding protein belonging to the hnRNP family. This protein binds to adenovirus early-1B-55kDa oncoprotein and may play a crucial role in nucleocytoplasmic RNA transport. The function of HNRNPUL1 is modulated by early-1B-55kDa in adenovirus-infected cells.,"There is limited information available on the disease implications of HNRNPUL1. However, recent studies have suggested that mutations in this gene may be associated with neurodevelopmental disorders such as autism spectrum disorder (ASD) and intellectual disability (ID). Targeted drug discovery efforts for HNRNPUL1 are currently underway, with a focus on identifying small molecule inhibitors that can modulate the function of this protein. While there are no drugs currently on the market that specifically target HNRNPUL1, there are several drugs that target other hnRNP family members, such as Eteplirsen, which is used to treat Duchenne muscular dystrophy by targeting hnRNP A1. Additionally, several drugs that target RNA-binding proteins are currently in clinical trials for various diseases, including cancer and neurodegenerative disorders.","GO:0000380 alternative mRNA splicing, via spliceosome;GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;GO:0000398 mRNA splicing, via spliceosome",,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000158615.9,ENSG00000158615,PPP1R15B,-0.82857429,-0.949000423,-0.951884241,-0.584838206,protein phosphatase 1 regulatory subunit 15B,"PPP1R15B is a gene that encodes a protein phosphatase I-interacting protein. This protein promotes the dephosphorylation of eukaryotic translation initiation factor 2A to regulate translation under conditions of cellular stress. The mRNA transcribed from this gene contains two upstream open reading frames that repress translation of the main protein coding ORF under normal conditions. However, the protein coding ORF is expressed at high levels in response to stress. This gene is also involved in membrane traffic that is independent of translation and is required for exocytosis from erythroleukemia cells. Allelic variants of this gene are associated with microcephaly, short stature, and impaired glucose metabolism.","There is limited information available on targeted drug discovery efforts for PPP1R15B. However, allelic variants of this gene have been associated with several diseases. For example, a missense mutation in PPP1R15B has been linked to microcephaly, a condition characterized by a smaller than normal head size and brain development. Additionally, variants in this gene have been associated with short stature and impaired glucose metabolism. 

Currently, there are no drugs on the market that specifically target PPP1R15B. However, there are drugs that indirectly affect the protein's function. For example, salubrinal, a small molecule inhibitor of eIF2? dephosphorylation, has been shown to induce endoplasmic reticulum stress and apoptosis in cancer cells. This drug indirectly affects PPP1R15B's function by inhibiting the dephosphorylation of eIF2?, which is regulated by PPP1R15B. 

In summary, PPP1R15B is associated with several diseases, including microcephaly, short stature, and impaired glucose metabolism. While there are no drugs on the market that specifically target this gene, there are drugs that indirectly affect its function. Further research is needed to fully understand the role of PPP1R15B in disease and to develop targeted therapies.",GO:0006983 ER overload response;GO:1903898 negative regulation of PERK-mediated unfolded protein response;GO:1903897 regulation of PERK-mediated unfolded protein response,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Golgi apparatus (Approved),,,(M5905)HALLMARK ADIPOGENESIS
ENSG00000068383.19,ENSG00000068383,INPP5A,-0.828410611,-0.948943774,-1.004170987,-0.532117071,inositol polyphosphate-5-phosphatase A,"INPP5A is a gene that encodes a type I inositol 1,4,5-trisphosphate (InsP3) 5-phosphatase protein. This protein is located in the cell membrane and is responsible for hydrolyzing Ins(1,4,5)P3, which is a second messenger that mobilizes intracellular calcium and mediates cell responses to various stimuli. The function of INPP5A is important in regulating intracellular calcium levels and cellular responses to external signals.","Mutations in the INPP5A gene have been associated with a variety of diseases, including cancer, neurological disorders, and immune system dysfunction. In particular, alterations in INPP5A expression or activity have been linked to the development and progression of several types of cancer, including breast, prostate, and ovarian cancer. As a result, there has been significant interest in developing drugs that target INPP5A as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of INPP5A have been identified and are currently being evaluated in preclinical studies. One example is the compound 5-ITu, which has been shown to inhibit INPP5A activity and reduce tumor growth in animal models of breast cancer. Another example is the drug buparlisib, which targets both INPP5A and other signaling pathways and has been approved for the treatment of advanced breast cancer. Overall, targeting INPP5A represents a promising approach for the development of new cancer therapies.",GO:1900737 negative regulation of phospholipase C-activating G protein-coupled receptor signaling pathway;GO:1900736 regulation of phospholipase C-activating G protein-coupled receptor signaling pathway;GO:0046856 phosphatidylinositol dephosphorylation,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol (Approved); Additional: Plasma membrane,,,
ENSG00000171634.18,ENSG00000171634,BPTF,-0.828235899,-1.176713971,-0.789215834,-0.518777893,bromodomain PHD finger transcription factor,"BPTF (bromodomain PHD finger transcription factor) is a gene that was initially identified through its reactivity to a monoclonal antibody prepared against brain homogenates from patients with Alzheimer's disease. The protein encoded by this gene was originally thought to be an 810 amino acid protein containing a DNA-binding domain and a zinc finger motif, and was named fetal Alz-50 reactive clone 1 (FAC1). However, it was later discovered that the protein is much larger and contains a C-terminal bromodomain that regulates transcription during proliferation. BPTF is highly similar to the largest subunit of the Drosophila NURF complex, which is necessary for chromatin remodeling required for transcription. Two alternative transcripts encoding different isoforms have been described.","BPTF has been implicated in various diseases, including cancer, neurodegenerative disorders, and developmental disorders. In cancer, BPTF has been shown to be overexpressed in several types of tumors, including breast, lung, and prostate cancer, and is associated with poor prognosis. Targeting BPTF has emerged as a potential therapeutic strategy for cancer treatment, and several small molecule inhibitors of BPTF have been developed and tested in preclinical studies. One example is the compound I-BET151, which has been shown to inhibit BPTF and other bromodomain-containing proteins and has demonstrated antitumor activity in preclinical models. In neurodegenerative disorders, BPTF has been implicated in Alzheimer's disease, and its inhibition has been shown to improve cognitive function in mouse models. However, there are currently no drugs targeting BPTF approved for clinical use.",GO:1990090 cellular response to nerve growth factor stimulus;GO:1990089 response to nerve growth factor;GO:0007492 endoderm development,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000163820.15,ENSG00000163820,FYCO1,-0.828067535,-1.571737966,-0.832951532,-0.079513106,FYVE and coiled-coil domain autophagy adaptor 1,"FYCO1 is a gene that encodes a protein involved in the transport of autophagosomes along microtubules. The protein contains several domains, including a RUN domain, a FYVE-type zinc finger domain, and a Golgi dynamics (GOLD) domain. It interacts with the small GTPase Rab7, phosphatidylinositol-3-phosphate (PI3P), the autophagosome marker LC3, and the kinesin KIF5 to facilitate the movement of autophagic vesicles. Mutations in FYCO1 have been linked to inclusion body myositis (IBM) and autosomal recessive congenital cataracts (CATC2).","Inclusion body myositis (IBM) is a progressive muscle disorder characterized by muscle weakness and wasting. Mutations in FYCO1 have been identified as a genetic cause of IBM. Targeted drug discovery efforts for IBM have focused on reducing inflammation and promoting muscle regeneration. However, there are currently no FDA-approved drugs specifically for IBM. 

On the other hand, FYCO1 mutations have also been linked to autosomal recessive congenital cataracts (CATC2), a condition characterized by clouding of the lens in the eye that affects vision. While there are no targeted drug discovery efforts for CATC2, surgical removal of the cataract and replacement with an artificial lens is a common treatment option.

There are currently no drugs on the market specifically targeting FYCO1 mutations in IBM or CATC2. However, there are drugs on the market that target related pathways involved in autophagy and lysosomal function, such as rapamycin and chloroquine. These drugs have been used in clinical trials for IBM and other muscle disorders, but their efficacy remains uncertain.",GO:0072383 plus-end-directed vesicle transport along microtubule;GO:0072386 plus-end-directed organelle transport along microtubule;GO:1901098 positive regulation of autophagosome maturation,,Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins; Transporters; Potential drug targets; Disease related genes,Vesicles (Enhanced),,,
ENSG00000100320.23,ENSG00000100320,RBFOX2,-0.827906685,-1.059591773,-1.126945666,-0.297182615,RNA binding fox-1 homolog 2,RBFOX2 is a human gene that encodes an RNA binding protein that regulates alternative exon splicing in the nervous system and other cell types. The protein binds to a conserved UGCAUG element found downstream of many alternatively spliced exons and promotes inclusion of the alternative exon in mature transcripts. RBFOX2 also interacts with the estrogen receptor 1 transcription factor and regulates its activity. Multiple transcript variants encoding different isoforms have been found for this gene.,"RBFOX2 has been implicated in several diseases, including cancer, autism spectrum disorder, and neurodegenerative disorders such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In cancer, RBFOX2 has been shown to promote tumor growth and metastasis in several types of cancer, including breast, lung, and pancreatic cancer. In neurodegenerative disorders, RBFOX2 dysregulation has been linked to aberrant splicing of genes involved in neuronal function and survival.

Targeted drug discovery efforts for RBFOX2 have focused on developing small molecule inhibitors that can disrupt its RNA binding activity and prevent its function in alternative splicing. One example is the compound Rbfox-1, which has been shown to inhibit RBFOX2 activity and promote exon skipping in vitro. However, there are currently no drugs targeting RBFOX2 in clinical use.

Successful drugs on the market that indirectly affect RBFOX2 activity include estrogen receptor modulators such as tamoxifen, which has been shown to interact with RBFOX2 and regulate its activity in breast cancer cells. Additionally, drugs that target downstream effectors of RBFOX2-regulated splicing events, such as the ALS drug riluzole, have been shown to improve survival in animal models of ALS.","GO:0030520 estrogen receptor signaling pathway;GO:0000381 regulation of alternative mRNA splicing, via spliceosome;GO:0030518 nuclear receptor-mediated steroid hormone signaling pathway",,Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000177479.20,ENSG00000177479,ARIH2,-0.826745894,-0.832351883,-1.148520202,-0.499365598,ariadne RBR E3 ubiquitin protein ligase 2,"ARIH2 is a gene that encodes for a protein called ariadne RBR E3 ubiquitin protein ligase 2. This protein is responsible for adding multiple ubiquitin molecules to certain proteins, marking them for degradation. ARIH2 has been shown to increase the levels of the tumor suppressor protein p53 in some cancer cells, and may also inhibit the formation of certain blood cells. There are multiple versions of the ARIH2 gene that produce different forms of the protein, but the full structure of some of these forms is not yet known.","ARIH2 has been implicated in various diseases, including cancer and autoimmune disorders. In some cancer cells, ARIH2 has been shown to regulate the levels of the tumor suppressor protein p53, which is often mutated or inactivated in cancer. Therefore, targeting ARIH2 could be a potential strategy for cancer therapy. Additionally, ARIH2 has been found to play a role in the regulation of immune responses, and its dysregulation has been linked to autoimmune disorders such as lupus and rheumatoid arthritis.

There are currently no drugs on the market that specifically target ARIH2. However, there have been efforts to develop small molecule inhibitors of ARIH2 for cancer therapy. One study identified a compound that inhibited ARIH2 activity and induced cell death in cancer cells. Another study found that inhibiting ARIH2 increased the sensitivity of cancer cells to chemotherapy. These findings suggest that targeting ARIH2 could be a promising approach for cancer treatment.

In conclusion, ARIH2 is a gene that has been implicated in various diseases, including cancer and autoimmune disorders. While there are currently no drugs on the market that target ARIH2, there have been efforts to develop small molecule inhibitors for cancer therapy. These studies suggest that targeting ARIH2 could be a promising strategy for cancer treatment.",GO:0071425 hematopoietic stem cell proliferation;GO:1903955 positive regulation of protein targeting to mitochondrion;GO:1903749 positive regulation of establishment of protein localization to mitochondrion,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Enhanced),,,
ENSG00000120063.10,ENSG00000120063,GNA13,-0.825235389,-1.06697032,-0.810167484,-0.598568364,G protein subunit alpha 13,"GNA13 is a human gene that encodes for a protein called G protein subunit alpha 13. This protein is predicted to have several functions, including binding to the D5 dopamine receptor, binding to the G-protein beta/gamma-subunit complex, and regulating GTPase activity. It is also involved in various processes, such as Rho protein signal transduction, activation of phospholipase D activity, and multicellular organism aging. GNA13 is believed to act upstream of or within several processes, including blood vessel morphogenesis, smooth muscle cell migration, and smooth muscle cell proliferation. The protein is located in both the cytosol and nucleus.","There is limited information available on the disease implications of GNA13 mutations. However, recent studies have suggested that GNA13 may play a role in the development and progression of certain cancers, including breast cancer, pancreatic cancer, and glioblastoma. Targeted drug discovery efforts are ongoing to develop drugs that can modulate GNA13 activity and potentially treat these cancers. One example of a successful drug targeting GNA13 is the small molecule inhibitor, Yoda1, which has been shown to selectively activate GNA13 and promote endothelial cell barrier function. Another potential drug target is the D5 dopamine receptor, which interacts with GNA13 and has been implicated in various neurological disorders, including schizophrenia and Parkinson's disease. However, no drugs targeting GNA13 or the D5 dopamine receptor have been approved for clinical use yet.",GO:1904753 negative regulation of vascular associated smooth muscle cell migration;GO:0001569 branching involved in blood vessel morphogenesis;GO:0010762 regulation of fibroblast migration,,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Cancer-related genes:Mutated cancer genes; Predicted intracellular proteins,Cytosol (Supported),,(M64)PID S1P S1P4 PATHWAY; (M138)PID THROMBIN PAR4 PATHWAY; (M155)PID S1P META PATHWAY,
ENSG00000113328.19,ENSG00000113328,CCNG1,-0.824915338,-0.64439936,-0.788767532,-1.041579121,cyclin G1,"CCNG1, also known as cyclin G1, is a member of the cyclin family that regulates the eukaryotic cell cycle through cyclin-dependent protein kinases (CDKs). Unlike other family members, CCNG1 lacks the protein destabilizing (PEST) sequence. The gene can be activated by tumor protein p53 and has two identified transcript variants that encode the same protein.","CCNG1 has been implicated in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, CCNG1 has been shown to be overexpressed in several types of tumors, including breast, lung, and liver cancer. Targeting CCNG1 has been proposed as a potential therapeutic strategy for cancer treatment. Several studies have identified small molecules that can inhibit CCNG1 expression or activity, including flavopiridol and roscovitine. However, these drugs have not yet been approved for clinical use.

In neurodegenerative disorders, CCNG1 has been shown to play a role in regulating neuronal survival and apoptosis. Targeting CCNG1 has been proposed as a potential therapeutic strategy for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. However, there are currently no drugs targeting CCNG1 for these indications.

In cardiovascular diseases, CCNG1 has been shown to be involved in regulating smooth muscle cell proliferation and migration. Targeting CCNG1 has been proposed as a potential therapeutic strategy for preventing restenosis after angioplasty. However, there are currently no drugs targeting CCNG1 for this indication.

Overall, while CCNG1 has been implicated in various diseases, there are currently no drugs targeting this gene on the market. Further research is needed to identify and develop effective drugs targeting CCNG1 for therapeutic use.",GO:0009629 response to gravity;GO:0007095 mitotic G2 DNA damage checkpoint signaling;GO:0006949 syncytium formation,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported),,(M261)PID P53 REGULATION PATHWAY; (M145)PID P53 DOWNSTREAM PATHWAY,(M5924)HALLMARK MTORC1 SIGNALING; (M5939)HALLMARK P53 PATHWAY
ENSG00000186635.14,ENSG00000186635,ARAP1,-0.824494081,-1.234884416,-0.755505453,-0.483092373,"ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1","ARAP1 is a human gene that encodes a protein with multiple domains, including SAM, ARF-GAP, RHO-GAP, ankyrin repeat, RAS-associating, and pleckstrin homology (PH) domains. The protein displays RHO-GAP and phosphatidylinositol (3,4,5) trisphosphate (PIP3)-dependent ARF-GAP activity in vitro. It is associated with the Golgi and mediates changes in the Golgi and the formation of filopodia. ARAP1 is thought to regulate the cell-specific trafficking of a receptor protein involved in apoptosis. Multiple transcript variants encoding different isoforms have been found for this gene.","Research on ARAP1 has suggested its involvement in various diseases, including cancer, cardiovascular diseases, and neurological disorders. In cancer, ARAP1 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. In cardiovascular diseases, ARAP1 has been linked to the regulation of endothelial cell function and blood vessel formation. In neurological disorders, ARAP1 has been implicated in the regulation of synaptic plasticity and neuronal development.

Targeted drug discovery efforts for ARAP1 are ongoing, with a focus on developing small molecule inhibitors that can selectively target its various domains and functions. One example is the development of ARAP1 inhibitors for the treatment of cancer, which has shown promising results in preclinical studies.

Currently, there are no drugs on the market that specifically target ARAP1. However, there are drugs that indirectly affect ARAP1 function, such as statins, which have been shown to inhibit ARAP1 expression and activity. Additionally, drugs that target other proteins in the same signaling pathways as ARAP1, such as Rho GTPases, have been approved for the treatment of various diseases, including cancer and cardiovascular diseases.",GO:0001921 positive regulation of receptor recycling;GO:0001919 regulation of receptor recycling;GO:0051491 positive regulation of filopodium assembly,,Predicted intracellular proteins,Nucleoplasm;Plasma membrane (Approved); Additional: Cytosol;Vesicles,,(M68)PID RHOA REG PATHWAY; (M186)PID PDGFRB PATHWAY,
ENSG00000054965.11,ENSG00000054965,FAM168A,-0.823979012,-1.572106665,-0.754437761,-0.145392611,family with sequence similarity 168 member A,"FAM168A is a human gene that belongs to the family with sequence similarity 168. It plays a role in the positive regulation of base-excision repair, which is a process that repairs damaged DNA. The gene's function is important for maintaining the integrity of the genome and preventing mutations that can lead to diseases such as cancer. The gene's exact mechanism of action is not yet fully understood, but it is believed to interact with other proteins involved in the base-excision repair pathway. Further research on FAM168A may provide insights into the development of new therapies for DNA damage-related diseases.","There is limited information available on the disease implications of FAM168A. However, mutations in this gene have been associated with a rare genetic disorder called autosomal recessive intellectual disability-50 (MRT50). This disorder is characterized by intellectual disability, delayed speech and language development, and other neurological abnormalities. 

As for targeted drug discovery efforts, there is currently no known drug that specifically targets FAM168A. However, research on the gene's function in base-excision repair may lead to the development of new therapies for DNA damage-related diseases, including cancer. 

There are currently no successful drugs on the market that target FAM168A. However, there are several drugs that target other proteins involved in the base-excision repair pathway, such as PARP inhibitors. These drugs have been approved for the treatment of certain types of cancer, including ovarian and breast cancer, and are being investigated for use in other types of cancer as well.",GO:1905053 positive regulation of base-excision repair;GO:1905051 regulation of base-excision repair;GO:0045739 positive regulation of DNA repair,,Disease related genes; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000113649.11,ENSG00000113649,TCERG1,-0.823832182,-0.805265389,-0.647280387,-1.018950771,transcription elongation regulator 1,The TCERG1 gene encodes a nuclear protein that plays a role in regulating transcriptional elongation and pre-mRNA splicing. It interacts with RNA polymerase II and pre-mRNA splicing factor SF1 through specific domains. Alternative splicing of the gene results in multiple transcript variants that encode different isoforms of the protein.,"The TCERG1 gene has been implicated in several diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, TCERG1 has been shown to be overexpressed in several types of tumors, including breast, lung, and prostate cancer, and may play a role in tumor progression and metastasis. Targeted drug discovery efforts have focused on developing small molecule inhibitors of TCERG1 to block its activity and potentially treat cancer. However, there are currently no drugs on the market that specifically target TCERG1. Some drugs that indirectly affect TCERG1 activity, such as the chemotherapy drug paclitaxel, have been used in cancer treatment. In neurodegenerative disorders, TCERG1 has been linked to the pathogenesis of Alzheimer's disease and Huntington's disease, and may be a potential therapeutic target for these conditions. In viral infections, TCERG1 has been shown to interact with the HIV-1 Tat protein and may play a role in the replication of the virus. However, no drugs targeting TCERG1 have been developed for viral infections.","GO:0034244 negative regulation of transcription elongation by RNA polymerase II;GO:0032785 negative regulation of DNA-templated transcription, elongation;GO:0032968 positive regulation of transcription elongation by RNA polymerase II",,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000145780.8,ENSG00000145780,FEM1C,-0.823073229,-1.10064444,-0.517753289,-0.850821959,fem-1 homolog C,"FEM1C is a human gene that encodes a protein involved in the ubiquitin-dependent protein catabolic process through the C-end degron rule pathway. The protein is located in the cytosol and nucleoplasm and is part of the Cul2-RING ubiquitin ligase complex. FEM1C enables ubiquitin ligase-substrate adaptor activity, which is important for the degradation of proteins in the cell.","Mutations in the FEM1C gene have been associated with several diseases, including cancer, developmental disorders, and neurodegenerative diseases. In particular, FEM1C has been found to be overexpressed in several types of cancer, including breast, ovarian, and lung cancer, and its expression levels have been correlated with poor prognosis. As a result, FEM1C has been identified as a potential therapeutic target for cancer treatment. Several drug discovery efforts have focused on developing small molecule inhibitors of FEM1C, with promising results in preclinical studies. However, no FEM1C-targeted drugs have been approved for clinical use yet. Overall, FEM1C represents an important target for drug discovery efforts in cancer and other diseases, and further research is needed to fully understand its role in disease pathogenesis and identify effective therapeutic strategies.",GO:0140627 ubiquitin-dependent protein catabolic process via the C-end degron rule pathway;GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process;GO:0010498 proteasomal protein catabolic process,,Disease related genes; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000141458.13,ENSG00000141458,NPC1,-0.822864641,-1.084847879,-0.909280763,-0.47446528,NPC intracellular cholesterol transporter 1,"The NPC1 gene encodes a large protein that is responsible for intracellular cholesterol trafficking by binding cholesterol to its N-terminal domain. The protein is located in the limiting membrane of endosomes and lysosomes and has a cytoplasmic C-terminus, 13 transmembrane domains, and 3 large loops in the lumen of the endosome. It transports low-density lipoproteins to late endosomal/lysosomal compartments where they are broken down and released as free cholesterol. Defects in this gene cause Niemann-Pick type C disease, a rare autosomal recessive neurodegenerative disorder characterized by the accumulation of cholesterol and glycosphingolipids in late endosomal/lysosomal compartments.","Niemann-Pick type C disease is a rare and devastating neurodegenerative disorder that affects approximately 1 in 150,000 individuals worldwide. The disease is caused by mutations in the NPC1 or NPC2 genes, which lead to the accumulation of cholesterol and glycosphingolipids in late endosomal/lysosomal compartments. This accumulation results in progressive neurodegeneration, hepatosplenomegaly, and premature death. There is currently no cure for Niemann-Pick type C disease, and treatment options are limited to symptomatic management.

Targeted drug discovery efforts for Niemann-Pick type C disease have focused on developing small molecule drugs that can correct the underlying defect in cholesterol trafficking. One such drug is cyclodextrin, which has been shown to reduce cholesterol accumulation and improve neurological symptoms in animal models of the disease. Another drug, miglustat, is an inhibitor of glycosphingolipid synthesis that has been approved for the treatment of Gaucher disease and has shown promise in clinical trials for Niemann-Pick type C disease.

In addition to cyclodextrin and miglustat, there are several other drugs in development for Niemann-Pick type C disease, including gene therapy approaches and other small molecule drugs that target cholesterol trafficking. While there is still much work to be done in developing effective treatments for this devastating disease, the progress made so far provides hope for patients and their families.",GO:2000900 cyclodextrin metabolic process;GO:0010878 cholesterol storage;GO:0030299 intestinal cholesterol absorption,,Disease related genes; Transporters:Electrochemical Potential-driven transporters; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Lysosomal storage diseases,,,,(M5948)HALLMARK BILE ACID METABOLISM; (M5934)HALLMARK XENOBIOTIC METABOLISM
ENSG00000166801.16,ENSG00000166801,FAM111A,-0.82283154,-1.11580451,-0.718382837,-0.634307273,FAM111 trypsin like peptidase A,"FAM111A is a human gene that is involved in cell-cycle regulation and has nuclear localization. The C-terminal half of the protein shares homology with trypsin-like peptidases and contains a PCNA-interacting peptide (PIP) box, which is necessary for its co-localization with proliferating cell nuclear antigen (PCNA). Reduced expression of this gene results in DNA replication defects, consistent with its role in Simian Virus 40 (SV40) viral replication. Mutations in this gene have been associated with Kenny-Caffey syndrome (KCS) type 2 and the more severe osteocraniostenosis (OCS), both characterized by short stature, hypoparathyroidism, bone development abnormalities, and hypocalcemia. Alternative splicing results in multiple transcript variants.","Mutations in the FAM111A gene have been associated with Kenny-Caffey syndrome (KCS) type 2 and osteocraniostenosis (OCS), both rare genetic disorders characterized by skeletal abnormalities, short stature, and hypocalcemia. There are currently no targeted drug discovery efforts for these conditions, and treatment is mainly supportive, focusing on managing symptoms such as hypocalcemia and bone abnormalities. However, recent studies have identified potential therapeutic targets for KCS and OCS, including the parathyroid hormone (PTH) pathway and the Wnt signaling pathway. Currently, there are no drugs specifically approved for the treatment of KCS or OCS. However, drugs such as calcitriol and calcium supplements are commonly used to manage hypocalcemia in affected individuals. Additionally, bisphosphonates have been used to improve bone density in some cases.",GO:0106300 protein-DNA covalent cross-linking repair;GO:0016540 protein autoprocessing;GO:0031297 replication fork processing,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Nucleoli fibrillar center;Nucleoplasm (Approved),,,
ENSG00000152520.14,ENSG00000152520,PAN3,-0.822329614,-0.988293545,-0.846250843,-0.632444454,poly(A) specific ribonuclease subunit PAN3,"PAN3 is a gene that contributes to poly(A)-specific ribonuclease activity and is predicted to be involved in shortening the poly(A) tail of nuclear-transcribed mRNA. It is also predicted to play a role in deadenylation-dependent decapping of nuclear-transcribed mRNA, positive regulation of cytoplasmic mRNA processing body assembly, and protein targeting. PAN3 is part of the PAN complex.","Research on PAN3 and its potential disease implications is still in its early stages. However, recent studies have suggested that PAN3 may play a role in cancer progression and metastasis. Specifically, it has been shown that PAN3 expression is upregulated in several types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts for PAN3 are currently limited, but there is potential for the development of drugs that target the PAN complex and its role in mRNA processing. One example of a successful drug targeting mRNA processing is the chemotherapy drug, gemcitabine, which inhibits the activity of ribonucleotide reductase, an enzyme involved in DNA synthesis. Further research on PAN3 and its role in disease could lead to the development of new targeted therapies for cancer and other diseases.",GO:0010606 positive regulation of cytoplasmic mRNA processing body assembly;GO:0010603 regulation of cytoplasmic mRNA processing body assembly;GO:0000290 deadenylation-dependent decapping of nuclear-transcribed mRNA,,Enzymes; Predicted intracellular proteins; Kinases,,,,
ENSG00000181192.12,ENSG00000181192,DHTKD1,-0.822229169,-1.274263254,-1.053600504,-0.138823749,dehydrogenase E1 and transketolase domain containing 1,"DHTKD1 is a gene that encodes a protein component of a mitochondrial complex involved in the degradation of several amino acids, including lysine. Mutations in this gene have been linked to two conditions: 2-aminoadipic 2-oxoadipic aciduria and Charcot-Marie-Tooth Disease Type 2Q. The former is a rare metabolic disorder characterized by the accumulation of certain amino acids in the urine, while the latter is a hereditary neurological disorder that affects the peripheral nerves. The protein encoded by DHTKD1 contains both dehydrogenase E1 and transketolase domains, which are important for its function in amino acid degradation pathways.","There are currently no targeted drug discovery efforts specifically for DHTKD1 mutations. However, there are drugs on the market that can help manage the symptoms of Charcot-Marie-Tooth Disease Type 2Q, which is caused by mutations in this gene. These drugs include gabapentin, which can help alleviate neuropathic pain, and physical therapy, which can help improve muscle strength and coordination. Additionally, there are ongoing clinical trials for gene therapy and other potential treatments for Charcot-Marie-Tooth Disease Type 2Q. As for 2-aminoadipic 2-oxoadipic aciduria, there are no specific drugs available for this rare metabolic disorder, but treatment typically involves managing symptoms and avoiding certain foods that can exacerbate the condition.",GO:0006096 glycolytic process;GO:0046032 ADP catabolic process;GO:0019364 pyridine nucleotide catabolic process,,Disease related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Predicted intracellular proteins,Mitochondria (Supported),,,
ENSG00000083535.16,ENSG00000083535,PIBF1,-0.821857811,-1.283194427,-0.867549583,-0.314829423,progesterone immunomodulatory binding factor 1,"PIBF1, or progesterone immunomodulatory binding factor 1, is a gene that is activated by the hormone progesterone and is involved in maintaining pregnancy. The protein encoded by this gene regulates various aspects of the immune system to support normal pregnancy, including cytokine synthesis, natural killer cell activity, and arachidonic acid metabolism. Low levels of this protein in the blood have been linked to spontaneous pre-term labor in humans. Additionally, PIBF1 may promote the growth, movement, and invasion of glioma, a type of brain tumor.","There are currently no targeted drug discovery efforts specifically focused on PIBF1, as it is primarily involved in maintaining pregnancy and its role in glioma is still being studied. However, there are drugs on the market that indirectly affect PIBF1 activity. For example, progesterone supplements are commonly prescribed to prevent pre-term labor and maintain pregnancy, which may increase PIBF1 expression. Additionally, nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen can inhibit arachidonic acid metabolism, which is regulated by PIBF1. NSAIDs are commonly used to treat pain and inflammation, but they can also have side effects such as gastrointestinal bleeding and increased risk of heart attack and stroke. Therefore, further research is needed to better understand the role of PIBF1 in disease and to develop more targeted therapies.",GO:0042976 activation of Janus kinase activity;GO:0031393 negative regulation of prostaglandin biosynthetic process;GO:0042532 negative regulation of tyrosine phosphorylation of STAT protein,,Disease related genes; Predicted secreted proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Centriolar satellite;Centrosome (Supported); Additional: Basal body,,,
ENSG00000055208.19,ENSG00000055208,TAB2,-0.821804027,-0.959940463,-0.878564839,-0.626906779,TGF-beta activated kinase 1 (MAP3K7) binding protein 2,"TAB2 is a human gene that encodes a protein that activates MAP3K7/TAK1, which is necessary for the activation of nuclear factor kappaB and MAPK8/JNK in response to IL-1. The protein forms a kinase complex with TRAF6, MAP3K7, and TAB1, serving as an adaptor that links MAP3K7 and TRAF6. It also participates in the signal transduction induced by TNFSF11/RANKl through the activation of TNFRSF11A/RANK, which may regulate the development and function of osteoclasts. Studies of the related mouse protein suggest that it protects against liver damage caused by chemical stressors. Mutations in this gene cause congenital heart defects, multiple types, 2 (CHTD2). Alternative splicing results in multiple transcript variants.","Mutations in the TAB2 gene have been associated with congenital heart defects, multiple types, 2 (CHTD2). This condition is characterized by abnormalities in the structure or function of the heart that are present at birth. There is currently no targeted drug discovery effort for TAB2, but research is ongoing to understand its role in various diseases. However, there are drugs on the market that target the downstream pathways activated by TAB2, such as inhibitors of nuclear factor kappaB (NF-?B) and MAPK8/JNK. For example, the drug adalimumab is a monoclonal antibody that targets TNF-alpha, a cytokine that activates NF-?B. It is used to treat autoimmune diseases such as rheumatoid arthritis and Crohn's disease. Another example is the drug trametinib, which inhibits the MAPK pathway and is used to treat certain types of cancer.",GO:0038061 non-canonical NF-kappaB signal transduction;GO:0010507 negative regulation of autophagy;GO:0045860 positive regulation of protein kinase activity,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the circulatory system; Predicted intracellular proteins,,,(M20)PID P38 MKK3 6PATHWAY; (M23)PID WNT NONCANONICAL PATHWAY; (M110)PID IL1 PATHWAY,
ENSG00000117500.13,ENSG00000117500,TMED5,-0.821431929,-0.764198491,-1.168523353,-0.531573941,transmembrane p24 trafficking protein 5,"TMED5 is a human gene that encodes for a transmembrane protein involved in the formation of the Golgi ribbon. It is located in various parts of the cell, including the cis-Golgi network, endoplasmic reticulum exit site, and endoplasmic reticulum-Golgi intermediate compartment. The protein is involved in the trafficking of proteins and other molecules within the cell. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of TMED5. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TMED5 are also limited, as the function of this protein is not fully understood. However, some studies have suggested that targeting TMED5 may be a potential strategy for treating certain types of cancer. Currently, there are no drugs on the market that specifically target TMED5. However, there are several drugs that target other proteins involved in the trafficking of molecules within the cell, such as brefeldin A and golgicide A, which have been used in research to study the function of TMED5 and other related proteins.",GO:0090161 Golgi ribbon formation;GO:0006888 endoplasmic reticulum to Golgi vesicle-mediated transport;GO:0007030 Golgi organization,,Predicted intracellular proteins,,,,
ENSG00000241973.11,ENSG00000241973,PI4KA,-0.821065059,-1.412419541,-0.857814283,-0.192961354,phosphatidylinositol 4-kinase alpha,"PI4KA is a gene that encodes a type III phosphatidylinositol (PI) 4-kinase, which is an enzyme that catalyzes the first step in the biosynthesis of phosphatidylinositol 4,5-bisphosphate. This gene is not inhibited by adenosine and has multiple transcript variants that encode distinct isoforms due to alternative splicing. The mammalian PI 4-kinases are classified into two types, II and III, based on their molecular mass and modulation by detergent and adenosine. PI4KA is important for the regulation of various cellular processes, including membrane trafficking, signal transduction, and cytoskeletal organization. Mutations in this gene have been associated with various diseases, including cancer and neurological disorders.","Mutations in the PI4KA gene have been associated with various diseases, including cancer and neurological disorders. In cancer, PI4KA has been shown to be overexpressed in several types of tumors, including breast, lung, and pancreatic cancer, and is associated with tumor growth and metastasis. Therefore, PI4KA has been identified as a potential therapeutic target for cancer treatment. Several small molecule inhibitors of PI4KA have been developed and are currently being evaluated in preclinical studies for their anti-cancer activity.

In neurological disorders, mutations in PI4KA have been linked to autosomal recessive intellectual disability and cerebellar ataxia. These mutations affect the function of the enzyme and lead to impaired phosphoinositide metabolism, which is critical for neuronal signaling and synaptic function. Therefore, PI4KA has also been identified as a potential therapeutic target for neurological disorders. However, there are currently no drugs targeting PI4KA for the treatment of these disorders on the market.

In summary, PI4KA is an important enzyme involved in various cellular processes and has been implicated in the pathogenesis of cancer and neurological disorders. While there are ongoing efforts to develop small molecule inhibitors of PI4KA for cancer treatment, there are currently no drugs targeting PI4KA for the treatment of neurological disorders on the market.",GO:0140754 reorganization of cellular membranes to establish viral sites of replication;GO:0048015 phosphatidylinositol-mediated signaling;GO:0044788 modulation by host of viral process,yes,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Nucleoplasm (Approved); Additional: Plasma membrane,,(M160)PID AVB3 INTEGRIN PATHWAY,
ENSG00000172594.13,ENSG00000172594,SMPDL3A,-0.821045993,-1.42659043,-0.671423661,-0.365123888,sphingomyelin phosphodiesterase acid like 3A,SMPDL3A is a human gene that encodes for a protein with phosphoric diester hydrolase activity and zinc ion binding activity. It is involved in the catabolic process of nucleoside triphosphate and is located in the extracellular space. This information is provided by the Alliance of Genome Resources as of April 2022.,"SMPDL3A has been implicated in several diseases, including Alzheimer's disease, Parkinson's disease, and cancer. In Alzheimer's disease, decreased expression of SMPDL3A has been observed in the brain, and it has been suggested that this may contribute to the accumulation of amyloid-beta plaques. In Parkinson's disease, SMPDL3A has been identified as a potential therapeutic target due to its involvement in the regulation of dopamine signaling. In cancer, SMPDL3A has been shown to play a role in the regulation of cell proliferation and migration, and its expression has been found to be dysregulated in several types of cancer.

Targeted drug discovery efforts for SMPDL3A are still in the early stages, but several potential drug candidates have been identified. One approach is to develop small molecule inhibitors of SMPDL3A, which could be used to modulate its activity in disease states. Another approach is to develop antibodies or other biologics that target SMPDL3A, which could be used to selectively target cancer cells or other diseased cells.

Currently, there are no drugs on the market that specifically target SMPDL3A. However, there are several drugs that indirectly modulate its activity. For example, statins, which are commonly used to lower cholesterol levels, have been shown to increase the expression of SMPDL3A in the liver. Additionally, some anti-cancer drugs, such as imatinib, have been shown to downregulate the expression of SMPDL3A in cancer cells.",GO:0009143 nucleoside triphosphate catabolic process;GO:0160049 negative regulation of cGAS/STING signaling pathway;GO:0039532 negative regulation of cytoplasmic pattern recognition receptor signaling pathway,,Predicted secreted proteins; Predicted intracellular proteins,Mitochondria;Nucleoli;Nucleoplasm (Approved),,,(M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000174953.14,ENSG00000174953,DHX36,-0.820664225,-1.151786269,-0.730241794,-0.579964611,DEAH-box helicase 36,DHX36 is a gene that belongs to the DEAH-box family of RNA-dependent NTPases. The protein encoded by this gene has been found to play a role in the decay of mRNAs with 3'-UTR AU-rich elements and in resolving the highly stable tetramolecular DNA configuration (G4) that can form spontaneously in guanine-rich regions of DNA. DHX36 has multiple transcript variants that encode different isoforms due to alternative splicing.,"There is limited information available on the disease implications of DHX36. However, recent studies have suggested that DHX36 may play a role in cancer progression and metastasis. In particular, DHX36 has been found to be overexpressed in several types of cancer, including breast, lung, and pancreatic cancer. Targeted drug discovery efforts for DHX36 are still in the early stages, but there is potential for the development of drugs that can inhibit its activity and prevent cancer progression. Currently, there are no drugs on the market that specifically target DHX36, but there are several drugs that target other members of the DEAH-box family of RNA-dependent NTPases, such as the anti-cancer drug, Pladienolide B, which targets the spliceosome-associated protein, SF3B1.",GO:1903842 response to arsenite ion;GO:1903843 cellular response to arsenite ion;GO:1904582 positive regulation of intracellular mRNA localization,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol;Nucleoplasm (Supported),,,
ENSG00000180357.9,ENSG00000180357,ZNF609,-0.820641782,-1.186359585,-0.763357524,-0.512208238,zinc finger protein 609,"ZNF609 is a human gene that encodes for a zinc finger protein 609. It is predicted to have the ability to bind to specific regions of DNA and regulate gene expression. ZNF609 is involved in the regulation of myoblast proliferation, which is the process of muscle cell growth and differentiation. It is located in the nucleoplasm, which is the fluid inside the nucleus of a cell. The function of ZNF609 is not fully understood, but it is believed to play a role in the development and maintenance of muscle tissue.","There is limited information available on the disease implications of ZNF609. However, recent studies have suggested that it may play a role in the development of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ZNF609 are currently underway, with a focus on identifying small molecules that can modulate its activity. While there are no drugs currently on the market that specifically target ZNF609, there are several drugs that have been approved for the treatment of breast cancer and hepatocellular carcinoma that may indirectly affect its activity. For example, tamoxifen and trastuzumab are commonly used to treat breast cancer by targeting estrogen receptors and HER2 receptors, respectively. Sorafenib is another drug that is used to treat hepatocellular carcinoma by inhibiting the activity of several kinases involved in cell proliferation and angiogenesis.",GO:2001224 positive regulation of neuron migration;GO:2000291 regulation of myoblast proliferation;GO:2001222 regulation of neuron migration,,Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Cytosol,,,
ENSG00000135387.21,ENSG00000135387,CAPRIN1,-0.820488402,-1.437131772,-0.815124931,-0.209208503,cell cycle associated protein 1,CAPRIN1 is a human gene that encodes for a protein called cell cycle associated protein 1. This protein is involved in RNA binding activity and is predicted to play a role in negative regulation of translation and positive regulation of dendritic spine morphogenesis. CAPRIN1 is located in the cell leading edge and cytosol.,"CAPRIN1 has been implicated in several diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, CAPRIN1 has been shown to promote tumor growth and metastasis by regulating the translation of oncogenic mRNAs. In neurodegenerative disorders, CAPRIN1 has been linked to the formation of toxic protein aggregates, such as those found in Alzheimer's disease. Additionally, CAPRIN1 has been shown to play a role in the replication of several viruses, including hepatitis C virus and Zika virus.

Targeted drug discovery efforts for CAPRIN1 are still in the early stages, but several potential drug targets have been identified. For example, small molecules that inhibit the RNA binding activity of CAPRIN1 could be developed as anti-cancer agents. Additionally, drugs that target the interaction between CAPRIN1 and viral proteins could be developed as antiviral therapies.

Currently, there are no drugs on the market that specifically target CAPRIN1. However, several drugs that indirectly affect CAPRIN1 activity have been approved for use in cancer and neurodegenerative disorders. For example, the cancer drug rapamycin inhibits the mTOR pathway, which regulates CAPRIN1 activity. Similarly, the Alzheimer's drug memantine has been shown to reduce the formation of toxic protein aggregates, which may be mediated in part by CAPRIN1.",GO:0106288 regulation of deadenylation-dependent decapping of nuclear-transcribed mRNA;GO:0062029 positive regulation of stress granule assembly;GO:0008298 intracellular mRNA localization,,Predicted intracellular proteins,Cytosol (Enhanced),,,
ENSG00000165997.5,ENSG00000165997,ARL5B,-0.820442544,-1.265332371,-0.909349792,-0.286645469,ARF like GTPase 5B,"ARL5B is a human gene that encodes for a protein belonging to a family of proteins that are structurally similar to ADP-ribosylation factors (ARFs). ARL5B and ARFs are part of the RAS superfamily of regulatory GTPases. The function of ARL5B is not well understood, but it is believed to play a role in intracellular trafficking and membrane dynamics. Mutations in ARL5B have been associated with certain types of cancer, including breast and lung cancer. Further research is needed to fully understand the function and potential clinical implications of ARL5B.","There is limited information available on the disease implications of ARL5B, and there are currently no targeted drug discovery efforts focused on this gene. However, mutations in ARL5B have been associated with certain types of cancer, including breast and lung cancer. It is possible that future research may identify ARL5B as a potential therapeutic target for these cancers. Currently, there are no drugs on the market that specifically target ARL5B. However, there are drugs that target other members of the RAS superfamily, such as KRAS, which is frequently mutated in cancer. Examples of successful drugs targeting KRAS include sotorasib and adagrasib, which have shown promising results in clinical trials for certain types of cancer.",GO:1903292 protein localization to Golgi membrane;GO:0034067 protein localization to Golgi apparatus;GO:0072657 protein localization to membrane,,Predicted intracellular proteins,,Guanosine-5'-Diphosphate,,
ENSG00000115524.17,ENSG00000115524,SF3B1,-0.820145957,-1.043557793,-0.788590508,-0.62828957,splicing factor 3b subunit 1,"SF3B1 is a gene that encodes subunit 1 of the splicing factor 3b protein complex. This complex, along with splicing factor 3a and a 12S RNA unit, forms the U2 small nuclear ribonucleoproteins complex (U2 snRNP). The splicing factor 3b/3a complex binds pre-mRNA upstream of the intron's branch site and may anchor the U2 snRNP to the pre-mRNA. SF3B1 is also a component of the minor U12-type spliceosome. The carboxy-terminal two-thirds of subunit 1 have 22 non-identical, tandem HEAT repeats that form rod-like, helical structures. Alternative splicing results in multiple transcript variants encoding different isoforms.","Mutations in the SF3B1 gene have been associated with various hematological malignancies, including myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), and uveal melanoma. SF3B1 mutations are particularly common in MDS with ring sideroblasts, a subtype of MDS characterized by the presence of iron-laden erythroblasts in the bone marrow. Targeted drug discovery efforts have focused on developing inhibitors of SF3B1 as a potential treatment for these malignancies. One such drug is H3B-8800, a small molecule inhibitor of SF3B1 that is currently in clinical trials for the treatment of MDS and other hematological malignancies. Another drug, pladienolide B, has been shown to inhibit SF3B1 and induce apoptosis in cancer cells, but its clinical development has been limited due to toxicity concerns.",GO:0045945 positive regulation of transcription by RNA polymerase III;GO:1903241 U2-type prespliceosome assembly;GO:0006359 regulation of transcription by RNA polymerase III,,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Predicted intracellular proteins; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Nuclear speckles (Enhanced),H3B-8800,,
ENSG00000138413.14,ENSG00000138413,IDH1,-0.819435183,-1.039533143,-0.572907109,-0.845865299,isocitrate dehydrogenase (NADP(+)) 1,"IDH1 is a gene that encodes for the NADP(+)-dependent isocitrate dehydrogenase enzyme found in the cytoplasm and peroxisomes. This enzyme plays a role in the oxidative decarboxylation of isocitrate to 2-oxoglutarate, which is important for energy production. The presence of this enzyme in peroxisomes suggests roles in the regeneration of NADPH for intraperoxisomal reductions and in peroxisomal reactions that consume 2-oxoglutarate. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production. Mutations in IDH1 have been associated with various cancers, including gliomas and acute myeloid leukemia.","Mutations in IDH1 have been found to be a driver of tumorigenesis in various cancers, including gliomas and acute myeloid leukemia. These mutations result in the production of an oncometabolite, D-2-hydroxyglutarate (D-2HG), which can interfere with cellular metabolism and epigenetic regulation. Targeted drug discovery efforts have focused on developing inhibitors of mutant IDH1 to reduce D-2HG levels and potentially slow or halt tumor growth. Ivosidenib (Tibsovo) is an FDA-approved drug that targets mutant IDH1 and has shown promising results in clinical trials for the treatment of acute myeloid leukemia and cholangiocarcinoma. Other IDH1 inhibitors, such as AG-120 and BAY 1436032, are currently in clinical trials for various cancers.",GO:0006097 glyoxylate cycle;GO:0006102 isocitrate metabolic process;GO:0060696 regulation of phospholipid catabolic process,,"Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Predicted intracellular proteins; Human disease related genes:Cardiovascular diseases:Hematologic diseases; ENZYME proteins:Oxidoreductases; Human disease related genes:Cancers:Cancers of eye, brain, and central nervous system; Citric acid cycle related proteins; FDA approved drug targets:Small molecule drugs; Disease related genes; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes",Cytosol;Nuclear bodies (Approved),Isocitric Acid; Nicotinamide adenine dinucleotide phosphate; Ivosidenib,,(M5949)HALLMARK PEROXISOME; (M5948)HALLMARK BILE ACID METABOLISM; (M5935)HALLMARK FATTY ACID METABOLISM
ENSG00000101191.17,ENSG00000101191,DIDO1,-0.819337119,-1.328123337,-0.568900223,-0.560987798,death inducer-obliterator 1,"DIDO1 (Death Inducer-Obliterator 1) is a gene that plays a role in apoptosis, a process of programmed cell death that is important for development and homeostasis in animals. In mice, the gene is upregulated by apoptotic signals and encodes a cytoplasmic protein that moves to the nucleus upon activation. Overexpression of the mouse protein induces apoptosis in cell lines grown in vitro. The human gene is thought to be involved in apoptosis as well and has multiple isoforms due to alternative splicing.","There is limited information on the disease implications of DIDO1, but some studies suggest that it may play a role in cancer. For example, one study found that DIDO1 expression was upregulated in breast cancer cells and that knockdown of the gene inhibited cell proliferation and induced apoptosis. Additionally, DIDO1 has been identified as a potential therapeutic target for acute myeloid leukemia (AML), as it is overexpressed in AML cells and its knockdown leads to decreased cell viability. However, there are currently no drugs on the market that specifically target DIDO1. 

There have been some efforts to develop drugs that target apoptosis pathways, which may indirectly affect DIDO1 activity. For example, the BCL-2 inhibitor venetoclax has been approved for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), as well as AML in certain cases. Venetoclax targets a protein that inhibits apoptosis, leading to increased apoptosis in cancer cells. Another example is the PARP inhibitor olaparib, which has been approved for the treatment of ovarian and breast cancers with BRCA mutations. PARP inhibitors target a DNA repair pathway that is important for cell survival, leading to increased apoptosis in cancer cells.",GO:0097190 apoptotic signaling pathway;GO:0006351 DNA-templated transcription;GO:0006915 apoptotic process,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol;Vesicles,,,
ENSG00000060749.16,ENSG00000060749,QSER1,-0.818939364,-1.330344196,-0.781554859,-0.344919038,glutamine and serine rich 1,"QSER1 (glutamine and serine rich 1) is a gene that encodes a protein involved in the regulation of gene expression and protein synthesis. The protein contains glutamine and serine-rich domains, which are thought to be important for protein-protein interactions. QSER1 has been implicated in a variety of cellular processes, including cell growth and differentiation, and has been linked to several diseases, including cancer and schizophrenia. Studies have also suggested that QSER1 may play a role in the regulation of insulin secretion and glucose metabolism. Further research is needed to fully understand the function of QSER1 and its potential therapeutic applications.","There is limited information available on the disease implications of QSER1, but studies have suggested that it may be involved in the development of certain types of cancer, including breast and lung cancer. Targeted drug discovery efforts for QSER1 are also limited, as its function is not fully understood. However, some studies have suggested that QSER1 may be a potential target for the development of drugs to treat metabolic disorders, such as diabetes. Currently, there are no drugs on the market that specifically target QSER1. However, there are several drugs that target related proteins involved in gene expression and protein synthesis, such as histone deacetylase inhibitors and mTOR inhibitors, which are used to treat cancer and other diseases.",,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000116604.18,ENSG00000116604,MEF2D,-0.818486991,-0.975706317,-0.803445836,-0.676308821,myocyte enhancer factor 2D,"MEF2D is a gene that belongs to the myocyte-specific enhancer factor 2 (MEF2) family of transcription factors. These factors are involved in the regulation of muscle and neuronal cell differentiation and development and are controlled by class II histone deacetylases. The gene has been found to be involved in leukemogenesis, Parkinson's disease, and myotonic dystrophy. Alternative splicing of the gene results in multiple transcript variants.","MEF2D has been implicated in several diseases, including leukemia, Parkinson's disease, and myotonic dystrophy. In leukemia, MEF2D is frequently overexpressed and has been identified as a potential therapeutic target. Targeted drug discovery efforts have focused on developing small molecule inhibitors of MEF2D to disrupt its function and inhibit leukemia cell growth. One example of a successful drug targeting MEF2D is the small molecule inhibitor, Ro 31-8220, which has been shown to inhibit MEF2D activity and induce apoptosis in leukemia cells. In Parkinson's disease, MEF2D has been found to be involved in the regulation of dopaminergic neuron survival and function. Targeted drug discovery efforts have focused on developing drugs that can enhance MEF2D activity and promote dopaminergic neuron survival. One example of a successful drug targeting MEF2D in Parkinson's disease is the dopamine agonist, pramipexole, which has been shown to enhance MEF2D activity and promote dopaminergic neuron survival. In myotonic dystrophy, MEF2D has been found to be involved in the regulation of muscle differentiation and function. Targeted drug discovery efforts have focused on developing drugs that can modulate MEF2D activity and improve muscle function in myotonic dystrophy patients. While there are currently no drugs on the market specifically targeting MEF2D in myotonic dystrophy, several drugs targeting other aspects of the disease have been approved, including the RNA-targeted therapy, nusinersen.",GO:0007512 adult heart development;GO:0001958 endochondral ossification;GO:0036075 replacement ossification,,Predicted intracellular proteins; Transcription factors:alpha-Helices exposed by beta-structures,Nucleoplasm (Enhanced); Additional: Vesicles,,(M32)PID HDAC CLASSIII PATHWAY; (M113)PID NFAT 3PATHWAY,(M5909)HALLMARK MYOGENESIS
ENSG00000068971.14,ENSG00000068971,PPP2R5B,-0.81815366,-1.729225561,-0.457014178,-0.268221242,protein phosphatase 2 regulatory subunit B'beta,"PPP2R5B is a gene that encodes a beta isoform of the regulatory subunit B56 subfamily of protein phosphatase 2A (PP2A). PP2A is a major Ser/Thr phosphatase that is involved in regulating cell growth and division. The enzyme consists of a catalytic subunit and a regulatory subunit, which can associate with various regulatory subunits. The B regulatory subunit, including PPP2R5B, is thought to modulate substrate selectivity and catalytic activity. PPP2R5B is a member of the phosphatase 2A regulatory subunit B family and is implicated in the negative control of cell growth and division.","PPP2R5B has been implicated in several diseases, including cancer, Alzheimer's disease, and schizophrenia. In cancer, PPP2R5B has been shown to act as a tumor suppressor by inhibiting cell growth and promoting apoptosis. Targeting PPP2R5B has been explored as a potential therapeutic strategy for cancer treatment. In Alzheimer's disease, PPP2R5B has been found to be involved in the regulation of tau phosphorylation, a key pathological feature of the disease. Targeting PPP2R5B may therefore have potential therapeutic benefits for Alzheimer's disease. In schizophrenia, PPP2R5B has been identified as a susceptibility gene, and its dysregulation has been linked to altered dopamine signaling. However, there are currently no drugs on the market that specifically target PPP2R5B. Nonetheless, several drugs that indirectly modulate PP2A activity, such as okadaic acid and fostriecin, have been developed and tested in preclinical studies for cancer treatment.",GO:0051388 positive regulation of neurotrophin TRK receptor signaling pathway;GO:0070317 negative regulation of G0 to G1 transition;GO:0051386 regulation of neurotrophin TRK receptor signaling pathway,,Predicted intracellular proteins,,,,(M5902)HALLMARK APOPTOSIS; (M5945)HALLMARK HEME METABOLISM
ENSG00000145041.15,ENSG00000145041,DCAF1,-0.818149969,-1.295047047,-0.814717267,-0.344685593,DDB1 and CUL4 associated factor 1,"DCAF1, also known as DDB1 and CUL4 associated factor 1, is a human gene that plays a role in various cellular processes. It enables estrogen receptor binding activity and histone kinase activity, specifically targeting histone H2A-T120. It is involved in cell competition in a multicellular organism, negative regulation of transcription by RNA polymerase II, and histone H2A-T120 phosphorylation. DCAF1 is located in the fibrillar center and nucleoplasm and is part of the Cul4-RING E3 ubiquitin ligase complex. It also colocalizes with COP9 signalosome. These findings suggest that DCAF1 may have important implications in gene regulation and cellular processes.","There is limited information on the disease implications of DCAF1. However, recent studies have suggested that DCAF1 may play a role in cancer development and progression. It has been found to be overexpressed in various types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts for DCAF1 are still in the early stages, but there is potential for the development of drugs that target the Cul4-RING E3 ubiquitin ligase complex, of which DCAF1 is a part. Currently, there are no drugs on the market that specifically target DCAF1, but there are drugs that target other components of the Cul4-RING E3 ubiquitin ligase complex, such as thalidomide and lenalidomide, which are used to treat multiple myeloma and other blood cancers.",GO:0035212 cell competition in a multicellular organism;GO:0033151 V(D)J recombination;GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus,yes,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported); Additional: Nucleoli fibrillar center,,,
ENSG00000140829.12,ENSG00000140829,DHX38,-0.818018325,-1.138849389,-1.039085244,-0.276120343,DEAH-box helicase 38,"DHX38 is a human gene that encodes a protein belonging to the DEAD/H box family of splicing factors. This protein is an ATPase and is essential for the catalytic step II in pre-mRNA splicing process. DEAD box proteins are RNA helicases that are involved in various cellular processes such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly. DHX38 is believed to be involved in embryogenesis, spermatogenesis, and cellular growth and division. This gene is also known as DEAH-box helicase 38 and its protein product is similar to yeast Prp16.","There is limited information available on the disease implications of DHX38. However, mutations in this gene have been associated with a rare genetic disorder called Perrault syndrome, which is characterized by hearing loss and ovarian failure in females. Targeted drug discovery efforts for DHX38 are also limited, as the function of this protein is essential for pre-mRNA splicing and any interference with its activity could have widespread effects on cellular processes. Currently, there are no drugs on the market that specifically target DHX38. However, there are drugs that target other RNA helicases, such as the DEAD box protein DDX3, which is involved in HIV replication. For example, the drug RG7834 is a small molecule inhibitor of DDX3 that has shown promise in preclinical studies as a potential treatment for HIV.","GO:0140588 chromatin looping;GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;GO:0000398 mRNA splicing, via spliceosome",,Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Nucleoplasm (Supported),,,
ENSG00000116580.18,ENSG00000116580,GON4L,-0.817560334,-1.018560408,-0.947663959,-0.486456635,gon-4 like,"GON4L, or gon-4 like, is a human gene that is predicted to have transcription coregulator activity and be involved in the regulation of transcription, DNA-templated. It is also predicted to act upstream of or within B cell differentiation. GON4L is located in the nuclear body.","There is limited information available on the disease implications of GON4L. However, recent studies have suggested that mutations in GON4L may be associated with intellectual disability and developmental delay. Targeted drug discovery efforts for GON4L are currently limited due to the lack of understanding of its exact function and role in disease. There are currently no drugs on the market that specifically target GON4L. However, there are drugs that target transcription coregulators and may have potential therapeutic applications for diseases associated with GON4L mutations. For example, BET inhibitors, which target the bromodomain and extraterminal domain (BET) family of transcription coregulators, have shown promise in preclinical studies for the treatment of various cancers and inflammatory diseases.",GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process;GO:0051252 regulation of RNA metabolic process,,Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Enhanced),,,
ENSG00000120008.16,ENSG00000120008,WDR11,-0.816838931,-1.139636328,-1.015640325,-0.29524014,WD repeat domain 11,"WDR11 is a gene that belongs to the WD repeat protein family. This family is involved in various cellular processes such as cell cycle progression, signal transduction, apoptosis, and gene regulation. WDR11 is located in the chromosome 10q25-26 region, which is often deleted in gliomas and other tumors. The gene is also disrupted by the t(10;19) translocation rearrangement in glioblastoma cells, indicating that it may be a candidate gene for the tumor suppressor locus. The protein encoded by WDR11 contains WD repeats, which are regions of approximately 40 amino acids that may facilitate the formation of heterotrimeric or multiprotein complexes.","There is limited information available on the disease implications of WDR11. However, studies have suggested that the gene may play a role in the development of gliomas and other tumors. Targeted drug discovery efforts for WDR11 are also limited, as the gene is not well-characterized and its function is not fully understood. Currently, there are no drugs on the market that specifically target WDR11. However, there are drugs that target other members of the WD repeat protein family, such as the proteasome inhibitor bortezomib, which is used to treat multiple myeloma. Additionally, there are ongoing efforts to develop drugs that target other WD repeat proteins, which may have implications for WDR11 in the future.",GO:0099041 vesicle tethering to Golgi;GO:0099022 vesicle tethering;GO:0006903 vesicle targeting,,Disease related genes; Human disease related genes:Endocrine and metabolic diseases:Hypothalamus and pituitary gland diseases; Predicted intracellular proteins,End piece;Microtubules;Primary cilium (Supported); Additional: Cytosol;Flagellar centriole;Plasma membrane;Principal piece;Vesicles,,,
ENSG00000157933.10,ENSG00000157933,SKI,-0.816486347,-1.034460873,-0.915798145,-0.499200022,SKI proto-oncogene,"The human gene SKI is a nuclear proto-oncogene protein that is similar to the avian sarcoma viral oncogene. It acts as a repressor of TGF-beta signaling and may be involved in the development of the neural tube and muscle differentiation. The gene is important in regulating cell growth and division, and mutations in this gene have been associated with various types of cancer. Overall, SKI plays a crucial role in the normal development and function of cells in the body.","Mutations in the SKI gene have been associated with various types of cancer, including breast, lung, and colorectal cancer. As a result, there has been significant interest in developing drugs that target SKI as a potential treatment for these cancers. One approach has been to develop small molecule inhibitors that can block the activity of SKI and restore TGF-beta signaling, which can help to slow or stop the growth of cancer cells. Several such inhibitors have been developed and are currently being tested in preclinical and clinical trials. One example is the drug TGF-beta receptor kinase inhibitor LY2157299, which has shown promise in early clinical trials for the treatment of pancreatic cancer. Another example is the drug SB431542, which has been shown to inhibit SKI activity and promote TGF-beta signaling in preclinical studies of breast cancer. While there is still much work to be done in this area, these early successes suggest that targeting SKI may be a promising approach for the development of new cancer therapies.",GO:0043585 nose morphogenesis;GO:0010626 negative regulation of Schwann cell proliferation;GO:0010624 regulation of Schwann cell proliferation,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Nucleoplasm (Supported); Additional: Nuclear bodies,,(M181)PID BMP PATHWAY; (M2)PID SMAD2 3NUCLEAR PATHWAY; (M195)PID CMYB PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING
ENSG00000132485.14,ENSG00000132485,ZRANB2,-0.815933598,-0.815473964,-0.844567224,-0.787759606,zinc finger RANBP2-type containing 2,"The human gene ZRANB2, also known as zinc finger RANBP2-type containing 2, is involved in RNA binding activity and is predicted to play a role in RNA splicing and mRNA processing. It is located in the nucleoplasm, which is the fluid inside the nucleus of a cell. The gene's function is not fully understood, but it is believed to be important for regulating gene expression and maintaining the integrity of the genome. Further research is needed to fully understand the role of ZRANB2 in human biology and disease.","There is limited information available on the disease implications of ZRANB2. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast and ovarian cancer. Targeted drug discovery efforts for ZRANB2 are still in the early stages, but there is potential for the development of drugs that target the RNA binding activity of the protein. Currently, there are no drugs on the market that specifically target ZRANB2. However, there are drugs that target other proteins involved in RNA splicing and mRNA processing, such as spliceosome inhibitors used in the treatment of certain types of cancer. Further research is needed to fully understand the potential therapeutic implications of targeting ZRANB2.",GO:0008380 RNA splicing;GO:0006397 mRNA processing;GO:0016071 mRNA metabolic process,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000066739.12,ENSG00000066739,ATG2B,-0.815905365,-0.956349649,-0.990715676,-0.50065077,autophagy related 2B,"ATG2B is a human gene that plays a crucial role in autophagy, a process by which cells break down and recycle their own components. The protein encoded by this gene is involved in the formation of autophagosomes, the structures that engulf and transport cellular material to be degraded. A duplication of a region that includes ATG2B has been linked to an increased risk of myeloid malignancies, a type of cancer that affects blood-forming cells. Overall, ATG2B is an important gene for maintaining cellular health and preventing the development of certain diseases.","There are currently no drugs on the market that specifically target ATG2B. However, research into autophagy and its role in disease has led to the development of drugs that indirectly affect this pathway. For example, the drug rapamycin, which is used to prevent organ rejection in transplant patients, inhibits a protein called mTOR that regulates autophagy. Other drugs that modulate autophagy are being investigated for their potential in treating cancer, neurodegenerative diseases, and other conditions.

In terms of disease implications, ATG2B has been linked to myeloid malignancies, as mentioned earlier. Additionally, mutations in other autophagy-related genes have been associated with a range of diseases, including Parkinson's disease, Alzheimer's disease, and Crohn's disease. Understanding the role of autophagy in these conditions may lead to the development of new treatments.

Overall, while there are currently no drugs that directly target ATG2B, research into autophagy and its role in disease has led to the development of promising new therapies.",GO:0000425 pexophagy;GO:0061723 glycophagy;GO:0030242 autophagy of peroxisome,,Predicted intracellular proteins; Transporters,Endoplasmic reticulum;Vesicles (Supported),,,
ENSG00000079432.7,ENSG00000079432,CIC,-0.815250891,-1.394217224,-0.660265896,-0.391269553,capicua transcriptional repressor,"CIC is a gene that encodes a transcriptional repressor protein belonging to the high mobility group (HMG)-box superfamily. It contains a conserved HMG domain involved in DNA binding and nuclear localization, and a conserved C-terminus. The N-terminal region of this protein interacts with Atxn1 to form a transcription repressor complex, and mutations in this gene have been associated with oligodendrogliomas. Translocation events resulting in gene fusions of this gene with both DUX4 and FOXO4 have been associated with round cell sarcomas. There are multiple pseudogenes of this gene found on chromosomes 1, 4, 6, 7, 16, 20, and the Y chromosome. Alternative splicing results in multiple transcript variants encoding different isoforms.","Mutations in the CIC gene have been associated with the development of oligodendrogliomas, a type of brain tumor. Targeted drug discovery efforts have focused on developing therapies that can inhibit the activity of the mutated CIC protein and prevent the growth and spread of these tumors. One example of a successful drug on the market is Temozolomide, which is used to treat glioblastoma, another type of brain tumor. However, there are currently no drugs specifically targeting CIC mutations. Further research is needed to identify new drug targets and develop effective therapies for patients with CIC-associated diseases.",GO:0035176 social behavior;GO:0051703 biological process involved in intraspecies interaction between organisms;GO:0007613 memory,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; Transcription factors:Other all-alpha-helical DNA-binding domains; Disease related genes; Cancer-related genes:Mutational cancer driver genes,Nucleoplasm (Supported); Additional: Vesicles,,,
ENSG00000110422.12,ENSG00000110422,HIPK3,-0.815237759,-1.209928997,-0.852664562,-0.383119718,homeodomain interacting protein kinase 3,"HIPK3, or homeodomain interacting protein kinase 3, is a gene that encodes a protein with serine/threonine kinase activity. It plays a role in mRNA transcription, negative regulation of apoptosis, and protein phosphorylation. HIPK3 is located in the cytosol, nuclear body, and plasma membrane.","There is limited information available on the disease implications of HIPK3. However, some studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for HIPK3 are also limited, but some studies have identified potential inhibitors of HIPK3 that could be used for cancer treatment. One example is a compound called CGP60474, which has been shown to inhibit HIPK3 activity and induce apoptosis in cancer cells. Another example is a compound called LLL12, which has been shown to inhibit HIPK3 and other kinases involved in cancer cell survival and proliferation. However, neither of these compounds have been approved for clinical use yet. Overall, more research is needed to fully understand the disease implications of HIPK3 and to develop effective targeted therapies.",GO:0043508 negative regulation of JUN kinase activity;GO:0043407 negative regulation of MAP kinase activity;GO:0046329 negative regulation of JNK cascade,yes,Enzymes; Kinases:CMGC Ser/Thr protein kinases; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Supported); Additional: Nuclear bodies,Fostamatinib,,
ENSG00000083799.18,ENSG00000083799,CYLD,-0.814586191,-1.027638422,-0.924955865,-0.491164286,CYLD lysine 63 deubiquitinase,"The CYLD gene encodes a protein that functions as a deubiquitinating enzyme with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains. Mutations in this gene have been linked to several inherited skin disorders, including cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome. The protein encoded by CYLD is found in the cytoplasm and is involved in the regulation of various cellular processes, including cell growth and division. Different isoforms of the protein are produced through alternate transcriptional splice variants.","Mutations in the CYLD gene have been linked to several inherited skin disorders, including cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome. These disorders are characterized by the development of benign skin tumors, which can become malignant in some cases. There are currently no targeted drugs available for these disorders, and treatment options are limited to surgical removal of the tumors. However, research efforts are underway to identify potential drug targets and develop new therapies. One promising approach is the use of histone deacetylase inhibitors, which have been shown to reduce tumor growth in animal models of cylindromatosis. Another potential target is the NF-kappaB signaling pathway, which is dysregulated in cells with CYLD mutations. Several drugs targeting this pathway are currently in clinical trials for other diseases, and may have potential for treating CYLD-related skin disorders in the future.",GO:2000493 negative regulation of interleukin-18-mediated signaling pathway;GO:0097343 ripoptosome assembly;GO:1901026 ripoptosome assembly involved in necroptotic process,,Human disease related genes:Skin diseases:Skin and soft tissue diseases; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Peptidases:Cysteine-type peptidases; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Mutational cancer driver genes,Centriolar satellite (Supported); Additional: Basal body;Nucleoplasm;Primary cilium transition zone;Principal piece,,(M37)PID NFKAPPAB CANONICAL PATHWAY; (M128)PID TNF PATHWAY,(M5902)HALLMARK APOPTOSIS
ENSG00000148484.18,ENSG00000148484,RSU1,-0.814552682,-1.123731269,-0.836599426,-0.483327349,Ras suppressor protein 1,"RSU1, or Ras suppressor protein 1, is a gene that plays a role in the Ras signal transduction pathway, growth inhibition, and nerve-growth factor induced differentiation processes. It was initially identified in mice for its ability to inhibit v-Ras transformation. Multiple variants of the gene have been reported, with one variant found only in glioma tumors. Studies in mouse and human cell lines have shown that RSU1 is involved in regulating cell growth and differentiation.","There is limited information available on the disease implications of RSU1. However, studies have suggested that the gene may play a role in the development and progression of certain cancers, including glioma and breast cancer. Targeted drug discovery efforts for RSU1 are also limited, with no drugs currently on the market specifically targeting this gene. However, there are drugs that target the Ras signaling pathway, which RSU1 is a part of, such as farnesyltransferase inhibitors and MEK inhibitors. These drugs have been approved for the treatment of certain cancers, including melanoma and non-small cell lung cancer. While RSU1 itself may not be a direct target for drug development, further research on its role in cancer development and progression may lead to the identification of new therapeutic targets and the development of novel treatments.",GO:0043547 positive regulation of GTPase activity;GO:0010811 positive regulation of cell-substrate adhesion;GO:0043087 regulation of GTPase activity,,Predicted intracellular proteins,Vesicles (Approved),,,(M5915)HALLMARK APICAL JUNCTION
ENSG00000198160.15,ENSG00000198160,MIER1,-0.814417263,-1.018609088,-1.113957285,-0.310685417,MIER1 transcriptional regulator,The MIER1 gene encodes a protein that was first discovered in Xenopus laevis and is involved in mesoderm induction early response. The protein acts as a transcriptional regulator and has multiple isoforms due to alternative splicing of its transcript variants. Some of these isoforms lack a C-terminal nuclear localization signal.,"There is limited information available on the disease implications of the MIER1 gene. However, recent studies have suggested that MIER1 may play a role in cancer progression and metastasis. Specifically, MIER1 has been shown to be overexpressed in several types of cancer, including breast, lung, and ovarian cancer. Targeted drug discovery efforts for MIER1 are still in the early stages, but there is potential for the development of drugs that target MIER1 expression or activity as a potential cancer therapy. Currently, there are no drugs on the market that specifically target MIER1, but there are several drugs that target other proteins involved in cancer progression and metastasis, such as chemotherapy drugs and targeted therapies like trastuzumab for HER2-positive breast cancer. Further research is needed to fully understand the role of MIER1 in cancer and to develop effective targeted therapies.",GO:0043123 positive regulation of canonical NF-kappaB signal transduction;GO:0043122 regulation of canonical NF-kappaB signal transduction;GO:0000122 negative regulation of transcription by RNA polymerase II,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000136738.15,ENSG00000136738,STAM,-0.814403906,-1.329721772,-0.717158553,-0.396331393,signal transducing adaptor molecule,"The human gene STAM (signal transducing adaptor molecule) belongs to a family of proteins that mediate downstream signaling of cytokine receptors and play a role in ER to Golgi trafficking by interacting with the coat protein II complex. STAM also associates with hepatocyte growth factor-regulated substrate to form the endosomal sorting complex required for transport-0 (ESCRT-0), which sorts ubiquitinated membrane proteins to the ESCRT-1 complex for lysosomal degradation. The gene has alternatively spliced transcript variants.","Research on the STAM gene has revealed its potential involvement in various diseases, including cancer, viral infections, and neurodegenerative disorders. For instance, studies have shown that STAM is overexpressed in several types of cancer, including breast, lung, and liver cancer, and its inhibition can lead to reduced tumor growth. Additionally, STAM has been found to play a role in the replication of certain viruses, such as HIV and hepatitis C virus, making it a potential target for antiviral drug development. In terms of neurodegenerative disorders, STAM has been implicated in the pathogenesis of Alzheimer's disease, and its inhibition has been shown to reduce the accumulation of amyloid-beta plaques in the brain. While there are currently no drugs on the market that specifically target STAM, research efforts are ongoing to develop small molecule inhibitors and other therapeutics that can modulate its activity.",GO:1903551 regulation of extracellular exosome assembly;GO:1903543 positive regulation of exosomal secretion;GO:0043328 protein transport to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway,,Predicted intracellular proteins,Vesicles (Supported),,(M122)PID IL2 1PATHWAY,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000158201.10,ENSG00000158201,ABHD3,-0.813955908,-1.09126511,-0.772856874,-0.577745741,"abhydrolase domain containing 3, phospholipase","ABHD3 is a human gene that encodes a protein with an alpha/beta hydrolase fold, a catalytic domain found in many enzymes. However, the function of this protein is currently unknown.","There is limited information available on the disease implications of ABHD3. However, some studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for ABHD3 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein. While there are no drugs currently on the market that specifically target ABHD3, there are several drugs that target other alpha/beta hydrolase fold proteins, such as acetylcholinesterase inhibitors used to treat Alzheimer's disease and organophosphate poisoning. These drugs provide a starting point for the development of ABHD3-targeted therapies.",GO:0051793 medium-chain fatty acid catabolic process;GO:0051792 medium-chain fatty acid biosynthetic process;GO:0051791 medium-chain fatty acid metabolic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoplasm;Plasma membrane (Approved); Additional: Vesicles,,,
ENSG00000182606.17,ENSG00000182606,TRAK1,-0.813851468,-1.251593445,-0.775815558,-0.4141454,trafficking kinesin protein 1,TRAK1 is a human gene that is involved in the transport of cellular components from endosomes to lysosomes. It is predicted to have GABA receptor binding activity and myosin binding activity. TRAK1 is located in early endosomes and mitochondria and has been implicated in developmental and epileptic encephalopathy 68.,"TRAK1 has been implicated in developmental and epileptic encephalopathy 68 (DEE68), a rare genetic disorder characterized by early-onset seizures, developmental delay, and intellectual disability. While there are currently no targeted drug discovery efforts specifically for TRAK1, there are several drugs on the market that are used to treat epilepsy and other seizure disorders, which may be beneficial for individuals with DEE68. Examples of successful drugs for epilepsy include valproic acid, carbamazepine, and lamotrigine. However, it is important to note that the effectiveness of these drugs can vary depending on the specific genetic mutation causing the disorder, and personalized treatment plans may be necessary.",GO:0098957 anterograde axonal transport of mitochondrion;GO:0019896 axonal transport of mitochondrion;GO:0048311 mitochondrion distribution,,Disease related genes; Human disease related genes:Nervous system diseases:Epilepsy; Predicted intracellular proteins,Endoplasmic reticulum (Approved); Additional: Nucleoplasm,,,
ENSG00000180398.13,ENSG00000180398,MCFD2,-0.812382569,-1.204833895,-0.943063261,-0.289250551,"multiple coagulation factor deficiency 2, ER cargo receptor complex subunit","MCFD2 is a gene that encodes a soluble luminal protein with two calmodulin-like EF-hand motifs at its C-terminus. This protein forms a complex with LMAN1 that facilitates the transport of coagulation factors V and VIII from the endoplasmic reticulum to the Golgi apparatus via an endoplasmic reticulum Golgi intermediate compartment. Mutations in this gene cause combined deficiency of FV and FVIII, a rare autosomal recessive bleeding disorder characterized by mild to moderate bleeding and coordinate reduction in plasma FV and FVIII levels. This protein has also been shown to maintain stem cell potential in adult central nervous system and is a marker for testicular germ cell tumors. Alternative splicing results in multiple transcript variants encoding distinct isoforms.","Combined deficiency of FV and FVIII is a rare bleeding disorder caused by mutations in the MCFD2 gene. There are currently no targeted drug discovery efforts specifically for this disorder, but treatment options include replacement therapy with FV and FVIII concentrates. In addition, antifibrinolytic agents such as tranexamic acid can be used to prevent bleeding episodes. There are no drugs on the market specifically for this disorder, but successful drugs for other bleeding disorders such as hemophilia A and B include factor replacement therapies such as Advate, Eloctate, and Alprolix. Gene therapy is also being explored as a potential treatment option for hemophilia, which may have implications for combined deficiency of FV and FVIII in the future.",GO:0015031 protein transport;GO:0016192 vesicle-mediated transport;GO:0045184 establishment of protein localization,,Predicted intracellular proteins; Transporters; Potential drug targets; Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases,,"Antihemophilic factor, human recombinant; Lonoctocog alfa; Moroctocog alfa",,
ENSG00000121486.12,ENSG00000121486,TRMT1L,-0.810472916,-1.125193533,-0.814066439,-0.492158777,tRNA methyltransferase 1 like,"TRMT1L is a human gene that encodes a protein with similarities to N2,N2-dimethylguanosine tRNA methyltransferase found in other organisms. The protein is involved in motor coordination and exploratory behavior, and it may also play a role in modulating postnatal neuronal functions. The gene has alternatively spliced transcripts.","There is limited information available on the disease implications of TRMT1L. However, recent studies have suggested that mutations in this gene may be associated with developmental disorders such as intellectual disability and autism spectrum disorder. Targeted drug discovery efforts for TRMT1L are currently in their early stages, and there are no drugs on the market that specifically target this gene. However, there are several drugs that have been approved for the treatment of developmental disorders that may indirectly affect TRMT1L function. For example, drugs such as risperidone and aripiprazole are commonly used to treat symptoms of autism spectrum disorder, while drugs such as methylphenidate and atomoxetine are used to treat attention deficit hyperactivity disorder (ADHD). While these drugs do not directly target TRMT1L, they may help to alleviate some of the symptoms associated with developmental disorders that are thought to be linked to this gene.",GO:0002940 tRNA N2-guanine methylation;GO:0030488 tRNA methylation;GO:0001510 RNA methylation,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Nucleoli,,,
ENSG00000143569.19,ENSG00000143569,UBAP2L,-0.810244495,-1.272443495,-0.732690985,-0.425599005,ubiquitin associated protein 2 like,The human gene UBAP2L is a ubiquitin associated protein 2 like gene that enables RNA binding activity and is involved in the binding activity of sperm to zona pellucida and stress granule assembly. It acts upstream of or within hematopoietic stem cell homeostasis and is part of the PcG protein complex. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of UBAP2L. However, recent studies have suggested that UBAP2L may play a role in the development and progression of certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for UBAP2L are still in the early stages, but there is potential for the development of novel therapies that target this gene. Currently, there are no drugs on the market that specifically target UBAP2L. However, there are several drugs that target other genes involved in similar pathways, such as the PcG protein complex, which UBAP2L is a part of. Examples of successful drugs in this category include EZH2 inhibitors, which are used to treat certain types of lymphoma, and BET inhibitors, which are being investigated for the treatment of various types of cancer.",GO:0062029 positive regulation of stress granule assembly;GO:0062028 regulation of stress granule assembly;GO:0061484 hematopoietic stem cell homeostasis,,Predicted intracellular proteins,Cytosol;Nuclear speckles (Approved),,,
ENSG00000020922.13,ENSG00000020922,MRE11,-0.80902323,-1.129448988,-0.724043035,-0.573577667,"MRE11 homolog, double strand break repair nuclease","The human gene MRE11 is involved in various DNA repair processes such as homologous recombination, telomere length maintenance, and DNA double-strand break repair. The protein encoded by this gene has both 3' to 5' exonuclease activity and endonuclease activity. It forms a complex with the RAD50 homolog, which is required for nonhomologous joining of DNA ends and has increased single-stranded DNA endonuclease and 3' to 5' exonuclease activities. This protein also promotes the joining of noncomplementary ends in vitro using short homologies near the ends of the DNA fragments. Alternative splicing of this gene results in two transcript variants encoding different isoforms.","Mutations in the MRE11 gene have been associated with several genetic disorders, including ataxia-telangiectasia-like disorder (ATLD), Nijmegen breakage syndrome (NBS), and breast cancer. ATLD is a rare autosomal recessive disorder characterized by progressive cerebellar ataxia, oculomotor apraxia, and telangiectasias. NBS is a rare autosomal recessive disorder characterized by microcephaly, growth retardation, immunodeficiency, and an increased risk of cancer. In breast cancer, MRE11 mutations have been found to be associated with an increased risk of developing the disease.

Targeted drug discovery efforts for MRE11 have focused on developing inhibitors that can sensitize cancer cells to radiation therapy. One such inhibitor is mirin, which has been shown to sensitize cancer cells to radiation therapy by inhibiting the MRE11-RAD50-NBS1 (MRN) complex. Another potential drug target is the interaction between MRE11 and ATM, a protein kinase that plays a critical role in DNA damage response. Inhibitors of this interaction have been shown to sensitize cancer cells to radiation therapy.

There are currently no drugs on the market that directly target MRE11. However, several drugs that indirectly target MRE11, such as PARP inhibitors, have been approved for the treatment of cancer. PARP inhibitors work by inhibiting the repair of single-strand DNA breaks, which can lead to the accumulation of double-strand DNA breaks that require MRE11 for repair. Olaparib, rucaparib, and niraparib are examples of PARP inhibitors that have been approved for the treatment of ovarian and breast cancer.",GO:0097551 mitochondrial double-strand break repair;GO:0097552 mitochondrial double-strand break repair via homologous recombination;GO:0031860 telomeric 3' overhang formation,,Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Disease related genes; Human disease related genes:Immune system diseases:Primary immunodeficiency; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Enhanced),,(M258)PID BARD1 PATHWAY; (M84)PID ATM PATHWAY; (M1)PID FANCONI PATHWAY,(M5925)HALLMARK E2F TARGETS
ENSG00000157510.14,ENSG00000157510,AFAP1L1,-0.809008651,-0.501053854,-0.6056401,-1.320331999,actin filament associated protein 1 like 1,"AFAP1L1 is a human gene that is predicted to have SH3 domain binding activity. It is also predicted to be located in cell junctions, cell projections, and podosomes, and to be active in the cytosol. The gene's function is associated with actin filaments, which are important for cell movement and shape. While the exact role of AFAP1L1 is not fully understood, it is believed to play a role in cell adhesion and migration. This gene may have implications in various diseases, including cancer and neurological disorders.","AFAP1L1 has been implicated in various diseases, including cancer and neurological disorders. In cancer, AFAP1L1 has been shown to promote tumor growth and metastasis by regulating cell migration and invasion. In particular, AFAP1L1 has been found to be overexpressed in breast, lung, and colorectal cancers. In neurological disorders, AFAP1L1 has been linked to schizophrenia and bipolar disorder, as well as to the development of the nervous system.

There are currently no drugs on the market that specifically target AFAP1L1. However, there have been efforts to develop drugs that target the protein-protein interactions involving AFAP1L1 and its binding partners. For example, a small molecule inhibitor of AFAP1L1 binding to cortactin has been developed and shown to inhibit cancer cell migration and invasion in vitro. Additionally, a peptide inhibitor of AFAP1L1 binding to the actin-binding protein Ena/VASP has been shown to reduce the growth and metastasis of breast cancer cells in vivo.

Overall, AFAP1L1 is a promising target for drug discovery efforts in cancer and neurological disorders. Further research is needed to fully understand the role of AFAP1L1 in these diseases and to develop effective therapies targeting this protein.",,,Predicted intracellular proteins,,,,
ENSG00000047056.16,ENSG00000047056,WDR37,-0.808793505,-1.234716333,-0.655272129,-0.536392053,WD repeat domain 37,"WDR37 is a gene that belongs to the WD repeat protein family. This family is involved in various cellular processes such as cell cycle progression, signal transduction, apoptosis, and gene regulation. WD repeats are regions of approximately 40 amino acids that are minimally conserved and are typically bracketed by gly-his and trp-asp (GH-WD). These regions may facilitate the formation of heterotrimeric or multiprotein complexes. The function of WDR37 is not yet fully understood, but it is believed to play a role in the regulation of gene expression.","There is limited information available on the disease implications of WDR37. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for WDR37 are still in the early stages, but there is potential for this gene to be a target for cancer therapies. Currently, there are no drugs on the market that specifically target WDR37. However, there are several drugs that target other members of the WD repeat protein family, such as the proteasome inhibitor bortezomib, which is used to treat multiple myeloma. Additionally, the drug rapamycin, which targets the protein mTOR, has been shown to interact with several WD repeat proteins and is used to treat certain types of cancer and autoimmune diseases.",GO:0022038 corpus callosum development;GO:0002260 lymphocyte homeostasis;GO:0001776 leukocyte homeostasis,,Disease related genes; Predicted intracellular proteins,Intermediate filaments (Approved),,,(M5942)HALLMARK UV RESPONSE DN
ENSG00000136560.14,ENSG00000136560,TANK,-0.808381424,-0.927781033,-0.848436079,-0.648927161,TRAF family member associated NFKB activator,"The human gene TANK, also known as TRAF family member associated NFKB activator, encodes a protein that can bind to other proteins in the TRAF family and inhibit their function by sequestering them in the cytoplasm. This can block certain signaling pathways, such as the NF-kappa-B activation pathway mediated by the Epstein-Barr virus transforming protein LMP1. TANK has three different isoforms due to alternative splicing.","Research has shown that TANK may play a role in various diseases, including cancer, autoimmune disorders, and viral infections. In cancer, TANK has been found to be overexpressed in certain types of tumors, such as breast and lung cancer, and may contribute to tumor growth and survival. In autoimmune disorders, TANK has been implicated in the regulation of immune responses and may be a potential target for therapeutic intervention. Additionally, TANK has been shown to be involved in the replication of certain viruses, such as hepatitis C virus and human immunodeficiency virus (HIV), making it a potential target for antiviral drug development.

Several drug discovery efforts have targeted TANK, including small molecule inhibitors and monoclonal antibodies. However, there are currently no drugs on the market that specifically target TANK. One example of a drug that indirectly affects TANK is bortezomib, a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. Bortezomib has been shown to downregulate TANK expression and inhibit NF-kappa-B activation, which may contribute to its anti-tumor effects. Other potential drug targets related to TANK include TRAF proteins and NF-kappa-B signaling pathways.",GO:2000158 positive regulation of ubiquitin-specific protease activity;GO:2000152 regulation of ubiquitin-specific protease activity;GO:1903003 positive regulation of protein deubiquitination,,Predicted intracellular proteins,Cytosol (Supported); Additional: Nucleoli,,,(M5890)HALLMARK TNFA SIGNALING VIA NFKB; (M5905)HALLMARK ADIPOGENESIS
ENSG00000073921.18,ENSG00000073921,PICALM,-0.808263281,-1.347225942,-0.862674205,-0.214889695,phosphatidylinositol binding clathrin assembly protein,"PICALM is a gene that encodes a protein involved in clathrin-mediated endocytosis, a process by which cells take in molecules from their environment. The protein recruits clathrin and adaptor protein complex 2 (AP2) to cell membranes to form coated pits and vesicles. It may also regulate the size of the clathrin cage, which determines the amount of membrane to be recycled. PICALM is involved in endocytosis at the neuromuscular junction and is associated with the risk of Alzheimer's disease. Chromosomal translocations involving PICALM have been found in various types of leukemia and lymphomas. Multiple isoforms of the protein are produced by alternative splicing.","PICALM has been implicated in the pathogenesis of Alzheimer's disease (AD), with genetic studies identifying it as a risk factor for the disease. The protein is involved in the endocytosis of amyloid precursor protein (APP), which is processed to form amyloid-beta (A?) peptides that accumulate in the brains of AD patients. Targeting PICALM could therefore be a potential therapeutic strategy for AD. However, there are currently no drugs on the market that specifically target PICALM. Some drugs that have been approved for AD, such as acetylcholinesterase inhibitors and memantine, target other aspects of the disease pathology. There are ongoing efforts to develop drugs that target PICALM, including small molecule inhibitors and gene therapy approaches.",GO:0097753 membrane bending;GO:0150093 amyloid-beta clearance by transcytosis;GO:0016185 synaptic vesicle budding from presynaptic endocytic zone membrane,,Disease related genes; Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Cancer-related genes; Predicted intracellular proteins,Vesicles (Enhanced),,,(M5945)HALLMARK HEME METABOLISM
ENSG00000058668.15,ENSG00000058668,ATP2B4,-0.808142061,-1.164354559,-0.93545207,-0.324619553,ATPase plasma membrane Ca2+ transporting 4,"ATP2B4 is a gene that encodes the plasma membrane calcium ATPase isoform 4, which belongs to the family of P-type primary ion transport ATPases. These enzymes play a critical role in intracellular calcium homeostasis by removing bivalent calcium ions from eukaryotic cells against very large concentration gradients. The mammalian plasma membrane calcium ATPase isoforms are encoded by at least four separate genes, and the diversity of these enzymes is further increased by alternative splicing of transcripts. The expression of different isoforms and splice variants is regulated in a developmental, tissue- and cell type-specific manner, suggesting that these pumps are functionally adapted to the physiological needs of particular cells and tissues.","ATP2B4 has been implicated in several diseases, including hypertension, heart failure, and neurodegenerative disorders such as Alzheimer's disease. In hypertension, ATP2B4 variants have been associated with altered calcium handling in vascular smooth muscle cells, leading to increased vasoconstriction and elevated blood pressure. In heart failure, decreased expression of ATP2B4 has been observed, leading to impaired calcium handling and contractility in cardiomyocytes. Targeted drug discovery efforts have focused on developing small molecule inhibitors of the plasma membrane calcium ATPase isoforms as potential treatments for hypertension and heart failure. One example of a successful drug on the market is the calcium channel blocker amlodipine, which indirectly inhibits ATP2B4 by reducing calcium influx into cells. Another example is the cardiac glycoside digoxin, which directly inhibits ATP2B4 and is used to treat heart failure.",GO:0098736 negative regulation of the force of heart contraction;GO:1903248 regulation of citrulline biosynthetic process;GO:1903249 negative regulation of citrulline biosynthetic process,,Predicted intracellular proteins; Transporters:Primary Active Transporters; FDA approved drug targets:Small molecule drugs; Enzymes; ENZYME proteins,Plasma membrane;Primary cilium (Supported); Additional: Basal body;Mitochondria,,,(M5942)HALLMARK UV RESPONSE DN; (M5907)HALLMARK ESTROGEN RESPONSE LATE
ENSG00000062725.10,ENSG00000062725,APPBP2,-0.807828663,-1.046126171,-0.867095816,-0.510264001,amyloid beta precursor protein binding protein 2,"APPBP2 is a gene that encodes a protein that interacts with microtubules and is involved in the transport and/or processing of beta-amyloid precursor protein, which is thought to play a role in Alzheimer's disease. The protein may also be involved in regulating cell death and has been found to be highly expressed in breast cancer. Alternative splicing of the gene results in multiple transcript variants.","APPBP2 has been implicated in Alzheimer's disease due to its involvement in the processing of beta-amyloid precursor protein, which is a key component of the amyloid plaques found in the brains of Alzheimer's patients. Targeting APPBP2 could potentially lead to the development of new treatments for Alzheimer's disease. However, there are currently no drugs on the market that specifically target APPBP2.

There have been some efforts to develop drugs that target beta-amyloid precursor protein processing, which indirectly affects APPBP2. For example, beta-secretase inhibitors, such as verubecestat and lanabecestat, have been developed to reduce the production of beta-amyloid, but their efficacy in clinical trials has been limited.

Another approach to targeting Alzheimer's disease is to focus on reducing inflammation in the brain, which is thought to contribute to the disease. One drug that has been successful in this regard is aducanumab, which targets beta-amyloid plaques and has shown promising results in clinical trials.

In terms of cancer, APPBP2 has been found to be highly expressed in breast cancer and may play a role in regulating cell death. However, there are currently no drugs on the market that specifically target APPBP2 in breast cancer.",GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process;GO:0010498 proteasomal protein catabolic process;GO:0006511 ubiquitin-dependent protein catabolic process,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported),,(M151)PID AR TF PATHWAY,(M5908)HALLMARK ANDROGEN RESPONSE
ENSG00000101911.13,ENSG00000101911,PRPS2,-0.807740666,-0.994733309,-0.825720609,-0.602768081,phosphoribosyl pyrophosphate synthetase 2,"The PRPS2 gene encodes a protein called phosphoribosyl pyrophosphate synthetase 2, which is involved in the production of purines and pyrimidines. The protein catalyzes the synthesis of 5-phosphoribosyl 1-pyrophosphate from ATP and D-ribose 5-phosphate. There are multiple transcript variants of the gene due to alternate splicing.","Mutations in the PRPS2 gene have been associated with several diseases, including Arts Syndrome, X-linked Charcot-Marie-Tooth disease, and X-linked non-syndromic sensorineural deafness. Arts Syndrome is a rare X-linked disorder characterized by developmental delay, intellectual disability, and sensorineural hearing loss. X-linked Charcot-Marie-Tooth disease is a hereditary motor and sensory neuropathy that affects the peripheral nerves, leading to muscle weakness and atrophy. X-linked non-syndromic sensorineural deafness is a type of hearing loss that affects only the inner ear.

Targeted drug discovery efforts for PRPS2-related diseases are still in the early stages. However, some studies have suggested that inhibition of PRPS2 activity could be a potential therapeutic strategy for certain cancers, such as acute myeloid leukemia and breast cancer. Inhibition of PRPS2 could lead to a decrease in the production of purines and pyrimidines, which are essential for cancer cell proliferation.

There are currently no drugs on the market that specifically target PRPS2. However, there are several drugs that target the purine and pyrimidine synthesis pathways, which could indirectly affect PRPS2 activity. For example, methotrexate is a chemotherapy drug that inhibits dihydrofolate reductase, an enzyme involved in the synthesis of purines and pyrimidines. Another example is azathioprine, an immunosuppressive drug that inhibits purine synthesis.",GO:0006015 5-phosphoribose 1-diphosphate biosynthetic process;GO:0046391 5-phosphoribose 1-diphosphate metabolic process;GO:0006098 pentose-phosphate shunt,yes,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Vesicles (Approved); Additional: Basal body;Nuclear speckles,,,(M5926)HALLMARK MYC TARGETS V1
ENSG00000137504.14,ENSG00000137504,CREBZF,-0.807725703,-1.058290682,-0.964845665,-0.400040761,CREB/ATF bZIP transcription factor,"CREBZF is a human gene that encodes for a CREB/ATF bZIP transcription factor. This gene is involved in negative regulation of gene expression, epigenetic regulation of transcription, DNA-templated, and response to virus. It enables identical protein binding activity and is located in both the mitochondrion and nucleoplasm.","There is limited information available on the disease implications of CREBZF. However, recent studies have suggested that this gene may play a role in the development and progression of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for CREBZF are still in the early stages, but there is potential for this gene to be targeted in cancer therapy. One example of a successful drug on the market that targets a related transcription factor is Imbruvica (ibrutinib), which targets the B-cell receptor signaling pathway in certain types of leukemia and lymphoma. However, more research is needed to fully understand the potential therapeutic applications of targeting CREBZF.",GO:0036500 ATF6-mediated unfolded protein response;GO:0006984 ER-nucleus signaling pathway;GO:0140467 integrated stress response signaling,,Transcription factors:Basic domains; Predicted intracellular proteins,Mitochondria;Nucleoplasm (Approved),,,
ENSG00000164117.14,ENSG00000164117,FBXO8,-0.807345334,-1.260347135,-1.037304796,-0.124384069,F-box protein 8,"FBXO8 is a gene that encodes a member of the F-box protein family, which is involved in phosphorylation-dependent ubiquitination. The F-box proteins are divided into three classes, and FBXO8 belongs to the Fbxs class. It contains a C-terminal amino acid sequence that is similar to a portion of yeast Sec7p, a regulator of vesicular protein transport. FBXO8 may interact with ADP-ribosylation factor(s) (ARFs) and exhibit ARF-GEF activity.","There is limited information available on the disease implications of FBXO8. However, recent studies have suggested that mutations in FBXO8 may be associated with neurological disorders such as Parkinson's disease and intellectual disability. Targeted drug discovery efforts for FBXO8 are also limited, but some studies have suggested that small molecule inhibitors of the F-box protein family may have therapeutic potential for certain types of cancer. Currently, there are no drugs on the market that specifically target FBXO8. However, there are several drugs that target other members of the F-box protein family, such as thalidomide and lenalidomide, which are used to treat multiple myeloma and other blood cancers. Additionally, bortezomib, a proteasome inhibitor, has been approved for the treatment of multiple myeloma and mantle cell lymphoma, and it works by inhibiting the degradation of proteins targeted by F-box proteins.",GO:0032012 regulation of ARF protein signal transduction;GO:0051056 regulation of small GTPase mediated signal transduction;GO:0006511 ubiquitin-dependent protein catabolic process,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,(M86)PID ARF6 PATHWAY,
ENSG00000163904.13,ENSG00000163904,SENP2,-0.806692389,-1.172610755,-0.553603392,-0.693863019,SUMO specific peptidase 2,"SENP2 is a gene that encodes for an enzyme called SUMO specific peptidase 2. This enzyme is responsible for processing newly synthesized SUMO1, a small ubiquitin-like protein, into a form that can be conjugated to other proteins. Additionally, SENP2 catalyzes the deconjugation of SUMO1-containing species. This gene is important for regulating protein function and stability, as well as cellular processes such as DNA repair and cell cycle progression. Mutations in SENP2 have been associated with various diseases, including cancer and neurodegenerative disorders.","SENP2 has been implicated in various diseases, including cancer and neurodegenerative disorders. In cancer, SENP2 has been shown to regulate the activity of several oncogenes and tumor suppressor genes, making it a potential target for cancer therapy. In neurodegenerative disorders, SENP2 has been linked to the regulation of protein aggregation and clearance, suggesting a potential role in the pathogenesis of these diseases.

Targeted drug discovery efforts for SENP2 have focused on developing small molecule inhibitors that can selectively target the enzyme. Several compounds have been identified that show promising activity against SENP2 in preclinical studies, including ML792 and ML792 analogs. These compounds have been shown to inhibit SENP2 activity and induce cell death in cancer cells.

Currently, there are no drugs on the market that specifically target SENP2. However, there are several drugs that indirectly affect SENP2 activity, such as proteasome inhibitors and histone deacetylase inhibitors. These drugs have been shown to modulate the activity of SENP2 and other enzymes involved in protein degradation and modification, leading to their use in cancer therapy.",GO:0016926 protein desumoylation;GO:0016925 protein sumoylation;GO:0031648 protein destabilization,,Peptidases:Cysteine-type peptidases; Enzymes; Transporters:Transporter channels and pores; Predicted intracellular proteins,Cytosol (Supported),,(M5493)WNT SIGNALING,
ENSG00000079150.18,ENSG00000079150,FKBP7,-0.806687848,-1.655510365,-0.613949558,-0.150603619,FKBP prolyl isomerase 7,"FKBP7 is a human gene that encodes a protein belonging to the FKBP-type peptidyl-prolyl cis/trans isomerase (PPIase) family. This protein exhibits PPIase activity and functions as a molecular chaperone. In mice, a similar protein is located in the endoplasmic reticulum and binds calcium.","There is limited information available on the disease implications of FKBP7. However, recent studies have suggested that this gene may play a role in cancer progression and metastasis. Specifically, FKBP7 has been found to be overexpressed in several types of cancer, including breast, lung, and pancreatic cancer. Targeted drug discovery efforts for FKBP7 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target FKBP7, several drugs that target other members of the FKBP family have been approved for use in various diseases. For example, the immunosuppressant drug tacrolimus (also known as FK506) targets FKBP12 and is used to prevent organ rejection in transplant patients.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Enzymes; ENZYME proteins:Isomerase; Predicted intracellular proteins,Endoplasmic reticulum (Approved),,,
ENSG00000225648.5,ENSG00000225648,SBDSP1,-0.805925738,-1.125769103,-1.233599551,-0.05840856,None,None,None,None,None,None,None,None,None,None
ENSG00000164961.16,ENSG00000164961,WASHC5,-0.805837709,-0.88406996,-1.042889235,-0.490553933,WASH complex subunit 5,"The WASHC5 gene encodes a protein called strumpellin, which is predicted to have multiple transmembrane domains and a spectrin-repeat-containing domain. This gene is expressed throughout the body, with the highest expression in skeletal muscle. The protein is named after Strumpell disease, a form of hereditary spastic paraplegia (HSP), which is characterized by progressive lower extremity spasticity caused by axonal degeneration in the longest descending and ascending corticospinal tracts. More than 30 loci have been implicated in hereditary spastic paraplegia diseases.","There is limited information available on the disease implications of the WASHC5 gene specifically. However, mutations in other genes associated with hereditary spastic paraplegia (HSP) have been linked to defects in axonal transport, mitochondrial function, and endoplasmic reticulum stress response. Targeted drug discovery efforts for HSP have focused on identifying compounds that can improve axonal transport, reduce oxidative stress, and enhance mitochondrial function. Some promising drug candidates include the antioxidant N-acetylcysteine, the mitochondrial-targeted compound SS-31, and the microtubule-stabilizing agent epothilone D. Currently, there are no FDA-approved drugs specifically for HSP, but some drugs used to treat related conditions such as multiple sclerosis and spinal cord injury may provide symptomatic relief for HSP patients.",GO:0140285 endosome fission;GO:0040038 polar body extrusion after meiotic divisions;GO:0033206 meiotic cytokinesis,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Human disease related genes:Congenital malformations:Other congenital malformations,Cytokinetic bridge;Cytosol;Mitotic spindle (Approved); Additional: Basal body;Centrosome;Primary cilium,,,
ENSG00000087338.5,ENSG00000087338,GMCL1,-0.805778584,-1.010695308,-0.991334124,-0.415306322,"germ cell-less 1, spermatogenesis associated","GMCL1 is a gene that encodes a nuclear envelope protein that is believed to be involved in spermatogenesis, either directly or indirectly by influencing other genes involved in the process. It is the human homolog of the germ cell-less gene found in mice and drosophila. The gene has multiple exons and is located on chromosome 2, but there is also a single-exon locus on chromosome 5 that encodes a highly-related protein. The exact role of GMCL1 in spermatogenesis is not yet fully understood, but it is thought to be important for the proper development and function of male germ cells.","There is limited information available on the disease implications of GMCL1. However, some studies have suggested that mutations in this gene may be associated with male infertility. Targeted drug discovery efforts for GMCL1 are also limited, as the exact role of the gene in spermatogenesis is not yet fully understood. However, there have been some studies exploring the potential of using GMCL1 as a target for male contraception. One study found that a small molecule inhibitor of GMCL1 was able to disrupt spermatogenesis in mice, leading to reversible infertility. Currently, there are no drugs on the market that specifically target GMCL1. However, there are several drugs used to treat male infertility, such as clomiphene citrate and gonadotropins, that indirectly affect spermatogenesis by targeting hormones involved in the process.",GO:0007281 germ cell development;GO:0022412 cellular process involved in reproduction in multicellular organism;GO:0007283 spermatogenesis,,Predicted intracellular proteins,,,,(M5951)HALLMARK SPERMATOGENESIS
ENSG00000176142.13,ENSG00000176142,TMEM39A,-0.804809989,-0.995723276,-0.632094629,-0.786612063,transmembrane protein 39A,"TMEM39A is a human gene that encodes for a transmembrane protein located in the endoplasmic reticulum membrane. It plays a role in regulating autophagosome assembly and maturation, as well as positively regulating viral genome replication. The gene's function in autophagy suggests it may be involved in cellular processes such as protein degradation and recycling. The gene's role in viral replication suggests it may be a potential target for antiviral therapies.","There is limited information available on the disease implications of TMEM39A. However, recent studies have suggested that mutations in this gene may be associated with the development of Alzheimer's disease. Targeted drug discovery efforts for TMEM39A are currently underway, with a focus on identifying small molecule inhibitors that can modulate its activity. While there are currently no drugs on the market that specifically target TMEM39A, there are several drugs that have been approved for the treatment of Alzheimer's disease, including cholinesterase inhibitors and memantine. These drugs work by increasing the levels of neurotransmitters in the brain and reducing the symptoms of cognitive decline. However, there is still a need for more effective treatments for Alzheimer's disease, and TMEM39A may represent a promising target for future drug development efforts.",GO:1901097 negative regulation of autophagosome maturation;GO:1902902 negative regulation of autophagosome assembly;GO:1901096 regulation of autophagosome maturation,,Transporters,Nucleoplasm (Approved); Additional: Vesicles,,,
ENSG00000138231.13,ENSG00000138231,DBR1,-0.804607836,-0.932164476,-1.123654123,-0.358004908,debranching RNA lariats 1,"The DBR1 gene encodes for an enzyme that breaks down branched phosphodiester bonds in RNA lariats. Specifically, it targets the bonds at the branch point of excised lariat intron RNA, converting them to linear molecules that are then degraded. This enzyme may also play a role in retroviral replication.","Mutations in the DBR1 gene have been associated with a rare autosomal recessive disorder called Woodhouse-Sakati syndrome (WSS), which is characterized by hypogonadism, alopecia, diabetes mellitus, hearing loss, and extrapyramidal signs. However, there are currently no targeted drug discovery efforts for DBR1-related disorders. 

As for drugs on the market, there are currently no drugs specifically targeting DBR1. However, there are drugs that target RNA processing and splicing, which may indirectly affect DBR1 function. For example, splice-modulating drugs such as nusinersen and eteplirsen have been approved for the treatment of spinal muscular atrophy and Duchenne muscular dystrophy, respectively. These drugs work by promoting the inclusion of exon(s) that are normally skipped due to mutations in the pre-mRNA, leading to the production of a functional protein. 

In summary, while mutations in the DBR1 gene have been linked to a rare disorder, there are currently no targeted drug discovery efforts for this gene. However, drugs that indirectly affect RNA processing and splicing may have potential therapeutic applications for DBR1-related disorders.",GO:0000292 RNA fragment catabolic process;GO:0006401 RNA catabolic process;GO:0141188 nucleic acid catabolic process,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases,Nucleoplasm (Enhanced),,,
ENSG00000196396.10,ENSG00000196396,PTPN1,-0.802629563,-1.422246516,-0.516571362,-0.469070811,protein tyrosine phosphatase non-receptor type 1,"PTPN1 is a gene that encodes for the protein tyrosine phosphatase non-receptor type 1, which is the founding member of the protein tyrosine phosphatase family. PTPs are signaling molecules that regulate various cellular processes, including cell growth, differentiation, and oncogenic transformation. PTPN1 acts as a negative regulator of insulin signaling by dephosphorylating the phosphotyrosine residues of insulin receptor kinase. It has also been reported to dephosphorylate epidermal growth factor receptor kinase, JAK2, and TYK2 kinases, implicating its role in cell growth control and cell response to interferon stimulation. Two transcript variants encoding different isoforms have been found for this gene.","PTPN1 has been implicated in various diseases, including type 2 diabetes, obesity, and cancer. In type 2 diabetes, PTPN1 is overexpressed in insulin-resistant tissues, leading to impaired insulin signaling and glucose uptake. Therefore, PTPN1 inhibitors have been explored as potential therapeutics for type 2 diabetes. Several small molecule inhibitors of PTPN1 have been developed, including trodusquemine and MSI-1436, which have shown promising results in preclinical studies. In addition, PTPN1 has been identified as a potential target for cancer therapy, as it is overexpressed in various cancer types and promotes tumor growth and metastasis. However, the development of PTPN1 inhibitors for cancer therapy is still in the early stages. Currently, there are no FDA-approved drugs targeting PTPN1, but ongoing research efforts suggest that PTPN1 inhibitors may have therapeutic potential for type 2 diabetes and cancer.",GO:0038020 insulin receptor recycling;GO:1902202 regulation of hepatocyte growth factor receptor signaling pathway;GO:1990264 peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity,,ENZYME proteins:Hydrolases; Enzymes,Endoplasmic reticulum (Supported); Additional: Cytosol,"3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid; 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid; 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid; 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid; 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide; [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid,; {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid; Compound 19; 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid; 2-(Oxalyl-Amino)-Benzoic Acid; {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid); Novo Nordisk a/S Compound; N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide; 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid; PNU177836; 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid; {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid; 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide; (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid; 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid; L-cysteic acid; 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid; 4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid; Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid; 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid; 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid; 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide; [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid; {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid; N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide; 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID; ISIS 113715; Trodusquemine; Ertiprotafib; 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID; [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid; 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID; 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE; 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID; [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid; 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID; 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID; 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID; 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN; N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE; [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid; 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE; 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID; ISOTHIAZOLIDINONE ANALOG; 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid; p-Benzoyl-L-phenylalanine; 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID; (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER; 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE; 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE; (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid",(M125)PID IGF1 PATHWAY; (M266)PID NCADHERIN PATHWAY; (M127)PID ERBB1 RECEPTOR PROXIMAL PATHWAY,(M5897)HALLMARK IL6 JAK STAT3 SIGNALING; (M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000114353.17,ENSG00000114353,GNAI2,-0.80223241,-1.37149208,-0.534310552,-0.500894597,G protein subunit alpha i2,GNAI2 is a human gene that encodes for the alpha subunit of guanine nucleotide binding proteins (G proteins). This protein contains the guanine nucleotide binding site and is involved in the hormonal regulation of adenylate cyclase. There are several transcript variants of GNAI2 that encode for different isoforms.,"GNAI2 has been implicated in several diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, GNAI2 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. In cardiovascular disease, GNAI2 has been linked to hypertension and heart failure, and drugs targeting GNAI2 signaling pathways are being developed as potential treatments. In neurological disorders, GNAI2 has been associated with schizophrenia and bipolar disorder, and drugs targeting GNAI2 signaling pathways are being investigated as potential treatments for these conditions.

One example of a successful drug targeting GNAI2 is carvedilol, which is used to treat hypertension and heart failure. Carvedilol works by blocking the beta-adrenergic receptors that activate GNAI2 signaling pathways, leading to a decrease in blood pressure and improved cardiac function. Another example is haloperidol, which is used to treat schizophrenia and bipolar disorder. Haloperidol works by blocking dopamine receptors, which are coupled to GNAI2 signaling pathways, leading to a decrease in psychotic symptoms. Overall, targeting GNAI2 signaling pathways has shown promise in the development of new treatments for a range of diseases.",GO:0071878 negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway;GO:0045955 negative regulation of calcium ion-dependent exocytosis;GO:0001973 G protein-coupled adenosine receptor signaling pathway,,Human disease related genes:Cardiovascular diseases:Cardiac diseases; Predicted intracellular proteins; Human disease related genes:Cancers:Cancers of endocrine organs,Cytosol (Supported); Additional: Basal body;Nucleoplasm;Plasma membrane,,(M64)PID S1P S1P4 PATHWAY; (M103)PID S1P S1P1 PATHWAY; (M155)PID S1P META PATHWAY,(M5915)HALLMARK APICAL JUNCTION; (M5921)HALLMARK COMPLEMENT
ENSG00000084093.19,ENSG00000084093,REST,-0.801758332,-1.221826789,-0.877971606,-0.3054766,RE1 silencing transcription factor,"The human gene REST, also known as RE1 silencing transcription factor, is a transcriptional repressor that was initially identified as a gene that represses neuronal genes in non-neuronal tissues. However, depending on the cellular context, it can act as either an oncogene or a tumor suppressor. REST is a member of the Kruppel-type zinc finger transcription factor family and represses transcription by binding to a DNA sequence element called the neuron-restrictive silencer element. It is also found in undifferentiated neuronal progenitor cells and is thought to act as a master negative regulator of neurogenesis. There are alternatively spliced transcript variants of this gene.","The REST gene has been implicated in several diseases, including cancer, neurodegenerative disorders, and epilepsy. In cancer, REST has been shown to promote tumor growth and metastasis in some types of cancer, such as breast and lung cancer, while acting as a tumor suppressor in others, such as prostate cancer. Targeted drug discovery efforts have focused on developing small molecule inhibitors of REST to treat cancer and neurodegenerative disorders. One example is the drug GSK-3 inhibitor, which has been shown to inhibit REST and improve cognitive function in animal models of Alzheimer's disease. Another example is the drug valproic acid, which has been shown to increase REST expression and reduce seizure activity in patients with epilepsy. However, more research is needed to fully understand the role of REST in disease and to develop effective targeted therapies.",GO:2000706 negative regulation of dense core granule biogenesis;GO:2000797 regulation of amniotic stem cell differentiation;GO:2000798 negative regulation of amniotic stem cell differentiation,,Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Ear disease; Human disease related genes:Cancers:Cancers of the urinary system; Human disease related genes:Digestive system diseases:Mouth and dental diseases; Disease related genes; Transcription factors:Zinc-coordinating DNA-binding domains,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000178252.18,ENSG00000178252,WDR6,-0.801459865,-1.439249978,-0.910810674,-0.054318942,WD repeat domain 6,"WDR6 is a gene that belongs to the WD repeat protein family. WD repeats are regions of about 40 amino acids that are not highly conserved and are typically bracketed by gly-his and trp-asp (GH-WD). These regions may help in the formation of heterotrimeric or multiprotein complexes. The protein encoded by WDR6 interacts with serine/threonine kinase 11 and is involved in cell growth arrest. Alternative splicing of the gene results in multiple transcript variants that encode different isoforms. The function of WDR6 is not fully understood, but it is believed to play a role in regulating cell growth and division.","There is limited information available on the disease implications of WDR6. However, recent studies have suggested that mutations in the gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for WDR6 are still in the early stages, but there is potential for the development of drugs that target the protein's interaction with serine/threonine kinase 11. Currently, there are no drugs on the market that specifically target WDR6. However, there are drugs that target serine/threonine kinase 11, such as metformin, which is used to treat type 2 diabetes and has been shown to have anti-cancer properties. Additionally, there are drugs that target other proteins in the WD repeat protein family, such as the anti-cancer drug bortezomib, which targets the proteasome and has been approved for the treatment of multiple myeloma.",GO:0002130 wobble position ribose methylation;GO:0002128 tRNA nucleoside ribose methylation;GO:0070314 G1 to G0 transition,,Predicted intracellular proteins,Cytosol (Supported); Additional: Plasma membrane,,,
ENSG00000130227.17,ENSG00000130227,XPO7,-0.801412184,-1.013077156,-0.780716294,-0.610443103,exportin 7,"XPO7, also known as exportin 7, is a protein involved in the transport of molecules through nuclear pore complexes. Specifically, it is responsible for exporting certain proteins and RNAs out of the nucleus. This process is energy-dependent and regulated, and involves recognition of specific amino acid clusters by the importin-alpha/beta complex. XPO7 is a member of the importin-beta superfamily of nuclear transport receptors, and interacts with the small GTPase RAN to facilitate its function. Mutations in XPO7 have been associated with various diseases, including cancer and neurodegenerative disorders.","There is limited information available on targeted drug discovery efforts for XPO7, as it is a relatively new target for drug development. However, mutations in XPO7 have been associated with various diseases, including cancer and neurodegenerative disorders. In cancer, XPO7 has been found to be downregulated in certain types of tumors, and its overexpression has been shown to inhibit tumor growth. This suggests that XPO7 may be a potential target for cancer therapy. In neurodegenerative disorders, XPO7 has been implicated in the transport of disease-associated proteins, such as tau and alpha-synuclein, and its dysfunction may contribute to the pathogenesis of these diseases. There are currently no drugs on the market that specifically target XPO7, but there are several drugs that target other members of the importin-beta superfamily, such as KPT-330, which targets exportin-1 and is approved for the treatment of certain types of leukemia and lymphoma.",GO:0006611 protein export from nucleus;GO:0051168 nuclear export;GO:0006913 nucleocytoplasmic transport,,Transporters:Transporter channels and pores; Predicted intracellular proteins,,,,(M5945)HALLMARK HEME METABOLISM
ENSG00000017260.20,ENSG00000017260,ATP2C1,-0.801338282,-1.090185661,-0.959721762,-0.354107422,ATPase secretory pathway Ca2+ transporting 1,"ATP2C1 is a gene that encodes a protein belonging to the family of P-type cation transport ATPases. This protein is responsible for the transport of calcium ions by catalyzing the hydrolysis of ATP. Defects in this gene lead to Hailey-Hailey disease, which is an autosomal dominant disorder. The gene has multiple alternatively spliced transcript variants that encode different isoforms.","Hailey-Hailey disease, also known as familial benign chronic pemphigus, is a rare autosomal dominant skin disorder caused by mutations in the ATP2C1 gene. The disease is characterized by recurrent blistering and erosions in the skin folds, such as the groin, armpits, and neck. There is currently no cure for Hailey-Hailey disease, and treatment is mainly focused on managing symptoms. Topical and systemic corticosteroids, antibiotics, and immunosuppressive agents have been used with varying degrees of success.

Targeted drug discovery efforts for Hailey-Hailey disease have been limited due to the rarity of the disease and the lack of understanding of the underlying molecular mechanisms. However, recent studies have identified potential therapeutic targets, such as the calcium signaling pathway and the unfolded protein response. Small molecule inhibitors of the calcium-activated protease calpain have shown promise in preclinical studies, but have not yet been tested in clinical trials.

Currently, there are no drugs specifically approved for the treatment of Hailey-Hailey disease. However, some drugs used for other skin disorders, such as retinoids and calcineurin inhibitors, have been used off-label with some success. Additionally, some patients have reported improvement with alternative therapies, such as phototherapy and acupuncture. Overall, more research is needed to better understand the molecular mechanisms underlying Hailey-Hailey disease and to develop effective targeted therapies.",GO:0032468 Golgi calcium ion homeostasis;GO:0032472 Golgi calcium ion transport;GO:0098629 trans-Golgi network membrane organization,,Transporters:Primary Active Transporters; Human disease related genes:Congenital malformations:Congenital malformations of skin; FDA approved drug targets:Small molecule drugs; Enzymes; Disease related genes; ENZYME proteins,Golgi apparatus (Supported),Enflurane; Isoflurane; Methoxyflurane; Desflurane; Sevoflurane; Calcium,,(M5942)HALLMARK UV RESPONSE DN; (M5932)HALLMARK INFLAMMATORY RESPONSE
ENSG00000084234.18,ENSG00000084234,APLP2,-0.801244503,-1.554314327,-0.796650099,-0.052769082,amyloid beta precursor like protein 2,"APLP2 is a protein that belongs to the amyloid precursor protein (APP) family, which also includes APP and APLP1. It is expressed throughout the body and contains various domains that bind to heparin, copper, and zinc. APLP2 interacts with major histocompatibility complex (MHC) class I molecules and works together with APP to mediate neuromuscular transmission, spatial learning, and synaptic plasticity. The protein has been linked to the development of Alzheimer's disease. There are multiple versions of APLP2 due to alternative splicing of its genetic material, resulting in different isoforms.","APLP2 has been implicated in the development of Alzheimer's disease, a neurodegenerative disorder characterized by the accumulation of amyloid-beta (A?) plaques in the brain. APLP2 interacts with APP and regulates its processing, which can lead to the production of A? peptides. Studies have shown that APLP2 levels are increased in the brains of Alzheimer's patients, and that reducing APLP2 expression can decrease A? production and improve cognitive function in mouse models of the disease.

Targeted drug discovery efforts for Alzheimer's disease have focused on developing drugs that can inhibit the production or aggregation of A? peptides. While there are currently no drugs on the market that specifically target APLP2, several drugs have been approved for the treatment of Alzheimer's that target A?, including acetylcholinesterase inhibitors (donepezil, rivastigmine, and galantamine) and the NMDA receptor antagonist memantine.

In addition to Alzheimer's disease, APLP2 has also been implicated in other neurological disorders, including epilepsy and schizophrenia. Targeted drug discovery efforts for these disorders are ongoing, but there are currently no drugs on the market that specifically target APLP2 for these indications.",GO:0007409 axonogenesis;GO:0061564 axon development;GO:0048667 cell morphogenesis involved in neuron differentiation,,Predicted intracellular proteins,Golgi apparatus;Vesicles (Approved),"Zinc; Zinc acetate; Zinc chloride; Zinc sulfate, unspecified form",,(M5905)HALLMARK ADIPOGENESIS
ENSG00000151135.10,ENSG00000151135,TMEM263,-0.801022652,-1.346341732,-0.550376233,-0.506349992,transmembrane protein 263,"TMEM263 is a human gene that is predicted to be an integral component of the membrane. The function of this gene is not yet fully understood, but it is believed to play a role in cellular processes that involve the membrane. TMEM263 is a transmembrane protein, meaning that it spans the membrane and is present on both sides. The gene is currently being studied to determine its exact function and potential implications for human health.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for TMEM263. As the function of this gene is not yet fully understood, it is difficult to determine its potential role in disease. However, research is ongoing to better understand the function of TMEM263 and its potential implications for human health. As a result, there are currently no drugs on the market that specifically target TMEM263. However, as research progresses, it is possible that new drug discovery efforts may emerge that target this gene and its associated pathways.",,,Disease related genes; Transporters:Accessory Factors Involved in Transport; Potential drug targets; Predicted intracellular proteins,Vesicles (Approved),,,
ENSG00000184677.18,ENSG00000184677,ZBTB40,-0.80016392,-1.110794307,-0.704350563,-0.585346889,zinc finger and BTB domain containing 40,"ZBTB40 is a human gene that is predicted to have DNA-binding transcription factor activity, specifically for RNA polymerase II and cis-regulatory region sequence-specific DNA binding. It is involved in the cellular response to DNA damage stimulus and is located in the nucleus.","There is limited information available on the disease implications of ZBTB40. However, some studies have suggested that it may play a role in cancer development and progression. For example, one study found that ZBTB40 expression was significantly decreased in breast cancer tissues compared to normal breast tissues, and that low ZBTB40 expression was associated with poor prognosis in breast cancer patients. 

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target ZBTB40. However, there are ongoing efforts to develop drugs that target other transcription factors involved in cancer development and progression, which may indirectly affect ZBTB40 activity. For example, some drugs that target the transcription factor STAT3 have shown promise in preclinical studies for the treatment of various types of cancer, including breast cancer. 

Overall, while the exact role of ZBTB40 in disease is still being investigated, it may have implications for cancer development and progression. However, more research is needed to fully understand its function and potential as a therapeutic target.",GO:0030282 bone mineralization;GO:0031214 biomineral tissue development;GO:0001503 ossification,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000125827.9,ENSG00000125827,TMX4,-0.800157807,-1.467888831,-0.481086933,-0.451497658,thioredoxin related transmembrane protein 4,"TMX4 is a human gene that encodes a protein belonging to the disulfide isomerase family of endoplasmic reticulum proteins. This protein is involved in catalyzing protein folding and thiol-disulfide interchange reactions. It contains an N-terminal ER-signal sequence, a catalytically active thioredoxin domain, one transmembrane domain, and a C-terminal ASP/GLU-rich calcium binding domain. Unlike most members of this gene family, it lacks a C-terminal ER-retention sequence. The protein has been shown to have reductase activity in vitro.","There is limited information available on the disease implications of TMX4. However, studies have suggested that it may play a role in the pathogenesis of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TMX4 are also limited, but some studies have explored the potential of small molecule inhibitors of thioredoxin-like proteins, including TMX4, as anticancer agents. One example of a successful drug targeting thioredoxin-like proteins is Auranofin, which is used to treat rheumatoid arthritis and has also shown promise in preclinical studies for the treatment of various cancers. However, further research is needed to fully understand the potential therapeutic applications of targeting TMX4.",,,,Nuclear membrane (Approved),,,
ENSG00000094880.11,ENSG00000094880,CDC23,-0.799980467,-1.139573179,-0.609937858,-0.650430364,cell division cycle 23,"CDC23 is a human gene that encodes a protein that is similar to the Cdc23 protein found in Saccharomyces cerevisiae. The protein is essential for cell cycle progression through the G2/M transition and is a component of the anaphase-promoting complex (APC), which is composed of eight protein subunits and is highly conserved in eukaryotic cells. The APC catalyzes the formation of cyclin B-ubiquitin conjugate, which is responsible for the ubiquitin-mediated proteolysis of B-type cyclins. The protein and three other members of the APC complex contain the TPR (tetratricopeptide repeat), a protein domain important for protein-protein interaction.","There is limited information available on the disease implications of CDC23. However, studies have shown that mutations in other APC complex subunits can lead to various types of cancer, including colorectal, breast, and pancreatic cancer. Therefore, it is possible that mutations in CDC23 could also contribute to the development of cancer. 

There are currently no targeted drug discovery efforts specifically focused on CDC23. However, there are drugs on the market that target the APC complex, such as bortezomib, which is used to treat multiple myeloma and mantle cell lymphoma. Bortezomib inhibits the proteasome, which prevents the degradation of cyclin B and other proteins, leading to cell cycle arrest and apoptosis. 

Another example of a drug that indirectly targets the APC complex is tamoxifen, which is used to treat breast cancer. Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks the estrogen receptor, leading to decreased expression of cyclin D1, a protein that is degraded by the APC complex. 

In summary, while there is limited information on the disease implications of CDC23, drugs that target the APC complex have shown success in treating various types of cancer.",GO:0007091 metaphase/anaphase transition of mitotic cell cycle;GO:0044784 metaphase/anaphase transition of cell cycle;GO:0045842 positive regulation of mitotic metaphase/anaphase transition,,Predicted intracellular proteins,,,,
ENSG00000080822.17,ENSG00000080822,CLDND1,-0.799663975,-0.941823558,-0.728448324,-0.728720044,claudin domain containing 1,"The human gene CLDND1, also known as claudin domain containing 1, is located on the cell surface. This information is provided by the Alliance of Genome Resources as of April 2022. Further details about the gene are not provided in this summary.","Unfortunately, there is limited information available on the disease implications and targeted drug discovery efforts for the CLDND1 gene. This may be due to the fact that the function of this gene is not well understood. However, there are some drugs on the market that target other genes involved in cell surface signaling and regulation, which may have implications for CLDND1. For example, drugs that target the epidermal growth factor receptor (EGFR), such as erlotinib and gefitinib, have been successful in treating certain types of cancer. Additionally, drugs that target the immune checkpoint protein PD-1, such as pembrolizumab and nivolumab, have shown promise in treating various types of cancer by enhancing the immune system's ability to recognize and attack cancer cells. Further research is needed to determine if targeting CLDND1 or related pathways could lead to new treatments for disease.",,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol;Nucleoli,,,
ENSG00000111266.9,ENSG00000111266,DUSP16,-0.799415629,-1.025880973,-0.693728118,-0.678637798,dual specificity phosphatase 16,"DUSP16 is a gene that encodes a protein called dual specificity phosphatase 16, which belongs to a subfamily of phosphatases that inactivate target kinases by removing phosphate groups from both phosphoserine/threonine and phosphotyrosine residues. This protein specifically regulates two important signaling pathways, c-Jun amino-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK). The JNK pathway is involved in cell growth, differentiation, and apoptosis, while the ERK pathway is involved in cell proliferation and differentiation. DUSP16 may play a role in regulating these pathways and could potentially be a target for therapeutic interventions in diseases such as cancer.","DUSP16 has been implicated in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, DUSP16 has been shown to act as a tumor suppressor by inhibiting the ERK and JNK pathways, which are often dysregulated in cancer cells. Targeted drug discovery efforts have focused on developing small molecule inhibitors of DUSP16 to enhance its tumor suppressor activity and potentially treat cancer. However, there are currently no drugs on the market that specifically target DUSP16. Some successful drugs that target the ERK and JNK pathways include trametinib and cobimetinib, which are used to treat melanoma, and ruxolitinib, which is used to treat myelofibrosis. Further research is needed to fully understand the role of DUSP16 in disease and to develop effective targeted therapies.",GO:0016311 dephosphorylation;GO:0043409 negative regulation of MAPK cascade;GO:0043408 regulation of MAPK cascade,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Supported),,(M76)PID P38 ALPHA BETA PATHWAY,
ENSG00000137177.20,ENSG00000137177,KIF13A,-0.79902567,-1.149723944,-0.66087953,-0.586473536,kinesin family member 13A,"KIF13A is a gene that encodes a motor protein belonging to the kinesin family. This protein is involved in the movement of endosomes and vesicles containing mannose-6-phosphate receptors from the trans-Golgi network to the plasma membrane. It is also necessary for the proper distribution of late endosomes/lysosomes and plays a role in melanosome maturation. Additionally, KIF13A is required for the translocation of FYVE-CENT and TTC19 from the centrosome to the midbody during cytokinesis. Alternative splicing of this gene results in multiple transcript variants.","There is limited information available on the disease implications of KIF13A. However, recent studies have suggested that mutations in this gene may be associated with neurodevelopmental disorders such as autism spectrum disorder and intellectual disability. Targeted drug discovery efforts for KIF13A are also limited, as the function of this protein is not well understood. However, there have been some studies exploring the potential of KIF13A as a therapeutic target for cancer treatment. For example, a recent study found that inhibiting KIF13A expression in breast cancer cells led to decreased cell proliferation and migration. Currently, there are no drugs on the market that specifically target KIF13A. However, there are several drugs that target other kinesin family members, such as the microtubule inhibitor paclitaxel, which is used to treat various types of cancer.",GO:0072383 plus-end-directed vesicle transport along microtubule;GO:0072386 plus-end-directed organelle transport along microtubule;GO:0043001 Golgi to plasma membrane protein transport,,Predicted intracellular proteins,Mid piece;Principal piece (Approved),,,
ENSG00000175216.15,ENSG00000175216,CKAP5,-0.798750436,-1.233975887,-0.572008714,-0.590266708,cytoskeleton associated protein 5,"CKAP5 is a gene that encodes a cytoskeleton-associated protein belonging to the TOG/XMAP215 family. The protein has two distinct roles in spindle formation, protecting kinetochore microtubules from depolymerization and playing an essential role in centrosomal microtubule assembly. It also plays a role in directional cell movement by interacting with microtubules and the cell cortex. Additionally, CKAP5 is involved in the translation of myelin basic protein mRNA by interacting with hnRNP A2. The gene has multiple alternatively spliced transcript variants encoding different isoforms.","There is limited information available on the disease implications of CKAP5. However, recent studies have suggested that CKAP5 may play a role in cancer progression and metastasis. Specifically, CKAP5 has been found to be overexpressed in several types of cancer, including breast, lung, and ovarian cancer. Targeted drug discovery efforts for CKAP5 are still in the early stages, but there is potential for the development of drugs that target CKAP5 to inhibit cancer cell growth and metastasis. Currently, there are no drugs on the market that specifically target CKAP5. However, there are several drugs that target microtubules, which are the primary binding partners of CKAP5. Examples of these drugs include paclitaxel and vinblastine, which are used in the treatment of various types of cancer.",GO:0030951 establishment or maintenance of microtubule cytoskeleton polarity;GO:0030952 establishment or maintenance of cytoskeleton polarity;GO:0090063 positive regulation of microtubule nucleation,,Predicted intracellular proteins,Basal body;Centrosome (Approved); Additional: Mitotic spindle;Nucleoli;Nucleoli rim;Plasma membrane;Primary cilium,,(M242)PID AURORA A PATHWAY; (M71)PID ILK PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000075568.17,ENSG00000075568,TMEM131,-0.797919836,-1.144799931,-0.626611227,-0.622348351,transmembrane protein 131,"TMEM131 is a human gene that is predicted to be an integral component of the membrane and active in the membrane. It is a transmembrane protein, meaning it spans the membrane and is involved in various cellular processes. However, the specific function of TMEM131 is currently unknown. The gene is located on chromosome 16 and has been identified as a potential candidate gene for certain diseases, including breast cancer and schizophrenia. Further research is needed to fully understand the role of TMEM131 in human biology and disease.","There is limited information available on the disease implications of TMEM131, but some studies have suggested that it may be involved in the development of breast cancer and schizophrenia. In breast cancer, TMEM131 has been identified as a potential candidate gene that may contribute to the development and progression of the disease. In schizophrenia, a genome-wide association study identified TMEM131 as a potential risk gene for the disorder. However, further research is needed to fully understand the role of TMEM131 in these diseases.

As TMEM131 is a relatively understudied gene, there are currently no targeted drug discovery efforts or drugs on the market that specifically target this gene. However, there are drugs on the market that target other genes and pathways that may be involved in the same diseases as TMEM131. For example, in breast cancer, drugs such as tamoxifen and trastuzumab target the estrogen receptor and HER2, respectively. In schizophrenia, drugs such as antipsychotics target dopamine and other neurotransmitter receptors. As more research is conducted on TMEM131 and its role in disease, it may become a target for drug discovery efforts in the future.",GO:0032964 collagen biosynthetic process;GO:0032963 collagen metabolic process;GO:0009058 biosynthetic process,,Predicted intracellular proteins,Intermediate filaments;Vesicles (Uncertain),,,
ENSG00000113391.19,ENSG00000113391,FAM172A,-0.797670436,-0.778420048,-0.758481154,-0.856110107,ARB2 cotranscriptional regulator A,"FAM172A is a human gene that is predicted to have siRNA binding activity and be involved in heterochromatin assembly by small RNA, neural crest cell development, and regulation of alternative mRNA splicing via spliceosome. It is located in the endoplasmic reticulum.","There is limited information available on the disease implications of FAM172A. However, recent studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for FAM172A are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein encoded by this gene. While there are currently no drugs on the market that specifically target FAM172A, there are several drugs that have been approved for the treatment of breast cancer and hepatocellular carcinoma that may indirectly affect the activity of this gene. These include tamoxifen, trastuzumab, and sorafenib, among others.","GO:0031048 regulatory ncRNA-mediated heterochromatin formation;GO:0000381 regulation of alternative mRNA splicing, via spliceosome;GO:0014032 neural crest cell development",,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000135503.13,ENSG00000135503,ACVR1B,-0.797202012,-0.939423374,-0.771954285,-0.680228377,activin A receptor type 1B,"ACVR1B is a gene that encodes for the activin A type IB receptor, which is essential for signaling. Activins are growth and differentiation factors that belong to the TGF-beta superfamily of signaling proteins. Activins signal through a complex of receptor serine kinases, including at least two type I and two type II receptors. Mutations in ACVR1B have been associated with pituitary tumors. The gene undergoes alternate splicing, resulting in multiple transcript variants.","Mutations in ACVR1B have been associated with pituitary tumors, specifically somatotroph adenomas, which are tumors that secrete excessive amounts of growth hormone. Targeted drug discovery efforts have focused on developing inhibitors of the activin receptor signaling pathway as a potential treatment for pituitary tumors. One example of a successful drug on the market is pasireotide, a somatostatin analog that inhibits the secretion of growth hormone and has been approved for the treatment of acromegaly, a condition caused by excessive growth hormone secretion. Another example is pegvisomant, a growth hormone receptor antagonist that has also been approved for the treatment of acromegaly. While these drugs do not directly target ACVR1B, they are effective in reducing the effects of excessive growth hormone secretion, which is often caused by mutations in ACVR1B.",GO:0032927 positive regulation of activin receptor signaling pathway;GO:1901165 positive regulation of trophoblast cell migration;GO:0038092 nodal signaling pathway,yes,Predicted intracellular proteins; Kinases:TKL Ser/Thr protein kinases; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Candidate cancer biomarkers,Cytosol (Approved); Additional: Primary cilium;Vesicles,ATP; Fostamatinib,,(M5897)HALLMARK IL6 JAK STAT3 SIGNALING; (M5932)HALLMARK INFLAMMATORY RESPONSE; (M5939)HALLMARK P53 PATHWAY
ENSG00000123728.10,ENSG00000123728,RAP2C,-0.796693977,-1.026917578,-0.618071532,-0.745092821,"RAP2C, member of RAS oncogene family","RAP2C is a human gene that belongs to the Ras-related protein subfamily of the Ras GTPase superfamily. This gene encodes a small GTPase that acts as a molecular switch to regulate cellular processes such as proliferation, differentiation, and apoptosis. RAP2C has been shown to activate the transcriptional activity of the serum response element in vitro. Alternative splicing of this gene results in multiple transcript variants.","There is limited information available on the disease implications of RAP2C. However, studies have shown that RAP2C is overexpressed in certain types of cancer, including breast cancer and hepatocellular carcinoma, suggesting a potential role in tumorigenesis. Targeted drug discovery efforts for RAP2C are also limited, as there are currently no drugs on the market that specifically target this gene. However, there are ongoing efforts to develop small molecule inhibitors of Ras-related proteins, including RAP2C, as potential cancer therapeutics. One example is the drug tipifarnib, which targets farnesyltransferase, an enzyme involved in the post-translational modification of Ras-related proteins. Tipifarnib has shown promising results in clinical trials for the treatment of various types of cancer, including acute myeloid leukemia and solid tumors.",GO:0032486 Rap protein signal transduction;GO:0090557 establishment of endothelial intestinal barrier;GO:0061097 regulation of protein tyrosine kinase activity,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,,,,
ENSG00000155313.15,ENSG00000155313,USP25,-0.796028279,-1.009576656,-1.170043599,-0.208464584,ubiquitin specific peptidase 25,"USP25 is a gene that encodes for a protein called ubiquitin specific peptidase 25. This protein is involved in the regulation of intracellular protein breakdown, cell cycle regulation, and stress response. Specifically, USP25 is a type of enzyme called a ubiquitin-specific protease, which helps to disassemble polyubiquitin chains that are released from degraded proteins. This process is important for maintaining proper cellular function and preventing the accumulation of damaged or misfolded proteins. USP25 has been studied for its potential role in various diseases, including cancer and neurodegenerative disorders.","USP25 has been implicated in various diseases, including cancer and neurodegenerative disorders. In cancer, USP25 has been shown to regulate the stability of several oncogenic proteins, including c-Myc and Cyclin D1, making it a potential target for cancer therapy. In neurodegenerative disorders, USP25 has been linked to the regulation of protein aggregates, such as those found in Alzheimer's and Parkinson's disease. Targeted drug discovery efforts for USP25 are ongoing, with several small molecule inhibitors being developed to target its enzymatic activity. However, there are currently no USP25-specific drugs on the market. One example of a successful drug targeting a related enzyme is bortezomib, which targets the proteasome and is used to treat multiple myeloma.",GO:1903882 negative regulation of interleukin-17-mediated signaling pathway;GO:1903881 regulation of interleukin-17-mediated signaling pathway;GO:1904293 negative regulation of ERAD pathway,,Peptidases:Cysteine-type peptidases; ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol (Supported),,,
ENSG00000157450.16,ENSG00000157450,RNF111,-0.795671686,-1.123297115,-0.842535267,-0.421182678,ring finger protein 111,"RNF111, also known as ring finger protein 111, is a gene that encodes a nuclear E3 ubiquitin ligase containing a RING domain. This protein interacts with the TGF-beta/NODAL signaling pathway by promoting the degradation of negative regulators, such as SMAD proteins, which enhances TGF-beta target-gene transcription. RNF111 plays a critical role in the induction of mesoderm during embryonic development as a modulator of the nodal signaling cascade. Alternative splicing of this gene results in multiple transcript variants encoding distinct isoforms.","There is limited information available on the disease implications of RNF111. However, recent studies have suggested that RNF111 may play a role in cancer development and progression. Specifically, RNF111 has been shown to regulate the stability of several tumor suppressor proteins, including p53 and PTEN, which are frequently mutated or deleted in various types of cancer. Targeted drug discovery efforts for RNF111 are currently limited, but there is potential for the development of small molecule inhibitors that can disrupt the interaction between RNF111 and its substrates. Currently, there are no drugs on the market that specifically target RNF111. However, there are several drugs that indirectly affect RNF111 activity, such as TGF-beta inhibitors, which have been approved for the treatment of various cancers and fibrotic diseases. Additionally, there are several ongoing clinical trials investigating the efficacy of TGF-beta inhibitors in combination with other therapies for the treatment of cancer.",GO:0070911 global genome nucleotide-excision repair;GO:0030511 positive regulation of transforming growth factor beta receptor signaling pathway;GO:1903846 positive regulation of cellular response to transforming growth factor beta stimulus,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported); Additional: Cytosol,,(M286)PID TGFBR PATHWAY,
ENSG00000111676.15,ENSG00000111676,ATN1,-0.794563128,-1.216579361,-0.774509556,-0.392600467,atrophin 1,"ATN1, also known as atrophin 1, is a gene that encodes a protein involved in the development and maintenance of the nervous system. Mutations in this gene have been linked to a rare neurodegenerative disorder called dentatorubral pallidoluysian atrophy (DRPLA), which is characterized by a range of symptoms including cerebellar ataxia, myoclonic epilepsy, choreoathetosis, and dementia. DRPLA is caused by the expansion of a trinucleotide repeat (CAG/CAA) within the ATN1 gene, resulting in the production of an abnormal protein. Alternative splicing of the gene results in two transcript variants that encode the same protein.","Dentatorubral pallidoluysian atrophy (DRPLA) is a rare neurodegenerative disorder caused by mutations in the ATN1 gene. There is currently no cure for DRPLA, and treatment is mainly supportive and aimed at managing symptoms. However, there have been efforts to develop targeted drugs for DRPLA. One approach has been to target the abnormal protein produced by the expanded CAG/CAA repeat in the ATN1 gene. For example, a small molecule called ASO-46 has been shown to reduce the levels of the abnormal protein in cells and animal models of DRPLA. Another approach has been to target downstream pathways affected by the abnormal protein. For example, a drug called valproic acid has been shown to improve symptoms in some DRPLA patients, possibly by modulating the activity of certain genes. However, more research is needed to develop effective treatments for DRPLA.",GO:0030011 maintenance of cell polarity;GO:0032094 response to food;GO:0008340 determination of adult lifespan,,Disease related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000129657.16,ENSG00000129657,SEC14L1,-0.793908073,-1.127627168,-0.861285606,-0.392811443,SEC14 like lipid binding 1,"SEC14L1 is a human gene that belongs to the SEC14 cytosolic factor family. It shares similarities with yeast SEC14 and Japanese flying squid RALBP, indicating a potential role in intracellular transport. The gene has multiple alternatively spliced transcript variants, some of which include exons from the upstream gene C17orf86.","There is limited information available on the disease implications of SEC14L1. However, recent studies have suggested that the gene may play a role in cancer progression and metastasis. Specifically, SEC14L1 has been found to be upregulated in several types of cancer, including breast, lung, and pancreatic cancer. Targeted drug discovery efforts for SEC14L1 are still in the early stages, but there is potential for the gene to be a therapeutic target for cancer treatment. Currently, there are no drugs on the market that specifically target SEC14L1. However, there are several drugs that target other members of the SEC14 cytosolic factor family, such as the antifungal drug, voriconazole, which targets SEC14-like protein 3 (SEC14L3). Further research is needed to fully understand the disease implications of SEC14L1 and to develop targeted therapies for its potential role in cancer.",GO:0039536 negative regulation of RIG-I signaling pathway;GO:0015871 choline transport;GO:0039535 regulation of RIG-I signaling pathway,,Predicted intracellular proteins; Transporters,Cytosol;Nucleoplasm (Supported),,,(M5945)HALLMARK HEME METABOLISM
ENSG00000166266.14,ENSG00000166266,CUL5,-0.793672596,-0.835390264,-1.09106726,-0.454560263,cullin 5,"CUL5, also known as cullin 5, is a gene that encodes a protein involved in the process of protein degradation through ubiquitination. It is predicted to play a role in the regulation of cell migration in the cerebral cortex and is located at sites of DNA damage. CUL5 is part of a complex called the Cul5-RING ubiquitin ligase complex, which is responsible for targeting specific proteins for degradation. Overall, CUL5 is an important gene involved in the regulation of protein turnover and cellular processes such as cell migration.","Mutations in the CUL5 gene have been associated with a variety of diseases, including cancer, neurodevelopmental disorders, and cardiovascular disease. In particular, CUL5 has been implicated in the development and progression of breast, lung, and ovarian cancers. As a result, there has been significant interest in developing drugs that target CUL5 and the Cul5-RING ubiquitin ligase complex as a potential therapeutic strategy for these cancers. However, there are currently no FDA-approved drugs that specifically target CUL5. Some drugs that indirectly affect CUL5 activity, such as proteasome inhibitors, have been approved for the treatment of multiple myeloma and other cancers. Additionally, research is ongoing to identify small molecules that can directly inhibit CUL5 activity and may have potential as cancer therapeutics.",GO:0038026 reelin-mediated signaling pathway;GO:0038128 ERBB2 signaling pathway;GO:0070979 protein K11-linked ubiquitination,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cytosol;Golgi apparatus (Approved),,,(M5901)HALLMARK G2M CHECKPOINT
ENSG00000152778.9,ENSG00000152778,IFIT5,-0.793346323,-1.269272987,-0.977253787,-0.133512196,interferon induced protein with tetratricopeptide repeats 5,"IFIT5 is a human gene that encodes for a protein called interferon induced protein with tetratricopeptide repeats 5. This protein is involved in various cellular processes, including nucleic acid binding activity, defense response to virus, negative regulation of viral genome replication, and positive regulation of I-kappaB kinase/NF-kappaB signaling. IFIT5 is located in the actin cytoskeleton, apical part of the cell, and ruffle membrane, and it colocalizes with the IkappaB kinase complex. This gene plays an important role in the immune response to viral infections and may have potential therapeutic applications in the treatment of viral diseases.","Research on IFIT5 has shown its potential as a therapeutic target for viral diseases such as influenza, hepatitis C, and HIV. Several drug discovery efforts have focused on developing small molecule inhibitors of IFIT5 to prevent viral replication and enhance the immune response. One example is the development of a small molecule inhibitor called 4EGI-1, which has been shown to inhibit IFIT5 and enhance the antiviral response in cells infected with influenza virus. Another example is the use of siRNA to knockdown IFIT5 expression, which has been shown to reduce viral replication in cells infected with hepatitis C virus. While there are currently no drugs on the market that directly target IFIT5, ongoing research suggests that this gene may hold promise as a therapeutic target for viral diseases.",GO:0045071 negative regulation of viral genome replication;GO:0045069 regulation of viral genome replication;GO:0048525 negative regulation of viral process,,Predicted intracellular proteins,Plasma membrane (Supported),,,
ENSG00000143376.14,ENSG00000143376,SNX27,-0.793328117,-1.065127155,-0.885932649,-0.428924548,sorting nexin 27,"SNX27 is a gene that belongs to the sorting nexin family, which includes proteins involved in the endocytosis of plasma membrane receptors and protein trafficking. All members of this family contain a phosphoinositide binding domain. In mice, a similar protein is responsible for recruiting a specific isoform of the serotonin 5-hydroxytryptamine 4 receptor into early endosomes, suggesting a similar role for the human protein. SNX27 is involved in the regulation of synaptic function and plasticity, and mutations in this gene have been associated with neurological disorders such as Alzheimer's disease and autism spectrum disorder.","SNX27 has been implicated in several neurological disorders, including Alzheimer's disease and autism spectrum disorder. In Alzheimer's disease, SNX27 has been shown to play a role in the trafficking of amyloid precursor protein (APP) and the generation of amyloid-beta (A?) peptides, which are thought to contribute to the development of the disease. In autism spectrum disorder, SNX27 has been linked to the regulation of synaptic function and plasticity, which are disrupted in the disorder.

Targeted drug discovery efforts for SNX27 are still in the early stages, but there is potential for the development of drugs that modulate its function in the endocytosis and trafficking of receptors. One example is the development of small molecules that target the phosphoinositide binding domain of SNX27, which could potentially regulate its interaction with receptors and affect their trafficking.

There are currently no drugs on the market that specifically target SNX27, but there are drugs that target related proteins in the sorting nexin family. For example, the drug bafilomycin A1 targets the vacuolar ATPase, which is involved in the acidification of endosomes and lysosomes, and is used to study the role of endosomal acidification in receptor trafficking. Another example is the drug dynasore, which targets dynamin, a protein involved in the scission of clathrin-coated vesicles during endocytosis.",GO:0001770 establishment of natural killer cell polarity;GO:0001767 establishment of lymphocyte polarity;GO:0090128 regulation of synapse maturation,,Predicted intracellular proteins; Transporters,Vesicles (Supported),,,
ENSG00000132842.14,ENSG00000132842,AP3B1,-0.792628098,-1.169094986,-0.786551263,-0.422238047,adaptor related protein complex 3 subunit beta 1,"The AP3B1 gene encodes a protein that is involved in the formation of organelles such as melanosomes, platelet dense granules, and lysosomes. This protein is a subunit of the AP-3 protein complex, which interacts with clathrin. Mutations in this gene have been linked to Hermansky-Pudlak syndrome type 2. There are two different versions of the AP3B1 gene that produce different isoforms of the protein.","Hermansky-Pudlak syndrome type 2 (HPS2) is a rare autosomal recessive disorder caused by mutations in the AP3B1 gene. HPS2 is characterized by oculocutaneous albinism, bleeding diathesis, and pulmonary fibrosis. There is currently no cure for HPS2, and treatment is mainly supportive. However, targeted drug discovery efforts are underway to develop therapies that can alleviate the symptoms of the disease. One approach is to target the lysosomal storage defects that occur in HPS2 patients. For example, miglustat, an inhibitor of glucosylceramide synthase, has been shown to reduce the accumulation of ceramide in HPS2 cells and improve lung function in HPS2 patients. Another approach is to target the platelet dysfunction that occurs in HPS2 patients. DDAVP, a synthetic analogue of vasopressin, has been shown to improve platelet function in HPS2 patients. While these drugs do not cure HPS2, they can improve the quality of life for patients with this rare disorder.",GO:0090152 establishment of protein localization to mitochondrial membrane involved in mitochondrial fission;GO:0051138 positive regulation of NK T cell differentiation;GO:0051136 regulation of NK T cell differentiation,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of amino acid metabolism; Predicted intracellular proteins,Vesicles (Approved); Additional: Cytosol;Nuclear membrane;Nucleoplasm,,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000100462.16,ENSG00000100462,PRMT5,-0.792250666,-1.206367703,-1.132235887,-0.038148407,protein arginine methyltransferase 5,"PRMT5 is a gene that encodes an enzyme belonging to the methyltransferase family. The protein produced by this gene is responsible for transferring methyl groups to the amino acid arginine in various target proteins, including histones, transcriptional elongation factors, and the tumor suppressor p53. PRMT5 plays a crucial role in several cellular processes, such as transcriptional regulation and the assembly of small nuclear ribonucleoproteins. Alternative splicing of this gene results in multiple transcript variants that encode different isoforms. A pseudogene of PRMT5 has also been identified on chromosome 4.","PRMT5 has been implicated in several diseases, including cancer, viral infections, and neurodegenerative disorders. In cancer, PRMT5 overexpression has been observed in various types of tumors, including breast, lung, and prostate cancer, and is associated with poor prognosis. Targeting PRMT5 has emerged as a promising therapeutic strategy for cancer treatment, and several small molecule inhibitors of PRMT5 are currently in preclinical and clinical development. One such inhibitor, GSK3326595, has shown promising results in preclinical studies and is currently being evaluated in phase I clinical trials for the treatment of solid tumors. Another inhibitor, EPZ015666, has shown efficacy in preclinical models of acute myeloid leukemia and is currently in phase I clinical trials for the treatment of advanced solid tumors and lymphomas. In addition to cancer, PRMT5 has also been implicated in viral infections, such as HIV and influenza, and neurodegenerative disorders, such as Alzheimer's disease and Huntington's disease, making it a potential target for drug discovery efforts in these areas as well.",GO:1904990 regulation of adenylate cyclase-inhibiting dopamine receptor signaling pathway;GO:1904992 positive regulation of adenylate cyclase-inhibiting dopamine receptor signaling pathway;GO:0035246 peptidyl-arginine N-methylation,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Nucleoplasm (Supported),,(M261)PID P53 REGULATION PATHWAY; (M101)PID HDAC CLASSI PATHWAY; (M40)PID E2F PATHWAY,(M5901)HALLMARK G2M CHECKPOINT
ENSG00000136243.17,ENSG00000136243,NUP42,-0.792175191,-1.270164077,-0.655341921,-0.451019576,nucleoporin 42,"NUP42, also known as nucleoporin 42, is a human gene that plays a role in enabling nuclear export signal receptor activity and is involved in protein export from the nucleus. It is located in both the cytosol and nucleoplasm and colocalizes with the nuclear envelope. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of NUP42. However, research has shown that mutations in other nucleoporin genes can lead to various diseases, including cancer, neurodegenerative disorders, and developmental abnormalities. Therefore, it is possible that mutations in NUP42 could also contribute to the development of these diseases. 

As for targeted drug discovery efforts, there is currently no information available on any specific drugs targeting NUP42. However, there has been research on drugs targeting other nucleoporin genes, such as selinexor, which targets the exportin XPO1 and has been approved for the treatment of multiple myeloma and diffuse large B-cell lymphoma. Additionally, there are ongoing clinical trials for other drugs targeting nucleoporins, such as verdinexor and KPT-9274.

In conclusion, while there is limited information available on the disease implications and targeted drug discovery efforts for NUP42 specifically, research on other nucleoporin genes suggests that mutations in NUP42 could potentially contribute to various diseases. Additionally, there are ongoing efforts to develop drugs targeting nucleoporins, which could potentially have implications for the treatment of diseases associated with NUP42.",GO:0006611 protein export from nucleus;GO:0051028 mRNA transport;GO:0051168 nuclear export,,Transporters:Transporter channels and pores; Predicted intracellular proteins,Nuclear membrane (Supported); Additional: Cytosol;Nucleoplasm,,,
ENSG00000177628.16,ENSG00000177628,GBA,-0.792135829,-1.601687996,-0.691826887,-0.082892603,glucosylceramidase beta 1,"GBA1 is a gene that encodes a lysosomal membrane protein responsible for breaking down glycosylceramide, an intermediate in glycolipid metabolism. Mutations in this gene lead to Gaucher disease, a lysosomal storage disease characterized by an accumulation of glucocerebrosides. The gene is located on chromosome 1, and there is a related pseudogene located approximately 12 kb downstream. Alternative splicing of the gene results in multiple transcript variants.","Gaucher disease is a rare genetic disorder caused by mutations in the GBA1 gene, resulting in a deficiency of the enzyme glucocerebrosidase. This leads to the accumulation of glucocerebroside in the lysosomes of cells, causing damage to various organs and tissues. Symptoms of Gaucher disease include an enlarged spleen and liver, anemia, bone pain, and fractures. There are three types of Gaucher disease, with varying degrees of severity.

Targeted drug discovery efforts have focused on developing enzyme replacement therapies (ERTs) to replace the missing or deficient glucocerebrosidase enzyme. The first ERT, imiglucerase, was approved by the FDA in 1994 and has been shown to improve symptoms and reduce organ damage in patients with Gaucher disease. Other ERTs, such as velaglucerase alfa and taliglucerase alfa, have also been approved for use.

In addition to ERTs, small molecule drugs have also been developed to treat Gaucher disease. Miglustat, an inhibitor of glucosylceramide synthase, has been shown to reduce the accumulation of glucocerebroside in cells and improve symptoms in patients with mild to moderate Gaucher disease. Eliglustat, a substrate reduction therapy that inhibits the production of glucocerebroside, has also been approved for use in patients with Gaucher disease type 1.

Overall, targeted drug discovery efforts have led to the development of several effective treatments for Gaucher disease, improving the quality of life for patients with this rare genetic disorder.",GO:1904457 positive regulation of neuronal action potential;GO:1901804 beta-glucoside metabolic process;GO:1901805 beta-glucoside catabolic process,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Lysosomal storage diseases; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,,"scyllo-inositol; N-acetyl-alpha-D-glucosamine; Velaglucerase alfa; (2R,3R,4R,5S)-2-(HYDROXYMETHYL)-1-NONYLPIPERIDINE-3,4,5-TRIOL",,
ENSG00000162734.13,ENSG00000162734,PEA15,-0.792060143,-0.942504699,-0.519052427,-0.914623302,proliferation and apoptosis adaptor protein 15,"PEA15 is a gene that encodes a protein that plays a role in regulating cell death. The protein contains a death effector domain and acts as a negative regulator of apoptosis. It is also a substrate for protein kinase C and is overexpressed in type 2 diabetes mellitus, where it may contribute to insulin resistance in glucose uptake. Alternative splicing of the gene results in multiple transcript variants.","PEA15 has been implicated in several diseases, including cancer, diabetes, and neurodegenerative disorders. In cancer, PEA15 has been shown to promote tumor growth and metastasis in some types of cancer, while inhibiting it in others. In diabetes, PEA15 is thought to contribute to insulin resistance by inhibiting glucose uptake in muscle cells. Targeted drug discovery efforts for PEA15 have focused on developing small molecule inhibitors that can block its activity and potentially treat diseases associated with its overexpression. However, there are currently no drugs on the market that specifically target PEA15. Some drugs that indirectly affect PEA15 activity, such as metformin, have been used to treat diabetes. Additionally, some cancer drugs, such as sorafenib and sunitinib, have been shown to inhibit PEA15 activity and may have potential as cancer therapies.",GO:1902043 positive regulation of extrinsic apoptotic signaling pathway via death domain receptors;GO:0046325 negative regulation of D-glucose import;GO:0010829 negative regulation of D-glucose transmembrane transport,,Predicted intracellular proteins,Cytosol (Supported); Additional: Nucleoplasm;Vesicles,,(M19)PID P73PATHWAY,(M5902)HALLMARK APOPTOSIS
ENSG00000104756.16,ENSG00000104756,KCTD9,-0.79158351,-1.08056157,-0.989893471,-0.30429549,potassium channel tetramerization domain containing 9,"KCTD9 is a human gene that encodes a protein called potassium channel tetramerization domain containing 9. This protein is involved in various cellular processes such as intracellular signal transduction, protein homooligomerization, and protein ubiquitination. It has been found to enable cullin family protein binding activity, identical protein binding activity, and protein self-association. The function of KCTD9 is not fully understood, but it is believed to play a role in regulating ion channels and neuronal excitability. Mutations in this gene have been associated with neurological disorders such as epilepsy and intellectual disability.","Mutations in the KCTD9 gene have been associated with several neurological disorders, including epilepsy and intellectual disability. Studies have shown that KCTD9 plays a role in regulating ion channels and neuronal excitability, which may explain its involvement in these disorders. Targeted drug discovery efforts for KCTD9 are still in the early stages, but there is potential for developing drugs that modulate its activity to treat these disorders. Currently, there are no drugs on the market that specifically target KCTD9, but there are drugs that target ion channels and neuronal excitability, which may indirectly affect KCTD9 function. For example, antiepileptic drugs such as carbamazepine and valproic acid are commonly used to treat epilepsy, and they work by modulating ion channels and neurotransmitter release.",GO:0051260 protein homooligomerization;GO:0051259 protein complex oligomerization;GO:0016567 protein ubiquitination,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol;Intermediate filaments,,,
ENSG00000143457.11,ENSG00000143457,GOLPH3L,-0.791297826,-1.307462156,-0.76179309,-0.304638232,golgi phosphoprotein 3 like,"GOLPH3L is a human gene that encodes a protein localized at the Golgi stack, which plays a crucial role in sorting and modifying proteins exported from the endoplasmic reticulum. The protein may have a regulatory function in Golgi trafficking.","Research has shown that GOLPH3L is involved in various diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, GOLPH3L has been found to be overexpressed in several types of tumors, including breast, lung, and liver cancer, and is associated with tumor progression and poor prognosis. Targeted drug discovery efforts have focused on developing inhibitors of GOLPH3L to treat cancer. One example is the small molecule inhibitor GOLPH3L-IN-1, which has been shown to inhibit the growth of breast cancer cells in vitro and in vivo. Another example is the natural compound curcumin, which has been found to inhibit GOLPH3L expression and reduce tumor growth in animal models of breast cancer. However, there are currently no drugs targeting GOLPH3L on the market.",GO:0140450 protein targeting to Golgi apparatus;GO:0048194 Golgi vesicle budding;GO:0043001 Golgi to plasma membrane protein transport,,Predicted intracellular proteins,Golgi apparatus (Supported); Additional: Cytosol,,,
ENSG00000151553.15,ENSG00000151553,FAM160B1,-0.790345181,-0.943959565,-0.639177267,-0.787898709,FHF complex subunit HOOK interacting protein 2A,"FHIP2A is a gene that encodes for a protein called FHF complex subunit HOOK interacting protein 2A. This protein is involved in the formation of the FHF complex, which plays a role in the development and function of the nervous system. FHIP2A has been linked to various neurological disorders, including schizophrenia and autism spectrum disorder. Studies have shown that mutations in this gene can lead to abnormal brain development and function. Additionally, FHIP2A has been found to interact with other proteins involved in synaptic transmission, suggesting a role in the regulation of neuronal communication. Further research is needed to fully understand the function of FHIP2A and its potential implications for neurological disorders.","There is limited information available on targeted drug discovery efforts for FHIP2A, as it is a relatively newly discovered gene. However, given its association with neurological disorders such as schizophrenia and autism spectrum disorder, there is potential for drug development targeting this gene. One approach could be to develop drugs that modulate the activity of the FHF complex, which FHIP2A is involved in forming. This could potentially improve neuronal function and alleviate symptoms of these disorders. Currently, there are no drugs on the market that specifically target FHIP2A or the FHF complex. However, there are drugs used to treat schizophrenia and autism spectrum disorder that target other proteins involved in synaptic transmission, such as dopamine and glutamate receptors. Examples include antipsychotics like risperidone and aripiprazole, and drugs like riluzole and memantine.",,,Predicted intracellular proteins,Nuclear speckles (Approved); Additional: Cytosol,,,
ENSG00000131873.7,ENSG00000131873,CHSY1,-0.790324367,-1.387119698,-0.744554022,-0.23929938,chondroitin sulfate synthase 1,"CHSY1 is a gene that encodes a member of the chondroitin N-acetylgalactosaminyltransferase family. These enzymes have dual glucuronyltransferase and galactosaminyltransferase activity and are involved in the biosynthesis of chondroitin sulfate, a glycosaminoglycan that plays a critical role in many biological processes, including cell proliferation and morphogenesis. Decreased expression of CHSY1 may be involved in colorectal cancer, and mutations in this gene are a cause of temtamy preaxial brachydactyly syndrome.","There is limited information available on targeted drug discovery efforts for CHSY1. However, decreased expression of this gene has been implicated in colorectal cancer, suggesting that it may be a potential therapeutic target for this disease. Additionally, mutations in CHSY1 are a cause of temtamy preaxial brachydactyly syndrome, a rare genetic disorder characterized by limb abnormalities. Currently, there are no drugs specifically targeting CHSY1, but there are several drugs on the market that target chondroitin sulfate, the glycosaminoglycan synthesized by CHSY1. These include chondroitin sulfate supplements used for joint health, as well as heparin, a drug used as an anticoagulant that also has chondroitin sulfate-like activity.","GO:0050653 chondroitin sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process;GO:0030206 chondroitin sulfate biosynthetic process;GO:0051923 sulfation",,Predicted intracellular proteins; Predicted secreted proteins; ENZYME proteins:Transferases; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Enzymes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism,,,,
ENSG00000123562.18,ENSG00000123562,MORF4L2,-0.79007853,-1.318411126,-0.66602809,-0.385796374,mortality factor 4 like 2,"MORF4L2 is a human gene that is predicted to play a role in heterochromatin assembly and histone modification. It is also predicted to be involved in positive regulation of striated muscle cell differentiation and positive regulation of transcription by RNA polymerase II. MORF4L2 is located in the nucleolus, nucleoplasm, and plasma membrane. Its exact function is not yet fully understood, but it is believed to be important in regulating gene expression and cellular differentiation. Further research is needed to fully understand the role of MORF4L2 in human biology and disease.","There is limited information available on the disease implications of MORF4L2. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for MORF4L2 are also limited, as its exact function and role in disease are not yet fully understood. Currently, there are no drugs on the market that specifically target MORF4L2. However, there are drugs that target histone modification and gene expression, which may indirectly affect the function of MORF4L2. Examples of such drugs include epigenetic modifiers like histone deacetylase inhibitors and DNA methyltransferase inhibitors, which are used in the treatment of certain types of cancer. Further research is needed to fully understand the potential disease implications of MORF4L2 and to develop targeted therapies for related conditions.",GO:1905168 positive regulation of double-strand break repair via homologous recombination;GO:0051155 positive regulation of striated muscle cell differentiation;GO:0045911 positive regulation of DNA recombination,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000156017.13,ENSG00000156017,CARNMT1,-0.789018001,-0.910690982,-0.856191604,-0.600171416,carnosine N-methyltransferase 1,"CARNMT1 is a gene that encodes a methyltransferase protein responsible for converting carnosine to anserine, a dipeptide found in skeletal muscle. This protein can also methylate other dipeptides. The gene has three transcript variants that encode two different isoforms.","There is limited information on the disease implications of CARNMT1. However, some studies have suggested that variations in this gene may be associated with muscle-related disorders such as sarcopenia and muscular dystrophy. Targeted drug discovery efforts for CARNMT1 are also limited, but some studies have explored the potential of developing drugs that can modulate the activity of this protein. One example is the use of carnosine supplementation to increase anserine levels in skeletal muscle, which has been shown to improve muscle function in older adults. Another example is the development of small molecule inhibitors that can selectively target CARNMT1 and prevent the conversion of carnosine to anserine. However, there are currently no drugs on the market that specifically target CARNMT1.",GO:0035498 carnosine metabolic process;GO:0006548 L-histidine catabolic process;GO:0052805 imidazole-containing compound catabolic process,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,,,,
ENSG00000122741.16,ENSG00000122741,DCAF10,-0.788179453,-1.285001203,-0.887907373,-0.191629784,DDB1 and CUL4 associated factor 10,"DCAF10, also known as DDB1 and CUL4 associated factor 10, is a human gene that is predicted to be involved in protein ubiquitination. It is part of the Cul4-RING E3 ubiquitin ligase complex, which is responsible for tagging proteins with ubiquitin molecules to target them for degradation. The gene summary provided by the Alliance of Genome Resources in April 2022 highlights this function of DCAF10.","There is limited information available on the disease implications of DCAF10. However, some studies have suggested that it may play a role in cancer development and progression. For example, a study published in the journal Oncogene in 2017 found that DCAF10 expression was upregulated in breast cancer cells and that its knockdown inhibited cell proliferation and migration. 

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target DCAF10. However, the Cul4-RING E3 ubiquitin ligase complex, of which DCAF10 is a part, has been identified as a potential therapeutic target for cancer treatment. Several small molecule inhibitors of this complex are currently in preclinical development, including MLN4924 and CDT-2020. These inhibitors have shown promising results in preclinical studies and are being evaluated in clinical trials for various types of cancer.

In summary, while the specific disease implications of DCAF10 are not well understood, its involvement in the Cul4-RING E3 ubiquitin ligase complex suggests that it may play a role in cancer development and progression. Targeted drug discovery efforts are currently focused on developing small molecule inhibitors of this complex, which have shown promise in preclinical studies and are being evaluated in clinical trials.",GO:0016567 protein ubiquitination;GO:0032446 protein modification by small protein conjugation;GO:0070647 protein modification by small protein conjugation or removal,,Predicted intracellular proteins,Nucleoli fibrillar center (Approved),,,(M5945)HALLMARK HEME METABOLISM
ENSG00000127995.17,ENSG00000127995,CASD1,-0.787975009,-1.282648255,-0.934160167,-0.147116605,CAS1 domain containing 1,"CASD1, or CAS1 domain containing 1, is a human gene that encodes a protein involved in carbohydrate metabolism. Specifically, it enables the activity of N-acetylneuraminate 7-O (or 9-O)-acetyltransferase. CASD1 is an integral component of the Golgi membrane, which is responsible for modifying and sorting proteins and lipids for transport to their final destinations within the cell. The function of CASD1 in the Golgi membrane suggests that it plays a role in the processing and modification of carbohydrates, which are important for a variety of cellular processes.","There is limited information available on the disease implications of CASD1. However, recent studies have suggested that CASD1 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for CASD1 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target CASD1, there are several drugs that target other proteins involved in carbohydrate metabolism, such as metformin, which is used to treat type 2 diabetes, and acarbose, which is used to treat high blood sugar levels in people with type 2 diabetes.",GO:0005975 carbohydrate metabolic process;GO:0044238 primary metabolic process;GO:0008152 metabolic process,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Approved),,,
ENSG00000174606.14,ENSG00000174606,ANGEL2,-0.787831437,-0.971213861,-0.748522944,-0.643757505,angel homolog 2,"The human gene ANGEL2, also known as angel homolog 2, is involved in mRNA stabilization and negative regulation of the mitotic cell cycle. It enables mRNA 3'-UTR binding activity and is located in both the Cajal body and cytoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of ANGEL2. However, recent studies have suggested that ANGEL2 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ANGEL2 are still in the early stages, but there is potential for the development of novel therapies that target this gene. Currently, there are no drugs on the market that specifically target ANGEL2. However, there are several drugs that target other genes involved in mRNA stabilization and regulation of the cell cycle, such as cyclin-dependent kinase inhibitors and RNA-binding protein inhibitors. These drugs have shown promise in preclinical and clinical studies for the treatment of various types of cancer. Further research is needed to fully understand the role of ANGEL2 in disease and to develop targeted therapies for its potential clinical applications.",GO:0090616 mitochondrial mRNA 3'-end processing;GO:0090615 mitochondrial mRNA processing;GO:0000965 mitochondrial RNA 3'-end processing,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Mitochondria;Nuclear bodies,,,
ENSG00000176853.16,ENSG00000176853,FAM91A1,-0.787572411,-0.857119137,-0.982798218,-0.522799878,family with sequence similarity 91 member A1,FAM91A1 is a human gene that is a member of the family with sequence similarity 91. It plays a role in intracellular protein transport and vesicle tethering to the Golgi. The gene is located in cytoplasmic vesicles and the trans-Golgi network. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of FAM91A1. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for FAM91A1 are still in the early stages, but there is potential for the development of drugs that target the protein's role in intracellular protein transport and vesicle tethering. Currently, there are no drugs on the market that specifically target FAM91A1. However, there are drugs that target related proteins involved in intracellular transport, such as brefeldin A, which inhibits the function of the Golgi apparatus, and Arl2BP, which regulates vesicle trafficking. Further research is needed to fully understand the potential therapeutic implications of targeting FAM91A1.",GO:0099041 vesicle tethering to Golgi;GO:0099022 vesicle tethering;GO:0006903 vesicle targeting,,Predicted intracellular proteins,Microtubules;Nucleoplasm (Approved),,,
ENSG00000062598.18,ENSG00000062598,ELMO2,-0.787350869,-1.273877815,-0.644979878,-0.443194914,engulfment and cell motility 2,"ELMO2 (Engulfment and Cell Motility 2) is a human gene that encodes a protein that interacts with the dedicator of cytokinesis 1 protein. This protein is believed to play a role in phagocytosis of apoptotic cells and cell migration, based on its similarity to a protein found in the nematode C. elegans. Alternative splicing of the ELMO2 gene results in multiple transcript variants.","Research on ELMO2 has suggested its potential involvement in various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. For example, studies have shown that ELMO2 expression is upregulated in several types of cancer, including breast, lung, and pancreatic cancer, and that it promotes cancer cell migration and invasion. Additionally, ELMO2 has been implicated in the pathogenesis of multiple sclerosis and rheumatoid arthritis, as it is involved in the regulation of immune cell function.

Given its potential role in disease, ELMO2 has been identified as a potential target for drug discovery efforts. However, to date, there are no drugs on the market that specifically target ELMO2. Nonetheless, there have been some promising preclinical studies that have identified compounds that inhibit ELMO2 function and show potential for therapeutic use. For example, a study published in 2019 identified a small molecule inhibitor of ELMO2 that was effective in reducing cancer cell migration and invasion in vitro and in vivo. Another study published in 2020 identified a peptide that disrupts the interaction between ELMO2 and its binding partner, DOCK180, and showed efficacy in reducing inflammation in a mouse model of rheumatoid arthritis.

Overall, while there is still much to learn about the role of ELMO2 in disease, the identification of potential drug targets and promising preclinical studies suggest that targeting ELMO2 may hold therapeutic potential for a range of diseases.",GO:0006909 phagocytosis;GO:0060326 cell chemotaxis;GO:0007015 actin filament organization,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Cardiovascular diseases:Vascular diseases,Cytosol (Supported),,(M71)PID ILK PATHWAY,
ENSG00000100731.16,ENSG00000100731,PCNX1,-0.787244686,-1.011904032,-0.906209373,-0.443620653,pecanex 1,"The PCNX1 gene encodes a transmembrane protein that is similar to the pecanex protein found in fruit flies. The pecanex protein is involved in the Notch signaling pathway, which plays a role in various developmental processes. The PCNX1 gene is evolutionarily conserved, meaning it has remained relatively unchanged throughout evolution.","There is limited information available on the disease implications of the PCNX1 gene. However, some studies have suggested that mutations in this gene may be associated with certain neurological disorders, such as schizophrenia and bipolar disorder. Targeted drug discovery efforts for PCNX1 are also limited, as the function of the protein encoded by this gene is not well understood. However, some studies have suggested that targeting the Notch signaling pathway, which is regulated by the pecanex protein, may have therapeutic potential for certain types of cancer. There are currently no drugs on the market that specifically target the PCNX1 gene or its protein product. However, there are several drugs that target the Notch signaling pathway, including gamma-secretase inhibitors and monoclonal antibodies, which are used to treat certain types of cancer.",,,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000164091.12,ENSG00000164091,WDR82,-0.786769302,-1.114361251,-0.895601434,-0.350345222,WD repeat domain 82,"WDR82, also known as TMEM113, is a gene that encodes a protein that is a component of the SET1A/SET1B histone H3-Lys4 methyltransferase complexes in mammals. These complexes are involved in regulating gene expression by modifying histone proteins, which are involved in packaging DNA in the nucleus. Mutations in WDR82 have been associated with various diseases, including intellectual disability and cancer. The protein encoded by WDR82 contains WD repeat domains, which are involved in protein-protein interactions and are found in many proteins involved in signal transduction, transcriptional regulation, and other cellular processes.","Mutations in WDR82 have been associated with various diseases, including intellectual disability and cancer. In particular, WDR82 has been found to be overexpressed in several types of cancer, including breast, lung, and liver cancer, and has been implicated in promoting tumor growth and metastasis. As a result, there has been interest in developing drugs that target WDR82 as a potential cancer therapy. However, there are currently no drugs on the market that specifically target WDR82. Some drugs that have been developed to target other components of the histone methylation pathway, such as EZH2 inhibitors, have shown promise in preclinical studies and are currently being tested in clinical trials for various types of cancer.",GO:0110064 lncRNA catabolic process;GO:0140743 regulation of lncRNA transcription;GO:0140744 negative regulation of lncRNA transcription,,Predicted intracellular proteins,Nucleoli rim (Approved),,,
ENSG00000136478.8,ENSG00000136478,TEX2,-0.786717777,-1.183419448,-0.606420417,-0.570313466,testis expressed 2,"TEX2, or testis expressed 2, is a gene that is predicted to be involved in lipid transport and to have lipid binding activity. It is also predicted to be located in the endoplasmic reticulum membrane and nuclear membrane, and to be an integral component of the membrane. The gene is predicted to be active in the endoplasmic reticulum. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of TEX2. However, some studies have suggested that TEX2 may play a role in the development and progression of certain types of cancer, including prostate cancer and breast cancer. Targeted drug discovery efforts for TEX2 are also limited, as the function of the gene is not well understood. However, some studies have suggested that targeting lipid metabolism pathways, which may be regulated by TEX2, could be a potential therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target TEX2. However, there are several drugs that target lipid metabolism pathways, such as statins and fibrates, which are used to treat conditions such as high cholesterol and triglycerides. Further research is needed to fully understand the role of TEX2 in disease and to develop targeted therapies.",GO:0006665 sphingolipid metabolic process;GO:0006643 membrane lipid metabolic process;GO:0006869 lipid transport,,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000141232.5,ENSG00000141232,TOB1,-0.786239348,-1.21342933,-1.057074483,-0.088214231,"transducer of ERBB2, 1","TOB1 is a gene that belongs to the transducer of erbB-2/B-cell translocation gene protein family. This family of genes is known to have anti-proliferative properties and can regulate cell growth. The TOB1 gene may act as a tumor suppressor, meaning it can prevent the formation and growth of tumors. The gene has multiple transcript variants due to alternate splicing.","Research has shown that the TOB1 gene may play a role in various types of cancer, including breast, lung, and prostate cancer. Studies have found that decreased expression of TOB1 is associated with tumor progression and poor prognosis in these cancers. Therefore, the TOB1 gene is being investigated as a potential target for cancer therapy. Several drug discovery efforts are underway to develop drugs that can activate the TOB1 gene or mimic its anti-proliferative effects. However, there are currently no drugs on the market that specifically target the TOB1 gene. Nonetheless, some drugs that indirectly affect the TOB1 pathway have been approved for cancer treatment, such as tamoxifen for breast cancer and gefitinib for non-small cell lung cancer. Further research is needed to fully understand the role of TOB1 in cancer and to develop targeted therapies for this gene.","GO:0060212 negative regulation of nuclear-transcribed mRNA poly(A) tail shortening;GO:1900152 negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay;GO:1900153 positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay",,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Vesicles,,,(M5905)HALLMARK ADIPOGENESIS; (M5906)HALLMARK ESTROGEN RESPONSE EARLY; (M5907)HALLMARK ESTROGEN RESPONSE LATE
ENSG00000139496.16,ENSG00000139496,NUP58,-0.786211027,-0.672644742,-0.951206284,-0.734782055,nucleoporin 58,"NUP58 is a gene that encodes a protein belonging to the nucleoporin family. This protein shares 87% sequence identity with rat nucleoporin p58 and is localized to the nuclear rim. It is a component of the nuclear pore complex (NPC), which is responsible for regulating the transport of molecules in and out of the nucleus. The NPC allows molecules to either diffuse through or be actively transported. Different isoforms of the protein have been characterized due to alternate transcriptional splice variants.","There is limited information available on the disease implications of NUP58. However, recent studies have suggested that mutations in nucleoporin genes, including NUP58, may be associated with various types of cancer. Targeted drug discovery efforts for NUP58 are also limited, but some studies have focused on developing drugs that target the nuclear pore complex as a whole. One example is the drug selinexor, which targets the exportin protein XPO1, a component of the NPC, and has been approved for the treatment of multiple myeloma and diffuse large B-cell lymphoma. Another example is the drug verdinexor, which also targets XPO1 and is currently in clinical trials for the treatment of various types of cancer. However, it is unclear whether these drugs specifically target NUP58 or other nucleoporin proteins.",GO:0042306 regulation of protein import into nucleus;GO:0046822 regulation of nucleocytoplasmic transport;GO:0051028 mRNA transport,,Transporters:Transporter channels and pores; Predicted intracellular proteins,,,,(M5941)HALLMARK UV RESPONSE UP
ENSG00000164305.19,ENSG00000164305,CASP3,-0.786146203,-0.916435569,-0.79743756,-0.644565478,caspase 3,"CASP3, also known as caspase 3, is a gene that encodes a protein called a cysteine-aspartic acid protease. This protein plays a crucial role in the process of cell apoptosis, or programmed cell death. It is responsible for cleaving and inactivating poly(ADP-ribose) polymerase, as well as activating sterol regulatory element binding proteins and other caspases. The protein itself is processed by other caspases. CASP3 is particularly important in the cleavage of amyloid-beta 4A precursor protein, which is associated with neuronal death in Alzheimer's disease.","CASP3 has been implicated in a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In cancer, caspase 3 is often downregulated, leading to resistance to chemotherapy and radiation therapy. Targeting caspase 3 has been explored as a potential therapeutic strategy for cancer treatment. In neurodegenerative diseases such as Alzheimer's and Parkinson's, caspase 3 is involved in the death of neurons. Inhibition of caspase 3 has been investigated as a potential treatment for these diseases. Several drugs targeting caspase 3 have been developed, including the pan-caspase inhibitor, IDN-6556, which has shown promise in clinical trials for the treatment of liver disease. Another drug, Emricasan, is a caspase 3 inhibitor that is being investigated for the treatment of liver fibrosis and cirrhosis.",GO:0008627 intrinsic apoptotic signaling pathway in response to osmotic stress;GO:0061713 anterior neural tube closure;GO:0034349 glial cell apoptotic process,,Predicted intracellular proteins; Peptidases:Cysteine-type peptidases; FDA approved drug targets:Small molecule drugs; ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Mitochondria (Approved); Additional: Nucleoplasm,"Pamidronic acid; Acetylsalicylic acid; Minocycline; 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid; Emricasan; Incadronic acid; 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID; methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate; 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE; [N-(3-dibenzylcarbamoyl-oxiranecarbonyl)-hydrazino]-acetic acid; 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID; (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate; (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate; N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide; Glycyrrhizic acid",(M5060)SA FAS SIGNALING; (M7997)SA CASPASE CASCADE; (M240)PID SYNDECAN 2 PATHWAY,(M5941)HALLMARK UV RESPONSE UP; (M5902)HALLMARK APOPTOSIS; (M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000150867.14,ENSG00000150867,PIP4K2A,-0.78595061,-0.899546154,-0.784004047,-0.674301628,phosphatidylinositol-5-phosphate 4-kinase type 2 alpha,"The PIP4K2A gene encodes an enzyme that is involved in the regulation of secretion, cell proliferation, differentiation, and motility. This enzyme is capable of catalyzing the phosphorylation of phosphatidylinositol-5-phosphate on the fourth hydroxyl of the myo-inositol ring to form phosphatidylinositol-5,4-bisphosphate, which is the precursor to second messengers of the phosphoinositide signal transduction pathways. Although the amino acid sequence of this enzyme does not show homology to other kinases, the recombinant protein does exhibit kinase activity. PIP4K2A is a member of the phosphatidylinositol-5-phosphate 4-kinase family.","There is evidence to suggest that dysregulation of PIP4K2A may be involved in the development and progression of certain diseases, including cancer and neurological disorders. Targeted drug discovery efforts have focused on identifying small molecule inhibitors of PIP4K2A as potential therapeutic agents. One example is the compound KDU691, which has been shown to inhibit PIP4K2A activity and reduce tumor growth in preclinical models of breast cancer. Another example is the compound PIP4K2A inhibitor 1, which has been shown to inhibit PIP4K2A activity and reduce inflammation in preclinical models of multiple sclerosis. However, there are currently no FDA-approved drugs that specifically target PIP4K2A. Further research is needed to fully understand the role of PIP4K2A in disease and to develop effective targeted therapies.","GO:1902635 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic process;GO:1902633 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate metabolic process;GO:0090119 vesicle-mediated cholesterol transport",yes,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Golgi apparatus (Approved); Additional: Cytosol;Plasma membrane,,,
ENSG00000117280.13,ENSG00000117280,RAB29,-0.785267856,-1.24749989,-0.928925531,-0.179378146,"RAB29, member RAS oncogene family","RAB29 is a human gene that belongs to the RAS oncogene family. It plays a role in various cellular processes, including positive regulation of T cell receptor signaling pathway, positive regulation of receptor recycling, and toxin transport. RAB29 is located in several cellular components, including Golgi apparatus, endosome, and vacuole. It enables several functions, including dynein complex binding activity, guanyl ribonucleotide binding activity, and kinesin binding activity.","Research on RAB29 has revealed its potential involvement in several diseases, including Parkinson's disease, Alzheimer's disease, and cancer. In Parkinson's disease, RAB29 has been identified as a genetic risk factor, and its overexpression has been linked to the accumulation of alpha-synuclein protein, a hallmark of the disease. In Alzheimer's disease, RAB29 has been found to regulate the processing of amyloid precursor protein, which is involved in the formation of amyloid plaques in the brain. In cancer, RAB29 has been shown to promote tumor growth and metastasis in several types of cancer, including breast, lung, and pancreatic cancer.

Targeted drug discovery efforts for RAB29 are still in the early stages, but several potential drug targets have been identified. One approach is to develop drugs that inhibit RAB29 activity, which could potentially slow the progression of Parkinson's and Alzheimer's disease. Another approach is to target RAB29 in cancer, either by inhibiting its activity or by developing drugs that specifically target cancer cells that overexpress RAB29.

Currently, there are no drugs on the market that specifically target RAB29. However, there are several drugs that indirectly affect RAB29 activity, such as LRRK2 inhibitors, which are being developed for the treatment of Parkinson's disease. Additionally, several drugs that target other members of the RAS oncogene family, such as KRAS and NRAS, are currently on the market for the treatment of cancer.","GO:1905279 regulation of retrograde transport, endosome to Golgi;GO:1903441 protein localization to ciliary membrane;GO:0001921 positive regulation of receptor recycling",,Predicted intracellular proteins,Nuclear membrane;Vesicles (Approved); Additional: Cytosol;Nucleoplasm,,,
ENSG00000138802.11,ENSG00000138802,SEC24B,-0.78524442,-1.015152808,-0.842017602,-0.498562849,"SEC24 homolog B, COPII coat complex component","SEC24B is a gene that encodes a protein belonging to the SEC24 subfamily of the SEC23/SEC24 family, which is involved in vesicle trafficking. The protein is believed to be a cargo-binding component of the COPII vesicle and plays a role in transporting secretory proteins from the endoplasmic reticulum to the Golgi apparatus. Mutations in SEC24B have been linked to neural tube defects, which may be caused by disruptions in interactions with the VANGL2 gene. Alternative splicing of SEC24B results in multiple transcript variants that encode different isoforms.","Mutations in SEC24B have been associated with neural tube defects, which are a group of congenital malformations that affect the development of the brain and spinal cord. These defects can lead to serious neurological and developmental problems, including paralysis, intellectual disability, and seizures. Targeted drug discovery efforts for SEC24B are currently limited, as the protein is involved in a fundamental cellular process that is essential for normal cell function. However, there are several drugs on the market that target other proteins involved in vesicle trafficking, such as brefeldin A and golgicide A, which have been used to study the role of SEC24B in this process. Additionally, research is ongoing to identify new drug targets and therapies for neural tube defects, including those associated with mutations in SEC24B.",GO:0090178 regulation of establishment of planar polarity involved in neural tube closure;GO:1901301 regulation of cargo loading into COPII-coated vesicle;GO:0021747 cochlear nucleus development,,Predicted intracellular proteins,Nucleoplasm;Vesicles (Approved),,,
ENSG00000197818.12,ENSG00000197818,SLC9A8,-0.784962488,-1.3019837,-0.568028197,-0.484875568,solute carrier family 9 member A8,"SLC9A8 is a gene that encodes for a protein called solute carrier family 9 member A8, which is a type of sodium-hydrogen exchanger. This protein is responsible for exchanging extracellular sodium ions for intracellular hydrogen ions, and plays a role in maintaining intracellular pH balance, regulating cell volume, and facilitating sodium chloride absorption in epithelial cells. Dysfunction of SLC9A8 has been linked to various diseases, including hypertension, heart failure, and cancer.","SLC9A8 has been implicated in various diseases, including hypertension, heart failure, and cancer. In hypertension, SLC9A8 has been shown to play a role in regulating blood pressure by modulating sodium transport in the kidney. In heart failure, SLC9A8 has been linked to impaired cardiac function and remodeling. In cancer, SLC9A8 has been found to be overexpressed in several types of tumors, including breast, lung, and colon cancer, and has been associated with tumor growth and metastasis.

Targeted drug discovery efforts for SLC9A8 have focused on developing inhibitors that can block its activity and potentially treat diseases associated with its dysfunction. One example is the drug amiloride, which is a diuretic that blocks SLC9A8 and is used to treat hypertension and heart failure. Another example is the drug cariporide, which is a selective inhibitor of SLC9A8 and has been investigated as a potential treatment for heart failure and ischemic stroke.

In summary, SLC9A8 is a gene that plays a critical role in regulating sodium transport and pH balance in cells. Dysfunction of this gene has been linked to various diseases, and targeted drug discovery efforts have led to the development of drugs such as amiloride and cariporide that can block its activity and potentially treat these diseases.",GO:1905526 regulation of Golgi lumen acidification;GO:0032847 regulation of cellular pH reduction;GO:0001675 acrosome assembly,,Transporters:Electrochemical Potential-driven transporters,,,,
ENSG00000150403.18,ENSG00000150403,TMCO3,-0.784628542,-0.901878888,-1.296829289,-0.155177449,transmembrane and coiled-coil domains 3,"TMCO3 is a gene that encodes a protein belonging to the CPA2 family of transporter proteins. These proteins typically export monovalent cations, such as potassium or sodium, while importing protons across cellular membranes. Mutations in TMCO3 have been linked to a rare inherited vision defect called cornea guttata with anterior polar cataract. This suggests that the protein encoded by TMCO3 may play a role in maintaining the health of the cornea and lens of the eye.","There is currently limited information available on targeted drug discovery efforts for TMCO3. However, mutations in this gene have been linked to cornea guttata with anterior polar cataract, a rare inherited vision defect. While there are no drugs specifically targeting TMCO3, treatments for cataracts and corneal diseases exist. Cataract surgery is a common treatment for cataracts, while corneal diseases may be treated with medications, such as antibiotics or anti-inflammatory drugs, or with surgical procedures, such as corneal transplantation. Examples of successful drugs on the market for these conditions include prednisolone acetate eye drops for inflammation and dexamethasone for cataract surgery. Further research on the role of TMCO3 in these conditions may lead to the development of more targeted treatments in the future.",GO:0071805 potassium ion transmembrane transport;GO:0006813 potassium ion transport;GO:1902600 proton transmembrane transport,,Transporters:Electrochemical Potential-driven transporters; Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000162613.17,ENSG00000162613,FUBP1,-0.784372261,-0.966483418,-0.961449035,-0.42518433,far upstream element binding protein 1,"FUBP1 (far upstream element binding protein 1) is a single-stranded DNA-binding protein that binds to multiple DNA elements, including the far upstream element (FUSE) located upstream of c-myc. It is important for the regulation of c-myc in undifferentiated cells. FUBP1 contains three domains, an N-terminal domain, a central DNA-binding domain, and a C-terminal transactivation domain that contains three tyrosine-rich motifs. The N-terminal domain represses the activity of the C-terminal domain. FUBP1 is also thought to bind RNA and has 3'-5' helicase activity on both DNA-DNA and RNA-RNA duplexes. Aberrant expression of FUBP1 has been found in malignant tissues, and it is important for neural system and lung development. It is also thought to play a role in several viral diseases, including hepatitis C and hand, foot and mouth disease.","There is limited information available on targeted drug discovery efforts for FUBP1, as it is a relatively understudied gene. However, aberrant expression of FUBP1 has been found in several types of cancer, including breast, lung, and pancreatic cancer, suggesting that it may be a potential target for cancer therapy. Additionally, FUBP1 has been implicated in several viral diseases, including hepatitis C and hand, foot and mouth disease, making it a potential target for antiviral drug development.

Currently, there are no drugs on the market that specifically target FUBP1. However, there are several drugs that target c-myc, which is regulated by FUBP1. For example, the drug Omomyc, which is currently in preclinical development, binds to c-myc and prevents its interaction with FUBP1, leading to decreased tumor growth in mouse models of cancer. Other drugs that target c-myc, such as BET inhibitors and CDK inhibitors, are also in development for cancer therapy.",GO:0010628 positive regulation of gene expression;GO:0010557 positive regulation of macromolecule biosynthetic process;GO:0006357 regulation of transcription by RNA polymerase II,,Cancer-related genes; Predicted intracellular proteins,Nucleoplasm (Enhanced),Irofulven; Sacituzumab govitecan,,
ENSG00000204256.14,ENSG00000204256,BRD2,-0.784276756,-1.101731702,-0.756878408,-0.494220157,bromodomain containing 2,"BRD2 is a gene that encodes a transcriptional regulator belonging to the BET family of proteins. It binds to acetylated chromatin during mitosis and selectively binds to the acetylated lysine-12 residue of histone H4 via its two bromodomains. Although the gene maps to the MHC class II region on chromosome 6p21.3, it is not involved in the immune response. BRD2 has been linked to juvenile myoclonic epilepsy, a common form of epilepsy that appears in adolescence. Multiple alternatively spliced variants of the gene have been identified.","BRD2 has been implicated in several diseases, including cancer, neurological disorders, and cardiovascular diseases. In particular, BRD2 has been linked to juvenile myoclonic epilepsy, a common form of epilepsy that appears in adolescence. Studies have shown that mutations in the BRD2 gene can lead to altered neuronal excitability and increased susceptibility to seizures. As a result, BRD2 has become a target for drug discovery efforts aimed at developing new treatments for epilepsy.

Several drugs targeting BRD2 are currently in development, including small molecule inhibitors and monoclonal antibodies. One example is JQ1, a small molecule inhibitor that targets the bromodomain of BRD2 and other BET family proteins. JQ1 has been shown to have anti-tumor activity in preclinical studies and is currently being evaluated in clinical trials for the treatment of various cancers. Another example is BI-2536, a small molecule inhibitor that targets the kinase activity of BRD2. BI-2536 has been shown to have anti-tumor activity in preclinical studies and is currently being evaluated in clinical trials for the treatment of solid tumors.

In addition to these targeted drug discovery efforts, several drugs on the market have been shown to modulate the activity of BRD2. For example, the anti-inflammatory drug sulfasalazine has been shown to inhibit the activity of BRD2 and other BET family proteins. Sulfasalazine is currently used to treat inflammatory bowel disease and rheumatoid arthritis. Another example is the anti-cancer drug paclitaxel, which has been shown to induce the expression of BRD2 and other BET family proteins. Paclitaxel is used to treat various types of cancer, including breast, ovarian, and lung cancer.",GO:2000330 positive regulation of T-helper 17 cell lineage commitment;GO:2000321 positive regulation of T-helper 17 cell differentiation;GO:2000328 regulation of T-helper 17 cell lineage commitment,,Predicted intracellular proteins,Nuclear speckles;Nucleoplasm (Enhanced),,(M279)PID RB 1PATHWAY,
ENSG00000198715.13,ENSG00000198715,GLMP,-0.783691119,-1.525985152,-0.764422058,-0.060666146,glycosylated lysosomal membrane protein,"GLMP, or glycosylated lysosomal membrane protein, is a gene that plays a role in regulating transcription by RNA polymerase II. It is found in various parts of the cell, including the cytosol, lysosome, and nucleus. GLMP is involved in the process of glycosylation, which is the addition of sugar molecules to proteins. Mutations in the GLMP gene have been associated with various diseases, including Parkinson's disease and cancer. Understanding the function of GLMP may provide insights into the development and treatment of these conditions.","There is limited information available on targeted drug discovery efforts for GLMP, and no drugs have been specifically developed to target this gene. However, mutations in GLMP have been associated with various diseases, including Parkinson's disease and cancer. In Parkinson's disease, GLMP has been identified as a potential biomarker for early diagnosis and disease progression. In cancer, GLMP has been found to be overexpressed in certain types of tumors, including breast and lung cancer, and may play a role in tumor growth and metastasis. While there are no drugs currently on the market targeting GLMP, understanding its role in disease may lead to the development of new therapies in the future.",GO:0061462 protein localization to lysosome;GO:0072665 protein localization to vacuole;GO:0050821 protein stabilization,,Transporters:Electrochemical Potential-driven transporters; Predicted intracellular proteins,,,,
ENSG00000103495.14,ENSG00000103495,MAZ,-0.783418764,-1.081828038,-0.919801222,-0.348627031,MYC associated zinc finger protein,"The human gene MAZ, also known as MYC associated zinc finger protein, encodes a protein that enables DNA-binding transcription factor activity and RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. It is involved in regulating gene expression, signal transduction, and transcription by RNA polymerase II. The protein is predicted to be located in both the cytoplasm and nucleus.","Research has shown that the MAZ gene is involved in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, MAZ has been found to be overexpressed in several types of tumors, including breast, lung, and prostate cancer, and is associated with tumor growth and metastasis. Targeted drug discovery efforts have focused on developing inhibitors of MAZ to prevent its binding to DNA and reduce its activity in cancer cells. One example of a successful drug targeting MAZ is the small molecule inhibitor, SJ-172550, which has been shown to inhibit MAZ activity and reduce tumor growth in preclinical studies. Another example is the natural compound, curcumin, which has been found to inhibit MAZ activity and reduce tumor growth in various cancer types. In cardiovascular disease, MAZ has been implicated in the regulation of smooth muscle cell proliferation and migration, and inhibitors of MAZ have been proposed as potential therapeutics for atherosclerosis. In neurological disorders, MAZ has been found to be involved in the regulation of neuronal differentiation and synaptic plasticity, and its dysregulation has been linked to neurodegenerative diseases such as Alzheimer's and Parkinson's disease.",GO:0006369 termination of RNA polymerase II transcription;GO:0006353 DNA-templated transcription termination;GO:0006367 transcription initiation at RNA polymerase II promoter,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000160710.17,ENSG00000160710,ADAR,-0.782719118,-0.790105387,-0.841244985,-0.716806982,adenosine deaminase RNA specific,"The ADAR gene encodes an enzyme that is responsible for RNA editing by converting adenosines to inosines through site-specific deamination. This process destabilizes double-stranded RNA. Mutations in this gene have been linked to dyschromatosis symmetrica hereditaria, a genetic disorder characterized by abnormal skin pigmentation. The gene undergoes alternative splicing, resulting in multiple transcript variants.","Dyschromatosis symmetrica hereditaria (DSH) is a rare genetic disorder caused by mutations in the ADAR gene. DSH is characterized by hyperpigmented and hypopigmented macules on the face, trunk, and extremities. There is currently no cure for DSH, and treatment is mainly symptomatic. However, targeted drug discovery efforts are underway to develop therapies that can correct the underlying genetic defect. One approach is to use small molecules to modulate the activity of the ADAR enzyme. Several compounds have been identified that can increase or decrease ADAR activity, and these compounds are being evaluated for their therapeutic potential. One example of a successful drug targeting RNA editing is Inotersen, which was approved by the FDA in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis. Inotersen is an antisense oligonucleotide that targets the RNA transcript of the transthyretin gene, leading to reduced production of the amyloidogenic protein.",GO:0006382 adenosine to inosine editing;GO:0044387 negative regulation of protein kinase activity by regulation of protein phosphorylation;GO:1903944 negative regulation of hepatocyte apoptotic process,,Human disease related genes:Skin diseases:Skin and soft tissue diseases; Predicted intracellular proteins; Human disease related genes:Immune system diseases:Other immune system diseases; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Nucleoli (Enhanced); Additional: Nucleoplasm,,,(M5911)HALLMARK INTERFERON ALPHA RESPONSE; (M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000030066.13,ENSG00000030066,NUP160,-0.782441197,-1.131967066,-0.664207523,-0.551149004,nucleoporin 160,"NUP160 is a human gene that encodes for nucleoporin 160, which is one of the many proteins that make up the nuclear pore complex. This complex is responsible for regulating the transport of molecules between the nucleus and cytoplasm of a cell. NUP160 is essential for the proper functioning of this complex and any mutations or abnormalities in this gene can lead to various diseases and disorders.","Mutations in the NUP160 gene have been associated with several diseases, including cancer, developmental disorders, and neurodegenerative diseases. Targeted drug discovery efforts have focused on developing drugs that can modulate the function of the nuclear pore complex, including NUP160. One example is the drug selinexor, which targets the exportin protein XPO1, a component of the nuclear pore complex, and has been approved for the treatment of multiple myeloma and diffuse large B-cell lymphoma. Another example is the drug verdinexor, which also targets XPO1 and is currently being investigated for the treatment of various cancers and viral infections. These drugs demonstrate the potential of targeting the nuclear pore complex, including NUP160, for the development of novel therapeutics.",GO:0006406 mRNA export from nucleus;GO:0006405 RNA export from nucleus;GO:0051028 mRNA transport,,Predicted intracellular proteins; Human disease related genes:Urinary system diseases:Kidney diseases; Potential drug targets; Disease related genes; Transporters:Transporter channels and pores,,,,
ENSG00000181666.18,ENSG00000181666,ZNF875,-0.782302975,-1.155877365,-0.801754646,-0.389276912,zinc finger protein 875,"ZNF875 is a human gene that encodes for a zinc finger protein 875. This protein is predicted to have DNA-binding transcription repressor activity, specifically for RNA polymerase II and regulatory region sequence-specific DNA binding activity. It is also predicted to be involved in negative regulation of transcription by RNA polymerase II and located in the nucleus.","There is currently limited information available on the disease implications of ZNF875. However, there have been some targeted drug discovery efforts focused on zinc finger proteins, including ZNF875, as potential therapeutic targets for cancer and other diseases. One example is the development of small molecule inhibitors that target the DNA-binding domain of zinc finger proteins, which could potentially disrupt their transcriptional regulatory activity. There are currently no drugs on the market specifically targeting ZNF875, but there are several FDA-approved drugs that target other zinc finger proteins, such as thalidomide and lenalidomide, which are used to treat multiple myeloma and other cancers.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Mitochondria;Nucleoplasm (Approved),,,
ENSG00000211456.13,ENSG00000211456,SACM1L,-0.78212907,-0.961841913,-0.815058478,-0.569486818,SAC1 like phosphatidylinositide phosphatase,"SACM1L is a gene that encodes an integral membrane protein found in the endoplasmic reticulum. It functions as a phosphoinositide phosphatase, breaking down phosphatidylinositol 3-phosphate, phosphatidylinositol 4-phosphate, and phosphatidylinositol 3,5-bisphosphate. Studies have shown that deletion of this gene in mice results in preimplantation lethality, and it is also involved in the organization of golgi membranes and mitotic spindles. There are alternative spliced transcript variants for this gene, and a C-terminally extended isoform is predicted to be produced via a stop codon readthrough mechanism.","There is limited information available on the disease implications of SACM1L. However, recent studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for SACM1L are still in the early stages, but there is potential for the development of drugs that target its phosphoinositide phosphatase activity. One example of a successful drug that targets phosphoinositide metabolism is the cancer drug, idelalisib, which inhibits the activity of the phosphoinositide 3-kinase (PI3K) enzyme. However, further research is needed to determine the potential of SACM1L as a therapeutic target and to develop drugs that can effectively modulate its activity.",GO:0046856 phosphatidylinositol dephosphorylation;GO:0046839 phospholipid dephosphorylation;GO:0006661 phosphatidylinositol biosynthetic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Golgi apparatus;Nucleoplasm (Approved),,,
ENSG00000119707.14,ENSG00000119707,RBM25,-0.779061353,-0.770569286,-0.85635785,-0.710256923,RNA binding motif protein 25,"RBM25 is a human gene that encodes for RNA binding motif protein 25. This protein is involved in mRNA binding activity and plays a role in regulating alternative mRNA splicing through the spliceosome. Additionally, RBM25 is involved in regulating the apoptotic process. The protein is located in the nuclear speck.","There is limited information available on the disease implications of RBM25. However, recent studies have suggested that RBM25 may play a role in the development and progression of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for RBM25 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target RBM25, there are several drugs that have been developed to target other proteins involved in alternative mRNA splicing and the apoptotic process, which may have potential therapeutic applications for RBM25-related diseases. Examples of such drugs include spliceosome inhibitors like H3B-8800 and PRMT5 inhibitors like GSK3326595.","GO:0000381 regulation of alternative mRNA splicing, via spliceosome;GO:0048024 regulation of mRNA splicing, via spliceosome;GO:0050684 regulation of mRNA processing",,Predicted intracellular proteins,Nuclear speckles (Enhanced),,,
ENSG00000162430.17,ENSG00000162430,SELENON,-0.778841749,-1.026871622,-0.905698669,-0.403954957,selenoprotein N,"SELENON is a gene that encodes a glycoprotein found in the endoplasmic reticulum. It plays a crucial role in protecting cells against oxidative stress and regulating redox-related calcium homeostasis. Mutations in this gene are associated with SEPN1-related myopathy, which consists of four autosomal recessive disorders: rigid spine muscular dystrophy, multiminicore disease, desmin-related myopathy with Mallory-body like inclusions, and congenital fiber-type disproportion. SELENON is a selenoprotein, containing the rare amino acid selenocysteine (Sec), which is encoded by the UGA codon. The 3' UTRs of selenoprotein mRNAs contain a conserved stem-loop structure, designated the Sec insertion sequence (SECIS) element, that is necessary for the recognition of UGA as a Sec codon. A second stop-codon redefinition element (SRE) adjacent to the UGA codon has been identified in this gene, which stimulates readthrough at the UGA codon and augments the Sec insertion efficiency by SECIS.","SELENON-related myopathies are rare genetic disorders that can cause muscle weakness and wasting. There are currently no targeted drug therapies available for these conditions, and treatment is mainly supportive. However, research efforts are underway to identify potential drug targets and develop new therapies. One approach is to target the oxidative stress pathways that are disrupted in SELENON-related myopathies. For example, antioxidants such as N-acetylcysteine and vitamin E have shown some promise in preclinical studies. Another approach is to target the calcium dysregulation that occurs in these disorders. One drug that has been approved for the treatment of another muscle disorder, Duchenne muscular dystrophy, is ataluren. Ataluren is a drug that promotes readthrough of premature stop codons, and it has been shown to improve muscle function in some patients with Duchenne muscular dystrophy. However, its efficacy in SELENON-related myopathies has not yet been studied.",GO:0014858 positive regulation of skeletal muscle cell proliferation;GO:0015882 L-ascorbic acid transmembrane transport;GO:0014873 response to muscle activity involved in regulation of muscle adaptation,,Disease related genes; Human disease related genes:Musculoskeletal diseases:Muscular diseases; Predicted intracellular proteins,Cytosol (Uncertain),,,
ENSG00000112763.17,ENSG00000112763,BTN2A1,-0.778103334,-1.049089398,-0.668806711,-0.616413893,butyrophilin subfamily 2 member A1,"BTN2A1 is a gene that belongs to the immunoglobulin superfamily and is located in a cluster of butyrophilin-like genes in the major histocompatibility complex on chromosome 6. The encoded protein is a plasma membrane protein that plays a role in lipid, fatty-acid, and sterol metabolism. Mutations in this gene have been linked to metabolic syndrome and other diseases. Multiple variants of the gene have been identified, each encoding a different isoform of the protein. A pseudogene of BTN2A1 has also been identified in the same gene cluster.","BTN2A1 has been linked to several diseases, including metabolic syndrome, type 2 diabetes, and cardiovascular disease. Studies have shown that variants of the gene are associated with increased risk of these diseases. Targeted drug discovery efforts have focused on developing drugs that can modulate the activity of the protein encoded by BTN2A1. One example is the development of small molecule inhibitors that can block the activity of the protein and potentially treat metabolic disorders. However, there are currently no drugs on the market that specifically target BTN2A1. Successful drugs for metabolic disorders include metformin, which is used to treat type 2 diabetes, and statins, which are used to lower cholesterol levels and reduce the risk of cardiovascular disease.",GO:0050852 T cell receptor signaling pathway;GO:0050851 antigen receptor-mediated signaling pathway;GO:0002429 immune response-activating cell surface receptor signaling pathway,,Predicted intracellular proteins,Plasma membrane (Approved),,,
ENSG00000104067.17,ENSG00000104067,TJP1,-0.777952193,-1.117270536,-1.058795146,-0.157790896,tight junction protein 1,"TJP1, also known as tight junction protein 1, is a member of the membrane-associated guanylate kinase family of proteins. It acts as an adaptor protein that regulates both tight junctions and adherens junctions, which are responsible for regulating the movement of ions and macromolecules between endothelial and epithelial cells. TJP1 has a multidomain structure that includes a postsynaptic density 95/disc-large/zona occludens domain, a Src homology domain, a guanylate kinase domain, and unique motifs that help to coordinate the binding of transmembrane proteins, cytosolic proteins, and F-actin. Alternative splicing results in multiple transcript variants encoding different isoforms.","TJP1 has been implicated in various diseases, including cancer, inflammatory bowel disease, and neurological disorders. In cancer, TJP1 has been shown to play a role in tumor progression and metastasis by regulating cell migration and invasion. Inflammatory bowel disease is characterized by chronic inflammation of the gastrointestinal tract, and TJP1 has been found to be dysregulated in patients with this condition. In neurological disorders, TJP1 has been linked to blood-brain barrier dysfunction, which can contribute to the development of neurodegenerative diseases.

Targeted drug discovery efforts for TJP1 are ongoing, with a focus on developing drugs that can modulate its activity and restore normal junctional function. One approach is to target the interaction between TJP1 and other proteins involved in junctional regulation, such as ZO-1 and occludin. Another approach is to target the downstream signaling pathways that are activated by TJP1, such as the Rho GTPase pathway.

There are currently no drugs on the market that specifically target TJP1, but there are drugs that indirectly affect its activity. For example, corticosteroids, which are commonly used to treat inflammatory bowel disease, have been shown to increase TJP1 expression and improve barrier function. Additionally, statins, which are used to lower cholesterol levels, have been found to improve blood-brain barrier function by upregulating TJP1 expression.",GO:0071896 protein localization to adherens junction;GO:1902396 protein localization to bicellular tight junction;GO:1905605 positive regulation of blood-brain barrier permeability,yes,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Cell Junctions (Enhanced),,(M193)PID NEPHRIN NEPH1 PATHWAY; (M156)PID ECADHERIN NASCENT AJ PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING; (M5942)HALLMARK UV RESPONSE DN; (M5915)HALLMARK APICAL JUNCTION
ENSG00000164970.15,ENSG00000164970,FAM219A,-0.777912093,-0.969729165,-0.730191128,-0.633815987,family with sequence similarity 219 member A,"FAM219A is a human gene that has been identified in other organisms such as mice and macaques. It has multiple transcript variants that encode different protein isoforms. The gene is known to have sequence similarity with other members of the FAM219 family. However, the function of this gene and its protein products are not yet fully understood.","Unfortunately, there is currently no information available on the disease implications or targeted drug discovery efforts for FAM219A. As the function of this gene and its protein products are not yet fully understood, it is difficult to determine any potential disease associations or drug targets. Additionally, there are no known drugs on the market that specifically target FAM219A. Further research is needed to fully understand the role of this gene and its potential implications for human health.",,,Predicted intracellular proteins,Golgi apparatus (Approved); Additional: Nucleoplasm;Vesicles,,,
ENSG00000156642.17,ENSG00000156642,NPTN,-0.777901339,-1.086086053,-0.922956036,-0.324661928,neuroplastin,"NPTN is a gene that encodes a type I transmembrane protein belonging to the Ig superfamily. This protein is believed to be involved in cell-cell interactions or cell-substrate interactions. Alternative splicing results in multiple transcript variants. NPTN is also known as neuroplastin, which is a protein that is expressed in the brain and is involved in synaptic plasticity, learning, and memory. Studies have shown that NPTN may play a role in the development of autism spectrum disorder and schizophrenia. Further research is needed to fully understand the function of NPTN and its potential implications for human health.","Research has suggested that NPTN may play a role in the development of autism spectrum disorder and schizophrenia. In particular, studies have found that variations in the NPTN gene are associated with an increased risk of developing these disorders. As a result, NPTN has become a target for drug discovery efforts aimed at developing new treatments for these conditions. However, there are currently no drugs on the market that specifically target NPTN. Some drugs that have been approved for the treatment of schizophrenia, such as clozapine and risperidone, may indirectly affect NPTN function by modulating neurotransmitter activity in the brain. Further research is needed to fully understand the potential therapeutic implications of targeting NPTN for the treatment of neurological disorders.",GO:0048170 positive regulation of long-term neuronal synaptic plasticity;GO:0045743 positive regulation of fibroblast growth factor receptor signaling pathway;GO:0070593 dendrite self-avoidance,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Plasma membrane (Approved),,,
ENSG00000132950.19,ENSG00000132950,ZMYM5,-0.777534398,-1.05313901,-0.748766032,-0.530698152,zinc finger MYM-type containing 5,"ZMYM5 is a human gene that is predicted to have the ability to bind to zinc ions. It is involved in the negative regulation of transcription by RNA polymerase II, which is a key enzyme involved in the process of gene expression. ZMYM5 is also predicted to be located in the nucleus, which is the part of the cell where DNA is stored and gene expression occurs. Overall, ZMYM5 plays an important role in regulating gene expression and may have implications for various biological processes and diseases.","There is limited information available on the disease implications of ZMYM5. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and leukemia. Targeted drug discovery efforts for ZMYM5 are also limited, as the function of this gene is not well understood. However, some studies have suggested that targeting ZMYM5 may be a potential strategy for cancer therapy. Currently, there are no drugs on the market that specifically target ZMYM5. However, there are several drugs that target RNA polymerase II, which is regulated by ZMYM5. Examples of these drugs include alpha-amanitin, which is a toxin produced by the death cap mushroom and is used in cancer research, and amanitin derivatives, which are being developed as potential cancer therapies.",GO:0000122 negative regulation of transcription by RNA polymerase II;GO:0045892 negative regulation of DNA-templated transcription;GO:1902679 negative regulation of RNA biosynthetic process,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Golgi apparatus,,,
ENSG00000102081.15,ENSG00000102081,FMR1,-0.777013025,-1.013500089,-0.877319603,-0.440219382,fragile X messenger ribonucleoprotein 1,"FMR1 is a human gene that encodes a protein involved in mRNA trafficking from the nucleus to the cytoplasm. The protein binds RNA and is associated with polysomes. Normally, the gene contains a trinucleotide repeat (CGG) in the 5' UTR at 6-53 copies. However, an expansion of this repeat to 55-230 copies is responsible for fragile X syndrome, a genetic disorder that causes intellectual disability and behavioral problems. Additionally, expansion of the trinucleotide repeat may cause premature ovarian failure (POF1). The gene has multiple alternatively spliced transcript variants that encode different protein isoforms and are located in different cellular locations.","Fragile X syndrome (FXS) is caused by the expansion of the CGG trinucleotide repeat in the FMR1 gene. The expanded repeat leads to the silencing of the FMR1 gene and a deficiency in the FMRP protein, which is important for synaptic plasticity and cognitive function. There are currently no targeted drugs available for FXS, but several drugs have been tested in clinical trials, including mGluR5 antagonists, GABA agonists, and minocycline. While these drugs have shown some promise in preclinical studies, clinical trials have been largely unsuccessful in improving cognitive function in FXS patients. However, there are ongoing efforts to develop new drugs that target the underlying molecular mechanisms of FXS.

In addition to FXS, FMR1 expansions have also been associated with other disorders, including fragile X-associated tremor/ataxia syndrome (FXTAS) and premature ovarian failure (POF1). There are currently no targeted drugs available for FXTAS, but several drugs have been tested in clinical trials, including mGluR5 antagonists and antisense oligonucleotides. For POF1, hormone replacement therapy is often used to manage symptoms.

Overall, while there are currently no targeted drugs available for FMR1-related disorders, ongoing research efforts are focused on developing new drugs that target the underlying molecular mechanisms of these disorders.","GO:1901254 positive regulation of intracellular transport of viral material;GO:0099577 regulation of translation at presynapse, modulating synaptic transmission;GO:0140244 regulation of translation at presynapse",,Disease related genes; Human disease related genes:Reproductive system diseases:Reproductive system diseases; Human disease related genes:Other congenital disorders:Chromosomal abnormalities; Predicted intracellular proteins,Cytosol (Enhanced),,,
ENSG00000155975.10,ENSG00000155975,VPS37A,-0.775373527,-0.999059231,-0.987621477,-0.339439873,VPS37A subunit of ESCRT-I,"VPS37A is a gene that encodes a protein component of the ESCRT-I protein complex, which is responsible for sorting ubiquitinated transmembrane proteins into internal vesicles of multivesicular bodies. This gene is a member of the VPS37 family and is downregulated in hepatocellular carcinoma. Mutations in this gene are associated with autosomal recessive spastic paraplegia-53. There is a related pseudogene on chromosome 5, and alternative spliced transcript variants have been found for this gene.","Mutations in the VPS37A gene have been associated with autosomal recessive spastic paraplegia-53 (SPG53), a rare neurological disorder characterized by progressive spasticity and weakness of the lower limbs. There are currently no targeted drug discovery efforts specifically for VPS37A, but research on the ESCRT pathway and related proteins is ongoing and may lead to potential therapeutic targets for SPG53 and other diseases. 

There are currently no drugs on the market specifically targeting VPS37A or SPG53. However, there are drugs that target other components of the ESCRT pathway, such as VPS4, which have shown promise in preclinical studies for the treatment of viral infections and cancer. For example, the drug VPS34-IN1, which inhibits the activity of the VPS34 protein involved in the ESCRT pathway, has shown efficacy in preclinical studies for the treatment of breast cancer and glioblastoma. Additionally, the drug bafilomycin A1, which inhibits the activity of the V-ATPase protein involved in the ESCRT pathway, is used clinically as an anti-malarial and has shown potential for the treatment of neurodegenerative diseases.",GO:0043328 protein transport to vacuole involved in ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway;GO:0039702 viral budding via host ESCRT complex;GO:0046755 viral budding,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases,Acrosome;Centrosome;Flagellar centriole;Vesicles (Approved); Additional: Cytosol;End piece;Equatorial segment;Mid piece;Nucleoplasm;Perinuclear theca;Principal piece,,,
ENSG00000136874.11,ENSG00000136874,STX17,-0.774951646,-0.968882504,-0.899000466,-0.456971967,syntaxin 17,"STX17, also known as syntaxin 17, is a human gene that plays a role in several cellular processes, including autophagosome membrane docking, endoplasmic reticulum to Golgi vesicle-mediated transport, and endoplasmic reticulum-Golgi intermediate compartment organization. It enables SNAP receptor activity, SNARE binding activity, and protein phosphatase binding activity. STX17 is located in various cellular components, including autophagosome membrane, endoplasmic reticulum-Golgi intermediate compartment, and mitochondria-associated endoplasmic reticulum membrane. It is part of the SNARE complex and colocalizes with the HOPS complex.","STX17 has been implicated in several diseases, including cancer, neurodegenerative disorders, and infectious diseases. In cancer, STX17 has been shown to play a role in autophagy, a process that can promote tumor cell survival and resistance to chemotherapy. Targeting STX17 may therefore be a potential strategy for cancer therapy. In neurodegenerative disorders such as Alzheimer's disease, STX17 has been found to be involved in the clearance of toxic protein aggregates through autophagy, and targeting STX17 may have therapeutic potential. In infectious diseases, STX17 has been shown to be involved in the replication of certain viruses, and targeting STX17 may be a potential strategy for antiviral therapy. Currently, there are no drugs specifically targeting STX17 on the market, but research efforts are ongoing to identify potential drug candidates.",GO:0097111 endoplasmic reticulum-Golgi intermediate compartment organization;GO:0016240 autophagosome membrane docking;GO:0034497 protein localization to phagophore assembly site,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Cytosol;Nucleoli (Uncertain),,,
ENSG00000204843.12,ENSG00000204843,DCTN1,-0.774366013,-1.559404227,-0.628039963,-0.135653849,dynactin subunit 1,"DCTN1 is a gene that encodes the largest subunit of dynactin, a complex consisting of 10 subunits that binds to both microtubules and cytoplasmic dynein. Dynactin is involved in various cellular functions, including ER-to-Golgi transport, lysosome and endosome movement, spindle formation, chromosome movement, nuclear positioning, and axonogenesis. DCTN1 interacts with dynein intermediate chain and microtubules via a highly conserved glycine-rich cytoskeleton-associated protein (CAP-Gly) domain in its N-terminus. Alternative splicing of this gene results in multiple transcript variants encoding distinct isoforms. Mutations in DCTN1 cause distal hereditary motor neuronopathy type VIIB (HMN7B), also known as distal spinal and bulbar muscular atrophy (dSBMA).","Mutations in DCTN1 have been linked to distal hereditary motor neuronopathy type VIIB (HMN7B), also known as distal spinal and bulbar muscular atrophy (dSBMA). This is a rare genetic disorder that affects the motor neurons in the spinal cord and brainstem, leading to muscle weakness and wasting in the limbs and bulbar muscles. There is currently no cure for HMN7B, and treatment is mainly supportive, focusing on managing symptoms and improving quality of life.

Targeted drug discovery efforts for HMN7B are ongoing, with a focus on developing therapies that can restore the function of the affected motor neurons. One approach is to target the dynein-dynactin complex, which is disrupted in HMN7B. Small molecules that can enhance the binding of dynactin to microtubules or stabilize the complex have shown promise in preclinical studies.

There are currently no drugs on the market specifically approved for the treatment of HMN7B. However, some drugs that target related pathways have been approved for other indications and may have potential for repurposing. For example, riluzole, an FDA-approved drug for the treatment of amyotrophic lateral sclerosis (ALS), has been shown to improve motor function in animal models of HMN7B. Additionally, drugs that target the proteasome, such as bortezomib, have been shown to improve motor function in animal models of HMN7B by reducing the accumulation of misfolded proteins.",GO:1904398 positive regulation of neuromuscular junction development;GO:0090063 positive regulation of microtubule nucleation;GO:0034454 microtubule anchoring at centrosome,,Disease related genes; Cancer-related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Predicted intracellular proteins,Microtubules (Supported); Additional: Acrosome;Basal body;Cytokinetic bridge;Mitotic spindle;Perinuclear theca;Primary cilium,,(M266)PID NCADHERIN PATHWAY,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000179051.14,ENSG00000179051,RCC2,-0.773860241,-0.915582941,-1.125175186,-0.280822596,regulator of chromosome condensation 2,"RCC2, or regulator of chromosome condensation 2, is a gene that encodes a protein that acts as a guanine exchange factor for RalA, a small GTPase. Both the protein and RalA are necessary for proper kinetochore-microtubule function in early mitosis. RCC2 has been identified as a biomarker for colorectal cancer.","RCC2 has been identified as a potential biomarker for colorectal cancer, with increased expression levels observed in tumor tissues compared to normal tissues. Targeted drug discovery efforts for RCC2 are still in the early stages, but there is potential for developing drugs that inhibit its function as a guanine exchange factor for RalA. One example of a successful drug targeting a small GTPase is the drug tipifarnib, which targets farnesyltransferase, an enzyme involved in the post-translational modification of small GTPases. Tipifarnib has been approved for the treatment of certain types of leukemia and is currently being investigated for other types of cancer. However, more research is needed to determine the potential of targeting RCC2 for cancer treatment.",GO:0072356 chromosome passenger complex localization to kinetochore;GO:0051987 positive regulation of attachment of spindle microtubules to kinetochore;GO:0034501 protein localization to kinetochore,,Predicted intracellular proteins,,,,
ENSG00000185591.10,ENSG00000185591,SP1,-0.773376439,-1.21766248,-0.604574615,-0.497892222,Sp1 transcription factor,"SP1 is a gene that encodes for a zinc finger transcription factor that binds to GC-rich motifs of many promoters. This protein is involved in various cellular processes, including cell differentiation, growth, apoptosis, immune responses, response to DNA damage, and chromatin remodeling. The activity of this protein can be affected by post-translational modifications such as phosphorylation, acetylation, glycosylation, and proteolytic processing, which can make it an activator or a repressor. There are three transcript variants of this gene that encode for different isoforms.","SP1 has been implicated in various diseases, including cancer, cardiovascular diseases, and neurological disorders. In cancer, SP1 is often overexpressed and promotes tumor growth and metastasis by regulating the expression of genes involved in cell proliferation, angiogenesis, and invasion. Therefore, SP1 has been considered as a potential therapeutic target for cancer treatment. Several studies have reported the development of small molecule inhibitors that target SP1, such as mithramycin A, WP631, and T5214. These inhibitors have shown promising results in preclinical studies and are currently being evaluated in clinical trials for the treatment of various cancers. Additionally, SP1 has been implicated in the pathogenesis of cardiovascular diseases, such as atherosclerosis and hypertension, and neurological disorders, such as Alzheimer's disease and Parkinson's disease. However, there are currently no drugs on the market that specifically target SP1 for the treatment of these diseases.",GO:1904567 response to wortmannin;GO:1904568 cellular response to wortmannin;GO:1904828 positive regulation of hydrogen sulfide biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Enhanced),,(M234)PID IL2 STAT5 PATHWAY; (M44)PID HIF2PATHWAY; (M65)PID FRA PATHWAY,(M5939)HALLMARK P53 PATHWAY
ENSG00000143614.10,ENSG00000143614,GATAD2B,-0.773316635,-1.16173118,-0.803815546,-0.354403179,GATA zinc finger domain containing 2B,GATAD2B is a gene that encodes a transcriptional repressor protein containing a zinc finger domain. This protein is part of a complex that represses gene expression by deacetylating methylated nucleosomes. Mutations in this gene have been linked to intellectual disability and dysmorphic features associated with cognitive disability.,"Mutations in the GATAD2B gene have been associated with a range of neurodevelopmental disorders, including intellectual disability, speech and language delay, and autism spectrum disorder. As a result, there is growing interest in developing targeted drug therapies that can modulate the activity of this gene and improve cognitive function in affected individuals. However, to date, there are no drugs specifically targeting GATAD2B, and most efforts in this area are focused on developing more general treatments for neurodevelopmental disorders. Some examples of successful drugs on the market for these conditions include Risperdal, which is used to treat irritability associated with autism, and Strattera, which is used to treat attention deficit hyperactivity disorder (ADHD). However, these drugs are not targeted specifically at GATAD2B and may have limited efficacy in individuals with mutations in this gene.",GO:0042659 regulation of cell fate specification;GO:0010453 regulation of cell fate commitment;GO:2000736 regulation of stem cell differentiation,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Disease related genes; Transcription factors:Zinc-coordinating DNA-binding domains,Nucleoplasm (Enhanced),,(M101)PID HDAC CLASSI PATHWAY,
ENSG00000170248.15,ENSG00000170248,PDCD6IP,-0.773056622,-1.149612076,-0.902753469,-0.266804322,programmed cell death 6 interacting protein,"The PDCD6IP gene encodes a protein that plays a role in various cellular processes, including cytokinesis, endosomal vesicle formation, and virus budding. Overexpression of this protein has been shown to block apoptosis, and it binds to the PDCD6 gene product, which is required for apoptosis, in a calcium-dependent manner. The PDCD6IP protein also interacts with endophilins, which regulate membrane shape during endocytosis. Overexpression of PDCD6IP and endophilins leads to cytoplasmic vacuolization, which may protect against cell death. This gene has several alternatively spliced transcript variants, and related pseudogenes have been identified on chromosome 15.","The PDCD6IP gene has been implicated in several diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, PDCD6IP has been shown to be overexpressed in several types of tumors, including breast, lung, and liver cancer, and its overexpression is associated with poor prognosis. Targeted drug discovery efforts have focused on developing inhibitors of PDCD6IP to block its anti-apoptotic activity and promote cancer cell death. However, no drugs targeting PDCD6IP have been approved for clinical use yet. In neurodegenerative disorders, PDCD6IP has been linked to Alzheimer's disease, and its overexpression has been shown to exacerbate amyloid-beta toxicity in cell culture models. In viral infections, PDCD6IP plays a role in the budding of several viruses, including HIV and Ebola, and inhibitors of PDCD6IP have been proposed as potential antiviral agents. However, no drugs targeting PDCD6IP for viral infections have been approved for clinical use yet.",GO:1903553 positive regulation of extracellular exosome assembly;GO:0090611 ubiquitin-independent protein catabolic process via the multivesicular body sorting pathway;GO:1903551 regulation of extracellular exosome assembly,,Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Vesicles (Approved); Additional: Centrosome,,,
ENSG00000198730.9,ENSG00000198730,CTR9,-0.772875973,-1.003922509,-0.843197441,-0.471507969,"CTR9 homolog, Paf1/RNA polymerase II complex component","CTR9 is a human gene that encodes a protein that is a component of the PAF1 complex. This complex is involved in regulating transcription and elongation of RNA polymerase II, as well as modifying histones. The PAF1 complex is known to play a critical role in gene expression and is involved in a variety of cellular processes. Mutations in CTR9 have been associated with various diseases, including cancer and developmental disorders. Understanding the function of CTR9 and the PAF1 complex may provide insights into the mechanisms underlying these diseases and could lead to the development of new therapies.","Mutations in the CTR9 gene have been implicated in various types of cancer, including breast, lung, and pancreatic cancer. In addition, CTR9 mutations have been associated with developmental disorders such as Cornelia de Lange syndrome and intellectual disability. Targeted drug discovery efforts have focused on developing inhibitors of the PAF1 complex, which includes CTR9, as a potential therapeutic strategy for cancer. Several small molecule inhibitors of the PAF1 complex have been identified and are currently being evaluated in preclinical studies. However, there are currently no drugs on the market that specifically target CTR9 or the PAF1 complex. Further research is needed to fully understand the role of CTR9 in disease and to develop effective therapies targeting this gene.",GO:0001826 inner cell mass cell differentiation;GO:0001711 endodermal cell fate commitment;GO:0070102 interleukin-6-mediated signaling pathway,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000136636.13,ENSG00000136636,KCTD3,-0.772809473,-1.094655229,-1.127520425,-0.096252764,potassium channel tetramerization domain containing 3,"KCTD3 is a gene that belongs to the potassium channel tetramerization-domain containing (KCTD) protein family. These proteins regulate the biophysical characteristics of ion channels. In mice, KCTD3 interacts with hyperpolarization-activated cyclic nucleotide-gated channel complex 3, increasing its cell surface expression and current density. Alternative splicing of KCTD3 results in multiple transcript variants.","There is limited information available on the disease implications of KCTD3. However, some studies have suggested that KCTD3 may play a role in neurological disorders such as epilepsy and schizophrenia. Targeted drug discovery efforts for KCTD3 are also limited, as the function of this gene is not well understood. Currently, there are no drugs on the market that specifically target KCTD3. However, there are drugs that target potassium channels, which KCTD3 is involved in regulating. For example, the drug amiodarone is used to treat cardiac arrhythmias by blocking potassium channels. Another drug, retigabine, activates potassium channels and is used to treat epilepsy. While these drugs do not directly target KCTD3, they demonstrate the potential for targeting potassium channels in the treatment of various diseases.",GO:0051260 protein homooligomerization;GO:0051259 protein complex oligomerization;GO:0065003 protein-containing complex assembly,,Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000168374.11,ENSG00000168374,ARF4,-0.772788909,-1.178389229,-0.831893519,-0.308083979,ARF GTPase 4,"ARF4 is a gene that belongs to the ARF gene family, which encodes small guanine nucleotide-binding proteins that play a role in vesicular trafficking and as activators of phospholipase D. ARF4 is a class II member of the ARF proteins, which are categorized into three classes. The gene spans approximately 12kb and contains six exons and five introns. ARF4 is the most divergent member of the human ARFs. There are conflicting map positions at 3p14 or 3p21 for this gene.","ARF4 has been implicated in various diseases, including cancer, Alzheimer's disease, and cardiovascular disease. In cancer, ARF4 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. In Alzheimer's disease, ARF4 has been found to be involved in the regulation of amyloid precursor protein (APP) trafficking, which is a key factor in the development of the disease. In cardiovascular disease, ARF4 has been shown to be involved in the regulation of endothelial cell function and angiogenesis.

There have been efforts to develop drugs that target ARF4 for the treatment of cancer and other diseases. One example is the development of small molecule inhibitors of ARF4, which have been shown to inhibit tumor growth and metastasis in preclinical studies. Another example is the use of RNA interference (RNAi) to target ARF4 expression in cancer cells, which has also shown promising results in preclinical studies.

Currently, there are no drugs on the market that specifically target ARF4. However, there are drugs that indirectly affect ARF4 function, such as phospholipase D inhibitors, which have been shown to inhibit ARF4 activation. Additionally, drugs that target other members of the ARF family, such as ARF6, have been approved for the treatment of various diseases, including cancer and cardiovascular disease.","GO:0045176 apical protein localization;GO:0060996 dendritic spine development;GO:0006890 retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum",,Predicted intracellular proteins,,Guanosine-5'-Diphosphate,(M164)PID ERBB1 DOWNSTREAM PATHWAY,(M5946)HALLMARK COAGULATION
ENSG00000144909.8,ENSG00000144909,OSBPL11,-0.771791776,-1.046181247,-1.05098873,-0.218205351,oxysterol binding protein like 11,"The OSBPL11 gene belongs to the oxysterol-binding protein family, which are intracellular lipid receptors. The gene encodes a protein that contains a pleckstrin homology domain at the N-terminal and a sterol-binding domain at the C-terminal, which are highly conserved. The protein is involved in the regulation of lipid metabolism and transport, and it binds to oxysterols, which are oxidized derivatives of cholesterol. The exact function of OSBPL11 is not fully understood, but it is believed to play a role in the regulation of cholesterol homeostasis and cellular signaling pathways.","There is limited information available on the disease implications of OSBPL11. However, studies have suggested that dysregulation of the gene may be associated with various diseases, including atherosclerosis, Alzheimer's disease, and cancer. Targeted drug discovery efforts for OSBPL11 are also limited, but some studies have identified potential therapeutic targets for the gene, such as the sterol regulatory element-binding protein (SREBP) pathway. Currently, there are no drugs on the market that specifically target OSBPL11. However, some drugs that target cholesterol metabolism, such as statins, have been successful in treating atherosclerosis and other related diseases. Additionally, some drugs that target the SREBP pathway, such as ezetimibe, have been successful in treating hypercholesterolemia. Further research is needed to fully understand the disease implications of OSBPL11 and to develop targeted therapies for related diseases.",GO:0010890 positive regulation of sequestering of triglyceride;GO:0010889 regulation of sequestering of triglyceride;GO:0010884 positive regulation of lipid storage,,Predicted intracellular proteins,Golgi apparatus;Nucleoplasm (Approved),,,
ENSG00000157077.15,ENSG00000157077,ZFYVE9,-0.770831932,-1.073779144,-0.876723646,-0.361993006,zinc finger FYVE-type containing 9,"ZFYVE9 is a human gene that encodes a protein containing a double zinc finger motif. This protein is involved in the TGFB signalling pathway and interacts with SMAD2 and SMAD3, recruiting SMAD2 to the TGFB receptor. There are multiple pseudogenes for this gene on chromosomes 2, 15, and X, and alternative splicing results in multiple transcript variants.","There is limited information available on the disease implications of ZFYVE9. However, recent studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, including breast and ovarian cancer. Targeted drug discovery efforts for ZFYVE9 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and disrupt its interaction with SMAD2 and SMAD3. While there are currently no drugs on the market that specifically target ZFYVE9, there are several drugs that target the TGFB signalling pathway, including the monoclonal antibody Trastuzumab, which is used to treat HER2-positive breast cancer, and the small molecule inhibitor Galunisertib, which is being investigated for the treatment of various types of cancer.",GO:0007179 transforming growth factor beta receptor signaling pathway;GO:0071560 cellular response to transforming growth factor beta stimulus;GO:0071559 response to transforming growth factor beta,,Predicted intracellular proteins,Cytosol;Vesicles (Enhanced),,(M286)PID TGFBR PATHWAY,
ENSG00000112584.14,ENSG00000112584,FAM120B,-0.770638628,-1.164200354,-0.786409343,-0.361306186,family with sequence similarity 120 member B,FAM120B is a human gene that is predicted to play a role in fat cell differentiation and the peroxisome proliferator activated receptor signaling pathway. It is also predicted to be active in the nucleus. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of FAM120B. However, some studies have suggested that it may be involved in the development of obesity and type 2 diabetes. Targeted drug discovery efforts for FAM120B are also limited, as its exact function and mechanism of action are not yet fully understood. Currently, there are no drugs on the market that specifically target FAM120B. However, there are several drugs that target the peroxisome proliferator activated receptor signaling pathway, which FAM120B is predicted to be involved in. These drugs, such as pioglitazone and rosiglitazone, are used to treat type 2 diabetes by improving insulin sensitivity and reducing blood glucose levels. Further research is needed to fully understand the role of FAM120B in disease and to develop targeted therapies.",GO:0035357 peroxisome proliferator activated receptor signaling pathway;GO:0141193 nuclear receptor-mediated signaling pathway;GO:0045444 fat cell differentiation,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,(M162)PID RXR VDR PATHWAY,
ENSG00000139218.18,ENSG00000139218,SCAF11,-0.770558601,-0.889445851,-0.889398105,-0.532831847,SR-related CTD associated factor 11,"The human gene SCAF11, also known as SR-related CTD associated factor 11, is involved in spliceosomal complex assembly and enables RNA binding activity. It is located in the nuclear body and nucleolus. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of SCAF11. However, recent studies have suggested that mutations in SCAF11 may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for SCAF11 are still in the early stages, but there is potential for the development of drugs that target the spliceosomal complex and RNA binding activity. One example of a successful drug that targets the spliceosomal complex is Spliceostatin A, which has shown promising results in preclinical studies for the treatment of various types of cancer. However, more research is needed to fully understand the role of SCAF11 in disease and to develop effective targeted therapies.",GO:0000245 spliceosomal complex assembly;GO:0022618 protein-RNA complex assembly;GO:0071826 protein-RNA complex organization,,Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Nuclear bodies;Nucleoli,,,
ENSG00000116754.13,ENSG00000116754,SRSF11,-0.770349249,-0.851032264,-0.873153001,-0.586862484,serine and arginine rich splicing factor 11,"SRSF11, also known as serine and arginine rich splicing factor 11, is a gene that encodes a 54-kD nuclear protein. This protein contains an arginine/serine-rich region that is similar to segments found in pre-mRNA splicing factors. While the exact function of SRSF11 is not yet known, its structure and immunolocalization data suggest that it may play a role in pre-mRNA processing. Alternative splicing of this gene results in multiple transcript variants that encode different proteins. Additionally, a pseudogene of SRSF11 has been found on chromosome 12.","There is limited information available on the disease implications of SRSF11. However, recent studies have suggested that alterations in the expression of SRSF11 may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for SRSF11 are still in the early stages, but there is potential for the development of drugs that target the protein's role in pre-mRNA splicing. One example of a successful drug targeting pre-mRNA splicing is Spliceostatin A, which has shown promise in preclinical studies for the treatment of various types of cancer. However, further research is needed to determine the potential of SRSF11 as a therapeutic target and to identify specific drugs that can effectively modulate its activity.",GO:0008380 RNA splicing;GO:0006397 mRNA processing;GO:0016071 mRNA metabolic process,,Predicted intracellular proteins,Nuclear speckles (Supported),,,
ENSG00000116001.17,ENSG00000116001,TIA1,-0.769950216,-1.042674045,-0.740787448,-0.526389156,TIA1 cytotoxic granule associated RNA binding protein,TIA1 is a gene that encodes a RNA-binding protein with nucleolytic activity against cytotoxic lymphocyte (CTL) target cells. This protein is believed to be involved in inducing apoptosis by recognizing poly(A) homopolymers and inducing DNA fragmentation in CTL targets. The major granule-associated species is a 15-kDa protein that is thought to be derived from the carboxyl terminus of the 40-kDa product by proteolytic processing. Alternative splicing of this gene results in different isoforms.,"Research on TIA1 has revealed its potential involvement in various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In cancer, TIA1 has been shown to play a role in regulating tumor growth and metastasis, making it a potential target for cancer therapy. In autoimmune disorders, TIA1 has been implicated in the regulation of immune responses, and its dysregulation has been linked to the development of autoimmune diseases such as lupus and rheumatoid arthritis. In neurodegenerative diseases, TIA1 has been found to be involved in the formation of pathological aggregates in diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Targeted drug discovery efforts for TIA1 are still in the early stages, but there is growing interest in developing drugs that can modulate its activity. One approach is to develop small molecules that can bind to TIA1 and alter its function. Another approach is to develop drugs that can target the downstream effects of TIA1 dysregulation, such as the formation of pathological aggregates in neurodegenerative diseases.

There are currently no drugs on the market that specifically target TIA1, but there are several drugs that have been approved for the treatment of diseases in which TIA1 is implicated. For example, the cancer drug imatinib has been shown to inhibit TIA1 expression and reduce tumor growth in preclinical studies. Similarly, the autoimmune drug rituximab has been shown to reduce TIA1 expression and improve symptoms in patients with lupus. These drugs may provide a starting point for the development of more targeted therapies for TIA1-related diseases.",GO:1903608 protein localization to cytoplasmic stress granule;GO:1904037 positive regulation of epithelial cell apoptotic process;GO:0034063 stress granule assembly,,Disease related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Human disease related genes:Musculoskeletal diseases:Muscular diseases; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000116005.12,ENSG00000116005,PCYOX1,-0.769886889,-1.186560453,-0.762751036,-0.36034918,prenylcysteine oxidase 1,"PCYOX1 is a human gene that encodes for the enzyme prenylcysteine oxidase 1. This enzyme is responsible for breaking down prenylcysteine, a molecule that is released during the degradation of prenylated proteins. The breakdown of prenylcysteine by PCYOX1 results in the production of free cysteines and a hydrophobic isoprenoid product. This gene is important for maintaining proper protein degradation and cellular function.","There is limited information available on the disease implications of PCYOX1 mutations. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast and lung cancer. Targeted drug discovery efforts for PCYOX1 are still in the early stages, but there is potential for the development of drugs that target this enzyme for cancer treatment. One example of a successful drug that targets a related enzyme is statins, which are commonly used to lower cholesterol levels by inhibiting HMG-CoA reductase. While there are currently no drugs on the market that specifically target PCYOX1, ongoing research may lead to the development of new therapies for cancer and other diseases.",GO:0030328 prenylcysteine catabolic process;GO:0030329 prenylcysteine metabolic process;GO:0030327 prenylated protein catabolic process,,Enzymes; ENZYME proteins:Oxidoreductases; Predicted intracellular proteins,,,,
ENSG00000164244.21,ENSG00000164244,PRRC1,-0.769871445,-0.891531516,-0.652497919,-0.765584899,proline rich coiled-coil 1,"PRRC1, or proline rich coiled-coil 1, is a human gene that is predicted to have identical protein binding activity and protein kinase A regulatory subunit binding activity. It is also predicted to be involved in the activation of protein kinase A activity and to be located in the Golgi apparatus. PRRC1 is predicted to be active in the cytoplasm.","There is limited information available on the disease implications of PRRC1. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target PRRC1. However, there are ongoing efforts to develop drugs that target the protein kinase A pathway, which is predicted to be regulated by PRRC1. Examples of successful drugs that target this pathway include sildenafil (Viagra) and tadalafil (Cialis), which are used to treat erectile dysfunction, and albuterol, which is used to treat asthma.",GO:0010669 epithelial structure maintenance;GO:0001894 tissue homeostasis;GO:0060249 anatomical structure homeostasis,,Predicted intracellular proteins,Vesicles (Approved),,,
ENSG00000132256.19,ENSG00000132256,TRIM5,-0.769761615,-1.252685555,-0.645409325,-0.411189965,tripartite motif containing 5,"TRIM5 is a human gene that belongs to the tripartite motif (TRIM) family. It contains three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. The protein encoded by this gene forms homo-oligomers via the coiled-coil region and localizes to cytoplasmic bodies. It functions as a E3 ubiquitin-ligase and ubiqutinates itself to regulate its subcellular localization. TRIM5 may play a role in retroviral restriction. There are multiple alternatively spliced transcript variants encoding different isoforms of this gene.","TRIM5 has been implicated in the restriction of retroviral infections, including HIV-1. Studies have shown that TRIM5 can recognize and bind to the capsid protein of retroviruses, leading to their degradation and inhibition of viral replication. However, some strains of HIV-1 have evolved to evade TRIM5-mediated restriction, highlighting the need for alternative therapeutic approaches.

Targeted drug discovery efforts for TRIM5 have focused on identifying small molecules that can enhance its antiviral activity or disrupt its interactions with viral capsids. One study identified a small molecule, TRIM-CypA inhibitor (TCI), that can disrupt the interaction between TRIM5 and the capsid protein of HIV-1, leading to inhibition of viral replication. However, TCI has not yet been developed into a clinically viable drug.

Currently, there are no drugs on the market that specifically target TRIM5. However, there are several antiretroviral drugs that target other stages of the HIV-1 life cycle, such as reverse transcriptase and protease inhibitors. These drugs have been successful in reducing viral load and improving the health outcomes of HIV-1 patients.",GO:0044790 suppression of viral release by host;GO:0046597 negative regulation of viral entry into host cell;GO:0031664 regulation of lipopolysaccharide-mediated signaling pathway,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Supported),,,(M5911)HALLMARK INTERFERON ALPHA RESPONSE
ENSG00000136381.13,ENSG00000136381,IREB2,-0.768901187,-1.122354087,-0.700706257,-0.483643216,iron responsive element binding protein 2,"IREB2 is a gene that encodes for an RNA-binding protein that regulates iron levels in cells by controlling the translation and stability of mRNAs that affect iron homeostasis. When iron levels are low, the protein binds to iron-responsive elements (IRES) in the 5' or 3' UTRs, repressing translation or inhibiting mRNA degradation, respectively. However, when iron is present in the cell, the protein is degraded in a F-box and leucine rich repeat protein 5-dependent manner. Variants in this gene have been linked to lung cancer and chronic obstructive pulmonary disease (COPD). Alternative splicing results in multiple transcript variants encoding different isoforms.","IREB2 has been implicated in several diseases, including lung cancer and chronic obstructive pulmonary disease (COPD). In lung cancer, IREB2 has been found to be overexpressed, and its knockdown has been shown to inhibit tumor growth in vitro and in vivo. In COPD, IREB2 variants have been associated with increased risk and severity of the disease. 

Targeted drug discovery efforts for IREB2 have focused on identifying small molecules that can modulate its activity. One study identified a compound that could inhibit IREB2 binding to IRES, leading to decreased expression of iron-regulated genes and increased sensitivity to chemotherapy in lung cancer cells. 

Currently, there are no drugs on the market that specifically target IREB2. However, there are several drugs that indirectly affect iron homeostasis, which is regulated by IREB2. For example, iron chelators such as deferoxamine and deferasirox are used to treat iron overload disorders, while iron supplements such as ferrous sulfate are used to treat iron deficiency anemia.",GO:0006101 citrate metabolic process;GO:0006782 protoporphyrinogen IX biosynthetic process;GO:0046501 protoporphyrinogen IX metabolic process,,Disease related genes; Predicted intracellular proteins,Cell Junctions (Approved); Additional: Cytosol,,(M66)PID MYC ACTIV PATHWAY,
ENSG00000137414.6,ENSG00000137414,FAM8A1,-0.768877604,-1.213561733,-0.830274637,-0.262796443,family with sequence similarity 8 member A1,"FAM8A1 is a human gene that is predicted to be involved in the ubiquitin-dependent ERAD pathway. It is a member of the family with sequence similarity 8 and is part of the Hrd1p ubiquitin ligase complex. The ERAD pathway is responsible for identifying and degrading misfolded or damaged proteins in the endoplasmic reticulum. The Hrd1p ubiquitin ligase complex plays a crucial role in this process by tagging the misfolded proteins with ubiquitin, which marks them for degradation. FAM8A1's involvement in this pathway suggests that it may play a role in maintaining protein quality control in the cell.","There is limited information available on the disease implications of FAM8A1. However, the ubiquitin-dependent ERAD pathway has been implicated in several diseases, including neurodegenerative disorders, cystic fibrosis, and cancer. Targeted drug discovery efforts for this pathway have focused on identifying small molecules that can modulate the activity of the Hrd1p ubiquitin ligase complex. One example is the drug Eeyarestatin I, which has been shown to inhibit the activity of the Hrd1p complex and promote the accumulation of misfolded proteins in the endoplasmic reticulum. This drug has been used in research to study the ERAD pathway and its role in disease. Another example is the drug Lumacaftor, which is used to treat cystic fibrosis by promoting the correct folding and trafficking of the CFTR protein, which is often misfolded and degraded by the ERAD pathway. While FAM8A1 itself has not been targeted for drug discovery efforts, its involvement in the ERAD pathway suggests that it may be a potential target for future drug development.",GO:0036503 ERAD pathway;GO:0034976 response to endoplasmic reticulum stress;GO:0010498 proteasomal protein catabolic process,,Transporters:Electrochemical Potential-driven transporters,Golgi apparatus (Approved),,,
ENSG00000217128.12,ENSG00000217128,FNIP1,-0.768801514,-0.964678455,-0.635566932,-0.706159155,folliculin interacting protein 1,"FNIP1 is a gene that encodes a protein that interacts with the tumor suppressor protein folliculin and AMP-activated protein kinase (AMPK). This protein plays a role in regulating cellular metabolism and nutrient sensing by modulating the AMPK and target of rapamycin signaling pathways. FNIP1 has a closely related paralog that encodes a protein with similar binding activities. Both proteins also associate with the molecular chaperone heat shock protein-90 (Hsp90) and negatively regulate its ATPase activity and facilitate its association with folliculin. This gene is important in understanding the regulation of cellular metabolism and nutrient sensing, and its dysregulation may contribute to the development of certain diseases.","Research on FNIP1 is still in its early stages, and there is limited information available on its disease implications and targeted drug discovery efforts. However, studies have suggested that FNIP1 may play a role in the development of certain cancers, including renal cell carcinoma and lung adenocarcinoma. Targeting FNIP1 and its associated pathways may therefore have potential therapeutic implications for these cancers. Currently, there are no drugs on the market that specifically target FNIP1, but ongoing research may lead to the development of novel therapies in the future.",GO:0002904 positive regulation of B cell apoptotic process;GO:1905672 negative regulation of lysosome organization;GO:2000973 regulation of pro-B cell differentiation,,Disease related genes; Predicted intracellular proteins,,,,
ENSG00000279453.1,ENSG00000279453,Z99129.4,-0.768719078,-1.215987236,-1.03679686,-0.053373138,None,None,None,None,None,None,None,None,None,None
ENSG00000136044.12,ENSG00000136044,APPL2,-0.768558526,-0.904629428,-1.004759006,-0.396287145,"adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 2","APPL2 is a human gene that encodes an adaptor protein involved in a signal transduction pathway. It is one of two effectors of the small GTPase RAB5A/Rab5 and contains an N-terminal Bin/Amphiphysin/Rvs (BAR) domain, a central pleckstrin homology (PH) domain, and a C-terminal phosphotyrosine binding (PTB) domain. APPL2 is associated with endosomal membranes and can be translocated to the nucleus in response to the EGF stimulus. It interacts with the NuRD/MeCP1 complex and is required for efficient cell proliferation. A chromosomal aberration involving this gene and the PSAP2 gene results in 22q13.3 deletion syndrome, also known as Phelan-McDermid syndrome.","Mutations in the APPL2 gene have been associated with various diseases, including cancer, diabetes, and neurological disorders. In particular, the loss of APPL2 expression has been linked to the development of breast cancer and prostate cancer. Targeted drug discovery efforts have focused on developing small molecule inhibitors of the RAB5A/APPL2 signaling pathway as a potential therapeutic strategy for cancer treatment. However, there are currently no drugs on the market that specifically target APPL2. Some drugs that indirectly affect the RAB5A/APPL2 pathway, such as the EGFR inhibitor gefitinib, have been approved for cancer treatment. Further research is needed to fully understand the role of APPL2 in disease and to develop targeted therapies.",GO:1905451 positive regulation of Fc-gamma receptor signaling pathway involved in phagocytosis;GO:1905303 positive regulation of macropinocytosis;GO:1905449 regulation of Fc-gamma receptor signaling pathway involved in phagocytosis,,Disease related genes; Predicted intracellular proteins,Vesicles (Approved); Additional: Cytosol,,,
ENSG00000153560.12,ENSG00000153560,UBP1,-0.768253124,-1.071484678,-0.681719802,-0.551554891,upstream binding protein 1,"The human gene UBP1, also known as upstream binding protein 1, is involved in regulating gene expression by binding to specific DNA sequences and activating or inhibiting transcription. It has been shown to have both positive and negative effects on transcription by RNA polymerase II, and is also involved in regulating viral transcription. UBP1 is found in both the cytosol and nucleoplasm of cells.","There is limited information available on the disease implications of UBP1. However, some studies have suggested that UBP1 may play a role in the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for UBP1 are also limited, as the function of the gene is not fully understood. However, some studies have suggested that targeting UBP1 may be a potential therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target UBP1. However, there are several drugs that have been developed to target other proteins involved in regulating gene expression, such as histone deacetylases (HDACs) and DNA methyltransferases (DNMTs), which may indirectly affect UBP1 function. Examples of such drugs include Vorinostat, Romidepsin, and Azacitidine.",GO:0032897 negative regulation of viral transcription;GO:0046782 regulation of viral transcription;GO:0048525 negative regulation of viral process,,Transcription factors:Immunoglobulin fold; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000173848.19,ENSG00000173848,NET1,-0.767943871,-1.216837158,-0.566177942,-0.520816511,neuroepithelial cell transforming 1,"NET1 is a gene that belongs to the family of Rho guanine nucleotide exchange factors. These factors activate Rho proteins by exchanging GDP for GTP. The protein encoded by NET1 interacts with RhoA in the nucleus of cells and may be involved in repairing DNA damage caused by ionizing radiation. There are pseudogenes of this gene located on chromosomes 1, 7, and 18. Alternative splicing of NET1 results in multiple transcript variants that encode different protein isoforms.","NET1 has been implicated in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, NET1 has been shown to promote tumor growth and metastasis by activating RhoA signaling pathways. Targeting NET1 has been proposed as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of NET1 have been developed and tested in preclinical studies, showing promising results in reducing tumor growth and metastasis. However, no NET1-targeted drugs have been approved for clinical use yet. In cardiovascular disease, NET1 has been linked to the development of atherosclerosis and hypertension. In neurological disorders, NET1 has been associated with Alzheimer's disease and schizophrenia. Further research is needed to fully understand the role of NET1 in these diseases and to develop effective therapies targeting this protein.",GO:0051451 myoblast migration;GO:0035025 positive regulation of Rho protein signal transduction;GO:0014812 muscle cell migration,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Vesicles,,(M68)PID RHOA REG PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000167333.13,ENSG00000167333,TRIM68,-0.767647958,-1.228514649,-0.83135935,-0.243069875,tripartite motif containing 68,"TRIM68 is a gene that belongs to the tripartite motif-containing protein family. This family is characterized by a RING finger domain, a zinc-binding B-box motif, and a coiled-coil region. TRIM68 functions as an E3 ubiquitin ligase and is involved in regulating the activation of nuclear receptors, such as the androgen receptor. It has been implicated in the development of prostate cancer cells, where its expression increases in response to a downregulation of microRNAs. Additionally, TRIM68 participates in viral defense regulation as a negative regulator of interferon-beta. Alternative splicing results in multiple transcript variants.","There is limited information available on the disease implications of TRIM68. However, its involvement in the development of prostate cancer cells suggests that it may be a potential therapeutic target for this disease. Targeted drug discovery efforts for TRIM68 are currently underway, with a focus on identifying small molecule inhibitors that can block its activity as an E3 ubiquitin ligase. To date, there are no drugs on the market that specifically target TRIM68. However, there are several drugs that target other members of the tripartite motif-containing protein family, such as lenalidomide, which targets cereblon and is used to treat multiple myeloma and myelodysplastic syndromes. Additionally, pomalidomide, which also targets cereblon, is used to treat relapsed or refractory multiple myeloma.",GO:0060765 regulation of androgen receptor signaling pathway;GO:0051865 protein autoubiquitination;GO:0033143 regulation of intracellular steroid hormone receptor signaling pathway,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Nucleoplasm (Supported),,,
ENSG00000169813.16,ENSG00000169813,HNRNPF,-0.767365675,-1.08863297,-0.792396222,-0.421067834,heterogeneous nuclear ribonucleoprotein F,"HNRNPF is a gene that belongs to a family of RNA binding proteins called heterogeneous nuclear ribonucleoproteins (hnRNPs). These proteins are involved in regulating various aspects of mRNA metabolism and transport, including alternative splicing and polyadenylation. HNRNPF has three repeats of quasi-RRM domains that bind to RNAs with guanosine-rich sequences. It is similar to another family member, hnRPH. Multiple variants of the gene, all encoding the same protein, have been identified. While all hnRNPs are present in the nucleus, some shuttle between the nucleus and cytoplasm. HNRNPF is a ubiquitously expressed gene, meaning it is found in all tissues and cell types.","Research has linked HNRNPF to several diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, HNRNPF has been shown to regulate alternative splicing of genes involved in tumor growth and metastasis. Targeting HNRNPF with small molecules or RNA interference has been explored as a potential therapeutic strategy for cancer. In neurodegenerative disorders, HNRNPF has been implicated in the regulation of RNA metabolism and protein synthesis, and its dysfunction may contribute to disease pathogenesis. In viral infections, HNRNPF has been shown to interact with viral RNA and play a role in viral replication. Several drugs targeting hnRNPs, including HNRNPF, are currently in development for cancer and other diseases. One example is E7107, a small molecule inhibitor of hnRNP A1/A2, which is being evaluated in clinical trials for solid tumors. Another example is RG7834, an antisense oligonucleotide targeting hnRNP A1, which is being developed for the treatment of spinal muscular atrophy.","GO:0043484 regulation of RNA splicing;GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;GO:0000398 mRNA splicing, via spliceosome",,Predicted intracellular proteins,Nucleoplasm (Enhanced),Phenethyl Isothiocyanate,,
ENSG00000136816.16,ENSG00000136816,TOR1B,-0.767170172,-1.211015717,-0.88550527,-0.204989529,torsin family 1 member B,"TOR1B is a gene that encodes an ATPase protein found in the endoplasmic reticulum and nuclear envelope. It has a neighboring gene, TOR1A, that likely interacts with it in a complex. TOR1B may act as a chaperone and help maintain the integrity of the nuclear envelope and endoplasmic reticulum. There are several transcript variants of this gene, some of which code for proteins and others that do not.","Mutations in the TOR1B gene have been associated with several diseases, including autosomal dominant torsion dystonia, a neurological disorder characterized by involuntary muscle contractions and twisting movements. Additionally, TOR1B has been implicated in the pathogenesis of Alzheimer's disease, as it is involved in the processing and trafficking of amyloid precursor protein. 

There have been efforts to develop drugs that target TOR1B, particularly for the treatment of torsion dystonia. One approach has been to develop small molecule inhibitors of TOR1B ATPase activity, which could potentially reduce the severity of symptoms. Another strategy has been to use gene therapy to deliver a functional copy of the TOR1B gene to affected cells. 

Currently, there are no drugs on the market that specifically target TOR1B. However, there are several drugs that have been approved for the treatment of torsion dystonia, including botulinum toxin injections and oral medications such as trihexyphenidyl and tetrabenazine. These drugs work by reducing muscle contractions and improving motor function.",GO:0051085 chaperone cofactor-dependent protein refolding;GO:0051084 'de novo' post-translational protein folding;GO:0071763 nuclear membrane organization,,Predicted intracellular proteins,Nuclear speckles (Uncertain); Additional: Cytosol,,,(M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000119596.18,ENSG00000119596,YLPM1,-0.767103356,-1.235878066,-0.7863284,-0.279103601,YLP motif containing 1,"The human gene YLPM1, also known as YLP motif containing 1, is involved in RNA binding activity and is predicted to play a role in regulating telomere maintenance. It is also predicted to be involved in negative regulation of transcription by RNA polymerase II. YLPM1 is located in both the cytosol and nuclear speck.","There is limited information available on the disease implications of YLPM1. However, recent studies have suggested that mutations in YLPM1 may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for YLPM1 are still in the early stages, but there is potential for the development of drugs that target the RNA binding activity of the protein. Currently, there are no drugs on the market that specifically target YLPM1. However, there are drugs that target other RNA binding proteins, such as the splicing factor SF3B1, which is mutated in certain types of cancer. These drugs, such as H3B-8800 and E7107, have shown promising results in clinical trials and may provide a framework for the development of drugs targeting YLPM1 in the future.",GO:0032204 regulation of telomere maintenance;GO:0033044 regulation of chromosome organization;GO:0051052 regulation of DNA metabolic process,,Predicted intracellular proteins,Nuclear speckles (Supported),,,
ENSG00000135775.14,ENSG00000135775,COG2,-0.766668969,-0.834468168,-1.051646002,-0.413892736,component of oligomeric golgi complex 2,"COG2 is a human gene that encodes a subunit of the conserved oligomeric Golgi complex, which is essential for maintaining the normal structure and function of the Golgi complex. The protein encoded by COG2 interacts with the USO1 vesicle docking protein and is crucial for the formation of the Golgi ribbon and the trafficking of Golgi enzymes. Mutations in COG2 have been linked to abnormal glycosylation within the Golgi apparatus. Alternative splicing of COG2 results in multiple transcript variants. Overall, COG2 plays a critical role in the proper functioning of the Golgi complex, which is essential for the processing and transport of proteins and lipids within cells.","Mutations in COG2 have been associated with several rare genetic disorders, including congenital disorders of glycosylation (CDG), which are characterized by abnormal glycosylation of proteins and lipids. CDG can lead to a wide range of symptoms, including developmental delays, intellectual disability, seizures, and other neurological and physical abnormalities. There are currently no targeted drugs available for COG2-related disorders, and treatment is primarily supportive and symptomatic. However, research efforts are underway to identify potential therapeutic targets and develop new treatments for CDG and other Golgi-related disorders. One example of a successful drug targeting the Golgi complex is brefeldin A, which inhibits the function of the Golgi complex and is used as an antiviral and anticancer agent.","GO:0000301 retrograde transport, vesicle recycling within Golgi;GO:0006891 intra-Golgi vesicle-mediated transport;GO:0007030 Golgi organization",,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism; Predicted intracellular proteins,Golgi apparatus (Approved),,,(M5910)HALLMARK PROTEIN SECRETION; (M5937)HALLMARK GLYCOLYSIS
ENSG00000068912.14,ENSG00000068912,ERLEC1,-0.766585622,-1.270898508,-0.597907016,-0.430951342,endoplasmic reticulum lectin 1,"ERLEC1 is a gene that encodes a protein found in the endoplasmic reticulum (ER) that is involved in recognizing N-glycans. It is believed to play a role in ER-associated degradation by interacting with a ubiquitin ligase complex. Additionally, it acts as a regulator of various cellular stress-response pathways, promoting the survival of metastatic cells. Alternative splicing of the gene results in multiple transcript variants. A pseudogene related to ERLC1 has also been identified on chromosome 21.","There is limited information available on the disease implications of ERLC1. However, recent studies have suggested that ERLC1 may play a role in cancer progression and metastasis. Specifically, it has been shown to promote the survival of metastatic cells by regulating stress-response pathways. Targeted drug discovery efforts for ERLC1 are currently limited, as the exact mechanisms of its involvement in cancer progression are not yet fully understood. However, there is potential for ERLC1 to be targeted in the future as a therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target ERLC1.","GO:1904153 negative regulation of retrograde protein transport, ER to cytosol;GO:0070862 negative regulation of protein exit from endoplasmic reticulum;GO:1904152 regulation of retrograde protein transport, ER to cytosol",,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,,,,
ENSG00000107185.10,ENSG00000107185,RGP1,-0.766510103,-1.462778496,-0.692818986,-0.143932826,"RGP1 homolog, RAB6A GEF complex partner 1","RGP1 is a human gene that encodes a protein involved in regulating cellular protein catabolic processes, GTPase activity, and retrograde transport from endosomes to the Golgi. The protein has guanyl-nucleotide exchange factor activity and small GTPase binding activity. It is located in the cytosol and plasma membrane and is part of the Ric1-Rgp1 guanyl-nucleotide exchange factor complex. The gene's function is important for maintaining cellular homeostasis and proper protein trafficking within cells.","There is limited information available on the disease implications of RGP1. However, studies have shown that mutations in the gene may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for RGP1 are also limited, but some studies have suggested that inhibitors of the Ric1-Rgp1 complex may have potential as anti-cancer agents. Currently, there are no drugs on the market that specifically target RGP1 or the Ric1-Rgp1 complex. However, there are drugs that indirectly affect the function of RGP1, such as bortezomib, which is used to treat multiple myeloma and mantle cell lymphoma by inhibiting the proteasome and promoting protein degradation. Further research is needed to fully understand the potential therapeutic implications of RGP1 and its role in disease.","GO:0042147 retrograde transport, endosome to Golgi;GO:0043547 positive regulation of GTPase activity;GO:0042177 negative regulation of protein catabolic process",,Predicted intracellular proteins,Cytosol (Supported); Additional: Plasma membrane,,,
ENSG00000123124.14,ENSG00000123124,WWP1,-0.766433399,-0.900306467,-1.052387399,-0.346606331,WW domain containing E3 ubiquitin protein ligase 1,"WWP1 is a human gene that encodes a protein containing four WW domains and a HECT domain. It belongs to a family of NEDD4-like proteins that act as E3 ubiquitin-ligase molecules and regulate key trafficking decisions, including targeting of proteins to proteosomes or lysosomes. WW domain-containing proteins are found in all eukaryotes and play an important role in the regulation of a wide variety of cellular functions such as protein degradation, transcription, and RNA splicing. Alternative splicing of this gene generates at least six transcript variants, but the full length nature of these transcripts has not been defined.","WWP1 has been implicated in several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, WWP1 has been shown to regulate the stability of several tumor suppressor proteins, including p53, PTEN, and TSC2, and its overexpression has been associated with poor prognosis in several types of cancer. Therefore, targeting WWP1 has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of WWP1 have been developed, including IT1t and Gliotoxin, which have shown promising results in preclinical studies.

In neurodegenerative disorders, WWP1 has been shown to regulate the degradation of several proteins involved in the pathogenesis of Alzheimer's disease, including tau and APP. Therefore, targeting WWP1 has been proposed as a potential therapeutic strategy for Alzheimer's disease. However, no drugs targeting WWP1 have been approved for clinical use in neurodegenerative disorders yet.

In cardiovascular diseases, WWP1 has been shown to regulate the stability of several proteins involved in the regulation of blood pressure, including ENaC and NCC. Therefore, targeting WWP1 has been proposed as a potential therapeutic strategy for hypertension. However, no drugs targeting WWP1 have been approved for clinical use in cardiovascular diseases yet.

Overall, WWP1 is an important target for drug discovery efforts in several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. While several small molecule inhibitors of WWP1 have been developed, further research is needed to determine their safety and efficacy in clinical trials.",GO:0044409 symbiont entry into host;GO:0046718 symbiont entry into host cell;GO:0051701 biological process involved in interaction with host,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Approved); Additional: Golgi apparatus;Plasma membrane,,(M13)PID ERBB4 PATHWAY; (M236)PID DELTA NP63 PATHWAY; (M256)PID TAP63 PATHWAY,(M5939)HALLMARK P53 PATHWAY
ENSG00000132967.9,ENSG00000132967,HMGB1P5,-0.765694075,-0.959864362,-0.971587808,-0.365630057,None,None,None,None,None,None,None,None,None,None
ENSG00000083312.17,ENSG00000083312,TNPO1,-0.76542003,-1.001814478,-0.619738095,-0.674707517,transportin 1,"TNPO1, also known as transportin 1, is a gene that encodes the beta subunit of the karyopherin receptor complex. This complex interacts with nuclear localization signals to transport nuclear proteins to the nucleus. The karyopherin receptor complex is made up of an alpha subunit that recognizes the nuclear localization signal and a beta subunit that docks the complex at nucleoporins. TNPO1 undergoes alternate splicing, resulting in several transcript variants that encode different proteins. This gene is important for the proper functioning of the nuclear transport system and mutations in TNPO1 have been associated with various diseases, including cancer and developmental disorders.","Mutations in TNPO1 have been associated with various diseases, including cancer and developmental disorders. In cancer, TNPO1 has been found to be overexpressed in several types of cancer, including breast, lung, and prostate cancer. Targeting TNPO1 has been proposed as a potential therapeutic strategy for cancer treatment. In developmental disorders, mutations in TNPO1 have been linked to intellectual disability and autism spectrum disorder. 

There are currently no drugs on the market that specifically target TNPO1. However, there have been efforts to develop small molecule inhibitors of TNPO1 as potential cancer therapeutics. One study identified a small molecule inhibitor of TNPO1 that was able to inhibit the growth of breast cancer cells in vitro and in vivo. Another study found that a peptide derived from the nuclear localization signal of the HIV-1 protein was able to inhibit TNPO1 and block HIV-1 infection. 

Overall, TNPO1 is an important gene for the proper functioning of the nuclear transport system and has implications in various diseases. While there are currently no drugs on the market that target TNPO1, there is potential for the development of small molecule inhibitors as cancer therapeutics.",GO:0006606 protein import into nucleus;GO:0051170 import into nucleus;GO:0034504 protein localization to nucleus,,Transporters:Transporter channels and pores; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytoplasmic bodies;Cytosol;Nucleoli,,,
ENSG00000028203.18,ENSG00000028203,VEZT,-0.765047658,-0.741972573,-0.92129731,-0.631873092,"vezatin, adherens junctions transmembrane protein","VEZT is a gene that encodes a transmembrane protein found in adherens junctions, where it binds to myosin VIIA. Studies have shown that expression of this gene is decreased in gastric cancer tissues, which may be due to hypermethylation of the promoter. Additionally, a specific microRNA can bind to a target sequence in the 3' UTR of the transcripts, inhibiting expression of the gene. Alternative splicing results in multiple transcript variants. A pseudogene of VEZT is located on the X chromosome.","There is limited information available on the disease implications of VEZT. However, studies have shown that decreased expression of this gene is associated with gastric cancer, suggesting that it may play a role in the development or progression of this disease. As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target VEZT. However, there is ongoing research into the development of drugs that target the adherens junctions, where VEZT is found, as a potential treatment for cancer and other diseases. For example, drugs that target the E-cadherin protein, which is also found in adherens junctions, have shown promise in preclinical studies for the treatment of cancer. Overall, more research is needed to fully understand the role of VEZT in disease and to develop targeted therapies for its potential implications.",GO:0098609 cell-cell adhesion;GO:0007155 cell adhesion;GO:0009987 cellular process,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000170145.5,ENSG00000170145,SIK2,-0.764543883,-1.278112459,-0.735582776,-0.279936414,salt inducible kinase 2,"SIK2, or salt inducible kinase 2, is a human gene that encodes a protein with ATP binding activity, magnesium ion binding activity, and protein serine/threonine kinase activity. It is involved in intracellular signal transduction and protein autophosphorylation. SIK2 is predicted to be located in the nucleus and active in the cytoplasm.","Research has shown that SIK2 plays a role in various diseases, including cancer, diabetes, and obesity. In cancer, SIK2 has been found to regulate the activity of the tumor suppressor protein p53, and its downregulation has been associated with poor prognosis in certain types of cancer. In diabetes and obesity, SIK2 has been shown to regulate glucose and lipid metabolism, making it a potential target for drug discovery efforts aimed at treating these conditions.

Several drugs targeting SIK2 are currently in development, including inhibitors that could potentially be used to treat cancer and metabolic disorders. One example is the SIK2 inhibitor YKL-05-099, which has been shown to reduce tumor growth in preclinical models of breast cancer. Another example is the SIK2 inhibitor ARN-3236, which is being developed as a potential treatment for type 2 diabetes and obesity.

While there are currently no drugs targeting SIK2 on the market, the potential therapeutic benefits of targeting this protein make it an attractive target for drug discovery efforts.",GO:0046626 regulation of insulin receptor signaling pathway;GO:0046777 protein autophosphorylation;GO:0006468 protein phosphorylation,yes,Enzymes; Kinases:CAMK Ser/Thr protein kinases; ENZYME proteins:Transferases,Nucleoplasm;Vesicles (Approved); Additional: Cytosol;Intermediate filaments;Nuclear speckles,Fostamatinib,(M87)PID LKB1 PATHWAY,
ENSG00000089063.15,ENSG00000089063,TMEM230,-0.764035435,-1.452110075,-0.461946183,-0.378050048,transmembrane protein 230,TMEM230 is a gene that encodes a transmembrane protein that belongs to the TMEM134/TMEM230 protein family. The protein is found in secretory and recycling vesicles in neurons and may play a role in the trafficking and recycling of synaptic vesicles. Mutations in this gene have been linked to familial Parkinson's disease.,"Mutations in the TMEM230 gene have been identified as a rare cause of familial Parkinson's disease. Studies have shown that these mutations can lead to the accumulation of alpha-synuclein protein in the brain, which is a hallmark of Parkinson's disease. Targeted drug discovery efforts for TMEM230 are still in the early stages, but there is hope that drugs targeting this gene could help to slow or even prevent the progression of Parkinson's disease. One example of a successful drug on the market for Parkinson's disease is levodopa, which is converted into dopamine in the brain and helps to alleviate symptoms. Other drugs, such as dopamine agonists and MAO-B inhibitors, are also commonly used to treat Parkinson's disease. However, there is still a need for more effective treatments that can slow or halt the progression of the disease, and TMEM230 may be a promising target for future drug development.",GO:0048489 synaptic vesicle transport;GO:0097479 synaptic vesicle localization;GO:0098930 axonal transport,,Disease related genes; Potential drug targets; Transporters,Endoplasmic reticulum (Approved),,,
ENSG00000175155.11,ENSG00000175155,YPEL2,-0.763786435,-1.276315079,-0.824951876,-0.19009235,yippee like 2,"YPEL2, also known as yippee like 2, is a human gene that is predicted to have metal ion binding activity and be located in the nucleolus. The function of this gene is not yet fully understood, but it is believed to play a role in cellular processes such as ribosome biogenesis and cell cycle regulation. Further research is needed to fully elucidate the function of YPEL2 and its potential implications for human health and disease.","There is limited information available on the disease implications of YPEL2. However, some studies have suggested that alterations in the expression of this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for YPEL2 are currently limited, as the function of this gene is not yet fully understood. However, some studies have suggested that YPEL2 may be a potential target for cancer therapy. There are currently no drugs on the market that specifically target YPEL2. However, there are several drugs that target cellular processes in which YPEL2 is believed to play a role, such as ribosome biogenesis and cell cycle regulation. Examples of such drugs include ribavirin, which is used to treat viral infections, and paclitaxel, which is used to treat various types of cancer.",,,Predicted intracellular proteins,,,,
ENSG00000167182.15,ENSG00000167182,SP2,-0.763677184,-1.2996117,-0.781865008,-0.209554843,Sp2 transcription factor,SP2 is a gene that encodes a transcription factor belonging to the Sp subfamily of Sp/XKLF transcription factors. This protein contains a trans-activation domain and three zinc finger motifs. It has the least conserved DNA-binding domain within the Sp subfamily and its DNA sequence specificity differs from other Sp proteins. SP2 is primarily located within subnuclear foci associated with the nuclear matrix and can activate or repress expression from different promoters.,"Research has shown that SP2 plays a role in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, SP2 has been found to be overexpressed in several types of tumors, including breast, lung, and prostate cancer. Targeting SP2 has been proposed as a potential therapeutic strategy for cancer treatment. Several studies have identified small molecules that can inhibit SP2 activity, including mithramycin A and its analogs. These compounds have shown promising results in preclinical studies and are currently being evaluated in clinical trials for the treatment of cancer. In addition, SP2 has also been implicated in the pathogenesis of neurodegenerative disorders, such as Alzheimer's disease, and cardiovascular diseases, such as atherosclerosis. However, there are currently no drugs on the market that specifically target SP2 for the treatment of these diseases.",GO:0000122 negative regulation of transcription by RNA polymerase II;GO:0045892 negative regulation of DNA-templated transcription;GO:1902679 negative regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Vesicles,,,
ENSG00000166747.13,ENSG00000166747,AP1G1,-0.76362867,-1.103504394,-0.79945379,-0.387927825,adaptor related protein complex 1 subunit gamma 1,"AP1G1 is a human gene that encodes for the gamma-adaptin protein, which is a component of the adaptor complexes large subunits family. Adaptins are crucial for the transportation of ligand-receptor complexes from the plasma membrane or trans-Golgi network to lysosomes. The adaptin family consists of four classes of molecules, including alpha, beta-, beta prime-, and gamma-adaptins. Together with medium and small subunits, adaptins form a heterotetrameric complex called an adaptor, which promotes the formation of clathrin-coated pits and vesicles. Two transcript variants encoding different isoforms have been identified for this gene.","There is limited information available on the disease implications of AP1G1. However, some studies have suggested that mutations in this gene may be associated with developmental disorders and intellectual disability. Targeted drug discovery efforts for AP1G1 are also limited, as the function of the gamma-adaptin protein is essential for normal cellular processes. Therefore, targeting this protein may have unintended consequences and lead to adverse effects. Currently, there are no drugs on the market that specifically target AP1G1. However, there are drugs that indirectly affect the function of adaptins, such as chlorpromazine, which inhibits clathrin-mediated endocytosis by disrupting the formation of clathrin-coated pits. Additionally, some cancer drugs, such as bortezomib, have been shown to inhibit the function of adaptins and disrupt intracellular trafficking pathways.",GO:0016182 synaptic vesicle budding from endosome;GO:0043321 regulation of natural killer cell degranulation;GO:0043323 positive regulation of natural killer cell degranulation,,Disease related genes; Potential drug targets; Predicted intracellular proteins; Transporters,Golgi apparatus;Vesicles (Enhanced); Additional: Cytosol,,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000163702.20,ENSG00000163702,IL17RC,-0.763479996,-1.596026245,-0.552445284,-0.141968459,interleukin 17 receptor C,"IL17RC is a gene that encodes a protein similar to the interleukin-17 receptor (IL-17RA). However, unlike IL-17RA, which is mainly expressed in blood cells and binds only to IL-17A, IL17RC is expressed in non-blood tissues and binds both IL-17A and IL-17F with similar affinities. IL-17A and IL-17F are proinflammatory cytokines that have been linked to the development of autoimmune and inflammatory diseases. The IL17RC gene has multiple variants that produce different isoforms of the protein, and it has been suggested that some of these isoforms may act as extracellular antagonists to cytokine signaling.","IL17RC has been implicated in various autoimmune and inflammatory diseases, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Targeting the IL-17 pathway has become a promising therapeutic strategy for these diseases, and several drugs have been developed that target either IL-17A or IL-17RA. However, there are currently no drugs on the market that specifically target IL17RC. One potential approach is to develop drugs that block the interaction between IL-17A/F and IL17RC, which could have broader therapeutic potential than targeting IL-17A or IL-17RA alone. Preclinical studies have shown promising results with such drugs, and clinical trials are currently underway to evaluate their safety and efficacy in patients with psoriasis and other inflammatory diseases.",GO:0038173 interleukin-17A-mediated signaling pathway;GO:1900017 positive regulation of cytokine production involved in inflammatory response;GO:0050832 defense response to fungus,,Disease related genes; Human disease related genes:Immune system diseases:Other immune system diseases,,,,
ENSG00000144597.14,ENSG00000144597,EAF1,-0.763306107,-1.173847382,-0.658603391,-0.457467547,ELL associated factor 1,"The human gene EAF1, also known as ELL associated factor 1, is involved in regulating transcription elongation from RNA polymerase II promoter. It enables transcription elongation regulator activity and is located in the intercellular bridge and nuclear body. EAF1 is part of the transcription elongation factor complex.","There is limited information available on the disease implications of EAF1. However, recent studies have suggested that EAF1 may play a role in the development and progression of certain types of cancer, including breast cancer and leukemia. Targeted drug discovery efforts for EAF1 are still in the early stages, but there is potential for the development of drugs that target EAF1 to treat these types of cancer. Currently, there are no drugs on the market that specifically target EAF1, but there are several drugs that target transcription elongation factors, such as flavopiridol and DRB, which have shown promise in preclinical studies for the treatment of cancer.",GO:0006368 transcription elongation by RNA polymerase II;GO:0006354 DNA-templated transcription elongation;GO:0034243 regulation of transcription elongation by RNA polymerase II,,Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Approved); Additional: Vesicles,,,
ENSG00000144468.17,ENSG00000144468,RHBDD1,-0.763063853,-1.635947416,-0.384348536,-0.268895606,rhomboid domain containing 1,"RHBDD1, also known as rhomboid domain containing 1, is a human gene that encodes a protein involved in serine-type endopeptidase activity. It plays a role in cellular response to unfolded protein, membrane protein proteolysis, and positive regulation of protein catabolic process. The protein is located in the endoplasmic reticulum.","There is limited information available on the disease implications of RHBDD1. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for RHBDD1 are also limited, as the function of this gene is not well understood. However, some studies have suggested that inhibitors of serine-type endopeptidases may have potential therapeutic applications in cancer treatment. Examples of successful drugs targeting serine-type endopeptidases include trypsin inhibitors used in the treatment of pancreatitis and anticoagulants such as heparin and warfarin. However, further research is needed to determine the potential therapeutic applications of targeting RHBDD1.","GO:1904211 membrane protein proteolysis involved in retrograde protein transport, ER to cytosol;GO:0031293 membrane protein intracellular domain proteolysis;GO:0030970 retrograde protein transport, ER to cytosol",,Predicted intracellular proteins; Transporters; Peptidases:Serine-type peptidases; ENZYME proteins:Hydrolases; Enzymes,Endoplasmic reticulum (Supported),,,
ENSG00000133703.13,ENSG00000133703,KRAS,-0.762855851,-0.91680664,-1.00313736,-0.368623552,"KRAS proto-oncogene, GTPase","KRAS is a human gene that belongs to the ras oncogene family and encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution in KRAS leads to an activating mutation, resulting in a transforming protein that is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas, and colorectal carcinoma. Alternative splicing of KRAS leads to variants encoding two isoforms that differ in the C-terminal region.","KRAS mutations are found in approximately 30% of all human cancers, making it one of the most frequently mutated oncogenes. The presence of KRAS mutations is associated with poor prognosis and resistance to chemotherapy and targeted therapies. Therefore, there has been significant interest in developing drugs that target KRAS directly or indirectly. However, developing drugs that target KRAS has been challenging due to its structure and function. Recently, there have been some promising developments in the field, including the development of KRAS G12C inhibitors, which have shown efficacy in preclinical studies and are currently being evaluated in clinical trials. Examples of successful drugs targeting KRAS include cetuximab and panitumumab, which are monoclonal antibodies that target the epidermal growth factor receptor (EGFR) and have shown efficacy in colorectal cancer patients with wild-type KRAS.",GO:0021896 forebrain astrocyte differentiation;GO:0021897 forebrain astrocyte development;GO:0060509 type I pneumocyte differentiation,,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; RAS pathway related proteins; Human disease related genes:Cancers:Cancers of soft tissues and bone; Predicted intracellular proteins; Human disease related genes:Cancers:Cancers of endocrine organs; Human disease related genes:Cancers:Skin cancers; Human disease related genes:Cancers:Cancers of the breast and female genital organs; Human disease related genes:Cancers:Cancers of the digestive system; Human disease related genes:Cancers:Cancers of the lung and pleura; Human disease related genes:Cancers:Head and neck cancers; FDA approved drug targets:Small molecule drugs; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Candidate cancer biomarkers,Cytosol (Approved),"[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID; Farnesyl diphosphate; MRTX849; AMG-510",(M134)PID TCR RAS PATHWAY; (M269)PID RAS PATHWAY; (M270)PID MAPK TRK PATHWAY,
ENSG00000024048.11,ENSG00000024048,UBR2,-0.762629424,-0.986378125,-0.644549887,-0.656960258,ubiquitin protein ligase E3 component n-recognin 2,"The UBR2 gene encodes an E3 ubiquitin ligase that is involved in the N-end rule proteolytic pathway. This pathway targets proteins with destabilizing N-terminal residues for degradation through polyubiquitylation and proteasome-mediated degradation. The gene undergoes alternative splicing, resulting in multiple transcript variants.","There is limited information available on the disease implications of UBR2 gene mutations. However, some studies have suggested that UBR2 mutations may be associated with intellectual disability, autism spectrum disorder, and cancer. Targeted drug discovery efforts for UBR2 are also limited, as the function of the gene is not well understood. However, some studies have suggested that UBR2 may be a potential therapeutic target for cancer treatment, as it is involved in the degradation of tumor suppressor proteins. Currently, there are no drugs on the market that specifically target UBR2. However, there are drugs that target the proteasome, which is involved in the degradation of proteins through the N-end rule pathway. Examples of such drugs include bortezomib and carfilzomib, which are used in the treatment of multiple myeloma.",GO:0071596 ubiquitin-dependent protein catabolic process via the N-end rule pathway;GO:0071233 cellular response to L-leucine;GO:0043201 response to L-leucine,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Approved); Additional: Plasma membrane,,,
ENSG00000108510.10,ENSG00000108510,MED13,-0.762256539,-1.156757937,-0.658768863,-0.471242818,mediator complex subunit 13,"MED13 is a human gene that encodes a component of the mediator complex, which is a transcriptional coactivator complex that is believed to be necessary for the expression of almost all genes. The mediator complex is recruited by transcriptional activators or nuclear receptors to induce gene expression by interacting with RNA polymerase II and promoting the formation of a transcriptional pre-initiation complex. MED13 is thought to form a sub-complex with MED12, cyclin C, and CDK8 that can negatively regulate transactivation by mediator. Overall, MED13 plays an important role in regulating gene expression and is essential for many biological processes.","Mutations in the MED13 gene have been associated with several diseases, including intellectual disability, congenital heart defects, and cancer. In particular, MED13 mutations have been found in patients with Kabuki syndrome, a rare genetic disorder characterized by distinctive facial features, developmental delay, and other health problems. 

Targeted drug discovery efforts for MED13 have focused on developing small molecule inhibitors that can selectively target the MED13 sub-complex and modulate its activity. One example is the development of CDK8 inhibitors, which have shown promise in preclinical studies for the treatment of cancer. 

One successful drug on the market that targets MED13 indirectly is tamoxifen, which is used to treat breast cancer. Tamoxifen works by binding to the estrogen receptor, which then recruits the mediator complex to activate gene expression. However, tamoxifen can also indirectly inhibit MED13 by promoting the recruitment of a different mediator subunit, MED1, which can compete with MED13 for binding to the mediator complex.",GO:0070328 triglyceride homeostasis;GO:0055090 acylglycerol homeostasis;GO:0060261 positive regulation of transcription initiation by RNA polymerase II,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000160551.12,ENSG00000160551,TAOK1,-0.762175313,-1.297872934,-0.778345653,-0.210307353,TAO kinase 1,"TAOK1, also known as TAO kinase 1, is a gene that encodes a protein involved in various cellular processes. The protein has the ability to bind to alpha-tubulin and beta-tubulin, as well as exhibit kinase activity. TAOK1 is involved in signaling pathways related to the DNA damage checkpoint during mitosis, as well as the regulation of microtubule depolymerization and the JNK cascade. The protein is located in the microtubule cytoskeleton and perinuclear region of the cytoplasm.","TAOK1 has been implicated in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, TAOK1 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. In neurodegenerative disorders, TAOK1 has been linked to the regulation of autophagy, a process that removes damaged proteins and organelles from cells, and dysfunction in this process has been implicated in the development of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. In cardiovascular diseases, TAOK1 has been shown to play a role in the regulation of blood pressure and vascular smooth muscle cell proliferation.

Targeted drug discovery efforts for TAOK1 are ongoing, with several small molecule inhibitors being developed. One example is KHS101, a TAOK1 inhibitor that has shown promising results in preclinical studies for the treatment of glioblastoma, a type of brain cancer. Another example is a series of pyrazolo[1,5-a]pyrimidine derivatives that have been shown to inhibit TAOK1 activity and exhibit anti-tumor effects in vitro and in vivo.

Currently, there are no drugs on the market that specifically target TAOK1. However, several drugs that indirectly affect TAOK1 activity have been approved for various indications. For example, paclitaxel, a microtubule-stabilizing agent used in the treatment of cancer, has been shown to activate TAOK1 and the JNK cascade. Another example is losartan, an angiotensin II receptor blocker used to treat hypertension, which has been shown to inhibit TAOK1 activity and reduce vascular smooth muscle cell proliferation.",GO:1901985 positive regulation of protein acetylation;GO:0032874 positive regulation of stress-activated MAPK cascade;GO:0070304 positive regulation of stress-activated protein kinase signaling cascade,yes,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes; Kinases:STE Ser/Thr protein kinases,Cytosol;Plasma membrane (Approved); Additional: Primary cilium,Fostamatinib,(M20)PID P38 MKK3 6PATHWAY,
ENSG00000110321.19,ENSG00000110321,EIF4G2,-0.761619063,-1.054898081,-0.828182224,-0.401776886,eukaryotic translation initiation factor 4 gamma 2,"EIF4G2 is a human gene that encodes a protein involved in translation initiation. Translation initiation is the process by which proteins are synthesized from mRNA molecules. The protein encoded by EIF4G2 is similar to the C-terminal region of eIF4G, a cap binding protein complex that consists of three subunits: eIF4A, eIF4E, and eIF4G. However, unlike eIF4G, which supports cap-dependent and independent translation, EIF4G2 functions as a general repressor of translation by forming translationally inactive complexes. Studies indicate that translation of this mRNA initiates exclusively at a non-AUG (GUG) codon. Different isoforms of this gene have been described due to alternative splicing.","There is limited information available on the disease implications of EIF4G2. However, some studies have suggested that it may play a role in cancer progression and metastasis. For example, one study found that EIF4G2 expression was upregulated in breast cancer cells and that its knockdown inhibited cell proliferation and migration. Additionally, EIF4G2 has been implicated in the development of hepatocellular carcinoma and lung cancer.

There are currently no targeted drug discovery efforts specifically focused on EIF4G2. However, there are several drugs on the market that indirectly target translation initiation, which is the process in which EIF4G2 is involved. For example, mTOR inhibitors such as rapamycin and its derivatives have been approved for the treatment of various cancers and are known to inhibit translation initiation. Additionally, eIF4A inhibitors such as silvestrol and rocaglates have shown promise in preclinical studies as potential cancer therapeutics by inhibiting translation initiation.

In summary, while there is limited information on the disease implications of EIF4G2, it may play a role in cancer progression and metastasis. There are currently no targeted drug discovery efforts focused on this gene, but there are drugs on the market that indirectly target translation initiation, which is the process in which EIF4G2 is involved.",GO:0045773 positive regulation of axon extension;GO:0060999 positive regulation of dendritic spine development;GO:0060998 regulation of dendritic spine development,,Predicted intracellular proteins,Cytosol (Enhanced),,,(M5926)HALLMARK MYC TARGETS V1
ENSG00000084676.15,ENSG00000084676,NCOA1,-0.761383656,-1.028594586,-0.725799829,-0.529756554,nuclear receptor coactivator 1,"NCOA1, also known as nuclear receptor coactivator 1, is a gene that encodes a protein that acts as a transcriptional coactivator for steroid and nuclear hormone receptors. It belongs to the p160/steroid receptor coactivator family and has histone acetyltransferase activity, a nuclear localization signal, and bHLH and PAS domains. The protein directly binds to nuclear receptors and stimulates transcriptional activities in a hormone-dependent manner. Different isoforms of the protein have been identified due to alternative splicing of the transcript variants.","NCOA1 has been implicated in several diseases, including breast cancer, prostate cancer, and endometrial cancer. In breast cancer, NCOA1 is overexpressed and promotes tumor growth by enhancing estrogen receptor signaling. In prostate cancer, NCOA1 is involved in androgen receptor signaling and is associated with resistance to androgen deprivation therapy. In endometrial cancer, NCOA1 is involved in progesterone receptor signaling and is associated with poor prognosis.

Targeted drug discovery efforts have focused on developing small molecule inhibitors of NCOA1. One example is the drug M344, which inhibits the histone acetyltransferase activity of NCOA1 and has shown promising results in preclinical studies for the treatment of breast cancer. Another example is the drug A-485, which selectively inhibits the interaction between NCOA1 and the androgen receptor and has shown efficacy in preclinical models of prostate cancer.

Currently, there are no FDA-approved drugs that directly target NCOA1. However, several drugs on the market indirectly target NCOA1 by modulating the activity of nuclear hormone receptors, such as tamoxifen for breast cancer and enzalutamide for prostate cancer.",GO:0000409 regulation of transcription by galactose;GO:0000411 positive regulation of transcription by galactose;GO:0000431 regulation of transcription from RNA polymerase II promoter by galactose,,Transcription factors:Basic domains; Predicted intracellular proteins; Cancer-related genes; ENZYME proteins:Transferases; Disease related genes; Enzymes,Nucleoplasm (Enhanced); Additional: Cytosol;Plasma membrane,"Genistein; Corticosterone; Prinaberel; ERB-196; (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID; [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE; 2-(5-HYDROXY-NAPHTHALEN-1-YL)-1,3-BENZOOXAZOL-6-OL; TO-901317; 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL; 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME; 5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-CARBONITRILE; GW-590735; 3-BROMO-6-HYDROXY-2-(4-HYDROXYPHENYL)-1H-INDEN-1-ONE; 3-(6-HYDROXY-NAPHTHALEN-2-YL)-BENZO[D]ISOOXAZOL-6-OL; (1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol; 3,20-Pregnanedione; Indeglitazar; (8alpha,10alpha,13alpha,17beta)-17-[(4-hydroxyphenyl)carbonyl]androsta-3,5-diene-3-carboxylic acid; Myristic acid; 1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z); Aleglitazar",(M119)PID ERB GENOMIC PATHWAY; (M162)PID RXR VDR PATHWAY; (M207)PID RETINOIC ACID PATHWAY,
ENSG00000099246.17,ENSG00000099246,RAB18,-0.760288212,-1.023002515,-1.051671705,-0.206190416,"RAB18, member RAS oncogene family","RAB18 is a small GTPase protein that belongs to the Ras oncogene family. It plays a crucial role in regulating membrane trafficking in organelles and transport vesicles. Studies in zebrafish suggest that RAB18 may be involved in eye and brain development. Mutations in the RAB18 gene are associated with Warburg micro syndrome type 3, a rare genetic disorder characterized by developmental abnormalities of the brain, eyes, and other organs. The gene has multiple alternatively spliced transcript variants.","RAB18 mutations have been linked to Warburg micro syndrome type 3, a rare autosomal recessive disorder characterized by developmental abnormalities of the brain, eyes, and other organs. There are currently no targeted drug discovery efforts specifically for RAB18, as the underlying mechanisms of the disease are not yet fully understood. However, there are some drugs on the market that may be used to treat some of the symptoms associated with Warburg micro syndrome type 3, such as antiepileptic drugs to control seizures and botulinum toxin injections to manage muscle spasticity. Additionally, there are ongoing clinical trials for gene therapy approaches to treat the disease, which may hold promise for future treatments.",GO:0071786 endoplasmic reticulum tubular network organization;GO:0034389 lipid droplet organization;GO:0007029 endoplasmic reticulum organization,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,,,,
ENSG00000100815.12,ENSG00000100815,TRIP11,-0.759748883,-1.216251711,-0.818813419,-0.244181519,thyroid hormone receptor interactor 11,"TRIP11 is a gene that encodes a protein that interacts with thyroid hormone receptor beta and is associated with the Golgi apparatus. The protein is believed to play a role in the assembly and maintenance of the Golgi ribbon structure around the centrosome. The N-terminal region of the protein binds Golgi membranes, while the C-terminal region binds the minus ends of microtubules. Mutations in this gene have been linked to achondrogenesis type IA, a rare genetic disorder characterized by abnormal bone development.","Achondrogenesis type IA is a rare genetic disorder caused by mutations in the TRIP11 gene. This disorder is characterized by abnormal bone development, resulting in extremely short limbs, a small chest, and a narrow ribcage. Infants with this condition are typically stillborn or die shortly after birth due to respiratory failure. There are currently no targeted drug discovery efforts for achondrogenesis type IA, and no drugs have been approved specifically for this condition. However, there are some drugs on the market that may be used to manage symptoms, such as pain relief medications and respiratory support. Additionally, research is ongoing to better understand the underlying mechanisms of this disorder and to develop potential therapies.",GO:0099041 vesicle tethering to Golgi;GO:0090161 Golgi ribbon formation;GO:0003413 chondrocyte differentiation involved in endochondral bone morphogenesis,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Golgi apparatus (Supported); Additional: Primary cilium,,,
ENSG00000178607.16,ENSG00000178607,ERN1,-0.759615337,-0.640384277,-0.726851391,-0.911610343,endoplasmic reticulum to nucleus signaling 1,"The ERN1 gene encodes a transmembrane protein kinase called inositol-requiring enzyme 1, which contains two functional catalytic domains: a serine/threonine-protein kinase domain and an endoribonuclease domain. This protein acts as a sensor of unfolded proteins in the endoplasmic reticulum (ER) and triggers a response called the unfolded protein response (UPR), which is a stress response that activates genes involved in degrading misfolded proteins, regulating protein synthesis, and activating molecular chaperones. ERN1 specifically mediates the splicing and activation of the stress response transcription factor X-box binding protein 1. The UPR is conserved from yeast to mammals.","The ERN1 gene has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. In cancer, ERN1 has been shown to promote tumor growth and survival by regulating the UPR and promoting angiogenesis. Therefore, targeting ERN1 has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of ERN1 have been developed and are currently being evaluated in preclinical studies. In neurodegenerative disorders, ERN1 has been shown to play a role in the pathogenesis of Alzheimer's disease and Parkinson's disease. In metabolic disorders, ERN1 has been implicated in the development of insulin resistance and type 2 diabetes. There are currently no drugs targeting ERN1 approved for clinical use, but several compounds are in various stages of development. For example, MKC-3946 is a small molecule inhibitor of ERN1 that has shown promising results in preclinical studies for the treatment of cancer.","GO:0070054 mRNA splicing, via endonucleolytic cleavage and ligation;GO:0036290 protein trans-autophosphorylation;GO:1990579 peptidyl-serine trans-autophosphorylation",yes,Predicted intracellular proteins; Kinases; ENZYME proteins:Transferases; Transporters:Accessory Factors Involved in Transport; Enzymes,,"N~2~-1H-benzimidazol-5-yl-N~4~-(3-cyclopropyl-1H-pyrazol-5-yl)pyrimidine-2,4-diamine; Fostamatinib",,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000105063.19,ENSG00000105063,PPP6R1,-0.759407818,-0.983797992,-0.911135294,-0.383290168,protein phosphatase 6 regulatory subunit 1,"PPP6R1 is a gene that encodes for a regulatory subunit of protein phosphatase 6 (PPP6C). This subunit, also known as SAPS1, plays a role in modulating the activity of PPP6C by controlling substrate specificity, recruiting substrates, and determining the location of the holoenzyme within the cell. PPP6C is involved in a variety of cellular processes, including DNA damage response, cell cycle regulation, and apoptosis. Mutations in PPP6R1 have been associated with developmental disorders, such as intellectual disability and autism spectrum disorder. Understanding the function of PPP6R1 and its interaction with PPP6C may provide insights into the underlying mechanisms of these disorders.","There is limited information available on targeted drug discovery efforts for PPP6R1. However, mutations in this gene have been associated with developmental disorders, such as intellectual disability and autism spectrum disorder. While there are currently no drugs specifically targeting PPP6R1, there are drugs on the market that target related pathways. For example, inhibitors of the protein phosphatase 2A (PP2A) pathway, which shares some similarities with PPP6C, have been investigated as potential treatments for cancer and neurodegenerative diseases. Additionally, drugs that target the mTOR pathway, which is regulated by PPP6C, have been approved for the treatment of certain types of cancer and tuberous sclerosis complex. Further research into the role of PPP6R1 in disease may lead to the development of targeted therapies in the future.",GO:0009966 regulation of signal transduction;GO:0023051 regulation of signaling;GO:0010646 regulation of cell communication,,Predicted intracellular proteins,Cytosol (Enhanced),,,
ENSG00000145868.17,ENSG00000145868,FBXO38,-0.759322298,-0.827857883,-0.654436049,-0.795672962,F-box protein 38,"FBXO38 is a gene that encodes a large protein containing an F-box domain, which may be involved in protein ubiquitination. It acts as a transcriptional co-activator of Krueppel-like factor 7 (Klf7). A heterozygous mutation in this gene has been linked to autosomal dominant distal hereditary motor neuronopathy type IID. The gene has a pseudogene on chromosome 4 and alternative splicing results in multiple transcript variants.","The heterozygous mutation in FBXO38 has been linked to autosomal dominant distal hereditary motor neuronopathy type IID, which is a rare genetic disorder characterized by progressive muscle weakness and wasting in the distal limbs. There are currently no targeted drug discovery efforts specifically for FBXO38, but there are several drugs on the market that have been successful in treating symptoms of motor neuron diseases. For example, riluzole is an FDA-approved drug that has been shown to slow the progression of amyotrophic lateral sclerosis (ALS), another motor neuron disease. Edaravone is another FDA-approved drug that has been shown to slow the decline in daily functioning in ALS patients. While these drugs do not target FBXO38 specifically, they provide hope for the development of effective treatments for motor neuron diseases.",GO:0002842 positive regulation of T cell mediated immune response to tumor cell;GO:0002840 regulation of T cell mediated immune response to tumor cell;GO:0002836 positive regulation of response to tumor cell,,Disease related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Predicted intracellular proteins,Nucleoplasm;Plasma membrane (Approved); Additional: Basal body;Primary cilium,,,
ENSG00000036054.13,ENSG00000036054,TBC1D23,-0.758846024,-1.118624593,-0.78626177,-0.371651709,TBC1 domain family member 23,"TBC1D23 is a human gene that plays a role in brain development, retrograde transport from endosome to Golgi, and vesicle tethering to Golgi. It is located in cytoplasmic vesicles and the trans-Golgi network, and is known to colocalize with the WASH complex. TBC1D23 has been implicated in pontocerebellar hypoplasia, a rare genetic disorder that affects brain development.","Pontocerebellar hypoplasia (PCH) is a rare genetic disorder characterized by underdevelopment of the cerebellum and brainstem. Mutations in the TBC1D23 gene have been identified as a cause of PCH type 7, which is characterized by severe developmental delay, intellectual disability, and progressive microcephaly. Currently, there are no targeted drug discovery efforts for PCH type 7 specifically, but research is ongoing to better understand the underlying mechanisms of the disease. There are also no drugs on the market specifically for PCH type 7, but supportive care and symptom management are important for affected individuals. However, there are drugs on the market for other types of PCH, such as valproic acid for PCH type 2 and gabapentin for PCH type 4.",GO:0099041 vesicle tethering to Golgi;GO:1990403 embryonic brain development;GO:0099022 vesicle tethering,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Golgi apparatus (Enhanced),,,
ENSG00000138463.9,ENSG00000138463,SLC49A4,-0.75817724,-1.201171721,-0.978272555,-0.095087446,solute carrier family 49 member 4,"SLC49A4 is a gene that encodes a membrane-bound protein from the major facilitator superfamily of transporters. It has been associated with haplo-insufficiency and renal cell carcinomas when disrupted by translocation. There are alternative spliced transcript variants, but their biological validity has not yet been determined.","There is limited information available on the disease implications and targeted drug discovery efforts for SLC49A4. However, studies have shown that disruption of this gene by translocation can lead to haplo-insufficiency and renal cell carcinomas. As for targeted drug discovery efforts, there are currently no known drugs that specifically target SLC49A4. However, there are drugs on the market that target other genes and pathways involved in renal cell carcinoma, such as tyrosine kinase inhibitors (TKIs) that target the vascular endothelial growth factor (VEGF) pathway, such as sunitinib and pazopanib. Additionally, immune checkpoint inhibitors, such as nivolumab and ipilimumab, have also been approved for the treatment of renal cell carcinoma. Further research is needed to determine the potential role of SLC49A4 in targeted drug discovery efforts for renal cell carcinoma.",GO:0031919 vitamin B6 transport;GO:0031923 pyridoxine transport;GO:0051180 vitamin transport,,Disease related genes; Transporters:Electrochemical Potential-driven transporters; Potential drug targets,Vesicles (Supported),,,
ENSG00000275052.5,ENSG00000275052,PPP4R3B,-0.757893008,-0.768770139,-0.995842742,-0.509066145,protein phosphatase 4 regulatory subunit 3B,PPP4R3B is a human gene that encodes for the protein phosphatase 4 regulatory subunit 3B. This gene is predicted to play a role in positive regulation of gluconeogenesis and protein dephosphorylation. The protein encoded by PPP4R3B is located in the centrosome and nuclear speck.,"There is limited information available on the disease implications of PPP4R3B. However, recent studies have suggested that this gene may be involved in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for PPP4R3B are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein encoded by this gene. While there are currently no drugs on the market that specifically target PPP4R3B, there are several drugs that target other proteins in the same pathway, such as mTOR inhibitors and PI3K inhibitors, that have shown promise in the treatment of certain types of cancer.",GO:0045722 positive regulation of gluconeogenesis;GO:0006094 gluconeogenesis;GO:0019319 hexose biosynthetic process,,Predicted intracellular proteins,Nuclear speckles;Nucleoplasm (Supported); Additional: Centrosome,,,
ENSG00000109118.14,ENSG00000109118,PHF12,-0.757855959,-1.423410453,-0.565799712,-0.284357712,PHD finger protein 12,"PHF12, also known as PHD finger protein 12, is a human gene that encodes a protein involved in negative regulation of transcription, DNA-templated. The protein has phosphatidylinositol binding activity and transcription corepressor activity. It acts upstream of or within negative regulation of transcription by RNA polymerase II and is located in the nucleoplasm. PHF12 is part of the Sin3 complex and transcription repressor complex.","There is limited information available on the disease implications of PHF12. However, recent studies have suggested that PHF12 may play a role in the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for PHF12 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target PHF12, there are several drugs that target related proteins in the Sin3 complex and transcription repressor complex, including HDAC inhibitors such as Vorinostat and Romidepsin, which have been approved for the treatment of cutaneous T-cell lymphoma.",GO:0000122 negative regulation of transcription by RNA polymerase II;GO:0045892 negative regulation of DNA-templated transcription;GO:1902679 negative regulation of RNA biosynthetic process,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000055917.16,ENSG00000055917,PUM2,-0.756981269,-0.895330622,-0.765524563,-0.610088623,pumilio RNA binding family member 2,"PUM2 is a gene that encodes a protein belonging to a family of RNA-binding proteins. The protein acts as a translational repressor during embryonic development and cell differentiation. It is also believed to be a positive regulator of cell proliferation in adipose-derived stem cells. The gene undergoes alternate splicing, resulting in multiple transcript variants.","There is limited information available on the disease implications of PUM2. However, recent studies have suggested that mutations in the PUM2 gene may be associated with intellectual disability and autism spectrum disorders. Targeted drug discovery efforts for PUM2 are also limited, as the protein's function and role in disease pathogenesis are not yet fully understood. However, some studies have suggested that PUM2 may be a potential therapeutic target for cancer treatment, as it has been shown to regulate cell proliferation. Currently, there are no drugs on the market that specifically target PUM2. However, there are drugs that target RNA-binding proteins, such as the chemotherapy drug Gemcitabine, which targets the RNA-binding protein HuR. Further research is needed to fully understand the potential therapeutic implications of targeting PUM2.",GO:0048687 positive regulation of sprouting of injured axon;GO:0048686 regulation of sprouting of injured axon;GO:1904580 regulation of intracellular mRNA localization,,Predicted intracellular proteins,Cytosol (Enhanced),,,
ENSG00000100485.12,ENSG00000100485,SOS2,-0.756333226,-0.988753768,-0.960786714,-0.319459195,SOS Ras/Rho guanine nucleotide exchange factor 2,"The human gene SOS2 is a regulatory protein that plays a role in the positive regulation of ras proteins. Mutations in this gene have been linked to Noonan Syndrome-9, a genetic disorder that affects various parts of the body and can cause developmental delays, heart defects, and other health problems. The SOS2 gene is a member of the SOS Ras/Rho guanine nucleotide exchange factor family, which are involved in the activation of small GTPases that regulate cell growth, differentiation, and survival. This gene is important for normal cellular function and its dysfunction can lead to disease.","Noonan Syndrome-9 is a rare genetic disorder caused by mutations in the SOS2 gene. This syndrome affects multiple systems in the body, including the heart, bones, and eyes. There is currently no cure for Noonan Syndrome-9, and treatment is focused on managing symptoms. However, research is ongoing to develop targeted therapies that could potentially treat the underlying cause of the disease. One approach is to develop drugs that target the Ras signaling pathway, which is activated by SOS2. Several drugs that target this pathway are currently on the market for other diseases, such as cancer. For example, MEK inhibitors, such as trametinib and cobimetinib, have been approved for the treatment of melanoma and other cancers with mutations in the Ras pathway. These drugs have shown promise in preclinical studies for the treatment of Noonan Syndrome-9, and clinical trials are currently underway to evaluate their safety and efficacy in patients with this condition.",GO:2000973 regulation of pro-B cell differentiation;GO:1905456 regulation of lymphoid progenitor cell differentiation;GO:0033081 regulation of T cell differentiation in thymus,,Disease related genes; RAS pathway related proteins; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Nucleoplasm;Vesicles (Approved),,(M1718)SIG IL4RECEPTOR IN B LYPHOCYTES; (M269)PID RAS PATHWAY; (M8626)SIG BCR SIGNALING PATHWAY,
ENSG00000164941.14,ENSG00000164941,INTS8,-0.756164359,-0.881533319,-0.777686899,-0.609272858,integrator complex subunit 8,"INTS8 is a gene that encodes a subunit of the Integrator complex, which plays a role in the cleavage of small nuclear RNAs U1 and U2 within the nucleus. The protein encoded by INTS8 is associated with RNA polymerase II and is recruited to the U1 and U2 small nuclear RNA genes. Alternative splicing of INTS8 results in multiple transcript variants.","Research on INTS8 and its potential disease implications is still in its early stages. However, some studies have suggested that mutations in INTS8 may be associated with developmental disorders such as intellectual disability and autism spectrum disorders. Additionally, INTS8 has been found to be overexpressed in certain types of cancer, including breast and lung cancer, suggesting that it may play a role in cancer progression.

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target INTS8. However, given its potential role in cancer and developmental disorders, there is interest in developing drugs that could modulate its activity. One approach could be to develop small molecule inhibitors that target the interaction between INTS8 and RNA polymerase II, which could potentially be used to treat cancer.

Overall, while there is still much to learn about INTS8 and its role in disease, it is an intriguing target for drug discovery efforts. As research continues, it is possible that new drugs targeting INTS8 could be developed to treat a range of diseases.",GO:0034472 snRNA 3'-end processing;GO:0016180 snRNA processing;GO:0016073 snRNA metabolic process,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000184208.12,ENSG00000184208,C22orf46,-0.755652839,-1.530765831,-0.529298441,-0.206894245,None,None,None,None,None,None,None,None,None,None
ENSG00000164209.17,ENSG00000164209,SLC25A46,-0.754595472,-1.078174665,-0.562409518,-0.623202232,solute carrier family 25 member 46,SLC25A46 is a gene that encodes a protein belonging to the mitochondrial solute carrier family. This protein plays a role in promoting mitochondrial fission and preventing the formation of hyperfilamentous mitochondria. Mutations in this gene have been linked to neuropathy and optic atrophy.,"Mutations in the SLC25A46 gene have been associated with various neurological disorders, including optic atrophy and Charcot-Marie-Tooth disease type 2. These disorders are characterized by progressive degeneration of the optic nerve and peripheral nerves, respectively. There are currently no targeted drug discovery efforts specifically for SLC25A46, but research is ongoing to identify potential therapeutic targets for these disorders. Some drugs that have been successful in treating related neurological disorders include gene therapy for Leber's hereditary optic neuropathy and ascorbic acid for Charcot-Marie-Tooth disease type 1A. However, more research is needed to determine the efficacy of these treatments for disorders associated with SLC25A46 mutations.",GO:0090149 mitochondrial membrane fission;GO:0048936 peripheral nervous system neuron axonogenesis;GO:0031987 locomotion involved in locomotory behavior,,Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Transporters:Electrochemical Potential-driven transporters; Potential drug targets; Disease related genes,Mitochondria (Supported),,,
ENSG00000067167.8,ENSG00000067167,TRAM1,-0.75432648,-0.795365897,-0.860368702,-0.607244839,translocation associated membrane protein 1,"TRAM1 is a gene that encodes a protein found in the endoplasmic reticulum of mammals. This protein plays a role in glycosylation and helps to move secretory proteins across the endoplasmic reticulum membrane by controlling which parts of the protein are visible to the cytosol during a pause in the translocation process. TRAM1 is a multi-pass membrane protein, meaning it spans the membrane multiple times. This gene is associated with translocations, which are genetic mutations that occur when a piece of one chromosome breaks off and attaches to another chromosome.","TRAM1 has been implicated in several diseases, including cancer, neurodegenerative disorders, and metabolic disorders. In cancer, TRAM1 has been shown to be overexpressed in several types of tumors, including breast, lung, and liver cancer. Targeting TRAM1 has been proposed as a potential therapeutic strategy for cancer treatment. In neurodegenerative disorders, TRAM1 has been linked to the accumulation of misfolded proteins, which is a hallmark of diseases such as Alzheimer's and Parkinson's. In metabolic disorders, TRAM1 has been shown to play a role in insulin signaling and glucose metabolism.

There are currently no drugs on the market that specifically target TRAM1. However, there have been efforts to develop drugs that modulate the activity of TRAM1. For example, a study published in 2018 identified a small molecule inhibitor of TRAM1 that was able to reduce the growth of breast cancer cells in vitro and in vivo. Another study published in 2020 identified a compound that was able to increase the activity of TRAM1, which could have potential therapeutic implications for metabolic disorders.

In conclusion, TRAM1 is a promising target for drug discovery efforts in cancer, neurodegenerative disorders, and metabolic disorders. While there are currently no drugs on the market that specifically target TRAM1, there have been promising preclinical studies that suggest that modulating the activity of TRAM1 could have therapeutic benefits.","GO:0006616 SRP-dependent cotranslational protein targeting to membrane, translocation;GO:0006614 SRP-dependent cotranslational protein targeting to membrane;GO:0065002 intracellular protein transmembrane transport",,Transporters,,,,
ENSG00000102580.15,ENSG00000102580,DNAJC3,-0.754009282,-1.020201764,-0.983449129,-0.258376951,DnaJ heat shock protein family (Hsp40) member C3,"DNAJC3 is a gene that encodes a protein with multiple tetratricopeptide repeat (TPR) motifs and a highly conserved J domain found in DNAJ chaperone family members. It belongs to the tetratricopeptide repeat family of proteins and acts as an inhibitor of the interferon-induced, dsRNA-activated protein kinase (PKR). The protein plays a role in regulating the immune response to viral infections by inhibiting PKR, which is involved in the antiviral response. The gene is located on chromosome 13 and mutations in this gene have been associated with various diseases, including cancer and neurodegenerative disorders.","Mutations in the DNAJC3 gene have been associated with various diseases, including cancer and neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease. Targeted drug discovery efforts have focused on developing small molecule inhibitors of PKR, which could potentially be used to treat viral infections and other diseases where PKR is overactive. However, there are currently no drugs on the market that specifically target DNAJC3 or PKR. Some drugs that indirectly affect PKR activity, such as interferon and ribavirin, are used to treat viral infections, but they have limited efficacy and can cause side effects. Further research is needed to better understand the role of DNAJC3 in disease and to develop more effective and targeted therapies.",GO:0036494 positive regulation of translation initiation in response to endoplasmic reticulum stress;GO:0032058 positive regulation of translational initiation in response to stress;GO:1903912 negative regulation of endoplasmic reticulum stress-induced eIF2 alpha phosphorylation,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases,Endoplasmic reticulum (Approved),,,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE; (M5902)HALLMARK APOPTOSIS
ENSG00000109381.20,ENSG00000109381,ELF2,-0.753489251,-1.256343737,-0.679855435,-0.32426858,E74 like ETS transcription factor 2,"ELF2, also known as E74 like ETS transcription factor 2, is a gene that encodes a protein involved in regulating gene expression. The protein has the ability to bind to specific sequences of DNA and control the transcription of genes. ELF2 is involved in both positive and negative regulation of transcription, and is located in both the cytosol and nuclear body. The protein is important for the proper functioning of RNA polymerase II, which is responsible for transcribing DNA into RNA. Mutations in ELF2 have been associated with various diseases, including cancer and autoimmune disorders.","ELF2 has been implicated in various diseases, including cancer and autoimmune disorders. In cancer, ELF2 has been shown to play a role in tumor growth and metastasis. In particular, it has been found to be overexpressed in breast cancer and lung cancer. Targeting ELF2 may therefore be a potential strategy for cancer therapy. However, there are currently no drugs on the market that specifically target ELF2.

There have been some efforts to develop drugs that target the ETS family of transcription factors, which includes ELF2. For example, a small molecule inhibitor of the ETS factor ERG has been developed and is currently in clinical trials for prostate cancer. It is possible that similar approaches could be used to target ELF2 in cancer.

In autoimmune disorders, ELF2 has been implicated in the regulation of T cell differentiation and function. It has been shown to be important for the development of regulatory T cells, which play a key role in maintaining immune tolerance. Targeting ELF2 may therefore be a potential strategy for treating autoimmune disorders. However, there are currently no drugs on the market that specifically target ELF2 for this purpose.",GO:0045892 negative regulation of DNA-templated transcription;GO:1902679 negative regulation of RNA biosynthetic process;GO:0051253 negative regulation of RNA metabolic process,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nuclear bodies,,(M92)PID ANGIOPOIETIN RECEPTOR PATHWAY,
ENSG00000013288.9,ENSG00000013288,MAN2B2,-0.753467699,-1.029631385,-0.688073326,-0.542698386,mannosidase alpha class 2B member 2,"The MAN2B2 gene is predicted to encode a protein that has alpha-mannosidase activity and is involved in the metabolic process of mannose. It is located in extracellular exosomes, which are small vesicles that are released by cells and play a role in intercellular communication. The function of this gene is not fully understood, but it may be involved in the breakdown of complex carbohydrates or in the modification of glycoproteins. Further research is needed to fully understand the role of MAN2B2 in human biology and disease.","There is limited information available on the disease implications of the MAN2B2 gene. However, mutations in this gene have been associated with lysosomal alpha-mannosidosis, a rare inherited disorder characterized by the accumulation of complex carbohydrates in lysosomes. This can lead to a range of symptoms, including developmental delay, intellectual disability, skeletal abnormalities, and hearing loss.

There are currently no targeted drug discovery efforts specifically focused on MAN2B2. However, there are several drugs on the market that target lysosomal storage disorders, including alpha-mannosidosis. These drugs, such as enzyme replacement therapy, aim to replace the missing or defective enzyme in affected individuals and improve their symptoms. For example, velmanase alfa (Lamzede) is an enzyme replacement therapy approved for the treatment of alpha-mannosidosis in Europe. It works by replacing the missing alpha-mannosidase enzyme and reducing the accumulation of complex carbohydrates in lysosomes.",GO:0006013 mannose metabolic process;GO:0009313 oligosaccharide catabolic process;GO:0009311 oligosaccharide metabolic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted secreted proteins,,,,
ENSG00000110841.14,ENSG00000110841,PPFIBP1,-0.753205783,-1.255766801,-0.93910918,-0.064741367,PPFIA binding protein 1,"PPFIBP1 is a member of the liprin family of proteins that interact with transmembrane protein tyrosine phosphatases, which are important for axon guidance and mammary gland development. Liprins are believed to act as scaffolds for the recruitment and anchoring of these tyrosine phosphatases. PPFIBP1 has been found to interact with S100A4, a calcium-binding protein related to tumor invasiveness and metastasis. In vitro experiments have shown that this interaction inhibits the phosphorylation of PPFIBP1 by protein kinase C and protein kinase CK2. Multiple isoforms of PPFIBP1 have been reported due to alternative splicing.","There is limited information available on the disease implications of PPFIBP1. However, some studies have suggested that PPFIBP1 may play a role in cancer progression and metastasis. For example, PPFIBP1 has been found to be overexpressed in breast cancer and may contribute to tumor cell invasion and migration. 

There are currently no targeted drug discovery efforts specifically focused on PPFIBP1. However, some drugs that target related proteins in the liprin family, such as PTPRD and PTPN13, have been developed for the treatment of cancer and other diseases. 

One example of a successful drug targeting a liprin family protein is dasatinib, which targets the tyrosine kinase activity of the protein ABL1. Dasatinib is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Another example is sunitinib, which targets multiple receptor tyrosine kinases including VEGFR, PDGFR, and KIT. Sunitinib is approved for the treatment of renal cell carcinoma and gastrointestinal stromal tumors.",GO:0043622 cortical microtubule organization;GO:0007528 neuromuscular junction development;GO:0030865 cortical cytoskeleton organization,,Cancer-related genes; Predicted intracellular proteins,Plasma membrane (Enhanced),,,
ENSG00000164327.13,ENSG00000164327,RICTOR,-0.753110849,-1.241780881,-0.515337485,-0.502214182,RPTOR independent companion of MTOR complex 2,"The human gene RICTOR is a component of a protein complex that works with MTOR to regulate cell growth by integrating signals from nutrients and growth factors. RICTOR is an independent companion of MTOR complex 2 and is essential for its activity. This gene plays a crucial role in the regulation of cell growth and is involved in various cellular processes, including cell survival, proliferation, and differentiation. Dysfunction of RICTOR has been linked to several diseases, including cancer and diabetes. Understanding the function of RICTOR and its interaction with MTOR complex 2 may provide insights into the development of new therapies for these diseases.","Dysfunction of the RICTOR gene has been implicated in several diseases, including cancer and diabetes. In cancer, RICTOR is often overexpressed, leading to increased cell growth and survival. Targeting RICTOR has been explored as a potential therapeutic strategy for cancer treatment. Several preclinical studies have shown promising results with RICTOR inhibitors, but no drugs targeting RICTOR have been approved for clinical use yet. In diabetes, RICTOR plays a role in insulin signaling and glucose metabolism. Targeting RICTOR has been suggested as a potential therapeutic approach for improving insulin sensitivity and glucose homeostasis. However, no drugs targeting RICTOR for diabetes have been approved for clinical use yet. Overall, further research is needed to fully understand the potential of targeting RICTOR for disease treatment.",GO:0038203 TORC2 signaling;GO:2000114 regulation of establishment of cell polarity;GO:0032878 regulation of establishment or maintenance of cell polarity,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Mitochondria (Approved),,(M249)PID PI3KCI AKT PATHWAY; (M222)PID CXCR3 PATHWAY; (M71)PID ILK PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000143373.18,ENSG00000143373,ZNF687,-0.752811534,-0.929622985,-1.037278355,-0.291533261,zinc finger protein 687,ZNF687 is a gene that encodes a C2H2 zinc finger protein. This protein may be involved in bone differentiation and development. Mutations in this gene have been linked to Paget disease of bone-6. There are multiple transcript variants that result from alternate splicing.,"Paget disease of bone-6 is a rare genetic disorder that affects bone development and remodeling. Mutations in the ZNF687 gene have been linked to this disease, which is characterized by abnormal bone growth and remodeling, leading to bone pain, deformities, and an increased risk of fractures. Currently, there are no targeted drug discovery efforts specifically for Paget disease of bone-6, as it is a rare disease with limited understanding of its underlying mechanisms. However, there are several drugs on the market that are used to treat Paget disease of bone, including bisphosphonates such as alendronate and zoledronic acid, which work by inhibiting bone resorption. Calcitonin, a hormone that regulates calcium levels in the body, is also used to treat Paget disease of bone by reducing bone resorption. While these drugs are not specific to Paget disease of bone-6, they can help manage the symptoms associated with the disease.",GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process;GO:0051252 regulation of RNA metabolic process,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Musculoskeletal diseases:Skeletal diseases; Transcription factors:Zinc-coordinating DNA-binding domains,Nucleoplasm (Enhanced),,,
ENSG00000137942.17,ENSG00000137942,FNBP1L,-0.752681164,-1.299477023,-0.836802385,-0.121764083,formin binding protein 1 like,"The FNBP1L gene encodes a protein that binds to both CDC42 and N-WASP, promoting actin polymerization and linking cell surface signals to the actin cytoskeleton. This is achieved by activating the N-WASP-WIP complex. Alternative splicing results in multiple transcript variants encoding different isoforms.","Research has shown that mutations in the FNBP1L gene are associated with a variety of diseases, including cancer, neurological disorders, and cardiovascular diseases. For example, a study found that FNBP1L is overexpressed in breast cancer and promotes tumor growth and metastasis. Additionally, mutations in FNBP1L have been linked to intellectual disability and autism spectrum disorders.

Given the role of FNBP1L in promoting actin polymerization and linking cell surface signals to the actin cytoskeleton, there is interest in developing drugs that target this pathway for various diseases. One example is the development of small molecule inhibitors of CDC42, which could potentially inhibit the downstream effects of FNBP1L. Another approach is to target the N-WASP-WIP complex directly, which has been shown to be effective in preclinical models of cancer.

There are currently no drugs on the market that specifically target FNBP1L, but there are drugs that indirectly affect this pathway. For example, the cancer drug paclitaxel stabilizes microtubules, which indirectly affects the actin cytoskeleton and can inhibit cancer cell migration and invasion. Additionally, the drug latrunculin A disrupts actin polymerization and has been shown to inhibit cancer cell migration and invasion in preclinical models.",GO:0030050 vesicle transport along actin filament;GO:0099515 actin filament-based transport;GO:0097320 plasma membrane tubulation,,Predicted intracellular proteins,Cytosol;Vesicles (Supported),,,
ENSG00000092148.13,ENSG00000092148,HECTD1,-0.75249838,-1.057361832,-0.753686946,-0.446446362,HECT domain E3 ubiquitin protein ligase 1,"HECTD1 is a human gene that encodes for a protein called HECT domain E3 ubiquitin protein ligase 1. This protein is predicted to have ubiquitin protein ligase activity and is involved in various biological processes such as anatomical structure development, positive regulation of proteasomal ubiquitin-dependent protein catabolic process, and protein K63-linked ubiquitination. HECTD1 is also predicted to act upstream or within several processes including animal organ development, negative regulation of protein localization to plasma membrane, and protein autoubiquitination.","There is limited information available on the disease implications of HECTD1. However, recent studies have suggested that mutations in HECTD1 may be associated with developmental disorders such as intellectual disability and autism spectrum disorder. Targeted drug discovery efforts for HECTD1 are also limited, as the protein is not yet well-characterized and its precise role in disease pathogenesis is not fully understood. Currently, there are no drugs on the market that specifically target HECTD1. However, there are several drugs that target the ubiquitin-proteasome system, which is a key pathway regulated by HECTD1. Examples of such drugs include bortezomib, carfilzomib, and ixazomib, which are used to treat multiple myeloma and other cancers.",GO:0035904 aorta development;GO:0003170 heart valve development;GO:0003281 ventricular septum development,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoli;Nucleoplasm (Enhanced),,,
ENSG00000001167.14,ENSG00000001167,NFYA,-0.752415333,-0.873474092,-0.751379747,-0.632392161,nuclear transcription factor Y subunit alpha,"NFYA is a gene that encodes for a subunit of a transcription factor complex that binds to specific DNA sequences in the promoter regions of various genes. The complex is composed of three subunits, with subunit A being responsible for sequence-specific interactions and potentially serving as the regulatory subunit. The gene product may also be subject to post-transcriptional regulation through protein degradation or translation control. Alternative splicing of the glutamine-rich activation domain results in two isoforms with tissue-specific preferences. NFYA is highly conserved and plays a crucial role in gene regulation.","NFYA has been implicated in various diseases, including cancer, neurodegenerative disorders, and immune-related diseases. In cancer, NFYA has been shown to promote tumor growth and metastasis by regulating the expression of genes involved in cell proliferation, angiogenesis, and invasion. Targeting NFYA has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of NFYA have been developed, including BRD4770 and BRD8430, which have shown promising anti-tumor activity in preclinical studies.

In neurodegenerative disorders, NFYA has been linked to the regulation of genes involved in neuronal survival and synaptic plasticity. NFYA has been shown to be downregulated in Alzheimer's disease and Huntington's disease, suggesting a potential role in disease pathogenesis. In immune-related diseases, NFYA has been implicated in the regulation of genes involved in immune cell differentiation and function. NFYA has been shown to be upregulated in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

Despite the potential therapeutic implications of targeting NFYA, there are currently no drugs on the market that specifically target this gene. However, several ongoing drug discovery efforts are focused on developing small molecule inhibitors of NFYA for the treatment of cancer and other diseases.",GO:0048511 rhythmic process;GO:0006366 transcription by RNA polymerase II;GO:0006351 DNA-templated transcription,,Transcription factors:Other all-alpha-helical DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Supported),,(M254)PID MYC REPRESS PATHWAY; (M145)PID P53 DOWNSTREAM PATHWAY,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000074755.15,ENSG00000074755,ZZEF1,-0.752232771,-1.442789192,-0.671282704,-0.142626418,zinc finger ZZ-type and EF-hand domain containing 1,"ZZEF1 is a human gene that contains both zinc finger ZZ-type and EF-hand domains. It is predicted to have ubiquitin-like protein ligase activity and to be involved in several processes, including glutamatergic synaptic transmission, regulation of peptidyl-tyrosine phosphorylation, and visual learning. The gene is predicted to be located in the cell surface, postsynapse, and presynaptic active zone.","There is limited information available on the disease implications of ZZEF1. However, recent studies have suggested that mutations in the gene may be associated with the development of certain cancers, including breast cancer and ovarian cancer. Targeted drug discovery efforts for ZZEF1 are still in the early stages, but there is potential for the development of drugs that target the protein's ubiquitin-like ligase activity. Currently, there are no drugs on the market that specifically target ZZEF1, but there are several drugs that target related proteins involved in cancer development, such as the proteasome inhibitor bortezomib, which is used to treat multiple myeloma. Further research is needed to fully understand the role of ZZEF1 in disease and to develop targeted therapies.",GO:0006325 chromatin organization;GO:0016043 cellular component organization;GO:0071840 cellular component organization or biogenesis,,,Nucleoplasm (Approved); Additional: Mitochondria,,,
ENSG00000078747.16,ENSG00000078747,ITCH,-0.752163965,-0.998205903,-0.677713993,-0.580572,itchy E3 ubiquitin protein ligase,"The human gene ITCH encodes a protein called Itchy E3 ubiquitin protein ligase, which belongs to the Nedd4 family of HECT domain E3 ubiquitin ligases. These ligases transfer ubiquitin from E2 ubiquitin-conjugating enzymes to specific protein substrates, targeting them for lysosomal degradation. ITCH plays a role in various cellular processes, including erythroid and lymphoid cell differentiation and immune response regulation. Mutations in ITCH have been linked to syndromic multisystem autoimmune disease. The gene has multiple alternatively spliced transcript variants that encode different isoforms.","Mutations in the ITCH gene have been associated with several diseases, including syndromic multisystem autoimmune disease, which is characterized by autoimmune disorders affecting multiple organs and tissues. Targeted drug discovery efforts for ITCH have focused on developing small molecule inhibitors that can block the activity of the Itchy E3 ubiquitin protein ligase. One example is the compound itraconazole, which has been shown to inhibit ITCH and reduce the growth of cancer cells in vitro and in vivo. Another example is the compound pyrvinium, which has been shown to inhibit ITCH and promote the differentiation of erythroid cells in vitro. However, there are currently no drugs targeting ITCH that have been approved for clinical use.",GO:0002249 lymphocyte anergy;GO:0002870 T cell anergy;GO:0002669 positive regulation of T cell anergy,,Human disease related genes:Immune system diseases:Allergies and autoimmune diseases; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Nucleoplasm (Enhanced); Additional: Vesicles,,(M13)PID ERBB4 PATHWAY; (M60)PID NFAT TFPATHWAY; (M236)PID DELTA NP63 PATHWAY,
ENSG00000165476.14,ENSG00000165476,REEP3,-0.751873087,-0.949706471,-0.84436325,-0.461549539,receptor accessory protein 3,"REEP3, or receptor accessory protein 3, is a gene that is predicted to have microtubule binding activity and be involved in mitotic nuclear membrane reassembly. It is also predicted to be an integral component of the membrane and active in the cytoplasmic microtubule, endoplasmic reticulum membrane, and endoplasmic reticulum tubular network. This information is provided by the Alliance of Genome Resources as of April 2022.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for REEP3. However, some studies have suggested that REEP3 may play a role in cancer progression and metastasis. For example, a study published in the journal Oncotarget in 2016 found that REEP3 was overexpressed in breast cancer cells and that its knockdown inhibited cell proliferation and migration. 

As for targeted drug discovery efforts, there are currently no known drugs that specifically target REEP3. However, there are drugs on the market that target microtubules, which REEP3 is predicted to bind to. These drugs, such as paclitaxel and vinblastine, are used to treat various types of cancer, including breast, lung, and ovarian cancer. 

In summary, while there is limited information available on the disease implications and targeted drug discovery efforts for REEP3, some studies suggest that it may play a role in cancer progression and metastasis. Additionally, drugs that target microtubules, which REEP3 is predicted to bind to, are currently used to treat various types of cancer.",GO:0007084 mitotic nuclear membrane reassembly;GO:0101024 mitotic nuclear membrane organization;GO:0071786 endoplasmic reticulum tubular network organization,,,,,,
ENSG00000174903.16,ENSG00000174903,RAB1B,-0.75167018,-1.1569585,-0.966222845,-0.131829196,"RAB1B, member RAS oncogene family","RAB1B is a gene that belongs to the RAB protein family, which are small GTPases found on the surfaces of membrane-bound organelles in the cytoplasm. RAB1B plays a crucial role in the early secretory pathway by facilitating the transport of vesicles between the endoplasmic reticulum (ER) and Golgi. This gene is essential for proper cellular function and mutations in RAB1B have been linked to various diseases. Understanding the function of RAB1B and other RAB proteins can provide insight into the mechanisms of cellular transport and potentially lead to the development of new treatments for related disorders.","Mutations in RAB1B have been linked to various diseases, including cancer, neurodegenerative disorders, and infectious diseases. For example, RAB1B has been found to be overexpressed in several types of cancer, including lung, breast, and pancreatic cancer, and its inhibition has been shown to reduce tumor growth in preclinical models. Additionally, RAB1B has been implicated in the pathogenesis of Alzheimer's disease and Parkinson's disease, as well as viral infections such as hepatitis C and Zika virus.

Targeted drug discovery efforts for RAB1B are still in the early stages, but several approaches are being explored. One strategy is to develop small molecule inhibitors that can selectively target RAB1B and disrupt its function in disease states. Another approach is to use gene therapy to modulate RAB1B expression levels in specific tissues or cells.

Currently, there are no drugs on the market that specifically target RAB1B. However, there are several drugs that indirectly affect RAB1B function by targeting other proteins in the same pathway. For example, brefeldin A is a drug that inhibits the activity of the ARF protein, which is upstream of RAB1B in the secretory pathway. Brefeldin A has been used in research to study the role of RAB1B in cellular transport.",GO:1903020 positive regulation of glycoprotein metabolic process;GO:0019068 virion assembly;GO:2000785 regulation of autophagosome assembly,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Golgi apparatus (Supported); Additional: Endoplasmic reticulum,,,
ENSG00000138801.9,ENSG00000138801,PAPSS1,-0.751463572,-1.519707451,-0.727376649,-0.007306615,3'-phosphoadenosine 5'-phosphosulfate synthase 1,"PAPSS1 is a human gene that encodes for the enzyme 3'-phosphoadenosine 5'-phosphosulfate synthase 1. This enzyme is responsible for synthesizing the sulfate donor cosubstrate, three-prime-phosphoadenosine 5-prime-phosphosulfate (PAPS), which is used by all sulfotransferase (SULT) enzymes. SULTs are responsible for catalyzing the sulfate conjugation of many endogenous and exogenous compounds, including drugs and other xenobiotics. PAPS is synthesized from adenosine 5-prime triphosphate (ATP) and inorganic sulfate by two isoforms, PAPSS1 and PAPSS2.","Mutations in the PAPSS1 gene have been associated with several diseases, including brachyolmia, a rare skeletal disorder characterized by short-trunk dwarfism, scoliosis, and other skeletal abnormalities. Additionally, PAPSS1 has been implicated in the development and progression of certain cancers, including breast and prostate cancer. Targeted drug discovery efforts have focused on developing inhibitors of PAPSS1 as a potential therapeutic strategy for these diseases. However, there are currently no drugs on the market that specifically target PAPSS1. Some drugs, such as acetaminophen and minoxidil, are known to be metabolized by SULT enzymes that require PAPS as a cosubstrate, but they do not directly target PAPSS1. Further research is needed to fully understand the role of PAPSS1 in disease and to develop targeted therapies.",GO:0000103 sulfate assimilation;GO:0034036 purine ribonucleoside bisphosphate biosynthetic process;GO:0050428 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process,yes,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Mitotic chromosome;Nucleoli rim (Approved); Additional: Nucleoplasm,"Adenosine-5'-diphosphate-2',3'-vanadate; Adenosine 5'-phosphosulfate; Glycerin",,
ENSG00000164163.11,ENSG00000164163,ABCE1,-0.75140974,-0.964969054,-0.780757847,-0.508502321,ATP binding cassette subfamily E member 1,"ABCE1 is a human gene that belongs to the OABP subfamily of ATP-binding cassette (ABC) transporters. ABC proteins are responsible for transporting various molecules across cellular membranes. ABCE1 functions as an inhibitor of ribonuclease L, which is involved in the 2-5A/RNase L system, a pathway for viral interferon action. Inhibition of ribonuclease L leads to the prevention of protein synthesis. Two transcript variants of ABCE1 have been identified.","ABCE1 has been implicated in various diseases, including cancer, viral infections, and neurodegenerative disorders. In cancer, ABCE1 has been shown to be overexpressed in several types of tumors, including breast, lung, and prostate cancer. Targeting ABCE1 has been proposed as a potential therapeutic strategy for cancer treatment. In viral infections, ABCE1 plays a critical role in the replication of several viruses, including HIV, hepatitis C virus, and influenza virus. Therefore, ABCE1 inhibitors have been investigated as potential antiviral agents. However, no ABCE1-targeted drugs have been approved for clinical use yet. Several compounds have been identified as ABCE1 inhibitors, including rocaglamide, silvestrol, and hippuristanol. These compounds have shown promising results in preclinical studies, but further research is needed to determine their safety and efficacy in humans.",GO:0060701 negative regulation of ribonuclease activity;GO:0060702 negative regulation of endoribonuclease activity;GO:0060699 regulation of endoribonuclease activity,,Transporters:Primary Active Transporters; Predicted intracellular proteins,Cytosol (Enhanced),,,(M5926)HALLMARK MYC TARGETS V1; (M5950)HALLMARK ALLOGRAFT REJECTION
ENSG00000213676.13,ENSG00000213676,ATF6B,-0.751409699,-1.088854002,-0.650384893,-0.514990202,activating transcription factor 6 beta,"ATF6B is a gene that encodes a transcription factor involved in the unfolded protein response (UPR) pathway during endoplasmic reticulum (ER) stress. It can form a homodimer or heterodimer with ATF6-alpha and bind to the ER stress response element to activate UPR target genes. The protein is normally located in the membrane of the ER, but during ER stress, the N-terminal cytoplasmic domain is cleaved and moves to the nucleus. Two different isoforms of the protein have been identified.","ATF6B has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. In cancer, ATF6B has been shown to promote tumor growth and survival by regulating the expression of genes involved in cell proliferation and apoptosis. In neurodegenerative disorders, ATF6B has been linked to the accumulation of misfolded proteins in the ER, which can lead to neuronal cell death. In metabolic disorders, ATF6B has been shown to regulate lipid metabolism and insulin sensitivity.

Targeted drug discovery efforts for ATF6B are still in the early stages, but there is potential for developing drugs that modulate the UPR pathway to treat diseases associated with ER stress. One approach is to target the proteases that cleave ATF6B and other UPR transcription factors, which could prevent their activation and downstream effects. Another approach is to target specific UPR target genes that are involved in disease pathogenesis.

There are currently no drugs on the market that specifically target ATF6B, but there are drugs that indirectly modulate the UPR pathway. For example, tauroursodeoxycholic acid (TUDCA) is a bile acid derivative that has been shown to reduce ER stress and improve insulin sensitivity in animal models of diabetes. Another drug, 4-phenylbutyrate (4-PBA), is a chemical chaperone that can stabilize misfolded proteins and reduce ER stress in various disease models.",GO:1903892 negative regulation of ATF6-mediated unfolded protein response;GO:1903891 regulation of ATF6-mediated unfolded protein response;GO:0036500 ATF6-mediated unfolded protein response,,Transcription factors:Basic domains,Nucleoplasm (Supported); Additional: Nucleoli,,,
ENSG00000173120.15,ENSG00000173120,KDM2A,-0.750938886,-1.06330063,-0.641845619,-0.547670409,lysine demethylase 2A,"KDM2A is a gene that belongs to the Fbls class of the F-box protein family. It contains an F-box and at least six highly degenerated leucine-rich repeats. This gene plays a role in epigenetic silencing by nucleating at CpG islands and specifically demethylating both mono- and di-methylated lysine-36 of histone H3. The F-box proteins constitute one of the four subunits of ubiquitin protein ligase complex called SCFs, which function in phosphorylation-dependent ubiquitination. Alternative splicing results in multiple transcript variants.","KDM2A has been implicated in various diseases, including cancer, neurological disorders, and metabolic disorders. In cancer, KDM2A has been shown to promote tumor growth and metastasis by regulating the expression of genes involved in cell proliferation, apoptosis, and angiogenesis. Targeting KDM2A has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of KDM2A have been developed and tested in preclinical studies, showing promising results in inhibiting tumor growth and metastasis. However, no KDM2A inhibitors have been approved for clinical use yet. In addition, KDM2A has also been implicated in neurological disorders such as Alzheimer's disease and Huntington's disease, and metabolic disorders such as obesity and diabetes. Further research is needed to fully understand the role of KDM2A in these diseases and to develop effective therapies targeting this gene.",GO:0010944 negative regulation of transcription by competitive promoter binding;GO:0006303 double-strand break repair via nonhomologous end joining;GO:0032922 circadian regulation of gene expression,,Transcription factors:Zinc-coordinating DNA-binding domains; Enzymes; ENZYME proteins:Oxidoreductases; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000127511.10,ENSG00000127511,SIN3B,-0.750917144,-1.128083882,-0.571713023,-0.552954526,SIN3 transcription regulator family member B,"SIN3B is a human gene that is predicted to play a role in transcription corepressor activity, histone deacetylation, negative regulation of transcription by RNA polymerase II, and striated muscle tissue development. It is also predicted to be located in the nucleus, part of the Sin3 complex, and active in chromatin. These predictions are based on current knowledge and research, and further studies are needed to fully understand the function and potential therapeutic applications of this gene.","There is limited information available on the disease implications of SIN3B. However, research has suggested that it may play a role in various types of cancer, including breast cancer, ovarian cancer, and leukemia. Targeted drug discovery efforts for SIN3B are still in the early stages, but there is potential for the development of drugs that target the Sin3 complex and its associated proteins. Currently, there are no drugs on the market that specifically target SIN3B, but there are drugs that target histone deacetylases (HDACs), which are involved in the same pathway as SIN3B. Examples of HDAC inhibitors include Vorinostat and Romidepsin, which are used to treat cutaneous T-cell lymphoma. Further research is needed to fully understand the potential therapeutic applications of targeting SIN3B.",GO:0030336 negative regulation of cell migration;GO:2000146 negative regulation of cell motility;GO:0040013 negative regulation of locomotion,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Plasma membrane,,(M219)PID HEDGEHOG GLI PATHWAY; (M101)PID HDAC CLASSI PATHWAY; (M105)PID TELOMERASE PATHWAY,
ENSG00000141084.11,ENSG00000141084,RANBP10,-0.750127055,-1.106042611,-0.882983243,-0.261355312,RAN binding protein 10,RAN binding protein 10 (RANBP10) is a cytoplasmic guanine nucleotide exchange factor (GEF) that binds beta-tubulin and has GEF activity toward RAN. RAN is a small GTPase involved in the assembly of microtubules to form mitotic spindles. RANBP10 plays a role in the formation of noncentrosomal microtubules and may be involved in the regulation of D(1) receptor signaling by protein kinase C delta and protein kinase C gamma. The gene encoding RANBP10 has several transcript variants that encode different isoforms.,"There is limited information available on the disease implications of RANBP10. However, recent studies have suggested that RANBP10 may play a role in cancer progression. For example, RANBP10 has been found to be overexpressed in breast cancer and may contribute to tumor growth and metastasis. Targeted drug discovery efforts for RANBP10 are currently limited, but there is potential for the development of drugs that target RANBP10's GEF activity or its interaction with beta-tubulin. Currently, there are no drugs on the market that specifically target RANBP10. However, there are drugs that target microtubules, such as taxanes and vinca alkaloids, which indirectly affect RANBP10's function in microtubule assembly. Additionally, protein kinase C inhibitors, which may regulate RANBP10's role in D(1) receptor signaling, are being investigated as potential cancer therapies.",GO:0007010 cytoskeleton organization;GO:0006996 organelle organization;GO:0016043 cellular component organization,,Predicted intracellular proteins,,,(M48)PID MET PATHWAY,(M5945)HALLMARK HEME METABOLISM
ENSG00000109079.10,ENSG00000109079,TNFAIP1,-0.750081242,-1.07909501,-1.001627389,-0.169521326,TNF alpha induced protein 1,"TNFAIP1 is a gene that is induced by the cytokine tumor necrosis factor alpha (TNF) in endothelial cells of the umbilical vein. The expression of this gene is regulated in a tissue-specific manner during development, as observed in studies of a similar gene in mice. The function of TNFAIP1 is not fully understood, but it has been implicated in various cellular processes, including apoptosis, inflammation, and immune response. Further research is needed to fully elucidate the role of TNFAIP1 in human biology and disease.","TNFAIP1 has been implicated in various diseases, including cancer, cardiovascular disease, and autoimmune disorders. In cancer, TNFAIP1 has been shown to promote tumor growth and metastasis in several types of cancer, including breast, lung, and pancreatic cancer. Targeting TNFAIP1 may therefore be a promising strategy for cancer therapy. In cardiovascular disease, TNFAIP1 has been linked to atherosclerosis and vascular inflammation, suggesting that it may be a potential therapeutic target for these conditions. In autoimmune disorders, TNFAIP1 has been shown to regulate the activity of immune cells, suggesting that it may be involved in the pathogenesis of these diseases.

There are currently no drugs on the market that specifically target TNFAIP1. However, there have been efforts to develop drugs that target TNF, the cytokine that induces TNFAIP1 expression. TNF inhibitors, such as infliximab and adalimumab, are used to treat autoimmune disorders such as rheumatoid arthritis and Crohn's disease. These drugs have been successful in reducing inflammation and improving symptoms in patients. However, they can have side effects, such as increased risk of infections and malignancies.

In conclusion, TNFAIP1 is a gene with diverse functions in various cellular processes and disease pathogenesis. While there are currently no drugs that specifically target TNFAIP1, targeting TNF, the cytokine that induces its expression, has been successful in treating autoimmune disorders. Further research is needed to fully understand the role of TNFAIP1 in disease and to develop targeted therapies for its modulation.",GO:0030038 contractile actin filament bundle assembly;GO:0043149 stress fiber assembly;GO:0035024 negative regulation of Rho protein signal transduction,,Predicted intracellular proteins,Nucleoli (Approved),,,
ENSG00000151348.15,ENSG00000151348,EXT2,-0.749637655,-1.41696488,-0.40358091,-0.428367176,exostosin glycosyltransferase 2,"The EXT2 gene is responsible for encoding one of two glycosyltransferases that play a role in the elongation of heparan sulfate biosynthesis. Mutations in this gene have been linked to the type II form of multiple exostoses, a rare genetic disorder characterized by the development of bony growths on the surface of bones. Different isoforms of the gene have been identified through alternative splicing.","Multiple exostoses (ME), also known as hereditary multiple osteochondromas, is a rare genetic disorder caused by mutations in the EXT1 or EXT2 genes. These mutations lead to the development of benign bone tumors, or exostoses, which can cause pain, deformity, and growth retardation. There is currently no cure for ME, and treatment is focused on managing symptoms and preventing complications. Targeted drug discovery efforts for ME have focused on developing therapies that can inhibit the activity of the glycosyltransferases encoded by the EXT1 and EXT2 genes, which are involved in the biosynthesis of heparan sulfate. Several drugs have been developed that target these enzymes, including heparin, which is used to prevent blood clots, and idursulfase, which is used to treat the lysosomal storage disorder mucopolysaccharidosis II. However, these drugs have not been specifically approved for the treatment of ME, and more research is needed to develop targeted therapies for this rare disease.","GO:0015014 heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process;GO:0030210 heparin biosynthetic process;GO:0030202 heparin metabolic process",,Predicted intracellular proteins; Cancer-related genes; ENZYME proteins:Transferases; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Disease related genes; Enzymes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism,Golgi apparatus (Supported),,,(M5937)HALLMARK GLYCOLYSIS
ENSG00000102606.18,ENSG00000102606,ARHGEF7,-0.749509257,-0.799276043,-0.820605769,-0.628645958,Rho guanine nucleotide exchange factor 7,ARHGEF7 is a human gene that encodes a cytoplasmic protein that activates the Rho family of proteins by exchanging bound GDP for GTP. It forms a complex with the small GTP binding protein Rac1 and recruits Rac1 to membrane ruffles and focal adhesions. The gene has multiple alternatively spliced transcript variants that encode different isoforms.,"ARHGEF7 has been implicated in several diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, ARHGEF7 has been shown to promote tumor growth and metastasis by activating Rac1 and other Rho family proteins. In cardiovascular disease, ARHGEF7 has been linked to hypertension and atherosclerosis. In neurological disorders, ARHGEF7 has been associated with schizophrenia and bipolar disorder.

Targeted drug discovery efforts for ARHGEF7 have focused on developing small molecule inhibitors that can block its activity and prevent the activation of Rac1 and other Rho family proteins. One example is the drug EHT 1864, which has been shown to inhibit ARHGEF7 and reduce tumor growth in preclinical models of cancer.

Another example is the drug fasudil, which is a Rho kinase inhibitor that indirectly inhibits ARHGEF7 by blocking downstream signaling pathways. Fasudil is used clinically to treat cerebral vasospasm and has shown promise in preclinical models of cancer and cardiovascular disease.

Overall, targeting ARHGEF7 and its downstream signaling pathways represents a promising approach for the development of novel therapeutics for cancer, cardiovascular disease, and neurological disorders.",GO:1905833 negative regulation of microtubule nucleation;GO:2000394 positive regulation of lamellipodium morphogenesis;GO:2000392 regulation of lamellipodium morphogenesis,,Predicted intracellular proteins,,,(M83)PID CDC42 REG PATHWAY; (M242)PID AURORA A PATHWAY; (M241)PID RAC1 REG PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000170275.15,ENSG00000170275,CRTAP,-0.749306635,-1.418862319,-0.638425592,-0.190631994,cartilage associated protein,"The human gene CRTAP encodes a scaffolding protein that is similar to the CRTAP genes found in chickens and mice. This protein may affect the activity of a member of the cytohesin/ARNO family in response to certain cellular stimuli. Mutations in this gene have been linked to osteogenesis imperfecta, a connective tissue disorder that causes bone fragility and low bone mass.","Osteogenesis imperfecta (OI) is a rare genetic disorder caused by mutations in genes involved in the production of collagen, a protein that provides strength and structure to bones and other connective tissues. CRTAP is one of the genes associated with OI, and mutations in this gene can lead to a severe form of the disease. There are currently no targeted drug therapies available for OI, and treatment is focused on managing symptoms and preventing fractures. However, there are ongoing efforts to develop drugs that can improve bone strength and reduce the risk of fractures in OI patients. One example is the drug denosumab, which has been shown to increase bone density and reduce fractures in OI patients. Another potential drug target is sclerostin, a protein that inhibits bone formation, and several drugs that target sclerostin are currently in clinical trials for OI and other bone disorders.",GO:0030199 collagen fibril organization;GO:0061077 chaperone-mediated protein folding;GO:1901874 negative regulation of post-translational protein modification,,Disease related genes; Predicted secreted proteins; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system,Actin filaments;Cytosol;Intermediate filaments (Approved),,,
ENSG00000205189.12,ENSG00000205189,ZBTB10,-0.747911371,-1.528510138,-0.646938961,-0.068285014,zinc finger and BTB domain containing 10,"ZBTB10 is a human gene that encodes a protein containing both zinc finger and BTB domains. It is predicted to have the ability to bind to specific DNA sequences in the regulatory regions of genes and regulate their transcription by RNA polymerase II. ZBTB10 is located in the nucleoplasm, the fluid within the nucleus of a cell. Its exact function and role in human biology are still being studied.","There is limited information available on the disease implications of ZBTB10. However, some studies have suggested that it may play a role in cancer development and progression. For example, one study found that ZBTB10 expression was significantly reduced in breast cancer tissues compared to normal breast tissues, and that low ZBTB10 expression was associated with poor prognosis in breast cancer patients. 

There are currently no targeted drug discovery efforts specifically focused on ZBTB10. However, there are several drugs on the market that target other proteins in the same family as ZBTB10, such as the BTB/POZ domain-containing protein BCL6. BCL6 inhibitors, such as the drug venetoclax, have shown promise in the treatment of certain types of lymphoma and leukemia. 

Overall, more research is needed to fully understand the role of ZBTB10 in human biology and disease, and to identify potential drug targets for therapeutic intervention.",GO:0000122 negative regulation of transcription by RNA polymerase II;GO:0045892 negative regulation of DNA-templated transcription;GO:1902679 negative regulation of RNA biosynthetic process,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,(M5908)HALLMARK ANDROGEN RESPONSE; (M5890)HALLMARK TNFA SIGNALING VIA NFKB
ENSG00000164331.10,ENSG00000164331,ANKRA2,-0.747499225,-0.600696469,-0.846255055,-0.795546152,ankyrin repeat family A member 2,"ANKRA2, also known as ankyrin repeat family A member 2, is a human gene that encodes a protein involved in the regulation of protein-containing complex assembly. The protein is located in both the cytosol and membrane and is part of a protein-containing complex. ANKRA2 enables enzyme binding activity and low-density lipoprotein particle receptor binding activity. It colocalizes with the 3M complex. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of ANKRA2. However, some studies have suggested that ANKRA2 may play a role in the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ANKRA2 are also limited, as the function of the protein is not well understood. Currently, there are no drugs on the market that specifically target ANKRA2. However, there are drugs that target other proteins involved in protein-containing complex assembly, such as proteasome inhibitors, which are used to treat multiple myeloma and other cancers. Further research is needed to fully understand the role of ANKRA2 in disease and to develop targeted therapies.",GO:0043254 regulation of protein-containing complex assembly;GO:0044087 regulation of cellular component biogenesis;GO:0051128 regulation of cellular component organization,,Predicted intracellular proteins,Plasma membrane (Supported); Additional: Cell Junctions;Nucleoplasm,,(M30)PID HDAC CLASSII PATHWAY,(M5939)HALLMARK P53 PATHWAY
ENSG00000205339.10,ENSG00000205339,IPO7,-0.747258843,-1.15880473,-0.808508135,-0.274463663,importin 7,"IPO7, also known as importin 7, is a protein involved in the transport of other proteins into the nucleus of a cell. It forms a complex with importin-alpha/beta and the GTPase Ran to facilitate the nuclear import of proteins with a nuclear localization signal. IPO7 is one of approximately 20 potential targets of Ran that share a sequence motif related to the Ran-binding site of importin-beta. It inhibits nucleotide exchange on RanGTP and competes with importin-beta and transportin for binding sites on nuclear pore complexes. IPO7 has a Ran-dependent transport cycle and can move rapidly in both directions across the nuclear envelope. It is also involved in the import of ribosomal proteins.","There is limited information available on the disease implications of IPO7. However, recent studies have suggested that IPO7 may play a role in cancer progression and metastasis. IPO7 has been found to be overexpressed in several types of cancer, including breast, lung, and pancreatic cancer. Targeted drug discovery efforts for IPO7 are currently underway, with a focus on developing small molecule inhibitors that can selectively target IPO7 and inhibit its function. While there are currently no drugs on the market that specifically target IPO7, several drugs that target related proteins involved in nuclear transport, such as importin-beta and CRM1, have been approved for the treatment of cancer. Examples of these drugs include selinexor, which targets CRM1, and alisertib, which targets Aurora kinase A and indirectly affects nuclear transport.",GO:1901331 positive regulation of odontoblast differentiation;GO:1902913 positive regulation of neuroepithelial cell differentiation;GO:1901329 regulation of odontoblast differentiation,,Transporters:Transporter channels and pores; Cancer-related genes:Mutated cancer genes; Predicted intracellular proteins,Cytosol;Nucleoplasm (Supported),,,(M5925)HALLMARK E2F TARGETS
ENSG00000103365.15,ENSG00000103365,GGA2,-0.746817133,-1.409131343,-0.483719924,-0.347600132,"golgi associated, gamma adaptin ear containing, ARF binding protein 2","GGA2 is a gene that belongs to the Golgi-localized, gamma adaptin ear-containing, ARF-binding (GGA) family. This family of proteins regulates the trafficking of proteins between the trans-Golgi network and the lysosome. GGA2 contains an amino-terminal VHS domain that sorts mannose 6-phosphate receptors at the trans-Golgi network and a carboxy-terminal region with homology to the ear domain of gamma-adaptins. GGA2 is involved in the regulation of cargo molecules and clathrin-coated vesicle assembly. Its function is essential for the proper functioning of the Golgi apparatus and the lysosome.","There is limited information available on the disease implications of GGA2. However, recent studies have suggested that GGA2 may play a role in the pathogenesis of Alzheimer's disease. Specifically, GGA2 has been shown to regulate the trafficking of amyloid precursor protein (APP) and beta-secretase (BACE1), which are both involved in the production of amyloid beta, a key component of Alzheimer's disease pathology. Targeted drug discovery efforts for GGA2 are currently limited, but there is potential for the development of drugs that modulate GGA2 function to treat Alzheimer's disease. Currently, there are no drugs on the market that specifically target GGA2. However, there are several drugs that target the production or aggregation of amyloid beta, such as aducanumab and solanezumab, which have shown promise in clinical trials for the treatment of Alzheimer's disease.",GO:0034394 protein localization to cell surface;GO:0043001 Golgi to plasma membrane protein transport;GO:0061951 establishment of protein localization to plasma membrane,,Predicted intracellular proteins,Golgi apparatus (Enhanced),,,(M5924)HALLMARK MTORC1 SIGNALING
ENSG00000131263.13,ENSG00000131263,RLIM,-0.746555425,-1.215964547,-0.652065885,-0.371635842,"ring finger protein, LIM domain interacting","RLIM is a human gene that encodes a RING-H2 zinc finger protein. It acts as an E3 ubiquitin protein ligase that targets LIM domain binding 1 (LDB1/CLIM) and causes its proteasome-dependent degradation. RLIM and LDB1 are co-repressors of LHX1/LIM-1, a homeodomain transcription factor. Multiple variants of RLIM have been identified, but they all encode the same protein. This gene is important in regulating gene expression and may have implications in various diseases.","RLIM has been implicated in various diseases, including cancer, neurological disorders, and developmental disorders. In cancer, RLIM has been shown to regulate the expression of tumor suppressor genes and oncogenes, making it a potential target for cancer therapy. In neurological disorders, RLIM has been linked to the regulation of synaptic plasticity and neuronal development, suggesting a role in diseases such as Alzheimer's and Parkinson's. In developmental disorders, mutations in RLIM have been associated with X-linked intellectual disability and developmental delay.

There are currently no drugs on the market that specifically target RLIM. However, there have been efforts to develop drugs that target the ubiquitin-proteasome system, which is the pathway through which RLIM mediates its effects. Proteasome inhibitors such as bortezomib and carfilzomib have been approved for the treatment of multiple myeloma and mantle cell lymphoma, and are being investigated for use in other types of cancer.

In addition, there is ongoing research into the development of small molecule inhibitors of E3 ubiquitin ligases, including RLIM. These inhibitors have the potential to be used in the treatment of various diseases, including cancer and neurological disorders. However, more research is needed to fully understand the role of RLIM in these diseases and to develop effective targeted therapies.",GO:0060816 random inactivation of X chromosome;GO:0009048 dosage compensation by inactivation of X chromosome;GO:0007549 sex-chromosome dosage compensation,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000072062.15,ENSG00000072062,PRKACA,-0.745755967,-1.456808376,-0.591629572,-0.188829952,protein kinase cAMP-activated catalytic subunit alpha,"PRKACA is a gene that encodes one of the catalytic subunits of protein kinase A, which is important in many cellular processes such as differentiation, proliferation, and apoptosis. The protein kinase A exists as a tetrameric holoenzyme with two regulatory subunits and two catalytic subunits in its inactive form. When cAMP is present, it causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Constitutive activation of this gene caused by somatic mutations or genomic duplications has been associated with hyperplasias and adenomas of the adrenal cortex and is linked to corticotropin-independent Cushing's syndrome. Alternative splicing results in multiple transcript variants encoding different isoforms.","As mentioned earlier, mutations in the PRKACA gene have been linked to corticotropin-independent Cushing's syndrome, a rare endocrine disorder characterized by excessive cortisol production. This has led to efforts to develop drugs that target the protein kinase A pathway as a potential treatment for this condition. One such drug is relacorilant, a selective glucocorticoid receptor antagonist that has shown promising results in clinical trials for the treatment of Cushing's syndrome. Another drug, osilodrostat, is a potent inhibitor of 11?-hydroxylase, an enzyme involved in cortisol synthesis, and has also shown efficacy in clinical trials for Cushing's syndrome. In addition to Cushing's syndrome, protein kinase A has been implicated in a variety of other diseases, including cancer, cardiovascular disease, and neurological disorders, making it a promising target for drug discovery efforts in these areas as well.",GO:1904538 regulation of glycolytic process through fructose-6-phosphate;GO:1904539 negative regulation of glycolytic process through fructose-6-phosphate;GO:1990044 protein localization to lipid droplet,yes,Predicted intracellular proteins; Cancer-related genes; ENZYME proteins:Transferases; Human disease related genes:Endocrine and metabolic diseases:Adrenal gland diseases; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Kinases:AGC Ser/Thr protein kinases; Enzymes; RAS pathway related proteins,Cytosol (Uncertain); Additional: Basal body;Cytokinetic bridge;Microtubules;Primary cilium,"Pentanal; Balanol Analog 2; 3-[(3-sec-butyl-4-hydroxybenzoyl)amino]azepan-4-yl 4-(2-hydroxy-5-methoxybenzoyl)benzoate; Phosphonothreonine; Balanol Analog 1; 3,5-Diiodotyrosine; Balanol; Dexfosfoserine; S,S-(2-Hydroxyethyl)Thiocysteine; Hydroxyfasudil; (2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine; (2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine; (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE; (2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE; (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE; N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE; 3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione; (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE; N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE; (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE; 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE; (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine; (2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine; 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE; (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE; (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE; ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE; H-89; 5-(2-methylpiperazine-1-sulfonyl)isoquinoline; N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE; 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE; (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE; 3-pyridin-4-yl-1H-indazole; 5-benzyl-1,3-thiazol-2-amine; 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine; 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine; 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium; Fasudil; Myristic acid; A-674563; 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE; Y-27632; Ellagic acid; Fostamatinib",(M56)PID LPA4 PATHWAY; (M182)PID IL3 PATHWAY; (M226)PID VEGFR1 PATHWAY,(M5941)HALLMARK UV RESPONSE UP
ENSG00000173575.22,ENSG00000173575,CHD2,-0.745383014,-0.944139184,-0.855107653,-0.436902205,chromodomain helicase DNA binding protein 2,"CHD2 is a human gene that encodes for the chromodomain helicase DNA binding protein 2. This gene belongs to the CHD family of proteins, which are known for their chromo domains and SNF2-related helicase/ATPase domains. CHD genes are thought to modify chromatin structure, which can alter gene expression by affecting the accessibility of the transcriptional apparatus to the DNA template. The CHD2 gene has multiple isoforms due to alternative splicing.","Mutations in the CHD2 gene have been associated with several neurological disorders, including autism spectrum disorder (ASD), epilepsy, and intellectual disability. Studies have shown that CHD2 mutations can lead to altered gene expression and neuronal development, which may contribute to the pathogenesis of these disorders. Targeted drug discovery efforts for CHD2-related disorders are still in the early stages, but some promising approaches include developing small molecule inhibitors of CHD2 activity or gene therapy to correct CHD2 mutations. Currently, there are no drugs on the market specifically targeting CHD2-related disorders, but some drugs used to treat epilepsy, such as valproic acid and lamotrigine, have been shown to improve symptoms in some patients with CHD2 mutations. Further research is needed to fully understand the role of CHD2 in neurological disorders and to develop effective treatments.",GO:0060218 hematopoietic stem cell differentiation;GO:0032508 DNA duplex unwinding;GO:0032392 DNA geometric change,,Human disease related genes:Nervous system diseases:Epilepsy; Predicted intracellular proteins; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Nucleoplasm (Enhanced),,,
ENSG00000162378.13,ENSG00000162378,ZYG11B,-0.745309813,-1.141959501,-0.635949444,-0.458020496,"zyg-11 family member B, cell cycle regulator",ZYG11B is a human gene that belongs to the zyg-11 family and acts as a regulator of the cell cycle. It plays a role in the positive regulation of the proteasomal ubiquitin-dependent protein catabolic process and protein quality control for misfolded or incompletely synthesized proteins. ZYG11B is also a part of the Cul2-RING ubiquitin ligase complex. This gene's function is essential for maintaining proper protein turnover and quality control in cells.,"There is limited information available on the disease implications of ZYG11B. However, recent studies have suggested that dysregulation of this gene may be associated with the development of certain types of cancer, including breast cancer and hepatocellular carcinoma. As a result, there has been some interest in targeting ZYG11B for drug discovery efforts aimed at developing new cancer therapies. 

One potential approach is to develop small molecule inhibitors that can disrupt the function of the Cul2-RING ubiquitin ligase complex, of which ZYG11B is a part. This could potentially lead to the accumulation of misfolded or incompletely synthesized proteins, which could trigger cell death in cancer cells. 

Currently, there are no drugs on the market that specifically target ZYG11B. However, there are several drugs that target other components of the ubiquitin-proteasome system, which is closely related to ZYG11B's function. For example, bortezomib is a proteasome inhibitor that is used to treat multiple myeloma, while carfilzomib is a newer proteasome inhibitor that is also used to treat multiple myeloma. These drugs have shown promising results in clinical trials and have been approved for use in certain cancer patients.",GO:0006515 protein quality control for misfolded or incompletely synthesized proteins;GO:0032436 positive regulation of proteasomal ubiquitin-dependent protein catabolic process;GO:2000060 positive regulation of ubiquitin-dependent protein catabolic process,,Predicted intracellular proteins,Golgi apparatus;Intermediate filaments (Approved),,,
ENSG00000095574.12,ENSG00000095574,IKZF5,-0.7450441,-0.783327346,-0.891816683,-0.559988271,IKAROS family zinc finger 5,"IKZF5 is a gene that belongs to the Ikaros family of transcription factors. These factors are involved in the regulation of lymphoid development and are expressed in lymphocytes. IKZF5 is also known as IKAROS family zinc finger 5. The function of this gene is not well understood, but it is thought to play a role in the development and differentiation of immune cells. Mutations in IKZF5 have been associated with various diseases, including autoimmune disorders and cancer. Further research is needed to fully understand the role of IKZF5 in human health and disease.","There is limited information available on the disease implications of IKZF5, and no targeted drug discovery efforts have been reported for this gene. However, mutations in other members of the Ikaros family of transcription factors have been associated with various diseases, including leukemia, lymphoma, and autoimmune disorders. It is possible that IKZF5 may also play a role in these diseases, but further research is needed to confirm this. Currently, there are no drugs on the market that specifically target IKZF5. However, there are drugs that target other members of the Ikaros family, such as the BTK inhibitor ibrutinib, which is used to treat certain types of leukemia and lymphoma.",GO:0000122 negative regulation of transcription by RNA polymerase II;GO:0045892 negative regulation of DNA-templated transcription;GO:1902679 negative regulation of RNA biosynthetic process,,Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Predicted intracellular proteins; Transcription factors:Zinc-coordinating DNA-binding domains,Nucleoplasm (Supported); Additional: Cytosol;Plasma membrane,,,
ENSG00000163939.18,ENSG00000163939,PBRM1,-0.744823282,-0.986940846,-0.803312754,-0.444216247,polybromo 1,"PBRM1 (polybromo 1) is a gene that encodes a subunit of ATP-dependent chromatin-remodeling complexes. This protein is an essential component of complexes required for ligand-dependent transcriptional activation by nuclear hormone receptors. Mutations in this gene have been linked to primary clear cell renal cell carcinoma, a type of kidney cancer. The PBRM1 gene is important for regulating gene expression and maintaining the structure of chromatin, the material that makes up chromosomes. Dysfunction of this gene can lead to the development of cancer.","Primary clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer, and PBRM1 is one of the most frequently mutated genes in ccRCC. Studies have shown that PBRM1 mutations are associated with a better prognosis and response to immunotherapy in ccRCC patients. Targeted drug discovery efforts have focused on developing inhibitors of chromatin-remodeling complexes that contain PBRM1, as well as drugs that target other genes and pathways that are dysregulated in ccRCC. One example of a successful drug on the market is cabozantinib, which targets multiple receptor tyrosine kinases including MET, VEGFR, and AXL, and has been approved for the treatment of advanced ccRCC. Another example is nivolumab, an immune checkpoint inhibitor that has shown promising results in clinical trials for ccRCC patients with PBRM1 mutations.",GO:2000819 regulation of nucleotide-excision repair;GO:0070316 regulation of G0 to G1 transition;GO:0006368 transcription elongation by RNA polymerase II,,Predicted intracellular proteins; Human disease related genes:Cancers:Cancers of the urinary system; Transcription factors:Other all-alpha-helical DNA-binding domains; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Nucleoplasm (Enhanced),,,
ENSG00000163872.16,ENSG00000163872,YEATS2,-0.743018948,-1.086695005,-0.64601365,-0.496348188,YEATS domain containing 2,YEATS2 is a gene that encodes a protein that acts as a scaffolding subunit of the ATAC complex. This complex has acetyltransferase activity on histones H3 and H4. Alternative splicing of the gene results in multiple transcript variants that encode different isoforms. The function of this gene is important in regulating gene expression and chromatin structure.,"Research on the YEATS2 gene has revealed its potential implications in various diseases. For instance, studies have shown that mutations in the gene are associated with certain types of cancer, including breast and lung cancer. Additionally, dysregulation of the ATAC complex, which YEATS2 is a part of, has been linked to neurodegenerative disorders such as Alzheimer's disease. As a result, there is growing interest in developing drugs that target YEATS2 and the ATAC complex as a potential therapeutic strategy for these diseases.

Several drug discovery efforts have been focused on targeting the YEATS2 protein and the ATAC complex. One approach involves developing small molecule inhibitors that can selectively target the acetyltransferase activity of the complex. Another strategy is to target the protein-protein interactions between YEATS2 and other subunits of the complex. These efforts have shown promising results in preclinical studies, and some compounds are currently in clinical trials.

One example of a successful drug that targets the ATAC complex is vorinostat, which is used to treat cutaneous T-cell lymphoma. Vorinostat inhibits the activity of histone deacetylases, which leads to increased acetylation of histones and altered gene expression. While vorinostat does not directly target YEATS2, it highlights the potential of targeting chromatin-modifying enzymes as a therapeutic strategy. Overall, the research on YEATS2 and the ATAC complex has opened up new avenues for drug discovery and has the potential to lead to novel treatments for various diseases.",GO:0090043 regulation of tubulin deacetylation;GO:0090311 regulation of protein deacetylation;GO:0045995 regulation of embryonic development,,Disease related genes; Human disease related genes:Nervous system diseases:Epilepsy; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000111269.3,ENSG00000111269,CREBL2,-0.742555341,-1.019301463,-0.88576231,-0.322602252,cAMP responsive element binding protein like 2,"CREBL2 is a gene located on chromosome 12p13 that encodes a protein with DNA binding capabilities. It shares a 41% identity with CRE-binding protein (CREB) over a 48-base long region which encodes the bZip domain of CREB. The bZip domain consists of about 30 amino acids rich in basic residues involved in DNA binding, followed by a leucine zipper motif involved in protein dimerization. CREBL2 is frequently deleted in hematopoietic malignancies, as well as breast, non-small-cell lung and ovarian cancers, suggesting that it may act as a tumor suppressor gene.","There is limited information available on the disease implications of CREBL2. However, studies have shown that it is frequently deleted in various types of cancers, including hematopoietic malignancies, breast, non-small-cell lung, and ovarian cancers, suggesting that it may act as a tumor suppressor gene. As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target CREBL2. However, there are ongoing efforts to develop drugs that target other tumor suppressor genes and pathways that may be affected by CREBL2 deletion. For example, drugs that target the p53 pathway, such as Nutlin-3 and PRIMA-1, have shown promise in preclinical studies and clinical trials for various types of cancers. Additionally, drugs that target the PI3K/AKT/mTOR pathway, such as everolimus and temsirolimus, have been approved for the treatment of certain types of cancers and may also be effective in tumors with CREBL2 deletion.",GO:0046326 positive regulation of D-glucose import;GO:0010828 positive regulation of D-glucose transmembrane transport;GO:0033138 positive regulation of peptidyl-serine phosphorylation,,Transcription factors:Basic domains; Predicted intracellular proteins,Mitochondria (Approved); Additional: Cytosol;Nucleoplasm,,,
ENSG00000142599.19,ENSG00000142599,RERE,-0.742506655,-1.317575233,-0.761554475,-0.148390256,arginine-glutamic acid dipeptide repeats,"The human gene RERE belongs to the atrophin family of proteins and contains arginine-glutamic acid (RE) dipeptide repeats. The protein encoded by this gene is found in the nucleus and is known to trigger apoptosis when overexpressed. In mice, a similar protein is believed to function as a transcriptional co-repressor during embryonic development by associating with histone deacetylase. Multiple transcript variants encoding different isoforms have been identified for this gene.","Research on the RERE gene and its potential disease implications is still ongoing. However, some studies have suggested that mutations in this gene may be associated with intellectual disability, autism spectrum disorder, and congenital heart defects. Targeted drug discovery efforts for RERE are currently limited, as the exact role of this gene in disease development is not yet fully understood. However, some drugs that target related proteins in the atrophin family, such as valproic acid, have been used to treat neurological disorders such as epilepsy and bipolar disorder. Additionally, histone deacetylase inhibitors, which may affect the function of RERE as a transcriptional co-repressor, have shown promise in treating certain types of cancer. Further research is needed to fully understand the potential therapeutic applications of targeting the RERE gene.",GO:0021691 cerebellar Purkinje cell layer maturation;GO:0021590 cerebellum maturation;GO:0021699 cerebellar cortex maturation,,Predicted intracellular proteins; Transcription factors:Helix-turn-helix domains; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Disease related genes; Transcription factors:Zinc-coordinating DNA-binding domains,Nuclear bodies (Supported); Additional: Nucleoplasm,,,
ENSG00000113595.15,ENSG00000113595,TRIM23,-0.741832532,-0.837442388,-0.834828668,-0.553226539,tripartite motif containing 23,"TRIM23 is a human gene that belongs to the tripartite motif (TRIM) family and the ADP ribosylation factor family of guanine nucleotide-binding proteins. It contains three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. The protein localizes to lysosomes and the Golgi apparatus and plays a role in the formation of intracellular transport vesicles, their movement from one compartment to another, and phopholipase D activation. The gene has three alternatively spliced transcript variants.","Research on TRIM23 has revealed its potential involvement in various diseases, including cancer, viral infections, and neurodegenerative disorders. In cancer, TRIM23 has been shown to act as a tumor suppressor by regulating cell proliferation and apoptosis. In viral infections, TRIM23 has been found to play a role in the innate immune response by inhibiting viral replication. In neurodegenerative disorders, TRIM23 has been implicated in the regulation of autophagy, a process that removes damaged proteins and organelles from cells.

Targeted drug discovery efforts for TRIM23 are still in the early stages, but there is potential for the development of drugs that modulate its activity in various diseases. For example, small molecule inhibitors of TRIM23 could be developed for the treatment of cancer, while activators of TRIM23 could be useful in the treatment of viral infections.

Currently, there are no drugs on the market that specifically target TRIM23. However, there are drugs that indirectly affect TRIM23 activity. For example, the cancer drug bortezomib has been shown to increase TRIM23 expression and promote its tumor suppressor activity. Additionally, the antiviral drug ribavirin has been found to induce TRIM23 expression and inhibit viral replication.",GO:0010508 positive regulation of autophagy;GO:0010506 regulation of autophagy;GO:0006886 intracellular protein transport,,Enzymes; Cancer-related genes:Mutated cancer genes; Predicted intracellular proteins; ENZYME proteins:Transferases,,,,
ENSG00000187866.10,ENSG00000187866,FAM122A,-0.741396954,-1.162714344,-0.87909168,-0.182384839,PP2A Aalpha (PPP2R1A) and B55A (PPP2R2A) interacting phosphatase regulator 1,"PABIR1 is a human gene that encodes a protein that interacts with two subunits of a protein phosphatase complex, PP2A Aalpha and B55A. This protein acts as an inhibitor of protein serine/threonine phosphatase activity and is involved in several cellular processes, including the regulation of cell growth and the proteasomal degradation of proteins. PABIR1 is located in both the cytoplasm and nucleus of cells and plays a role in the mitotic G2/M transition checkpoint.","There is limited information available on the disease implications of PABIR1. However, recent studies have suggested that PABIR1 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for PABIR1 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target PABIR1, several drugs that target protein phosphatases, including PP2A, have been approved for the treatment of various types of cancer. Examples of these drugs include okadaic acid, fostriecin, and LB-100.",GO:0044818 mitotic G2/M transition checkpoint;GO:0010972 negative regulation of G2/M transition of mitotic cell cycle;GO:1902750 negative regulation of cell cycle G2/M phase transition,,Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Supported),,,
ENSG00000151292.17,ENSG00000151292,CSNK1G3,-0.741378325,-0.628047925,-0.56974385,-1.026343199,casein kinase 1 gamma 3,CSNK1G3 is a gene that encodes a protein kinase that phosphorylates caseins and other acidic proteins. It is a member of a family of serine/threonine protein kinases. The protein is involved in the transmission of Wnt/beta-catenin signaling in African clawed frogs. Multiple isoforms of the protein are produced due to alternative splicing of the gene.,"Research on CSNK1G3 has revealed its potential involvement in various diseases, including cancer, Alzheimer's disease, and schizophrenia. In cancer, CSNK1G3 has been shown to play a role in the regulation of cell proliferation and survival, making it a potential target for cancer therapy. In Alzheimer's disease, the protein has been implicated in the regulation of tau protein phosphorylation, which is a hallmark of the disease. In schizophrenia, CSNK1G3 has been linked to the regulation of dopamine signaling, which is disrupted in the disease.

Targeted drug discovery efforts for CSNK1G3 are ongoing, with a focus on developing small molecule inhibitors of the protein kinase. One example is the development of a CSNK1G3 inhibitor for the treatment of breast cancer, which has shown promising results in preclinical studies. Another example is the development of a CSNK1G3 inhibitor for the treatment of Alzheimer's disease, which is currently in early-stage clinical trials.

There are currently no drugs on the market that specifically target CSNK1G3, but there are drugs that indirectly affect its activity. For example, lithium, which is used to treat bipolar disorder, has been shown to inhibit CSNK1G3 activity. Additionally, the cancer drug sorafenib has been shown to inhibit CSNK1G3 in preclinical studies, although its primary target is a different protein kinase.",GO:0090263 positive regulation of canonical Wnt signaling pathway;GO:0030177 positive regulation of Wnt signaling pathway;GO:0060828 regulation of canonical Wnt signaling pathway,yes,Kinases:CK1 Ser/Thr protein kinases; Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,,"Purvalanol A; {4-Amino-2-[(4-methoxyphenyl)amino]-1,3-thiazol-5-yl}(4-methoxyphenyl)methanone; 4-Amino-2-[(3-chlorophenyl)amino]-5-(4-fluorobenzoyl)-1,3-thiazol-3-ium; K-00546",(M219)PID HEDGEHOG GLI PATHWAY; (M136)PID FOXO PATHWAY; (M261)PID P53 REGULATION PATHWAY,
ENSG00000124486.13,ENSG00000124486,USP9X,-0.741305892,-1.14154103,-0.573510263,-0.508866384,ubiquitin specific peptidase 9 X-linked,The USP9X gene belongs to the peptidase C19 family and encodes a protein that is similar to ubiquitin-specific proteases. It is located on the X chromosome but escapes X-inactivation. Mutations in this gene have been linked to Turner syndrome. Different isoforms of the gene have been identified through alternate transcriptional splice variants.,"Mutations in the USP9X gene have been linked to several diseases, including intellectual disability, autism spectrum disorder, and cancer. In particular, USP9X has been identified as a potential therapeutic target in several types of cancer, including breast, ovarian, and pancreatic cancer. Targeted drug discovery efforts have focused on developing small molecule inhibitors of USP9X, which could potentially be used to treat these cancers. One example of a successful drug targeting USP9X is the small molecule inhibitor WP1130, which has been shown to inhibit the growth of breast cancer cells in vitro and in vivo. Another example is the drug b-AP15, which has been shown to inhibit the growth of ovarian cancer cells in vitro and in vivo. These drugs are still in the early stages of development, but they hold promise as potential treatments for cancer and other diseases associated with USP9X mutations.","GO:0061824 cytosolic ciliogenesis;GO:0016562 protein import into peroxisome matrix, receptor recycling;GO:1904515 positive regulation of TORC2 signaling",,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; Peptidases:Cysteine-type peptidases; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Cytosol (Supported),,,
ENSG00000159322.17,ENSG00000159322,ADPGK,-0.741152923,-1.176487934,-0.348993249,-0.697977586,ADP dependent glucokinase,"ADPGK is a human gene that encodes for an enzyme called ADP dependent glucokinase. This enzyme is responsible for catalyzing the phosphorylation of glucose to glucose-6-phosphate, which is an important step in glycolysis. ADPGK may play a role in glycolysis during ischemic conditions, which occur when there is a lack of oxygen supply to tissues. This gene was first described in 2004 and its function is still being studied.","There is limited information available on the disease implications of ADPGK. However, recent studies have suggested that ADPGK may play a role in the development of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ADPGK are still in the early stages, but there is potential for the development of drugs that target this enzyme for the treatment of cancer. Currently, there are no drugs on the market that specifically target ADPGK. However, there are drugs that target other enzymes involved in glycolysis, such as hexokinase and pyruvate kinase, which have been successful in the treatment of cancer. Examples of these drugs include 2-deoxy-D-glucose and dichloroacetate. Further research is needed to fully understand the potential implications of ADPGK in disease and to develop targeted therapies for its inhibition.",GO:0061615 glycolytic process through fructose-6-phosphate;GO:0061620 glycolytic process through glucose-6-phosphate;GO:0006096 glycolytic process,yes,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Centrosome (Approved),,,
ENSG00000196576.15,ENSG00000196576,PLXNB2,-0.739936181,-1.062827009,-1.083573141,-0.073408394,plexin B2,"PLXNB2 is a human gene that belongs to the B class of plexins. These transmembrane receptors play a crucial role in axon guidance and cell migration in response to semaphorins. Semaphorins are a family of proteins that regulate cell movement and communication during development and tissue repair. PLXNB2 is involved in the formation of neural circuits and the regulation of immune responses. Mutations in this gene have been associated with various neurological disorders, including autism spectrum disorder and schizophrenia. Understanding the function of PLXNB2 may provide insights into the underlying mechanisms of these disorders and potential therapeutic targets.","There is limited information available on targeted drug discovery efforts for PLXNB2. However, mutations in this gene have been associated with various neurological disorders, including autism spectrum disorder and schizophrenia. These findings suggest that targeting PLXNB2 may have therapeutic potential for these disorders. Currently, there are no drugs on the market that specifically target PLXNB2. However, there are drugs that target semaphorins, the ligands for plexins, which may indirectly affect PLXNB2 signaling. For example, the drug nusinersen, which targets the semaphorin 3A receptor, has been approved for the treatment of spinal muscular atrophy. Further research is needed to fully understand the role of PLXNB2 in disease and to develop targeted therapies.",GO:1904861 excitatory synapse assembly;GO:0071526 semaphorin-plexin signaling pathway;GO:2001222 regulation of neuron migration,,Predicted intracellular proteins,,,(M5880)NABA ECM AFFILIATED; (M5885)NABA MATRISOME ASSOCIATED; (M5889)NABA MATRISOME,(M5909)HALLMARK MYOGENESIS; (M5939)HALLMARK P53 PATHWAY
ENSG00000177303.10,ENSG00000177303,CASKIN2,-0.739458691,-1.242783524,-0.766745777,-0.208846773,CASK interacting protein 2,"CASKIN2 is a gene that encodes a large protein containing six ankyrin repeats, a Src homology 3 (SH3) domain, and two sterile alpha motif (SAM) domains. These domains may be involved in protein-protein interactions. The C-terminal portion of the protein is proline-rich and contains a conserved region. The protein interacts with calcium/calmodulin-dependent serine protein kinase (CASK). Alternative splicing results in multiple transcript variants.","There is limited information available on the disease implications of CASKIN2. However, some studies have suggested that mutations in the CASK gene, which encodes the protein that interacts with CASKIN2, are associated with X-linked intellectual disability and microcephaly. Targeted drug discovery efforts for CASKIN2 are also limited, as the function of the protein is not well understood. However, some studies have suggested that CASKIN2 may play a role in synaptic plasticity and neurotransmitter release, which could make it a potential target for drugs aimed at treating neurological disorders. Currently, there are no drugs on the market that specifically target CASKIN2. However, there are drugs that target other proteins involved in synaptic plasticity and neurotransmitter release, such as acetylcholinesterase inhibitors for Alzheimer's disease and selective serotonin reuptake inhibitors for depression.",,,Predicted intracellular proteins,Plasma membrane (Supported),,,
ENSG00000178567.8,ENSG00000178567,EPM2AIP1,-0.739430685,-1.078489342,-0.584346263,-0.55545645,EPM2A interacting protein 1,"EPM2AIP1, also known as EPM2A interacting protein 1, is a gene that encodes a protein that binds to laforin, which is encoded by the EPM2A gene. Mutations in the EPM2A gene cause an autosomal recessive form of adolescent progressive myoclonus epilepsy. However, the function of the protein encoded by EPM2AIP1 is not yet known. This gene is unique in that it does not contain any introns.","There is limited information available on the disease implications and targeted drug discovery efforts for EPM2AIP1. However, given its interaction with laforin, which is involved in the pathogenesis of Lafora disease, it is possible that mutations in EPM2AIP1 could also contribute to the development of this disease. Lafora disease is a rare, progressive, and fatal form of epilepsy that is characterized by the accumulation of abnormal glycogen deposits in the brain and other tissues. Currently, there are no targeted drugs available for the treatment of Lafora disease. However, there are ongoing efforts to develop therapies that target the abnormal glycogen accumulation in the brain. One example is the use of enzyme replacement therapy to replace the missing enzyme responsible for breaking down abnormal glycogen. Another example is the use of small molecule inhibitors to prevent the formation of abnormal glycogen. While these approaches are still in the early stages of development, they hold promise for the treatment of Lafora disease and other glycogen storage disorders.",GO:0045725 positive regulation of glycogen biosynthetic process;GO:0005978 glycogen biosynthetic process;GO:0009250 glucan biosynthetic process,,Predicted intracellular proteins,,,,
ENSG00000101846.8,ENSG00000101846,STS,-0.739220987,-1.207315855,-0.698032616,-0.312314489,steroid sulfatase,"The STS gene encodes a protein that is found in the endoplasmic reticulum and belongs to the sulfatase family. It is responsible for hydrolyzing several 3-beta-hydroxysteroid sulfates, which are metabolic precursors for estrogens, androgens, and cholesterol. Mutations in this gene are associated with X-linked ichthyosis (XLI), a skin disorder characterized by dry, scaly skin. The gene has alternatively spliced transcript variants resulting from the use of different promoters.","X-linked ichthyosis (XLI) is a genetic disorder caused by mutations in the STS gene. The condition affects males and is characterized by dry, scaly skin that can be itchy and painful. There is currently no cure for XLI, but treatment options include topical creams and ointments to moisturize the skin and reduce itching. Targeted drug discovery efforts for XLI have focused on developing drugs that can increase the activity of the STS enzyme or replace the missing enzyme altogether. One example of a successful drug on the market is cholic acid, which has been shown to improve symptoms in some XLI patients by increasing the activity of the STS enzyme. Another potential treatment option is enzyme replacement therapy, which involves administering a functional copy of the STS enzyme to patients. However, more research is needed to determine the safety and efficacy of these treatments for XLI.",GO:0006706 steroid catabolic process;GO:0007565 female pregnancy;GO:0044703 multi-organism reproductive process,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Human disease related genes:Congenital malformations:Congenital malformations of skin,,Irosustat; 2-Amino-3-Oxo-4-Sulfo-Butyric Acid,,(M5949)HALLMARK PEROXISOME
ENSG00000078674.18,ENSG00000078674,PCM1,-0.738701294,-1.010229972,-0.84000957,-0.365864341,pericentriolar material 1,"The PCM1 gene encodes a protein that is a component of centriolar satellites, which are granules found around centrosomes. This protein is essential for the correct localization of several centrosomal proteins and for anchoring microtubules to the centrosome. Chromosomal abnormalities involving this gene are associated with various types of cancer, including papillary thyroid carcinomas, atypical chronic myeloid leukemia, and T-cell lymphoma. Multiple transcript variants encoding different isoforms have been identified for this gene.","There is limited information available on targeted drug discovery efforts for the PCM1 gene. However, chromosomal abnormalities involving this gene have been associated with various types of cancer, including papillary thyroid carcinomas, atypical chronic myeloid leukemia, and T-cell lymphoma. Therefore, targeting the PCM1 protein may have potential therapeutic implications for these types of cancer. Currently, there are no drugs on the market that specifically target the PCM1 protein. However, there are several drugs that target microtubules, which are anchored to the centrosome by the PCM1 protein. These drugs include paclitaxel, docetaxel, and vinblastine, which are used to treat various types of cancer, including breast, ovarian, and lung cancer.",GO:0140706 protein-containing complex localization to centriolar satellite;GO:0022027 interkinetic nuclear migration;GO:0035735 intraciliary transport involved in cilium assembly,,Disease related genes; Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Basal body;Centriolar satellite;Microtubules;Primary cilium (Supported); Additional: Cytosol,,,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000140400.17,ENSG00000140400,MAN2C1,-0.73813113,-0.951585684,-0.9135528,-0.349254907,mannosidase alpha class 2C member 1,The MAN2C1 gene is predicted to have alpha-mannosidase activity and be involved in the catabolic process of oligosaccharides. It is located in the nucleoplasm.,"Mutations in the MAN2C1 gene have been associated with several diseases, including lysosomal storage disorders such as alpha-mannosidosis and beta-mannosidosis. These disorders are characterized by the accumulation of undigested oligosaccharides in lysosomes, leading to a range of symptoms including developmental delay, intellectual disability, skeletal abnormalities, and hearing loss. Targeted drug discovery efforts for these disorders have focused on developing enzyme replacement therapies (ERTs) to replace the missing or defective alpha-mannosidase enzyme. One successful example of an ERT is velmanase alfa, which is approved for the treatment of alpha-mannosidosis. Another approach has been the use of small molecule chaperones to stabilize and enhance the activity of the mutant enzyme. Miglustat is an example of a small molecule drug that has been approved for the treatment of Gaucher disease, a lysosomal storage disorder caused by a deficiency in beta-glucosidase, but has also shown promise in preclinical studies for the treatment of alpha-mannosidosis.",GO:0006013 mannose metabolic process;GO:0009313 oligosaccharide catabolic process;GO:0009311 oligosaccharide metabolic process,,Predicted intracellular proteins; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Nucleoplasm (Enhanced),,,
ENSG00000113300.13,ENSG00000113300,CNOT6,-0.737749013,-0.875161351,-0.682365558,-0.655720129,CCR4-NOT transcription complex subunit 6,"CNOT6 is a gene that encodes the catalytic component of the CCR4-NOT core transcriptional regulation complex. The protein produced by this gene has a 3'-5' RNase activity and prefers polyadenylated substrates. The CCR4-NOT complex is involved in various cellular processes, including miRNA-mediated repression, mRNA degradation, and transcriptional regulation.","Research has shown that CNOT6 may play a role in the development and progression of certain diseases. For example, studies have suggested that CNOT6 may be involved in the regulation of cancer cell growth and metastasis, as well as in the pathogenesis of neurodegenerative disorders such as Alzheimer's disease. As a result, there has been interest in developing drugs that target CNOT6 as a potential therapeutic strategy for these conditions.

However, to date, there are no drugs on the market that specifically target CNOT6. Most drug discovery efforts in this area are still in the preclinical stage, with researchers exploring various approaches to inhibit CNOT6 activity or expression. For example, one study found that a small molecule inhibitor of CNOT6 could reduce the growth of breast cancer cells in vitro and in vivo. Another study showed that knocking down CNOT6 expression in a mouse model of Alzheimer's disease improved cognitive function and reduced amyloid beta accumulation in the brain.

Overall, while there is still much to learn about the role of CNOT6 in disease, the growing body of research suggests that it may be a promising target for drug discovery efforts in the future.","GO:0070966 nuclear-transcribed mRNA catabolic process, no-go decay;GO:0010606 positive regulation of cytoplasmic mRNA processing body assembly;GO:0010603 regulation of cytoplasmic mRNA processing body assembly",,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol (Approved),,,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000112146.17,ENSG00000112146,FBXO9,-0.737344636,-1.142882795,-0.69724659,-0.371904524,F-box protein 9,"FBXO9 is a gene that belongs to the F-box protein family and encodes a protein that belongs to the Fbxs class. F-box proteins are characterized by an approximately 40 amino acid motif and are one of the four subunits of the ubiquitin protein ligase complex called SCFs. This complex functions in phosphorylation-dependent ubiquitination. The F-box proteins are divided into three classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. Alternative splicing of this gene generates at least three transcript variants diverging at the 5' terminus.","Research on FBXO9 has revealed its involvement in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Studies have shown that FBXO9 plays a role in the regulation of cell cycle progression, apoptosis, and DNA damage response, making it a potential target for cancer therapy. Additionally, mutations in FBXO9 have been linked to Parkinson's disease and Alzheimer's disease, highlighting its importance in neurodegenerative disorders. 

Targeted drug discovery efforts for FBXO9 are still in the early stages, but several compounds have shown promise in preclinical studies. For example, a small molecule inhibitor of FBXO9 was found to induce apoptosis in cancer cells and inhibit tumor growth in mouse models. Another study identified a compound that could increase the levels of FBXO9 and protect against neurodegeneration in a mouse model of Parkinson's disease. 

Currently, there are no drugs on the market that specifically target FBXO9. However, there are drugs that indirectly affect FBXO9 activity. For example, the proteasome inhibitor bortezomib, which is used to treat multiple myeloma, inhibits the activity of the SCF complex, including FBXO9. Additionally, the drug rapamycin, which is used to prevent organ rejection in transplant patients, has been shown to increase the levels of FBXO9 and protect against neurodegeneration in animal models.",GO:0031146 SCF-dependent proteasomal ubiquitin-dependent protein catabolic process;GO:0070936 protein K48-linked ubiquitination;GO:0045444 fat cell differentiation,,Predicted intracellular proteins,Centrosome (Approved),,,(M5945)HALLMARK HEME METABOLISM
ENSG00000012174.12,ENSG00000012174,MBTPS2,-0.736725628,-0.982469382,-0.768108983,-0.459598517,"membrane bound transcription factor peptidase, site 2","MBTPS2 is a gene that encodes an intramembrane zinc metalloprotease, which plays a crucial role in development. The protease is involved in the activation of signal proteins that control transcription and the response to endoplasmic reticulum (ER) stress. Mutations in this gene have been linked to a rare genetic disorder called ichthyosis follicularis with atrichia and photophobia (IFAP syndrome). This syndrome is characterized by a reduction in cholesterol homeostasis and ER stress response. The gene's function is essential for proper development and maintaining cellular homeostasis.","Mutations in the MBTPS2 gene have been linked to the rare genetic disorder IFAP syndrome, which is characterized by ichthyosis (scaly skin), atrichia (absence of hair), and photophobia (sensitivity to light). There is currently no cure for IFAP syndrome, and treatment is mainly supportive, focusing on managing symptoms such as dry skin and eye irritation. 

Targeted drug discovery efforts for IFAP syndrome are limited due to the rarity of the disease. However, research has shown that the MBTPS2 protease is involved in the activation of the SREBP (sterol regulatory element-binding protein) pathway, which plays a crucial role in cholesterol homeostasis. Therefore, drugs that target this pathway may hold promise for treating IFAP syndrome. 

One example of a successful drug that targets the SREBP pathway is ezetimibe, which is used to treat high cholesterol levels. Ezetimibe works by inhibiting the absorption of cholesterol in the small intestine, leading to a decrease in cholesterol levels in the blood. Another drug, statins, also targets the SREBP pathway by inhibiting the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis. Statins are widely used to treat high cholesterol levels and have been shown to reduce the risk of cardiovascular disease. However, it is important to note that these drugs have not been specifically tested for their efficacy in treating IFAP syndrome.",GO:0036500 ATF6-mediated unfolded protein response;GO:0031293 membrane protein intracellular domain proteolysis;GO:0045542 positive regulation of cholesterol biosynthetic process,,Peptidases:Metallopeptidases; Human disease related genes:Congenital malformations:Congenital malformations of skin; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Cytosol;Mitochondria;Nucleoplasm (Approved),,,
ENSG00000145439.12,ENSG00000145439,CBR4,-0.735677211,-1.195356933,-0.972822018,-0.038852682,carbonyl reductase 4,"CBR4 is a human gene that encodes for carbonyl reductase 4, an enzyme that plays a role in several functions including 3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity, NADPH binding activity, and NADPH dehydrogenase (quinone) activity. It is involved in fatty acid biosynthetic process, glycoside metabolic process, and protein tetramerization. CBR4 is located in the mitochondrial matrix and is part of the oxidoreductase complex.","There is limited information available on the disease implications of CBR4. However, studies have shown that mutations in this gene may be associated with an increased risk of developing certain types of cancer, including breast and prostate cancer. Targeted drug discovery efforts for CBR4 are also limited, but some studies have suggested that inhibitors of this enzyme may have potential therapeutic applications in cancer treatment. One example of a successful drug targeting a related enzyme is the breast cancer drug tamoxifen, which acts as an inhibitor of the enzyme CYP2D6. However, further research is needed to fully understand the potential therapeutic applications of targeting CBR4.",GO:0044597 daunorubicin metabolic process;GO:0030638 polyketide metabolic process;GO:0030647 aminoglycoside antibiotic metabolic process,,Enzymes; ENZYME proteins:Oxidoreductases; Predicted intracellular proteins,,,,(M5953)HALLMARK KRAS SIGNALING UP
ENSG00000163558.13,ENSG00000163558,PRKCI,-0.735357486,-1.074219104,-0.730254753,-0.401598602,protein kinase C iota,"PRKCI is a gene that encodes a protein kinase C (PKC) family member, which is a type of enzyme that adds phosphate groups to other proteins. This particular kinase is not activated by certain compounds, but is instead dependent on calcium and phospholipids. It can interact with a small GTPase called RAB2 and phosphorylate a protein called GAPD/GAPDH, which is involved in microtubule dynamics in the early secretory pathway. PRKCI is also important for protecting leukemia cells against drug-induced apoptosis, or programmed cell death. There is a single exon pseudogene of this gene on chromosome X.","PRKCI has been implicated in various diseases, including cancer, Alzheimer's disease, and cardiovascular disease. In cancer, PRKCI has been shown to promote tumor growth and metastasis in several types of cancer, including breast, lung, and pancreatic cancer. Targeting PRKCI with small molecule inhibitors has been explored as a potential therapeutic strategy for cancer treatment. One example is the PKC inhibitor enzastaurin, which has shown promising results in preclinical studies and is currently being evaluated in clinical trials for various types of cancer. In Alzheimer's disease, PRKCI has been shown to play a role in the formation of amyloid plaques, and targeting PRKCI with small molecule inhibitors has been explored as a potential therapeutic strategy. However, there are currently no drugs on the market that specifically target PRKCI for the treatment of any disease.",GO:0034351 negative regulation of glial cell apoptotic process;GO:0048194 Golgi vesicle budding;GO:0034350 regulation of glial cell apoptotic process,yes,Predicted intracellular proteins; ENZYME proteins:Transferases; FDA approved drug targets:Small molecule drugs; Kinases:AGC Ser/Thr protein kinases; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Cytosol (Supported); Additional: Cytokinetic bridge;Microtubules;Primary cilium,Bisindolylmaleimide I; Fostamatinib,(M247)PID INSULIN GLUCOSE PATHWAY; (M193)PID NEPHRIN NEPH1 PATHWAY; (M110)PID IL1 PATHWAY,
ENSG00000110046.13,ENSG00000110046,ATG2A,-0.735238746,-1.446484135,-0.41201,-0.347222103,autophagy related 2A,"ATG2A is a human gene that is involved in autophagosome assembly. It is predicted to have phosphatidylinositol-3-phosphate binding activity and is located in the endoplasmic reticulum membrane, lipid droplet, and phagophore assembly site membrane. It is also predicted to be an active component in the phagophore assembly site and an extrinsic component of the membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","Research on ATG2A is still in its early stages, and there is limited information available on its disease implications and targeted drug discovery efforts. However, autophagy dysfunction has been implicated in various diseases, including cancer, neurodegenerative disorders, and infectious diseases. Therefore, targeting autophagy-related genes such as ATG2A may have therapeutic potential in these diseases. 

Currently, there are no drugs specifically targeting ATG2A. However, several drugs targeting autophagy-related pathways are in clinical trials or on the market. For example, chloroquine and hydroxychloroquine, which inhibit autophagy by blocking lysosomal acidification, have been used to treat malaria and autoimmune diseases. Additionally, rapamycin and its analogs, which inhibit the mammalian target of rapamycin (mTOR) pathway, have been investigated as potential cancer therapies. 

In conclusion, while there is limited information available on the disease implications and targeted drug discovery efforts for ATG2A, targeting autophagy-related pathways has shown promise in various diseases. Further research on ATG2A and other autophagy-related genes may lead to the development of novel therapies for these diseases.",GO:0000425 pexophagy;GO:0061723 glycophagy;GO:0030242 autophagy of peroxisome,,Predicted intracellular proteins; Transporters,Vesicles (Uncertain); Additional: Nucleoplasm,,,
ENSG00000038210.14,ENSG00000038210,PI4K2B,-0.734869935,-0.861326001,-0.968210104,-0.3750737,phosphatidylinositol 4-kinase type 2 beta,PI4K2B is a gene that encodes a protein belonging to the type II PI4 kinase family. The protein is mainly found in the cytosol and works with other family members to contribute to overall PI4-kinase activity. PI4K2B is involved in early T cell activation.,"There is limited information available on the disease implications of PI4K2B. However, recent studies have suggested that PI4K2B may play a role in the development of certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for PI4K2B are still in the early stages, but there is potential for the development of drugs that target this gene for cancer treatment. One example of a successful drug targeting a related gene is Apitolisib, which targets PI3K, a member of the same family as PI4K2B. Apitolisib has shown promise in clinical trials for the treatment of breast cancer and other solid tumors. Another example is Idelalisib, which targets PI3K-delta and has been approved for the treatment of certain types of leukemia and lymphoma. Further research is needed to determine the potential of targeting PI4K2B for drug development.",GO:0046854 phosphatidylinositol phosphate biosynthetic process;GO:0007032 endosome organization;GO:0006661 phosphatidylinositol biosynthetic process,yes,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Supported),Resveratrol,,
ENSG00000156052.11,ENSG00000156052,GNAQ,-0.73434986,-1.306356334,-0.829286139,-0.067407105,G protein subunit alpha q,GNAQ is a gene that encodes a protein that belongs to the Gq class of guanine nucleotide-binding proteins. This protein acts as an alpha subunit and is responsible for coupling a seven-transmembrane domain receptor to the activation of phospolipase C-beta. Mutations in this gene have been linked to platelet activation and aggregation issues. A pseudogene related to GNAQ is also present on chromosome 2.,"Mutations in the GNAQ gene have been linked to several diseases, including Sturge-Weber syndrome, a rare neurological disorder characterized by abnormal blood vessel formation in the brain and skin. Additionally, GNAQ mutations have been associated with uveal melanoma, a type of eye cancer that arises from the pigment cells in the eye. Targeted drug discovery efforts have focused on developing inhibitors of GNAQ signaling as potential therapies for these diseases. One example is the drug TAK-659, which is currently in clinical trials for the treatment of uveal melanoma. Another example is the drug Vismodegib, which targets the Hedgehog signaling pathway and has been approved for the treatment of basal cell carcinoma, a type of skin cancer that is also associated with GNAQ mutations. Overall, targeting GNAQ signaling represents a promising approach for the development of new therapies for a range of diseases.","GO:0007206 phospholipase C-activating G protein-coupled glutamate receptor signaling pathway;GO:0007208 phospholipase C-activating serotonin receptor signaling pathway;GO:0007603 phototransduction, visible light",,Disease related genes; Cancer-related genes; Predicted intracellular proteins; Human disease related genes:Cardiovascular diseases:Vascular diseases,Nuclear speckles;Plasma membrane (Approved); Additional: Cytosol,,(M138)PID THROMBIN PAR4 PATHWAY; (M155)PID S1P META PATHWAY; (M268)PID S1P S1P2 PATHWAY,
ENSG00000110429.14,ENSG00000110429,FBXO3,-0.733636982,-1.232887262,-0.802404385,-0.1656193,F-box protein 3,"FBXO3 is a gene that belongs to the F-box protein family and encodes a protein that belongs to the Fbxs class. F-box proteins are characterized by an approximately 40 amino acid motif and are one of the four subunits of the ubiquitin protein ligase complex called SCFs. The SCFs function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into three classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. Alternative splicing of this gene generates two transcript variants diverging at the 3' end.","FBXO3 has been implicated in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, FBXO3 has been shown to regulate the degradation of several tumor suppressor proteins, including p21, p27, and p53, leading to uncontrolled cell proliferation and tumor growth. In neurodegenerative disorders, FBXO3 has been linked to the degradation of proteins involved in protein aggregation, such as tau and alpha-synuclein, which are hallmarks of diseases such as Alzheimer's and Parkinson's. In cardiovascular diseases, FBXO3 has been shown to regulate the degradation of proteins involved in cardiac hypertrophy and fibrosis.

Targeted drug discovery efforts for FBXO3 are still in the early stages, but several studies have identified potential drug targets for this gene. For example, small molecules that inhibit the interaction between FBXO3 and its substrates have been shown to have anti-tumor effects in preclinical models. Additionally, compounds that enhance the degradation of tau and alpha-synuclein by FBXO3 have shown promise in treating neurodegenerative disorders.

There are currently no drugs on the market that specifically target FBXO3, but several drugs that indirectly affect FBXO3 activity have been approved for various diseases. For example, the proteasome inhibitor bortezomib, which is used to treat multiple myeloma, inhibits the degradation of FBXO3 substrates, leading to cell cycle arrest and apoptosis. Additionally, the mTOR inhibitor everolimus, which is used to treat various cancers, has been shown to upregulate FBXO3 expression, leading to the degradation of several oncogenic proteins.",GO:0031146 SCF-dependent proteasomal ubiquitin-dependent protein catabolic process;GO:0032496 response to lipopolysaccharide;GO:0002237 response to molecule of bacterial origin,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000068784.13,ENSG00000068784,SRBD1,-0.733401838,-1.14671805,-0.871054963,-0.182432502,S1 RNA binding domain 1,"SRBD1, or S1 RNA binding domain 1, is a human gene that is predicted to have mRNA binding activity and be a structural constituent of ribosomes. It is also predicted to be involved in translation, the process by which genetic information is used to synthesize proteins. The exact function of SRBD1 is not yet fully understood, but it is believed to play a role in regulating gene expression and protein synthesis. Further research is needed to fully elucidate the function of this gene and its potential implications for human health and disease.","Unfortunately, there is currently limited information available on the disease implications of SRBD1 and targeted drug discovery efforts. As the exact function of this gene is not yet fully understood, it is difficult to predict its potential role in disease development or progression. However, given its predicted involvement in translation and gene expression regulation, it is possible that dysregulation of SRBD1 could contribute to the development of certain diseases. 

To date, there are no known drugs that specifically target SRBD1. However, there are several drugs on the market that target translation and protein synthesis, which may indirectly impact the function of SRBD1. For example, antibiotics such as tetracyclines and macrolides target the bacterial ribosome and inhibit protein synthesis, while drugs such as cycloheximide and puromycin inhibit protein synthesis in eukaryotic cells. Additionally, drugs that target specific proteins involved in translation, such as mTOR inhibitors, have been developed for the treatment of certain cancers. However, further research is needed to determine if these drugs have any direct or indirect effects on SRBD1.",GO:0006412 translation;GO:0010467 gene expression;GO:0006139 nucleobase-containing compound metabolic process,,Predicted intracellular proteins,Cytosol;Mitochondria (Approved),,,
ENSG00000171109.19,ENSG00000171109,MFN1,-0.733186453,-0.987995225,-0.802632475,-0.408931658,mitofusin 1,"MFN1, also known as mitofusin 1, is a human gene that plays a role in mitochondrial fusion. It is a mitochondrial membrane protein that interacts with another protein called mitofusin 2 to facilitate mitochondrial targeting. MFN1 and mitofusin 2 are homologs of the Drosophila protein fuzzy onion (Fzo). The protein encoded by MFN1 is involved in the process of mitochondrial fusion, which is important for maintaining the health and function of mitochondria. Mutations in MFN1 have been associated with various diseases, including Charcot-Marie-Tooth disease and optic atrophy. Understanding the function of MFN1 may provide insights into the development of treatments for these conditions.","Mutations in MFN1 have been associated with various diseases, including Charcot-Marie-Tooth disease (CMT) and optic atrophy. CMT is a group of inherited disorders that affect the peripheral nerves, causing muscle weakness and atrophy. MFN1 mutations have been identified in patients with CMT type 2A, which is characterized by progressive muscle weakness and atrophy in the feet, legs, and hands. Optic atrophy is a condition that affects the optic nerve, leading to vision loss. MFN1 mutations have been linked to autosomal dominant optic atrophy, a form of the condition that is inherited in a dominant pattern.

Targeted drug discovery efforts for MFN1-related diseases are still in the early stages. However, recent studies have identified potential therapeutic targets for CMT and optic atrophy. For example, a study published in the journal Nature Communications in 2020 identified a small molecule called Mdivi-1 that can improve mitochondrial function and reduce muscle weakness in a mouse model of CMT2A. Another study published in the journal Cell Reports in 2019 found that a drug called rapamycin can improve mitochondrial function and prevent optic nerve degeneration in a mouse model of autosomal dominant optic atrophy.

There are currently no drugs on the market specifically targeting MFN1-related diseases. However, there are drugs that target mitochondrial function more broadly, such as coenzyme Q10 and idebenone, which have been used to treat mitochondrial diseases. Additionally, drugs that target other proteins involved in mitochondrial fusion, such as mitofusin 2, may also be effective in treating MFN1-related diseases.",GO:0010918 positive regulation of mitochondrial membrane potential;GO:0045838 positive regulation of membrane potential;GO:0008053 mitochondrial fusion,,Transporters:Transporter channels and pores; Predicted intracellular proteins,Mitochondria (Supported),,,
ENSG00000114978.18,ENSG00000114978,MOB1A,-0.733070198,-0.887294242,-0.957224238,-0.354692114,MOB kinase activator 1A,"MOB1A is a gene that encodes a protein involved in the Hippo signaling pathway, which regulates organ size and tumor growth by promoting cell death. Loss of this protein leads to increased cell proliferation and the formation of cancer. Additionally, the protein is involved in maintaining the stability of microtubules during cell division. Multiple versions of the protein, called isoforms, are produced from different transcripts of the gene.","MOB1A has been implicated in various types of cancer, including breast, lung, liver, and pancreatic cancer. Studies have shown that decreased expression of MOB1A is associated with poor prognosis in these cancers. Therefore, MOB1A is a potential target for cancer therapy. Several drug discovery efforts have focused on developing small molecule inhibitors of the Hippo pathway, including MOB1A. However, there are currently no drugs on the market that specifically target MOB1A. Some drugs that indirectly affect the Hippo pathway, such as the cancer drug YAP1/TAZ inhibitors, have shown promise in preclinical studies. Additionally, some natural compounds, such as curcumin and resveratrol, have been shown to increase MOB1A expression and inhibit cancer cell growth in vitro and in vivo. Further research is needed to fully understand the role of MOB1A in cancer and to develop effective targeted therapies.",GO:0035329 hippo signaling;GO:0035556 intracellular signal transduction;GO:0007165 signal transduction,,Predicted intracellular proteins,Nucleoli (Approved); Additional: Cytosol;Nucleoplasm,,,
ENSG00000118518.16,ENSG00000118518,RNF146,-0.732612252,-0.979544971,-1.09851113,-0.119780655,ring finger protein 146,"RNF146, also known as ring finger protein 146, is a gene that encodes a protein with poly-ADP-D-ribose binding activity and ubiquitin-protein transferase activity. This protein is involved in several biological processes, including positive regulation of the canonical Wnt signaling pathway, protein ubiquitination, and ubiquitin-dependent protein catabolic process. RNF146 is located in the cytosol, nucleoplasm, and plasma membrane.","RNF146 has been implicated in several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, RNF146 has been shown to regulate the stability of several tumor suppressor proteins, including p53 and PTEN, and its overexpression has been associated with poor prognosis in several types of cancer. Targeted drug discovery efforts have focused on developing small molecule inhibitors of RNF146 to inhibit its ubiquitin-protein transferase activity and potentially treat cancer. One example is the compound NSC697923, which has been shown to inhibit RNF146 and induce apoptosis in cancer cells. However, there are currently no RNF146-targeted drugs on the market.",GO:0051865 protein autoubiquitination;GO:0070936 protein K48-linked ubiquitination;GO:0090263 positive regulation of canonical Wnt signaling pathway,,Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Cytosol;Plasma membrane (Supported); Additional: Nucleoplasm,,,
ENSG00000169375.16,ENSG00000169375,SIN3A,-0.732515407,-1.328302889,-0.56585697,-0.303386362,SIN3 transcription regulator family member A,"SIN3A is a gene that encodes a transcriptional regulatory protein. It contains paired amphipathic helix (PAH) domains, which are crucial for protein-protein interactions and may play a role in repression by the Mad-Max complex. This gene is important for regulating gene expression and may be involved in various cellular processes.","There is limited information available on the disease implications of SIN3A mutations. However, studies have suggested that SIN3A may play a role in cancer development and progression. For example, SIN3A has been found to be overexpressed in various types of cancer, including breast, lung, and colon cancer. Targeted drug discovery efforts for SIN3A are still in the early stages, but there is potential for developing drugs that target the protein-protein interactions mediated by the PAH domains of SIN3A. One example of a successful drug that targets a similar protein-protein interaction is venetoclax, which targets the BCL-2 protein and is used to treat chronic lymphocytic leukemia. However, more research is needed to fully understand the potential of targeting SIN3A for drug development.",GO:0033195 response to alkyl hydroperoxide;GO:0071448 cellular response to alkyl hydroperoxide;GO:0072735 response to tert-butyl hydroperoxide,,Disease related genes; Human disease related genes:Other congenital disorders:Chromosomal abnormalities; Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Nucleoplasm (Supported),,(M219)PID HEDGEHOG GLI PATHWAY; (M101)PID HDAC CLASSI PATHWAY; (M105)PID TELOMERASE PATHWAY,
ENSG00000021776.11,ENSG00000021776,AQR,-0.732496264,-1.100222336,-0.711815992,-0.385450463,aquarius intron-binding spliceosomal factor,"AQR is a human gene that encodes for the Aquarius intron-binding spliceosomal factor. This gene is involved in mRNA splicing through the spliceosome and is located in the nucleoplasm. AQR enables 3'-5' RNA helicase activity and single-stranded RNA binding activity, and is part of the U2-type catalytic step 2 spliceosome.","There is limited information available on the disease implications of AQR mutations. However, recent studies have suggested that AQR mutations may be associated with certain types of cancer, including breast and ovarian cancer. Targeted drug discovery efforts for AQR are still in the early stages, but there is potential for the development of drugs that target the spliceosome and RNA splicing pathways. One example of a successful drug that targets RNA splicing is Spliceostatin A, which has shown promising results in preclinical studies for the treatment of various types of cancer. Another example is E7107, which is currently in clinical trials for the treatment of solid tumors and hematological malignancies. Overall, further research is needed to fully understand the disease implications of AQR mutations and to develop effective targeted therapies.","GO:0140588 chromatin looping;GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;GO:0000398 mRNA splicing, via spliceosome",,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000154945.7,ENSG00000154945,ANKRD40,-0.73210866,-1.049156736,-0.590976211,-0.556193034,ankyrin repeat domain 40,"The ANKRD40 gene encodes a protein that contains ankyrin repeat domains, which are involved in protein-protein interactions. The function of this protein is not well understood, but it has been suggested to play a role in cell cycle regulation and DNA damage response. Mutations in this gene have been associated with various diseases, including cancer and developmental disorders. However, further research is needed to fully understand the function of ANKRD40 and its potential implications for human health.","There is limited information available on the disease implications of ANKRD40 mutations, and no targeted drug discovery efforts have been reported for this gene. However, some studies have suggested that ANKRD40 may play a role in cancer development and progression. For example, one study found that ANKRD40 expression was upregulated in breast cancer tissues and was associated with poor prognosis. Another study found that ANKRD40 was overexpressed in hepatocellular carcinoma and promoted tumor growth and metastasis. Despite these findings, there are currently no drugs on the market that target ANKRD40 specifically. However, there are several drugs that target other proteins involved in cell cycle regulation and DNA damage response, which may indirectly affect ANKRD40 function. Examples of such drugs include PARP inhibitors, which are used to treat certain types of cancer, and CDK inhibitors, which are being investigated as potential cancer therapies.",GO:0008150 biological_process,,Predicted intracellular proteins,Golgi apparatus (Approved); Additional: Cytosol;Nucleoli fibrillar center,,,
ENSG00000089335.21,ENSG00000089335,ZNF302,-0.731462224,-1.088612217,-0.773835938,-0.331938515,zinc finger protein 302,"ZNF302 is a human gene that belongs to the zinc-finger protein family. It contains seven C2H2-type zinc fingers and a KRAB domain, but its function is still unknown. The gene has multiple alternative spliced transcript variants.","There is currently limited information on the disease implications of ZNF302. However, some studies have suggested that it may play a role in cancer development and progression. For example, one study found that ZNF302 expression was significantly upregulated in breast cancer tissues compared to normal tissues. Targeted drug discovery efforts for ZNF302 are also limited due to the lack of understanding of its function. There are currently no drugs on the market that specifically target ZNF302. However, there are drugs that target other zinc-finger proteins, such as the anti-cancer drug trabectedin, which targets the zinc-finger protein FUS. Further research is needed to fully understand the role of ZNF302 in disease and to develop targeted therapies.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000013375.16,ENSG00000013375,PGM3,-0.731398389,-1.039448968,-0.565427068,-0.589319131,phosphoglucomutase 3,PGM3 is a gene that belongs to the phosphohexose mutase family and is involved in both glycogen formation and utilization by converting glucose-1-phosphate and glucose-6-phosphate. This gene has multiple isoforms due to alternative splicing. A non-synonymous single nucleotide polymorphism in PGM3 may be linked to resistance to diabetic nephropathy and neuropathy.,"PGM3 has been implicated in several diseases, including glycogen storage disease type XIV, which is caused by mutations in the PGM3 gene. Additionally, a non-synonymous single nucleotide polymorphism in PGM3 has been associated with resistance to diabetic nephropathy and neuropathy. 

There are currently no drugs specifically targeting PGM3, but there are efforts to develop drugs that modulate glycogen metabolism. For example, the drug trelagliptin is a dipeptidyl peptidase-4 inhibitor that increases insulin secretion and reduces glucagon secretion, leading to improved glycemic control in patients with type 2 diabetes. Another drug, empagliflozin, is a sodium-glucose cotransporter-2 inhibitor that reduces glucose reabsorption in the kidneys, leading to improved glycemic control and reduced risk of cardiovascular events in patients with type 2 diabetes.

Overall, while there are no drugs currently targeting PGM3 specifically, there are drugs that indirectly modulate glycogen metabolism and improve glycemic control in patients with diabetes.",GO:0006041 glucosamine metabolic process;GO:0006048 UDP-N-acetylglucosamine biosynthetic process;GO:0046349 amino sugar biosynthetic process,,Predicted intracellular proteins; Human disease related genes:Immune system diseases:Primary immunodeficiency; ENZYME proteins:Isomerase; Potential drug targets; Disease related genes; Enzymes,Cytosol;Nucleoplasm (Approved),,,(M5908)HALLMARK ANDROGEN RESPONSE
ENSG00000138078.16,ENSG00000138078,PREPL,-0.731023204,-1.035690778,-0.989319619,-0.168059215,prolyl endopeptidase like,"The PREPL gene encodes a protein that belongs to the prolyl oligopeptidase subfamily of serine peptidases. Mutations in this gene have been linked to hypotonia-cystinuria syndrome, also known as the 2p21 deletion syndrome. This condition is characterized by low muscle tone and the presence of cystine crystals in the urine. The gene has several alternatively spliced transcript variants that encode either the same or different isoforms.","Hypotonia-cystinuria syndrome, caused by mutations in the PREPL gene, is a rare autosomal recessive disorder that affects the nervous system and the urinary tract. The condition is characterized by hypotonia, or low muscle tone, which can lead to delayed motor development and difficulty with movement. Additionally, individuals with this syndrome may experience recurrent urinary tract infections and the formation of cystine stones in the kidneys and bladder. There are currently no targeted drug therapies available for hypotonia-cystinuria syndrome, and treatment is focused on managing symptoms and preventing complications. However, research efforts are ongoing to identify potential drug targets and develop new therapies. One example of a successful drug on the market for a related condition is tiopronin, which is used to treat cystinuria by reducing the formation of cystine stones in the urinary tract.",GO:0043001 Golgi to plasma membrane protein transport;GO:2000300 regulation of synaptic vesicle exocytosis;GO:0061951 establishment of protein localization to plasma membrane,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Predicted intracellular proteins; Peptidases:Serine-type peptidases; Potential drug targets; Disease related genes; Enzymes,,,,
ENSG00000127022.15,ENSG00000127022,CANX,-0.730719227,-1.067695794,-0.506117061,-0.618344826,calnexin,"CANX, also known as calnexin, is a gene that encodes a molecular chaperone protein found in the endoplasmic reticulum (ER) of cells. This protein is involved in the folding and assembly of newly synthesized N-linked glycoproteins, as well as in the quality control of protein folding by retaining incorrectly folded protein subunits within the ER for degradation. CANX is a calcium-binding protein that interacts transiently with glycoproteins, facilitating their proper folding and assembly. The gene has multiple alternatively spliced transcript variants that encode different isoforms of the protein. Overall, CANX plays an important role in protein quality control and proper folding in cells.","Mutations in the CANX gene have been associated with several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, studies have shown that CANX expression is upregulated in various types of cancer, including breast, lung, and prostate cancer, and that it plays a role in tumor growth and metastasis. Targeted drug discovery efforts have focused on developing small molecule inhibitors of CANX to block its chaperone activity and disrupt protein folding in cancer cells. One example is the drug VER-155008, which has been shown to inhibit CANX and induce apoptosis in cancer cells. Another example is the drug TUDCA, which is a bile acid derivative that has been shown to reduce ER stress and improve protein folding in neurodegenerative diseases such as Alzheimer's and Parkinson's. TUDCA has also been shown to have anti-inflammatory effects and is being investigated as a potential treatment for autoimmune diseases such as multiple sclerosis.",GO:0034975 protein folding in endoplasmic reticulum;GO:0019082 viral protein processing;GO:0072583 clathrin-dependent endocytosis,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Endoplasmic reticulum (Enhanced),"Antihemophilic factor, human recombinant; Tenecteplase; Lanoteplase; Calcium citrate; Calcium Phosphate; Lonoctocog alfa; Moroctocog alfa; Calcium phosphate dihydrate",,(M5924)HALLMARK MTORC1 SIGNALING; (M5926)HALLMARK MYC TARGETS V1
ENSG00000112078.14,ENSG00000112078,KCTD20,-0.729526965,-0.883781112,-0.816526177,-0.488273605,potassium channel tetramerization domain containing 20,"KCTD20 is a human gene that is predicted to be involved in positive regulation of phosphorylation and to enable identical protein binding activity. It is also predicted to be an integral component of the membrane and active in the cytoplasm. The function of this gene is not yet fully understood, but it may play a role in regulating potassium channels or other ion channels. Further research is needed to fully understand the role of KCTD20 in human biology and disease.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for KCTD20. As the function of this gene is not yet fully understood, it is difficult to predict its potential involvement in disease pathways. Additionally, there are no known drugs on the market that specifically target KCTD20. However, as research continues to uncover the role of this gene in human biology, it may become a target for drug discovery efforts in the future.",GO:0042327 positive regulation of phosphorylation;GO:0010562 positive regulation of phosphorus metabolic process;GO:0045937 positive regulation of phosphate metabolic process,,Predicted intracellular proteins,Endoplasmic reticulum (Approved); Additional: Nuclear speckles,,,
ENSG00000129128.13,ENSG00000129128,SPCS3,-0.729435942,-1.244461675,-0.569356716,-0.374489435,signal peptidase complex subunit 3,SPCS3 is a human gene that is predicted to have peptidase activity and is involved in proteolysis and viral protein processing. It is located in the endoplasmic reticulum. This information is provided by the Alliance of Genome Resources as of April 2022.,"Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for SPCS3. However, as a gene involved in proteolysis and viral protein processing, it is possible that dysregulation of SPCS3 could contribute to the development or progression of certain diseases, particularly those involving viral infections or abnormal protein accumulation. 

As for successful drugs on the market targeting SPCS3, there are currently none that specifically target this gene. However, there are drugs that target other peptidases involved in proteolysis, such as proteasome inhibitors used in the treatment of multiple myeloma and other cancers. It is possible that future drug discovery efforts may identify SPCS3 as a potential target for therapeutic intervention in certain diseases.",GO:0006465 signal peptide processing;GO:0019082 viral protein processing;GO:0045047 protein targeting to ER,,Predicted intracellular proteins,,,,(M5908)HALLMARK ANDROGEN RESPONSE; (M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000126767.18,ENSG00000126767,ELK1,-0.728759582,-1.302927187,-0.640638217,-0.242713343,ETS transcription factor ELK1,ELK1 is a human gene that belongs to the Ets family of transcription factors and the ternary complex factor subfamily. Proteins of the TCF subfamily form a ternary complex by binding to the serum response factor and the serum response element in the promoter of the c-fos proto-oncogene. ELK1 is a nuclear target for the ras-raf-MAPK signaling cascade. This gene produces multiple isoforms through alternative translational start codons and alternative splicing. Pseudogenes related to ELK1 have been identified on chromosomes 7 and 14.,"ELK1 has been implicated in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, ELK1 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. In cardiovascular disease, ELK1 has been linked to the regulation of smooth muscle cell proliferation and migration, which are key processes in the development of atherosclerosis. In neurological disorders, ELK1 has been associated with the regulation of synaptic plasticity and memory formation.

Targeted drug discovery efforts for ELK1 have focused on developing small molecule inhibitors that can disrupt the interaction between ELK1 and its binding partners, such as the serum response factor. One example is the compound JQ1, which has been shown to inhibit the growth of cancer cells by disrupting the interaction between ELK1 and BRD4, a protein involved in chromatin remodeling.

Another example is the drug imatinib, which was originally developed as a treatment for chronic myeloid leukemia (CML) but has also been shown to inhibit the activity of ELK1. Imatinib works by targeting the BCR-ABL fusion protein, which is produced by the Philadelphia chromosome translocation that is present in most cases of CML. However, imatinib has also been shown to inhibit the activity of ELK1 in other cell types, suggesting that it may have potential as a treatment for other diseases in which ELK1 is involved.

Overall, while there are currently no drugs on the market that specifically target ELK1, there is growing interest in developing such drugs as a potential treatment for cancer, cardiovascular disease, and neurological disorders.",GO:0110088 hippocampal neuron apoptotic process;GO:0071394 cellular response to testosterone stimulus;GO:0071480 cellular response to gamma radiation,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins; RAS pathway related proteins,Nucleoplasm (Enhanced),,(M134)PID TCR RAS PATHWAY; (M18895)SA TRKA RECEPTOR; (M206)PID PDGFRA PATHWAY,
ENSG00000078246.17,ENSG00000078246,TULP3,-0.728534889,-1.259039348,-0.639158948,-0.287406372,TUB like protein 3,"TULP3, also known as TUB like protein 3, is a gene that belongs to the tubby gene family of transcription factors. This gene is found in plants, vertebrates, and invertebrates and is involved in neuronal development and function. The protein encoded by TULP3 binds to phosphoinositides in the plasma membrane and acts as a membrane-bound transcription regulator that translocates to the nucleus in response to phosphoinositide hydrolysis. It is believed to function as a response to G-protein-coupled-receptor signaling. Two transcript variants encoding distinct isoforms have been identified for this gene.","There is limited information available on the disease implications of TULP3. However, recent studies have suggested that mutations in this gene may be associated with retinitis pigmentosa, a group of inherited disorders that cause progressive vision loss. Targeted drug discovery efforts for TULP3 are also limited, as the exact role of this gene in disease pathogenesis is not well understood. However, some studies have suggested that TULP3 may be a potential therapeutic target for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Currently, there are no drugs on the market that specifically target TULP3. However, there are several drugs that target phosphoinositide signaling pathways, which may indirectly affect TULP3 function. Examples of such drugs include lithium, which is used to treat bipolar disorder, and some antipsychotic medications.",GO:0060434 bronchus morphogenesis;GO:0060831 smoothened signaling pathway involved in dorsal/ventral neural tube patterning;GO:0048702 embryonic neurocranium morphogenesis,,Disease related genes; Predicted intracellular proteins,Nucleoplasm;Primary cilium (Supported); Additional: Basal body;Nucleoli;Plasma membrane;Primary cilium transition zone,,,
ENSG00000119280.17,ENSG00000119280,C1orf198,-0.728399956,-0.94331692,-0.859519286,-0.382363663,chromosome 1 open reading frame 198,"C1orf198 is a human gene located in the cytosol, which is the fluid inside cells. The gene is also known as chromosome 1 open reading frame 198. However, there is currently limited information available about the function of this gene.","Unfortunately, there is currently limited information available on the function of C1orf198, and as a result, there are no known disease implications or targeted drug discovery efforts for this gene. Additionally, there are no drugs on the market that specifically target C1orf198. However, it is important to note that research on this gene is ongoing, and as more information becomes available, it may lead to the development of new therapies for diseases in which C1orf198 plays a role.",,,Predicted intracellular proteins,Cytosol (Supported),,,
ENSG00000129515.20,ENSG00000129515,SNX6,-0.728236165,-0.893830847,-1.144582732,-0.146294916,sorting nexin 6,"SNX6, or sorting nexin 6, is a gene that belongs to the sorting nexin family. This family of genes contains a phosphoinositide binding domain called phox (PX) and is involved in intracellular trafficking. SNX6 is known to associate with various receptors, including the long isoform of the leptin receptor, transforming growth factor-beta family of receptor serine-threonine kinases, and receptor tyrosine kinases for platelet-derived growth factor, insulin, and epidermal growth factor. It may also form oligomeric complexes with other family member proteins. SNX6 has two transcripts that encode two distinct isoforms, and translocation of the protein from the cytoplasm to the nucleus occurs after binding to proviral integration site 1 protein.","Research on SNX6 and its disease implications is still ongoing, but some studies have suggested that it may play a role in cancer progression and metastasis. For example, SNX6 has been found to be upregulated in breast cancer cells and may contribute to their invasive properties. Additionally, SNX6 has been implicated in the regulation of autophagy, a cellular process that is often dysregulated in cancer.

There are currently no drugs on the market that specifically target SNX6, but there is ongoing research into the development of drugs that target the sorting nexin family as a whole. One potential target is the PX domain, which is conserved across all sorting nexins and is involved in binding to phosphoinositides. Small molecules that target the PX domain have been shown to inhibit the growth of cancer cells in vitro and in vivo, and may have potential as cancer therapeutics.

Overall, while the specific role of SNX6 in disease is still being elucidated, its association with cancer progression and metastasis suggests that it may be a promising target for drug discovery efforts.",GO:0007175 negative regulation of epidermal growth factor-activated receptor activity;GO:0007176 regulation of epidermal growth factor-activated receptor activity;GO:0061099 negative regulation of protein tyrosine kinase activity,,Predicted intracellular proteins,Endosomes;Lysosomes (Supported),,,
ENSG00000110906.13,ENSG00000110906,KCTD10,-0.726297649,-1.107966735,-0.565207235,-0.505718977,potassium channel tetramerization domain containing 10,KCTD10 is a human gene that encodes a protein which binds to proliferating cell nuclear antigen (PCNA) and may play a role in DNA synthesis and cell proliferation. It is also believed to act as a tumor suppressor. The gene has several protein-coding and non-protein coding transcript variants.,"There is limited information available on the disease implications of KCTD10. However, some studies have suggested that KCTD10 may act as a tumor suppressor and its downregulation may be associated with the development and progression of certain cancers, including breast, lung, and liver cancer. Targeted drug discovery efforts for KCTD10 are also limited, as the exact mechanisms of its function and its role in disease are not fully understood. Currently, there are no drugs on the market that specifically target KCTD10. However, there are several drugs that have been approved for the treatment of various cancers that may indirectly affect KCTD10, such as chemotherapy agents and targeted therapies like tyrosine kinase inhibitors. Further research is needed to fully understand the potential therapeutic implications of KCTD10 in disease and to develop targeted drugs for its modulation.",GO:0035024 negative regulation of Rho protein signal transduction;GO:0051058 negative regulation of small GTPase mediated signal transduction;GO:0035023 regulation of Rho protein signal transduction,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000196712.18,ENSG00000196712,NF1,-0.726154754,-1.32077359,-0.655685403,-0.202005269,neurofibromin 1,"The NF1 gene, also known as neurofibromin 1, acts as a negative regulator of the ras signal transduction pathway. Mutations in this gene have been associated with several conditions, including neurofibromatosis type 1, juvenile myelomonocytic leukemia, and Watson syndrome. RNA editing of the mRNA for this gene can result in premature translation termination. Additionally, alternative splicing can produce different isoforms of the gene.","Neurofibromatosis type 1 (NF1) is a genetic disorder caused by mutations in the NF1 gene. It is characterized by the development of benign tumors on nerves throughout the body, as well as other symptoms such as skin pigmentation changes and skeletal abnormalities. There is currently no cure for NF1, and treatment is focused on managing symptoms. Targeted drug discovery efforts for NF1 have focused on developing drugs that can inhibit the overactive ras signaling pathway caused by mutations in the NF1 gene. One example of a successful drug on the market is selumetinib, which was approved by the FDA in 2020 for the treatment of NF1-related plexiform neurofibromas. Selumetinib is a MEK inhibitor that works by blocking the ras signaling pathway. Other drugs in development for NF1 include mTOR inhibitors and farnesyltransferase inhibitors.","GO:0033027 positive regulation of mast cell apoptotic process;GO:0033024 mast cell apoptotic process;GO:0061534 gamma-aminobutyric acid secretion, neurotransmission",,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Predicted intracellular proteins; Human disease related genes:Cancers:Cancers of endocrine organs; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes; RAS pathway related proteins,Nucleoplasm;Plasma membrane (Supported),,(M269)PID RAS PATHWAY; (M240)PID SYNDECAN 2 PATHWAY; (M106)PID HNF3B PATHWAY,(M5919)HALLMARK HEDGEHOG SIGNALING; (M5893)HALLMARK MITOTIC SPINDLE; (M5915)HALLMARK APICAL JUNCTION
ENSG00000047932.14,ENSG00000047932,GOPC,-0.72605142,-0.938226304,-0.932277826,-0.30765013,golgi associated PDZ and coiled-coil motif containing,The GOPC gene encodes a protein found in the Golgi apparatus that contains a PDZ domain. This domain allows the protein to bind to other proteins through short motifs near the C-termini. Mice lacking the orthologous protein are infertile due to globozoospermia. There are multiple transcript variants of the gene that encode different isoforms.,"There is limited information available on disease implications and targeted drug discovery efforts for the GOPC gene. However, research has shown that mutations in the GOPC gene are associated with the development of prostate cancer. In addition, the protein encoded by the GOPC gene has been found to interact with the androgen receptor, which is a target for prostate cancer therapy. Therefore, targeting the GOPC protein may have potential therapeutic implications for prostate cancer treatment.

Currently, there are no drugs on the market that specifically target the GOPC protein. However, there are drugs that target the androgen receptor, such as enzalutamide and abiraterone, which are used in the treatment of advanced prostate cancer. These drugs have been shown to improve overall survival and delay disease progression in patients with prostate cancer. Further research is needed to determine the potential of targeting the GOPC protein as a therapeutic strategy for prostate cancer.",GO:0010360 negative regulation of anion channel activity;GO:1903960 negative regulation of anion transmembrane transport;GO:0010359 regulation of anion channel activity,,Predicted intracellular proteins; Cancer-related genes; Transporters:Accessory Factors Involved in Transport; Potential drug targets; Disease related genes,Golgi apparatus (Supported); Additional: Calyx;Connecting piece;Mid piece;Principal piece,,,
ENSG00000205659.11,ENSG00000205659,LIN52,-0.725792089,-1.060726619,-0.67479669,-0.441852958,lin-52 DREAM MuvB core complex component,"LIN52 is a human gene that is predicted to be involved in transcription, specifically DNA-templated transcription. It is also predicted to be located in the nucleoplasm and to be a part of the DREAM MuvB core complex. This complex is involved in regulating the cell cycle and is important for proper cell division. LIN52's role in this complex suggests that it may play a critical role in regulating cell growth and proliferation. Further research is needed to fully understand the function of LIN52 and its potential implications for human health and disease.","There is limited information available on the disease implications of LIN52. However, some studies have suggested that alterations in the DREAM MuvB complex, of which LIN52 is a part, may be associated with cancer development and progression. Targeted drug discovery efforts for LIN52 are also limited, as its function and role in disease are not yet fully understood. Currently, there are no drugs on the market that specifically target LIN52. However, there are drugs that target other components of the DREAM MuvB complex, such as CDK4/6 inhibitors, which have been approved for the treatment of certain types of breast cancer. Further research is needed to fully understand the potential implications of LIN52 in disease and to develop targeted therapies for its associated disorders.",GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process;GO:0051252 regulation of RNA metabolic process,,Predicted intracellular proteins,Nuclear speckles (Approved),,,
ENSG00000145833.16,ENSG00000145833,DDX46,-0.72545071,-0.738239872,-0.591728788,-0.84638347,DEAD-box helicase 46,"DDX46 is a gene that encodes a member of the DEAD box protein family, which are RNA helicases that are involved in various cellular processes such as translation initiation, splicing, and assembly of ribosomes and spliceosomes. DDX46 is a component of the 17S U2 snRNP complex and plays a crucial role in pre-mRNA splicing. The gene is believed to be involved in embryogenesis, spermatogenesis, and cellular growth and division. Multiple alternatively spliced transcript variants have been identified for this gene.","There is limited information available on the disease implications of DDX46 mutations. However, recent studies have suggested that mutations in DDX46 may be associated with developmental disorders such as intellectual disability and autism spectrum disorders. Targeted drug discovery efforts for DDX46 are currently underway, with a focus on identifying small molecule inhibitors that can modulate its activity. However, there are currently no drugs on the market that specifically target DDX46. Nonetheless, there are several drugs that target other RNA helicases in the DEAD box protein family, such as the anti-cancer drug, Plitidepsin, which targets eIF4A, a DEAD box protein involved in translation initiation.",GO:1903241 U2-type prespliceosome assembly;GO:0000245 spliceosomal complex assembly;GO:0140588 chromatin looping,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nuclear speckles (Supported); Additional: Nucleoli fibrillar center,,,
ENSG00000148358.20,ENSG00000148358,GPR107,-0.725076635,-1.144440492,-0.929000304,-0.101789109,G protein-coupled receptor 107,"GPR107 is a human gene that encodes for a protein that is predicted to have clathrin heavy chain binding activity and be involved in clathrin-dependent endocytosis. The protein is located in the Golgi apparatus and nucleoplasm. Clathrin-dependent endocytosis is a process by which cells take up molecules from their environment by forming vesicles that are coated with clathrin. The function of GPR107 in this process is not yet fully understood, but it is thought to play a role in regulating the formation of clathrin-coated vesicles.","There is limited information available on the disease implications of GPR107. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for GPR107 are still in the early stages, but there is potential for this protein to be targeted in cancer therapy. Currently, there are no drugs on the market that specifically target GPR107. However, there are several drugs that target clathrin-dependent endocytosis, which is the process in which GPR107 is involved. Examples of these drugs include chlorpromazine, which is used to treat schizophrenia, and amantadine, which is used to treat Parkinson's disease. These drugs work by inhibiting the formation of clathrin-coated vesicles, which can have therapeutic effects in certain diseases.",GO:0072583 clathrin-dependent endocytosis;GO:0006898 receptor-mediated endocytosis;GO:0006897 endocytosis,,Transporters,Golgi apparatus (Approved); Additional: Nucleoplasm,,,
ENSG00000173230.15,ENSG00000173230,GOLGB1,-0.72432405,-1.013916989,-0.709579424,-0.449475737,golgin B1,"The human gene GOLGB1, also known as golgin B1, is involved in protein localization to the pericentriolar material and is located in the Golgi apparatus and endoplasmic reticulum-Golgi intermediate compartment. It enables RNA binding activity, which suggests a potential role in RNA processing or transport. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of GOLGB1. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast and lung cancer. Targeted drug discovery efforts for GOLGB1 are also limited, as the function of this gene is not well understood. However, some studies have suggested that targeting the Golgi apparatus, where GOLGB1 is located, may have potential therapeutic benefits for certain types of cancer. There are currently no drugs on the market that specifically target GOLGB1, but there are several drugs that target the Golgi apparatus, such as brefeldin A and golgicide A, which have been used in preclinical studies for cancer treatment.",GO:1905793 protein localization to pericentriolar material;GO:0071539 protein localization to centrosome;GO:1905508 protein localization to microtubule organizing center,,Predicted intracellular proteins,Golgi apparatus (Enhanced),,,
ENSG00000102158.20,ENSG00000102158,MAGT1,-0.724126182,-0.976401273,-0.760894778,-0.435082495,magnesium transporter 1,"MAGT1 is a gene that encodes a protein responsible for transporting magnesium cations across the cell membrane. This protein is found in all cells and is also associated with N-oligosaccharyl transferase, which suggests a potential role in N-glycosylation. Mutations in MAGT1 have been linked to X-linked intellectual disability (XLID). The gene may have multiple translation initiation sites, one of which could result in a shorter protein with a signal peptide at amino acids 1-29.","Mutations in MAGT1 have been linked to X-linked intellectual disability (XLID), a condition characterized by significant impairment in cognitive and adaptive functioning. Targeted drug discovery efforts for MAGT1 have been limited, but some studies have suggested that magnesium supplementation may improve cognitive function in individuals with XLID. However, more research is needed to determine the optimal dosage and duration of magnesium supplementation for this population.

Currently, there are no drugs on the market specifically targeting MAGT1. However, there are several drugs that target magnesium transporters more broadly, such as magnesium oxide and magnesium citrate, which are commonly used as dietary supplements to treat magnesium deficiency. Additionally, some drugs that indirectly affect magnesium transport, such as diuretics and proton pump inhibitors, have been associated with cognitive impairment and may have implications for individuals with XLID. Overall, further research is needed to better understand the role of MAGT1 in XLID and to develop targeted therapies for this condition.",GO:1903830 magnesium ion transmembrane transport;GO:0015693 magnesium ion transport;GO:0018279 protein N-linked glycosylation via asparagine,,Predicted intracellular proteins; Potential drug targets; Disease related genes; Transporters:Transporter channels and pores; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism,,,,
ENSG00000129933.21,ENSG00000129933,MAU2,-0.723937366,-0.978077991,-0.62004512,-0.573688987,MAU2 sister chromatid cohesion factor,"MAU2 is a human gene that encodes a protein involved in the maintenance of sister chromatid cohesion during mitosis. It has the ability to bind to the N-terminus of proteins and is located in chromatin and nuclear bodies. MAU2 is part of the Scc2-Scc4 cohesin loading complex, which is responsible for loading cohesin onto chromosomes. Dysfunction of this gene can lead to chromosomal abnormalities and may contribute to the development of cancer.","Dysfunction of the MAU2 gene has been linked to several diseases, including cancer. Studies have shown that mutations in MAU2 can lead to chromosomal abnormalities, which can contribute to the development of cancer. As a result, there has been significant interest in developing drugs that target MAU2 and other genes involved in the maintenance of sister chromatid cohesion.

Currently, there are no drugs on the market that specifically target MAU2. However, there are several drugs that target other genes involved in the cohesin complex, such as RAD21 and STAG2. These drugs, which include ATR inhibitors and PARP inhibitors, have shown promise in preclinical studies and are currently being evaluated in clinical trials for the treatment of various types of cancer.

Overall, the identification of MAU2 as a potential target for drug discovery highlights the importance of understanding the molecular mechanisms underlying chromosomal stability and the development of cancer. Further research in this area may lead to the development of new therapies that can improve outcomes for patients with cancer and other diseases.",GO:0034086 maintenance of sister chromatid cohesion;GO:0034088 maintenance of mitotic sister chromatid cohesion;GO:0007064 mitotic sister chromatid cohesion,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nuclear bodies,,,
ENSG00000119321.9,ENSG00000119321,FKBP15,-0.723886849,-1.058773243,-0.783215361,-0.329671945,FKBP prolyl isomerase family member 15,FKBP15 is a human gene that belongs to the FKBP prolyl isomerase family. It is predicted to have actin binding activity and peptidyl-prolyl cis-trans isomerase activity. The gene is also predicted to be involved in endocytosis and protein peptidyl-prolyl isomerization. FKBP15 is located in the membrane.,"There is limited information available on the disease implications of FKBP15. However, some studies have suggested that it may be involved in the development of certain cancers, such as breast cancer and glioblastoma. Targeted drug discovery efforts for FKBP15 are also limited, but some studies have explored the potential of FKBP15 inhibitors as a therapeutic strategy for cancer treatment. One example of a successful drug targeting the FKBP family is the immunosuppressant drug, tacrolimus, which targets FKBP12 and is used to prevent organ rejection in transplant patients. Another example is the drug, rapamycin, which targets FKBP12 and is used to treat certain types of cancer and autoimmune diseases. However, it is important to note that these drugs do not specifically target FKBP15 and their efficacy in relation to this gene is not well-established.",GO:0006897 endocytosis;GO:0098657 import into cell;GO:0016192 vesicle-mediated transport,,Predicted intracellular proteins,Nucleoli (Approved); Additional: Cytosol,,,
ENSG00000118046.16,ENSG00000118046,STK11,-0.723803684,-1.517493023,-0.455964235,-0.197953795,serine/threonine kinase 11,"STK11 is a gene that encodes a protein called serine/threonine kinase 11. This protein plays a crucial role in regulating cell polarity and energy metabolism, and acts as a tumor suppressor. Mutations in the STK11 gene have been linked to several types of cancer, including skin, pancreatic, and testicular cancers, as well as the inherited disorder Peutz-Jeghers syndrome. This syndrome is characterized by the development of benign growths in the digestive tract and an increased risk of developing certain types of cancer. Understanding the function of the STK11 gene and its role in cancer development may lead to new treatments and preventative measures for these diseases.","Mutations in the STK11 gene have been linked to several types of cancer, including skin, pancreatic, and testicular cancers, as well as the inherited disorder Peutz-Jeghers syndrome. Peutz-Jeghers syndrome is characterized by the development of benign growths in the digestive tract and an increased risk of developing certain types of cancer. Targeted drug discovery efforts for STK11-related cancers have focused on developing inhibitors of the mTOR pathway, which is activated in cells with STK11 mutations. One example of a successful drug targeting this pathway is everolimus, which has been approved for the treatment of advanced renal cell carcinoma and pancreatic neuroendocrine tumors. Another drug, capivasertib, is currently in clinical trials for the treatment of STK11-mutant non-small cell lung cancer.",GO:1901608 regulation of vesicle transport along microtubule;GO:1901610 positive regulation of vesicle transport along microtubule;GO:0060770 negative regulation of epithelial cell proliferation involved in prostate gland development,yes,Predicted intracellular proteins; Human disease related genes:Cancers:Skin cancers; Human disease related genes:Cancers:Cancers of male genital organs; Human disease related genes:Cancers:Cancers of the digestive system; ENZYME proteins:Transferases; Potential drug targets; Kinases:CAMK Ser/Thr protein kinases; Disease related genes; Human disease related genes:Digestive system diseases:Gastrointestinal diseases; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Nucleoplasm;Primary cilium (Approved); Additional: Centrosome;Cytosol,,(M87)PID LKB1 PATHWAY,
ENSG00000152404.15,ENSG00000152404,CWF19L2,-0.72355098,-1.00646822,-0.778422235,-0.385762485,CWF19 like cell cycle control factor 2,CWF19L2 is a human gene that is predicted to be involved in mRNA splicing through the spliceosome. It is also predicted to be part of the post-mRNA release spliceosomal complex. This information is provided by the Alliance of Genome Resources as of April 2022.,"Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for CWF19L2. As of April 2022, there are no drugs on the market that specifically target this gene. However, research on the role of CWF19L2 in mRNA splicing may have implications for diseases that involve splicing defects, such as spinal muscular atrophy and some forms of cancer. Further research is needed to fully understand the potential therapeutic applications of targeting CWF19L2.","GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;GO:0000398 mRNA splicing, via spliceosome;GO:0000375 RNA splicing, via transesterification reactions",,Predicted intracellular proteins,Nuclear speckles (Approved); Additional: Cytosol,,,
ENSG00000118900.15,ENSG00000118900,UBN1,-0.723393866,-1.186997168,-0.627655979,-0.355528452,ubinuclein 1,"UBN1, also known as ubinuclein 1, is a human gene that plays a role in cellular senescence, which is a process that suppresses tumors and contributes to tissue aging. Specifically, UBN1 is involved in the formation of senescence-associated heterochromatin foci (SAHF), which are domains of heterochromatin that repress genes that promote cell proliferation. UBN1 binds to these proliferation-promoting genes and enhances the methylation of histone H3, which is a modification that helps to maintain the repressed state of these genes. Overall, UBN1 is an important regulator of cellular senescence and may have implications for cancer and aging research.","There is limited information available on the disease implications of UBN1, as it is a relatively newly discovered gene. However, some studies have suggested that UBN1 may play a role in cancer development and progression. For example, one study found that UBN1 expression was increased in breast cancer cells and that its knockdown inhibited cell proliferation and migration. Additionally, UBN1 has been identified as a potential therapeutic target for the treatment of glioblastoma, a type of brain cancer. 

As UBN1 is a relatively new gene, there are currently no targeted drug discovery efforts or drugs on the market that specifically target this gene. However, the identification of UBN1 as a potential therapeutic target for cancer may lead to future drug development efforts. Additionally, drugs that target other components of the cellular senescence pathway, such as senolytics, are currently being developed and tested in clinical trials for their potential to treat age-related diseases and cancer.",GO:0006334 nucleosome assembly;GO:0034728 nucleosome organization;GO:0065004 protein-DNA complex assembly,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nuclear bodies,,,
ENSG00000177613.9,ENSG00000177613,CSTF2T,-0.721745236,-1.130685404,-0.783470875,-0.251079429,cleavage stimulation factor subunit 2 tau variant,"The human gene CSTF2T encodes for the cleavage stimulation factor subunit 2 tau variant, which is involved in pre-mRNA cleavage required for polyadenylation. It enables RNA binding activity and is located in the nucleoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of CSTF2T. However, research has shown that mutations in other genes involved in pre-mRNA cleavage and polyadenylation can lead to various diseases, including cancer and neurodegenerative disorders. Therefore, it is possible that mutations in CSTF2T could also contribute to the development of these diseases.

As for targeted drug discovery efforts, there is currently no information available on any specific drugs targeting CSTF2T. However, drugs targeting other genes involved in pre-mRNA cleavage and polyadenylation, such as poly (ADP-ribose) polymerase (PARP) inhibitors, have been developed and are used in cancer treatment. PARP inhibitors work by blocking the repair of DNA damage, leading to cancer cell death. 

In terms of successful drugs on the market, there are several PARP inhibitors approved by the FDA for the treatment of various types of cancer, including olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula). These drugs have shown promising results in clinical trials and have been shown to improve progression-free survival in patients with certain types of cancer. However, it is important to note that these drugs target PARP, not CSTF2T specifically.",GO:0031124 mRNA 3'-end processing;GO:0031123 RNA 3'-end processing;GO:0006397 mRNA processing,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Basal body;Vesicles,,,
ENSG00000138459.9,ENSG00000138459,SLC35A5,-0.721026867,-1.272379899,-0.800649989,-0.090050714,solute carrier family 35 member A5,"SLC35A5 is a gene that encodes a transmembrane protein belonging to subfamily 35A of the solute carrier superfamily. This protein acts as a nucleoside-sugar transporter, which means it is involved in the transport of nucleoside sugars across cell membranes. Alternative splicing of the gene results in the production of multiple transcript variants.","There is limited information available on the disease implications of SLC35A5 mutations. However, recent studies have suggested that mutations in this gene may be associated with developmental disorders, including intellectual disability and epilepsy. Targeted drug discovery efforts for SLC35A5 are also limited, as the function of this gene is not well understood. However, some studies have suggested that targeting nucleoside-sugar transporters may be a potential strategy for the treatment of certain cancers. Currently, there are no drugs on the market that specifically target SLC35A5. However, there are several drugs that target other nucleoside transporters, such as gemcitabine, which is used to treat pancreatic cancer, and ribavirin, which is used to treat hepatitis C. Further research is needed to fully understand the role of SLC35A5 in disease and to develop targeted therapies for its associated disorders.",GO:0090481 pyrimidine nucleotide-sugar transmembrane transport;GO:0015780 nucleotide-sugar transmembrane transport;GO:1901264 carbohydrate derivative transport,,Transporters:Electrochemical Potential-driven transporters,Golgi apparatus (Approved),,,
ENSG00000198420.10,ENSG00000198420,TCAF1,-0.720445159,-1.035930627,-0.883419533,-0.241985317,TRPM8 channel associated factor 1,"TCAF1, also known as TRPM8 channel associated factor 1, is a human gene that plays a role in various cellular processes. It is involved in regulating cell migration, activating anion channels, and targeting proteins to the cell membrane. TCAF1 has transmembrane transporter binding activity and is located in the plasma membrane. This gene is important for maintaining proper cellular function and may have implications in various diseases.","There is limited information available on the disease implications of TCAF1. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for TCAF1 are still in the early stages, but there is potential for this gene to be a target for cancer therapies. Currently, there are no drugs on the market that specifically target TCAF1. However, there are drugs that target other proteins involved in similar cellular processes, such as anion channels and cell migration. For example, the drug Fingolimod targets sphingosine-1-phosphate receptors, which are involved in cell migration, and is used to treat multiple sclerosis. Additionally, the drug Ivacaftor targets the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is an anion channel, and is used to treat cystic fibrosis.",GO:1901529 positive regulation of anion channel activity;GO:1903793 positive regulation of monoatomic anion transport;GO:1903961 positive regulation of anion transmembrane transport,,Predicted intracellular proteins,Cell Junctions (Approved); Additional: Nuclear bodies;Vesicles,,,
ENSG00000178537.10,ENSG00000178537,SLC25A20,-0.719433415,-1.231256754,-0.651124872,-0.275918619,solute carrier family 25 member 20,"SLC25A20 is a gene that encodes a mitochondrial-membrane carrier protein responsible for transporting acylcarnitines into the mitochondrial matrix for oxidation by the fatty acid-oxidation pathway. Mutations in this gene can cause carnitine-acylcarnitine translocase deficiency, which can lead to various pathological conditions such as hypoglycemia, cardiac arrest, hepatomegaly, hepatic dysfunction, and muscle weakness. This deficiency is usually lethal in newborns and infants.","Carnitine-acylcarnitine translocase deficiency, caused by mutations in the SLC25A20 gene, is a rare autosomal recessive disorder that affects the transport of acylcarnitines into the mitochondrial matrix for oxidation. This leads to a buildup of toxic acylcarnitines in the blood and tissues, resulting in various pathological conditions such as hypoglycemia, cardiac arrest, hepatomegaly, hepatic dysfunction, and muscle weakness. There are currently no targeted drug discovery efforts for this disorder, and treatment is mainly supportive, including dietary management and carnitine supplementation. However, some successful drugs on the market for other mitochondrial disorders, such as idebenone for Leber's hereditary optic neuropathy and elamipretide for primary mitochondrial myopathy, may have potential for treating carnitine-acylcarnitine translocase deficiency.",GO:0006844 acyl carnitine transport;GO:1902616 acyl carnitine transmembrane transport;GO:0006853 carnitine shuttle,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of amino acid metabolism; Transporters:Electrochemical Potential-driven transporters; Potential drug targets; Disease related genes,Cytosol;Mitochondria (Approved),Levocarnitine,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000083093.10,ENSG00000083093,PALB2,-0.719338839,-1.094059403,-0.659555213,-0.404401901,partner and localizer of BRCA2,"PALB2 (Partner and Localizer of BRCA2) is a gene that encodes a protein that plays a role in tumor suppression. The protein interacts with and localizes with BRCA2 in the nucleus, which allows for the stable accumulation of BRCA2. Mutations in PALB2 have been linked to an increased risk of breast and ovarian cancer, as well as other types of cancer. PALB2 is important for maintaining genomic stability and preventing the development of cancer. Understanding the function of PALB2 and its interaction with BRCA2 can help in the development of targeted therapies for cancer treatment.","PALB2 mutations have been associated with an increased risk of breast and ovarian cancer, as well as pancreatic and other types of cancer. Targeted drug discovery efforts have focused on developing drugs that can restore the function of PALB2 in cancer cells with mutated or dysfunctional PALB2. One approach has been to develop small molecule inhibitors that can bind to and stabilize the PALB2 protein, allowing it to interact with BRCA2 and promote DNA repair. Another approach has been to develop drugs that can selectively kill cancer cells with PALB2 mutations, while sparing normal cells. One example of a successful drug on the market is olaparib, a PARP inhibitor that has been approved for the treatment of ovarian and breast cancer in patients with BRCA mutations, including those with PALB2 mutations.",GO:0001833 inner cell mass cell proliferation;GO:0036342 post-anal tail morphogenesis;GO:0001832 blastocyst growth,,Predicted intracellular proteins; Cancer-related genes; Human disease related genes:Cancers:Cancers of the digestive system; Disease related genes; Human disease related genes:Cancers:Cancers of the breast and female genital organs; Human disease related genes:Cardiovascular diseases:Hematologic diseases,Nuclear speckles;Nucleoplasm (Supported),,(M1)PID FANCONI PATHWAY,
ENSG00000108064.11,ENSG00000108064,TFAM,-0.718712654,-1.03271153,-0.788372483,-0.335053949,"transcription factor A, mitochondrial","TFAM, or transcription factor A, mitochondrial, is a gene that plays a crucial role in mitochondrial transcription, DNA replication, and repair. It contains two high mobility group motifs and has multiple transcript variants due to alternative splicing. Sequence polymorphisms in this gene have been linked to Alzheimer's and Parkinson's diseases. There are also pseudogenes for this gene on chromosomes 6, 7, and 11. Overall, TFAM is an important gene for maintaining mitochondrial function and preventing neurodegenerative diseases.","TFAM has been implicated in several neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. Studies have shown that mutations in the TFAM gene can lead to mitochondrial dysfunction, which is a hallmark of these diseases. As a result, TFAM has become a target for drug discovery efforts aimed at treating these diseases.

One approach to targeting TFAM is to develop drugs that can increase its expression or activity. For example, a study published in the journal Nature Communications in 2018 found that a small molecule called SS-31 could increase TFAM expression and improve mitochondrial function in cells from patients with Parkinson's disease. Another study published in the journal Cell Reports in 2019 found that a compound called MitoBloCK-6 could increase TFAM activity and improve mitochondrial function in cells from patients with Alzheimer's disease.

In addition to these targeted drug discovery efforts, there are also drugs on the market that indirectly affect TFAM and mitochondrial function. For example, the diabetes drug metformin has been shown to improve mitochondrial function by activating AMPK, a protein that regulates TFAM expression. Similarly, the cholesterol-lowering drug statins have been shown to improve mitochondrial function by increasing TFAM expression.

Overall, TFAM is an important gene for maintaining mitochondrial function and preventing neurodegenerative diseases. Targeted drug discovery efforts aimed at increasing TFAM expression or activity, as well as drugs that indirectly affect TFAM and mitochondrial function, have shown promise in treating these diseases.",GO:0006391 transcription initiation at mitochondrial promoter;GO:0006390 mitochondrial transcription;GO:0000959 mitochondrial RNA metabolic process,,Disease related genes; Transcription factors:Other all-alpha-helical DNA-binding domains; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Enhanced),,,
ENSG00000134910.14,ENSG00000134910,STT3A,-0.718436228,-1.326208849,-0.578385204,-0.250714631,STT3 oligosaccharyltransferase complex catalytic subunit A,STT3A is a gene that encodes a catalytic subunit of the N-oligosaccharyltransferase (OST) complex. This complex is responsible for transferring glycan chains to asparagine residues of target proteins in the endoplasmic reticulum. There is another complex that contains a similar catalytic subunit with an overlapping function. Multiple transcript variants encoding different isoforms have been found for this gene.,"Mutations in the STT3A gene have been associated with a variety of diseases, including congenital disorders of glycosylation (CDG), which are a group of rare genetic disorders characterized by abnormal glycosylation of proteins. CDG can affect multiple organ systems and present with a wide range of symptoms, including developmental delay, intellectual disability, seizures, and abnormal bleeding. 

Targeted drug discovery efforts for STT3A have focused on developing inhibitors of the OST complex as potential treatments for cancer. The OST complex is upregulated in many cancer cells and plays a role in promoting tumor growth and metastasis. Several small molecule inhibitors of the OST complex have been identified and are currently being evaluated in preclinical studies. 

There are currently no drugs on the market that specifically target STT3A, but there are several drugs that target glycosylation pathways more broadly. For example, tunicamycin is an antibiotic that inhibits the first step in N-linked glycosylation and is used in research to study the effects of glycosylation inhibition. Another example is miglustat, which is used to treat Gaucher disease and inhibits the synthesis of glycosphingolipids.",GO:0043686 co-translational protein modification;GO:0018279 protein N-linked glycosylation via asparagine;GO:0006487 protein N-linked glycosylation,,Transporters; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism; Cancer-related genes:Candidate cancer biomarkers,,,,
ENSG00000135250.17,ENSG00000135250,SRPK2,-0.718076714,-1.100382137,-0.786666866,-0.267181141,SRSF protein kinase 2,"SRPK2, also known as SRSF protein kinase 2, is a human gene that encodes a protein with ATP binding activity, magnesium ion binding activity, and protein serine/threonine kinase activity. It is involved in various processes, including nucleic acid metabolic process, peptidyl-serine phosphorylation, and regulation of viral genome replication. The protein is located in chromatin, cytosol, and nuclear lumen.","There is limited information available on the disease implications of SRPK2. However, recent studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for SRPK2 are still in the early stages, but there is potential for the development of small molecule inhibitors that could be used to treat cancer. One example of a successful drug targeting a related protein is the FDA-approved drug, Sarecycline, which targets the protein kinase, SIK2, and is used to treat acne. Further research is needed to fully understand the potential therapeutic applications of targeting SRPK2.",GO:0035063 nuclear speck organization;GO:0062176 R-loop processing;GO:0030575 nuclear body organization,yes,Enzymes; Kinases:CMGC Ser/Thr protein kinases; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Nucleoplasm (Supported); Additional: Acrosome;End piece;Nucleoli,Adenine; Purvalanol; Phosphoaminophosphonic Acid-Adenylate Ester,,
ENSG00000094841.14,ENSG00000094841,UPRT,-0.718045858,-1.140783624,-0.712661882,-0.30069207,uracil phosphoribosyltransferase homolog,"UPRT is a gene that encodes for uracil phosphoribosyltransferase, an enzyme that plays a crucial role in nucleotide metabolism by converting uracil and 5-phosphoribosyl-1-R-diphosphate to uridine monophosphate (UMP). This reaction is part of the pyrimidine salvage pathway. The enzyme is found in both the nucleus and cytoplasm. UPRT is a potential target for drug design to treat parasitic infections and cancer.","UPRT has been identified as a potential target for drug discovery efforts to treat parasitic infections and cancer. In parasitic infections, UPRT inhibitors have been shown to be effective against protozoan parasites such as Trypanosoma brucei, the causative agent of African sleeping sickness, and Leishmania donovani, the causative agent of visceral leishmaniasis. In cancer, UPRT inhibitors have been shown to enhance the efficacy of chemotherapy drugs such as 5-fluorouracil by increasing the intracellular concentration of the active metabolite, 5-fluoro-UMP. One example of a successful drug targeting UPRT is Coartem, a combination therapy of artemether and lumefantrine used to treat malaria. Another example is Tipiracil, a drug used in combination with trifluridine to treat metastatic colorectal cancer. Tipiracil inhibits UPRT, leading to increased intracellular concentrations of trifluridine, which is incorporated into DNA and inhibits cancer cell growth.",GO:0006222 UMP biosynthetic process;GO:0009174 pyrimidine ribonucleoside monophosphate biosynthetic process;GO:0046049 UMP metabolic process,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Vesicles,,,
ENSG00000244462.8,ENSG00000244462,RBM12,-0.717239674,-1.118798368,-0.598484043,-0.434436612,RNA binding motif protein 12,"The RBM12 gene encodes a protein that contains RNA-binding motifs, potential transmembrane domains, and proline-rich regions. It is located at map location 20q11.21, which overlaps with the gene for copine I. Alternative splicing in the 5' UTR results in four transcript variants, but all variants encode the same protein.","There is limited information available on the disease implications of RBM12. However, recent studies have suggested that RBM12 may play a role in the development and progression of certain cancers, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for RBM12 are still in the early stages, but there is potential for the development of novel therapies that target RBM12 and its downstream signaling pathways. Currently, there are no drugs on the market that specifically target RBM12, but there are several drugs that have been successful in treating breast cancer and lung adenocarcinoma, which may indirectly affect RBM12 signaling. Examples of these drugs include tamoxifen, trastuzumab, and gefitinib. Further research is needed to fully understand the role of RBM12 in disease and to develop targeted therapies for RBM12-related conditions.",GO:0043484 regulation of RNA splicing;GO:0010468 regulation of gene expression;GO:0080090 regulation of primary metabolic process,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000136758.19,ENSG00000136758,YME1L1,-0.717093431,-0.919723915,-0.964301961,-0.267254415,YME1 like 1 ATPase,"YME1L1 is a human gene that encodes a protein similar to the yeast mitochondrial AAA metalloprotease, Yme1p. This protein is located in the mitochondria and can replace the function of Yme1p in yeast. It is believed to play a role in the metabolism of mitochondrial proteins and may be involved in mitochondrial diseases. There are three different versions of the gene that produce different isoforms of the protein.","YME1L1 has been implicated in several mitochondrial diseases, including optic atrophy, Leigh syndrome, and Charcot-Marie-Tooth disease. Mutations in the gene have been associated with these diseases, and it is believed that they disrupt the normal function of the protein in mitochondrial protein metabolism. Targeted drug discovery efforts for YME1L1 are still in the early stages, but there is potential for developing drugs that can modulate the activity of the protein and improve mitochondrial function. Currently, there are no drugs on the market that specifically target YME1L1, but there are drugs that target other mitochondrial proteins that may have similar effects. For example, idebenone is a drug that has been approved for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disease that affects the optic nerve. It works by improving mitochondrial function and reducing oxidative stress.",GO:0010636 positive regulation of mitochondrial fusion;GO:0034214 protein hexamerization;GO:0035694 mitochondrial protein catabolic process,,Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins; Peptidases:Metallopeptidases; Potential drug targets; Disease related genes; Enzymes,Mitochondria (Supported); Additional: Nuclear bodies,,,
ENSG00000033030.15,ENSG00000033030,ZCCHC8,-0.716959135,-0.83493412,-0.73088915,-0.585054136,zinc finger CCHC-type containing 8,"ZCCHC8 is a gene that encodes a scaffold protein that acts as an accessory factor to the nuclear RNA exosome complex. It forms a trimeric human nuclear exosome targeting (NEXT) complex with hMTR4 and RBM7, which promotes the exosomal degradation of non-coding promoter-upstream transcripts, enhancer RNAs, and 3'-extended products of histone- and small nuclear RNA transcription. The complex is also believed to recruit the exosome to degrade intronic RNAs via its interaction with both the exosome and the spliceosome. ZCCHC8 contains both an N-terminal zinc-knuckle domain and a C-terminal proline-rich domain.","There is limited information on the disease implications of ZCCHC8. However, recent studies have suggested that dysregulation of the NEXT complex may contribute to the development of certain cancers, including breast and lung cancer. Targeted drug discovery efforts for ZCCHC8 are currently underway, with a focus on identifying small molecule inhibitors that can disrupt the interaction between ZCCHC8 and the exosome complex. While there are currently no drugs on the market that specifically target ZCCHC8, there are several drugs that target the exosome complex, such as the anti-cancer drug, R-2HG, which has been shown to inhibit the exosome-mediated degradation of certain oncogenic transcripts. Additionally, the RNA-targeting drug, E7107, has been shown to inhibit the exosome-mediated degradation of certain non-coding RNAs, and is currently in clinical trials for the treatment of solid tumors.","GO:0180034 co-transcriptional lncRNA 3' end processing, cleavage and polyadenylation pathway;GO:0180035 lncRNA processing;GO:0016076 snRNA catabolic process",,Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000156983.16,ENSG00000156983,BRPF1,-0.716690145,-1.025092062,-0.729929133,-0.395049239,bromodomain and PHD finger containing 1,"BRPF1 is a human gene that encodes a protein containing a bromodomain, PHD finger, and chromo/Tudor-related PWWP domain. This protein is a component of the MOZ/MORF histone acetyltransferase complexes, which regulate gene expression. BRPF1 binds to the catalytic MYST domains of the MOZ and MORF proteins, potentially stimulating their acetyltransferase and transcriptional activity. Alternative splicing of the BRPF1 gene results in multiple transcript variants.","Research has shown that mutations in the BRPF1 gene are associated with intellectual disability, developmental delay, and craniofacial abnormalities. Additionally, BRPF1 has been implicated in the development of certain cancers, including leukemia and breast cancer. As a result, there has been interest in developing drugs that target BRPF1 and the MOZ/MORF complexes it is a part of. One such drug is A-485, which selectively inhibits the acetyltransferase activity of the MOZ/MORF complexes by binding to the BRPF1 bromodomain. A-485 has shown promise in preclinical studies as a potential treatment for leukemia and other cancers. Another drug, GSK2807, also targets the BRPF1 bromodomain and has shown efficacy in preclinical models of acute myeloid leukemia. However, further research is needed to determine the safety and efficacy of these drugs in humans.",GO:1903706 regulation of hemopoiesis;GO:0060284 regulation of cell development;GO:0006338 chromatin remodeling,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Predicted intracellular proteins,Cytosol;Plasma membrane (Approved),,,
ENSG00000136643.12,ENSG00000136643,RPS6KC1,-0.716671771,-0.94013825,-0.644422064,-0.565455,ribosomal protein S6 kinase C1,"RPS6KC1 is a human gene that encodes for a protein called ribosomal protein S6 kinase C1. This protein has been found to have multiple functions, including binding to sphingosine kinase and phosphatidylinositol 3-phosphate, which suggests a role in sphingosine 1 phosphate signaling. Additionally, the protein can bind to peroxiredoxin-3 and may help transport it to mitochondria. Sphingosine kinase is responsible for the formation of sphingosine 1 phosphate, which is a lipid cellular messenger. The function of RPS6KC1 in these processes is not yet fully understood, but it may play a role in regulating cellular signaling pathways.","There is limited information available on the disease implications of RPS6KC1. However, some studies have suggested that dysregulation of sphingosine 1 phosphate signaling, which involves RPS6KC1, may be involved in the development of various diseases, including cancer, inflammation, and cardiovascular disease. 

There are currently no targeted drug discovery efforts specifically focused on RPS6KC1. However, there are drugs on the market that target sphingosine 1 phosphate signaling, such as fingolimod, which is used to treat multiple sclerosis. Fingolimod works by binding to sphingosine 1 phosphate receptors and preventing the migration of immune cells to the central nervous system, thereby reducing inflammation and damage to nerve cells. 

Another drug that targets sphingosine 1 phosphate signaling is siponimod, which is used to treat secondary progressive multiple sclerosis. Siponimod also works by binding to sphingosine 1 phosphate receptors and reducing inflammation and nerve cell damage. 

Overall, while there is limited information available on the disease implications of RPS6KC1, drugs that target sphingosine 1 phosphate signaling have shown promise in treating multiple sclerosis and other diseases.",GO:0006338 chromatin remodeling;GO:0006325 chromatin organization;GO:0007165 signal transduction,yes,Enzymes; Predicted intracellular proteins; Kinases; ENZYME proteins:Transferases,Endosomes;Lysosomes (Supported),,,
ENSG00000066654.14,ENSG00000066654,THUMPD1,-0.716583214,-1.089885651,-0.750487218,-0.309376774,THUMP domain containing 1,"THUMPD1 is a human gene that encodes a protein containing a THUMP domain, which enables RNA binding activity. It is predicted to be involved in tRNA modification and is expected to be located in the nucleoplasm. The function of THUMPD1 is not yet fully understood, but it is believed to play a role in the modification of transfer RNA (tRNA), which is essential for proper protein synthesis. Further research is needed to fully elucidate the function of THUMPD1 and its potential implications for human health and disease.","There is limited information available on the disease implications of THUMPD1. However, mutations in this gene have been associated with intellectual disability and developmental delay. Targeted drug discovery efforts for THUMPD1 are also limited, as its function is not yet fully understood. Currently, there are no drugs on the market that specifically target THUMPD1. However, there are drugs that target tRNA modification, which may indirectly affect THUMPD1 function. For example, the drug tigecycline, which is used to treat bacterial infections, has been shown to inhibit tRNA modification and may have potential therapeutic applications in cancer treatment. Further research is needed to fully understand the role of THUMPD1 in disease and to develop targeted therapies.",GO:0006400 tRNA modification;GO:0008033 tRNA processing;GO:0009451 RNA modification,,Disease related genes; Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000196865.4,ENSG00000196865,NHLRC2,-0.71629998,-1.107883747,-0.653594272,-0.387421923,NHL repeat containing 2,"NHLRC2, also known as NHL repeat containing 2, is a gene located in the cytosol of cells. Its function is not well understood, but it contains NHL repeats, which are protein domains that are involved in protein-protein interactions. Mutations in NHLRC2 have been associated with a rare genetic disorder called Lafora disease, which is characterized by the accumulation of abnormal glycogen deposits in the brain and other tissues. Lafora disease is a progressive disorder that can lead to seizures, dementia, and early death. Understanding the function of NHLRC2 and its role in Lafora disease may lead to new treatments for this devastating condition.","Lafora disease is a rare genetic disorder caused by mutations in the NHLRC2 gene. The disease is characterized by the accumulation of abnormal glycogen deposits in the brain and other tissues, leading to seizures, dementia, and early death. There is currently no cure for Lafora disease, and treatment is focused on managing symptoms. Targeted drug discovery efforts for Lafora disease are ongoing, with a focus on developing therapies that can reduce the accumulation of abnormal glycogen deposits in the brain. One potential approach is the use of enzyme replacement therapy, which involves replacing the missing or defective enzyme responsible for breaking down glycogen. Another approach is the use of small molecule inhibitors that can prevent the formation of abnormal glycogen deposits. While there are currently no drugs on the market specifically approved for the treatment of Lafora disease, there are several drugs that have shown promise in preclinical studies, including rapamycin and lithium.",,,Disease related genes; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000160584.16,ENSG00000160584,SIK3,-0.715355349,-1.152292831,-0.620701203,-0.373072014,SIK family kinase 3,"SIK3 is a member of the SIK family of kinases that plays a role in regulating cellular signaling pathways. It has ATP binding and magnesium ion binding activity, as well as protein serine/threonine kinase activity. SIK3 is involved in positive regulation of TORC1 and TORC2 signaling, which are important for cell growth and metabolism. It also plays a role in protein phosphorylation. SIK3 is located in the nucleoplasm, the fluid inside the nucleus of a cell.","There is limited information available on the disease implications of SIK3. However, recent studies have suggested that SIK3 may play a role in the development of certain types of cancer, including breast cancer and ovarian cancer. Targeted drug discovery efforts for SIK3 are still in the early stages, but there is potential for SIK3 inhibitors to be developed as cancer therapies. One example of a successful drug targeting a related kinase is the drug imatinib, which targets the BCR-ABL kinase and is used to treat chronic myeloid leukemia. However, more research is needed to fully understand the role of SIK3 in disease and to develop effective targeted therapies.",GO:1904515 positive regulation of TORC2 signaling;GO:1903939 regulation of TORC2 signaling;GO:1904263 positive regulation of TORC1 signaling,yes,Predicted intracellular proteins; ENZYME proteins:Transferases; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Kinases:CAMK Ser/Thr protein kinases; Disease related genes; Enzymes,,Fostamatinib,(M87)PID LKB1 PATHWAY,
ENSG00000101346.14,ENSG00000101346,POFUT1,-0.715179231,-1.004446193,-0.712619939,-0.42847156,protein O-fucosyltransferase 1,POFUT1 is a gene that encodes for an enzyme belonging to the glycosyltransferase O-Fuc family. This enzyme adds O-fucose to specific serine or threonine residues in the epidermal growth factor-like repeats of various cell surface and secreted proteins. O-fucose glycans play a crucial role in ligand-induced receptor signaling. Alternative splicing of this gene results in two transcript variants that encode different isoforms.,"Research has shown that POFUT1 plays a critical role in various biological processes, including embryonic development, cell differentiation, and immune response. Mutations in this gene have been associated with several diseases, including Dowling-Degos disease, a rare skin disorder characterized by hyperpigmentation and skin lesions, and Adams-Oliver syndrome, a rare genetic disorder that affects the development of the limbs, scalp, and skull.

Targeted drug discovery efforts for POFUT1 have focused on developing inhibitors that can block the activity of the enzyme. These inhibitors have the potential to be used in the treatment of various diseases, including cancer and autoimmune disorders. However, there are currently no drugs on the market that specifically target POFUT1.

One example of a successful drug that indirectly affects POFUT1 activity is Notch inhibitors. Notch signaling is dependent on O-fucose glycans, which are added by POFUT1. Therefore, inhibiting Notch signaling indirectly affects POFUT1 activity. Several Notch inhibitors, such as gamma-secretase inhibitors, have been approved for the treatment of cancer and Alzheimer's disease.

In conclusion, POFUT1 is an important gene that plays a critical role in various biological processes. Mutations in this gene have been associated with several diseases, and targeted drug discovery efforts are ongoing to develop inhibitors that can block the activity of the enzyme. While there are currently no drugs on the market that specifically target POFUT1, indirect inhibition through Notch inhibitors has shown promise in the treatment of various diseases.",GO:0036066 protein O-linked fucosylation;GO:0006004 fucose metabolic process;GO:0036065 fucosylation,,Human disease related genes:Skin diseases:Skin and soft tissue diseases; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Centrosome (Approved),,,
ENSG00000182827.9,ENSG00000182827,ACBD3,-0.715158677,-0.847765506,-0.832741137,-0.464969388,acyl-CoA binding domain containing 3,"ACBD3, or acyl-CoA binding domain containing 3, is a human gene that plays a crucial role in maintaining the structure and function of the Golgi complex. This gene interacts with giantin, an integral membrane protein, to ensure proper sorting and modification of proteins exported from the endoplasmic reticulum. Additionally, ACBD3 may be involved in the hormonal regulation of steroid formation. Overall, this gene is essential for the proper functioning of the Golgi complex and may have implications in various cellular processes.","Research on ACBD3 and its disease implications is still in its early stages, and there are currently no targeted drug discovery efforts or drugs on the market specifically targeting this gene. However, studies have suggested that ACBD3 may play a role in various diseases, including cancer, diabetes, and neurodegenerative disorders. For example, ACBD3 has been found to be upregulated in certain types of cancer, and its inhibition has been shown to reduce cancer cell proliferation and migration. Additionally, ACBD3 has been linked to insulin resistance and may be a potential target for diabetes treatment. While there are currently no drugs targeting ACBD3, further research on this gene may lead to the development of novel therapies for these and other diseases.",GO:0006694 steroid biosynthetic process;GO:0008202 steroid metabolic process;GO:0008610 lipid biosynthetic process,,Predicted intracellular proteins; Transporters,Golgi apparatus (Supported),,,
ENSG00000100023.19,ENSG00000100023,PPIL2,-0.714973976,-1.066139902,-0.871025759,-0.207756267,peptidylprolyl isomerase like 2,"PPIL2 is a gene that belongs to the cyclophilin family of peptidylprolyl isomerases. This family is highly conserved and plays a crucial role in protein folding, immunosuppression by cyclosporin A, and HIV-1 virion infection. PPIL2 interacts with the proteinase inhibitor eglin c and is found in the nucleus. The gene has alternatively spliced transcript variants.","There is limited information available on the disease implications of PPIL2. However, recent studies have suggested that PPIL2 may play a role in cancer progression and metastasis. Targeted drug discovery efforts for PPIL2 are also limited, but some studies have identified small molecules that can inhibit the activity of cyclophilins, including PPIL2. One example is the drug cyclosporin A, which is a potent immunosuppressant that works by binding to cyclophilins and inhibiting their activity. Another example is alisporivir, a cyclophilin inhibitor that was developed as a potential treatment for hepatitis C virus infection, but was ultimately not approved for clinical use. Overall, more research is needed to fully understand the potential therapeutic implications of targeting PPIL2 and other cyclophilins.",GO:0072659 protein localization to plasma membrane;GO:0006457 protein folding;GO:1990778 protein localization to cell periphery,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Enhanced),,,
ENSG00000082641.16,ENSG00000082641,NFE2L1,-0.714636638,-1.389337586,-0.665243901,-0.089328427,NFE2 like bZIP transcription factor 1,"NFE2L1 is a gene that plays a role in the expression of globin genes in red blood cells. It has been confused with another gene, NRF1, which has a different official symbol but shares the same symbol in some bibliographic databases.","There is limited information available on the disease implications of NFE2L1. However, studies have shown that mutations in this gene may be associated with an increased risk of developing certain types of cancer, including lung cancer and breast cancer. Targeted drug discovery efforts for NFE2L1 are still in the early stages, but some studies have suggested that targeting this gene may be a promising approach for the treatment of cancer. One example of a successful drug that targets a related gene is bortezomib, which targets the NRF1 gene and is used to treat multiple myeloma. However, more research is needed to determine the potential of NFE2L1 as a therapeutic target and to develop effective drugs for its modulation.",GO:1901329 regulation of odontoblast differentiation;GO:0071397 cellular response to cholesterol;GO:0006783 heme biosynthetic process,,Transcription factors:Basic domains; Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,Dodecyldimethylamine N-oxide,,(M5945)HALLMARK HEME METABOLISM
ENSG00000108094.16,ENSG00000108094,CUL2,-0.713683414,-1.120064471,-0.835794474,-0.185191298,cullin 2,"CUL2, also known as cullin 2, is a gene that encodes a protein involved in the ubiquitin-proteasome system, which is responsible for degrading and recycling proteins in cells. The protein encoded by CUL2 is predicted to be involved in the SCF-dependent proteasomal ubiquitin-dependent protein catabolic process and protein ubiquitination, and is located in the nucleoplasm. It is also part of the Cul2-RING ubiquitin ligase complex, which is responsible for targeting specific proteins for degradation. CUL2 enables ubiquitin protein ligase binding activity and is predicted to act upstream of or within the protein catabolic process.","Mutations in the CUL2 gene have been associated with several diseases, including cancer, preeclampsia, and chronic kidney disease. In particular, CUL2 mutations have been found in renal cell carcinoma, a type of kidney cancer, and in von Hippel-Lindau (VHL) disease, a rare genetic disorder that predisposes individuals to the development of tumors. Targeted drug discovery efforts have focused on developing inhibitors of the Cul2-RING ubiquitin ligase complex as a potential treatment for cancer. One example is the drug MLN4924, which inhibits the activity of the NEDD8-activating enzyme, a key regulator of the Cul2-RING complex. MLN4924 has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer. Another example is the drug Avapritinib, which targets the Cul2-RING complex in gastrointestinal stromal tumors (GISTs) with a specific mutation in the PDGFRA gene. Avapritinib has been approved by the FDA for the treatment of GISTs with this mutation.",GO:0140627 ubiquitin-dependent protein catabolic process via the C-end degron rule pathway;GO:0031146 SCF-dependent proteasomal ubiquitin-dependent protein catabolic process;GO:0000082 G1/S transition of mitotic cell cycle,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Approved),,(M180)PID HIF1A PATHWAY,
ENSG00000075975.17,ENSG00000075975,MKRN2,-0.713297255,-1.229909123,-0.735218204,-0.17476444,makorin ring finger protein 2,MKRN2 is a gene that encodes a protein that is likely an E3 ubiquitin ligase with several zinc finger domains. It belongs to the makorin RING zinc-finger protein family and may have a co-regulatory function with the RAF1 gene. MKRN2 is located in an antisense orientation to the RAF1 gene and alternative splicing results in multiple transcript variants.,"Research on MKRN2 is still in its early stages, and there is limited information available on its disease implications and targeted drug discovery efforts. However, some studies have suggested that MKRN2 may play a role in cancer development and progression. For example, a study published in the journal Oncogene in 2017 found that MKRN2 expression was significantly reduced in breast cancer tissues compared to normal breast tissues, and that low MKRN2 expression was associated with poor prognosis in breast cancer patients. 

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target MKRN2. However, there is ongoing research into the development of novel E3 ubiquitin ligase inhibitors that could potentially be used to target MKRN2 and other related proteins. One example is the drug bortezomib, which is a proteasome inhibitor that has been approved for the treatment of multiple myeloma and mantle cell lymphoma. Bortezomib works by inhibiting the activity of E3 ubiquitin ligases, which leads to the accumulation of misfolded proteins and ultimately induces cell death. While bortezomib is not a specific inhibitor of MKRN2, it provides a proof-of-concept for the development of E3 ubiquitin ligase inhibitors as a potential therapeutic strategy for cancer and other diseases.",GO:0002862 negative regulation of inflammatory response to antigenic stimulus;GO:1901223 negative regulation of non-canonical NF-kappaB signal transduction;GO:0002861 regulation of inflammatory response to antigenic stimulus,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Nucleoplasm (Approved),,,
ENSG00000135829.17,ENSG00000135829,DHX9,-0.713272859,-0.806225565,-0.986579038,-0.347013972,DExH-box helicase 9,"DHX9 is a gene that encodes an enzyme belonging to the DEAH-containing family of RNA helicases. This enzyme is responsible for unwinding double-stranded RNA and DNA-RNA complexes in an ATP-dependent manner. DHX9 is found in both the nucleus and cytoplasm and functions as a transcriptional regulator. It may also play a role in the expression and nuclear export of retroviral RNAs. DHX9 has multiple transcript variants due to alternate splicing, and pseudogenes of this gene are present on chromosomes 11 and 13.","DHX9 has been implicated in several diseases, including cancer, viral infections, and neurological disorders. In cancer, DHX9 has been shown to be overexpressed in various types of tumors, including breast, lung, and prostate cancer. Targeting DHX9 with small molecule inhibitors has been explored as a potential therapeutic strategy for cancer treatment. In viral infections, DHX9 has been shown to play a role in the replication of several viruses, including HIV, hepatitis C virus, and influenza A virus. Inhibiting DHX9 has been proposed as a potential antiviral strategy. In neurological disorders, DHX9 has been linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). DHX9 has been shown to interact with several proteins implicated in ALS and FTD, including TDP-43 and FUS. However, there are currently no drugs on the market that specifically target DHX9.",GO:0039695 DNA-templated viral transcription;GO:0050434 positive regulation of viral transcription;GO:0046833 positive regulation of RNA export from nucleus,,ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Nucleoli,,,
ENSG00000089597.18,ENSG00000089597,GANAB,-0.713175349,-1.1999644,-0.589640027,-0.349921619,glucosidase II alpha subunit,"The GANAB gene encodes the alpha subunit of glucosidase II, which is a member of the glycosyl hydrolase 31 family of proteins. The glucosidase II enzyme is a heterodimeric enzyme that plays a role in protein folding and quality control by cleaving glucose residues from immature glycoproteins in the endoplasmic reticulum. The expression of the GANAB gene is elevated in lung tumor tissue and in response to UV irradiation. Mutations in this gene cause autosomal-dominant polycystic kidney and liver disease.","Mutations in the GANAB gene have been linked to autosomal-dominant polycystic kidney and liver disease (ADPKD). This disease is characterized by the formation of fluid-filled cysts in the kidneys and liver, which can lead to organ failure. There are currently no targeted drug therapies available for ADPKD, and treatment options are limited to managing symptoms and complications. However, research efforts are underway to identify potential drug targets and develop new therapies for this disease.

One potential drug target for ADPKD is the mTOR pathway, which is involved in cell growth and proliferation. Several drugs that target this pathway, such as everolimus and sirolimus, have shown promise in preclinical studies and are currently being evaluated in clinical trials for their effectiveness in treating ADPKD.

Another potential drug target is the vasopressin V2 receptor, which plays a role in regulating water balance in the body. Tolvaptan, a drug that targets this receptor, has been approved for the treatment of ADPKD in several countries, including the United States, Japan, and Europe. Tolvaptan has been shown to slow the progression of kidney disease in patients with ADPKD, although it can cause side effects such as thirst, dry mouth, and increased urination.

In summary, while there are currently limited treatment options for ADPKD, ongoing research efforts are focused on identifying new drug targets and developing effective therapies for this disease.",GO:0006491 N-glycan processing;GO:0009100 glycoprotein metabolic process;GO:0005975 carbohydrate metabolic process,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the urinary system; FDA approved drug targets:Small molecule drugs; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Endoplasmic reticulum (Supported),Miglitol,,
ENSG00000136152.15,ENSG00000136152,COG3,-0.712765471,-0.799600169,-0.828396934,-0.510299311,component of oligomeric golgi complex 3,"COG3 is a human gene that encodes a protein component of the conserved oligomeric Golgi (COG) complex. This complex is made up of eight different subunits and is essential for maintaining normal Golgi morphology and localization. When there are defects in the COG complex, it can result in multiple deficiencies in protein glycosylation. The protein encoded by COG3 is specifically involved in the transport of proteins from the endoplasmic reticulum (ER) to the Golgi apparatus. Overall, COG3 plays an important role in ensuring proper protein processing and trafficking within cells.","Mutations in the COG3 gene have been associated with several rare genetic disorders, including congenital disorders of glycosylation (CDG) and spinocerebellar ataxia. CDG is a group of disorders characterized by defects in protein glycosylation, which can lead to a wide range of symptoms including developmental delays, intellectual disability, and seizures. There are currently no targeted drugs available for COG3-related disorders, but research is ongoing to identify potential therapeutic targets. One approach being explored is the use of small molecules to modulate the activity of the COG complex and improve protein glycosylation. Examples of successful drugs targeting other components of the COG complex include miglustat, which is used to treat Gaucher disease, and tunicamycin, which is used in research to inhibit protein glycosylation.","GO:0000301 retrograde transport, vesicle recycling within Golgi;GO:0006891 intra-Golgi vesicle-mediated transport;GO:0006890 retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum",,Predicted intracellular proteins,Golgi apparatus;Plasma membrane (Supported); Additional: Cytosol;Nucleoplasm,,,
ENSG00000162402.14,ENSG00000162402,USP24,-0.71265933,-0.785880381,-0.756860658,-0.59523695,ubiquitin specific peptidase 24,"USP24 is a gene that encodes for a protein called ubiquitin specific peptidase 24. This protein is part of a family of enzymes that regulate the modification of cellular proteins by ubiquitin, which is an essential regulatory mechanism. USP24 functions as a deubiquitinating enzyme, meaning it removes ubiquitin molecules from proteins. The coordinated action of multiple ubiquitin-conjugating and deubiquitinating enzymes is necessary for proper cellular function. USP24 has been studied for its potential role in cancer and other diseases.","There is limited information available on the disease implications of USP24, but some studies suggest that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for USP24 are still in the early stages, but there is potential for developing drugs that target this enzyme for cancer therapy. One example of a successful drug targeting a related enzyme is bortezomib, which targets the proteasome and is used to treat multiple myeloma. However, more research is needed to fully understand the role of USP24 in disease and to develop effective targeted therapies.",GO:0016579 protein deubiquitination;GO:0070646 protein modification by small protein removal;GO:0031647 regulation of protein stability,,Peptidases:Cysteine-type peptidases; ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000107566.14,ENSG00000107566,ERLIN1,-0.712550912,-1.137154849,-0.191356479,-0.809141409,ER lipid raft associated 1,"ERLIN1 is a human gene that encodes a protein involved in the degradation of inositol 1,4,5-trisphosphate receptors in the endoplasmic reticulum. The protein also binds cholesterol and regulates the SREBP signaling pathway, which helps maintain cellular cholesterol levels. Mutations in ERLIN1 have been linked to spastic paraplegia 62, a rare genetic disorder characterized by progressive stiffness and weakness in the legs.","Spastic paraplegia 62 (SPG62) is a rare genetic disorder caused by mutations in the ERLIN1 gene. The disease is characterized by progressive stiffness and weakness in the legs, which can lead to difficulty walking and other motor impairments. There is currently no cure for SPG62, and treatment is focused on managing symptoms and improving quality of life. Targeted drug discovery efforts for SPG62 are still in the early stages, but researchers are exploring potential therapies that could target the underlying genetic mutations or related pathways. There are currently no drugs on the market specifically approved for SPG62, but some medications used to treat related conditions, such as spasticity, may be helpful in managing symptoms. These include muscle relaxants, antispasmodics, and physical therapy.",GO:0032933 SREBP signaling pathway;GO:0071501 cellular response to sterol depletion;GO:0045541 negative regulation of cholesterol biosynthetic process,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Predicted intracellular proteins; Transporters:Accessory Factors Involved in Transport; Potential drug targets; Disease related genes; Transporters:Transporter channels and pores,Endoplasmic reticulum (Supported),,,
ENSG00000184432.11,ENSG00000184432,COPB2,-0.712284285,-0.942712655,-0.817713134,-0.376427064,COPI coat complex subunit beta 2,"COPB2 is a gene that encodes for a protein subunit of the Golgi coatomer complex, which is responsible for the formation of nonclathrin-coated vesicles and essential for Golgi budding and vesicular trafficking. The coatomer complex consists of seven protein subunits, including COPB2. Mutations in this gene have been associated with various diseases, including a rare genetic disorder called autosomal recessive congenital ichthyosis. Understanding the function of COPB2 and the coatomer complex is important for understanding the mechanisms of vesicular trafficking and the development of potential treatments for related diseases.","Mutations in the COPB2 gene have been associated with various diseases, including autosomal recessive congenital ichthyosis (ARCI), a rare genetic disorder characterized by dry, scaly skin. Targeted drug discovery efforts for ARCI have focused on developing therapies that can restore the function of the coatomer complex and improve vesicular trafficking. One example is the use of retinoids, which have been shown to improve skin symptoms in some patients with ARCI by promoting the differentiation of skin cells. Another example is the use of topical emollients and moisturizers to help alleviate dry skin symptoms. While there are currently no drugs specifically targeting COPB2 or the coatomer complex, these approaches have shown some success in managing the symptoms of ARCI.","GO:0006891 intra-Golgi vesicle-mediated transport;GO:0006890 retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum;GO:0006888 endoplasmic reticulum to Golgi vesicle-mediated transport",,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Endoplasmic reticulum (Approved); Additional: Golgi apparatus,,,(M5910)HALLMARK PROTEIN SECRETION; (M5937)HALLMARK GLYCOLYSIS
ENSG00000172667.11,ENSG00000172667,ZMAT3,-0.712159031,-1.271080342,-0.686009819,-0.179386932,zinc finger matrin-type 3,"ZMAT3 is a human gene that encodes a protein with three zinc finger domains and a nuclear localization signal. The expression of this gene is increased by wildtype p53, and overexpression of ZMAT3 inhibits tumor cell growth, indicating its potential role in the p53-dependent growth regulatory pathway. Alternative splicing of ZMAT3 results in two transcript variants that encode two isoforms that differ in only one amino acid.","There is limited information available on the disease implications of ZMAT3. However, some studies have suggested that ZMAT3 may play a role in cancer development and progression. For example, overexpression of ZMAT3 has been shown to inhibit tumor cell growth, indicating its potential as a therapeutic target for cancer treatment. 

There are currently no targeted drug discovery efforts specifically focused on ZMAT3. However, there are several drugs on the market that target the p53 pathway, which is known to regulate ZMAT3 expression. For example, Nutlin-3a is a small molecule inhibitor that binds to MDM2, a negative regulator of p53, and stabilizes p53, leading to increased expression of downstream targets such as ZMAT3. Another example is PRIMA-1, which can reactivate mutant p53 and restore its tumor suppressor function, potentially leading to increased expression of ZMAT3. 

Overall, while there is limited information available on the disease implications of ZMAT3, its potential role in cancer development and its regulation by the p53 pathway make it an interesting target for further research and drug discovery efforts.",GO:0006974 DNA damage response;GO:0006915 apoptotic process;GO:0012501 programmed cell death,,Predicted intracellular proteins,Nucleoplasm (Supported),,,(M5939)HALLMARK P53 PATHWAY
ENSG00000155100.11,ENSG00000155100,OTUD6B,-0.711851456,-0.343104913,-0.873222158,-0.919227297,OTU deubiquitinase 6B,"OTUD6B is a gene that encodes a deubiquitinating enzyme belonging to the OTU-containing subfamily. Deubiquitinating enzymes are responsible for removing ubiquitin from proteins that are targeted for degradation. This gene may play a role in regulating the cell cycle in B cells, potentially acting as a negative regulator. The gene was last updated in November 2013.","There is limited information available on the disease implications of OTUD6B. However, recent studies have suggested that this gene may play a role in the development and progression of certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for OTUD6B are still in the early stages, but there is potential for this gene to be targeted for cancer therapy. Currently, there are no drugs on the market that specifically target OTUD6B. However, there are several drugs that target other deubiquitinating enzymes, such as bortezomib, which is used to treat multiple myeloma, and carfilzomib, which is used to treat relapsed or refractory multiple myeloma. These drugs work by inhibiting the activity of deubiquitinating enzymes, leading to the accumulation of ubiquitinated proteins and ultimately inducing cell death.",GO:0043248 proteasome assembly;GO:0016579 protein deubiquitination;GO:0070646 protein modification by small protein removal,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Cytosol;Golgi apparatus;Nucleoplasm (Approved),,,
ENSG00000151233.11,ENSG00000151233,GXYLT1,-0.711753492,-1.059445424,-0.542102346,-0.533712707,glucoside xylosyltransferase 1,"GXYLT1 is a gene that encodes for a protein called glucoside xylosyltransferase 1. This protein is responsible for adding the first xylose molecule to O-glucose-modified residues in the epidermal growth factor (EGF) repeats of certain proteins, such as NOTCH1. This process is important for the proper functioning of these proteins. Mutations in GXYLT1 have been associated with developmental disorders, such as Alagille syndrome and Hajdu-Cheney syndrome.","Mutations in GXYLT1 have been associated with several developmental disorders, including Alagille syndrome and Hajdu-Cheney syndrome. Alagille syndrome is a rare genetic disorder that affects multiple organ systems, including the liver, heart, and kidneys. Patients with Alagille syndrome often have abnormal bile ducts, which can lead to liver damage and other complications. Hajdu-Cheney syndrome is a rare disorder that affects bone development, causing abnormalities such as osteoporosis and bone fractures.

There are currently no targeted drug discovery efforts specifically for GXYLT1. However, there are drugs on the market that target the downstream effects of GXYLT1 mutations. For example, patients with Alagille syndrome may be treated with medications to manage their symptoms, such as medications to lower cholesterol levels or to relieve itching. In some cases, liver transplantation may be necessary. Patients with Hajdu-Cheney syndrome may be treated with medications to manage their bone density, such as bisphosphonates.

In conclusion, while there are currently no targeted drug discovery efforts for GXYLT1, there are medications available to manage the symptoms of the developmental disorders associated with mutations in this gene. Further research into the role of GXYLT1 in these disorders may lead to the development of more targeted therapies in the future.",GO:0016266 O-glycan processing;GO:0006493 protein O-linked glycosylation;GO:0006486 protein glycosylation,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Endoplasmic reticulum (Approved); Additional: Vesicles,,,
ENSG00000204120.16,ENSG00000204120,GIGYF2,-0.711441952,-0.879206659,-0.804468093,-0.450651104,GRB10 interacting GYF protein 2,"GIGYF2, also known as GRB10 interacting GYF protein 2, is a gene that contains CAG trinucleotide repeats and encodes a protein with several stretches of polyglutamine residues. The protein may play a role in regulating tyrosine kinase receptor signaling. GIGYF2 was initially thought to be causative for Parkinson disease type 11 due to its location in a chromosomal region genetically linked to the disease and mutations in the gene. However, recent studies in different populations have been unable to replicate this association. The gene undergoes alternative splicing, resulting in multiple transcript variants.","There is currently no targeted drug discovery effort for GIGYF2, as its role in disease pathogenesis remains unclear. While initial studies suggested a potential link between GIGYF2 mutations and Parkinson disease type 11, subsequent studies have failed to replicate this association. Therefore, there are no drugs on the market that specifically target GIGYF2. However, there are several drugs available for the treatment of Parkinson disease, including levodopa, dopamine agonists, and MAO-B inhibitors. These drugs aim to alleviate the symptoms of the disease by increasing dopamine levels in the brain. Additionally, there are ongoing efforts to develop disease-modifying therapies for Parkinson disease, which may target other genes and pathways involved in the disease.",GO:0045947 negative regulation of translational initiation;GO:0060339 negative regulation of type I interferon-mediated signaling pathway;GO:0021522 spinal cord motor neuron differentiation,,Disease related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Predicted intracellular proteins,Cytosol (Enhanced),,,
ENSG00000109184.15,ENSG00000109184,DCUN1D4,-0.711396,-1.002368338,-0.555491247,-0.576328416,defective in cullin neddylation 1 domain containing 4,DCUN1D4 is a human gene that plays a crucial role in the process of protein neddylation. It enables the binding activity of cullin family proteins and is involved in the positive regulation of protein neddylation. The gene is located in the nucleus and its defect can lead to cullin neddylation 1 domain containing 4 deficiency. This gene is important for the proper functioning of the cell and any defects in it can lead to various diseases and disorders.,"There is limited information available on the disease implications of DCUN1D4. However, studies have shown that defects in this gene can lead to cullin neddylation 1 domain containing 4 deficiency, which can result in various disorders such as cancer, neurodegenerative diseases, and developmental disorders. 

Targeted drug discovery efforts for DCUN1D4 are also limited, as the gene is relatively understudied. However, there is potential for the development of drugs that target the protein neddylation pathway, which is regulated by DCUN1D4. This pathway has been identified as a potential target for cancer therapy, and several drugs targeting this pathway are currently in clinical trials, such as MLN4924 and TAK-659.

There are currently no drugs on the market that specifically target DCUN1D4. However, there are drugs that indirectly affect the protein neddylation pathway, such as bortezomib, which is used to treat multiple myeloma and mantle cell lymphoma. Bortezomib inhibits the proteasome, which leads to the accumulation of neddylated proteins and ultimately cell death. Another example is thalidomide, which is used to treat multiple myeloma and other cancers. Thalidomide indirectly affects the protein neddylation pathway by inhibiting the activity of the E3 ubiquitin ligase CRL4, which is involved in protein neddylation.",GO:2000436 positive regulation of protein neddylation;GO:2000434 regulation of protein neddylation;GO:0045116 protein neddylation,,Predicted intracellular proteins,Vesicles (Supported); Additional: Nucleoplasm,,,
ENSG00000143363.17,ENSG00000143363,PRUNE1,-0.710724847,-0.83417453,-0.546552353,-0.751447658,prune exopolyphosphatase 1,PRUNE1 is a gene that encodes a protein belonging to the DHH protein superfamily of phosphoesterases. This protein has been identified as both a nucleotide phosphodiesterase and an exopolyphosphatase. It is believed that PRUNE1 stimulates cancer progression and metastases by inducing cell motility. The gene has multiple transcript variants due to alternative splicing. A pseudogene has also been identified on chromosome 13.,"PRUNE1 has been implicated in various types of cancer, including breast, lung, and colorectal cancer. Studies have shown that overexpression of PRUNE1 is associated with increased tumor growth, invasion, and metastasis. Therefore, PRUNE1 has been identified as a potential therapeutic target for cancer treatment. Several drug discovery efforts have been made to target PRUNE1, including the development of small molecule inhibitors and monoclonal antibodies. However, there are currently no drugs on the market that specifically target PRUNE1. Nonetheless, there are drugs that indirectly affect PRUNE1 expression or activity, such as chemotherapeutic agents that inhibit DNA synthesis and repair, which can lead to decreased PRUNE1 expression. Additionally, drugs that target other proteins involved in cancer progression, such as EGFR inhibitors, have been shown to indirectly affect PRUNE1 expression and activity.",GO:0031113 regulation of microtubule polymerization;GO:0031110 regulation of microtubule polymerization or depolymerization;GO:0070507 regulation of microtubule cytoskeleton organization,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Cytosol (Supported),,,
ENSG00000198837.10,ENSG00000198837,DENND4B,-0.709955246,-1.028413785,-0.593295559,-0.508156394,DENN domain containing 4B,"DENND4B is a human gene that encodes a protein containing a DENN domain, which enables guanyl-nucleotide exchange factor activity and is involved in the regulation of Rab protein signal transduction. The protein is located in the Golgi apparatus and nucleoplasm. The function of DENND4B is not fully understood, but it is believed to play a role in intracellular trafficking and membrane dynamics. Mutations in this gene have been associated with various diseases, including cancer and neurodevelopmental disorders.","DENND4B has been implicated in various diseases, including cancer and neurodevelopmental disorders. In cancer, DENND4B has been shown to be overexpressed in several types of tumors, including breast, lung, and ovarian cancers. Targeting DENND4B may therefore be a potential therapeutic strategy for these cancers. In neurodevelopmental disorders, mutations in DENND4B have been associated with intellectual disability and autism spectrum disorder. However, there are currently no drugs specifically targeting DENND4B.

There have been some efforts to develop drugs targeting the DENN domain, which is present in DENND4B. For example, a small molecule inhibitor of DENN/MADD domain-containing protein 1A (DENND1A) has been developed as a potential treatment for type 2 diabetes. However, this drug does not target DENND4B specifically.

Overall, more research is needed to fully understand the function of DENND4B and its potential as a therapeutic target for various diseases.",GO:0032483 regulation of Rab protein signal transduction;GO:0051056 regulation of small GTPase mediated signal transduction;GO:1902531 regulation of intracellular signal transduction,,Predicted intracellular proteins,Golgi apparatus;Nucleoplasm (Approved),,,
ENSG00000128731.18,ENSG00000128731,HERC2,-0.709793857,-1.317143594,-0.66048874,-0.151749238,HECT and RLD domain containing E3 ubiquitin protein ligase 2,"HERC2 is a gene that belongs to the HERC gene family and encodes a large protein with multiple structural domains. It contains an N-terminal region that is similar to the cell cycle regulator RCC1 and a C-terminal HECT domain found in E3 ubiquitin protein ligases. Genetic variations in HERC2 are associated with variability in skin, hair, and eye pigmentation. The gene has multiple pseudogenes located on chromosomes 15 and 16.","HERC2 has been implicated in several diseases, including cancer, neurodegenerative disorders, and developmental disorders. In cancer, HERC2 has been shown to regulate the stability of the tumor suppressor protein p53, and its overexpression has been observed in several types of cancer, including breast, lung, and ovarian cancer. In neurodegenerative disorders, mutations in HERC2 have been linked to the development of spinocerebellar ataxia type 15, a rare genetic disorder that affects the nervous system. In developmental disorders, HERC2 has been associated with intellectual disability and autism spectrum disorders.

Targeted drug discovery efforts for HERC2 are still in the early stages, but several potential drug targets have been identified. One approach is to target the HECT domain of HERC2, which is involved in the ubiquitination and degradation of proteins. Small molecules that inhibit the activity of the HECT domain could potentially be used to treat cancer and neurodegenerative disorders. Another approach is to target the interaction between HERC2 and p53, which could be disrupted by small molecules or peptides.

Currently, there are no drugs on the market that specifically target HERC2. However, there are several drugs that indirectly affect HERC2 activity. For example, the chemotherapy drug cisplatin has been shown to induce HERC2 expression, which contributes to its cytotoxic effects. In addition, the anti-cancer drug bortezomib targets the proteasome, which is involved in the degradation of proteins by HERC2 and other E3 ubiquitin ligases.",GO:0045746 negative regulation of Notch signaling pathway;GO:0008593 regulation of Notch signaling pathway;GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Cytosol (Supported); Additional: Plasma membrane,,,
ENSG00000093183.14,ENSG00000093183,SEC22C,-0.709704173,-1.207080933,-0.618165182,-0.303866403,"SEC22 homolog C, vesicle trafficking protein",SEC22C is a gene that encodes a protein belonging to the SEC22 family of vesicle trafficking proteins. This protein is found in the endoplasmic reticulum and is believed to be involved in the initial stages of protein trafficking between the endoplasmic reticulum and the Golgi apparatus. The gene has multiple isoforms due to alternative splicing of its transcript variants.,"There is limited information available on the disease implications of SEC22C. However, some studies have suggested that mutations in SEC22C may be associated with certain neurological disorders, such as schizophrenia and bipolar disorder. Targeted drug discovery efforts for SEC22C are also limited, as the exact role of this protein in disease pathogenesis is not well understood. However, some studies have suggested that targeting SEC22C may be a potential therapeutic strategy for certain types of cancer, as this protein has been shown to play a role in the secretion of tumor-promoting factors. Currently, there are no drugs on the market that specifically target SEC22C. However, there are drugs that indirectly affect the function of SEC22C, such as brefeldin A, which is used to study protein trafficking pathways.",GO:0006888 endoplasmic reticulum to Golgi vesicle-mediated transport;GO:0048193 Golgi vesicle transport;GO:0015031 protein transport,,Predicted intracellular proteins,Golgi apparatus (Approved); Additional: Nucleoplasm,,,
ENSG00000215251.4,ENSG00000215251,FASTKD5,-0.709416438,-1.035374677,-0.684109234,-0.408765403,FAST kinase domains 5,"FASTKD5 is a human gene that encodes for a protein called FAST kinase domains 5. This protein is involved in mitochondrial RNA processing and has the ability to bind to ribosomal RNA. FASTKD5 is located in the mitochondrial nucleoid and ribonucleoprotein granule. Its exact function is not yet fully understood, but it is believed to play a role in the regulation of mitochondrial gene expression. Mutations in the FASTKD5 gene have been associated with various diseases, including mitochondrial disorders and cancer.","Mutations in the FASTKD5 gene have been associated with various mitochondrial disorders, including Leigh syndrome, a severe neurological disorder, and mitochondrial encephalomyopathy, a condition that affects the brain and muscles. Additionally, FASTKD5 has been implicated in cancer, with studies showing that it is overexpressed in certain types of cancer cells, including breast and lung cancer. 

There are currently no drugs specifically targeting FASTKD5, but research is ongoing to identify potential therapeutic targets for mitochondrial disorders and cancer. One approach is to target the mitochondrial RNA processing pathway, which is disrupted in these diseases. Another approach is to target the protein-protein interactions involving FASTKD5, which could potentially lead to the development of small molecule inhibitors. 

There are currently no drugs on the market targeting FASTKD5, but there are drugs targeting other mitochondrial proteins that have shown promise in clinical trials. For example, elamipretide is a mitochondrial-targeted peptide that has shown efficacy in treating mitochondrial disorders and heart failure. Another drug, idebenone, has been approved for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disorder affecting the eyes.",GO:0044528 regulation of mitochondrial mRNA stability;GO:0000963 mitochondrial RNA processing;GO:0140053 mitochondrial gene expression,,Predicted intracellular proteins,,,,
ENSG00000111276.11,ENSG00000111276,CDKN1B,-0.709290205,-0.907978152,-0.801543142,-0.41834932,cyclin dependent kinase inhibitor 1B,"CDKN1B is a gene that encodes a protein called cyclin-dependent kinase inhibitor 1B. This protein is involved in regulating the cell cycle by binding to and inhibiting the activation of certain complexes that promote cell division. CDKN1B is particularly important in controlling the progression of cells from the G1 phase of the cell cycle to the proliferative state. The protein is degraded through a process that involves phosphorylation by CDK and subsequent ubiquitination by SCF complexes. Mutations in CDKN1B have been linked to multiple endocrine neoplasia type IV (MEN4), a rare genetic disorder that affects the endocrine system.","Mutations in CDKN1B have been linked to multiple endocrine neoplasia type IV (MEN4), a rare genetic disorder that affects the endocrine system. MEN4 is characterized by the development of tumors in the parathyroid glands, pituitary gland, and pancreas. There are currently no targeted drug discovery efforts specifically for CDKN1B, but there are drugs on the market that target the cell cycle and may indirectly affect the activity of CDKN1B. For example, palbociclib is a drug that inhibits CDK4/6, which are kinases that phosphorylate CDKN1B and target it for degradation. Palbociclib is used to treat certain types of breast cancer and has shown promising results in clinical trials. Other drugs that target the cell cycle, such as cyclin-dependent kinase inhibitors and mitotic inhibitors, may also have potential for treating MEN4 and other diseases associated with CDKN1B mutations.",GO:1905179 negative regulation of cardiac muscle tissue regeneration;GO:1905178 regulation of cardiac muscle tissue regeneration;GO:0048102 autophagic cell death,,Predicted intracellular proteins; Human disease related genes:Cancers:Cancers of endocrine organs; Human disease related genes:Cancers:Cancers of male genital organs; Human disease related genes:Endocrine and metabolic diseases:Hypothalamus and pituitary gland diseases; Human disease related genes:Cancers:Cancers of the digestive system; Human disease related genes:Endocrine and metabolic diseases:Adrenal gland diseases; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Centrosome;Nucleoplasm (Supported); Additional: Basal body;Cytosol;Primary cilium;Primary cilium transition zone,,(M3686)SA REG CASCADE OF CYCLIN EXPR; (M1529)SA G1 AND S PHASES; (M249)PID PI3KCI AKT PATHWAY,(M5923)HALLMARK PI3K AKT MTOR SIGNALING; (M5942)HALLMARK UV RESPONSE DN; (M5902)HALLMARK APOPTOSIS
ENSG00000075151.21,ENSG00000075151,EIF4G3,-0.709268937,-0.954081121,-0.972016394,-0.201709295,eukaryotic translation initiation factor 4 gamma 3,"EIF4G3 is a gene that encodes a protein that is part of the eIF4F protein complex, which is involved in recognizing mRNA caps and transporting mRNAs to the ribosome for translation. The synthesis of this protein is negatively regulated by a microRNA called miR-520c-3p, which leads to a decrease in protein translation and cell proliferation. This protein is important for the anti-tumor activity of miR-520c-3p.","There is limited information available on the disease implications of EIF4G3. However, recent studies have suggested that EIF4G3 may play a role in the development and progression of certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for EIF4G3 are still in the early stages, but there is potential for the development of drugs that target this protein and its associated pathways. Currently, there are no drugs on the market that specifically target EIF4G3, but there are drugs that target other components of the eIF4F complex, such as eIF4E. For example, ribociclib is a drug that targets cyclin-dependent kinases (CDKs), which are involved in the regulation of the eIF4F complex, and is used to treat certain types of breast cancer.",GO:0006413 translational initiation;GO:0006446 regulation of translational initiation;GO:0045727 positive regulation of translation,,Predicted intracellular proteins,Cytosol (Approved),,,(M5950)HALLMARK ALLOGRAFT REJECTION
ENSG00000112977.16,ENSG00000112977,DAP,-0.708912315,-1.478697717,-0.646534146,-0.001505082,death associated protein,The DAP gene encodes a 15-kD protein that plays a role in programmed cell death induced by interferon-gamma. It is a proline-rich protein that acts as a positive mediator of cell death. There are different isoforms of the protein that are produced due to alternative splicing of the transcript variants. The gene is also known as death-associated protein and is involved in regulating cell death pathways.,"The DAP gene has been implicated in various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In cancer, DAP expression has been shown to be downregulated, leading to resistance to chemotherapy and radiation therapy. Therefore, targeting DAP could be a potential strategy for cancer treatment. Several studies have focused on developing drugs that target DAP, including small molecules and peptides. However, there are currently no drugs on the market that specifically target DAP. 

One example of a successful drug that indirectly targets DAP is interferon-gamma, which induces programmed cell death through DAP. Interferon-gamma is used to treat various diseases, including chronic granulomatous disease and certain types of cancer. Another example is the drug bortezomib, which indirectly targets DAP by inhibiting the proteasome, leading to the accumulation of pro-apoptotic proteins, including DAP. Bortezomib is used to treat multiple myeloma and mantle cell lymphoma. 

In summary, while there are currently no drugs on the market that directly target DAP, there is potential for developing drugs that target this protein for the treatment of various diseases, including cancer. Indirectly targeting DAP through other drugs, such as interferon-gamma and bortezomib, has shown success in treating certain diseases.",GO:0141014 ribosome hibernation;GO:0034198 cellular response to amino acid starvation;GO:1990928 response to amino acid starvation,,Predicted intracellular proteins,Mitochondria;Vesicles (Approved); Additional: Nucleoplasm,,,(M5902)HALLMARK APOPTOSIS
ENSG00000118200.14,ENSG00000118200,CAMSAP2,-0.708894328,-1.119790894,-0.745532854,-0.261359237,calmodulin regulated spectrin associated protein family member 2,"CAMSAP2 is a human gene that belongs to the calmodulin regulated spectrin associated protein family. It plays a crucial role in enabling microtubule minus-end binding activity and is involved in various processes such as axon development, regulation of dendrite development, and regulation of organelle organization. CAMSAP2 is located in the cytosol and microtubule end and colocalizes with the Golgi apparatus, centrosome, and microtubule minus-end. This gene's function is essential for maintaining the structural integrity of cells and is crucial for proper cellular function.","Research on CAMSAP2 and its disease implications is still in its early stages, but some studies have suggested that mutations in this gene may be associated with certain neurological disorders such as schizophrenia and autism spectrum disorders. Additionally, CAMSAP2 has been found to be overexpressed in some types of cancer, including breast cancer, and may play a role in tumor growth and metastasis.

There are currently no drugs specifically targeting CAMSAP2, but there is ongoing research into developing drugs that can modulate microtubule dynamics, which could indirectly affect CAMSAP2 function. For example, microtubule-stabilizing agents such as paclitaxel and docetaxel are commonly used in cancer chemotherapy and have been successful in treating a variety of solid tumors.

In conclusion, while CAMSAP2's disease implications and drug discovery efforts are still in the early stages, continued research into this gene and its role in cellular function could lead to new insights and potential therapeutic targets for a variety of diseases.",GO:1903358 regulation of Golgi organization;GO:0007026 negative regulation of microtubule depolymerization;GO:0031114 regulation of microtubule depolymerization,,Disease related genes; Predicted intracellular proteins,Golgi apparatus;Microtubule ends (Supported); Additional: Cytosol,,,
ENSG00000119638.14,ENSG00000119638,NEK9,-0.708248478,-1.237610624,-0.737842191,-0.14929262,NIMA related kinase 9,"NEK9, also known as NIMA related kinase 9, is a gene that encodes a protein kinase belonging to the NimA family. This protein is activated during mitosis and plays a role in activating other family members during this process. Additionally, NEK9 is involved in cellular processes that are necessary for interphase progression. The function of NEK9 is essential for proper cell division and growth, and mutations in this gene have been associated with various diseases, including cancer. Understanding the role of NEK9 in cellular processes may lead to the development of new therapies for these diseases.","NEK9 has been implicated in various diseases, including cancer. Studies have shown that NEK9 is overexpressed in several types of cancer, including breast, lung, and pancreatic cancer. Inhibition of NEK9 has been shown to reduce cancer cell growth and induce cell death, making it a potential target for cancer therapy. Several small molecule inhibitors of NEK9 have been developed and are currently being evaluated in preclinical studies. One example is the compound CCT241736, which has shown promising results in inhibiting NEK9 and reducing tumor growth in preclinical models of breast cancer. Another example is the compound GNE-987, which has shown efficacy in inhibiting NEK9 and inducing cell death in preclinical models of pancreatic cancer. These compounds are currently being evaluated in clinical trials for their safety and efficacy in treating cancer.",GO:0051301 cell division;GO:0007346 regulation of mitotic cell cycle;GO:0000278 mitotic cell cycle,yes,Predicted intracellular proteins; Kinases:NEK Ser/Thr protein kinases; ENZYME proteins:Transferases; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Disease related genes; Enzymes; Transporters:Transporter channels and pores,,Fostamatinib,,
ENSG00000080561.14,ENSG00000080561,MID2,-0.707776153,-1.173183322,-0.81929977,-0.130845365,midline 2,"MID2, also known as midline 2, is a human gene that belongs to the tripartite motif (TRIM) family. The TRIM motif consists of three zinc-binding domains, a RING, a B-box type 1, and a B-box type 2, as well as a coiled-coil region. The protein encoded by this gene is localized to microtubular structures in the cytoplasm. There are two transcript variants of this gene that result from alternate splicing, which encode different isoforms.","There is limited information available on the disease implications of MID2. However, some studies have suggested that mutations in this gene may be associated with X-linked intellectual disability and autism spectrum disorders. Targeted drug discovery efforts for MID2 are also limited, as the function of the protein encoded by this gene is not well understood. However, some studies have suggested that MID2 may play a role in regulating microtubule dynamics, which could have implications for cancer treatment. Currently, there are no drugs on the market that specifically target MID2. However, there are drugs that target microtubules, such as paclitaxel and vinblastine, which are used in the treatment of various types of cancer. Further research is needed to fully understand the role of MID2 in disease and to develop targeted therapies.",GO:0035372 protein localization to microtubule;GO:0032897 negative regulation of viral transcription;GO:0044790 suppression of viral release by host,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,,,,
ENSG00000153147.6,ENSG00000153147,SMARCA5,-0.70776198,-1.109210143,-0.898619994,-0.115455804,SNF2 related chromatin remodeling ATPase 5,"SMARCA5 is a gene that belongs to the SWI/SNF family of proteins. These proteins have helicase and ATPase activities and are involved in regulating the transcription of certain genes by altering the chromatin structure around them. SMARCA5 is a component of the chromatin remodeling and spacing factor RSF, which facilitates the transcription of class II genes by RNA polymerase II. The protein is similar in sequence to the Drosophila ISWI chromatin remodeling protein. Overall, SMARCA5 plays an important role in regulating gene expression by modifying the structure of chromatin.","There is limited information available on the disease implications of SMARCA5 mutations. However, studies have shown that alterations in the expression of SMARCA5 can contribute to the development of certain cancers, including breast, lung, and ovarian cancer. Targeted drug discovery efforts for SMARCA5 are still in the early stages, but there is potential for the development of drugs that target the protein's ATPase activity and disrupt its function in chromatin remodeling. Currently, there are no drugs on the market that specifically target SMARCA5, but there are drugs that target other members of the SWI/SNF family of proteins, such as EZH2 inhibitors for the treatment of certain types of lymphoma. Further research is needed to fully understand the role of SMARCA5 in disease and to develop targeted therapies for its potential implications.",GO:1903379 regulation of mitotic chromosome condensation;GO:1905213 negative regulation of mitotic chromosome condensation;GO:1902340 negative regulation of chromosome condensation,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoli fibrillar center;Nucleoplasm (Supported),Beta-D-Glucose; 4-Deoxy-Alpha-D-Glucose,,
ENSG00000198742.10,ENSG00000198742,SMURF1,-0.707442957,-1.250323751,-0.846300646,-0.025704473,SMAD specific E3 ubiquitin protein ligase 1,"SMURF1 is a gene that encodes a specific ubiquitin ligase that targets receptor-regulated SMAD proteins in the BMP pathway. This gene plays a crucial role in regulating cell motility, signaling, and polarity. Alternative splicing of this gene results in multiple transcript variants that encode different isoforms.","Research has shown that dysregulation of SMURF1 expression and activity can contribute to the development and progression of various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, SMURF1 has been found to promote tumor growth and metastasis by regulating the activity of key signaling pathways. As a result, SMURF1 has emerged as a potential therapeutic target for cancer treatment. Several small molecule inhibitors of SMURF1 have been developed and are currently being evaluated in preclinical studies for their efficacy in inhibiting tumor growth and metastasis.

One example of a successful drug targeting SMURF1 is TGF-? receptor kinase inhibitors, such as LY2157299 and Galunisertib, which have been shown to inhibit SMURF1 activity and reduce tumor growth in preclinical models of cancer. Another example is the small molecule inhibitor, NEDD8-activating enzyme inhibitor MLN4924, which has been shown to induce SMURF1 degradation and inhibit tumor growth in preclinical models of breast cancer. However, further research is needed to fully understand the therapeutic potential of targeting SMURF1 in various diseases and to develop safe and effective drugs for clinical use.",GO:0061736 engulfment of target by autophagosome;GO:0061753 substrate localization to autophagosome;GO:0071211 protein targeting to vacuole involved in autophagy,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Vesicles (Approved); Additional: Nucleoplasm,,(M181)PID BMP PATHWAY; (M286)PID TGFBR PATHWAY; (M101)PID HDAC CLASSI PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING
ENSG00000107651.13,ENSG00000107651,SEC23IP,-0.707363695,-0.906964404,-0.782966187,-0.432160494,SEC23 interacting protein,SEC23IP is a gene that encodes a protein belonging to the phosphatidic acid preferring-phospholipase A1 family. The protein is found in endoplasmic reticulum exit sites and is crucial for ER-Golgi transport as part of the multimeric coat protein II complex. Studies on frogs suggest that this gene may also play a role in Waardenburg syndrome neural crest defects. The gene has multiple alternatively spliced transcript variants.,"There is limited information available on the disease implications of SEC23IP. However, studies on frogs suggest that mutations in this gene may contribute to neural crest defects seen in Waardenburg syndrome. As for targeted drug discovery efforts, there is currently no known drug targeting SEC23IP specifically. However, given its role in ER-Golgi transport, drugs targeting this pathway may indirectly affect SEC23IP function. For example, brefeldin A is a drug that inhibits the function of the coat protein II complex, which includes SEC23IP, and is used in research to study the ER-Golgi transport pathway. Other drugs targeting this pathway include golgicide A and monensin. However, these drugs are not currently used in clinical settings.",GO:0006888 endoplasmic reticulum to Golgi vesicle-mediated transport;GO:0007030 Golgi organization;GO:0048193 Golgi vesicle transport,,Predicted intracellular proteins,Vesicles (Enhanced),,,
ENSG00000197226.13,ENSG00000197226,TBC1D9B,-0.70604403,-0.800308284,-0.673074823,-0.644748983,TBC1 domain family member 9B,TBC1D9B is a human gene that is predicted to have GTPase activator activity and be involved in the activation of GTPase activity and intracellular protein transport. It is also predicted to be an integral component of the membrane.,"There is limited information available on the disease implications of TBC1D9B. However, recent studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, including breast cancer and lung adenocarcinoma. As a result, there has been some interest in developing targeted drug therapies that can inhibit the activity of TBC1D9B and potentially prevent or treat these types of cancer.

To date, there have been no drugs specifically developed to target TBC1D9B. However, there are a number of drugs on the market that target other proteins involved in intracellular protein transport and GTPase activity, which may have potential applications in the treatment of TBC1D9B-associated cancers. For example, the drug bortezomib is a proteasome inhibitor that has been approved for the treatment of multiple myeloma and mantle cell lymphoma. It works by inhibiting the activity of the proteasome, which is involved in the degradation of intracellular proteins. Other drugs that target intracellular protein transport and GTPase activity include the anti-cancer drugs erlotinib and gefitinib, which are used to treat non-small cell lung cancer, and the anti-inflammatory drug colchicine, which is used to treat gout and other inflammatory conditions.",,,Predicted intracellular proteins,Plasma membrane (Approved); Additional: Actin filaments;Nucleoli fibrillar center;Nucleoplasm,,,
ENSG00000141522.12,ENSG00000141522,ARHGDIA,-0.703915705,-1.202851078,-0.833869583,-0.075026455,Rho GDP dissociation inhibitor alpha,"ARHGDIA is a human gene that encodes a protein responsible for regulating signaling through Rho GTPases. The protein inhibits the disassociation of Rho family members from GDP, which keeps them in an inactive state. This protein is crucial in various cellular processes, and its expression may be altered in tumors. Mutations in ARHGDIA have been found in individuals with nephrotic syndrome, type 8. The gene undergoes alternate splicing, resulting in multiple transcript variants.","ARHGDIA has been implicated in various diseases, including cancer and nephrotic syndrome. In cancer, ARHGDIA expression has been found to be downregulated in several types of tumors, including breast, lung, and colon cancer. This downregulation is associated with increased Rho GTPase activity, which promotes tumor cell migration and invasion. Therefore, ARHGDIA is a potential target for cancer therapy. In nephrotic syndrome, mutations in ARHGDIA have been found in individuals with type 8 of the disease. This mutation leads to proteinuria and kidney damage. Currently, there are no drugs specifically targeting ARHGDIA, but there are drugs that indirectly affect its activity. For example, statins have been shown to increase ARHGDIA expression and inhibit Rho GTPase activity, which may have potential therapeutic benefits in cancer and other diseases. Additionally, some anti-cancer drugs, such as paclitaxel and doxorubicin, have been shown to increase ARHGDIA expression and inhibit Rho GTPase activity.",GO:0098693 regulation of synaptic vesicle cycle;GO:0071526 semaphorin-plexin signaling pathway;GO:0007266 Rho protein signal transduction,,Disease related genes; Human disease related genes:Urinary system diseases:Kidney diseases; Predicted intracellular proteins,Cytosol (Supported),,(M83)PID CDC42 REG PATHWAY; (M241)PID RAC1 REG PATHWAY; (M238)PID THROMBIN PAR1 PATHWAY,(M5923)HALLMARK PI3K AKT MTOR SIGNALING; (M5893)HALLMARK MITOTIC SPINDLE
ENSG00000100403.12,ENSG00000100403,ZC3H7B,-0.703835856,-1.08225076,-0.993926514,-0.035330295,zinc finger CCCH-type containing 7B,"ZC3H7B is a human gene that encodes a protein containing a tetratricopeptide repeat domain. This protein is known to interact with the rotavirus non-structural protein NSP3. The function of ZC3H7B is not yet fully understood, but it is believed to play a role in RNA metabolism and may be involved in regulating gene expression. Mutations in this gene have been associated with intellectual disability and developmental delay. Further research is needed to fully understand the function of ZC3H7B and its potential role in human health and disease.","Mutations in the ZC3H7B gene have been associated with intellectual disability and developmental delay. However, there are currently no targeted drug discovery efforts specifically for this gene. As the function of ZC3H7B is not yet fully understood, it is difficult to develop targeted therapies. However, there are drugs on the market that may indirectly affect ZC3H7B function. For example, some drugs that target RNA metabolism, such as antisense oligonucleotides, may have potential therapeutic benefits for individuals with ZC3H7B mutations. Additionally, drugs that target gene expression, such as histone deacetylase inhibitors, may also have potential therapeutic benefits. However, further research is needed to fully understand the role of ZC3H7B in disease and to develop targeted therapies.",GO:0035196 miRNA processing;GO:0070918 regulatory ncRNA processing;GO:0031047 regulatory ncRNA-mediated gene silencing,,Predicted intracellular proteins,Cytosol (Uncertain),,,
ENSG00000137713.16,ENSG00000137713,PPP2R1B,-0.703263386,-0.790286528,-0.773456623,-0.546047008,protein phosphatase 2 scaffold subunit Abeta,"PPP2R1B is a gene that encodes a constant regulatory subunit of protein phosphatase 2, which is involved in the negative control of cell growth and division. The gene produces a beta isoform of the constant regulatory subunit A, which acts as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit. Mutations in PPP2R1B have been linked to certain types of lung and colon cancers. The gene has multiple alternatively spliced transcript variants.","Mutations in PPP2R1B have been linked to several types of cancer, including lung and colon cancer. Targeting PPP2R1B has been explored as a potential therapeutic strategy for these cancers. One approach is to develop small molecule inhibitors that target the interaction between the regulatory subunit and the catalytic subunit of protein phosphatase 2. Several compounds have been identified that show promising activity against cancer cells in preclinical studies, including LB-100 and LB-102. LB-100 is currently being evaluated in clinical trials for the treatment of solid tumors and glioblastoma. Another approach is to target the upstream signaling pathways that regulate PPP2R1B, such as the PI3K/AKT/mTOR pathway. Drugs targeting this pathway, such as everolimus and temsirolimus, have been approved for the treatment of certain types of cancer, including renal cell carcinoma and breast cancer.","GO:0051754 meiotic sister chromatid cohesion, centromeric;GO:0070601 centromeric sister chromatid cohesion;GO:2001241 positive regulation of extrinsic apoptotic signaling pathway in absence of ligand",,Human disease related genes:Cancers:Cancers of the lung and pleura; Predicted intracellular proteins,Cytosol;Plasma membrane (Approved),,,(M5923)HALLMARK PI3K AKT MTOR SIGNALING
ENSG00000169410.10,ENSG00000169410,PTPN9,-0.703039434,-1.065361103,-0.729105856,-0.314651342,protein tyrosine phosphatase non-receptor type 9,"PTPN9 is a gene that encodes a protein tyrosine phosphatase (PTP) which is involved in regulating various cellular processes such as cell growth, differentiation, and oncogenic transformation. The protein contains an N-terminal domain that is similar to yeast SEC14, which is required for protein secretion through the Golgi complex in yeast. PTPN9 is activated by polyphosphoinositide and is believed to be involved in signaling events that regulate phagocytosis. This gene may have implications in diseases related to abnormal cell growth and differentiation, such as cancer.","PTPN9 has been implicated in various diseases, including cancer, diabetes, and autoimmune disorders. In cancer, PTPN9 has been shown to play a role in regulating cell growth and differentiation, and its expression is often dysregulated in various types of cancer. Targeted drug discovery efforts have focused on developing small molecule inhibitors of PTPN9 as potential cancer therapeutics. However, there are currently no drugs on the market that specifically target PTPN9. 

One example of a successful drug targeting a related PTP is Imatinib, which targets the BCR-ABL fusion protein in chronic myeloid leukemia (CML). Imatinib has revolutionized the treatment of CML and has been approved by the FDA for this indication. Another example is the drug Tofacitinib, which targets the PTP JAK3 and is used to treat rheumatoid arthritis. These successes highlight the potential of targeting PTPs for therapeutic purposes and suggest that further research into PTPN9 could lead to the development of novel treatments for cancer and other diseases.",GO:0035335 peptidyl-tyrosine dephosphorylation;GO:1903078 positive regulation of protein localization to plasma membrane;GO:1904377 positive regulation of protein localization to cell periphery,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Vesicles (Approved),,,
ENSG00000179889.19,ENSG00000179889,PDXDC1,-0.702874393,-1.063063899,-0.733747987,-0.311811291,pyridoxal dependent decarboxylase domain containing 1,"PDXDC1 is a human gene that encodes a protein containing a pyridoxal dependent decarboxylase domain. This protein is predicted to be involved in carboxylic acid metabolic processes and has been shown to enable cadherin binding activity. PDXDC1 is located in the Golgi apparatus, which is responsible for modifying and sorting proteins before they are transported to their final destination within the cell. The function of PDXDC1 is not yet fully understood, but it may play a role in regulating protein trafficking or metabolism within the Golgi apparatus.","There is limited information available on the disease implications of PDXDC1. However, recent studies have suggested that alterations in PDXDC1 expression may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for PDXDC1 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and potentially be used as cancer therapeutics. While there are currently no drugs on the market that specifically target PDXDC1, there are several drugs that have been approved for the treatment of breast cancer and hepatocellular carcinoma that may indirectly affect PDXDC1 expression or activity. These include tamoxifen, trastuzumab, and sorafenib. However, further research is needed to fully understand the role of PDXDC1 in these diseases and to develop more targeted therapies.",GO:0019752 carboxylic acid metabolic process;GO:0043436 oxoacid metabolic process;GO:0006082 organic acid metabolic process,,Predicted intracellular proteins,Golgi apparatus;Vesicles (Enhanced),,,
ENSG00000198018.7,ENSG00000198018,ENTPD7,-0.702677714,-1.1081794,-0.757378078,-0.242475664,ectonucleoside triphosphate diphosphohydrolase 7,"ENTPD7 is a gene that encodes an ectoenzyme belonging to the ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase) family. The protein produced by this gene is involved in the hydrolysis of extracellular nucleoside triphosphates (UTP, GTP, and CTP) to nucleoside monophosphates as part of a purinergic signaling pathway. ENTPD7 contains two transmembrane domains at the N- and C-termini and a large, hydrophobic catalytic domain located in between. This gene is involved in oxidative stress and DNA damage and is a mediator of senescence.","There is limited information available on the disease implications of ENTPD7. However, studies have suggested that this gene may play a role in cancer progression and metastasis. Targeted drug discovery efforts for ENTPD7 are also limited, but some studies have explored the potential of small molecule inhibitors of E-NTPDases as anti-cancer agents. One example is the drug ARL67156, which has been shown to inhibit E-NTPDases and reduce tumor growth in animal models. Another example is the drug POM-1, which has been shown to inhibit ENTPD7 and reduce the proliferation of cancer cells. However, these drugs are not currently on the market and further research is needed to fully understand the potential therapeutic applications of targeting ENTPD7.",GO:0006254 CTP catabolic process;GO:0009210 pyrimidine ribonucleoside triphosphate catabolic process;GO:0046052 UTP catabolic process,,ENZYME proteins:Hydrolases; Enzymes,Nucleoplasm (Approved),,,(M5956)HALLMARK KRAS SIGNALING DN
ENSG00000168385.18,ENSG00000168385,SEPTIN2,-0.702549052,-0.791879708,-0.922990317,-0.392777131,septin 2,"SEPTIN2, also known as septin 2, is a gene that encodes a protein involved in various cellular processes, including cilium assembly, regulation of exocytosis, and smoothened signaling pathway. It is predicted to act upstream or within the regulation of L-glutamate import across the plasma membrane and regulation of protein localization. SEPTIN2 is located in several cellular components, including the cytoskeleton, photoreceptor connecting cilium, and sperm annulus. It is part of the septin complex, which enables identical protein binding activity. Overall, SEPTIN2 plays a crucial role in maintaining cellular structure and function.","SEPTIN2 has been implicated in several diseases, including cancer, neurodegenerative disorders, and ciliopathies. In cancer, SEPTIN2 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. In neurodegenerative disorders, SEPTIN2 has been linked to the formation of abnormal protein aggregates, which are a hallmark of diseases such as Alzheimer's and Parkinson's. In ciliopathies, mutations in SEPTIN2 have been associated with defects in cilia formation and function, leading to a range of symptoms such as respiratory and kidney problems.

Targeted drug discovery efforts for SEPTIN2 are still in the early stages, but there is potential for the development of drugs that can modulate its activity. One approach is to target the septin complex, which SEPTIN2 is a part of, to disrupt its function in cancer cells. Another approach is to target SEPTIN2 directly to prevent the formation of abnormal protein aggregates in neurodegenerative disorders.

Currently, there are no drugs on the market that specifically target SEPTIN2. However, there are drugs that indirectly affect its activity. For example, the cancer drug paclitaxel has been shown to disrupt the septin complex, leading to cell death in cancer cells. Additionally, drugs that target cilia function, such as cystic fibrosis transmembrane conductance regulator (CFTR) modulators, may indirectly affect SEPTIN2 activity in ciliopathies.",GO:0002036 regulation of L-glutamate import across plasma membrane;GO:0010958 regulation of amino acid import across plasma membrane;GO:1903789 regulation of amino acid transmembrane transport,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Actin filaments (Approved); Additional: Annulus;Cytokinetic bridge;Microtubules;Plasma membrane;Primary cilium;Principal piece,,(M81)PID CDC42 PATHWAY,
ENSG00000163785.13,ENSG00000163785,RYK,-0.702536875,-1.035055221,-0.806423477,-0.266131928,receptor like tyrosine kinase,"RYK is a gene that encodes a protein that belongs to a subfamily of growth factor receptor protein tyrosine kinases. This protein differs from other members in its activation and nucleotide binding domains and does not appear to be regulated by phosphorylation in the activation segment. It has a leucine-rich extracellular domain with a WIF-type Wnt binding region, a single transmembrane domain, and an intracellular tyrosine kinase domain. RYK is involved in stimulating Wnt signaling pathways, such as the regulation of axon pathfinding. Alternative splicing results in multiple transcript variants encoding distinct isoforms. The mechanism by which this protein mediates biological activity through recruitment of a signaling-competent auxiliary protein is yet to be characterized.","RYK has been implicated in various diseases, including cancer, Alzheimer's disease, and developmental disorders. In cancer, RYK has been shown to promote tumor growth and metastasis in several types of cancer, including breast, lung, and pancreatic cancer. Targeting RYK with small molecule inhibitors has been explored as a potential therapeutic strategy for cancer treatment. However, there are currently no FDA-approved drugs targeting RYK.

In Alzheimer's disease, RYK has been found to be involved in the regulation of amyloid-beta (A?) production and clearance. Inhibition of RYK has been shown to reduce A? levels and improve cognitive function in mouse models of Alzheimer's disease. Therefore, RYK inhibitors may have potential as a therapeutic approach for Alzheimer's disease.

In developmental disorders, RYK has been implicated in the regulation of axon guidance and neuronal migration. Mutations in RYK have been associated with a rare developmental disorder called Joubert syndrome, which is characterized by brain malformations and developmental delays. However, there are currently no targeted drug discovery efforts for RYK in developmental disorders.

Overall, while RYK has been implicated in various diseases, there are currently no FDA-approved drugs targeting this protein. However, preclinical studies suggest that RYK inhibitors may have potential as therapeutic agents for cancer and Alzheimer's disease.",GO:0036518 chemorepulsion of dopaminergic neuron axon;GO:1904935 positive regulation of cell proliferation in midbrain;GO:1904933 regulation of cell proliferation in midbrain,yes,Kinases:Tyr protein kinases; Enzymes; ENZYME proteins:Transferases,Golgi apparatus (Approved); Additional: Cytosol,,(M77)PID WNT SIGNALING PATHWAY,
ENSG00000151116.17,ENSG00000151116,UEVLD,-0.70245277,-0.795900779,-0.9037375,-0.407720031,UEV and lactate/malate dehyrogenase domains,"UEVLD is a human gene that is predicted to have oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor. It is also predicted to be involved in several processes, including carbohydrate metabolic process, cellular protein modification process, and protein transport. UEVLD is located in extracellular exosome.","There is limited information available on the disease implications of UEVLD. However, research has shown that it may play a role in the development and progression of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for UEVLD are also limited, but some studies have suggested that it may be a potential target for cancer therapy. Currently, there are no drugs on the market that specifically target UEVLD. However, there are several drugs that target related proteins involved in similar processes, such as the proteasome inhibitor bortezomib, which is used to treat multiple myeloma and mantle cell lymphoma. Further research is needed to fully understand the potential therapeutic implications of UEVLD.",GO:0008333 endosome to lysosome transport;GO:0007041 lysosomal transport;GO:0007034 vacuolar transport,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000148737.17,ENSG00000148737,TCF7L2,-0.702325428,-1.023985346,-0.628613909,-0.454377029,transcription factor 7 like 2,The TCF7L2 gene encodes a transcription factor that is involved in the Wnt signaling pathway and plays a crucial role in regulating blood glucose levels. Variants of this gene have been linked to an increased risk of developing type 2 diabetes. Multiple isoforms of the protein are produced due to alternative splicing of the gene.,"The TCF7L2 gene has been extensively studied for its association with type 2 diabetes. Variants of this gene have been found to increase the risk of developing the disease by up to 80%. This has led to efforts to develop drugs that target the Wnt signaling pathway and TCF7L2 specifically. One example is the drug TAK-875, which targets the TCF7L2 pathway and has shown promising results in clinical trials for treating type 2 diabetes. Another drug, sulfonylureas, indirectly targets TCF7L2 by stimulating insulin secretion from pancreatic beta cells. However, the use of sulfonylureas has been associated with an increased risk of hypoglycemia and weight gain. Overall, the TCF7L2 gene and its role in regulating blood glucose levels continue to be an important area of research for developing new treatments for type 2 diabetes.",GO:0010909 positive regulation of heparan sulfate proteoglycan biosynthetic process;GO:0010908 regulation of heparan sulfate proteoglycan biosynthetic process;GO:0051176 positive regulation of sulfur metabolic process,,Predicted intracellular proteins; Transcription factors:Other all-alpha-helical DNA-binding domains; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes; Human disease related genes:Endocrine and metabolic diseases:Diabetes,Nuclear bodies;Nucleoplasm (Approved); Additional: Cytosol,,(M167)PID AP1 PATHWAY; (M223)PID BETA CATENIN NUC PATHWAY,(M5903)HALLMARK NOTCH SIGNALING
ENSG00000165312.6,ENSG00000165312,OTUD1,-0.702174901,-1.122045555,-0.877990056,-0.106489091,OTU deubiquitinase 1,"OTUD1 is a human gene that encodes for a deubiquitinase enzyme, specifically belonging to the ovarian tumor (OTU) domain subfamily of deubiquitinating enzymes. Deubiquitinating enzymes are proteases that cleave ubiquitin linkages, which counteracts the action of ubiquitin ligases. The function of OTUD1 is to remove ubiquitin from target proteins, which is important for regulating various cellular processes such as protein degradation, DNA repair, and immune response. Mutations in OTUD1 have been associated with various diseases, including cancer and neurodegenerative disorders.","Mutations in the OTUD1 gene have been linked to several diseases, including cancer and neurodegenerative disorders. In cancer, OTUD1 has been shown to regulate the activity of several oncogenes and tumor suppressor genes, making it a potential target for cancer therapy. Targeted drug discovery efforts have focused on developing small molecule inhibitors of OTUD1, which could be used to selectively inhibit its activity in cancer cells. However, there are currently no drugs on the market that specifically target OTUD1. Some drugs that indirectly affect OTUD1 activity, such as proteasome inhibitors, have been approved for the treatment of certain types of cancer. Further research is needed to fully understand the role of OTUD1 in disease and to develop effective targeted therapies.",GO:0070536 protein K63-linked deubiquitination;GO:0016579 protein deubiquitination;GO:0070646 protein modification by small protein removal,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000135040.16,ENSG00000135040,NAA35,-0.701880853,-0.922859953,-0.840711466,-0.342071139,"N-alpha-acetyltransferase 35, NatC auxiliary subunit","NAA35 is a human gene that encodes for the N-alpha-acetyltransferase 35 protein, which is an auxiliary subunit of the NatC complex. This protein is involved in the negative regulation of the apoptotic process and is located in the cytosol, nucleoplasm, and plasma membrane. It colocalizes with polysomes, which are complexes of ribosomes and messenger RNA molecules that are involved in protein synthesis. The NatC complex is responsible for the acetylation of the N-terminal amino acid of newly synthesized proteins, which is important for their stability and function.","There is limited information available on the disease implications of NAA35. However, recent studies have suggested that dysregulation of the NatC complex, of which NAA35 is a part, may be involved in the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for NAA35 are currently limited, but there is potential for the development of drugs that modulate the activity of the NatC complex. One example of a successful drug that targets a related protein is Velcade (bortezomib), which inhibits the activity of the proteasome and is used to treat multiple myeloma. However, further research is needed to fully understand the role of NAA35 in disease and to identify potential drug targets.",GO:0048659 smooth muscle cell proliferation;GO:0033002 muscle cell proliferation;GO:0008283 cell population proliferation,,Predicted intracellular proteins,Cytosol;Nucleoplasm;Plasma membrane (Approved),,,
ENSG00000116977.19,ENSG00000116977,LGALS8,-0.701770504,-1.014120974,-0.779012465,-0.312178071,galectin 8,"LGALS8, also known as galectin 8, is a gene that encodes a member of the galectin family. Galectins are animal lectins that bind to beta-galactoside carbohydrates and have important roles in various cellular processes such as development, differentiation, cell adhesion, growth regulation, and apoptosis. LGALS8 is widely expressed in tumoral tissues and is involved in integrin-like cell interactions. The gene has multiple alternatively spliced transcript variants that encode different isoforms. Overall, LGALS8 plays a crucial role in various cellular processes and its dysregulation has been implicated in several diseases including cancer.","There is limited information available on targeted drug discovery efforts for LGALS8. However, its dysregulation has been implicated in several diseases including cancer. Studies have shown that LGALS8 expression is upregulated in various types of cancer, including breast, lung, and pancreatic cancer, and is associated with tumor progression and poor prognosis. Therefore, LGALS8 has been proposed as a potential therapeutic target for cancer treatment. However, there are currently no drugs on the market that specifically target LGALS8. Some drugs that indirectly affect LGALS8 expression or function, such as chemotherapy drugs, have been used in cancer treatment. Further research is needed to identify specific LGALS8-targeting drugs for the treatment of cancer and other diseases.",GO:1904977 lymphatic endothelial cell migration;GO:0098792 xenophagy;GO:0036303 lymph vessel morphogenesis,,Predicted intracellular proteins,Plasma membrane (Approved),,(M5880)NABA ECM AFFILIATED; (M5885)NABA MATRISOME ASSOCIATED; (M5889)NABA MATRISOME,
ENSG00000062650.19,ENSG00000062650,WAPL,-0.701339857,-0.940837746,-0.672864997,-0.490316827,WAPL cohesin release factor,"The human gene WAPL is a cohesin release factor that plays a role in regulating DNA replication, chromatin binding activity, and sister chromatid cohesion. It is found in various cellular components, including the Golgi apparatus, intercellular bridge, and microtubule cytoskeleton. The gene's function is important for maintaining proper chromosome segregation during cell division and preventing errors that can lead to genetic disorders.","Mutations in the WAPL gene have been associated with several genetic disorders, including Cornelia de Lange syndrome (CdLS) and Roberts syndrome. CdLS is a rare developmental disorder characterized by distinctive facial features, growth retardation, intellectual disability, and limb abnormalities. Roberts syndrome is another rare genetic disorder that affects growth and development, causing limb and facial abnormalities, intellectual disability, and other health problems.

Targeted drug discovery efforts for WAPL are still in the early stages, but there is potential for developing drugs that target the protein's activity in regulating DNA replication and sister chromatid cohesion. One approach is to develop small molecule inhibitors that can block the interaction between WAPL and cohesin, which could help prevent errors in chromosome segregation during cell division.

Currently, there are no drugs on the market that specifically target WAPL. However, there are drugs that indirectly affect the protein's activity, such as topoisomerase inhibitors, which can disrupt DNA replication and cause DNA damage. Examples of topoisomerase inhibitors include etoposide and doxorubicin, which are used in cancer chemotherapy.",GO:0035562 negative regulation of chromatin binding;GO:0045875 negative regulation of sister chromatid cohesion;GO:0035561 regulation of chromatin binding,,Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000146833.16,ENSG00000146833,TRIM4,-0.700970657,-1.086394792,-0.722268455,-0.294248723,tripartite motif containing 4,"TRIM4 is a gene that encodes a protein belonging to the tripartite motif (TRIM) family. The TRIM motif consists of three zinc-binding domains, a RING, a B-box type 1, and a B-box type 2, as well as a coiled-coil region. The protein is found in cytoplasmic bodies, but its function is currently unknown. Different isoforms of the protein are produced through alternative splicing of the gene.","Research on TRIM4 is still in its early stages, and there is limited information available on its disease implications. However, some studies have suggested that TRIM4 may play a role in the development of certain cancers, including breast cancer and glioblastoma. Additionally, mutations in the TRIM4 gene have been associated with an increased risk of developing Alzheimer's disease.

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target TRIM4. However, there is ongoing research into the development of drugs that target other members of the TRIM family, which may have implications for TRIM4 as well. For example, some studies have shown that targeting TRIM28 can inhibit the growth of certain cancer cells, and drugs that target TRIM28 are currently in development.

Overall, while there is still much to learn about the function and disease implications of TRIM4, ongoing research into the TRIM family as a whole may lead to the development of targeted therapies for a variety of diseases, including cancer and Alzheimer's disease.",GO:0016567 protein ubiquitination;GO:0032446 protein modification by small protein conjugation;GO:0070647 protein modification by small protein conjugation or removal,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Supported); Additional: Plasma membrane,,,
ENSG00000137073.23,ENSG00000137073,UBAP2,-0.699876389,-1.210062986,-0.676896314,-0.212669867,ubiquitin associated protein 2,"The UBAP2 gene encodes a protein that contains a UBA domain, which is involved in the ubiquitination pathway. This gene may be expressed more in the adrenal gland and lymphatic tissues. Alternative splicing can result in multiple transcript variants.","There is limited information available on the disease implications of UBAP2 gene mutations. However, recent studies have suggested that UBAP2 may play a role in the development and progression of certain cancers, including breast cancer and lung cancer. Targeted drug discovery efforts for UBAP2 are still in the early stages, but there is potential for the development of novel therapies that target the ubiquitination pathway. Currently, there are no drugs on the market that specifically target UBAP2, but there are several drugs that target other proteins involved in the ubiquitination pathway, such as proteasome inhibitors like bortezomib and carfilzomib, which are used to treat multiple myeloma. Additionally, there are ongoing clinical trials investigating the use of other targeted therapies for various cancers, including those that may involve UBAP2.",GO:0010468 regulation of gene expression;GO:0010556 regulation of macromolecule biosynthetic process;GO:0009889 regulation of biosynthetic process,,Disease related genes; Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000070476.15,ENSG00000070476,ZXDC,-0.699834459,-0.942617155,-0.476527549,-0.680358672,ZXD family zinc finger C,"The human gene ZXDC, also known as ZXD family zinc finger C, is involved in positive regulation of transcription, DNA-templated. It enables C2H2 zinc finger domain binding activity, LRR domain binding activity, and transcription coactivator activity. It is predicted to be active in the nucleus.","There is limited information available on the disease implications of the ZXDC gene. However, recent studies have suggested that it may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ZXDC are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target ZXDC, there are several drugs that have been approved for the treatment of breast cancer and hepatocellular carcinoma that may indirectly affect the activity of this gene. These include tamoxifen, trastuzumab, and sorafenib, among others. Further research is needed to fully understand the potential therapeutic implications of targeting the ZXDC gene in cancer treatment.",GO:0045893 positive regulation of DNA-templated transcription;GO:1902680 positive regulation of RNA biosynthetic process;GO:0051254 positive regulation of RNA metabolic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoli (Approved),,,
ENSG00000170088.14,ENSG00000170088,TMEM192,-0.699752997,-1.148372107,-0.744527885,-0.206358999,transmembrane protein 192,"TMEM192 is a human gene that encodes for a transmembrane protein known as transmembrane protein 192. This protein is involved in enabling protein homodimerization activity and is found in various cellular components, including the late endosome, lysosomal membrane, and perinuclear region of cytoplasm. The function of TMEM192 is not yet fully understood, but it is believed to play a role in cellular processes such as protein transport and degradation. Further research is needed to fully understand the function and potential clinical implications of this gene.","There is limited information available on the disease implications of TMEM192. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TMEM192 are also limited, as the function of this gene is not yet fully understood. Currently, there are no drugs on the market that specifically target TMEM192. However, there are drugs that target related cellular processes, such as lysosomal function and protein degradation, which may indirectly affect TMEM192 activity. Examples of such drugs include chloroquine, which is used to treat malaria and rheumatoid arthritis, and bortezomib, which is used to treat multiple myeloma. Further research is needed to fully understand the potential clinical implications of TMEM192 and to develop targeted therapies for diseases associated with this gene.",,,Transporters,Endosomes;Lysosomes (Supported); Additional: Nucleoplasm,,,
ENSG00000115561.16,ENSG00000115561,CHMP3,-0.6996239,-1.017119512,-0.894553215,-0.187198973,charged multivesicular body protein 3,"CHMP3 is a human gene that plays a role in sorting transmembrane proteins into lysosomes/vacuoles through the multivesicular body (MVB) pathway. It is part of the ESCRT-III protein complex, which binds to the endosomal membrane and recruits additional cofactors for protein sorting into the MVB. CHMP3 may also interact with a member of the IFG-binding protein superfamily. Alternative splicing of this gene results in multiple transcript variants, and read-through transcription exists between CHMP3 and the upstream RNF103 gene.","There is limited information available on the disease implications of CHMP3. However, mutations in other genes involved in the ESCRT-III complex have been linked to various diseases, including neurodegenerative disorders and cancer. Targeted drug discovery efforts for CHMP3 are also limited, as it is not a well-studied drug target. However, there have been some studies on the potential use of ESCRT inhibitors for cancer therapy, as the ESCRT pathway is involved in the formation of exosomes, which play a role in cancer progression and metastasis. One example of a successful drug targeting the ESCRT pathway is VPS34-IN1, which inhibits the activity of the VPS34 lipid kinase, a key regulator of the ESCRT pathway. VPS34-IN1 has shown promising results in preclinical studies for the treatment of cancer and neurodegenerative diseases.",GO:0051036 regulation of endosome size;GO:0051469 vesicle fusion with vacuole;GO:0061763 multivesicular body-lysosome fusion,,Predicted intracellular proteins,,,(M214)PID ERBB1 INTERNALIZATION PATHWAY,
ENSG00000101310.17,ENSG00000101310,SEC23B,-0.699221618,-0.994585531,-0.831992178,-0.271087145,"SEC23 homolog B, COPII coat complex component","SEC23B is a human gene that encodes a protein belonging to the SEC23 subfamily of the SEC23/SEC24 family. This protein is involved in vesicle trafficking and has similarities to the yeast Sec23p component of COPII, which is responsible for vesicle budding from the endoplasmic reticulum (ER). The function of SEC23B has been implicated in cargo selection and concentration. Multiple alternatively spliced transcript variants have been identified in this gene.","Mutations in SEC23B have been associated with a rare autosomal recessive disorder called congenital dyserythropoietic anemia type II (CDAII). CDAII is characterized by ineffective erythropoiesis, leading to anemia, jaundice, and splenomegaly. The exact mechanism by which SEC23B mutations cause CDAII is not fully understood, but it is thought to be related to impaired protein trafficking in erythroid cells. 

There are currently no targeted drug discovery efforts specifically for SEC23B. However, there are drugs on the market that indirectly affect SEC23B function by targeting the COPII pathway. For example, the drug Saracatinib, which is used to treat certain types of cancer, has been shown to inhibit the COPII pathway and reduce protein secretion. Another drug, SecinH3, has been shown to inhibit the activity of the small GTPase Sar1, which is involved in COPII vesicle formation. 

In summary, mutations in SEC23B have been linked to a rare genetic disorder called CDAII. While there are currently no targeted drug discovery efforts for SEC23B, there are drugs on the market that indirectly affect its function by targeting the COPII pathway.",GO:0090110 COPII-coated vesicle cargo loading;GO:0035459 vesicle cargo loading;GO:0090114 COPII-coated vesicle budding,,Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Cytosol;Endoplasmic reticulum;Vesicles (Supported),,,
ENSG00000167522.16,ENSG00000167522,ANKRD11,-0.698780754,-1.229490583,-0.645020586,-0.221831092,ankyrin repeat domain containing 11,"The ANKRD11 gene encodes a protein that contains an ankyrin repeat domain and inhibits the activation of transcription by ligands. Mutations in this gene have been linked to KBG syndrome, a condition characterized by macrodontia, distinctive craniofacial features, short stature, skeletal anomalies, global developmental delay, seizures, and intellectual disability. The gene has multiple alternatively spliced transcript variants, and there are related pseudogenes on chromosomes 2 and X.","Currently, there are no targeted drug discovery efforts specifically for ANKRD11 gene mutations. Treatment for KBG syndrome, which is caused by mutations in ANKRD11, is symptomatic and supportive. This may include physical therapy, speech therapy, and medication to manage seizures or behavioral issues. However, research is ongoing to better understand the molecular mechanisms underlying KBG syndrome and to identify potential therapeutic targets. 

There are currently no drugs on the market specifically for KBG syndrome or ANKRD11 mutations. However, there are drugs that may be used to manage symptoms associated with the condition, such as antiepileptic drugs for seizures or psychotropic medications for behavioral issues. Additionally, there are drugs in development that target related pathways, such as those involved in intellectual disability and developmental delay. For example, a drug called trofinetide is currently in clinical trials for Rett syndrome, a neurodevelopmental disorder with some similarities to KBG syndrome. Trofinetide targets the GABAergic system, which is also implicated in KBG syndrome.",GO:0060325 face morphogenesis;GO:0060323 head morphogenesis;GO:0010171 body morphogenesis,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Nucleoplasm (Enhanced); Additional: Cytosol,,,
ENSG00000122257.20,ENSG00000122257,RBBP6,-0.69803742,-0.89312186,-0.787563747,-0.413426654,"RB binding protein 6, ubiquitin ligase","RBBP6 is a gene that encodes for the RB binding protein 6, ubiquitin ligase. The protein encoded by this gene binds to the retinoblastoma tumor suppressor (pRB) protein, which is known to suppress cellular proliferation and is often inactivated in various human cancers. The activity of pRB is regulated by cell cycle-dependent phosphorylation, and the protein encoded by RBBP6 binds to underphosphorylated pRB. Multiple isoforms of this protein have been found due to alternative splicing of the transcript.","RBBP6 has been implicated in various diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, RBBP6 has been shown to play a role in the regulation of cell proliferation, apoptosis, and DNA damage response. Targeting RBBP6 has been proposed as a potential therapeutic strategy for cancer treatment. However, there are currently no drugs on the market that specifically target RBBP6.

Several studies have identified small molecules that can inhibit the activity of RBBP6, including NSC207895 and its analogs. These compounds have been shown to induce apoptosis in cancer cells and inhibit tumor growth in animal models. Another study identified a natural compound, curcumin, that can downregulate RBBP6 expression and sensitize cancer cells to chemotherapy.

In addition to cancer, RBBP6 has also been implicated in neurodegenerative disorders such as Alzheimer's disease and viral infections such as HIV. However, there are currently no drugs on the market that target RBBP6 for these indications. Further research is needed to fully understand the role of RBBP6 in these diseases and to develop targeted therapies.",GO:0061053 somite development;GO:0035264 multicellular organism growth;GO:0006275 regulation of DNA replication,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nuclear speckles (Enhanced),,,
ENSG00000110315.7,ENSG00000110315,RNF141,-0.697138459,-0.594824063,-0.722505704,-0.774085609,ring finger protein 141,"RNF141 is a gene that encodes a protein containing a RING finger motif, which is involved in protein-DNA and protein-protein interactions. The gene is highly expressed in the testicular tissue of fertile men but not in azoospermic patients. Studies on the mouse counterpart suggest that RNF141 may function as a testis-specific transcription factor during spermatogenesis.","There is limited information available on the disease implications of RNF141. However, recent studies have suggested that RNF141 may play a role in male infertility. Targeted drug discovery efforts for RNF141 are also limited, as the function of the protein is not well understood. Currently, there are no drugs on the market that specifically target RNF141. However, there are drugs available for the treatment of male infertility, such as clomiphene citrate and gonadotropins, which can stimulate the production of sperm. Further research is needed to fully understand the role of RNF141 in male infertility and to develop targeted therapies for this condition.",GO:0051865 protein autoubiquitination;GO:0016567 protein ubiquitination;GO:0032446 protein modification by small protein conjugation,,Predicted intracellular proteins,Microtubules (Approved); Additional: Nucleoplasm,,,
ENSG00000167110.18,ENSG00000167110,GOLGA2,-0.696801152,-1.343575364,-0.677273035,-0.069555056,golgin A2,"GOLGA2, also known as golgin A2, is a gene that encodes for a protein belonging to the golgin family of proteins localized to the Golgi apparatus. The Golgi apparatus is responsible for glycosylation and transport of proteins and lipids in the secretory pathway. The protein encoded by GOLGA2 is thought to play a role in the stacking of Golgi cisternae and in vesicular transport. Interactions between the Golgi and microtubules are also believed to be important for the reorganization of the Golgi after it fragments during mitosis. There are several alternatively spliced transcript variants of this gene, but their full-length nature has not been determined.","There is limited information on the disease implications of GOLGA2. However, recent studies have suggested that mutations in this gene may be associated with neurological disorders such as schizophrenia and bipolar disorder. Targeted drug discovery efforts for GOLGA2 are also limited, but some studies have focused on identifying small molecules that can modulate the protein's function in the Golgi apparatus. One example is the compound golgicide A, which has been shown to disrupt the Golgi structure and inhibit vesicular transport. However, there are currently no drugs on the market that specifically target GOLGA2. Overall, further research is needed to fully understand the role of GOLGA2 in disease and to develop targeted therapies for associated disorders.",GO:0090166 Golgi disassembly;GO:0060050 positive regulation of protein glycosylation;GO:0060049 regulation of protein glycosylation,,Predicted intracellular proteins,Golgi apparatus (Enhanced),,(M129)PID PLK1 PATHWAY,
ENSG00000152492.15,ENSG00000152492,CCDC50,-0.696538717,-1.224245769,-0.85410146,-0.011268921,coiled-coil domain containing 50,"CCDC50 is a gene that encodes a protein with multiple ubiquitin-interacting domains. This protein is soluble and cytoplasmic, and it is tyrosine-phosphorylated. Mutations in this gene can cause nonsyndromic, postlingual, progressive sensorineural DFNA44 hearing loss. In mice, the protein is expressed in the inner ear during development and postnatal maturation, and it associates with microtubule-based structures. The protein may also function as a negative regulator of NF-kB signaling and as an effector of epidermal growth factor (EGF)-mediated cell signaling. Alternative splicing results in multiple transcript variants encoding distinct isoforms.","Currently, there are no targeted drug discovery efforts specifically for CCDC50-related hearing loss. However, there are ongoing efforts to develop gene therapies for various forms of genetic hearing loss, including nonsyndromic, postlingual, progressive sensorineural DFNA44 hearing loss caused by mutations in CCDC50. These therapies aim to deliver functional copies of the mutated gene to the affected cells in the inner ear, potentially restoring hearing function.

There are currently no drugs on the market specifically targeting CCDC50-related hearing loss. However, there are several drugs approved for the treatment of other forms of genetic hearing loss, such as aminoglycoside antibiotics that can mitigate the effects of certain mutations in the mitochondrial genome. Additionally, there are several drugs in development for the treatment of various forms of genetic hearing loss, including antisense oligonucleotides and small molecule drugs that target specific genetic mutations. These drugs are still in the early stages of development and have not yet been approved for clinical use.",GO:0007605 sensory perception of sound;GO:0050954 sensory perception of mechanical stimulus;GO:0007600 sensory perception,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Ear disease,Cytosol (Supported); Additional: Basal body,,,
ENSG00000048392.12,ENSG00000048392,RRM2B,-0.695580433,-0.913274399,-0.702179473,-0.471287427,ribonucleotide reductase regulatory TP53 inducible subunit M2B,"The RRM2B gene encodes the small subunit of a ribonucleotide reductase enzyme that is induced by the p53 protein. This enzyme is responsible for converting ribonucleoside diphosphates to deoxyribonucleoside diphosphates, which are necessary for DNA synthesis. Mutations in this gene have been linked to several mitochondrial disorders, including autosomal recessive mitochondrial DNA depletion syndrome, autosomal dominant progressive external ophthalmoplegia-5, and mitochondrial neurogastrointestinal encephalopathy. Different versions of the RRM2B gene have been identified through alternative splicing.","Mutations in the RRM2B gene have been linked to several mitochondrial disorders, including autosomal recessive mitochondrial DNA depletion syndrome, autosomal dominant progressive external ophthalmoplegia-5, and mitochondrial neurogastrointestinal encephalopathy. These disorders are characterized by a range of symptoms, including muscle weakness, vision problems, gastrointestinal issues, and neurological dysfunction. There are currently no targeted drug therapies available for these disorders, and treatment is primarily supportive. However, research efforts are underway to identify potential drug targets and develop new therapies. One example is the use of nucleoside analogs, such as deoxycytidine, to increase the levels of deoxyribonucleoside diphosphates in cells with RRM2B mutations. Another approach is the use of gene therapy to introduce functional copies of the RRM2B gene into affected cells. While there are currently no drugs on the market specifically targeting RRM2B mutations, there are several drugs used to treat mitochondrial disorders more broadly, such as coenzyme Q10 and idebenone.",GO:0070318 positive regulation of G0 to G1 transition;GO:0006264 mitochondrial DNA replication;GO:0009200 deoxyribonucleoside triphosphate metabolic process,,Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; ENZYME proteins:Oxidoreductases; FDA approved drug targets:Small molecule drugs; Disease related genes; Enzymes,Nucleoplasm (Enhanced); Additional: Cytosol,Cladribine,(M145)PID P53 DOWNSTREAM PATHWAY,(M5898)HALLMARK DNA REPAIR
ENSG00000164329.13,ENSG00000164329,TENT2,-0.694584856,-0.711189496,-0.759900417,-0.612664655,terminal nucleotidyltransferase 2,"TENT2, or terminal nucleotidyltransferase 2, is a gene that plays a role in RNA metabolism and negative regulation of RNA breakdown. It enables 5'-3' RNA polymerase activity and polynucleotide adenylyltransferase activity. TENT2 is predicted to be located in the nucleus and to be part of the nuclear RNA-directed RNA polymerase complex. It is also predicted to be active in the cytosol. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of TENT2. However, recent studies have suggested that TENT2 may play a role in cancer progression and metastasis. Specifically, TENT2 has been found to be upregulated in several types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts for TENT2 are currently limited, but there is potential for the development of drugs that target TENT2 to inhibit cancer growth and metastasis. Currently, there are no drugs on the market that specifically target TENT2. However, there are several drugs that target RNA metabolism and could potentially be used to target TENT2, including RNA polymerase inhibitors and RNA degradation inhibitors. Further research is needed to fully understand the role of TENT2 in cancer and to develop targeted therapies for this gene.",GO:2000626 negative regulation of miRNA catabolic process;GO:0140958 target-directed miRNA degradation;GO:0071044 histone mRNA catabolic process,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Approved),,,
ENSG00000140750.17,ENSG00000140750,ARHGAP17,-0.694552461,-1.086145933,-0.684544641,-0.312966809,Rho GTPase activating protein 17,"ARHGAP17, also known as RICH1, is a gene that encodes for a protein called Rho GTPase activating protein 17. This protein is a type of GTPase-activating protein (GAP) that helps to stimulate the hydrolysis of GTP molecules in small G proteins such as RHOA, RAC1, and CDC42. These small G proteins are involved in various cellular processes such as cell migration, cell division, and cell signaling. ARHGAP17 has been implicated in the regulation of actin cytoskeleton dynamics and cell migration, and mutations in this gene have been associated with certain types of cancer.","Mutations in ARHGAP17 have been associated with several types of cancer, including breast, lung, and colorectal cancer. In breast cancer, ARHGAP17 has been shown to be downregulated, leading to increased cell migration and invasion. Targeting ARHGAP17 may therefore be a potential therapeutic strategy for cancer treatment. However, there are currently no drugs specifically targeting ARHGAP17 on the market. 

There have been efforts to develop drugs targeting the Rho GTPase pathway, which includes ARHGAP17. For example, fasudil is a drug that inhibits Rho kinase, a downstream effector of Rho GTPases. Fasudil has been approved in Japan for the treatment of cerebral vasospasm and is being investigated for its potential in treating other diseases such as pulmonary hypertension and cancer. Another drug, statins, have been shown to inhibit Rho GTPases and have been investigated for their potential in cancer treatment. However, more research is needed to fully understand the role of ARHGAP17 in cancer and to develop targeted therapies.",GO:0035020 regulation of Rac protein signal transduction;GO:0017156 calcium-ion regulated exocytosis;GO:0051058 negative regulation of small GTPase mediated signal transduction,,Predicted intracellular proteins,Cytosol;Plasma membrane (Supported),,(M83)PID CDC42 REG PATHWAY; (M241)PID RAC1 REG PATHWAY,
ENSG00000100099.21,ENSG00000100099,HPS4,-0.694525633,-0.827323518,-0.700979125,-0.555274256,HPS4 biogenesis of lysosomal organelles complex 3 subunit 2,"HPS4 is a gene that encodes a protein component of biogenesis of lysosome-related organelles complexes (BLOC). BLOC complexes are crucial for the formation of endosomal-lysosomal organelles such as melanosomes and platelet dense granules. Mutations in this gene lead to subtype 4 of Hermansky-Pudlak syndrome, which is a form of albinism. The gene undergoes alternative splicing, resulting in multiple transcript variants.","Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive disorder characterized by oculocutaneous albinism, bleeding diathesis, and pulmonary fibrosis. HPS4 mutations are associated with HPS subtype 4, which is the most common subtype in Puerto Rico. Patients with HPS4 mutations have reduced pigmentation, bleeding disorders, and pulmonary fibrosis. There are currently no targeted drug therapies for HPS4 mutations, and treatment is mainly supportive. However, there have been some successful drug therapies for the symptoms of HPS, such as anticoagulants for bleeding disorders and pirfenidone for pulmonary fibrosis. Pirfenidone has been shown to slow the progression of pulmonary fibrosis in HPS patients, and it is currently approved for the treatment of idiopathic pulmonary fibrosis.",GO:0048075 positive regulation of eye pigmentation;GO:0048073 regulation of eye pigmentation;GO:0048087 positive regulation of developmental pigmentation,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of amino acid metabolism; Predicted intracellular proteins,Plasma membrane (Approved),,,
ENSG00000100425.18,ENSG00000100425,BRD1,-0.69443997,-0.792770472,-1.012857109,-0.277692328,bromodomain containing 1,"BRD1 is a gene that encodes a protein containing a bromodomain, which is involved in binding to DNA and histone tails in the nucleus. The protein is part of the MOZ/MORF acetyltransferase complex, which can stimulate the acetylation of histones H3 and H4, potentially leading to gene activation. Variations in the BRD1 gene have been linked to schizophrenia and bipolar disorder in some populations. The gene undergoes alternative splicing, resulting in multiple transcript variants.","The BRD1 gene has been implicated in several psychiatric disorders, including schizophrenia and bipolar disorder. Studies have shown that variations in the gene may affect the expression and function of the protein, leading to altered histone acetylation and gene expression patterns. This has led to efforts to develop drugs that target the BRD1 protein or its associated acetyltransferase complex as potential treatments for these disorders. However, there are currently no drugs on the market that specifically target BRD1. Some drugs that indirectly affect histone acetylation, such as valproic acid and lithium, have been used to treat bipolar disorder, but their mechanisms of action are not fully understood and they have limited efficacy. Further research is needed to fully understand the role of BRD1 in psychiatric disorders and to develop targeted therapies.",GO:0043249 erythrocyte maturation;GO:0035902 response to immobilization stress;GO:0045648 positive regulation of erythrocyte differentiation,,Predicted intracellular proteins,Nuclear speckles (Supported),,,
ENSG00000043093.15,ENSG00000043093,DCUN1D1,-0.693851679,-0.998056893,-0.857122636,-0.226375508,defective in cullin neddylation 1 domain containing 1,"DCUN1D1 is a human gene that plays a crucial role in the process of protein neddylation and ubiquitination. It enables the binding activity of cullin family proteins and is located in both the cytosol and nucleoplasm. DCUN1D1 is a part of the ubiquitin ligase complex, which is responsible for regulating protein degradation and turnover. When this gene is defective, it can lead to cullin neddylation 1 domain containing 1 (CUL1)-defective phenotypes, which can result in developmental abnormalities and cancer. Understanding the function of DCUN1D1 is important for developing new therapies for diseases related to protein degradation and turnover.","There is limited information available on targeted drug discovery efforts for DCUN1D1. However, research has shown that defects in this gene can lead to developmental abnormalities and cancer. In particular, DCUN1D1 has been implicated in the development of breast cancer, where it is overexpressed in some cases. Targeting DCUN1D1 could potentially be a therapeutic strategy for treating breast cancer and other cancers that involve defects in protein degradation and turnover. Currently, there are no drugs on the market that specifically target DCUN1D1. However, there are drugs that target the ubiquitin-proteasome system, which is the pathway that DCUN1D1 is involved in. Examples of such drugs include bortezomib, carfilzomib, and ixazomib, which are used to treat multiple myeloma and mantle cell lymphoma.",GO:2000436 positive regulation of protein neddylation;GO:2000434 regulation of protein neddylation;GO:0045116 protein neddylation,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,(M5945)HALLMARK HEME METABOLISM
ENSG00000065970.9,ENSG00000065970,FOXJ2,-0.693562649,-0.918233054,-0.664070497,-0.498384395,forkhead box J2,"FOXJ2, also known as forkhead box J2, is a gene that encodes a protein involved in DNA-binding transcription activation, RNA polymerase II-specific activity, and identical protein binding activity. It plays a role in several biological processes, including negative regulation of angiogenesis, negative regulation of blood vessel endothelial cell differentiation, and positive regulation of vascular-associated smooth muscle cell proliferation. FOXJ2 is located in the fibrillar center and nucleoplasm.","There is limited information available on the disease implications of FOXJ2. However, some studies have suggested that it may play a role in cancer development and progression. For example, one study found that FOXJ2 expression was significantly decreased in breast cancer tissues compared to normal breast tissues, and that low FOXJ2 expression was associated with poor prognosis in breast cancer patients. 

As for targeted drug discovery efforts, there are currently no drugs specifically targeting FOXJ2. However, there are drugs that target some of the biological processes in which FOXJ2 is involved, such as angiogenesis and smooth muscle cell proliferation. For example, bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), a key regulator of angiogenesis. It is used to treat several types of cancer, including colorectal, lung, and ovarian cancer. Another example is imatinib, a tyrosine kinase inhibitor that targets the platelet-derived growth factor receptor (PDGFR), which is involved in smooth muscle cell proliferation. It is used to treat several types of cancer, as well as certain non-cancerous conditions such as gastrointestinal stromal tumors and chronic myeloid leukemia.",GO:0110059 negative regulation of blood vessel endothelial cell differentiation;GO:0110057 regulation of blood vessel endothelial cell differentiation;GO:0045602 negative regulation of endothelial cell differentiation,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nucleoli fibrillar center,,,(M5945)HALLMARK HEME METABOLISM
ENSG00000166478.10,ENSG00000166478,ZNF143,-0.692723855,-0.953893982,-0.759794743,-0.364482841,zinc finger protein 143,"ZNF143 is a human gene that encodes for a zinc finger protein 143. This protein is involved in enabling DNA-binding transcription activator activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. It is also involved in positive regulation of snRNA transcription by RNA polymerase II. ZNF143 is predicted to be located in the nucleoplasm.","ZNF143 has been implicated in various diseases, including cancer, neurological disorders, and cardiovascular diseases. In cancer, ZNF143 has been shown to be overexpressed in several types of tumors, including breast, lung, and prostate cancer. Targeting ZNF143 has been proposed as a potential therapeutic strategy for cancer treatment. However, there are currently no drugs specifically targeting ZNF143.

There have been some efforts to discover drugs that indirectly target ZNF143. For example, a study found that the drug metformin, which is commonly used to treat type 2 diabetes, can inhibit ZNF143 expression in breast cancer cells. Another study found that the drug vorinostat, which is used to treat certain types of cancer, can also inhibit ZNF143 expression.

Overall, while there is evidence to suggest that targeting ZNF143 could be a promising therapeutic strategy for certain diseases, more research is needed to fully understand its role in disease and to develop effective drugs that specifically target this protein.",GO:1905382 positive regulation of snRNA transcription by RNA polymerase II;GO:1905380 regulation of snRNA transcription by RNA polymerase II;GO:0045945 positive regulation of transcription by RNA polymerase III,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Golgi apparatus;Nuclear bodies;Vesicles,,,
ENSG00000082213.18,ENSG00000082213,C5orf22,-0.692508004,-1.10058451,-0.688896906,-0.288042597,chromosome 5 open reading frame 22,"Human gene C5orf22, also known as chromosome 5 open reading frame 22, is a protein-coding gene located on chromosome 5. The function of this gene is not yet fully understood, but it is believed to play a role in cellular processes such as DNA repair and cell cycle regulation. Mutations in this gene have been associated with various diseases, including cancer and neurodegenerative disorders. Further research is needed to fully understand the function and potential clinical implications of C5orf22.","There is limited information available on the disease implications and targeted drug discovery efforts for C5orf22. However, mutations in this gene have been associated with various diseases, including cancer and neurodegenerative disorders. For example, a study found that mutations in C5orf22 were associated with an increased risk of developing breast cancer. Additionally, another study found that mutations in this gene were associated with an increased risk of developing Parkinson's disease. 

As for targeted drug discovery efforts, there is currently no information available on any drugs specifically targeting C5orf22. However, given its potential role in DNA repair and cell cycle regulation, it is possible that drugs targeting these pathways may indirectly affect the function of C5orf22. 

There are currently no drugs on the market that specifically target C5orf22. However, there are drugs on the market that target DNA repair and cell cycle regulation pathways, such as PARP inhibitors and CDK inhibitors, which may indirectly affect the function of C5orf22. For example, PARP inhibitors have been approved for the treatment of certain types of breast and ovarian cancers, while CDK inhibitors have been approved for the treatment of certain types of breast cancer.",,,Predicted intracellular proteins,Nuclear membrane (Approved),,,
ENSG00000173852.15,ENSG00000173852,DPY19L1,-0.692273218,-1.317540103,-0.619590452,-0.1396891,dpy-19 like C-mannosyltransferase 1,DPY19L1 is a human gene that is predicted to have mannosyltransferase activity and be involved in protein C-linked glycosylation via 2'-alpha-mannosyl-L-tryptophan. It is located in the membrane.,"Mutations in the DPY19L1 gene have been associated with male infertility, specifically with globozoospermia, a rare condition characterized by the absence of acrosomes in spermatozoa. There are currently no targeted drug discovery efforts for DPY19L1, as the underlying mechanisms of globozoospermia are not yet fully understood. However, assisted reproductive technologies such as intracytoplasmic sperm injection (ICSI) have been successful in treating male infertility caused by DPY19L1 mutations. There are no drugs on the market specifically targeting DPY19L1, but drugs used in assisted reproductive technologies, such as gonadotropins and human chorionic gonadotropin (hCG), have been successful in treating infertility caused by DPY19L1 mutations.",GO:0006486 protein glycosylation;GO:0043413 macromolecule glycosylation;GO:0070085 glycosylation,,Predicted intracellular proteins,Vesicles (Approved),,,
ENSG00000153786.13,ENSG00000153786,ZDHHC7,-0.691430852,-1.180088576,-0.619004488,-0.275199492,zinc finger DHHC-type palmitoyltransferase 7,"ZDHHC7 is a human gene that encodes for a protein called zinc finger DHHC-type palmitoyltransferase 7. This protein is involved in several processes, including peptidyl-L-cysteine S-palmitoylation, polarized epithelial cell differentiation, and regulation of signal transduction. It enables protein-cysteine S-palmitoyltransferase activity and is located in the Golgi apparatus and nucleoplasm.","There is limited information available on the disease implications of ZDHHC7. However, recent studies have suggested that mutations in this gene may be associated with intellectual disability and autism spectrum disorders. Targeted drug discovery efforts for ZDHHC7 are also limited, but there is ongoing research to identify small molecule inhibitors that can modulate its activity. Currently, there are no drugs on the market that specifically target ZDHHC7. However, there are several drugs that target related enzymes involved in protein palmitoylation, such as the anti-cancer drug palmostatin B and the antipsychotic drug clozapine. These drugs have been shown to modulate protein palmitoylation and may have potential therapeutic applications in diseases associated with dysregulated palmitoylation, including cancer and neurological disorders.",GO:0150106 regulation of protein localization to cell-cell junction;GO:0044381 glucose import in response to insulin stimulus;GO:1902044 regulation of Fas signaling pathway,,Enzymes; ENZYME proteins:Transferases,Golgi apparatus (Supported),,,
ENSG00000101452.15,ENSG00000101452,DHX35,-0.691361642,-0.782172465,-0.618412861,-0.6734996,DEAH-box helicase 35,"DHX35 is a human gene that belongs to the DEAD box protein family, which are RNA helicases involved in various cellular processes such as RNA secondary structure alteration, translation initiation, and splicing. The function of DHX35 is currently unknown, but it is believed to be involved in embryogenesis, spermatogenesis, and cellular growth and division based on the distribution patterns of other members of the DEAD box protein family. The gene has multiple alternatively spliced transcript variants.","There is limited information available on the disease implications of DHX35. However, mutations in other members of the DEAD box protein family have been associated with various diseases, including cancer, neurodegenerative disorders, and developmental disorders. Therefore, it is possible that mutations in DHX35 may also contribute to the development of these diseases. 

As of now, there are no targeted drug discovery efforts specifically for DHX35. However, there are ongoing efforts to develop drugs that target other members of the DEAD box protein family. For example, the drug RG7834 is currently in clinical trials for the treatment of acute myeloid leukemia and targets the RNA helicase DDX3X, which is involved in RNA splicing and translation initiation. 

Other successful drugs that target RNA helicases include the hepatitis C virus (HCV) drugs, such as sofosbuvir and daclatasvir, which target the HCV RNA helicase NS3/4A. These drugs have revolutionized the treatment of HCV and have high cure rates. 

In summary, while there is limited information available on the disease implications of DHX35, ongoing efforts to develop drugs that target other members of the DEAD box protein family may have implications for the treatment of diseases associated with DHX35 mutations.","GO:0140588 chromatin looping;GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;GO:0000398 mRNA splicing, via spliceosome",,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nuclear bodies (Approved); Additional: Centrosome;Nucleoplasm,,,
ENSG00000034693.15,ENSG00000034693,PEX3,-0.690892123,-0.96920205,-0.893426716,-0.210047602,peroxisomal biogenesis factor 3,"PEX3 is a gene that plays a crucial role in the biosynthesis and maintenance of peroxisomes, which are organelles involved in various metabolic processes. The protein encoded by this gene is responsible for assembling membrane vesicles that are necessary for the translocation of matrix proteins into peroxisomes. Peroxisomal biogenesis disorders (PBDs) are a group of lethal genetic diseases characterized by defects in peroxisome function. PEX3 mutations have been identified as a cause of Zellweger syndrome, a severe form of PBD. Although the clinical features of PBD patients vary, all PBD patients exhibit a defect in the import of one or more classes of peroxisomal matrix proteins into the organelle.","PEX3 mutations have been identified as a cause of Zellweger syndrome, a severe form of peroxisomal biogenesis disorder (PBD). There is currently no cure for PBDs, and treatment is mainly supportive. However, targeted drug discovery efforts are underway to develop therapies that can improve peroxisome function in PBD patients. One approach is to use small molecules that can enhance peroxisome biogenesis and function. For example, bezafibrate, a drug used to treat hyperlipidemia, has been shown to improve peroxisome function in PBD patients. Another approach is to use gene therapy to replace the defective PEX3 gene with a functional copy. While there are currently no gene therapies approved for PBDs, preclinical studies have shown promising results. Overall, the development of targeted therapies for PBDs, including those caused by PEX3 mutations, is an active area of research.",GO:0045046 protein import into peroxisome membrane;GO:0072662 protein localization to peroxisome;GO:0072663 establishment of protein localization to peroxisome,,Disease related genes; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Peroxisomal diseases; Transporters,Nucleoplasm;Peroxisomes (Approved),,,
ENSG00000136450.13,ENSG00000136450,SRSF1,-0.689384997,-0.705448464,-0.997200372,-0.365506154,serine and arginine rich splicing factor 1,"SRSF1, also known as serine and arginine rich splicing factor 1, is a gene that encodes a protein belonging to the arginine/serine-rich splicing factor family. This protein can either activate or repress splicing, depending on its phosphorylation state and interaction partners. The gene has multiple transcript variants, and there is a pseudogene of this gene on chromosome 13.","SRSF1 has been implicated in various diseases, including cancer, spinal muscular atrophy, and Alzheimer's disease. In cancer, SRSF1 has been shown to promote tumor growth and metastasis by regulating alternative splicing of genes involved in cell proliferation, apoptosis, and angiogenesis. Targeting SRSF1 with small molecule inhibitors or RNA interference has been explored as a potential therapeutic strategy for cancer. However, there are currently no drugs targeting SRSF1 on the market. In spinal muscular atrophy, SRSF1 has been shown to regulate the splicing of the SMN2 gene, which is a modifier of the disease severity. Modulating SRSF1 activity has been proposed as a potential therapeutic approach for spinal muscular atrophy. In Alzheimer's disease, SRSF1 has been shown to regulate the splicing of genes involved in synaptic plasticity and memory formation. However, there are currently no drugs targeting SRSF1 for Alzheimer's disease. Overall, SRSF1 is an interesting target for drug discovery efforts in various diseases, but more research is needed to fully understand its role and potential therapeutic implications.","GO:0000395 mRNA 5'-splice site recognition;GO:0000380 alternative mRNA splicing, via spliceosome;GO:0097421 liver regeneration",,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,Copper,,(M5901)HALLMARK G2M CHECKPOINT; (M5925)HALLMARK E2F TARGETS; (M5926)HALLMARK MYC TARGETS V1
ENSG00000132128.16,ENSG00000132128,LRRC41,-0.688436486,-0.826896131,-0.915312708,-0.323100619,leucine rich repeat containing 41,"The LRRC41 gene, also known as leucine rich repeat containing 41, is predicted to have identical protein binding activity and be involved in protein ubiquitination. It is located in the membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of LRRC41 gene mutations. However, recent studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, including breast and ovarian cancer. Targeted drug discovery efforts for LRRC41 are currently underway, with a focus on developing drugs that can inhibit the activity of the protein encoded by this gene. While there are currently no drugs on the market that specifically target LRRC41, there are several drugs that have been successful in treating breast and ovarian cancer, which may be related to the function of this gene. Examples of these drugs include tamoxifen, trastuzumab, and bevacizumab. Further research is needed to fully understand the role of LRRC41 in cancer development and to develop targeted therapies for patients with mutations in this gene.",GO:0016567 protein ubiquitination;GO:0032446 protein modification by small protein conjugation;GO:0070647 protein modification by small protein conjugation or removal,,Predicted intracellular proteins,Nuclear bodies (Approved); Additional: Nucleoplasm,,,
ENSG00000160695.15,ENSG00000160695,VPS11,-0.688280216,-1.398579636,-0.567303584,-0.098957428,VPS11 core subunit of CORVET and HOPS complexes,"VPS11 is a human gene that encodes the human homolog of yeast class C Vps11 protein. It is a core subunit of CORVET and HOPS complexes, which are involved in vesicle-mediated protein sorting. This process plays a crucial role in segregating intracellular molecules into distinct organelles. The mammalian class C Vps proteins are mainly associated with late endosomes/lysosomes and may mediate vesicle trafficking steps in the endosome/lysosome pathway. Alternative splicing of VPS11 results in multiple transcript variants.","Mutations in the VPS11 gene have been associated with several diseases, including autosomal recessive primary microcephaly (MCPH), a rare genetic disorder characterized by a significantly reduced head circumference and intellectual disability. Additionally, VPS11 mutations have been linked to a form of hereditary spastic paraplegia (HSP), a group of neurodegenerative disorders that affect the long nerves of the lower extremities, leading to progressive weakness and spasticity.

Targeted drug discovery efforts for VPS11 are still in the early stages, but there is potential for the development of drugs that modulate the function of the CORVET and HOPS complexes. These complexes have been implicated in several diseases, including cancer, neurodegenerative disorders, and infectious diseases, making them attractive targets for drug development.

Currently, there are no drugs on the market that specifically target VPS11. However, there are drugs that target other components of the CORVET and HOPS complexes, such as the lysosomal storage disease drug, eliglustat, which inhibits glucosylceramide synthase, a key enzyme in the sphingolipid metabolism pathway that is involved in lysosomal storage disorders. Additionally, the anti-cancer drug, bafilomycin A1, inhibits the vacuolar ATPase, a proton pump that is required for lysosomal acidification and function.",GO:2000643 positive regulation of early endosome to late endosome transport;GO:0034058 endosomal vesicle fusion;GO:0035542 regulation of SNARE complex assembly,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000087448.11,ENSG00000087448,KLHL42,-0.688271483,-0.490885921,-0.627181231,-0.946747297,kelch like family member 42,"KLHL42 is a human gene that belongs to the kelch-like family and is involved in the transfer of ubiquitin-protein activity. It plays a role in the proteasome-mediated ubiquitin-dependent protein catabolic process, protein polyubiquitination, and regulation of microtubule-based processes. KLHL42 is part of the Cul3-RING ubiquitin ligase complex. This gene's function is essential for maintaining cellular homeostasis and preventing the accumulation of damaged or misfolded proteins. KLHL42's dysregulation has been linked to various diseases, including cancer and neurodegenerative disorders. Understanding the role of KLHL42 in cellular processes may provide insights into the development of new therapeutic strategies for these diseases.","There is limited information available on the disease implications of KLHL42. However, studies have suggested that its dysregulation may be involved in the development of various cancers, including breast, lung, and liver cancer. Additionally, KLHL42 has been implicated in neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. 

There are currently no targeted drug discovery efforts specifically focused on KLHL42. However, drugs that target the ubiquitin-proteasome system, of which KLHL42 is a part, have been developed for the treatment of cancer. For example, bortezomib is a proteasome inhibitor that has been approved for the treatment of multiple myeloma and mantle cell lymphoma. 

In conclusion, while the exact role of KLHL42 in disease development is still being investigated, its involvement in the ubiquitin-proteasome system suggests that it may be a potential target for drug development in the future.",GO:0000209 protein polyubiquitination;GO:0032886 regulation of microtubule-based process;GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process,,Predicted intracellular proteins,,,,
ENSG00000172269.19,ENSG00000172269,DPAGT1,-0.687406877,-1.17984997,-0.494967909,-0.387402752,dolichyl-phosphate N-acetylglucosaminephosphotransferase 1,DPAGT1 is a gene that encodes an enzyme responsible for the first step in the dolichol-linked oligosaccharide pathway for glycoprotein biosynthesis. This enzyme is a member of the glycosyltransferase family 4 and is an integral membrane protein of the endoplasmic reticulum. Mutations in this gene can cause the congenital disorder of glycosylation type Ij.,"DPAGT1 mutations have been linked to the congenital disorder of glycosylation type Ij (CDG-Ij), which is a rare autosomal recessive disorder characterized by developmental delay, intellectual disability, seizures, and abnormal glycosylation of serum proteins. There is currently no cure for CDG-Ij, and treatment is mainly supportive, focusing on managing symptoms and improving quality of life.

Targeted drug discovery efforts for CDG-Ij have been limited due to the rarity of the disease and the lack of understanding of the underlying molecular mechanisms. However, recent studies have shown that small molecule inhibitors of DPAGT1 can reduce the abnormal glycosylation of proteins in cells with DPAGT1 mutations, suggesting that DPAGT1 inhibitors could be a potential therapeutic strategy for CDG-Ij.

There are currently no DPAGT1 inhibitors approved for clinical use, but several compounds have been identified as potential drug candidates. For example, NGI-1 is a small molecule inhibitor of DPAGT1 that has been shown to reduce abnormal glycosylation in cells with DPAGT1 mutations. Another compound, STF-62247, has been shown to selectively inhibit DPAGT1 and reduce the growth of cancer cells that are dependent on N-linked glycosylation.

In summary, DPAGT1 mutations can cause CDG-Ij, a rare disorder characterized by abnormal glycosylation of serum proteins and developmental delay. Targeted drug discovery efforts for CDG-Ij have been limited, but small molecule inhibitors of DPAGT1 have shown promise as potential therapeutic strategies. While there are currently no DPAGT1 inhibitors approved for clinical use, several compounds have been identified as potential drug candidates.",GO:0019348 dolichol metabolic process;GO:0016093 polyprenol metabolic process;GO:0006047 UDP-N-acetylglucosamine metabolic process,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism,,,,
ENSG00000131051.24,ENSG00000131051,RBM39,-0.68705984,-0.921914578,-0.482539587,-0.656725355,RNA binding motif protein 39,"RBM39 is a gene that encodes a protein belonging to the U2AF65 family. The protein is located in the nucleus and is involved in both steroid hormone receptor-mediated transcription and alternative splicing. It also acts as a transcriptional coregulator of the viral oncoprotein v-Rel. The protein co-localizes with core spliceosomal proteins in the nucleus. Multiple transcript variants have been observed for this gene, and a related pseudogene has been identified on chromosome X.","There is limited information available on the disease implications of RBM39. However, recent studies have suggested that it may play a role in the development and progression of certain cancers, including breast cancer and lung cancer. Targeted drug discovery efforts for RBM39 are still in the early stages, but there is potential for the development of novel therapies that target the protein's role in alternative splicing and transcriptional regulation. Currently, there are no drugs on the market that specifically target RBM39, but there are several drugs that target other proteins involved in alternative splicing and transcriptional regulation, such as splicing modulators and histone deacetylase inhibitors. These drugs have shown promise in preclinical and clinical studies for the treatment of various cancers and other diseases.","GO:0048024 regulation of mRNA splicing, via spliceosome;GO:0050684 regulation of mRNA processing;GO:0043484 regulation of RNA splicing",,Predicted intracellular proteins,Nuclear speckles;Nucleoplasm (Supported); Additional: Centriolar satellite;Microtubules,,,
ENSG00000130749.10,ENSG00000130749,ZC3H4,-0.686880345,-1.097577069,-0.577426489,-0.385637479,zinc finger CCCH-type containing 4,"ZC3H4 is a human gene that encodes a protein belonging to the CCCH zinc finger domain-containing family. These zinc finger domains are known to bind to nucleic acids and are characterized by three cysteine residues and one histidine residue. The protein encoded by ZC3H4 is involved in post-transcriptional regulation, similar to other members of the family.","There is limited information available on the disease implications of ZC3H4. However, recent studies have suggested that mutations in this gene may be associated with intellectual disability and developmental delay. Targeted drug discovery efforts for ZC3H4 are currently underway, with a focus on identifying small molecules that can modulate the protein's activity. While there are no drugs currently on the market that specifically target ZC3H4, there are several drugs that target other members of the CCCH zinc finger domain-containing family. For example, the drug Arsenic trioxide is used to treat acute promyelocytic leukemia by targeting the protein PML, which also contains CCCH zinc finger domains. Additionally, the drug Celastrol has been shown to inhibit the activity of the protein tristetraprolin, which is involved in post-transcriptional regulation and also contains CCCH zinc finger domains.",GO:0110064 lncRNA catabolic process;GO:0140743 regulation of lncRNA transcription;GO:0140744 negative regulation of lncRNA transcription,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Cytosol,,,
ENSG00000135018.14,ENSG00000135018,UBQLN1,-0.686535501,-0.916307799,-0.872115239,-0.271183464,ubiquilin 1,"The UBQLN1 gene encodes for an ubiquitin-like protein called ubiquilin 1, which is similar to related products found in yeast, rat, and frog. Ubiquilins contain both an N-terminal ubiquitin-like domain and a C-terminal ubiquitin-associated domain, allowing them to physically associate with proteasomes and ubiquitin ligases. This association is thought to link the ubiquitination machinery to the proteasome, leading to protein degradation. UBQLN1 has also been shown to modulate the accumulation of presenilin proteins and is found in lesions associated with Alzheimer's and Parkinson's disease. Two transcript variants encoding different isoforms have been identified for this gene.","The UBQLN1 gene has been implicated in several neurodegenerative diseases, including Alzheimer's and Parkinson's disease. Mutations in UBQLN1 have been linked to an increased risk of developing these diseases. As a result, there has been significant interest in developing drugs that target UBQLN1 as a potential therapeutic strategy. However, there are currently no drugs on the market that specifically target UBQLN1. Instead, drug discovery efforts have focused on developing drugs that target the proteasome and ubiquitin ligases, which are the proteins that UBQLN1 interacts with. Examples of successful drugs in this area include bortezomib, which is used to treat multiple myeloma, and carfilzomib, which is used to treat relapsed or refractory multiple myeloma. These drugs work by inhibiting the proteasome, leading to the accumulation of misfolded proteins and ultimately cell death.",GO:1901340 negative regulation of store-operated calcium channel activity;GO:0034140 negative regulation of toll-like receptor 3 signaling pathway;GO:1901339 regulation of store-operated calcium channel activity,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,(M124)PID CXCR4 PATHWAY,(M5905)HALLMARK ADIPOGENESIS
ENSG00000152133.16,ENSG00000152133,GPATCH11,-0.684998223,-1.006875587,-0.723441501,-0.324677582,G-patch domain containing 11,"GPATCH11, also known as G-patch domain containing 11, is a human gene that is predicted to have nucleic acid binding activity. It is located in the kinetochore, a protein complex that plays a crucial role in chromosome segregation during cell division. The function of GPATCH11 is not yet fully understood, but it may be involved in regulating the activity of other proteins in the kinetochore or in other cellular processes. Further research is needed to fully elucidate the role of GPATCH11 in human biology and disease.","There is limited information available on the disease implications of GPATCH11. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and ovarian cancer. Targeted drug discovery efforts for GPATCH11 are also limited, as its function is not yet fully understood. However, some studies have suggested that targeting the kinetochore, where GPATCH11 is located, may be a potential strategy for developing new cancer therapies. Currently, there are no drugs on the market that specifically target GPATCH11. However, there are several drugs that target the kinetochore, such as taxanes and vinca alkaloids, which are commonly used in cancer chemotherapy.",,,Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000007866.22,ENSG00000007866,TEAD3,-0.683803245,-0.912959625,-0.603064554,-0.535385555,TEA domain transcription factor 3,TEAD3 is a transcription factor that belongs to the TEF family of transcription factors. It contains the TEA/ATTS DNA-binding domain and is mainly expressed in the placenta. TEAD3 is involved in the transactivation of the chorionic somatomammotropin-B gene enhancer. The protein is translated from a non-AUG (AUA) start codon.,"There is limited information available on the disease implications of TEAD3. However, some studies have suggested that TEAD3 may play a role in cancer development and progression. For example, TEAD3 has been found to be overexpressed in several types of cancer, including breast, lung, and ovarian cancer. Targeted drug discovery efforts for TEAD3 are still in the early stages, but some studies have identified potential small molecule inhibitors of TEAD3 that could be developed into drugs. One example is the compound YAP-TEAD Inhibitor-1, which has been shown to inhibit the interaction between TEAD3 and the transcriptional co-activator YAP, leading to decreased cancer cell proliferation. However, there are currently no drugs on the market that specifically target TEAD3.",GO:0055059 asymmetric neuroblast division;GO:0055057 neuroblast division;GO:0008356 asymmetric cell division,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,,,,
ENSG00000164733.22,ENSG00000164733,CTSB,-0.683439152,-1.050029227,-0.695942843,-0.304345386,cathepsin B,"The CTSB gene encodes a lysosomal cysteine protease called cathepsin B, which has both endopeptidase and exopeptidase activity and plays a role in protein turnover. Alternative splicing of the gene results in multiple transcript variants, including a preproprotein that is proteolytically processed to generate multiple protein products, such as the cathepsin B light and heavy chains. Cathepsin B is also known as amyloid precursor protein secretase and is involved in the proteolytic processing of amyloid precursor protein (APP), which has been suggested to be a causative factor in Alzheimer's disease. Overexpression of cathepsin B has been associated with esophageal adenocarcinoma and other tumors. Additionally, both cathepsin B and cathepsin L are involved in the cleavage of the spike protein from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon its entry to the human host cell.","Cathepsin B has been implicated in various diseases, including cancer, Alzheimer's disease, and cardiovascular disease. In cancer, cathepsin B has been shown to promote tumor invasion and metastasis by degrading extracellular matrix proteins. In Alzheimer's disease, cathepsin B has been suggested to play a role in the formation of amyloid plaques, which are a hallmark of the disease. In cardiovascular disease, cathepsin B has been linked to the development of atherosclerosis.

Targeted drug discovery efforts have focused on developing inhibitors of cathepsin B for the treatment of these diseases. Several small molecule inhibitors of cathepsin B have been developed and tested in preclinical studies, with some showing promising results. However, to date, no cathepsin B inhibitors have been approved for clinical use.

One example of a successful drug targeting cathepsin B is the chemotherapy drug, doxorubicin. Doxorubicin has been shown to inhibit cathepsin B activity, which may contribute to its anticancer effects. Another example is the drug, odanacatib, which was developed as a treatment for osteoporosis. Odanacatib is a selective inhibitor of cathepsin K, which is closely related to cathepsin B, and has been shown to reduce bone resorption and increase bone density in clinical trials.",GO:0097067 cellular response to thyroid hormone stimulus;GO:0006590 thyroid hormone generation;GO:0042403 thyroid hormone metabolic process,,Predicted intracellular proteins; Predicted secreted proteins; Human disease related genes:Digestive system diseases:Pancreas diseases; Peptidases:Cysteine-type peptidases; Potential drug targets; Candidate cardiovascular disease genes; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Vesicles (Supported); Additional: Nucleoli,"2-Aminoethanimidic Acid; 3-Amino-4-Oxybenzyl-2-Butanone; 3-Methylphenylalanine; N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline; 2-Pyridinethiol; Diphenylacetic acid; N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane; N-{[(2S,3S)-3-(Ethoxycarbonyl)-2-oxiranyl]carbonyl}-L-threonyl-L-isoleucine; N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE; BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE; METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE; N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE; N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE; N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE",(M3468)NABA ECM REGULATORS; (M5885)NABA MATRISOME ASSOCIATED; (M5889)NABA MATRISOME,(M5946)HALLMARK COAGULATION; (M5921)HALLMARK COMPLEMENT; (M5945)HALLMARK HEME METABOLISM
ENSG00000135801.10,ENSG00000135801,TAF5L,-0.683218358,-0.851753771,-0.670633245,-0.527268058,TATA-box binding protein associated factor 5 like,"TAF5L is a gene that encodes a protein belonging to the WD-repeat TAF5 family of proteins. This protein is a component of the PCAF histone acetylase complex, which is required for myogenic transcription and differentiation. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors to facilitate complex assembly and transcription initiation. The encoded protein is structurally similar to one of the histone-like TAFs, TAF5. Different isoforms of the protein have been identified due to alternative splicing of the transcript variants.","There is limited information available on the disease implications of TAF5L. However, recent studies have suggested that TAF5L may play a role in the development and progression of certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for TAF5L are still in the early stages, but there is potential for the development of drugs that target TAF5L as a therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target TAF5L. However, there are several drugs that target other components of the PCAF histone acetylase complex, such as the histone deacetylase inhibitors (HDAC inhibitors) vorinostat and romidepsin, which have been approved for the treatment of cutaneous T-cell lymphoma.",GO:1904672 regulation of somatic stem cell population maintenance;GO:2000036 regulation of stem cell population maintenance;GO:0043484 regulation of RNA splicing,,Predicted intracellular proteins,Nuclear speckles (Supported); Additional: Cytoplasmic bodies,,,
ENSG00000149792.9,ENSG00000149792,MRPL49,-0.682336357,-1.310201355,-0.717467018,-0.019340699,mitochondrial ribosomal protein L49,"MRPL49 is a gene that encodes for a mitochondrial ribosomal protein L49, which is involved in protein synthesis within the mitochondrion. Mitochondrial ribosomes consist of a small 28S subunit and a large 39S subunit, and have a different protein to rRNA composition compared to prokaryotic ribosomes. The proteins comprising the mitoribosome differ greatly in sequence among different species, making them difficult to recognize by sequence homology. Pseudogenes corresponding to this gene are found on chromosomes 5q and 8p.","There is limited information available on the disease implications of MRPL49. However, mutations in other mitochondrial ribosomal proteins have been associated with a range of mitochondrial disorders, including Leigh syndrome, mitochondrial encephalomyopathy, and mitochondrial myopathy. Targeted drug discovery efforts for mitochondrial disorders have focused on improving mitochondrial function and reducing oxidative stress. Some examples of successful drugs on the market for mitochondrial disorders include idebenone, which is used to treat Leber's hereditary optic neuropathy, and elamipretide, which is being developed for the treatment of primary mitochondrial myopathy. However, there are currently no drugs specifically targeting MRPL49 or mitochondrial ribosomal proteins in general.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Ribosomal proteins; Predicted intracellular proteins,,,,
ENSG00000129187.14,ENSG00000129187,DCTD,-0.68228443,-1.345554138,-0.473614913,-0.227684239,dCMP deaminase,"The DCTD gene encodes a protein that converts dCMP to dUMP, which is used as a substrate for thymidylate synthase. The protein is activated by dCTP and inhibited by dTTP, and is made up of six identical subunits. Zinc is required for the protein's activity. Two different versions of the gene have been identified, which produce slightly different forms of the protein.","The DCTD gene has been implicated in several types of cancer, including colorectal, breast, and lung cancer. Inhibition of the protein encoded by DCTD has been explored as a potential therapeutic strategy for these cancers. One example of a drug targeting DCTD is TAS-114, which is currently in clinical trials for the treatment of solid tumors. TAS-114 is a prodrug that is converted to a potent inhibitor of DCTD in the body. Another drug, trifluridine/tipiracil (Lonsurf), has been approved for the treatment of metastatic colorectal cancer and gastric cancer. Trifluridine is a thymidine analogue that is incorporated into DNA, while tipiracil inhibits the breakdown of trifluridine by DCTD. This combination therapy has shown improved survival rates in clinical trials.",GO:0006226 dUMP biosynthetic process;GO:0009177 pyrimidine deoxyribonucleoside monophosphate biosynthetic process;GO:0006231 dTMP biosynthetic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol;Nucleoplasm (Approved),,,
ENSG00000152700.14,ENSG00000152700,SAR1B,-0.682282466,-0.726016539,-0.671029823,-0.649801036,secretion associated Ras related GTPase 1B,"SAR1B is a small GTPase protein that functions as a homodimer and is activated by the guanine nucleotide exchange factor PREB. It plays a crucial role in protein transport from the endoplasmic reticulum to the Golgi and is a part of the COPII coat complex. Mutations in the SAR1B gene are associated with chylomicron retention disease (CMRD), also known as Anderson disease (ANDD). Two transcript variants of the gene have been identified, both encoding the same protein.","Chylomicron retention disease (CMRD), also known as Anderson disease (ANDD), is a rare autosomal recessive disorder caused by mutations in the SAR1B gene. CMRD is characterized by the accumulation of chylomicrons in the endoplasmic reticulum of enterocytes, leading to severe hypertriglyceridemia, malabsorption, and failure to thrive. There is currently no cure for CMRD, and treatment is mainly supportive, including dietary modifications and lipid-lowering medications. Targeted drug discovery efforts for CMRD are limited due to the rarity of the disease. However, recent studies have shown promising results with the use of antisense oligonucleotides (ASOs) targeting the SAR1B gene to reduce chylomicron retention in enterocytes. There are currently no drugs specifically approved for CMRD, but lipid-lowering medications such as fibrates and omega-3 fatty acids have been used to manage hypertriglyceridemia in affected individuals.",GO:0003400 regulation of COPII vesicle coating;GO:1990253 cellular response to leucine starvation;GO:0140353 lipid export from cell,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Predicted intracellular proteins,Endoplasmic reticulum (Approved),Guanosine-5'-Diphosphate,,(M5934)HALLMARK XENOBIOTIC METABOLISM
ENSG00000129083.13,ENSG00000129083,COPB1,-0.681532924,-0.747075098,-0.929567524,-0.367956149,COPI coat complex subunit beta 1,"COPB1 is a gene that encodes a protein subunit of the coatomer complex, which is associated with non-clathrin coated vesicles. The coatomer complex, also known as the coat protein complex 1, is formed in the cytoplasm and is recruited to the Golgi by activated guanosine triphosphatases. Once at the Golgi membrane, the coatomer complex may assist in the movement of protein and lipid components back to the endoplasmic reticulum. The gene has alternatively spliced transcript variants.","Mutations in the COPB1 gene have been associated with a few rare genetic disorders, including a form of autosomal recessive intellectual disability known as SPG56. Additionally, some studies have suggested that alterations in the expression of COPB1 may be involved in the development and progression of certain types of cancer, such as breast cancer and hepatocellular carcinoma. 

There are currently no drugs specifically targeting COPB1, but efforts are underway to develop drugs that target the coatomer complex as a whole. One approach is to target the interaction between the coatomer complex and the Golgi membrane, which could potentially disrupt the movement of proteins and lipids between the Golgi and the endoplasmic reticulum. Another approach is to target the interaction between the coatomer complex and cargo molecules, which could potentially disrupt the formation of transport vesicles. 

One example of a drug that indirectly affects the coatomer complex is brefeldin A, which is a fungal metabolite that inhibits the activation of the guanosine triphosphatases that recruit the coatomer complex to the Golgi membrane. Brefeldin A has been used as a research tool to study the role of the coatomer complex in intracellular transport, but it is not used clinically due to its toxicity and lack of specificity.",GO:0006891 intra-Golgi vesicle-mediated transport;GO:0006888 endoplasmic reticulum to Golgi vesicle-mediated transport;GO:0048193 Golgi vesicle transport,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Cytosol;Golgi apparatus;Vesicles (Enhanced),,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000167323.11,ENSG00000167323,STIM1,-0.681271188,-0.802463862,-0.636394819,-0.604954881,stromal interaction molecule 1,"STIM1 is a gene that encodes a transmembrane protein that plays a role in mediating calcium influx after depletion of intracellular calcium stores by gating of store-operated calcium influx channels. It is located in the imprinted gene domain of 11p15.5, which is an important tumor-suppressor gene region. Alterations in this region have been associated with various cancers and syndromes. Mutations in STIM1 have been linked to fatal classic Kaposi sarcoma, immunodeficiency due to defects in store-operated calcium entry, ectodermal dysplasia, and tubular aggregate myopathy. The gene is also involved in early hematopoiesis by mediating attachment to stromal cells. Alternative splicing of this gene results in multiple transcript variants.","STIM1 has been implicated in various diseases, including immunodeficiency, ectodermal dysplasia, and tubular aggregate myopathy. Mutations in STIM1 have been linked to fatal classic Kaposi sarcoma, a type of cancer that affects the skin and other organs. Targeted drug discovery efforts have focused on developing drugs that modulate STIM1 activity to treat these diseases. One example is the drug GSK-7975A, which is a small molecule inhibitor of STIM1 that has shown promise in preclinical studies for the treatment of autoimmune diseases. Another example is the drug Anavex 2-73, which is a small molecule activator of STIM1 that is being developed for the treatment of Alzheimer's disease. While these drugs are still in the early stages of development, they represent promising avenues for the treatment of diseases associated with STIM1 dysfunction.",GO:0032237 activation of store-operated calcium channel activity;GO:1901341 positive regulation of store-operated calcium channel activity;GO:1901339 regulation of store-operated calcium channel activity,,Human disease related genes:Musculoskeletal diseases:Muscular diseases; Predicted intracellular proteins; Potential drug targets; Disease related genes; Human disease related genes:Immune system diseases:Primary immunodeficiency; Transporters:Transporter channels and pores; Human disease related genes:Cardiovascular diseases:Hematologic diseases,Endoplasmic reticulum (Enhanced),,(M88)PID CD8 TCR PATHWAY; (M34)PID TCR PATHWAY,
ENSG00000178974.10,ENSG00000178974,FBXO34,-0.680694677,-1.055841506,-0.826736563,-0.159505962,F-box protein 34,"FBXO34 is a human gene that encodes for an F-box protein, which is a member of a family of proteins characterized by a 40-amino acid F-box motif. These proteins are involved in the formation of SCF complexes, which act as protein-ubiquitin ligases. F-box proteins interact with SKP1 through the F box and with ubiquitination targets through other protein interaction domains. The function of FBXO34 is not well understood, but it is thought to play a role in regulating protein degradation and turnover.","There is limited information available on the disease implications of FBXO34. However, recent studies have suggested that mutations in FBXO34 may be associated with the development of certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for FBXO34 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and prevent its interaction with other proteins in the SCF complex. While there are currently no drugs on the market that specifically target FBXO34, there are several drugs that target other members of the SCF complex, including bortezomib, which is used to treat multiple myeloma, and lenalidomide, which is used to treat myelodysplastic syndromes.",,,Predicted intracellular proteins,Nuclear speckles (Approved); Additional: Cytosol,,,(M5945)HALLMARK HEME METABOLISM
ENSG00000164144.16,ENSG00000164144,ARFIP1,-0.680429228,-0.91494687,-0.885139197,-0.241201618,ARF interacting protein 1,"ARFIP1, or ADP ribosylation factor interacting protein 1, is a gene that encodes a protein involved in intracellular protein transport and regulation of protein secretion. It has been found to have phosphatidylinositol-4-phosphate binding activity and is located in the Golgi membrane, cytosol, and trans-Golgi network membrane. ARFIP1 is also involved in negative regulation of retrograde transport, endosome to Golgi. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of ARFIP1. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ARFIP1 are also limited, but some studies have explored the potential of ARFIP1 as a therapeutic target for cancer treatment. One study found that inhibiting ARFIP1 expression in breast cancer cells led to decreased cell proliferation and increased apoptosis. However, there are currently no drugs on the market that specifically target ARFIP1. Overall, further research is needed to fully understand the disease implications and potential therapeutic applications of ARFIP1.","GO:1905280 negative regulation of retrograde transport, endosome to Golgi;GO:1905279 regulation of retrograde transport, endosome to Golgi;GO:0034315 regulation of Arp2/3 complex-mediated actin nucleation",,Predicted intracellular proteins,Golgi apparatus;Vesicles (Supported); Additional: Nucleoplasm,,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000152944.9,ENSG00000152944,MED21,-0.680310105,-0.87998731,-0.687639962,-0.473303042,mediator complex subunit 21,"MED21 is a gene that belongs to the mediator complex subunit 21 family. It plays a crucial role in regulating the transcription of RNA polymerase II transcribed genes by interacting with the human RNA polymerase II holoenzyme. Alternative splicing of this gene results in the formation of multiple transcript variants. A pseudogene of MED21 is also present on chromosome 8. The gene's function is essential for the proper functioning of the human body, and any mutations or dysregulation of MED21 can lead to various diseases and disorders.","There is limited information available on the disease implications of MED21. However, studies have shown that MED21 dysregulation may be associated with various cancers, including breast cancer, lung cancer, and colorectal cancer. Targeted drug discovery efforts for MED21 are still in the early stages, and there are currently no drugs on the market that specifically target this gene. However, there are drugs that indirectly affect MED21, such as inhibitors of the RNA polymerase II transcriptional machinery, which may have potential therapeutic applications in cancer treatment. For example, the drug Flavopiridol, which inhibits the activity of cyclin-dependent kinases, has been shown to inhibit RNA polymerase II-mediated transcription and has been tested in clinical trials for the treatment of various cancers.","GO:0032968 positive regulation of transcription elongation by RNA polymerase II;GO:0035019 somatic stem cell population maintenance;GO:0032786 positive regulation of DNA-templated transcription, elongation",,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol;Nucleoli,,,
ENSG00000095261.14,ENSG00000095261,PSMD5,-0.680098381,-0.82384174,-0.781018994,-0.43543441,"proteasome 26S subunit, non-ATPase 5","PSMD5 is a gene that encodes a non-ATPase subunit of the 19S regulator base of the 26S proteasome, a protein complex that cleaves peptides in a non-lysosomal pathway. The 26S proteasome is composed of a 20S core and a 19S regulator, with the latter containing a base and a lid. The base contains 6 ATPase subunits and 2 non-ATPase subunits, including PSMD5, which functions as a chaperone protein during 26S proteasome assembly. Proteasomes are found in high concentrations throughout eukaryotic cells and play a crucial role in protein degradation.","PSMD5 has been implicated in various diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, PSMD5 has been shown to be overexpressed in several types of tumors, including breast, lung, and prostate cancer, and its inhibition has been proposed as a potential therapeutic strategy. In neurodegenerative disorders, PSMD5 has been linked to the accumulation of misfolded proteins, such as alpha-synuclein in Parkinson's disease, and its inhibition has been suggested as a potential therapeutic approach. In viral infections, PSMD5 has been shown to play a role in the replication of several viruses, including HIV and hepatitis B virus, and its inhibition has been proposed as a potential antiviral strategy.

Several drug discovery efforts have targeted PSMD5, including the development of small molecule inhibitors and RNA interference-based approaches. One example of a successful drug targeting the proteasome is bortezomib, which targets the 20S core of the proteasome and is used to treat multiple myeloma and mantle cell lymphoma. Another example is carfilzomib, which targets the 20S core and is used to treat relapsed or refractory multiple myeloma. However, to date, no drugs specifically targeting PSMD5 have been approved for clinical use.",GO:0070682 proteasome regulatory particle assembly;GO:0043248 proteasome assembly;GO:0065003 protein-containing complex assembly,,Predicted intracellular proteins,Cytosol;Nucleoplasm (Approved); Additional: Basal body;Centrosome;Connecting piece;Mid piece,,,
ENSG00000153201.16,ENSG00000153201,RANBP2,-0.679663307,-0.868645795,-0.611805381,-0.558538747,RAN binding protein 2,"RANBP2 is a gene that encodes a large RAN-binding protein that is associated with the nuclear pore complex. RAN is a small GTP-binding protein that controls various cellular functions through its interactions with other proteins. The encoded protein is a scaffold and nucleoporin that is involved in the Ran-GTPase cycle and directly interacts with the E2 enzyme UBC9. It enhances the transfer of SUMO1 from UBC9 to the SUMO1 target SP100, suggesting that modification and nuclear import are linked events. The gene is partially duplicated in a gene cluster on chromosome 2q.","Mutations in the RANBP2 gene have been associated with several diseases, including Charcot-Marie-Tooth disease type 2B1, which is a hereditary neuropathy that affects the peripheral nerves, and juvenile myoclonic epilepsy, which is a type of epilepsy that typically begins in adolescence. Additionally, RANBP2 has been implicated in the development and progression of several types of cancer, including breast, lung, and prostate cancer.

Targeted drug discovery efforts for RANBP2 have focused on developing inhibitors of the protein's interaction with UBC9, as this interaction is critical for the protein's function in the Ran-GTPase cycle. However, there are currently no drugs on the market that specifically target RANBP2.

One example of a successful drug that indirectly affects RANBP2 is the chemotherapy drug doxorubicin, which has been shown to disrupt the Ran-GTPase cycle and inhibit nuclear import in cancer cells. Another example is the proteasome inhibitor bortezomib, which has been shown to induce the accumulation of SUMOylated proteins, including RANBP2, in cancer cells.",GO:0006607 NLS-bearing protein import into nucleus;GO:0051642 centrosome localization;GO:0061842 microtubule organizing center localization,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Predicted intracellular proteins; Potential drug targets; Disease related genes; Transporters:Transporter channels and pores; Cancer-related genes:Mutational cancer driver genes,Nuclear membrane (Supported); Additional: Cytosol;Nucleoplasm;Vesicles,,(M140)PID RANBP2 PATHWAY; (M30)PID HDAC CLASSII PATHWAY; (M101)PID HDAC CLASSI PATHWAY,
ENSG00000132824.14,ENSG00000132824,SERINC3,-0.678826634,-1.168091584,-0.460185784,-0.408202535,serine incorporator 3,"SERINC3 is a human gene that is predicted to enable L-serine transmembrane transporter activity. It is involved in defense response to virus, detection of virus, and innate immune response. The gene is predicted to be located in the Golgi apparatus and active in the membrane.","There is limited information available on the disease implications of SERINC3. However, recent studies have suggested that it may play a role in viral infections, particularly HIV-1. Inhibition of SERINC3 has been shown to enhance HIV-1 infectivity, making it a potential target for antiviral drug development. Several studies have identified small molecule inhibitors of SERINC3, including the compound IMB-26, which has been shown to reduce HIV-1 infectivity in vitro. However, there are currently no drugs on the market that specifically target SERINC3. Further research is needed to fully understand the role of SERINC3 in viral infections and to develop effective therapies targeting this gene.",GO:0006564 L-serine biosynthetic process;GO:0009597 detection of virus;GO:0015825 L-serine transport,,Transporters,,,,
ENSG00000107882.12,ENSG00000107882,SUFU,-0.678816281,-1.147905553,-0.468279946,-0.420263343,SUFU negative regulator of hedgehog signaling,"The SUFU gene is a negative regulator of the Hedgehog signaling pathway, which is important in early human development. This pathway is responsible for pattern formation and cellular proliferation during development. Defects in the SUFU gene have been linked to medulloblastoma, a type of brain tumor. Alternative splicing of the gene results in multiple transcript variants.","Mutations in the SUFU gene have been associated with various types of cancer, including medulloblastoma, basal cell carcinoma, and ovarian cancer. As a negative regulator of the Hedgehog signaling pathway, SUFU is an attractive target for drug discovery efforts aimed at inhibiting this pathway in cancer cells. Several drugs targeting the Hedgehog pathway have been approved for the treatment of basal cell carcinoma, including vismodegib and sonidegib. However, these drugs have shown limited efficacy in other types of cancer, and there is a need for more effective SUFU-targeted therapies. Preclinical studies have shown promising results with small molecule inhibitors of SUFU, such as TAK-441 and PF-5274857, which are currently being evaluated in clinical trials for the treatment of various cancers.",GO:2001025 positive regulation of response to drug;GO:2001040 positive regulation of cellular response to drug;GO:0021776 smoothened signaling pathway involved in spinal cord motor neuron cell fate specification,,"Human disease related genes:Skin diseases:Skin and soft tissue diseases; Predicted intracellular proteins; Cancer-related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Human disease related genes:Cancers:Cancers of eye, brain, and central nervous system; Disease related genes",Nucleoplasm (Supported); Additional: Primary cilium,,(M219)PID HEDGEHOG GLI PATHWAY,
ENSG00000144048.10,ENSG00000144048,DUSP11,-0.678756364,-1.077868278,-0.640574549,-0.317826264,dual specificity phosphatase 11,"DUSP11 is a gene that encodes a protein belonging to the dual specificity protein phosphatase subfamily. This protein is involved in the inactivation of target kinases by dephosphorylating both phosphoserine/threonine and phosphotyrosine residues. It negatively regulates members of the MAP kinase superfamily, which is associated with cellular proliferation and differentiation. DUSP11 is localized to the nucleus and binds directly to RNA and splicing factors, suggesting its participation in nuclear mRNA metabolism. Different members of the family of dual specificity phosphatases show distinct substrate specificities for various MAP kinases, different tissue distribution and subcellular localization, and different modes of inducibility of their expression by extracellular stimuli.","There is limited information available on the disease implications of DUSP11. However, some studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for DUSP11 are also limited, but some studies have identified potential small molecule inhibitors that could target this protein. One example is a study that identified a compound called NSC745887, which was found to inhibit DUSP11 activity and reduce cancer cell proliferation in vitro. However, there are currently no drugs on the market that specifically target DUSP11. Overall, more research is needed to fully understand the disease implications of DUSP11 and to develop targeted therapies for diseases associated with this gene.",GO:0006470 protein dephosphorylation;GO:0016311 dephosphorylation;GO:0006396 RNA processing,,Predicted intracellular proteins,Nucleoli fibrillar center;Nucleoplasm (Supported); Additional: Cytokinetic bridge,,,
ENSG00000173218.15,ENSG00000173218,VANGL1,-0.677116284,-1.071490769,-0.757541656,-0.202316428,VANGL planar cell polarity protein 1,"VANGL1 is a gene that encodes a protein belonging to the tetraspanin family. This protein may play a role in facilitating wound healing in the intestinal mucosa in response to intestinal trefoil factor. Mutations in VANGL1 have been linked to neural tube defects. The gene undergoes alternate splicing, resulting in the production of multiple transcript variants.","Mutations in VANGL1 have been linked to neural tube defects, specifically spina bifida. Targeted drug discovery efforts for VANGL1 are currently limited, as the exact function of the protein encoded by this gene is not fully understood. However, research has shown that VANGL1 may play a role in wound healing in the intestinal mucosa, suggesting potential therapeutic applications in the treatment of intestinal injuries or diseases. Currently, there are no drugs on the market specifically targeting VANGL1. However, there are drugs that target related proteins in the tetraspanin family, such as CD81, which is targeted by the hepatitis C drug, Olysio (simeprevir). Further research into the function of VANGL1 may lead to the development of targeted therapies for neural tube defects and other related conditions.","GO:0120197 mucociliary clearance;GO:0003016 respiratory system process;GO:0060071 Wnt signaling pathway, planar cell polarity pathway",,Transporters; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Disease related genes,Plasma membrane (Approved),,,
ENSG00000014824.14,ENSG00000014824,SLC30A9,-0.676866162,-0.835501949,-1.007340269,-0.18775627,solute carrier family 30 member 9,"SLC30A9 is a human gene that is predicted to enable nuclear receptor coactivator activity. It plays a role in cellular zinc ion homeostasis and transport. The gene is located in various cellular components, including cytoplasmic vesicles, cytoskeleton, and endoplasmic reticulum.","There is limited information available on the disease implications of SLC30A9. However, studies have suggested that mutations in this gene may be associated with various diseases, including Alzheimer's disease, Parkinson's disease, and cancer. Targeted drug discovery efforts for SLC30A9 are still in the early stages, and there are currently no drugs on the market that specifically target this gene. However, there are drugs that target zinc transporters, which may indirectly affect SLC30A9 function. For example, the drug clioquinol has been shown to increase zinc levels in the brain and improve cognitive function in Alzheimer's disease patients. Another drug, disulfiram, has been shown to inhibit zinc transporters and has potential as an anticancer agent. Further research is needed to fully understand the role of SLC30A9 in disease and to develop targeted therapies.",GO:0071577 zinc ion transmembrane transport;GO:0006829 zinc ion transport;GO:0006882 intracellular zinc ion homeostasis,,Disease related genes; Transporters:Electrochemical Potential-driven transporters; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of ion transport and metabolism; Potential drug targets,,,,
ENSG00000148730.7,ENSG00000148730,EIF4EBP2,-0.676832757,-1.261827162,-0.591781554,-0.176889554,eukaryotic translation initiation factor 4E binding protein 2,"EIF4EBP2 is a gene that encodes a protein belonging to the eukaryotic translation initiation factor 4E binding protein family. The protein product of this gene binds to eIF4E and inhibits translation initiation. However, insulin and other growth factors can release this inhibition by disrupting their binding to eIF4E through phosphorylation. The regulation of protein production through this gene has been linked to cell proliferation, cell differentiation, and viral infection.","EIF4EBP2 has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. In cancer, overexpression of EIF4EBP2 has been observed in several types of tumors, including breast, lung, and prostate cancer, and has been associated with poor prognosis. Targeting EIF4EBP2 has been explored as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of EIF4EBP2 have been developed, including 4EGI-1 and 4E1RCat, which have shown promising results in preclinical studies. However, no EIF4EBP2-targeted drugs have been approved for clinical use yet. In neurodegenerative disorders, EIF4EBP2 has been linked to Alzheimer's disease, and targeting this gene has been proposed as a potential therapeutic strategy. In metabolic disorders, EIF4EBP2 has been implicated in insulin resistance and type 2 diabetes, and targeting this gene has been explored as a potential therapeutic strategy. However, no EIF4EBP2-targeted drugs have been approved for clinical use in these diseases yet.",GO:0045947 negative regulation of translational initiation;GO:0031929 TOR signaling;GO:0035176 social behavior,,Predicted intracellular proteins,Mitochondria;Nucleoplasm (Approved),,,
ENSG00000082146.13,ENSG00000082146,STRADB,-0.676594933,-0.712362607,-0.396618121,-0.920804071,STE20 related adaptor beta,"STRADB, also known as STE20 related adaptor beta, is a pseudokinase protein that belongs to the serine/threonine protein kinase STE20 subfamily. It is a component of a complex that activates serine/threonine kinase 11, which regulates cell polarity and energy-generating metabolism. The protein is involved in the relocation of the kinase from the nucleus to the cytoplasm and is essential for G1 cell cycle arrest. It can also interact with the X chromosome-linked inhibitor of apoptosis protein, enhancing its anti-apoptotic activity via the JNK1 signal transduction pathway. Two pseudogenes have been found for this gene, and alternatively spliced transcript variants encoding different isoforms have been identified.","Research on STRADB's disease implications is still in its early stages, but some studies have suggested that it may play a role in cancer development and progression. For example, one study found that STRADB expression was significantly higher in breast cancer tissues compared to normal tissues, and that higher expression was associated with poorer prognosis. Additionally, STRADB has been implicated in the development of drug resistance in cancer cells.

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target STRADB. However, there is ongoing research into the development of small molecule inhibitors that could potentially target the protein and inhibit its activity. One study identified a compound called CCG-1423 that was able to inhibit STRADB activity in vitro and in vivo, and showed promise as a potential anti-cancer therapy.

Overall, while the role of STRADB in disease is still being investigated, it has the potential to be a target for future drug development efforts.",GO:0006611 protein export from nucleus;GO:1901099 negative regulation of signal transduction in absence of ligand;GO:2001240 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand,yes,Enzymes; Kinases:STE Ser/Thr protein kinases; Predicted intracellular proteins,Cytosol (Uncertain); Additional: Aggresome,,(M87)PID LKB1 PATHWAY,
ENSG00000107771.17,ENSG00000107771,CCSER2,-0.676131329,-0.981898986,-0.790130495,-0.256364506,coiled-coil serine rich protein 2,"CCSER2, or coiled-coil serine rich protein 2, is a human gene that is predicted to have microtubule binding activity and to act upstream of or within microtubule bundle formation. It is also predicted to be located in the cytoplasm and microtubule cytoskeleton. This information was provided by the Alliance of Genome Resources in April 2022.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for CCSER2. As of April 2022, there are no drugs on the market that specifically target CCSER2. However, further research on the function and role of CCSER2 in disease may lead to the development of targeted therapies in the future. It is important to note that the lack of information on CCSER2's disease implications and drug discovery efforts may be due to its relatively recent discovery and limited research on its function. Further studies are needed to fully understand the potential implications of CCSER2 in disease and its potential as a therapeutic target.",GO:0001578 microtubule bundle formation;GO:0000226 microtubule cytoskeleton organization;GO:0007017 microtubule-based process,,Predicted intracellular proteins,Cytosol;Nucleoplasm (Approved),,,(M5953)HALLMARK KRAS SIGNALING UP
ENSG00000149532.16,ENSG00000149532,CPSF7,-0.675002638,-0.925758872,-0.489440486,-0.609808555,cleavage and polyadenylation specific factor 7,"CPSF7 is a gene that encodes for the 59 kDa subunit of the Cleavage factor Im (CFIm), which is one of six factors required for the proper cleavage and polyadenylation of pre-mRNAs. CFIm is a heterotetramer composed of three different subunits, and the 59 kDa subunit interacts with the splicing factor U2 snRNP Auxiliary Factor (U2AF) 65 to connect the splicing and polyadenylation complexes. This gene plays a crucial role in the regulation of gene expression by ensuring the correct processing of pre-mRNAs.","There is limited information available on the disease implications of CPSF7 mutations. However, recent studies have suggested that CPSF7 may play a role in the development of certain cancers, including breast cancer and glioblastoma. Targeted drug discovery efforts for CPSF7 are still in the early stages, but there is potential for the development of drugs that target the interaction between CPSF7 and U2AF65. One example of a successful drug that targets the polyadenylation process is Patisiran, which was approved by the FDA in 2018 for the treatment of hereditary transthyretin-mediated amyloidosis. Patisiran is an RNA interference therapy that targets the transthyretin gene, which is involved in the polyadenylation process. While there are currently no drugs on the market that specifically target CPSF7, further research into the role of this gene in disease could lead to the development of new therapies in the future.","GO:0110104 mRNA alternative polyadenylation;GO:0180010 co-transcriptional mRNA 3'-end processing, cleavage and polyadenylation pathway;GO:0180012 co-transcriptional RNA 3'-end processing, cleavage and polyadenylation pathway",,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000182095.14,ENSG00000182095,TNRC18,-0.674967844,-1.244819241,-0.6103207,-0.169763591,trinucleotide repeat containing 18,"TNRC18, or trinucleotide repeat containing 18, is a human gene that is predicted to have chromatin binding activity. It is found in various cellular locations, including the cytosol, mitochondrion, and nucleus. The function of TNRC18 is not yet fully understood, but it is believed to play a role in regulating gene expression and chromatin structure. Mutations in TNRC18 have been associated with certain neurological disorders, including autism spectrum disorder and intellectual disability. Further research is needed to fully understand the function and potential clinical implications of TNRC18.","There is limited information available on the disease implications and targeted drug discovery efforts for TNRC18. However, mutations in this gene have been associated with certain neurological disorders, including autism spectrum disorder and intellectual disability. As such, there may be potential for drug discovery efforts targeting TNRC18 to treat these disorders. Currently, there are no drugs on the market specifically targeting TNRC18. However, there are drugs on the market that target other genes associated with autism spectrum disorder and intellectual disability, such as Risperidone and Aripiprazole. Further research is needed to fully understand the potential clinical implications of TNRC18 and to develop targeted drug therapies.",,,Predicted intracellular proteins,Mitochondria;Nuclear membrane;Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000105939.13,ENSG00000105939,ZC3HAV1,-0.674723633,-1.228480669,-0.474040242,-0.321649987,"zinc finger CCCH-type containing, antiviral 1","ZC3HAV1 is a gene that encodes a protein with CCCH-type zinc fingers. This protein is an antiviral agent that prevents viral replication by recruiting cellular RNA degradation mechanisms to break down viral mRNAs. ZC3HAV1 plays a crucial role in the innate immune response against various DNA and RNA viruses, including Ebola virus, HIV, and SARS-CoV-2, which causes COVID-19.","ZC3HAV1 has been implicated in various diseases, including viral infections, autoimmune disorders, and cancer. In viral infections, ZC3HAV1 has been shown to inhibit the replication of several viruses, including HIV, Ebola virus, and SARS-CoV-2. In autoimmune disorders, ZC3HAV1 has been found to regulate the expression of inflammatory cytokines, suggesting a potential role in the pathogenesis of these diseases. In cancer, ZC3HAV1 has been shown to inhibit the proliferation and migration of cancer cells, suggesting a potential role as a tumor suppressor.

Targeted drug discovery efforts for ZC3HAV1 are still in the early stages, but there is growing interest in developing drugs that can enhance the antiviral activity of this protein. One approach is to identify small molecules that can stabilize the interaction between ZC3HAV1 and viral RNA, thereby enhancing the degradation of viral mRNAs. Another approach is to develop gene therapies that can increase the expression of ZC3HAV1 in cells, thereby enhancing the innate immune response against viral infections.

There are currently no drugs on the market that directly target ZC3HAV1, but there are several drugs that indirectly modulate the activity of this protein. For example, interferon-alpha, a drug used to treat viral infections, has been shown to induce the expression of ZC3HAV1 in cells. Additionally, several drugs that target the innate immune system, such as Toll-like receptor agonists, have been shown to enhance the antiviral activity of ZC3HAV1.",GO:1900246 positive regulation of RIG-I signaling pathway;GO:0039535 regulation of RIG-I signaling pathway;GO:0032727 positive regulation of interferon-alpha production,,Predicted intracellular proteins,Cytosol (Supported); Additional: Golgi apparatus,,,
ENSG00000156671.15,ENSG00000156671,SAMD8,-0.674009704,-0.884952182,-0.588362767,-0.548714163,sterile alpha motif domain containing 8,"SAMD8 (sterile alpha motif domain containing 8) is a gene that is predicted to have ceramide cholinephosphotransferase activity and sphingomyelin synthase activity. It is involved in the biosynthesis and regulation of ceramide, a lipid molecule that plays a role in various cellular processes. SAMD8 is located in the cytosol and endoplasmic reticulum, and is an integral component of the endoplasmic reticulum membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of SAMD8. However, recent studies have suggested that SAMD8 may play a role in cancer progression and metastasis. Specifically, SAMD8 has been shown to inhibit the growth and migration of cancer cells, suggesting that it may have potential as a therapeutic target for cancer treatment. 

There are currently no targeted drug discovery efforts specifically focused on SAMD8. However, there are several drugs on the market that target ceramide biosynthesis and metabolism, which may indirectly affect SAMD8 activity. For example, Fingolimod (Gilenya) is a drug that targets sphingosine-1-phosphate receptors and is used to treat multiple sclerosis. It has been shown to modulate ceramide metabolism and may indirectly affect SAMD8 activity. Another example is the drug Cerliponase alfa (Brineura), which is used to treat a rare genetic disorder called neuronal ceroid lipofuscinosis type 2. This drug replaces the deficient enzyme responsible for ceramide metabolism and may also indirectly affect SAMD8 activity. 

Overall, while SAMD8 is not currently a direct target for drug discovery efforts, its involvement in ceramide metabolism and potential role in cancer progression make it an interesting candidate for further research and drug development.",GO:1905371 ceramide phosphoethanolamine metabolic process;GO:1905373 ceramide phosphoethanolamine biosynthetic process;GO:0006686 sphingomyelin biosynthetic process,,,Cytosol;Endoplasmic reticulum (Approved),,,
ENSG00000188811.14,ENSG00000188811,NHLRC3,-0.673539592,-1.054153862,-0.711173691,-0.255291225,NHL repeat containing 3,"The NHLRC3 gene encodes a protein that contains NHL family repeats, which are involved in various enzymatic processes, including protein modification through ubiquitination. This gene has multiple alternatively spliced transcript variants.","There is limited information available on the disease implications of NHLRC3 gene mutations. However, recent studies have suggested that mutations in this gene may be associated with the development of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. Targeted drug discovery efforts for NHLRC3 are currently underway, with a focus on identifying small molecule inhibitors that can modulate the activity of the protein encoded by this gene. While there are currently no drugs on the market that specifically target NHLRC3, there are several drugs that have been approved for the treatment of neurodegenerative disorders that may indirectly affect the activity of this protein. For example, drugs such as donepezil and memantine, which are used to treat Alzheimer's disease, have been shown to modulate the activity of enzymes involved in protein modification, including ubiquitination, which is a process that is regulated by NHLRC3.",GO:0000209 protein polyubiquitination;GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process;GO:0010498 proteasomal protein catabolic process,,Predicted secreted proteins; Predicted intracellular proteins,,,,
ENSG00000125676.20,ENSG00000125676,THOC2,-0.672972003,-0.880152516,-0.571906397,-0.566857096,THO complex subunit 2,"THOC2 is a human gene that encodes a protein that is a part of the THO complex, which is a subset of the TREX multiprotein complex. The THO complex binds to spliced mRNAs to facilitate their export. The THOC2 protein interacts with another protein called THOC1.","There is limited information available on the disease implications of THOC2. However, some studies have suggested that mutations in THOC2 may be associated with intellectual disability and developmental delay. As for targeted drug discovery efforts, there are currently no known drugs that specifically target THOC2. However, there are ongoing efforts to develop drugs that target the THO complex as a whole, which could potentially have implications for THOC2-related disorders. One example of a successful drug that targets the THO complex is E7107, which is currently in clinical trials for the treatment of various types of cancer. E7107 inhibits the function of the THO complex, leading to the accumulation of unprocessed mRNA and ultimately causing cell death in cancer cells.",GO:0016973 poly(A)+ mRNA export from nucleus;GO:0006406 mRNA export from nucleus;GO:0006405 RNA export from nucleus,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000134852.15,ENSG00000134852,CLOCK,-0.672876203,-0.999235879,-0.930799663,-0.088593067,clock circadian regulator,"The human gene CLOCK is a transcription factor that plays a crucial role in regulating circadian rhythms. It belongs to the basic helix-loop-helix (bHLH) family and has DNA binding histone acetyltransferase activity. CLOCK forms a heterodimer with ARNTL (BMAL1) that binds to E-box enhancer elements upstream of PER and CRY genes, activating their transcription. PER and CRY proteins then heterodimerize and repress their own transcription by interacting in a feedback loop with CLOCK/ARNTL complexes. Polymorphisms in this gene may be associated with behavioral changes, obesity, and metabolic syndrome. Alternative splicing results in multiple transcript variants.","Research on the CLOCK gene has revealed its potential implications in various diseases, including sleep disorders, mood disorders, and metabolic disorders such as obesity and diabetes. Targeted drug discovery efforts have focused on developing small molecule inhibitors of the CLOCK protein to modulate circadian rhythms and treat these disorders. One example is the drug Tasimelteon, which targets the melatonin receptor and regulates circadian rhythms in patients with non-24-hour sleep-wake disorder. Another example is the drug Lorcaserin, which targets the serotonin receptor and is used for weight loss in obese patients. However, further research is needed to fully understand the role of the CLOCK gene in disease and to develop more effective targeted therapies.",GO:2000323 negative regulation of glucocorticoid receptor signaling pathway;GO:2000322 regulation of glucocorticoid receptor signaling pathway;GO:2000074 regulation of type B pancreatic cell development,,Enzymes; Transcription factors:Basic domains; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported); Additional: Vesicles,,(M95)PID CIRCADIAN PATHWAY,
ENSG00000155508.14,ENSG00000155508,CNOT8,-0.672850223,-0.675381751,-0.521813146,-0.821355772,CCR4-NOT transcription complex subunit 8,"CNOT8 is a gene that encodes for a protein subunit of the CCR4-NOT transcription complex. This protein enables the activity of poly(A)-specific ribonuclease, which is involved in breaking down deadenylated mRNA. CNOT8 also plays a role in positively regulating cell population proliferation. The protein is located in the nucleus and is part of the CCR4-NOT complex.","Research has shown that CNOT8 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Inhibition of CNOT8 has been shown to reduce cancer cell proliferation and induce apoptosis, making it a potential target for cancer therapy. However, there are currently no drugs on the market that specifically target CNOT8.

Efforts to develop drugs targeting the CCR4-NOT complex, of which CNOT8 is a subunit, have focused on the development of small molecule inhibitors of the complex. One such inhibitor, KIN-1148, has been shown to inhibit the growth of cancer cells in vitro and in vivo by targeting the CCR4-NOT complex. However, it is not clear whether KIN-1148 specifically targets CNOT8 or other subunits of the complex.

Overall, while CNOT8 and the CCR4-NOT complex are promising targets for cancer therapy, more research is needed to fully understand their role in cancer development and to develop effective drugs that specifically target these proteins.","GO:0000289 nuclear-transcribed mRNA poly(A) tail shortening;GO:0000288 nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay;GO:0000956 nuclear-transcribed mRNA catabolic process",,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,,,,
ENSG00000114745.13,ENSG00000114745,GORASP1,-0.672440772,-1.326723489,-0.556437016,-0.134161811,golgi reassembly stacking protein 1,"GORASP1 is a membrane protein that plays a crucial role in establishing the stacked structure of the Golgi apparatus, which is responsible for sorting and modifying proteins exported from the endoplasmic reticulum. It can form a complex with the Golgi matrix protein GOLGA2, and this complex binds to the vesicle docking protein p115. The protein is a caspase-3 substrate, and its cleavage contributes to Golgi fragmentation in apoptosis. Alternative splicing results in multiple transcript variants of this gene.","There is limited information available on the disease implications of GORASP1. However, recent studies have suggested that alterations in GORASP1 expression and function may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for GORASP1 are currently underway, with a focus on identifying small molecule inhibitors that can disrupt its interaction with other Golgi proteins and potentially inhibit tumor growth. While there are currently no drugs on the market that specifically target GORASP1, several drugs that indirectly affect its function have been approved for the treatment of cancer, including taxanes and vinca alkaloids. These drugs disrupt microtubule dynamics, which can lead to Golgi fragmentation and ultimately inhibit cell division.",GO:0050774 negative regulation of dendrite morphogenesis;GO:0090161 Golgi ribbon formation;GO:0061951 establishment of protein localization to plasma membrane,,Predicted intracellular proteins,Golgi apparatus (Supported),,(M12705)SIG CD40PATHWAYMAP; (M129)PID PLK1 PATHWAY,
ENSG00000140577.16,ENSG00000140577,CRTC3,-0.671441463,-1.152667767,-0.649039551,-0.212617072,CREB regulated transcription coactivator 3,"CRTC3 is a gene that belongs to the CREB regulated transcription coactivator gene family. This family regulates gene transcription in a phosphorylation-independent manner and may be selective for cAMP-responsive genes. The protein encoded by this gene may induce mitochondrial biogenesis and attenuate catecholamine signaling in adipose tissue. Alternative splicing results in multiple transcript variants that encode different protein isoforms. A translocation event between this gene and Notch coactivator mastermind-like gene 2, which results in a fusion protein, has been reported in mucoepidermoid carcinomas.","Research on CRTC3 has revealed its potential involvement in various diseases, including obesity, diabetes, and cancer. In obesity, CRTC3 has been shown to play a role in regulating energy metabolism and adipocyte differentiation. In diabetes, CRTC3 has been implicated in insulin resistance and glucose homeostasis. In cancer, the translocation event between CRTC3 and Notch coactivator mastermind-like gene 2 has been observed in mucoepidermoid carcinomas.

Targeted drug discovery efforts for CRTC3 are still in the early stages, but there is potential for developing drugs that modulate its activity in various diseases. For example, small molecule inhibitors of CRTC3 have been identified as potential anti-obesity drugs. Additionally, compounds that activate CRTC3 have been investigated as potential treatments for diabetes.

There are currently no drugs on the market that specifically target CRTC3, but there are drugs that indirectly affect its activity. For example, metformin, a commonly used drug for type 2 diabetes, has been shown to activate CRTC3 and improve glucose homeostasis. Another example is the anti-obesity drug liraglutide, which has been shown to decrease CRTC3 expression in adipose tissue.",GO:0071878 negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway;GO:0106072 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway;GO:0106070 regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway,,Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Cytosol,,,
ENSG00000108733.11,ENSG00000108733,PEX12,-0.671432089,-1.08680078,-0.766709271,-0.160786217,peroxisomal biogenesis factor 12,"PEX12 is a gene that belongs to the peroxin-12 family and is essential for the assembly of functional peroxisomes. Peroxisomes are organelles that play a crucial role in various metabolic processes. Defects in PEX12 can lead to peroxisomal biogenesis disorders (PBDs), a group of genetically heterogeneous autosomal recessive, lethal diseases characterized by multiple defects in peroxisome function. PBDs are a heterogeneous group with at least 14 complementation groups, and defects in PEX12 are a cause of Zellweger syndrome (ZWS), a severe form of PBD. Patients with PBDs exhibit a defect in the import of one or more classes of peroxisomal matrix proteins into the organelle.","There are currently no targeted drug discovery efforts for PEX12-related disorders, and no drugs have been approved specifically for the treatment of these disorders. However, there are some treatments available that can help manage the symptoms of PBDs, such as dietary modifications, vitamin supplementation, and physical therapy. In some cases, liver transplantation may be necessary. Gene therapy is also being explored as a potential treatment option for PBDs, including those caused by PEX12 mutations. One example of a successful drug for a related disorder is Lorenzo's oil, which is used to treat X-linked adrenoleukodystrophy (X-ALD), another peroxisomal disorder. However, this drug is not effective for PBDs caused by PEX12 mutations.","GO:0044721 protein import into peroxisome matrix, substrate release;GO:0016562 protein import into peroxisome matrix, receptor recycling;GO:0006625 protein targeting to peroxisome",,Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Peroxisomal diseases; Transporters:Primary Active Transporters; Potential drug targets; Disease related genes,,,,(M5948)HALLMARK BILE ACID METABOLISM
ENSG00000108669.16,ENSG00000108669,CYTH1,-0.670676258,-0.987464756,-0.540352964,-0.484211055,cytohesin 1,"CYTH1, also known as cytohesin 1, is a member of the PSCD family of proteins. It contains a coiled-coil motif, a Sec7 domain, and a pleckstrin homology (PH) domain. The coiled-coil motif is involved in homodimerization, the Sec7 domain contains guanine-nucleotide exchange protein activity, and the PH domain interacts with phospholipids and is responsible for association of PSCDs with membranes. CYTH1 is highly expressed in natural killer and peripheral T cells and regulates the adhesiveness of integrins at the plasma membrane of lymphocytes. It appears to mediate the regulation of protein sorting and membrane trafficking. Alternative splicing results in multiple transcript variants. A pseudogene of this gene has been defined on the X chromosome.","Research on CYTH1 has revealed its potential involvement in various diseases, including cancer, inflammation, and neurological disorders. In cancer, CYTH1 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. Inflammation-related diseases such as rheumatoid arthritis and multiple sclerosis have also been linked to CYTH1, suggesting its potential as a therapeutic target for these conditions. In terms of drug discovery efforts, small molecule inhibitors targeting CYTH1 have been developed and tested in preclinical studies, showing promising results in reducing tumor growth and metastasis. However, no drugs targeting CYTH1 have been approved for clinical use yet. Overall, CYTH1 represents a promising target for drug discovery efforts in various diseases, and further research is needed to fully understand its role in disease pathogenesis and develop effective therapies.",GO:0032012 regulation of ARF protein signal transduction;GO:0090162 establishment of epithelial cell polarity;GO:0030010 establishment of cell polarity,,Predicted intracellular proteins,,,(M141)PID PI3KCI PATHWAY,
ENSG00000008952.17,ENSG00000008952,SEC62,-0.669566386,-0.841103653,-0.588749711,-0.578845794,"SEC62 homolog, preprotein translocation factor","SEC62 is a human gene that encodes a protein involved in protein translocation into the endoplasmic reticulum (ER) membrane. It is a homolog of the SEC62 gene found in yeast. The protein encoded by SEC62 is associated with the ribosome-free SEC61 complex, which is the central component of the protein translocation apparatus in the ER membrane. It is believed that the SEC61-Sec62-Sec63 complex may be involved in post-translational protein translocation into the ER, as well as the backward transport of ER proteins that are targeted for degradation. The SEC62 protein is an integral membrane protein located in the rough ER.","There is limited information available on the disease implications of SEC62. However, recent studies have suggested that SEC62 may play a role in the development and progression of certain types of cancer, including breast, lung, and pancreatic cancer. Targeted drug discovery efforts are currently underway to develop drugs that can inhibit the activity of SEC62 and potentially treat these types of cancer. One example of a successful drug on the market that targets the protein translocation machinery in the ER is tunicamycin, which is used as an antibiotic and antifungal agent. However, there are currently no drugs available that specifically target SEC62. Further research is needed to fully understand the role of SEC62 in disease and to develop targeted therapies.","GO:0031204 post-translational protein targeting to membrane, translocation;GO:0006620 post-translational protein targeting to endoplasmic reticulum membrane;GO:0065002 intracellular protein transmembrane transport",,Transporters:Transporter channels and pores,Endoplasmic reticulum (Approved); Additional: Intermediate filaments,,,
ENSG00000104164.12,ENSG00000104164,BLOC1S6,-0.669544113,-0.704879699,-0.679685863,-0.624066777,biogenesis of lysosomal organelles complex 1 subunit 6,"BLOC1S6 is a gene that is involved in intracellular vesicle trafficking and interacts with Syntaxin 13 to mediate intracellular membrane fusion. Mutations in this gene are associated with Hermansky-Pudlak syndrome-9, a disorder characterized by albinism, bleeding disorders, and pulmonary fibrosis. Alternative splicing of this gene results in multiple transcript variants, and a related pseudogene is located on the X chromosome.","Hermansky-Pudlak syndrome-9 (HPS-9) is a rare genetic disorder caused by mutations in the BLOC1S6 gene. This disorder is characterized by oculocutaneous albinism, bleeding disorders, and pulmonary fibrosis. There is currently no cure for HPS-9, and treatment is mainly supportive. However, targeted drug discovery efforts are underway to develop therapies that can alleviate the symptoms of this disorder. One such approach is the use of small molecule chaperones that can stabilize the mutant protein and enhance its function. Another approach is the use of gene therapy to replace the defective gene with a functional copy. While there are currently no drugs on the market specifically for HPS-9, there are drugs that can be used to manage the symptoms of this disorder. For example, anticoagulants can be used to manage bleeding disorders, and oxygen therapy can be used to manage pulmonary fibrosis.",GO:0002936 bradykinin biosynthetic process;GO:0033484 intracellular nitric oxide homeostasis;GO:0033299 secretion of lysosomal enzymes,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of amino acid metabolism; Predicted intracellular proteins,,,,
ENSG00000138760.10,ENSG00000138760,SCARB2,-0.669246263,-0.984494717,-0.769192134,-0.254051936,scavenger receptor class B member 2,"SCARB2 is a glycoprotein that is primarily located in the membranes of lysosomes and endosomes. It is involved in membrane transportation and the reorganization of endosomal/lysosomal compartments. In mice, a deficiency of this protein impairs cell membrane transport processes and causes pelvic junction obstruction, deafness, and peripheral neuropathy. In humans, SCARB2 is involved in the pathogenesis of hand, foot, and mouth disease caused by enterovirus-71 and possibly by coxsackievirus A16. Mutations in this gene cause an autosomal recessive progressive myoclonic epilepsy-4 (EPM4), also known as action myoclonus-renal failure syndrome (AMRF). Different isoforms of this gene have been found through alternative splicing.","SCARB2 mutations have been linked to the development of autosomal recessive progressive myoclonic epilepsy-4 (EPM4), also known as action myoclonus-renal failure syndrome (AMRF). This rare disorder is characterized by progressive myoclonus epilepsy, renal failure, and variable degrees of ataxia, neuropathy, and cognitive decline. There are currently no targeted drug discovery efforts for SCARB2-related disorders, and treatment is mainly supportive. However, some drugs have been used to manage the symptoms of EPM4, including antiepileptic drugs such as valproic acid and levetiracetam, and immunosuppressive agents such as mycophenolate mofetil. Additionally, some studies have suggested that enzyme replacement therapy may be a potential treatment option for SCARB2-related disorders, although further research is needed to confirm this.",GO:1904978 regulation of endosome organization;GO:2000752 regulation of glucosylceramide catabolic process;GO:0015917 aminophospholipid transport,,Disease related genes; Human disease related genes:Nervous system diseases:Epilepsy; Potential drug targets; Transporters,Cytosol (Approved),,,
ENSG00000119787.14,ENSG00000119787,ATL2,-0.668938438,-1.079365803,-0.595836452,-0.331613059,atlastin GTPase 2,"ATL2, also known as atlastin GTPase 2, is a human gene that plays a role in Golgi organization, endoplasmic reticulum tubular network membrane organization, and protein homooligomerization. It is located in the endoplasmic reticulum tubular network membrane and is an integral component of the membrane. The gene enables identical protein binding activity, which is important for proper cellular function. This information is provided by the Alliance of Genome Resources as of April 2022.","Mutations in the ATL2 gene have been associated with several neurological disorders, including hereditary spastic paraplegia (HSP) and Charcot-Marie-Tooth disease (CMT). HSP is a group of inherited disorders characterized by progressive weakness and spasticity of the lower limbs, while CMT is a group of inherited disorders that affect the peripheral nerves, leading to muscle weakness and wasting. 

Targeted drug discovery efforts for ATL2 are currently underway, with a focus on developing small molecule inhibitors that can modulate the activity of the protein. One potential approach is to target the GTPase activity of ATL2, which is essential for its function in membrane fusion and tubulation. 

There are currently no drugs on the market that specifically target ATL2, but there are several drugs that have been approved for the treatment of HSP and CMT. These include baclofen, a muscle relaxant that can help alleviate spasticity in HSP patients, and ascorbic acid, which has been shown to improve nerve function in CMT patients. Other drugs, such as gabapentin and pregabalin, may also be used to manage symptoms of these disorders. However, there is still a need for more targeted therapies that can address the underlying molecular mechanisms of these diseases.",GO:1990809 endoplasmic reticulum tubular network membrane organization;GO:0090158 endoplasmic reticulum membrane organization;GO:0071786 endoplasmic reticulum tubular network organization,,Predicted intracellular proteins; Transporters,Endoplasmic reticulum (Supported),,,(M5905)HALLMARK ADIPOGENESIS
ENSG00000165650.12,ENSG00000165650,PDZD8,-0.668777654,-1.050547349,-0.845023375,-0.110762238,PDZ domain containing 8,"PDZD8 is a human gene that encodes a protein containing a PDZ domain, which is predicted to enable lipid and metal ion binding activities. The protein is involved in various biological processes, including the regulation of mitochondrial calcium ion homeostasis, mitochondrion-endoplasmic reticulum membrane tethering, and cell morphogenesis. PDZD8 is located in the endoplasmic reticulum membrane and the mitochondria-associated endoplasmic reticulum membrane.","There is limited information available on the disease implications of PDZD8. However, recent studies have suggested that mutations in PDZD8 may be associated with neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease. Targeted drug discovery efforts for PDZD8 are currently underway, with a focus on identifying small molecule inhibitors that can modulate its activity and potentially treat these diseases. However, there are currently no drugs on the market that specifically target PDZD8. Nonetheless, there are several drugs that target related proteins involved in mitochondrial calcium ion homeostasis and endoplasmic reticulum stress, such as dantrolene and tauroursodeoxycholic acid, which have been approved for the treatment of muscle spasticity and primary biliary cholangitis, respectively.",GO:1990456 mitochondrion-endoplasmic reticulum membrane tethering;GO:0051560 mitochondrial calcium ion homeostasis;GO:0140056 organelle localization by membrane tethering,,Transporters:Transporter channels and pores; Predicted intracellular proteins,Nucleoli fibrillar center (Approved); Additional: Plasma membrane,,,
ENSG00000131653.13,ENSG00000131653,TRAF7,-0.668719796,-0.905494983,-1.001820552,-0.098843852,TNF receptor associated factor 7,"TRAF7 (TNF receptor associated factor 7) is a gene that encodes a protein involved in signal transduction for members of the TNF receptor superfamily. TNF receptor-associated factors, including TRAF7, contain a cysteine/histidine-rich region with zinc RING and/or zinc finger motifs, a coiled-coil motif, and a homologous region that defines the TRAF family, the TRAF domain. The TRAF domain is involved in self-association and receptor binding. TRAF7 is important in regulating cell growth and differentiation, and mutations in this gene have been associated with developmental disorders and cancer.","Mutations in the TRAF7 gene have been associated with a range of developmental disorders, including intellectual disability, craniofacial abnormalities, and skeletal anomalies. Additionally, TRAF7 mutations have been identified in several types of cancer, including meningiomas, schwannomas, and gliomas. Targeted drug discovery efforts for TRAF7-related cancers are still in the early stages, but preclinical studies have shown promising results with inhibitors of the NF-?B pathway, which is downstream of TRAF7 signaling. One example of a successful drug targeting the TNF receptor superfamily is etanercept, which is used to treat autoimmune diseases such as rheumatoid arthritis and psoriasis by blocking TNF signaling. However, etanercept is not specific to TRAF7 and is not currently approved for cancer treatment.",GO:0035519 protein K29-linked ubiquitination;GO:0043525 positive regulation of neuron apoptotic process;GO:2000060 positive regulation of ubiquitin-dependent protein catabolic process,,"Predicted intracellular proteins; Cancer-related genes; ENZYME proteins:Transferases; Human disease related genes:Cancers:Cancers of eye, brain, and central nervous system; Potential drug targets; Disease related genes; Enzymes",Vesicles (Supported),,,
ENSG00000137776.17,ENSG00000137776,SLTM,-0.668596342,-0.837124958,-0.717582682,-0.451081384,SAFB like transcription modulator,"SLTM, or SAFB like transcription modulator, is a human gene that is involved in regulating mRNA processing and transcription by RNA polymerase II. It enables RNA binding activity and is located in the nuclear body. The gene's function is predicted to be important in controlling gene expression and may have implications in various biological processes.","There is limited information available on the disease implications of SLTM. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast and ovarian cancer. Targeted drug discovery efforts for SLTM are still in the early stages, but there is potential for the development of drugs that target this gene to treat cancer and other diseases. Currently, there are no drugs on the market that specifically target SLTM, but there are several drugs that target related genes involved in mRNA processing and transcription, such as CDK inhibitors and RNA polymerase inhibitors. Examples of successful drugs in this category include Palbociclib, a CDK4/6 inhibitor used to treat breast cancer, and Actinomycin D, an RNA polymerase inhibitor used to treat various types of cancer.",GO:0050684 regulation of mRNA processing;GO:1903311 regulation of mRNA metabolic process;GO:0006915 apoptotic process,,Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Enhanced),,,
ENSG00000077380.16,ENSG00000077380,DYNC1I2,-0.668546787,-0.942478116,-0.786840675,-0.276321568,dynein cytoplasmic 1 intermediate chain 2,"DYNC1I2 is a gene that encodes a non-catalytic component of the cytoplasmic dynein 1 complex, which is responsible for transporting organelles and vesicles along microtubules in a retrograde manner. This gene belongs to the dynein intermediate chain family and has multiple transcript variants due to alternative splicing. A pseudogene of this gene is also present on chromosome 10.","Mutations in the DYNC1I2 gene have been associated with several neurological disorders, including Charcot-Marie-Tooth disease, spinal muscular atrophy, and hereditary spastic paraplegia. These disorders are characterized by progressive muscle weakness and atrophy, as well as impaired motor function. Targeted drug discovery efforts for these disorders have focused on developing therapies that can restore or enhance the function of the cytoplasmic dynein 1 complex. One example of a successful drug on the market is nusinersen, which is used to treat spinal muscular atrophy by increasing the production of functional SMN protein, a component of the dynein complex. Another example is tetrabenazine, which is used to treat Huntington's disease by reducing the levels of dopamine in the brain, thereby reducing the hyperkinetic movements associated with the disease.",GO:0010970 transport along microtubule;GO:0030705 cytoskeleton-dependent intracellular transport;GO:0099111 microtubule-based transport,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Centrosome;Cytosol;Flagellar centriole;Microtubules;Mid piece;Principal piece (Approved); Additional: End piece,,,
ENSG00000033100.16,ENSG00000033100,CHPF2,-0.668202582,-1.369727093,-0.568551167,-0.066329485,chondroitin polymerizing factor 2,"The human gene CHPF2, also known as chondroitin polymerizing factor 2, is predicted to have the ability to enable glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity. It is also predicted to be involved in the biosynthesis of chondroitin sulfate. CHPF2 is located in the membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of CHPF2. However, research has suggested that chondroitin sulfate, which is synthesized by CHPF2, may play a role in various diseases such as osteoarthritis, atherosclerosis, and cancer. Targeted drug discovery efforts for CHPF2 are also limited, but there is potential for the development of drugs that target the biosynthesis of chondroitin sulfate. Currently, there are no drugs on the market that specifically target CHPF2 or chondroitin sulfate biosynthesis. However, there are drugs that target the degradation of chondroitin sulfate, such as chondroitinase ABC, which has been used in preclinical studies for spinal cord injury and stroke. Additionally, there are drugs that contain chondroitin sulfate as an active ingredient, such as chondroitin sulfate supplements used for joint health.",GO:0030206 chondroitin sulfate biosynthetic process;GO:0050650 chondroitin sulfate proteoglycan biosynthetic process;GO:0030204 chondroitin sulfate metabolic process,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Nucleoplasm (Approved),,,(M5937)HALLMARK GLYCOLYSIS
ENSG00000001629.10,ENSG00000001629,ANKIB1,-0.667943125,-1.160387939,-0.797033889,-0.046407546,ankyrin repeat and IBR domain containing 1,"ANKIB1 is a human gene that encodes a protein containing ankyrin repeat and IBR domains. It is predicted to have ubiquitin conjugating enzyme binding activity and ubiquitin protein ligase activity, and to be involved in positive regulation of proteasomal ubiquitin-dependent protein catabolic process, protein polyubiquitination, and ubiquitin-dependent protein catabolic process. ANKIB1 is also predicted to be part of a ubiquitin ligase complex and to be active in the cytoplasm.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for ANKIB1. As of now, there are no known drugs on the market that specifically target ANKIB1. However, research on the protein's role in ubiquitin-dependent protein catabolic processes may have implications for diseases related to protein degradation, such as cancer and neurodegenerative disorders. Further research on ANKIB1 and its potential as a therapeutic target may lead to the development of new drugs in the future.",GO:0006511 ubiquitin-dependent protein catabolic process;GO:0019941 modification-dependent protein catabolic process;GO:0043632 modification-dependent macromolecule catabolic process,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Plasma membrane (Supported),,,
ENSG00000166037.11,ENSG00000166037,CEP57,-0.667763677,-0.853467505,-0.868155605,-0.28166792,centrosomal protein 57,"CEP57 is a gene that encodes a cytoplasmic protein called Translokin, which is crucial for maintaining correct chromosomal number during cell division. This protein localizes to the centrosome and has a function in microtubular stabilization. The N-terminal half of this protein is required for its centrosome localization and for its multimerization, and the C-terminal half is required for nucleating, bundling and anchoring microtubules to the centrosomes. CEP57 interacts with various proteins, including fibroblast growth factor 2 (FGF2), cyclin D1, and kinesins KIF3A and KIF3B, and mediates the nuclear translocation and mitogenic activity of FGF2. Mutations in this gene cause mosaic variegated aneuploidy syndrome, a rare autosomal recessive disorder.","Mosaic variegated aneuploidy syndrome (MVA) is a rare autosomal recessive disorder caused by mutations in the CEP57 gene. MVA is characterized by chromosomal instability, mosaic aneuploidy, and an increased risk of cancer. There is currently no cure for MVA, and treatment is mainly supportive. However, targeted drug discovery efforts are underway to identify potential therapies for this disorder. One approach is to target the microtubule-stabilizing function of CEP57, which is essential for proper chromosomal segregation during cell division. Several microtubule-targeting drugs, such as paclitaxel and vinblastine, have been used in cancer treatment and may have potential for treating MVA. However, further research is needed to determine their efficacy and safety in MVA patients. Currently, there are no drugs specifically approved for the treatment of MVA.",GO:0008543 fibroblast growth factor receptor signaling pathway;GO:0044344 cellular response to fibroblast growth factor stimulus;GO:0071774 response to fibroblast growth factor,,Disease related genes; Human disease related genes:Other congenital disorders:Chromosomal abnormalities; Predicted intracellular proteins,Centrosome;Cytosol (Supported); Additional: Centriolar satellite,,,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000132952.12,ENSG00000132952,USPL1,-0.667665225,-0.886072627,-0.712787392,-0.404135657,ubiquitin specific peptidase like 1,"USPL1 is a human gene that encodes for a protein called ubiquitin specific peptidase like 1. This protein has the ability to bind to SUMO (small ubiquitin-like modifier) and also has SUMO-specific isopeptidase activity. It plays a role in various biological processes such as Cajal body organization, protein desumoylation, and snRNA transcription. USPL1 is located in the Cajal body, a subnuclear structure involved in the biogenesis of small nuclear ribonucleoproteins (snRNPs) and telomerase. The function of USPL1 is still being studied, but it is believed to have important roles in regulating cellular processes and maintaining cellular homeostasis.","There is limited information available on the disease implications of USPL1. However, recent studies have suggested that dysregulation of USPL1 expression may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for USPL1 are still in the early stages, but there is potential for the development of drugs that target the protein's SUMO-specific isopeptidase activity. Currently, there are no drugs on the market that specifically target USPL1. However, there are drugs that target the ubiquitin-proteasome system, which is closely related to the SUMO pathway. Examples of such drugs include bortezomib, which is used to treat multiple myeloma, and carfilzomib, which is used to treat relapsed or refractory multiple myeloma.",GO:0030576 Cajal body organization;GO:0016926 protein desumoylation;GO:0009301 snRNA transcription,,Peptidases:Cysteine-type peptidases; Enzymes; Predicted intracellular proteins,,,,
ENSG00000111011.18,ENSG00000111011,RSRC2,-0.666429761,-0.722086873,-0.885006566,-0.392195844,arginine and serine rich coiled-coil 2,"RSRC2, or arginine and serine rich coiled-coil 2, is a human gene that encodes a protein involved in RNA binding activity. The protein contains regions rich in arginine and serine, as well as a coiled-coil structure. The exact function of RSRC2 is not fully understood, but it is believed to play a role in regulating gene expression and RNA processing. Mutations in RSRC2 have been associated with certain types of cancer, including breast and ovarian cancer. Further research is needed to fully understand the role of RSRC2 in human biology and disease.","There is limited information available on the disease implications of RSRC2, but mutations in this gene have been associated with certain types of cancer, including breast and ovarian cancer. Targeted drug discovery efforts for RSRC2 are also limited, as the exact function of the protein is not fully understood. However, there are ongoing efforts to develop drugs that target RNA binding proteins, which may have potential therapeutic applications for cancer and other diseases. One example of a successful drug targeting RNA binding proteins is Onvansertib, which is currently in clinical trials for the treatment of various types of cancer. Onvansertib targets the protein PLK1, which is involved in RNA processing and has been implicated in cancer progression. Further research is needed to determine if targeting RSRC2 or other RNA binding proteins could be a viable therapeutic strategy for cancer and other diseases.",,,Predicted intracellular proteins,Nuclear speckles (Approved); Additional: Cytosol;Nucleoli fibrillar center,,,
ENSG00000169398.19,ENSG00000169398,PTK2,-0.666034294,-0.994998773,-0.639952202,-0.363151906,protein tyrosine kinase 2,"PTK2, also known as protein tyrosine kinase 2, is a gene that encodes a cytoplasmic protein tyrosine kinase found in focal adhesions between cells growing in the presence of extracellular matrix constituents. It is a member of the FAK subfamily of protein tyrosine kinases and is activated in response to certain neural peptides or cell interactions with the extracellular matrix. PTK2 is an important early step in cell growth and intracellular signal transduction pathways. The gene has several transcript variants that encode different isoforms.","PTK2 has been implicated in various diseases, including cancer, cardiovascular diseases, and neurological disorders. In cancer, PTK2 is often overexpressed and plays a critical role in tumor growth, invasion, and metastasis. Therefore, PTK2 has been identified as a potential therapeutic target for cancer treatment. Several small molecule inhibitors targeting PTK2 have been developed and are currently in clinical trials, including VS-6063, PF-562,271, and GSK2256098. These inhibitors have shown promising results in preclinical studies and early-phase clinical trials.

In addition to cancer, PTK2 has also been implicated in cardiovascular diseases, such as atherosclerosis and heart failure. PTK2 inhibitors have been shown to reduce inflammation and improve cardiac function in animal models of heart failure. However, there are currently no PTK2 inhibitors approved for the treatment of cardiovascular diseases.

In neurological disorders, PTK2 has been implicated in the pathogenesis of Alzheimer's disease and Parkinson's disease. PTK2 inhibitors have been shown to reduce neuroinflammation and improve cognitive function in animal models of Alzheimer's disease. However, there are currently no PTK2 inhibitors approved for the treatment of neurological disorders.

Overall, PTK2 is an important therapeutic target for various diseases, particularly cancer. Several PTK2 inhibitors are currently in clinical trials, and more research is needed to fully understand the potential of PTK2 as a therapeutic target for other diseases.",GO:0120041 positive regulation of macrophage proliferation;GO:0035995 detection of muscle stretch;GO:0120040 regulation of macrophage proliferation,yes,Kinases:Tyr protein kinases; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Focal adhesion sites (Supported); Additional: Cytosol;Primary cilium;Primary cilium tip;Vesicles,"Endostatin; 7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE; 2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE; Fostamatinib",(M273)PID EPHA2 FWD PATHWAY; (M125)PID IGF1 PATHWAY; (M72)PID NECTIN PATHWAY,(M5944)HALLMARK ANGIOGENESIS; (M5902)HALLMARK APOPTOSIS; (M5915)HALLMARK APICAL JUNCTION
ENSG00000138069.18,ENSG00000138069,RAB1A,-0.665077003,-0.899086343,-0.743106682,-0.353037983,"RAB1A, member RAS oncogene family",RAB1A is a gene that belongs to the Ras superfamily of GTPases. It regulates the movement of vesicles from the endoplasmic reticulum to the Golgi apparatus. The gene has multiple alternatively spliced transcript variants that encode different protein isoforms.,"Research has shown that RAB1A may play a role in various diseases, including cancer, neurodegenerative disorders, and infectious diseases. In cancer, RAB1A has been found to be overexpressed in several types of tumors, including lung, breast, and pancreatic cancer, and may contribute to tumor growth and metastasis. Targeted drug discovery efforts have focused on developing inhibitors of RAB1A to treat cancer and other diseases. One example is Brefeldin A, a natural product that inhibits RAB1A and has been shown to have anti-cancer activity in preclinical studies. Another example is ML141, a small molecule inhibitor of RAB1A that has shown promise in treating neurodegenerative diseases such as Parkinson's and Huntington's disease. While there are currently no drugs on the market that specifically target RAB1A, ongoing research suggests that it may be a promising target for the development of new therapies.",GO:0030252 growth hormone secretion;GO:0090110 COPII-coated vesicle cargo loading;GO:0032402 melanosome transport,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol;Endoplasmic reticulum (Supported),,(M129)PID PLK1 PATHWAY,(M5924)HALLMARK MTORC1 SIGNALING
ENSG00000038274.17,ENSG00000038274,MAT2B,-0.664817408,-0.870471399,-0.799142026,-0.324838797,methionine adenosyltransferase 2 non-catalytic beta subunit,"MAT2B is a human gene that encodes for the regulatory beta subunit of methionine adenosyltransferase (MAT), which is responsible for catalyzing the biosynthesis of S-adenosylmethionine from methionine and ATP. Alternative splicing of the gene results in the production of multiple transcript variants that encode for different isoforms of the protein.","Dysregulation of MAT2B has been implicated in various diseases, including liver cancer, non-alcoholic fatty liver disease, and alcoholic liver disease. Targeting MAT2B has been explored as a potential therapeutic strategy for these diseases. Several small molecule inhibitors of MAT2B have been developed, including 2-hydroxy-4-methylthiobutanoic acid (HMTBA) and its derivatives. HMTBA has been shown to inhibit MAT2B activity and reduce liver cancer cell growth in vitro and in vivo. Another drug, S-adenosylmethionine (SAMe), is a natural substrate of MAT2B and has been used clinically to treat depression, osteoarthritis, and liver disease. SAMe has been shown to improve liver function and reduce liver damage in patients with alcoholic liver disease and non-alcoholic fatty liver disease. Overall, targeting MAT2B and its downstream metabolite S-adenosylmethionine has shown promise as a therapeutic approach for liver diseases.",GO:0006556 S-adenosylmethionine biosynthetic process;GO:0046500 S-adenosylmethionine metabolic process;GO:0006730 one-carbon metabolic process,,Predicted intracellular proteins,Plasma membrane (Approved),,,
ENSG00000170759.11,ENSG00000170759,KIF5B,-0.664582213,-0.951830816,-0.667798618,-0.374117207,kinesin family member 5B,"KIF5B is a human gene that encodes for a protein belonging to the kinesin family. This protein is involved in various cellular processes, including lysosome localization, natural killer cell mediated cytotoxicity, and positive regulation of protein localization to the plasma membrane. KIF5B has been found to have identical protein binding activity, microtubule binding activity, and microtubule motor activity. It is located in the centriolar satellite, cytosol, and vesicle.","KIF5B has been implicated in various diseases, including cancer and neurodegenerative disorders. In cancer, KIF5B has been found to be involved in the fusion of the ALK gene, leading to the formation of an oncogenic fusion protein that drives the development of certain types of lung cancer. Targeted drug discovery efforts have focused on developing inhibitors of the ALK-KIF5B fusion protein, with crizotinib being the first FDA-approved drug for the treatment of ALK-positive non-small cell lung cancer. Other drugs targeting ALK, such as ceritinib and alectinib, have also been approved for the treatment of ALK-positive lung cancer. In neurodegenerative disorders, KIF5B has been found to be involved in the transport of vesicles containing amyloid precursor protein (APP), which is implicated in the development of Alzheimer's disease. Targeting KIF5B-mediated transport of APP vesicles may provide a potential therapeutic strategy for Alzheimer's disease. However, no drugs targeting KIF5B in neurodegenerative disorders have been approved yet.","GO:0098987 regulation of modification of synapse structure, modulating synaptic transmission;GO:1990048 anterograde neuronal dense core vesicle transport;GO:0140495 migracytosis",,Cancer-related genes; Transporters:Transporter channels and pores; Predicted intracellular proteins,Centriolar satellite;Cytosol (Supported); Additional: End piece,,(M266)PID NCADHERIN PATHWAY,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE; (M5893)HALLMARK MITOTIC SPINDLE; (M5901)HALLMARK G2M CHECKPOINT
ENSG00000185129.8,ENSG00000185129,PURA,-0.663964402,-0.420353672,-0.663142359,-0.908397176,purine rich element binding protein A,"The PURA gene encodes a protein called purine-rich element binding protein A, which is a single-stranded DNA-binding protein that binds to the purine-rich element (PUR) present in the origins of replication and gene flanking regions in various eukaryotes, including humans. This protein is involved in regulating both DNA replication and transcription. Deletion of the PURA gene has been linked to myelodysplastic syndrome and acute myelogenous leukemia.","The PURA gene has been implicated in several diseases, including myelodysplastic syndrome and acute myelogenous leukemia. In these diseases, mutations in the PURA gene can lead to abnormal cell growth and proliferation. Targeted drug discovery efforts have focused on developing drugs that can inhibit the activity of the PURA protein, with the goal of slowing or stopping the growth of cancer cells. One example of a successful drug targeting the PURA protein is the small molecule compound NSC-139021, which has been shown to inhibit the binding of PURA to DNA and reduce the growth of cancer cells in vitro. Another potential drug target is the interaction between PURA and the protein p53, which is often mutated in cancer. Inhibition of this interaction could lead to increased sensitivity of cancer cells to chemotherapy. Overall, targeting the PURA gene and its protein product shows promise as a potential therapeutic strategy for cancer treatment.",GO:0098963 dendritic transport of messenger ribonucleoprotein complex;GO:0098935 dendritic transport;GO:0006268 DNA unwinding involved in DNA replication,,Transcription factors:Yet undefined DNA-binding domains; Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; Disease related genes; Cancer-related genes:Candidate cancer biomarkers,,,,(M5901)HALLMARK G2M CHECKPOINT
ENSG00000117758.14,ENSG00000117758,STX12,-0.663958122,-1.081419271,-0.763411848,-0.147043246,syntaxin 12,"The human gene STX12, also known as syntaxin 12, is predicted to have SNAP receptor activity and SNARE binding activity. It is involved in autophagosome assembly, cholesterol efflux, and protein stabilization. The gene is located in several cellular components, including membrane raft, phagocytic vesicle, and phagophore assembly site. It is part of the SNARE complex and colocalizes with the BLOC-1 complex. These findings suggest that STX12 plays an important role in various cellular processes and may have potential implications in disease research.","There is limited information available on the disease implications of STX12. However, some studies have suggested that mutations in the gene may be associated with certain neurological disorders, such as Parkinson's disease and Alzheimer's disease. Targeted drug discovery efforts for STX12 are also limited, but some studies have explored the potential of small molecule inhibitors of the SNARE complex as a therapeutic strategy for neurodegenerative diseases. Currently, there are no drugs on the market that specifically target STX12. However, there are drugs that target other components of the SNARE complex, such as botulinum toxin, which is used to treat muscle spasms and wrinkles, and tetrodotoxin, which is used as a local anesthetic.",GO:0033344 cholesterol efflux;GO:0048278 vesicle docking;GO:0030301 cholesterol transport,,Predicted intracellular proteins,Golgi apparatus;Nucleoplasm;Vesicles (Enhanced),,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000107643.16,ENSG00000107643,MAPK8,-0.66297346,-1.067466935,-0.738540879,-0.182912566,mitogen-activated protein kinase 8,"MAPK8, also known as mitogen-activated protein kinase 8, is a member of the MAP kinase family that acts as an integration point for multiple biochemical signals and is involved in various cellular processes such as proliferation, differentiation, transcription regulation, and development. This kinase is activated by different cell stimuli and targets specific transcription factors, mediating immediate-early gene expression in response to cell stimuli. MAPK8 is required for TNF-alpha induced apoptosis and is involved in UV radiation induced apoptosis. Studies of the mouse counterpart of this gene suggest that it plays a key role in T cell proliferation, apoptosis, and differentiation. Several alternatively spliced transcript variants encoding distinct isoforms have been reported.","MAPK8 has been implicated in various diseases, including cancer, neurodegenerative disorders, and inflammatory diseases. In cancer, MAPK8 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. Several drugs targeting MAPK8 are currently in development, including inhibitors of the upstream kinases that activate MAPK8 and direct inhibitors of MAPK8 itself. One example of a successful drug targeting MAPK8 is SP600125, which is a selective inhibitor of MAPK8 and has been shown to have anti-inflammatory and anti-tumor effects in preclinical studies. However, its clinical development has been limited due to its poor pharmacokinetic properties. Another example is TAK-715, which is a more potent and selective inhibitor of MAPK8 and has shown promising results in preclinical studies for the treatment of inflammatory diseases. Overall, targeting MAPK8 remains an active area of drug discovery research, with the potential to provide new treatments for a range of diseases.",GO:0007258 JUN phosphorylation;GO:0051403 stress-activated MAPK cascade;GO:0038095 Fc-epsilon receptor signaling pathway,yes,Kinases:CMGC Ser/Thr protein kinases; Predicted intracellular proteins; ENZYME proteins:Transferases; Cancer-related genes:Candidate cancer biomarkers; Enzymes; RAS pathway related proteins,Nucleoplasm (Supported),"Tamoxifen; Pyrazolanthrone; 6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE; 2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE; N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE; 5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE; 2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide",(M190)PID TCR JNK PATHWAY; (M268)PID S1P S1P2 PATHWAY; (M69)PID REELIN PATHWAY,(M5923)HALLMARK PI3K AKT MTOR SIGNALING
ENSG00000179021.10,ENSG00000179021,C3orf38,-0.662856167,-0.823934296,-0.737562188,-0.427072017,chromosome 3 open reading frame 38,C3orf38 is a human gene located on chromosome 3 and is involved in the positive regulation of the apoptotic process. It is located in the nucleus of cells. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of C3orf38. However, some studies have suggested that dysregulation of apoptosis, which is positively regulated by C3orf38, can contribute to the development of various diseases, including cancer and neurodegenerative disorders. Therefore, targeting C3orf38 may have therapeutic potential in these diseases. 

Currently, there are no targeted drug discovery efforts specifically focused on C3orf38. However, there are several drugs on the market that target apoptosis, which is regulated by C3orf38. For example, Venetoclax is a B-cell lymphoma 2 (BCL-2) inhibitor that has been approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Another example is ABT-263, which is also a BCL-2 inhibitor and has been tested in clinical trials for various types of cancer. 

In summary, while there is limited information available on the disease implications of C3orf38, targeting apoptosis, which is positively regulated by this gene, may have therapeutic potential in various diseases. There are currently no targeted drug discovery efforts focused on C3orf38, but there are several drugs on the market that target apoptosis and have been successful in treating certain types of cancer.",GO:0043065 positive regulation of apoptotic process;GO:0043068 positive regulation of programmed cell death;GO:0006915 apoptotic process,,Predicted intracellular proteins,Cytosol;Plasma membrane (Approved); Additional: Nucleoplasm,,,
ENSG00000110048.12,ENSG00000110048,OSBP,-0.662624001,-1.106267665,-0.729319371,-0.152284967,oxysterol binding protein,"The human gene OSBP, or oxysterol binding protein, is responsible for transporting sterols from lysosomes to the nucleus. Once in the nucleus, the sterol down-regulates the genes for the LDL receptor, HMG-CoA reductase, and HMG synthetase. This process is believed to play a role in regulating cholesterol levels in the body.","Mutations in the OSBP gene have been associated with several diseases, including Niemann-Pick type C disease, a rare genetic disorder characterized by the accumulation of cholesterol and other lipids in lysosomes. Targeted drug discovery efforts have focused on developing drugs that can modulate the activity of OSBP and its related proteins. One example is the drug K-604, which has been shown to inhibit the activity of OSBP and reduce cholesterol levels in cells. Another example is the drug avasimibe, which targets the related protein ACAT and has been shown to reduce cholesterol levels in animal models. However, there are currently no drugs on the market that specifically target OSBP or its related proteins.",GO:1904409 regulation of secretory granule organization;GO:1904411 positive regulation of secretory granule organization;GO:0006686 sphingomyelin biosynthetic process,,Predicted intracellular proteins,Golgi apparatus (Supported); Additional: Cytosol;Nucleoplasm,,,
ENSG00000141664.10,ENSG00000141664,ZCCHC2,-0.662123785,-0.430746401,-0.641627062,-0.913997891,zinc finger CCHC-type containing 2,"ZCCHC2 is a human gene that is predicted to have nucleic acid binding activity, phosphatidylinositol binding activity, and zinc ion binding activity. It is located in the cytoplasm.","ZCCHC2 has been implicated in several diseases, including cancer, neurological disorders, and viral infections. In cancer, ZCCHC2 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. In neurological disorders, ZCCHC2 has been linked to Alzheimer's disease and Huntington's disease, suggesting a role in neurodegeneration. Additionally, ZCCHC2 has been shown to interact with viral proteins, indicating a potential role in viral infections.

Targeted drug discovery efforts for ZCCHC2 are still in the early stages, but several potential drug targets have been identified. One approach is to inhibit the nucleic acid binding activity of ZCCHC2, which could prevent its role in tumor growth and metastasis. Another approach is to target the phosphatidylinositol binding activity of ZCCHC2, which could disrupt its interaction with viral proteins and prevent viral infections.

Currently, there are no drugs on the market that specifically target ZCCHC2. However, there are several drugs that target related proteins, such as PI3K inhibitors for cancer therapy and antiviral drugs for viral infections. As research on ZCCHC2 continues, it is possible that new drugs targeting this gene will be developed for the treatment of cancer, neurological disorders, and viral infections.",,,Predicted intracellular proteins,Nucleoli (Approved); Additional: Cytosol;Nucleoli rim;Nucleoplasm,,,
ENSG00000136699.19,ENSG00000136699,SMPD4,-0.661878199,-0.964993428,-0.571688569,-0.4489526,sphingomyelin phosphodiesterase 4,"SMPD4 is a gene that encodes for a protein called sphingomyelin phosphodiesterase 4, which is responsible for breaking down sphingomyelin in cell membranes to form phosphorylcholine and ceramide. The gene is activated by DNA damage, cellular stress, and tumor necrosis factor, but is downregulated by wild-type p53. The protein localizes to the endoplasmic reticulum and Golgi network.","Research has shown that mutations in the SMPD4 gene are associated with various types of cancer, including colorectal, gastric, and breast cancer. Additionally, decreased expression of SMPD4 has been linked to poor prognosis in patients with hepatocellular carcinoma. These findings suggest that SMPD4 may play a role in tumor suppression and could be a potential target for cancer therapy.

Several drug discovery efforts have focused on targeting SMPD4. One study found that a small molecule inhibitor of SMPD4, called GW4869, was able to induce apoptosis in cancer cells and inhibit tumor growth in mice. Another study identified a natural compound, called ursolic acid, that was able to upregulate SMPD4 expression and inhibit cancer cell proliferation.

Currently, there are no drugs on the market that specifically target SMPD4. However, the success of GW4869 and ursolic acid in preclinical studies suggests that targeting SMPD4 could be a promising approach for cancer therapy. Further research is needed to fully understand the role of SMPD4 in cancer and to develop effective drugs that target this gene.",GO:0006685 sphingomyelin catabolic process;GO:0006684 sphingomyelin metabolic process;GO:0046475 glycerophospholipid catabolic process,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Nuclear membrane (Approved); Additional: Cytosol,Phosphatidyl serine,,
ENSG00000205302.7,ENSG00000205302,SNX2,-0.661825044,-0.770546985,-0.633429183,-0.581498964,sorting nexin 2,"SNX2, or sorting nexin 2, is a gene that belongs to the sorting nexin family and contains the phosphoinositide-binding phox (PX) domain. It is a component of the retromer complex, which plays a role in protein sorting in the endocytic pathway. SNX2 may form oligomeric complexes with other family members, and alternate splicing results in multiple transcript variants of this gene. Pseudogenes associated with SNX2 are located on chromosomes 1 and 7.","Research on SNX2 has revealed its potential involvement in various diseases, including cancer, Alzheimer's disease, and Parkinson's disease. In cancer, SNX2 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. In Alzheimer's disease, SNX2 has been implicated in the clearance of amyloid-beta peptides, which are known to accumulate in the brains of Alzheimer's patients. Targeting SNX2 could therefore be a potential strategy for treating Alzheimer's disease. In Parkinson's disease, SNX2 has been shown to be involved in the clearance of alpha-synuclein, a protein that accumulates in the brains of Parkinson's patients. Targeting SNX2 could therefore be a potential strategy for treating Parkinson's disease.

There are currently no drugs on the market that specifically target SNX2. However, there are ongoing efforts to develop drugs that target the retromer complex, of which SNX2 is a component. One example is the drug Riluzole, which has been shown to enhance retromer-mediated trafficking and reduce amyloid-beta levels in the brains of Alzheimer's disease patients. Another example is the drug PEP005, which has been shown to enhance retromer-mediated trafficking and reduce alpha-synuclein levels in the brains of Parkinson's disease patients. These drugs are not specific to SNX2, but they demonstrate the potential of targeting the retromer complex for the treatment of various diseases.",GO:0072673 lamellipodium morphogenesis;GO:0034498 early endosome to Golgi transport;GO:0097581 lamellipodium organization,,Predicted intracellular proteins,Endosomes (Enhanced); Additional: Lysosomes,,(M238)PID THROMBIN PAR1 PATHWAY,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000103353.16,ENSG00000103353,UBFD1,-0.661756597,-0.98668049,-0.531874091,-0.466715211,ubiquitin family domain containing 1,"The human gene UBFD1, also known as ubiquitin family domain containing 1, is involved in RNA binding activity and cadherin binding activity. This gene is responsible for encoding a protein that contains a ubiquitin-like domain, which is involved in protein degradation and regulation. The protein also contains a RNA recognition motif, which is involved in RNA binding and processing. The exact function of UBFD1 is not fully understood, but it is believed to play a role in various cellular processes, including cell signaling, protein degradation, and RNA processing. Further research is needed to fully understand the function and potential therapeutic applications of UBFD1.","There is limited information available on the disease implications of UBFD1. However, recent studies have suggested that dysregulation of UBFD1 expression may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for UBFD1 are currently underway, with a focus on identifying small molecule inhibitors that can modulate the activity of the protein. While there are currently no drugs on the market that specifically target UBFD1, there are several drugs that target the ubiquitin-proteasome system, which is involved in protein degradation and regulation, and may indirectly affect UBFD1 activity. Examples of such drugs include bortezomib, which is used to treat multiple myeloma, and carfilzomib, which is used to treat relapsed or refractory multiple myeloma.",,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Nucleoli,,,
ENSG00000145907.16,ENSG00000145907,G3BP1,-0.660239362,-0.669174627,-0.459972775,-0.851570684,G3BP stress granule assembly factor 1,"G3BP1 is a gene that encodes an enzyme involved in DNA unwinding and RNA duplex unwinding in an ATP-dependent manner. It is a member of the heterogeneous nuclear RNA-binding proteins and is also part of the Ras signal transduction pathway. G3BP1 specifically binds to the Ras-GTPase-activating protein by associating with its SH3 domain. The gene has several alternatively spliced transcript variants, but the full-length nature of some of these variants is unknown. G3BP1 is also known as a stress granule assembly factor 1, which plays a role in stress granule formation during cellular stress.","G3BP1 has been implicated in several diseases, including cancer, viral infections, and neurodegenerative disorders. In cancer, G3BP1 has been shown to promote tumor growth and metastasis by regulating the expression of genes involved in cell proliferation, migration, and invasion. Targeting G3BP1 has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of G3BP1 have been developed, including BTYNB, which has been shown to inhibit the growth of breast cancer cells in vitro and in vivo. In viral infections, G3BP1 plays a role in the replication of several viruses, including hepatitis C virus and Zika virus. Targeting G3BP1 has been proposed as a potential antiviral strategy. In neurodegenerative disorders, G3BP1 has been implicated in the formation of pathological aggregates in diseases such as amyotrophic lateral sclerosis and frontotemporal dementia. However, there are currently no drugs targeting G3BP1 for the treatment of neurodegenerative disorders on the market.",GO:0062029 positive regulation of stress granule assembly;GO:0062028 regulation of stress granule assembly;GO:0034063 stress granule assembly,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol (Enhanced),,,(M5901)HALLMARK G2M CHECKPOINT; (M5926)HALLMARK MYC TARGETS V1
ENSG00000162695.12,ENSG00000162695,SLC30A7,-0.659260977,-0.850197579,-1.012633729,-0.114951624,solute carrier family 30 member 7,"SLC30A7 is a human gene that belongs to the zinc transporter (ZNT)/SLC30 subfamily of the cation diffusion facilitator family. Zinc is an important cofactor for many enzymes, nuclear factors, and hormones, and also functions as an intra- and intercellular signal ion. SLC30A7 is involved in the efflux of zinc from cells.","There is limited information available on the disease implications of SLC30A7. However, studies have suggested that alterations in the expression of this gene may be associated with certain types of cancer, including breast and prostate cancer. Targeted drug discovery efforts for SLC30A7 are currently underway, with the aim of developing drugs that can modulate the activity of this gene and potentially treat diseases associated with zinc dysregulation. One example of a successful drug targeting zinc transporters is Disulfiram, which is used to treat alcoholism and has been shown to inhibit the activity of zinc transporters, including SLC30A7. However, further research is needed to fully understand the potential therapeutic applications of targeting SLC30A7.",GO:1904257 zinc ion import into Golgi lumen;GO:0140820 cytosol to Golgi apparatus transport;GO:0062111 zinc ion import into organelle,,Transporters:Electrochemical Potential-driven transporters; Predicted intracellular proteins,Golgi apparatus (Supported),,,
ENSG00000142892.15,ENSG00000142892,PIGK,-0.658506576,-0.921841261,-0.904973256,-0.148705209,phosphatidylinositol glycan anchor biosynthesis class K,"The human gene PIGK is involved in the biosynthesis of glycosylphosphatidylinositol (GPI)-anchor, a glycolipid found on many blood cells that anchors proteins to the cell surface. PIGK is a member of the cysteine protease family C13 and is thought to be the enzymatic component of the multisubunit enzyme GPI transamidase. GPI transamidase mediates GPI anchoring in the endoplasmic reticulum by transferring fully assembled GPI units to proteins.","Mutations in the PIGK gene have been associated with a rare genetic disorder called hyperphosphatasia with mental retardation syndrome (HPMRS), which is characterized by elevated levels of alkaline phosphatase in the blood and developmental delay. Targeted drug discovery efforts for HPMRS have been limited due to the rarity of the disease. However, research on GPI-anchor biosynthesis and the role of PIGK in this process has led to the development of drugs targeting other components of the GPI transamidase complex, such as eculizumab, which is used to treat paroxysmal nocturnal hemoglobinuria (PNH). PNH is a blood disorder caused by a deficiency in GPI-anchor biosynthesis, leading to the destruction of red blood cells. Eculizumab targets the complement system, which is activated in PNH due to the absence of GPI-anchored proteins that normally regulate complement activation. Other drugs targeting GPI-anchor biosynthesis are currently in development for various diseases, including cancer and inflammatory disorders.",GO:0016255 attachment of GPI anchor to protein;GO:0006505 GPI anchor metabolic process;GO:0006506 GPI anchor biosynthetic process,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Predicted intracellular proteins; Peptidases:Cysteine-type peptidases; Potential drug targets; Disease related genes; Enzymes,,,,
ENSG00000068323.17,ENSG00000068323,TFE3,-0.658236799,-0.807479274,-0.773243898,-0.393987226,transcription factor binding to IGHM enhancer 3,"TFE3 is a gene that encodes a transcription factor that binds to MUE3-type E-box sequences in gene promoters. This protein promotes the expression of genes downstream of TGF-beta signaling and may be involved in chromosomal translocations in renal cell carcinomas and other cancers, resulting in the production of fusion proteins. TFE3 has multiple transcript variants due to alternative splicing.","Mutations in the TFE3 gene have been associated with a rare genetic disorder called Xp11.2 translocation renal cell carcinoma (RCC), which is characterized by the fusion of TFE3 with other genes. This fusion protein drives the uncontrolled growth of kidney cells, leading to the development of cancer. Targeted drug discovery efforts have focused on developing inhibitors of the TFE3 fusion protein, with promising results in preclinical studies. One example is the drug tazemetostat, which inhibits the activity of the TFE3 fusion protein and has shown efficacy in preclinical models of Xp11.2 RCC. Tazemetostat has been approved by the FDA for the treatment of epithelioid sarcoma, a rare soft tissue cancer that is also driven by TFE3 fusion proteins. Other drugs targeting TFE3 are currently in clinical trials for the treatment of Xp11.2 RCC and other cancers.",GO:0090336 positive regulation of brown fat cell differentiation;GO:0090335 regulation of brown fat cell differentiation;GO:0120163 negative regulation of cold-induced thermogenesis,,Human disease related genes:Cancers:Cancers of soft tissues and bone; Transcription factors:Basic domains; Predicted intracellular proteins; Cancer-related genes; Human disease related genes:Cancers:Cancers of the urinary system; Disease related genes,Cytosol;Nucleoplasm (Approved),,(M40)PID E2F PATHWAY; (M2)PID SMAD2 3NUCLEAR PATHWAY,
ENSG00000003402.20,ENSG00000003402,CFLAR,-0.658040704,-0.851985588,-0.514696699,-0.607439826,CASP8 and FADD like apoptosis regulator,"CFLAR, also known as CASP8 and FADD like apoptosis regulator, is a gene that encodes a protein involved in regulating apoptosis, or programmed cell death. The protein is similar in structure to caspase-8, but does not have caspase activity. Instead, it appears to be cleaved into two peptides by caspase-8. There are several different isoforms of the protein encoded by different transcript variants of the gene, and evidence suggests that there may be even more variants. Overall, CFLAR plays an important role in controlling cell death and may have implications for diseases such as cancer.","CFLAR has been implicated in several diseases, including cancer, autoimmune disorders, and viral infections. In cancer, CFLAR has been shown to be overexpressed in some tumors, leading to resistance to chemotherapy and radiation therapy. Targeting CFLAR with small molecule inhibitors or RNA interference has been explored as a potential therapeutic strategy for cancer treatment. However, there are currently no drugs on the market that specifically target CFLAR. Some drugs that indirectly affect CFLAR, such as the proteasome inhibitor bortezomib, have been approved for the treatment of multiple myeloma. Additionally, some natural compounds, such as curcumin and resveratrol, have been shown to inhibit CFLAR expression and induce apoptosis in cancer cells. Further research is needed to fully understand the role of CFLAR in disease and to develop targeted therapies.",GO:1901740 negative regulation of myoblast fusion;GO:0034242 negative regulation of syncytium formation by plasma membrane fusion;GO:0014732 skeletal muscle atrophy,,Peptidases:Cysteine-type peptidases; Enzymes; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cytosol;Nucleoplasm;Plasma membrane (Supported); Additional: Nuclear bodies,,(M5060)SA FAS SIGNALING; (M79)PID TRAIL PATHWAY; (M197)PID HIV NEF PATHWAY,(M5902)HALLMARK APOPTOSIS; (M5890)HALLMARK TNFA SIGNALING VIA NFKB
ENSG00000135870.12,ENSG00000135870,RC3H1,-0.65776458,-0.788776829,-0.847125667,-0.337391244,ring finger and CCCH-type domains 1,"RC3H1 is a human gene that encodes a protein with RING-type and C3H1-type zinc finger motifs. This protein recognizes and binds to a constitutive decay element (CDE) in the 3' UTR of mRNAs, leading to mRNA deadenylation and degradation. The gene undergoes alternative splicing, resulting in multiple transcript variants.","There is limited information available on the disease implications of RC3H1. However, recent studies have suggested that mutations in this gene may be associated with the development of certain cancers, including hepatocellular carcinoma and colorectal cancer. Targeted drug discovery efforts for RC3H1 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and prevent its interaction with CDEs in mRNA. While there are currently no drugs on the market that specifically target RC3H1, there are several drugs that have been approved for the treatment of cancer that may indirectly affect the activity of this protein. For example, the chemotherapy drug 5-fluorouracil has been shown to induce the degradation of RC3H1 in cancer cells, leading to increased mRNA stability and protein expression.",GO:0002635 negative regulation of germinal center formation;GO:0002634 regulation of germinal center formation;GO:0061470 T follicular helper cell differentiation,,Predicted intracellular proteins; Human disease related genes:Immune system diseases:Primary immunodeficiency; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Cytosol (Supported); Additional: Golgi apparatus;Plasma membrane,,,
ENSG00000054282.16,ENSG00000054282,SDCCAG8,-0.656820553,-0.879713529,-0.888744238,-0.202003891,SHH signaling and ciliogenesis regulator SDCCAG8,"The SDCCAG8 gene encodes a protein that is involved in organizing the centrosome during cell division. It is also a regulator of the SHH signaling pathway and ciliogenesis. Mutations in this gene have been linked to a condition called retinal-renal ciliopathy, which affects the development and function of cilia in the retina and kidneys. Cilia are hair-like structures on the surface of cells that play important roles in sensing and signaling. Dysfunction of cilia can lead to a range of health problems, including vision and kidney disorders.","Mutations in the SDCCAG8 gene have been linked to several diseases, including retinal-renal ciliopathy, Joubert syndrome, and Meckel-Gruber syndrome. These conditions are characterized by abnormalities in cilia structure and function, leading to a range of symptoms such as vision loss, kidney dysfunction, and developmental defects.

Targeted drug discovery efforts for SDCCAG8-related diseases are still in the early stages, but there is growing interest in developing therapies that can restore cilia function. One approach is to target the SHH signaling pathway, which is regulated by SDCCAG8 and plays a key role in ciliogenesis. Small molecule inhibitors of the SHH pathway have shown promise in preclinical studies, and clinical trials are underway for several SHH pathway inhibitors in various cancers.

There are currently no drugs on the market specifically targeting SDCCAG8-related diseases, but there are several drugs approved for other conditions that may have potential for repurposing. For example, the drug cysteamine, which is approved for the treatment of cystinosis, has been shown to improve cilia function in preclinical studies and is being evaluated in clinical trials for the treatment of Joubert syndrome. Another drug, called tolvaptan, is approved for the treatment of polycystic kidney disease and may have potential for treating SDCCAG8-related kidney disorders.",GO:1902017 regulation of cilium assembly;GO:0007098 centrosome cycle;GO:0031023 microtubule organizing center organization,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the urinary system; Human disease related genes:Congenital disorders of metabolism:Other congenital disorders of metabolism; Predicted intracellular proteins,Basal body;Centrosome (Supported); Additional: Primary cilium,,,(M5953)HALLMARK KRAS SIGNALING UP
ENSG00000171206.15,ENSG00000171206,TRIM8,-0.655962791,-1.108411311,-0.635832178,-0.223644885,tripartite motif containing 8,"TRIM8 is a gene that belongs to the tripartite motif (TRIM) protein family. It is believed to encode an E3 ubiquitin-protein ligase, which is involved in the regulation of protein degradation. The gene has been linked to some cancers, and mutations that result in a truncated protein product have been observed in early-onset epileptic encephalopathy (EOEE). The exact function of TRIM8 is not yet fully understood, but it is thought to play a role in various cellular processes, including immune response, cell differentiation, and apoptosis. Further research is needed to fully elucidate the function of TRIM8 and its potential role in disease.","TRIM8 has been implicated in several diseases, including cancer and early-onset epileptic encephalopathy (EOEE). In cancer, TRIM8 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. Targeted drug discovery efforts have focused on developing small molecule inhibitors of TRIM8, which could potentially be used to treat cancer. However, there are currently no drugs on the market that specifically target TRIM8.

In EOEE, mutations in the TRIM8 gene have been linked to the development of the disease. These mutations result in a truncated protein product that is thought to disrupt normal brain development and function. While there are currently no drugs available that target TRIM8 in EOEE, research is ongoing to better understand the role of TRIM8 in the disease and to develop potential therapies.

Overall, while TRIM8 has been implicated in several diseases, there are currently no drugs on the market that specifically target this gene. However, ongoing research into the function of TRIM8 and its potential role in disease could lead to the development of new therapies in the future.",GO:0032897 negative regulation of viral transcription;GO:0044790 suppression of viral release by host;GO:0046782 regulation of viral transcription,,Predicted intracellular proteins; Human disease related genes:Urinary system diseases:Kidney diseases; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Nucleoplasm (Supported); Additional: Cytosol;Vesicles,,,
ENSG00000189067.13,ENSG00000189067,LITAF,-0.655785346,-0.948469731,-0.587916739,-0.430969568,lipopolysaccharide induced TNF factor,LITAF (lipopolysaccharide-induced TNF-alpha factor) is a gene that encodes a DNA-binding protein that can mediate the expression of tumor necrosis factor-alpha (TNF-alpha) by directly binding to the promoter region of the TNF-alpha gene. TNF-alpha is a potent inflammatory mediator secreted by monocytes and macrophages in response to lipopolysaccharide. The transcription of LITAF is induced by the tumor suppressor p53 and has been implicated in the p53-induced apoptotic pathway. Mutations in LITAF are associated with Charcot-Marie-Tooth disease type 1C (CMT1C) and may be involved in the development of extramammary Paget's disease (EMPD). Multiple alternatively spliced transcript variants of LITAF have been identified.,"Charcot-Marie-Tooth disease type 1C (CMT1C) is a rare inherited neurological disorder that affects the peripheral nerves, leading to muscle weakness and wasting in the hands, feet, and lower legs. Mutations in the LITAF gene have been identified as a cause of CMT1C. There are currently no targeted drug therapies available for CMT1C, and treatment is mainly supportive.

In terms of drug discovery efforts, LITAF has been identified as a potential therapeutic target for the treatment of inflammatory diseases such as rheumatoid arthritis and multiple sclerosis. Several small molecule inhibitors of LITAF have been developed and tested in preclinical studies, showing promising results in reducing inflammation and improving disease outcomes.

One example of a successful drug targeting TNF-alpha, the downstream product of LITAF, is adalimumab (Humira). Adalimumab is a monoclonal antibody that binds to TNF-alpha, preventing its interaction with cell surface receptors and reducing inflammation. It is approved for the treatment of several inflammatory diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease.

Another example is etanercept (Enbrel), which is also a TNF-alpha inhibitor. Etanercept is a fusion protein that binds to TNF-alpha and prevents its interaction with cell surface receptors. It is approved for the treatment of rheumatoid arthritis, psoriasis, and ankylosing spondylitis.

Overall, while there are currently no targeted therapies available for LITAF-associated diseases such as CMT1C, there is ongoing research into the development of small molecule inhibitors of LITAF for the treatment of inflammatory diseases. Successful drugs targeting TNF-alpha, the downstream product of LITAF, have been developed and approved for the treatment of several inflammatory diseases.",GO:0010935 regulation of macrophage cytokine production;GO:1901223 negative regulation of non-canonical NF-kappaB signal transduction;GO:1901222 regulation of non-canonical NF-kappaB signal transduction,,Disease related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Golgi apparatus;Vesicles,,,(M5890)HALLMARK TNFA SIGNALING VIA NFKB
ENSG00000143437.21,ENSG00000143437,ARNT,-0.655351642,-0.832506651,-0.816124471,-0.317423805,aryl hydrocarbon receptor nuclear translocator,"The ARNT gene encodes a protein that contains a basic helix-loop-helix domain, two PAS domains, and a PAC domain. This protein binds to the aryl hydrocarbon receptor and helps move the complex to the nucleus, where it promotes the expression of genes involved in xenobiotic metabolism. Additionally, the protein acts as a co-factor for transcriptional regulation by hypoxia-inducible factor 1. Chromosomal translocation of this gene with the ETV6 gene has been observed in leukemias. Alternative splicing of the ARNT gene results in multiple transcript variants.","The ARNT gene has been implicated in several diseases, including cancer, diabetes, and cardiovascular disease. In cancer, ARNT has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. Targeted drug discovery efforts have focused on developing small molecule inhibitors of ARNT, with some promising results in preclinical studies. One example is the compound YH439, which has been shown to inhibit ARNT and suppress tumor growth in mouse models of breast cancer. In diabetes, ARNT is involved in the regulation of glucose metabolism, and mutations in the gene have been associated with an increased risk of developing type 2 diabetes. In cardiovascular disease, ARNT has been shown to play a role in the development of atherosclerosis, and inhibitors of ARNT have been proposed as a potential therapy for this condition. However, there are currently no drugs targeting ARNT on the market.",GO:0046886 positive regulation of hormone biosynthetic process;GO:0033235 positive regulation of protein sumoylation;GO:0032352 positive regulation of hormone metabolic process,,Transcription factors:Basic domains; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Nuclear bodies;Nucleoplasm (Supported),,(M180)PID HIF1A PATHWAY; (M44)PID HIF2PATHWAY; (M288)PID HES HEY PATHWAY,
ENSG00000103197.18,ENSG00000103197,TSC2,-0.655192818,-1.29049214,-0.513176412,-0.161909902,TSC complex subunit 2,"TSC2 is a tumor suppressor gene that encodes the protein tuberin, which interacts with hamartin to form the TSC protein complex. This complex plays a crucial role in controlling cell growth by negatively regulating the mTORC1 signaling pathway, which is a major regulator of anabolic cell growth. Mutations in TSC2 have been linked to the development of tuberous sclerosis and lymphangioleiomyomatosis. Tuberous sclerosis is a genetic disorder that causes benign tumors to grow in various organs, while lymphangioleiomyomatosis is a rare lung disease characterized by the abnormal growth of smooth muscle cells in the lungs. Understanding the function of TSC2 and its role in regulating cell growth may lead to the development of new treatments for these diseases.","TSC2 mutations have been linked to the development of tuberous sclerosis and lymphangioleiomyomatosis, both of which are rare genetic disorders. Tuberous sclerosis causes benign tumors to grow in various organs, including the brain, heart, kidneys, and skin. Lymphangioleiomyomatosis is a lung disease characterized by the abnormal growth of smooth muscle cells in the lungs, which can lead to respiratory failure. 

Targeted drug discovery efforts for TSC2-related diseases have focused on developing drugs that target the mTORC1 signaling pathway, which is dysregulated in these disorders. One example is everolimus, an mTOR inhibitor that has been approved for the treatment of subependymal giant cell astrocytomas (SEGAs) and renal angiomyolipomas (AMLs) associated with tuberous sclerosis. Another example is sirolimus, which has been shown to improve lung function in patients with lymphangioleiomyomatosis.

In addition to these targeted therapies, other treatments for TSC2-related diseases include surgery to remove tumors and supportive care to manage symptoms. Ongoing research is focused on developing new therapies that can more effectively target the underlying molecular mechanisms of these disorders.",GO:1901525 negative regulation of mitophagy;GO:1903147 negative regulation of autophagy of mitochondrion;GO:0043276 anoikis,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Predicted intracellular proteins; Human disease related genes:Urinary system diseases:Kidney diseases; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Human disease related genes:Cardiovascular diseases:Vascular diseases; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Cancer-related genes:Mutational cancer driver genes,Cytosol (Enhanced),,(M199)PID P38 MK2 PATHWAY; (M87)PID LKB1 PATHWAY; (M254)PID MYC REPRESS PATHWAY,(M5923)HALLMARK PI3K AKT MTOR SIGNALING; (M5909)HALLMARK MYOGENESIS
ENSG00000179134.15,ENSG00000179134,SAMD4B,-0.654132906,-1.183383384,-0.590418064,-0.18859727,sterile alpha motif domain containing 4B,SAMD4B is a human gene that encodes a protein containing a sterile alpha motif domain. This protein is involved in RNA binding activity and is predicted to play a role in nuclear-transcribed mRNA poly(A) tail shortening. It is also predicted to be involved in cerebellar neuron development. The protein is located in the cytosol.,"There is limited information available on the disease implications of SAMD4B. However, recent studies have suggested that SAMD4B may play a role in the development of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for SAMD4B are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target SAMD4B, there are several drugs that have been approved for the treatment of breast cancer and hepatocellular carcinoma that may indirectly affect the activity of SAMD4B. These include tamoxifen, trastuzumab, and sorafenib. Further research is needed to fully understand the potential therapeutic implications of targeting SAMD4B in cancer treatment.","GO:0000289 nuclear-transcribed mRNA poly(A) tail shortening;GO:0000288 nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay;GO:0000956 nuclear-transcribed mRNA catabolic process",,Predicted intracellular proteins,Cytosol (Enhanced),,,
ENSG00000163161.14,ENSG00000163161,ERCC3,-0.654051796,-0.931520489,-0.559342473,-0.471292427,"ERCC excision repair 3, TFIIH core complex helicase subunit","ERCC3 is a gene that encodes an ATP-dependent DNA helicase, which plays a crucial role in nucleotide excision repair. It is also a subunit of the basal transcription factor 2 (TFIIH) and is involved in class II transcription. Mutations in ERCC3 have been linked to several genetic disorders, including Xeroderma pigmentosum B, Cockayne's syndrome, and trichothiodystrophy. Alternative splicing of ERCC3 results in multiple transcript variants.","Mutations in ERCC3 have been linked to several genetic disorders, including Xeroderma pigmentosum B, Cockayne's syndrome, and trichothiodystrophy. Xeroderma pigmentosum B is a rare autosomal recessive disorder characterized by extreme sensitivity to sunlight, leading to an increased risk of skin cancer. Cockayne's syndrome is a rare autosomal recessive disorder characterized by growth failure, neurological abnormalities, and premature aging. Trichothiodystrophy is a rare autosomal recessive disorder characterized by brittle hair, intellectual disability, and photosensitivity.

Targeted drug discovery efforts for ERCC3-related disorders are still in the early stages. However, some studies have shown promising results in using small molecule inhibitors to target the ATPase activity of ERCC3. These inhibitors have been shown to sensitize cancer cells to chemotherapy and radiation therapy, suggesting that they may have potential as adjuvant therapies for cancer treatment.

There are currently no drugs on the market specifically targeting ERCC3-related disorders. However, some drugs used in cancer treatment, such as cisplatin and carboplatin, work by inducing DNA damage and activating the nucleotide excision repair pathway, which involves ERCC3. These drugs have been shown to be effective in treating some ERCC3-related disorders, such as Xeroderma pigmentosum B.","GO:0000717 nucleotide-excision repair, DNA duplex unwinding;GO:0006265 DNA topological change;GO:0006283 transcription-coupled nucleotide-excision repair",,Human disease related genes:Skin diseases:Skin and soft tissue diseases; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Human disease related genes:Congenital malformations:Congenital malformations of skin; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported); Additional: Vesicles,,,(M5949)HALLMARK PEROXISOME; (M5898)HALLMARK DNA REPAIR
ENSG00000196367.14,ENSG00000196367,TRRAP,-0.653532871,-1.247264198,-0.665492977,-0.047841438,transformation/transcription domain associated protein,"TRRAP is a gene that encodes a large protein belonging to the PIKK family. It is a crucial component of many histone acetyltransferase (HAT) complexes and is involved in transcription and DNA repair by recruiting HAT complexes to chromatin. The gene is alternatively spliced, resulting in multiple isoforms. Deregulation of TRRAP may contribute to the development of various cancers, including glioblastoma multiforme.","TRRAP has been implicated in various cancers, including glioblastoma multiforme, breast cancer, and lung cancer. In glioblastoma multiforme, TRRAP has been shown to be overexpressed and associated with poor prognosis. Targeting TRRAP has been proposed as a potential therapeutic strategy for cancer treatment. However, there are currently no drugs specifically targeting TRRAP on the market. Some drugs that indirectly affect TRRAP function, such as histone deacetylase inhibitors, have been approved for cancer treatment. For example, vorinostat (Zolinza) and romidepsin (Istodax) are FDA-approved drugs for the treatment of cutaneous T-cell lymphoma that inhibit histone deacetylases and increase histone acetylation, leading to changes in gene expression that may affect TRRAP function.",GO:0140861 DNA repair-dependent chromatin remodeling;GO:1905168 positive regulation of double-strand break repair via homologous recombination;GO:0045911 positive regulation of DNA recombination,,Disease related genes; Cancer-related genes; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Ear disease,Nucleoplasm (Supported); Additional: Golgi apparatus,,(M139)PID MYC PATHWAY; (M40)PID E2F PATHWAY; (M66)PID MYC ACTIV PATHWAY,
ENSG00000081154.12,ENSG00000081154,PCNP,-0.652701759,-0.773834187,-0.766603451,-0.417667638,PEST proteolytic signal containing nuclear protein,"PCNP, or PEST proteolytic signal containing nuclear protein, is a gene involved in the process of breaking down proteins through the proteasome and in protein ubiquitination. It is located in the nuclear body. This information is provided by the Alliance of Genome Resources as of April 2022.","Unfortunately, there is currently very limited information available on the disease implications and targeted drug discovery efforts for PCNP. As of April 2022, there are no known drugs on the market that specifically target PCNP. However, given its involvement in protein degradation and ubiquitination, it is possible that dysregulation of PCNP could contribute to the development or progression of certain diseases, such as cancer or neurodegenerative disorders. Further research is needed to fully understand the role of PCNP in these processes and to identify potential therapeutic targets.",GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process;GO:0010498 proteasomal protein catabolic process;GO:0006511 ubiquitin-dependent protein catabolic process,,Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Nuclear bodies,,,
ENSG00000221914.11,ENSG00000221914,PPP2R2A,-0.652444392,-0.739438142,-0.795229634,-0.4226654,protein phosphatase 2 regulatory subunit Balpha,"PPP2R2A is a gene that encodes for the alpha isoform of the regulatory subunit B55 subfamily of protein phosphatase 2 (PP2A). PP2A is a major Ser/Thr phosphatase that is involved in the negative control of cell growth and division. The enzyme consists of a heteromeric core composed of a catalytic subunit and a constant regulatory subunit, which associates with various regulatory subunits. The B regulatory subunit, including PPP2R2A, may modulate substrate selectivity and catalytic activity. Alternative splicing of PPP2R2A has been observed, resulting in different transcript variants.","PPP2R2A has been implicated in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, PPP2R2A has been shown to act as a tumor suppressor by regulating cell cycle progression and apoptosis. Loss of PPP2R2A expression or function has been observed in several types of cancer, including breast, prostate, and liver cancer. Therefore, PPP2R2A is a potential target for cancer therapy. Several drugs targeting PP2A, including FTY720 and LB-100, have been developed and are currently being tested in clinical trials for cancer treatment. In addition, PPP2R2A has also been implicated in neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease, and drugs targeting PP2A are being investigated for their potential therapeutic effects in these diseases. However, there are currently no drugs on the market specifically targeting PPP2R2A.",GO:0043278 response to morphine;GO:0014072 response to isoquinoline alkaloid;GO:0006470 protein dephosphorylation,,Predicted intracellular proteins,Cytosol (Approved),"2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid",(M286)PID TGFBR PATHWAY; (M164)PID ERBB1 DOWNSTREAM PATHWAY,
ENSG00000117859.19,ENSG00000117859,OSBPL9,-0.652219952,-0.864030702,-1.065300406,-0.027328748,oxysterol binding protein like 9,"OSBPL9 is a gene that belongs to the oxysterol-binding protein (OSBP) family, which are intracellular lipid receptors. This gene encodes a protein that acts as a cholesterol transfer protein, regulating the structure and function of the Golgi. The protein contains a pleckstrin homology domain and a sterol-binding domain, which are highly conserved among OSBP family members. Multiple transcript variants have been identified, resulting in distinct isoforms of the protein. Pseudogenes related to OSBPL9 have also been found on chromosomes 3, 11, and 12.","Research on OSBPL9 and its potential disease implications is still ongoing, but some studies have suggested that it may play a role in certain cancers, including breast and prostate cancer. Additionally, mutations in the OSBPL9 gene have been associated with a rare genetic disorder called Niemann-Pick disease type C (NPC), which is characterized by the abnormal accumulation of cholesterol and other lipids in the body's cells.

As for targeted drug discovery efforts, there is currently no drug specifically targeting OSBPL9. However, there are drugs on the market that target other members of the OSBP family, such as OSBPL8 and OSBPL10. For example, the drug Ketas (also known as OS2966) is a small molecule inhibitor of OSBPL8 that has shown promise in preclinical studies for the treatment of cancer. Another drug, OSW-1, is a natural compound that targets OSBPL10 and has demonstrated anticancer activity in vitro and in vivo.

Overall, while the specific role of OSBPL9 in disease is still being investigated, the broader OSBP family has shown potential as a target for drug discovery efforts in cancer and other diseases.",GO:0006699 bile acid biosynthetic process;GO:0008206 bile acid metabolic process;GO:0015918 sterol transport,,Predicted intracellular proteins,Golgi apparatus (Supported); Additional: Vesicles,,,
ENSG00000163795.14,ENSG00000163795,ZNF513,-0.651209145,-1.060527001,-0.634571804,-0.25852863,zinc finger protein 513,"ZNF513 is a human gene that encodes for a zinc finger protein involved in regulating gene expression during retinal development. Mutations in this gene have been linked to autosomal-recessive retinitis pigmentosa, a genetic disorder that causes progressive vision loss. Two different versions of the gene have been identified, each producing a slightly different protein isoform.","Mutations in the ZNF513 gene have been linked to autosomal-recessive retinitis pigmentosa, a genetic disorder that causes progressive vision loss. While there are currently no targeted drug discovery efforts specifically for ZNF513, there are several drugs on the market that have been successful in treating retinitis pigmentosa. One such drug is Luxturna, which was approved by the FDA in 2017 and is used to treat a specific type of inherited retinal disease caused by mutations in the RPE65 gene. Another drug, ProQR's QR-421a, is currently in clinical trials for the treatment of retinitis pigmentosa caused by mutations in the USH2A gene. These drugs work by targeting specific genetic mutations that cause retinal degeneration, and may provide hope for individuals with retinitis pigmentosa caused by mutations in the ZNF513 gene in the future.",GO:0060041 retina development in camera-type eye;GO:0007601 visual perception;GO:0050953 sensory perception of light stimulus,,Disease related genes; Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins; Transcription factors:Zinc-coordinating DNA-binding domains,,,,
ENSG00000178921.14,ENSG00000178921,PFAS,-0.650972468,-1.217447268,-0.634420953,-0.101049184,phosphoribosylformylglycinamidine synthase,"The PFAS gene encodes an enzyme that is involved in the synthesis of purines, which are essential for various cellular processes. Specifically, this enzyme catalyzes the fourth step in the de novo pathway of purine biosynthesis, which is necessary for the production of inosine monophosphate (IMP). Purines are important for DNA replication, transcription, and energy metabolism.","There is limited information available on the disease implications of the PFAS gene. However, mutations in this gene have been associated with rare metabolic disorders such as phosphoribosylpyrophosphate synthetase superactivity (PRPS1 superactivity) and Arts syndrome. PRPS1 superactivity is characterized by overproduction of purines, leading to neurological symptoms such as developmental delay, intellectual disability, and seizures. Arts syndrome is a rare X-linked disorder that affects the nervous system and immune system, causing developmental delay, hearing loss, and recurrent infections.

There are currently no targeted drug discovery efforts specifically for the PFAS gene. However, drugs that target the purine biosynthesis pathway, such as allopurinol and febuxostat, are used to treat conditions such as gout and hyperuricemia. These drugs inhibit the enzyme xanthine oxidase, which is involved in the final steps of purine metabolism, leading to a decrease in uric acid production.

In addition, drugs that target purine metabolism have been used in the treatment of cancer. For example, mercaptopurine and azathioprine are used in the treatment of leukemia and autoimmune diseases, respectively. These drugs are metabolized to active purine analogs that interfere with DNA synthesis and cell division, leading to cell death.

Overall, while there is limited information on the disease implications of the PFAS gene, drugs that target the purine biosynthesis pathway have been successful in treating a variety of conditions, including gout, hyperuricemia, leukemia, and autoimmune diseases.",GO:0097065 anterior head development;GO:0006189 'de novo' IMP biosynthetic process;GO:0097292 XMP metabolic process,,ENZYME proteins:Ligase; Enzymes; Predicted intracellular proteins,Vesicles (Approved),Glutamic acid,,
ENSG00000172939.9,ENSG00000172939,OXSR1,-0.650309933,-1.080969349,-0.58501429,-0.284946159,oxidative stress responsive kinase 1,"OXSR1 is a gene that encodes for a protein belonging to the Ser/Thr protein kinase family. This protein is involved in regulating downstream kinases in response to environmental stress and may also play a role in regulating the actin cytoskeleton. The gene is known as oxidative stress responsive kinase 1, indicating its involvement in the cellular response to oxidative stress. The function of OXSR1 is important for maintaining cellular homeostasis and preventing damage caused by environmental stressors.","There is limited information available on the disease implications of OXSR1 mutations. However, studies have suggested that OXSR1 may play a role in the development of hypertension and kidney disease. Targeted drug discovery efforts for OXSR1 are still in the early stages, but there is potential for the development of drugs that target this protein for the treatment of hypertension and other related conditions. One example of a successful drug that targets a related protein is losartan, which is used to treat hypertension by inhibiting the angiotensin II receptor. Another example is the drug aliskiren, which targets renin, an enzyme involved in the regulation of blood pressure. Further research is needed to fully understand the potential of targeting OXSR1 for drug development.",GO:0038116 chemokine (C-C motif) ligand 21 signaling pathway;GO:0038146 chemokine (C-X-C motif) ligand 12 signaling pathway;GO:0007231 osmosensory signaling pathway,yes,Enzymes; Kinases:STE Ser/Thr protein kinases; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Supported),Fostamatinib,,(M5938)HALLMARK REACTIVE OXYGEN SPECIES PATHWAY
ENSG00000070047.13,ENSG00000070047,PHRF1,-0.649743596,-1.102570691,-0.500647434,-0.346012663,PHD and ring finger domains 1,PHRF1 is a human gene that is predicted to have RNA polymerase binding activity and be involved in mRNA processing and transcription by RNA polymerase II. It is located in the membrane. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of PHRF1. However, recent studies have suggested that mutations in this gene may be associated with intellectual disability and developmental delay. Targeted drug discovery efforts for PHRF1 are currently limited, as the exact function of this gene is not well understood. However, given its predicted role in mRNA processing and transcription, it is possible that drugs targeting these pathways may have therapeutic potential for diseases associated with PHRF1 mutations. Currently, there are no drugs on the market specifically targeting PHRF1. However, there are several drugs that target RNA polymerase II, such as alpha-amanitin, which is used in research to inhibit transcription, and the chemotherapy drug actinomycin D, which also inhibits transcription by binding to DNA.",GO:0016567 protein ubiquitination;GO:0032446 protein modification by small protein conjugation;GO:0070647 protein modification by small protein conjugation or removal,,Predicted intracellular proteins,,,,
ENSG00000188529.15,ENSG00000188529,SRSF10,-0.64937738,-0.697447245,-0.802923464,-0.44776143,serine and arginine rich splicing factor 10,"SRSF10, also known as serine and arginine rich splicing factor 10, is a member of the serine-arginine (SR) family of proteins that are involved in RNA splicing. It contains N-terminal RNP1 and RNP2 motifs that are required for binding to RNA, and multiple C-terminal SR/RS repeats that mediate association with other cellular proteins. SRSF10 interacts with the oncoprotein TLS and inhibits its influence on adenovirus E1A pre-mRNA splicing. The gene has pseudogenes on several chromosomes, and alternative splicing results in multiple transcript variants.","There is limited information available on the disease implications of SRSF10. However, recent studies have suggested that SRSF10 may play a role in cancer progression and metastasis. Specifically, SRSF10 has been shown to promote the splicing of oncogenic isoforms of the protein kinase PKC?, which is associated with increased cell proliferation and migration in breast cancer cells. Additionally, SRSF10 has been implicated in the regulation of alternative splicing events in other cancer-related genes, such as BCL2L1 and CD44.

There are currently no targeted drug discovery efforts specifically focused on SRSF10. However, there are several drugs on the market that target RNA splicing, which may indirectly affect SRSF10 activity. For example, the spliceosome inhibitor H3B-8800 has shown promising results in preclinical studies for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Additionally, the splicing modulator E7107 has been evaluated in clinical trials for the treatment of solid tumors and hematological malignancies.

In summary, while the disease implications of SRSF10 are not well understood, there is evidence to suggest that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for SRSF10 are currently lacking, but there are drugs on the market that indirectly affect RNA splicing and may have therapeutic potential for cancer treatment.","GO:0048025 negative regulation of mRNA splicing, via spliceosome;GO:0050686 negative regulation of mRNA processing;GO:0033119 negative regulation of RNA splicing",,Predicted intracellular proteins,Nucleoplasm (Supported),,,(M5901)HALLMARK G2M CHECKPOINT
ENSG00000176953.12,ENSG00000176953,NFATC2IP,-0.648647172,-0.87103824,-0.651372622,-0.423530652,nuclear factor of activated T cells 2 interacting protein,"NFATC2IP, also known as nuclear factor of activated T cells 2 interacting protein, is a gene that is predicted to play a role in the positive regulation of transcription by RNA polymerase II. It is also predicted to be located in both the cytoplasm and nucleus. The function of this gene is not yet fully understood, but it is believed to be involved in various cellular processes, including cell proliferation and differentiation. Further research is needed to fully understand the role of NFATC2IP in human biology and disease.","There is limited information available on the disease implications of NFATC2IP. However, some studies have suggested that it may be involved in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for NFATC2IP are currently limited, as the function of this gene is not yet fully understood. However, some studies have suggested that targeting NFATC2IP may be a potential therapeutic strategy for cancer treatment. There are currently no drugs on the market that specifically target NFATC2IP. However, there are several drugs that target related pathways, such as calcineurin inhibitors, which are used to prevent organ rejection in transplant patients. Further research is needed to fully understand the potential therapeutic implications of targeting NFATC2IP.",GO:0016925 protein sumoylation;GO:0018205 peptidyl-lysine modification;GO:0018193 peptidyl-amino acid modification,,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000131381.12,ENSG00000131381,RBSN,-0.648458728,-0.968157726,-0.523418966,-0.453799492,"rabenosyn, RAB effector",The RBSN gene encodes a protein that is part of the FYVE zinc finger family and interacts with Ras-related proteins involved in membrane trafficking. A mutation in this gene is linked to a defect in the early endocytic pathway. Alternative splicing produces multiple transcript variants.,"There is limited information available on the disease implications of RBSN gene mutations. However, studies have suggested that mutations in this gene may be associated with developmental disorders and intellectual disability. Targeted drug discovery efforts for RBSN gene mutations are also limited, as the exact function of the protein encoded by this gene is not fully understood. However, some studies have suggested that targeting the Ras-related proteins that interact with RBSN may be a potential therapeutic strategy. Currently, there are no drugs on the market specifically targeting RBSN gene mutations. However, there are drugs targeting Ras-related proteins, such as farnesyltransferase inhibitors, which have been approved for the treatment of certain types of cancer.",GO:0090160 Golgi to lysosome transport;GO:0034498 early endosome to Golgi transport;GO:1903358 regulation of Golgi organization,,Predicted intracellular proteins,Vesicles (Supported),,,(M5921)HALLMARK COMPLEMENT
ENSG00000072803.17,ENSG00000072803,FBXW11,-0.648410969,-0.846750928,-0.591126069,-0.507355909,F-box and WD repeat domain containing 11,"FBXW11 is a gene that encodes a member of the F-box protein family, which is involved in phosphorylation-dependent ubiquitination. The F-box proteins are part of the SCF complex and are divided into three classes: Fbws, Fbls, and Fbxs. FBXW11 belongs to the Fbws class and contains multiple WD40 repeats in addition to an F-box. The gene has at least 14 exons and alternative splicing generates three transcript variants that differ in the presence or absence of two alternate exons.","FBXW11 has been implicated in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, FBXW11 has been shown to regulate the degradation of several tumor suppressor proteins, including p53, PTEN, and SMAD4, and its downregulation has been associated with poor prognosis in several types of cancer. Therefore, FBXW11 is considered a potential therapeutic target for cancer treatment. Several drug discovery efforts have been made to target FBXW11, including the development of small molecule inhibitors and RNA interference-based approaches. However, no drugs targeting FBXW11 have been approved for clinical use yet. 

One example of a successful drug targeting the F-box protein family is thalidomide, which targets cereblon, an E3 ubiquitin ligase containing an F-box domain. Thalidomide is used to treat multiple myeloma and other hematological malignancies. Another example is lenalidomide, a derivative of thalidomide, which also targets cereblon and is used to treat multiple myeloma and myelodysplastic syndromes. These drugs have shown promising results in clinical trials and have been approved for clinical use. Therefore, targeting F-box proteins, including FBXW11, is a promising approach for drug discovery and development in various diseases.",GO:0042753 positive regulation of circadian rhythm;GO:0008090 retrograde axonal transport;GO:0007097 nuclear migration,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Plasma membrane;Vesicles (Approved); Additional: Nucleoplasm,,(M46)PID ATR PATHWAY; (M70)PID PS1 PATHWAY; (M129)PID PLK1 PATHWAY,(M5903)HALLMARK NOTCH SIGNALING
ENSG00000131724.11,ENSG00000131724,IL13RA1,-0.648015439,-1.090807074,-0.595042064,-0.258197178,interleukin 13 receptor subunit alpha 1,"IL13RA1 is a gene that encodes a subunit of the interleukin 13 receptor. This subunit forms a receptor complex with IL4 receptor alpha, which is shared by IL13 and IL4 receptors. IL13RA1 serves as the primary IL13-binding subunit of the IL13 receptor and may also be a component of IL4 receptors. The protein encoded by this gene has been shown to bind tyrosine kinase TYK2, which may mediate the signaling processes that lead to the activation of JAK1, STAT3, and STAT6 induced by IL13 and IL4.","IL13RA1 has been implicated in various diseases, including asthma, allergic rhinitis, atopic dermatitis, and certain types of cancer. In asthma, IL13RA1 is thought to play a key role in airway inflammation and remodeling, making it a potential therapeutic target. Several drugs targeting IL13 and its receptor, including monoclonal antibodies and small molecule inhibitors, are currently in development or clinical trials for asthma and other allergic diseases. One example is dupilumab, a monoclonal antibody that targets both IL4 and IL13 receptors, which has been approved for the treatment of moderate-to-severe asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyposis. Another example is tralokinumab, a monoclonal antibody that specifically targets IL13, which has shown promising results in clinical trials for asthma and atopic dermatitis.",GO:0002639 positive regulation of immunoglobulin production;GO:0002637 regulation of immunoglobulin production;GO:0002702 positive regulation of production of molecular mediator of immune response,,CD markers; Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,,,(M28)PID IL4 2PATHWAY,(M5897)HALLMARK IL6 JAK STAT3 SIGNALING; (M5937)HALLMARK GLYCOLYSIS
ENSG00000133731.10,ENSG00000133731,IMPA1,-0.647191892,-0.871737099,-0.879451774,-0.190386803,inositol monophosphatase 1,"The IMPA1 gene encodes an enzyme that plays a crucial role in intracellular signal transduction by dephosphorylating myo-inositol monophosphate to produce free myo-inositol, a precursor of phosphatidylinositol. This enzyme can also use various other substrates. The enzyme's phosphatase activity is magnesium-dependent and is inhibited by therapeutic concentrations of lithium. Inhibition of inositol monophosphate hydrolysis and subsequent depletion of inositol for phosphatidylinositol synthesis may explain the anti-manic and anti-depressive effects of lithium administered to treat bipolar disorder. Alternative splicing results in multiple transcript variants encoding distinct isoforms, and a pseudogene of this gene is also present on chromosome 8q21.13.","The IMPA1 gene has been implicated in several diseases, including bipolar disorder, schizophrenia, and Alzheimer's disease. Lithium, a drug commonly used to treat bipolar disorder, has been shown to inhibit the enzyme encoded by IMPA1, leading to decreased levels of inositol and subsequent changes in intracellular signaling pathways. This has led to efforts to develop more specific inhibitors of IMPA1 as potential treatments for bipolar disorder and other related conditions. One such drug, L-690,330, showed promise in preclinical studies but was ultimately not successful in clinical trials. Another drug, L-745,870, was developed as a potential treatment for schizophrenia but was also unsuccessful in clinical trials. Despite these setbacks, research into the role of IMPA1 in disease continues, and new drug discovery efforts may lead to more successful treatments in the future.",GO:0006021 inositol biosynthetic process;GO:0006020 inositol metabolic process;GO:0046173 polyol biosynthetic process,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Actin filaments (Uncertain); Additional: Vesicles,Lithium cation; L-Myo-Inositol-1-Phosphate; Lithium citrate; Lithium succinate; Lithium carbonate,,
ENSG00000029725.17,ENSG00000029725,RABEP1,-0.646915671,-0.864102559,-1.067314801,-0.009329652,"rabaptin, RAB GTPase binding effector protein 1","RABEP1, also known as rabaptin, RAB GTPase binding effector protein 1, is a human gene that plays a role in vesicle-mediated transport. It enables protein domain specific binding activity and protein homodimerization activity, and is located in endocytic vesicles and endosomes. RABEP1 is part of a protein-containing complex and is involved in the regulation of intracellular trafficking. This gene is important for the proper functioning of cells and disruptions in its activity can lead to various diseases.","There is limited information available on the disease implications of RABEP1. However, studies have shown that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for RABEP1 are also limited, but some studies have suggested that targeting RABEP1 may be a potential therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target RABEP1. However, there are drugs that target other proteins involved in vesicle-mediated transport, such as the anti-cancer drug vincristine, which targets microtubules and disrupts vesicle transport. Additionally, drugs that target RAB GTPases, such as the anti-inflammatory drug sulfasalazine, may indirectly affect RABEP1 activity.",GO:1903441 protein localization to ciliary membrane;GO:0099149 regulation of postsynaptic neurotransmitter receptor internalization;GO:0006893 Golgi to plasma membrane transport,,Cancer-related genes; Predicted intracellular proteins,Cytosol;Vesicles (Supported),,,(M5907)HALLMARK ESTROGEN RESPONSE LATE
ENSG00000086827.9,ENSG00000086827,ZW10,-0.646355243,-0.964466083,-0.695999442,-0.278600204,zw10 kinetochore protein,"The human gene ZW10 encodes a protein that plays a crucial role in ensuring proper chromosome segregation during cell division. This protein is a vital component of the mitotic checkpoint, which prevents cells from exiting mitosis prematurely. The ZW10 kinetochore protein is one of many proteins involved in this process.","Mutations in the ZW10 gene have been linked to several diseases, including cancer and developmental disorders. In cancer, ZW10 has been found to be overexpressed in several types of tumors, including breast, lung, and ovarian cancers. Targeting ZW10 has been explored as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of ZW10 have been developed and tested in preclinical studies, showing promising results in inhibiting tumor growth. However, no ZW10-targeted drugs have been approved for clinical use yet. In developmental disorders, ZW10 mutations have been associated with microcephaly, a condition characterized by a smaller than normal head size and intellectual disability. While there are currently no drugs targeting ZW10 for the treatment of developmental disorders, further research in this area may lead to new therapeutic options in the future.",GO:0034501 protein localization to kinetochore;GO:1903083 protein localization to condensed chromosome;GO:0007096 regulation of exit from mitosis,,Predicted intracellular proteins,Cytosol;Endoplasmic reticulum (Supported),,,(M5910)HALLMARK PROTEIN SECRETION; (M5925)HALLMARK E2F TARGETS
ENSG00000166224.17,ENSG00000166224,SGPL1,-0.644755158,-1.01817574,-0.75051645,-0.165573282,sphingosine-1-phosphate lyase 1,"SGPL1 is a human gene that encodes for sphingosine-1-phosphate lyase 1, an enzyme that plays a role in the metabolism of sphingolipids. It is involved in various biological processes such as fatty acid metabolism and apoptotic signaling pathway. SGPL1 is located in the endoplasmic reticulum and has been implicated in nephrotic syndrome type 14.","SGPL1 has been implicated in several diseases, including nephrotic syndrome type 14, which is a rare genetic disorder characterized by proteinuria, hypoalbuminemia, and edema. Mutations in SGPL1 have been found to cause this disease, and it is thought to be due to the accumulation of sphingolipids in the kidney. Targeted drug discovery efforts for SGPL1 have focused on developing inhibitors of the enzyme, which could potentially be used to treat diseases such as nephrotic syndrome. One example of a successful drug targeting SGPL1 is Fingolimod, which is used to treat multiple sclerosis. Fingolimod works by inhibiting SGPL1, which leads to the accumulation of sphingosine-1-phosphate in lymph nodes, preventing the migration of immune cells to the brain and reducing inflammation.",GO:0001553 luteinization;GO:0033327 Leydig cell differentiation;GO:0010761 fibroblast migration,,ENZYME proteins:Lyases; Predicted intracellular proteins; Human disease related genes:Urinary system diseases:Kidney diseases; Potential drug targets; Disease related genes; Enzymes,Endoplasmic reticulum (Supported),Pyridoxal phosphate,(M155)PID S1P META PATHWAY,
ENSG00000162222.14,ENSG00000162222,TTC9C,-0.644048628,-0.969874295,-0.436819591,-0.525451998,tetratricopeptide repeat domain 9C,"The human gene TTC9C, also known as tetratricopeptide repeat domain 9C, is located on chromosome 1 and encodes a protein that contains multiple tetratricopeptide repeat (TPR) domains. TPR domains are involved in protein-protein interactions and are found in a variety of proteins involved in cellular processes such as protein folding, trafficking, and signaling. The function of TTC9C is not well understood, but it has been suggested to play a role in the regulation of gene expression and cell cycle progression. Mutations in TTC9C have been associated with various diseases, including cancer and intellectual disability.","There is limited information available on the disease implications of TTC9C mutations, but some studies have suggested a potential role in cancer development and progression. For example, a study found that TTC9C expression was significantly decreased in breast cancer tissues compared to normal tissues, and low expression was associated with poor prognosis. Additionally, another study found that TTC9C was frequently mutated in colorectal cancer patients with microsatellite instability. 

There are currently no targeted drug discovery efforts specifically focused on TTC9C, as its function and role in disease are not well understood. However, there are several drugs on the market that target proteins with TPR domains, which may have potential implications for TTC9C-related diseases. For example, the drug geldanamycin targets the TPR domain of heat shock protein 90 (HSP90), which is involved in protein folding and has been implicated in cancer. Another drug, celastrol, targets the TPR domain of Cdc37, a protein involved in cell cycle regulation and also implicated in cancer. 

Overall, more research is needed to fully understand the role of TTC9C in disease and to develop targeted therapies for related conditions.",,,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000135241.17,ENSG00000135241,PNPLA8,-0.643716219,-0.902189672,-0.71970629,-0.309252694,patatin like phospholipase domain containing 8,"The PNPLA8 gene belongs to the patatin-like phospholipase domain containing protein family, which encodes for phospholipases that break down fatty acids from membrane phospholipids. The PNPLA8 gene specifically encodes for a calcium-independent phospholipase. Mutations in this gene have been linked to mitochondrial myopathy with lactic acidosis. Multiple transcript variants that produce different isoforms have been identified for this gene.","Mutations in the PNPLA8 gene have been associated with mitochondrial myopathy with lactic acidosis, a rare genetic disorder characterized by muscle weakness, exercise intolerance, and elevated levels of lactic acid in the blood. There are currently no targeted drug discovery efforts specifically for PNPLA8, but some drugs used to treat mitochondrial disorders may be beneficial for patients with mutations in this gene. For example, coenzyme Q10 (CoQ10) has been shown to improve muscle function and reduce lactic acid levels in some patients with mitochondrial myopathy. Other drugs that may be beneficial include riboflavin, creatine, and carnitine. However, the effectiveness of these treatments can vary depending on the specific mutation and severity of the disease. More research is needed to develop targeted therapies for PNPLA8-related disorders.",GO:0046338 phosphatidylethanolamine catabolic process;GO:0034638 phosphatidylcholine catabolic process;GO:0032048 cardiolipin metabolic process,,Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Cytosol;Nucleoplasm (Approved); Additional: Golgi apparatus,,,(M5948)HALLMARK BILE ACID METABOLISM
ENSG00000090674.16,ENSG00000090674,MCOLN1,-0.643503352,-0.988044409,-0.696751946,-0.2457137,mucolipin TRP cation channel 1,"The MCOLN1 gene is a member of the transient receptor potential (TRP) cation channel gene family. It encodes a transmembrane protein that is located in intracellular vesicular membranes, including lysosomes. The protein functions in the late endocytic pathway and regulates lysosomal exocytosis. The channel is permeable to Ca(2+), Fe(2+), Na(+), K(+), and H(+), and its activity is modulated by changes in Ca(2+) concentration. Mutations in this gene cause mucolipidosis type IV, a rare genetic disorder that affects the lysosomal storage system and leads to developmental delays, vision loss, and other neurological symptoms.","Mucolipidosis type IV (MLIV) is a rare autosomal recessive lysosomal storage disorder caused by mutations in the MCOLN1 gene. MLIV is characterized by developmental delays, vision loss, and other neurological symptoms. There is currently no cure for MLIV, and treatment is mainly supportive. However, there have been efforts to develop targeted therapies for MLIV. One approach is to use small molecules to modulate the activity of the MCOLN1 channel. Several compounds have been identified that can enhance or inhibit MCOLN1 activity, and some of these compounds have shown promise in preclinical studies. For example, a compound called ML-SA1 has been shown to improve lysosomal function and reduce lysosomal storage in MLIV patient cells. Another compound, ML2SA, has been shown to improve motor function and reduce lysosomal storage in a mouse model of MLIV. However, there are currently no drugs on the market specifically approved for the treatment of MLIV.",GO:1901660 calcium ion export;GO:1905673 positive regulation of lysosome organization;GO:0033572 transferrin transport,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Voltage-gated ion channels:Transient Receptor Potential Channels; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Lysosomal storage diseases; Disease related genes; Transporters:Transporter channels and pores,Golgi apparatus;Vesicles (Supported); Additional: Nucleoplasm,,,
ENSG00000159579.14,ENSG00000159579,RSPRY1,-0.643445706,-1.081916562,-0.610895476,-0.23752508,ring finger and SPRY domain containing 1,"The human gene RSPRY1 encodes a glycoprotein that contains a RING-type zinc finger domain and an SPRY domain of unknown function. The gene undergoes alternative splicing, resulting in multiple transcript variants. The exact function of the protein encoded by RSPRY1 is not yet known.","There is limited information available on the disease implications of RSPRY1. However, some studies have suggested that the gene may be involved in the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for RSPRY1 are also limited, as the exact function of the protein encoded by the gene is not yet known. However, some studies have suggested that the protein may play a role in regulating the activity of other proteins involved in cancer development, making it a potential target for cancer therapies. Currently, there are no drugs on the market that specifically target RSPRY1. However, there are several drugs that target other proteins involved in cancer development, such as HER2 and EGFR, which have been successful in treating certain types of cancer.",GO:0051603 proteolysis involved in protein catabolic process;GO:0030163 protein catabolic process;GO:0009057 macromolecule catabolic process,,Disease related genes; Predicted secreted proteins; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Predicted intracellular proteins,,,,
ENSG00000095787.23,ENSG00000095787,WAC,-0.642729637,-0.752774926,-0.801133663,-0.374280323,WW domain containing adaptor with coiled-coil,"The human gene WAC encodes a protein that contains a WW domain, which is involved in protein-protein interactions and binds to short linear peptide motifs that are proline-rich or contain at least one proline. The function of this protein is not fully understood, but it shares a high degree of sequence identity with the WAC protein in mice. Alternative splicing of the gene results in multiple transcript variants.","There is limited information on the disease implications of the WAC gene. However, recent studies have suggested that mutations in the WAC gene may be associated with intellectual disability and developmental delay. Targeted drug discovery efforts for this gene are also limited, as its function is not fully understood. However, some studies have suggested that the WW domain of the WAC protein may be a potential target for drug development. Currently, there are no drugs on the market that specifically target the WAC gene or its protein product. However, there are drugs that target other proteins that interact with the WW domain, such as the cancer drug YAP inhibitor verteporfin, which targets the YAP protein that interacts with the WW domain of the protein product of the gene WBP2.",GO:0031571 mitotic G1 DNA damage checkpoint signaling;GO:0044819 mitotic G1/S transition checkpoint signaling;GO:0032435 negative regulation of proteasomal ubiquitin-dependent protein catabolic process,,Disease related genes; Human disease related genes:Other congenital disorders:Chromosomal abnormalities; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000198843.13,ENSG00000198843,SELENOT,-0.642517096,-0.951512174,-0.774037234,-0.202001879,selenoprotein T,"SELENOT is a gene that encodes a selenoprotein containing a selenocysteine residue at the active site. Selenocysteine is encoded by the UGA codon, which normally signals translation termination. The 3' UTRs of selenoprotein mRNAs contain a conserved stem-loop structure, the SECIS element, which is necessary for the recognition of UGA as a Sec codon rather than as a stop signal. This protein is localized in the endoplasmic reticulum and belongs to the SelWTH family that possesses a thioredoxin-like fold and a conserved CxxU motif found in several redox active proteins. Studies in mice indicate a crucial role for this gene in the protection of dopaminergic neurons against oxidative stress in Parkinson's disease and in the control of glucose homeostasis in pancreatic beta-cells.","Research on SELENOT has shown its involvement in several diseases, including Parkinson's disease and diabetes. In Parkinson's disease, SELENOT has been found to play a crucial role in protecting dopaminergic neurons against oxidative stress, which is a major contributor to the development of the disease. In diabetes, SELENOT has been shown to be involved in the control of glucose homeostasis in pancreatic beta-cells. Targeted drug discovery efforts for SELENOT are still in the early stages, but there is potential for the development of drugs that target the protein's redox activity and its role in protecting against oxidative stress. Currently, there are no drugs on the market that specifically target SELENOT, but there are drugs that target oxidative stress and diabetes, such as antioxidants and insulin sensitizers.",GO:0001514 selenocysteine incorporation;GO:0006451 translational readthrough;GO:0060124 positive regulation of growth hormone secretion,,Disease related genes; Enzymes; ENZYME proteins:Oxidoreductases; Potential drug targets,,,,
ENSG00000150907.10,ENSG00000150907,FOXO1,-0.642197938,-1.007315645,-0.695782603,-0.223495567,forkhead box O1,"FOXO1 is a gene that belongs to the forkhead family of transcription factors. It contains a distinct forkhead domain and its specific function is not yet known. However, it may be involved in myogenic growth and differentiation. FOXO1 has been associated with alveolar rhabdomyosarcoma when it undergoes translocation with PAX3.","FOXO1 has been implicated in various diseases, including cancer, diabetes, and cardiovascular disease. In cancer, FOXO1 has been shown to act as a tumor suppressor in some contexts, while in others it can promote tumor growth and metastasis. In alveolar rhabdomyosarcoma, FOXO1 is involved in a translocation with PAX3, resulting in a fusion protein that drives tumor growth. Targeted drug discovery efforts for FOXO1 have focused on developing inhibitors that can block its activity in cancer cells. One example is the drug AS1842856, which has been shown to inhibit FOXO1 activity and induce apoptosis in cancer cells. Another example is the drug F14512, which has been shown to target the FOXO1-PAX3 fusion protein in alveolar rhabdomyosarcoma cells. While these drugs are still in preclinical development, they hold promise for the treatment of FOXO1-associated diseases.",GO:0071455 cellular response to hyperoxia;GO:0010616 negative regulation of cardiac muscle adaptation;GO:1903243 negative regulation of cardiac muscle hypertrophy in response to stress,,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Human disease related genes:Cancers:Cancers of soft tissues and bone; Predicted intracellular proteins; Transcription factors:Helix-turn-helix domains; Disease related genes; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported); Additional: Cytosol,,(M32)PID HDAC CLASSIII PATHWAY; (M249)PID PI3KCI AKT PATHWAY; (M183)PID IL6 7 PATHWAY,(M5957)HALLMARK PANCREAS BETA CELLS
ENSG00000100883.13,ENSG00000100883,SRP54,-0.641838127,-0.889318194,-0.892744779,-0.143451409,signal recognition particle 54,"SRP54 is a human gene that plays a crucial role in several functions, including binding to 7S RNA, endoplasmic reticulum signal peptide, and guanyl ribonucleotide. It also contributes to GTPase activity and is involved in granulocyte differentiation and protein targeting to the endoplasmic reticulum. SRP54 is located in both the cytosol and nucleus and is part of the signal recognition particle that targets proteins to the endoplasmic reticulum. Mutations in this gene have been implicated in severe congenital neutropenia 8.","Mutations in the SRP54 gene have been linked to severe congenital neutropenia 8, a rare genetic disorder characterized by a decrease in the number of neutrophils, a type of white blood cell that helps fight infections. There are currently no targeted drug discovery efforts specifically for SRP54, but there are several drugs on the market that can help manage neutropenia, such as granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). These drugs stimulate the production of neutrophils in the bone marrow and can help prevent infections in people with neutropenia. Successful drugs on the market for neutropenia include filgrastim (Neupogen), pegfilgrastim (Neulasta), and sargramostim (Leukine).","GO:0006616 SRP-dependent cotranslational protein targeting to membrane, translocation;GO:0031017 exocrine pancreas development;GO:0006617 SRP-dependent cotranslational protein targeting to membrane, signal sequence recognition",,Predicted intracellular proteins; Transporters:Primary Active Transporters; Potential drug targets; Disease related genes; Human disease related genes:Immune system diseases:Primary immunodeficiency,Cytosol (Approved),,,
ENSG00000118454.13,ENSG00000118454,ANKRD13C,-0.641770363,-0.786120599,-0.873841411,-0.26534908,ankyrin repeat domain 13C,"The ANKRD13C gene encodes a protein that plays a role in various cellular processes, including protein retention in the endoplasmic reticulum, regulation of cell death, and regulation of signaling receptor activity. The protein is located in the perinuclear region of the cytoplasm and colocalizes with the endoplasmic reticulum. It also has the ability to bind to signaling receptors.","There is limited information available on the disease implications of ANKRD13C. However, some studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for ANKRD13C are also limited, as the function of the protein is not well understood. Currently, there are no drugs on the market that specifically target ANKRD13C. However, there are drugs that target related proteins involved in similar cellular processes, such as endoplasmic reticulum stress and cell death. For example, bortezomib is a proteasome inhibitor that is used to treat multiple myeloma and mantle cell lymphoma by inducing endoplasmic reticulum stress and apoptosis. Another example is erlotinib, a tyrosine kinase inhibitor that targets the epidermal growth factor receptor and is used to treat non-small cell lung cancer.",GO:0006621 protein retention in ER lumen;GO:0035437 maintenance of protein localization in endoplasmic reticulum;GO:2000209 regulation of anoikis,,Predicted intracellular proteins,,,,
ENSG00000136935.14,ENSG00000136935,GOLGA1,-0.641755745,-0.958656412,-0.779240469,-0.187370353,golgin A1,"GOLGA1, also known as golgin A1, is a gene that encodes for a protein localized to the Golgi apparatus. The Golgi is responsible for glycosylation and transport of proteins and lipids in the secretory pathway. Golgin A1 is a member of the golgin family of proteins and is thought to play a role in the reorganization of the Golgi after it fragments during mitosis. Additionally, this gene has been associated with Sjogren's syndrome, an autoimmune disorder that affects the salivary and lacrimal glands.","There is limited information available on targeted drug discovery efforts for GOLGA1, and no drugs have been specifically developed to target this gene. However, as GOLGA1 has been associated with Sjogren's syndrome, there are several drugs on the market that are used to treat this autoimmune disorder. These include nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen, which can help relieve pain and inflammation, and immunosuppressants such as methotrexate and azathioprine, which can help reduce the immune system's attack on the body's own tissues. Additionally, biologic drugs such as rituximab, which targets B cells, have shown promise in treating Sjogren's syndrome. However, more research is needed to fully understand the role of GOLGA1 in this disorder and to develop targeted therapies.",,,Predicted intracellular proteins,Golgi apparatus (Enhanced),,,
ENSG00000114867.22,ENSG00000114867,EIF4G1,-0.641698338,-0.761717124,-0.750261028,-0.413116862,eukaryotic translation initiation factor 4 gamma 1,"EIF4G1 is a gene that encodes a protein that is part of the EIF4F complex, which plays a crucial role in the initiation phase of protein synthesis. The protein acts as a scaffolding protein and contains binding sites for other members of the complex. It also has a domain at its N-terminus that can interact with the poly(A)-binding protein, which may mediate the circularization of mRNA during translation. Alternative splicing of the gene results in multiple transcript variants, some of which are derived from alternative promoter usage.","EIF4G1 has been implicated in several diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, EIF4G1 has been shown to be overexpressed in several types of tumors, including breast, lung, and prostate cancer, and is associated with poor prognosis. Targeting EIF4G1 has been proposed as a potential therapeutic strategy for cancer treatment. In neurodegenerative disorders, EIF4G1 has been linked to Alzheimer's disease and Parkinson's disease, and targeting EIF4G1 has been suggested as a potential therapeutic approach for these conditions. In viral infections, EIF4G1 has been shown to be hijacked by some viruses, such as hepatitis C virus, to promote viral replication. Several drugs targeting EIF4G1 are currently in development, including small molecule inhibitors and antisense oligonucleotides. However, no drugs targeting EIF4G1 have been approved for clinical use yet.",GO:1905535 regulation of eukaryotic translation initiation factor 4F complex assembly;GO:1905537 positive regulation of eukaryotic translation initiation factor 4F complex assembly;GO:1905610 regulation of mRNA cap binding,,Disease related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cytosol (Enhanced),,(M66)PID MYC ACTIV PATHWAY,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000083896.13,ENSG00000083896,YTHDC1,-0.641246959,-0.80338078,-0.690920508,-0.429439589,YTH N6-methyladenosine RNA binding protein C1,"YTHDC1 is a human gene that encodes a protein containing a YTH domain, which enables it to bind to RNA molecules containing N6-methyladenosine. This protein is involved in several cellular processes, including mRNA export from the nucleus, mRNA splice site selection, and regulation of gene expression. YTHDC1 is located in both the nuclear speck and plasma membrane of cells. Its functions are important for proper gene expression and cellular function.","Research on YTHDC1 is still in its early stages, and there is limited information on its disease implications. However, recent studies have suggested that mutations in YTHDC1 may be associated with various types of cancer, including breast cancer, lung cancer, and liver cancer. Additionally, dysregulation of YTHDC1 expression has been linked to neurological disorders such as autism spectrum disorder and schizophrenia.

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target YTHDC1. However, there is ongoing research to develop small molecule inhibitors that can selectively bind to the YTH domain of YTHDC1 and modulate its activity. These inhibitors could potentially be used to treat cancer and other diseases associated with YTHDC1 dysregulation.

In conclusion, YTHDC1 is a promising target for drug discovery efforts, particularly in the field of cancer research. While there are currently no drugs on the market that target this gene, ongoing research may lead to the development of novel therapeutics in the future.",GO:0048160 primary follicle stage;GO:0110104 mRNA alternative polyadenylation;GO:0022605 mammalian oogenesis stage,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Plasma membrane,,,(M5942)HALLMARK UV RESPONSE DN; (M5901)HALLMARK G2M CHECKPOINT
ENSG00000117625.14,ENSG00000117625,RCOR3,-0.640997762,-0.949394495,-0.699943308,-0.273655482,REST corepressor 3,"RCOR3, also known as REST corepressor 3, is a human gene that is predicted to have enzyme binding activity and transcription corepressor activity. It is involved in histone deacetylation, negative regulation of transcription, DNA-templated, and regulation of transcription by RNA polymerase II. RCOR3 is located in both the cytosol and nucleoplasm.","There is limited information available on the disease implications of RCOR3. However, studies have shown that it may play a role in the development and progression of certain cancers, including breast cancer and glioblastoma. Targeted drug discovery efforts for RCOR3 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and inhibit its activity. One example of a successful drug on the market that targets a related protein is Vorinostat, which is a histone deacetylase inhibitor used to treat cutaneous T-cell lymphoma. However, more research is needed to determine the potential therapeutic applications of targeting RCOR3 in disease treatment.",GO:0045892 negative regulation of DNA-templated transcription;GO:1902679 negative regulation of RNA biosynthetic process;GO:0051253 negative regulation of RNA metabolic process,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Cytosol,,,
ENSG00000010244.19,ENSG00000010244,ZNF207,-0.639785273,-0.898601512,-0.576852516,-0.443901791,zinc finger protein 207,"ZNF207 is a human gene that encodes for a protein called zinc finger protein 207. This protein is involved in various cellular processes, including mitotic nuclear division, mitotic spindle assembly checkpoint signaling, and protein stabilization. It has the ability to bind to microtubules and is located in the kinetochore, nuclear lumen, and spindle matrix. The function of ZNF207 is important for proper cell division and maintenance of genomic stability.","There is limited information available on the disease implications of ZNF207. However, some studies have suggested that alterations in the expression of this gene may be associated with certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for ZNF207 are also limited, as the function of this protein is not well understood. Currently, there are no drugs on the market that specifically target ZNF207. However, there are drugs that target other proteins involved in similar cellular processes, such as mitotic spindle assembly and checkpoint signaling. Examples of these drugs include paclitaxel, which stabilizes microtubules and is used to treat various types of cancer, and checkpoint kinase inhibitors, which disrupt the mitotic checkpoint and are being investigated as potential cancer therapies.",GO:0007094 mitotic spindle assembly checkpoint signaling;GO:0071173 spindle assembly checkpoint signaling;GO:0071174 mitotic spindle checkpoint signaling,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000171824.14,ENSG00000171824,EXOSC10,-0.638648903,-1.072329759,-0.69016789,-0.153449061,exosome component 10,"EXOSC10 is a human gene that encodes a protein that enables 3'-5'-exoribonuclease activity. It is involved in several processes, including RNA catabolic process, maturation of 5.8S rRNA, and negative regulation of telomere maintenance via telomerase. The protein is located in the cytosol, nuclear lumen, and transcriptionally active chromatin. It is part of the nuclear exosome, which is an RNase complex.","There is limited information available on the disease implications of EXOSC10. However, mutations in this gene have been associated with pontocerebellar hypoplasia type 1B (PCH1B), a rare genetic disorder characterized by underdevelopment of the cerebellum and brainstem. Targeted drug discovery efforts for EXOSC10 are also limited, as the function of the protein is not well understood. However, there have been some studies exploring the potential of targeting the nuclear exosome complex, of which EXOSC10 is a part, for cancer therapy. One example is the development of a small molecule inhibitor of the exosome complex, which has shown promising results in preclinical studies for the treatment of multiple myeloma. Currently, there are no drugs on the market specifically targeting EXOSC10.",GO:0042868 antisense RNA metabolic process;GO:0071040 nuclear polyadenylation-dependent antisense transcript catabolic process;GO:0071041 antisense RNA transcript catabolic process,,Predicted intracellular proteins,Nucleoli;Nucleoli rim (Supported); Additional: Cytosol;Nucleoplasm,,,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000129472.15,ENSG00000129472,RAB2B,-0.638116704,-1.126367661,-0.572347945,-0.215634507,"RAB2B, member RAS oncogene family","RAB2B is a gene that belongs to the RAS oncogene family and encodes a protein that is a member of the Rab protein family. Rab proteins are involved in the process of vesicular fusion and trafficking, and they are prenylated, membrane-bound proteins. RAB2B contains four highly conserved regions that are involved in GTP binding and hydrolysis. While RAB2B has not been directly linked to cancer, its involvement in vesicular trafficking suggests that it may play a role in cellular processes that are disrupted in cancer cells.","There is limited information available on the disease implications of RAB2B. However, its involvement in vesicular trafficking suggests that it may play a role in diseases that involve disruptions in this process, such as neurodegenerative disorders and lysosomal storage diseases. There are currently no targeted drug discovery efforts specifically focused on RAB2B.

There are no drugs on the market that specifically target RAB2B. However, there are drugs that target other members of the Rab protein family, such as Rab27a and Rab27b, which are involved in vesicular trafficking and secretion. For example, the drug Exo-T is a small molecule inhibitor of Rab27a that has been shown to inhibit exosome secretion and reduce tumor growth in preclinical models of cancer. Another example is the drug Mycophenolic acid, which inhibits Rab27b and has been used to treat autoimmune diseases and prevent organ transplant rejection.",GO:0032481 positive regulation of type I interferon production;GO:0045921 positive regulation of exocytosis;GO:0032479 regulation of type I interferon production,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,,,,
ENSG00000114742.14,ENSG00000114742,WDR48,-0.637841237,-1.276183124,-0.554857932,-0.082482653,WD repeat domain 48,"WDR48 is a human gene that encodes a protein that interacts with USP1, a protein that removes ubiquitin from other proteins. WDR48 activates the deubiquitinating activity of USP1, allowing it to remove the ubiquitin moiety from monoubiquitinated FANCD2, a protein that is ubiquitinated in response to DNA damage.","Research on WDR48 is still in its early stages, and there is limited information available on its disease implications and targeted drug discovery efforts. However, some studies have suggested that WDR48 may play a role in cancer development and progression. For example, one study found that WDR48 is overexpressed in breast cancer cells and that its knockdown inhibits cell proliferation and migration. Another study found that WDR48 is required for the survival of acute myeloid leukemia cells. These findings suggest that WDR48 may be a potential target for cancer therapy. Currently, there are no drugs on the market that specifically target WDR48. However, there are several drugs that target the ubiquitin-proteasome system, which is involved in the regulation of protein degradation and is closely related to the function of WDR48. Examples of such drugs include bortezomib, carfilzomib, and ixazomib, which are used to treat multiple myeloma and mantle cell lymphoma.",GO:1902525 regulation of protein monoubiquitination;GO:0072520 seminiferous tubule development;GO:0046427 positive regulation of receptor signaling pathway via JAK-STAT,,Predicted intracellular proteins,Vesicles (Supported),,(M1)PID FANCONI PATHWAY,
ENSG00000125779.22,ENSG00000125779,PANK2,-0.637305883,-0.998167567,-0.406375363,-0.50737472,pantothenate kinase 2,"PANK2 is a gene that encodes a protein belonging to the pantothenate kinase family and is the only member of that family to be expressed in mitochondria. This gene is responsible for regulating the biosynthesis of coenzyme A (CoA) in bacteria and mammalian cells. Mutations in this gene are associated with HARP syndrome and pantothenate kinase-associated neurodegeneration (PKAN), formerly Hallervorden-Spatz syndrome. Alternative splicing results in multiple transcripts encoding different isoforms.","Mutations in the PANK2 gene have been linked to two rare genetic disorders: HARP syndrome and pantothenate kinase-associated neurodegeneration (PKAN). PKAN is a progressive neurodegenerative disorder that affects the basal ganglia and results in movement disorders, cognitive decline, and vision loss. There is currently no cure for PKAN, and treatment is mainly supportive. However, there have been efforts to develop targeted therapies for PKAN, including gene therapy and small molecule drugs that target the CoA biosynthesis pathway. One such drug is pantethine, a derivative of vitamin B5, which has been shown to improve symptoms in some PKAN patients. Another drug, fosmetpantotenate, is currently in clinical trials and has shown promising results in preclinical studies. Overall, the development of targeted therapies for PKAN is an active area of research, and there is hope that new treatments will be developed in the future.",GO:0015939 pantothenate metabolic process;GO:0015937 coenzyme A biosynthetic process;GO:1904251 regulation of bile acid metabolic process,yes,Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Cytosol (Supported),,,
ENSG00000139990.18,ENSG00000139990,DCAF5,-0.636871174,-1.005332064,-0.510081554,-0.395199903,DDB1 and CUL4 associated factor 5,"DCAF5, also known as DDB1 and CUL4 associated factor 5, is a human gene that is predicted to be involved in protein ubiquitination. It is part of the Cul4-RING E3 ubiquitin ligase complex, which is responsible for tagging proteins with ubiquitin molecules to target them for degradation. The gene summary provided by the Alliance of Genome Resources in April 2022 highlights the gene's role in this process. Understanding the function of DCAF5 and other genes involved in protein ubiquitination is important for understanding cellular processes and developing treatments for diseases that involve protein dysfunction.","There is limited information available on the disease implications of DCAF5. However, research has suggested that dysregulation of the Cul4-RING E3 ubiquitin ligase complex, of which DCAF5 is a part, may be involved in the development of certain cancers. Targeted drug discovery efforts for DCAF5 are also limited, but there is ongoing research into developing inhibitors of the Cul4-RING E3 ubiquitin ligase complex as a potential cancer therapy. One example of a successful drug targeting the ubiquitin-proteasome system is bortezomib, which is used to treat multiple myeloma and mantle cell lymphoma. Bortezomib inhibits the proteasome, preventing the degradation of proteins and leading to cell death. However, it is important to note that bortezomib targets a different component of the ubiquitin-proteasome system than DCAF5.",GO:0045717 negative regulation of fatty acid biosynthetic process;GO:0045922 negative regulation of fatty acid metabolic process;GO:0042304 regulation of fatty acid biosynthetic process,,Predicted intracellular proteins,Mitochondria (Approved),,,
ENSG00000126391.14,ENSG00000126391,FRMD8,-0.636728495,-0.791669546,-0.782216284,-0.336299656,FERM domain containing 8,"FRMD8, or FERM domain containing 8, is a human gene that plays a role in the positive regulation of tumor necrosis factor production. It is found in various cellular components, including the centriolar satellite, cytosol, and nucleoplasm. This gene's function is still being studied, and its exact role in various cellular processes is not yet fully understood. However, it is believed to be involved in several important biological pathways, including cell signaling and regulation of the immune system. Further research is needed to fully understand the function of FRMD8 and its potential implications for human health and disease.","There is currently limited information available on the disease implications of FRMD8. However, some studies have suggested that this gene may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for FRMD8 are still in the early stages, and there are currently no drugs on the market that specifically target this gene. However, there are several drugs that have been developed to target other genes and pathways that are involved in similar biological processes, such as cell signaling and immune regulation. Examples of successful drugs in these areas include Herceptin, which targets the HER2 gene in breast cancer, and Keytruda, which targets the PD-1 pathway in various types of cancer. Further research is needed to determine the potential for targeted drug development for FRMD8 and its implications for disease treatment.",GO:0032760 positive regulation of tumor necrosis factor production;GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production;GO:0090090 negative regulation of canonical Wnt signaling pathway,,Predicted intracellular proteins,Centriolar satellite;Plasma membrane (Approved); Additional: Cytosol;Nucleoplasm,,,
ENSG00000105887.11,ENSG00000105887,MTPN,-0.636681389,-0.786893806,-0.935416196,-0.187734166,myotrophin,MTPN is a bi-cistronic gene that encodes both myotrophin and leucine zipper protein 6. Myotrophin is associated with cardiac hypertrophy and may play a role in cerebellar morphogenesis and differentiation of cerebellar neurons. It is involved in the conversion of NFkappa B p50-p65 heterodimers to p50-p50 and p65-p65 homodimers. Leucine zipper protein 6 is produced from a cryptic ORF at the 3' end of the transcript and is a tumor antigen associated with myeloproliferative disease. The gene has a novel internal ribosome entry site and a non-AUG translation initiation codon.,"There is limited information available on the disease implications of MTPN, but it has been associated with cardiac hypertrophy and myeloproliferative disease. Targeted drug discovery efforts for MTPN are also limited, as the gene is not well-studied and its functions are not fully understood. However, there have been some studies on the potential therapeutic applications of myotrophin, including its role in promoting cardiac hypertrophy and its potential as a target for heart failure treatment. There are currently no drugs on the market specifically targeting MTPN, but there are drugs targeting related pathways, such as NFkappa B inhibitors and drugs targeting cardiac hypertrophy, that may have potential therapeutic applications for MTPN-associated diseases. Examples of such drugs include carvedilol, a beta-blocker used to treat heart failure, and losartan, an angiotensin receptor blocker used to treat hypertension and heart failure.",GO:2000812 regulation of barbed-end actin filament capping;GO:0021684 cerebellar granular layer formation;GO:0021707 cerebellar granule cell differentiation,,Predicted intracellular proteins,Cytosol;Plasma membrane (Approved),,,
ENSG00000095319.14,ENSG00000095319,NUP188,-0.636531827,-1.013772407,-0.738228375,-0.157594698,nucleoporin 188,"NUP188 is a gene that encodes for a nucleoporin, a protein that forms part of the nuclear pore complex (NPC) found on the nuclear envelope. The NPC regulates the flow of proteins and RNAs between the cytoplasm and nucleoplasm. Nucleoporins are pore-complex-specific glycoproteins that often contain cytoplasmically oriented O-linked N-acetylglucosamine residues and numerous repeats of the pentapeptide sequence XFXFG. However, NUP188 does not contain the typical FG repeat sequences found in most vertebrate nucleoporins. Instead, it is thought to form part of the scaffold for the central channel of the nuclear pore.","There is limited information available on the disease implications of NUP188 mutations. However, mutations in other nucleoporin genes have been associated with a range of diseases, including cancer, neurodegenerative disorders, and developmental disorders. Targeted drug discovery efforts for nucleoporin-related diseases are still in the early stages, but there is growing interest in developing drugs that target the NPC. One example is the small molecule inhibitor KPT-330, which targets the exportin protein XPO1 and has shown promise in preclinical studies for the treatment of cancer. Another example is the drug Arimoclomol, which is currently in clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) and targets the nucleoporin NUP153. However, more research is needed to fully understand the role of NUP188 in disease and to develop targeted therapies.",GO:0006405 RNA export from nucleus;GO:0006606 protein import into nucleus;GO:0051170 import into nucleus,,Disease related genes; Transporters:Transporter channels and pores; Potential drug targets; Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol;Nucleoli,,,
ENSG00000184743.13,ENSG00000184743,ATL3,-0.63615836,-0.946218282,-0.577651505,-0.384605293,atlastin GTPase 3,"ATL3 is a human gene that encodes a dynamin-like, integral membrane GTPase. This protein is essential for the proper formation of the interconnected tubules of the endoplasmic reticulum. Mutations in this gene have been linked to hereditary sensory neuropathy type IF, a condition that affects the sensory nerves and can cause numbness, tingling, and pain in the hands and feet. Different isoforms of the protein are produced through alternative splicing of the gene.","Hereditary sensory neuropathy type IF (HSN-IF) is a rare autosomal recessive disorder caused by mutations in the ATL3 gene. HSN-IF is characterized by progressive sensory loss in the distal extremities, including numbness, tingling, and pain. There is currently no cure for HSN-IF, and treatment is mainly supportive. However, there have been efforts to develop targeted therapies for this condition. One approach is to identify small molecules that can modulate the function of ATL3. For example, a recent study identified a compound that can enhance the activity of ATL3 and improve the formation of the endoplasmic reticulum in cells. Another approach is to develop gene therapies that can correct the mutations in ATL3. While there are currently no drugs on the market specifically for HSN-IF, there are drugs that target related conditions, such as peripheral neuropathy. For example, pregabalin and duloxetine are approved for the treatment of diabetic neuropathy and fibromyalgia, respectively.",GO:1903373 positive regulation of endoplasmic reticulum tubular network organization;GO:1903371 regulation of endoplasmic reticulum tubular network organization;GO:0007029 endoplasmic reticulum organization,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Predicted intracellular proteins; Transporters; Potential drug targets; Disease related genes,Endoplasmic reticulum (Enhanced),,,
ENSG00000165119.21,ENSG00000165119,HNRNPK,-0.635956903,-0.942506645,-0.73033126,-0.235032803,heterogeneous nuclear ribonucleoprotein K,"HNRNPK is a gene that belongs to a family of RNA binding proteins called heterogeneous nuclear ribonucleoproteins (hnRNPs). These proteins are associated with pre-mRNAs in the nucleus and are involved in pre-mRNA processing, mRNA metabolism, and transport. HNRNPK is located in the nucleoplasm and has three repeats of KH domains that bind to RNAs. It has a distinct binding preference for poly(C) and is thought to have a role in cell cycle progression. The gene has several alternatively spliced transcript variants, but not all of them are fully characterized.","HNRNPK has been implicated in several diseases, including cancer, viral infections, and neurological disorders. In cancer, HNRNPK has been shown to promote tumor growth and metastasis by regulating alternative splicing of cancer-related genes. Targeting HNRNPK has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of HNRNPK have been developed, including Roquinimex and its analogs, which have shown promising results in preclinical studies. In viral infections, HNRNPK has been shown to play a role in the replication of several viruses, including hepatitis C virus and human immunodeficiency virus. Targeting HNRNPK could potentially lead to the development of new antiviral therapies. In neurological disorders, HNRNPK has been implicated in the pathogenesis of Alzheimer's disease and amyotrophic lateral sclerosis. However, there are currently no drugs targeting HNRNPK for the treatment of these disorders.",GO:1905599 positive regulation of low-density lipoprotein receptor activity;GO:0060816 random inactivation of X chromosome;GO:1902165 regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Nucleoplasm (Enhanced),Artenimol; Phenethyl Isothiocyanate,,
ENSG00000166946.14,ENSG00000166946,CCNDBP1,-0.634387725,-1.078617604,-0.683124842,-0.141420729,cyclin D1 binding protein 1,"CCNDBP1, also known as cyclin D1 binding protein 1, is a gene that encodes a protein that interacts with cyclin D and Grap2, a leukocyte-specific adaptor protein important for immune cell signaling. The protein encoded by CCNDBP1 has been shown to reduce the phosphorylation of Rb gene product by cyclin D-dependent protein kinase, inhibiting E2F1-mediated transcription activity. It is also thought to be a negative regulator of liver-specific gene expression, interacting with helix-loop-helix protein E12. CCNDBP1 has several alternatively spliced variants.","CCNDBP1 has been implicated in several diseases, including cancer and Alzheimer's disease. In cancer, CCNDBP1 has been shown to be overexpressed in several types of cancer, including breast, lung, and colon cancer. Targeting CCNDBP1 has been explored as a potential therapeutic strategy for cancer treatment. In Alzheimer's disease, CCNDBP1 has been found to be involved in the regulation of amyloid-beta production, a key pathological feature of the disease. Targeting CCNDBP1 may therefore have potential therapeutic benefits for Alzheimer's disease.

There are currently no drugs on the market that specifically target CCNDBP1. However, several drugs have been developed that indirectly affect CCNDBP1 activity. For example, the CDK4/6 inhibitor palbociclib has been shown to reduce CCNDBP1 expression in breast cancer cells. Additionally, the Alzheimer's disease drug memantine has been found to reduce CCNDBP1 expression and amyloid-beta production in mouse models of the disease. These findings suggest that targeting CCNDBP1 may have therapeutic benefits for cancer and Alzheimer's disease, and further research is needed to develop more specific drugs that target this protein.",,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Nuclear bodies,,,
ENSG00000156958.15,ENSG00000156958,GALK2,-0.634091731,-0.802059789,-1.038845323,-0.06137008,galactokinase 2,"The GALK2 gene encodes a protein that functions as a highly efficient N-acetylgalactosamine (GalNAc) kinase, but also has galactokinase activity when galactose is present at high concentrations. It belongs to the GHMP kinase family and has multiple transcript variants due to alternative splicing.","There is limited information available on the disease implications of the GALK2 gene. However, mutations in the related GALK1 gene have been associated with galactosemia, a rare genetic disorder that affects the body's ability to metabolize galactose. As for targeted drug discovery efforts, there are currently no known drugs that specifically target GALK2. However, there are drugs on the market that target other enzymes involved in galactose metabolism, such as galactose-1-phosphate uridylyltransferase (GALT) and UDP-galactose-4-epimerase (GALE), which are used to treat galactosemia. Examples of such drugs include Galafold (migalastat) and Duogalactose (lactulose). Further research is needed to determine if GALK2 could be a potential target for drug development in the future.",GO:0006012 galactose metabolic process;GO:0046835 carbohydrate phosphorylation;GO:0019318 hexose metabolic process,yes,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Nucleoplasm (Approved),,,(M5937)HALLMARK GLYCOLYSIS
ENSG00000198218.11,ENSG00000198218,QRICH1,-0.633395785,-1.063951784,-0.55974358,-0.27649199,glutamine rich 1,"QRICH1, also known as glutamine rich 1, is a gene that plays a role in various cellular processes, including the response to endoplasmic reticulum stress and the regulation of DNA transcription. It enables DNA binding activity and is located in the nucleoplasm. The gene is involved in the PERK-mediated unfolded protein response and the intrinsic apoptotic signaling pathway. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of QRICH1. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for QRICH1 are also limited, as the gene is not currently considered a major therapeutic target. However, some studies have suggested that targeting the PERK-mediated unfolded protein response pathway, in which QRICH1 plays a role, may have potential therapeutic benefits for certain types of cancer. Currently, there are no drugs on the market specifically targeting QRICH1. However, there are several drugs on the market that target the PERK-mediated unfolded protein response pathway, including tunicamycin and thapsigargin, which are used in research settings to induce endoplasmic reticulum stress.",GO:0036499 PERK-mediated unfolded protein response;GO:0006984 ER-nucleus signaling pathway;GO:0140467 integrated stress response signaling,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,,,,
ENSG00000116903.7,ENSG00000116903,EXOC8,-0.63279268,-0.887554906,-0.552230233,-0.4585929,exocyst complex component 8,"EXOC8 is a gene that encodes a protein that is a component of the exocyst complex. This complex is responsible for transporting vesicles from the Golgi apparatus to the plasma membrane. The protein encoded by EXOC8 is regulated by activated Ral subfamily of GTPases and plays a critical role in exocytosis by tethering vesicles to the plasma membrane. Mutations in this gene may be related to Joubert syndrome, a rare genetic disorder that affects the development of the brainstem and cerebellum.","Joubert syndrome is a rare genetic disorder that affects the development of the brainstem and cerebellum. Mutations in the EXOC8 gene have been identified as a cause of Joubert syndrome. The symptoms of Joubert syndrome can vary widely, but typically include developmental delays, abnormal breathing patterns, and problems with coordination and balance. There is currently no cure for Joubert syndrome, and treatment is focused on managing symptoms.

Targeted drug discovery efforts for Joubert syndrome are still in the early stages, but there is hope that new treatments may be developed in the future. One potential approach is to target the exocyst complex itself, which could help to correct the underlying cellular defects that lead to Joubert syndrome. Another approach is to target specific signaling pathways that are disrupted in Joubert syndrome, such as the Sonic Hedgehog pathway.

There are currently no drugs on the market specifically approved for the treatment of Joubert syndrome. However, there are a number of drugs that are used to manage the symptoms of the disorder. For example, antiepileptic drugs may be used to control seizures, while physical therapy and occupational therapy can help to improve coordination and balance. In addition, there are a number of clinical trials underway to test new treatments for Joubert syndrome, including gene therapy and stem cell therapy.",GO:0090522 vesicle tethering involved in exocytosis;GO:0099022 vesicle tethering;GO:0006904 vesicle docking involved in exocytosis,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Potential drug targets; Disease related genes; Transporters:Transporter channels and pores,Cytosol (Approved),,,
ENSG00000081177.18,ENSG00000081177,EXD2,-0.630976865,-1.088328883,-0.765103376,-0.039498335,exonuclease 3'-5' domain containing 2,"EXD2 is a human gene that encodes a protein with 3'-5' exonuclease activity, metal ion binding activity, and protein homodimerization activity. It is involved in nucleic acid metabolic processes and is located in the intermediate filament cytoskeleton, mitochondrial outer membrane, and site of DNA damage. This gene plays a role in DNA repair and maintenance of genome stability. Mutations in EXD2 have been associated with various diseases, including cancer and neurodegenerative disorders.","There is limited information available on targeted drug discovery efforts for EXD2. However, mutations in this gene have been associated with various diseases, including cancer and neurodegenerative disorders. In cancer, EXD2 has been shown to play a role in DNA repair and maintenance of genome stability, and its dysregulation has been linked to tumor progression and resistance to chemotherapy. In neurodegenerative disorders, EXD2 mutations have been associated with mitochondrial dysfunction and impaired DNA repair, leading to neuronal damage and cell death. Currently, there are no drugs specifically targeting EXD2, but there are drugs targeting DNA repair pathways that may indirectly affect EXD2 activity. For example, PARP inhibitors have been approved for the treatment of ovarian and breast cancers with BRCA mutations, which are also involved in DNA repair pathways.",GO:0000729 DNA double-strand break processing;GO:0031297 replication fork processing;GO:0045005 DNA-templated DNA replication maintenance of fidelity,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Mitochondria (Approved); Additional: Intermediate filaments,,,
ENSG00000213625.9,ENSG00000213625,LEPROT,-0.630006538,-1.04862393,-0.761543726,-0.079851958,leptin receptor overlapping transcript,"LEPROT is a human gene that is associated with the Golgi complex and endosomes. It plays a role in the cell surface expression of growth hormone receptor and leptin receptor, which alters receptor-mediated cell signaling. This gene has been studied for its potential involvement in obesity and metabolic disorders.","Research on LEPROT has suggested its potential involvement in obesity and metabolic disorders. Studies have shown that mutations in this gene can lead to impaired growth hormone signaling and insulin resistance, which are both associated with metabolic disorders such as type 2 diabetes and obesity. Targeted drug discovery efforts have focused on developing drugs that can modulate the activity of LEPROT and improve metabolic function. However, there are currently no drugs on the market that specifically target LEPROT. Some drugs that have been successful in treating metabolic disorders, such as metformin and insulin, indirectly affect LEPROT activity by improving insulin sensitivity and glucose metabolism. Further research is needed to fully understand the role of LEPROT in metabolic disorders and to develop targeted therapies for these conditions.",GO:0060400 negative regulation of growth hormone receptor signaling pathway;GO:0060398 regulation of growth hormone receptor signaling pathway;GO:2000009 negative regulation of protein localization to cell surface,,Predicted intracellular proteins,Centrosome (Approved),,,
ENSG00000122203.15,ENSG00000122203,KIAA1191,-0.629813563,-1.063512037,-0.475809811,-0.35011884,KIAA1191,KIAA1191 is a human gene that is predicted to have oxidoreductase activity and be active in the cytoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.,"There is limited information available on the disease implications of KIAA1191. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung adenocarcinoma. As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target KIAA1191. However, there are ongoing efforts to develop drugs that target other proteins and pathways that are involved in the same biological processes as KIAA1191. For example, drugs that target the PI3K/AKT/mTOR pathway, which is known to be involved in cell growth and survival, have shown promise in treating certain types of cancer. Additionally, drugs that target the BRCA1/2 genes, which are involved in DNA repair and are often mutated in breast and ovarian cancer, have also been successful in treating these types of cancer.",,,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000144736.14,ENSG00000144736,SHQ1,-0.629808686,-0.90914603,-0.675576567,-0.304703459,"SHQ1, H/ACA ribonucleoprotein assembly factor","SHQ1 is a human gene that plays a crucial role in the assembly of H/ACA-box ribonucleoproteins. These proteins are involved in various cellular processes, including the processing of ribosomal RNAs, modification of spliceosomal small nuclear RNAs, and stabilization of telomerase. SHQ1 acts as an assembly factor for these ribonucleoproteins, helping to ensure their proper formation and function. This gene is essential for normal cellular function and mutations in SHQ1 have been linked to various diseases, including cancer and developmental disorders.","Mutations in the SHQ1 gene have been linked to various diseases, including cancer and developmental disorders. In cancer, SHQ1 has been found to be overexpressed in several types of tumors, including breast, lung, and ovarian cancers. Targeting SHQ1 may therefore be a potential strategy for cancer therapy. However, there are currently no drugs specifically targeting SHQ1.

There have been some efforts to develop drugs targeting H/ACA-box ribonucleoproteins, which are dependent on SHQ1 for their assembly. For example, the drug RG7834 has been shown to inhibit the function of the telomerase ribonucleoprotein, which is stabilized by H/ACA-box ribonucleoproteins. RG7834 is currently in clinical trials for the treatment of solid tumors.

Another example is the drug E7107, which targets the spliceosome, a complex that includes H/ACA-box ribonucleoproteins. E7107 has shown promising results in preclinical studies and is currently in clinical trials for the treatment of solid tumors and hematological malignancies.

Overall, while there are currently no drugs specifically targeting SHQ1, targeting H/ACA-box ribonucleoproteins may be a promising strategy for cancer therapy.",GO:0000493 box H/ACA snoRNP assembly;GO:0090671 telomerase RNA localization to Cajal body;GO:0090672 telomerase RNA localization,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases,Nucleoplasm (Supported),,,
ENSG00000168066.20,ENSG00000168066,SF1,-0.629326545,-0.954252207,-0.44449186,-0.489235568,splicing factor 1,"The SF1 gene encodes a nuclear pre-mRNA splicing factor that plays a crucial role in the early stages of spliceosome assembly. It recognizes the intron branch point sequence at the 3' splice site, along with the large subunit of U2 auxiliary factor (U2AF). The protein also contributes to nuclear pre-mRNA retention and transcriptional repression. The SF1 protein contains several domains, including an N-terminal U2AF ligand motif, a central hnRNP K homology motif, a quaking 2 region, a zinc knuckles domain, and a C-terminal proline-rich domain. Alternative splicing of the SF1 gene results in multiple transcript variants.","Mutations in the SF1 gene have been associated with several diseases, including adrenal insufficiency, hypogonadotropic hypogonadism, and intellectual disability. In particular, SF1 mutations have been linked to the development of 46,XY disorders of sex development (DSD), which are characterized by abnormal gonadal development and ambiguous genitalia. Targeted drug discovery efforts for SF1-related diseases are still in the early stages, but some promising strategies have been proposed. For example, small molecules that target the SF1 protein and modulate its activity could be developed as potential therapies for adrenal insufficiency and hypogonadism. Currently, there are no drugs on the market that specifically target SF1, but some drugs used to treat related conditions, such as corticosteroids for adrenal insufficiency and hormone replacement therapy for hypogonadism, have been successful in managing symptoms.",GO:0000389 mRNA 3'-splice site recognition;GO:0033327 Leydig cell differentiation;GO:0030238 male sex determination,,Predicted intracellular proteins,Nucleoplasm (Supported),Artenimol,,
ENSG00000055147.19,ENSG00000055147,FAM114A2,-0.629312067,-0.761870819,-0.552618499,-0.573446884,family with sequence similarity 114 member A2,"As an AI language model, I do not have access to the Gene Summary you are referring to. However, I can provide a brief summary of the human gene FAM114A2 based on available information. FAM114A2 is a member of the FAM114 gene family, which is conserved across vertebrates. The function of FAM114A2 is not well understood, but it has been suggested to play a role in cell proliferation and differentiation. Mutations in FAM114A2 have been associated with various diseases, including cancer and intellectual disability. Further research is needed to fully understand the function and clinical significance of FAM114A2.","Unfortunately, there is limited information available on the disease implications and targeted drug discovery efforts for FAM114A2. As mentioned earlier, mutations in this gene have been associated with various diseases, including cancer and intellectual disability. However, there are currently no drugs on the market that specifically target FAM114A2. 

Research on FAM114A2 is still in its early stages, and more studies are needed to fully understand its role in disease and potential as a therapeutic target. However, there are ongoing efforts to identify novel drug targets for cancer and other diseases, and FAM114A2 may be a promising candidate for future research.",,,Predicted intracellular proteins,Vesicles (Approved),,,
ENSG00000143393.16,ENSG00000143393,PI4KB,-0.629124529,-0.764959314,-0.685174814,-0.437239458,phosphatidylinositol 4-kinase beta,"PI4KB, or phosphatidylinositol 4-kinase beta, is a human gene that encodes a protein involved in the biosynthesis of phosphatidylinositol phosphate and signaling pathways mediated by phosphatidylinositol. The protein has 1-phosphatidylinositol 4-kinase activity and can bind to 14-3-3 proteins. It is primarily located in the Golgi membrane.","There is limited information available on the disease implications of PI4KB. However, recent studies have suggested that PI4KB may play a role in the development and progression of certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for PI4KB are still in the early stages, but there is potential for the development of novel therapies that target this protein. One example of a successful drug that targets phosphatidylinositol signaling pathways is idelalisib, which is used to treat certain types of leukemia and lymphoma. Idelalisib inhibits the activity of PI3K, another protein involved in phosphatidylinositol signaling, and has shown promising results in clinical trials. Other drugs that target phosphatidylinositol signaling pathways, such as buparlisib and alpelisib, are also being developed for the treatment of various types of cancer.",GO:0048015 phosphatidylinositol-mediated signaling;GO:0046854 phosphatidylinositol phosphate biosynthetic process;GO:0007040 lysosome organization,yes,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Golgi apparatus (Supported),Fostamatinib,(M160)PID AVB3 INTEGRIN PATHWAY,
ENSG00000028528.15,ENSG00000028528,SNX1,-0.626927128,-0.870104219,-0.793950771,-0.216726394,sorting nexin 1,"SNX1, or sorting nexin 1, is a gene that belongs to the sorting nexin family. It contains a phosphoinositide binding domain and is involved in intracellular trafficking. SNX1 regulates the cell-surface expression of epidermal growth factor receptor and plays a role in sorting protease-activated receptor-1 from early endosomes to lysosomes. It may also form oligomeric complexes with other family members. The gene has three transcript variants that encode distinct isoforms. SNX1 is an endosomal protein that is important for proper cellular function.","There is limited information on the disease implications of SNX1. However, recent studies have suggested that SNX1 may play a role in the pathogenesis of Alzheimer's disease. Specifically, SNX1 has been shown to interact with amyloid precursor protein (APP) and regulate its trafficking, which may contribute to the accumulation of amyloid beta plaques in the brain. 

There are currently no targeted drug discovery efforts specifically focused on SNX1. However, there are several drugs on the market that indirectly target SNX1 by modulating its downstream signaling pathways. For example, inhibitors of the epidermal growth factor receptor (EGFR), such as gefitinib and erlotinib, have been shown to reduce the cell-surface expression of EGFR by promoting its internalization and degradation via the endosomal pathway, which is regulated by SNX1. Similarly, drugs that target lysosomal function, such as chloroquine and hydroxychloroquine, may indirectly affect SNX1-mediated sorting of proteins to lysosomes. 

Overall, while SNX1 is an important protein for cellular function, its disease implications and targeted drug discovery efforts are still in the early stages of investigation.",GO:0072673 lamellipodium morphogenesis;GO:0034498 early endosome to Golgi transport;GO:0097581 lamellipodium organization,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Endosomes;Lysosomes (Enhanced),,(M238)PID THROMBIN PAR1 PATHWAY; (M142)PID AJDISS 2PATHWAY,
ENSG00000148481.14,ENSG00000148481,MINDY3,-0.626917264,-0.880406932,-0.707866325,-0.292478536,MINDY lysine 48 deubiquitinase 3,"MINDY3 is a human gene that encodes a protein containing a caspase-associated recruitment domain and may play a role in apoptosis. It has been identified as a tumor suppressor in lung and gastric cancers, and a genetic variation in the gene may be linked to an increased risk of gastric cancer. The gene undergoes alternative splicing, resulting in multiple transcript variants.","Research on MINDY3 has shown its potential as a target for cancer therapy. The protein it encodes has been found to play a role in regulating cell death, and its loss has been associated with the development of various cancers. As a result, efforts have been made to develop drugs that can target MINDY3 and inhibit its activity. One example is the drug ABT-263, which has been shown to induce apoptosis in cancer cells by binding to and inhibiting the activity of Bcl-2, a protein that interacts with MINDY3. ABT-263 has been approved for the treatment of chronic lymphocytic leukemia and is currently being investigated for use in other types of cancer. Other potential drugs targeting MINDY3 are currently in preclinical development, and further research is needed to fully understand the potential of this gene as a therapeutic target.",GO:0071108 protein K48-linked deubiquitination;GO:0016579 protein deubiquitination;GO:0070646 protein modification by small protein removal,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nuclear membrane;Nucleoplasm (Supported),,,
ENSG00000075945.13,ENSG00000075945,KIFAP3,-0.626806406,-1.00678153,-0.626411443,-0.247226245,kinesin associated protein 3,"KIFAP3, also known as kinesin associated protein 3, is a gene that encodes a protein containing 9 'Armadillo' repeats. This protein interacts with the regulator protein smg GDS, which stimulates GDP/GTP exchange reactions and inhibits interactions with membranes in small G proteins such as Rho, Rap1, and Ki-Ras. KIFAP3 is highly concentrated around the endoplasmic reticulum and is phosphorylated by v-src, which reduces its affinity for smg GDS. It is believed that KIFAP3 serves as a linker between human chromosome-associated polypeptide (HCAP) and KIF3A/B, a kinesin superfamily protein in the nucleus, and plays a role in the interaction of chromosomes with an ATPase motor protein. Multiple transcript variants encoding different isoforms have been identified for this gene.","There is limited information available on the disease implications of KIFAP3. However, recent studies have suggested that mutations in this gene may be associated with the development of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord. Targeted drug discovery efforts for ALS have focused on identifying compounds that can modulate the activity of KIFAP3 and other proteins involved in the disease pathway. While there are currently no drugs on the market that specifically target KIFAP3, several drugs have been approved for the treatment of ALS, including riluzole and edaravone. These drugs work by modulating glutamate signaling and reducing oxidative stress, respectively, and have been shown to slow the progression of the disease in some patients.",GO:0046587 positive regulation of calcium-dependent cell-cell adhesion;GO:0046586 regulation of calcium-dependent cell-cell adhesion;GO:0072383 plus-end-directed vesicle transport along microtubule,,Predicted intracellular proteins,Basal body;Microtubules (Approved); Additional: Nucleoplasm,,,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000128191.16,ENSG00000128191,DGCR8,-0.625568941,-0.857359248,-0.5783516,-0.440995976,DGCR8 microprocessor complex subunit,"DGCR8 is a gene that encodes a subunit of the microprocessor complex, which is responsible for the biogenesis of microRNAs from primary microRNA transcripts. The protein encoded by DGCR8 is a double-stranded RNA binding protein that acts as the non-catalytic subunit of the microprocessor complex. It is necessary for binding the double-stranded RNA substrate and facilitating its cleavage by the ribonuclease III protein, Drosha. DGCR8 is involved in the regulation of gene expression and has been linked to various diseases, including cancer and neurological disorders. Multiple transcript variants of DGCR8 are produced through alternate splicing.","DGCR8 has been implicated in various diseases, including cancer and neurological disorders. In cancer, DGCR8 has been shown to be dysregulated, leading to altered microRNA expression and contributing to tumor growth and metastasis. In neurological disorders, mutations in DGCR8 have been linked to intellectual disability, epilepsy, and autism spectrum disorders.

Targeted drug discovery efforts for DGCR8 have focused on developing small molecule inhibitors that can disrupt the interaction between DGCR8 and Drosha, thereby inhibiting microRNA biogenesis. However, there are currently no drugs on the market that specifically target DGCR8.

One example of a successful drug that indirectly affects DGCR8 is the chemotherapy drug cisplatin, which has been shown to downregulate DGCR8 expression and inhibit microRNA biogenesis. Another example is the anti-cancer drug sorafenib, which has been shown to inhibit the expression of DGCR8 and other microRNA biogenesis factors, leading to decreased tumor growth. However, these drugs do not specifically target DGCR8 and have other mechanisms of action.",GO:2000633 positive regulation of pre-miRNA processing;GO:1903800 positive regulation of miRNA processing;GO:2000631 regulation of pre-miRNA processing,,Human disease related genes:Other congenital disorders:Chromosomal abnormalities; Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Supported),,(M145)PID P53 DOWNSTREAM PATHWAY,(M5898)HALLMARK DNA REPAIR
ENSG00000064601.20,ENSG00000064601,CTSA,-0.62445356,-1.269910335,-0.544555978,-0.058894367,cathepsin A,"The CTSA gene encodes a serine carboxypeptidase that belongs to the peptidase S10 family. The gene undergoes alternative splicing, resulting in multiple transcript variants, one of which generates a preproprotein that is proteolytically processed to form two chains that make up the active enzyme. The enzyme has deamidase, esterase, and carboxypeptidase activities and acts as a scaffold in the lysosomal multienzyme complex. Mutations in the CTSA gene are linked to galactosialidosis, a rare genetic disorder characterized by the accumulation of glycolipids and oligosaccharides in lysosomes.","Galactosialidosis is a rare genetic disorder caused by mutations in the CTSA gene. The disease is characterized by the accumulation of glycolipids and oligosaccharides in lysosomes, leading to a range of symptoms including developmental delay, skeletal abnormalities, hepatosplenomegaly, and neurological dysfunction. There is currently no cure for galactosialidosis, and treatment is mainly supportive. However, targeted drug discovery efforts are underway to develop therapies that can address the underlying cause of the disease. One approach is to use enzyme replacement therapy (ERT) to replace the missing or defective enzyme. A successful example of this approach is the drug Naglazyme, which is used to treat another lysosomal storage disorder called mucopolysaccharidosis VI. Another approach is to use small molecule drugs to enhance the activity of the residual enzyme. One such drug is the chaperone drug Galafold, which is used to treat Fabry disease, another lysosomal storage disorder.",GO:1904715 negative regulation of chaperone-mediated autophagy;GO:1904714 regulation of chaperone-mediated autophagy;GO:0010507 negative regulation of autophagy,,Predicted intracellular proteins; Peptidases:Serine-type peptidases; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Lysosomal storage diseases; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism,Vesicles (Enhanced),,(M3468)NABA ECM REGULATORS; (M5885)NABA MATRISOME ASSOCIATED; (M5889)NABA MATRISOME,
ENSG00000171862.11,ENSG00000171862,PTEN,-0.622197088,-1.02026569,-0.505980251,-0.340345324,phosphatase and tensin homolog,"PTEN (phosphatase and tensin homolog) is a tumor suppressor gene that is frequently mutated in various cancers. The protein encoded by this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase, which contains a tensin-like domain and a catalytic domain similar to that of dual specificity protein tyrosine phosphatases. Unlike most protein tyrosine phosphatases, PTEN preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating the AKT/PKB signaling pathway. PTEN has multiple transcript variants encoding different isoforms, and a pseudogene of this gene is found on chromosome 9.","PTEN mutations have been implicated in a variety of cancers, including prostate, breast, endometrial, and glioblastoma. Loss of PTEN function leads to increased activation of the PI3K/AKT pathway, which promotes cell survival, proliferation, and migration. Therefore, PTEN is an attractive target for cancer therapy. Several drugs targeting the PI3K/AKT pathway have been developed, including PI3K inhibitors, AKT inhibitors, and mTOR inhibitors. However, these drugs have shown limited efficacy in clinical trials, possibly due to compensatory signaling pathways. One successful drug targeting PTEN is temsirolimus, an mTOR inhibitor approved for the treatment of renal cell carcinoma. Another drug, buparlisib, is a pan-PI3K inhibitor that has shown promising results in clinical trials for breast cancer and glioblastoma. Overall, targeting PTEN and the PI3K/AKT pathway remains an active area of research for cancer therapy.",GO:2000808 negative regulation of synaptic vesicle clustering;GO:0051548 negative regulation of keratinocyte migration;GO:0060024 rhythmic synaptic transmission,,"Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Predicted intracellular proteins; Human disease related genes:Cancers:Skin cancers; Human disease related genes:Cancers:Cancers of the breast and female genital organs; Human disease related genes:Cancers:Cancers of male genital organs; Human disease related genes:Cancers:Cancers of the digestive system; Human disease related genes:Cancers:Cancers of the lung and pleura; Human disease related genes:Cancers:Cancers of eye, brain, and central nervous system; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes",Cytosol (Supported); Additional: Mid piece;Nucleoplasm;Principal piece,Phosphatidylethanolamine,(M12771)SA PTEN PATHWAY; (M1315)SIG PIP3 SIGNALING IN B LYMPHOCYTES; (M12)PID RHOA PATHWAY,(M5923)HALLMARK PI3K AKT MTOR SIGNALING; (M5942)HALLMARK UV RESPONSE DN; (M5915)HALLMARK APICAL JUNCTION
ENSG00000108395.14,ENSG00000108395,TRIM37,-0.620595383,-0.980635694,-0.70987506,-0.171275395,tripartite motif containing 37,"TRIM37 is a gene that belongs to the tripartite motif (TRIM) family, which plays a role in various cellular functions such as developmental patterning and oncogenesis. The TRIM motif consists of zinc-binding domains, a RING finger region, a B-box motif, and a coiled-coil domain. TRIM37 is involved in peroxisomal biogenesis disorders and is located in peroxisomal membranes. Mutations in this gene are associated with mulibrey nanism, an autosomal recessive disorder that affects multiple tissues of mesodermal origin. The RING finger and B-box domains of TRIM37 may be involved in protein-protein and/or protein-nucleic acid interactions, and they chelate zinc.","Mutations in the TRIM37 gene are associated with mulibrey nanism, a rare autosomal recessive disorder characterized by growth retardation, dysmorphic features, and multiple organ involvement. There is currently no cure for mulibrey nanism, and treatment is mainly supportive. However, targeted drug discovery efforts are underway to identify potential therapies for this disorder. One approach is to target the peroxisomal biogenesis pathway, which is disrupted in mulibrey nanism. Several drugs that target peroxisomal biogenesis have been approved for other disorders, such as Zellweger syndrome, including bezafibrate and glyceryl trioleate. These drugs may have potential for treating mulibrey nanism, although further research is needed to determine their efficacy and safety in this context.",GO:0070842 aggresome assembly;GO:0046600 negative regulation of centriole replication;GO:0070841 inclusion body assembly,,Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Enzymes,,,,
ENSG00000116473.14,ENSG00000116473,RAP1A,-0.620236916,-0.778158958,-0.736674637,-0.345877153,"RAP1A, member of RAS oncogene family","RAP1A is a small GTPase protein that belongs to the Ras family of oncogenes. Its activity and conformational state are dependent on whether it is bound to GTP or GDP. The protein is activated by guanine nucleotide exchange factors (GEFs) and inactivated by GTPase-activating proteins (GAPs). The balance of intracellular levels of GEFs and GAPs affects the activation status of RAP1A. The protein regulates signaling pathways that affect cell proliferation and adhesion and may play a role in tumor malignancy. Alternative splicing results in multiple transcript variants, and pseudogenes of this gene have been identified on chromosomes 14 and 17.","Research has shown that RAP1A may play a role in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, RAP1A has been found to be overexpressed in several types of tumors, including breast, lung, and pancreatic cancer. Targeting RAP1A has been explored as a potential therapeutic strategy for cancer treatment. For example, a study found that inhibiting RAP1A expression in pancreatic cancer cells led to decreased cell proliferation and increased apoptosis. However, there are currently no drugs on the market that specifically target RAP1A. Instead, drugs that indirectly affect RAP1A signaling pathways, such as inhibitors of the PI3K/AKT/mTOR pathway, have been used in clinical trials for cancer treatment. Successful drugs on the market that indirectly affect RAP1A signaling include everolimus and temsirolimus, which are used to treat renal cell carcinoma and mantle cell lymphoma.",GO:2000301 negative regulation of synaptic vesicle exocytosis;GO:0032486 Rap protein signal transduction;GO:2001214 positive regulation of vasculogenesis,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins; RAS pathway related proteins,,,(M69)PID REELIN PATHWAY; (M72)PID NECTIN PATHWAY; (M233)PID EPO PATHWAY,
ENSG00000188566.14,ENSG00000188566,NDOR1,-0.619590472,-0.858899997,-0.704126519,-0.2957449,NADPH dependent diflavin oxidoreductase 1,NDOR1 is a human gene that encodes for an NADPH-dependent diflavin reductase. This protein contains both flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) binding domains and is responsible for transferring electrons from NADPH through FAD and FMN cofactors to potential redox partners. Alternative splicing of the gene results in multiple transcript variants.,"There is limited information available on the disease implications of NDOR1. However, recent studies have suggested that NDOR1 may play a role in cancer development and progression. Specifically, NDOR1 has been found to be overexpressed in several types of cancer, including breast, lung, and liver cancer. This overexpression has been linked to increased tumor growth and resistance to chemotherapy. As a result, NDOR1 has become a potential target for drug discovery efforts aimed at developing new cancer treatments. While there are currently no drugs on the market that specifically target NDOR1, several drugs that target related proteins involved in electron transfer have been successful in treating cancer. For example, the drug Trastuzumab targets the HER2 protein, which is involved in electron transfer, and is used to treat breast cancer.",GO:0016226 iron-sulfur cluster assembly;GO:0031163 metallo-sulfur cluster assembly;GO:0022900 electron transport chain,,Predicted intracellular proteins,Cytosol (Approved); Additional: Intermediate filaments;Nucleoplasm,,,
ENSG00000137509.11,ENSG00000137509,PRCP,-0.619395937,-0.940159557,-0.542491654,-0.375536599,prolylcarboxypeptidase,"The PRCP gene encodes for the lysosomal prolylcarboxypeptidase enzyme, which belongs to the peptidase S28 family of serine exopeptidases. This enzyme is responsible for cleaving C-terminal amino acids linked to proline in peptides such as angiotensin II, III, and des-Arg9-bradykinin. The enzyme activity is retained with some substrates at neutral pH, and it has been shown to be an activator of the cell matrix-associated prekallikrein. The gene may be related to essential hypertension due to the importance of angiotensin II in regulating blood pressure and electrolyte balance. Alternative splicing results in multiple transcript variants, and a pseudogene of this gene has been identified on chromosome 2.","Research has suggested that variations in the PRCP gene may be associated with essential hypertension, a common and complex cardiovascular disease characterized by high blood pressure. Several studies have identified single nucleotide polymorphisms (SNPs) in the PRCP gene that are associated with hypertension risk. Targeted drug discovery efforts have focused on developing inhibitors of the PRCP enzyme as potential treatments for hypertension and other cardiovascular diseases. One example is the drug omapatrilat, which was designed to inhibit both angiotensin-converting enzyme (ACE) and PRCP. However, clinical trials showed that omapatrilat was associated with an increased risk of angioedema, a serious adverse effect, and it was not approved for use in the United States. Another example is the drug captopril, which is an ACE inhibitor that indirectly inhibits PRCP activity by reducing the production of angiotensin II. Captopril is widely used to treat hypertension and heart failure.",GO:0002254 kinin cascade;GO:0002353 plasma kallikrein-kinin cascade;GO:0002155 regulation of thyroid hormone receptor signaling pathway,,ENZYME proteins:Hydrolases; Enzymes; Peptidases:Serine-type peptidases; Predicted intracellular proteins,Vesicles (Supported),,,(M5921)HALLMARK COMPLEMENT
ENSG00000074603.19,ENSG00000074603,DPP8,-0.618043221,-0.869030062,-0.653035198,-0.332064402,dipeptidyl peptidase 8,"DPP8, or dipeptidyl peptidase 8, is a gene that belongs to the peptidase S9B family. It encodes a protein that is similar to dipeptidyl peptidase IV and is capable of cleaving peptide substrates at a prolyl bond. DPP8 is expressed ubiquitously and may play a role in T-cell activation and immune function, similar to dipeptidyl peptidase IV. Different isoforms of the protein have been described due to alternative splicing of the transcript variants.","DPP8 has been implicated in various diseases, including cancer, inflammation, and autoimmune disorders. In particular, DPP8 has been shown to be overexpressed in certain types of cancer, such as breast and prostate cancer, and may play a role in tumor growth and metastasis. Targeted drug discovery efforts have focused on developing inhibitors of DPP8 as potential cancer therapeutics. One example is the drug talabostat, which was initially developed as a DPP8 inhibitor but was later found to also inhibit DPP9. Talabostat has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer. Another example is the drug sitagliptin, which is a DPP4 inhibitor used to treat type 2 diabetes. While sitagliptin does not directly target DPP8, it is structurally similar to DPP8 inhibitors and may have some off-target effects on DPP8. Overall, DPP8 represents a promising target for drug discovery efforts in various disease areas.",GO:0043069 negative regulation of programmed cell death;GO:0006915 apoptotic process;GO:0012501 programmed cell death,,ENZYME proteins:Hydrolases; Enzymes; Peptidases:Serine-type peptidases; Predicted intracellular proteins,Cytosol (Supported),,,
ENSG00000253352.10,ENSG00000253352,TUG1,-0.617791568,-0.840573379,-0.635626925,-0.377174401,taurine up-regulated 1,"TUG1, also known as taurine up-regulated 1, is a human gene that is predicted to play a role in the development and regulation of photoreceptor cells and gene expression. It is believed to be active in the nucleus of cells. TUG1 has also been identified as a biomarker for Huntington's disease, a genetic disorder that affects the brain and causes progressive neurological symptoms.","There is limited information available on the disease implications of TUG1, but it has been identified as a potential biomarker for Huntington's disease. This genetic disorder is caused by a mutation in the huntingtin gene, which leads to the progressive degeneration of neurons in the brain. TUG1 may be involved in the regulation of gene expression in the brain, and its dysregulation could contribute to the development of Huntington's disease. 

There are currently no targeted drug discovery efforts specifically focused on TUG1, as its function and role in disease are still being studied. However, there are several drugs on the market that target the symptoms of Huntington's disease, such as tetrabenazine, which is used to treat chorea, a movement disorder commonly associated with the disease. Other drugs, such as deutetrabenazine and valbenazine, have also been approved for the treatment of chorea in Huntington's disease patients. These drugs work by reducing the levels of dopamine in the brain, which can help to alleviate symptoms.",,,,,,,
ENSG00000168283.14,ENSG00000168283,BMI1,-0.61747463,-0.852237697,-0.742005716,-0.258180476,"BMI1 proto-oncogene, polycomb ring finger","BMI1 is a gene that encodes a ring finger protein that is a major component of the polycomb group complex 1 (PRC1). This complex plays a crucial role in chromatin remodeling, acting as an essential epigenetic repressor of multiple regulatory genes involved in embryonic development and self-renewal in somatic stem cells. BMI1 also plays a central role in DNA damage repair. However, aberrant expression of BMI1 is associated with numerous cancers and resistance to certain chemotherapies. A pseudogene of BMI1 is found on chromosome X, and read-through transcription also exists between BMI1 and the upstream COMM domain containing 3 (COMMD3) gene.","Aberrant expression of BMI1 has been implicated in various cancers, including leukemia, breast cancer, lung cancer, and glioblastoma. BMI1 overexpression has been associated with poor prognosis and resistance to chemotherapy and radiation therapy. Therefore, BMI1 has been identified as a potential therapeutic target for cancer treatment. Several small molecule inhibitors of BMI1 have been developed and tested in preclinical studies, including PTC-209, PTC596, and BMI1-IN-1. These inhibitors have shown promising results in reducing tumor growth and increasing sensitivity to chemotherapy in animal models. However, no BMI1 inhibitors have been approved for clinical use yet. Additionally, BMI1 has been identified as a potential target for immunotherapy, as it is involved in the regulation of immune checkpoint molecules. Overall, targeting BMI1 holds great potential for cancer therapy, and further research is needed to develop effective drugs targeting this gene.",GO:2000011 regulation of adaxial/abaxial pattern formation;GO:0033091 positive regulation of immature T cell proliferation;GO:0033092 positive regulation of immature T cell proliferation in thymus,,Human disease related genes:Cancers:Cancers of male genital organs; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Nuclear bodies;Nucleoplasm (Approved); Additional: Cytosol;Nucleoli,,(M66)PID MYC ACTIV PATHWAY,
ENSG00000175582.20,ENSG00000175582,RAB6A,-0.617370517,-0.910392647,-0.750467318,-0.191251587,"RAB6A, member RAS oncogene family","RAB6A is a gene that belongs to the RAB family of small GTPases, which regulate the targeting and fusion of transport carriers to acceptor compartments. This gene is located at the Golgi apparatus and is involved in both retrograde and anterograde trafficking. Myosin II is an effector of this protein in these processes. Additionally, RAB6A is involved in the assembly of human cytomegalovirus (HCMV) by interacting with the cellular protein Bicaudal D1, which interacts with the HCMV virion tegument protein, pp150. Multiple alternatively spliced transcript variants encoding different isoforms have been identified.","There is limited information available on the disease implications of RAB6A. However, recent studies have suggested that RAB6A may play a role in the pathogenesis of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for RAB6A are also limited, but some studies have explored the potential of small molecule inhibitors of RAB6A as a therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target RAB6A. However, there are drugs that indirectly affect RAB6A function, such as brefeldin A, which inhibits the activity of RAB6A by disrupting the Golgi apparatus. Additionally, some cancer drugs, such as paclitaxel and doxorubicin, have been shown to affect RAB6A expression and function in cancer cells.",GO:0018125 peptidyl-cysteine methylation;GO:0072385 minus-end-directed organelle transport along microtubule;GO:1903292 protein localization to Golgi membrane,,Predicted intracellular proteins,Golgi apparatus (Supported); Additional: Basal body,,,
ENSG00000173473.11,ENSG00000173473,SMARCC1,-0.617273927,-0.931881039,-0.580786293,-0.339154448,SWI/SNF related BAF chromatin remodeling complex subunit C1,"SMARCC1 is a gene that encodes a protein belonging to the SWI/SNF family of proteins. These proteins are thought to regulate the transcription of certain genes by altering the chromatin structure around those genes. SMARCC1 is part of the SNF/SWI complex, which is an ATP-dependent chromatin remodeling complex. The protein contains a predicted leucine zipper motif, which is typical of many transcription factors.","SMARCC1 has been implicated in various diseases, including cancer, developmental disorders, and neurological disorders. In cancer, SMARCC1 has been found to be overexpressed in several types of tumors, including breast, lung, and ovarian cancers. Targeting SMARCC1 has been proposed as a potential therapeutic strategy for these cancers. In developmental disorders, mutations in SMARCC1 have been linked to Coffin-Siris syndrome, a rare genetic disorder characterized by developmental delay, intellectual disability, and other physical abnormalities. In neurological disorders, SMARCC1 has been found to be involved in the regulation of synaptic plasticity, and mutations in the gene have been linked to autism spectrum disorders.

There are currently no drugs on the market that specifically target SMARCC1. However, there are ongoing efforts to develop drugs that target the SWI/SNF complex, of which SMARCC1 is a part. One example is the development of EZH2 inhibitors, which target a different component of the complex but have shown promise in preclinical studies for the treatment of certain cancers. Another example is the development of BET inhibitors, which target a different chromatin remodeling complex but have also shown promise in preclinical studies for the treatment of certain cancers. Overall, targeting chromatin remodeling complexes such as SWI/SNF is an emerging area of drug discovery with potential therapeutic implications for a variety of diseases.",GO:0006337 nucleosome disassembly;GO:0032986 protein-DNA complex disassembly;GO:2000819 regulation of nucleotide-excision repair,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoplasm (Enhanced),,(M151)PID AR TF PATHWAY; (M115)PID REG GR PATHWAY,(M5949)HALLMARK PEROXISOME; (M5901)HALLMARK G2M CHECKPOINT; (M5926)HALLMARK MYC TARGETS V1
ENSG00000108599.15,ENSG00000108599,AKAP10,-0.616492427,-0.952816514,-0.735497725,-0.161163043,A-kinase anchoring protein 10,AKAP10 is a gene that encodes a member of the A-kinase anchor protein family. These proteins bind to the regulatory subunits of protein kinase A (PKA) and keep the holoenzyme in specific locations within the cell. AKAP10 is found in mitochondria and interacts with both type I and type II regulatory subunits of PKA. Polymorphisms in this gene may increase the risk of arrhythmias and sudden cardiac death.,"Polymorphisms in the AKAP10 gene have been associated with an increased risk of arrhythmias and sudden cardiac death. This suggests that AKAP10 may play a role in the regulation of cardiac function. Targeted drug discovery efforts have focused on developing drugs that can modulate the interaction between AKAP10 and PKA regulatory subunits. One example is the development of small molecule inhibitors that can disrupt the interaction between AKAP10 and PKA, which may have potential therapeutic applications in the treatment of cardiac arrhythmias. Another example is the use of gene therapy to modify the expression of AKAP10 in cardiac cells, which may provide a novel approach for the treatment of cardiac diseases. However, there are currently no drugs on the market that specifically target AKAP10.",GO:0008104 protein localization;GO:0070727 cellular macromolecule localization;GO:0033036 macromolecule localization,,Predicted intracellular proteins,Cytosol;Plasma membrane (Supported),,,(M5921)HALLMARK COMPLEMENT
ENSG00000137513.10,ENSG00000137513,NARS2,-0.616008585,-0.989243883,-0.746491426,-0.112290446,"asparaginyl-tRNA synthetase 2, mitochondrial","NARS2 is a gene that encodes a member of the class II family of aminoacyl-tRNA synthetases. These enzymes play a crucial role in protein biosynthesis by charging tRNAs with their corresponding amino acids. Although this protein is encoded by the nuclear genome, it is likely to be imported to the mitochondrion, where it is thought to catalyze the ligation of asparagine to tRNA molecules. Mutations in this gene have been linked to combined oxidative phosphorylation deficiency 24 (COXPD24), a rare genetic disorder that affects the function of mitochondria, leading to a range of symptoms, including developmental delay, muscle weakness, and respiratory problems.","There is currently no targeted drug discovery effort for NARS2-related disorders, as the underlying molecular mechanisms are not yet fully understood. However, some treatments have been developed to alleviate the symptoms of mitochondrial diseases, including COXPD24. These treatments typically involve the use of antioxidants, vitamins, and cofactors that support mitochondrial function. For example, coenzyme Q10 (CoQ10) has been shown to improve muscle strength and reduce fatigue in patients with mitochondrial myopathies. Other drugs, such as idebenone and elamipretide, have also shown promise in clinical trials for mitochondrial diseases. However, there are currently no drugs specifically approved for the treatment of COXPD24 or other NARS2-related disorders. Further research is needed to identify new therapeutic targets and develop effective treatments for these rare genetic disorders.",GO:0006421 asparaginyl-tRNA aminoacylation;GO:0006418 tRNA aminoacylation for protein translation;GO:0043039 tRNA aminoacylation,,Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Ear disease; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; Potential drug targets; Disease related genes; ENZYME proteins:Ligase; Enzymes,Mitochondria;Nucleoplasm (Approved); Additional: Cytosol,Asparagine,,
ENSG00000128590.5,ENSG00000128590,DNAJB9,-0.615649731,-1.137947751,-0.534072237,-0.174929207,DnaJ heat shock protein family (Hsp40) member B9,DNAJB9 is a member of the J protein family and belongs to the type 2 subgroup of DnaJ proteins. It is localized to the endoplasmic reticulum and plays a role in regulating the ATPase activity of 70 kDa heat shock proteins. The gene is induced by endoplasmic reticulum stress and helps protect stressed cells from apoptosis.,"Research on DNAJB9 and its disease implications is still in its early stages. However, recent studies have suggested that DNAJB9 may play a role in the development of certain types of cancer, including breast cancer and lung cancer. In addition, mutations in the DNAJB9 gene have been linked to the development of Charcot-Marie-Tooth disease, a neurological disorder that affects the peripheral nerves.

Targeted drug discovery efforts for DNAJB9 are also in their early stages. However, there is growing interest in developing drugs that target the endoplasmic reticulum stress response, of which DNAJB9 is a key component. These drugs could potentially be used to treat a range of diseases, including cancer, neurodegenerative disorders, and metabolic diseases.

There are currently no drugs on the market that specifically target DNAJB9. However, there are several drugs that target the endoplasmic reticulum stress response, including tunicamycin, thapsigargin, and 4-phenylbutyrate. These drugs have shown promise in preclinical studies for the treatment of a range of diseases, including cancer and neurodegenerative disorders.",GO:1903895 negative regulation of IRE1-mediated unfolded protein response;GO:1903894 regulation of IRE1-mediated unfolded protein response;GO:1900102 negative regulation of endoplasmic reticulum unfolded protein response,,Predicted intracellular proteins,Cytosol;Endoplasmic reticulum (Approved),,,(M5908)HALLMARK ANDROGEN RESPONSE; (M5922)HALLMARK UNFOLDED PROTEIN RESPONSE; (M5905)HALLMARK ADIPOGENESIS
ENSG00000070367.16,ENSG00000070367,EXOC5,-0.615629206,-0.870987308,-0.682868943,-0.293031368,exocyst complex component 5,"EXOC5 is a human gene that encodes a protein that is a component of the exocyst complex. This complex is essential for targeting exocytic vesicles to specific docking sites on the plasma membrane. The exocyst complex has been shown to be highly conserved in higher eukaryotes, and at least eight components of the complex, including EXOC5, interact with the actin cytoskeletal remodeling and vesicle transport machinery. The complex is also important for the biogenesis of epithelial cell surface polarity.","There is limited information available on the disease implications of EXOC5. However, recent studies have suggested that mutations in the exocyst complex may be associated with various diseases, including cancer, neurological disorders, and developmental disorders. Targeted drug discovery efforts for EXOC5 are also limited, but there is ongoing research on developing drugs that target the exocyst complex as a whole. One example of a successful drug that targets the exocyst complex is Exo1, which has been shown to inhibit exocytosis and reduce insulin secretion in pancreatic beta cells. However, this drug has not yet been approved for clinical use. Overall, more research is needed to fully understand the disease implications of EXOC5 and to develop targeted drugs for its potential therapeutic applications.",GO:0090522 vesicle tethering involved in exocytosis;GO:0001736 establishment of planar polarity;GO:0007164 establishment of tissue polarity,,Transporters:Transporter channels and pores; Predicted intracellular proteins,Vesicles (Approved),,(M16)PID INSULIN PATHWAY; (M67)PID ARF6 TRAFFICKING PATHWAY,
ENSG00000166908.18,ENSG00000166908,PIP4K2C,-0.615531432,-1.17454452,-0.521619212,-0.150430565,phosphatidylinositol-5-phosphate 4-kinase type 2 gamma,"PIP4K2C is a human gene that encodes for the protein phosphatidylinositol-5-phosphate 4-kinase type 2 gamma. This protein is involved in various biological processes, including the biosynthesis of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate, negative regulation of 1-phosphatidylinositol-4-phosphate 5-kinase activity, and positive regulation of autophagosome assembly. PIP4K2C has 1-phosphatidylinositol-4-phosphate 5-kinase activity and identical protein binding activity. It is located in different cellular components, including autophagosome, cytosol, and nucleoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of PIP4K2C. However, some studies have suggested that alterations in PIP4K2C expression or activity may be associated with certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for PIP4K2C are also limited, but some studies have identified potential small molecule inhibitors of PIP4K2C that could be developed as anticancer agents. One example is the compound AS-252424, which has been shown to inhibit PIP4K2C activity and induce apoptosis in cancer cells. However, there are currently no drugs on the market that specifically target PIP4K2C. Further research is needed to fully understand the disease implications of PIP4K2C and to develop targeted therapies for diseases associated with alterations in PIP4K2C expression or activity.","GO:1902635 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate biosynthetic process;GO:1902633 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate metabolic process;GO:2000786 positive regulation of autophagosome assembly",yes,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol (Supported); Additional: Nucleoplasm;Plasma membrane,Fostamatinib,,
ENSG00000081791.9,ENSG00000081791,DELE1,-0.615301827,-0.591735104,-0.416150195,-0.838020183,DAP3 binding cell death enhancer 1,"DELE1, also known as DAP3 binding cell death enhancer 1, is a human gene that plays a role in various cellular processes, including protein kinase binding and activation, extrinsic apoptotic signaling, and regulation of cysteine-type endopeptidase activity involved in apoptosis. It is located in both the cytosol and mitochondrial inner membrane. DELE1 is involved in HRI-mediated signaling, which is important for regulating protein synthesis in response to cellular stress. Additionally, it is involved in the extrinsic apoptotic signaling pathway via death domain receptors, which is a mechanism for inducing programmed cell death. Overall, DELE1 is an important gene involved in regulating cell death and survival.","There is limited information available on the disease implications of DELE1. However, some studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for DELE1 are also limited, as it is not currently considered a major drug target. There are no drugs on the market that specifically target DELE1. However, there are drugs that target the extrinsic apoptotic signaling pathway, which DELE1 is involved in. For example, the drug Fasudil has been shown to induce apoptosis in cancer cells by activating the extrinsic apoptotic signaling pathway. Additionally, some chemotherapy drugs, such as cisplatin and doxorubicin, also induce apoptosis in cancer cells by activating this pathway.",GO:1990641 response to iron ion starvation;GO:0140468 HRI-mediated signaling;GO:1901526 positive regulation of mitophagy,,Predicted intracellular proteins,Nucleoplasm (Uncertain); Additional: Golgi apparatus,,,
ENSG00000029363.17,ENSG00000029363,BCLAF1,-0.615292455,-0.710256379,-0.77085103,-0.364769956,BCL2 associated transcription factor 1,"BCLAF1, also known as BCL2 associated transcription factor 1, is a gene that encodes a transcriptional repressor that interacts with various members of the BCL2 family of proteins. When overexpressed, this protein induces apoptosis, which can be prevented by co-expression of BCL2 proteins. The protein is found in dot-like structures throughout the nucleus and moves to a zone near the nuclear envelope in cells undergoing apoptosis. Multiple transcript variants encoding different isoforms have been identified for this gene.","Research has shown that BCLAF1 plays a role in various diseases, including cancer, viral infections, and autoimmune disorders. In cancer, BCLAF1 has been found to be overexpressed in several types of tumors, including breast, lung, and colon cancer. Targeting BCLAF1 has been proposed as a potential therapeutic strategy for cancer treatment. In viral infections, BCLAF1 has been shown to play a role in the replication of certain viruses, such as HIV and hepatitis C virus. Targeting BCLAF1 could potentially lead to the development of new antiviral therapies. In autoimmune disorders, BCLAF1 has been implicated in the regulation of immune responses. However, there are currently no drugs on the market that specifically target BCLAF1. Nonetheless, research efforts are ongoing to identify potential drug candidates that could target this protein.",GO:2001244 positive regulation of intrinsic apoptotic signaling pathway;GO:2000144 positive regulation of DNA-templated transcription initiation;GO:2000142 regulation of DNA-templated transcription initiation,,Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Mutated cancer genes; Predicted intracellular proteins,Nuclear speckles (Enhanced),,,
ENSG00000103194.16,ENSG00000103194,USP10,-0.614434789,-0.949801101,-0.642421496,-0.251081769,ubiquitin specific peptidase 10,"USP10 is a gene that encodes a member of the ubiquitin-specific protease family of cysteine proteases. The protein specifically cleaves ubiquitin from ubiquitin-conjugated protein substrates, which regulates their function and degradation. It is found in the nucleus and cytoplasm and functions as a co-factor of the DNA-bound androgen receptor complex. The gene is inhibited by a protein in the Ras-GTPase pathway and the human genome contains several pseudogenes similar to this gene. There are several transcript variants, some protein-coding and others not protein-coding, that have been found for this gene.","Research has shown that mutations in the USP10 gene may be associated with the development of certain types of cancer, including breast, prostate, and lung cancer. In addition, USP10 has been implicated in the regulation of immune responses and inflammation, suggesting potential implications in autoimmune diseases. Targeted drug discovery efforts have focused on developing small molecule inhibitors of USP10 as a potential therapeutic strategy for cancer treatment. One example is the compound WP1130, which has been shown to inhibit USP10 activity and induce cancer cell death in preclinical studies. Another example is the compound GNE-6640, which has shown promising results in preclinical studies for the treatment of prostate cancer. However, further research is needed to determine the safety and efficacy of these compounds in clinical trials.",GO:0062030 negative regulation of stress granule assembly;GO:0035520 monoubiquitinated protein deubiquitination;GO:0062028 regulation of stress granule assembly,,Peptidases:Cysteine-type peptidases; ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol (Supported); Additional: Nucleoplasm,,,
ENSG00000118564.15,ENSG00000118564,FBXL5,-0.61442243,-0.828156224,-0.848478099,-0.166632967,F-box and leucine rich repeat protein 5,"FBXL5 is a human gene that belongs to the F-box protein family. This gene encodes a protein that contains an F-box motif and several tandem leucine-rich repeats. The F-box proteins are one of the four subunits of the SCF complex, which is involved in phosphorylation-dependent ubiquitination. The F-box proteins are divided into three classes, and FBXL5 belongs to the Fbls class. This gene has multiple alternatively spliced transcript variants.","FBXL5 has been implicated in several diseases, including cancer, iron metabolism disorders, and neurodegenerative diseases. In cancer, FBXL5 has been shown to regulate the stability of several oncogenic proteins, including c-Myc and cyclin D1, making it a potential target for cancer therapy. In iron metabolism disorders, FBXL5 plays a critical role in regulating the stability of the iron regulatory protein IRP2, and mutations in FBXL5 have been linked to hereditary hemochromatosis. In neurodegenerative diseases, FBXL5 has been shown to regulate the stability of the Parkinson's disease-associated protein alpha-synuclein.

Targeted drug discovery efforts for FBXL5 are still in the early stages, but several small molecule inhibitors of the SCF complex have been identified and are being investigated for their potential as cancer therapeutics. One example is MLN4924, which inhibits the activity of the NEDD8-activating enzyme and thereby disrupts the function of the SCF complex. MLN4924 has shown promising results in preclinical studies and is currently in clinical trials for the treatment of various types of cancer.

Another example of a successful drug targeting the SCF complex is thalidomide, which is used to treat multiple myeloma and other blood cancers. Thalidomide works by binding to the E3 ubiquitin ligase cereblon, which is a component of the SCF complex, and promoting the degradation of several oncogenic proteins. While thalidomide has been associated with severe birth defects, newer derivatives such as lenalidomide and pomalidomide have been developed that have improved safety profiles and are effective in treating multiple myeloma.",GO:0060586 multicellular organismal-level iron ion homeostasis;GO:0031146 SCF-dependent proteasomal ubiquitin-dependent protein catabolic process;GO:0006879 intracellular iron ion homeostasis,,Predicted intracellular proteins,,,,
ENSG00000165219.22,ENSG00000165219,GAPVD1,-0.614318227,-0.851841018,-0.630515186,-0.360598478,GTPase activating protein and VPS9 domains 1,GAPVD1 is a human gene that encodes a protein with both GTPase activating protein binding activity and guanyl-nucleotide exchange factor activity. This protein is involved in regulating protein transport and is located in both the cytosol and plasma membrane. The gene's function is important for maintaining proper cellular processes and disruptions in its activity can lead to various diseases.,"There is limited information available on the disease implications of GAPVD1. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and colorectal cancer. Targeted drug discovery efforts for GAPVD1 are also limited, but some studies have explored the potential of small molecule inhibitors to target the protein's activity. Currently, there are no drugs on the market that specifically target GAPVD1. However, there are drugs that indirectly affect its activity, such as statins, which have been shown to inhibit the protein's guanyl-nucleotide exchange factor activity. Additionally, some cancer treatments, such as cetuximab, have been shown to downregulate the expression of GAPVD1 in cancer cells. Further research is needed to fully understand the potential therapeutic implications of targeting GAPVD1.",GO:0051223 regulation of protein transport;GO:0006897 endocytosis;GO:0070201 regulation of establishment of protein localization,,Predicted intracellular proteins,Plasma membrane (Supported); Additional: Cytosol,,,(M5945)HALLMARK HEME METABOLISM
ENSG00000163605.15,ENSG00000163605,PPP4R2,-0.613237101,-0.820886489,-0.751558758,-0.267266056,protein phosphatase 4 regulatory subunit 2,"PPP4R2 is a gene that encodes a regulatory subunit of the protein phosphatase 4 complex, which is involved in DNA double strand break repair, microtubule organization at centrosomes, and processing of spliceosomal snRNPs. The gene has several transcript variants that encode different isoforms.","Research on PPP4R2 has revealed its potential involvement in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, PPP4R2 has been found to be overexpressed in several types of tumors, including breast, lung, and liver cancer, and its inhibition has been shown to reduce tumor growth and metastasis. In neurodegenerative disorders, PPP4R2 has been linked to the regulation of tau protein phosphorylation, which is a hallmark of Alzheimer's disease. In cardiovascular diseases, PPP4R2 has been implicated in the regulation of smooth muscle cell proliferation and migration, which are key processes in the development of atherosclerosis.

Targeted drug discovery efforts for PPP4R2 are still in the early stages, but several potential drug candidates have been identified through high-throughput screening and structure-based drug design. One example is the small molecule inhibitor, CIP-137401, which has been shown to selectively inhibit PPP4R2 and reduce tumor growth in preclinical models of breast cancer. Another example is the natural product, cantharidin, which has been found to inhibit PPP4R2 and induce apoptosis in cancer cells.

Currently, there are no drugs on the market that specifically target PPP4R2, but the potential therapeutic benefits of targeting this gene make it an attractive target for drug discovery efforts. Further research is needed to fully understand the role of PPP4R2 in disease and to develop safe and effective drugs that can modulate its activity.",GO:0010569 regulation of double-strand break repair via homologous recombination;GO:0000018 regulation of DNA recombination;GO:2000779 regulation of double-strand break repair,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000186350.12,ENSG00000186350,RXRA,-0.613233856,-0.283954214,-0.7340192,-0.821728154,retinoid X receptor alpha,"RXRA is a human gene that encodes for the retinoid X receptor alpha, a nuclear receptor that plays a role in retinoic acid-mediated gene activation. This receptor functions as a transcription factor by binding to specific sequences in the promoters of target genes as homodimers or heterodimers with other nuclear receptors. The RXRA gene belongs to the steroid and thyroid hormone receptor superfamily of transcriptional regulators and undergoes alternative splicing, resulting in multiple transcript variants.","The RXRA gene has been implicated in various diseases, including cancer, metabolic disorders, and neurological disorders. In cancer, RXRA has been shown to play a role in tumor growth and progression, and its expression has been associated with poor prognosis in certain types of cancer. In metabolic disorders, RXRA has been linked to insulin resistance and obesity. In neurological disorders, RXRA has been implicated in Alzheimer's disease and schizophrenia.

Targeted drug discovery efforts have focused on developing drugs that modulate the activity of RXRA. One approach has been to develop agonists that activate RXRA, which could be used to treat metabolic disorders and cancer. Another approach has been to develop antagonists that inhibit RXRA, which could be used to treat neurological disorders and cancer.

There are several successful drugs on the market that target RXRA. One example is bexarotene, which is used to treat cutaneous T-cell lymphoma. Bexarotene is a synthetic retinoid that activates RXRA, leading to the inhibition of tumor growth. Another example is pioglitazone, which is used to treat type 2 diabetes. Pioglitazone is a thiazolidinedione that activates RXRA, leading to improved insulin sensitivity. These drugs demonstrate the potential of targeting RXRA for the treatment of various diseases.",GO:0002157 positive regulation of thyroid hormone receptor signaling pathway;GO:0070564 positive regulation of vitamin D receptor signaling pathway;GO:0002155 regulation of thyroid hormone receptor signaling pathway,,Predicted intracellular proteins; Nuclear receptors; FDA approved drug targets:Small molecule drugs; Transcription factors:Zinc-coordinating DNA-binding domains; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported); Additional: Golgi apparatus,"alpha-Linolenic acid; Adapalene; Bexarotene; Rosiglitazone; Acitretin; Alitretinoin; Etodolac; Tretinoin; Etretinate; Bezafibrate; Alfacalcidol; Phthalic Acid; Doconexent; Oleic Acid; Arachidonic Acid; EVT-101; 3,20-Pregnanedione; 2-chloro-5-nitro-N-phenylbenzamide; 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE; 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID; Tributyltin",(M162)PID RXR VDR PATHWAY; (M207)PID RETINOIC ACID PATHWAY; (M239)PID A6B1 A6B4 INTEGRIN PATHWAY,(M5948)HALLMARK BILE ACID METABOLISM; (M5942)HALLMARK UV RESPONSE DN; (M5939)HALLMARK P53 PATHWAY
ENSG00000171314.9,ENSG00000171314,PGAM1,-0.612861377,-0.867420893,-0.939931112,-0.031232127,phosphoglycerate mutase 1,"The PGAM1 gene encodes a mutase enzyme that catalyzes the conversion of 3-phosphoglycerate to 2-phosphoglycerate in the glycolytic pathway. This reaction is reversible and plays a crucial role in energy production in cells. There are two different isoforms of the protein encoded by this gene, which are produced by alternative splicing of the gene's transcript.","The PGAM1 gene has been implicated in various diseases, including cancer, diabetes, and neurological disorders. In cancer, PGAM1 is overexpressed and promotes tumor growth by enhancing glycolysis and providing energy to cancer cells. Therefore, PGAM1 has been identified as a potential therapeutic target for cancer treatment. Several small molecule inhibitors of PGAM1 have been developed and tested in preclinical studies, showing promising results in reducing tumor growth and metastasis. One example is the compound PGMI-004A, which has been shown to inhibit PGAM1 activity and reduce tumor growth in mouse models of breast cancer. In addition, PGAM1 inhibitors have also been investigated as potential treatments for metabolic disorders such as diabetes and obesity. However, there are currently no PGAM1-targeted drugs on the market.",GO:0006735 NADH regeneration;GO:0061621 canonical glycolysis;GO:0061718 glucose catabolic process to pyruvate,,Enzymes; ENZYME proteins:Isomerase; Predicted intracellular proteins; Candidate cardiovascular disease genes,Nucleoplasm (Approved); Additional: Mid piece,Copper; Artenimol,,(M5937)HALLMARK GLYCOLYSIS
ENSG00000198833.7,ENSG00000198833,UBE2J1,-0.612780268,-0.733228812,-0.764970157,-0.340141835,ubiquitin conjugating enzyme E2 J1,"The UBE2J1 gene encodes a member of the E2 ubiquitin-conjugating enzyme family, which is involved in the modification of proteins with ubiquitin for degradation. This enzyme is located in the membrane of the endoplasmic reticulum (ER) and may contribute to quality control ER-associated degradation by the ubiquitin-proteasome system. The ubiquitination process involves at least three classes of enzymes: ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin-protein ligases (E3s). UBE2J1 is a ubiquitin-conjugating enzyme (E2) and plays a role in targeting abnormal or short-lived proteins for degradation.","There is limited information available on the disease implications of UBE2J1. However, recent studies have suggested that dysregulation of the ubiquitin-proteasome system, including UBE2J1, may contribute to the pathogenesis of neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Targeted drug discovery efforts for UBE2J1 are currently limited, but there is potential for the development of drugs that modulate the activity of this enzyme for therapeutic purposes. Currently, there are no drugs on the market that specifically target UBE2J1. However, there are drugs that target other components of the ubiquitin-proteasome system, such as proteasome inhibitors like bortezomib, which are used to treat multiple myeloma and mantle cell lymphoma.","GO:1904153 negative regulation of retrograde protein transport, ER to cytosol;GO:0070862 negative regulation of protein exit from endoplasmic reticulum;GO:1904152 regulation of retrograde protein transport, ER to cytosol",,Enzymes; ENZYME proteins:Transferases,,,,(M5908)HALLMARK ANDROGEN RESPONSE
ENSG00000125944.21,ENSG00000125944,HNRNPR,-0.612596939,-0.665655237,-0.846056104,-0.326079476,heterogeneous nuclear ribonucleoprotein R,"HNRNPR is a gene that encodes an RNA-binding protein that is part of the spliceosome C complex. This protein is involved in pre-mRNA processing and transport, as well as promoting transcription at the c-fos gene. Alternative splicing of this gene results in multiple transcript variants. There are also pseudogenes for this gene on chromosomes 4, 11, and 10.","Research has shown that HNRNPR may play a role in several diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, HNRNPR has been found to be overexpressed in several types of tumors, including breast, lung, and colon cancer. Targeting HNRNPR with small molecule inhibitors or RNA interference has shown promise in preclinical studies as a potential therapeutic strategy for cancer treatment. In neurodegenerative disorders, HNRNPR has been implicated in the regulation of alternative splicing of genes involved in neuronal function and survival. In viral infections, HNRNPR has been shown to interact with viral RNA and play a role in viral replication. However, there are currently no drugs on the market that specifically target HNRNPR. Further research is needed to fully understand the role of HNRNPR in disease and to develop targeted therapies.","GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;GO:0000398 mRNA splicing, via spliceosome;GO:0000375 RNA splicing, via transesterification reactions",,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,(M5926)HALLMARK MYC TARGETS V1
ENSG00000121749.15,ENSG00000121749,TBC1D15,-0.611541101,-0.795448961,-0.565722933,-0.473451407,TBC1 domain family member 15,"TBC1D15 is a human gene that belongs to the Ras-like proteins in brain-GTPase activating protein superfamily. It contains a conserved Tre-2/Bub2/Cdc16 domain and interacts with Ras-like protein in brain 5A. TBC1D15 may function as a regulator of intracellular trafficking. The gene undergoes alternate splicing, resulting in multiple transcript variants.","There is limited information available on the disease implications of TBC1D15. However, recent studies have suggested that mutations in TBC1D15 may be associated with the development of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TBC1D15 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target TBC1D15, there are several drugs that have been developed to target other members of the Ras-like proteins in brain-GTPase activating protein superfamily, including the FDA-approved drug Trametinib, which targets the protein MEK and is used to treat certain types of cancer.",GO:0043087 regulation of GTPase activity;GO:0051336 regulation of hydrolase activity;GO:0050790 regulation of catalytic activity,,Predicted intracellular proteins,Cytosol;Mitochondria (Supported),,,
ENSG00000198373.13,ENSG00000198373,WWP2,-0.610891439,-0.838013005,-0.832532175,-0.162129138,WW domain containing E3 ubiquitin protein ligase 2,"WWP2 is a gene that encodes a protein belonging to the Nedd4 family of E3 ligases, which are involved in protein ubiquitination. The protein contains four WW domains and is thought to be involved in various processes, including chondrogenesis and the regulation of oncogenic signaling pathways. It interacts with Smad proteins and the tumor suppressor PTEN. The gene has multiple alternatively spliced transcript variants that encode different isoforms. A pseudogene of this gene is also present on chromosome 10.","WWP2 has been implicated in various diseases, including cancer, osteoarthritis, and neurodegenerative disorders. In cancer, WWP2 has been shown to regulate the stability of several oncogenic proteins, including c-Myc, c-Jun, and Notch1, making it a potential target for cancer therapy. In osteoarthritis, WWP2 has been found to regulate the degradation of cartilage matrix proteins, suggesting that it may play a role in the pathogenesis of the disease. In neurodegenerative disorders, WWP2 has been shown to regulate the degradation of tau protein, which is implicated in Alzheimer's disease and other tauopathies.

Targeted drug discovery efforts for WWP2 are still in the early stages, but several small molecule inhibitors have been identified that can block the activity of WWP2. For example, a recent study identified a small molecule inhibitor of WWP2 that was able to reduce the growth of breast cancer cells in vitro and in vivo. Another study found that a natural compound called curcumin can inhibit the activity of WWP2 and reduce the accumulation of tau protein in a mouse model of Alzheimer's disease.

There are currently no drugs on the market that specifically target WWP2, but the identification of small molecule inhibitors and natural compounds that can block its activity suggests that it may be a promising target for drug development in the future.",GO:0045746 negative regulation of Notch signaling pathway;GO:1901016 regulation of potassium ion transmembrane transporter activity;GO:0006858 extracellular transport,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,,,,
ENSG00000152683.14,ENSG00000152683,SLC30A6,-0.609023982,-0.759880618,-0.680739891,-0.386451437,solute carrier family 30 member 6,SLC30A6 is a gene that encodes a protein that acts as a zinc transporter. This protein is responsible for regulating the levels of zinc in the Golgi and vesicles within cells. The expression of this gene has been found to be altered in the brain plaques of individuals with Alzheimer's disease.,"There is limited information available on the disease implications of SLC30A6. However, studies have shown that alterations in the expression of this gene may be associated with Alzheimer's disease. Targeted drug discovery efforts for SLC30A6 are also limited, but there is potential for the development of drugs that modulate the activity of the protein encoded by this gene. Currently, there are no drugs on the market that specifically target SLC30A6. However, there are drugs that target zinc transporters in general, such as the zinc chelator clioquinol, which has been investigated for its potential use in the treatment of Alzheimer's disease. Additionally, zinc supplementation has been studied as a potential therapeutic approach for various diseases, including Alzheimer's disease, although its efficacy remains unclear.",GO:0071579 regulation of zinc ion transport;GO:1904257 zinc ion import into Golgi lumen;GO:0140820 cytosol to Golgi apparatus transport,,Transporters:Electrochemical Potential-driven transporters,Golgi apparatus (Enhanced),,,
ENSG00000134851.13,ENSG00000134851,TMEM165,-0.607830882,-0.776618797,-0.932183094,-0.114690754,transmembrane protein 165,"TMEM165 is a gene that encodes a transmembrane protein with a perinuclear Golgi-like distribution in fibroblasts. Mutations in this gene are linked to the autosomal recessive disorder congenital disorder of glycosylation, type IIk. Knockdown of TMEM165 expression leads to reduced sialylation in HEK cells, indicating that the gene plays a role in terminal Golgi glycosylation. Alternative splicing of the gene results in multiple transcript variants.","Congenital disorder of glycosylation, type IIk (CDG-IIk) is a rare genetic disorder caused by mutations in the TMEM165 gene. The disorder affects the glycosylation process, which is essential for the proper functioning of many proteins in the body. Symptoms of CDG-IIk can include developmental delays, intellectual disability, seizures, and abnormal facial features. There is currently no cure for CDG-IIk, and treatment is focused on managing symptoms.

Targeted drug discovery efforts for CDG-IIk are ongoing, with a focus on developing therapies that can correct the glycosylation defects caused by TMEM165 mutations. One approach is to use small molecules that can enhance the activity of other glycosylation enzymes to compensate for the loss of TMEM165 function. Another approach is to develop gene therapies that can replace or repair the mutated TMEM165 gene.

There are currently no drugs on the market specifically approved for the treatment of CDG-IIk. However, some drugs used to treat other types of CDG, such as mannose supplements and fucose supplements, may be beneficial for some patients with CDG-IIk. Additionally, some patients with CDG-IIk may benefit from therapies that address specific symptoms, such as antiepileptic drugs for seizures or physical therapy for developmental delays.",GO:0032468 Golgi calcium ion homeostasis;GO:0032472 Golgi calcium ion transport;GO:0071421 manganese ion transmembrane transport,,Disease related genes; Transporters:Electrochemical Potential-driven transporters; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism; Potential drug targets,Golgi apparatus (Enhanced),,,
ENSG00000079805.18,ENSG00000079805,DNM2,-0.607748424,-0.929856768,-0.645963941,-0.247424562,dynamin 2,"DNM2, also known as dynamin 2, is a GTP-binding protein that is associated with microtubules and plays a role in cell processes such as endocytosis and cell motility. It is also involved in alterations of the membrane that accompany certain activities such as bone resorption by osteoclasts. DNM2 binds many proteins that bind actin and other cytoskeletal proteins and can self-assemble, which stimulates GTPase activity. There are five alternatively spliced transcripts encoding different proteins that have been described, and additional alternatively spliced transcripts may exist, but their full-length nature has not been determined.","DNM2 mutations have been associated with several diseases, including centronuclear myopathy, Charcot-Marie-Tooth disease, and hereditary spastic paraplegia. In centronuclear myopathy, mutations in DNM2 lead to abnormal muscle fiber structure and function, resulting in muscle weakness and wasting. In Charcot-Marie-Tooth disease, mutations in DNM2 affect the peripheral nerves, leading to muscle weakness and atrophy in the limbs. In hereditary spastic paraplegia, mutations in DNM2 cause progressive stiffness and weakness in the legs.

Targeted drug discovery efforts for DNM2-related diseases are still in the early stages, but there are some promising leads. One approach is to develop drugs that target the abnormal protein-protein interactions that occur in DNM2-related diseases. Another approach is to develop drugs that enhance the activity of DNM2 or its downstream effectors, such as microtubules.

There are currently no drugs on the market that specifically target DNM2-related diseases. However, there are drugs that can help manage the symptoms of these diseases. For example, corticosteroids and immunosuppressants can help manage the muscle weakness and inflammation associated with centronuclear myopathy. Physical therapy and assistive devices can also help improve mobility and quality of life for patients with DNM2-related diseases.",GO:0099050 vesicle scission;GO:1903526 negative regulation of membrane tubulation;GO:0097749 membrane tubulation,,Human disease related genes:Musculoskeletal diseases:Muscular diseases; Predicted intracellular proteins; Cancer-related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Transporters:Accessory Factors Involved in Transport; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Transporters:Transporter channels and pores,Cytosol;Golgi apparatus (Supported),,(M165)PID SYNDECAN 4 PATHWAY; (M238)PID THROMBIN PAR1 PATHWAY; (M142)PID AJDISS 2PATHWAY,
ENSG00000087502.18,ENSG00000087502,ERGIC2,-0.607360452,-1.001860152,-0.818806704,-0.001414501,ERGIC and golgi 2,"ERGIC2, also known as PTX1, is a gene that is expressed in all tissues and is involved in the regulation of nuclear proteins. It is downregulated in prostate carcinoma, a type of cancer that affects the prostate gland in men. The ERGIC2 gene is located in the endoplasmic reticulum-Golgi intermediate compartment (ERGIC) and the Golgi apparatus, which are both involved in protein processing and transport within cells. The exact function of ERGIC2 is not fully understood, but it is thought to play a role in the regulation of protein trafficking and secretion.","There is limited information available on the disease implications of ERGIC2, but studies have shown that it is downregulated in prostate carcinoma, suggesting a potential role in cancer development. However, there are currently no targeted drug discovery efforts specifically focused on ERGIC2. 

As for successful drugs on the market, there are none that directly target ERGIC2. However, there are drugs that target the endoplasmic reticulum (ER) and Golgi apparatus, where ERGIC2 is located. For example, tunicamycin is an antibiotic that inhibits protein glycosylation in the ER, and brefeldin A is a fungal metabolite that disrupts protein transport from the ER to the Golgi. These drugs have been used in research to study the function of the ER and Golgi, but they are not approved for clinical use in humans.","GO:0006890 retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum;GO:0006888 endoplasmic reticulum to Golgi vesicle-mediated transport;GO:0048193 Golgi vesicle transport",,Predicted intracellular proteins,Golgi apparatus;Vesicles (Supported); Additional: Nucleoli rim,,,
ENSG00000102974.16,ENSG00000102974,CTCF,-0.607039931,-0.824024093,-0.615121209,-0.381974491,CCCTC-binding factor,"CTCF (CCCTC-binding factor) is a transcriptional regulator protein that belongs to the BORIS + CTCF gene family. It contains 11 highly conserved zinc finger domains that allow it to bind different DNA target sequences and proteins. Depending on the context of the site, CTCF can function as a transcriptional activator or repressor by binding to either a histone acetyltransferase (HAT)-containing complex or a histone deacetylase (HDAC)-containing complex. When bound to a transcriptional insulator element, CTCF can block communication between enhancers and upstream promoters, thereby regulating imprinted expression. Mutations in this gene have been associated with invasive breast cancers, prostate cancers, and Wilms' tumors. Different isoforms of CTCF have been found due to alternative splicing.","CTCF has been implicated in various diseases, including cancer and neurological disorders. In cancer, CTCF has been shown to play a role in tumor growth, invasion, and metastasis. Targeting CTCF has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of CTCF have been developed, including BRD9876 and BRD3731, which have shown promising results in preclinical studies. In addition, CTCF-targeted immunotherapy has also been explored as a potential treatment for cancer. In neurological disorders, CTCF has been linked to neurodevelopmental disorders such as autism spectrum disorder and schizophrenia. However, there are currently no drugs on the market that specifically target CTCF for the treatment of these diseases.",GO:0070602 regulation of centromeric sister chromatid cohesion;GO:0044027 negative regulation of gene expression via chromosomal CpG island methylation;GO:0007063 regulation of sister chromatid cohesion,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes; Transcription factors:Zinc-coordinating DNA-binding domains,Nucleoplasm (Supported),,,(M5901)HALLMARK G2M CHECKPOINT; (M5925)HALLMARK E2F TARGETS
ENSG00000114316.13,ENSG00000114316,USP4,-0.606761933,-1.123958235,-0.542267165,-0.154060398,ubiquitin specific peptidase 4,USP4 is a gene that encodes a protease that removes ubiquitin from target proteins such as ADORA2A and TRIM21. This protein shuttles between the nucleus and cytoplasm and plays a role in maintaining the proper function of the endoplasmic reticulum. There are three different isoforms of the protein that are produced from different transcript variants of the gene.,"USP4 has been implicated in various diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, USP4 has been shown to regulate the activity of several oncogenes and tumor suppressors, making it a potential target for cancer therapy. In neurodegenerative disorders, USP4 has been linked to the accumulation of misfolded proteins, such as alpha-synuclein in Parkinson's disease, and tau in Alzheimer's disease. In viral infections, USP4 has been shown to play a role in the replication of certain viruses, such as hepatitis B virus.

Targeted drug discovery efforts for USP4 are ongoing, with several small molecule inhibitors and peptides being developed to target the enzyme. One example is the compound WP1130, which has been shown to inhibit USP4 activity and induce apoptosis in cancer cells. Another example is the peptide inhibitor, TSP4-2, which has been shown to inhibit USP4 activity and reduce the accumulation of misfolded proteins in neurodegenerative disease models.

There are currently no USP4-targeted drugs on the market, but the ongoing research suggests that targeting this enzyme could have therapeutic potential in various diseases.",GO:0000244 spliceosomal tri-snRNP complex assembly;GO:0034394 protein localization to cell surface;GO:0000387 spliceosomal snRNP assembly,,Peptidases:Cysteine-type peptidases; ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Basal body;Cytosol;Vesicles,,,
ENSG00000147416.11,ENSG00000147416,ATP6V1B2,-0.605427501,-0.931877271,-0.635681799,-0.248723434,ATPase H+ transporting V1 subunit B2,"ATP6V1B2 is a gene that encodes a component of vacuolar ATPase (V-ATPase), an enzyme that acidifies intracellular organelles in eukaryotic cells. This acidification is necessary for various intracellular processes, including protein sorting, zymogen activation, receptor-mediated endocytosis, and synaptic vesicle proton gradient generation. V-ATPase is composed of a cytosolic V1 domain and a transmembrane V0 domain. The V1 domain contains the ATP catalytic site and consists of three A, three B, and two G subunits, as well as a C, D, E, F, and H subunit. ATP6V1B2 is one of two V1 domain B subunit isoforms and is highly expressed in osteoclasts.","Mutations in ATP6V1B2 have been associated with autosomal recessive cutis laxa type II (ARCL2), a rare genetic disorder characterized by loose and wrinkled skin, joint laxity, and other connective tissue abnormalities. However, the exact role of ATP6V1B2 in the pathogenesis of ARCL2 is not fully understood. 

There are currently no targeted drug discovery efforts specifically for ATP6V1B2. However, V-ATPase inhibitors have been investigated as potential anticancer agents due to their ability to disrupt the acidic tumor microenvironment and inhibit tumor cell proliferation. Bafilomycin A1, a natural product V-ATPase inhibitor, has been shown to have antitumor activity in preclinical studies. 

Other V-ATPase inhibitors, such as concanamycin A and saliphenylhalamide, have also been investigated as potential therapeutic agents for osteoporosis, osteopetrosis, and other bone disorders. However, these compounds have not yet been approved for clinical use. 

Overall, while there are currently no drugs on the market that specifically target ATP6V1B2, V-ATPase inhibitors have shown promise as potential therapeutic agents for various diseases, including cancer and bone disorders.",GO:0097401 synaptic vesicle lumen acidification;GO:0016188 synaptic vesicle maturation;GO:0007035 vacuolar acidification,,Predicted intracellular proteins; Transporters:Primary Active Transporters; FDA approved drug targets:Small molecule drugs; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes,Vesicles (Supported),Gallium nitrate; 4-(2-Aminoethyl)Benzenesulfonyl Fluoride,,
ENSG00000122545.20,ENSG00000122545,SEPTIN7,-0.60492466,-0.939830049,-0.762606832,-0.112337098,septin 7,"SEPTIN7, also known as septin 7, is a human gene that encodes a protein similar to the CDC10 protein found in yeast. The protein contains a GTP-binding motif and is a structural component of the 10 nm filament inside the cytoplasmic membrane, which is essential for cytokinesis. SEPTIN7 is involved in gliomagenesis and the suppression of glioma cell growth, and is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants, and several related pseudogenes have been identified on various chromosomes.","SEPTIN7 has been implicated in various diseases, including cancer and neurodegenerative disorders. In gliomas, SEPTIN7 expression is downregulated, and its overexpression has been shown to suppress glioma cell growth. Additionally, mutations in SEPTIN7 have been linked to Parkinson's disease and Alzheimer's disease. 

Targeted drug discovery efforts for SEPTIN7 are still in the early stages, but there is potential for the development of drugs that target SEPTIN7 in cancer and neurodegenerative diseases. One study found that a small molecule inhibitor of SEPTIN7, called forchlorfenuron, inhibited the growth of glioma cells in vitro and in vivo. 

Currently, there are no drugs on the market that specifically target SEPTIN7. However, there are drugs that indirectly affect SEPTIN7 function. For example, paclitaxel, a chemotherapy drug used to treat various cancers, has been shown to disrupt SEPTIN7 filaments and inhibit cytokinesis. Additionally, lithium, a drug used to treat bipolar disorder, has been shown to increase SEPTIN7 expression and promote neurite outgrowth in neurons.",GO:0016476 regulation of embryonic cell shape;GO:1902857 positive regulation of non-motile cilium assembly;GO:1902855 regulation of non-motile cilium assembly,,Predicted intracellular proteins,Actin filaments (Supported); Additional: Cytokinetic bridge;Midbody;Primary cilium,,,
ENSG00000128989.11,ENSG00000128989,ARPP19,-0.604834348,-0.875069058,-0.742031543,-0.197402442,cAMP regulated phosphoprotein 19,"ARPP19 is a gene that encodes for a 19-kD cAMP-regulated phosphoprotein. This protein plays a crucial role in regulating mitosis by inhibiting protein phosphatase-2A (PP2A). PP2A is an enzyme that is involved in many cellular processes, including cell division. By inhibiting PP2A, ARPP19 helps to regulate the timing and progression of mitosis. This gene has been studied extensively and its function has been linked to various diseases, including cancer. Understanding the role of ARPP19 in mitosis regulation may provide insights into the development of new treatments for cancer and other diseases.","ARPP19 has been implicated in various types of cancer, including breast, lung, and prostate cancer. Studies have shown that overexpression of ARPP19 can lead to uncontrolled cell growth and division, which is a hallmark of cancer. Therefore, targeting ARPP19 may be a promising strategy for developing new cancer treatments. Several drug discovery efforts have focused on developing small molecule inhibitors of ARPP19. One such inhibitor, called E9, has been shown to inhibit the growth of breast cancer cells in vitro and in vivo. Another inhibitor, called ARPP-16, has been shown to inhibit the growth of lung cancer cells. However, there are currently no drugs on the market that specifically target ARPP19. Further research is needed to fully understand the role of ARPP19 in cancer and to develop effective therapies targeting this gene.",GO:0045722 positive regulation of gluconeogenesis;GO:0046326 positive regulation of D-glucose import;GO:0010828 positive regulation of D-glucose transmembrane transport,,Predicted intracellular proteins,Basal body;Vesicles (Approved); Additional: Cytosol;Nucleoli,,,(M5934)HALLMARK XENOBIOTIC METABOLISM; (M5937)HALLMARK GLYCOLYSIS
ENSG00000156639.12,ENSG00000156639,ZFAND3,-0.604686559,-0.901000348,-0.690915414,-0.222143916,zinc finger AN1-type containing 3,"ZFAND3 is a human gene that is predicted to have DNA binding activity and zinc ion binding activity. It belongs to the zinc finger AN1-type containing family of genes. The function of this gene is not yet fully understood, but it is believed to play a role in regulating gene expression and cellular processes. Mutations in this gene have been associated with certain types of cancer, including breast and ovarian cancer. Further research is needed to fully understand the function and potential clinical implications of ZFAND3.","There is limited information available on the disease implications and targeted drug discovery efforts for ZFAND3. However, studies have shown that mutations in this gene are associated with certain types of cancer, including breast and ovarian cancer. This suggests that ZFAND3 may be a potential target for cancer therapy. Currently, there are no drugs on the market that specifically target ZFAND3. However, there are several drugs that target other genes and pathways involved in cancer, such as PARP inhibitors and HER2 inhibitors, which have shown success in treating breast and ovarian cancer. Further research is needed to fully understand the role of ZFAND3 in cancer and to develop targeted therapies for this gene.",,,Predicted intracellular proteins,Nucleoplasm;Vesicles (Approved),,,
ENSG00000263465.4,ENSG00000263465,SRSF8,-0.604175827,-0.975388648,-0.504634956,-0.332503876,serine and arginine rich splicing factor 8,SRSF8 is a gene that encodes a protein involved in pre-mRNA splicing. The protein contains an RNA binding motif and an RS domain. Alternative splicing of the gene results in multiple transcript variants. A pseudogene for this gene is located on chromosome 7.,"Research on SRSF8 has revealed its potential involvement in various diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, SRSF8 has been shown to promote tumor growth and metastasis by regulating alternative splicing of genes involved in cell proliferation, apoptosis, and angiogenesis. Targeting SRSF8 with small molecule inhibitors or RNA interference has been explored as a potential therapeutic strategy for cancer treatment. In neurodegenerative disorders, SRSF8 has been implicated in the regulation of alternative splicing of genes involved in neuronal function and survival. In viral infections, SRSF8 has been shown to play a role in the replication of certain viruses, such as HIV and influenza. However, there are currently no drugs on the market that specifically target SRSF8. Further research is needed to fully understand the role of SRSF8 in disease and to develop effective targeted therapies.","GO:0000381 regulation of alternative mRNA splicing, via spliceosome;GO:0048024 regulation of mRNA splicing, via spliceosome;GO:0050684 regulation of mRNA processing",,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000155827.12,ENSG00000155827,RNF20,-0.604105261,-0.744294323,-0.882929424,-0.185092035,ring finger protein 20,"RNF20, also known as ring finger protein 20, is a human gene that encodes an E3 ubiquitin ligase. This protein is involved in regulating chromosome structure by monoubiquitinating histone H2B. It acts as a tumor suppressor and positively regulates the p53 tumor suppressor, as well as numerous histone H2A and H2B genes. However, it also suppresses the expression of several protooncogenes and growth-related genes, including those induced by epidermal growth factor. RNF20 selectively suppresses the expression of some genes by interfering with chromatin recruitment of transcription elongation factor SII (TFIIS).","RNF20 has been implicated in several diseases, including cancer, neurodegenerative disorders, and immune-related disorders. In cancer, RNF20 has been shown to act as a tumor suppressor, and its downregulation has been observed in various types of cancer, including breast, prostate, and colorectal cancer. Targeted drug discovery efforts have focused on developing small molecule inhibitors of RNF20 to treat cancer. However, there are currently no drugs on the market that specifically target RNF20. Some drugs that indirectly affect RNF20 activity, such as histone deacetylase inhibitors, have been approved for cancer treatment. Further research is needed to fully understand the role of RNF20 in disease and to develop targeted therapies.",GO:0000209 protein polyubiquitination;GO:0030336 negative regulation of cell migration;GO:2000146 negative regulation of cell motility,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Enhanced),,,
ENSG00000166260.13,ENSG00000166260,COX11,-0.603672045,-1.135485448,-0.458964992,-0.216565695,cytochrome c oxidase copper chaperone COX11,"COX11 is a human gene that encodes a protein involved in the formation of cytochrome c oxidase (COX), the terminal component of the mitochondrial respiratory chain. COX catalyzes the transfer of electrons from reduced cytochrome c to oxygen. The gene encodes a protein that is not a structural subunit but may be involved in heme A biosynthesis, according to yeast mutant studies. However, studies in Rhodobacter sphaeroides suggest that the gene is not required for heme A biosynthesis but is required for stable formation of the Cu(B) and magnesium centers of COX. The protein is predicted to contain a transmembrane domain localized in the mitochondrial inner membrane. Multiple transcript variants encoding different isoforms have been found for this gene.","Mutations in the COX11 gene have been associated with several mitochondrial disorders, including Leigh syndrome, a severe neurological disorder, and hypertrophic cardiomyopathy, a condition that affects the heart muscle. These mutations can lead to a decrease in COX activity, resulting in impaired mitochondrial respiration and energy production. 

Targeted drug discovery efforts for COX11 have focused on developing small molecules that can increase COX activity and improve mitochondrial function. One example is elamipretide, a peptide drug that targets the inner mitochondrial membrane and enhances electron transport and ATP production. Elamipretide has shown promising results in clinical trials for various mitochondrial diseases, including primary mitochondrial myopathy and Barth syndrome. 

Another example is idebenone, a synthetic analog of coenzyme Q10 that has been shown to improve mitochondrial function and reduce oxidative stress. Idebenone is currently approved for the treatment of Leber's hereditary optic neuropathy, a rare genetic disorder that causes vision loss. 

Overall, targeting COX11 and mitochondrial function has shown potential for the development of therapies for various mitochondrial disorders.",GO:0006754 ATP biosynthetic process;GO:0009206 purine ribonucleoside triphosphate biosynthetic process;GO:0009145 purine nucleoside triphosphate biosynthetic process,,,,,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000106682.15,ENSG00000106682,EIF4H,-0.60293855,-0.981505797,-0.726093036,-0.101216817,eukaryotic translation initiation factor 4H,"EIF4H is a gene that encodes a protein involved in the initiation of protein synthesis at the mRNA level. This gene is important for the proper functioning of cells and is deleted in Williams syndrome, a developmental disorder caused by the deletion of contiguous genes at 7q11.23. Alternative splicing of this gene generates two transcript variants.","EIF4H has been implicated in various diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, EIF4H has been shown to be overexpressed in several types of tumors, including breast, lung, and prostate cancer, and is associated with poor prognosis. Targeting EIF4H has been proposed as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of EIF4H have been developed, including rocaglamide and silvestrol, which have shown promising results in preclinical studies.

In neurodegenerative disorders, EIF4H has been linked to the pathogenesis of Alzheimer's disease and Huntington's disease. In Alzheimer's disease, EIF4H has been shown to be upregulated in the brains of patients and is involved in the regulation of amyloid beta production. In Huntington's disease, EIF4H has been shown to be involved in the regulation of mutant huntingtin protein translation. Targeting EIF4H has been proposed as a potential therapeutic strategy for these disorders.

In viral infections, EIF4H has been shown to be involved in the replication of several viruses, including hepatitis C virus and human immunodeficiency virus (HIV). Targeting EIF4H has been proposed as a potential therapeutic strategy for viral infections. Several small molecule inhibitors of EIF4H have been developed, including hippuristanol and silvestrol, which have shown antiviral activity in preclinical studies.

Overall, EIF4H is an important gene with implications in various diseases, and targeting it has shown promise as a therapeutic strategy. However, more research is needed to fully understand the role of EIF4H in disease pathogenesis and to develop effective drugs targeting this gene.",GO:0097010 eukaryotic translation initiation factor 4F complex assembly;GO:0001731 formation of translation preinitiation complex;GO:0002183 cytoplasmic translational initiation,,Disease related genes; Human disease related genes:Other congenital disorders:Chromosomal abnormalities; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cytosol (Approved); Additional: Nuclear bodies;Nucleoplasm,,,(M5926)HALLMARK MYC TARGETS V1
ENSG00000099995.19,ENSG00000099995,SF3A1,-0.601601524,-0.806919544,-0.84049053,-0.157394498,splicing factor 3a subunit 1,"The SF3A1 gene encodes a subunit of the splicing factor 3a protein complex, which is a component of the U2 small nuclear ribonucleoprotein particle (snRNP). The U2 snRNP is critical in spliceosome assembly and pre-mRNA splicing.","Mutations in the SF3A1 gene have been associated with various types of cancer, including uveal melanoma, chronic lymphocytic leukemia, and breast cancer. SF3A1 mutations have also been linked to myelodysplastic syndromes, a group of disorders characterized by abnormal blood cell production. Targeted drug discovery efforts for SF3A1 mutations are ongoing, with a focus on developing small molecule inhibitors that can selectively target cancer cells with SF3A1 mutations. One example of a successful drug targeting SF3A1 mutations is H3B-8800, a splicing modulator that has shown promising results in preclinical studies for the treatment of uveal melanoma. Another example is E7107, a splicing inhibitor that has shown efficacy in preclinical studies for the treatment of breast cancer. However, further clinical trials are needed to determine the safety and efficacy of these drugs in humans.","GO:0000389 mRNA 3'-splice site recognition;GO:1903241 U2-type prespliceosome assembly;GO:0045292 mRNA cis splicing, via spliceosome",,Predicted intracellular proteins,Nuclear speckles;Nucleoplasm (Enhanced),,,(M5926)HALLMARK MYC TARGETS V1
ENSG00000184178.16,ENSG00000184178,SCFD2,-0.600635758,-0.870738456,-0.494377725,-0.436791093,sec1 family domain containing 2,"The human gene SCFD2, also known as sec1 family domain containing 2, is predicted to have syntaxin binding activity and be involved in intracellular protein transport and vesicle docking involved in exocytosis. It is also predicted to be active in the plasma membrane and secretory granule. This information is provided by the Alliance of Genome Resources as of April 2022.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for the SCFD2 gene. As of April 2022, there are no drugs on the market that specifically target this gene. However, research on the function of SCFD2 and its involvement in intracellular protein transport and vesicle docking may have implications for diseases related to these processes, such as neurodegenerative disorders and diabetes. Further research is needed to fully understand the potential disease implications of SCFD2 and to develop targeted drug therapies.",GO:0006886 intracellular protein transport;GO:0015031 protein transport;GO:0046907 intracellular transport,,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000145388.15,ENSG00000145388,METTL14,-0.600570245,-0.938085106,-0.618557418,-0.24506821,"methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit","METTL14 is a gene that encodes for a protein called methyltransferase 14, N6-adenosine-methyltransferase subunit. This protein is involved in mRNA binding and contributes to mRNA methylation. It plays a role in mRNA metabolism, negative regulation of hematopoietic progenitor cell differentiation, and positive regulation of translation. METTL14 is located in the nucleoplasm and is part of the RNA N6-methyladenosine methyltransferase complex.","METTL14 has been implicated in various diseases, including cancer, neurological disorders, and cardiovascular diseases. In cancer, METTL14 has been shown to regulate tumor growth and metastasis by modulating mRNA stability and translation. In neurological disorders, METTL14 has been linked to the regulation of synaptic plasticity and memory formation. In cardiovascular diseases, METTL14 has been associated with the regulation of endothelial cell function and angiogenesis.

Targeted drug discovery efforts for METTL14 are still in the early stages, but there is growing interest in developing drugs that target the RNA N6-methyladenosine methyltransferase complex. One approach is to develop small molecule inhibitors that can selectively target METTL14 and disrupt its function. Another approach is to develop RNA-based therapeutics that can modulate METTL14 expression or activity.

Currently, there are no drugs on the market that specifically target METTL14. However, there are drugs that indirectly affect METTL14 function. For example, the chemotherapy drug cisplatin has been shown to downregulate METTL14 expression in cancer cells, leading to increased sensitivity to the drug. Additionally, the antidepressant drug fluoxetine has been shown to increase METTL14 expression in the brain, leading to improved synaptic plasticity and memory formation.",GO:0021861 forebrain radial glial cell differentiation;GO:0060019 radial glial cell differentiation;GO:1901533 negative regulation of hematopoietic progenitor cell differentiation,,Cancer-related genes:Mutational cancer driver genes; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000162819.12,ENSG00000162819,BROX,-0.598554666,-0.78781568,-0.871203328,-0.13664499,BRO1 domain and CAAX motif containing,"BROX is a human gene that contains both the BRO1 domain and CAAX motif. It is located in the extracellular exosome, which is a small vesicle that is released from cells and contains various molecules, including proteins and nucleic acids. The BRO1 domain is a conserved protein domain that is involved in regulating membrane trafficking and protein sorting, while the CAAX motif is a common protein modification that is involved in protein prenylation. The function of BROX is not yet fully understood, but it may play a role in regulating cellular processes such as cell signaling and protein trafficking.","There is limited information available on the disease implications of BROX. However, some studies have suggested that mutations in the BROX gene may be associated with certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for BROX are also limited, as its function is not yet fully understood. However, some studies have suggested that targeting the BRO1 domain may be a potential strategy for developing new cancer therapies. Currently, there are no drugs on the market that specifically target BROX. However, there are drugs that target the CAAX motif, such as statins, which are commonly used to lower cholesterol levels. Additionally, there are drugs that target the BRO1 domain, such as Vps4 inhibitors, which are being investigated as potential cancer therapies.",GO:0007084 mitotic nuclear membrane reassembly;GO:0101024 mitotic nuclear membrane organization;GO:0031468 nuclear membrane reassembly,,Predicted intracellular proteins,Golgi apparatus (Approved); Additional: Cytosol;Nucleoplasm,,,
ENSG00000148248.14,ENSG00000148248,SURF4,-0.596980099,-0.883766501,-0.553295615,-0.353878179,surfeit 4,"SURF4, also known as surfeit 4, is a gene located in a cluster of housekeeping genes that are tightly linked and do not share sequence similarity. The protein encoded by this gene is an integral membrane protein that interacts with proteins in the endoplasmic reticulum-Golgi intermediate compartment. When this gene is disrupted, there is a reduction in the number of endoplasmic reticulum-Golgi intermediate compartment clusters and a redistribution of coat protein I to the cytosol. There are multiple transcript variants of this gene due to alternate splicing. Overall, SURF4 plays an important role in the proper functioning of the endoplasmic reticulum-Golgi intermediate compartment.","There is limited information available on the disease implications of SURF4. However, recent studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, including breast cancer and lung adenocarcinoma. Targeted drug discovery efforts for SURF4 are also limited, as the exact function of the protein encoded by this gene is not fully understood. However, some studies have suggested that targeting SURF4 may be a potential therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target SURF4. However, there are several drugs that target the endoplasmic reticulum-Golgi intermediate compartment, such as brefeldin A and golgicide A, which have been used in cancer research and may have potential therapeutic applications in the future.",GO:0140353 lipid export from cell;GO:0090110 COPII-coated vesicle cargo loading;GO:0042953 lipoprotein transport,,Transporters,Endoplasmic reticulum;Golgi apparatus;Nuclear membrane (Supported); Additional: Cytosol,,,
ENSG00000171497.5,ENSG00000171497,PPID,-0.596549072,-1.182955605,-0.572075864,-0.034615748,peptidylprolyl isomerase D,"PPID is a human gene that encodes a protein belonging to the peptidyl-prolyl cis-trans isomerase (PPIase) family. PPIases are enzymes that catalyze the isomerization of proline imidic peptide bonds in oligopeptides, which helps accelerate protein folding. PPID has been shown to possess PPIase activity and can bind to the immunosuppressant cyclosporin A, similar to other family members.","PPID has been implicated in several diseases, including cancer, Alzheimer's disease, and autoimmune disorders. In cancer, PPID has been shown to be overexpressed in several types of tumors, including breast, lung, and prostate cancer, and may play a role in tumor progression and metastasis. In Alzheimer's disease, PPID has been found to be upregulated in the brains of patients, and may contribute to the formation of amyloid plaques and neurofibrillary tangles. In autoimmune disorders, PPID has been shown to be involved in the regulation of T-cell activation and cytokine production.

Targeted drug discovery efforts for PPID have focused on developing inhibitors of its PPIase activity, as well as compounds that can disrupt its interaction with cyclosporin A. Several compounds have been identified as potential PPID inhibitors, including FK506 and its analogs, which are currently used as immunosuppressants in transplant patients. Other compounds, such as cyclophilin inhibitors and cyclosporin derivatives, are also being investigated as potential PPID inhibitors.

One successful drug on the market that targets PPID is cyclosporin A, which is used as an immunosuppressant in transplant patients to prevent rejection of the transplanted organ. Cyclosporin A works by binding to PPID and inhibiting its PPIase activity, which in turn suppresses T-cell activation and cytokine production. Another drug, alisporivir, is a cyclophilin inhibitor that was developed as a treatment for hepatitis C, but was ultimately not approved due to safety concerns. However, alisporivir is still being investigated as a potential treatment for other diseases, including autoimmune disorders and cancer.",GO:0071492 cellular response to UV-A;GO:0070141 response to UV-A;GO:0019076 viral release from host cell,,Enzymes; ENZYME proteins:Isomerase; Predicted intracellular proteins,Cytosol (Supported); Additional: Nucleoli;Nucleoli rim;Nucleoplasm;Primary cilium,,(M195)PID CMYB PATHWAY,
ENSG00000158545.16,ENSG00000158545,ZC3H18,-0.59611599,-1.129205351,-0.534389903,-0.124752717,zinc finger CCCH-type containing 18,"ZC3H18 is a human gene that encodes a protein containing a zinc finger CCCH-type domain. This protein is involved in RNA destabilization and is located in the nuclear speck. It enables mRNA cap binding complex binding activity and protein-macromolecule adaptor activity, and is part of a ribonucleoprotein complex. The function of ZC3H18 is not fully understood, but it is believed to play a role in regulating gene expression and RNA processing. This gene may have implications in various diseases, including cancer and neurological disorders.","There is limited information available on the disease implications of ZC3H18. However, recent studies have suggested that mutations in this gene may be associated with various neurological disorders, including autism spectrum disorder and intellectual disability. Additionally, ZC3H18 has been found to be overexpressed in certain types of cancer, such as breast cancer, and may play a role in tumor growth and metastasis.

Currently, there are no targeted drug discovery efforts specifically focused on ZC3H18. However, there are several drugs on the market that target RNA destabilization and RNA processing, which are functions that ZC3H18 is involved in. For example, the drug Actinomycin D is a potent inhibitor of RNA synthesis and is used to treat various types of cancer. Another drug, Eteplirsen, is used to treat Duchenne muscular dystrophy by targeting RNA splicing.

In conclusion, while the function of ZC3H18 is not fully understood, it may have implications in various diseases, including cancer and neurological disorders. While there are no targeted drug discovery efforts focused on this gene, there are several drugs on the market that target RNA destabilization and RNA processing, which are functions that ZC3H18 is involved in.",GO:0050779 RNA destabilization;GO:0043487 regulation of RNA stability;GO:0009896 positive regulation of catabolic process,,Predicted intracellular proteins,Nuclear speckles (Enhanced),,,
ENSG00000131236.18,ENSG00000131236,CAP1,-0.595839226,-0.967662907,-0.692810776,-0.127043996,cyclase associated actin cytoskeleton regulatory protein 1,"CAP1, or cyclase associated actin cytoskeleton regulatory protein 1, is a human gene that is related to the S. cerevisiae CAP protein, which is involved in the cyclic AMP pathway. CAP1 is able to interact with other molecules of the same protein, as well as with CAP2 and actin. There are different isoforms of CAP1 that have been identified due to alternative splicing of transcript variants.","Research has shown that CAP1 may play a role in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, CAP1 has been found to be overexpressed in several types of tumors, including breast, lung, and colon cancer, and may contribute to tumor growth and metastasis. Targeted drug discovery efforts have focused on developing inhibitors of CAP1 as potential cancer therapeutics. One example is the small molecule compound, CK-666, which has been shown to inhibit the interaction between CAP1 and actin, leading to decreased cancer cell migration and invasion. Another example is the natural compound, curcumin, which has been found to inhibit CAP1 expression and activity in breast cancer cells. However, there are currently no drugs targeting CAP1 on the market.",GO:0098885 modification of postsynaptic actin cytoskeleton;GO:0099010 modification of postsynaptic structure;GO:0007190 activation of adenylate cyclase activity,,Predicted intracellular proteins,Cytosol (Approved),,(M7955)SIG INSULIN RECEPTOR PATHWAY IN CARDIAC MYOCYTES,(M5915)HALLMARK APICAL JUNCTION
ENSG00000125637.16,ENSG00000125637,PSD4,-0.595658049,-0.763391444,-0.625394321,-0.398188381,pleckstrin and Sec7 domain containing 4,"PSD4, also known as pleckstrin and Sec7 domain containing 4, is a human gene that is predicted to have guanyl-nucleotide exchange factor activity and phospholipid binding activity. It is also believed to be involved in the regulation of ARF protein signal transduction and catalytic activity. PSD4 is located in the ruffle membrane. This information is provided by the Alliance of Genome Resources as of April 2022.","PSD4 has been implicated in several diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, PSD4 has been shown to promote tumor growth and metastasis by regulating cell migration and invasion. In cardiovascular disease, PSD4 has been linked to the regulation of platelet activation and thrombosis. In neurological disorders, PSD4 has been associated with the regulation of synaptic plasticity and memory formation.

Targeted drug discovery efforts for PSD4 are still in the early stages, but there is potential for the development of drugs that target PSD4 to treat cancer, cardiovascular disease, and neurological disorders. One approach is to develop small molecule inhibitors that block the guanyl-nucleotide exchange factor activity of PSD4, which could inhibit tumor growth and metastasis, reduce platelet activation and thrombosis, and improve synaptic plasticity and memory formation.

Currently, there are no drugs on the market that specifically target PSD4. However, there are drugs that indirectly affect PSD4 signaling pathways. For example, statins, which are commonly used to lower cholesterol levels, have been shown to inhibit PSD4 expression and reduce platelet activation. Additionally, some anti-cancer drugs, such as paclitaxel and doxorubicin, have been shown to inhibit PSD4 expression and reduce tumor growth and metastasis.",GO:0032012 regulation of ARF protein signal transduction;GO:0051056 regulation of small GTPase mediated signal transduction;GO:1902531 regulation of intracellular signal transduction,,Predicted intracellular proteins,,,,
ENSG00000166783.22,ENSG00000166783,MARF1,-0.595476965,-0.793498837,-0.767651879,-0.22528018,meiosis regulator and mRNA stability factor 1,"MARF1 is a gene that encodes a protein that is believed to be involved in regulating meiosis and stabilizing mRNA. It is conserved across Euteleostomi, a group of vertebrates that includes bony fish and mammals. In humans, the protein may be autoantigenic, meaning that it can trigger an immune response against the body's own tissues. The exact function of MARF1 is not yet fully understood, but it is thought to play a role in the development and maintenance of reproductive cells. Further research is needed to fully elucidate the function of this gene and its potential implications for human health.","There is limited information available on the disease implications of MARF1. However, studies have suggested that mutations in this gene may be associated with male infertility. Targeted drug discovery efforts for MARF1 are also currently limited, as the exact function of the protein encoded by this gene is not yet fully understood. There are currently no drugs on the market that specifically target MARF1. However, there are drugs that target other proteins involved in meiosis and mRNA stabilization, which may indirectly affect MARF1 function. For example, drugs that target the protein kinase ATR have been shown to affect meiosis and may have potential therapeutic applications in cancer treatment. Further research is needed to fully understand the role of MARF1 in disease and to develop targeted therapies.",GO:0007143 female meiotic nuclear division;GO:0048477 oogenesis;GO:0007292 female gamete generation,,Predicted intracellular proteins,Golgi apparatus;Vesicles (Approved),,,
ENSG00000011451.21,ENSG00000011451,WIZ,-0.593940671,-1.007578048,-0.542644176,-0.231599788,WIZ zinc finger,"The human gene WIZ encodes a protein that has several functions, including DNA-binding transcription factor activity, histone methyltransferase binding activity, and transcription corepressor binding activity. It is involved in positive regulation of nuclear cell cycle DNA replication and protein stabilization. The protein is located in the midbody and nucleoplasm.","There is limited information available on the disease implications of the WIZ gene. However, recent studies have suggested that mutations in the WIZ gene may be associated with intellectual disability and developmental delay. Targeted drug discovery efforts for this gene are also limited, as its exact role in disease pathogenesis is not well understood. Currently, there are no drugs on the market that specifically target the WIZ gene. However, there are several drugs that target related pathways, such as histone methyltransferase inhibitors and DNA replication inhibitors, which may indirectly affect the function of the WIZ protein. Examples of such drugs include azacitidine, decitabine, and gemcitabine. Further research is needed to fully understand the role of the WIZ gene in disease and to develop targeted therapies.",GO:0010571 positive regulation of nuclear cell cycle DNA replication;GO:0033262 regulation of nuclear cell cycle DNA replication;GO:2000105 positive regulation of DNA-templated DNA replication,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,(M5941)HALLMARK UV RESPONSE UP
ENSG00000128908.17,ENSG00000128908,INO80,-0.591071118,-0.932485139,-0.611869321,-0.228858894,INO80 complex ATPase subunit,"The INO80 gene encodes a catalytic ATPase subunit of the INO80 chromatin remodeling complex, which is responsible for modifying the structure of chromatin. This complex is classified into subfamilies based on sequence features, and this protein is part of the subfamily with a DNA-binding domain. It is proposed that this protein binds to DNA and is recruited by the YY1 transcription factor to activate certain genes. Alternative splicing of the gene results in multiple transcript variants.","Research has shown that the INO80 gene is involved in various diseases, including cancer, neurological disorders, and developmental disorders. In cancer, the INO80 complex has been found to play a role in tumor progression and metastasis, making it a potential target for cancer therapy. Targeted drug discovery efforts have focused on developing inhibitors of the INO80 complex, with some promising results in preclinical studies. For example, a small molecule inhibitor of the INO80 complex has been shown to inhibit tumor growth in mouse models of breast cancer. However, there are currently no drugs targeting the INO80 complex on the market. Further research is needed to fully understand the role of the INO80 complex in disease and to develop effective therapies targeting this complex.",GO:0010571 positive regulation of nuclear cell cycle DNA replication;GO:0070914 UV-damage excision repair;GO:0033262 regulation of nuclear cell cycle DNA replication,,Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Enhanced); Additional: Cytosol,,,
ENSG00000084463.8,ENSG00000084463,WBP11,-0.590951198,-0.992558834,-0.638811777,-0.141482984,WW domain binding protein 11,"WBP11, also known as NpwBP, is a nuclear protein that is involved in mRNA splicing and is found in perinuclear networks. It has a high degree of similarity to the mouse Wbp11 protein and contains two proline-rich regions that bind to the WW domain of Npw38, another nuclear protein. The Npw38-NpwBP complex may play a role in the formation of mRNA factories in the nucleus.","There is limited information available on the disease implications of WBP11. However, recent studies have suggested that it may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for WBP11 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and inhibit its function. While there are currently no drugs on the market that specifically target WBP11, there are several drugs that have been approved for the treatment of breast cancer and hepatocellular carcinoma that may indirectly affect the protein's activity. These include tamoxifen, trastuzumab, and sorafenib, among others. Further research is needed to fully understand the potential therapeutic implications of targeting WBP11 in cancer treatment.",GO:0006364 rRNA processing;GO:0016072 rRNA metabolic process;GO:0042254 ribosome biogenesis,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Other congenital malformations,Nucleoplasm (Supported); Additional: Acrosome;Cytosol;End piece;Principal piece;Vesicles,,,
ENSG00000164975.15,ENSG00000164975,SNAPC3,-0.590526323,-0.968631865,-0.638164269,-0.164782835,small nuclear RNA activating complex polypeptide 3,"SNAPC3 is a gene that is involved in the transcription of small nuclear RNAs (snRNAs) by RNA polymerase II and III. It is predicted to have DNA binding activity and is located in the nuclear body and nucleolus. The gene is also predicted to contribute to RNA polymerase II cis-regulatory region sequence-specific DNA binding activity and core promoter sequence-specific DNA binding activity. Overall, SNAPC3 plays an important role in the regulation of gene expression and the production of snRNAs, which are essential for various cellular processes such as splicing and translation.","There is limited information available on the disease implications of SNAPC3. However, recent studies have suggested that mutations in the gene may be associated with developmental disorders such as intellectual disability and autism spectrum disorder. Targeted drug discovery efforts for SNAPC3 are also limited, as the gene is not currently considered a therapeutic target. However, there are ongoing efforts to develop drugs that target RNA polymerase II and III, which are involved in the transcription of snRNAs and may indirectly affect SNAPC3 activity. Examples of successful drugs that target RNA polymerase II and III include alpha-amanitin, which is derived from the mushroom Amanita phalloides and is used in cancer research, and mycophenolic acid, which is used as an immunosuppressant in organ transplantation.",GO:0042796 snRNA transcription by RNA polymerase III;GO:0042795 snRNA transcription by RNA polymerase II;GO:0009301 snRNA transcription,,Predicted intracellular proteins,Nuclear bodies;Nucleoplasm (Supported); Additional: Nucleoli,,,
ENSG00000198060.10,ENSG00000198060,MARCHF5,-0.590288732,-0.78016267,-0.855511681,-0.135191845,membrane associated ring-CH-type finger 5,"MARCHF5 is a gene that codes for a protein called membrane associated ring-CH-type finger 5. This protein is a ubiquitin ligase found in the outer membrane of mitochondria and is involved in regulating mitochondrial morphology by controlling the activity of two other proteins, mitofusin-2 and DRP1. MARCHF5 helps to maintain the proper shape and function of mitochondria, which are important organelles responsible for producing energy in cells. Mutations in this gene have been associated with various diseases, including Parkinson's disease and cancer.","Mutations in the MARCHF5 gene have been linked to several diseases, including Parkinson's disease and cancer. In Parkinson's disease, MARCHF5 has been shown to play a role in the clearance of damaged mitochondria, which is impaired in patients with the disease. This suggests that targeting MARCHF5 could be a potential therapeutic strategy for Parkinson's disease. In cancer, MARCHF5 has been found to be overexpressed in several types of tumors, including breast, lung, and liver cancer. This overexpression has been associated with increased tumor growth and poor prognosis, making MARCHF5 a potential target for cancer therapy.

There are currently no drugs on the market that specifically target MARCHF5. However, there are ongoing efforts to develop drugs that can modulate the activity of MARCHF5 and other proteins involved in mitochondrial dynamics. One approach is to develop small molecules that can inhibit the activity of MARCHF5, which could potentially be used to treat Parkinson's disease and cancer. Another approach is to develop drugs that can activate the clearance of damaged mitochondria, which could also be beneficial in these diseases.

Overall, MARCHF5 is an important protein involved in regulating mitochondrial dynamics and has implications for several diseases. While there are currently no drugs on the market that target MARCHF5, ongoing research efforts hold promise for the development of new therapies for Parkinson's disease and cancer.",GO:0090141 positive regulation of mitochondrial fission;GO:0090140 regulation of mitochondrial fission;GO:0051865 protein autoubiquitination,,Enzymes; ENZYME proteins:Transferases,Mitochondria (Supported),,,
ENSG00000144043.12,ENSG00000144043,TEX261,-0.589871746,-0.990272776,-0.513019591,-0.266322872,testis expressed 261,"TEX261, also known as Testis Expressed 261, is a gene that is predicted to play a role in COPII receptor activity and endoplasmic reticulum to Golgi vesicle-mediated transport. It is also predicted to be involved in positive regulation of apoptotic process and is located in the cytoplasm. TEX261 is predicted to be an integral component of the membrane and is active in COPII-coated ER to Golgi transport vesicle. It is also predicted to be an integral component of the Golgi membrane and endoplasmic reticulum membrane. These predictions were provided by the Alliance of Genome Resources in April 2022.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for TEX261. As of April 2022, there are no known drugs on the market that specifically target this gene. However, further research on the function and role of TEX261 may lead to the identification of potential therapeutic targets for diseases related to COPII receptor activity and endoplasmic reticulum to Golgi vesicle-mediated transport. Additionally, understanding the role of TEX261 in the regulation of apoptosis may provide insights into the development of treatments for diseases related to abnormal cell death. Further research is needed to fully understand the potential implications of TEX261 in disease and drug discovery efforts.",GO:0006888 endoplasmic reticulum to Golgi vesicle-mediated transport;GO:0048193 Golgi vesicle transport;GO:0043065 positive regulation of apoptotic process,,,Nucleoplasm (Uncertain); Additional: Cytosol,,,
ENSG00000065548.18,ENSG00000065548,ZC3H15,-0.589775959,-0.72947875,-0.571309825,-0.468539301,zinc finger CCCH-type containing 15,"ZC3H15 is a human gene that encodes a protein containing zinc finger CCCH-type domains. This protein is involved in RNA binding and cadherin binding activities, and is also involved in the positive regulation of GTPase activity. ZC3H15 is located in the cytosol, which is the fluid inside cells that surrounds the organelles. The function of this gene is not fully understood, but it may play a role in regulating cellular processes such as cell signaling and gene expression.","There is limited information available on the disease implications of ZC3H15. However, recent studies have suggested that mutations in this gene may be associated with intellectual disability and developmental delay. Targeted drug discovery efforts for ZC3H15 are also limited, as the function of this gene is not fully understood. However, some studies have suggested that ZC3H15 may play a role in cancer progression, and as such, there may be potential for developing targeted therapies for cancer treatment. Currently, there are no drugs on the market that specifically target ZC3H15. However, there are several drugs that target GTPases, which ZC3H15 is involved in regulating. Examples of such drugs include statins, which are commonly used to lower cholesterol levels, and bisphosphonates, which are used to treat osteoporosis.",GO:0043547 positive regulation of GTPase activity;GO:0002181 cytoplasmic translation;GO:0043087 regulation of GTPase activity,,Predicted intracellular proteins,Cytosol (Enhanced),,,
ENSG00000105879.12,ENSG00000105879,CBLL1,-0.588509507,-1.071014291,-0.599026072,-0.095488159,Cbl proto-oncogene like 1,"CBLL1 is a human gene that encodes an E3 ubiquitin-ligase responsible for the ubiquitination, endocytosis, and degradation of the E-cadherin complex in lysosomes. The gene contains a RING-finger domain and is believed to play a role in regulating cell proliferation. A pseudogene related to CBLL1 has been identified on chromosome X. Alternative splicing of the gene results in a non-coding transcript variant.","CBLL1 has been implicated in various types of cancer, including breast, lung, and gastric cancer. In breast cancer, CBLL1 has been shown to promote tumor growth and metastasis by regulating the E-cadherin complex. Targeting CBLL1 has been proposed as a potential therapeutic strategy for cancer treatment. However, there are currently no drugs on the market that specifically target CBLL1.

Efforts to develop drugs targeting CBLL1 are still in the early stages. One study identified a small molecule inhibitor of CBLL1 that was able to reduce the growth of breast cancer cells in vitro and in vivo. Another study found that a natural compound called curcumin could inhibit CBLL1 expression and reduce the growth of lung cancer cells.

Overall, CBLL1 is a promising target for cancer therapy, but more research is needed to develop effective drugs that specifically target this gene.",GO:0045807 positive regulation of endocytosis;GO:0030100 regulation of endocytosis;GO:0007162 negative regulation of cell adhesion,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nuclear speckles (Supported),,(M142)PID AJDISS 2PATHWAY,
ENSG00000103168.17,ENSG00000103168,TAF1C,-0.588469321,-1.007228991,-0.551304067,-0.206874904,"TATA-box binding protein associated factor, RNA polymerase I subunit C","TAF1C is a gene that encodes the largest TBP-associated factor (TAF) specific for RNA polymerase I. This TAF is a component of the SL1 complex, which is required for the initiation of transcription by RNA polymerase I. The SL1 complex binds to the core promoter of ribosomal RNA genes and positions the polymerase properly, while also acting as a channel for regulatory signals. Multiple isoforms of TAF1C have been identified due to alternative splicing of the gene.","There is limited information available on the disease implications of TAF1C mutations. However, recent studies have suggested that TAF1C may play a role in cancer development and progression. For example, TAF1C has been found to be overexpressed in various types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts for TAF1C are still in the early stages, but there is potential for the development of drugs that target TAF1C to treat cancer. Currently, there are no drugs on the market that specifically target TAF1C. However, there are drugs that target other components of the SL1 complex, such as CX-5461, which is a small molecule inhibitor of RNA polymerase I transcription that has shown promise in preclinical studies for the treatment of cancer.",GO:0001188 RNA polymerase I preinitiation complex assembly;GO:0006361 transcription initiation at RNA polymerase I promoter;GO:0006360 transcription by RNA polymerase I,,Predicted intracellular proteins,Nucleoli fibrillar center;Nucleoplasm (Supported),,,(M5898)HALLMARK DNA REPAIR
ENSG00000168710.18,ENSG00000168710,AHCYL1,-0.587645881,-0.802830704,-0.780972666,-0.179134274,adenosylhomocysteinase like 1,"AHCYL1 is a human gene that encodes a protein that interacts with inositol 1,4,5-trisphosphate receptor, type 1. This protein may play a role in the conversion of S-adenosyl-L-homocysteine to L-homocysteine and adenosine. The gene has several transcript variants that encode two different isoforms.","There is limited information available on the disease implications of AHCYL1. However, some studies have suggested that mutations in this gene may be associated with an increased risk of developing certain types of cancer, including breast and prostate cancer. Targeted drug discovery efforts for AHCYL1 are also limited, but some studies have suggested that targeting this gene may be a potential therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target AHCYL1. However, there are several drugs that indirectly affect the function of this gene, including methotrexate, which is used to treat cancer and autoimmune diseases, and azathioprine, which is used to prevent organ rejection in transplant patients. Further research is needed to fully understand the role of AHCYL1 in disease and to develop targeted therapies for its associated conditions.",GO:0033353 S-adenosylmethionine cycle;GO:1990456 mitochondrion-endoplasmic reticulum membrane tethering;GO:0031440 regulation of mRNA 3'-end processing,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Cytosol (Supported),,,
ENSG00000141027.21,ENSG00000141027,NCOR1,-0.587206707,-0.952906833,-0.590147654,-0.218565633,nuclear receptor corepressor 1,"NCOR1, or nuclear receptor corepressor 1, is a gene that encodes a protein responsible for repressing the transcription of thyroid-hormone and retinoic-acid receptors. This is achieved by promoting chromatin condensation and preventing access of the transcription machinery. NCOR1 is part of a complex that includes histone deacetylases and transcriptional regulators similar to the yeast protein Sin3p. The gene is located on chromosome 17 between the Charcot-Marie-Tooth and Smith-Magenis syndrome critical regions. Alternate splicing results in multiple transcript variants, and pseudogenes of this gene are found on chromosomes 17 and 20.","NCOR1 has been implicated in several diseases, including cancer, metabolic disorders, and neurological disorders. In cancer, NCOR1 has been shown to play a role in tumor growth and metastasis, and its overexpression has been associated with poor prognosis in several types of cancer, including breast, prostate, and colorectal cancer. In metabolic disorders, NCOR1 has been linked to insulin resistance and obesity, and its inhibition has been shown to improve glucose homeostasis and reduce adiposity in animal models. In neurological disorders, NCOR1 has been implicated in Alzheimer's disease and Huntington's disease, and its inhibition has been shown to improve cognitive function and reduce neurodegeneration in animal models.

Targeted drug discovery efforts for NCOR1 have focused on developing small molecule inhibitors that can disrupt the interaction between NCOR1 and its binding partners, such as histone deacetylases and transcriptional regulators. Several compounds have been identified that can inhibit NCOR1 activity, including the HDAC inhibitor vorinostat and the synthetic retinoid bexarotene. Vorinostat has been approved by the FDA for the treatment of cutaneous T-cell lymphoma, while bexarotene has been approved for the treatment of refractory cutaneous T-cell lymphoma and is being investigated for the treatment of Alzheimer's disease.

In conclusion, NCOR1 is a promising target for drug discovery efforts in several disease areas, including cancer, metabolic disorders, and neurological disorders. While several compounds have been identified that can inhibit NCOR1 activity, further research is needed to fully understand the therapeutic potential of targeting this gene.",GO:0045475 locomotor rhythm;GO:0060766 negative regulation of androgen receptor signaling pathway;GO:0030812 negative regulation of nucleotide catabolic process,,Transcription factors:Helix-turn-helix domains; Cancer-related genes:Mutational cancer driver genes; Cancer-related genes:Mutated cancer genes; Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,(M13)PID ERBB4 PATHWAY; (M288)PID HES HEY PATHWAY; (M17)PID NOTCH PATHWAY,
ENSG00000149930.18,ENSG00000149930,TAOK2,-0.584966204,-1.094178787,-0.515125071,-0.145594753,TAO kinase 2,"TAOK2 is a gene that encodes a protein kinase involved in various cellular processes such as cell signaling, microtubule organization and stability, and apoptosis. The gene produces different isoforms due to alternative splicing of its transcript variants.","TAOK2 has been implicated in several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, TAOK2 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. In neurodegenerative disorders, TAOK2 has been linked to the regulation of tau protein, which is involved in the development of Alzheimer's disease. In cardiovascular diseases, TAOK2 has been shown to regulate the proliferation and migration of vascular smooth muscle cells, which are involved in the development of atherosclerosis.

Several drug discovery efforts have targeted TAOK2, with a focus on developing small molecule inhibitors that can selectively target the kinase activity of TAOK2. One example is the drug KIN-1148, which has been shown to inhibit the kinase activity of TAOK2 and suppress the growth of cancer cells in vitro and in vivo. Another example is the drug TAK-659, which is currently in clinical trials for the treatment of lymphoma and other hematological malignancies. TAK-659 is a selective inhibitor of several kinases, including TAOK2, and has shown promising results in preclinical studies.

Overall, TAOK2 is an important target for drug discovery efforts in various diseases, and several drugs targeting TAOK2 are currently in development or on the market.",GO:0150018 basal dendrite development;GO:0150019 basal dendrite morphogenesis;GO:0150020 basal dendrite arborization,yes,Enzymes; Kinases:STE Ser/Thr protein kinases; Predicted intracellular proteins; ENZYME proteins:Transferases,Cytosol;Nucleoplasm (Approved); Additional: Nucleoli,Dexfosfoserine; Fostamatinib,(M20)PID P38 MKK3 6PATHWAY,(M5893)HALLMARK MITOTIC SPINDLE; (M5915)HALLMARK APICAL JUNCTION
ENSG00000112308.13,ENSG00000112308,C6orf62,-0.584923696,-0.77120221,-0.782535814,-0.201033064,chromosome 6 open reading frame 62,"The human gene C6orf62, also known as chromosome 6 open reading frame 62, is a protein-coding gene located on chromosome 6. The function of the protein encoded by this gene is not yet fully understood, but it is believed to play a role in cellular processes such as DNA repair and cell cycle regulation. Mutations in this gene have been associated with various diseases, including cancer and neurodegenerative disorders. Further research is needed to fully understand the function and potential clinical implications of C6orf62.","There is limited information available on the disease implications and targeted drug discovery efforts for C6orf62. However, mutations in this gene have been associated with various diseases, including cancer and neurodegenerative disorders. Targeted drug discovery efforts for C6orf62 are currently underway, but there are no drugs on the market that specifically target this gene. However, there are drugs on the market that target cellular processes that C6orf62 is believed to be involved in, such as DNA repair and cell cycle regulation. Examples of such drugs include PARP inhibitors, which are used to treat certain types of cancer, and CDK inhibitors, which are used to treat breast cancer and other types of cancer. Further research is needed to fully understand the potential clinical implications of C6orf62 and to develop targeted therapies for diseases associated with mutations in this gene.",GO:0008150 biological_process,,Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000227345.8,ENSG00000227345,PARG,-0.584281297,-0.792736951,-0.705825823,-0.254281118,poly(ADP-ribose) glycohydrolase,"Poly(ADP-ribose) glycohydrolase (PARG) is an enzyme responsible for breaking down poly(ADP-ribose), a molecule that modifies chromosomal proteins. PARG is found in many tissues and can be broken down into smaller, active products. There are several different isoforms of PARG that have been identified through transcript variants.","PARG has been implicated in several diseases, including cancer, neurodegenerative disorders, and inflammation. In cancer, PARG inhibition has been shown to enhance the efficacy of chemotherapy and radiation therapy, making it a promising target for cancer treatment. Several PARG inhibitors have been developed and are currently being tested in preclinical and clinical trials for cancer treatment. In neurodegenerative disorders, PARG inhibition has been shown to protect against neuronal damage and improve cognitive function in animal models. Inflammation is also associated with PARG dysregulation, and PARG inhibitors have shown promise in reducing inflammation in animal models of inflammatory diseases. One example of a successful PARG inhibitor is talazoparib, which is approved for the treatment of breast cancer with BRCA mutations.","GO:1990966 ATP generation from poly-ADP-D-ribose;GO:0006287 base-excision repair, gap-filling;GO:0006284 base-excision repair",,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol;Nuclear bodies,,,
ENSG00000115486.12,ENSG00000115486,GGCX,-0.582436802,-0.923951952,-0.637719718,-0.185638735,gamma-glutamyl carboxylase,"The GGCX gene encodes an integral membrane protein that is responsible for carboxylating glutamate residues of vitamin K-dependent proteins to gamma carboxyl glutamate, which is necessary for their activity. Vitamin K-dependent proteins play a role in various physiological processes, including blood coagulation, prevention of vascular calcification, and inflammation. The enzyme binds to the propeptide of the protein substrate, along with carbon dioxide, dioxide, and reduced vitamin K as co-substrates. Allelic variants of this gene have been linked to pseudoxanthoma elasticum-like disorder with associated multiple coagulation factor deficiency. Alternative splicing of the gene results in multiple transcript variants.","Mutations in the GGCX gene have been associated with a rare genetic disorder called combined deficiency of vitamin K-dependent clotting factors (VKCFD), which is characterized by bleeding diathesis due to the deficiency of multiple coagulation factors. Additionally, mutations in GGCX have been linked to pseudoxanthoma elasticum-like disorder (PXE-like), which is a rare connective tissue disorder that affects the skin, eyes, and cardiovascular system. There are currently no targeted drug discovery efforts for GGCX, and treatment for VKCFD and PXE-like is mainly supportive. However, vitamin K supplementation has been shown to improve the coagulation defect in VKCFD patients. Warfarin, a commonly used anticoagulant, works by inhibiting the activity of vitamin K-dependent clotting factors, including those carboxylated by GGCX. Other drugs that target the coagulation cascade, such as direct oral anticoagulants (DOACs), have also been developed and are widely used in clinical practice.",GO:0042373 vitamin K metabolic process;GO:0006775 fat-soluble vitamin metabolic process;GO:0042180 ketone metabolic process,,ENZYME proteins:Lyases; Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of skin; FDA approved drug targets:Small molecule drugs; Disease related genes; Enzymes; Human disease related genes:Congenital disorders of metabolism:Other congenital disorders of metabolism; Human disease related genes:Cardiovascular diseases:Hematologic diseases,,Coagulation factor VIIa Recombinant Human; Coagulation Factor IX (Recombinant); Glutamic acid; Menadione; Phylloquinone; Anisindione; Kappadione; Coagulation Factor IX Human,,
ENSG00000108946.15,ENSG00000108946,PRKAR1A,-0.582409915,-0.929037205,-0.584813964,-0.233378575,protein kinase cAMP-dependent type I regulatory subunit alpha,"PRKAR1A is a gene that encodes one of the regulatory subunits of the cAMP-dependent protein kinase, which is important for various cellular functions. The inactive kinase holoenzyme is composed of two regulatory and two catalytic subunits, and cAMP causes its dissociation into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Mutations in PRKAR1A cause Carney complex (CNC) and can also lead to the formation of the thyroid tumor-specific chimeric oncogene known as PTC2. This protein has been found to be a tissue-specific extinguisher that down-regulates the expression of seven liver genes in hepatoma x fibroblast hybrids. Additionally, a nonconventional nuclear localization sequence (NLS) has been found for this protein, suggesting a role in DNA replication via nuclear transport of the second subunit of the Replication Factor C (RFC40).","Carney complex (CNC) is a rare genetic disorder caused by mutations in the PRKAR1A gene. It is characterized by the development of multiple benign tumors in various parts of the body, including the heart, skin, and endocrine glands. There is currently no cure for CNC, and treatment is focused on managing the symptoms and complications associated with the disease. Targeted drug discovery efforts for CNC are ongoing, with a focus on developing drugs that can specifically target the underlying genetic mutations. One example of a successful drug on the market for a related condition is cabergoline, which is used to treat pituitary tumors associated with CNC. Other potential drug targets for CNC include the cAMP signaling pathway and the mTOR pathway.",GO:0141162 negative regulation of cAMP/PKA signal transduction;GO:0071377 cellular response to glucagon stimulus;GO:0046007 negative regulation of activated T cell proliferation,,Predicted intracellular proteins; Human disease related genes:Endocrine and metabolic diseases:Hypothalamus and pituitary gland diseases; Human disease related genes:Endocrine and metabolic diseases:Adrenal gland diseases; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Human disease related genes:Other diseases:Others; Disease related genes; Cancer-related genes:Mutational cancer driver genes,Cytosol (Approved),(Rp)-cAMPS; Cyclic GMP; Cyclic adenosine monophosphate; GEM-231,(M277)PID INTEGRIN A4B1 PATHWAY,
ENSG00000167977.9,ENSG00000167977,KCTD5,-0.581500276,-0.821073998,-0.635077808,-0.288349023,potassium channel tetramerization domain containing 5,"KCTD5 is a human gene that encodes a protein called potassium channel tetramerization domain containing 5. This protein is involved in binding identical proteins and is predicted to play a role in the breakdown of proteins through a process called proteasome-mediated ubiquitin-dependent protein catabolism. KCTD5 is located in the cytosol, which is the fluid inside cells that surrounds the organelles.","There is limited information available on the disease implications of KCTD5. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for KCTD5 are also limited, as the function of this protein is not well understood. However, some studies have suggested that KCTD5 may be a potential target for cancer therapy. Currently, there are no drugs on the market that specifically target KCTD5. However, there are several drugs that target the proteasome, which is the cellular machinery responsible for the breakdown of proteins, and may indirectly affect KCTD5 function. Examples of such drugs include bortezomib, carfilzomib, and ixazomib, which are used to treat multiple myeloma and other types of cancer.",GO:0051260 protein homooligomerization;GO:0051259 protein complex oligomerization;GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process,,Predicted intracellular proteins,,,,
ENSG00000260032.2,ENSG00000260032,NORAD,-0.581194101,-0.991111113,-0.47247228,-0.279998909,non-coding RNA activated by DNA damage,,,GO:0043488 regulation of mRNA stability;GO:0043487 regulation of RNA stability;GO:0061013 regulation of mRNA catabolic process,,,,,,
ENSG00000144744.17,ENSG00000144744,UBA3,-0.58113182,-0.781077683,-0.880835222,-0.081482554,ubiquitin like modifier activating enzyme 3,"The UBA3 gene encodes a member of the E1 ubiquitin-activating enzyme family, which is involved in the modification of proteins with ubiquitin for degradation. The encoded enzyme forms a heterodimer with AppBp1 and activates NEDD8, a ubiquitin-like protein that regulates cell division, signaling, and embryogenesis. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.","Research on UBA3 has shown its involvement in various diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, UBA3 has been found to be overexpressed in several types of tumors, including breast, lung, and prostate cancer, and its inhibition has been shown to reduce tumor growth. In neurodegenerative disorders, UBA3 has been linked to the formation of protein aggregates, which are a hallmark of diseases such as Alzheimer's and Parkinson's. Additionally, UBA3 has been shown to play a role in the replication of certain viruses, such as hepatitis B and C.

Targeted drug discovery efforts for UBA3 have focused on developing inhibitors that can selectively block its activity. One such inhibitor, MLN4924, has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer. MLN4924 works by inhibiting the activation of NEDD8, which is necessary for the function of UBA3.

Another successful drug that targets UBA3 is bortezomib, which is used to treat multiple myeloma and mantle cell lymphoma. Bortezomib inhibits the activity of the proteasome, which is responsible for the degradation of ubiquitinated proteins, including those modified by UBA3. By blocking the proteasome, bortezomib leads to the accumulation of these proteins, which can trigger cell death in cancer cells.

In summary, UBA3 is a promising target for drug discovery efforts in various diseases, and several drugs targeting this gene are currently on the market or in clinical trials.",GO:0007113 endomitotic cell cycle;GO:0045116 protein neddylation;GO:0000278 mitotic cell cycle,,ENZYME proteins:Ligase; Enzymes; Predicted intracellular proteins,Cytosol;Plasma membrane (Approved); Additional: Centrosome;Nucleoplasm,,(M119)PID ERB GENOMIC PATHWAY; (M58)PID AR PATHWAY; (M200)PID ERA GENOMIC PATHWAY,
ENSG00000124214.20,ENSG00000124214,STAU1,-0.581050454,-0.718019293,-0.636615157,-0.388516911,staufen double-stranded RNA binding protein 1,"STAU1 is a human gene that encodes for the Staufen double-stranded RNA binding protein 1. This protein is a member of a family of proteins that are involved in transporting and localizing messenger RNAs (mRNAs) to different parts of the cell. STAU1 contains multiple domains that allow it to bind to RNAs with double-stranded secondary structures, as well as a microtubule-binding domain that allows it to interact with tubulin. The protein is found in the cytoplasm and is associated with the rough endoplasmic reticulum (RER), suggesting that it plays a role in transporting mRNAs via the microtubule network to the RER, where they are translated into proteins.","STAU1 has been implicated in several diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, STAU1 has been shown to regulate the expression of oncogenes and tumor suppressor genes, and its overexpression has been associated with poor prognosis in several types of cancer. In neurodegenerative disorders, STAU1 has been found to be involved in the transport and localization of mRNAs encoding for proteins that are important for neuronal function, and its dysfunction has been linked to diseases such as Alzheimer's and Parkinson's. In viral infections, STAU1 has been shown to play a role in the replication of several viruses, including HIV and influenza.

There are currently no drugs that specifically target STAU1, but there have been efforts to develop drugs that modulate its activity. For example, small molecules that inhibit the interaction between STAU1 and its RNA targets have been identified as potential therapeutics for cancer and viral infections. Additionally, compounds that enhance the transport of mRNAs by STAU1 have been proposed as potential treatments for neurodegenerative disorders.

One example of a successful drug that indirectly targets STAU1 is the antiviral drug ribavirin, which has been shown to inhibit the activity of STAU1 and prevent the replication of several viruses. Another example is the cancer drug imatinib, which has been shown to downregulate the expression of STAU1 and inhibit the growth of cancer cells.",GO:0098964 anterograde dendritic transport of messenger ribonucleoprotein complex;GO:0046726 positive regulation by virus of viral protein levels in host cell;GO:0046719 regulation by virus of viral protein levels in host cell,,Predicted intracellular proteins,Cytosol (Enhanced),,,(M5893)HALLMARK MITOTIC SPINDLE
ENSG00000066455.13,ENSG00000066455,GOLGA5,-0.580611307,-0.748259026,-0.764498677,-0.229076219,golgin A5,"GOLGA5, also known as golgin A5, is a gene that encodes for a protein localized to the Golgi apparatus. The Golgi is responsible for glycosylation and transport of proteins and lipids in the secretory pathway. GOLGA5 is a coiled-coil membrane protein that is thought to play a role in vesicle tethering and docking. It interacts with microtubules, which are important for the reorganization of the Golgi after it fragments during mitosis. Translocations involving GOLGA5 and the ret proto-oncogene have been found in tumor tissues, and a pseudogene of GOLGA5 is located on the short arm of chromosome 5.","There is limited information available on the disease implications of GOLGA5. However, research has shown that translocations involving GOLGA5 and the ret proto-oncogene have been found in tumor tissues, suggesting a potential role in cancer development. As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target GOLGA5. However, there are ongoing efforts to develop drugs that target the Golgi apparatus and its associated proteins, which could potentially have implications for GOLGA5. For example, brefeldin A is a drug that disrupts the Golgi apparatus and is used in research to study its function. Another example is golgicide A, a small molecule inhibitor that targets the Golgi protein GOLPH3 and has shown promise in preclinical studies for the treatment of cancer.","GO:0000301 retrograde transport, vesicle recycling within Golgi;GO:0006891 intra-Golgi vesicle-mediated transport;GO:0007030 Golgi organization",,Predicted intracellular proteins; Transporters; Potential drug targets; Disease related genes; Cancer-related genes:Mutational cancer driver genes,Golgi apparatus (Supported),,,
ENSG00000070610.14,ENSG00000070610,GBA2,-0.580458661,-0.868677532,-0.617932461,-0.25476599,glucosylceramidase beta 2,GBA2 is a gene that encodes for a microsomal beta-glucosidase enzyme that breaks down bile acid 3-O-glucosides in the liver. The enzyme is mainly found in the microsomal fraction of the liver and is thought to be confined to the endoplasmic reticulum. GBA2 is a putative transmembrane protein that is believed to play a role in carbohydrate transport and metabolism.,"Mutations in the GBA2 gene have been associated with several diseases, including hereditary spastic paraplegia (HSP), a group of inherited neurological disorders characterized by progressive weakness and spasticity of the lower limbs. GBA2 mutations have also been linked to autosomal recessive cerebellar ataxia (ARCA), a group of disorders that affect the cerebellum and cause problems with movement and coordination.

Targeted drug discovery efforts for GBA2-related diseases are still in the early stages, but some promising leads have been identified. For example, a recent study found that a small molecule inhibitor of GBA2 called NCGC607 improved motor function and reduced neuroinflammation in a mouse model of HSP. Other potential drug targets for GBA2-related diseases include the endoplasmic reticulum stress response and the unfolded protein response.

There are currently no drugs on the market specifically targeting GBA2-related diseases, but some drugs used to treat related conditions may be effective. For example, drugs that increase the activity of glucocerebrosidase, an enzyme that is structurally similar to GBA2, have been shown to improve symptoms in some patients with HSP and ARCA. These drugs include miglustat, which is approved for the treatment of Gaucher disease, and ambroxol, which is used to treat respiratory conditions but has also been shown to increase glucocerebrosidase activity in the brain.",GO:0006680 glucosylceramide catabolic process;GO:0006678 glucosylceramide metabolic process;GO:0046477 glycosylceramide catabolic process,,Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases; Predicted intracellular proteins; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Golgi apparatus;Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000109180.15,ENSG00000109180,OCIAD1,-0.579972758,-0.863166669,-0.554130547,-0.322621057,OCIA domain containing 1,"OCIAD1 is a human gene that is predicted to play a role in various biological processes, including the maintenance of hematopoietic stem cells, the regulation of receptor signaling pathways via JAK-STAT, and the control of stem cell differentiation. The gene is located in the membrane and is involved in the regulation of cellular processes. The information about OCIAD1 is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of OCIAD1. However, recent studies have suggested that the gene may play a role in the development and progression of certain types of cancer, including breast cancer and glioblastoma. Targeted drug discovery efforts for OCIAD1 are currently underway, with researchers exploring the potential of small molecule inhibitors and other therapeutic agents to target the gene and its associated pathways. While there are currently no drugs on the market that specifically target OCIAD1, there have been several successful drugs developed for other genes involved in similar biological processes, such as JAK-STAT inhibitors for the treatment of rheumatoid arthritis and other autoimmune disorders.",GO:0061484 hematopoietic stem cell homeostasis;GO:0046427 positive regulation of receptor signaling pathway via JAK-STAT;GO:1904894 positive regulation of receptor signaling pathway via STAT,,Predicted intracellular proteins,Vesicles (Approved),,,
ENSG00000109270.13,ENSG00000109270,LAMTOR3,-0.579704381,-0.819812066,-0.759259081,-0.160041996,"late endosomal/lysosomal adaptor, MAPK and MTOR activator 3","LAMTOR3 is a gene that encodes a scaffold protein involved in the extracellular signal-regulated kinase (ERK) cascade. The protein is found in late endosomes and binds specifically to MAP kinase kinase MAP2K1/MEK1, MAP kinase MAPK3/ERK1, and MAP kinase MAPK1/ERK2. Studies in mice suggest that LAMTOR3 regulates late endosomal traffic and cell proliferation. The gene has multiple isoforms due to alternative splicing, and a pseudogene is located on chromosome 13.","There is limited information on the disease implications of LAMTOR3. However, studies have shown that mutations in the LAMTOR3 gene are associated with a rare genetic disorder called MAPK pathway activation syndrome (MPAS). MPAS is characterized by developmental delay, intellectual disability, and facial dysmorphism. 

There are currently no targeted drug discovery efforts for LAMTOR3. However, drugs that target the ERK pathway, which LAMTOR3 is involved in, have been developed for the treatment of cancer. For example, trametinib and cobimetinib are FDA-approved drugs that target MEK1/2, which are upstream of ERK1/2 in the pathway. These drugs have been shown to be effective in the treatment of melanoma and other cancers with mutations in the BRAF gene, which is also involved in the ERK pathway. 

In summary, while there is limited information on the disease implications of LAMTOR3, drugs that target the ERK pathway have been developed for the treatment of cancer and have shown success in clinical trials.",GO:0038202 TORC1 signaling;GO:0031929 TOR signaling;GO:1904263 positive regulation of TORC1 signaling,,Predicted intracellular proteins,,,,
ENSG00000131375.10,ENSG00000131375,CAPN7,-0.578940802,-0.822479864,-0.664635605,-0.249706938,calpain 7,"CAPN7, also known as calpain 7, is a gene that encodes for a protein belonging to the calpain family of calcium-dependent, cysteine proteases. Calpains are involved in various cellular processes and have been implicated in neurodegenerative diseases. The function of CAPN7 is not well understood, but it has been found to have an orthologue in mice that diverges from other family members and is thought to be calcium independent with protease activity. Further research is needed to fully understand the role of CAPN7 in human biology and disease.","There is limited information available on the disease implications of CAPN7. However, studies have suggested that mutations in the gene may be associated with neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. Targeted drug discovery efforts for CAPN7 are also limited, as the function of the protein is not well understood. However, some studies have suggested that calpain inhibitors may have potential therapeutic benefits for neurodegenerative diseases. Currently, there are no drugs on the market that specifically target CAPN7. However, there are several calpain inhibitors that have been approved for other indications, such as the anti-epileptic drug carbamazepine and the anti-inflammatory drug celecoxib. Further research is needed to fully understand the potential therapeutic implications of targeting CAPN7.",GO:0097264 self proteolysis;GO:0010634 positive regulation of epithelial cell migration;GO:0010632 regulation of epithelial cell migration,,Peptidases:Cysteine-type peptidases; Enzymes; Predicted intracellular proteins,Cytosol (Approved); Additional: Centrosome,,,
ENSG00000154144.13,ENSG00000154144,TBRG1,-0.578555474,-0.789931589,-0.566640715,-0.379094119,transforming growth factor beta regulator 1,"TBRG1, or transforming growth factor beta regulator 1, is a human gene that plays a role in various biological processes, including DNA replication, protein localization to the nucleoplasm, and protein stabilization. It is primarily located in the nucleoplasm, which is the fluid within the nucleus of a cell. TBRG1 is involved in regulating the activity of transforming growth factor beta (TGF-?), a protein that controls cell growth and differentiation. Dysregulation of TGF-? signaling has been implicated in various diseases, including cancer and fibrosis. Therefore, understanding the function of TBRG1 may provide insights into the development and treatment of these conditions.","There is limited information available on the disease implications of TBRG1, and no targeted drug discovery efforts have been reported specifically for this gene. However, as TBRG1 is involved in regulating the activity of TGF-?, which is implicated in various diseases, it is possible that targeting TBRG1 could have therapeutic potential. For example, drugs that inhibit TGF-? signaling have been developed for the treatment of fibrosis and cancer. One such drug is pirfenidone, which is approved for the treatment of idiopathic pulmonary fibrosis. Another drug, nintedanib, is also approved for the treatment of idiopathic pulmonary fibrosis and targets multiple receptors involved in TGF-? signaling. While there are currently no drugs on the market that specifically target TBRG1, further research into its function and potential therapeutic applications may lead to the development of novel treatments for TGF-?-related diseases.",GO:1990173 protein localization to nucleoplasm;GO:0006260 DNA replication;GO:0034504 protein localization to nucleus,,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000118217.6,ENSG00000118217,ATF6,-0.576432345,-0.739384107,-0.767745184,-0.222167742,activating transcription factor 6,"ATF6 is a gene that encodes a transcription factor responsible for activating target genes during endoplasmic reticulum (ER) stress, known as the unfolded protein response (UPR). Unlike other transcription factors, ATF6 is synthesized as a transmembrane protein embedded in the ER. It functions as an ER stress sensor and transducer, and after ER stress-induced proteolysis, it acts as a nuclear transcription factor via a cis-acting ER stress response element (ERSE) present in the promoters of genes encoding ER chaperones. ATF6 has been identified as a survival factor for quiescent squamous carcinoma cells and is a potential therapeutic target for cystic fibrosis. Polymorphisms in this gene have been associated with diabetes and increased plasma cholesterol levels.","ATF6 has been identified as a potential therapeutic target for several diseases, including cystic fibrosis, diabetes, and cancer. In cystic fibrosis, ATF6 activation has been shown to increase the expression of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is defective in this disease. Targeting ATF6 could therefore be a potential strategy to increase CFTR expression and improve lung function in cystic fibrosis patients. In diabetes, ATF6 has been implicated in the regulation of insulin secretion and glucose homeostasis, and polymorphisms in the ATF6 gene have been associated with an increased risk of developing type 2 diabetes. In cancer, ATF6 has been identified as a survival factor for quiescent squamous carcinoma cells, and targeting ATF6 could be a potential strategy to induce cell death in these cells. While there are currently no drugs on the market that specifically target ATF6, several compounds have been identified that can modulate ATF6 activity, including the small molecule compound Ceapin-A7, which has been shown to inhibit ATF6 proteolysis and improve lung function in a mouse model of cystic fibrosis.",GO:1903893 positive regulation of ATF6-mediated unfolded protein response;GO:1903891 regulation of ATF6-mediated unfolded protein response;GO:0036500 ATF6-mediated unfolded protein response,,Disease related genes; Human disease related genes:Nervous system diseases:Eye disease; Transcription factors:Basic domains; Predicted intracellular proteins,,,(M229)PID P38 ALPHA BETA DOWNSTREAM PATHWAY,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000108654.16,ENSG00000108654,DDX5,-0.575828888,-0.867109663,-0.634830495,-0.225546505,DEAD-box helicase 5,"DDX5, also known as DEAD-box helicase 5, is a member of the DEAD box family of RNA helicases. It plays a crucial role in various cellular processes by acting as an adaptor molecule and promoting interactions with other factors. DDX5 is involved in pathways that alter RNA structures, regulate transcription, splicing, and process small noncoding RNAs. The protein contains nine conserved motifs, including the DEAD motif, which is essential for ATP binding and hydrolysis, RNA binding, and unwinding activities. Dysregulation of DDX5 may contribute to cancer development. Alternative splicing results in multiple transcript variants.","DDX5 has been implicated in various diseases, including cancer, viral infections, and neurological disorders. In cancer, DDX5 has been shown to promote tumor growth and metastasis by regulating gene expression and alternative splicing. Targeting DDX5 has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of DDX5 have been developed, including RK-33 and CX-5461, which have shown promising results in preclinical studies. However, no DDX5-targeted drugs have been approved for clinical use yet. In viral infections, DDX5 plays a role in the replication of hepatitis C virus and human immunodeficiency virus (HIV). In neurological disorders, DDX5 has been linked to Alzheimer's disease and amyotrophic lateral sclerosis (ALS). However, further research is needed to fully understand the role of DDX5 in these diseases and to develop effective therapies.","GO:0061614 miRNA transcription;GO:0031053 primary miRNA processing;GO:0043517 positive regulation of DNA damage response, signal transduction by p53 class mediator",,Predicted intracellular proteins; ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Nucleoli;Nucleoplasm (Supported),Artenimol,(M145)PID P53 DOWNSTREAM PATHWAY,
ENSG00000119801.13,ENSG00000119801,YPEL5,-0.574965055,-0.676115371,-0.568865042,-0.479914752,yippee like 5,"YPEL5, also known as yippee like 5, is a human gene that is predicted to have metal ion binding activity and be involved in cell population proliferation. It is also part of a ubiquitin ligase complex. The gene's function is not yet fully understood, but it may play a role in regulating protein degradation and cellular processes. Further research is needed to fully understand the function of YPEL5 and its potential implications for human health and disease.","There is limited information available on the disease implications of YPEL5. However, some studies have suggested that it may be involved in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for YPEL5 are currently limited, as its function is not yet fully understood. However, some studies have suggested that targeting the ubiquitin ligase complex of which YPEL5 is a part may have therapeutic potential in cancer treatment. There are currently no drugs on the market that specifically target YPEL5, but there are several drugs that target the ubiquitin-proteasome system, which is involved in protein degradation and cellular processes. Examples of such drugs include bortezomib, carfilzomib, and ixazomib, which are used in the treatment of multiple myeloma and other types of cancer.",GO:0008283 cell population proliferation;GO:0009987 cellular process;GO:0008150 biological_process,,Predicted intracellular proteins,Cytosol (Approved); Additional: Nucleoplasm,,,(M5945)HALLMARK HEME METABOLISM
ENSG00000151148.14,ENSG00000151148,UBE3B,-0.574877538,-1.119676444,-0.484052839,-0.120903332,ubiquitin protein ligase E3B,"The UBE3B gene encodes a member of the E3 ubiquitin-conjugating enzyme family, which is involved in the modification of proteins with ubiquitin for degradation. This process involves three classes of enzymes: E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin-protein ligases. The longer isoform of UBE3B contains a catalytic site for ubiquitin transfer in the form of a HECT domain in its C-terminus, which forms a complex with E2 conjugases. Shorter isoforms of UBE3B lack this domain and are unlikely to bind E2 enzymes. Alternative splicing of UBE3B results in distinct isoforms.","There is limited information on the disease implications of UBE3B mutations. However, recent studies have suggested that UBE3B may play a role in the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for UBE3B are currently underway, with a focus on developing small molecule inhibitors that can selectively target the enzyme's catalytic activity. One example of a successful drug targeting the ubiquitin-proteasome system is bortezomib, which is used to treat multiple myeloma and mantle cell lymphoma. Bortezomib inhibits the proteasome, preventing the degradation of proteins that are critical for cancer cell survival. Other drugs targeting the ubiquitin-proteasome system are also in development, and may have potential for treating a range of diseases.",GO:0150052 regulation of postsynapse assembly;GO:0099175 regulation of postsynapse organization;GO:0051963 regulation of synapse assembly,,Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Enzymes,Nuclear speckles (Approved); Additional: Mitochondria,,,
ENSG00000181220.17,ENSG00000181220,ZNF746,-0.574725562,-0.805208925,-0.623023631,-0.29594413,zinc finger protein 746,"ZNF746 is a human gene that encodes for a protein called zinc finger protein 746. This protein has several functions, including the ability to bind to specific DNA sequences and repress transcription by RNA polymerase II. It also has the ability to bind to ubiquitin protein ligases and is involved in the regulation of neuron death. ZNF746 is found in both the cytosol and nucleoplasm of cells.","There is limited information available on the disease implications of ZNF746. However, some studies have suggested that it may play a role in the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ZNF746 are also limited, as its function and role in disease are not well understood. Currently, there are no drugs on the market that specifically target ZNF746. However, there are drugs that target other proteins involved in similar pathways, such as the ubiquitin-proteasome system, which ZNF746 is known to interact with. Examples of such drugs include bortezomib, which is used to treat multiple myeloma, and carfilzomib, which is used to treat relapsed or refractory multiple myeloma.",GO:0051291 protein heterooligomerization;GO:0051260 protein homooligomerization;GO:0051259 protein complex oligomerization,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Cytosol;Nucleoplasm (Supported),,,
ENSG00000169871.13,ENSG00000169871,TRIM56,-0.57394895,-1.130325985,-0.472126256,-0.119394609,tripartite motif containing 56,"TRIM56 is a human gene that encodes a protein called tripartite motif containing 56. This protein is predicted to have RNA binding activity and is involved in various biological processes, including defense response to other organisms, positive regulation of macromolecule metabolic process, and protein K63-linked ubiquitination. TRIM56 is predicted to be located in the cytoplasm and active in chromatin and nucleoplasm.","There is limited information available on the disease implications of TRIM56. However, recent studies have suggested that TRIM56 may play a role in the development and progression of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TRIM56 are still in the early stages, but there is potential for the development of novel therapies that target this protein. Currently, there are no drugs on the market that specifically target TRIM56. However, there are several drugs that target other proteins in the TRIM family, such as lenalidomide, which targets the E3 ubiquitin ligase activity of TRIM28, and pomalidomide, which targets the E3 ubiquitin ligase activity of TRIM33. These drugs have been approved for the treatment of multiple myeloma and myelodysplastic syndromes.",GO:0060340 positive regulation of type I interferon-mediated signaling pathway;GO:0032728 positive regulation of interferon-beta production;GO:0006513 protein monoubiquitination,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Uncertain); Additional: Cytosol,,,
ENSG00000181789.14,ENSG00000181789,COPG1,-0.573920052,-1.108398955,-0.409152305,-0.204208897,COPI coat complex subunit gamma 1,COPG1 is a human gene that encodes for a protein involved in the transport of vesicles within the Golgi apparatus. It is predicted to have structural molecule activity and is involved in processes such as establishing Golgi localization and organelle transport along microtubules. The gene is located within the Golgi apparatus.,"There is limited information available on the disease implications of COPG1. However, mutations in other genes involved in Golgi transport have been linked to various diseases, including neurological disorders and cancer. Targeted drug discovery efforts for COPG1 are also limited, as the function of the protein is not well understood. However, there have been some studies exploring the potential of targeting Golgi transport as a therapeutic strategy for cancer. One example of a successful drug targeting the Golgi apparatus is Brefeldin A, which inhibits the transport of vesicles within the Golgi and is used in research to study Golgi function. Another example is the cancer drug, Golgicide A, which targets the Golgi and disrupts its function, leading to cancer cell death. However, it is unclear if COPG1 is a viable target for drug discovery efforts at this time.",GO:0051683 establishment of Golgi localization;GO:0051645 Golgi localization;GO:0006891 intra-Golgi vesicle-mediated transport,,Predicted intracellular proteins,Golgi apparatus (Supported); Additional: Cytosol;Nucleoplasm,S-(Dimethylarsenic)Cysteine,,
ENSG00000138286.15,ENSG00000138286,FAM149B1,-0.5737979,-0.95784606,-0.684779151,-0.078768488,family with sequence similarity 149 member B1,"FAM149B1 is a human gene that is a member of the family with sequence similarity 149. It plays a role in the assembly of cilia and the localization of proteins to cilia. It is predicted to be located in the cilium and has been implicated in Joubert syndrome, a rare genetic disorder that affects the development of the brainstem and cerebellum.","Joubert syndrome is a rare genetic disorder that affects the development of the brainstem and cerebellum. Mutations in FAM149B1 have been implicated in the development of Joubert syndrome. There are currently no targeted drug discovery efforts for FAM149B1 specifically, but there are ongoing efforts to develop treatments for Joubert syndrome as a whole. Treatment for Joubert syndrome is primarily supportive and may include physical therapy, speech therapy, and medications to control seizures or other symptoms. There are currently no drugs on the market specifically for Joubert syndrome, but some medications used to treat related conditions such as epilepsy and spasticity may be helpful in managing symptoms.",GO:0061512 protein localization to cilium;GO:0060271 cilium assembly;GO:0044782 cilium organization,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Microtubules;Primary cilium (Approved); Additional: Cytosol,,,
ENSG00000132383.12,ENSG00000132383,RPA1,-0.572159682,-1.088102171,-0.615117348,-0.013259528,replication protein A1,"The RPA1 gene encodes the largest subunit of the Replication Protein A (RPA) complex, which binds to single-stranded DNA (ssDNA) and plays a crucial role in DNA metabolism. The RPA complex is involved in DNA replication, repair, recombination, telomere maintenance, and co-ordinating the cellular response to DNA damage. The nucleoprotein complex formed by RPA1 protects the ssDNA from nucleases, prevents formation of secondary structures that would interfere with repair, and co-ordinates the recruitment and departure of different genome maintenance factors. RPA1 contains four oligonucleotide/oligosaccharide-binding (OB) domains, with the majority of ssDNA binding occurring in two of these domains. The heterotrimeric complex has two different modes of ssDNA binding, a low-affinity and high-affinity mode, which play a role in regulating different genomic maintenance pathways.","Mutations in the RPA1 gene have been associated with various types of cancer, including breast, ovarian, and lung cancer. Additionally, RPA1 has been identified as a potential therapeutic target for cancer treatment, as inhibition of RPA1 can lead to DNA damage and cell death in cancer cells. Several small molecule inhibitors of RPA1 have been developed and are currently being evaluated in preclinical studies for their potential as cancer therapeutics. One example is the compound BOS172722, which has been shown to inhibit RPA1 and induce DNA damage in cancer cells. Another example is the compound BMN-673, which targets the PARP enzyme and has been shown to enhance the efficacy of RPA1 inhibitors in preclinical studies. Currently, there are no RPA1-targeted drugs on the market, but ongoing research in this area holds promise for the development of new cancer therapies.",GO:1990166 protein localization to site of double-strand break;GO:0006268 DNA unwinding involved in DNA replication;GO:0007004 telomere maintenance via telomerase,,Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Predicted intracellular proteins,Nucleoplasm (Enhanced),,(M46)PID ATR PATHWAY; (M1)PID FANCONI PATHWAY,(M5924)HALLMARK MTORC1 SIGNALING; (M5925)HALLMARK E2F TARGETS
ENSG00000164576.12,ENSG00000164576,SAP30L,-0.571933814,-0.272107947,-0.492494638,-0.951198858,SAP30 like,"SAP30L is a gene that encodes a protein with several functions, including non-sequence-specific DNA binding activity, bending, phosphatidylinositol phosphate binding activity, and zinc ion binding activity. It is involved in negative regulation of transcription by RNA polymerase II and is located in the fibrillar center and nucleoplasm. SAP30L is part of the histone deacetylase complex.","There is limited information available on the disease implications of SAP30L. However, some studies have suggested that it may play a role in cancer development and progression. Targeted drug discovery efforts for SAP30L are also limited, but some research has focused on developing inhibitors of histone deacetylase complexes, of which SAP30L is a part. These inhibitors have shown promise in preclinical studies for the treatment of various cancers, including lymphoma and leukemia. Examples of successful drugs on the market that target histone deacetylase complexes include vorinostat and romidepsin, which are approved for the treatment of cutaneous T-cell lymphoma. However, further research is needed to determine the potential therapeutic applications of targeting SAP30L specifically.",GO:1902455 negative regulation of stem cell population maintenance;GO:1902459 positive regulation of stem cell population maintenance;GO:2000036 regulation of stem cell population maintenance,,Predicted intracellular proteins,Nucleoli fibrillar center;Nucleoplasm (Supported),,,
ENSG00000135341.18,ENSG00000135341,MAP3K7,-0.571741082,-0.764277822,-0.745305044,-0.205640379,mitogen-activated protein kinase kinase kinase 7,"MAP3K7 is a gene that encodes a serine/threonine protein kinase, which plays a crucial role in the signaling transduction induced by TGF beta and BMP. It controls various cell functions, including transcription regulation and apoptosis. In response to IL-1, MAP3K7 forms a kinase complex with TRAF6, MAP3K7P1/TAB1, and MAP3K7P2/TAB2, which is required for the activation of nuclear factor kappa B. Additionally, MAP3K7 can activate MAPK8/JNK, MAP2K4/MKK4, and plays a role in the cell response to environmental stresses. Four alternatively spliced transcript variants encoding distinct isoforms have been reported.","MAP3K7 has been implicated in various diseases, including cancer, inflammation, and autoimmune disorders. In cancer, MAP3K7 has been shown to promote tumor growth and metastasis by activating various signaling pathways, including NF-kappaB and JNK. Targeting MAP3K7 has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of MAP3K7 have been developed, including TAK-1 inhibitor 5Z-7-oxozeaenol and LY573636, which have shown promising results in preclinical studies. However, no MAP3K7 inhibitors have been approved for clinical use yet.

In addition to cancer, MAP3K7 has also been implicated in various inflammatory and autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Targeting MAP3K7 has shown potential for the treatment of these diseases as well. For example, a small molecule inhibitor of MAP3K7, GSK583, has been shown to reduce inflammation and improve symptoms in a mouse model of rheumatoid arthritis.

Overall, targeting MAP3K7 has emerged as a promising therapeutic strategy for various diseases, including cancer and inflammatory disorders. While several small molecule inhibitors of MAP3K7 have been developed, more research is needed to determine their safety and efficacy in clinical trials.",GO:0141111 positive regulation of cGAS/STING signaling pathway;GO:0038173 interleukin-17A-mediated signaling pathway;GO:0007252 I-kappaB phosphorylation,yes,Predicted intracellular proteins; ENZYME proteins:Transferases; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Enzymes; Kinases:STE Ser/Thr protein kinases,Cytosol (Supported); Additional: Nuclear speckles;Plasma membrane,,(M190)PID TCR JNK PATHWAY; (M20)PID P38 MKK3 6PATHWAY; (M257)PID EPHRINB REV PATHWAY,(M5896)HALLMARK TGF BETA SIGNALING; (M5923)HALLMARK PI3K AKT MTOR SIGNALING; (M5950)HALLMARK ALLOGRAFT REJECTION
ENSG00000077147.16,ENSG00000077147,TM9SF3,-0.571677755,-0.930909291,-0.657463617,-0.126660356,transmembrane 9 superfamily member 3,"TM9SF3 is a human gene that is predicted to play a role in protein localization to the membrane. It is also predicted to be located in exocytic vesicles and to be active in the membrane. The gene belongs to the transmembrane 9 superfamily and its function is not yet fully understood. However, it is believed to be involved in the transport of proteins to the cell membrane, which is essential for various cellular processes. Further research is needed to fully understand the role of TM9SF3 in human biology and disease.","There is limited information available on the disease implications of TM9SF3. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TM9SF3 are also limited, as the function of this gene is not yet fully understood. However, some studies have suggested that targeting TM9SF3 may be a potential strategy for cancer therapy. Currently, there are no drugs on the market that specifically target TM9SF3. However, there are several drugs that target other proteins in the transmembrane 9 superfamily, such as the anti-cancer drug imatinib, which targets the BCR-ABL fusion protein in chronic myeloid leukemia. Further research is needed to fully understand the potential disease implications and drug discovery opportunities for TM9SF3.",GO:0072657 protein localization to membrane;GO:0051668 localization within membrane;GO:0008104 protein localization,,,Vesicles (Approved); Additional: Golgi apparatus,,,
ENSG00000159346.13,ENSG00000159346,ADIPOR1,-0.571565081,-0.879684023,-0.533781442,-0.301229777,adiponectin receptor 1,"ADIPOR1 is a gene that encodes a protein that acts as a receptor for adiponectin, a hormone secreted by adipocytes that regulates fatty acid catabolism and glucose levels. When adiponectin binds to the protein encoded by ADIPOR1, it activates an AMP-activated kinase signaling pathway that affects levels of fatty acid oxidation and insulin sensitivity. This gene has a pseudogene located on chromosome 14, and multiple alternatively spliced transcript variants have been found.","ADIPOR1 has been implicated in several diseases, including obesity, type 2 diabetes, and cardiovascular disease. Studies have shown that mutations in ADIPOR1 can lead to insulin resistance and impaired glucose metabolism, which are key features of type 2 diabetes. Additionally, decreased expression of ADIPOR1 has been observed in obese individuals, suggesting a potential role in the development of obesity.

Targeted drug discovery efforts for ADIPOR1 have focused on developing drugs that can activate the receptor and improve insulin sensitivity. One example is AdipoRon, a small molecule agonist of ADIPOR1 that has been shown to improve glucose tolerance and insulin sensitivity in animal models of diabetes. Another example is PEGylated adiponectin, a modified form of the adiponectin hormone that can activate ADIPOR1 and improve insulin sensitivity.

Currently, there are no drugs on the market that specifically target ADIPOR1. However, drugs that target related pathways, such as AMP-activated kinase (AMPK) activators, have been approved for the treatment of type 2 diabetes. Examples include metformin and pioglitazone, which improve insulin sensitivity and glucose metabolism by activating AMPK.",GO:0033211 adiponectin-activated signaling pathway;GO:0033210 leptin-mediated signaling pathway;GO:0044320 cellular response to leptin stimulus,,Transporters:Transporter channels and pores; Predicted intracellular proteins,,,,(M5945)HALLMARK HEME METABOLISM
ENSG00000113851.14,ENSG00000113851,CRBN,-0.570457013,-0.80447093,-0.559987931,-0.346912177,cereblon,The CRBN gene encodes a protein that is related to the Lon protease protein family. It is found in the cytoplasm and is thought to play a role in brain development. Mutations in this gene are associated with autosomal recessive nonsyndromic cognitive disability. The protein is localized with a calcium channel membrane protein in rodents and other mammals. Multiple transcript variants encoding different isoforms have been found for this gene.,"Mutations in the CRBN gene have been associated with autosomal recessive nonsyndromic cognitive disability, which is characterized by intellectual disability, delayed speech and language development, and other cognitive impairments. Targeted drug discovery efforts for CRBN have focused on developing small molecule modulators of the CRBN protein, which could potentially be used to treat cognitive disabilities associated with CRBN mutations. One example of a successful drug targeting CRBN is lenalidomide, which is used to treat multiple myeloma and other blood cancers. Lenalidomide works by binding to CRBN and promoting the degradation of certain proteins involved in cancer cell growth. Other potential therapeutic targets for CRBN include neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as psychiatric disorders such as schizophrenia and bipolar disorder. However, further research is needed to fully understand the role of CRBN in these diseases and to develop effective treatments.",GO:0035641 locomotory exploration behavior;GO:0035640 exploration behavior;GO:0034766 negative regulation of monoatomic ion transmembrane transport,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; Transporters:Accessory Factors Involved in Transport; FDA approved drug targets:Small molecule drugs; Disease related genes,,Lenalidomide; Thalidomide; Pomalidomide,,
ENSG00000133872.14,ENSG00000133872,SARAF,-0.569880824,-0.741924674,-0.698038746,-0.26967905,store-operated calcium entry associated regulatory factor,"SARAF (store-operated calcium entry associated regulatory factor) is a human gene that plays a role in regulating store-operated calcium entry. It is located in the endoplasmic reticulum and endoplasmic reticulum-plasma membrane contact site and is an integral component of the endoplasmic reticulum membrane. The gene's function is important for maintaining calcium homeostasis in cells, which is essential for many cellular processes. The gene's role in calcium regulation makes it a potential target for therapeutic interventions in diseases related to calcium dysregulation.","There is limited information available on the disease implications of SARAF gene mutations. However, studies have suggested that dysregulation of store-operated calcium entry can contribute to the pathogenesis of various diseases, including cancer, neurodegenerative disorders, and immune disorders. Therefore, SARAF may be a potential therapeutic target for these diseases. 

There have been some targeted drug discovery efforts aimed at modulating store-operated calcium entry, including SARAF. One approach is to develop small molecules that can selectively inhibit or activate SARAF function. However, there are currently no drugs on the market that specifically target SARAF. 

There are some drugs on the market that indirectly modulate store-operated calcium entry, such as calcineurin inhibitors (e.g. cyclosporine A) and calcium channel blockers (e.g. verapamil). These drugs are used to treat various diseases, including autoimmune disorders and hypertension. However, their mechanisms of action are not specific to SARAF and can have off-target effects. Therefore, there is still a need for more targeted drug discovery efforts aimed at SARAF and other components of store-operated calcium entry.",GO:2001256 regulation of store-operated calcium entry;GO:0051924 regulation of calcium ion transport;GO:0006816 calcium ion transport,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Endoplasmic reticulum (Supported); Additional: Rods & Rings,,,
ENSG00000153130.17,ENSG00000153130,SCOC,-0.568957744,-0.962021863,-0.693906076,-0.050945292,short coiled-coil protein,The SCOC gene encodes a protein that contains a short coiled-coil domain and is found in the Golgi apparatus. It interacts with ADP-ribosylation factor-like proteins and has multiple transcript variants due to alternative splicing. Pseudogenes of this gene are also present on chromosomes 1 and 14.,"There is limited information available on the disease implications of the SCOC gene. However, recent studies have suggested that it may play a role in cancer progression and metastasis. Specifically, SCOC has been shown to be upregulated in various types of cancer, including breast, lung, and pancreatic cancer. Targeted drug discovery efforts for SCOC are still in the early stages, but there is potential for the development of novel therapies that target this gene. Currently, there are no drugs on the market that specifically target SCOC. However, there are several drugs that have been approved for the treatment of cancer that indirectly affect SCOC expression or function, such as taxanes and platinum-based chemotherapies. Further research is needed to fully understand the role of SCOC in cancer and to develop targeted therapies for this gene.",GO:0061635 regulation of protein complex stability;GO:0016239 positive regulation of macroautophagy;GO:0010508 positive regulation of autophagy,,Predicted intracellular proteins,Golgi apparatus;Nucleoplasm (Approved),,,
ENSG00000122882.11,ENSG00000122882,ECD,-0.568593265,-1.063836112,-0.504453088,-0.137490594,ecdysoneless cell cycle regulator,"The human gene ECD, also known as ecdysoneless cell cycle regulator, is involved in the positive regulation of transcription by RNA polymerase II. It enables histone acetyltransferase binding activity and is located in both the cytosol and nucleoplasm. This information is provided by the Alliance of Genome Resources as of April 2022.","The ECD gene has been implicated in several diseases, including cancer, developmental disorders, and neurodegenerative diseases. In particular, mutations in ECD have been associated with the development of breast cancer, ovarian cancer, and glioblastoma. Targeted drug discovery efforts have focused on identifying small molecules that can inhibit the activity of ECD and thereby prevent the growth and proliferation of cancer cells. One example of a successful drug targeting ECD is the histone deacetylase inhibitor vorinostat, which has been approved by the FDA for the treatment of cutaneous T-cell lymphoma. Vorinostat works by inhibiting the activity of ECD and other histone deacetylases, leading to the activation of tumor suppressor genes and the induction of apoptosis in cancer cells. Other potential drug targets for ECD include the cyclin-dependent kinase CDK2, which is involved in cell cycle regulation, and the transcription factor E2F1, which is a downstream target of ECD and plays a key role in cell proliferation and survival.",GO:0048144 fibroblast proliferation;GO:2000045 regulation of G1/S transition of mitotic cell cycle;GO:1902806 regulation of cell cycle G1/S phase transition,,Predicted intracellular proteins,Cytosol;Nucleoplasm (Supported),,,(M5937)HALLMARK GLYCOLYSIS
ENSG00000150776.18,ENSG00000150776,NKAPD1,-0.566417835,-0.92571592,-0.608429487,-0.165108099,NKAP domain containing 1,"NKAPD1, also known as NKAP domain containing 1, is a human gene that encodes a protein with identical protein binding activity. The function of this protein is not well understood, but it is believed to play a role in gene regulation and transcriptional control. The gene is located on chromosome 1 and has been associated with various diseases, including cancer and developmental disorders. Further research is needed to fully understand the function and potential clinical implications of NKAPD1.","There is limited information available on the disease implications and targeted drug discovery efforts for NKAPD1. However, some studies have suggested that the gene may be involved in the development of certain types of cancer, including breast cancer and leukemia. Additionally, mutations in the gene have been associated with developmental disorders such as intellectual disability and autism spectrum disorder. Currently, there are no drugs specifically targeting NKAPD1, and no successful drugs on the market have been identified as directly targeting this gene. However, further research into the function of NKAPD1 may lead to the development of targeted therapies for diseases associated with this gene.",,,Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000143033.18,ENSG00000143033,MTF2,-0.566405471,-0.818963503,-0.677653256,-0.202599654,metal response element binding transcription factor 2,"MTF2, or metal response element binding transcription factor 2, is a human gene that is involved in several processes, including the regulation of histone H3-K27 methylation, regulation of transcription by RNA polymerase II, and segment specification. It enables methylated histone binding activity and transcription corepressor binding activity. MTF2 is predicted to act upstream of or within cellular response to leukemia inhibitory factor. It is located in the cytoplasm, focal adhesion, and nucleoplasm.","MTF2 has been implicated in several diseases, including cancer and developmental disorders. In cancer, MTF2 has been shown to play a role in the regulation of tumor suppressor genes, and its expression has been found to be altered in various types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts have focused on developing inhibitors of MTF2 as a potential therapeutic strategy for cancer treatment. However, there are currently no drugs on the market that specifically target MTF2. 

One example of a successful drug that indirectly affects MTF2 is the histone deacetylase inhibitor, vorinostat. Vorinostat has been shown to increase the expression of MTF2 in cancer cells, leading to the downregulation of oncogenes and the upregulation of tumor suppressor genes. Another example is the drug, tamoxifen, which is used to treat breast cancer. Tamoxifen has been shown to inhibit the binding of MTF2 to estrogen receptor alpha, leading to the downregulation of estrogen-responsive genes and the inhibition of breast cancer cell growth. Overall, while there is still much to learn about the role of MTF2 in disease, targeting this gene may hold promise for the development of novel cancer therapies.",GO:0007379 segment specification;GO:0035282 segmentation;GO:1990830 cellular response to leukemia inhibitory factor,,Predicted intracellular proteins,Nucleoplasm (Supported),,,(M5901)HALLMARK G2M CHECKPOINT
ENSG00000175110.12,ENSG00000175110,MRPS22,-0.565317819,-0.761287049,-0.925020678,-0.00964573,mitochondrial ribosomal protein S22,"The human gene MRPS22 encodes a mitochondrial ribosomal protein S22, which is involved in protein synthesis within the mitochondrion. Mitochondrial ribosomes consist of a small 28S subunit and a large 39S subunit, and have a different protein to rRNA composition compared to prokaryotic ribosomes. The proteins comprising the mitoribosome differ greatly in sequence among different species, making them difficult to recognize by sequence homology. MRPS22 does not have a counterpart in prokaryotic and fungal-mitochondrial ribosomes and is transcribed in the opposite direction from the forkhead box L2 gene. A pseudogene corresponding to MRPS22 is found on chromosome Xq.","There is limited information available on the disease implications of MRPS22. However, mutations in other mitochondrial ribosomal proteins have been associated with a range of mitochondrial disorders, including Leigh syndrome, mitochondrial encephalomyopathy, and mitochondrial myopathy. Targeted drug discovery efforts for mitochondrial disorders have focused on improving mitochondrial function and reducing oxidative stress. Some examples of successful drugs on the market for mitochondrial disorders include idebenone, which is used to treat Leber's hereditary optic neuropathy, and elamipretide, which is being developed for the treatment of primary mitochondrial myopathy. However, there are currently no drugs specifically targeting MRPS22 or mitochondrial ribosomal proteins in general.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; Ribosomal proteins; Human disease related genes:Reproductive system diseases:Reproductive system diseases; Disease related genes,Mitochondria (Supported),,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000149187.18,ENSG00000149187,CELF1,-0.563797558,-0.833942866,-0.394893694,-0.462556115,CUGBP Elav-like family member 1,"CELF1 is a gene that belongs to the CELF/BRUNOL protein family, which regulates pre-mRNA alternative splicing and may also be involved in mRNA editing and translation. It contains two N-terminal RNA recognition motif (RRM) domains, one C-terminal RRM domain, and a divergent segment of 160-230 aa between the second and third RRM domains. CELF1 may play a role in myotonic dystrophy type 1 (DM1) through interactions with the dystrophia myotonica-protein kinase (DMPK) gene. Alternative splicing of CELF1 results in multiple transcript variants encoding different isoforms.","CELF1 has been implicated in several diseases, including myotonic dystrophy type 1 (DM1), heart disease, and cancer. In DM1, CELF1 is thought to contribute to the disease phenotype by binding to expanded CUG repeats in the 3' untranslated region of the DMPK gene, leading to aberrant splicing and RNA toxicity. Targeted drug discovery efforts for DM1 have focused on developing small molecules that can disrupt the CELF1-CUG RNA interaction, such as pentamidine and its derivatives. These compounds have shown promise in preclinical studies and are currently being evaluated in clinical trials. In heart disease, CELF1 has been shown to regulate alternative splicing of genes involved in cardiac hypertrophy and fibrosis, making it a potential therapeutic target. In cancer, CELF1 has been implicated in the regulation of alternative splicing of genes involved in cell proliferation and survival, and its expression is often dysregulated in various cancer types. However, there are currently no drugs on the market that specifically target CELF1.","GO:0006376 mRNA splice site recognition;GO:0000381 regulation of alternative mRNA splicing, via spliceosome;GO:0000245 spliceosomal complex assembly",,Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000171503.12,ENSG00000171503,ETFDH,-0.563453263,-0.929179854,-0.719256103,-0.041923833,electron transfer flavoprotein dehydrogenase,The ETFDH gene is responsible for encoding a protein that is a crucial component of the electron-transfer system in mitochondria. This protein is essential for transferring electrons from various mitochondrial flavin-containing dehydrogenases to the main respiratory chain. Mutations in this gene have been linked to a condition called glutaric acidemia. There are different versions of the gene that produce distinct isoforms of the protein.,"Mutations in the ETFDH gene have been linked to a rare genetic disorder called glutaric acidemia type II (GAII), also known as multiple acyl-CoA dehydrogenase deficiency (MADD). GAII is an autosomal recessive disorder that affects the body's ability to break down certain amino acids and fatty acids, leading to a buildup of toxic compounds in the blood and tissues. Symptoms of GAII can include muscle weakness, lethargy, hypoglycemia, and metabolic acidosis. There is currently no cure for GAII, and treatment typically involves managing symptoms through dietary changes and supplementation with carnitine and riboflavin.

Targeted drug discovery efforts for GAII have focused on developing therapies that can improve the function of the ETFDH protein or bypass its role in the electron-transfer system. One approach has been to develop small molecules that can act as electron shuttles, allowing electrons to bypass the defective ETFDH protein and enter the respiratory chain. Another approach has been to develop gene therapies that can introduce functional copies of the ETFDH gene into affected cells.

There are currently no drugs on the market specifically approved for the treatment of GAII. However, several drugs have shown promise in preclinical and clinical studies. One example is bezafibrate, a drug that has been used to treat hyperlipidemia and other metabolic disorders. Bezafibrate has been shown to improve the function of the electron-transfer system in cells with ETFDH mutations, and is currently being evaluated in clinical trials for the treatment of GAII. Another example is idebenone, a synthetic analog of coenzyme Q10 that has been shown to improve mitochondrial function in a variety of disorders. Idebenone has been tested in clinical trials for the treatment of GAII, but results have been mixed.",GO:0033539 fatty acid beta-oxidation using acyl-CoA dehydrogenase;GO:0006635 fatty acid beta-oxidation;GO:0019395 fatty acid oxidation,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of amino acid metabolism; Predicted intracellular proteins; ENZYME proteins:Oxidoreductases; FDA approved drug targets:Small molecule drugs; Disease related genes; Enzymes,Mitochondria (Supported); Additional: Cytosol;Nucleoplasm,"Metformin; 2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol",,(M5935)HALLMARK FATTY ACID METABOLISM; (M5934)HALLMARK XENOBIOTIC METABOLISM; (M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000100991.12,ENSG00000100991,TRPC4AP,-0.562315675,-0.9722084,-0.1434115,-0.571327126,transient receptor potential cation channel subfamily C member 4 associated protein,TRPC4AP is a human gene that encodes for a protein that has phosphatase binding activity and ubiquitin ligase-substrate adaptor activity. It is involved in protein ubiquitination and the ubiquitin-dependent protein catabolic process through the C-end degron rule pathway. TRPC4AP is part of the Cul4A-RING E3 ubiquitin ligase complex and is active in this complex.,"There is limited information available on the disease implications of TRPC4AP. However, recent studies have suggested that TRPC4AP may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for TRPC4AP are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target TRPC4AP, there are several drugs that target the ubiquitin-proteasome system, which is the pathway through which TRPC4AP functions. Examples of such drugs include bortezomib, which is used to treat multiple myeloma, and carfilzomib, which is used to treat relapsed or refractory multiple myeloma.",GO:0048820 hair follicle maturation;GO:0140627 ubiquitin-dependent protein catabolic process via the C-end degron rule pathway;GO:0001942 hair follicle development,,Predicted intracellular proteins,Cytosol (Supported),,,
ENSG00000107758.16,ENSG00000107758,PPP3CB,-0.560096702,-0.986322272,-0.686391782,-0.007576052,protein phosphatase 3 catalytic subunit beta,"PPP3CB is a human gene that encodes for the protein phosphatase 3 catalytic subunit beta. This gene is involved in several functions, including calmodulin binding activity, calmodulin-dependent protein phosphatase activity, and protein phosphatase 2B binding activity. It is located in the cytoplasm and is part of the calcineurin complex. PPP3CB is implicated in the calcineurin-NFAT signaling cascade, positive regulation of transcription by RNA polymerase II, and protein dephosphorylation. It is also a biomarker of focal segmental glomerulosclerosis and schizophrenia and has been linked to aortic valve stenosis.","PPP3CB has been implicated in several diseases, including focal segmental glomerulosclerosis (FSGS), schizophrenia, and aortic valve stenosis. In FSGS, PPP3CB expression is upregulated, and it has been suggested as a potential biomarker for the disease. In schizophrenia, PPP3CB has been found to be downregulated in the prefrontal cortex, and its dysregulation has been linked to cognitive deficits in the disease. In aortic valve stenosis, PPP3CB has been shown to be involved in the calcification of the valve, leading to stenosis.

Targeted drug discovery efforts for PPP3CB have focused on developing inhibitors of the calcineurin-NFAT signaling pathway, which is regulated by PPP3CB. Several drugs have been developed that target this pathway, including cyclosporine, tacrolimus, and pimecrolimus. Cyclosporine and tacrolimus are used as immunosuppressants in organ transplantation and autoimmune diseases, while pimecrolimus is used to treat atopic dermatitis. These drugs have been successful in treating their respective diseases, demonstrating the potential of targeting PPP3CB and the calcineurin-NFAT pathway in drug development.",GO:1905673 positive regulation of lysosome organization;GO:0031987 locomotion involved in locomotory behavior;GO:1905949 negative regulation of calcium ion import across plasma membrane,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol (Supported); Additional: Calyx;Nucleoplasm,,(M235)PID TCR CALCIUM PATHWAY; (M290)PID IL12 STAT4 PATHWAY; (M175)PID ERBB2 ERBB3 PATHWAY,
ENSG00000072518.21,ENSG00000072518,MARK2,-0.559564632,-0.79928145,-0.55361225,-0.325800195,microtubule affinity regulating kinase 2,"MARK2 is a gene that encodes a protein kinase belonging to the Par-1 family. This protein plays a crucial role in regulating cell polarity in epithelial and neuronal cells. It also controls the stability of microtubules by phosphorylating and inactivating several microtubule-associating proteins. The protein is found on cell membranes and has multiple transcript variants that encode different isoforms. MARK2 is essential for maintaining the proper structure and function of cells, and mutations in this gene have been linked to various diseases, including cancer and neurodegenerative disorders.","MARK2 has been implicated in several diseases, including cancer and neurodegenerative disorders. In cancer, MARK2 has been shown to promote tumor growth and metastasis by regulating cell migration and invasion. In neurodegenerative disorders, such as Alzheimer's disease, MARK2 has been found to play a role in the formation of neurofibrillary tangles, a hallmark of the disease.

Targeted drug discovery efforts for MARK2 have focused on developing small molecule inhibitors that can selectively target the kinase activity of the protein. Several compounds have been identified that show promising activity against MARK2, including the compounds LXR-623 and OTSSP167. These compounds have been shown to inhibit the growth of cancer cells and improve cognitive function in animal models of Alzheimer's disease.

Currently, there are no drugs on the market that specifically target MARK2. However, several drugs that target related kinases, such as the PARP inhibitors used in cancer treatment, have shown some activity against MARK2. Further research is needed to develop more specific and effective drugs targeting this protein.",GO:0071963 establishment or maintenance of cell polarity regulating cell shape;GO:1904526 regulation of microtubule binding;GO:0045197 establishment or maintenance of epithelial cell apical/basal polarity,yes,Enzymes; Predicted intracellular proteins; Kinases:CAMK Ser/Thr protein kinases; ENZYME proteins:Transferases,Plasma membrane (Supported); Additional: Nucleoplasm,Fostamatinib,(M87)PID LKB1 PATHWAY; (M17)PID NOTCH PATHWAY,(M5941)HALLMARK UV RESPONSE UP
ENSG00000075785.14,ENSG00000075785,RAB7A,-0.558146934,-0.848327407,-0.534492197,-0.291621196,"RAB7A, member RAS oncogene family",RAB7A is a member of the RAB family of small GTP-binding proteins that regulate vesicular transport in exocytic/endocytic pathways. It specifically regulates vesicle traffic in late endosomes and from late endosomes to lysosomes. RAB7A is also involved in the cellular vacuolation of the VacA cytotoxin of Helicobacter pylori. Mutations in RAB7A have been linked to some forms of Charcot-Marie-Tooth (CMT) type 2 neuropathies.,"Mutations in RAB7A have been linked to some forms of Charcot-Marie-Tooth (CMT) type 2 neuropathies. CMT is a group of inherited peripheral neuropathies that affect motor and sensory nerves, leading to muscle weakness and atrophy, as well as sensory loss. There are currently no targeted drug discovery efforts specifically for RAB7A mutations in CMT, but there are ongoing efforts to develop treatments for CMT as a whole. Some examples of successful drugs on the market for CMT include ascorbic acid (vitamin C), which has been shown to improve nerve function in some patients, and PXT3003, a combination of three drugs that has shown promising results in clinical trials for CMT1A.",GO:0007174 epidermal growth factor catabolic process;GO:1904979 negative regulation of endosome organization;GO:1905365 regulation of intralumenal vesicle formation,,Predicted intracellular proteins; Transporters; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,Lysosomes;Primary cilium transition zone (Approved),Guanosine-5'-Diphosphate,(M210)PID IL8 CXCR2 PATHWAY; (M142)PID AJDISS 2PATHWAY; (M54)PID IL12 2PATHWAY,
ENSG00000126653.18,ENSG00000126653,NSRP1,-0.557749069,-0.760812259,-0.755648121,-0.156786828,nuclear speckle splicing regulatory protein 1,"NSRP1, or nuclear speckle splicing regulatory protein 1, is a gene that encodes a protein involved in mRNA binding and regulation of alternative mRNA splicing through the spliceosome. It is located in the nuclear speck and is part of a ribonucleoprotein complex. NSRP1 is also involved in developmental processes.","There is limited information available on the disease implications of NSRP1. However, recent studies have suggested that NSRP1 may play a role in cancer development and progression. Targeted drug discovery efforts for NSRP1 are currently underway, with a focus on developing small molecule inhibitors that can disrupt the protein's function and potentially inhibit cancer growth. While there are currently no drugs on the market that specifically target NSRP1, there are several drugs that target the spliceosome, which is the complex that NSRP1 is involved in regulating. These drugs, such as Spliceostatin A and Pladienolide B, have shown promise in preclinical studies and are currently being evaluated in clinical trials for the treatment of various types of cancer.","GO:0000381 regulation of alternative mRNA splicing, via spliceosome;GO:0048024 regulation of mRNA splicing, via spliceosome;GO:0050684 regulation of mRNA processing",,Disease related genes; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000163788.14,ENSG00000163788,SNRK,-0.55772775,-0.862089895,-0.719004946,-0.09208841,SNF related kinase,"SNRK is a type of serine/threonine kinase that belongs to the SNF-related kinase family. This gene is responsible for encoding the protein that regulates various cellular processes, including metabolism and energy homeostasis. SNRK has been found to play a role in the regulation of glucose and lipid metabolism, as well as in the development of obesity and diabetes. It is also involved in the regulation of autophagy, a process that helps to maintain cellular homeostasis by degrading damaged or unnecessary cellular components. SNRK has been identified as a potential therapeutic target for the treatment of metabolic disorders and cancer.","There is growing interest in targeting SNRK for the treatment of metabolic disorders and cancer. In particular, SNRK has been implicated in the development of obesity and type 2 diabetes, making it a potential target for the development of new therapies for these conditions. Several drug discovery efforts are currently underway to identify small molecule inhibitors of SNRK, with the goal of developing new treatments for metabolic disorders and cancer. While there are currently no drugs on the market that specifically target SNRK, there are several drugs that indirectly affect SNRK activity, such as metformin, which is commonly used to treat type 2 diabetes. Additionally, several natural compounds, such as resveratrol and curcumin, have been shown to activate SNRK and may have potential therapeutic applications.",GO:0030099 myeloid cell differentiation;GO:0006468 protein phosphorylation;GO:0016310 phosphorylation,yes,Enzymes; Predicted intracellular proteins; Kinases:CAMK Ser/Thr protein kinases; ENZYME proteins:Transferases,Cell Junctions;Plasma membrane;Vesicles (Approved); Additional: Nucleoplasm,Fostamatinib,,
ENSG00000091527.16,ENSG00000091527,CDV3,-0.5569053,-0.691855213,-0.575596113,-0.403264573,CDV3 homolog,"CDV3 is a human gene that is homologous to the CDV3 gene found in other organisms. It is located in both the cytosol and plasma membrane. The function of CDV3 is not well understood, but it has been implicated in various cellular processes, including cell growth and differentiation. Further research is needed to fully understand the role of CDV3 in human biology.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for CDV3. As the function of this gene is not well understood, it is difficult to determine its potential role in disease development or progression. Additionally, there are no known drugs on the market that specifically target CDV3. However, further research on the function of CDV3 may lead to the identification of potential therapeutic targets and the development of new drugs for the treatment of diseases in which this gene plays a role.",,,Predicted intracellular proteins,Cytosol (Approved); Additional: Nucleoli;Plasma membrane,,,
ENSG00000136436.15,ENSG00000136436,CALCOCO2,-0.555998526,-0.944685382,-0.424195445,-0.29911475,calcium binding and coiled-coil domain 2,The CALCOCO2 gene encodes a protein that contains a coiled-coil domain. This protein acts as a receptor for bacteria coated with ubiquitin and is involved in innate immunity by facilitating macroautophagy. Multiple isoforms of the protein are produced through alternative splicing of the gene.,"There is limited information available on the disease implications of the CALCOCO2 gene. However, some studies have suggested that mutations in this gene may be associated with the development of autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Targeted drug discovery efforts for CALCOCO2 are currently limited, but some studies have explored the potential of targeting the protein encoded by this gene for the treatment of infectious diseases. For example, a study published in the journal Nature Communications in 2018 reported the development of a small molecule inhibitor of CALCOCO2 that was effective against Mycobacterium tuberculosis, the bacterium that causes tuberculosis. However, there are currently no drugs on the market that specifically target CALCOCO2.",GO:1901098 positive regulation of autophagosome maturation;GO:0098792 xenophagy;GO:1901096 regulation of autophagosome maturation,,Predicted intracellular proteins,Cytosol (Supported); Additional: Vesicles,,,
ENSG00000183475.13,ENSG00000183475,ASB7,-0.555985977,-0.891705068,-0.501227304,-0.27502556,ankyrin repeat and SOCS box containing 7,"ASB7 is a human gene that encodes a protein belonging to a family of ankyrin repeat proteins. This protein, along with four other protein families, contains a C-terminal SOCS box motif. The SOCS box is believed to act as a bridge between specific substrate-binding domains and E3 ubiquitin protein ligases, which regulate protein turnover by targeting proteins for polyubiquination and proteasome-mediated degradation. ASB7 has two alternative transcripts that encode different isoforms.","There is limited information available on the disease implications of ASB7. However, recent studies have suggested that ASB7 may play a role in the development and progression of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ASB7 are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and inhibit its activity. While there are currently no drugs on the market that specifically target ASB7, there are several drugs that target the ubiquitin-proteasome system, which is the pathway through which ASB7 regulates protein turnover. Examples of such drugs include bortezomib, which is used to treat multiple myeloma, and carfilzomib, which is used to treat relapsed or refractory multiple myeloma.",GO:0016567 protein ubiquitination;GO:0032446 protein modification by small protein conjugation;GO:0070647 protein modification by small protein conjugation or removal,,Predicted intracellular proteins,Golgi apparatus;Vesicles (Approved); Additional: Nucleoplasm,,,(M5956)HALLMARK KRAS SIGNALING DN
ENSG00000144566.11,ENSG00000144566,RAB5A,-0.554842268,-0.900067924,-0.60189475,-0.162564129,"RAB5A, member RAS oncogene family","RAB5A is a human gene that belongs to the RAS oncogene family. It plays a role in various cellular processes, including the transport of molecules from early endosomes to late endosomes, regulation of exocytosis, and clearance of amyloid-beta by transcytosis. RAB5A has the ability to bind to GDP and GTP, and it also exhibits GTPase activity. It is found in different cellular components, such as the cytoplasmic side of early endosome membrane, nucleoplasm, and terminal bouton.","RAB5A has been implicated in various diseases, including cancer, Alzheimer's disease, and infectious diseases. In cancer, RAB5A has been shown to promote tumor growth and metastasis by regulating endocytic trafficking and signaling pathways. Targeting RAB5A has been proposed as a potential therapeutic strategy for cancer treatment. In Alzheimer's disease, RAB5A has been found to be involved in the clearance of amyloid-beta by transcytosis, and its dysfunction may contribute to the pathogenesis of the disease. Several drugs targeting RAB5A are currently in development, including small molecule inhibitors and monoclonal antibodies. However, there are currently no drugs targeting RAB5A on the market.",GO:0150093 amyloid-beta clearance by transcytosis;GO:0051036 regulation of endosome size;GO:0097494 regulation of vesicle size,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins; RAS pathway related proteins,Nucleoplasm;Vesicles (Supported),L-methionine (S)-S-oxide; Guanosine-5'-Triphosphate; Guanosine-5'-Diphosphate,(M252)PID IL8 CXCR1 PATHWAY; (M210)PID IL8 CXCR2 PATHWAY; (M229)PID P38 ALPHA BETA DOWNSTREAM PATHWAY,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000136827.12,ENSG00000136827,TOR1A,-0.554011527,-0.893087583,-0.600097297,-0.1688497,torsin family 1 member A,"TOR1A is a gene that encodes a protein belonging to the AAA family of ATPases. It is closely related to the Clp protease/heat shock family and is primarily expressed in the substantia nigra pars compacta. Mutations in this gene lead to the development of torsion dystonia 1, an autosomal dominant disorder characterized by involuntary muscle contractions and twisting movements.","Torsion dystonia 1 is a rare neurological disorder caused by mutations in the TOR1A gene. The disease is characterized by involuntary muscle contractions and twisting movements, which can be painful and debilitating. There is currently no cure for torsion dystonia 1, and treatment options are limited to symptomatic relief. However, there have been efforts to develop targeted drugs for this disorder. One approach has been to target the abnormal protein produced by the mutated TOR1A gene. For example, tetrabenazine, a drug that reduces the amount of dopamine released in the brain, has been shown to be effective in treating the symptoms of torsion dystonia 1. Another drug, botulinum toxin, can be injected into affected muscles to temporarily relieve muscle spasms. While these drugs do not cure the underlying genetic defect, they can provide significant relief for patients with torsion dystonia 1.",GO:1900244 positive regulation of synaptic vesicle endocytosis;GO:0051584 regulation of dopamine uptake involved in synaptic transmission;GO:0051940 regulation of catecholamine uptake involved in synaptic transmission,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases,Nuclear membrane;Vesicles (Supported),,(M275)PID ALPHA SYNUCLEIN PATHWAY,
ENSG00000133961.20,ENSG00000133961,NUMB,-0.553918813,-0.807986772,-0.694226479,-0.159543188,NUMB endocytic adaptor protein,"NUMB is a human gene that encodes for a membrane-bound protein involved in determining cell fates during development. The protein interacts with other proteins such as EPS15, LNX1, and NOTCH1. Its degradation is induced by MDM2 in a proteasome-dependent manner. Alternative splicing of the gene results in multiple transcript variants.","The NUMB gene has been implicated in various diseases, including cancer, Alzheimer's disease, and developmental disorders. In cancer, NUMB has been shown to act as a tumor suppressor by regulating cell proliferation and differentiation. Targeted drug discovery efforts have focused on developing drugs that can modulate NUMB activity, either by increasing its expression or inhibiting its degradation. One example is the small molecule inhibitor of MDM2, Nutlin-3, which has been shown to increase NUMB expression and inhibit tumor growth in preclinical models. Another example is the use of gamma-secretase inhibitors, which block the cleavage of NOTCH1 by NUMB and have shown promise in treating Alzheimer's disease. Currently, there are no drugs specifically targeting NUMB on the market, but ongoing research suggests that it may be a promising target for future drug development.",GO:0021849 neuroblast division in subventricular zone;GO:0021670 lateral ventricle development;GO:0055057 neuroblast division,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cell Junctions;Plasma membrane (Supported); Additional: Cytosol,,(M17)PID NOTCH PATHWAY; (M48)PID MET PATHWAY,(M5895)HALLMARK WNT BETA CATENIN SIGNALING
ENSG00000105397.14,ENSG00000105397,TYK2,-0.553363509,-1.203743319,-0.445711981,-0.010635228,tyrosine kinase 2,TYK2 is a gene that encodes a protein belonging to the Janus kinases (JAKs) family. This protein is involved in cytokine signaling by phosphorylating receptor subunits and is a component of both type I and type III interferon signaling pathways. It plays a role in anti-viral immunity and is associated with Immunodeficiency 35 when mutated. TYK2 associates with the cytoplasmic domain of type I and type II cytokine receptors to propagate cytokine signals.,"Mutations in the TYK2 gene have been associated with various autoimmune diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. As a result, TYK2 has become a target for drug discovery efforts aimed at treating these diseases. Several small molecule inhibitors of TYK2 have been developed and are currently in clinical trials, including BMS-986165, PF-06700841, and TAK-659. These drugs have shown promising results in early trials and may offer a new treatment option for patients with autoimmune diseases. Additionally, the JAK inhibitor tofacitinib, which targets both TYK2 and other JAK family members, has been approved for the treatment of rheumatoid arthritis and ulcerative colitis.",GO:0038155 interleukin-23-mediated signaling pathway;GO:0051142 positive regulation of NK T cell proliferation;GO:0051140 regulation of NK T cell proliferation,yes,Kinases:Tyr protein kinases; Predicted intracellular proteins; Human disease related genes:Immune system diseases:Primary immunodeficiency; ENZYME proteins:Transferases; FDA approved drug targets:Small molecule drugs; Disease related genes; Enzymes,Cytosol (Approved),"2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one; Tofacitinib; Fostamatinib",(M36)PID IL27 PATHWAY; (M196)PID IL23 PATHWAY; (M183)PID IL6 7 PATHWAY,(M5897)HALLMARK IL6 JAK STAT3 SIGNALING
ENSG00000167721.11,ENSG00000167721,TSR1,-0.552633072,-0.943296194,-0.680995556,-0.033607464,TSR1 ribosome maturation factor,"TSR1 is a human gene that encodes for the TSR1 ribosome maturation factor. This gene is predicted to be involved in the endonucleolytic cleavage of tricistronic rRNA transcript and the maturation of SSU-rRNA from tricistronic rRNA transcript. TSR1 is also predicted to be located in the nucleolus and part of the preribosome, small subunit precursor. Additionally, TSR1 enables RNA binding activity. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of TSR1. However, mutations in TSR1 have been associated with Diamond-Blackfan anemia (DBA), a rare genetic disorder characterized by a failure of the bone marrow to produce red blood cells. DBA is typically caused by mutations in genes involved in ribosome biogenesis, including TSR1. 

There are currently no targeted drug discovery efforts specifically for TSR1. However, there are drugs on the market that target ribosome biogenesis, which may indirectly affect TSR1 function. For example, corticosteroids such as prednisone and deflazacort are commonly used to treat DBA by increasing red blood cell production. These drugs are thought to work by suppressing the immune system and reducing inflammation, which can improve bone marrow function. Additionally, a drug called lenalidomide has shown promise in treating DBA by increasing the production of red blood cells. Lenalidomide is thought to work by targeting a protein called cereblon, which is involved in the regulation of ribosome biogenesis. 

In summary, while there is limited information available on the disease implications of TSR1, mutations in this gene have been associated with DBA. There are currently no targeted drug discovery efforts for TSR1, but drugs that indirectly affect ribosome biogenesis, such as corticosteroids and lenalidomide, have shown promise in treating DBA.","GO:0000479 endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);GO:0000462 maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);GO:0030490 maturation of SSU-rRNA",,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000096746.17,ENSG00000096746,HNRNPH3,-0.5525475,-0.761281871,-0.673858658,-0.222501972,heterogeneous nuclear ribonucleoprotein H3,"HNRNPH3 is a gene that belongs to a family of RNA binding proteins called heterogeneous nuclear ribonucleoproteins (hnRNPs). These proteins are involved in pre-mRNA processing and other aspects of mRNA metabolism and transport. HNRNPH3 has two repeats of quasi-RRM domains that bind to RNAs and is localized in nuclear bodies of the nucleus. It is involved in the splicing process and participates in early heat shock-induced splicing arrest by leaving the hnRNP complexes. There are several alternatively spliced transcript variants of this gene, but not all are fully characterized.","There is limited information available on the disease implications of HNRNPH3. However, mutations in other hnRNP genes have been associated with various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Targeted drug discovery efforts for hnRNP proteins are ongoing, with a focus on developing small molecule inhibitors that can modulate their activity. One example is the development of splicing modulators that target hnRNP A1, which has shown promise in preclinical studies for the treatment of spinal muscular atrophy. Another example is the development of inhibitors of hnRNP K, which have shown potential for the treatment of cancer. However, there are currently no drugs on the market that specifically target HNRNPH3.","GO:0043484 regulation of RNA splicing;GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;GO:0000398 mRNA splicing, via spliceosome",,Predicted intracellular proteins,Nucleoplasm (Supported),Copper,,
ENSG00000140280.14,ENSG00000140280,LYSMD2,-0.552514551,-0.107544021,-0.59202473,-0.957974901,LysM domain containing 2,"LYSMD2 is a gene that encodes for a protein containing a LysM domain, which is involved in binding to peptidoglycans found in bacterial cell walls. The function of LYSMD2 is not well understood, but it has been suggested to play a role in innate immunity and inflammation. Studies have shown that LYSMD2 expression is upregulated in response to bacterial infection and that it may be involved in the recognition and clearance of bacterial pathogens. Additionally, LYSMD2 has been implicated in the development of certain cancers, including breast and lung cancer. Further research is needed to fully understand the role of LYSMD2 in these processes.","There is limited information available on the disease implications of LYSMD2, and there are currently no targeted drug discovery efforts focused on this gene. However, as mentioned earlier, LYSMD2 has been implicated in the development of certain cancers, including breast and lung cancer. In breast cancer, LYSMD2 expression has been shown to be associated with poor prognosis and increased risk of metastasis. In lung cancer, LYSMD2 has been identified as a potential therapeutic target due to its role in promoting cancer cell proliferation and survival. Despite these findings, there are currently no drugs on the market that specifically target LYSMD2. Further research is needed to identify potential drug targets and develop effective therapies for diseases associated with LYSMD2.",,,Predicted intracellular proteins,Mitochondria (Approved); Additional: Nuclear bodies,,,(M5913)HALLMARK INTERFERON GAMMA RESPONSE
ENSG00000126858.18,ENSG00000126858,RHOT1,-0.551804568,-0.898647239,-0.645476968,-0.111289497,ras homolog family member T1,"RHOT1, also known as ras homolog family member T1, is a human gene that is predicted to have GTP binding and GTPase activity. It is involved in maintaining cellular homeostasis, regulating mitochondrial outer membrane permeabilization, and facilitating the transport of mitochondria along microtubules. RHOT1 is an integral component of the mitochondrial outer membrane.","RHOT1 has been implicated in several diseases, including Parkinson's disease, Alzheimer's disease, and cancer. In Parkinson's disease, RHOT1 has been shown to play a role in the regulation of mitochondrial dynamics, which is disrupted in the disease. RHOT1 has also been linked to the regulation of autophagy, a process that is important for the clearance of damaged mitochondria and other cellular components. Dysregulation of autophagy has been implicated in the pathogenesis of several diseases, including cancer.

There are currently no drugs on the market that specifically target RHOT1. However, there are ongoing efforts to develop drugs that target mitochondrial dynamics and autophagy, which may indirectly affect RHOT1. For example, several drugs that target the mitochondrial fission/fusion machinery, such as Mdivi-1 and P110, have been shown to have neuroprotective effects in preclinical models of Parkinson's disease. Additionally, several drugs that target autophagy, such as rapamycin and chloroquine, have been investigated for their potential therapeutic effects in cancer.

In conclusion, RHOT1 is an important gene involved in maintaining cellular homeostasis and regulating mitochondrial dynamics. While there are currently no drugs on the market that specifically target RHOT1, ongoing research into mitochondrial dynamics and autophagy may lead to the development of new therapies for diseases such as Parkinson's disease and cancer.",GO:0097345 mitochondrial outer membrane permeabilization;GO:1902110 positive regulation of mitochondrial membrane permeability involved in apoptotic process;GO:1902686 mitochondrial outer membrane permeabilization involved in programmed cell death,,Predicted intracellular proteins,,,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000079950.14,ENSG00000079950,STX7,-0.551709666,-0.635674354,-0.834133823,-0.185320821,syntaxin 7,"STX7, also known as syntaxin 7, is a gene that encodes a membrane receptor belonging to the syntaxin family. This protein is involved in the transport of vesicles and interacts with alpha-SNAP, a regulator of vesicle fusion. Together with syntaxin 13, STX7 plays a role in the fusion of endosomes and lysosomes with the phagosome. This gene is important for intracellular trafficking and plays a crucial role in maintaining cellular homeostasis. Mutations in STX7 have been associated with various diseases, including cancer and neurological disorders.","STX7 has been implicated in various diseases, including cancer and neurological disorders. In cancer, STX7 has been shown to play a role in tumor growth and metastasis. Targeting STX7 with small molecule inhibitors has been explored as a potential therapeutic strategy for cancer treatment. In neurological disorders, STX7 has been linked to the pathogenesis of Alzheimer's disease and Parkinson's disease. However, there are currently no drugs on the market that specifically target STX7. Nevertheless, several small molecule inhibitors of STX7 have been developed and are being evaluated in preclinical studies for their potential therapeutic efficacy in cancer and neurological disorders. These include compounds such as N-ethylmaleimide, which inhibits the interaction between STX7 and alpha-SNAP, and 3,4-dihydroxybenzaldehyde, which inhibits STX7-mediated vesicle fusion. Further research is needed to determine the safety and efficacy of these compounds in clinical trials.",GO:1902685 positive regulation of receptor localization to synapse;GO:1902683 regulation of receptor localization to synapse;GO:0001916 positive regulation of T cell mediated cytotoxicity,,Predicted intracellular proteins,Lysosomes (Supported),,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000181704.12,ENSG00000181704,YIPF6,-0.550702696,-0.734640477,-0.590255383,-0.327212227,Yip1 domain family member 6,"YIPF6, also known as Yip1 domain family member 6, is a human gene that is predicted to have identical protein binding activity. It is also predicted to play a role in intestinal epithelial cell development, potentially acting upstream of or within this process. YIPF6 is located in the Golgi apparatus subcompartment and endoplasmic reticulum. This information is provided by the Alliance of Genome Resources as of April 2022.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for YIPF6. As of April 2022, there are no drugs on the market that specifically target this gene. However, it is possible that future research may uncover potential therapeutic targets related to YIPF6 and its role in intestinal epithelial cell development. Additionally, further investigation into the function of YIPF6 may reveal potential disease implications and therapeutic opportunities.",GO:0060576 intestinal epithelial cell development;GO:0060575 intestinal epithelial cell differentiation;GO:0002066 columnar/cuboidal epithelial cell development,,,Vesicles (Approved),,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000170633.16,ENSG00000170633,RNF34,-0.548891953,-0.915028491,-0.543740511,-0.187906856,ring finger protein 34,"RNF34, or ring finger protein 34, is a gene that encodes a protein containing a RINF finger motif, which is involved in protein-protein and protein-DNA interactions. The protein interacts with DNAJA3/hTid-1, a protein that modulates apoptosis, and overexpression of RNF34 has been shown to confer resistance to TNF-alpha induced apoptosis, suggesting an anti-apoptotic function. Caspase-3 can cleave the protein during apoptosis induction, and it also targets p53 and phospho-p53 for degradation. Multiple transcript variants encoding distinct isoforms can result from alternative splicing.","Research on RNF34 has suggested its involvement in various diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, RNF34 has been shown to regulate the stability of tumor suppressor proteins, such as p53 and PTEN, and its overexpression has been associated with poor prognosis in several types of cancer. Targeted drug discovery efforts for RNF34 are still in the early stages, but some studies have identified potential small molecule inhibitors of RNF34 that could be developed as anti-cancer agents. One example is a compound called NSC687852, which has been shown to inhibit RNF34-mediated degradation of p53 and induce apoptosis in cancer cells. However, more research is needed to determine the safety and efficacy of these compounds in clinical settings. Currently, there are no drugs on the market that specifically target RNF34.","GO:2000374 regulation of oxygen metabolic process;GO:0070417 cellular response to cold;GO:0035872 nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway",,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported); Additional: Nuclear bodies,,,
ENSG00000054118.15,ENSG00000054118,THRAP3,-0.548316769,-0.676548351,-0.789215684,-0.179186274,thyroid hormone receptor associated protein 3,"THRAP3 is a human gene that encodes for a protein called thyroid hormone receptor associated protein 3. This protein has several functions, including the ability to bind to phosphoproteins and thyroid hormone receptors, as well as act as a transcription coactivator. THRAP3 is involved in various biological processes, such as the breakdown of nuclear-transcribed mRNA, the regulation of circadian rhythm, and the regulation of RNA metabolism. It plays a role in the positive regulation of transcription by RNA polymerase II and is located in the nuclear speck. THRAP3 is also part of the mediator complex and colocalizes with the exon-exon junction complex.","There is limited information available on the disease implications of THRAP3. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, such as breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for THRAP3 are also limited, as the exact role of this protein in disease pathogenesis is not well understood. However, some studies have suggested that targeting THRAP3 may be a potential therapeutic strategy for certain types of cancer. Currently, there are no drugs on the market that specifically target THRAP3. However, there are several drugs that target related proteins, such as thyroid hormone receptors and transcription coactivators, which may indirectly affect THRAP3 function. Examples of such drugs include levothyroxine, a synthetic thyroid hormone, and tamoxifen, a selective estrogen receptor modulator used in breast cancer treatment.","GO:0042753 positive regulation of circadian rhythm;GO:0048026 positive regulation of mRNA splicing, via spliceosome;GO:0050685 positive regulation of mRNA processing",,Predicted intracellular proteins,Nuclear speckles (Enhanced),,,
ENSG00000104660.19,ENSG00000104660,LEPROTL1,-0.546057271,-0.628670902,-0.543062264,-0.466438646,leptin receptor overlapping transcript like 1,LEPROTL1 is a human gene that encodes a protein with identical protein binding activity. It is predicted to be involved in the late endosome to vacuole transport via the multivesicular body sorting pathway and the negative regulation of the growth hormone receptor signaling pathway. The protein is also predicted to be an integral component of the membrane and active in the endosome. This information was provided by the Alliance of Genome Resources in April 2022.,"There is limited information available on the disease implications of LEPROTL1. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Additionally, LEPROTL1 has been implicated in the regulation of insulin signaling and glucose metabolism, suggesting a potential role in diabetes and metabolic disorders.

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target LEPROTL1. However, given its potential involvement in cancer and metabolic disorders, there may be interest in developing drugs that modulate its activity. One approach could be to identify small molecules that interact with LEPROTL1 and alter its function, either by promoting or inhibiting its activity.

Overall, while LEPROTL1 is an interesting gene with potential implications for disease, further research is needed to fully understand its role in human health and to identify potential therapeutic targets.",GO:0060400 negative regulation of growth hormone receptor signaling pathway;GO:0060398 regulation of growth hormone receptor signaling pathway;GO:0032511 late endosome to vacuole transport via multivesicular body sorting pathway,,,,,,
ENSG00000103035.11,ENSG00000103035,PSMD7,-0.545829955,-0.720047142,-0.725550068,-0.191892656,"proteasome 26S subunit, non-ATPase 7","PSMD7 is a gene that encodes a non-ATPase subunit of the 19S regulator of the 26S proteasome, a protein complex that cleaves peptides in a non-lysosomal pathway. The 26S proteasome is composed of a 20S core and a 19S regulator, with the latter containing a base and a lid. The base contains 6 ATPase subunits and 2 non-ATPase subunits, while the lid contains up to 10 non-ATPase subunits. PSMD7 is essential for the function of the 19S regulator, which is responsible for recognizing and binding to ubiquitinated proteins and unfolding them for degradation by the 20S core. A pseudogene of PSMD7 has been identified on chromosome 17.","PSMD7 has been implicated in various diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, PSMD7 has been shown to be overexpressed in several types of tumors, including breast, lung, and prostate cancer, and its inhibition has been proposed as a potential therapeutic strategy. In neurodegenerative disorders, PSMD7 has been linked to the accumulation of misfolded proteins, such as alpha-synuclein in Parkinson's disease and beta-amyloid in Alzheimer's disease. In viral infections, PSMD7 has been shown to interact with viral proteins and play a role in viral replication and pathogenesis.

Targeted drug discovery efforts for PSMD7 have focused on developing small molecule inhibitors that can selectively target the 19S regulator of the proteasome. Several compounds have been identified that can inhibit PSMD7 and show promising anti-cancer activity in preclinical studies. For example, b-AP15 is a small molecule inhibitor of PSMD7 that has been shown to induce apoptosis in cancer cells and sensitize them to chemotherapy. Another compound, RA190, has been shown to inhibit PSMD7 and suppress tumor growth in mouse models of breast cancer.

Currently, there are no drugs on the market that specifically target PSMD7. However, several proteasome inhibitors, such as bortezomib and carfilzomib, have been approved for the treatment of multiple myeloma and other cancers. These drugs target the 20S core of the proteasome and have shown clinical efficacy in several types of cancer.",GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process;GO:0010498 proteasomal protein catabolic process;GO:0006511 ubiquitin-dependent protein catabolic process,,Peptidases:Metallopeptidases; Enzymes; Predicted intracellular proteins,Acrosome;Equatorial segment;Mid piece;Nucleoplasm;Principal piece (Approved),,,(M5926)HALLMARK MYC TARGETS V1
ENSG00000115073.8,ENSG00000115073,ACTR1B,-0.544226587,-1.074377868,-0.534899608,-0.023402286,actin related protein 1B,"ACTR1B is a gene that encodes a subunit of dynactin, a complex consisting of 10 subunits that binds to microtubules and cytoplasmic dynein. Dynactin is involved in various cellular functions, including ER-to-Golgi transport, lysosome and endosome movement, spindle formation, chromosome movement, nuclear positioning, and axonogenesis. ACTR1B is an actin-related protein that shares 90% amino acid identity with ACTR1A, another subunit of dynactin. These two proteins are present in a constant ratio of approximately 1:15 in the dynactin complex.","There is limited information available on the disease implications of ACTR1B. However, mutations in other subunits of the dynactin complex have been associated with various neurological disorders, including Perry syndrome, amyotrophic lateral sclerosis (ALS), and Charcot-Marie-Tooth disease. Targeted drug discovery efforts for dynactin-related disorders are still in the early stages, but there is potential for developing drugs that modulate the function of the dynactin complex. One example of a successful drug targeting the microtubule cytoskeleton is paclitaxel, which stabilizes microtubules and is used to treat various cancers. Another example is the drug tazemetostat, which inhibits the activity of the histone methyltransferase EZH2 and is used to treat certain types of cancer. While these drugs do not directly target ACTR1B or dynactin, they demonstrate the potential for developing drugs that modulate the function of the microtubule cytoskeleton.",,,Predicted intracellular proteins,Microtubules (Uncertain); Additional: Cytokinetic bridge;Cytosol;Primary cilium,,,
ENSG00000143549.21,ENSG00000143549,TPM3,-0.542103731,-0.618691874,-0.80727718,-0.20034214,tropomyosin 3,"TPM3 is a gene that encodes a protein called tropomyosin 3, which is a member of the tropomyosin family of actin-binding proteins. Tropomyosins are important for stabilizing actin filaments and regulating access of other actin-binding proteins. Mutations in TPM3 can lead to muscle disorders such as autosomal dominant nemaline myopathy. This gene is also involved in translocations with other genes, resulting in the formation of fusion proteins that act as oncogenes. There are multiple transcript variants of TPM3 due to alternative splicing, and there are also numerous pseudogenes for this gene on different chromosomes.","Mutations in TPM3 have been linked to several muscle disorders, including autosomal dominant nemaline myopathy (ADNM), which is characterized by muscle weakness and wasting. There is currently no cure for ADNM, and treatment is mainly supportive, focusing on managing symptoms and improving quality of life. However, research efforts are underway to develop targeted therapies for this and other muscle disorders. One approach is to target the actin-myosin interaction, which is disrupted in these disorders. Several drugs targeting this interaction, such as CK-2017357 and tirasemtiv, are currently in clinical trials for various muscle disorders. Additionally, gene therapy approaches are being explored to replace or repair the mutated TPM3 gene. While there are currently no approved drugs specifically targeting TPM3, the development of targeted therapies for muscle disorders holds promise for improving the lives of patients with these conditions.",GO:0006936 muscle contraction;GO:0007015 actin filament organization;GO:0003012 muscle system process,,Human disease related genes:Musculoskeletal diseases:Muscular diseases; Predicted intracellular proteins; Human disease related genes:Cancers:Cancers of endocrine organs; Cancer-related genes; Disease related genes,Actin filaments (Approved); Additional: Cytosol,Phenethyl Isothiocyanate,,(M5909)HALLMARK MYOGENESIS
ENSG00000109083.14,ENSG00000109083,IFT20,-0.540816893,-0.909243884,-0.693806431,-0.019400364,intraflagellar transport 20,"The IFT20 gene is responsible for encoding an intraflagellar transport protein that plays a crucial role in intracellular transport. It is a part of a complex that is involved in the trafficking of proteins from the Golgi body, including the recycling of immune signaling components. The gene is part of a set of sense-antisense loci that may be co-regulated. Multiple isoforms of the gene have been observed due to alternative splicing. A pseudogene of this gene is located on the long arm of chromosome 14. Overall, the IFT20 gene is essential for proper intracellular transport and plays a critical role in maintaining cellular function.","Research has shown that mutations in the IFT20 gene can lead to a variety of diseases, including ciliopathies such as Bardet-Biedl syndrome and Jeune syndrome. In addition, dysregulation of IFT20 expression has been linked to cancer, particularly in breast and lung cancer. As a result, there has been significant interest in developing drugs that target IFT20 as a potential therapeutic strategy. However, there are currently no drugs on the market that specifically target IFT20. Instead, researchers have focused on identifying compounds that can modulate the activity of the intraflagellar transport system as a whole, which includes IFT20. One example is the drug ciliobrevin, which inhibits the activity of the AAA+ ATPase motor protein dynein, thereby disrupting intraflagellar transport. While not specific to IFT20, ciliobrevin has shown promise in preclinical studies as a potential treatment for ciliopathies and certain types of cancer.",GO:0036372 opsin transport;GO:2000583 regulation of platelet-derived growth factor receptor-alpha signaling pathway;GO:0035845 photoreceptor cell outer segment organization,,Predicted intracellular proteins,Microtubules (Approved); Additional: Basal body;End piece;Flagellar centriole;Mid piece;Mitotic spindle;Primary cilium;Principal piece,,,
ENSG00000085721.13,ENSG00000085721,RRN3,-0.540536835,-0.702092744,-0.562774824,-0.356742937,"RRN3 homolog, RNA polymerase I transcription factor","RRN3 is a human gene that encodes a protein called RRN3 homolog, RNA polymerase I transcription factor. This protein is involved in the regulation of transcription initiation from RNA polymerase I promoter, which is responsible for the synthesis of ribosomal RNA. RRN3 enables DNA binding activity specific to the core promoter sequence of RNA polymerase I. It is predicted to act upstream or within several processes, including DNA-templated transcription initiation, negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator, and regulation of transcription, DNA-templated. RRN3 is located in the nucleolus, a subnuclear structure where ribosomal RNA is synthesized and ribosome assembly occurs.","There is limited information available on the disease implications of RRN3. However, some studies have suggested that RRN3 may play a role in cancer development and progression. For example, overexpression of RRN3 has been observed in various types of cancer, including breast, lung, and ovarian cancer. Targeted drug discovery efforts for RRN3 are also limited, but some studies have explored the potential of small molecule inhibitors to target RRN3 and inhibit its activity. One example is CX-5461, a small molecule inhibitor that targets RNA polymerase I transcription and has shown promising results in preclinical studies for the treatment of various types of cancer. However, more research is needed to fully understand the potential of RRN3 as a therapeutic target and to develop effective drugs for its inhibition.",GO:0001188 RNA polymerase I preinitiation complex assembly;GO:0007000 nucleolus organization;GO:0006361 transcription initiation at RNA polymerase I promoter,,Predicted intracellular proteins,Nucleoli rim (Supported),,(M121)PID MTOR 4PATHWAY,
ENSG00000187742.15,ENSG00000187742,SECISBP2,-0.540345524,-0.929838116,-0.575454047,-0.115744409,SECIS binding protein 2,"SECIS binding protein 2 (SECISBP2) is a crucial component of the machinery involved in the insertion of selenocysteine (Sec) into selenoproteins during translation. Sec is encoded by the UGA codon, which normally signals translation termination, but recoding of UGA as Sec codon requires a Sec insertion sequence (SECIS) element present in the 3' untranslated regions of eukaryotic selenoprotein mRNAs. SECISBP2 specifically binds to the SECIS element, which is stimulated by a Sec-specific translation elongation factor. Mutations in SECISBP2 have been linked to reduced enzymatic activity of type II iodothyronine deiodinase, a selenoprotein, and abnormal thyroid hormone metabolism. The gene has alternatively spliced transcript variants.","Mutations in SECISBP2 have been associated with a rare autosomal recessive disorder called pontocerebellar hypoplasia type 2D (PCH2D), which is characterized by severe developmental delay, microcephaly, and progressive pontocerebellar atrophy. There are currently no targeted drug discovery efforts for SECISBP2-related disorders, and no drugs have been approved specifically for the treatment of PCH2D. However, some drugs that target the symptoms of PCH2D, such as antiepileptic drugs and muscle relaxants, may be used to manage the condition. Additionally, some selenoprotein-related disorders, such as Keshan disease and Kashin-Beck disease, have been treated with selenium supplementation, which may also be beneficial for individuals with SECISBP2-related disorders.","GO:0001514 selenocysteine incorporation;GO:0006451 translational readthrough;GO:2000623 negative regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay",,Disease related genes; Human disease related genes:Endocrine and metabolic diseases:Thyroid gland diseases; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000084073.10,ENSG00000084073,ZMPSTE24,-0.540276906,-0.828218886,-0.740746769,-0.051865062,zinc metallopeptidase STE24,ZMPSTE24 is a gene that encodes a zinc metalloproteinase involved in the post-translational proteolytic cleavage of prelamin A to form mature lamin A. This gene belongs to the peptidase M48A family. Mutations in ZMPSTE24 have been linked to mandibuloacral dysplasia and restrictive dermopathy.,"Mutations in the ZMPSTE24 gene have been linked to two rare genetic disorders: mandibuloacral dysplasia (MAD) and restrictive dermopathy (RD). MAD is characterized by skeletal abnormalities, skin changes, and lipodystrophy, while RD is a lethal disorder that affects the skin, lungs, and bones. There are currently no targeted drug therapies available for these disorders, and treatment is mainly supportive. However, there have been efforts to develop drugs that target the processing of prelamin A by ZMPSTE24. One example is the farnesyltransferase inhibitor lonafarnib, which has shown promise in clinical trials for the treatment of progeria, a rare genetic disorder that also involves abnormal processing of prelamin A. Another example is the small molecule compound ZMPSTE24 inhibitor, which has been shown to reduce prelamin A accumulation in cells and improve cellular function in vitro. However, further research is needed to determine the safety and efficacy of these drugs for the treatment of MAD and RD.",GO:2000730 regulation of termination of RNA polymerase I transcription;GO:0043007 maintenance of rDNA;GO:0030327 prenylated protein catabolic process,,Transporters; Peptidases:Metallopeptidases; Human disease related genes:Congenital malformations:Congenital malformations of skin; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; ENZYME proteins:Hydrolases; Enzymes,,,,
ENSG00000050130.18,ENSG00000050130,JKAMP,-0.540160215,-0.796135848,-0.636327391,-0.188017404,JNK1/MAPK8 associated membrane protein,"JKAMP, also known as JNK1/MAPK8 associated membrane protein, is a gene that encodes a protein involved in the ubiquitin-dependent ERAD pathway. The protein is predicted to be located in the endoplasmic reticulum membrane and is an integral component of the membrane. JKAMP enables ubiquitin protein ligase binding activity, which is important for the degradation of misfolded or damaged proteins in the ER. This gene may have implications in diseases related to protein misfolding and ER stress.","There is limited information available on the specific disease implications of JKAMP. However, given its involvement in the ERAD pathway, it is possible that mutations or dysregulation of this gene could contribute to diseases related to protein misfolding and ER stress, such as neurodegenerative diseases and certain types of cancer. 

As of now, there are no targeted drug discovery efforts specifically focused on JKAMP. However, there are drugs on the market that target the ERAD pathway more broadly, such as proteasome inhibitors and chaperone modulators. For example, bortezomib is a proteasome inhibitor that is used to treat multiple myeloma, a type of cancer that involves the accumulation of misfolded proteins in the ER. Another example is lumacaftor, a chaperone modulator that is used to treat cystic fibrosis, a disease caused by mutations in the CFTR gene that lead to protein misfolding and ER stress. 

Overall, while there is still much to learn about the specific role of JKAMP in disease, targeting the ERAD pathway more broadly has shown promise in the development of drugs for diseases related to protein misfolding and ER stress.",GO:0036503 ERAD pathway;GO:0006986 response to unfolded protein;GO:0035966 response to topologically incorrect protein,,Cancer-related genes:Candidate cancer biomarkers,Vesicles (Approved); Additional: Nucleoplasm,,,
ENSG00000103005.12,ENSG00000103005,USB1,-0.539716391,-1.009092014,-0.52427373,-0.085783429,U6 snRNA biogenesis phosphodiesterase 1,"The human gene USB1 is responsible for encoding a protein with several conserved domains, but its exact function is not yet known. Mutations in this gene are linked to poikiloderma with neutropenia (PN), which shares some clinical features with Rothmund-Thomson syndrome (RTS) caused by mutations in the RECQL4 gene. It is believed that the USB1 protein interacts with the RECQL4 protein via SMAD4 proteins, which explains the partial clinical overlap between PN and RTS. Different isoforms of the gene have been identified through alternative splicing.","Poikiloderma with neutropenia (PN) is a rare autosomal recessive disorder caused by mutations in the USB1 gene. PN is characterized by skin pigmentation abnormalities, recurrent infections, and neutropenia. There is currently no cure for PN, and treatment is mainly supportive, focusing on managing infections and skin lesions. Targeted drug discovery efforts for PN are limited due to the lack of understanding of the exact function of the USB1 protein. However, recent studies have shown that the USB1 protein interacts with the RECQL4 protein, which is involved in DNA repair and maintenance. This interaction suggests that targeting the DNA repair pathway may be a potential therapeutic strategy for PN. There are currently no drugs specifically approved for PN, but some drugs used to treat neutropenia, such as granulocyte colony-stimulating factor (G-CSF), have been used to manage the neutropenia associated with PN.",GO:0034477 U6 snRNA 3'-end processing;GO:0034472 snRNA 3'-end processing;GO:0016180 snRNA processing,,Disease related genes; Human disease related genes:Skin diseases:Skin and soft tissue diseases; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000158290.18,ENSG00000158290,CUL4B,-0.539000267,-0.729793492,-0.530201724,-0.357005585,cullin 4B,"CUL4B is a gene that belongs to the cullin family and encodes a protein that acts as an E3 ubiquitin ligase. This protein forms a complex that catalyzes the polyubiquitination of specific protein substrates in the cell. It interacts with a ring finger protein and is necessary for the proteolysis of several regulators of DNA replication, including chromatin licensing and DNA replication factor 1 and cyclin E. The gene has multiple transcript variants that encode different isoforms.","Mutations in the CUL4B gene have been associated with X-linked intellectual disability (XLID), a condition characterized by impaired cognitive function and intellectual disability. Additionally, CUL4B has been implicated in the development of several types of cancer, including breast, lung, and liver cancer. As a result, there has been interest in developing drugs that target CUL4B as a potential therapeutic strategy for these diseases.

One example of a drug that targets CUL4B is MLN4924, a small molecule inhibitor that has shown promise in preclinical studies for the treatment of various types of cancer. MLN4924 works by inhibiting the activity of the NEDD8-activating enzyme, which is required for the activation of CUL4B. By blocking CUL4B activity, MLN4924 can induce cell death in cancer cells and inhibit tumor growth.

Another potential drug target for CUL4B is the E3 ubiquitin ligase complex that it forms with other proteins. Several small molecule inhibitors of E3 ubiquitin ligases are currently in development, and some have shown promising results in preclinical studies for the treatment of cancer. However, more research is needed to determine the safety and efficacy of these drugs in humans.",GO:0070914 UV-damage excision repair;GO:1900087 positive regulation of G1/S transition of mitotic cell cycle;GO:0048708 astrocyte differentiation,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Cancer-related genes:Mutated cancer genes; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,
ENSG00000134308.14,ENSG00000134308,YWHAQ,-0.538700972,-0.819518083,-0.733292602,-0.06329223,tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta,"YWHAQ is a gene that belongs to the 14-3-3 family of proteins, which are involved in signal transduction by binding to phosphoserine-containing proteins. This gene is highly conserved and is found in both plants and mammals. It is 99% identical to the mouse and rat orthologs. YWHAQ is upregulated in patients with amyotrophic lateral sclerosis, a neurodegenerative disease. The gene contains a 6 bp tandem repeat sequence in its 5' UTR that is polymorphic, but there is no correlation between the repeat number and the disease.","YWHAQ has been implicated in several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, YWHAQ has been shown to be overexpressed in several types of tumors, including breast, ovarian, and lung cancer. Targeting YWHAQ has been proposed as a potential therapeutic strategy for cancer treatment. In neurodegenerative disorders, YWHAQ has been found to be upregulated in patients with Alzheimer's disease and Parkinson's disease. Targeting YWHAQ has been suggested as a potential therapeutic approach for these diseases. However, there are currently no drugs on the market that specifically target YWHAQ. Several compounds have been identified as potential YWHAQ inhibitors, including fusicoccin, a natural product that has been shown to inhibit YWHAQ in vitro. Further research is needed to develop effective YWHAQ-targeted drugs for the treatment of various diseases.",GO:0021762 substantia nigra development;GO:0048857 neural nucleus development;GO:0030901 midbrain development,,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Cytosol (Supported); Additional: Nucleoplasm,Phenethyl Isothiocyanate,(M199)PID P38 MK2 PATHWAY; (M247)PID INSULIN GLUCOSE PATHWAY; (M249)PID PI3KCI AKT PATHWAY,(M5926)HALLMARK MYC TARGETS V1
ENSG00000196961.13,ENSG00000196961,AP2A1,-0.5386861,-0.962371578,-0.616082959,-0.037603764,adaptor related protein complex 2 subunit alpha 1,"AP2A1 is a gene that encodes the alpha 1 adaptin subunit of the adaptor protein 2 (AP-2) complex found in clathrin coated vesicles. The AP-2 complex is a protein coat on the cytoplasmic face of coated vesicles that links clathrin to receptors in vesicles. The complex is a heterotetramer consisting of two large adaptins (alpha or beta), a medium adaptin (mu), and a small adaptin (sigma). Alternative splicing of this gene results in two transcript variants encoding two different isoforms. A third transcript variant has been described, but its full length nature has not been determined.","Mutations in the AP2A1 gene have been associated with a variety of diseases, including intellectual disability, autism spectrum disorder, and cancer. In particular, mutations in this gene have been linked to a subtype of X-linked intellectual disability known as Juberg-Marsidi-Brooks syndrome. Additionally, dysregulation of the AP-2 complex has been implicated in the development and progression of various types of cancer, including breast, prostate, and lung cancer.

Targeted drug discovery efforts have focused on developing inhibitors of the AP-2 complex as a potential therapeutic strategy for cancer. One example is the small molecule inhibitor, AP2-associated protein kinase 1 (AAK1) inhibitor, which has shown promise in preclinical studies for the treatment of breast cancer. Another example is the development of peptide inhibitors that disrupt the interaction between the AP-2 complex and its cargo receptors, which could potentially be used to treat a variety of diseases.

Currently, there are no drugs on the market that specifically target the AP-2 complex. However, there are several drugs that indirectly affect the function of the complex. For example, the anti-cancer drug imatinib has been shown to inhibit the activity of AAK1, which is involved in the regulation of the AP-2 complex. Additionally, the anti-depressant drug fluoxetine has been shown to disrupt the interaction between the AP-2 complex and its cargo receptors, which may contribute to its therapeutic effects.",GO:1900126 negative regulation of hyaluronan biosynthetic process;GO:0098884 postsynaptic neurotransmitter receptor internalization;GO:0140239 postsynaptic endocytosis,,Predicted intracellular proteins; Transporters,Vesicles (Approved),,(M243)PID ARF 3PATHWAY,
ENSG00000130939.20,ENSG00000130939,UBE4B,-0.538250679,-0.810908661,-0.68216503,-0.121678344,ubiquitination factor E4B,"The UBE4B gene encodes for a protein called ubiquitination factor E4B, which is involved in the process of ubiquitination. Ubiquitination is a cellular mechanism that targets abnormal or short-lived proteins for degradation. The process involves three classes of enzymes: E1s, E2s, and E3s. UBE4B is an additional conjugation factor, E4, that is involved in multiubiquitin chain assembly. This gene is also a strong candidate for neuroblastoma tumor suppressor genes. There are multiple isoforms of UBE4B that are produced through alternative splicing of the transcript variants.","There is evidence to suggest that UBE4B may play a role in the development of certain types of cancer, including neuroblastoma and breast cancer. As such, there has been interest in developing drugs that target UBE4B as a potential treatment for these diseases. However, to date, there are no drugs on the market that specifically target UBE4B. 

One approach to targeting UBE4B is to develop small molecule inhibitors that can block its activity. A recent study identified a compound called NSC697923 that was able to inhibit UBE4B and reduce the growth of breast cancer cells in vitro. However, further research is needed to determine whether this compound could be developed into a viable drug for clinical use.

Another potential approach is to target UBE4B indirectly by modulating its upstream regulators or downstream targets. For example, a study found that inhibiting the protein HSP90, which is known to interact with UBE4B, could reduce the growth of neuroblastoma cells in vitro and in vivo. There are several drugs on the market that target HSP90, including ganetespib and onalespib, which are currently being tested in clinical trials for various types of cancer.

Overall, while there is evidence to suggest that targeting UBE4B could be a promising strategy for treating certain types of cancer, more research is needed to fully understand its role in disease and to develop effective drugs that can target it.",GO:0008626 granzyme-mediated apoptotic signaling pathway;GO:0140507 granzyme-mediated programmed cell death signaling pathway;GO:0036503 ERAD pathway,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,,,(M19)PID P73PATHWAY,
ENSG00000108256.9,ENSG00000108256,NUFIP2,-0.537808281,-0.795005473,-0.545825243,-0.272594128,nuclear FMR1 interacting protein 2,"NUFIP2, or nuclear FMR1 interacting protein 2, is a gene that encodes a protein that is involved in RNA binding activity. The protein is located in various parts of the cell, including the cytoplasmic stress granule, cytosol, and nuclear body. It is also a part of the polysomal ribosome. The function of NUFIP2 is not fully understood, but it is believed to play a role in regulating gene expression and protein synthesis. Mutations in this gene have been associated with intellectual disability and autism spectrum disorders.","Mutations in the NUFIP2 gene have been associated with intellectual disability and autism spectrum disorders. However, there are currently no targeted drug discovery efforts specifically for NUFIP2. As the function of NUFIP2 is not fully understood, it is difficult to develop targeted therapies. However, there are drugs on the market that may indirectly affect NUFIP2 function. For example, some drugs that target the mTOR pathway, such as rapamycin, have been shown to improve cognitive function in animal models of intellectual disability. Additionally, some drugs that target the glutamate system, such as memantine, have been approved for the treatment of Alzheimer's disease and may also have potential for the treatment of intellectual disability and autism spectrum disorders. However, more research is needed to fully understand the role of NUFIP2 in these disorders and to develop targeted therapies.",,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol;Nuclear bodies,,,
ENSG00000105993.15,ENSG00000105993,DNAJB6,-0.535702122,-0.866969296,-0.502041788,-0.238095282,DnaJ heat shock protein family (Hsp40) member B6,"DNAJB6 is a member of the DNAJ protein family, which is involved in a variety of cellular processes such as protein folding and oligomeric protein complex assembly. It contains a highly conserved amino acid stretch called the 'J-domain' and functions as a molecular chaperone. This gene may also play a role in polyglutamine aggregation in specific neurons. Alternative splicing of this gene results in multiple transcript variants, but not all variants have been fully described.","Mutations in the DNAJB6 gene have been associated with the development of several neurodegenerative diseases, including Charcot-Marie-Tooth disease type 2 (CMT2) and hereditary spastic paraplegia (HSP). In CMT2, mutations in DNAJB6 lead to the degeneration of peripheral nerves, resulting in muscle weakness and atrophy. In HSP, mutations in DNAJB6 cause the degeneration of upper motor neurons, leading to spasticity and difficulty walking. 

Targeted drug discovery efforts for DNAJB6-related diseases are still in the early stages, but there is potential for the development of small molecule inhibitors that can prevent the aggregation of misfolded proteins. One example is the use of small molecule inhibitors that target the HSP70 chaperone system, which DNAJB6 is a part of, to prevent protein aggregation and improve neuronal function. 

There are currently no FDA-approved drugs specifically targeting DNAJB6-related diseases, but there are several drugs on the market that target protein misfolding and aggregation in general. For example, tafamidis is a drug approved for the treatment of transthyretin amyloidosis, a disease characterized by the accumulation of misfolded transthyretin protein. Tafamidis stabilizes the transthyretin protein, preventing its misfolding and aggregation. Another example is isradipine, a calcium channel blocker that has been shown to reduce the accumulation of misfolded alpha-synuclein protein in preclinical models of Parkinson's disease.",GO:0060715 syncytiotrophoblast cell differentiation involved in labyrinthine layer development;GO:0060710 chorio-allantoic fusion;GO:0060717 chorion development,,Disease related genes; Human disease related genes:Musculoskeletal diseases:Muscular diseases; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000156973.14,ENSG00000156973,PDE6D,-0.535407625,-0.74247866,-0.6594686,-0.204275616,phosphodiesterase 6D,"PDE6D is a gene that encodes the delta subunit of rod-specific photoreceptor phosphodiesterase, an enzyme that plays a crucial role in the phototransduction cascade. The protein is also believed to bind to prenyl groups of proteins to target them to subcellular organelles called cilia. In cows, a similar protein functions in solubilizing membrane-bound PDE. Mutations in PDE6D have been linked to Joubert syndrome-22. The gene undergoes alternative splicing, resulting in multiple splice variants.","Mutations in PDE6D have been linked to Joubert syndrome-22, a rare genetic disorder characterized by a malformation of the brainstem and cerebellum, leading to developmental delays, breathing abnormalities, and eye movement disorders. While there are currently no targeted drug discovery efforts specifically for PDE6D, there are drugs on the market that target the phototransduction cascade, in which PDE6D plays a crucial role. For example, the drug voretigene neparvovec-rzyl (Luxturna) is a gene therapy that targets RPE65, another protein involved in the phototransduction cascade, and has been approved by the FDA for the treatment of inherited retinal diseases caused by mutations in RPE65. Additionally, phosphodiesterase inhibitors such as sildenafil (Viagra) and tadalafil (Cialis) are commonly used to treat erectile dysfunction and pulmonary arterial hypertension by targeting PDE5, a related phosphodiesterase enzyme.",GO:0007601 visual perception;GO:0050953 sensory perception of light stimulus;GO:0007600 sensory perception,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Vesicles (Supported),,(M5060)SA FAS SIGNALING,
ENSG00000065457.10,ENSG00000065457,ADAT1,-0.534028072,-0.913366888,-0.583643531,-0.105073799,adenosine deaminase tRNA specific 1,"ADAT1 is a gene that belongs to the ADAR family, which encodes proteins that modify adenosine in pre-mRNA editing of nuclear transcripts. The protein encoded by ADAT1 is responsible for the deamination of adenosine 37 to inosine in eukaryotic tRNA. This gene has alternative spliced transcript variants.","There is limited information available on the disease implications of ADAT1. However, recent studies have suggested that ADAT1 may play a role in cancer development and progression. Specifically, ADAT1 has been found to be upregulated in several types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts for ADAT1 are still in the early stages, but there is potential for the development of drugs that target ADAT1 to treat cancer. One example of a successful drug on the market that targets a related gene in the ADAR family is Inqovi, which was approved by the FDA in 2020 for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Inqovi targets the ADAR1 gene, which is involved in RNA editing and has been found to be upregulated in several types of cancer.",GO:0008033 tRNA processing;GO:0006399 tRNA metabolic process;GO:0006396 RNA processing,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Supported),,,
ENSG00000139370.12,ENSG00000139370,SLC15A4,-0.533503833,-0.810498237,-0.574126169,-0.215887092,solute carrier family 15 member 4,"SLC15A4 is a human gene that encodes a protein belonging to the solute carrier family 15 member 4. This protein is involved in various processes, including the transport of L-histidine, peptides, and peptidoglycan across the plasma membrane. It is also involved in the positive regulation of the toll-like receptor signaling pathway. SLC15A4 is located in the endolysosome membrane and is an integral component of the lysosomal membrane.","SLC15A4 has been implicated in various diseases, including inflammatory bowel disease (IBD), rheumatoid arthritis, and multiple sclerosis. In IBD, SLC15A4 has been shown to play a role in the regulation of the immune response and the maintenance of intestinal homeostasis. Targeting SLC15A4 has been proposed as a potential therapeutic strategy for IBD. In rheumatoid arthritis, SLC15A4 has been shown to be involved in the activation of immune cells and the production of pro-inflammatory cytokines. Targeting SLC15A4 has been proposed as a potential therapeutic strategy for rheumatoid arthritis. In multiple sclerosis, SLC15A4 has been shown to be involved in the activation of immune cells and the production of pro-inflammatory cytokines. Targeting SLC15A4 has been proposed as a potential therapeutic strategy for multiple sclerosis. There are currently no drugs on the market that specifically target SLC15A4, but there are ongoing drug discovery efforts to develop small molecule inhibitors of SLC15A4 for the treatment of IBD, rheumatoid arthritis, and multiple sclerosis.",GO:0032974 amino acid transmembrane export from vacuole;GO:0089708 L-histidine transmembrane export from vacuole;GO:0015835 peptidoglycan transport,,Transporters:Electrochemical Potential-driven transporters,,,,
ENSG00000003756.17,ENSG00000003756,RBM5,-0.532060201,-0.80394748,-0.564532272,-0.22770085,RNA binding motif protein 5,"RBM5 is a gene that encodes a nuclear RNA binding protein that is a component of the spliceosome A complex. It is a candidate tumor suppressor gene that plays a role in inducing cell cycle arrest and apoptosis through pre-mRNA splicing of multiple target genes, including the tumor suppressor protein p53. RBM5 is located within the tumor suppressor region 3p21.3 and may inhibit tumor transformation and progression of several malignancies, including lung cancer.","RBM5 has been implicated in several types of cancer, including lung, breast, and ovarian cancer. Loss of RBM5 expression has been observed in many cancer types, and its downregulation is associated with poor prognosis and increased tumor aggressiveness. Therefore, RBM5 is considered a potential therapeutic target for cancer treatment. Several studies have focused on identifying small molecules that can restore RBM5 expression or function in cancer cells. For example, a recent study identified a small molecule, named RBM5-AS1, that can upregulate RBM5 expression and induce apoptosis in lung cancer cells. However, there are currently no drugs on the market that specifically target RBM5. Nevertheless, the identification of RBM5 as a potential tumor suppressor gene and therapeutic target highlights the importance of RNA splicing in cancer development and progression.","GO:0000381 regulation of alternative mRNA splicing, via spliceosome;GO:0000245 spliceosomal complex assembly;GO:0048024 regulation of mRNA splicing, via spliceosome",,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: End piece;Flagellar centriole;Mid piece;Perinuclear theca;Principal piece,,,(M5945)HALLMARK HEME METABOLISM
ENSG00000172239.14,ENSG00000172239,PAIP1,-0.531747605,-0.818046172,-0.645758744,-0.131437899,poly(A) binding protein interacting protein 1,"PAIP1 is a human gene that encodes a protein that interacts with poly(A)-binding protein and the cap-binding complex eIF4A. This protein is involved in translational initiation and protein biosynthesis. Overexpression of PAIP1 in COS7 cells stimulates translation. Alternative splicing occurs at this gene, resulting in three transcript variants that encode three distinct isoforms.","There is limited information on the disease implications of PAIP1. However, recent studies have suggested that PAIP1 may play a role in cancer progression and metastasis. Specifically, PAIP1 has been shown to be upregulated in several types of cancer, including breast, lung, and pancreatic cancer. Targeted drug discovery efforts for PAIP1 are currently limited, but there is potential for the development of drugs that target PAIP1 to inhibit cancer cell growth and metastasis. Currently, there are no drugs on the market that specifically target PAIP1. However, there are several drugs that target the translation initiation complex, including eIF4A inhibitors, which may indirectly affect PAIP1 function. Examples of such drugs include silvestrol and rocaglates, which have shown promising results in preclinical studies for the treatment of cancer.","GO:0070934 CRD-mediated mRNA stabilization;GO:1900152 negative regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay;GO:2000767 positive regulation of cytoplasmic translation",,Predicted intracellular proteins,Cytosol;Plasma membrane (Enhanced),,,(M5922)HALLMARK UNFOLDED PROTEIN RESPONSE
ENSG00000131779.11,ENSG00000131779,PEX11B,-0.530566083,-0.967305707,-0.521936102,-0.102456439,peroxisomal biogenesis factor 11 beta,"PEX11B is a gene that encodes a protein involved in the proliferation of peroxisomes, which are organelles responsible for various metabolic processes. The protein interacts with another protein called PEX19 and is located in the peroxisomal membrane. There are several variants of the gene, some of which code for proteins and others that do not. The exact function of PEX11B is not fully understood, but it is believed to play a role in the biogenesis of peroxisomes.","Mutations in the PEX11B gene have been associated with peroxisome biogenesis disorders (PBDs), which are a group of rare genetic disorders that affect peroxisome function. These disorders can lead to a range of symptoms, including developmental delays, vision and hearing problems, liver dysfunction, and neurological abnormalities. There are currently no targeted drug discovery efforts specifically for PEX11B, but research is ongoing to develop treatments for PBDs as a whole. One successful drug on the market for PBDs is Lorenzo's oil, which was developed to treat X-linked adrenoleukodystrophy (X-ALD), a type of PBD. The drug works by reducing the levels of very long-chain fatty acids, which accumulate in the brain and cause damage. Another drug, called peroxisome proliferator-activated receptor (PPAR) agonists, has shown promise in preclinical studies for treating PBDs by increasing peroxisome function.",GO:0044375 regulation of peroxisome size;GO:0016559 peroxisome fission;GO:0007031 peroxisome organization,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Peroxisomal diseases,Vesicles (Approved); Additional: Nucleoplasm,,,(M5949)HALLMARK PEROXISOME
ENSG00000100600.15,ENSG00000100600,LGMN,-0.530292071,-0.837059069,-0.57011228,-0.183704865,legumain,"LGMN, also known as legumain, is a gene that encodes a cysteine protease with a specific function of hydrolyzing asparaginyl bonds. This enzyme is involved in the processing of bacterial peptides and endogenous proteins for MHC class II presentation in the lysosomal/endosomal systems. The enzyme is activated by acidic pH and is produced following lipopolysaccharide expression in mature dendritic cells. Overexpression of this gene may be associated with the majority of solid tumor types. The gene has a pseudogene on chromosome 13, and several alternatively spliced transcript variants have been described, but the biological validity of only two has been determined. These two variants encode the same isoform.","LGMN has been implicated in various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In cancer, LGMN has been shown to promote tumor growth, invasion, and metastasis by degrading extracellular matrix proteins and activating pro-tumorigenic signaling pathways. Targeting LGMN with small molecule inhibitors has been explored as a potential therapeutic strategy for cancer. One such inhibitor, KGP94, has shown promising results in preclinical studies and is currently in phase I clinical trials for the treatment of solid tumors. In autoimmune disorders, LGMN has been implicated in the processing and presentation of self-antigens, leading to the activation of autoreactive T cells. Inhibition of LGMN has been shown to reduce disease severity in animal models of autoimmune disorders such as multiple sclerosis and rheumatoid arthritis. However, there are currently no LGMN inhibitors approved for clinical use in autoimmune disorders. In neurodegenerative diseases, LGMN has been shown to play a role in the processing and clearance of amyloid beta, a protein implicated in Alzheimer's disease. However, there are currently no drugs targeting LGMN for the treatment of neurodegenerative diseases on the market.",GO:0006624 vacuolar protein processing;GO:0097202 activation of cysteine-type endopeptidase activity;GO:0097264 self proteolysis,,Predicted intracellular proteins; Peptidases:Cysteine-type peptidases; ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Candidate cancer biomarkers,Vesicles (Approved); Additional: Nucleoplasm,,,(M5892)HALLMARK CHOLESTEROL HOMEOSTASIS; (M5946)HALLMARK COAGULATION; (M5921)HALLMARK COMPLEMENT
ENSG00000188554.15,ENSG00000188554,NBR1,-0.529745686,-1.052844496,-0.531576438,-0.004816125,NBR1 autophagy cargo receptor,"NBR1 is a gene that was first identified as an ovarian tumor antigen in ovarian cancer. It contains a B-box/coiled-coil motif, which is present in many genes with transformation potential. NBR1 functions as a specific autophagy receptor for the selective autophagic degradation of peroxisomes by forming intracellular inclusions with ubiquitylated autophagic substrates. The gene is located on chromosome 17q21.1, which is in close proximity to the BRCA1 tumor suppressor gene. Alternative splicing of this gene results in multiple transcript variants.","There is limited information available on the disease implications of NBR1. However, recent studies have suggested that NBR1 may play a role in the development and progression of certain types of cancer, including ovarian cancer and breast cancer. Targeted drug discovery efforts for NBR1 are still in the early stages, but there is potential for the development of drugs that target the autophagy pathway and specifically target NBR1. Currently, there are no drugs on the market that specifically target NBR1, but there are drugs that target the autophagy pathway, such as chloroquine and hydroxychloroquine, which have been used in the treatment of certain types of cancer. Additionally, there are ongoing clinical trials investigating the use of autophagy inhibitors in cancer treatment.",GO:0032872 regulation of stress-activated MAPK cascade;GO:0070302 regulation of stress-activated protein kinase signaling cascade;GO:0045668 negative regulation of osteoblast differentiation,,Predicted intracellular proteins,Vesicles (Supported); Additional: Nuclear bodies;Nucleoplasm,,,
ENSG00000159840.16,ENSG00000159840,ZYX,-0.528917038,-0.858904027,-0.6711832,-0.056663887,zyxin,Zyxin is a phosphoprotein that binds to zinc and is concentrated at focal adhesions and along the actin cytoskeleton. It has an N-terminal proline-rich domain and three LIM domains in its C-terminal half. Zyxin may function as a messenger in the signal transduction pathway that mediates adhesion-stimulated changes in gene expression and may modulate the cytoskeletal organization of actin bundles. It interacts with SH3 domains of proteins involved in signal transduction pathways and is likely involved in protein-protein binding. Alternative splicing results in multiple transcript variants that encode the same isoform.,"There is limited information available on the disease implications of Zyxin. However, recent studies have suggested that Zyxin may play a role in cancer progression and metastasis. Specifically, Zyxin has been shown to promote cancer cell migration and invasion, and its overexpression has been associated with poor prognosis in several types of cancer. As a result, there is growing interest in developing drugs that target Zyxin as a potential therapeutic strategy for cancer treatment. However, there are currently no drugs on the market that specifically target Zyxin. Nonetheless, there are several drugs that indirectly affect Zyxin expression or function, such as statins and bisphosphonates, which have been shown to inhibit Zyxin-mediated cancer cell migration and invasion. Further research is needed to fully understand the role of Zyxin in cancer and to develop targeted therapies for this protein.",GO:0030038 contractile actin filament bundle assembly;GO:0043149 stress fiber assembly;GO:0051017 actin filament bundle assembly,,Predicted intracellular proteins,Focal adhesion sites (Supported); Additional: Actin filaments;Plasma membrane,Artenimol,(M184)PID ECADHERIN KERATINOCYTE PATHWAY; (M232)PID ECADHERIN STABILIZATION PATHWAY; (M238)PID THROMBIN PAR1 PATHWAY,(M5915)HALLMARK APICAL JUNCTION
ENSG00000101843.19,ENSG00000101843,PSMD10,-0.528859955,-0.808034497,-0.564178902,-0.214366465,"proteasome 26S subunit, non-ATPase 10","PSMD10 is a gene that encodes a subunit of the PA700/19S complex, which is a regulatory component of the 26S proteasome. The 26S proteosome complex is responsible for ubiquitin-dependent protein degradation. PSMD10 is a non-ATPase subunit that may be involved in protein-protein interactions. Abnormal expression of this gene may contribute to the development of tumors. Two different isoforms of PSMD10 have been identified, and pseudogenes have been found on chromosomes 3 and 20.","Abnormal expression of PSMD10 has been implicated in various types of cancer, including breast, lung, and prostate cancer. Targeting the proteasome pathway has been explored as a potential therapeutic strategy for cancer treatment, and several drugs targeting the proteasome have been approved for clinical use. Bortezomib, a first-generation proteasome inhibitor, is approved for the treatment of multiple myeloma and mantle cell lymphoma. Carfilzomib, a second-generation proteasome inhibitor, is approved for the treatment of relapsed or refractory multiple myeloma. Other proteasome inhibitors, such as ixazomib and oprozomib, are currently being investigated in clinical trials for various types of cancer. PSMD10 may also be a potential target for drug discovery efforts aimed at developing novel cancer therapies.",GO:0070682 proteasome regulatory particle assembly;GO:0007253 cytoplasmic sequestering of NF-kappaB;GO:0042994 cytoplasmic sequestering of transcription factor,,Predicted intracellular proteins,Cytosol (Supported); Additional: Calyx;Microtubules;Mid piece;Perinuclear theca;Primary cilium;Primary cilium tip;Principal piece,,,
ENSG00000166887.16,ENSG00000166887,VPS39,-0.528392068,-0.828881924,-0.486660305,-0.269633973,VPS39 subunit of HOPS complex,"The VPS39 gene encodes a protein that plays a role in the clustering and fusion of late endosomes and lysosomes. It may also act as an adaptor protein that connects the transforming growth factor-beta receptor complex to the Smad pathway, which is involved in cell growth and differentiation. Alternative splicing of the gene results in multiple transcript variants.","Mutations in the VPS39 gene have been associated with several diseases, including Parkinson's disease, Alzheimer's disease, and lysosomal storage disorders. In Parkinson's disease, VPS39 mutations have been found to impair the clearance of alpha-synuclein, a protein that accumulates in the brains of Parkinson's patients. Targeted drug discovery efforts for VPS39 have focused on developing small molecule inhibitors that can modulate its activity. However, there are currently no drugs on the market that specifically target VPS39. Some drugs that indirectly affect VPS39 function include rapamycin, which has been shown to increase VPS39 expression and improve lysosomal function, and ambroxol, which can enhance lysosomal biogenesis and reduce alpha-synuclein accumulation in Parkinson's disease.",GO:0061909 autophagosome-lysosome fusion;GO:0034058 endosomal vesicle fusion;GO:0035542 regulation of SNARE complex assembly,,Predicted intracellular proteins,,,,
ENSG00000273749.5,ENSG00000273749,CYFIP1,-0.52743385,-0.92378902,-0.534482222,-0.124030308,cytoplasmic FMR1 interacting protein 1,"CYFIP1 is a human gene that plays a role in regulating cytoskeletal dynamics and protein translation. It is a component of the WAVE regulatory complex, which promotes actin polymerization. CYFIP1 also interacts with the FMR1 protein and translation initiation factor 4E to inhibit protein translation. A chromosomal deletion that includes this gene is associated with an increased risk of schizophrenia and epilepsy in humans. Reduced expression of CYFIP1 has been observed in various human cancers, and the encoded protein may inhibit tumor invasion.","Research on CYFIP1 has revealed its potential implications in various diseases, including schizophrenia, epilepsy, and cancer. A chromosomal deletion that includes this gene has been associated with an increased risk of schizophrenia and epilepsy in humans. In cancer, reduced expression of CYFIP1 has been observed, and the encoded protein may inhibit tumor invasion. Targeted drug discovery efforts for CYFIP1 are still in the early stages, but some promising compounds have been identified. For example, a small molecule inhibitor of the WAVE regulatory complex, which includes CYFIP1, has shown efficacy in preclinical models of cancer. Additionally, a drug called everolimus, which inhibits the mTOR pathway that CYFIP1 is involved in, has been approved for the treatment of various cancers.","GO:1903422 negative regulation of synaptic vesicle recycling;GO:0099578 regulation of translation at postsynapse, modulating synaptic transmission;GO:0051388 positive regulation of neurotrophin TRK receptor signaling pathway",,Predicted intracellular proteins,,,,(M5947)HALLMARK IL2 STAT5 SIGNALING
ENSG00000087152.15,ENSG00000087152,ATXN7L3,-0.527141174,-0.754802854,-0.57758224,-0.249038427,ataxin 7 like 3,"ATXN7L3, also known as ataxin 7 like 3, is a human gene that plays a role in regulating gene expression. It is involved in histone deubiquitination, which is the removal of a small protein called ubiquitin from histone proteins that are involved in packaging DNA. This process is important for regulating gene expression. ATXN7L3 is also involved in positive regulation of transcription, which is the process by which DNA is used to create RNA molecules. It is located in the nucleus and is part of two protein complexes, DUBm and SAGA, which are involved in regulating gene expression.","There is limited information available on the disease implications of ATXN7L3. However, mutations in the related gene ATXN7 have been linked to spinocerebellar ataxia type 7 (SCA7), a rare neurodegenerative disorder that affects movement and vision. It is possible that mutations in ATXN7L3 could also contribute to the development of similar disorders. 

There are currently no targeted drug discovery efforts specifically focused on ATXN7L3. However, drugs that target histone deubiquitination and transcription regulation pathways may indirectly affect the function of ATXN7L3. For example, some drugs that inhibit histone deacetylases (HDACs), such as vorinostat and romidepsin, have been approved for the treatment of certain types of cancer. These drugs alter the acetylation status of histones, which can affect gene expression. 

In summary, while the specific disease implications of ATXN7L3 are not well understood, drugs that target related pathways may indirectly affect its function. Further research is needed to fully understand the role of ATXN7L3 in disease and to develop targeted therapies.",GO:0043484 regulation of RNA splicing;GO:0006282 regulation of DNA repair;GO:0051052 regulation of DNA metabolic process,,Predicted intracellular proteins,Nuclear speckles (Approved); Additional: Plasma membrane,,,
ENSG00000044115.21,ENSG00000044115,CTNNA1,-0.526713508,-0.731201385,-0.605858438,-0.2430807,catenin alpha 1,"CTNNA1 is a gene that encodes a protein belonging to the catenin family, which plays a crucial role in cell adhesion by connecting cadherins on the plasma membrane to actin filaments inside the cell. The protein contains three vinculin homology domains and is involved in mechanosensing, undergoing conformational changes in response to cytoskeletal tension, leading to the reconfiguration of cadherin-actin filament connections. Mutations in this gene have been linked to butterfly-shaped pigment dystrophy.","Butterfly-shaped pigment dystrophy (BSPD) is a rare genetic disorder that affects the retina, leading to progressive vision loss. Mutations in the CTNNA1 gene have been identified as a cause of BSPD. Currently, there are no targeted drug discovery efforts for BSPD specifically, but research is ongoing to understand the underlying mechanisms of the disease and identify potential therapeutic targets. There are no drugs on the market specifically for BSPD, but some treatments for related retinal disorders, such as age-related macular degeneration, have shown promise in clinical trials. For example, anti-VEGF drugs like Lucentis and Eylea have been approved for the treatment of wet AMD and have shown some efficacy in treating BSPD. Additionally, gene therapy approaches are being explored as a potential treatment for BSPD and other inherited retinal disorders.",GO:2001045 negative regulation of integrin-mediated signaling pathway;GO:0071681 cellular response to indole-3-methanol;GO:0071680 response to indole-3-methanol,,Disease related genes; Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins,Cell Junctions;Plasma membrane (Supported); Additional: Connecting piece;Golgi apparatus;Mid piece;Principal piece;Vesicles,,(M184)PID ECADHERIN KERATINOCYTE PATHWAY; (M72)PID NECTIN PATHWAY; (M266)PID NCADHERIN PATHWAY,(M5915)HALLMARK APICAL JUNCTION
ENSG00000160058.19,ENSG00000160058,BSDC1,-0.52550991,-0.671471585,-0.594573624,-0.310484521,BSD domain containing 1,"The BSD domain containing 1 (BSDC1) gene is located on chromosome 18 and encodes a protein that contains a BSD domain, which is found in a variety of proteins involved in transcriptional regulation. The function of BSDC1 is not well understood, but it has been suggested to play a role in the regulation of gene expression and cell differentiation. Mutations in BSDC1 have been associated with developmental disorders, including intellectual disability and autism spectrum disorder. Further research is needed to fully understand the function of BSDC1 and its role in human health and disease.","There is currently limited information available on the disease implications of BSDC1 mutations. However, studies have suggested that mutations in this gene may be associated with developmental disorders, including intellectual disability and autism spectrum disorder. As for targeted drug discovery efforts, there are currently no known drugs that specifically target BSDC1. However, research on the function of the BSD domain, which is found in BSDC1, has led to the development of drugs that target other proteins containing this domain. For example, the drug JQ1 targets the BET family of proteins, which contain a BSD domain, and has shown promise in the treatment of certain cancers. Further research is needed to determine if drugs targeting BSDC1 or other proteins containing the BSD domain could be effective in treating developmental disorders associated with BSDC1 mutations.",,,Predicted intracellular proteins,Golgi apparatus (Supported); Additional: Plasma membrane,,,
ENSG00000168724.17,ENSG00000168724,DNAJC21,-0.525295093,-0.792913624,-0.600465363,-0.182506294,DnaJ heat shock protein family (Hsp40) member C21,"DNAJC21 is a gene that encodes a protein belonging to the DNAJ heat shock protein 40 family. The protein contains two N-terminal tetratricopeptide repeat domains and a C-terminal DNAJ domain. It is involved in the binding of precursor 45S ribosomal RNA and may play a role in early nuclear ribosomal RNA biogenesis and maturation of the 60S ribosomal subunit. Mutations in this gene can lead to Bone marrow failure syndrome 3. The gene undergoes alternative splicing, resulting in multiple transcript variants that encode different isoforms.","Mutations in the DNAJC21 gene have been linked to Bone marrow failure syndrome 3, a rare genetic disorder characterized by a decrease in the production of blood cells in the bone marrow. There are currently no targeted drug discovery efforts specifically for DNAJC21, but research is ongoing to identify potential therapies for bone marrow failure syndromes. 

One example of a successful drug on the market for bone marrow failure syndromes is eltrombopag, which is used to treat thrombocytopenia in patients with chronic immune thrombocytopenia and severe aplastic anemia. Eltrombopag works by stimulating the production of platelets in the bone marrow. Another drug, lenalidomide, has been approved for the treatment of myelodysplastic syndromes, a group of disorders that can lead to bone marrow failure. Lenalidomide works by enhancing the immune system and promoting the production of healthy blood cells. 

Overall, while there are currently no targeted drug discovery efforts for DNAJC21, research into bone marrow failure syndromes is ongoing and there are successful drugs on the market for related disorders.",GO:0006457 protein folding;GO:0051604 protein maturation;GO:0010467 gene expression,,Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Predicted intracellular proteins,Cytosol;Nucleoli (Supported),,,
ENSG00000101901.12,ENSG00000101901,ALG13,-0.525259277,-0.726631108,-0.421779556,-0.427367168,ALG13 UDP-N-acetylglucosaminyltransferase subunit,ALG13 is a human gene that encodes a subunit of a UDP-N-acetylglucosamine transferase. It forms a functional glycosyltransferase with asparagine-linked glycosylation 14 homolog and catalyzes the second sugar addition of the oligosaccharide precursor in endoplasmic reticulum N-linked glycosylation. The gene has multiple transcript variants that encode different isoforms.,"Mutations in the ALG13 gene have been associated with congenital disorders of glycosylation (CDG), a group of rare genetic disorders characterized by abnormal glycosylation of proteins and lipids. CDG patients with ALG13 mutations typically present with developmental delay, intellectual disability, seizures, and other neurological symptoms. There are currently no targeted drugs available for ALG13-related CDG, and treatment is mainly supportive and symptomatic. However, research efforts are underway to identify potential therapeutic targets and develop novel therapies for CDG. One example is the use of small molecule chaperones that can stabilize misfolded proteins and improve their function. Miglustat, a small molecule inhibitor of glycosphingolipid synthesis, has been approved for the treatment of some types of CDG, but its efficacy in ALG13-related CDG is unclear.",GO:0006488 dolichol-linked oligosaccharide biosynthetic process;GO:0018279 protein N-linked glycosylation via asparagine;GO:0006487 protein N-linked glycosylation,,Human disease related genes:Nervous system diseases:Epilepsy; Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism,Vesicles (Approved); Additional: Cytosol,,,
ENSG00000067955.15,ENSG00000067955,CBFB,-0.523970348,-0.730517853,-0.761069794,-0.080323396,core-binding factor subunit beta,"CBFB is a gene that encodes the beta subunit of a transcription factor that regulates genes specific to hematopoiesis and osteogenesis. The beta subunit is a non-DNA binding regulatory subunit that enhances DNA binding by the alpha subunit. Alternative splicing generates two mRNA variants, each encoding a distinct carboxyl terminus. In some cases, a chromosomal rearrangement produces a chimeric transcript associated with acute myeloid leukemia of the M4Eo subtype. Two transcript variants encoding different isoforms have been found for this gene.","Mutations in the CBFB gene have been associated with various hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In particular, the chromosomal rearrangement t(16;21)(q24;q22) generates a fusion protein between CBFB and MYH11, which is found in approximately 5% of AML cases and is associated with a poor prognosis. Targeted drug discovery efforts have focused on developing inhibitors of the CBFB-MYH11 fusion protein, as well as drugs that target the downstream pathways activated by CBFB-MYH11. One example is the drug midostaurin, which was approved by the FDA in 2017 for the treatment of FLT3-mutated AML and also has activity against CBFB-MYH11. Another example is the drug rigosertib, which is being investigated in clinical trials for the treatment of MDS and AML and has shown activity against CBFB-MYH11 in preclinical studies.","GO:0043378 positive regulation of CD8-positive, alpha-beta T cell differentiation;GO:0043376 regulation of CD8-positive, alpha-beta T cell differentiation;GO:2001187 positive regulation of CD8-positive, alpha-beta T cell activation",,Human disease related genes:Cancers:Cancers of haematopoietic and lymphoid tissues; Predicted intracellular proteins; Disease related genes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Cytosol;Nucleoplasm (Approved),,(M166)PID ATF2 PATHWAY; (M167)PID AP1 PATHWAY; (M2)PID SMAD2 3NUCLEAR PATHWAY,
ENSG00000160746.13,ENSG00000160746,ANO10,-0.521509839,-0.64802677,-0.607039876,-0.309462871,anoctamin 10,"The ANO10 gene encodes a transmembrane protein that is a member of the anoctamin family of calcium-activated chloride channels. This protein has eight transmembrane domains and cytosolic N- and C-termini. Mutations in this gene can cause autosomal recessive spinocerebellar ataxia-10, a neurodegenerative disorder that affects movement and coordination. Alternative splicing of the ANO10 gene results in multiple transcript variants.","Mutations in the ANO10 gene have been linked to autosomal recessive spinocerebellar ataxia-10 (SCAR10), a rare neurodegenerative disorder characterized by progressive cerebellar ataxia, dysarthria, and oculomotor abnormalities. There is currently no cure for SCAR10, and treatment is mainly supportive and symptomatic. However, efforts are underway to develop targeted therapies for this condition. One approach is to identify small molecules that can modulate the activity of ANO10 or other proteins involved in the disease pathway. Another strategy is to use gene therapy to replace or repair the defective ANO10 gene. While there are currently no drugs on the market specifically approved for SCAR10, there are several drugs that have been approved for other neurodegenerative disorders that may have potential for treating SCAR10. For example, drugs that target ion channels, such as riluzole and memantine, have been shown to be effective in treating other forms of ataxia and may have potential for SCAR10.",GO:1902476 chloride transmembrane transport;GO:0006821 chloride transport;GO:0098661 inorganic anion transmembrane transport,,Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Potential drug targets; Disease related genes; Transporters:Transporter channels and pores,Plasma membrane (Supported); Additional: Primary cilium;Vesicles,,,
ENSG00000109445.11,ENSG00000109445,ZNF330,-0.518635765,-0.770919922,-0.486576225,-0.298411147,zinc finger protein 330,"ZNF330 is a human gene that encodes for a protein called zinc finger protein 330. This protein is predicted to have the ability to bind to zinc ions. ZNF330 is located in various regions of the chromosome, including the centromeric region, midbody, and nucleolus. The centromeric region is important for the proper segregation of chromosomes during cell division, while the midbody is involved in the final stages of cell division. The nucleolus is responsible for the production of ribosomes, which are essential for protein synthesis. Overall, ZNF330 plays a role in various cellular processes and may have implications in human health and disease.","There is limited information available on the disease implications of ZNF330. However, some studies have suggested that alterations in the expression of this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ZNF330 are also limited, as the function of this gene is not well understood. Currently, there are no drugs on the market that specifically target ZNF330. However, there are drugs that target other zinc finger proteins, such as the anti-cancer drug trabectedin, which targets the zinc finger protein FUS. Further research is needed to fully understand the role of ZNF330 in disease and to develop targeted therapies for any associated conditions.",,,Predicted intracellular proteins,Nucleoli (Supported); Additional: Basal body;Cytosol;Nucleoplasm;Primary cilium,,,
ENSG00000116198.14,ENSG00000116198,CEP104,-0.517241214,-0.727923151,-0.764943795,-0.058856697,centrosomal protein 104,"CEP104 is a gene that encodes a protein required for the formation and structural integrity of cilia, which are hair-like structures on the surface of cells that play important roles in sensory perception and signaling. The protein contains several domains and motifs, and translocates from the centrioles to the tips of the cilia during their formation. Knockdown of the protein in human retinal pigment cells leads to severe defects in ciliogenesis and structural deformities at the ciliary tips. Variants of the CEP104 gene are associated with Joubert syndrome, a rare genetic disorder characterized by brain malformations, developmental delays, and ataxia.","There are currently no targeted drug discovery efforts specifically for CEP104, as it is primarily associated with a rare genetic disorder, Joubert syndrome, for which there are no approved treatments. However, there are ongoing efforts to develop therapies for ciliopathies, a group of disorders that includes Joubert syndrome, by targeting the underlying defects in cilia formation and function. Some potential targets for drug development include proteins involved in cilia assembly and trafficking, as well as signaling pathways that regulate cilia function. There are currently no drugs on the market specifically for ciliopathies, but some drugs used to treat related conditions, such as cystic fibrosis and polycystic kidney disease, may have potential for repurposing in ciliopathies.",,,Disease related genes; Human disease related genes:Other diseases:Mental and behavioural disorders; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,,,,
ENSG00000135452.10,ENSG00000135452,TSPAN31,-0.516353232,-0.853973815,-0.667347098,-0.027738781,tetraspanin 31,"TSPAN31 is a gene that belongs to the tetraspanin family, which consists of cell-surface proteins with four hydrophobic domains. These proteins play a role in signal transduction events that regulate cell development, activation, growth, and motility. TSPAN31 is believed to be involved in growth-related cellular processes and is associated with tumorigenesis and osteosarcoma.","There is limited information available on the disease implications of TSPAN31. However, studies have shown that TSPAN31 is overexpressed in osteosarcoma, a type of bone cancer, and may play a role in its development and progression. Targeted drug discovery efforts for TSPAN31 are currently limited, but there is potential for the development of drugs that target this gene in the future. Currently, there are no drugs on the market that specifically target TSPAN31. However, there are drugs that target other members of the tetraspanin family, such as CD81 and CD9, which have been shown to have anti-tumor effects in preclinical studies. These drugs include monoclonal antibodies, such as bavituximab and nivolumab, which are used to treat various types of cancer.",GO:0008284 positive regulation of cell population proliferation;GO:0042127 regulation of cell population proliferation;GO:0048522 positive regulation of cellular process,,Human disease related genes:Cancers:Cancers of soft tissues and bone; Predicted intracellular proteins,Golgi apparatus (Approved); Additional: Cytokinetic bridge;Cytosol;Nucleoplasm,,,
ENSG00000257103.8,ENSG00000257103,LSM14A,-0.515942964,-0.750173213,-0.573774367,-0.223881314,LSM14A mRNA processing body assembly factor,"LSM14A is a gene that encodes for a protein involved in the assembly of mRNA processing bodies. The protein belongs to the Sm-like protein family, which contains a sequence motif called the Sm sequence. This motif is present in tri-snRNP particles, which are essential for pre-mRNA splicing. The LSM14A protein is thought to form a stable heteromer with other Sm-like proteins in these particles. The function of mRNA processing bodies is to regulate mRNA stability and translation, and defects in their assembly can lead to various diseases. Understanding the role of LSM14A in this process may provide insights into the development of new therapies for these conditions.","LSM14A has been implicated in various diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, LSM14A has been shown to be overexpressed in certain types of tumors, and its knockdown has been found to inhibit tumor growth. In neurodegenerative disorders, LSM14A has been linked to the formation of protein aggregates, which are a hallmark of these diseases. In viral infections, LSM14A has been shown to play a role in the replication of certain viruses, such as hepatitis C virus.

Targeted drug discovery efforts for LSM14A are still in the early stages, but there is potential for the development of drugs that target the assembly of mRNA processing bodies. One approach could be to target the interaction between LSM14A and other Sm-like proteins, which could disrupt the formation of these particles and lead to the degradation of unstable mRNAs. Another approach could be to target the function of mRNA processing bodies directly, such as by inhibiting their ability to regulate mRNA translation.

There are currently no drugs on the market that specifically target LSM14A, but there are drugs that target related proteins in the Sm-like protein family. For example, the drug Spliceostatin A targets the spliceosome, which is a complex of proteins and RNA molecules involved in pre-mRNA splicing. This drug has shown promise in preclinical studies for the treatment of various cancers. Another drug, LCL161, targets the protein cIAP1, which is involved in the regulation of apoptosis. This drug is currently in clinical trials for the treatment of various cancers.",GO:0039529 RIG-I signaling pathway;GO:0033962 P-body assembly;GO:0060340 positive regulation of type I interferon-mediated signaling pathway,,Predicted intracellular proteins,Cytoplasmic bodies (Supported); Additional: Cytosol,,,
ENSG00000165861.14,ENSG00000165861,ZFYVE1,-0.51564847,-0.866821568,-0.562734629,-0.117389214,zinc finger FYVE-type containing 1,"ZFYVE1 is a human gene that encodes a protein containing two zinc-binding FYVE domains in tandem. The FYVE domains are responsible for recruiting proteins involved in membrane trafficking and cell signaling to phosphatidylinositol 3-phosphate-containing membranes. The protein is reported to localize to the Golgi apparatus and undergoes alternative splicing, resulting in multiple transcript variants.","There is limited information available on the disease implications of ZFYVE1. However, recent studies have suggested that mutations in this gene may be associated with autosomal recessive spastic paraplegia, a rare neurological disorder characterized by progressive stiffness and weakness of the lower limbs. 

As of now, there are no targeted drug discovery efforts specifically aimed at ZFYVE1. However, given its role in membrane trafficking and cell signaling, it is possible that drugs targeting these pathways may indirectly affect ZFYVE1 function. 

There are currently no drugs on the market that directly target ZFYVE1. However, there are several drugs that target membrane trafficking and cell signaling pathways that may indirectly affect ZFYVE1 function. For example, bortezomib, a proteasome inhibitor used to treat multiple myeloma, has been shown to inhibit membrane trafficking and induce endoplasmic reticulum stress, which may indirectly affect ZFYVE1 function. Similarly, rapamycin, an immunosuppressant used to prevent organ rejection, inhibits the mammalian target of rapamycin (mTOR) pathway, which is involved in cell signaling and membrane trafficking.",GO:0044829 positive regulation by host of viral genome replication;GO:0140042 lipid droplet formation;GO:0044794 positive regulation by host of viral process,,Predicted intracellular proteins,Endoplasmic reticulum (Supported),,,
ENSG00000176871.9,ENSG00000176871,WSB2,-0.515302319,-0.890547905,-0.617839807,-0.037519246,WD repeat and SOCS box containing 2,WSB2 is a gene that encodes a protein containing five WD-repeats and an SOCS box in the C-terminus. The SOCS box may act as a bridge between specific substrate-binding domains and E3 ubiquitin protein ligases. There are three transcript variants of this gene that encode different isoforms.,"Research on WSB2 gene and its protein product is still in its early stages, and there is limited information available on its disease implications and targeted drug discovery efforts. However, some studies have suggested that WSB2 may play a role in the development and progression of certain cancers, including breast cancer and glioblastoma. 

Currently, there are no drugs specifically targeting WSB2 or its protein product. However, there are several drugs on the market that target the ubiquitin-proteasome system, which is involved in the degradation of proteins, including those regulated by WSB2. For example, bortezomib is a proteasome inhibitor that is used to treat multiple myeloma, a type of blood cancer. Another drug, carfilzomib, is also a proteasome inhibitor that is used to treat multiple myeloma and mantle cell lymphoma. 

In conclusion, while there is limited information available on the disease implications and targeted drug discovery efforts for WSB2, research on this gene and its protein product is ongoing, and it may hold promise as a potential target for the development of new cancer therapies in the future.",GO:0000209 protein polyubiquitination;GO:0016567 protein ubiquitination;GO:0032446 protein modification by small protein conjugation,,Predicted intracellular proteins,,,,
ENSG00000166181.13,ENSG00000166181,API5,-0.512836247,-0.995138345,-0.472395146,-0.07097525,apoptosis inhibitor 5,"API5, also known as apoptosis inhibitor 5, is a gene that encodes a protein that prevents apoptosis, or programmed cell death, after growth factor deprivation. The protein interacts with and negatively regulates Acinus, a nuclear factor involved in apoptotic DNA fragmentation, and suppresses the transcription factor E2F1-induced apoptosis. Depletion of API5 enhances the cytotoxic action of chemotherapeutic drugs. Multiple alternatively spliced transcript variants encoding different isoforms have been identified.","API5 has been implicated in various types of cancer, including breast, lung, and prostate cancer. Overexpression of API5 has been observed in cancer cells and is associated with resistance to chemotherapy and poor prognosis. Therefore, API5 has been identified as a potential therapeutic target for cancer treatment. Several studies have focused on developing small molecule inhibitors of API5 to sensitize cancer cells to chemotherapy. For example, a study found that a small molecule inhibitor of API5, called NSC59984, enhanced the cytotoxic effects of chemotherapy in breast cancer cells. Another study showed that a peptide inhibitor of API5, called API5-PD, sensitized lung cancer cells to chemotherapy. However, there are currently no FDA-approved drugs targeting API5. Further research is needed to develop effective API5 inhibitors for cancer treatment.",GO:2000270 negative regulation of fibroblast apoptotic process;GO:0044346 fibroblast apoptotic process;GO:2000269 regulation of fibroblast apoptotic process,,Predicted intracellular proteins,Nuclear speckles (Enhanced),,,
ENSG00000103111.15,ENSG00000103111,MON1B,-0.51219341,-0.810474482,-0.62326865,-0.102837098,"MON1 homolog B, secretory trafficking associated","MON1B is a human gene that encodes for a protein called MON1 homolog B, which is involved in the regulation of secretory trafficking. It plays a role in both early and late viral transcription and is located in the cytoplasm. MON1B is part of the Mon1-Ccz1 complex, which is involved in the regulation of endosomal trafficking and fusion. The Mon1-Ccz1 complex is essential for the proper functioning of the endosomal system, which is responsible for the transport of molecules within cells. Mutations in MON1B have been associated with various diseases, including cancer and neurological disorders.","There is limited information available on the disease implications of MON1B, but studies have suggested that mutations in this gene may be associated with various diseases, including cancer and neurological disorders. Targeted drug discovery efforts for MON1B are also limited, as the function of this gene is not fully understood. However, some studies have suggested that targeting the Mon1-Ccz1 complex, of which MON1B is a part, may have therapeutic potential for certain diseases. Currently, there are no drugs on the market that specifically target MON1B or the Mon1-Ccz1 complex. However, there are drugs that target other components of the endosomal system, such as lysosomal storage disorders, which may indirectly affect the function of MON1B. Examples of such drugs include enzyme replacement therapies for diseases such as Gaucher's disease and Fabry disease.",GO:0019085 early viral transcription;GO:0019086 late viral transcription;GO:0019083 viral transcription,,Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000135506.16,ENSG00000135506,OS9,-0.509470374,-0.74523187,-0.713663244,-0.069516008,OS9 endoplasmic reticulum lectin,"The OS9 gene encodes a protein that is found in high levels in osteosarcomas. This protein binds to HIF-1, a regulator of the hypoxic response and angiogenesis, and promotes the degradation of one of its subunits. Different isoforms of the protein have been identified through alternate transcriptional splice variants.","Osteosarcoma is a rare but aggressive bone cancer that primarily affects children and young adults. The overexpression of the OS9 gene in osteosarcomas suggests that it may play a role in the development and progression of this disease. Targeted drug discovery efforts have focused on identifying small molecules that can inhibit the interaction between OS9 and HIF-1, thereby preventing the degradation of HIF-1 and reducing the angiogenic potential of osteosarcoma cells. While no drugs specifically targeting OS9 have been approved for clinical use, several drugs that target HIF-1 or angiogenesis have shown promise in preclinical studies and clinical trials. Examples include bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), and sorafenib, a multi-kinase inhibitor that targets VEGF receptors and other angiogenic pathways.","GO:0006621 protein retention in ER lumen;GO:1904153 negative regulation of retrograde protein transport, ER to cytosol;GO:0070862 negative regulation of protein exit from endoplasmic reticulum",,Transporters:Accessory Factors Involved in Transport; Predicted intracellular proteins,Endoplasmic reticulum (Supported),,(M180)PID HIF1A PATHWAY,
ENSG00000197746.14,ENSG00000197746,PSAP,-0.505723595,-0.815986558,-0.475648687,-0.225535539,prosaposin,"PSAP, also known as prosaposin, is a highly conserved preproprotein that is processed to generate four cleavage products, saposins A, B, C, and D. These saposins are primarily found in lysosomes where they aid in the breakdown of glycosphingolipids with short oligosaccharide groups. PSAP exists as both a secretory protein and an integral membrane protein and has neurotrophic activities. Mutations in this gene have been linked to Gaucher disease and metachromatic leukodystrophy. Alternative splicing results in multiple transcript variants, including an isoform that is proteolytically processed.","PSAP mutations have been linked to two lysosomal storage disorders, Gaucher disease and metachromatic leukodystrophy. Gaucher disease is caused by a deficiency in the enzyme glucocerebrosidase, which leads to the accumulation of glucocerebroside in lysosomes. PSAP mutations can cause a secondary deficiency in saposin C, which is required for the degradation of glucocerebroside. Metachromatic leukodystrophy is caused by a deficiency in the enzyme arylsulfatase A, which leads to the accumulation of sulfatides in lysosomes. PSAP mutations can cause a secondary deficiency in saposin B, which is required for the degradation of sulfatides.

Targeted drug discovery efforts for Gaucher disease have focused on developing enzyme replacement therapies (ERTs) that replace the missing glucocerebrosidase enzyme. Two ERTs, imiglucerase and velaglucerase alfa, are currently approved for the treatment of Gaucher disease. For metachromatic leukodystrophy, there are currently no approved treatments, but gene therapy approaches are being investigated.

In addition to its role in lysosomal storage disorders, PSAP has been implicated in neurodegenerative diseases such as Alzheimer's and Parkinson's disease. Targeted drug discovery efforts for these diseases have focused on developing small molecule modulators of PSAP activity. One example is the compound P4, which has been shown to enhance PSAP activity and improve cognitive function in mouse models of Alzheimer's disease.",GO:1903771 positive regulation of beta-galactosidase activity;GO:1905572 ganglioside GM1 transport to membrane;GO:0046836 glycolipid transport,,Human disease related genes:Congenital disorders of metabolism:Congenital disorders of lipid/glycolipid metabolism; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Potential drug targets; Human disease related genes:Congenital disorders of metabolism:Lysosomal storage diseases; Disease related genes; Transporters:Transporter channels and pores,Vesicles (Supported),Di-Stearoyl-3-Sn-Phosphatidylethanolamine,,
ENSG00000150527.17,ENSG00000150527,MIA2,-0.505513293,-0.893461373,-0.621479014,-0.001599491,MIA SH3 domain ER export factor 2,"MIA2, also known as MIA SH3 domain ER export factor 2, is a gene that encodes a receptor in the endoplasmic reticulum. This receptor plays a role in the export of large pre-chylomicrons and pre-very low density lipoproteins. The gene produces three major classes of transcripts, including melanoma inhibitory activity 2-specific transcripts, cTAGE family member 5-specific transcripts, and transcripts that include exons from both these transcript species (TANGO1-like or TALI). Alternative splicing in these transcripts results in multiple transcript variants encoding multiple isoforms.","Research on MIA2 has primarily focused on its role in lipid metabolism and transport, and there is limited information on its disease implications. However, recent studies have suggested that MIA2 may play a role in the development and progression of certain cancers, including breast and lung cancer. Targeted drug discovery efforts for MIA2 are still in the early stages, but there is potential for the development of drugs that target MIA2 to treat these cancers. Currently, there are no drugs on the market that specifically target MIA2, but there are several drugs that target lipid metabolism and transport pathways that may indirectly affect MIA2 function. Examples of these drugs include statins, which are commonly used to lower cholesterol levels, and fibrates, which are used to treat hypertriglyceridemia.",GO:0070973 protein localization to endoplasmic reticulum exit site;GO:0042953 lipoprotein transport;GO:0044872 lipoprotein localization,,Disease related genes; Potential drug targets; Predicted intracellular proteins; Transporters,Endoplasmic reticulum (Supported),,,
ENSG00000198001.14,ENSG00000198001,IRAK4,-0.501012177,-0.957968604,-0.399331933,-0.145735993,interleukin 1 receptor associated kinase 4,"The IRAK4 gene encodes a kinase that plays a crucial role in activating NF-kappaB in both the Toll-like receptor and T-cell receptor signaling pathways. This protein is essential for most innate immune responses. Mutations in this gene can lead to IRAK4 deficiency, which is associated with recurrent invasive pneumococcal disease. The gene has multiple transcript variants that encode different isoforms.","IRAK4 deficiency is a rare genetic disorder that affects the immune system's ability to fight off infections. Patients with IRAK4 deficiency are susceptible to recurrent bacterial infections, particularly invasive pneumococcal disease. There are currently no targeted drug therapies available for IRAK4 deficiency, and treatment is primarily focused on managing infections with antibiotics and immunoglobulin replacement therapy. However, there is ongoing research into developing targeted therapies for IRAK4 deficiency, including small molecule inhibitors and gene therapy approaches.

In addition to IRAK4 deficiency, the IRAK4 gene has also been implicated in several autoimmune and inflammatory diseases, including rheumatoid arthritis, lupus, and inflammatory bowel disease. Targeting IRAK4 has emerged as a promising therapeutic strategy for these diseases, and several small molecule inhibitors of IRAK4 are currently in clinical development. One such drug, known as TAK-242, has shown promising results in early clinical trials for the treatment of sepsis and other inflammatory conditions.

Another successful drug targeting IRAK4 is rilzabrutinib, which is currently in clinical trials for the treatment of autoimmune diseases such as pemphigus and IgG4-related disease. Rilzabrutinib is a selective inhibitor of IRAK4 that has shown efficacy in preclinical models of autoimmune disease and has demonstrated a favorable safety profile in early clinical trials.

Overall, targeting IRAK4 has emerged as a promising therapeutic strategy for a range of immune-related diseases, and ongoing research efforts are focused on developing safe and effective drugs that can modulate IRAK4 activity.",GO:0008063 Toll signaling pathway;GO:0038172 interleukin-33-mediated signaling pathway;GO:0034162 toll-like receptor 9 signaling pathway,yes,Predicted intracellular proteins; Kinases:TKL Ser/Thr protein kinases; Human disease related genes:Immune system diseases:Primary immunodeficiency; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Cytosol;Microtubules (Supported); Additional: Nucleoli;Plasma membrane,1-(3-HYDROXYPROPYL)-2-[(3-NITROBENZOYL)AMINO]-1H-BENZIMIDAZOL-5-YL PIVALATE; Fostamatinib,(M264)PID TOLL ENDOGENOUS PATHWAY; (M110)PID IL1 PATHWAY,(M5923)HALLMARK PI3K AKT MTOR SIGNALING
ENSG00000141367.12,ENSG00000141367,CLTC,-0.500909986,-0.792369485,-0.565176836,-0.145183636,clathrin heavy chain,"CLTC, also known as clathrin heavy chain, is a gene that encodes a major protein component of coated vesicles and coated pits in cells. These organelles are involved in the intracellular trafficking of receptors and endocytosis of macromolecules. The clathrin coat is made up of three heavy chains and three light chains. Mutations in CLTC have been associated with a variety of diseases, including Charcot-Marie-Tooth disease, intellectual disability, and cancer. Understanding the function of CLTC and its role in cellular processes is important for developing treatments for these conditions.","Mutations in CLTC have been associated with a variety of diseases, including Charcot-Marie-Tooth disease, intellectual disability, and cancer. In Charcot-Marie-Tooth disease, mutations in CLTC have been found to disrupt the formation of myelin, the protective coating around nerve fibers, leading to nerve damage and muscle weakness. In cancer, CLTC has been shown to play a role in the formation of clathrin-coated vesicles that transport growth factor receptors, which can contribute to tumor growth and metastasis.

Targeted drug discovery efforts for CLTC have focused on developing inhibitors of clathrin-mediated endocytosis as a potential cancer therapy. One example is pitstop 2, a small molecule inhibitor that disrupts the formation of clathrin-coated pits and vesicles, leading to decreased internalization of growth factor receptors and inhibition of tumor growth. Another example is dynasore, which inhibits the activity of dynamin, a protein involved in the final stages of clathrin-mediated endocytosis.

Currently, there are no drugs on the market specifically targeting CLTC. However, drugs targeting clathrin-mediated endocytosis, such as pitstop 2 and dynasore, are being investigated as potential cancer therapies. Additionally, drugs targeting other proteins involved in clathrin-mediated endocytosis, such as the EGFR inhibitor erlotinib, have been approved for the treatment of certain types of cancer.",GO:1900126 negative regulation of hyaluronan biosynthetic process;GO:0150093 amyloid-beta clearance by transcytosis;GO:0072318 clathrin coat disassembly,,Predicted intracellular proteins; Human disease related genes:Other diseases:Mental and behavioural disorders; Transporters:Accessory Factors Involved in Transport; Potential drug targets; Disease related genes; Cancer-related genes:Mutational cancer driver genes,Endosomes;Lysosomes (Enhanced); Additional: Centriolar satellite;Cytosol;Mid piece;Mitotic spindle,,(M94)PID FAS PATHWAY; (M67)PID ARF6 TRAFFICKING PATHWAY,(M5910)HALLMARK PROTEIN SECRETION; (M5923)HALLMARK PI3K AKT MTOR SIGNALING
ENSG00000147164.12,ENSG00000147164,SNX12,-0.499547556,-0.653114442,-0.609431473,-0.236096751,sorting nexin 12,"SNX12 is a gene that belongs to the sorting nexin family and encodes a protein that contains a phosphoinositide binding domain. This protein is involved in intracellular trafficking and does not have a coiled coil region like some other family members. In mice, a similar protein may play a role in regulating neurite outgrowth. The gene undergoes alternate splicing, resulting in multiple transcript variants.","There is limited information available on the disease implications of SNX12. However, some studies have suggested that SNX12 may play a role in cancer progression and metastasis. For example, one study found that SNX12 expression was upregulated in breast cancer cells and that knockdown of SNX12 inhibited cell migration and invasion. 

As of now, there are no targeted drug discovery efforts specifically focused on SNX12. However, there are drugs on the market that target other members of the sorting nexin family, such as SNX-2112, which is a Hsp90 inhibitor that has shown promise in preclinical studies for the treatment of cancer. Additionally, some drugs that target phosphoinositide binding domains, such as buparlisib, have been approved for the treatment of certain types of cancer. 

Overall, more research is needed to fully understand the disease implications of SNX12 and to identify potential drug targets for the treatment of diseases associated with this gene.",GO:2000642 negative regulation of early endosome to late endosome transport;GO:0034499 late endosome to Golgi transport;GO:2000641 regulation of early endosome to late endosome transport,,Predicted intracellular proteins,,,,
ENSG00000244038.11,ENSG00000244038,DDOST,-0.498844448,-0.899689686,-0.499147339,-0.09769632,dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit,"The DDOST gene encodes a non-catalytic subunit of the oligosaccharyltransferase complex, which transfers high-mannose oligosaccharides to asparagine residues on nascent polypeptides in the rough endoplasmic reticulum. The protein complex is associated with ribosomes and is also involved in the processing of advanced glycation endproducts (AGEs), which are formed from non-enzymatic reactions between sugars and proteins or lipids and are linked to aging and hyperglycemia.","Mutations in the DDOST gene have been associated with a rare genetic disorder called congenital disorder of glycosylation type 1P (CDG1P), which is characterized by developmental delay, intellectual disability, seizures, and other neurological symptoms. There are currently no targeted drug discovery efforts specifically for DDOST, but there are drugs on the market that target the oligosaccharyltransferase complex, such as tunicamycin and castanospermine, which inhibit the transfer of oligosaccharides to nascent polypeptides. These drugs have been used in research to study the effects of inhibiting N-linked glycosylation, but they are not approved for clinical use. Other drugs that target AGEs, such as aminoguanidine and ALT-711, have been developed and tested in clinical trials for the treatment of diabetic complications, but their efficacy remains controversial.",GO:0018279 protein N-linked glycosylation via asparagine;GO:0006487 protein N-linked glycosylation;GO:0006486 protein glycosylation,,Predicted intracellular proteins; Transporters; Potential drug targets; Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism,Endoplasmic reticulum (Supported),,,
ENSG00000189241.8,ENSG00000189241,TSPYL1,-0.498575967,-0.667563697,-0.698598253,-0.129565949,TSPY like 1,"TSPYL1 is a gene that encodes a protein found in the nucleolus, which is similar to a family of genes on the Y-chromosome. This gene has no introns and defects in it have been linked to sudden infant death with dysgenesis of the testes syndrome (SIDDT).","Defects in the TSPYL1 gene have been linked to SIDDT, a rare genetic disorder characterized by sudden infant death and underdeveloped testes in males. There are currently no targeted drug discovery efforts specifically for TSPYL1, but research is ongoing to better understand the role of this gene in the development of SIDDT. 

There are no drugs on the market that specifically target TSPYL1, but there are treatments available for the symptoms associated with SIDDT, such as hormone replacement therapy for underdeveloped testes. Additionally, research into the genetic basis of SIDDT may lead to the development of targeted therapies in the future. 

Overall, while TSPYL1 has been linked to a rare genetic disorder, there are currently no targeted drug discovery efforts for this gene. However, ongoing research into the genetic basis of SIDDT may lead to the development of new treatments in the future.",GO:0006334 nucleosome assembly;GO:0034728 nucleosome organization;GO:0065004 protein-DNA complex assembly,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Nervous system diseases:Other nervous and sensory system diseases,Nucleoli;Nucleoplasm (Supported),,,
ENSG00000177889.10,ENSG00000177889,UBE2N,-0.498244213,-0.73412345,-0.45804118,-0.30256801,ubiquitin conjugating enzyme E2 N,"The UBE2N gene encodes a member of the E2 ubiquitin-conjugating enzyme family, which is involved in the modification of proteins with ubiquitin for degradation. This gene plays a role in DNA postreplication repair, according to studies in mice. The ubiquitination process involves three classes of enzymes: E1s, E2s, and E3s. The E2s, including UBE2N, are responsible for transferring ubiquitin from E1s to target proteins. The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation.","The UBE2N gene has been implicated in several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In cancer, UBE2N has been shown to be overexpressed in several types of tumors, including breast, lung, and pancreatic cancer, and is associated with poor prognosis. Targeting UBE2N has emerged as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of UBE2N have been developed and are currently being evaluated in preclinical studies. One example is the compound CC0651, which has been shown to inhibit the growth of breast cancer cells in vitro and in vivo. In addition, a recent study has shown that targeting UBE2N can enhance the efficacy of immune checkpoint inhibitors in cancer treatment. Overall, targeting UBE2N holds promise as a novel therapeutic approach for cancer treatment.",GO:0140252 regulation protein catabolic process at postsynapse;GO:0140250 regulation protein catabolic process at synapse;GO:1902523 positive regulation of protein K63-linked ubiquitination,,Enzymes; ENZYME proteins:Transferases; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported); Additional: Nucleoli fibrillar center,,(M84)PID ATM PATHWAY; (M110)PID IL1 PATHWAY,(M5923)HALLMARK PI3K AKT MTOR SIGNALING; (M5950)HALLMARK ALLOGRAFT REJECTION
ENSG00000163527.10,ENSG00000163527,STT3B,-0.495829677,-0.776128642,-0.581628718,-0.129731672,STT3 oligosaccharyltransferase complex catalytic subunit B,The STT3B gene encodes a protein that is part of a complex responsible for adding sugar molecules to specific amino acids in proteins. Mutations in this gene can lead to a congenital disorder of glycosylation known as CDG1X.,"CDG1X is a rare genetic disorder caused by mutations in the STT3B gene. This disorder affects the glycosylation process, which is essential for the proper functioning of many proteins in the body. Symptoms of CDG1X can vary widely, but may include developmental delays, intellectual disability, seizures, and abnormal facial features. There is currently no cure for CDG1X, and treatment is focused on managing symptoms.

Targeted drug discovery efforts for CDG1X are ongoing, with a focus on developing therapies that can correct the glycosylation defects caused by mutations in the STT3B gene. One approach being explored is the use of small molecule inhibitors that can selectively target the STT3B protein and improve glycosylation. Another approach is the use of gene therapy to replace the mutated STT3B gene with a healthy copy.

There are currently no drugs on the market specifically approved for the treatment of CDG1X. However, some drugs used to treat other disorders affecting glycosylation, such as mannose therapy for PMM2-CDG, have shown promise in improving symptoms in some CDG1X patients. Additionally, some patients may benefit from supportive therapies such as physical therapy, speech therapy, and special education services.",GO:0043686 co-translational protein modification;GO:0006516 glycoprotein catabolic process;GO:0018279 protein N-linked glycosylation via asparagine,,Transporters; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of glycan/glycoprotein metabolism,Endoplasmic reticulum (Supported),,,
ENSG00000149823.9,ENSG00000149823,VPS51,-0.494667452,-0.915873257,-0.545117094,-0.023012005,VPS51 subunit of GARP complex,"The VPS51 gene encodes a protein that is part of the Golgi-associated retrograde protein complex, which helps transport molecules from endosomes to the trans-Golgi network. This protein acts as a tethering factor for carriers during retrograde transport. Alternative splicing of the gene results in multiple transcript variants.","Mutations in the VPS51 gene have been associated with several diseases, including autosomal recessive intellectual disability and spastic paraplegia. These conditions are characterized by impaired cognitive function and motor control, respectively. Targeted drug discovery efforts for VPS51-related diseases are still in the early stages, but there is potential for small molecule inhibitors or gene therapies to be developed. Currently, there are no drugs on the market specifically targeting VPS51, but there are drugs that target other proteins involved in retrograde transport, such as brefeldin A and golgicide A. These drugs have been used in research to study the role of retrograde transport in disease and may have potential for therapeutic use in the future.",GO:0090119 vesicle-mediated cholesterol transport;GO:0032367 intracellular cholesterol transport;GO:0032366 intracellular sterol transport,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Predicted intracellular proteins,Golgi apparatus;Vesicles (Approved); Additional: Nucleoli,,,
ENSG00000119414.12,ENSG00000119414,PPP6C,-0.493077032,-0.705951005,-0.685909103,-0.087370988,protein phosphatase 6 catalytic subunit,"PPP6C is a gene that encodes the catalytic subunit of protein phosphatase, which is involved in regulating cell cycle progression. This gene has different splice variants that produce different protein isoforms. A pseudogene of this gene is also present on chromosome X.","PPP6C has been implicated in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, PPP6C has been shown to play a role in regulating cell proliferation, apoptosis, and DNA damage response. Targeting PPP6C has been proposed as a potential therapeutic strategy for cancer treatment. In neurodegenerative disorders, PPP6C has been linked to the regulation of tau protein phosphorylation, which is a hallmark of Alzheimer's disease. In cardiovascular diseases, PPP6C has been shown to regulate vascular smooth muscle cell proliferation and migration.

There have been efforts to develop drugs that target PPP6C. One example is the small molecule inhibitor, LB-100, which has been shown to inhibit PPP6C activity and induce apoptosis in cancer cells. Another example is the natural compound, curcumin, which has been shown to inhibit PPP6C activity and reduce tau protein phosphorylation in Alzheimer's disease models.

Currently, there are no drugs targeting PPP6C on the market. However, the potential therapeutic value of targeting PPP6C in various diseases warrants further investigation and drug discovery efforts.","GO:0160049 negative regulation of cGAS/STING signaling pathway;GO:0048207 vesicle targeting, rough ER to cis-Golgi;GO:0048208 COPII vesicle coating",,ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Mutated cancer genes; Predicted intracellular proteins,,,,
ENSG00000103423.14,ENSG00000103423,DNAJA3,-0.490756549,-0.964367099,-0.496306968,-0.01159558,DnaJ heat shock protein family (Hsp40) member A3,"DNAJA3 is a gene that encodes a member of the DNAJ/Hsp40 protein family. This protein family plays a critical role in protein folding, degradation, and multimeric complex assembly by stimulating the ATPase activity of Hsp70 chaperones. The encoded protein is localized to mitochondria and is involved in several cellular processes, including proliferation, survival, and apoptotic signal transduction. Additionally, it plays a crucial role in tumor suppression by interacting with oncogenic proteins such as ErbB2 and the p53 tumor suppressor protein. Multiple isoforms of this gene have been observed due to alternative splicing.","Research has shown that DNAJA3 may play a role in several diseases, including cancer, neurodegenerative disorders, and cardiovascular disease. In cancer, DNAJA3 has been found to interact with oncogenic proteins such as ErbB2 and p53, suggesting that it may be a potential target for cancer therapy. Targeted drug discovery efforts have focused on identifying small molecules that can inhibit the ATPase activity of Hsp70 chaperones, which are stimulated by DNAJA3. Several compounds have been identified as potential inhibitors of Hsp70, including VER-155008 and MKT-077. However, no drugs targeting DNAJA3 specifically have been approved for clinical use yet. Successful drugs on the market that target Hsp70 chaperones include 17-AAG and its derivative, IPI-504, which have shown promise in clinical trials for the treatment of cancer.",GO:0006924 activation-induced cell death of T cells;GO:0060331 negative regulation of response to type II interferon;GO:0060336 negative regulation of type II interferon-mediated signaling pathway,,Predicted intracellular proteins,Mitochondria (Supported); Additional: Vesicles,,(M187)PID TRKR PATHWAY,
ENSG00000112335.15,ENSG00000112335,SNX3,-0.48789448,-0.664745483,-0.783451986,-0.01548597,sorting nexin 3,"SNX3 is a gene that belongs to the sorting nexin family and encodes a protein that interacts with phosphatidylinositol-3-phosphate. This protein is involved in intracellular trafficking and does not contain a coiled coil region like most family members. Alternative splicing of this gene results in multiple transcript variants that encode distinct isoforms. A pseudogene of this gene is present on the sex chromosomes. Overall, SNX3 plays a crucial role in protein trafficking within cells and is an important member of the sorting nexin family.","There is limited information available on the disease implications of SNX3. However, recent studies have suggested that SNX3 may play a role in the pathogenesis of Alzheimer's disease. Specifically, SNX3 has been shown to interact with amyloid precursor protein (APP), a protein that is involved in the formation of amyloid plaques in the brain, a hallmark of Alzheimer's disease. Targeted drug discovery efforts for SNX3 are also limited, as the function of this protein is not well understood. However, there have been some studies exploring the potential of SNX3 as a therapeutic target for cancer. For example, one study found that SNX3 expression was significantly reduced in breast cancer cells and that overexpression of SNX3 inhibited tumor growth in vitro and in vivo. Currently, there are no drugs on the market that specifically target SNX3.",GO:0070676 intralumenal vesicle formation;GO:2000642 negative regulation of early endosome to late endosome transport;GO:0022615 protein to membrane docking,,Disease related genes; Potential drug targets; Predicted intracellular proteins; Transporters,,"S,S-(2-Hydroxyethyl)Thiocysteine",,
ENSG00000161217.12,ENSG00000161217,PCYT1A,-0.484474658,-0.789789202,-0.479919861,-0.183714911,"phosphate cytidylyltransferase 1A, choline",PCYT1A is a gene that belongs to the cytidylyltransferase family and plays a role in regulating the biosynthesis of phosphatidylcholine. Mutations in this gene have been linked to a rare genetic disorder called spondylometaphyseal dysplasia with cone-rod dystrophy. This disorder affects bone development and can cause vision loss. The gene has multiple transcript variants due to alternative splicing.,"Spondylometaphyseal dysplasia with cone-rod dystrophy is a rare genetic disorder caused by mutations in the PCYT1A gene. This disorder affects bone development and can cause vision loss due to cone-rod dystrophy, a type of retinal degeneration. Currently, there are no targeted drug discovery efforts for this specific disorder, and treatment is mainly supportive, focusing on managing symptoms such as bone pain and vision loss. However, research on the PCYT1A gene and its role in phosphatidylcholine biosynthesis has led to the development of drugs targeting this pathway. For example, choline kinase inhibitors have been developed as potential cancer therapeutics, as cancer cells have an increased demand for phosphatidylcholine. Additionally, drugs targeting the phosphatidylcholine biosynthesis pathway have been investigated for their potential in treating liver diseases such as non-alcoholic fatty liver disease. However, these drugs have not yet been approved for clinical use in these indications.",GO:0006657 CDP-choline pathway;GO:0006656 phosphatidylcholine biosynthetic process;GO:0002204 somatic recombination of immunoglobulin genes involved in immune response,,Predicted intracellular proteins; ENZYME proteins:Transferases; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Disease related genes; Enzymes,Nucleoplasm (Approved); Additional: Cytosol,Choline; Choline salicylate,,
ENSG00000104824.17,ENSG00000104824,HNRNPL,-0.482973982,-0.740660795,-0.426616244,-0.281644906,heterogeneous nuclear ribonucleoprotein L,"HNRNPL is a gene that encodes for the heterogeneous nuclear ribonucleoprotein L, which is a protein that is stably associated with hnRNP complexes. These complexes are involved in the formation, packaging, processing, and function of mRNA, which includes mRNA precursors and mature mRNAs. Heterogeneous nuclear ribonucleoprotein L is present in the nucleoplasm as part of the HNRP complex, but HNRP proteins have also been identified outside of the nucleoplasm. The exchange of hnRNP for mRNA-binding proteins accompanies the transport of mRNA from the nucleus to the cytoplasm. HNRP proteins have been shown to shuttle between the nucleus and the cytoplasm, suggesting that they may also have cytoplasmic functions. Two transcript variants encoding different isoforms have been found for this gene.","There is limited information available on the disease implications of HNRNPL mutations. However, recent studies have suggested that HNRNPL may play a role in the development and progression of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for HNRNPL are still in the early stages, but there is potential for the development of drugs that target the protein's role in mRNA processing and transport. One example of a successful drug that targets mRNA processing is Spliceostatin A, which has been shown to inhibit the splicing of pre-mRNA and has potential as an anti-cancer agent. Another example is E7107, which targets the spliceosome and has shown promise in preclinical studies for the treatment of solid tumors. However, more research is needed to fully understand the role of HNRNPL in disease and to develop effective targeted therapies.","GO:0000381 regulation of alternative mRNA splicing, via spliceosome;GO:0048024 regulation of mRNA splicing, via spliceosome;GO:0050684 regulation of mRNA processing",,Predicted intracellular proteins,Nucleoplasm (Enhanced),Copper,,
ENSG00000165660.8,ENSG00000165660,ABRAXAS2,-0.477458349,-0.816511834,-0.521612237,-0.094250975,"abraxas 2, BRISC complex subunit","ABRAXAS2 is a human gene that encodes a protein called abraxas 2, which is a subunit of the BRISC complex. This protein is involved in various cellular processes, including mitotic spindle assembly, protein K63-linked deubiquitination, and response to ischemia. It has microtubule binding activity and polyubiquitin modification-dependent protein binding activity. ABRAXAS2 is located in the cytoplasm and colocalizes with microtubule minus-end, midbody, and spindle pole centrosome. This gene's function is essential for proper cell division and maintenance of genomic stability.","There is limited information available on the disease implications of ABRAXAS2. However, recent studies have suggested that mutations in this gene may be associated with breast cancer and Fanconi anemia, a rare genetic disorder characterized by bone marrow failure and an increased risk of cancer. Targeted drug discovery efforts for ABRAXAS2 are currently underway, with a focus on developing small molecule inhibitors that can selectively target the protein and disrupt its function. While there are currently no drugs on the market that specifically target ABRAXAS2, several drugs that target related proteins in the BRISC complex, such as USP15 and BRCC3, have shown promise in preclinical studies for the treatment of cancer and other diseases. These include VLX1570, a small molecule inhibitor of USP14 and UCHL5, and TAK-659, a selective inhibitor of BRD4.",GO:0070536 protein K63-linked deubiquitination;GO:0008608 attachment of spindle microtubules to kinetochore;GO:0090307 mitotic spindle assembly,,Predicted intracellular proteins,Cytosol (Supported); Additional: Basal body;Primary cilium transition zone,,,
ENSG00000100226.16,ENSG00000100226,GTPBP1,-0.473044053,-0.709224217,-0.509099074,-0.200808869,GTP binding protein 1,"GTPBP1 is a gene that is activated by interferon-gamma and encodes a protein that belongs to the AGP11/GTPBP1 family of GTP-binding proteins. This gene is responsible for producing a protein that is structurally similar to a protein found in mice. However, the disruption of the gene for this protein in mice did not result in any observable phenotype.","There is limited information available on the disease implications of GTPBP1. However, recent studies have suggested that mutations in this gene may be associated with certain neurological disorders, including Parkinson's disease and amyotrophic lateral sclerosis (ALS). Targeted drug discovery efforts for GTPBP1 are still in the early stages, and there are currently no drugs on the market that specifically target this gene. However, there are several drugs that have been approved for the treatment of Parkinson's disease and ALS, which may indirectly affect the function of GTPBP1. For example, levodopa is a commonly used drug for Parkinson's disease that increases dopamine levels in the brain, while riluzole is an FDA-approved drug for ALS that may help to slow the progression of the disease.",GO:0046039 GTP metabolic process;GO:0006414 translational elongation;GO:0002181 cytoplasmic translation,,Predicted intracellular proteins,Cytosol;Golgi apparatus (Approved); Additional: Nuclear bodies,,,
ENSG00000108587.16,ENSG00000108587,GOSR1,-0.472782081,-0.81895381,-0.516135492,-0.08325694,golgi SNAP receptor complex member 1,"GOSR1 is a gene that encodes a membrane protein responsible for transporting proteins between the endoplasmic reticulum and the Golgi, as well as between different compartments within the Golgi. It is an essential component of the Golgi SNAP receptor complex, which is involved in the fusion of vesicles with target membranes. The gene has multiple alternatively spliced transcript variants that produce distinct isoforms of the protein.","Mutations in the GOSR1 gene have been associated with several diseases, including Parkinson's disease, schizophrenia, and intellectual disability. In Parkinson's disease, GOSR1 mutations have been linked to impaired dopamine release, which is a hallmark of the disease. Targeted drug discovery efforts have focused on developing drugs that modulate the function of the Golgi SNAP receptor complex, which includes GOSR1. One example is the drug brefeldin A, which inhibits the function of the Golgi apparatus and has been used in research to study the role of GOSR1 in protein transport. Another example is the drug tunicamycin, which inhibits protein glycosylation and has been shown to affect the function of the Golgi apparatus and GOSR1. While there are currently no drugs on the market that specifically target GOSR1, research into the function of this gene and its role in disease continues to provide insights into potential therapeutic targets for a range of disorders.","GO:0048219 inter-Golgi cisterna vesicle-mediated transport;GO:0006891 intra-Golgi vesicle-mediated transport;GO:0042147 retrograde transport, endosome to Golgi",,,,,,
ENSG00000126107.15,ENSG00000126107,HECTD3,-0.472368477,-0.939008166,-0.457969395,-0.02012787,HECT domain E3 ubiquitin protein ligase 3,"HECTD3 is a human gene that encodes for a protein that acts as an E3 ubiquitin ligase. This means that it transfers ubiquitin molecules from an E2 enzyme to specific target proteins, leading to their degradation. HECTD3 has been shown to transfer ubiquitin to TRIOBP, which helps to facilitate cell cycle progression, as well as to STX8. The exact function of HECTD3 is still being studied, but it is believed to play a role in regulating protein turnover and maintaining cellular homeostasis.","There is limited information available on the disease implications of HECTD3. However, recent studies have suggested that HECTD3 may play a role in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for HECTD3 are still in the early stages, but there is potential for the development of drugs that can inhibit the activity of this protein. Currently, there are no drugs on the market that specifically target HECTD3. However, there are drugs that target other E3 ubiquitin ligases, such as bortezomib, which is used to treat multiple myeloma and mantle cell lymphoma by inhibiting the activity of the proteasome. Further research is needed to fully understand the potential therapeutic implications of targeting HECTD3.",GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process;GO:0010498 proteasomal protein catabolic process;GO:0006511 ubiquitin-dependent protein catabolic process,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,,,,
ENSG00000158863.22,ENSG00000158863,FAM160B2,-0.469836478,-0.808400635,-0.501371784,-0.099737015,FHF complex subunit HOOK interacting protein 2B,"FHIP2B is a gene that encodes for a protein called FHF complex subunit HOOK interacting protein 2B. This protein is involved in the formation of the FHF complex, which plays a role in the development and function of the nervous system. FHIP2B has been found to be expressed in various regions of the brain, including the hippocampus and cortex. Mutations in this gene have been associated with intellectual disability and developmental delay. Additionally, FHIP2B has been implicated in the regulation of cell growth and differentiation, suggesting a potential role in cancer development. Further research is needed to fully understand the function of FHIP2B and its implications for human health.","There is limited information available on the disease implications of FHIP2B mutations, and no targeted drug discovery efforts have been reported for this gene. However, FHIP2B has been implicated in the regulation of cell growth and differentiation, suggesting a potential role in cancer development. As such, drugs targeting this pathway may have potential therapeutic applications in cancer treatment. Currently, there are no drugs on the market specifically targeting FHIP2B or its associated pathways. However, there are several drugs targeting related pathways that have been successful in treating various types of cancer, including tyrosine kinase inhibitors and monoclonal antibodies targeting growth factor receptors. Further research is needed to fully understand the potential therapeutic applications of targeting FHIP2B and its associated pathways.",,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000156599.11,ENSG00000156599,ZDHHC5,-0.469804357,-0.825596676,-0.553574952,-0.030241443,zinc finger DHHC-type palmitoyltransferase 5,"ZDHHC5 is a human gene that encodes for a protein called zinc finger DHHC-type palmitoyltransferase 5. This protein is involved in enabling palmitoyltransferase activity, which is important for the regulation of protein localization to the plasma membrane. ZDHHC5 is also involved in positive regulation of the pattern recognition receptor signaling pathway, which is important for the immune response. The protein is located in both the phagocytic vesicle and the plasma membrane, suggesting that it plays a role in cellular processes related to these structures. Overall, ZDHHC5 is an important gene involved in regulating protein localization and immune response.","ZDHHC5 has been implicated in several diseases, including cancer, neurological disorders, and infectious diseases. In cancer, ZDHHC5 has been shown to be upregulated in several types of tumors, including breast, lung, and prostate cancer, and may play a role in tumor growth and metastasis. In neurological disorders, ZDHHC5 has been linked to schizophrenia and Alzheimer's disease, with studies suggesting that it may be involved in synaptic function and neuronal signaling. In infectious diseases, ZDHHC5 has been shown to be important for the replication of several viruses, including HIV and hepatitis C virus.

Targeted drug discovery efforts for ZDHHC5 are still in the early stages, but there is potential for the development of drugs that target the palmitoylation activity of the protein. One study found that a small molecule inhibitor of ZDHHC5 was able to reduce the growth of breast cancer cells in vitro, suggesting that targeting this protein may be a promising approach for cancer therapy.

Currently, there are no drugs on the market that specifically target ZDHHC5. However, there are several drugs that indirectly affect the activity of the protein. For example, statins, which are commonly used to lower cholesterol levels, have been shown to reduce the palmitoylation of certain proteins, including ZDHHC5. Additionally, some antiviral drugs, such as interferon-alpha, have been shown to inhibit the replication of viruses by targeting ZDHHC5.",GO:1905169 regulation of protein localization to phagocytic vesicle;GO:1905171 positive regulation of protein localization to phagocytic vesicle;GO:0140639 positive regulation of pyroptotic inflammatory response,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm;Plasma membrane (Approved),,,
ENSG00000174839.13,ENSG00000174839,DENND6A,-0.469453842,-0.751659059,-0.572762997,-0.083939469,DENN domain containing 6A,"DENND6A is a human gene that encodes a protein containing a DENN domain, which enables guanyl-nucleotide exchange factor activity. This protein is involved in the positive regulation of cell-cell adhesion mediated by cadherin and is located in the recycling endosome. The function of DENND6A is not fully understood, but it is believed to play a role in intracellular trafficking and signaling pathways. Mutations in this gene have been associated with various diseases, including cancer and neurological disorders. Further research is needed to fully understand the role of DENND6A in human biology and disease.","There is limited information available on the disease implications of DENND6A, but mutations in this gene have been associated with various diseases, including cancer and neurological disorders. For example, a study found that DENND6A is frequently mutated in glioblastoma, a type of brain cancer, and that these mutations may contribute to tumor growth and progression. Additionally, mutations in DENND6A have been linked to intellectual disability and developmental delay.

As for targeted drug discovery efforts, there is currently no known drug that specifically targets DENND6A. However, research on the protein's function and role in disease may lead to the development of targeted therapies in the future.

There are currently no drugs on the market that target DENND6A. However, there are drugs that target other proteins involved in similar cellular processes, such as endosomal trafficking and signaling pathways. For example, the drug bafilomycin A1 inhibits the activity of the vacuolar-type H+-ATPase, which is involved in endosomal acidification and trafficking. This drug has been used to treat various diseases, including cancer and neurodegenerative disorders.",GO:2000049 positive regulation of cell-cell adhesion mediated by cadherin;GO:2000047 regulation of cell-cell adhesion mediated by cadherin;GO:0022409 positive regulation of cell-cell adhesion,,Predicted intracellular proteins,Vesicles (Supported),,,
ENSG00000117751.18,ENSG00000117751,PPP1R8,-0.467437686,-0.793966228,-0.577113462,-0.031233368,protein phosphatase 1 regulatory subunit 8,PPP1R8 is a human gene that produces three different protein isoforms through alternative splicing. Two of these isoforms act as inhibitors of type 1 serine/threonine protein phosphatases and can bind RNA but not cleave it. The third isoform lacks the inhibitory function but acts as a single-strand endoribonuclease similar to E. coli's RNase E. This isoform requires magnesium to function and cleaves specific sites in RNA regions that are rich in A+U.,"PPP1R8 has been implicated in several diseases, including cancer, Alzheimer's disease, and schizophrenia. In cancer, PPP1R8 has been shown to promote tumor growth and metastasis, making it a potential target for cancer therapy. In Alzheimer's disease, PPP1R8 has been found to be upregulated in the brains of patients, suggesting a role in the disease pathology. In schizophrenia, PPP1R8 has been identified as a potential risk gene, although its exact role in the disease is still unclear.

Targeted drug discovery efforts for PPP1R8 are ongoing, with a focus on developing inhibitors of its inhibitory isoforms for cancer therapy. One example is the development of small molecule inhibitors that can disrupt the interaction between PPP1R8 and its target protein, leading to decreased tumor growth. Another approach is the use of RNA interference to specifically target the inhibitory isoforms of PPP1R8.

Currently, there are no drugs on the market that specifically target PPP1R8. However, there are drugs that indirectly affect its function. For example, the chemotherapy drug paclitaxel has been shown to decrease the expression of PPP1R8 in cancer cells, leading to decreased tumor growth. Additionally, the Alzheimer's drug memantine has been found to decrease the expression of PPP1R8 in the brains of mice, suggesting a potential therapeutic effect in the disease.",GO:0006401 RNA catabolic process;GO:0141188 nucleic acid catabolic process;GO:0034655 nucleobase-containing compound catabolic process,,Predicted intracellular proteins,Nuclear speckles (Enhanced); Additional: Nucleoplasm,,,(M5925)HALLMARK E2F TARGETS
ENSG00000132005.9,ENSG00000132005,RFX1,-0.467160179,-0.812135596,-0.463194077,-0.126150864,regulatory factor X1,"RFX1 is a gene that belongs to the regulatory factor X (RFX) family of transcription factors. It contains an activation domain and a repression domain, and its function depends on the cellular context. RFX1 has been shown to regulate genes involved in immunity and cancer, including MHC class II genes and those involved in cancer progression. The gene is expressed differently in glioblastoma and the autoimmune disease systemic lupus erythematosus (SLE).","RFX1 has been implicated in several diseases, including cancer and autoimmune disorders. In cancer, RFX1 has been shown to regulate genes involved in tumor progression and metastasis, making it a potential target for cancer therapy. In autoimmune disorders such as SLE, RFX1 has been found to be downregulated, suggesting a potential role in disease pathogenesis. 

Targeted drug discovery efforts for RFX1 are still in the early stages, but there is potential for the development of drugs that modulate its activity. One approach is to identify small molecules that can activate or inhibit RFX1, which could be used to treat cancer or autoimmune disorders. Another approach is to develop gene therapies that target RFX1 expression, which could be used to restore its function in diseases where it is downregulated.

Currently, there are no drugs on the market that specifically target RFX1. However, there are drugs that indirectly affect RFX1 activity. For example, the immunosuppressive drug cyclosporine A has been shown to increase RFX1 expression and activity, leading to increased MHC class II expression. Additionally, the cancer drug imatinib has been shown to inhibit RFX1 expression, leading to decreased tumor growth and metastasis in preclinical models.",GO:0006955 immune response;GO:0002376 immune system process;GO:0006357 regulation of transcription by RNA polymerase II,,Transcription factors:Helix-turn-helix domains; Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Vesicles,,,
ENSG00000135956.9,ENSG00000135956,TMEM127,-0.465438596,-0.81643035,-0.37291955,-0.206965887,transmembrane protein 127,"TMEM127 is a gene that encodes a transmembrane protein with four predicted transmembrane domains. The protein is associated with early endosomal structures, the Golgi, and lysosomes, and may play a role in protein trafficking between these structures. Mutations in this gene, along with several other genes, have been linked to the development of pheochromocytomas. Multiple alternatively spliced transcript variants encoding the same protein have been identified.","Mutations in the TMEM127 gene have been linked to the development of pheochromocytomas, a rare type of tumor that arises from the adrenal gland. These tumors can cause high blood pressure, headaches, and other symptoms. Targeted drug discovery efforts for pheochromocytomas have focused on identifying drugs that can inhibit the activity of the proteins encoded by the mutated genes. However, there are currently no drugs specifically targeting TMEM127 mutations. Successful drugs on the market for pheochromocytomas include tyrosine kinase inhibitors such as sunitinib and pazopanib, which have been shown to be effective in treating some cases of the disease. Additionally, surgical removal of the tumor is often the primary treatment option for pheochromocytomas.",GO:0032007 negative regulation of TOR signaling;GO:0007032 endosome organization;GO:0032006 regulation of TOR signaling,,Transporters; Human disease related genes:Cancers:Cancers of endocrine organs; Cancer-related genes; Potential drug targets; Disease related genes,,,,
ENSG00000110435.12,ENSG00000110435,PDHX,-0.461126913,-0.839412673,-0.504980459,-0.038987606,pyruvate dehydrogenase complex component X,"The PDHX gene encodes the E3 binding protein subunit, also known as component X, of the pyruvate dehydrogenase (PDH) complex. This complex is responsible for converting pyruvate to acetyl coenzyme A, linking glycolysis to the Krebs cycle. The E3 binding protein subunit tethers E3 dimers to the E2 core of the PDH complex. Defects in this gene can cause pyruvate dehydrogenase deficiency, resulting in neurological dysfunction and lactic acidosis in infancy and early childhood. Additionally, this protein is a minor antigen for antimitochondrial antibodies, which are present in nearly 95% of patients with the autoimmune liver disease primary biliary cirrhosis (PBC). In PBC, activated T lymphocytes attack and destroy epithelial cells in the bile duct where this protein is abnormally distributed and overexpressed, eventually leading to cirrhosis and liver failure.","Pyruvate dehydrogenase complex deficiency caused by mutations in the PDHX gene is a rare genetic disorder that affects the function of the PDH complex, leading to the buildup of lactic acid in the body and neurological symptoms such as developmental delay, seizures, and intellectual disability. There are currently no targeted drug therapies available for PDHX-related PDH deficiency, and treatment is mainly supportive, focusing on managing symptoms and preventing complications. However, research efforts are underway to develop novel therapies that can restore PDH complex function and improve outcomes for patients with this condition. One promising approach is the use of small molecule compounds that can activate or stabilize the PDH complex, such as dichloroacetate (DCA) and its derivatives. DCA has been shown to improve metabolic function and reduce lactic acidosis in patients with PDH deficiency, and is currently being evaluated in clinical trials for other mitochondrial disorders.",GO:0006086 acetyl-CoA biosynthetic process from pyruvate;GO:0006085 acetyl-CoA biosynthetic process;GO:0006084 acetyl-CoA metabolic process,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of carbohydrate metabolism,Mitochondria;Nucleoplasm (Approved); Additional: Plasma membrane,,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000136878.14,ENSG00000136878,USP20,-0.45723205,-0.669611831,-0.487716919,-0.214367399,ubiquitin specific peptidase 20,"USP20 is a gene that encodes a protein called ubiquitin specific peptidase 20. This protein is involved in regulating various cellular processes, including angiogenesis, glucose metabolism, cell proliferation, and metastasis. It does so by deubiquitinating hypoxia-inducible factor (HIF)-1 alpha, which leads to increased expression of HIF-1alpha targeted genes. Additionally, USP20 regulates G-protein coupled receptor signaling by mediating the deubiquitination of beta-2 adrenergic receptor (ADRB2). This gene is expressed in many different tissues and undergoes alternative splicing, resulting in multiple transcript variants that encode the same protein.","Research on USP20 has revealed its potential as a therapeutic target for various diseases, including cancer, diabetes, and cardiovascular diseases. In cancer, USP20 has been shown to promote tumor growth and metastasis by regulating HIF-1alpha and ADRB2 signaling pathways. Therefore, targeting USP20 could be a promising strategy for cancer treatment. In diabetes, USP20 has been implicated in regulating glucose metabolism, and its inhibition could improve insulin sensitivity. In cardiovascular diseases, USP20 has been shown to regulate angiogenesis, and its inhibition could prevent the formation of new blood vessels that contribute to the progression of the disease.

Several drug discovery efforts have been made to target USP20, including small molecule inhibitors and RNA interference. However, no USP20-targeted drugs have been approved for clinical use yet. One study identified a small molecule inhibitor of USP20 that showed promising anti-tumor effects in vitro and in vivo. Another study used RNA interference to knockdown USP20 expression in cancer cells, resulting in reduced tumor growth and metastasis.

In conclusion, USP20 is a promising therapeutic target for various diseases, and drug discovery efforts are ongoing to develop USP20-targeted drugs. While no drugs have been approved for clinical use yet, the potential of USP20 inhibition as a therapeutic strategy is promising.",GO:0071108 protein K48-linked deubiquitination;GO:0070536 protein K63-linked deubiquitination;GO:0140374 antiviral innate immune response,,Peptidases:Cysteine-type peptidases; ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Cytosol;Nucleoplasm;Plasma membrane (Approved),,,
ENSG00000163798.13,ENSG00000163798,SLC4A1AP,-0.454881758,-0.646957033,-0.431370186,-0.286318056,solute carrier family 4 member 1 adaptor protein,SLC4A1AP is a gene that encodes for a protein that is predicted to have mRNA binding activity. The protein is located in both the nucleoplasm and plasma membrane.,"SLC4A1AP has been implicated in several diseases, including breast cancer, colorectal cancer, and Alzheimer's disease. In breast cancer, SLC4A1AP has been shown to be overexpressed and associated with poor prognosis. In colorectal cancer, SLC4A1AP has been identified as a potential therapeutic target due to its role in regulating cell proliferation and migration. In Alzheimer's disease, SLC4A1AP has been found to be downregulated in the hippocampus, a region of the brain important for memory and learning.

Targeted drug discovery efforts for SLC4A1AP are still in the early stages, but there is potential for the development of small molecule inhibitors that could target the mRNA binding activity of the protein. One example of a successful drug targeting mRNA binding is Spinraza, which is used to treat spinal muscular atrophy by increasing the production of a specific protein.

Currently, there are no drugs on the market specifically targeting SLC4A1AP. However, there are drugs that indirectly affect the protein's activity. For example, the chemotherapy drug 5-fluorouracil has been shown to downregulate SLC4A1AP expression in colorectal cancer cells. Additionally, the Alzheimer's drug memantine has been found to increase SLC4A1AP expression in the hippocampus.",,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Plasma membrane;Vesicles,,,
ENSG00000185115.6,ENSG00000185115,NSMCE3,-0.454737004,-0.913352525,-0.425380858,-0.025477627,"NSE3 homolog, SMC5-SMC6 complex component","NSMCE3 is a human gene that encodes a protein that is a component of the SMC5-6 chromatin reorganizing complex. This gene is a homolog of the NSE3 gene and is a member of the MAGE superfamily. NSMCE3 is an intronless gene, meaning that it lacks introns, which are non-coding regions of DNA that are typically removed during the process of gene expression. The SMC5-6 complex is involved in DNA repair and maintenance of genome stability, and mutations in NSMCE3 have been associated with developmental disorders and cancer.","Mutations in NSMCE3 have been associated with developmental disorders such as Cornelia de Lange syndrome (CdLS) and cancer. CdLS is a rare genetic disorder characterized by developmental abnormalities, intellectual disability, and distinctive facial features. NSMCE3 mutations have been identified in a small subset of CdLS patients, suggesting a potential role in the pathogenesis of the disorder. In terms of targeted drug discovery efforts, there is currently limited research on NSMCE3-specific drugs. However, the SMC5-6 complex has been identified as a potential target for cancer therapy, and several drugs targeting this complex are currently in preclinical development. For example, the small molecule inhibitor NSC 109555 has been shown to selectively target the SMC5-6 complex and induce cell death in cancer cells. Other drugs targeting the SMC5-6 complex, such as triptolide and curcumin, have also shown promising results in preclinical studies. However, further research is needed to determine the potential therapeutic applications of these drugs for NSMCE3-related disorders.",GO:0072711 cellular response to hydroxyurea;GO:0072710 response to hydroxyurea;GO:0016925 protein sumoylation,,Disease related genes; Predicted intracellular proteins,,,(M153)PID P75 NTR PATHWAY,
ENSG00000165630.14,ENSG00000165630,PRPF18,-0.453902115,-0.709410541,-0.576897334,-0.075398471,pre-mRNA processing factor 18,"PRPF18 is a human gene that encodes a protein involved in pre-mRNA splicing, specifically in the catalytic step II of the process. The protein contains seven WD repeats that facilitate protein-protein interactions and is found in the spliceosome. PRPF18 has a sequence similarity to the yeast splicing factor Prp18. Its function is essential for pre-mRNA processing, which is a crucial step in gene expression regulation.","Mutations in the PRPF18 gene have been associated with retinitis pigmentosa, a group of inherited disorders that cause progressive vision loss. In addition, mutations in PRPF18 have been linked to autosomal dominant cerebellar ataxia, a rare neurological disorder characterized by progressive problems with movement and coordination. 

There are currently no targeted drug discovery efforts specifically for PRPF18, but research is ongoing to develop therapies for retinitis pigmentosa and cerebellar ataxia. Some potential approaches include gene therapy, stem cell therapy, and small molecule drugs that target specific pathways involved in the diseases. 

There are currently no drugs on the market that specifically target PRPF18, but there are several drugs approved for the treatment of retinitis pigmentosa and cerebellar ataxia. For example, the drug idebenone has been shown to improve visual acuity in patients with retinitis pigmentosa, while the drug riluzole has been approved for the treatment of cerebellar ataxia. However, these drugs do not target PRPF18 directly and their mechanisms of action are not fully understood.",GO:0000350 generation of catalytic spliceosome for second transesterification step;GO:0000393 spliceosomal conformational changes to generate catalytic conformation;GO:0022618 protein-RNA complex assembly,,Predicted intracellular proteins,Nuclear speckles (Approved); Additional: Cytosol,,,
ENSG00000168288.13,ENSG00000168288,MMADHC,-0.451702428,-0.557226737,-0.575947555,-0.221932993,metabolism of cobalamin associated D,"The MMADHC gene is responsible for encoding a mitochondrial protein that plays a crucial role in the early stages of vitamin B12 metabolism. Vitamin B12 is essential for normal human development and survival. Mutations in this gene can lead to a disorder called methylmalonic aciduria and homocystinuria type cblD (MMADHC), which is characterized by reduced levels of adenosylcobalamin and methylcobalamin, two important coenzymes. Pseudogenes have also been identified on chromosomes 11 and X.","Mutations in the MMADHC gene can lead to a rare autosomal recessive disorder called methylmalonic aciduria and homocystinuria type cblD (MMADHC). This disorder is characterized by a deficiency in the enzymes required for the metabolism of vitamin B12, leading to the accumulation of toxic metabolites in the body. Symptoms of the disorder include developmental delays, intellectual disability, seizures, and failure to thrive. Treatment for MMADHC typically involves lifelong vitamin B12 supplementation and a low-protein diet.

There are currently no targeted drug discovery efforts specifically for MMADHC mutations. However, there are several drugs on the market that can be used to treat the symptoms of the disorder. For example, anticonvulsants can be used to control seizures, while growth hormone therapy can be used to promote growth and development in affected individuals. Additionally, vitamin B12 supplementation is a key component of treatment for MMADHC and can help to alleviate some of the symptoms of the disorder.

Overall, while there are no targeted drug discovery efforts for MMADHC mutations, there are several treatment options available to help manage the symptoms of the disorder. Ongoing research into the underlying mechanisms of the disorder may lead to the development of more effective treatments in the future.",GO:0009235 cobalamin metabolic process;GO:0033013 tetrapyrrole metabolic process;GO:0006767 water-soluble vitamin metabolic process,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of cofactor/vitamin metabolism; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of amino acid metabolism; Predicted intracellular proteins,,,,
ENSG00000215193.13,ENSG00000215193,PEX26,-0.447688368,-0.731545329,-0.593598625,-0.017921149,peroxisomal biogenesis factor 26,"PEX26 is a gene that belongs to the peroxin-26 gene family and is involved in protein import into peroxisomes. It helps anchor PEX1 and PEX6 to peroxisome membranes, possibly forming heteromeric AAA ATPase complexes required for protein import. Defects in this gene cause peroxisome biogenesis disorder complementation group 8 (PBD-CG8), which is a type of peroxisomal disorder resulting from a failure of protein import into the peroxisomal membrane or matrix. PBD-CG8 is one of four disorders in the PBD group, which includes Zellweger syndrome, neonatal adrenoleukodystrophy, infantile Refsum disease, and classical rhizomelic chondrodysplasia punctata. This gene has alternatively spliced transcript variants.","Peroxisome biogenesis disorder complementation group 8 (PBD-CG8) is a rare genetic disorder caused by mutations in the PEX26 gene. The disorder is characterized by the absence or malfunction of peroxisomes, which are cellular organelles involved in various metabolic processes. Symptoms of PBD-CG8 include developmental delays, vision and hearing problems, liver dysfunction, and skeletal abnormalities. There is currently no cure for PBD-CG8, and treatment is mainly supportive.

Targeted drug discovery efforts for PBD-CG8 are limited due to the rarity of the disease. However, some studies have focused on identifying compounds that can enhance peroxisome biogenesis or function. For example, a study published in the journal PLOS ONE in 2015 identified a compound called bezafibrate that can increase peroxisome biogenesis in cells from PBD patients. Bezafibrate is an FDA-approved drug used to treat hyperlipidemia, and its potential use in PBD-CG8 is currently being investigated.

There are currently no drugs specifically approved for the treatment of PBD-CG8. However, some drugs used to treat related peroxisomal disorders may be beneficial for PBD-CG8 patients. For example, Lorenzo's oil, a combination of two fatty acids, is used to treat X-linked adrenoleukodystrophy, another peroxisomal disorder. Lorenzo's oil has been shown to reduce the levels of very-long-chain fatty acids, which are elevated in PBD-CG8 patients. Additionally, some patients with PBD-CG8 may benefit from liver transplantation, which can improve liver function and prolong survival.",GO:0022615 protein to membrane docking;GO:0045046 protein import into peroxisome membrane;GO:0016558 protein import into peroxisome matrix,,Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Peroxisomal diseases; Transporters:Primary Active Transporters; Potential drug targets; Disease related genes,,,,(M5948)HALLMARK BILE ACID METABOLISM
ENSG00000110851.12,ENSG00000110851,PRDM4,-0.447170484,-0.751750057,-0.524977818,-0.064783577,PR/SET domain 4,PRDM4 is a gene that encodes a transcription factor belonging to the PR-domain protein family. It contains a PR-domain and multiple zinc finger motifs. PR-domain family transcription factors are involved in cell differentiation and tumorigenesis. The expression of PRDM4 is elevated in PC12 cells treated with nerve growth factor. The gene is located in a chromosomal region that is believed to contain tumor suppressor genes.,"There is limited information available on the disease implications of PRDM4. However, studies have shown that PRDM4 is involved in tumorigenesis and may act as a tumor suppressor gene. Targeted drug discovery efforts for PRDM4 are currently limited, but there is potential for the development of drugs that target PRDM4 expression or activity in cancer cells. Currently, there are no drugs on the market that specifically target PRDM4. However, there are drugs that target other members of the PR-domain protein family, such as PRDM1, which is targeted by the drug lenalidomide for the treatment of multiple myeloma and myelodysplastic syndromes. Further research is needed to fully understand the disease implications of PRDM4 and to develop targeted therapies for diseases associated with its dysregulation.",GO:0032259 methylation;GO:0006366 transcription by RNA polymerase II;GO:0006351 DNA-templated transcription,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Supported),,(M153)PID P75 NTR PATHWAY,(M5921)HALLMARK COMPLEMENT
ENSG00000116350.17,ENSG00000116350,SRSF4,-0.445380125,-0.689777406,-0.630576896,-0.015786072,serine and arginine rich splicing factor 4,"SRSF4, or serine and arginine rich splicing factor 4, is a gene that belongs to the arginine/serine-rich splicing factor family. It is involved in mRNA processing, which is the process of converting genetic information from DNA into functional proteins. The exact function of SRSF4 in this process is not yet fully understood. This gene is located on chromosome 1 and mutations in SRSF4 have been associated with various diseases, including cancer and neurodegenerative disorders.","Mutations in SRSF4 have been associated with various diseases, including cancer and neurodegenerative disorders. In cancer, SRSF4 has been found to be overexpressed in several types of tumors, including breast, lung, and colon cancer. This overexpression has been linked to increased tumor growth and metastasis. Therefore, SRSF4 is being investigated as a potential therapeutic target for cancer treatment. 

There are currently no drugs on the market that specifically target SRSF4. However, there are ongoing drug discovery efforts to develop small molecule inhibitors that can target SRSF4 and inhibit its activity. One study found that a small molecule inhibitor of SRSF4 was able to reduce the growth of breast cancer cells in vitro and in vivo. 

In addition to cancer, SRSF4 has also been implicated in neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. In Alzheimer's disease, SRSF4 has been found to be dysregulated, leading to abnormal splicing of genes involved in neuronal function. Therefore, targeting SRSF4 may also have potential therapeutic benefits for neurodegenerative disorders. 

Overall, while there are currently no drugs on the market that target SRSF4, ongoing research suggests that it may be a promising therapeutic target for cancer and neurodegenerative disorders.","GO:0048025 negative regulation of mRNA splicing, via spliceosome;GO:0050686 negative regulation of mRNA processing;GO:0033119 negative regulation of RNA splicing",,Predicted intracellular proteins,Nuclear speckles (Supported),Artenimol,,
ENSG00000182149.21,ENSG00000182149,IST1,-0.440928194,-0.640784389,-0.534436261,-0.147563932,IST1 factor associated with ESCRT-III,"IST1 is a gene that encodes a protein with MIT-interacting motifs that interacts with components of endosomal sorting complexes required for transport (ESCRT). The ESCRT functions in vesicle budding, such as that which occurs during membrane abscission in cytokinesis. The gene has a pseudogene on chromosome 19, and multiple isoforms have been observed due to alternative splicing of transcript variants.","IST1 has been implicated in several diseases, including cancer, neurodegenerative disorders, and viral infections. In cancer, IST1 has been shown to play a role in tumor growth and metastasis, making it a potential target for cancer therapy. In neurodegenerative disorders, IST1 has been linked to the accumulation of toxic protein aggregates, such as those seen in Alzheimer's and Parkinson's diseases. Additionally, IST1 has been shown to interact with viral proteins, suggesting a potential role in viral infections.

Targeted drug discovery efforts for IST1 are still in the early stages, but several small molecule inhibitors have been identified that target the protein's interaction with ESCRT components. These inhibitors have shown promise in preclinical studies, demonstrating anti-tumor activity in cancer cell lines and reducing the accumulation of toxic protein aggregates in neurodegenerative disease models.

Currently, there are no drugs on the market that specifically target IST1. However, several drugs that indirectly affect IST1 function have been approved for other indications. For example, the anti-cancer drug bortezomib has been shown to inhibit IST1 expression, and the Alzheimer's drug memantine has been shown to reduce the accumulation of toxic protein aggregates by modulating IST1 activity. These drugs provide proof-of-concept for the potential therapeutic value of targeting IST1 in disease.",GO:0048672 positive regulation of collateral sprouting;GO:1904896 ESCRT complex disassembly;GO:1904903 ESCRT III complex disassembly,,Predicted intracellular proteins,Vesicles (Supported),,,
ENSG00000180233.11,ENSG00000180233,ZNRF2,-0.439351766,-0.708428041,-0.465479745,-0.144147513,zinc and ring finger 2,"The human gene ZNRF2, also known as zinc and ring finger 2, is involved in enabling ubiquitin protein ligase activity and is predicted to be involved in protein ubiquitination. It is located in various parts of the cell, including the cytoplasmic vesicle membrane, nuclear lumen, and plasma membrane, and is part of a protein-containing complex. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of ZNRF2. However, recent studies have suggested that ZNRF2 may play a role in the development and progression of certain types of cancer, including breast cancer and colorectal cancer. Targeted drug discovery efforts for ZNRF2 are still in the early stages, but there is potential for the development of drugs that target the protein and its associated pathways. One example of a successful drug that targets a related protein is bortezomib, which targets the proteasome and is used to treat multiple myeloma. However, further research is needed to fully understand the potential therapeutic applications of targeting ZNRF2.",GO:0160177 positive regulation of autophagosome-lysosome fusion;GO:0031340 positive regulation of vesicle fusion;GO:0031338 regulation of vesicle fusion,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm;Vesicles (Uncertain); Additional: Nucleoli fibrillar center,,,
ENSG00000124380.11,ENSG00000124380,SNRNP27,-0.435313882,-0.638292718,-0.557707122,-0.109941806,small nuclear ribonucleoprotein U4/U6.U5 subunit 27,"SNRNP27 is a gene that encodes a serine/arginine-rich (SR) protein, which plays a crucial role in pre-mRNA splicing by facilitating the recognition and selection of splice sites. The protein is associated with the 25S U4/U6.U5 tri-snRNP, a major component of the U2-type spiceosome. The expression of this gene may be altered in cells infected with the human T-cell lymphotropic virus type 1 (HTLV-1) retrovirus. A pseudogene of this gene is located on the long arm of chromosome 5. Alternative spliced transcript variants have been observed for this gene.","There is limited information available on the disease implications of SNRNP27. However, mutations in other genes encoding SR proteins have been associated with various diseases, including cancer and neurological disorders. Therefore, it is possible that mutations in SNRNP27 may also contribute to the development of these diseases. 

As of now, there are no targeted drug discovery efforts specifically for SNRNP27. However, drugs targeting pre-mRNA splicing have been developed for other diseases, such as spinal muscular atrophy (SMA). SMA is caused by mutations in the SMN1 gene, which encodes a protein involved in pre-mRNA splicing. Nusinersen, an antisense oligonucleotide drug, has been approved for the treatment of SMA by increasing the production of functional SMN protein. 

In addition, spliceosome inhibitors have been developed as potential cancer therapies. Spliceosome inhibitors target the spliceosome, a complex of proteins and RNA molecules involved in pre-mRNA splicing. These inhibitors have shown promising results in preclinical studies and are currently being evaluated in clinical trials for various types of cancer. Examples of spliceosome inhibitors include H3B-8800 and E7107. 

Overall, while there is limited information on the disease implications of SNRNP27, drugs targeting pre-mRNA splicing have shown promise in the treatment of various diseases, including SMA and cancer.","GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile;GO:0000398 mRNA splicing, via spliceosome;GO:0000375 RNA splicing, via transesterification reactions",,Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000132300.19,ENSG00000132300,PTCD3,-0.430178353,-0.679618913,-0.520784345,-0.090131801,pentatricopeptide repeat domain 3,"PTCD3, or pentatricopeptide repeat domain 3, is a gene that plays a role in mitochondrial translation and is involved in rRNA binding activity and ribosomal small subunit binding activity. It is found in various cellular components, including the cytosol, mitochondrion, and nucleoplasm. PTCD3 has been implicated in combined oxidative phosphorylation deficiency 51, a rare genetic disorder that affects the function of mitochondria, the energy-producing organelles in cells.","Combined oxidative phosphorylation deficiency 51 (COXPD51) is a rare genetic disorder caused by mutations in the PTCD3 gene. This disorder affects the function of mitochondria, leading to a range of symptoms such as developmental delay, muscle weakness, and respiratory problems. There is currently no cure for COXPD51, and treatment is mainly supportive and focused on managing symptoms.

As PTCD3 plays a role in mitochondrial translation, it has been identified as a potential target for drug discovery efforts aimed at treating mitochondrial disorders. However, there are currently no drugs on the market that specifically target PTCD3.

There are, however, several drugs on the market that are used to treat mitochondrial disorders more broadly. For example, coenzyme Q10 (CoQ10) is a dietary supplement that has been shown to improve mitochondrial function and reduce symptoms in some patients with mitochondrial disorders. Another drug, idebenone, has been approved in Europe for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disorder that affects vision. Idebenone has also shown promise in clinical trials for other mitochondrial disorders.

Overall, while PTCD3 has been identified as a potential target for drug discovery efforts, there are currently no drugs on the market that specifically target this gene. However, there are several drugs available that can help manage symptoms of mitochondrial disorders more broadly.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Disease related genes; Ribosomal proteins; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Supported),,,(M5905)HALLMARK ADIPOGENESIS
ENSG00000143183.18,ENSG00000143183,TMCO1,-0.42803964,-0.561248213,-0.587449629,-0.135421077,transmembrane and coiled-coil domains 1,"TMCO1 is a gene that encodes a transmembrane protein. Mutations in this gene have been linked to craniofacial dysmorphism, skeletal abnormalities, and cognitive impairment. Additionally, mutations in TMCO1 have been associated with open-angle glaucoma, a condition that can lead to blindness. The gene has multiple alternatively spliced transcript variants.","There is currently no targeted drug discovery effort for TMCO1, as the exact function of the protein it encodes is not well understood. However, mutations in TMCO1 have been linked to several diseases, including craniofacial dysmorphism, skeletal abnormalities, cognitive impairment, and open-angle glaucoma. Open-angle glaucoma is a condition that can lead to blindness and is typically treated with eye drops that lower intraocular pressure. There are several drugs on the market that are used to treat open-angle glaucoma, including prostaglandin analogs, beta blockers, and alpha agonists. These drugs work by either increasing the outflow of aqueous humor or decreasing its production, thereby reducing intraocular pressure. While there are currently no drugs that target TMCO1 specifically, further research into the function of the protein may lead to the development of new treatments for diseases associated with mutations in this gene.",GO:0160063 multi-pass transmembrane protein insertion into ER membrane;GO:0006983 ER overload response;GO:0032469 endoplasmic reticulum calcium ion homeostasis,,Disease related genes; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Transporters:Transporter channels and pores,Endoplasmic reticulum (Supported),,,
ENSG00000215717.7,ENSG00000215717,TMEM167B,-0.423714343,-0.690557507,-0.534693154,-0.045892366,transmembrane protein 167B,"TMEM167B is a human gene that encodes for a transmembrane protein known as transmembrane protein 167B. This protein is involved in the constitutive secretory pathway and is primarily located in the Golgi apparatus. The Golgi apparatus is responsible for modifying, sorting, and packaging proteins and lipids for transport to their final destinations within the cell or for secretion outside of the cell. The exact function of TMEM167B in this process is not yet fully understood, but it is believed to play a role in the regulation of protein trafficking and secretion. Further research is needed to fully elucidate the function of TMEM167B and its potential implications for human health and disease.","There is limited information available on the disease implications of TMEM167B. However, mutations in this gene have been associated with a rare genetic disorder known as congenital disorder of glycosylation type IIw (CDG-IIw). CDG-IIw is characterized by developmental delay, intellectual disability, and abnormal glycosylation of proteins. There are currently no targeted drug discovery efforts or drugs on the market specifically targeting TMEM167B. However, there are drugs available for the treatment of CDG-IIw, such as mannose supplements and fucose supplements, which aim to correct the abnormal glycosylation of proteins. These treatments have shown some success in improving symptoms in individuals with CDG-IIw. Further research is needed to fully understand the role of TMEM167B in CDG-IIw and to develop more targeted therapies for this disorder.",GO:0045054 constitutive secretory pathway;GO:0006887 exocytosis;GO:0032940 secretion by cell,,Predicted intracellular proteins,,,,
ENSG00000122958.15,ENSG00000122958,VPS26A,-0.421364045,-0.746897296,-0.513634625,-0.003560213,VPS26 retromer complex component A,"VPS26A is a gene that belongs to a group of vacuolar protein sorting genes. It encodes a protein that is a component of the retromer complex, which is involved in retrograde transport of proteins from endosomes to the trans-Golgi network. The protein interacts directly with VPS35, which serves as the core of the retromer complex. The gene undergoes alternative splicing, resulting in multiple transcript variants encoding different isoforms. Studies in yeast and mammalian cells suggest that the function of the human protein is similar to that of the yeast protein.","Mutations in the VPS26A gene have been associated with Parkinson's disease and Alzheimer's disease. In Parkinson's disease, VPS26A mutations have been found to impair the function of the retromer complex, leading to the accumulation of alpha-synuclein protein in neurons. This accumulation is thought to contribute to the neurodegeneration seen in Parkinson's disease. Targeted drug discovery efforts have focused on developing small molecules that can enhance the function of the retromer complex and reduce the accumulation of alpha-synuclein. One example is the drug Riluzole, which has been shown to enhance retromer function and reduce alpha-synuclein accumulation in preclinical studies. Another example is the drug Anle138b, which has been shown to reduce alpha-synuclein aggregation and improve motor function in a mouse model of Parkinson's disease.","GO:0032456 endocytic recycling;GO:0042147 retrograde transport, endosome to Golgi;GO:0016482 cytosolic transport",,Predicted intracellular proteins; Transporters,Endosomes;Lysosomes (Enhanced),,,
ENSG00000107625.13,ENSG00000107625,DDX50,-0.420444209,-0.7499192,-0.460653012,-0.050760413,DExD-box helicase 50,"DDX50 is a gene that encodes a DEAD box enzyme, which is a putative RNA helicase involved in various cellular processes such as ribosome and spliceosome assembly, nuclear and mitochondrial splicing, and translation initiation. It may also be involved in ribosomal RNA synthesis or processing. DDX50 and DDX21 have similar genomic structures and are in tandem orientation on chromosome 10, suggesting that they arose by gene duplication in evolution. This gene has pseudogenes on chromosomes 2, 3, and 4. Alternative splicing of this gene generates multiple transcript variants, but the full-length nature of all variants except one has not been defined.","There is limited information available on the disease implications of DDX50. However, recent studies have suggested that DDX50 may play a role in cancer progression and metastasis. For example, DDX50 has been found to be upregulated in various types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts for DDX50 are currently limited, but there is potential for the development of drugs that target the RNA helicase activity of DDX50. Currently, there are no drugs on the market that specifically target DDX50. However, there are drugs that target other RNA helicases, such as the FDA-approved drug Rigosertib, which targets the RNA helicase DDX3 and is being investigated for the treatment of various types of cancer. Further research is needed to fully understand the disease implications of DDX50 and to develop targeted therapies for diseases associated with this gene.",GO:0140588 chromatin looping;GO:0006338 chromatin remodeling;GO:0006325 chromatin organization,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoli (Enhanced),,,
ENSG00000068400.13,ENSG00000068400,GRIPAP1,-0.419919365,-0.743187372,-0.395522933,-0.121047789,GRIP1 associated protein 1,"GRIPAP1 is a gene that encodes a protein called a guanine nucleotide exchange factor, which is involved in regulating the activity of small G proteins in the Ras family. This protein interacts with another protein called glutamate receptor interacting protein 1 (GRIP1) and is involved in regulating the function of AMPA receptors, which are important for synaptic transmission in the brain. The exact role of GRIPAP1 in these processes is not fully understood, but it is thought to play a key role in the regulation of neuronal activity and synaptic plasticity.","There is limited information available on the disease implications of GRIPAP1. However, some studies have suggested that mutations in this gene may be associated with certain neurological disorders, such as schizophrenia and bipolar disorder. Targeted drug discovery efforts for GRIPAP1 are also limited, as the exact role of this gene in disease pathogenesis is not fully understood. However, some studies have suggested that targeting the interaction between GRIPAP1 and AMPA receptors may have therapeutic potential for certain neurological disorders. Currently, there are no drugs on the market that specifically target GRIPAP1. However, there are drugs that target AMPA receptors, such as the drug perampanel, which is used to treat epilepsy.","GO:0099158 regulation of recycling endosome localization within postsynapse;GO:0099152 regulation of neurotransmitter receptor transport, endosome to postsynaptic membrane;GO:1903910 negative regulation of receptor clustering",,Predicted intracellular proteins,Cytosol;Vesicles (Approved),,,
ENSG00000162735.19,ENSG00000162735,PEX19,-0.41937179,-0.686687975,-0.547969588,-0.023457806,peroxisomal biogenesis factor 19,"PEX19 is a gene that plays a crucial role in the early stages of peroxisomal biogenesis. It acts as both a cytosolic chaperone and an import receptor for peroxisomal membrane proteins. Peroxisomes are essential organelles involved in various metabolic processes, and defects in their function can lead to peroxisome biogenesis disorders (PBDs), a group of lethal diseases with at least 14 complementation groups. Zellweger syndrome (ZWS) and PBD-CG14 are two such disorders caused by defects in the PEX19 gene. Alternative splicing of the gene results in multiple transcript variants.","Defects in the PEX19 gene have been linked to peroxisome biogenesis disorders (PBDs), including Zellweger syndrome (ZWS) and PBD-CG14. These disorders are characterized by the absence or malfunction of peroxisomes, leading to a range of symptoms such as developmental delays, liver dysfunction, and vision and hearing problems. Currently, there are no targeted drug therapies available for PBDs, and treatment is mainly supportive. However, research efforts are underway to identify potential drug targets and develop therapies for these disorders. One promising approach is the use of small molecules that can enhance peroxisome biogenesis and function. For example, bezafibrate, a drug used to treat hyperlipidemia, has been shown to improve peroxisome function in patients with PBDs. Other potential drug targets include enzymes involved in peroxisome biogenesis and membrane proteins that are essential for peroxisome function.",GO:0016557 peroxisome membrane biogenesis;GO:1900130 regulation of lipid binding;GO:1900131 negative regulation of lipid binding,,Predicted intracellular proteins; Transporters; Human disease related genes:Congenital disorders of metabolism:Peroxisomal diseases; Potential drug targets; Disease related genes,Peroxisomes (Supported),,,(M5948)HALLMARK BILE ACID METABOLISM
ENSG00000114784.4,ENSG00000114784,EIF1B,-0.417895584,-0.733197635,-0.477189283,-0.043299836,eukaryotic translation initiation factor 1B,"EIF1B is a human gene that encodes for the eukaryotic translation initiation factor 1B. This protein is involved in the initiation of protein synthesis by enabling RNA binding activity and is predicted to be part of the eukaryotic 43S preinitiation complex. The gene is also predicted to be involved in translational initiation. Overall, EIF1B plays an important role in the regulation of protein synthesis in eukaryotic cells.","There is limited information available on the disease implications of EIF1B. However, some studies have suggested that alterations in the expression of this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for EIF1B are also limited, as the function of this gene is not well understood. However, some studies have suggested that targeting the eukaryotic translation initiation factor complex, of which EIF1B is a part, may be a potential strategy for cancer therapy. Currently, there are no drugs on the market that specifically target EIF1B. However, there are several drugs that target the eukaryotic translation initiation factor complex, including the anticancer drugs omacetaxine and silvestrol.",GO:0006413 translational initiation;GO:0006446 regulation of translational initiation;GO:0006412 translation,,Predicted intracellular proteins,,,,(M5898)HALLMARK DNA REPAIR
ENSG00000108788.12,ENSG00000108788,MLX,-0.41611467,-0.554887916,-0.500547769,-0.192908327,MAX dimerization protein MLX,"The human gene MLX encodes for a basic helix-loop-helix leucine zipper (bHLH-Zip) transcription factor that forms heterodimers with Mad proteins. These heterodimers play a role in proliferation, determination, and differentiation. MLX may diversify the function of the Mad family of transcriptional repressors by its restricted association with a subset of Mad proteins, specifically Mad1 and Mad4. Different isoforms of MLX have been identified due to alternative splicing of the transcript variants.","MLX has been implicated in several diseases, including cancer, diabetes, and metabolic disorders. In cancer, MLX has been shown to play a role in tumor growth and progression by regulating glucose metabolism and angiogenesis. In diabetes, MLX is involved in the regulation of insulin secretion and glucose homeostasis. Targeted drug discovery efforts for MLX have focused on developing small molecule inhibitors that can disrupt the interaction between MLX and its binding partners, such as Mad1 and Mad4. However, there are currently no drugs on the market that specifically target MLX. Some drugs that indirectly affect MLX activity include metformin, which is used to treat type 2 diabetes, and rapamycin, which is used to treat certain types of cancer.",GO:0000122 negative regulation of transcription by RNA polymerase II;GO:0045944 positive regulation of transcription by RNA polymerase II;GO:0045892 negative regulation of DNA-templated transcription,,Transcription factors:Basic domains; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol;Nuclear membrane,,,
ENSG00000179387.10,ENSG00000179387,ELMOD2,-0.41412661,-0.779510712,-0.422809103,-0.040060014,ELMO domain containing 2,ELMOD2 is a gene that encodes for one of the six ELMO domain-containing proteins. It is believed to play a role in antiviral responses and mutations in this gene may be linked to familial idiopathic pulmonary fibrosis.,"Mutations in the ELMOD2 gene have been linked to familial idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease characterized by the formation of scar tissue in the lungs. Targeted drug discovery efforts for IPF have focused on inhibiting the activity of fibroblasts, the cells responsible for producing excess scar tissue. Pirfenidone and nintedanib are two drugs that have been approved for the treatment of IPF. Pirfenidone works by inhibiting the production of inflammatory molecules and reducing the activity of fibroblasts, while nintedanib targets multiple signaling pathways involved in fibrosis. Both drugs have been shown to slow the decline in lung function and improve survival in patients with IPF. However, there is still a need for more effective treatments for this devastating disease.",GO:0050688 regulation of defense response to virus;GO:0051607 defense response to virus;GO:0009615 response to virus,,Predicted intracellular proteins,Actin filaments;Nuclear bodies (Approved); Additional: Cytosol;Nucleoplasm,,,
ENSG00000119487.17,ENSG00000119487,MAPKAP1,-0.412072312,-0.599416026,-0.606937605,-0.029863303,MAPK associated protein 1,"The human gene MAPKAP1, also known as MAPK associated protein 1, encodes a protein that is similar to the yeast SIN1 protein, which is a stress-activated protein kinase. The gene has multiple alternate spliced transcript variants that encode distinct isoforms, and alternate polyadenylation sites and 3' UTRs have been identified for transcripts of this gene. The gene's function is not fully understood, but it is believed to play a role in stress response and cellular signaling pathways.","Research on the MAPKAP1 gene has suggested its potential involvement in various diseases, including cancer, cardiovascular disease, and neurological disorders. For example, studies have shown that MAPKAP1 may play a role in the development and progression of breast cancer, and its expression has been found to be upregulated in certain types of cancer cells. Additionally, mutations in the gene have been associated with an increased risk of developing coronary artery disease.

Given its potential involvement in disease pathways, MAPKAP1 has been a target for drug discovery efforts. One example is the development of inhibitors targeting the protein kinase mTORC1, which is activated by MAPKAP1. These inhibitors have shown promise in preclinical studies for the treatment of cancer and other diseases.

There are currently no drugs on the market specifically targeting MAPKAP1, but there are several drugs that indirectly affect its activity. For example, the mTORC1 inhibitor everolimus is approved for the treatment of certain types of cancer, and the anti-inflammatory drug colchicine has been shown to inhibit MAPKAP1 activity in vitro. Further research on the gene's function and potential therapeutic targets may lead to the development of more targeted therapies in the future.",GO:0038203 TORC2 signaling;GO:0046580 negative regulation of Ras protein signal transduction;GO:1900407 regulation of cellular response to oxidative stress,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol;Primary cilium,,(M249)PID PI3KCI AKT PATHWAY; (M222)PID CXCR3 PATHWAY; (M121)PID MTOR 4PATHWAY,(M5923)HALLMARK PI3K AKT MTOR SIGNALING
ENSG00000138942.16,ENSG00000138942,RNF185,-0.407704737,-0.640380966,-0.559051937,-0.023681309,ring finger protein 185,"RNF185, also known as ring finger protein 185, is a gene that encodes a protein involved in several cellular processes. The protein has the ability to bind to ubiquitin, a small protein that plays a crucial role in protein degradation and other cellular processes. RNF185 also acts as a ubiquitin ligase, which means it can attach ubiquitin molecules to other proteins, marking them for degradation. The gene is located in the endoplasmic reticulum, a cellular organelle involved in protein synthesis and folding. RNF185 is involved in the positive regulation of the ERAD pathway, a process that eliminates misfolded proteins from the endoplasmic reticulum. The gene is also involved in protein autoubiquitination and ubiquitin-dependent ERAD pathway.","There is limited information available on the disease implications of RNF185. However, recent studies have suggested that mutations in the gene may be associated with the development of certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for RNF185 are currently underway, with a focus on developing small molecule inhibitors that can block the activity of the protein. While there are currently no drugs on the market that specifically target RNF185, there are several drugs that target the ubiquitin-proteasome system, which is the cellular pathway that RNF185 is involved in. Examples of successful drugs in this category include bortezomib, which is used to treat multiple myeloma, and carfilzomib, which is used to treat relapsed or refractory multiple myeloma.",GO:0044314 protein K27-linked ubiquitination;GO:1904380 endoplasmic reticulum mannose trimming;GO:0036507 protein demannosylation,,Enzymes; ENZYME proteins:Transferases,,,,
ENSG00000122566.22,ENSG00000122566,HNRNPA2B1,-0.401230588,-0.623372751,-0.489741933,-0.09057708,heterogeneous nuclear ribonucleoprotein A2/B1,"HNRNPA2B1 is a gene that belongs to the A/B subfamily of heterogeneous nuclear ribonucleoproteins (hnRNPs). These RNA binding proteins complex with heterogeneous nuclear RNA (hnRNA) and are associated with pre-mRNAs in the nucleus, influencing pre-mRNA processing and other aspects of mRNA metabolism and transport. HNRNPA2B1 has two repeats of quasi-RRM domains that bind to RNAs and generates two alternatively spliced transcript variants that encode different isoforms. While all hnRNPs are present in the nucleus, some shuttle between the nucleus and the cytoplasm. HNRNPA2B1 is ubiquitously expressed and plays a role in RNA processing and transport.","HNRNPA2B1 has been implicated in several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In cancer, HNRNPA2B1 has been shown to regulate alternative splicing events that contribute to tumor progression and metastasis. Targeting HNRNPA2B1 has been proposed as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of HNRNPA2B1 have been developed, including Meayamycin and its analogs, which have shown promising anti-cancer activity in preclinical studies. In neurodegenerative disorders, HNRNPA2B1 has been linked to the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Mutations in HNRNPA2B1 have been identified in patients with ALS and FTD, and these mutations have been shown to disrupt RNA metabolism and contribute to disease pathology. However, there are currently no targeted drugs available for the treatment of ALS or FTD that specifically target HNRNPA2B1.",GO:1990428 miRNA transport;GO:0044806 G-quadruplex DNA unwinding;GO:0031053 primary miRNA processing,,Disease related genes; Cancer-related genes; Human disease related genes:Musculoskeletal diseases:Muscular diseases; Predicted intracellular proteins,Nucleoplasm (Enhanced),Copper; Artenimol,,(M5926)HALLMARK MYC TARGETS V1
ENSG00000185787.15,ENSG00000185787,MORF4L1,-0.349203806,-0.634155157,-0.403213163,-0.010243099,mortality factor 4 like 1,"MORF4L1, also known as mortality factor 4 like 1, is a gene that encodes a protein involved in various cellular processes. The protein has the ability to bind to the N-terminus of other proteins and is involved in repairing double-strand breaks in DNA through homologous recombination. It also plays a role in modifying histones, which are proteins that help package DNA in the nucleus. MORF4L1 is located in the nuclear speck and is part of two protein complexes, NuA4 histone acetyltransferase complex and Sin3 complex. Overall, MORF4L1 is an important gene involved in maintaining the integrity of DNA and regulating gene expression.","There is limited information on the disease implications of MORF4L1 mutations. However, studies have shown that MORF4L1 is overexpressed in various types of cancer, including breast, lung, and liver cancer. This suggests that MORF4L1 may play a role in cancer development and progression. Targeted drug discovery efforts for MORF4L1 are currently limited, but there is potential for the development of drugs that target the protein's role in DNA repair and histone modification. Currently, there are no drugs on the market that specifically target MORF4L1. However, there are drugs that target other proteins in the NuA4 histone acetyltransferase complex and Sin3 complex, such as HDAC inhibitors and BET inhibitors, which have shown promise in cancer treatment. Further research is needed to fully understand the potential of targeting MORF4L1 in disease treatment.",GO:0048144 fibroblast proliferation;GO:1905168 positive regulation of double-strand break repair via homologous recombination;GO:0045911 positive regulation of DNA recombination,,Predicted intracellular proteins,Nuclear speckles (Supported),,,
ENSG00000170473.17,ENSG00000170473,PYM1,0.291340642,0.527767829,0.341330903,0.004923193,"PYM homolog 1, exon junction complex associated factor","PYM1, also known as PYM homolog 1, is a human gene that plays a role in various cellular processes. It is involved in disassembling the exon-exon junction complex, a structure that connects exons in mRNA, and in regulating the decay of mRNA through a process called nonsense-mediated decay. PYM1 also positively regulates translation, the process by which mRNA is used to synthesize proteins. The gene is located in several cellular compartments, including cell junctions, the cytosol, and the nuclear lumen. It is part of the exon-exon junction complex, a complex of proteins that is involved in mRNA processing.","There is limited information available on the disease implications of PYM1. However, recent studies have suggested that PYM1 may play a role in cancer progression and metastasis. Specifically, PYM1 has been shown to promote the translation of oncogenic mRNAs, which can contribute to tumor growth and survival. As such, PYM1 may be a potential target for cancer therapy. 

There are currently no drugs on the market that specifically target PYM1. However, there have been efforts to develop drugs that target the exon-exon junction complex, of which PYM1 is a component. One example is the drug E7107, which inhibits the splicing of pre-mRNA and has shown promise in preclinical studies for the treatment of various cancers. Another example is the drug Pladienolide B, which also inhibits splicing and has shown efficacy in preclinical studies for the treatment of leukemia and other cancers. 

Overall, while there is still much to be learned about the role of PYM1 in disease, targeting the exon-exon junction complex, of which PYM1 is a part, may hold promise for the development of novel cancer therapies.","GO:1903259 exon-exon junction complex disassembly;GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay;GO:0000956 nuclear-transcribed mRNA catabolic process",,Predicted intracellular proteins,Cytosol;Nucleoli;Nucleoplasm (Supported); Additional: Cell Junctions,,,
ENSG00000173163.10,ENSG00000173163,COMMD1,0.394364145,0.647667089,0.433481836,0.10194351,copper metabolism domain containing 1,"COMMD1 is a human gene that plays a crucial role in regulating copper homeostasis, sodium uptake, and NF-kappa-B signaling. It is a copper metabolism domain-containing protein that helps maintain the balance of copper in the body. The gene is involved in the regulation of various cellular processes, including inflammation, cell proliferation, and apoptosis. Mutations in the COMMD1 gene have been associated with several diseases, including Wilson's disease, a rare genetic disorder that causes copper to accumulate in the liver, brain, and other organs. Understanding the function of COMMD1 may lead to the development of new treatments for these diseases.","Mutations in the COMMD1 gene have been associated with several diseases, including Wilson's disease, a rare genetic disorder that causes copper to accumulate in the liver, brain, and other organs. Targeted drug discovery efforts have focused on developing drugs that can regulate copper homeostasis and reduce copper accumulation in the body. One example is the drug trientine, which is used to treat Wilson's disease by binding to excess copper and removing it from the body. Another drug, tetrathiomolybdate, has been shown to reduce copper levels in patients with Wilson's disease and may also have potential in treating other copper-related disorders. Additionally, research is ongoing to develop new drugs that can target the NF-kappa-B signaling pathway, which is regulated by COMMD1 and plays a role in inflammation and cancer.",GO:0048227 plasma membrane to endosome transport;GO:2000009 negative regulation of protein localization to cell surface;GO:1902306 negative regulation of sodium ion transmembrane transport,,Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,
ENSG00000174444.15,ENSG00000174444,RPL4,0.410805169,0.61180282,0.579495608,0.041117079,ribosomal protein L4,"RPL4 is a gene that encodes a ribosomal protein, specifically a component of the 60S subunit. Ribosomes are organelles that catalyze protein synthesis and are composed of RNA and proteins. RPL4 belongs to the L4E family of ribosomal proteins and is located in the cytoplasm. This gene has multiple processed pseudogenes dispersed throughout the genome, which is typical for genes encoding ribosomal proteins.","There is limited information available on the disease implications of RPL4 mutations. However, some studies have suggested that alterations in ribosomal proteins, including RPL4, may be associated with various types of cancer. Targeted drug discovery efforts for RPL4 have been limited, but some studies have explored the potential of targeting ribosomal proteins as a therapeutic strategy for cancer treatment. One example of a successful drug targeting ribosomal proteins is the antibiotic doxorubicin, which binds to the 60S subunit of the ribosome and inhibits protein synthesis. Doxorubicin is used to treat a variety of cancers, including breast cancer, leukemia, and lymphoma. Another example is the drug everolimus, which targets the mTOR pathway and inhibits protein synthesis by binding to the 60S subunit. Everolimus is used to treat several types of cancer, including breast cancer and renal cell carcinoma.",GO:0002181 cytoplasmic translation;GO:0006412 translation;GO:0010467 gene expression,,Ribosomal proteins; Predicted intracellular proteins,Cytosol;Endoplasmic reticulum (Supported); Additional: Nuclear bodies;Nucleoli,Artenimol,,
ENSG00000144029.12,ENSG00000144029,MRPS5,0.412635779,0.673842044,0.384780174,0.179285118,mitochondrial ribosomal protein S5,"The human gene MRPS5 encodes a protein that is a component of the small 28S subunit of the mitochondrial ribosome. Mitochondrial ribosomes are responsible for protein synthesis within the mitochondrion, and are composed of a small 28S subunit and a large 39S subunit. Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and have a protein to rRNA composition of approximately 75%, which is the reverse of prokaryotic ribosomes. The proteins comprising the mitoribosome differ greatly in sequence and biochemical properties among different species, making them difficult to recognize by sequence homology. Pseudogenes corresponding to MRPS5 are found on chromosomes 4q, 5q, and 18q.","There is limited information available on the disease implications of MRPS5 mutations. However, mutations in other mitochondrial ribosomal proteins have been associated with a range of mitochondrial diseases, including Leigh syndrome, mitochondrial encephalomyopathy, and mitochondrial myopathy. Targeted drug discovery efforts for mitochondrial diseases have focused on improving mitochondrial function and reducing oxidative stress. Some examples of successful drugs on the market for mitochondrial diseases include idebenone, which is used to treat Leber's hereditary optic neuropathy, and elamipretide, which is being developed for the treatment of primary mitochondrial myopathy. However, there are currently no drugs specifically targeting MRPS5 or the mitochondrial ribosome.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Ribosomal proteins; Predicted intracellular proteins,Mitochondria (Supported),,,
ENSG00000108298.12,ENSG00000108298,RPL19,0.427107378,0.56712756,0.509755549,0.204439024,ribosomal protein L19,"RPL19 is a gene that encodes a ribosomal protein, specifically a component of the 60S subunit. Ribosomes are organelles that catalyze protein synthesis and are composed of RNA and proteins. RPL19 belongs to the L19E family of ribosomal proteins and is located in the cytoplasm. This gene has multiple processed pseudogenes dispersed throughout the genome, which is typical for genes encoding ribosomal proteins.","There is limited information on the disease implications of RPL19 mutations. However, some studies have suggested that alterations in ribosomal proteins, including RPL19, may be associated with various types of cancer. For example, RPL19 has been found to be overexpressed in hepatocellular carcinoma and lung cancer. Targeted drug discovery efforts for RPL19 have been limited, but some studies have explored the potential of targeting ribosomal proteins for cancer therapy. One example is the drug CX-5461, which targets RNA polymerase I and disrupts ribosome biogenesis, leading to cancer cell death. Another example is the drug omacetaxine mepesuccinate, which inhibits protein synthesis by targeting the ribosome and has been approved for the treatment of chronic myeloid leukemia. However, it is unclear whether these drugs specifically target RPL19 or other ribosomal proteins.",GO:0002181 cytoplasmic translation;GO:0006412 translation;GO:0010467 gene expression,,Ribosomal proteins; Predicted intracellular proteins,Cytosol;Nucleoli (Enhanced),(S)-3-phenyllactic acid; Anisomycin; Puromycin,,
ENSG00000126749.16,ENSG00000126749,EMG1,0.430335661,0.79437957,0.464204696,0.032422716,EMG1 N1-specific pseudouridine methyltransferase,"EMG1 is a gene that encodes a protein responsible for methylating pseudouridine in 18S rRNA, an essential process in the biogenesis of the ribosomal 40S subunit. The related protein in yeast is a component of the small subunit processome. Mutations in this gene have been associated with Bowen-Conradi syndrome. Alternative splicing results in multiple transcript variants.","Mutations in the EMG1 gene have been associated with Bowen-Conradi syndrome, a rare genetic disorder characterized by severe growth retardation, microcephaly, and facial dysmorphism. There are currently no targeted drug discovery efforts specifically for EMG1 mutations, but research is ongoing to better understand the molecular mechanisms underlying the disease. There are also no drugs on the market that specifically target EMG1 mutations, but some treatments may be used to manage symptoms, such as growth hormone therapy for growth retardation. However, research into the role of EMG1 in ribosome biogenesis may have implications for the development of new antibiotics that target the ribosome, as well as for the treatment of other diseases related to ribosome dysfunction.",GO:0017126 nucleologenesis;GO:0070475 rRNA base methylation;GO:0007000 nucleolus organization,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Other congenital disorders:Ribosomopathies,Nucleoli rim (Supported); Additional: Mitotic chromosome;Nucleoplasm,,,
ENSG00000105197.11,ENSG00000105197,TIMM50,0.430680542,0.637452831,0.513098313,0.141490484,translocase of inner mitochondrial membrane 50,TIMM50 is a gene that encodes a subunit of the TIM23 inner mitochondrial membrane translocase complex. This protein acts as a receptor subunit that recognizes the mitochondrial targeting signal on protein cargo that is destined for the mitochondrial inner membrane and matrix. It also plays a role in maintaining the membrane permeability barrier. Knockdown of this gene in human cells results in the release of cytochrome c and apoptosis.,"Mutations in the TIMM50 gene have been associated with several mitochondrial disorders, including Leigh syndrome, a severe neurological disorder, and mitochondrial encephalomyopathy. These disorders are characterized by defects in mitochondrial function, leading to impaired energy production and cellular damage. Targeted drug discovery efforts for these disorders have focused on developing therapies that can improve mitochondrial function and reduce oxidative stress. One example is idebenone, a synthetic analog of coenzyme Q10, which has been shown to improve respiratory chain function and reduce oxidative stress in patients with mitochondrial disorders. Another example is elamipretide, a peptide that targets the inner mitochondrial membrane and has shown promise in preclinical studies for the treatment of mitochondrial diseases. However, more research is needed to fully understand the role of TIMM50 in these disorders and to develop effective therapies.",GO:0030150 protein import into mitochondrial matrix;GO:0001836 release of cytochrome c from mitochondria;GO:0044743 protein transmembrane import into intracellular organelle,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of amino acid metabolism; Predicted intracellular proteins,Mitochondria;Nucleoplasm (Supported),,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000071462.12,ENSG00000071462,BUD23,0.436035077,0.7297784,0.422255352,0.156071479,BUD23 rRNA methyltransferase and ribosome maturation factor,"BUD23 is a gene that encodes a protein with a nuclear localization signal and an S-adenosyl-L-methionine binding motif, indicating that it may be involved in DNA methylation. It is also a ribosome maturation factor and rRNA methyltransferase. The gene is deleted in Williams syndrome, a developmental disorder caused by the deletion of contiguous genes at 7q11.23. There are multiple transcript variants of the gene due to alternative splicing.","There is limited information available on the disease implications of BUD23. However, its deletion in Williams syndrome suggests that it may play a role in the development of this disorder. As for targeted drug discovery efforts, there are currently no known drugs that specifically target BUD23. However, its involvement in ribosome maturation and rRNA methylation suggests that it may be a potential target for antibiotics. In fact, a few successful antibiotics on the market, such as erythromycin and azithromycin, target the ribosome and inhibit protein synthesis. Further research on the role of BUD23 in ribosome maturation and rRNA methylation may lead to the development of new antibiotics with improved efficacy and reduced side effects.",GO:0070476 rRNA (guanine-N7)-methylation;GO:0036265 RNA (guanine-N7)-methylation;GO:0070475 rRNA base methylation,,Disease related genes; Human disease related genes:Other congenital disorders:Chromosomal abnormalities; Predicted intracellular proteins,Nucleoli;Nucleoplasm (Supported),,,
ENSG00000105677.12,ENSG00000105677,TMEM147,0.440206427,0.738783906,0.555176626,0.026658748,transmembrane protein 147,"TMEM147 is a human gene that encodes for a transmembrane protein known as transmembrane protein 147. This protein is involved in ribosome binding activity and is located in the endoplasmic reticulum membrane. It is also a part of a protein-containing complex. The function of TMEM147 is not fully understood, but it is believed to play a role in protein synthesis and folding. This gene is of interest to researchers studying the molecular mechanisms of protein synthesis and the endoplasmic reticulum.","There is limited information available on the disease implications of TMEM147. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for TMEM147 are currently underway, with a focus on developing drugs that can modulate the activity of this protein. While there are no drugs currently on the market that specifically target TMEM147, there are several drugs that have been developed to target other proteins involved in protein synthesis and folding, such as chaperones and proteasome inhibitors. Examples of successful drugs in this category include bortezomib, which is used to treat multiple myeloma, and tafamidis, which is used to treat transthyretin amyloidosis.",GO:0036228 protein localization to nuclear inner membrane;GO:0160063 multi-pass transmembrane protein insertion into ER membrane;GO:0090435 protein localization to nuclear envelope,,Disease related genes; Transporters:Accessory Factors Involved in Transport; Potential drug targets,,,,
ENSG00000196531.14,ENSG00000196531,NACA,0.450918524,0.872319828,0.418292395,0.062143349,nascent polypeptide associated complex subunit alpha,"The NACA gene encodes a protein that forms the nascent polypeptide-associated complex (NAC) with basic transcription factor 3 (BTF3). The NAC complex binds to newly synthesized proteins that lack a signal peptide motif, preventing mistranslocation to the endoplasmic reticulum. NACA is also an IgE autoantigen in atopic dermatitis patients. Alternative splicing results in multiple transcript variants, but the full length nature of some of these variants, including those encoding very large proteins, has not been determined. There are multiple pseudogenes of this gene on different chromosomes.","There is limited information on the disease implications of the NACA gene. However, it has been identified as an IgE autoantigen in atopic dermatitis patients, suggesting a potential role in the development of this skin condition. There are currently no targeted drug discovery efforts specifically focused on NACA. However, drugs that target protein synthesis and folding pathways, such as chaperones and proteasome inhibitors, may indirectly affect the function of NACA and its associated complex. Examples of successful drugs in this category include bortezomib, which is used to treat multiple myeloma, and tafamidis, which is used to treat transthyretin amyloidosis. Further research is needed to fully understand the role of NACA in disease and to identify potential drug targets.",GO:1905551 negative regulation of protein localization to endoplasmic reticulum;GO:1905550 regulation of protein localization to endoplasmic reticulum;GO:0048633 positive regulation of skeletal muscle tissue growth,,Predicted intracellular proteins,Cytosol (Approved),,(M71)PID ILK PATHWAY,
ENSG00000156928.5,ENSG00000156928,MALSU1,0.455728183,0.601723598,0.389879204,0.375581746,mitochondrial assembly of ribosomal large subunit 1,MALSU1 is a human gene that is predicted to have ribosomal large subunit binding activity. It is involved in negative regulation of mitochondrial translation and ribosomal large subunit biogenesis. MALSU1 is located in both the cytosol and mitochondrion and colocalizes with the mitochondrial large ribosomal subunit.,"There is limited information available on the disease implications of MALSU1. However, recent studies have suggested that mutations in MALSU1 may be associated with mitochondrial disorders, such as Leigh syndrome and mitochondrial encephalomyopathy. Targeted drug discovery efforts for MALSU1 are currently underway, with a focus on identifying small molecules that can modulate its activity and potentially treat mitochondrial disorders. However, there are currently no drugs on the market that specifically target MALSU1. Some drugs that have been approved for the treatment of mitochondrial disorders, such as coenzyme Q10 and idebenone, work by improving mitochondrial function and reducing oxidative stress.",GO:0070130 negative regulation of mitochondrial translation;GO:0090071 negative regulation of ribosome biogenesis;GO:0090069 regulation of ribosome biogenesis,,Predicted intracellular proteins,Mitochondria (Enhanced),,,
ENSG00000116586.12,ENSG00000116586,LAMTOR2,0.470498943,0.676524763,0.510749645,0.224222423,"late endosomal/lysosomal adaptor, MAPK and MTOR activator 2","LAMTOR2 is a human gene that encodes a protein involved in endosomal biogenesis. It is highly conserved with a mouse protein that interacts with MAPK scaffold protein 1, a component of the mitogen-activated protein kinase pathway. Multiple transcript variants encoding different isoforms have been found for this gene. A mutation in this gene has been associated with a primary immunodeficiency syndrome, indicating a potential role for this protein in the immune system. The protein is associated with the cytoplasmic face of late endosomes and lysosomes, suggesting a role in the regulation of these organelles.","A mutation in the LAMTOR2 gene has been associated with a primary immunodeficiency syndrome called immunodeficiency 38 (IMD38). This syndrome is characterized by recurrent bacterial and viral infections, impaired antibody production, and decreased T-cell function. Targeted drug discovery efforts for LAMTOR2 are currently limited, as the exact role of the protein in the immune system is not fully understood. However, there is potential for the development of drugs that target the protein's interaction with MAPK scaffold protein 1, which could have implications for the treatment of diseases involving dysregulated MAPK signaling, such as cancer. Currently, there are no drugs on the market specifically targeting LAMTOR2. However, there are drugs targeting the MAPK pathway, such as BRAF inhibitors for melanoma, that indirectly affect LAMTOR2 function.",GO:0010761 fibroblast migration;GO:0038202 TORC1 signaling;GO:0031929 TOR signaling,,Disease related genes; Human disease related genes:Immune system diseases:Primary immunodeficiency; Predicted intracellular proteins,Nucleoplasm;Vesicles (Approved),,,
ENSG00000125691.14,ENSG00000125691,RPL23,0.476100646,0.673362133,0.525708917,0.229230889,ribosomal protein L23,"RPL23 is a gene that encodes a ribosomal protein, specifically a component of the 60S subunit. Ribosomes are organelles that catalyze protein synthesis and are composed of RNA and proteins. RPL23 belongs to the L14P family of ribosomal proteins and is located in the cytoplasm. Although it has been referred to as rpL17 due to its amino acid identity with ribosomal protein L17 from Saccharomyces cerevisiae, its official symbol is RPL23. Like other genes encoding ribosomal proteins, there are multiple processed pseudogenes of RPL23 dispersed throughout the genome.","There is limited information on the disease implications of RPL23 mutations. However, recent studies have suggested that alterations in ribosomal proteins, including RPL23, may contribute to the development of various cancers. Targeted drug discovery efforts have focused on developing inhibitors of ribosome biogenesis as a potential therapeutic strategy for cancer treatment. One example is CX-5461, a small molecule inhibitor of RNA polymerase I transcription, which has shown promising results in preclinical studies and is currently in clinical trials for the treatment of hematological malignancies. Another example is the drug TAK-659, which targets the ribosomal protein S6 kinase (S6K) and is being evaluated in clinical trials for the treatment of lymphoma and other hematological malignancies. However, there are currently no drugs on the market specifically targeting RPL23 or other ribosomal proteins.",GO:0006610 ribosomal protein import into nucleus;GO:0072717 cellular response to actinomycin D;GO:0072716 response to actinomycin D,,Ribosomal proteins; Predicted intracellular proteins,Cytosol (Supported),(S)-3-phenyllactic acid; Anisomycin; Puromycin,(M261)PID P53 REGULATION PATHWAY,
ENSG00000127184.13,ENSG00000127184,COX7C,0.479468387,0.729683947,0.512949387,0.195771828,cytochrome c oxidase subunit 7C,"COX7C is a gene that encodes for subunit VIIc of cytochrome c oxidase (COX), which is the final component of the mitochondrial respiratory chain. COX catalyzes the transfer of electrons from reduced cytochrome c to oxygen. The complex is made up of three catalytic subunits encoded by mitochondrial genes and multiple structural subunits encoded by nuclear genes. The mitochondrially-encoded subunits are responsible for electron transfer, while the nuclear-encoded subunits may regulate and assemble the complex. COX7C is found in all tissues and shares a high degree of amino acid sequence identity with mouse and bovine COX VIIc. A pseudogene, COX7CP1, has also been identified on chromosome 13.","Mutations in COX7C have been associated with mitochondrial diseases such as Leigh syndrome, a severe neurological disorder that typically presents in infancy or early childhood. However, the exact role of COX7C mutations in the development of mitochondrial disease is not fully understood. 

There are currently no targeted drug discovery efforts specifically for COX7C mutations. However, drugs that target the mitochondrial respiratory chain, including COX inhibitors, have been developed for the treatment of various diseases such as cancer and neurodegenerative disorders. For example, the COX inhibitor celecoxib is used as an anti-inflammatory drug for the treatment of arthritis, and has also been shown to have potential as a cancer therapy. Another COX inhibitor, elamipretide, is currently in clinical trials for the treatment of mitochondrial diseases and heart failure.

In summary, while mutations in COX7C have been linked to mitochondrial disease, there are currently no targeted drug discovery efforts for this gene specifically. However, drugs that target the mitochondrial respiratory chain, including COX inhibitors, have been developed for the treatment of various diseases.","GO:0006123 mitochondrial electron transport, cytochrome c to oxygen;GO:0019646 aerobic electron transport chain;GO:0042773 ATP synthesis coupled electron transport",,Transporters:Primary Active Transporters,,Cholic Acid; N-Formylmethionine,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000184281.15,ENSG00000184281,TSSC4,0.479978187,0.687215614,0.58241882,0.170300128,tumor suppressing subtransferable candidate 4,"TSSC4 (tumor suppressing subtransferable candidate 4) is a gene located in the imprinted gene domain of 11p15.5, which is an important tumor-suppressor gene region. This gene, along with several other imprinted genes, has been associated with various cancers and syndromes, including Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer. TSSC4 is unique in that it escapes imprinting, and may play a role in malignancies and diseases that involve this region. The gene has several transcript variants encoding two different isoforms.","There is limited information available on targeted drug discovery efforts for TSSC4, as it is a relatively understudied gene. However, its association with various cancers and syndromes suggests that it may be a potential target for cancer therapies. Some studies have shown that TSSC4 expression is downregulated in certain cancers, such as lung and ovarian cancer, indicating that it may have a tumor-suppressive role. 

Currently, there are no drugs on the market that specifically target TSSC4. However, there are drugs that target other genes in the 11p15.5 imprinted gene domain, such as insulin-like growth factor 2 (IGF2), which is overexpressed in many cancers and has been implicated in the development of Beckwith-Wiedemann syndrome. One example is MEDI-573, a monoclonal antibody that targets IGF2 and is being investigated in clinical trials for the treatment of solid tumors. 

In summary, while there is limited information on targeted drug discovery efforts for TSSC4, its association with various cancers and syndromes suggests that it may be a potential target for cancer therapies. Further research is needed to fully understand the role of TSSC4 in disease and to develop targeted therapies.",GO:0000244 spliceosomal tri-snRNP complex assembly;GO:0000387 spliceosomal snRNP assembly;GO:0022618 protein-RNA complex assembly,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000105669.14,ENSG00000105669,COPE,0.481218232,0.607383099,0.59444697,0.241824626,COPI coat complex subunit epsilon,"The COPE gene encodes the epsilon subunit of the coatomer protein complex, which is a cytosolic protein complex that binds to dilysine motifs and associates with Golgi non-clathrin-coated vesicles. This complex is essential for the retrograde Golgi-to-ER transport of dilysine-tagged proteins and is required for budding from Golgi membranes. The coatomer complex is made up of at least seven subunits, including alpha, beta, beta', gamma, delta, epsilon, and zeta. Different isoforms of the COPE gene have been identified through alternative splicing.","There is limited information available on the disease implications of the COPE gene. However, some studies have suggested that mutations in the COPE gene may be associated with certain neurological disorders, such as Alzheimer's disease and Parkinson's disease. Targeted drug discovery efforts for COPE have been limited, but some studies have explored the potential of COPE inhibitors as a therapeutic strategy for cancer treatment. One example of a successful drug targeting the coatomer complex is Brefeldin A, which inhibits COPE and other coatomer subunits, and is used as a research tool to study Golgi trafficking. However, Brefeldin A is not suitable for clinical use due to its toxicity. Overall, further research is needed to fully understand the disease implications of COPE and to develop targeted therapies for related disorders.","GO:0099612 protein localization to axon;GO:0006891 intra-Golgi vesicle-mediated transport;GO:0006890 retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum",,Predicted intracellular proteins,Golgi apparatus (Enhanced),,,(M5910)HALLMARK PROTEIN SECRETION
ENSG00000106355.10,ENSG00000106355,LSM5,0.487384204,0.703129606,0.450643464,0.308379543,"LSM5 homolog, U6 small nuclear RNA and mRNA degradation associated","LSM5 is a human gene that encodes for a protein homologous to the Sm-like (LSm) protein family. LSm proteins contain a sequence motif called the Sm motif, which is important for pre-mRNA splicing. LSM5 is specifically associated with U6 small nuclear RNA and mRNA degradation. It is thought to form a stable heteromer present in tri-snRNP particles, which are important for pre-mRNA splicing. The function of LSM5 in mRNA degradation is not fully understood, but it is believed to play a role in the degradation of mRNAs that are not properly processed or have errors. Overall, LSM5 is an important gene involved in RNA processing and degradation.","There is limited information available on the disease implications of LSM5. However, studies have shown that mutations in LSM5 may be associated with certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for LSM5 are also limited, as the function of the protein is not fully understood. However, some studies have suggested that targeting LSM5 could be a potential strategy for cancer therapy. Currently, there are no drugs on the market that specifically target LSM5. However, there are drugs that target other proteins involved in pre-mRNA splicing, such as spliceosome inhibitors, which have shown promise in the treatment of certain types of cancer. Further research is needed to fully understand the role of LSM5 in disease and to develop targeted therapies.",GO:0006402 mRNA catabolic process;GO:0006401 RNA catabolic process;GO:0141188 nucleic acid catabolic process,,Predicted intracellular proteins,,,,
ENSG00000183605.17,ENSG00000183605,SFXN4,0.490216563,0.805272521,0.560241441,0.105135725,sideroflexin 4,"SFXN4, also known as sideroflexin 4, is a gene that encodes a transmembrane protein found in the inner mitochondrial membrane. This protein is essential for maintaining mitochondrial respiratory homeostasis and erythropoiesis. Mutations in SFXN4 have been linked to mitochondriopathy and macrocytic anemia. There are multiple variants of the SFXN4 gene due to alternative splicing.","Mutations in the SFXN4 gene have been linked to several diseases, including mitochondrial disorders and macrocytic anemia. Mitochondrial disorders are a group of genetic diseases that affect the function of mitochondria, leading to a wide range of symptoms, including muscle weakness, neurological problems, and developmental delays. Macrocytic anemia is a type of anemia characterized by abnormally large red blood cells, which can lead to fatigue, weakness, and shortness of breath.

There are currently no targeted drug discovery efforts specifically for SFXN4, but there are drugs on the market that can help manage the symptoms of mitochondrial disorders and macrocytic anemia. For example, erythropoietin (EPO) is a hormone that stimulates the production of red blood cells and is used to treat anemia. Coenzyme Q10 (CoQ10) is a dietary supplement that can help improve mitochondrial function and is sometimes used to treat mitochondrial disorders. Additionally, there are several drugs that can help manage the symptoms of mitochondrial disorders, such as anticonvulsants for seizures and physical therapy for muscle weakness.",GO:1990542 mitochondrial transmembrane transport;GO:0006865 amino acid transport;GO:0006839 mitochondrial transport,,Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; Transporters:Electrochemical Potential-driven transporters; Potential drug targets; Disease related genes,Mitochondria;Nucleoplasm (Approved); Additional: Vesicles,,,
ENSG00000170889.14,ENSG00000170889,RPS9,0.491055612,0.850552235,0.569755708,0.052858892,ribosomal protein S9,"RPS9 is a gene that encodes a ribosomal protein that is a component of the 40S subunit of ribosomes, which are organelles that catalyze protein synthesis. The protein belongs to the S4P family of ribosomal proteins and is located in the cytoplasm. While variable expression of this gene has been observed in colorectal cancers compared to adjacent normal tissues, no correlation between the level of expression and the severity of the disease has been found. Multiple processed pseudogenes derived from this gene are dispersed through the genome, which is typical for genes encoding ribosomal proteins.","There is limited information available on the disease implications of RPS9. However, some studies have suggested that alterations in ribosomal proteins, including RPS9, may play a role in the development and progression of certain cancers. Targeted drug discovery efforts for RPS9 have not been reported, likely due to the lack of understanding of its specific role in disease. Currently, there are no drugs on the market that specifically target RPS9. However, there are drugs that target other ribosomal proteins, such as the macrolide antibiotics erythromycin and azithromycin, which bind to the 50S subunit of ribosomes and inhibit protein synthesis. Additionally, the drug tigecycline, which targets the 30S subunit of ribosomes, has been approved for the treatment of certain bacterial infections.",GO:0042274 ribosomal small subunit biogenesis;GO:0002181 cytoplasmic translation;GO:0042254 ribosome biogenesis,,Ribosomal proteins; Predicted intracellular proteins,,Artenimol,,(M5950)HALLMARK ALLOGRAFT REJECTION
ENSG00000185262.9,ENSG00000185262,UBALD2,0.491397528,0.744531475,0.609919249,0.11974186,UBA like domain containing 2,"UBALD2 is a human gene that encodes for a protein containing a UBA-like domain. The function of this gene is not well understood, but it has been suggested to play a role in protein degradation and cellular stress response. UBALD2 has been found to be expressed in various tissues, including the brain, heart, and liver. Mutations in this gene have been associated with intellectual disability and developmental delay. However, further research is needed to fully understand the function and implications of UBALD2 in human health and disease.","Unfortunately, there is currently very limited information available on the disease implications and targeted drug discovery efforts for UBALD2. As mentioned earlier, mutations in this gene have been associated with intellectual disability and developmental delay, but the exact mechanisms by which these mutations lead to disease are not well understood. Additionally, there are no known drugs on the market that specifically target UBALD2. However, as research on this gene continues, it is possible that new insights into its function and disease implications may lead to the development of targeted therapies in the future.",,,Predicted intracellular proteins,,,,
ENSG00000232472.1,ENSG00000232472,EEF1B2P3,0.492774135,0.946732534,0.528933641,0.002656229,eukaryotic translation elongation factor 1 beta 2 pseudogene 3,,,,,,,,,
ENSG00000111639.8,ENSG00000111639,MRPL51,0.496751004,0.787772775,0.388386245,0.314093993,mitochondrial ribosomal protein L51,"The human gene MRPL51 encodes a protein that is a component of the large 39S subunit of mitochondrial ribosomes. Mitochondrial ribosomes are responsible for protein synthesis within the mitochondrion, and are composed of a small 28S subunit and a large 39S subunit. Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and have a protein to rRNA composition of approximately 75%, which is the reverse of prokaryotic ribosomes. The proteins comprising the mitoribosome differ greatly in sequence and biochemical properties among different species, making them difficult to recognize by sequence homology. Pseudogenes corresponding to MRPL51 are found on chromosomes 4p and 21q.","There is limited information available on the disease implications of MRPL51. However, mutations in other mitochondrial ribosomal proteins have been associated with a range of mitochondrial disorders, including Leigh syndrome, mitochondrial encephalomyopathy, and mitochondrial myopathy. Targeted drug discovery efforts for mitochondrial disorders have focused on improving mitochondrial function and reducing oxidative stress. Some examples of successful drugs on the market for mitochondrial disorders include idebenone, which is used to treat Leber's hereditary optic neuropathy, and elamipretide, which is being developed for the treatment of primary mitochondrial myopathy. However, there are currently no drugs specifically targeting MRPL51 or mitochondrial ribosomal proteins in general.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Ribosomal proteins; Predicted intracellular proteins,Mitochondria (Supported),,,
ENSG00000131469.15,ENSG00000131469,RPL27,0.503521127,0.731396982,0.554129408,0.225036992,ribosomal protein L27,"RPL27 is a gene that encodes a ribosomal protein L27, which is a component of the 60S subunit of ribosomes. Ribosomes are organelles that catalyze protein synthesis and are composed of a small 40S subunit and a large 60S subunit. Mutations in this gene have been associated with Diamond-Blackfan anemia (DBA), a rare genetic disorder that affects the production of red blood cells. The gene has multiple processed pseudogenes dispersed throughout the genome, which is typical for genes encoding ribosomal proteins.","Diamond-Blackfan anemia (DBA) is a rare genetic disorder characterized by a failure of the bone marrow to produce red blood cells, leading to anemia. Mutations in RPL27 have been identified in a small number of DBA patients. While there are currently no targeted drugs available for DBA, treatment options include blood transfusions and corticosteroids to stimulate red blood cell production. However, these treatments can have significant side effects and are not always effective. Recent research has focused on identifying new therapeutic targets and developing novel treatments for DBA. One promising approach is the use of gene therapy to correct the underlying genetic defect. Another potential strategy is the use of small molecules to modulate the activity of ribosomal proteins, including RPL27. While there are currently no drugs on the market specifically targeting RPL27 or DBA, several drugs that target ribosomal proteins have been approved for the treatment of cancer, including the mTOR inhibitor everolimus and the protein synthesis inhibitor omacetaxine mepesuccinate.",GO:1904044 response to aldosterone;GO:0051385 response to mineralocorticoid;GO:0002181 cytoplasmic translation,,Predicted intracellular proteins; Ribosomal proteins; Human disease related genes:Other congenital disorders:Ribosomopathies; Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases; Cancer-related genes:Candidate cancer biomarkers,Nucleoli (Enhanced); Additional: Nucleoplasm,,,
ENSG00000137818.12,ENSG00000137818,RPLP1,0.506389771,0.759603568,0.758587237,0.000978507,ribosomal protein lateral stalk subunit P1,"RPLP1 is a gene that encodes a ribosomal phosphoprotein that is a component of the 60S subunit of ribosomes. It belongs to the L12P family of ribosomal proteins and plays an important role in the elongation step of protein synthesis. Unlike most ribosomal proteins, RPLP1 is acidic and its C-terminal end is nearly identical to the C-terminal ends of the ribosomal phosphoproteins P0 and P2. RPLP1 can interact with P0 and P2 to form a pentameric complex consisting of P1 and P2 dimers, and a P0 monomer. The protein is located in the cytoplasm and there are multiple processed pseudogenes of this gene dispersed through the genome.","There is limited information on the disease implications of RPLP1. However, recent studies have suggested that RPLP1 may play a role in cancer development and progression. For example, RPLP1 has been found to be overexpressed in several types of cancer, including breast, lung, and gastric cancer. Targeted drug discovery efforts for RPLP1 are still in the early stages, but there is potential for the development of drugs that target RPLP1 to treat cancer. Currently, there are no drugs on the market that specifically target RPLP1. However, there are several drugs that target ribosomes, including antibiotics such as erythromycin and tetracycline, which inhibit bacterial protein synthesis by binding to the ribosome. Additionally, there are several drugs that target the ribosome in cancer cells, such as the chemotherapeutic agent doxorubicin, which binds to the ribosome and inhibits protein synthesis in cancer cells.",GO:0006414 translational elongation;GO:0002181 cytoplasmic translation;GO:0006412 translation,,Ribosomal proteins; Predicted intracellular proteins,Cytosol;Endoplasmic reticulum (Supported),,,
ENSG00000100575.14,ENSG00000100575,TIMM9,0.510460967,0.77337392,0.477501076,0.280507906,translocase of inner mitochondrial membrane 9,TIMM9 is a human gene that encodes a protein called translocase of inner mitochondrial membrane 9. This protein is part of a family of proteins that are found in the intermembrane space of mitochondria and are involved in the import and insertion of hydrophobic membrane proteins into the inner membrane of the mitochondria. TIMM9 is an evolutionarily conserved protein that is organized in heterooligomeric complexes. Mutations in this gene have been associated with various mitochondrial disorders.,"Mutations in the TIMM9 gene have been associated with various mitochondrial disorders, including Leigh syndrome, a severe neurological disorder that typically presents in infancy or early childhood. There are currently no targeted drug discovery efforts specifically for TIMM9, but there are drugs on the market that target mitochondrial dysfunction more broadly. For example, idebenone is a synthetic analog of coenzyme Q10 that has been shown to improve respiratory function in patients with mitochondrial disorders, including Leigh syndrome. Another drug, elamipretide, is a mitochondrial-targeted peptide that has shown promise in preclinical studies for the treatment of mitochondrial diseases. While there are no drugs currently approved specifically for TIMM9-related disorders, these existing treatments may provide some benefit to patients with mitochondrial dysfunction.",GO:0045039 protein insertion into mitochondrial inner membrane;GO:0090151 establishment of protein localization to mitochondrial membrane;GO:0007007 inner mitochondrial membrane organization,,Predicted intracellular proteins,Mitochondria (Supported),,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000242485.6,ENSG00000242485,MRPL20,0.510536578,0.755049978,0.573996308,0.202563449,mitochondrial ribosomal protein L20,"The human gene MRPL20 encodes a protein that is a component of the large 39S subunit of mitochondrial ribosomes, which are responsible for protein synthesis within the mitochondrion. Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and have a different composition compared to prokaryotic ribosomes, with an estimated 75% protein to rRNA ratio. The proteins comprising the mitoribosome differ greatly in sequence and biochemical properties among different species, making them difficult to recognize by sequence homology. Alternative splicing of MRPL20 results in multiple transcript variants encoding different isoforms. A pseudogene corresponding to this gene is also found on chromosome 21q.","There is limited information available on the disease implications of MRPL20. However, mutations in other mitochondrial ribosomal proteins have been associated with a range of mitochondrial disorders, including Leigh syndrome, mitochondrial encephalomyopathy, and mitochondrial myopathy. Targeted drug discovery efforts for mitochondrial disorders have focused on improving mitochondrial function and reducing oxidative stress. Some examples of successful drugs on the market for mitochondrial disorders include idebenone, which is used to treat Leber's hereditary optic neuropathy, and elamipretide, which is being developed for the treatment of primary mitochondrial myopathy. However, there are currently no drugs specifically targeting MRPL20 or mitochondrial ribosomal proteins in general.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Ribosomal proteins; Predicted intracellular proteins,Mitochondria (Supported),,,
ENSG00000129084.18,ENSG00000129084,PSMA1,0.515852872,0.819337057,0.603049443,0.125172115,proteasome 20S subunit alpha 1,"PSMA1 is a gene that encodes for a subunit of the proteasome, a protein complex that breaks down peptides in a non-lysosomal pathway. The proteasome is composed of four rings of 28 subunits, with two rings made up of seven alpha subunits and two rings made up of seven beta subunits. PSMA1 is a member of the peptidase T1A family and is a 20S core alpha subunit. Alternative splicing of the gene results in multiple transcript variants that encode different isoforms. The proteasome is essential for the processing of class I MHC peptides, and a modified version of the proteasome, called the immunoproteasome, is responsible for this function.","PSMA1 has been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In cancer, PSMA1 has been found to be overexpressed in several types of tumors, including breast, lung, and prostate cancer. Targeting PSMA1 has been explored as a potential therapeutic strategy for cancer treatment. For example, bortezomib, a proteasome inhibitor, has been approved for the treatment of multiple myeloma and mantle cell lymphoma. Other proteasome inhibitors, such as carfilzomib and ixazomib, are also being investigated for their potential in cancer therapy. In addition, PSMA1 has been suggested as a potential target for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus. However, more research is needed to fully understand the role of PSMA1 in these diseases and to develop effective therapies targeting this gene.",GO:0002862 negative regulation of inflammatory response to antigenic stimulus;GO:0002861 regulation of inflammatory response to antigenic stimulus;GO:0050728 negative regulation of inflammatory response,,Peptidases:Threonine-type peptidases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Centrosome;Nuclear bodies,"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,(M5926)HALLMARK MYC TARGETS V1
ENSG00000142534.7,ENSG00000142534,RPS11,0.516731756,0.766184087,0.645117875,0.138893307,ribosomal protein S11,"RPS11 is a gene that encodes a ribosomal protein S11, which is a component of the small 40S subunit of ribosomes. Ribosomes are organelles that catalyze protein synthesis and are composed of four RNA species and approximately 80 structurally distinct proteins. RPS11 belongs to the S17P family of ribosomal proteins and is co-transcribed with the small nucleolar RNA gene U35B, which is located in the third intron. This gene has multiple processed pseudogenes dispersed throughout the genome, which is typical for genes encoding ribosomal proteins.","RPS11 has been implicated in various diseases, including cancer and Diamond-Blackfan anemia (DBA). In cancer, RPS11 has been shown to play a role in tumor growth and progression, and its expression has been associated with poor prognosis in several types of cancer. In DBA, mutations in RPS11 have been identified as a cause of the disease, which is characterized by a failure of erythropoiesis and anemia. 

Targeted drug discovery efforts for RPS11 have focused on developing inhibitors that can selectively target cancer cells while sparing normal cells. One approach has been to target the interaction between RPS11 and MDM2, a protein that regulates the activity of the tumor suppressor protein p53. Inhibition of this interaction can lead to activation of p53 and induction of apoptosis in cancer cells. 

There are currently no drugs on the market that specifically target RPS11, but there are several drugs that indirectly affect its function. For example, the chemotherapy drug doxorubicin has been shown to inhibit ribosomal biogenesis by targeting RPS11, among other ribosomal proteins. Another example is the drug lenalidomide, which is used to treat DBA and other blood disorders. Lenalidomide has been shown to increase the expression of RPS11 and other ribosomal proteins, leading to improved erythropoiesis.",GO:0042274 ribosomal small subunit biogenesis;GO:0002181 cytoplasmic translation;GO:0042254 ribosome biogenesis,,Ribosomal proteins; Predicted intracellular proteins,Cytosol (Approved); Additional: Endoplasmic reticulum;Nucleoli,,,
ENSG00000116898.12,ENSG00000116898,MRPS15,0.53069838,0.766136043,0.59253909,0.233420005,mitochondrial ribosomal protein S15,"The human gene MRPS15 encodes a mitochondrial ribosomal protein S15, which is involved in protein synthesis within the mitochondrion. Mitochondrial ribosomes consist of a small 28S subunit and a large 39S subunit, with an estimated 75% protein to rRNA composition. The proteins comprising the mitoribosome differ greatly in sequence among different species, making recognition by sequence homology difficult. MRPS15 belongs to the ribosomal protein S15P family and is more than two times the size of its E. coli counterpart, with conserved 12S rRNA binding sites. The encoded protein is the least conserved among small subunit ribosomal proteins between human and mouse, and pseudogenes corresponding to this gene are found on chromosomes 15q and 19q.","There is limited information available on the disease implications of MRPS15. However, recent studies have suggested that mutations in mitochondrial ribosomal proteins, including MRPS15, may be associated with mitochondrial diseases such as Leigh syndrome and mitochondrial encephalomyopathy. Targeted drug discovery efforts for mitochondrial diseases have been challenging due to the complex nature of mitochondrial function and the difficulty in delivering drugs to the mitochondria. However, some promising approaches include the use of small molecules that can enhance mitochondrial function or target specific mitochondrial pathways. Examples of successful drugs on the market for mitochondrial diseases include idebenone, which is used to treat Leber's hereditary optic neuropathy, and elamipretide, which is being developed for the treatment of primary mitochondrial myopathy.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Ribosomal proteins; Predicted intracellular proteins,Mitochondria (Supported),,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000180992.7,ENSG00000180992,MRPL14,0.533876089,0.771622159,0.751734361,0.078271747,mitochondrial ribosomal protein L14,"The human gene MRPL14 encodes a protein that is a component of the 39S subunit of the mitochondrial ribosome. This gene is located in the nucleus of the cell and a non-functional copy of the gene, called a pseudogene, is found on chromosome 17. The mitochondrial ribosome is responsible for synthesizing proteins that are essential for the function of the mitochondria, which are organelles that produce energy for the cell. Mutations in genes that encode mitochondrial ribosomal proteins have been associated with a variety of mitochondrial diseases.","Mutations in MRPL14 have been associated with mitochondrial diseases such as Leigh syndrome, a severe neurological disorder that typically presents in infancy or early childhood. Targeted drug discovery efforts for mitochondrial diseases have focused on improving mitochondrial function and reducing oxidative stress. One example of a successful drug on the market is idebenone, which has been approved for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disease that causes vision loss. Idebenone is a synthetic analog of coenzyme Q10, which is involved in the electron transport chain of the mitochondria. Other potential drug targets for mitochondrial diseases include antioxidants, mitochondrial biogenesis activators, and compounds that improve mitochondrial protein synthesis.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Ribosomal proteins; Predicted intracellular proteins,Mitochondria (Supported),,,
ENSG00000213619.11,ENSG00000213619,NDUFS3,0.539563861,0.438257361,0.560865447,0.619568776,NADH:ubiquinone oxidoreductase core subunit S3,"The NDUFS3 gene encodes a protein that is a component of the mitochondrial NADH:ubiquinone oxidoreductase complex I. This protein is involved in the transfer of electrons during cellular respiration. Mutations in this gene have been linked to Leigh syndrome, a rare genetic disorder that affects the central nervous system and is caused by a deficiency in mitochondrial complex I. Symptoms of Leigh syndrome can include developmental delays, muscle weakness, seizures, and respiratory problems. Understanding the function of the NDUFS3 gene and its role in mitochondrial complex I may lead to new treatments for Leigh syndrome and other mitochondrial disorders.","There are currently no targeted drug discovery efforts specifically for the NDUFS3 gene. However, research into mitochondrial complex I and its role in various diseases, including Leigh syndrome, is ongoing. Some potential therapeutic approaches being explored include gene therapy, stem cell therapy, and the use of small molecules to target mitochondrial dysfunction.

There are currently no drugs on the market specifically targeting the NDUFS3 gene. However, there are some drugs that have been approved for the treatment of mitochondrial disorders, including Leigh syndrome. For example, dichloroacetate (DCA) has been shown to improve mitochondrial function and reduce lactic acidosis in patients with mitochondrial disorders. Another drug, idebenone, has been approved for the treatment of Friedreich's ataxia, a mitochondrial disorder that affects the nervous system. Idebenone is thought to improve mitochondrial function by acting as an electron carrier in the respiratory chain.","GO:0006120 mitochondrial electron transport, NADH to ubiquinone;GO:0021762 substantia nigra development;GO:0010257 NADH dehydrogenase complex assembly",,Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; Potential drug targets; Enzymes; Disease related genes; ENZYME proteins,Mitochondria (Supported); Additional: Nuclear bodies;Principal piece,NADH,,(M5905)HALLMARK ADIPOGENESIS; (M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000158792.16,ENSG00000158792,SPATA2L,0.54133077,0.710274431,0.661900079,0.251817801,spermatogenesis associated 2 like,"SPATA2L is a human gene that is predicted to be active in the cytoplasm. It is associated with spermatogenesis, the process of sperm cell development. The gene is similar to another gene called SPATA2, which is also involved in spermatogenesis. However, the exact function of SPATA2L is not yet fully understood.","There is limited information available on the disease implications of SPATA2L. However, mutations in the related gene SPATA2 have been associated with male infertility. Therefore, it is possible that mutations in SPATA2L may also contribute to infertility in men. Currently, there are no targeted drug discovery efforts or drugs on the market specifically targeting SPATA2L. However, there are drugs available for the treatment of male infertility, such as clomiphene citrate and gonadotropins. These drugs work by stimulating the production of hormones that are involved in sperm production. Additionally, assisted reproductive technologies, such as in vitro fertilization, can also be used to overcome male infertility.",,,Predicted intracellular proteins,Mitochondria;Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000149806.11,ENSG00000149806,FAU,0.543159684,0.889238408,0.710104886,0.030135758,FAU ubiquitin like and ribosomal protein S30 fusion,"The FAU gene encodes a fusion protein consisting of the ubiquitin-like protein fubi and ribosomal protein S30. It is proposed that the fusion protein is post-translationally processed to generate free fubi and free ribosomal protein S30. Fubi is a member of the ubiquitin family, and ribosomal protein S30 belongs to the S30E family of ribosomal proteins. Ribosomal protein S30 is a component of the 40S subunit of the cytoplasmic ribosome and displays antimicrobial activity. Pseudogenes derived from this gene are present in the genome. Ribosomal proteins S27a and L40 are synthesized as fusion proteins with ubiquitin, similar to ribosomal protein S30. The function of fubi is currently unknown.","There is limited information on the disease implications of the FAU gene. However, some studies have suggested that alterations in the expression of FAU may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for FAU are also limited, but some studies have explored the potential of targeting the ubiquitin-proteasome system, which is involved in the degradation of FAU, as a therapeutic strategy for cancer. Currently, there are no drugs on the market that specifically target FAU. However, there are several drugs that target the ubiquitin-proteasome system, such as bortezomib and carfilzomib, which are approved for the treatment of multiple myeloma.",GO:0000028 ribosomal small subunit assembly;GO:0002227 innate immune response in mucosa;GO:0002385 mucosal immune response,,Ribosomal proteins; Predicted intracellular proteins,Cytosol;Endoplasmic reticulum (Enhanced); Additional: Nucleoli,,,
ENSG00000178741.12,ENSG00000178741,COX5A,0.544603997,0.532534884,0.44588349,0.655393617,cytochrome c oxidase subunit 5A,"COX5A is a gene that encodes for the subunit Va of the cytochrome c oxidase enzyme complex, which is responsible for transferring electrons from cytochrome c to molecular oxygen in the mitochondrial respiratory chain. This complex is made up of 13 subunits, some of which are encoded by the mitochondria and others by the nucleus. The nuclear-encoded subunits are thought to play a role in the regulation and assembly of the complex. COX5A is located in the nucleus and its function is not fully understood. A pseudogene, COX5AP1, has also been identified on chromosome 14q22.","Mutations in COX5A have been associated with mitochondrial complex IV deficiency, a rare genetic disorder that affects the function of the cytochrome c oxidase enzyme complex. This can lead to a wide range of symptoms, including muscle weakness, developmental delays, seizures, and respiratory problems. However, targeted drug discovery efforts for COX5A have been limited, as the function of this gene is not well understood and there are currently no drugs on the market that specifically target this gene. Some drugs that target the mitochondrial respiratory chain, such as idebenone and elamipretide, have shown promise in treating mitochondrial disorders, but their mechanisms of action are not specific to COX5A. Further research is needed to better understand the role of COX5A in mitochondrial function and to develop targeted therapies for mitochondrial complex IV deficiency.","GO:0006123 mitochondrial electron transport, cytochrome c to oxygen;GO:0019646 aerobic electron transport chain;GO:0042773 ATP synthesis coupled electron transport",,Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; Transporters:Primary Active Transporters; Potential drug targets; Disease related genes,,Cholic Acid; N-Formylmethionine,,(M5926)HALLMARK MYC TARGETS V1; (M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000205138.4,ENSG00000205138,SDHAF1,0.546054563,0.828678801,0.620414356,0.189070531,succinate dehydrogenase complex assembly factor 1,"SDHAF1 is a gene that encodes a protein essential for the assembly of the succinate dehydrogenase (SDH) complex, also known as complex II, in the mitochondria. Although it does not physically associate with the complex in vivo, mutations in this gene have been linked to SDH-defective infantile leukoencephalopathy, a condition characterized by mitochondrial complex II deficiency. The SDH complex is a crucial component of the mitochondrial respiratory chain, and is composed of four individual subunits. The function of SDHAF1 is to ensure proper assembly of the complex, which is necessary for the proper functioning of the respiratory chain and cellular energy production.","SDHAF1 mutations have been linked to SDH-defective infantile leukoencephalopathy, a rare and severe mitochondrial disorder that affects the brain and nervous system. Patients with this condition typically present with developmental delay, seizures, hypotonia, and leukodystrophy, a condition in which the white matter of the brain is damaged. There are currently no targeted drug discovery efforts for SDHAF1 mutations specifically, but there are ongoing efforts to develop treatments for mitochondrial disorders in general. One example is elamipretide, a mitochondrial-targeted peptide that has shown promise in preclinical studies for the treatment of mitochondrial diseases. Another example is idebenone, a synthetic analog of coenzyme Q10 that has been approved for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disorder that affects the eyes. However, there are currently no drugs on the market specifically targeting SDHAF1 mutations.",GO:0034552 respiratory chain complex II assembly;GO:0034553 mitochondrial respiratory chain complex II assembly;GO:0033108 mitochondrial respiratory chain complex assembly,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Supported),,,
ENSG00000140990.15,ENSG00000140990,NDUFB10,0.565032652,0.558617065,0.653023041,0.483457849,NADH:ubiquinone oxidoreductase subunit B10,NDUFB10 is a human gene that plays a crucial role in the assembly of mitochondrial respiratory chain complex I. It is located in the mitochondrial inner membrane and is a part of the complex I. Mutations in this gene have been linked to nuclear type mitochondrial complex I deficiency 35.,"Mutations in the NDUFB10 gene have been associated with mitochondrial complex I deficiency, which is a rare genetic disorder that affects the function of the mitochondria, leading to a wide range of symptoms such as muscle weakness, developmental delays, and neurological problems. There are currently no targeted drug discovery efforts specifically for NDUFB10 mutations, but there are ongoing efforts to develop treatments for mitochondrial diseases in general. One example is elamipretide, a small peptide that targets the inner mitochondrial membrane and has shown promising results in clinical trials for various mitochondrial diseases. Another example is idebenone, which has been approved in Europe for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disease that affects the eyes. While there are no drugs currently on the market specifically targeting NDUFB10 mutations, these examples demonstrate the potential for targeted treatments for mitochondrial diseases.","GO:0006120 mitochondrial electron transport, NADH to ubiquinone;GO:0010257 NADH dehydrogenase complex assembly;GO:0032981 mitochondrial respiratory chain complex I assembly",,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,,NADH,,
ENSG00000092841.19,ENSG00000092841,MYL6,0.56525613,0.898475193,0.517356102,0.279937093,myosin light chain 6,"MYL6 is a gene that encodes for a myosin alkali light chain, which is a component of the hexameric ATPase cellular motor protein called myosin. This protein is found in smooth muscle and non-muscle tissues and is involved in various cellular processes such as muscle contraction and cell movement. The gene has several pseudogenes and two transcript variants that encode for different isoforms of the protein.","MYL6 has been implicated in various diseases, including cancer, cardiovascular diseases, and neurological disorders. In cancer, MYL6 has been found to be upregulated in several types of tumors, including breast, lung, and colon cancer, and is associated with tumor progression and metastasis. In cardiovascular diseases, MYL6 has been linked to hypertension and atherosclerosis. In neurological disorders, MYL6 has been found to be involved in the regulation of synaptic plasticity and memory formation.

Targeted drug discovery efforts for MYL6 have focused on developing inhibitors that can selectively target the protein and its functions. One example is the development of small molecule inhibitors that can disrupt the interaction between MYL6 and its binding partners, such as calmodulin and actin. These inhibitors have shown promising results in preclinical studies for the treatment of cancer and cardiovascular diseases.

There are currently no drugs on the market that specifically target MYL6. However, there are drugs that indirectly affect MYL6 function, such as calcium channel blockers that can inhibit the interaction between MYL6 and calmodulin, and statins that can reduce the expression of MYL6 in smooth muscle cells. These drugs are commonly used for the treatment of hypertension and atherosclerosis.",GO:0030049 muscle filament sliding;GO:0033275 actin-myosin filament sliding;GO:0070252 actin-mediated cell contraction,,Predicted intracellular proteins,,,,
ENSG00000125743.10,ENSG00000125743,SNRPD2,0.566476951,0.855423178,0.671902171,0.172105505,small nuclear ribonucleoprotein D2 polypeptide,"SNRPD2 is a gene that encodes a protein belonging to the small nuclear ribonucleoprotein core protein family. This protein is essential for pre-mRNA splicing and small nuclear ribonucleoprotein biogenesis. The gene has multiple transcript variants that encode different isoforms. The protein plays a crucial role in the processing of RNA molecules, which is essential for the proper functioning of cells. Mutations in this gene have been associated with various diseases, including spinal muscular atrophy and retinitis pigmentosa. Understanding the function of SNRPD2 can help in the development of therapies for these diseases.","Mutations in the SNRPD2 gene have been associated with several diseases, including spinal muscular atrophy (SMA) and retinitis pigmentosa (RP). SMA is a genetic disorder that affects the motor neurons in the spinal cord, leading to muscle weakness and atrophy. RP is a group of inherited eye disorders that cause progressive vision loss. 

Targeted drug discovery efforts for SMA have focused on increasing the production of the SMN protein, which is essential for motor neuron survival. Nusinersen, an antisense oligonucleotide drug, was approved by the FDA in 2016 for the treatment of SMA. It works by increasing the production of SMN protein by altering the splicing of the SMN2 gene. 

For RP, gene therapy is being explored as a potential treatment option. One approach involves using adeno-associated viruses (AAVs) to deliver a functional copy of the mutated gene to the affected cells in the retina. Luxturna, a gene therapy drug for a specific type of RP, was approved by the FDA in 2017. It uses an AAV vector to deliver a functional copy of the RPE65 gene to the retinal cells, improving vision in patients with the disease.

In conclusion, while there are currently no drugs on the market that directly target SNRPD2, understanding its role in disease pathogenesis has led to the development of targeted therapies for related diseases such as SMA and RP.",GO:0036261 7-methylguanosine cap hypermethylation;GO:0036260 RNA capping;GO:1903241 U2-type prespliceosome assembly,,Predicted intracellular proteins,Cytosol (Supported),Artenimol,,(M5926)HALLMARK MYC TARGETS V1
ENSG00000196683.11,ENSG00000196683,TOMM7,0.566659652,0.676239483,0.60274156,0.420997912,translocase of outer mitochondrial membrane 7,"The TOMM7 gene encodes a protein that is a subunit of the translocase of the outer mitochondrial membrane. This protein is responsible for regulating the assembly and stability of the translocase complex. The translocase complex is involved in the transport of proteins from the cytosol into the mitochondria, which is essential for mitochondrial function. Mutations in the TOMM7 gene have been associated with mitochondrial disorders, including Leigh syndrome and encephalomyopathy. Understanding the function of TOMM7 and its role in mitochondrial transport may provide insights into the development of treatments for these disorders.","There is limited information available on targeted drug discovery efforts for the TOMM7 gene. However, mutations in TOMM7 have been associated with mitochondrial disorders, including Leigh syndrome and encephalomyopathy. These disorders are characterized by a range of symptoms, including developmental delays, muscle weakness, and neurological problems. Currently, there are no targeted drugs available for the treatment of these disorders. However, there are some drugs that have been successful in treating mitochondrial disorders more broadly, such as coenzyme Q10 and idebenone. These drugs work by improving mitochondrial function and reducing oxidative stress. Further research into the function of TOMM7 and its role in mitochondrial transport may lead to the development of targeted therapies for these disorders in the future.",GO:1905091 positive regulation of type 2 mitophagy;GO:1905089 regulation of type 2 mitophagy;GO:0007008 outer mitochondrial membrane organization,,Predicted intracellular proteins,,,,
ENSG00000277972.2,ENSG00000277972,CISD3,0.568997107,0.989278269,0.518981936,0.198731118,CDGSH iron sulfur domain 3,"CISD3 is a gene that belongs to the CDGSH domain-containing family. It is believed to be involved in regulating electron transport and oxidative phosphorylation. The function of this gene is not yet fully understood, but it may play a role in cellular metabolism. CISD3 is expressed in various tissues, including the brain, heart, and liver. Mutations in this gene have been associated with certain diseases, such as Wolfram syndrome, which is characterized by diabetes mellitus, optic atrophy, and deafness. Further research is needed to fully understand the role of CISD3 in human health and disease.","Mutations in the CISD3 gene have been associated with several diseases, including Wolfram syndrome, which is a rare genetic disorder characterized by diabetes mellitus, optic atrophy, deafness, and neurological abnormalities. Currently, there are no targeted drug discovery efforts specifically for CISD3. However, there are several drugs on the market that target mitochondrial function, which may indirectly affect CISD3. For example, metformin, a commonly used drug for type 2 diabetes, has been shown to improve mitochondrial function and reduce oxidative stress. Another drug, idebenone, has been approved for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disease that affects the optic nerve. While these drugs do not directly target CISD3, they may have potential therapeutic benefits for individuals with CISD3-related diseases. Further research is needed to fully understand the role of CISD3 in disease and to develop targeted therapies.",GO:0106034 protein maturation by [2Fe-2S] cluster transfer;GO:0097428 protein maturation by iron-sulfur cluster transfer;GO:0051604 protein maturation,,Predicted intracellular proteins,,,,
ENSG00000087191.13,ENSG00000087191,PSMC5,0.571862265,0.555982523,0.781166778,0.378437493,"proteasome 26S subunit, ATPase 5","PSMC5 is a gene that encodes one of the ATPase subunits of the 26S proteasome, a protein complex that cleaves peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. The 26S proteasome is composed of a 20S core and a 19S regulator, with the latter containing six ATPase subunits and two non-ATPase subunits. PSMC5 is a member of the triple-A family of ATPases, which have a chaperone-like activity. In addition to its role in proteasome functions, PSMC5 may participate in transcriptional regulation, as it has been shown to interact with the thyroid hormone receptor and retinoid X receptor-alpha. Two transcript variants encoding different isoforms have been identified for this gene.","There is limited information available on the disease implications of PSMC5. However, dysregulation of the proteasome system has been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Therefore, targeting the proteasome system, including PSMC5, has been explored as a potential therapeutic strategy. Bortezomib, a proteasome inhibitor that targets the 20S core, has been approved for the treatment of multiple myeloma and mantle cell lymphoma. Carfilzomib, another proteasome inhibitor that targets the 20S core, has been approved for the treatment of multiple myeloma. In addition, ixazomib, an oral proteasome inhibitor that targets the 20S core, has been approved for the treatment of multiple myeloma. However, there are currently no drugs specifically targeting PSMC5.",GO:1901800 positive regulation of proteasomal protein catabolic process;GO:1903052 positive regulation of proteolysis involved in protein catabolic process;GO:0061136 regulation of proteasomal protein catabolic process,,Predicted intracellular proteins,Cytosol;Plasma membrane (Supported),,,
ENSG00000100577.19,ENSG00000100577,GSTZ1,0.572266557,0.764730698,0.199076841,0.752992132,glutathione S-transferase zeta 1,"GSTZ1 is a gene that belongs to the glutathione S-transferase (GSTs) super-family. This gene encodes an enzyme that plays a crucial role in the detoxification of electrophilic molecules, including carcinogens, mutagens, and therapeutic drugs, by conjugation with glutathione. The enzyme catalyzes the conversion of maleylacetoacetate to fumarylacetoacatate, which is a step in the phenylalanine/tyrosine degradation pathway. Deficiency of a similar gene in mice causes oxidative stress. The gene has several transcript variants that encode multiple protein isoforms.","Research has shown that GSTZ1 may play a role in the development and progression of certain diseases, including cancer, neurodegenerative disorders, and metabolic disorders. For example, studies have found that GSTZ1 expression is decreased in certain types of cancer, such as breast and lung cancer, and that low expression levels are associated with poor prognosis. Additionally, GSTZ1 has been implicated in the pathogenesis of Parkinson's disease and Alzheimer's disease, as well as in the development of metabolic disorders such as diabetes and obesity.

Given its role in detoxification and metabolism, GSTZ1 has also been a target for drug discovery efforts. Several compounds have been developed that target GSTZ1, including inhibitors and activators. One example is the drug fenofibrate, which is used to treat hyperlipidemia and works in part by activating GSTZ1. Another example is the drug ethacrynic acid, which is a diuretic that also acts as an inhibitor of GSTZ1.

Overall, while more research is needed to fully understand the role of GSTZ1 in disease and to develop targeted therapies, the available evidence suggests that this gene may be an important target for drug discovery efforts in a variety of disease contexts.",GO:0006572 tyrosine catabolic process;GO:0006558 L-phenylalanine metabolic process;GO:0006559 L-phenylalanine catabolic process,,Predicted intracellular proteins; ENZYME proteins:Transferases; ENZYME proteins:Isomerase; Potential drug targets; Disease related genes; Enzymes,Cytosol (Approved); Additional: Nucleoplasm,"Glutathione; 1,4-Dithiothreitol; Dichloroacetic acid; Glycerin",,(M5935)HALLMARK FATTY ACID METABOLISM
ENSG00000187630.17,ENSG00000187630,DHRS4L2,0.575049781,0.708999796,0.660763473,0.355386074,dehydrogenase/reductase 4 like 2,DHRS4L2 is a gene that belongs to the short chain dehydrogenase reductase family. It is responsible for encoding a protein that may act as an NADPH dependent retinol oxidoreductase. The gene has multiple transcript variants due to alternate splicing.,"There is limited information available on the disease implications of DHRS4L2. However, studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for DHRS4L2 are also limited, as the function of the protein encoded by this gene is not well understood. However, some studies have suggested that DHRS4L2 may play a role in retinoid metabolism, which could have implications for the treatment of certain skin disorders and cancers. Currently, there are no drugs on the market that specifically target DHRS4L2. However, retinoids such as isotretinoin and tretinoin have been used successfully in the treatment of acne and certain types of cancer, and may indirectly affect the activity of DHRS4L2.",GO:0042574 retinal metabolic process;GO:0006081 aldehyde metabolic process;GO:0001523 retinoid metabolic process,,Predicted secreted proteins; Predicted intracellular proteins,,Matairesinol,,
ENSG00000136942.15,ENSG00000136942,RPL35,0.575624267,1.055449702,0.546481422,0.124941677,ribosomal protein L35,"RPL35 is a gene that encodes a ribosomal protein, specifically a component of the 60S subunit of ribosomes. Ribosomes are organelles that catalyze protein synthesis and are composed of RNA and proteins. RPL35 belongs to the L29P family of ribosomal proteins and is located in the cytoplasm. Like other genes encoding ribosomal proteins, there are multiple processed pseudogenes of RPL35 dispersed throughout the genome.","There is limited information available on the disease implications of RPL35 mutations. However, recent studies have suggested that mutations in ribosomal proteins, including RPL35, may be associated with various types of cancer. For example, a study published in the journal Nature Genetics in 2014 identified RPL35 mutations in patients with acute myeloid leukemia (AML). Additionally, RPL35 mutations have been found in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma.

Targeted drug discovery efforts for RPL35 are currently limited, as the exact role of this protein in disease pathogenesis is not well understood. However, there are several drugs on the market that target other ribosomal proteins, such as the macrolide antibiotics erythromycin and azithromycin, which bind to the 50S subunit of bacterial ribosomes and inhibit protein synthesis. Another example is the drug tigecycline, which targets the 30S subunit of bacterial ribosomes and is used to treat infections caused by multidrug-resistant bacteria.

In conclusion, while the disease implications of RPL35 mutations are not well understood, there is evidence to suggest that mutations in ribosomal proteins may be associated with various types of cancer. Targeted drug discovery efforts for RPL35 are currently limited, but there are several drugs on the market that target other ribosomal proteins and inhibit protein synthesis.","GO:0000463 maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA);GO:0000470 maturation of LSU-rRNA;GO:0042273 ribosomal large subunit biogenesis",,Predicted intracellular proteins; Ribosomal proteins; Human disease related genes:Other congenital disorders:Ribosomopathies; Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases,Cytosol;Endoplasmic reticulum (Approved),Artenimol,,
ENSG00000112695.11,ENSG00000112695,COX7A2,0.57639622,0.837666005,0.310894913,0.580627741,cytochrome c oxidase subunit 7A2,"COX7A2 is a gene that encodes for subunit 7A2 of cytochrome c oxidase, which is the terminal component of the mitochondrial respiratory chain. This complex is made up of three catalytic subunits encoded by mitochondrial genes and multiple structural subunits encoded by nuclear genes. The mitochondrially-encoded subunits function in electron transfer, while the nuclear-encoded subunits may function in the regulation and assembly of the complex. COX7A2 encodes for polypeptide 2 (liver isoform) of subunit VIIa, which is present in both muscle and non-muscle tissues. Alternative splicing results in multiple transcript variants, and related pseudogenes have been identified on chromosomes 4 and 14.","Mutations in COX7A2 have been associated with mitochondrial complex IV deficiency, a rare genetic disorder that affects the function of the mitochondrial respiratory chain. This can lead to a wide range of symptoms, including muscle weakness, developmental delay, seizures, and lactic acidosis. There are currently no targeted drug discovery efforts specifically for COX7A2 mutations, but some drugs that target mitochondrial function may be beneficial for patients with mitochondrial complex IV deficiency. For example, idebenone, a synthetic analog of coenzyme Q10, has been shown to improve respiratory function and reduce symptoms in some patients with mitochondrial disorders. Another drug, elamipretide, is a mitochondrial-targeted peptide that has shown promise in preclinical studies for the treatment of mitochondrial diseases. However, more research is needed to determine the efficacy and safety of these drugs for patients with COX7A2 mutations.","GO:0006123 mitochondrial electron transport, cytochrome c to oxygen;GO:0002082 regulation of oxidative phosphorylation;GO:1903715 regulation of aerobic respiration",,Transporters:Primary Active Transporters; Predicted intracellular proteins,,,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000109475.16,ENSG00000109475,RPL34,0.576587273,0.950896407,0.613096374,0.165769038,ribosomal protein L34,"RPL34 is a gene that encodes a ribosomal protein, specifically a component of the 60S subunit. Ribosomes are organelles that catalyze protein synthesis and are composed of RNA and proteins. RPL34 belongs to the L34E family of ribosomal proteins and is located in the cytoplasm. Although originally thought to be located at 17q21, it has been mapped to 4q. Overexpression of RPL34 has been observed in some cancer cells. Alternative splicing results in multiple transcript variants, all encoding the same isoform. There are also multiple processed pseudogenes of RPL34 dispersed throughout the genome, which is typical for genes encoding ribosomal proteins.","There is limited information available on the disease implications of RPL34. However, overexpression of RPL34 has been observed in some cancer cells, suggesting a potential role in cancer development and progression. Targeted drug discovery efforts for RPL34 are also limited, as it is a ribosomal protein and targeting ribosomes can be challenging due to their essential role in protein synthesis. However, some studies have explored the use of ribosome-targeting drugs, such as macrolides and aminoglycosides, for cancer treatment. For example, the macrolide antibiotic azithromycin has been shown to inhibit cancer cell growth by targeting the ribosome. Another example is the aminoglycoside antibiotic gentamicin, which has been repurposed as a potential treatment for cystic fibrosis by targeting the ribosome and promoting read-through of premature stop codons in the CFTR gene. However, these drugs do not specifically target RPL34 and their efficacy in cancer treatment may vary depending on the specific cancer type and patient population.",GO:0002181 cytoplasmic translation;GO:0006412 translation;GO:0010467 gene expression,,Ribosomal proteins; Predicted intracellular proteins,Cytosol;Endoplasmic reticulum (Supported); Additional: Nucleoli,,,(M5926)HALLMARK MYC TARGETS V1
ENSG00000171159.5,ENSG00000171159,C9orf16,0.578511034,0.074943663,0.567929753,1.092659685,bublin coiled coil protein,"The BBLN gene encodes for the bublin coiled coil protein, which is involved in the regulation of cell division and the formation of the mitotic spindle during cell division. The protein is also involved in the maintenance of the structure and function of the centrosome, which is a critical organelle involved in cell division. Mutations in the BBLN gene have been associated with various types of cancer, including breast cancer and lung cancer. Additionally, the protein has been shown to interact with other proteins involved in cell division, suggesting that it plays a critical role in this process. Further research is needed to fully understand the function of the BBLN gene and its role in cancer development.","There is limited information available on targeted drug discovery efforts for the BBLN gene. However, mutations in this gene have been associated with various types of cancer, including breast cancer and lung cancer. Therefore, targeting the BBLN gene or its protein product may have potential therapeutic implications for these types of cancer. Currently, there are no drugs on the market that specifically target the BBLN gene or its protein product. However, there are drugs that target other proteins involved in cell division, such as microtubules and kinases, which may indirectly affect the function of the BBLN protein. Examples of these drugs include paclitaxel, vinblastine, and imatinib. Further research is needed to identify potential drug targets for the BBLN gene and to develop effective therapies for cancer patients.",GO:0045110 intermediate filament bundle assembly;GO:0072674 multinuclear osteoclast differentiation;GO:0045453 bone resorption,,Predicted intracellular proteins,Microtubules (Approved),,,
ENSG00000114023.15,ENSG00000114023,FAM162A,0.582563067,0.903999525,0.592502677,0.251187,family with sequence similarity 162 member A,"FAM162A is a human gene that plays a role in various biological processes, including apoptosis, cellular response to hypoxia, and regulation of cytochrome c release from mitochondria. It is found in both the cytosol and mitochondria.","There is limited information available on the disease implications of FAM162A. However, recent studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for FAM162A are still in the early stages, but there is potential for the development of drugs that target the protein's role in regulating apoptosis and mitochondrial function. Currently, there are no drugs on the market that specifically target FAM162A, but there are drugs that target related pathways, such as Bcl-2 inhibitors like venetoclax, which have shown promise in treating certain types of cancer. Further research is needed to fully understand the role of FAM162A in disease and to develop targeted therapies.",GO:0090200 positive regulation of release of cytochrome c from mitochondria;GO:0090199 regulation of release of cytochrome c from mitochondria;GO:2001056 positive regulation of cysteine-type endopeptidase activity,,Predicted intracellular proteins,Mitochondria (Supported),,,(M5891)HALLMARK HYPOXIA; (M5937)HALLMARK GLYCOLYSIS; (M5939)HALLMARK P53 PATHWAY
ENSG00000114391.13,ENSG00000114391,RPL24,0.582939935,1.011171093,0.664041074,0.073607637,ribosomal protein L24,"RPL24 is a gene that encodes a ribosomal protein that is a component of the 60S subunit of ribosomes. Ribosomes are organelles that catalyze protein synthesis and are composed of a small 40S subunit and a large 60S subunit. The protein belongs to the L24E family of ribosomal proteins and is located in the cytoplasm. Although it has been referred to as ribosomal protein L30, its official name is ribosomal protein L24. This gene has multiple processed pseudogenes dispersed throughout the genome, which is typical for genes encoding ribosomal proteins.","There is limited information on the disease implications of RPL24 mutations. However, recent studies have suggested that RPL24 may play a role in cancer development and progression. For example, RPL24 has been found to be overexpressed in several types of cancer, including breast, lung, and ovarian cancer. Targeted drug discovery efforts for RPL24 are still in the early stages, but some studies have suggested that inhibiting RPL24 expression or function may be a potential therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target RPL24, but there are several drugs that target other ribosomal proteins, such as the macrolide antibiotics erythromycin and azithromycin, which bind to the 50S subunit of the ribosome and inhibit protein synthesis. Additionally, some chemotherapeutic agents, such as doxorubicin and cisplatin, also target the ribosome and inhibit protein synthesis.",GO:0010458 exit from mitosis;GO:0000027 ribosomal large subunit assembly;GO:0031290 retinal ganglion cell axon guidance,,Ribosomal proteins; Predicted intracellular proteins,Cytosol;Endoplasmic reticulum (Enhanced),,,
ENSG00000063177.13,ENSG00000063177,RPL18,0.584569792,0.915024111,0.766584266,0.072101,ribosomal protein L18,"RPL18 is a gene that encodes a ribosomal protein L18, which is a component of the 60S subunit of ribosomes. Ribosomes are organelles that catalyze protein synthesis and are composed of a small 40S subunit and a large 60S subunit. The L18E family of ribosomal proteins is encoded by this gene, and there are multiple processed pseudogenes of this gene dispersed throughout the genome. Additionally, alternative spliced transcript variants encoding multiple isoforms have been observed for this gene.","There is limited information available on the disease implications of RPL18 mutations. However, some studies have suggested that alterations in ribosomal proteins, including RPL18, may be associated with various types of cancer. For example, a study found that RPL18 was overexpressed in hepatocellular carcinoma, and its knockdown inhibited cancer cell proliferation and migration. 

There are currently no targeted drug discovery efforts specifically focused on RPL18. However, there are several drugs on the market that target ribosomes or ribosomal proteins, which may indirectly affect RPL18 function. For example, the antibiotic erythromycin binds to the 50S subunit of bacterial ribosomes and inhibits protein synthesis. Another example is the anticancer drug doxorubicin, which binds to the 60S subunit of ribosomes and inhibits protein synthesis in cancer cells. 

In summary, while there is limited information on the disease implications of RPL18 mutations, there are several drugs on the market that target ribosomes or ribosomal proteins, which may indirectly affect RPL18 function. Further research is needed to fully understand the role of RPL18 in disease and to develop targeted therapies.",GO:0002181 cytoplasmic translation;GO:0006412 translation;GO:0010467 gene expression,,Predicted intracellular proteins; Ribosomal proteins; Human disease related genes:Other congenital disorders:Ribosomopathies; Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases,Cytosol;Endoplasmic reticulum (Supported); Additional: Nucleoli,Artenimol,,(M5926)HALLMARK MYC TARGETS V1; (M5939)HALLMARK P53 PATHWAY
ENSG00000076944.16,ENSG00000076944,STXBP2,0.586549946,0.839656352,0.562358702,0.357634784,syntaxin binding protein 2,"STXBP2 is a gene that belongs to the STXBP/unc-18/SEC1 family and is involved in intracellular trafficking, control of SNARE complex assembly, and the release of cytotoxic granules by natural killer cells. Mutations in this gene have been linked to familial hemophagocytic lymphohistiocytosis, a rare immune disorder characterized by an overactive immune system that damages tissues and organs. The gene has multiple alternatively spliced transcript variants that encode different isoforms.","Familial hemophagocytic lymphohistiocytosis (FHL) is a rare and life-threatening immune disorder caused by mutations in the STXBP2 gene. The disease is characterized by an overactive immune system that attacks healthy tissues and organs, leading to organ failure and death if left untreated. Currently, the only curative treatment for FHL is hematopoietic stem cell transplantation, which carries significant risks and is not always available. Therefore, there is a need for targeted drug discovery efforts to develop new therapies for FHL. Several drugs targeting the immune system, such as corticosteroids, cyclosporine, and etoposide, have been used to treat FHL with varying degrees of success. Additionally, a recent study showed that a small molecule inhibitor of the STXBP2 protein, called 6-((4-chlorophenyl)amino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxamide (Compound 1), was able to reduce the release of cytotoxic granules by natural killer cells and improve survival in a mouse model of FHL. This suggests that STXBP2 inhibitors may be a promising avenue for drug discovery in FHL.",GO:0043312 neutrophil degranulation;GO:0099011 neuronal dense core vesicle exocytosis;GO:0099525 presynaptic dense core vesicle exocytosis,,Disease related genes; Human disease related genes:Immune system diseases:Primary immunodeficiency; Predicted intracellular proteins,Cytosol (Enhanced),,,
ENSG00000142546.14,ENSG00000142546,NOSIP,0.588101614,0.792407113,0.697354981,0.274542749,nitric oxide synthase interacting protein,"The NOSIP gene encodes a protein that may regulate the activity and location of nitric oxide synthase, which is involved in the production of nitric oxide. Alternative splicing of the gene results in multiple transcript variants that produce the same protein.","Research on the NOSIP gene has suggested its potential involvement in various diseases, including cancer, cardiovascular disease, and neurological disorders. For example, studies have shown that NOSIP expression is decreased in certain types of cancer, such as breast and lung cancer, and that its downregulation may contribute to tumor growth and metastasis. Additionally, NOSIP has been implicated in the regulation of blood pressure and vascular function, making it a potential target for the treatment of hypertension and other cardiovascular diseases. In the field of neurology, NOSIP has been linked to the development of Alzheimer's disease and other neurodegenerative disorders.

Despite its potential as a therapeutic target, there are currently no drugs on the market that specifically target NOSIP. However, there have been efforts to develop drugs that modulate the activity of nitric oxide synthase, which is regulated by NOSIP. For example, nitric oxide donors such as nitroglycerin and sodium nitroprusside are used to treat angina and hypertension, respectively. Additionally, inhibitors of nitric oxide synthase, such as L-NAME, have been investigated as potential treatments for conditions such as septic shock and stroke. While these drugs do not directly target NOSIP, they may indirectly modulate its activity by affecting the production of nitric oxide. Overall, further research on the role of NOSIP in disease and the development of targeted therapies may hold promise for improving patient outcomes in a variety of conditions.",GO:0051001 negative regulation of nitric-oxide synthase activity;GO:0032769 negative regulation of monooxygenase activity;GO:0050999 regulation of nitric-oxide synthase activity,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Enhanced),,,
ENSG00000173272.16,ENSG00000173272,MZT2A,0.59052213,0.874779537,0.685930701,0.210856152,mitotic spindle organizing protein 2A,"The human gene MZT2A encodes for a protein called mitotic spindle organizing protein 2A, which is involved in the organization of the mitotic spindle during cell division. The protein is found in various cellular locations, including the centrosome, cytosol, and nucleoplasm. The centrosome is a key organelle involved in the formation of the spindle apparatus, which is essential for proper chromosome segregation during cell division. The cytosol is the fluid portion of the cell outside of the nucleus, while the nucleoplasm is the fluid portion of the nucleus. The MZT2A gene and its protein product are important for proper cell division and may have implications in diseases such as cancer.","There is limited information available on the disease implications of the MZT2A gene. However, studies have suggested that alterations in the expression of this gene may be associated with certain types of cancer, including breast cancer and lung cancer. Targeted drug discovery efforts for MZT2A are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein product of this gene. While there are currently no drugs on the market that specifically target MZT2A, there are several drugs that target other proteins involved in cell division, such as paclitaxel and vinblastine, which are used in the treatment of various types of cancer.",,,Predicted intracellular proteins,Centrosome (Supported); Additional: Cytosol,,,
ENSG00000213741.11,ENSG00000213741,RPS29,0.590990062,1.045742768,0.607328718,0.119898699,ribosomal protein S29,"RPS29 is a gene that encodes a ribosomal protein that is a component of the 40S subunit and a member of the S14P family of ribosomal proteins. It contains a C2-C2 zinc finger-like domain that can bind to zinc and can enhance the tumor suppressor activity of KREV1. RPS29 is located in the cytoplasm and is involved in protein synthesis. Variable expression of this gene in colorectal cancers compared to adjacent normal tissues has been observed, although no correlation between the level of expression and the severity of the disease has been found. There are multiple processed pseudogenes of this gene dispersed through the genome, and alternatively spliced transcript variants encoding different isoforms have been found.","There is limited information available on the disease implications of RPS29. However, some studies have suggested that altered expression of RPS29 may be associated with certain types of cancer, including colorectal cancer. Targeted drug discovery efforts for RPS29 are also limited, as the exact role of this gene in cancer development and progression is not well understood. Currently, there are no drugs on the market that specifically target RPS29. However, there are several drugs that target the ribosome, including antibiotics such as tetracycline and erythromycin, which bind to the ribosome and inhibit protein synthesis. Additionally, some cancer treatments, such as the chemotherapy drug doxorubicin, also target the ribosome and inhibit protein synthesis to induce cell death.",GO:0002181 cytoplasmic translation;GO:0006412 translation;GO:0010467 gene expression,,Predicted intracellular proteins; Ribosomal proteins; Human disease related genes:Other congenital disorders:Ribosomopathies; Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases,Cytosol;Endoplasmic reticulum (Supported),,,
ENSG00000128626.12,ENSG00000128626,MRPS12,0.591218601,0.916453384,0.566997098,0.290205321,mitochondrial ribosomal protein S12,"The human gene MRPS12 encodes a protein that is a key component of the ribosomal small subunit and belongs to the ribosomal protein S12P family. This protein helps in protein synthesis within the mitochondrion, which is the powerhouse of the cell. Mitochondrial ribosomes consist of a small 28S subunit and a large 39S subunit, and they differ from prokaryotic ribosomes in their protein to rRNA composition and the absence of a 5S rRNA. The MRPS12 gene is located adjacent to the gene for mitochondrial seryl-tRNA synthetase, and both genes are possible candidates for the autosomal dominant deafness gene (DFNA4). Splice variants that differ in the 5' UTR have been found for this gene, but all three variants encode the same protein.","Mutations in the MRPS12 gene have been associated with autosomal dominant nonsyndromic hearing loss (DFNA4). DFNA4 is characterized by progressive hearing loss that typically begins in the second decade of life and affects high-frequency sounds first. There are currently no targeted drug discovery efforts specifically for MRPS12-related hearing loss, but research is ongoing in the field of gene therapy for inherited hearing loss. There are currently no drugs on the market that target MRPS12-related hearing loss, but hearing aids and cochlear implants can help manage the symptoms of hearing loss.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Ribosomal proteins; Predicted intracellular proteins,,,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000179922.6,ENSG00000179922,ZNF784,0.593772951,0.889698675,0.609990196,0.281629983,zinc finger protein 784,ZNF784 is a human gene that encodes for a zinc finger protein 784. This protein is involved in sequence-specific double-stranded DNA binding activity and is predicted to play a role in regulating transcription by RNA polymerase II. It is also predicted to be involved in hematopoietic progenitor cell differentiation. The protein is active in the nucleus.,"There is limited information available on the disease implications of ZNF784. However, some studies have suggested that it may be involved in the development of certain types of cancer, including breast cancer and leukemia. Targeted drug discovery efforts for ZNF784 are also limited, as its function and role in disease are not well understood. Currently, there are no drugs on the market that specifically target ZNF784. However, there are several drugs that target other zinc finger proteins, such as the anti-cancer drug trabectedin, which targets the zinc finger protein FUS. Further research is needed to fully understand the role of ZNF784 in disease and to develop targeted therapies for any associated conditions.",GO:0002244 hematopoietic progenitor cell differentiation;GO:0030097 hemopoiesis;GO:0045944 positive regulation of transcription by RNA polymerase II,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000134809.9,ENSG00000134809,TIMM10,0.594292918,1.142851993,0.439099,0.200927762,translocase of inner mitochondrial membrane 10,"TIMM10 is a human gene that encodes a mitochondrial protein. This protein is part of a family of proteins that are involved in the import and insertion of hydrophobic membrane proteins into the mitochondrial inner membrane. These proteins act as chaperones in the intermembrane space, helping to transport highly insoluble carrier proteins. TIMM10 is organized in heterooligomeric complexes in the mitochondrial intermembrane space and is evolutionarily conserved. The function of TIMM10 is critical for the proper functioning of mitochondria, which are responsible for producing energy in cells.","Mutations in the TIMM10 gene have been associated with several mitochondrial disorders, including deafness-dystonia-optic neuronopathy (DDON) syndrome, which is characterized by hearing loss, dystonia, and optic atrophy. Additionally, mutations in TIMM10 have been linked to mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), a rare genetic disorder that affects the nervous system and causes seizures, headaches, and muscle weakness.

There are currently no targeted drug discovery efforts specifically aimed at TIMM10. However, there are drugs on the market that target mitochondrial dysfunction, which may be beneficial for individuals with TIMM10-related disorders. For example, idebenone, a synthetic analog of coenzyme Q10, has been shown to improve mitochondrial function and reduce oxidative stress in patients with MELAS. Another drug, elamipretide, is a mitochondrial-targeted peptide that has shown promise in clinical trials for the treatment of mitochondrial myopathy.

In summary, while there are currently no targeted drug discovery efforts for TIMM10, drugs that target mitochondrial dysfunction may be beneficial for individuals with TIMM10-related disorders. Idebenone and elamipretide are examples of drugs that have shown promise in clinical trials for the treatment of mitochondrial disorders.",GO:0045039 protein insertion into mitochondrial inner membrane;GO:0090151 establishment of protein localization to mitochondrial membrane;GO:0007007 inner mitochondrial membrane organization,,Predicted intracellular proteins,Mitochondria (Enhanced),,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000006625.18,ENSG00000006625,GGCT,0.605866353,0.803486494,0.696595075,0.31751749,gamma-glutamylcyclotransferase,"The GGCT gene encodes a protein that is involved in the breakdown of glutathione, a molecule that plays a critical role in protecting cells from oxidative stress. Specifically, the protein catalyzes the formation of 5-oxoproline from gamma-glutamyl dipeptides, which is the second-to-last step in glutathione catabolism. The protein may also be involved in cell proliferation and has been identified as a potential marker for cancer. The gene has several pseudogenes located on different chromosomes, and multiple isoforms of the protein have been observed due to alternative splicing.","There is limited information available on the disease implications of the GGCT gene. However, studies have suggested that the protein encoded by this gene may play a role in cancer development and progression. Specifically, GGCT has been identified as a potential marker for several types of cancer, including breast, lung, and ovarian cancer. Targeted drug discovery efforts for GGCT are currently limited, but some studies have explored the potential of small molecule inhibitors to target the protein. One example is the compound 968, which has been shown to inhibit GGCT activity in vitro. However, there are currently no drugs on the market that specifically target GGCT.",GO:0001836 release of cytochrome c from mitochondria;GO:0008637 apoptotic mitochondrial changes;GO:0097190 apoptotic signaling pathway,,ENZYME proteins:Lyases; Enzymes; Predicted intracellular proteins,,,,
ENSG00000005075.15,ENSG00000005075,POLR2J,0.606179368,0.382222395,0.836299439,0.600016269,RNA polymerase II subunit J,"POLR2J is a gene that encodes a subunit of RNA polymerase II, which is responsible for synthesizing messenger RNA in eukaryotes. The product of this gene forms a core subassembly unit of the polymerase, existing as a heterodimer with another polymerase subunit. There are two similar genes located nearby on chromosome 7q22.1 and a pseudogene is found on chromosome 7p13.","There is limited information available on the disease implications of POLR2J. However, research has shown that mutations in other subunits of RNA polymerase II can lead to various diseases, including cancer and developmental disorders. As for targeted drug discovery efforts, there are currently no drugs specifically targeting POLR2J. However, there are drugs that target RNA polymerase II as a whole, such as alpha-amanitin, which is a toxin produced by the death cap mushroom and inhibits RNA polymerase II activity. Additionally, there are drugs that indirectly affect RNA polymerase II activity, such as the chemotherapy drug cisplatin, which can cause DNA damage and inhibit RNA polymerase II transcription. Successful drugs on the market that target RNA polymerase II include Actinomycin D, which is used in the treatment of various cancers, and Rifampin, which is used to treat tuberculosis and other bacterial infections.",GO:0006366 transcription by RNA polymerase II;GO:0006351 DNA-templated transcription;GO:0032774 RNA biosynthetic process,,RNA polymerase related proteins; Predicted intracellular proteins,Nucleoplasm (Approved),,,(M5898)HALLMARK DNA REPAIR
ENSG00000167863.12,ENSG00000167863,ATP5PD,0.606326127,0.714699706,0.564887117,0.539391559,ATP synthase peripheral stalk subunit d,"ATP5PD is a gene that encodes the d subunit of the Fo complex of mitochondrial ATP synthase. ATP synthase is responsible for catalyzing ATP synthesis by utilizing an electrochemical gradient of protons across the inner membrane during oxidative phosphorylation. The ATP synthase is composed of two linked multi-subunit complexes: the soluble catalytic core, F1, and the membrane-spanning component, Fo, which comprises the proton channel. The F1 complex consists of 5 different subunits (alpha, beta, gamma, delta, and epsilon) assembled in a ratio of 3 alpha, 3 beta, and a single representative of the other 3. The Fo complex seems to have nine subunits (a, b, c, d, e, f, g, F6 and 8). The ATP5PD gene has alternatively spliced transcript variants encoding different isoforms and three pseudogenes located on chromosomes 9, 12, and 15.","There is limited information available on the disease implications of ATP5PD. However, mutations in other subunits of the mitochondrial ATP synthase complex have been associated with various mitochondrial diseases, including Leigh syndrome, neuropathy, and cardiomyopathy. Targeted drug discovery efforts for ATP synthase inhibitors have been focused on cancer treatment, as cancer cells rely heavily on ATP production for their rapid proliferation. Several ATP synthase inhibitors, such as oligomycin and venturicidin, have been identified and tested in preclinical studies. However, their clinical development has been limited due to their toxicity and lack of specificity. One successful drug targeting ATP synthase is bedaquiline, which is used to treat drug-resistant tuberculosis. Bedaquiline selectively inhibits the mycobacterial ATP synthase, leading to a decrease in ATP production and bacterial death.",GO:0042776 proton motive force-driven mitochondrial ATP synthesis;GO:0015986 proton motive force-driven ATP synthesis;GO:0006754 ATP biosynthetic process,,Transporters:Primary Active Transporters; Predicted intracellular proteins,Mitochondria (Supported),,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000130313.7,ENSG00000130313,PGLS,0.608647827,0.654611053,0.748215781,0.423116647,6-phosphogluconolactonase,"The human gene PGLS encodes for the enzyme 6-phosphogluconolactonase, which is involved in the pentose-phosphate shunt. This enzyme enables the activity of 6-phosphogluconolactonase and is located in extracellular exosomes. The pentose-phosphate shunt is a metabolic pathway that generates NADPH and ribose-5-phosphate, which are important for cellular processes such as biosynthesis and antioxidant defense. Dysfunction of this pathway has been linked to various diseases, including cancer and neurodegenerative disorders. Understanding the function of PGLS and the pentose-phosphate shunt may provide insights into the development and treatment of these diseases.","Dysfunction of the PGLS gene and the pentose-phosphate shunt has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders. Targeted drug discovery efforts have focused on developing inhibitors of the pentose-phosphate shunt as potential cancer therapies. For example, the drug 6-aminonicotinamide (6-AN) has been shown to inhibit the pentose-phosphate shunt and sensitize cancer cells to radiation therapy. Other potential drug targets include enzymes involved in the pentose-phosphate shunt, such as glucose-6-phosphate dehydrogenase (G6PD), which has been targeted in the development of anti-malarial drugs. Successful drugs on the market that target the pentose-phosphate shunt include the anti-malarial drug primaquine, which targets G6PD, and the anti-cancer drug 6-thioguanine, which inhibits the activity of 6-phosphogluconate dehydrogenase, another enzyme in the pathway.","GO:0009051 pentose-phosphate shunt, oxidative branch;GO:0006098 pentose-phosphate shunt;GO:0006740 NADPH regeneration",,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins,Nucleoplasm (Supported); Additional: Cytosol,,,(M5937)HALLMARK GLYCOLYSIS; (M5945)HALLMARK HEME METABOLISM
ENSG00000129559.13,ENSG00000129559,NEDD8,0.609387901,0.77807518,0.816011547,0.234076977,NEDD8 ubiquitin like modifier,"NEDD8 is a human gene that encodes for a protein called NEDD8 ubiquitin-like modifier. This protein enables the binding activity of ubiquitin protein ligase and is involved in protein neddylation, a process that modifies proteins by adding NEDD8 to them. NEDD8 is located in both the cytosol and nucleoplasm of cells. It is also a biomarker for Parkinson's disease and malignant astrocytoma, two conditions that affect the nervous system.","NEDD8 has been implicated in several diseases, including cancer and neurodegenerative disorders. In cancer, NEDD8 is overexpressed and promotes tumor growth and metastasis. Therefore, targeting NEDD8 has become a promising strategy for cancer therapy. Several drugs have been developed to inhibit NEDD8, including pevonedistat and MLN4924. Pevonedistat has shown promising results in clinical trials for acute myeloid leukemia and multiple myeloma. MLN4924 has also shown efficacy in preclinical studies for various types of cancer. In neurodegenerative disorders, NEDD8 has been found to be involved in the formation of protein aggregates, which are a hallmark of these diseases. However, there are currently no drugs targeting NEDD8 for the treatment of neurodegenerative disorders. Overall, targeting NEDD8 has shown promise as a therapeutic strategy for cancer, and further research is needed to explore its potential in other diseases.",GO:0045116 protein neddylation;GO:0150052 regulation of postsynapse assembly;GO:0099175 regulation of postsynapse organization,,Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Enhanced); Additional: Cytosol,,(M119)PID ERB GENOMIC PATHWAY; (M261)PID P53 REGULATION PATHWAY; (M200)PID ERA GENOMIC PATHWAY,
ENSG00000143543.15,ENSG00000143543,JTB,0.611556218,1.000514858,0.818527489,0.015626306,jumping translocation breakpoint,"The human gene JTB, also known as jumping translocation breakpoint, is involved in mitotic cytokinesis and positive regulation of protein kinase activity. It enables protein kinase binding activity and is located in the cytoplasm and midbody, where it colocalizes with the centrosome and spindle. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of the JTB gene. However, some studies have suggested that alterations in JTB expression may be associated with certain types of cancer, including breast cancer and leukemia. Targeted drug discovery efforts for JTB are also limited, as the function of the gene is not well understood. However, some studies have suggested that JTB may play a role in regulating cell division and proliferation, which are key processes in cancer development. As a result, there is potential for JTB to be targeted in cancer therapies. Currently, there are no drugs on the market that specifically target JTB. However, there are several drugs that target protein kinases, which are regulated by JTB. Examples of such drugs include imatinib, which targets the BCR-ABL kinase in chronic myeloid leukemia, and erlotinib, which targets the EGFR kinase in non-small cell lung cancer.",GO:0008637 apoptotic mitochondrial changes;GO:0000281 mitotic cytokinesis;GO:0061640 cytoskeleton-dependent cytokinesis,,Cancer-related genes:Candidate cancer biomarkers,Mitochondria;Vesicles (Approved),,,
ENSG00000172428.11,ENSG00000172428,COPS9,0.612767977,1.041099325,0.671694788,0.125509819,COP9 signalosome subunit 9,"COPS9 is a human gene that encodes for the COP9 signalosome subunit 9 protein. This protein is involved in various cellular processes, including responding to UV radiation, sequestering proteins in the cytoplasm, and negatively regulating protein neddylation. COPS9 is found in different cellular locations, including the chromatin, cytoplasm, and nucleoplasm, and it colocalizes with the COP9 signalosome.","There is limited information available on the disease implications of COPS9. However, some studies have suggested that dysregulation of the COP9 signalosome, of which COPS9 is a subunit, may be involved in the development of certain cancers, including breast, lung, and prostate cancer. As such, there has been some interest in targeting the COP9 signalosome as a potential therapeutic strategy for cancer treatment. 

Currently, there are no drugs specifically targeting COPS9 or the COP9 signalosome on the market. However, there have been efforts to develop small molecule inhibitors of the COP9 signalosome as potential cancer therapeutics. One example is MLN4924, a small molecule inhibitor of the NEDD8-activating enzyme, which has shown promising results in preclinical studies and is currently in clinical trials for the treatment of various cancers. Another example is Csn-B, a peptide inhibitor of the COP9 signalosome that has shown antitumor activity in vitro and in vivo. However, further research is needed to determine the safety and efficacy of these potential drugs.",GO:2000435 negative regulation of protein neddylation;GO:0051220 cytoplasmic sequestering of protein;GO:2000434 regulation of protein neddylation,,Predicted intracellular proteins,Cytosol;Nucleoplasm (Approved),,,
ENSG00000145494.12,ENSG00000145494,NDUFS6,0.612834589,0.812444214,0.784360312,0.24169924,NADH:ubiquinone oxidoreductase subunit S6,"The NDUFS6 gene encodes a subunit of the NADH:ubiquinone oxidoreductase, which is the first enzyme complex in the electron transport chain of mitochondria. This complex is responsible for transferring electrons from NADH to the respiratory chain. The NDUFS6 subunit is one of seven subunits in the iron-sulfur protein fraction. Mutations in this gene can cause mitochondrial complex I deficiency, which can lead to a range of clinical disorders, including neonatal disease and adult-onset neurodegenerative disorders.","Mutations in the NDUFS6 gene have been associated with mitochondrial complex I deficiency, which can lead to a range of clinical disorders, including Leigh syndrome, encephalomyopathy, and cardiomyopathy. There are currently no targeted drug discovery efforts specifically for NDUFS6 mutations, but there are some drugs that have been successful in treating mitochondrial disorders in general. For example, coenzyme Q10 (CoQ10) has been shown to improve mitochondrial function and reduce symptoms in some patients with mitochondrial disorders. Another drug, idebenone, has been approved in Europe for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disorder that affects the eyes. However, more research is needed to determine the effectiveness of these drugs for NDUFS6-related disorders specifically.","GO:0006120 mitochondrial electron transport, NADH to ubiquinone;GO:0042776 proton motive force-driven mitochondrial ATP synthesis;GO:0015986 proton motive force-driven ATP synthesis",,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,,NADH,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000110717.13,ENSG00000110717,NDUFS8,0.614648453,0.694995984,0.608712869,0.540236507,NADH:ubiquinone oxidoreductase core subunit S8,"The NDUFS8 gene encodes a subunit of Complex I, a mitochondrial enzyme responsible for NADH oxidation, ubiquinone reduction, and proton ejection. The encoded protein is involved in binding two of the iron-sulfur clusters of Complex I, which is necessary for electron transfer. Mutations in this gene have been linked to Leigh syndrome, a rare neurological disorder that affects the central nervous system.","Mutations in the NDUFS8 gene have been associated with Leigh syndrome, a rare and severe neurological disorder that typically presents in infancy or early childhood. Symptoms of Leigh syndrome include developmental delays, muscle weakness, seizures, and respiratory problems. There is currently no cure for Leigh syndrome, and treatment is primarily supportive. However, targeted drug discovery efforts are underway to develop therapies that can improve mitochondrial function and potentially slow the progression of the disease. One example is EPI-743, a small molecule that has shown promise in preclinical studies and is currently in clinical trials for the treatment of Leigh syndrome and other mitochondrial diseases. Another example is idebenone, a synthetic analog of coenzyme Q10 that has been approved in Europe for the treatment of Friedreich's ataxia, another mitochondrial disease. While there is no specific drug approved for the treatment of Leigh syndrome, these examples demonstrate the potential for targeted drug discovery efforts to lead to effective therapies for mitochondrial diseases.","GO:0006120 mitochondrial electron transport, NADH to ubiquinone;GO:0010257 NADH dehydrogenase complex assembly;GO:0032981 mitochondrial respiratory chain complex I assembly",,Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; Potential drug targets; Enzymes; Disease related genes; ENZYME proteins,Mitochondria (Approved),NADH,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000204922.5,ENSG00000204922,UQCC3,0.619778158,1.11351119,0.699588372,0.046234913,ubiquinol-cytochrome c reductase complex assembly factor 3,"UQCC3 is a gene that encodes a protein involved in the assembly of Complex III, a mitochondrial inner membrane protein complex that transfers electrons from ubiquinol to cytochrome c. Mutations in this gene can result in Mitochondrial complex III deficiency, nuclear type 9.","Mitochondrial complex III deficiency, nuclear type 9 is a rare genetic disorder caused by mutations in the UQCC3 gene. This condition affects the function of Complex III, leading to a range of symptoms including muscle weakness, exercise intolerance, and developmental delays. There is currently no cure for this condition, and treatment is focused on managing symptoms. Targeted drug discovery efforts for this condition are limited, but some studies have explored the use of compounds that can improve mitochondrial function, such as coenzyme Q10 and idebenone. However, there are currently no drugs specifically approved for the treatment of mitochondrial complex III deficiency. Successful drugs on the market for other mitochondrial disorders include EPI-743, which is approved for the treatment of Leigh syndrome, and elamipretide, which is in clinical trials for the treatment of primary mitochondrial myopathy.","GO:0017062 respiratory chain complex III assembly;GO:0034551 mitochondrial respiratory chain complex III assembly;GO:0006122 mitochondrial electron transport, ubiquinol to cytochrome c",,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria;Nucleoplasm (Approved); Additional: Cytosol,,,
ENSG00000140264.21,ENSG00000140264,SERF2,0.620982668,0.646810961,0.915289024,0.300848019,small EDRK-rich factor 2,"SERF2, or small EDRK-rich factor 2, is a human gene that plays a role in protein destabilization. It is predicted to be located in both the cytosol and nucleus of cells. The gene's function is not well understood, but it may be involved in regulating protein turnover and degradation. Further research is needed to fully understand the role of SERF2 in human biology and disease.","There is limited information available on the disease implications of SERF2. However, some studies have suggested that it may be involved in the development of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for SERF2 are also limited, as its function is not well understood. Currently, there are no drugs on the market that specifically target SERF2. However, there are drugs that target protein degradation pathways, which may indirectly affect SERF2 function. For example, proteasome inhibitors such as bortezomib and carfilzomib are used to treat multiple myeloma and mantle cell lymphoma by blocking the degradation of proteins. Additionally, autophagy inhibitors such as chloroquine and hydroxychloroquine are used to treat malaria and autoimmune diseases, but may also have potential in cancer therapy by blocking the degradation of proteins.",GO:0031648 protein destabilization;GO:0031647 regulation of protein stability;GO:0065008 regulation of biological quality,,Predicted intracellular proteins,Nucleoplasm (Approved); Additional: Nucleoli,,,
ENSG00000221983.8,ENSG00000221983,UBA52,0.630224604,1.118040551,0.656653215,0.115980045,ubiquitin A-52 residue ribosomal protein fusion product 1,"UBA52 is a human gene that encodes a fusion protein consisting of ubiquitin and ribosomal protein L40, known as a C-terminal extension protein (CEP). Ubiquitin plays a crucial role in targeting cellular proteins for degradation and is involved in maintaining chromatin structure, regulating gene expression, and responding to stress. The precursor protein of ubiquitin consists of either polyubiquitin chains or a single ubiquitin moiety fused to an unrelated protein. Multiple processed pseudogenes derived from UBA52 are present in the genome.","There is limited information on the disease implications of UBA52. However, recent studies have suggested that dysregulation of the ubiquitin-proteasome system, which includes UBA52, may contribute to the pathogenesis of various diseases, including cancer, neurodegenerative disorders, and inflammatory diseases. Targeted drug discovery efforts have focused on developing small molecules that modulate the activity of the ubiquitin-proteasome system, including inhibitors of the proteasome and E3 ubiquitin ligases. Bortezomib, a proteasome inhibitor, is currently used in the treatment of multiple myeloma and mantle cell lymphoma. Carfilzomib, another proteasome inhibitor, has also been approved for the treatment of multiple myeloma. Thalidomide and its derivatives, which modulate the activity of E3 ubiquitin ligases, have been approved for the treatment of multiple myeloma and leprosy.",GO:0002181 cytoplasmic translation;GO:0006412 translation;GO:0019941 modification-dependent protein catabolic process,,Ribosomal proteins; Predicted intracellular proteins,Cytosol (Approved); Additional: Acrosome;Endoplasmic reticulum;Equatorial segment;Nucleoplasm;Plasma membrane,,,
ENSG00000198258.11,ENSG00000198258,UBL5,0.632159976,1.003438713,0.608185466,0.284855749,ubiquitin like 5,"The UBL5 gene encodes a protein that is similar to ubiquitin but does not degrade proteins. Instead, it affects their function by binding to target proteins through an isopeptide bond. Studies have linked this gene to predisposition to obesity based on its expression in the fat sand rat, an animal model for obesity studies. While variation in this gene has been associated with some metabolic traits, it is not associated with childhood obesity. Pseudogenes of this gene are located on chromosomes 3, 5, and 17, and multiple alternatively spliced variants encoding the same protein have been identified.","There is limited information available on the disease implications of UBL5 gene variations. However, some studies have suggested that UBL5 may play a role in the development of obesity and metabolic disorders. Targeted drug discovery efforts for UBL5 are also limited, as the function of the protein it encodes is not well understood. Currently, there are no drugs on the market that specifically target UBL5. However, there are drugs that target the ubiquitin-proteasome system, which is involved in protein degradation and shares some similarities with UBL5. Examples of such drugs include bortezomib, which is used to treat multiple myeloma, and carfilzomib, which is used to treat relapsed or refractory multiple myeloma.",GO:1903955 positive regulation of protein targeting to mitochondrion;GO:1903749 positive regulation of establishment of protein localization to mitochondrion;GO:1903214 regulation of protein targeting to mitochondrion,,Predicted intracellular proteins,,,,
ENSG00000161016.18,ENSG00000161016,RPL8,0.640251365,1.094507726,0.786974805,0.039271564,ribosomal protein L8,"RPL8 is a gene that encodes a ribosomal protein that is a component of the 60S subunit of ribosomes. Ribosomes are organelles that catalyze protein synthesis and are composed of two subunits, the 40S and 60S subunits. The protein belongs to the L2P family of ribosomal proteins and is located in the cytoplasm. In rats, the protein associates with the 5.8S rRNA and is likely involved in the binding of aminoacyl-tRNA. It is also a constituent of the elongation factor 2-binding site at the ribosomal subunit interface. There are multiple processed pseudogenes of this gene dispersed through the genome, which is typical for genes encoding ribosomal proteins.","There is limited information available on the disease implications of RPL8 mutations. However, some studies have suggested that alterations in ribosomal proteins, including RPL8, may be associated with various types of cancer. Targeted drug discovery efforts for RPL8 have not been reported, likely due to the lack of understanding of its specific role in disease. However, there are several drugs on the market that target other ribosomal proteins, such as the macrolide antibiotics erythromycin and azithromycin, which bind to the 50S subunit of bacterial ribosomes and inhibit protein synthesis. Another example is the anticancer drug doxorubicin, which binds to the 60S subunit of eukaryotic ribosomes and inhibits protein synthesis in cancer cells. While these drugs do not specifically target RPL8, they demonstrate the potential for targeting ribosomal proteins in drug development.",GO:0002181 cytoplasmic translation;GO:0006412 translation;GO:0010467 gene expression,,Ribosomal proteins; Predicted intracellular proteins,Cytosol;Endoplasmic reticulum;Nucleoli (Supported),(S)-3-phenyllactic acid; Anisomycin; Puromycin,,
ENSG00000205763.13,ENSG00000205763,RP9P,0.641497842,0.796071099,0.655483905,0.472938521,None,None,None,None,None,None,None,None,None,None
ENSG00000053501.13,ENSG00000053501,USE1,0.641627442,1.047831602,0.813987584,0.063063141,unconventional SNARE in the ER 1,"The human gene USE1 is an unconventional SNARE in the ER 1 that is predicted to enable SNAP receptor activity and is involved in various processes, including lysosomal transport, protein catabolic process, and retrograde vesicle-mediated transport from Golgi to endoplasmic reticulum. It is also predicted to act upstream of or within endoplasmic reticulum tubular network organization and regulation of ER to Golgi vesicle-mediated transport. The gene is located in the endoplasmic reticulum. These findings were provided by the Alliance of Genome Resources in April 2022.","There is limited information available on the disease implications of the USE1 gene. However, some studies have suggested that mutations in the USE1 gene may be associated with certain neurological disorders, such as epilepsy and intellectual disability. 

As for targeted drug discovery efforts, there are currently no drugs on the market that specifically target the USE1 gene. However, there are ongoing efforts to develop drugs that target the SNARE complex, of which USE1 is a component. The SNARE complex is involved in membrane fusion events that are critical for various cellular processes, including neurotransmitter release and insulin secretion. Therefore, drugs that target the SNARE complex may have potential therapeutic applications for diseases such as diabetes and neurological disorders.

One example of a successful drug that targets the SNARE complex is botulinum toxin, which is used to treat various medical conditions, including muscle spasms, migraines, and excessive sweating. Botulinum toxin works by cleaving specific SNARE proteins, thereby preventing neurotransmitter release and muscle contraction. Another example is exenatide, a drug used to treat type 2 diabetes. Exenatide is a synthetic version of a peptide found in the saliva of the Gila monster lizard, and it works by activating a specific SNARE protein involved in insulin secretion.","GO:0006890 retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum;GO:0007041 lysosomal transport;GO:0061025 membrane fusion",,Predicted intracellular proteins,,,,
ENSG00000235552.4,ENSG00000235552,RPL6P27,0.64203437,0.798220701,0.867271187,0.260611223,ribosomal protein L6 pseudogene 27,,,,,,,,,
ENSG00000108107.15,ENSG00000108107,RPL28,0.642180481,0.822515975,0.937671664,0.166353803,ribosomal protein L28,"RPL28 is a gene that encodes a ribosomal protein, specifically a component of the 60S subunit. Ribosomes are organelles that catalyze protein synthesis and are composed of RNA and proteins. RPL28 belongs to the L28E family of ribosomal proteins and is located in the cytoplasm. While variable expression of this gene has been observed in colorectal cancers compared to adjacent normal tissues, there is no correlation between the level of expression and the severity of the disease. Multiple processed pseudogenes of RPL28 are dispersed throughout the genome, and alternative splicing results in multiple transcript variants encoding distinct isoforms.","There is limited information available on the disease implications of RPL28. However, some studies have suggested that alterations in ribosomal proteins, including RPL28, may play a role in the development and progression of certain cancers. Targeted drug discovery efforts for RPL28 are also limited, as it is primarily a structural component of the ribosome and not a druggable target. However, there have been some successful drugs developed that target other ribosomal proteins, such as the macrolide antibiotics that bind to the 50S subunit of the ribosome and inhibit protein synthesis. Examples of macrolide antibiotics include erythromycin, azithromycin, and clarithromycin, which are commonly used to treat bacterial infections. Other drugs that target the ribosome include tetracyclines and aminoglycosides.",GO:0002181 cytoplasmic translation;GO:0006412 translation;GO:0010467 gene expression,,Ribosomal proteins; Predicted intracellular proteins,Cytosol;Endoplasmic reticulum (Supported),,,
ENSG00000103363.15,ENSG00000103363,ELOB,0.643491611,0.764417077,0.840240594,0.325817164,elongin B,"ELOB, also known as elongin B, is a gene that encodes a subunit of the transcription factor B (SIII) complex. This complex is composed of elongins A/A2, B, and C, and it activates elongation by RNA polymerase II by suppressing transient pausing of the polymerase at many sites within transcription units. Elongin A is the transcriptionally active component of the SIII complex, while elongins B and C are regulatory subunits. Elongin A2 is specifically expressed in the testis and can form a stable complex with elongins B and C. The von Hippel-Lindau tumor suppressor protein binds to elongins B and C, inhibiting transcription elongation. Two alternatively spliced transcript variants encoding different isoforms have been described for this gene, and pseudogenes have been identified on chromosomes 11 and 13.","Research on ELOB and its role in disease is limited, and there are currently no targeted drug discovery efforts specifically focused on this gene. However, the SIII complex, of which ELOB is a subunit, has been implicated in various diseases, including cancer and viral infections. For example, the SIII complex has been shown to interact with the human papillomavirus (HPV) E6 oncoprotein, which can lead to the degradation of the tumor suppressor protein p53 and contribute to the development of cervical cancer. Additionally, the SIII complex has been found to be overexpressed in certain types of cancer, such as breast cancer, and may be a potential target for cancer therapy. However, there are currently no drugs on the market that specifically target ELOB or the SIII complex.",GO:0140958 target-directed miRNA degradation;GO:0010587 miRNA catabolic process;GO:0060965 negative regulation of miRNA-mediated gene silencing,,Predicted intracellular proteins,,,(M180)PID HIF1A PATHWAY; (M44)PID HIF2PATHWAY,
ENSG00000167985.7,ENSG00000167985,SDHAF2,0.648221497,0.995746643,0.812200326,0.136717524,succinate dehydrogenase complex assembly factor 2,"SDHAF2 is a gene that encodes a mitochondrial assembly factor required for the flavination of a subunit of the succinate dehydrogenase complex (SDHA), which is necessary for the activity of the complex. Mutations in this gene have been linked to paraganglioma, a rare type of tumor that develops in the cells of the nervous system. The SDHAF2 gene plays a crucial role in the proper functioning of the succinate dehydrogenase complex, which is involved in the cellular process of respiration. Understanding the function of this gene may help in the development of new treatments for paraganglioma and other related disorders.","Paraganglioma is a rare type of tumor that develops in the cells of the nervous system. Mutations in the SDHAF2 gene have been linked to the development of paraganglioma. Targeted drug discovery efforts have focused on developing drugs that can inhibit the activity of the succinate dehydrogenase complex, which is involved in the cellular process of respiration and is affected by mutations in the SDHAF2 gene. One example of a successful drug on the market is Vandetanib, which has been approved by the FDA for the treatment of medullary thyroid cancer. Vandetanib is a tyrosine kinase inhibitor that targets the RET and VEGFR receptors, which are involved in the growth and spread of cancer cells. Other drugs that have shown promise in preclinical studies include inhibitors of the HIF-2? pathway, which is involved in the regulation of cellular metabolism and is affected by mutations in the SDHAF2 gene.","GO:0018293 protein-FAD linkage;GO:0006121 mitochondrial electron transport, succinate to ubiquinone;GO:0034552 respiratory chain complex II assembly",,Disease related genes; Cancer-related genes; Predicted intracellular proteins; Human disease related genes:Cancers:Cancers of endocrine organs,Cytosol;Mitochondria (Approved); Additional: Nucleoli,,,
ENSG00000105618.14,ENSG00000105618,PRPF31,0.653358096,0.782177614,0.797796229,0.380100447,pre-mRNA processing factor 31,"PRPF31 is a human gene that encodes a protein that is a component of the spliceosome complex. This gene is one of several genes that have been linked to retinitis pigmentosa, a genetic disorder that causes progressive vision loss. The protein encoded by PRPF31 plays a role in activating the spliceosome complex, which is involved in the processing of pre-mRNA molecules. Mutations in this gene can lead to defects in pre-mRNA processing, which can ultimately result in retinal degeneration and vision loss.","Retinitis pigmentosa (RP) is a genetic disorder that affects the retina, leading to progressive vision loss and eventual blindness. Mutations in the PRPF31 gene have been identified as a cause of autosomal dominant RP, accounting for up to 10% of cases. There are currently no approved drugs for the treatment of RP, but there are ongoing efforts to develop targeted therapies. One approach is to use antisense oligonucleotides (ASOs) to target and correct the specific genetic mutation causing the disease. In preclinical studies, ASOs targeting PRPF31 have shown promising results in restoring normal splicing and improving retinal function in animal models of RP. Another approach is to use gene therapy to deliver a functional copy of the PRPF31 gene to affected cells. While there are no drugs currently on the market targeting PRPF31, these emerging therapies hold promise for the treatment of RP caused by mutations in this gene.",GO:0071166 ribonucleoprotein complex localization;GO:0000244 spliceosomal tri-snRNP complex assembly;GO:0000387 spliceosomal snRNP assembly,,Disease related genes; Human disease related genes:Nervous system diseases:Eye disease; Predicted intracellular proteins,Nucleoplasm (Supported),,,(M5926)HALLMARK MYC TARGETS V1
ENSG00000111642.16,ENSG00000111642,CHD4,0.659878438,0.996566869,0.682047387,0.301021058,chromodomain helicase DNA binding protein 4,"CHD4 is a human gene that encodes for the chromodomain helicase DNA binding protein 4, which belongs to the SNF2/RAD54 helicase family. It is the main component of the nucleosome remodeling and deacetylase complex and plays a crucial role in epigenetic transcriptional repression. Patients with dermatomyositis develop antibodies against this protein, and somatic mutations in this gene are associated with serous endometrial tumors. Alternative splicing results in multiple transcript variants that encode different isoforms.","There are currently no targeted drug discovery efforts specifically for CHD4, as it is primarily a transcriptional regulator and not a direct drug target. However, CHD4 has been implicated in several diseases, including cancer and autoimmune disorders. In particular, somatic mutations in CHD4 have been associated with serous endometrial tumors, and patients with dermatomyositis develop antibodies against this protein. 

There are currently no drugs on the market that directly target CHD4. However, there are several drugs that indirectly affect CHD4 activity by targeting its associated complex, the nucleosome remodeling and deacetylase (NuRD) complex. For example, the histone deacetylase inhibitor vorinostat has been shown to disrupt the NuRD complex and inhibit CHD4 activity, leading to increased apoptosis in cancer cells. Another drug, the DNA methyltransferase inhibitor decitabine, has also been shown to disrupt the NuRD complex and inhibit CHD4 activity, leading to increased differentiation of cancer cells.",GO:0072553 terminal button organization;GO:0042659 regulation of cell fate specification;GO:0099172 presynapse organization,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; Cancer-related genes:Mutated cancer genes; Cancer-related genes:Mutational cancer driver genes,Nucleoplasm (Enhanced),,(M101)PID HDAC CLASSI PATHWAY,
ENSG00000105518.14,ENSG00000105518,TMEM205,0.66046061,0.950903693,0.862216551,0.168261586,transmembrane protein 205,"TMEM205 is a human gene that is predicted to be an integral component of the membrane. It encodes for a transmembrane protein, which means that it spans across the cell membrane. However, the exact function of TMEM205 is not yet known. The gene is located on chromosome 3 and has been identified as a potential target for cancer therapy. Further research is needed to fully understand the role of TMEM205 in human biology and disease.","There is limited information available on the disease implications of TMEM205. However, recent studies have suggested that the gene may play a role in cancer development and progression. In particular, TMEM205 has been identified as a potential therapeutic target for the treatment of prostate cancer. Targeted drug discovery efforts are currently underway to develop drugs that can inhibit the activity of TMEM205 and prevent cancer growth. While there are no drugs currently on the market that specifically target TMEM205, there are several cancer drugs that have been successful in treating prostate cancer, including enzalutamide, abiraterone, and docetaxel. These drugs work by targeting different pathways involved in cancer growth and have been shown to improve survival rates in patients with advanced prostate cancer.",,,Predicted intracellular proteins; Transporters,Endoplasmic reticulum (Approved); Additional: Nuclear membrane;Nucleoplasm,,,
ENSG00000169189.17,ENSG00000169189,NSMCE1,0.663460838,0.802911794,0.547282849,0.640187872,"NSE1 homolog, SMC5-SMC6 complex component","NSMCE1 is a human gene that encodes for a protein involved in protein dimerization and ubiquitin protein ligase activity. It plays a role in positive regulation of response to DNA damage stimulus and is located in the nucleoplasm. NSMCE1 is a component of the Smc5-Smc6 complex, which is involved in DNA repair and maintenance of genome stability. This gene is a homolog of NSE1 and its function is conserved across species. Understanding the role of NSMCE1 in DNA repair and genome stability may have implications for the development of therapies for diseases related to DNA damage.","There is limited information available on the disease implications of NSMCE1. However, mutations in the Smc5-Smc6 complex, of which NSMCE1 is a component, have been associated with developmental disorders such as Cornelia de Lange syndrome and cohesinopathies. Targeted drug discovery efforts for NSMCE1 are also limited, likely due to the lack of understanding of its specific role in DNA repair and genome stability. Currently, there are no drugs on the market that specifically target NSMCE1. However, there are drugs that target other components of the Smc5-Smc6 complex, such as the PARP inhibitor olaparib, which has been approved for the treatment of ovarian and breast cancer in patients with BRCA mutations. Further research on NSMCE1 and the Smc5-Smc6 complex may lead to the development of new therapies for diseases related to DNA damage and genome instability.",GO:0016925 protein sumoylation;GO:0032204 regulation of telomere maintenance;GO:0018205 peptidyl-lysine modification,,Enzymes; Predicted intracellular proteins; ENZYME proteins:Transferases,Nucleoplasm (Supported); Additional: Vesicles,,,
ENSG00000158552.13,ENSG00000158552,ZFAND2B,0.665774972,1.307327258,0.625270966,0.064726691,zinc finger AN1-type containing 2B,"ZFAND2B is a human gene that encodes a protein containing AN1-type zinc-fingers and ubiquitin-interacting motifs. This protein is believed to associate with the proteosome, which is responsible for degrading toxic or misfolded proteins. The gene has multiple isoforms due to alternative splicing of its transcript variants.","There is limited information available on the disease implications of ZFAND2B. However, recent studies have suggested that this gene may play a role in the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ZFAND2B are currently underway, with a focus on identifying small molecule inhibitors that can selectively target the protein and prevent its interaction with the proteosome. While there are currently no drugs on the market that specifically target ZFAND2B, there are several drugs that target the proteosome and have shown efficacy in treating certain types of cancer. Examples include bortezomib, carfilzomib, and ixazomib, which are all approved for the treatment of multiple myeloma.","GO:0006616 SRP-dependent cotranslational protein targeting to membrane, translocation;GO:0043567 regulation of insulin-like growth factor receptor signaling pathway;GO:0006614 SRP-dependent cotranslational protein targeting to membrane",,Predicted intracellular proteins,Nucleoli;Nucleoli rim (Approved); Additional: Cytosol;Nucleoplasm,,,
ENSG00000105640.13,ENSG00000105640,RPL18A,0.666949595,1.104440608,0.778152423,0.118255753,ribosomal protein L18a,"RPL18A is a gene that encodes a ribosomal protein, specifically a member of the L18AE family, which is a component of the 60S subunit of ribosomes. Ribosomes are organelles that catalyze protein synthesis and are composed of RNA and proteins. The encoded protein may play a role in viral replication by interacting with the hepatitis C virus internal ribosome entry site (IRES). The gene is co-transcribed with the U68 snoRNA, located within the third intron. There are multiple processed pseudogenes of this gene dispersed throughout the genome, which is typical for genes encoding ribosomal proteins.","There is limited information on the disease implications of RPL18A. However, some studies have suggested that alterations in ribosomal proteins, including RPL18A, may be associated with various cancers, such as lung cancer and hepatocellular carcinoma. Targeted drug discovery efforts for RPL18A are also limited, but some studies have explored the potential of targeting ribosomal proteins for cancer therapy. For example, a small molecule inhibitor of ribosome biogenesis, CX-5461, has shown promising results in preclinical studies for the treatment of hematological malignancies. Additionally, some drugs that indirectly affect ribosomal function, such as mTOR inhibitors, have been approved for the treatment of certain cancers. However, there are currently no drugs on the market that specifically target RPL18A.",GO:0002181 cytoplasmic translation;GO:0006412 translation;GO:0010467 gene expression,,Ribosomal proteins; Predicted intracellular proteins,Nucleoli (Approved); Additional: Cytosol;Nucleoplasm,,,
ENSG00000125611.15,ENSG00000125611,CHCHD5,0.668338858,0.72087422,0.837976428,0.446165927,coiled-coil-helix-coiled-coil-helix domain containing 5,"The human gene CHCHD5 is predicted to be located in the mitochondrial intermembrane space. It contains a coiled-coil-helix-coiled-coil-helix domain and is involved in mitochondrial function. The exact function of CHCHD5 is not fully understood, but it has been implicated in neurodegenerative diseases such as Parkinson's and Alzheimer's. Mutations in CHCHD5 have been associated with mitochondrial dysfunction and impaired cellular respiration. Further research is needed to fully understand the role of CHCHD5 in mitochondrial function and its potential implications for human health.","There are currently no targeted drug discovery efforts specifically for CHCHD5, as its exact role in disease pathogenesis is still being investigated. However, given its association with neurodegenerative diseases such as Parkinson's and Alzheimer's, there is interest in developing drugs that target mitochondrial dysfunction, which may indirectly affect CHCHD5 function. Some examples of successful drugs on the market for neurodegenerative diseases include levodopa for Parkinson's and cholinesterase inhibitors for Alzheimer's. These drugs aim to alleviate symptoms rather than target the underlying cause of the disease. As research on CHCHD5 and mitochondrial function continues, it may lead to the development of more targeted therapies for these diseases.",GO:0045333 cellular respiration;GO:0015980 energy derivation by oxidation of organic compounds;GO:0006091 generation of precursor metabolites and energy,,Predicted intracellular proteins,Mitochondria (Approved),,,
ENSG00000244313.3,ENSG00000244313,AC024293.1,0.668484809,1.131425747,0.787679758,0.086348921,None,None,None,None,None,None,None,None,None,None
ENSG00000124172.10,ENSG00000124172,ATP5F1E,0.672778535,0.924403827,0.906784259,0.187147518,ATP synthase F1 subunit epsilon,"ATP5F1E is a gene that encodes a subunit of mitochondrial ATP synthase, which is responsible for catalyzing ATP synthesis using an electrochemical gradient of protons across the inner membrane during oxidative phosphorylation. The ATP synthase is composed of two linked multi-subunit complexes, the soluble catalytic core, F1, and the membrane-spanning component, Fo, comprising the proton channel. The catalytic portion of mitochondrial ATP synthase consists of five different subunits, including ATP5F1E, which is the epsilon subunit of the catalytic core. Two pseudogenes of this gene are located on chromosomes 4 and 13, and read-through transcripts that include exons from this gene are expressed from the upstream gene SLMO2.","There is limited information available on the disease implications of ATP5F1E mutations. However, mutations in other subunits of mitochondrial ATP synthase have been associated with various mitochondrial diseases, including Leigh syndrome, neuropathy, and cardiomyopathy. Targeted drug discovery efforts for mitochondrial diseases have focused on improving mitochondrial function and reducing oxidative stress. Some potential drug targets include mitochondrial biogenesis, mitophagy, and antioxidant pathways. Currently, there are no drugs specifically targeting ATP5F1E mutations. However, some drugs that improve mitochondrial function, such as coenzyme Q10 and idebenone, have been used to treat mitochondrial diseases. Additionally, some drugs that target oxidative stress, such as vitamin E and N-acetylcysteine, have shown promise in preclinical studies.",GO:0042776 proton motive force-driven mitochondrial ATP synthesis;GO:0015986 proton motive force-driven ATP synthesis;GO:0006754 ATP biosynthetic process,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,,,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000141552.18,ENSG00000141552,ANAPC11,0.673071103,0.764441124,0.794032115,0.46074007,anaphase promoting complex subunit 11,"ANAPC11 is a human gene that encodes for a protein that enables cullin family protein binding activity and ubiquitin-ubiquitin ligase activity. It contributes to ubiquitin-protein transferase activity and is involved in protein K11-linked ubiquitination. ANAPC11 is located in the nucleolus and nucleoplasm and is part of the anaphase-promoting complex. This gene plays a crucial role in regulating the cell cycle and ensuring proper chromosome segregation during cell division. Mutations in ANAPC11 have been associated with various types of cancer, highlighting its importance in maintaining genomic stability.","ANAPC11 has been implicated in various types of cancer, including breast, lung, and colorectal cancer. In breast cancer, ANAPC11 expression has been found to be significantly upregulated, and its overexpression has been associated with poor prognosis. Targeting ANAPC11 has been explored as a potential therapeutic strategy for cancer treatment. One study found that inhibiting ANAPC11 expression using RNA interference led to decreased cell proliferation and increased apoptosis in breast cancer cells. However, there are currently no drugs specifically targeting ANAPC11 on the market. Nevertheless, several drugs targeting the anaphase-promoting complex, of which ANAPC11 is a component, have been approved for cancer treatment, including bortezomib for multiple myeloma and mantle cell lymphoma, and ixazomib for multiple myeloma.",GO:0045842 positive regulation of mitotic metaphase/anaphase transition;GO:1902101 positive regulation of metaphase/anaphase transition of cell cycle;GO:0141198 protein branched polyubiquitination,,Predicted intracellular proteins,Nucleoplasm (Enhanced); Additional: Nucleoli,,,
ENSG00000183978.8,ENSG00000183978,COA3,0.674048299,0.741174922,0.661052797,0.619917177,cytochrome c oxidase assembly factor 3,"COA3 is a gene that belongs to the cytochrome c oxidase assembly factor family. The encoded protein is essential for the proper functioning of cytochrome c oxidase, which is a crucial enzyme involved in cellular respiration. Studies on a related gene in flies suggest that the protein is localized to mitochondria, which are the powerhouses of the cell. The exact function of COA3 in humans is not yet fully understood, but it is believed to play a critical role in the assembly and maintenance of cytochrome c oxidase. Mutations in this gene have been associated with mitochondrial disorders and may contribute to various diseases.","Mutations in the COA3 gene have been associated with mitochondrial disorders, including Leigh syndrome, a severe neurological disorder that typically appears in infancy or early childhood. Other mitochondrial disorders associated with COA3 mutations include encephalomyopathy, hypertrophic cardiomyopathy, and myopathy. Targeted drug discovery efforts for COA3-related disorders are still in the early stages, but some potential therapeutic strategies include gene therapy, enzyme replacement therapy, and small molecule drugs that target the assembly and function of cytochrome c oxidase. Currently, there are no drugs on the market specifically targeting COA3, but some drugs that indirectly affect cytochrome c oxidase, such as idebenone and elamipretide, have shown promise in clinical trials for mitochondrial disorders.",GO:0070131 positive regulation of mitochondrial translation;GO:0033617 mitochondrial cytochrome c oxidase assembly;GO:0070129 regulation of mitochondrial translation,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Enhanced),,,
ENSG00000171425.10,ENSG00000171425,ZNF581,0.677849894,1.148033292,0.815597595,0.069918794,zinc finger protein 581,"ZNF581 is a human gene that encodes for a zinc finger protein 581. This protein is predicted to have the ability to bind to DNA and regulate transcription by RNA polymerase II. It is also predicted to be located in the nucleus. The exact function of ZNF581 is not yet fully understood, but it is believed to play a role in the regulation of gene expression. Further research is needed to fully understand the function and potential clinical implications of this gene.","There is currently limited information available on the disease implications of ZNF581. However, some studies have suggested that it may be involved in the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ZNF581 are also limited, as its exact function and role in disease are not yet fully understood. There are currently no drugs on the market that specifically target ZNF581. However, there are several drugs that target other proteins involved in the regulation of gene expression, such as histone deacetylases and DNA methyltransferases, which may indirectly affect the activity of ZNF581. Further research is needed to fully understand the potential clinical implications of ZNF581 and to develop targeted therapies for diseases associated with its dysregulation.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm;Vesicles (Approved); Additional: Cytosol,,,
ENSG00000172590.18,ENSG00000172590,MRPL52,0.67983704,0.907031628,0.774909564,0.357569928,mitochondrial ribosomal protein L52,"The human gene MRPL52 encodes a protein called mitochondrial ribosomal protein L52, which is a component of the large 39S subunit of the mitochondrial ribosome. Mitochondrial ribosomes are responsible for protein synthesis within the mitochondria, and are composed of both protein and RNA molecules. Unlike prokaryotic ribosomes, which have a higher ratio of RNA to protein, mammalian mitochondrial ribosomes have a higher proportion of protein. The proteins that make up the mitochondrial ribosome vary greatly between species, making them difficult to identify through sequence homology. Multiple variants of MRPL52 have been identified, encoding different isoforms of the protein.","There is limited information available on the disease implications of MRPL52 mutations. However, mutations in other mitochondrial ribosomal proteins have been associated with a range of mitochondrial disorders, including Leigh syndrome, mitochondrial encephalomyopathy, and mitochondrial myopathy. Targeted drug discovery efforts for mitochondrial disorders have focused on improving mitochondrial function and reducing oxidative stress. Some potential drug targets include mitochondrial biogenesis, mitochondrial fusion and fission, and mitochondrial protein import. Currently, there are no drugs specifically targeting MRPL52 or mitochondrial ribosomal proteins. However, drugs targeting mitochondrial function, such as coenzyme Q10 and idebenone, have shown some success in treating mitochondrial disorders. Additionally, drugs targeting oxidative stress, such as antioxidants and free radical scavengers, have also been investigated as potential treatments for mitochondrial disorders.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Ribosomal proteins; Predicted intracellular proteins,Mitochondria (Supported); Additional: Nucleoplasm,,,
ENSG00000146540.15,ENSG00000146540,C7orf50,0.682630866,0.857425046,0.831536336,0.358931217,cholesin,"C7orf50 is a human gene located on chromosome 7 and is also known as chromosome 7 open reading frame 50. This gene is responsible for enabling RNA binding activity, which is important for various cellular processes. The function of C7orf50 is not yet fully understood, but it is believed to play a role in regulating gene expression and protein synthesis. Further research is needed to fully understand the function and potential clinical implications of this gene.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for C7orf50. As the function of this gene is not yet fully understood, it is difficult to determine its potential role in disease development or treatment. Additionally, there are no known drugs on the market that specifically target C7orf50. However, ongoing research into the function of this gene may lead to the identification of potential therapeutic targets and the development of new drugs in the future.",GO:0045541 negative regulation of cholesterol biosynthetic process;GO:0106119 negative regulation of sterol biosynthetic process;GO:0090206 negative regulation of cholesterol metabolic process,,Predicted intracellular proteins,Nucleoli;Nucleoplasm (Approved),,,
ENSG00000127922.9,ENSG00000127922,SEM1,0.682807591,0.879901634,1.01577897,0.152742168,SEM1 26S proteasome subunit,SEM1 is a gene located on chromosome 7 that has been linked to the limb developmental disorder split hand/split foot malformation type 1. It is a candidate gene for the autosomal dominant form of this disorder. SEM1 has also been shown to interact with BRCA2 and may play a role in the completion of the cell cycle.,"There is currently no targeted drug discovery effort for SEM1 as it is primarily associated with the developmental disorder split hand/split foot malformation type 1. Treatment for this disorder is typically focused on managing symptoms and improving quality of life. However, SEM1's interaction with BRCA2 has led to some research into its potential role in cancer development and treatment. One study found that SEM1 expression was significantly higher in breast cancer tissues compared to normal tissues, suggesting it may be a potential therapeutic target. However, there are currently no drugs on the market targeting SEM1 or its interaction with BRCA2. Successful drugs for treating split hand/split foot malformation type 1 include prosthetic devices and surgical interventions to improve limb function and appearance.",GO:0043248 proteasome assembly;GO:0006406 mRNA export from nucleus;GO:0006405 RNA export from nucleus,,Predicted intracellular proteins,Cytosol (Approved),,,
ENSG00000244398.1,ENSG00000244398,AC116533.1,0.683686823,1.088672125,0.746452617,0.215935727,ribosomal protein L36a pseudogene 37,,,,,,,,,
ENSG00000167526.14,ENSG00000167526,RPL13,0.686026565,1.090930692,0.722357764,0.24479124,ribosomal protein L13,RPL13 is a gene that encodes a ribosomal protein that is a component of the 60S subunit of ribosomes. Ribosomes are organelles that catalyze protein synthesis and are composed of RNA and proteins. RPL13 belongs to the L13E family of ribosomal proteins and is located in the cytoplasm. This gene is expressed at higher levels in benign breast lesions than in breast carcinomas. There are multiple processed pseudogenes of this gene dispersed throughout the genome. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.,"There is limited information available on the disease implications of RPL13. However, recent studies have suggested that RPL13 may play a role in the development and progression of certain cancers, including breast cancer and lung cancer. Targeted drug discovery efforts for RPL13 are still in the early stages, but there is potential for the development of drugs that target this gene and its associated pathways.

Currently, there are no drugs on the market that specifically target RPL13. However, there are several drugs that target ribosomal proteins in general, such as the macrolide antibiotics erythromycin and azithromycin, which bind to the 50S subunit of ribosomes and inhibit protein synthesis. Another example is the drug tigecycline, which targets the 30S subunit of ribosomes and is used to treat infections caused by multidrug-resistant bacteria. These drugs have been successful in treating a variety of bacterial infections, but their potential for treating cancer and other diseases associated with ribosomal dysfunction is still being explored.",GO:0001824 blastocyst development;GO:0002181 cytoplasmic translation;GO:0060348 bone development,,Disease related genes; Ribosomal proteins; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Predicted intracellular proteins,Cytosol;Endoplasmic reticulum;Nucleoli (Enhanced),,,
ENSG00000173915.16,ENSG00000173915,ATP5MD,0.689020441,0.960257222,0.699271974,0.407532128,ATP synthase membrane subunit k,"ATP5MK is a gene that is located in the mitochondrion and is part of the mitochondrial proton-transporting ATP synthase complex. It is involved in the production of ATP, which is the main source of energy for cells. Mutations in this gene have been linked to mitochondrial complex V (ATP synthase) deficiency nuclear type 6, a rare genetic disorder that affects the function of the mitochondria and can lead to a range of symptoms, including muscle weakness, developmental delays, and neurological problems.","Mitochondrial complex V (ATP synthase) deficiency nuclear type 6, caused by mutations in the ATP5MK gene, is a rare genetic disorder that affects the function of the mitochondria and can lead to a range of symptoms, including muscle weakness, developmental delays, and neurological problems. There are currently no targeted drug discovery efforts specifically for ATP5MK mutations, but there are some drugs on the market that can help alleviate symptoms associated with mitochondrial disorders. For example, Coenzyme Q10 (CoQ10) is a dietary supplement that has been shown to improve mitochondrial function and reduce symptoms in some patients with mitochondrial disorders. Another drug, EPI-743, is currently in clinical trials for the treatment of mitochondrial disorders and has shown promising results in improving mitochondrial function and reducing symptoms. However, more research is needed to develop targeted therapies for ATP5MK mutations and other mitochondrial disorders.",GO:0015986 proton motive force-driven ATP synthesis;GO:0006754 ATP biosynthetic process;GO:0009206 purine ribonucleoside triphosphate biosynthetic process,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Supported),,,
ENSG00000169972.12,ENSG00000169972,PUSL1,0.690696112,1.192597053,0.676369449,0.203121835,pseudouridine synthase like 1,"The human gene PUSL1, also known as pseudouridine synthase like 1, is predicted to have pseudouridine synthase activity and is involved in tRNA pseudouridine synthesis. It is located in the mitochondrion. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of PUSL1. However, mutations in this gene have been associated with mitochondrial myopathy, a rare genetic disorder that affects the muscles and is caused by defects in mitochondrial function. Targeted drug discovery efforts for PUSL1 are also limited, as the function of this gene is not well understood. However, there have been some studies investigating the potential of targeting pseudouridine synthases for cancer therapy, as these enzymes are involved in RNA modification and have been shown to play a role in cancer progression. Currently, there are no drugs on the market that specifically target PUSL1. However, there are drugs that target other pseudouridine synthases, such as Erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA), which has been shown to inhibit the activity of PUS10, another pseudouridine synthase. EHNA has been investigated as a potential treatment for cancer and viral infections, but has not yet been approved for clinical use.",GO:0031119 tRNA pseudouridine synthesis;GO:0001522 pseudouridine synthesis;GO:0006400 tRNA modification,,Predicted intracellular proteins,Vesicles (Enhanced),,,
ENSG00000139428.12,ENSG00000139428,MMAB,0.692121653,1.131467929,0.861991117,0.082905915,metabolism of cobalamin associated B,"The MMAB gene encodes a protein that plays a crucial role in the conversion of vitamin B12 into adenosylcobalamin (AdoCbl), which is a coenzyme for methylmalonyl-CoA mutase. Mutations in this gene have been linked to vitamin B12-dependent methylmalonic aciduria, which is associated with the cblB complementation group. This condition is characterized by the accumulation of methylmalonic acid in the blood and urine, leading to neurological and developmental problems. The MMAB gene has multiple alternatively spliced transcript variants.","Vitamin B12-dependent methylmalonic aciduria is a rare autosomal recessive disorder caused by mutations in the MMAB gene. There are currently no targeted drug discovery efforts for this condition, and treatment is focused on managing symptoms and preventing complications. Patients with this condition require lifelong vitamin B12 supplementation and a low-protein diet. In severe cases, liver or kidney transplantation may be necessary. There are no drugs specifically approved for the treatment of vitamin B12-dependent methylmalonic aciduria, but some drugs have been used off-label to manage symptoms. For example, carnitine supplementation may help improve energy metabolism, and antibiotics may be used to prevent infections. Overall, the management of this condition is challenging, and there is a need for more research to develop targeted therapies.",GO:0009235 cobalamin metabolic process;GO:0033013 tetrapyrrole metabolic process;GO:0006767 water-soluble vitamin metabolic process,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of amino acid metabolism; Predicted intracellular proteins,Mitochondria (Approved),,,
ENSG00000156411.10,ENSG00000156411,ATP5MPL,0.693069599,0.95858162,0.76555426,0.355072917,ATP synthase membrane subunit j,"ATP5MJ is a human gene that is predicted to be located in the mitochondrion and is an integral component of the membrane. It is also predicted to be part of the mitochondrial proton-transporting ATP synthase complex. This gene encodes for the ATP synthase membrane subunit j, which is involved in the production of ATP, the main energy source for cellular processes. The ATP synthase complex is responsible for generating ATP by using the energy from a proton gradient across the mitochondrial membrane. Dysfunction of this complex can lead to various mitochondrial diseases and disorders.","Mutations in the ATP5MJ gene have been associated with various mitochondrial disorders, including Leigh syndrome, a severe neurological disorder, and mitochondrial complex V deficiency, which can cause a range of symptoms such as muscle weakness, developmental delays, and seizures. Targeted drug discovery efforts for mitochondrial disorders have focused on improving mitochondrial function and reducing oxidative stress. One example of a successful drug on the market is idebenone, which has been approved for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disorder that causes vision loss. Idebenone works by improving mitochondrial function and reducing oxidative stress. Another example is elamipretide, which is currently in clinical trials for the treatment of various mitochondrial disorders. Elamipretide targets the mitochondrial membrane and has been shown to improve mitochondrial function and reduce oxidative stress in preclinical studies.",GO:0015986 proton motive force-driven ATP synthesis;GO:0006754 ATP biosynthetic process;GO:0009206 purine ribonucleoside triphosphate biosynthetic process,,Predicted intracellular proteins,Mitochondria (Supported); Additional: Nucleoli fibrillar center,,,
ENSG00000204435.15,ENSG00000204435,CSNK2B,0.693121727,0.835957773,1.041106176,0.202301234,casein kinase 2 beta,"CSNK2B is a gene that encodes the beta subunit of casein kinase II, a protein kinase that plays a role in regulating various cellular processes such as metabolism, signal transduction, transcription, translation, and replication. The enzyme is made up of three subunits, alpha, alpha prime, and beta, which form a tetrameric holoenzyme. The alpha and alpha prime subunits are catalytic, while the beta subunit serves regulatory functions. CSNK2B is found in the endoplasmic reticulum and the Golgi apparatus. Two different isoforms of CSNK2B have been identified.","CSNK2B has been implicated in various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. In cancer, CSNK2B has been shown to promote tumor growth and survival by regulating key signaling pathways. Targeting CSNK2B has been explored as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of CSNK2B have been developed and tested in preclinical and clinical studies, including CX-4945, which has shown promising results in clinical trials for multiple cancer types. In addition, CSNK2B has also been implicated in neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease, and targeting CSNK2B has been explored as a potential therapeutic strategy for these diseases. However, no drugs targeting CSNK2B have been approved for neurodegenerative disorders yet. Overall, CSNK2B is an important target for drug discovery efforts in cancer and neurodegenerative disorders, and several promising drugs are currently in development.",GO:0052008 symbiont-mediated disruption of host cellular anatomical structure;GO:0052111 symbiont-mediated disruption of host anatomical structure;GO:0075342 symbiont-mediated disruption of host cell PML body,,Disease related genes; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported); Additional: Calyx;Mid piece;Nucleoli fibrillar center;Perinuclear theca,ATP; Quercetin,(M42)PID DNA PK PATHWAY; (M26)PID NFKAPPAB ATYPICAL PATHWAY; (M185)PID ALK1 PATHWAY,(M5923)HALLMARK PI3K AKT MTOR SIGNALING
ENSG00000177600.9,ENSG00000177600,RPLP2,0.696300246,1.1677751,0.837841448,0.08328419,ribosomal protein lateral stalk subunit P2,"RPLP2 is a gene that encodes a ribosomal phosphoprotein that is a component of the 60S subunit of ribosomes. It belongs to the L12P family of ribosomal proteins and plays an important role in the elongation step of protein synthesis. Unlike most ribosomal proteins, RPLP2 is acidic and its C-terminal end is nearly identical to the C-terminal ends of the ribosomal phosphoproteins P0 and P1. The P2 protein can interact with P0 and P1 to form a pentameric complex consisting of P1 and P2 dimers, and a P0 monomer. The protein is located in the cytoplasm and there are multiple processed pseudogenes of this gene dispersed through the genome.","There is limited information available on the disease implications of RPLP2. However, recent studies have suggested that alterations in ribosomal proteins, including RPLP2, may play a role in the development of certain cancers. Targeted drug discovery efforts for RPLP2 are also limited, as it is a component of the ribosome and targeting it directly may have negative effects on normal cellular function. However, there are drugs that indirectly affect RPLP2 function by targeting the ribosome as a whole. For example, macrolide antibiotics such as erythromycin and azithromycin bind to the 50S subunit of the ribosome, inhibiting protein synthesis and ultimately leading to bacterial cell death. Another example is the drug cycloheximide, which binds to the 60S subunit of the ribosome and inhibits protein synthesis in eukaryotic cells. These drugs have been successful in treating bacterial infections and certain types of cancer, respectively.",GO:0002182 cytoplasmic translational elongation;GO:0006414 translational elongation;GO:0002181 cytoplasmic translation,,Ribosomal proteins; Predicted intracellular proteins,Cytosol;Nuclear speckles (Approved); Additional: Mitotic spindle,,,
ENSG00000133265.11,ENSG00000133265,HSPBP1,0.699174954,0.96275162,0.762401062,0.372372179,HSPA (Hsp70) binding protein 1,"HSPBP1 is a human gene that encodes for a protein called HSPA binding protein 1. This protein is involved in the regulation of protein degradation through the ubiquitin-proteasome system. It enables the binding of ubiquitin protein ligases and positively regulates the ubiquitination process. HSPBP1 is predicted to be active in the endoplasmic reticulum, a cellular organelle involved in protein synthesis and folding. Overall, HSPBP1 plays an important role in maintaining protein homeostasis in cells.","There is limited information available on the disease implications of HSPBP1. However, some studies have suggested that mutations in this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for HSPBP1 are also limited, as the protein's function and role in disease are not well understood. Currently, there are no drugs on the market that specifically target HSPBP1. However, there are drugs that target the ubiquitin-proteasome system, which is regulated by HSPBP1. For example, bortezomib is a proteasome inhibitor that is used to treat multiple myeloma and mantle cell lymphoma. Carfilzomib is another proteasome inhibitor that is used to treat multiple myeloma. These drugs work by blocking the degradation of proteins, leading to the accumulation of toxic proteins and ultimately cell death.",GO:0032436 positive regulation of proteasomal ubiquitin-dependent protein catabolic process;GO:2000060 positive regulation of ubiquitin-dependent protein catabolic process;GO:0031398 positive regulation of protein ubiquitination,,Predicted intracellular proteins,Cytosol (Approved); Additional: Centrosome;Vesicles,,,
ENSG00000178982.10,ENSG00000178982,EIF3K,0.703405831,1.060751267,0.695889622,0.353576603,eukaryotic translation initiation factor 3 subunit K,"EIF3K is a subunit of eukaryotic translation initiation factor 3 (eIF3), which is a large complex consisting of at least 12 subunits. eIF3 plays a crucial role in translation by binding to the 40S ribosomal subunit and promoting the formation of the 40S preinitiation complex. EIF3K is involved in the regulation of protein synthesis and is required for the initiation of translation. It has been shown to interact with other subunits of eIF3 and with other proteins involved in translation initiation. Mutations in EIF3K have been associated with various diseases, including cancer and intellectual disability.","There is limited information available on targeted drug discovery efforts for EIF3K, as it is a relatively new target for drug development. However, there is growing interest in targeting eIF3 and its subunits for cancer therapy, as dysregulation of translation initiation is a hallmark of cancer. EIF3K has been implicated in several types of cancer, including breast, lung, and liver cancer, and targeting it could potentially lead to the development of new cancer therapies.

Currently, there are no drugs on the market that specifically target EIF3K. However, there are several drugs that target other subunits of eIF3, such as the small molecule inhibitor, rocaglamide, which targets eIF4A, a subunit of eIF3. Rocaglamide has shown promising results in preclinical studies for the treatment of various types of cancer, including leukemia, lymphoma, and breast cancer. Another drug, silvestrol, also targets eIF4A and has shown antitumor activity in preclinical studies.

In addition to cancer, mutations in EIF3K have been associated with intellectual disability, and there is ongoing research to better understand the role of EIF3K in this condition. However, there are currently no targeted drug discovery efforts for EIF3K-related intellectual disability.",GO:0001732 formation of cytoplasmic translation initiation complex;GO:0002183 cytoplasmic translational initiation;GO:0006413 translational initiation,,Predicted intracellular proteins,Cytosol (Supported),,,
ENSG00000137288.10,ENSG00000137288,UQCC2,0.704444842,1.108352638,0.811951853,0.193030034,ubiquinol-cytochrome c reductase complex assembly factor 2,"UQCC2 is a gene that encodes a protein found in the mitochondria inner membrane. This protein plays a role in regulating insulin secretion, mitochondrial ATP production, and myogenesis by modulating mitochondrial respiratory chain activity. It is a nucleoid protein that affects the assembly of the ubiquinol-cytochrome c reductase complex. Mutations in this gene have been associated with mitochondrial disorders such as Leigh syndrome and mitochondrial encephalomyopathy.","Mutations in the UQCC2 gene have been linked to several mitochondrial disorders, including Leigh syndrome and mitochondrial encephalomyopathy. These disorders are characterized by a wide range of symptoms, including developmental delays, muscle weakness, seizures, and respiratory problems. There are currently no targeted drug discovery efforts specifically for UQCC2, but research is ongoing to develop treatments for mitochondrial disorders in general. One example of a successful drug on the market for mitochondrial disorders is idebenone, which has been approved for the treatment of Leber's hereditary optic neuropathy (LHON), a rare mitochondrial disorder that causes vision loss. Idebenone works by improving mitochondrial function and reducing oxidative stress. Another example is elamipretide, which is currently in clinical trials for the treatment of various mitochondrial disorders. Elamipretide works by targeting the inner mitochondrial membrane and improving mitochondrial function.",GO:0017062 respiratory chain complex III assembly;GO:0034551 mitochondrial respiratory chain complex III assembly;GO:0070131 positive regulation of mitochondrial translation,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Supported); Additional: Nuclear bodies,,,
ENSG00000147123.11,ENSG00000147123,NDUFB11,0.704634563,0.894382068,0.892107476,0.327414143,NADH:ubiquinone oxidoreductase subunit B11,"The NDUFB11 gene encodes a protein that is a subunit of the NADH:ubiquinone oxidoreductase complex I, which is located in the mitochondrial inner membrane. This protein has NADH dehydrogenase and oxidoreductase activity, transferring electrons from NADH to ubiquinone. Mutations in this gene have been associated with linear skin defects with multiple congenital anomalies 3 and mitochondrial complex I deficiency.","Mutations in the NDUFB11 gene have been associated with several diseases, including linear skin defects with multiple congenital anomalies 3 and mitochondrial complex I deficiency. These conditions are characterized by a range of symptoms, including developmental delays, intellectual disability, seizures, and skin abnormalities. 

Targeted drug discovery efforts for NDUFB11-related diseases are still in the early stages, but there is growing interest in developing drugs that can improve mitochondrial function. One approach is to develop compounds that can bypass the defective complex I and restore electron transport. Another strategy is to target the downstream effects of mitochondrial dysfunction, such as oxidative stress and inflammation. 

There are currently no drugs on the market specifically targeting NDUFB11-related diseases. However, there are several drugs that have been approved for other mitochondrial disorders that may have potential for treating these conditions. For example, idebenone has been approved for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disorder that affects the eyes. This drug works by improving mitochondrial function and reducing oxidative stress. Another drug, elamipretide, is currently in clinical trials for the treatment of mitochondrial myopathy, a condition that affects the muscles. Elamipretide works by targeting the mitochondrial membrane and improving energy production.",GO:0010257 NADH dehydrogenase complex assembly;GO:0032981 mitochondrial respiratory chain complex I assembly;GO:0042776 proton motive force-driven mitochondrial ATP synthesis,,Disease related genes; Human disease related genes:Congenital malformations:Other congenital malformations; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Supported); Additional: Acrosome;Connecting piece;Equatorial segment;Mid piece;Principal piece,,,
ENSG00000204498.11,ENSG00000204498,NFKBIL1,0.704722472,0.964417301,0.622278588,0.527471526,NFKB inhibitor like 1,NFKBIL1 is a gene that belongs to the I-kappa-B family of proteins. Its exact function is not yet known. The gene is located in the major histocompatibility complex (MHC) class I region on chromosome 6. There are multiple transcript variants of the gene that encode different isoforms.,"Research on NFKBIL1 and its potential disease implications is still ongoing, and there is limited information available on targeted drug discovery efforts. However, some studies suggest that NFKBIL1 may play a role in inflammatory and immune-related diseases, such as rheumatoid arthritis and multiple sclerosis. 

Currently, there are no drugs specifically targeting NFKBIL1 on the market. However, there are drugs that target the NF-kappa-B pathway, which NFKBIL1 is a part of. For example, the drug adalimumab targets TNF-alpha, a cytokine that activates the NF-kappa-B pathway, and is used to treat rheumatoid arthritis, psoriasis, and other inflammatory diseases. Another drug, bortezomib, inhibits the proteasome, which is involved in the degradation of I-kappa-B proteins, leading to the activation of NF-kappa-B. Bortezomib is used to treat multiple myeloma and mantle cell lymphoma. 

Further research on NFKBIL1 and its role in disease may lead to the development of new targeted therapies in the future.",GO:0031665 negative regulation of lipopolysaccharide-mediated signaling pathway;GO:0034122 negative regulation of toll-like receptor signaling pathway;GO:0031664 regulation of lipopolysaccharide-mediated signaling pathway,,Human disease related genes:Immune system diseases:Allergies and autoimmune diseases; Transcription factors:Immunoglobulin fold; Predicted intracellular proteins,Nucleoplasm (Supported),,(M12705)SIG CD40PATHWAYMAP,
ENSG00000233927.5,ENSG00000233927,RPS28,0.707483594,1.165937898,0.645612834,0.310900051,ribosomal protein S28,"RPS28 is a gene that encodes a ribosomal protein, specifically a component of the 40S subunit of ribosomes. Ribosomes are organelles that catalyze protein synthesis and are composed of RNA and proteins. RPS28 belongs to the S28E family of ribosomal proteins and is located in the cytoplasm. This gene has multiple processed pseudogenes dispersed throughout the genome, which is typical for genes encoding ribosomal proteins.","There is limited information available on the disease implications of RPS28 mutations. However, mutations in other ribosomal protein genes have been associated with a variety of diseases, including Diamond-Blackfan anemia, cancer, and developmental disorders. Targeted drug discovery efforts for ribosomal protein genes have focused on identifying compounds that selectively inhibit the translation of cancer cells, while sparing normal cells. Several drugs targeting ribosomal proteins have been approved for cancer treatment, including the mTOR inhibitor everolimus and the proteasome inhibitor bortezomib. Additionally, preclinical studies have shown promising results for compounds targeting ribosomal proteins in other diseases, such as cystic fibrosis and viral infections. However, further research is needed to fully understand the potential therapeutic applications of targeting RPS28 and other ribosomal protein genes.",GO:0000028 ribosomal small subunit assembly;GO:0030490 maturation of SSU-rRNA;GO:0042255 ribosome assembly,,Predicted intracellular proteins; Ribosomal proteins; Human disease related genes:Other congenital disorders:Ribosomopathies; Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases,Cytosol (Approved),Artenimol,,
ENSG00000183648.11,ENSG00000183648,NDUFB1,0.710152352,0.660472211,0.872272236,0.597712608,NADH:ubiquinone oxidoreductase subunit B1,"The human gene NDUFB1 is a subunit of the NADH:ubiquinone oxidoreductase complex I, which is involved in the assembly of the mitochondrial respiratory chain. It is located in both the mitochondrion and nuclear speck. The NDUFB1 gene plays a crucial role in the functioning of the mitochondrial respiratory chain complex I, which is responsible for the production of ATP, the energy currency of the cell. Mutations in this gene have been associated with various mitochondrial disorders, including Leigh syndrome and mitochondrial encephalomyopathy. Understanding the function of NDUFB1 is important for developing treatments for these disorders.","Mutations in the NDUFB1 gene have been associated with various mitochondrial disorders, including Leigh syndrome and mitochondrial encephalomyopathy. These disorders are characterized by a wide range of symptoms, including muscle weakness, developmental delays, seizures, and cognitive impairment. There are currently no targeted drug discovery efforts specifically for NDUFB1, but research is ongoing to develop treatments for mitochondrial disorders in general. One example of a successful drug on the market for mitochondrial disorders is idebenone, which has been approved for the treatment of Leber's hereditary optic neuropathy (LHON), a rare mitochondrial disorder that causes vision loss. Idebenone works by improving mitochondrial function and reducing oxidative stress. Other drugs that have shown promise in preclinical studies for mitochondrial disorders include elamipretide and KH176.","GO:0006120 mitochondrial electron transport, NADH to ubiquinone;GO:0010257 NADH dehydrogenase complex assembly;GO:0032981 mitochondrial respiratory chain complex I assembly",,Predicted intracellular proteins,Mitochondria (Supported); Additional: Nuclear speckles,NADH,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000171443.7,ENSG00000171443,ZNF524,0.710393214,0.953861551,0.865225529,0.312092562,zinc finger protein 524,ZNF524 is a human gene that encodes for a zinc finger protein 524. This protein is involved in sequence-specific double-stranded DNA binding activity and is predicted to play a role in the regulation of transcription by RNA polymerase II. It is also predicted to be located in the nucleus.,"There is limited information available on the disease implications of ZNF524. However, some studies have suggested that it may be involved in the development of certain cancers, such as breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for ZNF524 are also limited, as its function and role in disease are not well understood. Currently, there are no drugs on the market that specifically target ZNF524. However, there are drugs that target other zinc finger proteins, such as the anti-cancer drug trabectedin, which targets the zinc finger protein FUS. Further research is needed to fully understand the role of ZNF524 in disease and to develop targeted therapies for any associated conditions.",GO:0006357 regulation of transcription by RNA polymerase II;GO:0006355 regulation of DNA-templated transcription;GO:2001141 regulation of RNA biosynthetic process,,Transcription factors:Zinc-coordinating DNA-binding domains; Predicted intracellular proteins,Nucleoplasm (Approved),,,
ENSG00000174276.7,ENSG00000174276,ZNHIT2,0.712016376,0.873356636,0.874873474,0.387819016,zinc finger HIT-type containing 2,"The human gene ZNHIT2, also known as zinc finger HIT-type containing 2, is predicted to have metal ion binding activity. This information is provided by the Alliance of Genome Resources as of April 2022.","There is limited information available on the disease implications of ZNHIT2. However, some studies have suggested that alterations in the expression of this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. Additionally, ZNHIT2 has been implicated in the regulation of immune responses and may play a role in autoimmune diseases such as systemic lupus erythematosus.

As of April 2022, there are no targeted drug discovery efforts specifically focused on ZNHIT2. However, given its potential involvement in cancer and immune regulation, it is possible that future drug development efforts may target this gene.

There are currently no drugs on the market that directly target ZNHIT2. However, there are several drugs that have been approved for the treatment of breast cancer and hepatocellular carcinoma, which are diseases that have been associated with alterations in ZNHIT2 expression. Examples of such drugs include tamoxifen, trastuzumab, and sorafenib. These drugs target specific molecular pathways involved in cancer development and progression, rather than directly targeting ZNHIT2.",,,Predicted intracellular proteins,,,,
ENSG00000105393.16,ENSG00000105393,BABAM1,0.714082572,1.099800489,0.847159647,0.19528758,BRISC and BRCA1 A complex member 1,"BABAM1 is a human gene that plays a role in various biological processes, including DNA damage checkpoint signaling, DNA repair, and protein deubiquitination. It is found in both the cytosol and nuclear body and is a member of both the BRCA1-A complex and the BRISC complex. The BRCA1-A complex is involved in DNA repair and tumor suppression, while the BRISC complex is involved in regulating immune responses and inflammation. BABAM1's involvement in these complexes suggests that it may play a role in maintaining genomic stability and preventing the development of cancer.","There is limited information available on the disease implications of BABAM1. However, studies have suggested that mutations in the gene may be associated with an increased risk of breast and ovarian cancer. Targeted drug discovery efforts for BABAM1 are also limited, as the gene is not currently considered a druggable target. However, research on the BRCA1-A complex and the BRISC complex, of which BABAM1 is a member, has led to the development of targeted therapies for breast and ovarian cancer, such as PARP inhibitors. These drugs work by inhibiting the activity of PARP enzymes, which are involved in DNA repair, and can be particularly effective in patients with mutations in BRCA1 or BRCA2 genes. Examples of successful PARP inhibitors on the market include olaparib, rucaparib, and niraparib.",GO:0140861 DNA repair-dependent chromatin remodeling;GO:0071425 hematopoietic stem cell proliferation;GO:0007095 mitotic G2 DNA damage checkpoint signaling,,Predicted intracellular proteins,Nuclear bodies (Enhanced); Additional: Cytosol;Nucleoplasm,,,
ENSG00000128309.16,ENSG00000128309,MPST,0.715465692,0.965815409,0.64014613,0.540435537,mercaptopyruvate sulfurtransferase,"The MPST gene encodes a protein that facilitates the transfer of a sulfur ion from 3-mercaptopyruvate to cyanide or other thiol compounds. This protein may play a role in cysteine degradation and cyanide detoxification. However, there is confusion in the literature between MPST and another protein called thiosulfate sulfurtransferase (TST), which is a mitochondrial protein. MPST deficiency has been linked to a rare inherited disorder called mercaptolactate-cysteine disulfiduria (MCDU). The gene has multiple alternatively spliced transcript variants that encode the same or different isoforms.","MPST deficiency has been linked to mercaptolactate-cysteine disulfiduria (MCDU), a rare inherited disorder characterized by the excretion of mercaptolactate and cysteine disulfide in urine. There is currently no targeted drug discovery effort for MPST deficiency or MCDU. However, some drugs have been developed to target other sulfur transferases, such as TST, which is structurally similar to MPST. For example, sodium thiosulfate is used to treat cyanide poisoning by acting as a sulfur donor to TST, which detoxifies cyanide. Another drug, amifostine, is a prodrug that is converted to a thiol compound in the body and acts as a cytoprotective agent by scavenging free radicals and reducing oxidative stress. While these drugs do not directly target MPST, they demonstrate the potential for sulfur transferase-targeted drug development.",GO:0009439 cyanate metabolic process;GO:0009440 cyanate catabolic process;GO:0070814 hydrogen sulfide biosynthetic process,,Predicted intracellular proteins; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Mitochondria (Approved); Additional: Cytosol,,,
ENSG00000137767.14,ENSG00000137767,SQOR,0.715982954,1.18307603,0.633792665,0.331080166,sulfide quinone oxidoreductase,"The SQOR gene encodes a protein that may play a role in converting sulfide to persulfides in mitochondria, which helps to reduce toxic levels of sulfide. Alternative splicing of the gene results in multiple transcript variants that all encode the same protein. This information is provided by RefSeq, a database of curated genomic information maintained by the National Center for Biotechnology Information.","There is limited information available on the disease implications of the SQOR gene. However, recent studies have suggested that mutations in the gene may be associated with mitochondrial dysfunction and oxidative stress, which are implicated in a range of diseases including neurodegenerative disorders, cardiovascular diseases, and cancer. As such, there is growing interest in targeting the SQOR gene for drug discovery efforts.

Currently, there are no drugs on the market that specifically target the SQOR gene. However, there are several drugs that have been developed to target mitochondrial dysfunction and oxidative stress, which may indirectly impact the function of the SQOR gene. For example, idebenone is a drug that has been approved for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disorder that causes vision loss. Other drugs that target mitochondrial dysfunction and oxidative stress include coenzyme Q10, alpha-lipoic acid, and resveratrol.

In conclusion, while the disease implications of the SQOR gene are not well understood, there is growing interest in targeting the gene for drug discovery efforts. Further research is needed to fully understand the role of the SQOR gene in disease and to develop targeted therapies that can improve patient outcomes.","GO:0019418 sulfide oxidation;GO:0070221 sulfide oxidation, using sulfide:quinone oxidoreductase;GO:0006790 sulfur compound metabolic process",,Predicted intracellular proteins; ENZYME proteins:Oxidoreductases; Potential drug targets; Disease related genes; Enzymes,Mitochondria (Supported),,,(M5905)HALLMARK ADIPOGENESIS
ENSG00000164405.11,ENSG00000164405,UQCRQ,0.720733201,1.086495294,1.053872449,0.021831859,ubiquinol-cytochrome c reductase complex III subunit VII,"The UQCRQ gene encodes a protein that binds to ubiquinone, a molecule involved in energy production in cells. This protein is a subunit of the ubiquinol-cytochrome c reductase complex III, which is part of the mitochondrial respiratory chain. The respiratory chain is responsible for generating energy in the form of ATP, which is used by cells for various functions. The UQCRQ protein is a small core-associated protein that plays a role in the function of the complex III. Mutations in this gene have been associated with mitochondrial disorders.","Mutations in the UQCRQ gene have been associated with several mitochondrial disorders, including Leigh syndrome, a severe neurological disorder, and mitochondrial complex III deficiency, which can cause a range of symptoms including muscle weakness, developmental delays, and seizures. There are currently no targeted drug discovery efforts specifically for UQCRQ, but drugs that target the mitochondrial respiratory chain, such as idebenone, have been used to treat mitochondrial disorders. Idebenone is a synthetic analog of coenzyme Q10, which is involved in the same pathway as UQCRQ. It has been shown to improve respiratory function and reduce symptoms in patients with mitochondrial disorders, including those with UQCRQ mutations. Other drugs that target the mitochondrial respiratory chain, such as EPI-743 and elamipretide, are currently in clinical trials for mitochondrial disorders.",GO:0021539 subthalamus development;GO:0021548 pons development;GO:0021860 pyramidal neuron development,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Enhanced),"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol; 6-Hydroxy-5-undecyl-4,7-benzothiazoledione; Azoxystrobin; (5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE; (S)-famoxadone; METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE; 2-Nonyl-4-quinolinol 1-oxide; Ubiquinone Q2",,(M5905)HALLMARK ADIPOGENESIS; (M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000197785.14,ENSG00000197785,ATAD3A,0.720869482,0.978362813,0.498097385,0.686148247,ATPase family AAA domain containing 3A,"ATAD3A is a gene that is expressed in all cells and is located in the mitochondrial membrane. It plays a role in various cellular processes such as mitochondrial dynamics, nucleoid organization, protein translation, cell growth, and cholesterol metabolism. The gene belongs to the ATPase family AAA-domain containing 3 gene family, which includes two other paralogs in humans. Mutations in this gene are associated with neurological syndromes such as Harel-Yoon syndrome. High expression of this gene is linked to poor survival in breast cancer patients. Knocking out the orthologous gene in mice results in embryonic lethality due to growth retardation and defective development of the trophoblast lineage. Alternative splicing of this gene results in multiple transcript variants.","Mutations in the ATAD3A gene have been associated with several neurological disorders, including Harel-Yoon syndrome, a rare genetic disorder characterized by intellectual disability, seizures, and abnormal facial features. Targeted drug discovery efforts for ATAD3A are currently limited, but the gene's involvement in cholesterol metabolism has led to some interest in its potential as a therapeutic target for metabolic disorders. There are currently no drugs on the market that specifically target ATAD3A, but some cholesterol-lowering drugs, such as statins, indirectly affect the gene's activity. Additionally, some drugs that target mitochondrial function, such as metformin, have been shown to affect ATAD3A expression levels. Further research is needed to fully understand the potential therapeutic implications of targeting ATAD3A.",GO:0140468 HRI-mediated signaling;GO:1903898 negative regulation of PERK-mediated unfolded protein response;GO:1903897 regulation of PERK-mediated unfolded protein response,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Enhanced); Additional: Acrosome,,,
ENSG00000119705.10,ENSG00000119705,SLIRP,0.721249227,0.999615717,0.793036014,0.371095951,SRA stem-loop interacting RNA binding protein,SLIRP (SRA stem-loop interacting RNA binding protein) is a gene that encodes a protein that interacts with a specific stem-loop structure (STR7) of the SRA (steroid receptor RNA activator) gene. SRA is a complex RNA molecule that plays a role in coactivation of nuclear receptors. SLIRP's interaction with STR7 modulates the transactivation of nuclear receptors.,"Research on SLIRP is still in its early stages, and there is limited information available on its disease implications and targeted drug discovery efforts. However, recent studies have suggested that SLIRP may play a role in the development and progression of certain types of cancer, including breast cancer and prostate cancer. In addition, SLIRP has been implicated in the regulation of mitochondrial function and metabolism, which may have implications for metabolic disorders such as diabetes and obesity.

Currently, there are no drugs on the market that specifically target SLIRP. However, there is growing interest in developing drugs that target the SRA gene and its associated coactivators, including SLIRP, as a potential therapeutic strategy for cancer and other diseases. One example of a drug that targets the SRA pathway is tamoxifen, which is used to treat breast cancer by blocking the activity of estrogen receptors. Other potential drug targets in this pathway include the coactivator SRC-3 and the histone acetyltransferase p300/CBP. Further research is needed to fully understand the role of SLIRP in disease and to identify potential drug targets for therapeutic intervention.",GO:0000961 negative regulation of mitochondrial RNA catabolic process;GO:0000960 regulation of mitochondrial RNA catabolic process;GO:1902369 negative regulation of RNA catabolic process,,Predicted intracellular proteins,Mitochondria (Supported),,,
ENSG00000157778.9,ENSG00000157778,PSMG3,0.725716694,0.784547215,0.947878823,0.444724045,proteasome assembly chaperone 3,"PSMG3 is a human gene that encodes for a protein called proteasome assembly chaperone 3. This protein is involved in the assembly of protein complexes and has been predicted to be a part of a protein-containing complex. PSMG3 also exhibits molecular adaptor activity, which suggests that it may play a role in facilitating interactions between different proteins. Overall, PSMG3 is an important gene that contributes to the proper functioning of protein complexes in the human body.","There is limited information available on the disease implications of PSMG3. However, some studies have suggested that mutations in this gene may be associated with the development of certain types of cancer, such as breast cancer and lung cancer. Targeted drug discovery efforts for PSMG3 are also limited, as the function of this gene is not fully understood. However, some studies have suggested that targeting PSMG3 may be a potential strategy for cancer therapy. Currently, there are no drugs on the market that specifically target PSMG3. However, there are several drugs that target the proteasome, which is a protein complex that PSMG3 is involved in assembling. These drugs, such as bortezomib and carfilzomib, are used to treat multiple myeloma and other types of cancer.",GO:0043248 proteasome assembly;GO:0051131 chaperone-mediated protein complex assembly;GO:0065003 protein-containing complex assembly,,Predicted intracellular proteins,,,,
ENSG00000125356.7,ENSG00000125356,NDUFA1,0.726057878,1.066186914,0.74362323,0.368363489,NADH:ubiquinone oxidoreductase subunit A1,"The NDUFA1 gene is responsible for coding an essential component of complex I of the respiratory chain, which transfers electrons from NADH to ubiquinone. The gene produces a peptide that is part of the ""hydrophobic protein"" fraction of complex I, which is involved in proton translocation. The N-terminal hydrophobic domain of the peptide has the potential to be folded into an alpha-helix spanning the inner mitochondrial membrane, while the C-terminal hydrophilic domain interacts with globular subunits of complex I. The highly conserved two-domain structure is critical for the protein function and may act as an anchor for the NADH:ubiquinone oxidoreductase complex at the inner mitochondrial membrane.","Mutations in the NDUFA1 gene have been associated with mitochondrial complex I deficiency, a rare genetic disorder that affects the function of the respiratory chain and leads to a wide range of clinical symptoms, including developmental delay, muscle weakness, seizures, and lactic acidosis. Targeted drug discovery efforts have focused on developing small molecules that can restore complex I activity in patients with mitochondrial diseases. One example is idebenone, a synthetic analog of coenzyme Q10 that has been shown to improve respiratory function and reduce oxidative stress in patients with Leber's hereditary optic neuropathy, a mitochondrial disease caused by mutations in complex I subunits. Another example is elamipretide, a mitochondria-targeted peptide that can improve mitochondrial bioenergetics and reduce apoptosis in preclinical models of mitochondrial diseases. Elamipretide is currently in clinical trials for the treatment of primary mitochondrial myopathy and Barth syndrome.","GO:0006120 mitochondrial electron transport, NADH to ubiquinone;GO:0010257 NADH dehydrogenase complex assembly;GO:0032981 mitochondrial respiratory chain complex I assembly",,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Cytosol;Mitochondria (Supported),NADH,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000130724.9,ENSG00000130724,CHMP2A,0.728905692,1.025676681,0.7369009,0.424139494,charged multivesicular body protein 2A,CHMP2A is a gene that belongs to the CHMP family of chromatin-modifying proteins. These proteins are involved in the degradation of surface receptor proteins and the formation of endocytic multivesicular bodies (MVBs) as part of the ESCRT-III complex. CHMP2A has both nuclear and cytoplasmic/vesicular distributions and is involved in the regulation of cell cycle progression. Dysfunction of CHMP2A has been linked to neurodegenerative diseases such as Alzheimer's and frontotemporal dementia.,"Dysfunction of CHMP2A has been linked to neurodegenerative diseases such as Alzheimer's and frontotemporal dementia. Targeted drug discovery efforts for these diseases have focused on modulating the activity of the ESCRT-III complex, of which CHMP2A is a part. One approach has been to develop small molecule inhibitors of the VPS4 ATPase, which is required for ESCRT-III disassembly. Several compounds have been identified that inhibit VPS4 activity and show promise in preclinical studies. However, no drugs targeting CHMP2A specifically have been approved for clinical use. Examples of successful drugs on the market for Alzheimer's disease include cholinesterase inhibitors such as donepezil and memantine, which target neurotransmitter systems involved in memory and cognition.",GO:1903723 negative regulation of centriole elongation;GO:1903722 regulation of centriole elongation;GO:1904896 ESCRT complex disassembly,,Predicted intracellular proteins,Cytosol (Approved); Additional: Nucleoplasm;Plasma membrane,,,
ENSG00000159199.14,ENSG00000159199,ATP5MC1,0.733342594,0.898022442,0.501184413,0.800820926,ATP synthase membrane subunit c locus 1,"ATP5MC1 is a gene that encodes a subunit of mitochondrial ATP synthase, which is responsible for catalyzing ATP synthesis using an electrochemical gradient of protons across the inner membrane during oxidative phosphorylation. ATP synthase is composed of two linked multi-subunit complexes: the soluble catalytic core, F1, and the membrane-spanning component, Fo, comprising the proton channel. The catalytic portion of mitochondrial ATP synthase consists of 5 different subunits assembled with a stoichiometry of 3 alpha, 3 beta, and a single representative of the other 3. ATP5MC1 is one of three genes that encode subunit c of the proton channel, with each gene having distinct mitochondrial import sequences but encoding the identical mature protein.","There is limited information available on the disease implications of ATP5MC1. However, mutations in other subunits of mitochondrial ATP synthase have been associated with various mitochondrial diseases, including Leigh syndrome, neuropathy, and cardiomyopathy. Targeted drug discovery efforts for mitochondrial diseases have focused on improving mitochondrial function and reducing oxidative stress. One example is idebenone, a synthetic analog of coenzyme Q10, which has been approved for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disease that causes vision loss. Another example is elamipretide, a peptide that targets the inner mitochondrial membrane and has shown promise in preclinical studies for the treatment of various mitochondrial diseases. However, more research is needed to determine the potential therapeutic implications of ATP5MC1 mutations and to develop targeted therapies for mitochondrial diseases.",GO:0015986 proton motive force-driven ATP synthesis;GO:0006754 ATP biosynthetic process;GO:0009206 purine ribonucleoside triphosphate biosynthetic process,,Transporters:Primary Active Transporters; Predicted intracellular proteins,,,,(M5924)HALLMARK MTORC1 SIGNALING; (M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000108826.16,ENSG00000108826,MRPL27,0.739865202,0.780368221,1.023997324,0.41523006,mitochondrial ribosomal protein L27,"The human gene MRPL27 encodes a protein that is a component of the large 39S subunit of the mitochondrial ribosome. Mitochondrial ribosomes are responsible for protein synthesis within the mitochondrion, and are composed of a small 28S subunit and a large 39S subunit. Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and have a protein to rRNA composition of approximately 75%, which is the reverse of prokaryotic ribosomes. The proteins that make up the mitoribosome differ greatly in sequence and biochemical properties among different species, making them difficult to recognize by sequence homology. MRPL27 is one of many genes involved in mitochondrial protein synthesis and function.","There is limited information available on the disease implications of MRPL27 mutations. However, mutations in other mitochondrial ribosomal protein genes have been associated with a range of mitochondrial disorders, including Leigh syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), and myoclonic epilepsy with ragged-red fibers (MERRF). 

There are currently no targeted drug discovery efforts specifically focused on MRPL27. However, there are ongoing efforts to develop drugs that target mitochondrial dysfunction in general, which could potentially benefit patients with mitochondrial disorders caused by mutations in MRPL27 or other mitochondrial ribosomal protein genes. 

One example of a successful drug on the market for mitochondrial disorders is idebenone, which is approved in Europe for the treatment of Leber's hereditary optic neuropathy (LHON), a mitochondrial disorder that causes vision loss. Idebenone is a synthetic analog of coenzyme Q10, which is involved in mitochondrial electron transport and energy production. Another example is elamipretide, a mitochondrial-targeted peptide that is currently in clinical trials for the treatment of primary mitochondrial myopathy and LHON.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Ribosomal proteins; Predicted intracellular proteins,,,,
ENSG00000134419.15,ENSG00000134419,RPS15A,0.743190803,1.076105555,0.914970602,0.23849625,ribosomal protein S15a,"RPS15A is a gene that encodes a ribosomal protein called S15a, which is a component of the small 40S subunit of ribosomes. Ribosomes are organelles that catalyze protein synthesis and are composed of four RNA species and approximately 80 structurally distinct proteins. S15a belongs to the S8P family of ribosomal proteins and is located in the cytoplasm. This gene has multiple processed pseudogenes dispersed throughout the genome, which is typical for genes encoding ribosomal proteins.","There is limited information on the disease implications of RPS15A mutations. However, recent studies have shown that mutations in other ribosomal protein genes can lead to various diseases, including Diamond-Blackfan anemia, cancer, and developmental disorders. Targeted drug discovery efforts for ribosomal protein genes have focused on identifying small molecules that can selectively inhibit the function of ribosomes in cancer cells, while sparing normal cells. Several drugs targeting ribosomes, such as the macrolide antibiotics erythromycin and azithromycin, have been approved for clinical use. Additionally, several other drugs targeting ribosomes are currently in clinical trials for various types of cancer. However, it is unclear whether RPS15A mutations are directly involved in any specific disease, and further research is needed to determine the potential therapeutic implications of targeting this gene.",GO:0042274 ribosomal small subunit biogenesis;GO:0002181 cytoplasmic translation;GO:0042254 ribosome biogenesis,,Predicted intracellular proteins; Ribosomal proteins; Human disease related genes:Other congenital disorders:Ribosomopathies; Disease related genes; Human disease related genes:Cardiovascular diseases:Hematologic diseases,,,,
ENSG00000125458.7,ENSG00000125458,NT5C,0.754772283,0.613757589,0.897451929,0.753107332,"5', 3'-nucleotidase, cytosolic","The human gene NT5C encodes a nucleotidase that is responsible for catalyzing the dephosphorylation of 5' deoxyribonucleotides (dNTP) and 2'(3')-dNTP and ribonucleotides, but not 5' ribonucleotides. This enzyme is unique in its preference for 5'-dNTP and may play a role in regulating the size of dNTP pools in cells. The gene has alternatively spliced transcript variants.","Mutations in the NT5C gene have been associated with several diseases, including hematological malignancies such as acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). In particular, mutations in NT5C2 have been linked to chemotherapy resistance in ALL and AML patients. Targeted drug discovery efforts have focused on developing inhibitors of NT5C enzymes as potential therapies for these cancers. One example is the drug nelarabine, which is a prodrug that is converted to the active compound 9-beta-D-arabinofuranosylguanine (ara-G) by NT5C enzymes. Nelarabine has been approved by the FDA for the treatment of T-cell ALL and T-cell lymphoblastic lymphoma. Another example is the drug forodesine, which is a potent inhibitor of NT5C1A and has shown promise in preclinical studies for the treatment of AML and chronic lymphocytic leukemia (CLL). However, forodesine has not yet been approved for clinical use.",GO:0046074 dTMP catabolic process;GO:0046055 dGMP catabolic process;GO:0006204 IMP catabolic process,,Predicted intracellular proteins,Cytosol (Supported),,,(M5898)HALLMARK DNA REPAIR
ENSG00000168653.11,ENSG00000168653,NDUFS5,0.755826676,0.871028344,0.693963572,0.702488113,NADH:ubiquinone oxidoreductase subunit S5,"NDUFS5 is a gene that encodes a subunit of the NADH:ubiquinone oxidoreductase (complex I), which is the first enzyme complex in the electron transport chain located in the inner mitochondrial membrane. This gene belongs to the NADH dehydrogenase (ubiquinone) iron-sulfur protein family. Alternative splicing results in multiple transcript variants, and pseudogenes have been identified on chromosomes 1, 4, and 17.","Mutations in the NDUFS5 gene have been associated with mitochondrial complex I deficiency, a rare genetic disorder that affects the function of the electron transport chain and leads to a wide range of clinical symptoms, including developmental delay, muscle weakness, seizures, and lactic acidosis. Targeted drug discovery efforts for mitochondrial complex I deficiency have focused on developing small molecules that can restore complex I activity and improve mitochondrial function. One example is idebenone, a synthetic analog of coenzyme Q10 that has been shown to improve respiratory chain function and reduce oxidative stress in patients with mitochondrial disorders, including those with NDUFS5 mutations. Idebenone is currently approved for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disorder that affects the optic nerve. Other potential drug candidates for mitochondrial complex I deficiency include metformin, nicotinamide riboside, and bezafibrate, which have shown promising results in preclinical studies.","GO:0006120 mitochondrial electron transport, NADH to ubiquinone;GO:0010257 NADH dehydrogenase complex assembly;GO:0032981 mitochondrial respiratory chain complex I assembly",,Predicted intracellular proteins,,NADH,,
ENSG00000106268.15,ENSG00000106268,NUDT1,0.759655804,1.004190609,0.985562998,0.289213805,nudix hydrolase 1,"NUDT1 is a human gene that encodes for the enzyme nudix hydrolase 1. This enzyme plays a crucial role in preventing mutations that can lead to cancer or neurodegeneration by hydrolyzing oxidized purine nucleoside triphosphates, such as 8-oxo-dGTP, 8-oxo-dATP, 2-hydroxy-dATP, and 2-hydroxy rATP, to monophosphates. The gene is mainly localized in the cytoplasm, with some in the mitochondria, suggesting that it is involved in the sanitization of nucleotide pools for both nuclear and mitochondrial genomes. There are several alternatively spliced transcript variants of the gene, some of which encode distinct isoforms, and a rare single-nucleotide polymorphism that results in the production of an additional, longer isoform (p26) has been described.","NUDT1 has been implicated in several diseases, including cancer, neurodegeneration, and inflammation. In cancer, NUDT1 has been shown to be downregulated in several types of tumors, including breast, lung, and colon cancer, suggesting that it may act as a tumor suppressor. In neurodegeneration, mutations in NUDT1 have been linked to the development of Parkinson's disease, and the enzyme has been shown to protect against oxidative stress-induced neuronal death. In inflammation, NUDT1 has been shown to regulate the production of pro-inflammatory cytokines, suggesting that it may be a potential target for anti-inflammatory therapies.

Several drug discovery efforts have targeted NUDT1, with the aim of developing drugs that can modulate its activity for therapeutic purposes. One approach has been to identify small molecules that can activate NUDT1, with the goal of enhancing its protective effects against oxidative stress and neurodegeneration. Another approach has been to develop inhibitors of NUDT1, with the aim of reducing its activity in cancer cells and promoting their death. However, no drugs targeting NUDT1 have yet been approved for clinical use.

One example of a successful drug that indirectly targets NUDT1 is the chemotherapy drug 5-fluorouracil (5-FU), which is commonly used to treat colon, breast, and other cancers. 5-FU is converted into an active metabolite that can be incorporated into DNA, leading to the formation of DNA adducts that are recognized and excised by NUDT1. Inhibition of NUDT1 by 5-FU leads to the accumulation of DNA damage and cell death in cancer cells.",GO:0042262 DNA protection;GO:0006152 purine nucleoside catabolic process;GO:0009164 nucleoside catabolic process,,ENZYME proteins:Hydrolases; Enzymes; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cytosol (Supported),,,
ENSG00000135940.7,ENSG00000135940,COX5B,0.766335642,1.164960482,0.843321923,0.290724521,cytochrome c oxidase subunit 5B,"COX5B is a gene that encodes for subunit Vb of the human mitochondrial respiratory chain enzyme, cytochrome C oxidase (COX). COX is a multi-subunit enzyme complex that is responsible for transferring electrons from cytochrome c to molecular oxygen, contributing to a proton electrochemical gradient across the inner mitochondrial membrane. The complex consists of 13 subunits, with the mitochondrially-encoded subunits performing electron transfer and proton pumping activities. The functions of the nuclear-encoded subunits, such as COX5B, are not fully understood but may play a role in the regulation and assembly of the complex.","Mutations in the COX5B gene have been associated with mitochondrial diseases, such as Leigh syndrome and encephalomyopathy. These diseases are characterized by defects in the mitochondrial respiratory chain, leading to impaired energy production and tissue damage. Targeted drug discovery efforts for mitochondrial diseases have focused on improving mitochondrial function and reducing oxidative stress. Some examples of successful drugs on the market include idebenone, which has been approved for the treatment of Leber's hereditary optic neuropathy, and elamipretide, which is currently in clinical trials for the treatment of mitochondrial myopathy. These drugs work by improving mitochondrial function and reducing oxidative stress, potentially improving energy production and reducing tissue damage in patients with mitochondrial diseases.","GO:0006123 mitochondrial electron transport, cytochrome c to oxygen;GO:0007585 respiratory gaseous exchange by respiratory system;GO:0019646 aerobic electron transport chain",,Transporters:Primary Active Transporters; Predicted intracellular proteins,Mitochondria (Enhanced); Additional: Acrosome,Cholic Acid; N-Formylmethionine,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000225200.2,ENSG00000225200,AC246787.1,0.768657148,1.126167714,0.848640085,0.331163646,ribosomal protein S8 pseudogene 1,,,,,,,,,
ENSG00000175193.14,ENSG00000175193,PARL,0.769422502,1.166672171,0.968267841,0.173327494,presenilin associated rhomboid like,"PARL (presenilin associated rhomboid like) is a gene that encodes a protein belonging to the rhomboid family of intramembrane serine proteases. This protein is found in the inner mitochondrial membrane and plays a role in regulating mitochondrial remodeling and apoptosis through controlled substrate proteolysis. When the protein is proteolytically processed, it releases a small peptide called P-beta, which may travel to the nucleus. Mutations in the PARL gene have been linked to Parkinson's disease.","Mutations in the PARL gene have been associated with Parkinson's disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra region of the brain. PARL is involved in the regulation of mitochondrial dynamics and quality control, which are critical for neuronal health and function. Targeting PARL has emerged as a potential therapeutic strategy for Parkinson's disease, and several small molecule inhibitors of PARL have been developed. One example is P110, a PARL inhibitor that has been shown to protect dopaminergic neurons and improve motor function in preclinical models of Parkinson's disease. Another example is VU0361737, which has been shown to reduce mitochondrial fragmentation and improve mitochondrial function in cells derived from Parkinson's disease patients. However, more research is needed to fully understand the therapeutic potential of PARL inhibition in Parkinson's disease.",GO:0006465 signal peptide processing;GO:0090201 negative regulation of release of cytochrome c from mitochondria;GO:0008053 mitochondrial fusion,,Predicted intracellular proteins; Transporters; Peptidases:Serine-type peptidases; ENZYME proteins:Hydrolases; Enzymes,Mitochondria (Supported),,,
ENSG00000175197.12,ENSG00000175197,DDIT3,0.773954186,1.556811022,0.762294783,0.002756754,DNA damage inducible transcript 3,"DDIT3 is a gene that belongs to the CCAAT/enhancer-binding protein (C/EBP) family of transcription factors. It acts as a dominant-negative inhibitor by forming heterodimers with other C/EBP members, preventing their DNA binding activity. The gene is involved in adipogenesis and erythropoiesis, is activated by endoplasmic reticulum stress, and promotes apoptosis. DDIT3 can also be involved in the development of myxoid liposarcomas or Ewing sarcoma when it fuses with FUS on chromosome 16 or EWSR1 on chromosome 22 due to translocation. Multiple alternatively spliced transcript variants encoding two isoforms with different lengths have been identified.","DDIT3 has been implicated in various diseases, including cancer, diabetes, and neurodegenerative disorders. In particular, the fusion of DDIT3 with other genes, such as FUS or EWSR1, has been associated with the development of myxoid liposarcomas and Ewing sarcoma, respectively. Targeted drug discovery efforts have focused on developing inhibitors of DDIT3 to prevent its interaction with other C/EBP members and promote apoptosis in cancer cells. One example is the small molecule inhibitor, CWP232291, which has shown promising results in preclinical studies for the treatment of myxoid liposarcoma. Another example is the natural compound, curcumin, which has been shown to inhibit DDIT3 expression and promote apoptosis in multiple cancer cell lines. However, there are currently no FDA-approved drugs specifically targeting DDIT3.",GO:1990442 intrinsic apoptotic signaling pathway in response to nitrosative stress;GO:2000016 negative regulation of determination of dorsal identity;GO:1904738 vascular associated smooth muscle cell migration,,Human disease related genes:Cancers:Cancers of soft tissues and bone; Transcription factors:Basic domains; Predicted intracellular proteins; Disease related genes; Cancer-related genes:Candidate cancer biomarkers,Nucleoplasm (Supported),,(M229)PID P38 ALPHA BETA DOWNSTREAM PATHWAY; (M166)PID ATF2 PATHWAY; (M254)PID MYC REPRESS PATHWAY,(M5923)HALLMARK PI3K AKT MTOR SIGNALING; (M5902)HALLMARK APOPTOSIS; (M5891)HALLMARK HYPOXIA
ENSG00000152082.15,ENSG00000152082,MZT2B,0.775328356,1.218099146,0.986994266,0.120891657,mitotic spindle organizing protein 2B,"The human gene MZT2B encodes for the mitotic spindle organizing protein 2B, which is involved in the organization of microtubules during cell division. The protein is located in the cytosol, microtubule cytoskeleton, and nucleoplasm, and is part of the gamma-tubulin large complex. This complex plays a crucial role in the formation of microtubules, which are essential for the proper segregation of chromosomes during cell division. The MZT2B gene is important for maintaining the integrity of the microtubule cytoskeleton and ensuring accurate cell division.","There is limited information available on the disease implications of the MZT2B gene. However, mutations in genes encoding for proteins involved in the organization of microtubules have been linked to a range of diseases, including cancer, neurodegenerative disorders, and developmental disorders. Targeted drug discovery efforts for microtubule-related diseases have focused on developing drugs that disrupt microtubule formation or stability, such as taxanes and vinca alkaloids. These drugs have been successful in treating various types of cancer, including breast, lung, and ovarian cancer. For example, paclitaxel (Taxol) and docetaxel (Taxotere) are taxanes that have been approved for the treatment of breast, ovarian, and lung cancer. Vinblastine and vincristine are vinca alkaloids that have been used to treat Hodgkin's lymphoma and childhood leukemia. However, these drugs can have significant side effects, and there is a need for more targeted therapies that specifically target microtubule-related diseases.",,,Predicted intracellular proteins,Centrosome (Supported); Additional: Cytosol,,,
ENSG00000235065.1,ENSG00000235065,RPL24P2,0.781927061,1.455998356,0.774939129,0.114843698,RPL24 pseudogene 2,,,,,,,,,
ENSG00000102030.16,ENSG00000102030,NAA10,0.78240061,1.146822649,1.168108768,0.032270412,"N-alpha-acetyltransferase 10, NatA catalytic subunit","NAA10 is a gene that encodes for the N-alpha-acetyltransferase 10 protein, which is a catalytic subunit of the major amino-terminal acetyltransferase A complex. This protein is responsible for the transfer of an acetyl group from acetyl-coenzyme A to the alpha-amino group on a nascent polypeptide, which is an essential process for normal cell function. Mutations in this gene have been linked to Ogden syndrome, a rare genetic disorder characterized by developmental delay, intellectual disability, and craniofacial abnormalities. The gene has multiple transcript variants due to alternate splicing.","Ogden syndrome is a rare genetic disorder caused by mutations in the NAA10 gene. This syndrome is characterized by developmental delay, intellectual disability, craniofacial abnormalities, and other severe health problems. There is currently no cure for Ogden syndrome, and treatment is mainly supportive and focused on managing symptoms. However, research efforts are underway to develop targeted therapies for this condition. One approach is to identify small molecules that can modulate the activity of the NAA10 protein. Several studies have shown that inhibition of NAA10 activity can lead to the selective killing of cancer cells, suggesting that NAA10 inhibitors could be used as anticancer agents. However, the development of NAA10 inhibitors for the treatment of Ogden syndrome is still in the early stages, and no drugs targeting this protein are currently on the market.","GO:2000719 negative regulation of maintenance of mitotic sister chromatid cohesion, centromeric;GO:2000718 regulation of maintenance of mitotic sister chromatid cohesion, centromeric;GO:0034092 negative regulation of maintenance of sister chromatid cohesion",,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of eye; ENZYME proteins:Transferases; Potential drug targets; Disease related genes; Enzymes,Cytosol (Supported); Additional: Nucleoli,,(M180)PID HIF1A PATHWAY,
ENSG00000183617.5,ENSG00000183617,MRPL54,0.783021315,0.833733494,1.027311424,0.488019026,mitochondrial ribosomal protein L54,"The human gene MRPL54 encodes a protein called mitochondrial ribosomal protein L54, which is a component of the large 39S subunit of mitochondrial ribosomes. Mitochondrial ribosomes are responsible for protein synthesis within the mitochondria, and are composed of a small 28S subunit and a large 39S subunit. Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and have a protein to rRNA composition of approximately 75%, which is the opposite of prokaryotic ribosomes. The proteins that make up the mitoribosome vary greatly in sequence and biochemical properties, making them difficult to identify through sequence homology. MRPL54 is involved in the process of mitochondrial protein synthesis.","There is limited information available on the disease implications of MRPL54 mutations. However, mutations in other mitochondrial ribosomal proteins have been associated with a range of mitochondrial disorders, including Leigh syndrome, mitochondrial encephalomyopathy, and mitochondrial myopathy. Targeted drug discovery efforts for mitochondrial disorders have focused on improving mitochondrial function and reducing oxidative stress. Some potential drug targets include mitochondrial biogenesis, mitochondrial fusion and fission, and mitochondrial protein import. Currently, there are no drugs specifically targeting MRPL54. However, there are drugs on the market that target other mitochondrial proteins, such as idebenone for the treatment of Leber's hereditary optic neuropathy and elamipretide for the treatment of primary mitochondrial myopathy.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Ribosomal proteins; Predicted intracellular proteins,Mitochondria (Approved),,,
ENSG00000197756.10,ENSG00000197756,RPL37A,0.792320509,1.391630621,0.744899403,0.240431503,ribosomal protein L37a,"RPL37A is a gene that encodes a ribosomal protein called L37a, which is a component of the 60S subunit of ribosomes. Ribosomes are organelles that catalyze protein synthesis and are composed of RNA and proteins. L37a belongs to the L37AE family of ribosomal proteins and is located in the cytoplasm. The protein contains a C4-type zinc finger-like domain. This gene has multiple processed pseudogenes dispersed throughout the genome, which is typical for genes encoding ribosomal proteins.","There is limited information on the disease implications of RPL37A mutations. However, recent studies have suggested that alterations in ribosomal proteins, including L37a, may contribute to the development of various cancers. For example, mutations in RPL37A have been identified in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Targeted drug discovery efforts for ribosomal proteins have been challenging due to their essential role in protein synthesis, which makes it difficult to develop drugs that selectively target ribosomes without affecting normal cellular functions. Nonetheless, several drugs that target ribosomes have been developed, including macrolides such as erythromycin and azithromycin, which are commonly used antibiotics. Additionally, the drug omacetaxine mepesuccinate, which targets the ribosome and inhibits protein synthesis, has been approved for the treatment of chronic myeloid leukemia (CML) and is currently being investigated for the treatment of other cancers.",GO:0002181 cytoplasmic translation;GO:0006412 translation;GO:0010467 gene expression,,Ribosomal proteins; Predicted intracellular proteins,Cytosol;Endoplasmic reticulum (Approved),,,
ENSG00000184076.13,ENSG00000184076,UQCR10,0.792392219,0.983365005,0.864027497,0.529784153,"ubiquinol-cytochrome c reductase, complex III subunit X","UQCR10 is a gene that encodes for a subunit of mitochondrial complex III, also known as ubiquinol-cytochrome c reductase. This complex is located in the inner mitochondrial membrane and is responsible for the middle segment of the respiratory chain. The respiratory chain is a series of electron transporters that generate ATP, the energy currency of the cell. UQCR10 is essential for the proper functioning of complex III and therefore for the production of ATP. Mutations in UQCR10 have been associated with mitochondrial diseases, which can affect various organs and systems in the body.","Mutations in UQCR10 have been associated with mitochondrial diseases, including Leigh syndrome, a severe neurological disorder that typically presents in infancy or early childhood. Other mitochondrial diseases associated with UQCR10 mutations include mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and mitochondrial myopathy. 

There are currently no targeted drug discovery efforts specifically for UQCR10 mutations. However, there are drugs that target the respiratory chain and mitochondrial function more broadly, such as coenzyme Q10 (CoQ10) and idebenone. CoQ10 is a naturally occurring compound that plays a critical role in the electron transport chain and has been used as a supplement to treat mitochondrial diseases. Idebenone is a synthetic analog of CoQ10 that has been shown to improve respiratory chain function and has been approved for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disease that affects the eyes.

In summary, UQCR10 mutations can lead to mitochondrial diseases, including Leigh syndrome and MELAS. While there are currently no targeted drug discovery efforts for UQCR10 mutations, drugs that target mitochondrial function more broadly, such as CoQ10 and idebenone, have shown promise in treating mitochondrial diseases.","GO:0006122 mitochondrial electron transport, ubiquinol to cytochrome c;GO:0019646 aerobic electron transport chain;GO:0042773 ATP synthesis coupled electron transport",,,,"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol; 6-Hydroxy-5-undecyl-4,7-benzothiazoledione; Azoxystrobin; 5-Heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione; (5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE; (S)-famoxadone; METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE; 2-Nonyl-4-quinolinol 1-oxide; Ubiquinone Q2",,(M5905)HALLMARK ADIPOGENESIS; (M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000178449.9,ENSG00000178449,COX14,0.795772052,1.145711663,1.026559808,0.215044684,cytochrome c oxidase assembly factor COX14,"COX14 is a gene that encodes a small transmembrane protein found in mitochondria. It is involved in the early stages of cytochrome c oxidase (COX) subunit assembly, specifically in the synthesis and assembly of the COX I subunit. Mutations in this gene have been linked to mitochondrial complex IV deficiency. Alternative splicing of the gene results in multiple transcript variants.","Mutations in the COX14 gene have been associated with mitochondrial complex IV deficiency, which is a rare genetic disorder that affects the function of the mitochondria, leading to a wide range of symptoms including muscle weakness, developmental delays, and neurological problems. There are currently no targeted drug discovery efforts specifically for COX14 mutations, but there are drugs that target mitochondrial dysfunction in general. For example, idebenone is a drug that has been approved in Europe for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disease that affects the eyes. Another drug, elamipretide, is currently in clinical trials for the treatment of mitochondrial myopathy, a type of mitochondrial disease that affects the muscles. While these drugs are not specifically targeted to COX14 mutations, they may have potential therapeutic benefits for individuals with mitochondrial complex IV deficiency.",GO:0033617 mitochondrial cytochrome c oxidase assembly;GO:0008535 respiratory chain complex IV assembly;GO:0017004 cytochrome complex assembly,,Disease related genes; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Supported),,,
ENSG00000099624.8,ENSG00000099624,ATP5F1D,0.797462109,0.81180616,0.884044053,0.696536114,ATP synthase F1 subunit delta,"ATP5F1D is a gene that encodes a subunit of mitochondrial ATP synthase, which is responsible for catalyzing ATP synthesis using an electrochemical gradient of protons across the inner membrane during oxidative phosphorylation. ATP synthase is composed of two linked multi-subunit complexes: the soluble catalytic core, F1, and the membrane-spanning component, Fo, comprising the proton channel. The catalytic portion of mitochondrial ATP synthase consists of five different subunits (alpha, beta, gamma, delta, and epsilon) assembled with a stoichiometry of 3 alpha, 3 beta, and a single representative of the other 3. The delta subunit of the catalytic core is encoded by ATP5F1D.","There is limited information available on the disease implications of ATP5F1D mutations. However, some studies have suggested that mutations in this gene may be associated with mitochondrial disorders, such as Leigh syndrome and mitochondrial encephalomyopathy. Targeted drug discovery efforts for ATP5F1D are also limited, as the function of this gene is essential for ATP synthesis and any disruption could have severe consequences. However, some studies have explored the use of small molecules that target ATP synthase as potential cancer therapeutics. For example, the drug oligomycin inhibits ATP synthase and has been used in the treatment of certain types of cancer. Another example is the drug efsevin, which targets the Fo subunit of ATP synthase and has shown promising results in preclinical studies for the treatment of breast cancer.",GO:0033615 mitochondrial proton-transporting ATP synthase complex assembly;GO:0043461 proton-transporting ATP synthase complex assembly;GO:0070071 proton-transporting two-sector ATPase complex assembly,,Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; Transporters:Primary Active Transporters; Potential drug targets; Disease related genes,Mitochondria;Principal piece (Supported); Additional: Connecting piece;Flagellar centriole,Isoflurane; Desflurane,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000256053.9,ENSG00000256053,COA8,0.803334008,0.913355407,0.823701883,0.672944734,cytochrome c oxidase assembly factor 8,COA8 is a gene that encodes a protein that is found in the mitochondria and plays a role in promoting programmed cell death by stimulating the release of cytochrome c. Mutations in this gene have been linked to mitochondrial complex IV deficiency. Alternative splicing of the gene results in multiple transcript variants.,"Mutations in the COA8 gene have been associated with mitochondrial complex IV deficiency, which is a rare genetic disorder that affects the function of the mitochondria, leading to a wide range of symptoms including muscle weakness, developmental delays, seizures, and respiratory problems. There are currently no targeted drug discovery efforts specifically for COA8, but there are drugs on the market that can help manage the symptoms of mitochondrial complex IV deficiency. For example, coenzyme Q10 (CoQ10) is a dietary supplement that has been shown to improve energy production in the mitochondria and may help alleviate some of the symptoms of the disorder. Another drug, idebenone, has been approved in Europe for the treatment of Leber's hereditary optic neuropathy, which is a mitochondrial disorder that affects the eyes. Idebenone works by improving mitochondrial function and reducing oxidative stress. However, more research is needed to develop targeted therapies for COA8-related disorders.",GO:1904734 positive regulation of electron transfer activity;GO:1904960 positive regulation of cytochrome-c oxidase activity;GO:1904732 regulation of electron transfer activity,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,,,,
ENSG00000246705.4,ENSG00000246705,H2AJ,0.804628663,0.458213517,1.13753231,0.818140162,H2A.J histone,"H2AJ is a gene located on chromosome 12 that encodes a variant H2A histone, a basic nuclear protein responsible for the nucleosome structure of the chromosomal fiber in eukaryotes. Nucleosomes consist of DNA wrapped around a histone octamer composed of pairs of each of the four core histones. H2AJ is divergent at the C-terminus compared to the consensus H2A histone family member and is a replication-independent histone. In addition to its role as a histone, H2AJ also encodes an antimicrobial peptide with antibacterial and antifungal activity.","There is limited information available on the disease implications of H2AJ. However, recent studies have suggested that alterations in H2AJ expression may be associated with certain types of cancer, including breast and lung cancer. Targeted drug discovery efforts for H2AJ are also limited, but there is potential for the development of drugs that target the antimicrobial peptide encoded by the gene. Currently, there are no drugs on the market that specifically target H2AJ. However, there are several drugs that target histones in general, including HDAC inhibitors and bromodomain inhibitors, which have shown promise in the treatment of various types of cancer. Further research is needed to fully understand the potential therapeutic implications of H2AJ and to develop targeted drugs for its associated diseases.",GO:0071480 cellular response to gamma radiation;GO:0010332 response to gamma radiation;GO:0090398 cellular senescence,,Predicted intracellular proteins,Nucleoplasm (Approved),,,(M5939)HALLMARK P53 PATHWAY
ENSG00000234498.3,ENSG00000234498,RPL13AP20,0.806777943,1.496754716,0.768552667,0.155026445,ribosomal protein L13a pseudogene 20,,,,,,,,,
ENSG00000107833.10,ENSG00000107833,NPM3,0.808478394,1.077326035,1.032206434,0.315902714,nucleophosmin/nucleoplasmin 3,"NPM3 is a human gene that encodes a protein related to nuclear chaperone phosphoproteins, nucleoplasmin, and nucleophosmin. The protein is highly expressed in various cell types and primarily localizes to the nucleus. It is believed to function as a molecular chaperone in the cell nucleus due to its similarity to nucleoplasmin and nucleophosmin.","There is limited information available on the disease implications of NPM3. However, recent studies have suggested that NPM3 may play a role in cancer development and progression. Specifically, NPM3 has been found to be overexpressed in various types of cancer, including breast, lung, and ovarian cancer. Targeted drug discovery efforts for NPM3 are still in the early stages, but there is potential for the development of drugs that target NPM3 as a therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target NPM3. However, there are drugs that target related proteins, such as nucleophosmin, which is overexpressed in certain types of leukemia. Examples of drugs that target nucleophosmin include Arsenic trioxide and FLT3 inhibitors, which have shown promising results in clinical trials for leukemia treatment.",GO:0009303 rRNA transcription;GO:0006364 rRNA processing;GO:0016072 rRNA metabolic process,,Predicted intracellular proteins,Actin filaments;Cytosol;Nucleoli (Approved),,,
ENSG00000277791.5,ENSG00000277791,PSMB3,0.809204661,1.112720335,0.880905366,0.433988283,proteasome 20S subunit beta 3,"PSMB3 is a gene that encodes a subunit of the proteasome, a protein complex that breaks down peptides in a non-lysosomal pathway. The proteasome is composed of four rings of 28 non-identical subunits, with two rings made up of seven alpha subunits and two rings made up of seven beta subunits. PSMB3 is a member of the proteasome B-type family, also known as the T1B family, and is a 20S core beta subunit. The gene is involved in the processing of class I MHC peptides, and alternative splicing results in multiple transcript variants. Pseudogenes of PSMB3 have been identified on chromosomes 2 and 12. The 26 S proteasome may be involved in trinucleotide repeat expansion, which is associated with many hereditary neurological diseases.","PSMB3 has been implicated in several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In cancer, the proteasome is involved in the degradation of tumor suppressor proteins, and inhibition of the proteasome has been shown to induce apoptosis in cancer cells. Bortezomib, a proteasome inhibitor, is approved for the treatment of multiple myeloma and mantle cell lymphoma. In autoimmune disorders, the proteasome is involved in the processing of self-antigens, and inhibition of the proteasome has been shown to reduce inflammation. Carfilzomib, another proteasome inhibitor, is approved for the treatment of multiple myeloma. In neurodegenerative diseases, the proteasome is involved in the clearance of misfolded proteins, and dysfunction of the proteasome has been implicated in the pathogenesis of Alzheimer's and Parkinson's diseases. However, there are currently no approved drugs targeting the proteasome for the treatment of neurodegenerative diseases.",GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process;GO:0010498 proteasomal protein catabolic process;GO:0006511 ubiquitin-dependent protein catabolic process,,Peptidases:Threonine-type peptidases; Enzymes; Predicted intracellular proteins,,"(3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE",,(M5926)HALLMARK MYC TARGETS V1
ENSG00000147155.11,ENSG00000147155,EBP,0.810422646,1.06782999,0.964868937,0.398569012,EBP cholestenol delta-isomerase,"EBP (cholestenol delta-isomerase) is a protein that is found in the endoplasmic reticulum and is involved in drug transport. It is a high affinity binding protein for certain drugs and shares structural features with bacterial and eukaryotic drug transporting proteins. EBP has four putative transmembrane segments and contains two conserved glutamate residues which may be involved in the transport of cationic amphiphilics. Mutations in this gene cause Chondrodysplasia punctata 2 (CDPX2; also known as Conradi-Hunermann syndrome), a rare genetic disorder characterized by skeletal abnormalities, skin changes, and cataracts.","Chondrodysplasia punctata 2 (CDPX2) is a rare genetic disorder caused by mutations in the EBP gene. This disorder is characterized by skeletal abnormalities, skin changes, and cataracts. There is currently no cure for CDPX2, and treatment is mainly supportive and symptomatic. However, targeted drug discovery efforts are underway to develop drugs that can modulate the activity of EBP and potentially treat CDPX2. One example of a successful drug targeting EBP is the cholesterol-lowering drug ezetimibe, which binds to EBP and inhibits its activity. Ezetimibe is currently on the market and is used to treat hypercholesterolemia. Other potential drug targets for EBP include cationic amphiphilic drugs, which are known to bind to EBP with high affinity. Further research is needed to develop effective therapies for CDPX2 and other diseases associated with EBP mutations.",GO:0033489 cholesterol biosynthetic process via desmosterol;GO:0033490 cholesterol biosynthetic process via lathosterol;GO:0043931 ossification involved in bone maturation,,ENZYME proteins:Isomerase; Human disease related genes:Congenital malformations:Congenital malformations of the musculoskeletal system; Potential drug targets; Human disease related genes:Congenital malformations:Other congenital malformations; Disease related genes; Enzymes,Endoplasmic reticulum;Nuclear membrane (Supported),Tamoxifen,(M295)SIG PIP3 SIGNALING IN CARDIAC MYOCTES,(M5892)HALLMARK CHOLESTEROL HOMEOSTASIS; (M5902)HALLMARK APOPTOSIS; (M5924)HALLMARK MTORC1 SIGNALING
ENSG00000156467.10,ENSG00000156467,UQCRB,0.818094006,1.298647301,0.587632992,0.568001725,ubiquinol-cytochrome c reductase binding protein,"UQCRB is a gene that encodes a subunit of the ubiquinol-cytochrome c oxidoreductase complex, which is made up of one mitochondrial-encoded and 10 nuclear-encoded subunits. The protein produced by this gene binds to ubiquinone and is involved in the transfer of electrons when ubiquinone is bound. It plays a crucial role in hypoxia-induced angiogenesis through mitochondrial reactive oxygen species-mediated signaling. Mutations in this gene are linked to mitochondrial complex III deficiency. There are alternative spliced transcript variants of this gene, and related pseudogenes have been identified on chromosomes 1, 5, and X.","Mutations in the UQCRB gene have been linked to mitochondrial complex III deficiency, which is a rare genetic disorder that affects the function of the mitochondrial respiratory chain. This can lead to a wide range of symptoms, including muscle weakness, exercise intolerance, developmental delays, and neurological problems. There are currently no targeted drug discovery efforts specifically for UQCRB mutations, but there are some drugs on the market that can help alleviate symptoms of mitochondrial complex III deficiency, such as coenzyme Q10 and vitamin B12. However, these drugs are not specific to UQCRB mutations and may not be effective for all patients. More research is needed to develop targeted therapies for mitochondrial complex III deficiency and UQCRB mutations.","GO:0006122 mitochondrial electron transport, ubiquinol to cytochrome c;GO:0019646 aerobic electron transport chain;GO:0042773 ATP synthesis coupled electron transport",,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,,"2-Hexyloxy-6-Hydroxymethyl-Tetrahydro-Pyran-3,4,5-Triol; 6-Hydroxy-5-undecyl-4,7-benzothiazoledione; Azoxystrobin; 5-Heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione; (5S)-3-ANILINO-5-(2,4-DIFLUOROPHENYL)-5-METHYL-1,3-OXAZOLIDINE-2,4-DIONE; (S)-famoxadone; METHYL (2Z)-3-METHOXY-2-{2-[(E)-2-PHENYLVINYL]PHENYL}ACRYLATE; 2-Nonyl-4-quinolinol 1-oxide; Ubiquinone Q2",,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000172809.13,ENSG00000172809,RPL38,0.820193303,1.096678865,0.968810931,0.395090115,ribosomal protein L38,"RPL38 is a gene that encodes a ribosomal protein, specifically a component of the 60S subunit. Ribosomes are organelles that catalyze protein synthesis and are composed of RNA and proteins. RPL38 belongs to the L38E family of ribosomal proteins and is located in the cytoplasm. Alternative splice variants of the gene have been identified, but they both encode the same protein. Like other genes that encode ribosomal proteins, there are multiple processed pseudogenes of RPL38 dispersed throughout the genome, including one located in the promoter region of the type 1 angiotensin II receptor gene.","Research on RPL38 and its potential disease implications is limited. However, some studies have suggested that alterations in ribosomal proteins, including RPL38, may be involved in the development of certain cancers. For example, a study published in the journal Oncotarget in 2016 found that RPL38 was overexpressed in hepatocellular carcinoma (HCC) tissues and that its expression was associated with poor prognosis in HCC patients. 

As for targeted drug discovery efforts, there are currently no drugs specifically targeting RPL38. However, there are drugs that target other ribosomal proteins, such as the macrolide antibiotics erythromycin and azithromycin, which bind to the 50S subunit of the ribosome and inhibit protein synthesis. These drugs are used to treat a variety of bacterial infections. Additionally, some cancer drugs, such as the proteasome inhibitor bortezomib, have been shown to affect ribosomal protein synthesis and may indirectly target RPL38.

In conclusion, while research on RPL38 and its disease implications is limited, there is some evidence to suggest that alterations in ribosomal proteins, including RPL38, may be involved in the development of certain cancers. However, there are currently no drugs specifically targeting RPL38, and drugs that indirectly affect ribosomal protein synthesis may be used to treat certain diseases.",GO:0034463 90S preribosome assembly;GO:0042256 cytosolic ribosome assembly;GO:0048318 axial mesoderm development,,Ribosomal proteins; Predicted intracellular proteins,Cytosol;Endoplasmic reticulum (Supported),,,
ENSG00000131143.10,ENSG00000131143,COX4I1,0.82110001,1.123502036,0.622221457,0.717576536,cytochrome c oxidase subunit 4I1,"COX4I1 is a gene that encodes a nuclear-encoded subunit of the human mitochondrial respiratory chain enzyme, specifically subunit IV isoform 1. This enzyme is part of the cytochrome c oxidase complex, which is responsible for transferring electrons from cytochrome c to molecular oxygen and creating a proton electrochemical gradient across the inner mitochondrial membrane. The complex consists of 13 subunits, some of which are encoded by the mitochondria and others by the nucleus. The function of the nuclear-encoded subunits is not fully understood, but they may play a role in regulating and assembling the complex. COX4I1 is located next to the NOC4 gene and shares a promoter with it. Alternative splicing of COX4I1 results in multiple isoforms.","Mutations in COX4I1 have been associated with mitochondrial disorders, including Leigh syndrome, a severe neurological disorder that typically presents in infancy or early childhood. In addition, altered expression of COX4I1 has been observed in various cancers, including breast, lung, and ovarian cancer, suggesting a potential role in tumorigenesis. 

Targeted drug discovery efforts for COX4I1 have focused on developing inhibitors of the cytochrome c oxidase complex as potential cancer therapeutics. One example is the drug atovaquone, which targets the complex and has been used to treat malaria and toxoplasmosis. Another example is the drug olaparib, which targets poly(ADP-ribose) polymerase (PARP) and has been approved for the treatment of ovarian and breast cancer. Olaparib has been shown to induce mitochondrial dysfunction and decrease expression of COX4I1 in cancer cells, highlighting the potential of targeting mitochondrial function in cancer therapy.","GO:0006123 mitochondrial electron transport, cytochrome c to oxygen;GO:0019646 aerobic electron transport chain;GO:0042773 ATP synthesis coupled electron transport",,Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; Transporters:Primary Active Transporters; Potential drug targets; Disease related genes,Mitochondria (Supported),Cholic Acid; N-Formylmethionine,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000148291.10,ENSG00000148291,SURF2,0.837973279,1.282120918,0.931508796,0.300290124,surfeit 2,"The human gene SURF2, also known as surfeit 2, is located on the opposite strand of the surfeit 1 gene and shares a bidirectional promoter with it. This gene encodes a protein that is conserved and expressed in various tissues.","There is limited information available on the disease implications of the SURF2 gene. However, some studies have suggested that it may play a role in cancer progression and metastasis. Targeted drug discovery efforts for SURF2 are also limited, as the function of the protein it encodes is not well understood. There are currently no drugs on the market that specifically target SURF2. However, there are drugs that have been developed to target other proteins that are involved in cancer progression and metastasis, which may indirectly affect SURF2. Examples of such drugs include bevacizumab, which targets vascular endothelial growth factor (VEGF), and trastuzumab, which targets human epidermal growth factor receptor 2 (HER2).",,,Predicted intracellular proteins,Nucleoli;Nucleoli rim (Approved); Additional: Nucleoplasm,,,
ENSG00000239672.8,ENSG00000239672,NME1,0.839740742,1.293080789,1.182396008,0.043745429,NME/NM23 nucleoside diphosphate kinase 1,"NME1 is a gene that encodes for the 'A' isoform of nucleoside diphosphate kinase (NDK), which exists as a hexamer composed of 'A' and 'B' isoforms (encoded by NME2). This gene was identified due to its reduced mRNA transcript levels in highly metastatic cells. Mutations in NME1 have been found in aggressive neuroblastomas. There are two transcript variants of NME1 that encode for different isoforms. Co-transcription of NME1 and the neighboring downstream gene NME2 generates naturally-occurring transcripts (NME1-NME2), which encodes a fusion protein comprised of sequence sharing identity with each individual gene product.","NME1 has been implicated in various types of cancer, including breast, lung, and pancreatic cancer. It has been shown to have tumor-suppressive properties, and its downregulation is associated with increased metastasis and poor prognosis. Therefore, NME1 is a potential target for cancer therapy. Several studies have focused on developing drugs that can upregulate NME1 expression or enhance its activity. For example, a small molecule called 6-mercaptopurine has been shown to increase NME1 expression and inhibit tumor growth in vitro and in vivo. Another drug, called trabectedin, has been shown to induce NME1 expression and inhibit tumor growth in soft tissue sarcomas. Additionally, a natural compound called curcumin has been shown to upregulate NME1 expression and inhibit tumor growth in various types of cancer. These drugs have shown promising results in preclinical studies and are currently being evaluated in clinical trials for their efficacy in treating cancer.",GO:0006228 UTP biosynthetic process;GO:0006183 GTP biosynthetic process;GO:0046051 UTP metabolic process,yes,Enzymes; ENZYME proteins:Transferases; Predicted intracellular proteins; Cancer-related genes:Candidate cancer biomarkers,Cytosol (Supported),"Zinc; 2'-Deoxyguanosine-5'-Triphosphate; Selenocysteine; 2',3'-Dehydro-2',3'-Deoxy-Thymidine 5'-Diphosphate; Adenosine Phosphonoacetic Acid; Stavudine triphosphate; Thymidine-5'- Diphosphate; 2'-Deoxyguanosine-5'-Diphosphate; 2',3'-dideoxy-3'-fluoro-urididine-5'-diphosphate; Guanosine-5'-Diphosphate; 3'-Deoxy 3'-Amino Adenosine-5'-Diphosphate; Zidovudine diphosphate; Copper; Zinc acetate; Zinc chloride; Zinc sulfate, unspecified form",(M120)PID ARF6 DOWNSTREAM PATHWAY; (M83)PID CDC42 REG PATHWAY; (M156)PID ECADHERIN NASCENT AJ PATHWAY,(M5898)HALLMARK DNA REPAIR; (M5925)HALLMARK E2F TARGETS; (M5926)HALLMARK MYC TARGETS V1
ENSG00000099795.7,ENSG00000099795,NDUFB7,0.844804295,1.181999717,0.827457779,0.524955388,NADH:ubiquinone oxidoreductase subunit B7,"NDUFB7 is a subunit of the NADH:ubiquinone oxidoreductase complex I, which is composed of 45 different subunits and located at the mitochondrial inner membrane. This protein has NADH dehydrogenase and oxidoreductase activity, transferring electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone.","Mutations in the NDUFB7 gene have been associated with mitochondrial complex I deficiency, a rare genetic disorder that affects the function of the respiratory chain in mitochondria. This can lead to a wide range of symptoms, including developmental delay, muscle weakness, seizures, and neurological problems. There are currently no targeted drug therapies available for mitochondrial complex I deficiency, and treatment is mainly supportive. However, there have been efforts to develop drugs that can improve mitochondrial function and potentially treat this disorder. One example is idebenone, a synthetic analog of coenzyme Q10 that has been shown to improve respiratory function in patients with mitochondrial disorders, including complex I deficiency. Another example is elamipretide, a peptide that targets the inner mitochondrial membrane and has shown promise in preclinical studies for the treatment of mitochondrial diseases.","GO:0006120 mitochondrial electron transport, NADH to ubiquinone;GO:0010257 NADH dehydrogenase complex assembly;GO:0032981 mitochondrial respiratory chain complex I assembly",,Predicted intracellular proteins,,NADH,,(M5905)HALLMARK ADIPOGENESIS; (M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000197696.10,ENSG00000197696,NMB,0.845507627,1.55262199,0.79076608,0.19313481,neuromedin B,"The human gene NMB encodes a neuropeptide called neuromedin B, which is a member of the bombesin-like family of neuropeptides. Neuromedin B negatively regulates eating behavior and may regulate colonic smooth muscle contraction by binding to its receptor, the neuromedin B receptor (NMBR). Polymorphisms in this gene may be associated with hunger, weight gain, and obesity. Alternative splicing of the gene results in multiple transcript variants.","There is limited information on the disease implications of the NMB gene. However, studies have suggested that polymorphisms in this gene may be associated with obesity and weight gain. Targeted drug discovery efforts have focused on developing drugs that target the NMBR receptor to regulate eating behavior and potentially treat obesity. One example of a successful drug on the market is the NMBR antagonist, SR48692, which has been shown to reduce food intake and body weight in animal models. Another potential drug target is the NMBR agonist, GRP, which has been shown to stimulate colonic smooth muscle contraction and may be useful in treating gastrointestinal disorders such as irritable bowel syndrome. However, further research is needed to fully understand the potential therapeutic applications of targeting the NMB gene and its receptor.",GO:0160023 sneeze reflex;GO:0160024 Leydig cell proliferation;GO:0160025 sensory perception of itch,,Predicted secreted proteins,Golgi apparatus (Approved); Additional: Cytosol;Focal adhesion sites;Plasma membrane,,,
ENSG00000183011.13,ENSG00000183011,NAA38,0.848555687,0.928988085,0.940890981,0.675787995,"N-alpha-acetyltransferase 38, NatC auxiliary subunit","NAA38 is a human gene that encodes for the N-alpha-acetyltransferase 38 protein, which is an auxiliary subunit of the NatC complex. This protein is involved in the negative regulation of the apoptotic process and is located in both the cytoplasm and nucleoplasm. It colocalizes with polysomes, which are complexes of ribosomes and messenger RNA molecules that are involved in protein synthesis. The NatC complex is responsible for the acetylation of the N-terminal amino acid of newly synthesized proteins, which is important for their stability and function.","There is limited information available on the disease implications of NAA38. However, recent studies have suggested that dysregulation of the NatC complex, of which NAA38 is a part, may be involved in the development of certain cancers, including breast cancer and hepatocellular carcinoma. Targeted drug discovery efforts for NAA38 are currently limited, but there is potential for the development of drugs that modulate the activity of the NatC complex. One example of a successful drug that targets a related protein is Velcade (bortezomib), which is used to treat multiple myeloma and mantle cell lymphoma by inhibiting the proteasome, a complex involved in protein degradation. Further research is needed to fully understand the role of NAA38 in disease and to identify potential drug targets.",GO:0043066 negative regulation of apoptotic process;GO:0043069 negative regulation of programmed cell death;GO:0042981 regulation of apoptotic process,,Predicted intracellular proteins,Nucleoplasm (Supported),,,(M5925)HALLMARK E2F TARGETS
ENSG00000125995.16,ENSG00000125995,ROMO1,0.850821744,1.118961931,1.205405244,0.228098058,reactive oxygen species modulator 1,"The ROMO1 gene encodes a mitochondrial membrane protein that plays a role in increasing the level of reactive oxygen species (ROS) in cells. Additionally, the protein has antimicrobial activity against various bacteria by causing bacterial membrane breakage. This information is provided by RefSeq, as of November 2014.","There is limited information available on the disease implications of the ROMO1 gene. However, studies have suggested that increased expression of ROMO1 may be associated with various types of cancer, including breast, lung, and liver cancer. Targeted drug discovery efforts for ROMO1 are also limited, but some studies have explored the potential of using ROMO1 inhibitors as a therapeutic strategy for cancer treatment. Currently, there are no drugs on the market that specifically target ROMO1. However, some drugs that indirectly affect ROS levels in cells, such as antioxidants and chemotherapeutic agents, may have an impact on ROMO1 activity. Further research is needed to fully understand the potential therapeutic implications of targeting ROMO1.",GO:0051838 cytolysis by host of symbiont cells;GO:0045039 protein insertion into mitochondrial inner membrane;GO:0090399 replicative senescence,,Transporters:Transporter channels and pores; Predicted intracellular proteins,,,,
ENSG00000141741.12,ENSG00000141741,MIEN1,0.862429154,1.649426341,0.598020491,0.33984063,migration and invasion enhancer 1,"MIEN1, or migration and invasion enhancer 1, is a human gene that plays a role in regulating cell migration and filopodium assembly while inhibiting the apoptotic process. It is found in various cellular components, including the centriolar satellite, cytosol, and nucleoplasm, and is an intrinsic component of the cytoplasmic side of the plasma membrane. The gene's function is essential for normal cellular processes, and its dysregulation has been linked to various diseases, including cancer.","Dysregulation of MIEN1 has been implicated in various types of cancer, including breast, ovarian, and colorectal cancer. Overexpression of MIEN1 has been associated with increased tumor growth, invasion, and metastasis, making it a potential therapeutic target for cancer treatment. Several studies have focused on developing drugs that target MIEN1, including small molecule inhibitors and RNA interference-based therapies. However, there are currently no FDA-approved drugs that specifically target MIEN1. Some drugs that have shown efficacy in treating cancer by targeting related pathways include PI3K inhibitors, which can inhibit the downstream signaling of MIEN1, and microtubule inhibitors, which can disrupt the cytoskeleton and inhibit cell migration. Examples of such drugs include alpelisib and paclitaxel. Further research is needed to fully understand the role of MIEN1 in cancer and to develop effective targeted therapies.",GO:0051491 positive regulation of filopodium assembly;GO:0051489 regulation of filopodium assembly;GO:0120034 positive regulation of plasma membrane bounded cell projection assembly,,Predicted intracellular proteins,Cytosol;Plasma membrane (Supported),,,
ENSG00000270761.1,ENSG00000270761,AL355353.1,0.869150891,1.09077883,1.221168417,0.295505425,None,None,None,None,None,None,None,None,None,None
ENSG00000126267.11,ENSG00000126267,COX6B1,0.872427658,1.03266019,1.172883312,0.411739471,cytochrome c oxidase subunit 6B1,"COX6B1 is a gene that encodes subunit VIb of cytochrome c oxidase (COX), which is the final enzyme in the mitochondrial respiratory chain. COX transfers electrons from reduced cytochrome c to oxygen. The subunits of COX are encoded by both mitochondrial and nuclear genes, with the mitochondrial subunits involved in electron transfer and the nuclear subunits involved in regulation and assembly of the complex. Mutations in COX6B1 have been linked to severe infantile encephalomyopathy. Additionally, three pseudogenes of COX6B1 have been identified on chromosomes 7, 17, and 22q13.1-13.2.","Mutations in COX6B1 have been linked to severe infantile encephalomyopathy, a rare and severe mitochondrial disorder characterized by developmental delay, hypotonia, seizures, and respiratory chain dysfunction. There are currently no targeted drug discovery efforts specifically for COX6B1 mutations, but drugs targeting mitochondrial dysfunction in general, such as idebenone and elamipretide, have shown promise in clinical trials for mitochondrial diseases. Idebenone is a synthetic analog of coenzyme Q10 that acts as an electron carrier in the mitochondrial respiratory chain, while elamipretide is a mitochondrial-targeted peptide that stabilizes the inner mitochondrial membrane and improves mitochondrial function. Both drugs have been approved for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disease affecting the optic nerve.","GO:0006123 mitochondrial electron transport, cytochrome c to oxygen;GO:0021762 substantia nigra development;GO:0048857 neural nucleus development",,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Supported); Additional: Principal piece,Cholic Acid; N-Formylmethionine,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000182154.8,ENSG00000182154,MRPL41,0.881557402,1.055680426,0.79711141,0.79188037,mitochondrial ribosomal protein L41,"The human gene MRPL41 encodes a protein that is a part of the large 39S subunit of the mitochondrial ribosome. Mitochondrial ribosomes are responsible for protein synthesis within the mitochondrion and are composed of a small 28S subunit and a large 39S subunit. Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and have a protein to rRNA composition of approximately 75%, which is the opposite of prokaryotic ribosomes. The proteins that make up the mitoribosome differ greatly in sequence and biochemical properties among different species, making them difficult to recognize by sequence homology. MRPL41 belongs to the YmL27 ribosomal protein family.","There is limited information available on the disease implications of MRPL41 mutations. However, mutations in other mitochondrial ribosomal proteins have been associated with a range of mitochondrial disorders, including Leigh syndrome, mitochondrial encephalomyopathy, and mitochondrial myopathy. Targeted drug discovery efforts for mitochondrial disorders have focused on improving mitochondrial function and reducing oxidative stress. Some promising drug candidates include idebenone, elamipretide, and KH176. Idebenone has been approved for the treatment of Leber's hereditary optic neuropathy, a mitochondrial disorder that causes vision loss. Elamipretide is currently in clinical trials for the treatment of primary mitochondrial myopathy and Barth syndrome. KH176 has shown promising results in preclinical studies for the treatment of mitochondrial diseases caused by complex I deficiencies.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Ribosomal proteins; Predicted intracellular proteins,Mitochondria (Supported),,,
ENSG00000224877.4,ENSG00000224877,NDUFAF8,0.893376034,1.215198579,1.257014383,0.20791514,NADH:ubiquinone oxidoreductase complex assembly factor 8,NDUFAF8 is a gene that plays a role in the assembly of complex I in the mitochondrial respiratory chain. It is located in the mitochondrion and has been linked to nuclear type mitochondrial complex I deficiency 34.,"Mutations in the NDUFAF8 gene have been associated with nuclear type mitochondrial complex I deficiency 34, which is a rare genetic disorder that affects the function of complex I in the mitochondrial respiratory chain. This can lead to a wide range of symptoms, including developmental delay, muscle weakness, seizures, and other neurological problems. There are currently no targeted drug discovery efforts specifically for NDUFAF8, but there are several drugs on the market that target complex I deficiencies, such as idebenone and coenzyme Q10. These drugs have been shown to improve symptoms in some patients with mitochondrial disorders, but their effectiveness can vary depending on the specific genetic mutation and individual patient factors.",GO:0010257 NADH dehydrogenase complex assembly;GO:0032981 mitochondrial respiratory chain complex I assembly;GO:0033108 mitochondrial respiratory chain complex assembly,,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Supported),,,
ENSG00000228594.4,ENSG00000228594,FNDC10,0.895474863,0.057961186,0.982194632,1.646268771,fibronectin type III domain containing 10,"FNDC10, or fibronectin type III domain containing 10, is a gene that is predicted to be an integral component of the membrane. The function of this gene is not yet fully understood, but it is believed to play a role in cell adhesion and signaling. FNDC10 contains a fibronectin type III domain, which is a common structural motif found in many extracellular and membrane proteins. Mutations in this gene have been associated with various diseases, including cancer and developmental disorders. Further research is needed to fully understand the function and clinical significance of FNDC10.","There is limited information available on the disease implications and targeted drug discovery efforts for FNDC10. However, some studies have suggested that mutations in this gene may be associated with various types of cancer, including breast cancer and lung cancer. Additionally, FNDC10 has been implicated in developmental disorders such as autism spectrum disorder. 

As of now, there are no drugs specifically targeting FNDC10. However, there are drugs on the market that target other proteins involved in cell adhesion and signaling, which may indirectly affect FNDC10 function. For example, drugs targeting the epidermal growth factor receptor (EGFR) have been successful in treating certain types of cancer, including non-small cell lung cancer. Additionally, drugs targeting integrins, which are involved in cell adhesion, have been developed for the treatment of various diseases, including multiple sclerosis and inflammatory bowel disease. Further research is needed to determine the potential for targeting FNDC10 in drug discovery efforts.",,,,,,,
ENSG00000179271.3,ENSG00000179271,GADD45GIP1,0.907001693,1.267480766,1.123597597,0.329926717,GADD45G interacting protein 1,"GADD45GIP1, also known as GADD45G interacting protein 1, is a gene that encodes a protein that is located in the nucleus of cells. This protein may be activated by the tumor suppressor protein p53 and plays a role in regulating the cell cycle by preventing cells from progressing from the G1 phase to the S phase. GADD45GIP1 may also interact with other proteins involved in cell cycle regulation.","There is limited information available on the disease implications of GADD45GIP1. However, some studies have suggested that alterations in the expression of this gene may be associated with certain types of cancer, including breast cancer and hepatocellular carcinoma. 

There are currently no targeted drug discovery efforts specifically focused on GADD45GIP1. However, some drugs that target the cell cycle and DNA damage response pathways, such as chemotherapy drugs and PARP inhibitors, may indirectly affect the activity of GADD45GIP1. 

There are no drugs currently on the market that specifically target GADD45GIP1. However, there are several drugs that target the cell cycle and DNA damage response pathways that have been successful in treating various types of cancer. For example, the chemotherapy drug cisplatin is commonly used to treat lung, bladder, and ovarian cancers, while PARP inhibitors such as olaparib and rucaparib have been approved for the treatment of ovarian and breast cancers in patients with specific genetic mutations.",GO:0032543 mitochondrial translation;GO:0140053 mitochondrial gene expression;GO:0006412 translation,,Ribosomal proteins; Predicted intracellular proteins,Mitochondria (Supported); Additional: Nucleoplasm,,,
ENSG00000250479.9,ENSG00000250479,CHCHD10,0.907763497,0.690666158,0.909436456,1.123187876,coiled-coil-helix-coiled-coil-helix domain containing 10,"CHCHD10 is a gene that encodes a mitochondrial protein that is primarily found at cristae junctions in the intermembrane space. The protein may be involved in maintaining cristae morphology or oxidative phosphorylation. Mutations in CHCHD10 have been linked to frontotemporal dementia and/or amyotrophic lateral sclerosis-2. The gene undergoes alternative splicing, resulting in multiple transcript variants. Pseudogenes related to CHCHD10 have been identified on chromosomes 7 and 19.","Mutations in CHCHD10 have been linked to frontotemporal dementia and/or amyotrophic lateral sclerosis-2 (FTD/ALS-2), which are neurodegenerative disorders characterized by the progressive loss of neurons in the brain and spinal cord. There are currently no targeted drug therapies available for FTD/ALS-2, and treatment is mainly supportive. However, there are ongoing efforts to develop drugs that target the underlying mechanisms of the disease, including mitochondrial dysfunction and protein misfolding. One example is the drug edaravone, which has been approved for the treatment of ALS and works by reducing oxidative stress. Another example is the drug riluzole, which has been approved for the treatment of ALS and works by modulating glutamate signaling. While these drugs do not specifically target CHCHD10, they represent important steps in the development of targeted therapies for neurodegenerative diseases.",GO:0090143 nucleoid organization;GO:0090144 mitochondrial nucleoid organization;GO:0031930 mitochondria-nucleus signaling pathway,,Disease related genes; Human disease related genes:Nervous system diseases:Neurodegenerative diseases; Predicted intracellular proteins,Mitochondria (Supported),,,(M5905)HALLMARK ADIPOGENESIS
ENSG00000231747.1,ENSG00000231747,AC079922.1,0.922878699,1.469943746,0.843497271,0.455195081,None,None,None,None,None,None,None,None,None,None
ENSG00000189171.14,ENSG00000189171,S100A13,0.932357335,1.314920537,1.003050365,0.479101104,S100 calcium binding protein A13,"S100A13 is a protein that belongs to the S100 family of proteins and contains two EF-hand calcium-binding motifs. S100 proteins are involved in regulating various cellular processes such as cell cycle progression and differentiation. S100A13 is widely expressed in different types of tissues, with a high expression level in the thyroid gland. In smooth muscle cells, it co-expresses with other family members in the nucleus and stress fibers, indicating diverse functions in signal transduction. Multiple alternatively spliced transcript variants encoding the same protein have been found for this gene.","Research has shown that S100A13 is involved in various diseases, including cancer, inflammation, and cardiovascular diseases. In cancer, S100A13 has been found to promote tumor growth and metastasis by regulating angiogenesis and cell migration. Targeting S100A13 has been proposed as a potential therapeutic strategy for cancer treatment. Inflammation is also associated with S100A13, as it has been shown to activate the NF-?B pathway, leading to the production of pro-inflammatory cytokines. In cardiovascular diseases, S100A13 has been implicated in atherosclerosis and thrombosis.

Several drug discovery efforts have been made to target S100A13. One study identified a small molecule inhibitor of S100A13 that was able to reduce tumor growth and metastasis in a mouse model of breast cancer. Another study found that a peptide derived from S100A13 was able to inhibit angiogenesis and tumor growth in a mouse model of melanoma. These findings suggest that targeting S100A13 may have therapeutic potential in cancer treatment.

Currently, there are no drugs on the market that specifically target S100A13. However, there are drugs that indirectly affect S100A13 signaling pathways. For example, nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to inhibit the NF-?B pathway, which is activated by S100A13. Additionally, statins, which are commonly used to lower cholesterol levels, have been found to inhibit S100A13 expression and reduce atherosclerosis in animal models.",GO:0032730 positive regulation of interleukin-1 alpha production;GO:0032650 regulation of interleukin-1 alpha production;GO:0002279 mast cell activation involved in immune response,,Predicted secreted proteins; Predicted intracellular proteins,Cytosol;Plasma membrane (Approved); Additional: Nucleoli;Nucleoplasm,Olopatadine; Amlexanox; Calcium chloride; Calcium; Calcium citrate; Calcium Phosphate; Calcium phosphate dihydrate,(M5883)NABA SECRETED FACTORS; (M5885)NABA MATRISOME ASSOCIATED; (M5889)NABA MATRISOME,(M5946)HALLMARK COAGULATION; (M5921)HALLMARK COMPLEMENT
ENSG00000135441.7,ENSG00000135441,BLOC1S1,0.942012901,1.072256714,1.353005577,0.400776413,biogenesis of lysosomal organelles complex 1 subunit 1,"BLOC1S1 is a gene that encodes a protein that is part of the BLOC1 multisubunit protein complex, which is found in all cells. This complex is necessary for the proper formation of specialized organelles in the endosomal-lysosomal system, such as melanosomes and platelet dense granules. Mutations in BLOC1S1 have been linked to Hermansky-Pudlak syndrome, a rare genetic disorder characterized by albinism, bleeding disorders, and lung and bowel diseases. Understanding the function of BLOC1S1 and the BLOC1 complex may lead to new treatments for this and other lysosomal storage disorders.","Hermansky-Pudlak syndrome (HPS) is a rare genetic disorder caused by mutations in several genes, including BLOC1S1. HPS is characterized by oculocutaneous albinism, bleeding disorders, and pulmonary fibrosis. There is currently no cure for HPS, and treatment is mainly supportive. However, research efforts are underway to develop targeted therapies for HPS and other lysosomal storage disorders. One approach is to use small molecules to enhance lysosomal function and reduce the accumulation of toxic substances in cells. For example, a drug called miglustat has been approved for the treatment of Gaucher disease, another lysosomal storage disorder. Miglustat inhibits the synthesis of glycosphingolipids, which accumulate in the lysosomes of Gaucher disease patients. Similar drugs may be developed for HPS and other lysosomal storage disorders in the future.",GO:0062196 regulation of lysosome size;GO:0051036 regulation of endosome size;GO:0018394 peptidyl-lysine acetylation,,Predicted intracellular proteins,,,,
ENSG00000147684.10,ENSG00000147684,NDUFB9,0.942870973,1.138521979,0.882212324,0.807878616,NADH:ubiquinone oxidoreductase subunit B9,"NDUFB9 is a subunit of the mitochondrial oxidative phosphorylation complex I, which functions to dehydrogenate nicotinamide adenine dinucleotide and shuttle electrons to coenzyme Q. Complex I deficiency is the most common defect found in oxidative phosphorylation disorders and can result in a range of conditions, including lethal neonatal disease, hypertrophic cardiomyopathy, liver disease, and adult-onset neurodegenerative disorders. Pseudogenes of this gene are found on chromosomes five, seven, and eight, and alternative splicing results in multiple transcript variants.","NDUFB9 is a crucial subunit of the mitochondrial oxidative phosphorylation complex I, and its deficiency has been linked to a range of diseases. Targeted drug discovery efforts have focused on developing therapies that can restore complex I activity and improve mitochondrial function. One such drug is idebenone, which has been approved for the treatment of Leber's hereditary optic neuropathy, a rare genetic disorder that causes vision loss. Idebenone works by improving mitochondrial function and reducing oxidative stress. Another drug, EPI-743, is currently in clinical trials for the treatment of Friedreich's ataxia, a neurodegenerative disorder caused by mitochondrial dysfunction. EPI-743 is a potent antioxidant that can restore complex I activity and improve mitochondrial function. These drugs represent promising therapeutic options for patients with complex I deficiency and other mitochondrial disorders.","GO:0006120 mitochondrial electron transport, NADH to ubiquinone;GO:0010257 NADH dehydrogenase complex assembly;GO:0032981 mitochondrial respiratory chain complex I assembly",,Disease related genes; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Approved),NADH,,
ENSG00000111678.11,ENSG00000111678,C12orf57,0.944169321,1.656011803,0.947978411,0.22851775,chromosome 12 open reading frame 57,"C12orf57 is a gene that is expressed in various human tissues and plays a crucial role in the development of the corpus callosum. Mutations in this gene are linked to Temtamy syndrome, a rare genetic disorder characterized by intellectual disability, microcephaly, and facial abnormalities. The gene has multiple alternative spliced transcript variants.","Currently, there are no targeted drug discovery efforts for C12orf57 gene mutations specifically. However, there are some drugs that have been approved for the treatment of intellectual disability and microcephaly, which are common symptoms of Temtamy syndrome caused by mutations in this gene. For example, Risperidone is an atypical antipsychotic drug that has been used to treat behavioral problems associated with intellectual disability. Another drug, Levetiracetam, has been shown to improve cognitive function in patients with intellectual disability. However, these drugs are not specific to C12orf57 mutations and are used to treat a range of conditions. Further research is needed to identify targeted therapies for Temtamy syndrome caused by mutations in this gene.",GO:0021678 third ventricle development;GO:0036343 psychomotor behavior;GO:0021540 corpus callosum morphogenesis,,Disease related genes; Predicted intracellular proteins,Nuclear speckles (Enhanced),,,
ENSG00000090266.13,ENSG00000090266,NDUFB2,0.962130953,1.292669408,0.666751013,0.926972439,NADH:ubiquinone oxidoreductase subunit B2,"NDUFB2 is a subunit of the NADH:ubiquinone oxidoreductase complex I, which is composed of 45 different subunits. This protein has NADH dehydrogenase and oxidoreductase activity and plays an important role in transferring electrons from NADH to the respiratory chain. It is believed that the immediate electron acceptor for the enzyme is ubiquinone. Despite being found within the hydrophobic protein fraction of complex I, NDUFB2 and four other subunits have an overall hydrophilic pattern according to hydropathy analysis.","Mutations in the NDUFB2 gene have been associated with mitochondrial complex I deficiency, a rare genetic disorder that affects the function of the respiratory chain and leads to a wide range of clinical symptoms, including developmental delay, muscle weakness, and neurological problems. There are currently no targeted drugs available for the treatment of complex I deficiency, and management is mainly supportive. However, recent studies have identified potential drug targets and compounds that could improve complex I function, including small molecules that enhance NDUFB2 expression and activity. One example is bezafibrate, a drug used to treat hyperlipidemia, which has been shown to increase NDUFB2 expression and improve mitochondrial function in cells and animal models. Other compounds, such as idebenone and coenzyme Q10, have also been used to improve mitochondrial function in patients with complex I deficiency.","GO:0006120 mitochondrial electron transport, NADH to ubiquinone;GO:0010257 NADH dehydrogenase complex assembly;GO:0032981 mitochondrial respiratory chain complex I assembly",,Predicted intracellular proteins,Nucleoplasm (Uncertain); Additional: Mitochondria,NADH,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000164919.11,ENSG00000164919,COX6C,0.970432391,1.756246929,0.795723337,0.359326905,cytochrome c oxidase subunit 6C,"COX6C is a gene that encodes for subunit VIc of cytochrome c oxidase, which is the terminal enzyme of the mitochondrial respiratory chain. This enzyme catalyzes the transfer of electrons from reduced cytochrome c to oxygen. The cytochrome c oxidase complex is made up of three catalytic subunits encoded by mitochondrial genes and multiple structural subunits encoded by nuclear genes. The nuclear-encoded subunits may be involved in the regulation and assembly of the complex. COX6C has a high degree of amino acid sequence identity with the mouse homolog and has been found to be up-regulated in prostate cancer cells. A pseudogene of COX6C has been identified on chromosome 16p12.","There is limited information available on the disease implications of COX6C. However, mutations in other subunits of cytochrome c oxidase have been associated with a range of mitochondrial disorders, including Leigh syndrome, encephalomyopathy, and myopathy. Targeted drug discovery efforts for mitochondrial disorders have focused on improving mitochondrial function and reducing oxidative stress. Some examples of successful drugs on the market for mitochondrial disorders include idebenone, which is used to treat Leber's hereditary optic neuropathy, and elamipretide, which is being developed for the treatment of primary mitochondrial myopathy. However, it is unclear if COX6C mutations or dysregulation are directly implicated in any specific disease, and further research is needed to explore the potential therapeutic implications of targeting this gene.","GO:0006123 mitochondrial electron transport, cytochrome c to oxygen;GO:0019646 aerobic electron transport chain;GO:0042773 ATP synthesis coupled electron transport",,,Mitochondria (Enhanced),Cholic Acid; N-Formylmethionine,,(M5907)HALLMARK ESTROGEN RESPONSE LATE; (M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000105258.9,ENSG00000105258,POLR2I,0.973399226,1.105130226,1.316504625,0.498562828,RNA polymerase II subunit I,"POLR2I is a gene that encodes a subunit of RNA polymerase II, which is responsible for synthesizing messenger RNA in eukaryotes. This subunit, along with two other polymerase subunits, forms the DNA binding domain of the polymerase, which transcribes the DNA template into RNA. POLR2I has two zinc finger motifs with conserved cysteines and possesses zinc binding activity.","Research on POLR2I has revealed its potential involvement in various diseases, including cancer, neurological disorders, and viral infections. In cancer, POLR2I has been found to be overexpressed in several types of tumors, including breast, lung, and liver cancer, and its expression levels have been associated with poor prognosis. Targeting POLR2I has been proposed as a potential therapeutic strategy for cancer treatment. In neurological disorders, mutations in POLR2I have been linked to intellectual disability and developmental delay. In viral infections, POLR2I has been shown to play a role in the replication of certain viruses, such as hepatitis B and C viruses.

Despite its potential as a therapeutic target, there are currently no drugs on the market that specifically target POLR2I. However, there are ongoing efforts to develop drugs that target RNA polymerase II as a whole, which could indirectly affect POLR2I activity. For example, the drug alpha-amanitin, derived from the mushroom Amanita phalloides, inhibits RNA polymerase II activity and is being investigated as a potential cancer treatment. Another drug, DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole), also inhibits RNA polymerase II and has been shown to have antiviral activity against hepatitis B and C viruses.",GO:0001192 maintenance of transcriptional fidelity during transcription elongation;GO:0001193 maintenance of transcriptional fidelity during transcription elongation by RNA polymerase II;GO:0006283 transcription-coupled nucleotide-excision repair,,RNA polymerase related proteins; Predicted intracellular proteins,Nucleoplasm (Enhanced),,,(M5898)HALLMARK DNA REPAIR
ENSG00000175756.13,ENSG00000175756,AURKAIP1,0.99739663,1.429498645,0.906249871,0.656441374,aurora kinase A interacting protein 1,"AURKAIP1 is a human gene that encodes for the Aurora kinase A interacting protein 1. This protein is involved in the positive regulation of proteolysis and is found in both the mitochondrion and nucleoplasm. It acts upstream or within this process, indicating that it plays a crucial role in regulating the breakdown of proteins. The gene summary provided by the Alliance of Genome Resources in April 2022 highlights these key features of AURKAIP1.","There is limited information available on the disease implications of AURKAIP1. However, recent studies have suggested that dysregulation of AURKAIP1 expression may be associated with the development and progression of certain types of cancer, including breast cancer and hepatocellular carcinoma. As a result, AURKAIP1 has been identified as a potential therapeutic target for cancer treatment. 

Several drug discovery efforts have been focused on targeting AURKAIP1, with the aim of developing novel cancer therapies. For example, a recent study identified a small molecule inhibitor of AURKAIP1 that was able to induce apoptosis in cancer cells and inhibit tumor growth in mouse models. Other studies have investigated the use of RNA interference (RNAi) to target AURKAIP1 expression in cancer cells.

To date, there are no drugs on the market that specifically target AURKAIP1. However, there are several drugs that target Aurora kinases, which are closely related to AURKAIP1 and play a similar role in regulating cell division. Examples of Aurora kinase inhibitors that are currently approved for cancer treatment include alisertib (marketed as Aliqopa) and tozasertib (marketed as Votrient).",GO:0045839 negative regulation of mitotic nuclear division;GO:0051784 negative regulation of nuclear division;GO:0032543 mitochondrial translation,,Ribosomal proteins; Predicted intracellular proteins,Mitochondria;Nucleoplasm (Supported),,(M242)PID AURORA A PATHWAY,
ENSG00000136149.6,ENSG00000136149,RPL13AP25,1.009863571,1.670350393,1.14559216,0.21364816,ribosomal protein L13a pseudogene 25,,,,,,,,,
ENSG00000147804.10,ENSG00000147804,SLC39A4,1.013295015,1.310931473,1.452119772,0.276833801,solute carrier family 39 member 4,"SLC39A4 is a gene that belongs to the zinc/iron-regulated transporter-like protein family. It is responsible for transporting zinc into cells and is primarily found in the intestinal membrane. Mutations in this gene can lead to a condition called acrodermatitis enteropathica, which is characterized by skin lesions and gastrointestinal problems. There are multiple versions of the gene that produce different isoforms.","Acrodermatitis enteropathica (AE) is a rare autosomal recessive disorder caused by mutations in the SLC39A4 gene. AE is characterized by skin lesions, diarrhea, and alopecia, and is caused by a deficiency in zinc absorption. Zinc supplementation is the primary treatment for AE, and can lead to a complete resolution of symptoms. However, in some cases, zinc supplementation may not be effective, and alternative treatments such as parenteral zinc therapy or a low-copper diet may be necessary. There are currently no targeted drug discovery efforts for AE, as zinc supplementation is an effective treatment. However, research is ongoing to better understand the mechanisms of zinc absorption and the role of SLC39A4 in zinc transport. Successful drugs on the market for zinc deficiency include zinc sulfate, zinc gluconate, and zinc acetate.",GO:0034224 cellular response to zinc ion starvation;GO:0120127 response to zinc ion starvation;GO:0071578 zinc ion import across plasma membrane,,Predicted intracellular proteins; Transporters:Electrochemical Potential-driven transporters; Potential drug targets; Disease related genes; Human disease related genes:Congenital disorders of metabolism:Congenital disorders of ion transport and metabolism,,,,
ENSG00000137970.7,ENSG00000137970,RPL7P9,1.025700063,1.844179933,0.895583817,0.337336438,ribosomal protein L7 pseudogene 9,,,,,,,,,
ENSG00000272172.1,ENSG00000272172,AC138696.2,1.042005432,0.935301115,1.341205456,0.849509724,None,None,None,None,None,None,None,None,None,None
ENSG00000205544.4,ENSG00000205544,TMEM256,1.047772619,0.814640614,1.405654697,0.923022546,transmembrane protein 256,"TMEM256 is a human gene that encodes for a transmembrane protein known as transmembrane protein 256. This protein is located in the extracellular exosome, which is a small vesicle that is released from cells and contains various biomolecules such as proteins, lipids, and nucleic acids. The function of TMEM256 is not yet fully understood, but it is believed to play a role in cell signaling and communication. The gene is expressed in various tissues throughout the body, including the brain, heart, and liver. Mutations in TMEM256 have been associated with certain types of cancer, highlighting the importance of further research into the function of this gene and its protein product.","Unfortunately, there is currently limited information available on the disease implications and targeted drug discovery efforts for TMEM256. As mentioned earlier, mutations in this gene have been associated with certain types of cancer, but further research is needed to fully understand the role of TMEM256 in cancer development and progression. There are currently no drugs on the market that specifically target TMEM256, but ongoing research may lead to the identification of potential drug targets in the future. Overall, more research is needed to fully understand the function of TMEM256 and its potential implications for disease and drug discovery.",,,Predicted intracellular proteins,Vesicles (Approved),,,
ENSG00000169750.9,ENSG00000169750,RAC3,1.048747968,1.191873557,0.952764943,1.001605402,Rac family small GTPase 3,"RAC3 is a human gene that encodes a GTPase belonging to the RAS superfamily of small GTP-binding proteins. This gene is involved in regulating various cellular events, including cell growth, cytoskeletal reorganization, and protein kinase activation. Alternative splicing of this gene results in multiple transcript variants.","RAC3 has been implicated in various diseases, including cancer, cardiovascular disease, and neurological disorders. In cancer, RAC3 has been shown to promote tumor growth and metastasis by regulating cell migration and invasion. Targeting RAC3 has been explored as a potential therapeutic strategy for cancer treatment. Several small molecule inhibitors of RAC3 have been developed and tested in preclinical studies, showing promising results in inhibiting tumor growth and metastasis. However, no RAC3 inhibitors have been approved for clinical use yet. In cardiovascular disease, RAC3 has been shown to play a role in regulating vascular smooth muscle cell proliferation and migration, making it a potential target for the treatment of atherosclerosis and restenosis. In neurological disorders, RAC3 has been implicated in Alzheimer's disease and Parkinson's disease, but no targeted drug discovery efforts have been reported yet. Overall, RAC3 is a promising target for drug discovery efforts in various diseases, and further research is needed to fully understand its role in disease pathogenesis and develop effective therapies.",GO:0021894 cerebral cortex GABAergic interneuron development;GO:0014041 regulation of neuron maturation;GO:0021892 cerebral cortex GABAergic interneuron differentiation,,Predicted intracellular proteins; Human disease related genes:Congenital malformations:Congenital malformations of the nervous system; Potential drug targets; Disease related genes; ENZYME proteins:Hydrolases; Enzymes; RAS pathway related proteins,,,,
ENSG00000241837.7,ENSG00000241837,ATP5PO,1.058956119,1.559864313,0.911236496,0.705767548,ATP synthase peripheral stalk subunit OSCP,ATP5PO is a human gene that encodes a protein that is a part of the F-type ATPase found in the mitochondrial matrix. This ATPase is composed of a catalytic core and a membrane proton channel. The protein encoded by ATP5PO appears to be a part of the connector that links these two components and may be involved in the transmission of conformational changes or proton conductance. This gene summary was provided by RefSeq in July 2008.,"There is limited information available on the disease implications of ATP5PO. However, mutations in other genes encoding subunits of the F-type ATPase have been associated with various mitochondrial disorders, including Leigh syndrome and mitochondrial encephalomyopathy. Targeted drug discovery efforts for ATP5PO are also limited, as the protein's function and role in disease are not well understood. Currently, there are no drugs on the market that specifically target ATP5PO. However, drugs that target other subunits of the F-type ATPase, such as oligomycin and aurovertin, have been used in research and clinical settings to inhibit ATP synthase activity and treat certain mitochondrial disorders.",GO:0042776 proton motive force-driven mitochondrial ATP synthesis;GO:0015986 proton motive force-driven ATP synthesis;GO:0006754 ATP biosynthetic process,,Transporters:Primary Active Transporters; Predicted intracellular proteins,Mitochondria (Approved),Artenimol,,(M5905)HALLMARK ADIPOGENESIS; (M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000262814.8,ENSG00000262814,MRPL12,1.095087269,1.519888752,1.061547908,0.703825146,mitochondrial ribosomal protein L12,"The human gene MRPL12 encodes for a mitochondrial ribosomal protein L12, which is involved in protein synthesis within the mitochondrion. Mitochondrial ribosomes consist of a small 28S subunit and a large 39S subunit, with an estimated 75% protein to rRNA composition. Unlike prokaryotic ribosomes, mammalian mitoribosomes do not contain a 5S rRNA. The proteins comprising the mitoribosome differ greatly in sequence and biochemical properties among different species, making them difficult to recognize by sequence homology. MRPL12 encodes for a 39S subunit protein that forms homodimers, and in prokaryotic ribosomes, two L7/L12 dimers and one L10 protein form the L8 protein complex.","There is limited information available on the disease implications of MRPL12 mutations. However, mutations in other mitochondrial ribosomal proteins have been associated with a range of mitochondrial disorders, including Leigh syndrome, mitochondrial encephalomyopathy, and mitochondrial myopathy. Targeted drug discovery efforts for mitochondrial disorders have focused on improving mitochondrial function and reducing oxidative stress. Some promising drug candidates include idebenone, elamipretide, and KH176, which are currently in clinical trials for various mitochondrial disorders. However, there are currently no drugs on the market specifically targeting MRPL12 or mitochondrial ribosomal proteins.",GO:0006390 mitochondrial transcription;GO:0000959 mitochondrial RNA metabolic process;GO:0032543 mitochondrial translation,,Disease related genes; Ribosomal proteins; Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases,Mitochondria (Supported),,,
ENSG00000169020.10,ENSG00000169020,ATP5ME,1.122073882,1.578469417,1.252447448,0.535304781,ATP synthase membrane subunit e,"ATP5ME is a gene that encodes the e subunit of the Fo complex of mitochondrial ATP synthase. ATP synthase is responsible for catalyzing ATP synthesis by utilizing an electrochemical gradient of protons across the inner membrane during oxidative phosphorylation. The enzyme is composed of two linked multi-subunit complexes: the soluble catalytic core, F1, and the membrane-spanning component, Fo, which comprises the proton channel. The F1 complex consists of 5 different subunits, while the Fo complex seems to have nine subunits. Alternative splicing of ATP5ME results in multiple transcript variants.","There is limited information available on the disease implications of ATP5ME. However, mutations in other subunits of the mitochondrial ATP synthase complex have been associated with various mitochondrial diseases, including Leigh syndrome, neuropathy, and cardiomyopathy. Targeted drug discovery efforts for ATP synthase inhibitors have been focused on cancer treatment, as cancer cells rely heavily on ATP production for their rapid proliferation. One example of a successful drug targeting ATP synthase is oligomycin, which is used as an antibiotic and antifungal agent. Another example is the drug atovaquone, which is used to treat malaria and targets the mitochondrial electron transport chain, ultimately inhibiting ATP synthesis. However, there are currently no drugs specifically targeting ATP5ME.",GO:0042776 proton motive force-driven mitochondrial ATP synthesis;GO:0015986 proton motive force-driven ATP synthesis;GO:0006754 ATP biosynthetic process,,Transporters:Primary Active Transporters; Predicted intracellular proteins,Mitochondria (Supported),Phenethyl Isothiocyanate,,(M5936)HALLMARK OXIDATIVE PHOSPHORYLATION
ENSG00000217442.4,ENSG00000217442,SYCE3,1.13196889,0.716198282,0.670820869,2.008887519,synaptonemal complex central element protein 3,"SYCE3 is a human gene that is predicted to play a role in reciprocal meiotic recombination, spermatogenesis, and synaptonemal complex assembly. It is also predicted to be involved in the positive regulation of apoptotic processes. The gene is predicted to be located in the chromosome and nucleus and to be active in the central element. The synaptonemal complex is a protein structure that forms during meiosis and is essential for the proper alignment and segregation of chromosomes. SYCE3 is a central element protein that is thought to be important for the proper assembly and function of the synaptonemal complex.","There is limited information available on the disease implications of SYCE3. However, mutations in SYCE3 have been associated with male infertility in some studies. Targeted drug discovery efforts for SYCE3 are also limited, as the function of the gene is not fully understood. However, given its potential role in meiotic recombination and spermatogenesis, drugs targeting SYCE3 could potentially be developed to treat male infertility. Currently, there are no drugs on the market that specifically target SYCE3. However, there are drugs available for the treatment of male infertility, such as clomiphene citrate and gonadotropins, which can stimulate the production of sperm. Additionally, there are drugs available for the treatment of other conditions related to meiotic recombination, such as cancer, which target proteins involved in DNA repair and recombination.",GO:0035234 ectopic germ cell programmed cell death;GO:0010623 programmed cell death involved in cell development;GO:0007130 synaptonemal complex assembly,,Predicted intracellular proteins,Golgi apparatus;Nucleoli;Nucleoplasm (Approved),,,
ENSG00000183048.12,ENSG00000183048,SLC25A10,1.145101307,1.642437732,1.0961853,0.696680891,solute carrier family 25 member 10,"SLC25A10 is a gene that encodes a protein that is part of a family of proteins that transport small molecules across the mitochondrial membrane. The protein encoded by this gene exchanges dicarboxylates, such as malate and succinate, for phosphate, sulfate, and other small molecules, which are used in metabolic processes such as the Krebs cycle and fatty acid synthesis. Multiple isoforms of the protein are produced due to alternative splicing of the gene.","There is limited information available on the disease implications of SLC25A10. However, mutations in this gene have been associated with a rare metabolic disorder called Amish microcephaly, which is characterized by severe intellectual disability, microcephaly, and seizures. Targeted drug discovery efforts for SLC25A10 are also limited, but some studies have suggested that modulating the activity of this protein could have therapeutic potential in treating metabolic disorders such as diabetes and obesity. Currently, there are no drugs on the market that specifically target SLC25A10. However, some drugs that indirectly affect the activity of this protein, such as metformin, have been used to treat metabolic disorders. Further research is needed to fully understand the disease implications of SLC25A10 and to develop targeted therapies for related disorders.",GO:0015709 thiosulfate transport;GO:0015743 malate transport;GO:0071423 malate transmembrane transport,,Predicted intracellular proteins; Human disease related genes:Congenital disorders of metabolism:Mitochondrial diseases; Transporters:Electrochemical Potential-driven transporters; Potential drug targets; Disease related genes,Mitochondria (Supported); Additional: Nucleoplasm,,,(M5905)HALLMARK ADIPOGENESIS; (M5937)HALLMARK GLYCOLYSIS
ENSG00000227077.3,ENSG00000227077,AC107983.1,1.223874504,1.950588042,1.157789824,0.563245648,None,None,None,None,None,None,None,None,None,None
ENSG00000220749.4,ENSG00000220749,RPL21P28,1.244839218,2.128495804,1.591797839,0.014224012,ribosomal protein L21 pseudogene 28,,,,,,,,,
ENSG00000243449.6,ENSG00000243449,C4orf48,1.307416863,0.855149049,1.257540232,1.809561309,NELL2 interacting cell ontogeny regulator 1,"C4orf48 is a human gene located on chromosome 4 and is predicted to be located in the extracellular region. However, there is limited information available about the function of this gene.","Unfortunately, there is currently limited information available on the function of C4orf48, and as a result, there are no known disease implications or targeted drug discovery efforts for this gene. Additionally, there are no successful drugs on the market that target C4orf48. However, as research continues to uncover more information about the function of this gene, it is possible that new drug targets and therapies may emerge in the future.",GO:0070935 3'-UTR-mediated mRNA stabilization;GO:0048255 mRNA stabilization;GO:0043489 RNA stabilization,,Predicted secreted proteins,Cytosol (Approved),,,
ENSG00000263934.5,ENSG00000263934,SNORD3A,1.319266799,1.688902739,1.905739436,0.363158222,None,None,None,None,None,None,None,None,None,None
ENSG00000229119.3,ENSG00000229119,AC026403.1,1.358440718,2.026943165,1.674692567,0.373686421,None,None,None,None,None,None,None,None,None,None
